<SEC-DOCUMENT>0000882095-22-000007.txt : 20220223
<SEC-HEADER>0000882095-22-000007.hdr.sgml : 20220223
<ACCEPTANCE-DATETIME>20220223165527
ACCESSION NUMBER:		0000882095-22-000007
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		116
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220223
DATE AS OF CHANGE:		20220223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		22664719

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>gild-20211231.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:4eb1680c-5761-45c7-95ef-3c78b834062a,g:a0cedc55-fc60-4d3f-bea8-ef196ffaa864,d:72faa4a0a4974dcca6db2bf491b63d7a--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:gild="http://www.gilead.com/20211231" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gild-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV80L2ZyYWc6OWU3YTA4YjhlNzg3NDY0MWJmMjIxZGY5Mjk5YjhhOGYvdGFibGU6N2QzNDc0ZGVlM2Y5NGU3YzhhYmFhNDlhY2NhMmZiNDkvdGFibGVyYW5nZTo3ZDM0NzRkZWUzZjk0ZTdjOGFiYWE0OWFjY2EyZmI0OV8zLTEtMS0xLTEyMTQw_3ca7f6bc-124f-4104-8841-a89be1f55210">0000882095</ix:nonNumeric><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV80L2ZyYWc6OWU3YTA4YjhlNzg3NDY0MWJmMjIxZGY5Mjk5YjhhOGYvdGFibGU6N2QzNDc0ZGVlM2Y5NGU3YzhhYmFhNDlhY2NhMmZiNDkvdGFibGVyYW5nZTo3ZDM0NzRkZWUzZjk0ZTdjOGFiYWE0OWFjY2EyZmI0OV80LTEtMS0xLTEyMTQw_eed59f00-9e0d-453d-8fff-83694f801f58">2021</ix:nonNumeric><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV80L2ZyYWc6OWU3YTA4YjhlNzg3NDY0MWJmMjIxZGY5Mjk5YjhhOGYvdGFibGU6N2QzNDc0ZGVlM2Y5NGU3YzhhYmFhNDlhY2NhMmZiNDkvdGFibGVyYW5nZTo3ZDM0NzRkZWUzZjk0ZTdjOGFiYWE0OWFjY2EyZmI0OV81LTEtMS0xLTEyMTQw_90803964-6d8b-480f-a72b-b9b26d59baf8">FY</ix:nonNumeric><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV80L2ZyYWc6OWU3YTA4YjhlNzg3NDY0MWJmMjIxZGY5Mjk5YjhhOGYvdGFibGU6N2QzNDc0ZGVlM2Y5NGU3YzhhYmFhNDlhY2NhMmZiNDkvdGFibGVyYW5nZTo3ZDM0NzRkZWUzZjk0ZTdjOGFiYWE0OWFjY2EyZmI0OV82LTEtMS0xLTEyMTQw_b686eefc-1436-4c44-8772-e3451a582777">false</ix:nonNumeric><ix:nonNumeric contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_bf1a57bf-a703-4b3f-bc9b-0294a5049060">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_c74f8a0a-3c1e-43dc-9a44-91448c3a81f3">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_3f97a2d5-98a1-46a4-8619-f3becdea71f5">http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_c90d340b-270c-4dd6-bbe4-3b313ad42434">http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_511d014a-a5ee-4a2c-a65f-0d75ca7b60e9">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_7e2903b1-a222-4253-bf44-fbb3ee9aa161">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ibcb5969787714c0d8190646f3cb425cf_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIzMDE_e5e44bde-010a-4057-a014-5f91fdc040cb">P3Y0M0D</ix:nonNumeric><ix:nonNumeric contextRef="ie7c2ae063b354630b9b4eb98c12579cb_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzM4OTI_528fb9fb-324d-4172-b895-26994db1e7b3">P3Y0M0D</ix:nonNumeric><ix:nonNumeric contextRef="ic8fcbd9748d94709b73ce8d6ca1b9f32_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzUwNzA_664e182d-33f3-4d5a-92ea-3c6d4ced19cd">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ic09fef48c1da4be29e79de02aa01573a_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzUwNzY_9109fd84-6601-41a5-b36b-3897b4762db9">P2Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gild-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8055c5201bb24e4ba49e863f9223067f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i115c1ea1db9c44ee8a4f7b1b25c2690f_I20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iaeaf99ac576f40e684136704e997f1ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc317247ac9840c9b997af09c66368bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia4befd4212fc4248a63e9b436b533760_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c51a506a019465dba53c1f088a945dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203243bdd8194063a5b0d20127c91ead_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aad07ceecdc471a9ee9d0a50de54618_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c80ef090990421ba4cb204bcc7a4aed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2f35d93745f44ac84aacec6dc9540d1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2942187c687440aae7d8307f89a6296_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id50e1295d74143879d750b13cda63300_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8555f34a84a4c3887459093bd255d74_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7703ce81d19946348842d9982c50c0c4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id46d2d21dd6a43a89e740948d75f9380_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7602de391c434d368154fe3329c135b4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i890acc6b92a24d29907006991e3f99d3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8222e290a2284cb0bf64a4ac2b6995b5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie196e7c846694582b374a274089a496d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib588e93b222b4f21902099d1901de114_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa3d1ac282964e3380614a0c573278a4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb1cc1349e424089965fc6662bf35a48_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01dacb3a581346e187edae0a347d2eeb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a0c1ca4ff4429d9883b9d439e8e910_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33a8d6544a084df5b9c6407ecb2d93a0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4b5ab47f4054d119ad163b7730160e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbd5347ef13d4d63a1e7031f22995187_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9da767fe6764cc8955010ca3f076633_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40b1731fe1b744a2b37e1b7157cc1c89_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib64b3709e27d4ea2961642638f9cbf2c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i326d4d7af8aa42a1b1948ed90603ab96_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1928c028f694d83885d06a82f22ca4d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac80893052fd42e9be5a92f71c18cdb2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b1636d6a27341d4903b179394689324_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0fc16e772ac480c9e4ad4516e16c190_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfc1931160c049e2b69a1fafb5719ec8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i851b03314d344a5e8ad436aa9235bf9c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f7ba76a51544cbd895730452d44bb48_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0fd40f1bbe64b64bafc77d0138fdc55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9832261d41e74ecb88de8acbbbb81ca7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i803ae583deba4f7683154aaeec947d69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab9a9d73e541440bbe6a602affd5a7b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i124557415b5546be81b290394bba971e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81bd8c38c79a44cd82ea0da460afeda2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffaa88726d364819baced65640a14653_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i626caba187154b4d9558b2cc5d8c94d0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8023d2e7ae2f498fa0385be7010b4f25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b1ea74ddca943afada26dff9a0ef62b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89cf74ab64a34cba879cbc8c8211ff81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d04ab1d0b074473902d53b2c6fa11cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ebb0b9dc1384269a861d7b5216e73fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia37682e7f2e748009cff968cbeae3311_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93ce718fd81f499ba51f827334051126_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>gild:country</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>gild:segment</xbrli:measure></xbrli:unit><xbrli:context id="ib4576883c8c04416a8ac3190f1f6a401_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22f92d3d761342058252995e5000c7e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i187ee787664447d585348e1a2ab56b30_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e6b53c8ca604244a32c0b5e15fd5c66_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdad0157d3ca4b4ab89aa860186ff56c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ab90c3fe714f4582356530234c3e60_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a627bb411ba4fa0a3e31a768339b2a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b2ff7c2261943cab1a06f2276326cdf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id689626e4dac444288f45776a25c0250_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc14ce605c54400c9ebe1fd7a321d9dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1051065ca69b4dd8bb278a9086b3981a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4c1e93ba27243a0aec3ab8933b85547_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac7be3325a864dcebdad2dd2a9d61b1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8579426159424e1d88ee2838574cdf79_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16010a377327448d8c04798bd84bd4cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b8647216f134ccfad7f18b6eeda9b4e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bf76245cb82416b89541253976dc956_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e5ed4771df344bf88d282203fb2c81a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id41a7b3cfd3a43729906149c4301f905_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81029626ddfb4f7bb7bcfe5c2fdfd743_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38b5f06b93954d2c8a448f52813c472b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e49c049a1ee4d1da001f9b14eede3d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia257aaf476dc490ea9ce67b59628191f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i319aecbf35ee424caa4536ae8a070bd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id923790754d142bc8a4cff9f0db14fea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i004f42a19a0d4012ba76b651ac1781ad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2e2462e823a488aadd395993cbcf54c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3773b5856594296a0e0d5470b07272b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb1ecc27305240afb7454391b76e7b3f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i955f95df25784bb981f16b33c53d7016_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4364249c081e4a8299d35a203bc4202f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15018f96b285492e9e58e9a7cf7f0920_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i943c0379de1a40db9377d8fb6d67ef66_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4554155264024aac9262c654e677f172_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9044ed3ca9147dab388bcc7b177eecb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07512868ee774a0cb3f3e62e504ffa2d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c30c6f5a8742afa25ed987810c2b23_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a307049b7074acabfbc2358d76df30a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7e743ecbe404abcad5a9fe1514264d3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61b1914f864b447d97ea0e13f1ce972d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a64962cf3bf49aa9644fc7d563ca33b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e847a9210e84d69b80c3e8dc9157357_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief23171a182d4edda65a49c01d6e62a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823165f9f0194830b142fcc6bf699a90_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia58f199843b04c59b0faec348789a897_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90cc329330df4a528c8cab6d9cd3edf1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i479225886ad945e0b76b956d468e6f12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87fb52f7d4e44663ad1d8a82f09c8017_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia83c565a30a54c94b2209c76652e2a74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc63491101dd42d9a961519e1c143cee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67f5cfa462304b0ab9cbaf412e605c14_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i216a83afd3da4697ac13672ce7f19d1d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabce25c37a564a34b5d87a9ca20dccaf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04ffde7221c6428c97f3d45227146507_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic50c2c139b864d0f9714887a2e19e6db_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb309902460441469df9d941328c83d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d1dc009e9554fdd9f501b84f9a0359f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i936e4f60767e4e1b831396cbdc15a198_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07a10f58aa8a4d788bb183517127b71a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibba1f6a417454414a52eee67b903f766_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i578e91a5c0ef41cd8792efd4d19387a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40d8621788548d7bf411858ff7ba95c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5afd54b578514567a98284af66dd6ac4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eb94cadea964808acc7aa15bff37b06_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf61ee83088444bebb4f09663550f050_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d0947b224444048e064e12269cb830_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia577fbe14a0c4e0d927470b3a7fbd587_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i977d9314cc04434e91070353392923ff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d310b1fa75d4a7da984b20d948c2184_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bbc93fa20d84074b84f54ab99be3ff8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73de952e119a4e8193f9d06daafad3e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1a3692437a140df85ba1b362d2ab850_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia94003099e5143b788e8be9985a431ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5dc050b70c4243b5d650b622754554_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b3a4868171e44de9828b7b8b593f50c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e9af54cfc5343f9a51ab0c702ca66b2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib00d8c27b3274579a8ddb2794664ce8c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i925632f08b5b443abc506c4e0023ae1d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i127c66e034bb456aac9234e1af982283_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02c935862970477fa978f1f0a2d5a975_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56588b2fbaa54723a442c57323d9358e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie911ed307ffe4eb880442fd8415ae516_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47483424d79343caad903d50f18fbc27_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23d5b07c3dba496b87eed5481cc9e061_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6888f767fb5540a89c1b977dc34701f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bcfe9bc16c64a6998c2ecc8a00a59a7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab5c0a688812413b97b23617889fdc29_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a3ab7f327aa411ca8cd78c5b9c55878_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f67d4b107054320b3c16b7722812905_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20615d735e3f4feb876b0d68cb833b1d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafcee73041034a3bb538769755411935_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e8a386144940089c04595189b92780_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida4bff1ec94d45e89d93a2f8a45a8829_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if42c088f381c4f66821c3e14150643fd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a12972820c549f7975a5bf002bb6538_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1f2aad4ccbe4eb0b88c2df952d0f837_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i897e806822094d188dfde4952fccd379_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba451b80fc88410cb6da9b54c955e4ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43aa85da84bc4a6aa2f0f6e6c94ce6ab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic75353bae5a445d5bc123e7e2497e07f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacec9e096e3e44b99059f74fabeb6b7e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib56fe44333d84038b5fbbdbcc054b3c6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53379b0e65dc4f64ae5b9bebdfe46157_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i893bbd6422a34883a23ca3d826e5330b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i448e732ad9d54ac69e5a1bd7cbe328c8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia91566e38f88433997c0da1de1f66272_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ff0ba8e2df54068b6656075016def3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb20f84492cc40dc9b975458263e0c09_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43f373d73c8b47b1b9b16c76da6f8272_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0472aa0ea92940198b6e45b72223726e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c4c20540eb44838445a3c3bf6934db_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i736248e52f04435497e629400596475c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83bcf63461a9483abe4dfe87ed5458a8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2faa4357e47d498d8cbb90bc8b52484f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i396c07fd8f3441388406ead2bb7d7a43_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i444aa902d7d24a6bb6ae1f79b9b2c713_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54a837cfa59946e4a95ef8a3cda149f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id88fe6e33c8e46bb9324f5323a45bae7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaecb4bf28d542abb8f6e6fd2b7265d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if60bb22a46354d29b9219ed7fef954d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42f5a348b1384a0383f1142c48fbdfd1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa5c024b83bd4d2aa79c46874679d786_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i504f85f6c7224b00875ce2499cf0be63_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f908e96d164ff1b01f8baaa3fd197e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia251084190c34f55a95d6b2d64e37c96_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i229cf3b61ba147a3bbcb87ad7c31cda8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifac706cf047e462d9dfc15fd7dac6e57_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3eb81dce73a4ed49c600ae52236de95_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i618a49f5343d4aecbde299dd826aab16_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dee7da238ca415a918de272a337f32d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbaf6564706d428191f126d2bc0e85d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie107375dab0449d29330362386bad92f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeaab2348e4b4632be02c7e9827151b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e04004aaf38470babb8b33e23b0be74_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e3ea7d2e5d849d7a255cb4ca655164a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ace274ff98a410dba00afed59352d83_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i465510434439422dbfe78d94feefa0d9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d552aa7c2b84ac880c86df8863dfdb2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ec344efbbcb4ac58cc8fa406d405f6c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id54f9b7f9d7c4a1eafcfcbb1db87e3c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a47ad4a66a490c87ebcbdb533b3462_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c6ba686d4024e4cb3fe4e32aaa54c4a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i628f3e6013424bf6b278bfbb87d91521_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i099a39b4eb484948a229c49d6d7556b0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide13091f185d41cf95813a1577de725f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee9158b1c9f74ee081ba38f7155459e2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief38edf0775b4b9ca4f0e44ff59522b2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bf73a2b190f407094b4c112c16ea000_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e97db273aa4eb795da9d6d163926de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2c54277b224652bb5f481e8899b9e6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i941c012023db4169add7305278b25afb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8b3da75ff53437da4d0ebb7b7fce5dc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie98d85f6a23645e7b3666fb72be32521_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i110bc03b8b9a4f39af6919c8022f5247_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9461e732efa7439c98e730817b44bd6c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39e0c50452714cc3bed41c678ceb7699_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4a05a18dbff43cda41f2c88b1526af2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i071292c322124b9bbbf6c05bedcf533c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6d911747d0e4dd896dcbd36aa8d64b6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3db91593e7ae46df9458a6d27efd34e2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice67dd103e8747c6a85c1155ca7fb3be_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72885015d43e44598a373a66ba3cd518_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25d706b9871c4ec09d84165adbfdc1bd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9744c1bb608145caa3c32e7f1f1e62c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf61fdee7ed484a8cf5ef1a28ae513c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib68f13d7d65f4a3f9d6b6fa6fe779f16_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad62ec6434ec4a489357913014ef40c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i632ecea3d6a14bcd8aba4b551ab1b109_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6977f8ca20334e9a848c24badc467c74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad186c8130da4cb0a163b46e15ef8e0e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad332b2083f6422aa4d34ccad607df30_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic402cdf5c95049fab3f5cb084e3b4a9e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie91e317bcce84be491b677bb32bc6edd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375f98b35c614e57bf7b3740ade479e6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ee01bce4fff478da0c0d8e0717ceab3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19612080d7a04eb680dd7e62452339bd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0528cba9d58149eeb50487d8e0d93ffa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id10376e1051b4ab49d4409daa6db3caf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaccc6fe1894b406ea52f03be7d11f6d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08fdcc10444240b5b0e2612cc6f7a33b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6778d1e87c764b129992c37e1b4c7453_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02a3a1f229ec4abb83405668328a28bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5ae4a747de409780ccfa5e25f24d81_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f226ca327245028082583aeea18794_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic223455e19124079bccd18d5b6d19b66_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i729e30cec34d4651bcc4fffc012176bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53f528f5ab3e479f8750f39c2d1cda40_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c21b57a311843c7928c23075197493b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i165baeb18574423899e97572f4ad2303_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie276a8d1c5114e51906a50380e6079af_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808173f115644f8887374d0ccd5b7c2b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af4bf5983dc4d368f5f7d4d273418b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47170c44772d4eca8e1e5e6506def2c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51636ea5513d4d358e7a7b90f6dbbcd9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf522a1b7f6646bbabcc782e8dc1b51b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd3a2239f5b4e01a783ba6d8ec0df2b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f8928add9a34ec3ad3f06c8d26024e0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b4a7b3c0e8c4e2a853a78f842c29fa7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4827aab7f394a64b3d94fcd0bb16303_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia26aa6ff603d43d18f70315e2b916968_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i871089dbd36740338ee626df7623365a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b4e1408e03e47fb82f8f85c9eb666a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51ce404a1df3479280a332700013fcf0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i146057c31eb14e13a7a9e858bb60ead3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed2d462dfa849f6afe13f2ebcd6d4e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b1a81e689e545ee948a81eef2e1c110_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b28d7f764ed4df6a8fc6e996578f509_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2151dc48e6c947d99adf672da18b5df0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb410dca7a24d078ff1663fdf12406a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ea9f66d534416db1d7a1827cf95ef3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1647c6936bc43fcbdf243a9abdc515c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aae349b58074fb090feca87f57d6a14_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ced3c15a03640a7835d719b1561a52c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73345ea2314645cfb8820974c816098d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bd332574d544b2c82443ba3f73ee034_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91bc7aa72e1a4adf90ce08b4fc392bee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8eb76b459c940c1b2329abee0b99396_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09754db5820b49ccaccb7b061b0de557_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e265173cbd142768e582d998dc84774_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i172a3eda78c94e1a9b766caab41395d0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4459dfdc5346422aa45ece2ad20dbcf7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieebec0082c664646b4c00fc161a76516_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7d099c53b1d444b94f937435b1658f9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2ff0b32543a42a4abba6624736b33da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7f1ebdb534d481b8b99013849133a98_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i970f012679314778a69b58c8c857088d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff2b48995cec427d8433b77a188fc0e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11fe2f0b1fc7469e95477b31fceb41b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f64c38e9ee4bb4a4adfed263dae20a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4513c4c6a873402fb73e21a4c06e9516_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3976c38729943bca9dadbf1a4d46799_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib547fcae84e34c80b007576498382eda_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica6cb120280c44aba952a2c8c31a2750_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0079f3b20eae4a329e4b8ab2e229a710_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c533a97e93b4daea96b3f68f4b71cb1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i336a3356c30a4e60afd917f34ba87b7f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80ab1d03e53b40818f7339579267f386_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d26996cce54be89bc4f5b1de53509c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73430cf69e6a4a81b0cb6ca9f2f1bcce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b4092e37bcc4090a2f341d283035c62_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8edb5cc13dcc444f8d32a508d719f99d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id72cab863f9944e49a8a3f6a212cfdf8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eb6a7e8649e43ea9cb507ca4dfa26de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24161ce3ce19498d973322014f5a38f9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ca7841873c343278c0054426a718e6c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id98a790faa824c7aa313d67d0d0d9def_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd711f6c7d6a4b3caf2c838786295c50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3b37a4b21504974b6a12ee7143b36f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2966258a34f945a6a240f933b9ea68a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaacff29670a64fc3b828391eaad52b5c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51653a7404d243bbb8c6b8587d15c302_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2206384caac54219b456deb7b0f73604_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i062b8b99606f460291f3600b276f88f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65701b8285f24b0196e2fbb93db58af3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2df490d82b849ba8e735ab25f5a83b8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c114e0218d342d9bb4a36cbb9d68b4d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a119fbc00c649cd9b0a5f71bb9c51c3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9de5a23fb8f43d08be01ea9f3270bb5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i860b9ef8d88648b2bd14fdb1a1c02780_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb532a2686334aa5bead08d5c4f00b78_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic037528273e74f499033a150e619b4ff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f699c45319641abb957b330b47c6d1f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ff2ab162b88421d9ba989dd81c8eca5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if208e11d45a94784a19929ca1f05b974_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic808e56b4fb14e02a5bc2f7449a1a9b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idba5b8558d6d4ff38879057fdcd4aea5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8de715ffb064281b509585e98cc69f2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92935c1825d54cbd8511cdb6abcb6c47_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3529227ebc7e4c039ce5ffffb338ca93_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea72c97e32144938bb26b805ed4c89b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i213cbdd848e94530b0d92ccdf1a75dfa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5056823e9ae347a2933637a7bbe6b448_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b4696f53ab1428d8c9d1112eeaa551e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c27d0f7d2c45fb98bdefdbb85bae75_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ceb977bf93a41088454e4c206235415_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ee0f595be264b08b8f9806028bf9b51_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie09f0fd7313646458071d017d8175cb8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab8836d9a4ce4fc5ba393c942ed97e61_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaae822cf2d924f3ea765b050bbaa39b3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i336854a9631445dfa14f917b4c21eb5e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a0b5eb4e390464fb3247a2dcdbaebac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e00b704a1f44803ada987adac8e13c0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i293b3b4563e14edfbe7fc51df8a013bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7df84051b024c53a6a840e6cdfb14a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i961b952327124924a5e23eb37b9e7069_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i137abd7ca81b458e88261321792ec71b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i781c570cd3034947a327d3ee47e152fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f704090e060470bae3918d46cb8a9c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a218e9a42374b4db9008f33b6126318_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e25b298d34d4c5cb36e6a52a778cd3a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4403855d5dcd4d63b3eb5be25dbcfd64_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35e32326f834884ac9a61bb0b8b479c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65db5049fdd3411fb63e909ef2ec8e5a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3938c584a5744b148070f5afb631ce36_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i713866d6cf0e4d8fb0f713df57c870bb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i681e654b253346a9b076a1bf6a0ca271_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a0f560cfb9a4aa2802a62ac6becbf6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i090096a8205c4fea847fc56558d9886b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9722c0087b814ddfb113130f0e25579a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9900dfcf355e4c32bcfd2373bce186dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie52246df773043eaa8b85b321512c538_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3622a78565bc4859927f6689c3c01aa0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92c7202f262d495b8e4e4a2f24623eba_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6c9456ecdfe444ea9be0065da372c97_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e0d01fa66074181a48c9de2389193a3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib586d74aa0da4b4185dfddf3ded39f03_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia794817e23b245eea3847eac57b7d78b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if987c46515874fb6a72a3a47e8e1d347_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28e77e92b5ac4b18b7764f67456f114d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21fe0e0298e4466c9ea8fc6c07e67b92_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7269f1f07c444f62b04e9950f4fb49eb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1134f6515efc48459a0f5a14aacf594e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02940b7802cf4f7d9c2b6a7f03527332_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5221e66f2614f1ebe73bce91d2dfe18_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac9cbee0c234416b4f8bf6424c7f023_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32f4fa85bcfe4c6183ce30b8e5b62370_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aea019cc63f4da6bd0e2026516da88a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833b13271d42409cbfe54ea29a5832d9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43cf8de658eb444fb180c5e973190ced_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e2e3bf847e34446b91d9e3adb7b393a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i206db45c6dbf4ada8039f50d374ad057_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2747de847a5a4b9abe5da80ee4f4328b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c35b4c8bdc540088472e6d5f39ad3af_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f8f38eb4cc941558bac08a5c690e998_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dcff95b8dbf48c6be5de5c404ab2dc8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icec3ad77c73243afafa557c15ec72da5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3eb32f54a11425b833021836e9f39f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id01f488874b24cf494dc9072dca62c34_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d9115ac2882474086a95ff0a92a7499_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ba2a5b00213403bba9525748da240d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d9039b4162443b796b32d897293cede_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f0bdd9cdd64dc9b7e998b0c6c0cae5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id619cc15e212429087aad1c7c9680827_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74a1f18b294146738afbce7fb84f04c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cde46ee36a2466ea21eb5d4fc29b9e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f7a8cfea5e24a51b71987e1407913e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47da50f7e1714e2581271c261dcae57b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14e531dc995d488b890a3208e0543ede_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66a0c129f84b440988cf1c09361bf9a8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aec4ea6992b43ce82e0f558dfd36b00_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d020553073843e5b6b7936014d32d7e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bdf71c266dd49129cd99f86795f30f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedff3b1944b64c3f8541ba18488844a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cae6eb7eace4771bc5b03cb7d5d7c3e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieefadac07e0742a9bcc209927edca502_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805cfc944d9648f5ab99fe13e0bd400c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9340b12589ed4cf8870255d67072e0b2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if302e604d9c647f2aa117693d6731a70_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f28249859146e18cebb4ada570cbe3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269a61a8cdb949e899eeb283218bebe3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ec1ab3dfa64442192f0b94587b08674_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9783ccaee044c3192afdd2303af4975_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8bb901328ad48a18b0d7ffb9e41d685_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i080a4966175c497dae95d90a6ab9979c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb880ef93270463586306266d0d1d82d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd188229a764f009b5c46cdd0daab4e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade7fb25dc3444df929d6b582363121b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c8b2e16b7a4af0bfd9779c4e42717f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97a22b0fa2914e7a8689aaa9bb993522_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b2f4b1ba3c24bcc9400a0bac9f2f5d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec069c130bc64661af4695041ea3fcc3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf64712f0538422da3dddc8951a5c75a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9206ff4ea2634a9b8710d3da4ab817eb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ac613e5c50a4f4685f5d72248c51ab0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b40444516934410acd5af26d4cc9cfa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4de92c1c900c41d58eaceb16cae8dab2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84f7c42de6914a59a2ad2c63f6e1730b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d6e05e9b75b4907bf54d729d73cccd2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a662c83a2aa4f978862cdbb062bd8a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a71363ffee44c8e958961f85ef4e870_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id771bf711f3a4abf927510c6700ba371_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4949a1736044f93b646e6613b1043f2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8462cf492cfc495cb1b6159e93665280_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i468ec8b3e2f040d686ff31e4dc41d689_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07489b4d42474f138fdfd6dfb3286ac4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d6184cd0bd4777bb8666956ef185f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb89a05869c84c4f8583d492d2024255_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ffea525fc61463397a9083c8c20ffd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc50225e8b064effa4994483dcb578e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2623fb937a24938b56dcd468a751f90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18a31f47fe134b108ed30bbed48a5c3f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db6ad4693a9411eaacfd1efa9b38245_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i307ad909b7ac4a7bad744035b5fdb3ee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc40e9061b2e4d7e8c573dcda94bbc8e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63e77ce4e9354eee9898d81ad4e106f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i466b9478bbef4388a85e27c598939910_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cbf3bc1bc41429b801a094750174f13_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb99587d2f584abeadc910467e333c6f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c2eab591b3243489738a3ce929a3f56_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad5223de57dd4696a199e9db73eaadcc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5015e8cece1d484b8333c5dc5371eb78_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ff77f687774eab827d133749a17db9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id462101bfca04327af64a9543c8a833b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic6af6e3232dc45a196b190b37e6c1439_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d6c7b10944a4914acc093ef93f55e30_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb1faac3f7f34f6cbdca10553062dea9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b21d294f3d14aaa889eb58f573882e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19d534eb0c65483390415a8fdd2e4915_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ae8dc2f110f40cfbd42e80f081e08d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i912278219236443aa0a53f2ed6c5335c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a8bfac32dd43bdadd46b2b5c450cf9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d8ec0117d844149bf15fb93a66a98b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife19703a21e24deda943371d11289462_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0fc481856f34a4dbd84bccfc4f900e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c0246e87d7d4539b64d5bc5c091b3df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbc5fc480e4b4729b2803202c43ada08_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2286a95065594d6d9ca4944ff53d5394_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b2d20da4bd4cfbbc5ac7bff1a5b643_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e69d167f82a4883925ec64ac6b590dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf113888c5464692b6ffbe8e4a732bae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if58ceba457fa41819c0289f982ba7126_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia353233b00564c41a4d9cd25abd93e70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cb417101fed43a7b4ac1d574f6f9524_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195c8db92c30457c89e804d5f743ea65_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23b07529177a4ad8898665bf99bb8bd4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4694f2b970149499d768396c277556c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7fd02cc204a4fcca4854f1cc54fdc75_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa9c593efcab48c292fef975883cb901_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4f01b9dc465412898be06b78bed526e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d0f95467284563a2793f3b45d55692_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if92ffa56cee1465981e8289446960059_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25ec023f9542416ab812e9b107619ed7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec65128416ed4c2caa95ff502b873f17_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic00702509b5b435495cf0ec01ce3bab9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifad92d842d244ddd8c185fba7ec11571_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf683e991aa04e84b6b581929bc8a52d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678f3e8e9c0c4393bd7bbbd1dbc823bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17fc0330f5ae4c9aaf6ebfc057402b0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03cf8ed895c84bf6a0b0a590b3791db3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2c6eb6568ed498290563719477a6d6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0d3c79ea2c4c72810e8c002a5c14b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide6b42f3b50c40e7a356f40b566dd53a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35bf4c1622964f4ba66d71293935d060_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i946749b11bdc47e88afcab1bddcdef12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e50b420b9d24798a8608dae51733253_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb796c40fa2149c29dbc27aa4bb85775_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63935bd985224f0189d1730574c0313e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id37ad7d3e58949e28ec38d38ed20873a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ca1fc3df69c4ea6a527e5aadbaed99e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i314b3d48689b48a78390fdb9120b06f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3331ea5fd3984313b34746715ba4ae93_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25dc7b22e3f541188c657f4004692097_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a8230e74cb644c5a3e520fc9a03f39e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i152a4600edde4d04b65202787532de71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5b6f43984b043f1838533b38d3e5e38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i598fc7abce8f43bdaca52d6637a92fc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6d92e9d06d49fa842aa61301fede5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i933d89b1d3e04e03901b0acbce724bc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35a96651d23b4cf0b0d1b40e9bd9a52b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i856d25ed6103414d89dbd76e3f9e2cc5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if793cdfa691a4047923ae5fbfa0651eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia68f6c8a6e4b40be839701a8158a7994_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5d5ef90d851431ea311b8514b301646_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c0099914e9b47e3b8c377d2d5605c48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7be17b88e76541728d2d52bc5c2c9912_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ba9f036d1c6491b8d70e0393484bd55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31176ade8b484178bc6cd4473ef6e2aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67cdde391bee4e1aa62b4fe62d765eb8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i319991ed67fc46fe879ccb7ee406b2bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7ec4799858746d28f2672bb3328c313_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie988bf37059d48c0bcc4ac229bbb92d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7858389cba8440abda830a77b3c5dd7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a6c459ee244343821c1e3c44035a12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d056305515d420da7c42e745bb193c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b510802aa0349f48dcb8a8e7cbf9a21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c1b6d7dddb473ea3e00bef51b2e0f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1c1f4de39c94a96aee95ff2f88a2128_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib041556bab2d43ea87cd7b61b04e2646_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8fddfac82b4eac885606ee08c7a905_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d1be345220f478da51f25e82698124a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic404165c5df74a6f8352e0db325e95c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i089e25d92ca54c8985ea2dec50042b89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ada8ca7ebe9435e8e842501c7ad3ae3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i016b509afd8947f3b511effbe125af0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71323cd5e83d4d6d87b2eed504ce751e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i727438de14724066816f95ee9809e17d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b832f22f4be4e61b0de45142590027e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf631f09cad14340965003dda42b76f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic387fe29a75d489788a450be894254a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2093e60191934786be5e9f3c4d997270_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea1fae5ea08948ba843477c2e34181be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ea29fc78efe4c18b496239d1891b476_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9af306f4c8d042af84347454c60ca09d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85a8909028d04fe1a126acdf567947cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90c285b633ed488fbf315d7bcb4b9c40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9869805732e4312926496da94a42e12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92185773c58344ce928789fdf5535c76_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0065f36a81224792b11e6b48f9770c23_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd8ddd71ad6a4934a591d1a60321c3c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id803bb97e7f740d6ad0af3395e67147d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c806a171cbf4ef99d78d293d9736606_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3167c1fc9a3e4a5788cfa0858e185c3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideec20edc39c49fa90ed919a34d06198_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i271339ca119345d694d3d33dc37ebda3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83fe215fd3514c48a9b0408fc2c8d430_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1d5b54c27be44f58ad2ee7c5da2c1bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e7706841e6648cab9e75afad945d3ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie627b2b228da4beaa2c490c412620ab6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac8673365254bbdbf17e38b4c77bfd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia43f9293bebd43209b55a1f81a2eb994_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5efa57e75bba46fa80520cf5680bd744_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fbab0dba432455d952aca9feddd5630_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee18145a966642cc8e1ce5da7d258519_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbb049a4497b4214bac4f90ea6d795dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83d09ac1c4594e0da8f577558b10d846_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3ae968a144943c69767909be7df131b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72ec7b074d434e8bbc8f74ca1c51fa6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba409e656a3f48ab972be2b06a795ed2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id77217ce37d644ed8b218aa4572cd4b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bd3a01aa1b84a7f86ff1f7e00427920_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863d391d7654400d8d7b18b4f8ed2d6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id24b38f7656b4bdc843563195dcfddce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bba9a34d1de4972a00d03116c7adcf1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5795fbc1c3341f29a10bb7056a260ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeba2733f3294d8fbb36b69036097ed7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i537d6236c6684eb8b511aa68e41c2195_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i752e52cf961f4af794ad9d51504ea5ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9957ec642e74491187d1c03568dc54e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82771ba0871b4c818fe4a95aad641c8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia13c72dd8cf642e199152f20a3bf4a87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f5c1170d657408696883656ec2bd949_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2adb19e0ca44d459898b6f842970ad2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gild:GileadFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gild:EquitySecuritiesDonationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67a406b4b0a049ffb974da9082946416_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f6470cf7f5d4d0ebb2b950757008455_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99fc02b86f154dc9aef67ccbad4572b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10ea058e4eea4ab9a26e8149179fc6e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i366d837490844422b12ca69c2324a42b_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i601744dfe4a449f588dff2ea9f459c7a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if747ff5ccb394525bf8dd861a2391455_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7987a3dc65e4b51a622b5dcbc55adcc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45bc386594ad4ae993ce88114eb4e62f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i347295d908ea47bd9ef9a8fa1edea941_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2afdba519b8b455cbb7ae9cfc063ba8a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie04ebb87f24d4c1dab5e3b201c5cb6ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b2cbea5bc7c4a8b854e2ea7a3ef27c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cd664388de741a283f40d467c2b991a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic431d321c32f4a148e09f407728ba829_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b2dfff9a8cf44d0a774eb9d6d1b49d3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f0e3695ed25418e9b23c7b9dfd2aae5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec1287280e9a4deb8aa835abc6a56556_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d59af8c16674ee3b51662b5f23c4dd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i656a88d21ed14481983deda32ba5c61e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12f871061a224dd98a831397d2bb871d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5683ccd60fc477ca7ea1aa59d4ccc1e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81c0aae6ccc84b7db071d1c937c18fe9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf1c274e36c24d35acaf02b87f54cdbc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87a8e5050483425f801196f211abfa22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib77bd1f1f55144c3b95b11c8a831313a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ba0806a7f7a4733846c919f29140932_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iade4a4ff784541f9894f489c3fb0b38b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>gild:position</xbrli:measure></xbrli:unit><xbrli:context id="i37b11b51a2b54cf4a3a9e85b864611a7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5810a2be53eb4780af1fcce52fdb4182_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018037d6d5a34a678330d1e08439237d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7c8d27c7190478abd912de07485cf67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48f32c2561ae4b3293149592ac05f4a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45bc7259ae6041fbb19709a9cae25597_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i971521b0df674be6820599f3a1fc538a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaf88e28a5724eb4a56d2dfc0bf0392f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47f76a18801e482ab060956da5e0577e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib44df45962204ad590aa3deb292d480c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ef1ef2f4ad142b98639be3f14e6ee99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8547beeb32459aa1afd7e5ca598ef5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2303cfde655d46948b6bf62eb15ca0de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ea1ac770ed8451ab24e1400a67a9c3e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id145919643ae4857950cf7eea0d60f0c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id29ad5c6bdc744ae996da36f45e56366_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82b12e0c7d5d4ac7972fa5266a3d7e8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3154b2ea498c47eca679490b457a3b8c_D20210304-20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-04</xbrli:startDate><xbrli:endDate>2021-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i359a44a00217459b8f4262c8fc42c933_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if51b044176e94e2bb20e9f08a40d5ebe_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7c7aac8a2ee4a4ba775220f0d9f2cb3_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4935cfb394d8470eafcd34defaed7483_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb48d6051df7485eb73cdb8b7df0e985_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i921b8d77d4f84f529ce58e9660da8dcf_D20210304-20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-04</xbrli:startDate><xbrli:endDate>2021-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2177833d44d42918c6ce32854820034_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21ced31d30014719bdf7d7d18248633e_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9a673ba30ed4f0e806f09b015c95ec7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cc76f278d7d430794fea351f77cb6c7_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f5da942c50945a2940da6ebd718841a_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf63b79601f41cbbbb79ce216ea77a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3183f05cabb4466ba0779104322ecffc_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d4bb748a364d08802e6d345ae95f56_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48fbb200fd474e8c86b19b2980d80c7a_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee6771abbf6845e9b749e3f2f831a535_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c0a66904d084d55b9dbeacaaa99fc01_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4914efbe4a514e3a9b1e8ce1c3d1f7a8_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea54bfd7cd894da1a9dc4dab9d27fd06_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e4d4939ae6f4eacb0ac9fcf29a6a86b_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cc576f3ddae4cccba9f06dea7d86258_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17b0826d35c24c928061c1e5a0cc3d90_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic064b955d17a405a8e93d4ced0a24b8b_D20200407-20200407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-07</xbrli:startDate><xbrli:endDate>2020-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if390b664ad9b4a3fa1db0cce3b5ead91_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic616f3942a304ac4ab23e63afeed5a7d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i799ec7afbe884df09fd62386211ca69c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb077705a6144313995575f715ac8647_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9130594e600c402b8c0b978840773abf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2809f8582076480fa7e0927fefc603b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9515dcb5dcd4ed096a37c411b6c94a8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">gild:InventoryWritedownsforExcessRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ac72ff3c91e41dda636f4481b43d8d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if86d40bd14d6458096e0c4c590a93b2d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i954f79dbc23344e2bc4a6cc0b85ebc55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d05732d25884b3886f2b6eb46e0c7a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e5cf4e62a72481988dcf8c0806f41bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a7db52d1e4a414281cb490a081d6dfc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c2781ca10ac41f5983b9e118c2abf70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneCiloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1ad0c1f171b4177b15cd5e56d09b6c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneCiloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaf491080c57475991aa98abcc4fbcc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bdf2ca12670410281b8c08d6e3e7fcc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1f8421f3e1d46c38dbaab52dda2ef27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf23ded0c1324053bcaf589d66627968_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30947e974d8c479392d193aad7a782fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d94d5c1399f498a9997b438dd170d14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52f89193810b43f085be64ba7f474b2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4094fc9d8da341cea659d729c71c046d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1d241566dd94df38a909334019a059a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6252373178cb4cf6833d9fea5111db48_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneCiloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i034b60a8653f4767b2a7133e87e4160c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i808afce6234d4f44b02493f616cfcdad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i157409bb1ea342b2a3f94ed6091834b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e62f0a33b96429bb3fe4df85eb86fd7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaddd81bb83f462cae89580391426788_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55469af46ac6444babd1103f64cce260_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gild:MerckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie62b8bd54ac5417b86b9d244cf6f31e4_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OralFormulationProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1366e28f1db34aa6adddcb7dc9cc3fe0_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:InjectableFormulationProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0358f4e9723644c2ad88455c39676410_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-13</xbrli:startDate><xbrli:endDate>2020-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb4c98e8e51d40a1b47f8612c6763bdb_I20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i123ae893a43346c69c0dbe160845d982_D20200713-20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-13</xbrli:startDate><xbrli:endDate>2020-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30f6211f84014d5fb004dbfaa00c87ea_I20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia724223fb3ac4ac189bcbeacf8570846_D20200529-20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-29</xbrli:startDate><xbrli:endDate>2020-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i097284d2fd8842978d347c1888e015ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef41f89acb2446a8d12c64235b715ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c0c8d8e8e5041718f4702400109bd45_I20210208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ed865dca089431bac2babc189c7b73e_D20200527-20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-27</xbrli:startDate><xbrli:endDate>2020-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a21258292b74537b89e8497e7a5f1a1_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>gild:program</xbrli:measure></xbrli:unit><xbrli:context id="i7fffbc21fc7d4b79950ac95fd954ed10_D20211221-20211221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-21</xbrli:startDate><xbrli:endDate>2021-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if55eb0ad124b4e9881655f8d21b1defb_I20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib55eff2de05b4735962a5178e2d0c136_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91b41bd2879340d590e60e9612a0f797_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide14895bf0d94cfda60b8f404be8046a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dbdcfe118594570aa52cb141478f07d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if414b8855b364ef693704d5b8001f3de_I20200619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e1550a829c24cdb927d71b758e41d28_D20200713-20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-13</xbrli:startDate><xbrli:endDate>2020-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7c095b57994471c805950b5c5648d45_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade36ecd4b2f43d18bc13b3efe3cfbb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i440f8eb082024226b3b774d89e0637e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ffb74e13be94db9b8207cb1d854b5c7_I20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d004159e86645f4b54571d61ef34b7a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb5f6c23a9644726bde59d143b28193d_I20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id404a80a80e44a99a559bfcef8dd06bd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i697aa6050edb4e629c83ae942ed52f29_I20200717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i397dc877c7694d19958b40ce06f66597_D20200825-20200825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-25</xbrli:startDate><xbrli:endDate>2020-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49d256c267ef40f8ab7c6c8aa7a19bf9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b799eb641ab49b28bf86c39cc6029ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b9c16a178a84867be9f2a8338568380_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib17c6ee7308a4338b6c4a503ef2f8d57_I20200825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6db4377ec93e4d7bbbe59b9ebfaba7ca_I20200825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i339e56a5445e42a7bd636e9572986490_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TangoTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-17</xbrli:startDate><xbrli:endDate>2020-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i218f3bf11f8c42b7b70c818ee6cc5f8f_D20200817-20200817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TangoTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-17</xbrli:startDate><xbrli:endDate>2020-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6623efe8bef84a7791fcfec2fcc2f16b_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb7bf0dc4a3e43daaefa71f64c8916e5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9750074cced84b80b470f7d052116226_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85f6aa2b44894183be1329a1fd12b947_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4143eccc523441058a76f70c0b3fe14a_I20160119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i38d8e949cd7d431c99be65bf7f658b30_I20201215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfef5580108a40bb81fbb13f508788a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67c0a0b9d43540d6bb4a7d7d6f17ebcc_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67e54ce58cd24263aa47b0dc690946cc_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97319e361fc94cc9a211d39a12605abd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i696425f28417451f92ec8151983911c1_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ebdcf15388b47788ebf7553317d34c4_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7927d3d1315d45eab4bbe1b07f2029c6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib85c08bffd6947139520ddf1b963fae1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2011c1fa80f041a5b06d24015e3d5227_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9a5706c39e84b85ac9e1d0f522c9890_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4db427db2e8f4ebfa1972445ce88c38c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db86d92098f4af891245ad653df5061_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7372c5e4ed6845fca519e44a4bb17431_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dad1dfaca274c1799a38e45db78a46f_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45c072246c2f4e6d946c5c5570d2fed8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ce860376b2440a786d96346e8ce0f89_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i578443185f7749589002f4f312b78678_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dba157973574ff69d357c2d296e62e9_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58b324bcac2249b5930ebbcdea8ee4c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bdde946e55442a1aa5d7882ec1e7427_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00e7665e176c479ea7bb308c8eeca6b6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d244f0e9b79475cb0ba4b314b832cfe_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie60c8cd3db5843dc97136850ade2673e_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GadetaBVCollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ba0c9e44c9746718a04e414e6de9857_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GadetaBVCollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5beb0d51c4e54f94969f8c6cd1ba0419_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e25b453d1fa4d85a5dca483e607e4d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icde588c2a460402c9deeff992fa80573_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88553ac9d9624f42958c6f396678542b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4800b053ef3c4136a3cc63c8103e707a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15ff3826397c4b51af10501cdfc1ffbd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic90520151d5e45a5b3bafe9e36c40ab1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbd11fa3c26e4fd38091c2e840bb69d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if49d256ecf4c4fccb417a3006ed896b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2d9c33739db4dc08bf4edd765bd7407_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if32ef749e53840578fa5654cc25b8c69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43afc0414e494b869b770762bc4d9a52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51ed2cd34ce84554940fc25d819f2777_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibab69215b4e64f54a4722114423cf768_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia79e2cc5633d4132a25a764b4a709783_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6efa694deb2427e8f5f99cf4f174aa3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4db7fc21d050453fb55088da46769875_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if57ff25bef0d4bf4a3e07a11a72aa1c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7fe7b7bd7a749eca2309daea67e59ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff239ca5ea6542a1b65cc0ff2d9218fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24f46a74be3740deb3686fa5d733f011_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dea7ef2353348b9b97eb413fb4c0d7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85abfdacc7a34da5888f65dc84ca6fca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20a94020fb22453791fa3f7a17071381_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44be2f180cd740a2817d4a90b827ce9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5f33f1a524c46ef989dcaf10d803a74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie05fed16be294c6fb4bbc7419f3eaef4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e4a183e1199483b92ed085372e796c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb302b98be6d4fe8bcaa37065ebb5a54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib60a477703704a5b8d5fee9be6c07b0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d459efd6b0147f8b01649f355747ec3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fc6d5d4b12c47c9a6edd38827bfbdce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa4722d53ca492d86cb72a4394bdad1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ee4ce7cca0b42fc81e5cae1b1b19a25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9c38cd0fcf7429e905732a6030b0115_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99ac4c08ddd043138479c7a929366808_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7107a8f3798a4b4f85c5c3934cc538a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42c4206352ed45c49b1ffe6a976a0723_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i067ec910ab5441abb89d5d73967bc967_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8738af8e5e5d481482a0aff98aacdf90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d50e8b499914bcd8bf4ea2da01301ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i671b7a2302524fd38cee3f6ff2f98b3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78530d2e8d6b45118714c099f29d8e67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00e1ab6155ce4b2ca7387b0e499b13ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8027a7afa87d4545a246f3cfa058ecc1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i775bc80f0b4046eb933f175fa23054be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i600f96952ca74888901fe56db25f0a9f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80a1b0b283de4323a915636bf3154c0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57e9c5b3387647bbbf9a05d29bc125b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48f7619e739144e8ad45877990dc8b4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6efa1b3c097d4e8bbb0044de2e0eb97e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00f996e674334831a4b702a6dab1227c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8731d482f54944dcbc86441135f6aadf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if30937e6ac3d4bb5a4c2184d7905886c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i452b8349934f45998316aa6b615f395c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9268c9e7d32a4d089a0df68305d6cdd8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icde2c819b2eb481a82769fd804c55108_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb910542d9424ab9b95e5810565ad466_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebf9a43b220342c69783776e723e023f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81f6869ed0c24ce4871816f7d2e7cb43_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba530d87b0864376a38558b02d16b8c3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a350670d64d4f1e800774de0810abc7_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id678a65bd8bf4578bec8bbcc0aa50cc6_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2318fc40c5a4044a5e207e06b104152_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0591f02f274c108fd4f307409ea95c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="repayment"><xbrli:measure>gild:repayment</xbrli:measure></xbrli:unit><xbrli:context id="i2149910737774396859ee858a7be3b62_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23a0d3b2005a437792898712c9d8fd19_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42858b3c72b14dd29fd0366fad42b66d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b6ed812482443698e8524ebc5028ef4_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e04a1496e924fd6aaa5cf09f6d3974b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib86f88f4366542d4b2110433d8eb2472_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a0dca0a129d4621881c8db9cee9561b_I20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueMay2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i424653e19ba342da9528563065ececec_D20160531-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueMay2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-31</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebfeba12e19f4f08b20c868b3c5aae4f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc9ab8f16b194dca9d59c47d3bca5701_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie345d4f41b194bbebb717ccc62b975f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i811b6102317d403db8c7febef98c0b3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if472a036278a4d88a49fe0a47d9404ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a0a5d98945240a491ca261188cf0b76_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f4cd81637934eb4bfcfc5bb4da29021_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06eb7508edc54e1d963da3d320aa56cd_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0515ea18ac744e009b23a9242a725ab9_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58312b3302b9493cb83df643b7d08e9a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i265d4a6f0a374d1dab17e075aed111ab_D20220201-20220201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib937eacd40624de4b33e1818017eaa04_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:PreExposureProphylaxisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>gild:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i7a0546071ccb452889c1fb141764dfef_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>gild:patent</xbrli:measure></xbrli:unit><xbrli:context id="i0639e3db3b664793a6beb77eb685f7b0_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f23bfe0992f40f3b1234a110848985b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2024ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="opposingparty"><xbrli:measure>gild:opposingParty</xbrli:measure></xbrli:unit><xbrli:context id="ie0d5cca66648457e8765b48c19c1fe65_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2026ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8a659c08da049ae986c9c29e62e00e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2032ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i225c85c01cb74eef9ba4b88802d3cdf6_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2027ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="party"><xbrli:measure>gild:party</xbrli:measure></xbrli:unit><xbrli:context id="ifa3f8743db084c41b63d403832f512f3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2027ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i327f548a38ab4392948582ff7fef469a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>gild:lawsuit</xbrli:measure></xbrli:unit><xbrli:unit id="plaintiff"><xbrli:measure>gild:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i25a9bfaaa2514554b1836ba98b4643cb_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:QuiTamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d943fc6896d42a2a402f7355165d0db_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2016StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0ac11cc10c94ff59a93bc7def17ae5b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88ed2a00d0174820ad767760e9f24578_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:PubliclyAnnouncedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a679c0b45db4ea5bbb87a138014433a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:PubliclyAnnouncedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic28e0d3d171544a895828b1b399da271_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:PubliclyAnnouncedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8488cd00ad754d66a2f89c28ef0113ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23e97ce3ab7e42c8b5eddc72bc3e2957_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee9756a76bba457e81595f5fdbe576fc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cc38953c3ec4d0c9b3cbf82dde62ac8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5501384b52f44d51a145ef3f4f3e7ca5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bea2cadcf9646f58956abc926e1586f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d11aa8c23bc48e69c02c674ce48e4b1_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bf6d6d327dd4e03a5847141baa75c2b_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea289ffec3b458087dccbfc47e573d0_D20220201-20220201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cf763f4ea7f4880a47f0e6a403877f4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff25d3116ceb4bbab1c6c9c8d145401c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9f1e0014a754c4cb3066bf85c4a2570_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa632be9dee643cc918655e93fa6c0f6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ba6a2a2d50c4a6db88d7c68e239a2b0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39bec68158bd4af6bb2c347ac792a9ae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f580454e7604d7785de9823f350085c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i031ae4d8e4484c4e9b1cadccb6c88ff9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7baa42c3821a4c50ae27b170e3c7858f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a7063cdae7438bb8481aee4e692325_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i193cbc90df134a0d9735d84dde8ed9ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d96d9b09d2a48cfa30e6bf373b5f762_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb145868ff1249dab7c2d803aac491ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie75f65899cfb4ee38ea27dd37daca0ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0afde8034f24eb688bd439bf07e61b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5240156832f4cc8ba8aa92faeec8f85_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d19504e53c460ebb2acf511d875bc6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a09a18820154418b65c5db65a9e8ef6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaea04c5cb73429c92a11dfc633c9a7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9f4f8bc79c4814960889868046cc5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a1104220914dc19840bbf261ce2cf7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica652e76a6974f3cb7f5a6d0f8d94017_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:GileadSciencesInc2004EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib59a14c778a94c75975c4acb8a10179d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:GileadSciencesInc2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba210e1a3e384daca10160c7ffbc3ee5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb5969787714c0d8190646f3cb425cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63aedd4c33d5433b8067d84fd5b6f093_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0729bf1c13614c1dbd5464ad3b216cd1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i354b6ee389b345259779247e1761d741_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i978af2e4f66d4a0598365cc6a4df3a60_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ac2832a817c4b079e7e753df575c2fd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7c2ae063b354630b9b4eb98c12579cb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea60cbe1d7984731a8c9400ef7641432_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6305a82bd394408e9eb61ee6d9a6b096_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icec935a6b97544d6a97b10b0c0f9a6b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8fcbd9748d94709b73ce8d6ca1b9f32_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09fef48c1da4be29e79de02aa01573a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e0958f8c926485eae5d31e7b78ed257_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35a87915496f4f0f918d93a07f297c71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17e83904e7c84fe4ba24ed426244affb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12f8795691e94495b697bd3ee9e10a01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f4fbfc0f6ca4a74b926e26a7212b4d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i092e7210064445688e64ea085cde62b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i597fc5ca87d64f79987a4deb4814a2cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb8bcd0d8ecf4205b8fe6029870b6fba_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f4b7466ad0243e69a21d012954cb83e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27e180b4cd6e425b8489f50bc779226d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74136efa08b74a10bd1a8c546eacd605_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bc9c86928c74673ab301285440c1661_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatVestingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c35aff509b4c369b6860cf48fb5cac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatVestingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b1a7a2d096046eea14fab1d821f637f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatVestingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff82fe9d37f642f6bd89267088886a42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icad35ac1806e4f21a40d3a0946de361d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife2e5f0230844117bbb72a6267db6609_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic63775c3a22e4db9805ee00e5e0ad2f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09ace142a66d4ef093c014ea5eb86836_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6851218a40374235b12bad014064a29d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ee369dd27f4f9fa86ebb38e3b71a65_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94fdbc3b74014794bf026a159fb15aa2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4d0883810134f519ae9afb0d14ed77a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i490b5d2fa50a4d27ba621c355f27e7c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bea36ad4f2b4224bf60b33eecac3150_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie16d6139caf042729e09c331c0223fee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ab5beb24194822982742d602f870c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77335a2113da496c800ece78587ef758_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie33787d4b92844f0b3f49ee4b16ba703_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.774%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">&#160;UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM185MA_21be1d2e-559b-43f3-8130-7d457782136f">10-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> </span></div><div style="padding-left:218.25pt;padding-right:218.25pt;text-indent:-220.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One) </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6ZTk3MzNlMDcyM2Y2NGMxNmI3NmNiZmE2OTI1OGM3ZGMvdGFibGVyYW5nZTplOTczM2UwNzIzZjY0YzE2Yjc2Y2JmYTY5MjU4YzdkY18wLTAtMS0xLTEyMTQw_d5f445be-c773-40d3-b230-29cf0ed72cc0">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18xMTI_c00c19b3-fd9e-465b-b3dc-cc0e410745f2"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18xMTI_f4edbe35-0c8c-46fa-8797-cefeb71d9e8d">December 31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or </span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6NzZkNmM1MjM2MDdmNGVhOGJjMTk2ZDdkMmVjMDkyMjQvdGFibGVyYW5nZTo3NmQ2YzUyMzYwN2Y0ZWE4YmMxOTZkN2QyZWMwOTIyNF8wLTAtMS0xLTEyMTQw_45b27e31-95bd-4d44-9cab-f134f4d99233">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:29.25pt;text-indent:-29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yMTg_8ef067a9-6cd6-4d9b-ba3c-082213d25eb1">000-19731</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yMjU_b0d26d83-63bc-46f0-b9c2-7518936d11ee">GILEAD SCIENCES, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.161%"><tr><td style="width:1.0%"></td><td style="width:48.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6OTNlYTlkMDM5MzM5NGIwM2IzYmVkMTBjMThlMzU5MzcvdGFibGVyYW5nZTo5M2VhOWQwMzkzMzk0YjAzYjNiZWQxMGMxOGUzNTkzN18wLTAtMS0xLTEyMTQw_6684fae1-b3da-4699-b550-e659b7231c08">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6OTNlYTlkMDM5MzM5NGIwM2IzYmVkMTBjMThlMzU5MzcvdGFibGVyYW5nZTo5M2VhOWQwMzkzMzk0YjAzYjNiZWQxMGMxOGUzNTkzN18wLTEtMS0xLTEyMTQw_283dbf85-42ba-4ba1-8cb9-f608a44faa37">94-3047598</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yOTA_802c4d34-e8cc-45f3-b991-64352256be82">333 Lakeside Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yOTQ_ab83156a-b406-4d66-8148-45702a609919">Foster City</ix:nonNumeric>, <ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yOTg_0655eca0-e67a-42c8-922d-ce96c64a7b20">California</ix:nonNumeric> <ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zMDE_ae62955f-def1-4f1a-b756-6a7832838ae4">94404</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices, Including Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNTc_a13ea46e-d8f4-4c79-a9d3-174525be8e14">650</ix:nonNumeric>-<ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNjA_5c6f116d-1e62-4768-9f2f-fa35c9b7d5fc">574-3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.026%"><tr><td style="width:1.0%"></td><td style="width:36.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6YTQ0YmE5OWU5Mjc3NGQyY2I1Mjk3NmIyNDdjMWYxOGUvdGFibGVyYW5nZTphNDRiYTk5ZTkyNzc0ZDJjYjUyOTc2YjI0N2MxZjE4ZV8xLTAtMS0xLTEyMTQw_2be205bb-27a9-48ef-814b-c369bb5a0110">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6YTQ0YmE5OWU5Mjc3NGQyY2I1Mjk3NmIyNDdjMWYxOGUvdGFibGVyYW5nZTphNDRiYTk5ZTkyNzc0ZDJjYjUyOTc2YjI0N2MxZjE4ZV8xLTItMS0xLTEyMTQw_d57322d0-9bc7-4c86-94ee-27aa595ad5fe">GILD</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6YTQ0YmE5OWU5Mjc3NGQyY2I1Mjk3NmIyNDdjMWYxOGUvdGFibGVyYW5nZTphNDRiYTk5ZTkyNzc0ZDJjYjUyOTc2YjI0N2MxZjE4ZV8xLTQtMS0xLTEyMTQw_ff0bdf85-e34f-4c77-887e-d62bb8371f0c">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Exchange Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> None</span></div><div style="margin-bottom:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM182MDM_3cb270a0-1b06-45ce-9968-cd604adf8a7b">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.&#160;&#160;&#160;&#160;Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;<ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM183NTM_fe49b166-ef4b-44a3-a886-52d1547fe5dc">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18xMTA3_c11d4671-6b43-4a76-aa14-7b135fdffb56">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18xNDQ0_8c415a4a-fd46-49af-97c2-d73258dc1a5a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18xNzc1_be3bc2e7-eb49-41e5-80d6-1d4e10cfe9e8">Large accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                  Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">       Non-accelerated&#160;filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNzcz_1be45fca-568d-43ff-a94d-c145ca15ea6e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">         Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNzc0_336331f8-9a6e-49a4-80f9-9e9bddf56e5a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNzc1_189f4819-d56e-4681-b37e-c085928875e2">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNzcw_00558739-192e-4773-9613-4aeee472f6fc">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based upon the closing price of its Common Stock on the Nasdaq Global Select Market on June&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i8055c5201bb24e4ba49e863f9223067f_I20210630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yODM5_3c4ed8f8-7500-4afa-bd28-f242d3d950a7">62.6</ix:nonFraction> billion.* </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant&#8217;s Common Stock on February&#160;18, 2022 was <ix:nonFraction unitRef="shares" contextRef="i115c1ea1db9c44ee8a4f7b1b25c2690f_I20220218" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yOTIx_a8e596f1-c23d-43a4-a41d-6e0b0ad30d60">1,253,886,724</ix:nonFraction></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNzcx_647719fc-656b-4557-bcfe-bcd7d2651cfb" escape="true">Specified portions of the registrant&#8217;s proxy statement, which will be filed with the Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2022 Annual Meeting of Stockholders, to be held on May 4, 2022, are incorporated by reference into Part&#160;III of this Report.</ix:nonNumeric> </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Based on a closing price of  $68.86 per share on June&#160;30, 2021. Excludes 344,972,966 shares of the registrant&#8217;s Common Stock held by executive officers, directors and any stockholders whose ownership exceeds 5% of registrant&#8217;s common stock outstanding at June&#160;30, 2021. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.</span></div><div style="padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.774%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Form 10-K Annual Report</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;I</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_16">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_19">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_22">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_25">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_28">30</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_34">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_1662">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_1662">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_40">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_64">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_64">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_67">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_67">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_157">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_157">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_163">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_163">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_166">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_166">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_1732">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_1732">100</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;III</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_172">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_172">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_175">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_175">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_178">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_178">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_181">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_181">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_184">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_184">101</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_190">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_190">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_196">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_196">104</a></span></div></td></tr><tr style="height:6pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_199">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_199">105</a></span></div></td></tr></table></div><div style="margin-top:8.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GILEAD SCIENCES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AMBISOME</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ATRIPLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BIKTARVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CAYSTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, COMPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DESCOVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DESCOVY FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EMTRIVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EPCLUSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EVIPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GENVOYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HARVONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HEPCLUDEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (BULEVIRTIDE), HEPSERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, JYSELECA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(FILGOTINIB), LETAIRIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ODEFSEY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RANEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SOVALDI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, STRIBILD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TECARTUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRODELVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRUVADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRUVADA FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TYBOST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VEKLURY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VEMLIDY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VIREAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VOSEVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, YESCARTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ZYDELIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This report also refers to trademarks, service marks and trade names of other companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;project,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;might,&#8221; &#8220;forecast,&#8221; and variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, any statements other than statements of historical fact are forward-looking statements, including statements regarding overall trends; operating cost and revenue trends; liquidity and capital needs; plans and expectations with respect to products, product candidates, corporate strategy, business and operations, financial projections and the use of capital; collaboration and licensing arrangements; ongoing litigation and investigation matters; statements regarding the anticipated future impact on our business of the ongoing coronavirus disease 2019 (&#8220;COVID-19&#8221;) and related public health measures; and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified in Part I, Item 1A of this Annual Report on Form 10-K under the heading &#8220;Risk Factors.&#8221; Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof unless otherwise specified. Except as required under federal securities laws and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;), we do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise. In evaluating our business, you should carefully consider the risks described in the section entitled &#8220;Risk Factors&#8221; under Part I, Item 1A of this Annual Report on Form 10-K. Any of the risks contained herein could materially and adversely affect our business, results of operations and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_13"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative medicines represent advancements by offering first-in-class treatments, greater efficacy, enhanced modes of delivery, more convenient treatment regimens, improved resistance profiles and reduced side effects. Our focus on innovation has allowed us to deliver marketed products across multiple therapeutic areas. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, our primary revenue-generating products and the approved indications in the United States were as follows:</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">HIV/AIDS</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Biktarvy is a single-tablet regimen of a fixed-dose combination of our antiretroviral medications, bictegravir, emtricitabine and tenofovir alafenamide (&#8220;TAF&#8221;).</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Genvoya is a single-tablet regimen of a fixed-dose combination of our antiretroviral medicines, elvitegravir, cobicistat, emtricitabine and TAF.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in certain patients. Descovy is a fixed-dose combination of our antiretroviral medications, emtricitabine and TAF. Descovy is also approved by U.S. Food and Drug Administration (&#8220;FDA&#8221;) for a pre-exposure prophylaxis (&#8220;PrEP&#8221;) indication to reduce the risk of sexually acquired HIV-1 infection in certain at-risk patients.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Odefsey is a single-tablet regimen of a fixed-dose combination of our antiretroviral medications, emtricitabine and TAF, and rilpivirine marketed by Janssen Sciences Ireland Unlimited Company, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson (&#8220;Janssen&#8221;).</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in certain patients. Truvada is a fixed-dose combination of our antiretroviral medications, tenofovir disoproxil fumarate (&#8220;TDF&#8221;) and emtricitabine. Truvada is also approved by FDA for a PrEP indication to reduce the risk of sexually acquired HIV-1 infection in certain at-risk patients.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">/Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. The product, marketed in the United States as Complera and in Europe as Eviplera, is a single-tablet regimen of a fixed-dose combination of our antiretroviral medications, TDF and emtricitabine, and Janssen&#8217;s rilpivirine hydrochloride.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Stribild is a single-tablet regimen of a fixed-dose combination of our antiretroviral medications, elvitegravir, cobicistat, TDF and emtricitabine.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation indicated as a complete regimen for the treatment of HIV-1 infection in certain patients. Atripla is a fixed-dose combination of our antiretroviral medications, TDF and emtricitabine, and Bristol-Myers Squibb Company (&#8220;BMS&#8221;)&#8217;s efavirenz. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">COVID-19</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(remdesivir), an injection for intravenous use, is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (&#8220;COVID-19&#8221;) in certain adults and children 12 years of age and older and weighing at least 88 pounds (40 kg) who are (i) hospitalized or (ii) not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death*. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*This indication received expedited approval by FDA in January 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Liver Diseases</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of a once-daily single-tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus (&#8220;HCV&#8221;) infection in adults and certain pediatric patients with genotype 1, 2, 3, 4, 5 or 6: (i) without cirrhosis or with compensated cirrhosis or (ii) with decompensated cirrhosis for use in combination with ribavirin. In addition, we have an authorized generic version of Epclusa distributed by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of a once-daily, single-tablet regimen of ledipasvir and sofosbuvir for the treatment of chronic HCV infection in: (i) adults with genotype 1, 4, 5 or 6 without cirrhosis or with compensated cirrhosis, (ii) adults with genotype 1 with decompensated cirrhosis, in combination with ribavirin, (iii) adults with genotype 1 or 4 who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin, or (iv) certain pediatric patients with genotype 1, 4, 5 or 6 without cirrhosis or with compensated cirrhosis. In addition, we have an authorized generic version of Harvoni distributed by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of a once-daily, single-tablet regimen of sofosbuvir, velpatasvir and voxilaprevir for the re-treatment of chronic HCV infection in adults: (i) with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen or (ii) with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of TAF dosed once a day for the treatment of chronic hepatitis B virus (&#8220;HBV&#8221;) infection in adults with compensated liver disease.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of TDF dosed once a day for the treatment of chronic HBV infection in adults and certain pediatric patients. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Hematology/Oncology/Cell Therapy</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (axicabtagene ciloleucel), a suspension for intravenous infusion, is a chimeric antigen receptor (&#8220;CAR&#8221;) T-cell therapy for the treatment of (i) adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma, and (ii) adult patients with relapsed or refractory follicular lymphoma (&#8220;FL&#8221;) after two or more lines of systemic therapy*. </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*This indication is approved under accelerated approval by FDA, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brexucabtagene autoleucel), a suspension for intravenous infusion, is a CAR T cell therapy for the treatment of (i) adult patients with relapsed or refractory mantle cell lymphoma (&#8220;MCL&#8221;) and (ii) adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (&#8220;ALL&#8221;). </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(sacituzumab govitecan-hziy), an injection for intravenous use, is a Trop-2 directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of (i) adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (&#8220;TNBC&#8221;) who have received two or more prior systemic therapies, at least one of them for metastatic disease, and (ii) adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (&#8220;PD-1&#8221;) or programmed death-ligand 1 (&#8220;PD-L1&#8221;) inhibitor*. </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*This indication is approved under accelerated approval by FDA, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (idelalisib) is an oral formulation of a kinase inhibitor for the treatment of patients with relapsed chronic lymphocytic leukemia, in combination with rituximab, for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ambrisentan) is an oral formulation of an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;) (WHO Group I) (i) to improve exercise capacity and delay clinical worsening or (ii) in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. </span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ranolazine) is an oral formulation of an extended-release tablet of an antianginal for the treatment of chronic angina. </span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amphotericin B liposome for injection) is a proprietary liposomal formulation of amphotericin B, an antifungal agent, for the treatment of serious invasive fungal infections caused by various fungal species in adults.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our revenue-generating products, including the amount of revenue contributed by the products listed above, see Note 2. Revenues of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Share and Other Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also generate revenues from other activities, including revenue share from combination products, royalties for outbound licenses of our intellectual property and other payments received from our collaborations with third-party partners. For example, pursuant to our collaboration with Janssen, we receive revenue share from cobicistat, emtricitabine and TAF that are components of Symtuza (darunavir/cobicistat/emtricitabine/TAF), a fixed-dose combination product commercialized by Janssen. We include our revenue share from Symtuza in our Product sales. For a description of our collaborations with Janssen and other partners, see Note 11. Collaborations and Other Arrangements of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization and Distribution</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have U.S. and international commercial sales operations, with marketing subsidiaries in more than 35 countries. Our products are marketed through our commercial teams and/or in conjunction with third-party distributors and corporate partners. Our commercial teams promote our products through direct field contact with physicians, hospitals, clinics and other healthcare providers. We generally grant our third-party distributors the exclusive right to promote our product in a territory for a specified period of time. Most of our agreements with these distributors provide for collaborative efforts between the distributor and Gilead in obtaining and maintaining regulatory approval for the product in the specified territory.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell and distribute most of our products in the United States exclusively through the wholesale channel. During the year ended December&#160;31, 2021, approximately 91% of our product sales in the United States and approximately 65% of our total worldwide revenues were to three large wholesalers, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. We sell and distribute our products in Europe and countries outside the United States where the product is approved, either through our commercial teams, third-party distributors or corporate partners.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive environment. We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers. Our products compete with other commercially available products based primarily on efficacy, safety, tolerability, acceptance by doctors, ease of patient compliance, ease of use, price, insurance and other reimbursement coverage, distribution and marketing. As our products mature, pricing pressures from private insurers and government payers often result in a reduction of the net product prices. Further, as new branded or generic products are introduced into major markets, our ability to maintain pricing and market share may be affected. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development (&#8220;R&amp;D&#8221;) mission is to discover and develop transformational therapies in areas of high unmet medical need. Our product development efforts are focused primarily in viral diseases, inflammatory diseases and oncology. Our team of research scientists is engaged in the discovery and development of new molecules and technologies that we hope will lead to the approval of innovative medicines and therapies that will advance the current standard of care and address unmet medical needs. We intend to continue committing significant resources to internal R&amp;D opportunities and external business development activity to drive innovation and growth of our business. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of product candidates and investigational therapies in our pipeline is subject to various risks and uncertainties. These risks and uncertainties include our ability to enroll patients in clinical trials, the possibility of unfavorable results of our clinical trials, the need to modify or delay our clinical trials, including on account of clinical holds placed by regulatory authorities, or to perform additional trials and the risk of failing to obtain regulatory approvals. As a result, our product candidates and investigational therapies may never be successfully commercialized. Drug development is inherently risky, and many product candidates and investigational therapies fail during the development process.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we continued to invest in and advance our R&amp;D pipeline across our therapeutic areas. Below is a summary of our product candidates that were in Phase 3 or registrational Phase 2 clinical trials or pending marketing authorization review by FDA or European Medicines Agency (&#8220;EMA&#8221;) as of the end of 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Candidates in Viral Diseases</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Candidates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulatory Filings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lenacapavir</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A New Drug Application and a Marketing Authorization Application have been filed with FDA and EMA, respectively, for lenacapavir, an HIV capsid inhibitor, as a component of a long-acting regimen for the treatment of HIV infection in heavily treatment-experienced people living with HIV. It has been granted Breakthrough Therapy designation by FDA for this indication.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bulevirtide</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A Biologics License Application has been filed with FDA for bulevirtide for the treatment of chronic hepatitis delta virus (&#8220;HDV&#8221;) infection. It has been granted both Orphan Drug and Breakthrough Therapy designations by FDA for this indication. In Europe, Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (bulevirtide) has been granted Conditional Marketing Authorization by the European Commission and PRIority MEdicines (PRIME) scheme eligibility by the EMA as the first approved treatment in adults with chronic HDV infection with compensated liver disease.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lenacapavir</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lenacapavir is being evaluated for an HIV PrEP indication. Program timeline is pending resolution of clinical hold placed by FDA on studies evaluating injectable lenacapavir.</span></div></td></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Candidates in Inflammatory Diseases</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Product Candidate</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Description</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cilofexor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cilofexor, an FXR agonist, is being evaluated for the treatment of primary sclerosing cholangitis.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filgotinib</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filgotinib, a JAK1 inhibitor, is being evaluated for the treatment of Crohn&#8217;s disease.</span></td></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Candidates in Oncology</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Candidates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulatory Filings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Yescarta (axicabtagene ciloleucel)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A supplemental Biologics License Application and a Type II Variation Marketing Authorization Application have been filed with FDA and EMA, respectively, for axicabtagene ciloleucel, a CAR T cell therapy for the treatment of second-line DLBCL.<br/>A Type II Variation Marketing Authorization Application has been filed with EMA for axicabtagene ciloleucel for the treatment of relapsed or refractory FL. Yescarta has received accelerated approval by FDA for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tecartus (brexucabtagene autoleucel)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A Type II Variation Marketing Authorization Application has been filed with EMA for brexucabtagene autoleucel, a CAR T cell therapy, for the treatment of adult ALL. Tecartus has received FDA approval for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sacituzumab govitecan-hziy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sacituzumab govitecan-hziy, a Trop-2 directed antibody and topoisomerase inhibitor conjugate, is being evaluated for (i) hormone receptor positive (&#8220;HR+&#8221;), human epidermal growth factor receptor 2 negative (&#8220;HER2-&#8221;), metastatic breast cancer and (ii) non-small cell lung cancer (&#8220;NSCLC&#8221;) as a second-line or third-line treatment.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Magrolimab</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Magrolimab, an anti-CD47, is being evaluated for (i) higher risk myelodysplastic syndrome (&#8220;MDS&#8221;) as a first-line treatment and (ii) acute myeloid leukemia (&#8220;AML&#8221;) as a first-line treatment. Program timelines are pending resolution of partial clinical holds placed by FDA on studies evaluating magrolimab.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Zimberelimab*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Zimberelimab, an </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">anti-PD-1 monoclonal antibody, is being evaluated for NSCLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as a first-line treatment.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Domvanalimab*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Domvanalimab, an </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fc-silent anti-TIGIT antibody, is being evaluated for NSCLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as a first-line treatment.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Registrational Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel is being evaluated for the treatment of pediatric ALL.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*In collaboration with Arcus Biosciences, Inc. (&#8220;Arcus&#8221;). See Note 11. Collaborations and Other Arrangements of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for additional information regarding this collaboration.</span></div><div><span><br/></span></div><div style="margin-bottom:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we also received regulatory approvals or authorizations from FDA and the European Commission to expand the indications of our products, including:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.866%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulatory Approval or Authorization</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biktarvy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approved a new low-dose tablet dosage form of Biktarvy for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Epclusa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approved an expansion of the pediatric indication of Epclusa for the treatment of chronic HCV infection to include pediatric patients 3 years of age and older, regardless of HCV genotype or liver disease severity.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Veklury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European Commission approved a variation to the Conditional Marketing Authorization for Veklury to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Yescarta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA granted accelerated approval of Yescarta for the treatment of adult patients with relapsed or refractory FL.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tecartus</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approved Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Trodelvy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA granted full approval of Trodelvy for adult patients with unresectable locally advanced or metastatic TNBC. FDA granted accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic UC. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European Commission granted marketing authorization for Trodelvy as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease.</span></div></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we seek to enhance our commercial portfolio and clinical pipeline across multiple therapeutic areas through acquisitions, in-licensing and strategic collaborations. For example, in October 2021, we entered into a clinical trial collaboration with Merck Sharp &amp; Dohme, Corp., a subsidiary of Merck &amp; Co., Inc. (&#8220;Merck&#8221;), to evaluate Trodelvy in combination with Merck&#8217;s Keytruda in patients with first-line metastatic TNBC. In November 2021, we expanded our research collaboration with Arcus and exercised our options to three programs in Arcus&#8217;s clinical-stage portfolio, including domvanalimab, which is in Phase 2 and 3 studies in NSCLC. Our strategic business development activity reflects our commitment to focus on transformative science, build a sustainable and diverse portfolio and position ourselves for the near-, medium- and long-term growth of our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. and European Patent Expiration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of U.S. and foreign patents, patent applications and rights to patents related to our compounds, products and technology, but we cannot be certain that issued patents will be enforceable or provide adequate protection or that pending patent applications will result in issued patents.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the estimated expiration dates (including patent term extensions, supplementary protection certificates and/or pediatric exclusivity where granted) in the United States and the European Union for the primary (typically compound) patents for our key product candidates as described above. For our product candidates that are fixed-dose combinations of single-tablet regimens, the estimated patent expiration date provided corresponds to the latest expiring compound patent for one of the active ingredients in the single-tablet regimen.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Key Product Candidates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Patent Expiration</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">U.S.</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">E.U.</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Viral Diseases:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Lenacapavir</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2037</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2037</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bulevirtide</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Inflammatory Diseases:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cilofexor</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2032</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2032</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Filgotinib</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Oncology:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Axicabtagene ciloleucel</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2031</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Sacituzumab govitecan-hziy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Magrolimab</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2031</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2031</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Zimberelimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2036</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2036</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Domvanalimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2037</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2036</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;The composition of matter patent has expired in the European Union. In the European Union and the United States, patent applications are pending relating to proprietary manufacturing processes of Kite, a Gilead company (&#8220;Kite&#8221;).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;An application for patent term extension was filed in the United States that, if granted, would extend the U.S. expiration date to at least 2028. Regulatory exclusivity in the United States expires in 2032.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In collaboration with Arcus.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the actual or estimated expiration dates (including patent term extensions, supplementary protection certificates and/or pediatric exclusivity where granted) in the United States and the European Union for the primary (typically compound) patents for our principal products. For our products that are fixed-dose combinations or single-tablet regimens, the estimated patent expiration dates provided correspond to the latest expiring compound patent for one of the active ingredients in the single-tablet regimen.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Products</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Patent Expiration</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">U.S.</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">E.U.</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ranexa</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2019</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2023</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Descovy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2026</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vemlidy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2026</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Complera/Eviplera</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2026</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Zydelig</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Odefsey</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2026</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Yescarta</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2031</span></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stribild</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2028</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Genvoya</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2028</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Harvoni</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Epclusa</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2033</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2032</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Biktarvy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2033</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2033</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vosevi</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2034</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2033</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Veklury</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2035</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2035</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tecartus</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Trodelvy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Jyseleca</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hepcludex</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">These estimated expiration dates do not include any potential additional exclusivity (e.g., patent term extensions, supplementary protection certificates or pediatric exclusivity) that has not yet been granted.</span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In 2013, Gilead and Lupin Limited reached an agreement to settle a patent litigation matter related to Ranexa.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Applications for patent term extensions are pending in the United States and/or SPCs are pending in one or more countries in the European Union for these products.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;The composition of matter patent has expired in the European Union. In the European Union and the United States, patent applications are pending relating to proprietary manufacturing processes of Kite.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In 2018, Gilead and Mylan Pharmaceuticals reached an agreement to settle the patent litigation concerning patents that protect cobicistat in our Stribild and Genvoya products.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;An application for patent term extension was filed in the United States that, if granted, would extend the U.S. expiration date to at least 2028. Regulatory exclusivity in the United States expires in 2032.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Protection and Certain Challenges </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are very important to our business. If we have a properly drafted and enforceable patent, it can be more difficult for our competitors to use our technology to create competitive products and more difficult for our competitors to obtain a patent that prevents us from using technology we create. As part of our business strategy, we actively seek patent protection both in the United States and internationally and file additional patent applications, when appropriate, to cover improvements in our compounds, products and technology.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents covering certain of the active pharmaceutical ingredients (&#8220;API&#8221;) of most of our HIV products as well as cell therapy products are held by third parties. We acquired exclusive rights to these patents in the agreements we have with these parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may obtain patents for certain products many years before marketing approval is obtained. Because patents have a limited life that may begin to run prior to the commercial sale of the related product, the commercial value of the patent may be limited. However, we may be able to apply for patent term extensions or supplementary protection certificates in some countries. For example, extensions for the patents or supplementary protection certificates on many of our products have been granted in the United States and in a number of European countries, compensating in part for delays in obtaining marketing approval. Similar patent term extensions may be available for other products we are developing, but we cannot be certain we will obtain them in some countries.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also important that we do not infringe the valid patents of third parties. If we infringe the valid patents of third parties, our reputation may be harmed and we may be required to pay significant monetary damages, we may be prevented from commercializing products or we may be required to obtain licenses from these third parties. We may not be able to obtain alternative technologies or any required license on reasonable terms or at all. If we fail to obtain these licenses or alternative technologies, we may be unable to develop or commercialize some or all of our products. For example, we are aware of patents and patent applications owned by other parties that such parties may claim to cover the use of sofosbuvir, axicabtagene ciloleucel, brexucabtagene autoleucel, tenofovir disoproxil, tenofovir alafenamide and bictegravir.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications are confidential for a period of time until a patent is issued, we may not know if our competitors have filed patent applications for technology covered by our pending applications or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent applications. Competitors may have filed patent applications or received patents and may obtain additional patents and proprietary rights that block or compete with our products. In addition, if competitors file patent applications covering our technology, we may have to participate in litigation, post-grant proceedings before the U.S. Patent and Trademark Office or other proceedings to determine the right to a patent or validity of any patent granted. Such litigation and proceedings are unpredictable and expensive, and could divert management attention from other operations, such that, even if we are ultimately successful, we may be adversely impacted. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents relating to pharmaceutical, biopharmaceutical and biotechnology products, compounds and processes such as those that cover our existing compounds, products and processes and those that we will likely file in the future, do not always provide complete or adequate protection. Future litigation or other proceedings regarding the enforcement or validity of our existing patents or any future patents could result in the invalidation of our patents or substantially reduce their protection. From time to time, certain individuals or entities may challenge our patents.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending patent applications and the patent applications filed by our collaborative partners may not result in the issuance of any patents or may result in patents that do not provide adequate protection. As a result, we may not be able to prevent third parties from developing compounds or products that are closely related to those which we have developed or are developing. In addition, certain countries do not provide effective enforcement of our patents, and third-party manufacturers may be able to sell generic versions of our products in those countries.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant pending legal proceedings, see Note 14. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. See also Item&#160;1A Risk Factors &#8220;Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade Secrets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on unpatented trade secrets and improvements, unpatented internal know-how and technological innovation. For example, a great deal of our liposomal manufacturing expertise, which is a key component of our liposomal technology, is not covered by patents but is instead protected as a trade secret. We protect these rights mainly through confidentiality agreements with our corporate partners, employees, consultants and vendors. These agreements provide that all confidential information developed or made known to an individual during the course of their relationship with us will be kept confidential and will not be used or disclosed to third parties except in specified circumstances. In the case of employees, the agreements provide that all inventions made by an individual while employed by us will be our exclusive property. We cannot be certain that these parties will comply with these confidentiality agreements, that we have adequate remedies for any breach or that our trade secrets, internal know-how or technological innovation will not otherwise become known or be independently discovered by our competitors. Under some of our R&amp;D agreements, inventions become jointly owned by us and our corporate partners and in other cases become the exclusive property of one party. In certain circumstances, it can be difficult to determine who owns a particular invention and disputes could arise regarding those inventions. If our trade secrets or confidential information become known or independently discovered by competitors, or if we enter into disputes over ownership of inventions, our business and results of operations could be adversely affected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Raw Materials</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are manufactured either at our own facilities or by third-party contract manufacturers. We depend on third parties to perform manufacturing activities for the majority of our API and drug products. For most of our products, including our HIV and HCV products, we use multiple third-party contract manufacturers so that we have primary and back-up suppliers and manufacturing sites. For our cell therapy products, we have established clinical and commercial manufacturing facilities for cell processing activities. For our future products, we continue to develop additional manufacturing capabilities and establish additional third-party suppliers to manufacture sufficient quantities of our product candidates to undertake clinical trials and to manufacture sufficient quantities of any product that is approved for commercial sale.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Manufacturing Facilities </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease manufacturing facilities to manufacture and distribute certain products and API for clinical and/or commercial uses. These facilities include:</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foster City, California: We conduct process chemistry research and formulation development activities, manufacture API and drug product for our clinical trials and oversee our third-party contract manufacturers.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">San Dimas and La Verne, California: We manufacture AmBisome and also package and label the majority of our commercial products for distribution to the Americas and Pacific Rim.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Oceanside, California: We utilize the facility for clinical manufacturing and process development of our biologics candidates.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">El Segundo, California: We utilize the facility for clinical and commercial manufacturing and processing of our cell therapy products.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Frederick, Maryland: We utilize the facility for clinical manufacturing and processing of our cell therapy products.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Morris Plains, New Jersey: We utilize the facility for manufacturing for monoclonal antibody intermediate and process optimization of our antibody drug conjugate products.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cork and Dublin, Ireland: We utilize the Cork facility for commercial manufacturing, packaging and labeling of our products. We also perform quality control testing, labeling, packaging and final release of many of our products at the Cork facility, which are distributed to the European Union and other international markets through our facility in Dublin. We utilize our other facility in central Dublin as a drug development hub for our pediatric programs where we perform clinical development, safety, quality, biostatistics and data sciences, regulatory and compliance functions. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Edmonton, Canada: We conduct process chemistry research and scale-up activities for our clinical development candidates, manufacture API for both investigational and commercial products and conduct chemical development activities to improve existing commercial manufacturing processes.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hoofddorp, Netherlands: We utilize the facility for commercial manufacturing and processing of our cell therapy products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third-Party Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the technology we use to manufacture our products is proprietary. For products manufactured by our third-party contract manufacturers, we have disclosed all necessary aspects of this technology to enable them to manufacture the products for us. We have agreements with these third-party manufacturers that are intended to restrict them from using or revealing this technology, but we cannot be certain that these third-party manufacturers will comply with these restrictions. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information about our third-party manufacturers, see Item&#160;1A Risk Factors &#8220;We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Manufacturing Process</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for pharmaceutical products is highly regulated and regulators may shut down manufacturing facilities that they observe do not comply with regulations. We, our third-party manufacturers and our corporate partners are subject to current Good Manufacturing Practices (&#8220;GMP&#8221;), which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by FDA and the EMA. Similar regulations are in effect in other jurisdictions. Our manufacturing operations are subject to routine inspections by regulatory agencies. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our cell therapy products, we are required by FDA to comply with the Risk Evaluation and Mitigation Strategy program, which includes educating and certifying medical personnel regarding the therapy procedures and the potential side effect profile of our therapy, such as the potential adverse side effects related to cytokine release syndrome and neurologic toxicities. Additionally, we are required to maintain a complex chain of identity and custody with respect to patient material as such material moves to the manufacturing facilities, through the manufacturing process, and back to the patient.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Access to Raw Materials </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need access to certain raw materials to conduct our clinical trials and manufacture our products. These raw materials are generally available from multiple sources, purchased worldwide and normally available in quantities adequate to meet the needs of our business. We attempt to manage the risks associated with our supply chain by inventory management, relationship management and evaluation of alternative sources when feasible. For more information, see Item&#160;1A Risk Factors &#8220;We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead&#8217;s success depends on the work of its dedicated employees who embrace a shared sense of purpose and a culture of excellence. Our human capital objective is to make Gilead the employer of choice for the best talent in our industry. Gilead&#8217;s key priorities for human capital management include inclusion and diversity, health and safety, total rewards, employee development and engagement. The Compensation and Talent Committee of our Board of Directors oversees our overall human capital management. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inclusion &amp; Diversity</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusion is a Gilead core value, and we believe building an inclusive and diverse workforce is critical to enabling Gilead&#8217;s mission. Our Global Inclusion and Diversity Council is responsible for governance of these matters, tracking progress on our goals and promoting a culture of inclusion. The Global Inclusion and Diversity Council is chaired by our Chairman and Chief Executive Officer and includes members of our leadership team. In 2020, we introduced our Advancing Black Leadership Strategy, a multi-year initiative that outlines our commitments to create internal and external pipelines for diverse talent and to build awareness, capabilities and accountability among our people managers. As part of this strategy, we set clear targets for representation within our overall workforce and executive populations, including goals to increase the percentage of female, Black and Hispanic employees with well-defined annual targets through 2025. Gilead also implemented multiple programs to train managers on inclusion and diversity topics, and created strategies and initiatives focused on attracting, developing and retaining diverse talent and driving an inclusive culture in our workplace, which organizational leaders were required to regularly review starting in 2021. In addition, our employee resource groups (&#8220;ERGs&#8221;) support diverse employees and aim to raise awareness of different cultures within the workplace, cultivate diversity as a business strength and support Gilead&#8217;s talent acquisition strategy to source, attract and recruit diverse candidates. Executive sponsors and leaders of our ERGs contribute to the advancement of our inclusion and diversity commitments through service on our Global Inclusion and Diversity Council.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Gilead&#8217;s inclusive and diverse workforce is the foundation for innovation and productivity. Gilead&#8217;s commitment to equal employment opportunity furthers its efforts to cultivate and celebrate an equitable culture of belonging. As of December&#160;31, 2021, Gilead had approximately 14,400 employees, and Gilead&#8217;s global workforce was approximately 52% female and 48% male. Additionally, women represented 34% of Gilead&#8217;s leadership (defined as vice president level and above). In the United States, based on our employees&#8217; voluntary self-identification, our workforce was 40% White, 38% Asian, 11% Hispanic, 7% Black and 4% Other.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health and Safety</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead is committed to providing a workplace for its employees that promotes health, safety, wellness and productivity. We have a workplace safety, training and security program together with various compliance protocols to support this commitment. We routinely train and educate our employees on workplace safety and security. In response to the COVID-19 pandemic, most Gilead sites required flexible location employees to work from home, while employees who needed to be physically present for their positions (such as laboratory technicians) continued to work at Gilead sites. In the fourth quarter of 2021, Gilead transitioned to a return-to-site phase for our U.S. flexible location employees. During the pandemic, we implemented job site enhancements and risk protocols, including health screenings, COVID-19 testing and vaccine requirements, reconfiguration of work and common spaces to allow for physical distancing, in our effort to support the safe occupancy of our sites. Gilead also maintains a robust contact tracing and notification process for any employee who reports COVID-19 infection. We continue to monitor the state of the pandemic and we remain committed to maintaining a work environment that promotes the health, safety and productivity of our workforce.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Rewards</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead&#8217;s compensation and benefits programs are designed to help attract, develop and retain the industry&#8217;s most talented workforce. Our Total Rewards program (which varies by country) includes competitive base salary and incentive compensation, stock awards, an employee stock purchase plan, a 401(k) savings plan with a company match that vests immediately, health and welfare and other valuable benefits, such as flexible work arrangements, flexible spending accounts, paid time off, family leave, family care resources, fertility, adoption and surrogacy assistance, student loan repayment and tuition assistance, employee assistance programs, global wellbeing reimbursement and tuition assistance, among many others. Each year, we reassess our Total Rewards package to confirm whether it offers benefits and incentives that align with our total reward philosophy.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a pay-for-performance company and are committed to addressing pay equity. Our employee salaries are informed by market-based ranges and are assessed annually through performance and career development reviews. Our policy is that compensation decisions are made without regard to personal characteristics such as gender, race, color, national or ethnic origin, age, disability, sexual orientation, gender identity or expression, genetic information, religion, or veteran status. We also conduct an annual pay equity review of employee compensation in an effort to strive to make our pay practices gender and race neutral. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Development and Engagement</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee development and engagement maximizes the potential and performance of each member of our workforce and is critical to achieving our business goals. Gilead offers a number of internal and external professional, management and leadership development training programs to help our employees develop technical, cross-functional and leadership skills and tools to grow their careers. In addition, employees can receive reimbursement for tuition expenses incurred while pursuing undergraduate, graduate or certificate courses at an accredited college or university.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we strive to be the employer of choice in our industry, our listening strategy gathers input from our employees to shape our engagement strategies and programs and measure our progress. In addition to ongoing internal and external data collection, we conducted a large-scale review of the employee experience in 2021 with an employee survey. The results of this survey played a key role in determining the direction of our culture as well as the company&#8217;s broader response to the continuing COVID-19 pandemic, including the meaningful benefits we provided to employees and our approach to flexible work arrangements. We believe our flexible work program positions us to be competitive for talent and support employee well-being while also creating the collaborative environment and connections that fuel innovation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Social and Governance (&#8220;ESG&#8221;) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in corporate responsibility is core to our business strategy and reflects our values of accountability, inclusion, teamwork, excellence and integrity. This is in service to our mission to advance global health by providing innovative therapeutics in areas of unmet need in a way that is socially responsible and environmentally sustainable. Gilead&#8217;s ESG programs reflect this commitment to our stakeholders. ESG strategy and performance are overseen by the Nominating and Corporate Governance Committee of its Board of Directors, and managed by a Corporate Responsibility Committee comprised of leaders from key departments across our company. The Corporate Responsibility Committee is responsible for reviewing material ESG issues and integrating them into our overall business strategy and operations. Additional information about this program and ESG highlights are available in Gilead&#8217;s 2020 year in review under Gilead&#8217;s website at www.gilead.com/news-and-press/annual-report/year-in-review-2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ESG goals are aspirational and may change. Statements regarding these goals and related initiatives are not guarantees or promises that they will be met.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality of Operations</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our worldwide product sales do not reflect any significant degree of seasonality in end-user demand. However, in the United States, fluctuations in wholesaler inventory levels impact our product sales. We typically observe strong wholesaler and sub-wholesaler purchases of our products in the fourth quarter resulting in inventory draw-down by wholesalers and sub-wholesalers in the subsequent first quarter. Several other factors, including government budgets, annual grant cycles for federal and state funds, the COVID-19 pandemic, and other buying patterns, also could impact the product sales recorded in a particular quarter. For more information, see Item&#160;1A Risk Factors &#8220;We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories.&#8221;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and activities are subject to extensive regulation by numerous government authorities in the United States, the European Union and other countries, including laws and regulations governing the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of our products. As a result of these regulations, product development and product approval processes are very expensive and time consuming, which has a significant impact on our capital expenditures and results of operations. The regulatory requirements applicable to drug development and approval are subject to change. Any legal and regulatory changes may impact our operations in the future.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A country&#8217;s regulatory agency, such as FDA in the United States and the EMA and European Commission for the European Union, as well as the national authorities of the European Union Member States, must approve a drug before it can be sold in the respective country or countries. The general process for drug approval in the United States is summarized below. Many other countries, including countries in the European Union (and the European Union under a centralized procedure), have similar regulatory structures.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Testing</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can test a drug candidate in humans, we must study the drug in laboratory experiments and in animals to generate data to support the drug candidate&#8217;s potential benefits and safety. We submit this data to FDA in an investigational new drug (&#8220;IND&#8221;) application seeking its approval to test the compound in humans.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If FDA accepts the IND, the drug candidate can then be studied in human clinical trials to determine if the drug candidate is safe and effective. These clinical trials involve three separate phases that often overlap, can take many years and are very expensive. These three phases, which are subject to considerable regulation, are as follows:</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1. The drug candidate is given to a small number of healthy human control subjects or patients suffering or at risk from the indicated disease, to test for safety, dose tolerance, pharmacokinetics, metabolism, distribution and excretion.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2. The drug candidate is given to a limited patient population to determine the effect of the drug candidate in treating or preventing the disease, the best dose of the drug candidate, and the possible side effects and safety risks of the drug candidate. It is not uncommon for a drug candidate that appears promising in Phase 1 clinical trials to fail in the more rigorous and extensive Phase 2 clinical trials.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3. If a drug candidate appears to be effective and have an appropriate safety profile in Phase 2 clinical trials, Phase 3 clinical trials are commenced to confirm those results. Phase 3 clinical trials are conducted over a longer term, involve a significantly larger population, are conducted at numerous sites in different geographic regions and are carefully designed to provide reliable and conclusive data regarding the safety and benefits of a drug candidate. It is not uncommon for a drug candidate that appears promising in Phase 2 clinical trials to fail in the more rigorous and extensive Phase 3 clinical trials.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FDA Approval Process</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we believe that the data from our clinical trials show an acceptable benefit-risk profile, we submit the appropriate filing, usually in the form of a New Drug Application, Biologics License Application or supplemental application, with FDA, seeking approval to sell the drug candidate for a particular use. At FDA&#8217;s discretion, FDA may hold a public hearing where an independent advisory committee of expert advisors asks additional questions and makes recommendations regarding the drug candidate. This committee makes a recommendation to FDA that is not binding but is generally followed by FDA. If FDA agrees that the drug has met the required level of safety and efficacy for a particular use, it will approve the application and allow us to sell the drug in the United States for that use. It is not unusual, however, for FDA to decline to approve an application because it believes that the drug candidate is not safe enough or efficacious enough (i.e., does not have an appropriate benefit-risk profile) or because it does not believe that the data submitted is reliable or conclusive.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any point in this process, the development of a drug candidate can be stopped for a number of reasons, including safety concerns, lack of treatment benefit or manufacturing issues. We cannot be certain that any clinical trials that we are currently conducting or any that we conduct in the future will be completed successfully or within any specified time period. We may choose, or FDA may require us, to delay or suspend our clinical trials at any time if it appears that patients are being exposed to an unacceptable health risk or if the drug candidate does not appear to have sufficient treatment benefit.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after approving a drug, FDA may also require Phase 4 non-registrational studies to explore scientific questions to further characterize safety and efficacy during commercial use of our drug. FDA may also require us to provide additional data or information, improve our manufacturing processes, procedures or facilities or may require extensive surveillance to monitor the safety or benefits of our product candidates if it determines that our filing does not contain adequate evidence of the safety and benefits of the drug. In addition, even if FDA approves a drug, it could limit the uses of the drug. FDA can withdraw approvals if it does not believe that we are complying with regulatory standards or if concerns about the safety or efficacy are uncovered or occur after approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to obtaining FDA approval for each drug, we obtain FDA approval of the manufacturing facilities for any drug we sell, including those of companies who manufacture our drugs for us. All of these facilities are subject to periodic inspections by FDA. FDA must also approve foreign establishments that manufacture products to be sold in the United States and these facilities are subject to periodic regulatory inspection. Our manufacturing facilities located in California also must be licensed by the State of California in compliance with local regulatory requirements. Our manufacturing facilities in Canada, Ireland and Netherlands also must obtain local licenses and permits in compliance with local regulatory requirements.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA may employ one of several tools to facilitate and expedite the development and review of a drug, including fast track designation, Breakthrough Therapy designation, accelerated approval and Priority Review designation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast track designation is designed to facilitate the development and review of a drug that treats a serious condition and fills an unmet medical need. Breakthrough Therapy designation is designed to expedite the development and review of a drug that treats a serious condition and preliminary clinical evidence demonstrates substantial improvement over available therapies. Accelerated approval of a drug may be granted by FDA where the drug treats a serious condition, fills an unmet medical need and has been studied for safety and efficacy. Priority Review designation means FDA&#8217;s goal is to take action on an application within six months of filing. FDA may grant Priority Review designation to a drug that would provide significant improvement in the safety or effectiveness of a treatment, diagnosis or prevention of a serious condition. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union Regulatory System and Approval Process</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union (&#8220;EU&#8221;), our products are subject to a variety of EU and EU Member State regulations governing clinical trials, commercial sales and distribution. We are required to obtain a marketing authorization in the EU before we can market our medicinal products on the relevant market. The conduct of clinical trials in the EU is governed by, among others, Directive 2001/20/EC and Directive 2005/28/EC and the EU (ICH) Good Clinical Practice rules. These impose legal and regulatory obligations that are similar to those provided in applicable U.S. laws. The conduct of clinical trials in the EU must be approved by the competent authorities of each EU Member States in which the clinical trials take place, and a positive opinion must be obtained from the relevant Ethics Committee in the relevant Member State. In 2014, the EU legislator adopted Regulation (EU) No 536/2014 to replace Directive 2001/20/EC and to introduce a coordinated procedure for authorization of clinical trials. This Regulation entered into application in January 2022. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing authorization holders, manufacturers, importers, wholesalers and distributors of medicinal products placed on the market in the EU are required to comply with a number of regulatory requirements including pharmacovigilance, GMP compliance and the requirement to obtain manufacturing, import and/or distribution licenses issued by the competent authorities of the EU Member States. Failure to comply with these requirements may lead to the imposition of civil, criminal or administrative sanctions, including suspension of marketing or manufacturing authorizations.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pricing and Reimbursement</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of our products depends, in part, on the availability of third-party payer reimbursement for the cost of such products and related treatments and medical services in the markets where we sell our products. Government health authorities, private health insurers and other organizations generally provide reimbursement. In the United States, the European Union and other significant or potentially significant markets for our products and product candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services. A significant portion of our sales of the majority of our products are subject to substantial discounts from their list prices, including rebates we may be required to pay to Medicaid agencies or discounts we may be required to pay to 340B covered entities. As a result, the price increases we implement from time to time on certain products may have a limited effect on our net product sales in certain markets. In addition, standard reimbursement structures may not adequately reimburse for innovative therapies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our products mature, pricing pressures from private insurers and government payers often result in a reduction of the net product prices. Further, as new branded or generic products are introduced into major markets, our ability to maintain pricing and market share may be affected. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, see Item&#160;1A Risk Factors &#8220;Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.&#8221; and &#8220;We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Fraud and Abuse Laws; Anti-Bribery Laws</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various U.S. federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claim laws. Anti-kickback laws make it illegal for a prescription drug manufacturer to knowingly and willingly solicit, offer, receive or pay any remuneration in exchange for, or to induce, the referral of business reimbursed by a federal healthcare program, including the purchase or prescription of a particular drug. False claims laws generally prohibit anyone from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment by federal and certain state payers (including Medicare and Medicaid), or knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim. In addition, the FDA regulates written and verbal communications about our products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to federal law, states also have consumer protection and false claims laws.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the breadth of the statutory provisions and the attention being given to them by law enforcement authorities, our sales, marketing, patient support, medical, clinical and public affairs activities may be subject to scrutiny under these laws. For example, recently there has been enhanced scrutiny by government enforcement authorities of company-sponsored patient assistance programs, including co-pay assistance programs and manufacturer donations to third-party charities that provide such assistance, reimbursement support offerings, clinical education programs and promotional speaker programs. Similarly, in Europe, interactions between pharmaceutical companies and physicians are subject to strict laws, regulations, industry self&#8209;regulation codes of conduct and physicians&#8217; codes of professional conduct, as applicable, including the EU Member States anti-corruption laws and the UK Bribery Act 2010.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or retaining business. Our policies mandate compliance with these anti-bribery laws. We operate in parts of the world that have experienced governmental corruption to some degree. In certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state controlled, in a manner that is different than local custom. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our training and compliance program, our internal control policies and procedures may not protect us from unlawful acts committed by our employees or agents. Violations of fraud and abuse laws or anti-bribery laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as the possibility of exclusion from federal health care programs (including Medicare and Medicaid). Violations can also lead to the imposition of a Corporate Integrity Agreement or similar government oversight program, even if we disagree with the government&#8217;s perspective that we have violated any rules or guidance. Any similar violations by our competitors could also negatively impact the reputation of our industry and increase governmental and public scrutiny over our business and our products.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Healthcare Reform</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal and state governments continue to propose and pass legislation designed to regulate the healthcare industry, including legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, see Item&#160;1A Risk Factors &#8220;We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the health care industry.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of laws and regulations that require compliance with federal, state, and local regulations for the protection of the environment. The regulatory landscape continues to evolve, and we anticipate additional regulations in the future. Laws and regulations are implemented and under consideration to mitigate the effects of climate change mainly caused by greenhouse gas emissions. Our business is not energy intensive. Therefore, we do not anticipate being subject to a cap and trade system or other mitigation measure that would materially impact our capital expenditures, operations or competitive position. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the information requirements of the Securities Exchange Act of 1934 (&#8220;Exchange Act&#8221;). Therefore, we file periodic reports, proxy and information statements and other information with the SEC. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website is www.gilead.com. Through a link on the &#8220;Investors&#8221; page of our website (under the &#8220;SEC Filings&#8221; section), we make available the following filings free of charge as soon as reasonably practicable after they are electronically filed with or furnished to the SEC: our Annual Reports on Form 10-K; Quarterly Reports on Form 10-Q; Current Reports on Form 8-K; and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Website references are provided throughout this document for convenience. The content on the referenced websites does not constitute a part of and is not incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In evaluating our business, you should carefully consider the following discussion of material risks, events and uncertainties that make an investment in us speculative or risky in addition to the other information in this Annual Report on Form 10-K. A manifestation of any of the following risks and uncertainties could, in circumstances we may or may not be able to accurately predict, materially and adversely affect our business and operations, growth, reputation (including the commercial or scientific reputation of our products), prospects, product pipeline and sales, operating and financial results, financial condition, cash flows, liquidity and stock price. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. It is not possible to predict or identify all such factors; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product and Commercialization Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain of our products subject us to additional or heightened risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HIV Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection. During 2021, sales of our HIV products accounted for approximately 60% of our total product sales. We may be unable to sustain or increase sales of our HIV products for any number of reasons, including market share gains by competitive products, including generics, or the inability to introduce new HIV medications necessary to remain competitive. In such case, we may need to scale back our operations, including our future drug development and spending on research and development (&#8220;R&amp;D&#8221;) efforts. For example, many of our HIV products contain tenofovir alafenamide (&#8220;TAF&#8221;), which belongs to the nucleoside class of antiviral therapeutics, and any changes to the treatment paradigm for HIV may cause nucleoside-based therapeutics to fall out of favor.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to our supply and distribution of Veklury, which was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in October 2020 as a treatment for patients hospitalized with coronavirus disease 2019 (&#8220;COVID-19&#8221;) and in January 2022 as a treatment for non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death. While the utilization of Veklury has largely tracked rates of COVID-19 hospitalizations, we are unable to accurately predict our revenues or supply needs over the short and long term due to the dynamic nature of the pandemic, including the availability, uptake and effectiveness of vaccines and alternative treatments for COVID-19, fluctuating hospital utilization rates, the emergence of new variants and timing of surges in infection. If we do not accurately forecast demand or manufacture Veklury at levels sufficient to meet demand, then we may experience product shortages or build excess inventory that may be written off. We also remain subject to significant public attention and scrutiny over the complex decisions made regarding clinical data, supply, allocation, distribution and pricing of Veklury, all of which affects our corporate reputation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Therapy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advancing a novel and personalized therapy such as Yescarta or Tecartus, which are chimeric antigen receptor (&#8220;CAR&#8221;) T cell therapies, creates significant challenges, including:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">educating and certifying medical personnel regarding the procedures and the potential side effects, such as cytokine release syndrome and neurologic toxicities, in compliance with the Risk Evaluation and Mitigation Strategy program required by FDA;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">securing sufficient supply of other medications to manage side effects, such as tocilizumab and corticosteroids, which may not be available in sufficient quantities, may not adequately control the side effects and/or may have detrimental impacts on the efficacy of cell therapy;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and maintaining a robust and reliable process for engineering a patient&#8217;s T cells in our facilities and infusing them back into the patient; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditioning patients with chemotherapy in advance of administering our therapy, which may increase the risk of adverse side effects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of engineered T cells as a potential cancer treatment is a recent development and may not be broadly accepted by physicians, patients, hospitals, cancer treatment centers, payers and others in the medical community. While FDA has approved some cell therapies, including Yescarta and Tecartus, we must continue to demonstrate to the medical community the potential advantages of cell therapy compared to existing and future therapeutics. For challenges related to the reimbursement of Yescarta and Tecartus, see also &#8220;Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party sites to collect patients&#8217; white blood cells, known as apheresis centers, as well as shippers, couriers, and hospitals for the logistical collection of patients&#8217; white blood cells and ultimate delivery of Yescarta or Tecartus to patients. These vendors may encounter disruptions or difficulties that could result in product loss and regulatory action. Apheresis centers may also choose not to participate in our quality certification process, or we may be unable to complete such certification in a timely manner or at all, which could delay or constrain our manufacturing and commercialization efforts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a new automated manufacturing facility in Frederick, Maryland. The facility is pending FDA approval for commercial manufacturing and, even if we obtain such approval, we have not manufactured our products in an automated facility on a commercial scale. As a result, we may not be able to produce or otherwise obtain an amount of supply sufficient to satisfy demand for our products. If we are unable to meet product demand, we will have difficulty meeting sales forecasts for products that we plan to manufacture at this facility.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our success depends on developing and commercializing new products or expanding the indications for existing products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to launch commercially successful new products or new indications for existing products, our business will be adversely impacted. The launch of commercially successful products is necessary to grow our business, cover our substantial R&amp;D expenses, and offset revenue losses when existing products lose market share due to factors such as competition and loss of patent exclusivity. There are many difficulties and uncertainties inherent in drug development and the introduction of new products. The product development cycle is characterized by significant investments of resources, long lead times and unpredictable outcomes due to the nature of developing medicines for human use. We expend significant time and resources on our product pipeline without any assurance that we will recoup our investments or that our efforts will be commercially successful. A high rate of failure is inherent in the discovery and development of new products, and failure can occur at any point in the process, including late in the process after substantial investment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to accurately predict demand for our products, including the uptake of new products, as demand depends on a number of factors. For example, product demand may be adversely affected if physicians do not see the benefit of our products. Additionally, the non-retail sector in the United States, which includes government institutions, including state AIDS Drug Assistance Programs, the U.S. Department of Veterans Affairs, correctional facilities and large health maintenance organizations, tends to be less consistent in terms of buying patterns and often causes quarter-over-quarter fluctuations that do not necessarily mirror patient demand for our products. Federal and state budget pressures, as well as the annual grant cycles for federal and state funds, may cause purchasing patterns to not reflect patient demand for our products. We expect to continue to experience fluctuations in the purchasing patterns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We believe these measures have caused some government agencies and other purchasers to reduce inventory of our products in the distribution channels, and we may continue to see this trend in the future.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell and distribute most of our products in the United States exclusively through the wholesale channel. For the year ended December 31, 2021, approximately 91% of our product sales in the United States were to three wholesalers, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. The U.S. wholesalers with whom we have entered into inventory management agreements make estimates to determine end-user demand and may not be completely effective in matching their inventory levels to actual end-user demand. As a result, changes in inventory levels held by those wholesalers can cause our operating results to fluctuate unexpectedly if our sales to these wholesalers do not match end-user demand. In addition, inventory is held at retail pharmacies and other non-wholesaler locations with whom we have no inventory management agreements and no control over buying patterns. Adverse changes in economic conditions, increased competition or other factors may cause retail pharmacies to reduce their inventories of our products, which would reduce their orders from wholesalers and, consequently, the wholesalers&#8217; orders from us, even if end-user demand has not changed. In addition, we have observed that strong wholesaler and sub-wholesaler purchases of our products in the fourth quarter typically results in inventory draw-down by wholesalers and sub-wholesalers in the subsequent first quarter. As inventory in the distribution channel fluctuates from quarter to quarter, we may continue to see fluctuations in our earnings and a mismatch between prescription demand for our products and our revenues. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New branded or generic products entering major markets affects our ability to maintain pricing and market share. Our products compete with other available products based primarily on efficacy, safety, tolerability, acceptance by doctors, ease of patient compliance, ease of use, price, insurance and other reimbursement coverage, distribution and marketing. A number of companies are pursuing the development of technologies which are competitive with our existing products or research programs. These competing companies include large pharmaceutical and biotechnology companies and specialized pharmaceutical firms acting either independently or together with other such companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection or may establish collaborative arrangements for competitive products or programs. We may be adversely impacted if any of these competitors gain market share as a result of new technologies, commercialization strategies or otherwise.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Reimbursements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of our products depends, in part, on the availability of third-party payer reimbursement for the cost of such products and related treatments and medical services in the markets where we sell our products. Government health authorities, private health insurers and other organizations generally provide reimbursement. As our products mature, pricing pressures from private insurers and government payers often result in a reduction of the net product prices.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. For example, in September 2020, FDA issued a final rule implementing a pathway for the importation of certain prescription drugs from Canada. This rule is subject to ongoing litigation. We may be adversely impacted by any such legislative and regulatory actions, though it is difficult to predict the impact, if any, on the use and reimbursement of our products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Pricing, Discounts and Rebates</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the European Union (&#8220;EU&#8221;) and other significant or potentially significant markets for our products and product candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services. In the United States, the volume of drug pricing-related bills has dramatically increased in recent years. For example, Congress has enacted laws requiring manufacturer refunds on certain amounts of discarded drug from single-use vials beginning in 2023 and eliminating the existing cap on Medicaid rebate amounts beginning in 2024. Congress has also proposed bills to require the Department of Health and Human Services to negotiate prices for certain drugs, impose an inflation-based rebate on Medicare Part B and D drugs when list prices for drugs grow faster than inflation, and increase manufacturer contributions in some or all of the Medicare Part D benefit phases. In addition, many state legislatures are considering, or have already passed into law, legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as requiring manufacturers to publicly report proprietary pricing information, creating review boards for prices to state agencies, and encouraging the use of generic drugs. Such initiatives and legislation may cause added pricing pressures on our products, and the resulting impact on our business is uncertain. Many countries outside the United States, including the EU Member States, have established complex and lengthy procedures to obtain price approvals and coverage reimbursement and periodically review their pricing and reimbursement decisions. The outcome of this review cannot be predicted and could have an adverse effect on the pricing and reimbursement of our medicinal products in the EU member states. Reductions in the pricing of our medicinal products in one member state could affect the price in other member states and have a negative impact on our financial results. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our product sales is subject to significant discounts from list price, including rebates that we may be required to pay state Medicaid agencies and discounts provided to 340B covered entities. Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, in December 2020, Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) issued a final rule that will make certain changes to the calculation of rebates under the Medicaid Drug Rebate Program. Among other changes, effective January 1, 2023, the final rule will change the requirements for excluding manufacturer co-pay coupons from the Medicaid &#8220;best price.&#8221; These changes are subject to ongoing litigation. If these changes go into effect, they could substantially increase our Medicaid rebate obligations and decrease the prices we charge 340B covered entities. The continued growth of the 340B program also limits the prices we may charge on an increasing percentage of sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, standard reimbursement structures may not adequately reimburse for innovative therapies. For example, beginning in fiscal year 2021, CMS established a new severity-adjusted diagnosis-related group (&#8220;DRG&#8221;) 018 for Medicare inpatient reimbursement of CAR T products such as Yescarta and Tecartus. While the new DRG has a significantly higher base payment amount than the prior DRG 016, the payment available may not be sufficient to reimburse some hospitals for their cost of care for patients receiving Yescarta and Tecartus. When reimbursement is not aligned well to account for treatment costs, Medicare beneficiaries may be denied access as this misalignment could impact the willingness of some hospitals to offer the therapy and of doctors to recommend the therapy. Additionally, in the EU, there are barriers to reimbursement in individual countries that could limit the uptake of Yescarta and Tecartus.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we estimate the rebates we will be required to pay in connection with sales during a particular quarter based on claims data from prior quarters. In the United States, actual rebate claims are typically made by payers one to three quarters in arrears. Actual claims and payments may vary significantly from our estimates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may experience adverse impacts resulting from the importation of our products from lower price markets or the distribution of illegally diverted or counterfeit versions of our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices for our products are based on local market economics and competition and sometimes differ from country to country. Our sales in countries with relatively higher prices may be reduced if products can be imported and resold into those countries from lower price markets. For example, U.S. sales could also be affected if FDA permits importation of drugs from Canada. We have entered into agreements with generic drug manufacturers as well as licensing agreements with the Medicines Patent Pool, a United Nations-backed public health organization, which allows generic drug manufacturers to manufacture generic versions of certain of our products for distribution in certain low- and middle-income countries. We may be adversely affected if any generic versions of our products, whether or not produced and/or distributed under these agreements, are exported to the United States, Europe or markets with higher prices. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, we are required to permit products purchased in one EU member state to be sold in another member state. Purchases of our products in countries where our selling prices are relatively low for resale in countries in which our selling prices are relatively high can affect the inventory level held by our wholesalers and can cause the relative sales levels in the various countries to fluctuate from quarter to quarter and not reflect the actual consumer demand in any given quarter. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, diverted products may be used in countries where they have not been approved and patients may source the diverted products outside the legitimate supply chain. These diverted products may be handled, shipped and stored inappropriately, which may affect the efficacy of the products and could harm patients and adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of the existence of various suppliers around the world that source our products and generic versions of our products without Gilead&#8217;s authorization and sell them for use in countries where those products have not been approved. As a result, patients may be at risk of taking unapproved medications that may not be what they purport to be, may not have the potency they claim to have or may contain harmful substances, which could adversely impact us. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, third parties have illegally distributed and sold, and may continue to illegally distribute and sell, illegally diverted and counterfeit versions of our medicines, which do not meet the rigorous quality standards of our manufacturing and supply chain. For example, as part of an ongoing investigation in coordination with the U.S. Marshals and local law enforcement, we recently executed court-ordered seizures at 17 locations across eight U.S. states and seized thousands of bottles of Gilead-labeled medication with counterfeit supply chain documentation, including bottles labeled as Biktarvy and Descovy. Our investigation revealed that pharmaceutical distributors that are not authorized by Gilead to sell Gilead medicine, sold to independent pharmacies nationwide, purported genuine Gilead medicine sourced from an illegal counterfeiting scheme.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Illegally diverted and counterfeit medicines pose a serious risk to patient health and safety. Our actions to stop or prevent the distribution and sale of illegally diverted and counterfeit versions of our medicines around the world may be costly and unsuccessful, which may adversely affect our reputation and business, including our product revenues and financial results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product Development and Supply Chain Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to demonstrate the safety and efficacy of product candidates that we develop for each intended use through extensive preclinical studies and clinical trials. The results from preclinical and early clinical studies do not always accurately predict results in later, large-scale clinical trials. Even successfully completed large-scale clinical trials may not result in marketable products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face numerous risks and uncertainties with our clinical trials that could result in delays or prevent completion of the development and approval of our product candidates. These risks and uncertainties include challenges in clinical trial protocol design, our ability to enroll patients in clinical trials, and the possibility of unfavorable or inadequate trial results to support further development of our product candidates, including failure to meet a trial&#8217;s primary endpoint, safety issues arising from our clinical trials, and the need to modify or delay our clinical trials or to perform additional trials. For example, we recently announced clinical holds placed by FDA on clinical trials evaluating (1) injectable lenacapavir, (2) lenacapavir in combination with islatravir and (3) magrolimab, including in combination with azacitidine. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we may be unable to successfully complete our clinical trials on our anticipated timelines, or at all. Based on trial results, it is possible that FDA and other regulatory authorities may not approve our product candidates, or that any market approvals may include significant limitations on the products&#8217; use. In addition, clinical trials involving our commercial products could raise new safety issues for our existing products, which could adversely impact our business. Further, we may make a strategic decision to discontinue development of our product candidates if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline. Therefore, our product candidates may never be successfully commercialized, and we may be unable to recoup the significant R&amp;D and clinical trial expenses incurred. In 2022, we anticipate the continued expansion of our clinical pipeline, which includes multiple planned Phase 3 study initiations in oncology and virology. We expect to expend significant time and resources on our clinical trial activities without any assurance that we will recoup our investments or that our efforts will be commercially successful. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also risks associated with the use of third parties in our clinical trial activities. We extensively outsource our clinical trial activities and usually perform only a small portion of the start-up activities in-house. We rely on independent third-party contract research organizations (&#8220;CROs&#8221;) to perform most of our clinical studies, including document preparation, site identification, screening and preparation, pre-study visits, training, program management, patient enrollment, ongoing monitoring, site management and bioanalytical analysis. Many important aspects of the services performed for us by the CROs are out of our direct control. If there is any dispute or disruption in our relationship with our CROs, our clinical trials may be delayed. Moreover, in our regulatory submissions, we rely on the quality and validity of the clinical work performed by third-party CROs. If any of our CROs&#8217; processes, methodologies or results were determined to be invalid or inadequate, our own clinical data and results and related regulatory approvals may be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products, which are manufactured at our own facilities or by third-party manufacturers and corporate partners, are the result of complex, highly regulated manufacturing processes. We depend on third-party manufacturers and corporate partners to perform manufacturing activities effectively and on a timely basis for the majority of our active pharmaceutical ingredients and drug products. These third parties are independent entities subject to their own unique operational and financial risks that are out of our control. We and our third-party manufacturers and corporate partners are subject to Good Manufacturing Practices (&#8220;GMP&#8221;), which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by FDA and the European Medicines Agency (&#8220;EMA&#8221;), as well as comparable regulations in other jurisdictions. Manufacturing operations are also subject to routine inspections by regulatory agencies.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting or resulting from our manufacturing operations or the operations of our third-party manufacturers and corporate partners may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also need to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications and quality standards, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share and damage our reputation. In addition, manufacturing issues may cause delays in our clinical trials and applications for regulatory approval. For example, if we are unable to remedy any deficiencies cited by FDA or other regulatory agencies in their inspections, our existing products and the timing of regulatory approval of product candidates in development could be adversely affected. Further, there is risk that regulatory agencies in other countries where marketing applications are pending will undertake similar additional reviews or apply a heightened standard of review, which could delay the regulatory approvals for products in those countries. Our business may be adversely affected if approval of any of our product candidates were delayed or if production of our products were interrupted.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need access to certain supplies and products to conduct our clinical trials and to manufacture and sell our products. If we are unable to purchase sufficient quantities of these materials or find suitable alternative materials in a timely manner, our development efforts for our product candidates may be delayed or our ability to manufacture and sell our products could be limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suppliers of key components and materials must be named in the new drug application or marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking marketing approval, and significant delays can occur if the qualification of a new supplier is required. Even after a manufacturer is qualified by the regulatory authority, the manufacturer must continue to expend time, money and effort in the area of production and quality control to maintain full compliance with GMP. Manufacturers are subject to regular periodic inspections by regulatory authorities following initial approval. If, as a result of these inspections, a regulatory authority determines that the equipment, facilities, laboratories or processes do not comply with applicable regulations and conditions of product approval, the regulatory authority may suspend the manufacturing operations. If the manufacturing operations of any of the single suppliers for our products are suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet market demand. In addition, if deliveries of materials from our suppliers are interrupted for any reason, we may be unable to ship certain of our products for commercial supply or to supply our product candidates in development for clinical trials. Also, some of our products and the materials that we utilize in our operations are manufactured by only one supplier or at only one facility, which we may not be able to replace in a timely manner and on commercially reasonable terms, or at all. Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the raw materials and intermediates used to manufacture our antiviral products are supplied by third-party manufacturers and corporate partners outside of the United States. As a result, any political or economic factors in a specific country or region, including any changes in or interpretations of trade regulations, compliance requirements or tax legislation, that would limit or prevent third parties outside of the United States from supplying these materials could adversely affect our ability to manufacture and supply our antiviral products to meet market needs and have a material and adverse effect on our operating results.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to encounter any of these difficulties, our ability to conduct clinical trials on product candidates and to manufacture and sell our products could be impaired.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Regulatory and Other Legal Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we develop must be approved for marketing and sale by regulatory authorities and, once approved, are subject to extensive regulation by FDA, EMA and comparable regulatory agencies in other countries. We have filed, and anticipate that we will file, for marketing approval in additional countries and for additional indications and products over the next several years. These and any future marketing applications we file may not be approved by the regulatory authorities on a timely basis, or at all. Even if marketing approval is granted for these products, there may be significant limitations on their use. We cannot state with certainty when or whether any of our product candidates under development will be approved or launched; whether we will be able to develop, license or acquire additional product candidates or products; or whether any products, once launched, will be commercially successful. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, how we manufacture and sell our products is subject to extensive regulation and review. For example, under FDA rules, we are often required to conduct post-approval clinical studies to assess a known serious risk, signals of serious risk or to identify an unexpected serious risk. In certain circumstances, we may be required to implement a Risk Evaluation and Mitigation Strategy program for our products, which could include a medication guide, patient package insert, a communication plan to healthcare providers, restrictions on distribution or use of a product and other elements FDA deems necessary to assure safe use of the drug. Discovery of previously unknown problems with our marketed products or product candidates, including serious safety, resistance or drug interaction issues, or problems with our manufacturing, safety reporting or promotional activities may result in regulatory approvals being delayed, denied or granted with significant restrictions on our products, including limitations on or the withdrawal of the products from the market. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these or other requirements imposed by FDA could result in significant civil monetary penalties, fines, suspensions of regulatory approvals, product recalls, seizure of products and criminal prosecutions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the health care industry. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care industry is subject to various federal, state and international laws and regulations pertaining to drug reimbursement, rebates, price reporting, health care fraud and abuse, and data privacy and security. In the United States, these laws include anti-kickback and false claims laws, laws and regulations relating to the Medicare and Medicaid programs and other federal and state programs, the Medicaid Rebate Statute, laws that regulate written and verbal communications about our products, individual state laws relating to pricing and sales and marketing practices, the Health Insurance Portability and Accountability Act and other federal and state laws relating to the privacy and security of health information. Actual or alleged violations of these laws or any related regulations may be punishable by criminal and/or civil sanctions, including, in some instances, substantial fines, civil monetary penalties, exclusion from participation in federal and state health care programs, including Medicare, Medicaid and Department of Veterans Affairs and Department of Defense health programs, actions against executives overseeing our business and significant remediation measures, negative publicity or other consequences. These laws and regulations are broad in scope and subject to changing and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our sales or marketing practices. The resulting impact on our business is uncertain and could be material.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government price reporting and payment regulations are complex, and we are continually assessing the methods by which we calculate and report pricing in accordance with these obligations. Our methodologies for calculations are inherently subjective and may be subject to review and challenge by various government agencies, which may disagree with our interpretation. If the government disagrees with our reported calculations, we may need to restate previously reported data and could be subject to additional financial and legal liability.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also continues to be enhanced scrutiny of company-sponsored patient assistance programs, including co-pay assistance programs, and manufacturer donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement and other patient support offerings, clinical education programs and promotional speaker programs. If we, or our agents and vendors, are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our government investigations and related litigation, see Note 14. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to risks if significant safety issues arise for our marketed products or our product candidates.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As additional studies are conducted subsequent to obtaining marketing approval for our products, and as our products are used over longer periods of time by many patients, including patients with underlying health problems or patients taking other medicines, we expect to continue finding new issues related to safety, resistance or drug interactions. Any such issues may require changes to our product labels, such as additional warnings, contraindications or even narrowed indications, or to halt sales of a product.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have been moving towards more active and transparent pharmacovigilance and are making greater amounts of stand-alone safety information and clinical trial data directly available to the public through websites and other means, such as periodic safety update report summaries, risk management plan summaries and various adverse event data. Safety information, without the appropriate context and expertise, may be misinterpreted and lead to misperception or legal action.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are very important to our business. As part of our business strategy, we actively seek patent protection both in the United States and internationally and file additional patent applications, when appropriate, to cover improvements in our compounds, products and technology. Our success depends to a significant degree on our ability to:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patents and licenses to patent rights;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve trade secrets and internal know-how;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defend against infringement of our patents and efforts to invalidate them; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing on the intellectual property of others.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications are confidential for a period of time before a patent is issued, we may not know if our competitors have filed patent applications for technology covered by our pending applications or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent applications. If competitors file patent applications covering our technology, we may have to participate in litigation, post-grant proceedings before the U.S. Patent and Trademark Office or other proceedings to determine the right to a patent or validity of any patent granted. Such litigation and proceedings are unpredictable and expensive, and could divert management attention from other operations, such that, even if we are ultimately successful, we may be adversely impacted. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic manufacturers have sought, and may continue to seek, FDA approval to market generic versions of our products through an abbreviated new drug application (&#8220;ANDA&#8221;), the application process typically used by manufacturers seeking approval of a generic drug. For a description of our ANDA litigation, see Note 14. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. The entry of generic versions of our products has, and may in the future, lead to market share and price erosion. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe the valid patents of third parties, we may be required to pay significant monetary damages or we may be prevented from commercializing products or may be required to obtain licenses from these third parties. We may not be able to obtain alternative technologies or any required license on commercially reasonable terms or at all. If we fail to obtain these licenses or alternative technologies, we may be unable to develop or commercialize some or all of our products. For example, we are aware of patents and patent applications owned by third parties that such parties may claim cover the use of sofosbuvir, axicabtagene ciloleucel or bictegravir, as well as certain uses of combinations of emtricitabine (&#8220;FTC&#8221;) and tenofovir disoproxil fumarate (&#8220;TDF&#8221;) or TAF. For a description of our pending patent litigation, see Note 14. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we also rely on unpatented trade secrets and improvements, unpatented internal know-how and technological innovation. For example, a great deal of our liposomal manufacturing expertise, which is a key component of our liposomal technology, is not covered by patents but is instead protected as a trade secret. We protect these rights mainly through confidentiality agreements with our corporate partners, employees, consultants and vendors. We cannot be certain that these parties will comply with these confidentiality agreements, that we have adequate remedies for any breach or that our trade secrets, internal know-how or technological innovation will not otherwise become known or be independently discovered by our competitors. Under some of our R&amp;D agreements, inventions become jointly owned by us and our corporate partner and in other cases become the exclusive property of one party. In certain circumstances, it can be difficult to determine who owns a particular invention and disputes could arise regarding those inventions. We could be adversely affected if our trade secrets, internal know-how, technological innovation or confidential information become known or independently discovered by competitors or if we enter into disputes over ownership of inventions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face potentially significant liability and increased expenses from litigation and government investigations relating to our products and operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of litigation, investigation and other dispute-related matters that require us to expend substantial internal and financial resources. These matters could require us to pay significant monetary amounts, including royalty payments for past and future sales. For example, on February 1, 2022, we reached an agreement with ViiV Healthcare Company and related parties (collectively, &#8220;ViiV&#8221;) for a global resolution of all pending or potential claims related to our sales of Biktarvy, pursuant to which (1) ViiV granted Gilead a broad worldwide license and covenant not to sue relating to any past, present or future development or commercialization of bictegravir, and (2) Gilead agreed to make a one-time payment of $1.25 billion and an ongoing royalty at a rate of 3% on future sales of Biktarvy and the bictegravir component of bictegravir-containing products in the United States until October 5, 2027.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these matters will continue to require a high level of internal and financial resources for the foreseeable future. These matters have reduced, and are expected to continue to reduce, our earnings and require significant management attention. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the testing, manufacturing, marketing and use of our commercial products, as well as product candidates in development, involve substantial risk of product liability claims. These claims may be made directly by consumers, healthcare providers, pharmaceutical companies or others. We have limited insurance for product liabilities that may arise and claims may exceed our coverage.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our litigation, investigation and other dispute-related matters, see Note 14. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. The outcome of such legal proceedings or any other legal proceedings that may be brought against us, the investigations or any other investigations that may be initiated and any other dispute-related matters, are inherently uncertain, and adverse developments or outcomes can result in significant expenses, monetary damages, penalties or injunctive relief against us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operational Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business has been, and may in the future be, adversely affected by outbreaks of epidemic, pandemic or contagious diseases, including the ongoing COVID-19 outbreak.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual or threatened outbreaks of epidemic, pandemic or contagious diseases, such as COVID-19, may significantly disrupt our global operations and adversely affect our business, financial condition and results of operations. For example, the COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets and has resulted in increased risks and adverse impacts to our operations, including as described below. In addition to the developments discussed in Part II, Item 7 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; we are monitoring a number of risks related to the pandemic, including the following:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain: The pandemic could result in disruptions to our global supply chain and distribution in the future. For example, quarantines, shelter-in-place and other governmental orders and policies, travel restrictions, airline capacity and route reductions, safety guidelines and health impacts of the pandemic could impact the availability or productivity of products and personnel at manufacturers, distributors, freight carriers and other necessary components of our supply chain. In addition, there may be unfavorable changes in the availability or cost of raw materials, intermediates and other materials necessary for production, which may result in higher costs, disruptions in our supply chain and interruptions in our distribution capabilities.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical Trials: The pandemic has adversely affected and may continue to adversely affect certain of our clinical trials, including our ability to initiate and complete our clinical trials within the anticipated timelines. For ongoing trials, clinical trial sites have imposed restrictions on patient visits to limit risks of possible COVID-19 exposure, and we may experience issues with participant compliance with clinical trial protocols as a result of quarantines, travel restrictions and interruptions to healthcare services. There is also a risk that closures at clinical sites may be necessary as the pandemic and related guidance and restrictions continue to evolve. For the foregoing reasons, we have experienced delays with new subject enrollment for most clinical trials during the course of the pandemic, and may continue to experience overall delays in our clinical trials. There is also the risk of biased data collection if only certain clinical trial sites remain open. As a result of these challenges, our anticipated filing and marketing timelines for certain products may be adversely impacted.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory Reviews: The operations of FDA, EMA or other regulatory agencies may be adversely affected. We may also experience delays in necessary interactions with regulatory authorities around the world, including with respect to any anticipated filing, which, together with other factors resulting from the pandemic, may adversely impact our ability to launch new commercial products.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Access to Healthcare Providers: The pandemic has limited patients&#8217; ability or willingness to access and seek care from healthcare providers and initiate or continue therapies, which has resulted in lower demand for our products during the course of the pandemic, particularly with respect to hepatitis C virus (&#8220;HCV&#8221;) treatment and HIV treatment and prevention. For example, we have observed lower levels of patient visits and testing volumes in HCV, resulting in fewer patient starts. In addition, at times during the pandemic, we have seen lower levels of screening and diagnosis for HIV, resulting in fewer treatment initiations, as well as higher levels of discontinuations, resulting in a reduction in prescription refills. With increased levels of unemployment at times during the pandemic, we have also experienced shifts in payer mix towards more government-funded coverage and the uninsured segment. Our field personnel have also had reduced access to healthcare personnel during the pandemic, including fewer in-person interactions, which has adversely impacted and may continue to adversely impact our commercial activities.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employees: We face risks related to the health, safety, morale and productivity of our employees, including the safe occupancy of our sites during the pandemic. In the fourth quarter of 2021, we transitioned to a return-to-site phase for our U.S. flexible location employees. Our job site enhancements and risk protocols, which include health screenings and COVID-19 testing and vaccine requirements, do not guarantee that we can maintain the continued safe occupancy of our sites and may adversely impact employee recruitment and retention. On-site employees testing positive for COVID-19 could lead to mandatory quarantines and potential site shutdowns.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Financial: The pandemic has had, and may continue to have, an adverse financial impact in the short term and potentially beyond. In particular, our HCV and HIV businesses have been and continue to be adversely impacted. For example, we have observed reductions in the overall U.S. HCV treatment, HIV treatment and HIV pre-exposure prophylaxis (&#8220;PrEP&#8221;) volumes at times during the pandemic, and it is uncertain when these volumes will all return to pre-pandemic levels. We may continue to experience fluctuating revenues as infection rates rise and fall and as pandemic restrictions are periodically tightened and eased. We have also experienced, and may continue to experience, volatility in our short-term revenues due to fluctuations in inventory channel purchases during the pandemic. We could also have additional unexpected expenses related to the pandemic, which could negatively affect our results of operations. These factors together with the overall uncertainty and disruption caused by the pandemic could result in increased volatility and decreased predictability in our results of operations and volatility in our stock price.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic has also amplified many of the other risks described throughout the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. The extent to which the pandemic impacts our business and results will depend on future developments, which are uncertain and cannot be predicted with confidence, including any potential future waves of the pandemic, new variants of the virus that impact the severity and duration of the pandemic, the development, distribution, effectiveness and public acceptance of vaccines, and any other ongoing and future actions taken to contain the pandemic.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face risks associated with our global operations.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations are accompanied by certain financial, political, economic and other risks, including those listed below:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign Currency Exchange: For the year ended December 31, 2021, approximately 29% of our product sales were outside the United States. Because a significant percentage of our product sales is denominated in foreign currencies, primarily the Euro, we face exposure to adverse movements in foreign currency exchange rates. Overall, we are a net receiver of foreign currencies, and therefore, we benefit from a weaker U.S. dollar and are adversely affected by a stronger U.S. dollar. Our hedging program does not eliminate our exposure to currency fluctuations. We may be adversely impacted if the U.S. dollar appreciates significantly against certain currencies and our hedging program does not sufficiently offset the effects of such appreciation.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest Rates and Inflation: We hold interest-generating assets and interest-bearing liabilities, including our available-for-sale debt securities and our senior unsecured notes and credit facilities. Fluctuations in the interest rate could expose us to increased financial risk. In addition, changes in the inflation rate could also adversely impact our business and financial results.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-Bribery: We are subject to the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws that govern our international operations with respect to payments to government officials. Our international operations are heavily regulated and require significant interaction with foreign officials. We operate in parts of the world that have experienced governmental corruption to some degree. In certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state-controlled, in a manner that is different than local custom. It is possible that certain of our practices may be challenged under these laws. In addition, our internal control policies and procedures may not protect us from reckless or criminal acts committed by our employees and agents. Enforcement activities under anti-bribery laws could subject us to administrative and legal proceedings and actions, which could result in civil and criminal sanctions, including monetary penalties and exclusion from healthcare programs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks inherent in conducting a global business include:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictive government actions against our intellectual property and other foreign assets such as nationalization, expropriation, the imposition of compulsory licenses or similar actions, including waiver of intellectual property protections.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Protective economic policies taken by foreign governments, such as trade protection measures and import and export licensing requirements, which may result in the imposition of trade sanctions or similar restrictions by the United States or other governments.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Business interruptions stemming from natural or man-made disasters, such as climate change, earthquakes, hurricanes, flooding, fires, extreme heat, drought or actual or threatened public health emergencies, or efforts taken by third parties to prevent or mitigate such disasters, such as public safety power shutoffs and facility shutdowns, for which we may be uninsured or inadequately insured. For example, our corporate headquarters in Foster City and certain R&amp;D and manufacturing facilities are located in California, a seismically active region. In the event of a major earthquake, we may not carry adequate earthquake insurance and significant recovery time could be required to resume operations. </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Political instability or disruption in a geographic region where we operate, regardless of cause, including war, terrorism, social unrest and political changes. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our aspirations, goals and disclosures related to environmental, social and governance (&#8220;ESG&#8221;) matters expose us to numerous risks, including risks to our reputation and stock price.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Institutional and individual investors are increasingly using ESG screening criteria to determine whether Gilead qualifies for inclusion in their investment portfolios. We are frequently asked by investors and other stakeholders to set ambitious ESG goals and provide new and more robust disclosure on goals, progress toward goals and other matters of interest to ESG stakeholders. In response, we have adapted the tracking and reporting of our corporate responsibility program to various evolving ESG frameworks, and we have established and announced goals and other objectives related to ESG matters. These goal statements reflect our current plans and aspirations and are not guarantees that we will be able to achieve them. Our efforts to accomplish and accurately report on these goals and objectives present numerous operational, reputational, financial, legal and other risks, any of which could have a material negative impact, including on our reputation and stock price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to achieve any goal or objective, including with respect to environmental and diversity initiatives, is subject to numerous risks, many of which are outside of our control. Examples of such risks include: (1) the availability and cost of low- or non-carbon-based energy sources and technologies, (2) evolving regulatory requirements affecting ESG standards or disclosures, (3) the availability of suppliers that can meet our sustainability, diversity and other standards, (4) our ability to recruit, develop and retain diverse talent in our labor markets, and (5) the impact of our organic growth and acquisitions or dispositions of businesses or operations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standards for tracking and reporting on ESG matters are relatively new, have not been harmonized and continue to evolve. Our selection of disclosure frameworks that seek to align with various reporting standards may change from time to time and may result in a lack of consistent or meaningful comparative data from period to period. In addition, our processes and controls may not always comply with evolving standards for identifying, measuring and reporting ESG metrics, our interpretation of reporting standards may differ from those of others and such standards may change over time, any of which could result in significant revisions to our goals or reported progress in achieving such goals. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ESG practices do not meet evolving investor or other stakeholder expectations and standards, then our reputation, our ability to attract or retain employees and our attractiveness as an investment, business partner or acquiror could be negatively impacted. Similarly, our failure or perceived failure to pursue or fulfill our goals, targets and objectives or to satisfy various reporting standards within the timelines we announce, or at all, could also have similar negative impacts and expose us to government enforcement actions and private litigation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products. Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative relationships with third parties for our sales and marketing performance in certain territories. For example, we have collaboration arrangements with Janssen Sciences Ireland UC for Odefsey, Complera/Eviplera and Symtuza. In some countries, we rely on international distributors for sales of certain of our products. Some of these relationships also involve the clinical development of these products by our partners. Reliance on collaborative relationships poses a number of risks, including the risk that:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are unable to control the resources our corporate partners devote to our programs or products;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of rights to technology developed with our corporate partners;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with our corporate partners could cause delays in, or termination of, the research, development or commercialization of product candidates or result in litigation or arbitration;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contracts with our corporate partners may fail to provide significant protection or may fail to be effectively enforced if one of these partners fails to perform;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners have considerable discretion in electing whether to pursue the development of any additional products and may pursue alternative technologies or products either on their own or in collaboration with our competitors;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners with marketing rights may choose to pursue competing technologies or to devote fewer resources to the marketing of our products than they do to products of their own development; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our distributors and our corporate partners may be unable to pay us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is a great deal of uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Due to the specialized and technical nature of our business, the failure to attract, develop and retain highly qualified personnel could adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success will depend in large part on our continued ability to attract, develop and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, governmental regulation and commercialization. Our ability to do so also depends in part on how well we maintain a strong workplace culture that is attractive to employees. In addition, competition for qualified personnel in the biopharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Additionally, changes to U.S. immigration and work authorization laws and regulations could make it more difficult for employees to work in or transfer to one of the jurisdictions in which we operate. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant cybersecurity incidents could give rise to legal liability and regulatory action under data protection and privacy laws and adversely affect our business and operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent upon information technology systems, infrastructure and data, including our Kite Konnect platform, which is critical to maintain chain of identity and chain of custody of Yescarta and Tecartus. The multitude and complexity of our computer systems make them inherently vulnerable to service interruption or destruction, malicious intrusion and ransomware attack. Likewise, data privacy or security breaches by employees or others can result in the exposure of sensitive data, including our intellectual property or trade secrets or the personal information of our employees, patients, customers or other business partners to unauthorized persons or to the public. Cybersecurity incidents are increasing in their frequency, sophistication and intensity, including during the COVID-19 pandemic. Cybersecurity incidents include, for example, the deployment of harmful malware, ransomware, denial-of-service, social engineering and other means to affect service reliability and threaten data confidentiality, integrity and availability. Our business and technology partners face similar risks and any security breach of their systems could adversely affect our security posture.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like many companies, we have experienced cybersecurity incidents, including data breaches and service interruptions. When cybersecurity incidents occur, we respond and address them in accordance with applicable governmental regulations and other legal requirements, including our cybersecurity protocols. There can be no assurance that our efforts in response to cybersecurity incidents, as well as our investments to protect our information technology infrastructure and data, will shield us from significant losses and potential liability or prevent any future interruption or breach of our systems. Such cybersecurity incidents can cause the loss of critical or sensitive information, including personal information, and could give rise to legal liability and regulatory action under data protection and privacy laws. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators globally are also imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the General Data Protection Regulation (&#8220;GDPR&#8221;) established regulations regarding the handling of personal data, and non-compliance with the GDPR may result in monetary penalties of up to four percent of worldwide revenue. In addition, new domestic data privacy and security laws, such as the California Consumer Privacy Act and the California Privacy Rights Act and other laws that have been or may be passed, similarly introduce requirements with respect to personal information, and non-compliance with such laws may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Other changes or new laws or regulations associated with the enhanced protection of personal information, including, in some cases, healthcare data or other personal information, could greatly increase our cost of providing our products and services or even prevent us from offering certain services in jurisdictions in which we operate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Strategic and Financial Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to risks associated with engaging in business acquisitions, licensing arrangements, collaborations, options, equity investments, asset divestitures and other strategic transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged in, and may in the future engage in, such transactions as part of our business strategy. We may not identify suitable transactions in the future and, if we do, we may not complete such transactions in a timely manner, on a cost-effective basis, or at all, and may not realize the expected benefits. If we are successful in making an acquisition or closing a licensing arrangement or collaboration, the products, intellectual property and technologies that are acquired or licensed may not be successful or may require significantly greater resources and investments than anticipated. As part of our annual impairment testing of our goodwill and other indefinite-lived intangible assets in the fourth quarter, and earlier if impairment indicators exist, as required under U.S. generally accepted accounting principles, we may need to recognize impairment charges if the products, intellectual property and technologies that are acquired or licensed are not successful. For option structured deals, there is no assurance that we will elect to exercise our option right, and it is possible that disagreements, uncertainties or other circumstances may arise, including with respect to whether our option rights have been appropriately triggered, which may hinder our ability to realize the expected benefits. For equity investments in our strategic transactions, such as in connection with our collaborations with Arcus Biosciences, Inc. and Galapagos NV, the value of our equity investments may fluctuate and decline in value. If we are not successful in the execution or implementation of these transactions, our financial condition, cash flows and results of operations may be adversely affected, and our stock price could decline.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid substantial amounts of cash and incurred additional debt to finance our strategic transactions. Additional indebtedness and a lower cash balance could result in a downgrade of our credit ratings, limit our ability to borrow additional funds or refinance existing debt on favorable terms, increase our vulnerability to adverse economic or industry conditions, and reduce our financial flexibility to continue with our capital investments, stock repurchases and dividend payments. For example, as a result of the cash used and the debt issued in connection with our acquisition of Immunomedics, Inc. in 2020, S&amp;P Global Ratings downgraded our credit rating. We may be adversely impacted by any failure to overcome these additional risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in our effective income tax rate could reduce our earnings.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the United States and various foreign jurisdictions. Due to economic and political conditions, various countries are actively considering and have made changes to existing tax laws, and we cannot predict the form or timing of such changes. Our effective tax rates are affected by changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, the introduction of new taxes, and changes in tax laws, regulations, administrative practices and interpretations, including in the United States, Germany and Ireland.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the examination of our tax returns and other tax matters by the U.S. Internal Revenue Service and tax authorities in various foreign jurisdictions. There are differing interpretations of tax laws and regulations and, as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We may be adversely affected by the resolution of one or more of these exposures in any reporting period.</span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_19"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNRESOLVED STAFF COMMENTS </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_22"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPERTIES </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Foster City, California, where we house our administrative, manufacturing and R&amp;D activities. We also have R&amp;D facilities in Emeryville, Oceanside and Santa Monica, California; Seattle, Washington; Morris Plains, New Jersey; Frederick, Maryland; Edmonton, Canada; and Dublin, Ireland. Our principal manufacturing facilities are in El Segundo, La Verne, Oceanside and San Dimas, California; Edmonton, Canada; Cork, Ireland and Hoofddorp, Netherlands. For more information about our manufacturing facilities, see Item&#160;1. Business &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Manufacturing Facilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; Our global operations include offices in Europe, North America, Asia, South America, Africa, Australia and the Middle East.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing properties, including both owned and leased sites, are adequate and suitable for the conduct of our business. We believe our capital resources are sufficient to purchase, lease or construct any additional facilities required to meet our expected long-term growth needs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant pending legal proceedings, see&#160;Note 14. Commitments and Contingencies - Legal Proceedings of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_28"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MINE SAFETY DISCLOSURES </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_31"></div><div style="margin-top:13.5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_34"></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;GILD.&#8221; </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;18, 2022, we had approximately 1,456 stockholders of record of our common stock.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares our cumulative total stockholder return for the past five years to&#160;two indices: the&#160;Standard&#160;&amp; Poor&#8217;s 500 Stock Index (&#8220;S&amp;P 500 Index&#8221;) and the Nasdaq Biotechnology Index (&#8220;NBI Index&#8221;). The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns. </span></div><div style="margin-top:4.5pt;text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of Cumulative Total Return on Investment for the Past Five Years</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><img src="gild-20211231_g1.jpg" alt="gild-20211231_g1.jpg" style="height:463px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">______________________________________________________&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This section is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the Securities and Exchange Commission (&#8220;SEC&#8221;) and is not to be incorporated by reference in any of our filings under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) or the Securities Exchange Act of 1934 (&#8220;Exchange Act&#8221;) whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Shows the cumulative return on investment assuming an investment of $100 in our common stock, the NBI Index and the S&amp;P 500 Index on December&#160;31, 2016, and assuming that all dividends were reinvested.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information with respect to our equity compensation plans in effect as of December&#160;31, 2021:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of Common Shares to be Issued Upon Exercise of Outstanding Options, Warrants and Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-average Exercise Price of Outstanding Options, Warrants and Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of Common Shares Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(c) </span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2004 Equity Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity compensation plans approved by security holders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 25.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">______________________________________________________&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Does not take into account 22&#160;million restricted stock units, performance share awards or units and phantom shares, which have no exercise price and were granted under our 2004 and 2018 Equity Incentive Plans.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes awards and shares previously issuable under The Immunomedics, Inc. Amended and Restated 2014 Long-Term Incentive Plan (the &#8220;Immunomedics Plan&#8221;), which was assumed in connection with our acquisition of Immunomedics, Inc. and subsequently merged into the 2004 Equity Incentive Plan.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under our Employee Stock Purchase Plan, participants are permitted to purchase our common stock at a discount on certain dates through payroll deductions within a pre-determined purchase period. Accordingly, these numbers are not determinable.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes awards and shares issuable under the Forty Seven, Inc. 2018 Equity Incentive Plan, which was assumed in connection with our acquisition of Forty Seven, Inc. (&#8220;Forty Seven&#8221;) and subsequently amended and restated as our 2018 Equity Incentive Plan.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Material Features of the Gilead Sciences, Inc. 2018 Equity Incentive Plan</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Forty Seven, Inc. 2018 Equity Incentive Plan was originally established by Forty Seven in June 2018. In connection with Gilead&#8217;s acquisition of Forty Seven in April 2020, Gilead assumed the Forty Seven, Inc. 2018 Equity Incentive Plan, and amended and restated it as the Gilead Sciences, Inc. 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;). The 2018 Plan is intended to help the Gilead secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of Gilead and any affiliate, and provide a means by which the eligible recipients may benefit from increases in value of Gilead common stock. From and after April 7, 2020, only employees and consultants of Forty Seven as of immediately prior to such date and employees and consultants of Gilead hired on or following such date are eligible to receive grants of new awards under the 2018 Plan.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 Plan provides for the award of incentive stock options and non-qualified stock options, each of which must generally have an exercise price equal to at least the fair market value of our common stock on the date of grant; stock appreciation rights; restricted stock awards; restricted stock unit awards; performance stock awards; other stock awards; and performance cash awards.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 7, 2020, the aggregate number of shares of common stock issuable under the 2018 Plan (from and after such date) was 12,069,378. From and after April 7, 2020, Gilead has granted restricted stock units, performance share awards or units and stock options under the 2018 Plan, and these are the only types of equity awards outstanding under the plan. As of December&#160;31, 2021, 6.7 million shares of Gilead common stock remained available for issuance under the 2018 Plan.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (the &#8220;2016 Program&#8221;) under which repurchases may be made in the open market or in privately negotiated transactions. We made repurchases under the 2016 Program starting in April 2016. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion stock repurchase program (the &#8220;2020 Program&#8221;), which will commence upon the completion of the 2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we repurchased and retired 8 million shares of our common stock for $546 million through open market transactions under the 2016 Program.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the remaining authorized repurchase amount from both programs was $6.3 billion.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our stock repurchase activity for the three months ended December&#160;31, 2021:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average<br/>Price Paid<br/>per Share (in dollars)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of<br/>Shares Purchased<br/>as Part of a Publicly<br/>Announced Program (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Fair<br/>Value of Shares<br/>that May Yet Be<br/>Purchased Under<br/>the Programs (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 - October 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.47&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 - November 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">______________________________________________________&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program is due to shares of common stock withheld by us from employee restricted stock awards in order to satisfy applicable tax withholding obligations.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we paid quarterly dividends. We expect to continue to pay quarterly dividends, although the amount and timing of any future dividends are subject to declaration by our Board of Directors. Additional information is included in Item 7</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations to the Consolidated Financial Statements.</span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_1662"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">[RESERVED]</span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_40"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand our results of operations and financial condition. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our audited Consolidated Financial Statements and the accompanying Notes to Consolidated Financial Statements and other disclosures included in this Annual Report on Form 10-K (including the disclosures under Part I, Item&#160;1A. Risk Factors). Additional i</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nformation related to the comparison of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results of operations</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> between the years 2020 and 2019 is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 7.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/882095/000088209521000008/gild-20201231.htm">2020 Form 10-K</a> filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles and are presented in U.S. dollars.</span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT OVERVIEW</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketed products includes AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cayston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Emtriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(bulevirtide), Hepsera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jyseleca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (filgotinib), Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sovaldi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tybost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The approval status of Hepcludex and Jyseleca vary worldwide, and Hepcludex and Jyseleca are not approved in the United States. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the United States through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Highlights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We delivered strong financial performance in 2021. Veklury continued to play a critical role in addressing the coronavirus disease 2019 (&#8220;COVID-19&#8221;) pandemic. Veklury&#8217;s performance helped mitigate the impacts of COVID-19 on other parts of the business, including on our HIV and chronic</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">hepatitis C virus (&#8220;HCV&#8221;) franchises, and the impacts of the October 2020 loss of exclusivity of Truvada and Atripla in the United States. Despite these transitory headwinds, underlying demand for our virology portfolio remained strong, led by the continued growth of our Biktarvy franchise. We also received increased contributions from our oncology franchise, experiencing growth in Trodelvy, as well as our Cell Therapy franchise.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued to expand and strengthen both our commercial portfolio and clinical pipeline across therapeutic focus areas to drive future growth potential. During 2021, we announced an additional six filings for regulatory approval. In addition to investing in our internal pipeline programs, we also continued to enter into and leverage our existing strategic collaborations and partnerships, including opting into four additional pipeline assets from our collaboration with Arcus Biosciences, Inc. (&#8220;Arcus&#8221;) to further develop the foundation for a more sustainable and diversified business.</span></div><div style="margin-top:4.5pt;padding-left:11.25pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Viral Diseases</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In October 2021, U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved a new low-dose tablet dosage form of Biktarvy for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In August 2021, our Marketing Authorization Application for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, was fully validated and is now under evaluation with the European Medicines Agency (&#8220;EMA&#8221;).</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In June 2021, FDA granted approval of a new oral pellet formulation of Epclusa, expanding the pediatric indication to treat children as young as 3 years of age with chronic HCV. </span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In June 2021, we submitted a New Drug Application to FDA for lenacapavir, an investigational, long-acting agent in development for the treatment of HIV-1 in people with limited therapy options. </span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In March 2021, we entered into an agreement with Merck Sharp &amp; Dohme Corp. (&#8220;Merck&#8221;), a subsidiary of Merck &amp; Co., Inc., to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#8217;s investigational capsid inhibitor, lenacapavir, and Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In March 2021, we completed the acquisition of MYR GmbH (&#8220;MYR&#8221;). The acquisition provides us with Hepcludex, which is conditionally approved by EMA for the treatment of chronic hepatitis delta virus (&#8220;HDV&#8221;) in adults with compensated liver disease.</span></div><div style="margin-top:4.5pt;padding-left:11.25pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In January 2022, FDA granted expedited approval for Veklury for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In December 2021, the European Commission granted approval to expand the indication for Veklury for use in the earlier stages of the disease in adult patients who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2021, we announced that we will (i) provide assistance and support for expansion of local manufacturing capacity of remdesivir in India and will donate the active pharmaceutical ingredient and (ii) donate a minimum of 450,000 vials of Veklury (remdesivir) to the government of India.</span></div><div style="margin-top:4.5pt;padding-left:11.25pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-top:4.5pt;padding-left:11.25pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cell Therapy</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In January 2022, FDA approved an update to the prescribing information for Yescarta to include the use of prophylactic corticosteroids across all approved indications. Yescarta is now the first and only chimeric antigen receptor (&#8220;CAR&#8221;) T-cell therapy with information in the label to help physicians manage, and potentially prevent, treatment side effects.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In October 2021, FDA approved Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (&#8220;ALL&#8221;). Tecartus is the first and only CAR T cell therapy approved for adults with ALL.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In September 2021, Kite, a Gilead company (&#8220;Kite&#8221;) submitted a supplemental Biologics License Application to FDA for Yescarta to expand its current indication to include the treatment of adults with relapsed or refractory large B-cell lymphoma (&#8220;LBCL&#8221;) in the second-line setting.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In August 2021, Kite and Appia Bio, Inc. entered into a collaboration and license agreement to research and develop hematopoietic stem cell derived cell therapies directed toward hematological malignancies.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In June 2021, Kite entered into a research collaboration and license agreement with Shoreline Biosciences, Inc. to develop novel allogeneic cell therapies across a variety of cancer targets. </span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In June 2021, Fosun Kite Biotechnology Co. Ltd, a joint venture between Kite and Shanghai Fosun Pharmaceutical (Group) Co., Ltd, received approval from the China National Medical Products Administration for axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory LBCL in China.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In March 2021, FDA granted accelerated approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma (&#8220;FL&#8221;).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:11.25pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In January 2022, we entered into a clinical trial collaboration agreement with Merck to evaluate Trodelvy in combination with Merck&#8217;s anti-programmed death receptor-1 (&#8220;PD-1&#8221;) therapy, Keytruda, in a first-line setting for patients with non-small cell lung cancer (&#8220;NSCLC&#8221;).</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In November 2021, the European Commission granted marketing authorization for Trodelvy for treatment of metastatic triple-negative breast cancer (&#8220;TNBC&#8221;) in adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In November 2021, we exercised options to three programs in the clinical-stage portfolio of Arcus, including anti-TIGIT molecules domvanalimab and AB308, as well as clinical candidates etrumadenant (dual adenosine A2a/A2b receptor antagonist) and quemliclustat (small molecule CD73 inhibitor). The transaction closed in December 2021.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In October 2021, we entered into a clinical trial collaboration and supply agreement with Merck to evaluate the efficacy of Trodelvy in combination with Keytruda as a first-line treatment for patients with locally advanced or metastatic TNBC. </span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In September 2021, Health Canada approved Trodelvy for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more therapies, at least one of them for metastatic disease. Canada joined Australia, Great Britain, Switzerland and the United States among the countries that have approved Trodelvy for use under Project Orbis, a global collaborative review program for high impact oncology marketing applications across participating countries.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2021, FDA granted accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (&#8220;UC&#8221;), a new indication.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2021, FDA granted full approval of Trodelvy for adult patients with unresectable locally advanced or metastatic TNBC.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">______________________________________________________&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We announced and discussed these updates in further detail in press releases available on our website at www.gilead.com. Readers are also encouraged to review all other press releases available on our website mentioned above. The content on the referenced websites does not constitute a part of and is not incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Financial Highlights</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,305&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,689&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues increased by 11% to $27.3 billion in 2021, compared to $24.7 billion in 2020, primarily due to increased sales of Veklury, our FDA-approved treatment for hospitalized patients with COVID-19. The increase also reflects the continued growth of Biktarvy in all geographies and the continued uptake of Trodelvy, Cell Therapy and chronic hepatitis B virus (&#8220;HBV&#8221;) and HDV products. The increases were partially offset by the decrease in Truvada and Atripla sales in the United States, as expected, primarily due to the continued generic competition following the October 2020 loss of exclusivity in the United States. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to Gilead was $6.2 billion or $4.93 diluted earnings per share in 2021, compared to $123 million or $0.10 diluted earnings per share in 2020. The increase was primarily due to lower acquired in-process research and development (&#8220;IPR&amp;D&#8221;) charges, revenue growth and lower unrealized losses from our equity investments, partially offset by a $1.25 billion charge for a settlement related to bictegravir litigation, and a charge of $625 million related to the Arcus collaboration opt-in. Our acquired IPR&amp;D expenses in 2020 were $5.9 billion primarily related to our acquisition of Forty Seven as well as collaborations and other investments that we entered into during the year with Arcus, Pionyr Immunotherapeutics, Inc. (&#8220;Pionyr&#8221;), Tango Therapeutics, Inc. (&#8220;Tango&#8221;), Tizona Therapeutics, Inc. (&#8220;Tizona&#8221;) and Jounce Therapeutics, Inc. (&#8220;Jounce&#8221;).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy and Outlook 2022</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purpose is to deliver life-changing medications to patients in need through scientific breakthroughs, innovation and strong operational execution. Our strategic ambitions are to (i) bring 10+ transformative therapies to patients by 2030; (ii) be the biotech employer and partner of choice; and (iii) deliver shareholder value in a sustainable and responsible manner. Our strategic priorities reflect how we will deliver those ambitions: (i) expand internal and external innovation; (ii) strengthen portfolio strategy and decision making; (iii) increase patient benefit and access; and (iv) continue to evolve our culture. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we will continue to focus on executing our strategy to expand and diversify our commercial portfolio and clinical pipelines across our three therapeutic focus areas: virology, oncology and inflammation. Specifically, we plan to significantly increase clinical development studies across our novel oncology portfolio while maintaining our leadership in antiviral medications through our work in HIV, hepatitis, the COVID-19 pandemic and emerging viruses. Our collaboration with Arcus provides additional opportunities for us to further develop the foundation for a more sustainable and diversified business. Beyond expanding our products and pipeline, we also continue to focus on our employees, the evolution of our culture and our efforts to promote racial equity and social justice. Additionally, we expect to maintain a rigorous focus on disciplined expense management.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While, the COVID-19 pandemic continues to impact our business and broader market dynamics, we expect revenue growth of between 2 &#8211; 4% in 2022 product sales, excluding Veklury, as compared to 2021. Our HIV product sales will continue to recover from the COVID-19 pandemic and demonstrate year-over-year growth, as the financial impact of the Truvada and Atripla loss of exclusivity will be largely behind us starting in the second quarter of 2022. We also expect our oncology businesses, including Cell Therapy and Trodelvy, to contribute to our growth.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veklury sales are generated in a highly dynamic and complex global environment, which continues to evolve. As a result, Veklury sales are subject to significant volatility and uncertainty. Future product demand will depend on the nature of the COVID-19 pandemic, including duration, infection rates, hospitalizations, and availability and adoption of alternative therapies and vaccines. While we anticipate a year-over-year decline in Veklury product sales, we expect Veklury to continue to play a key role in the pandemic and contribute meaningfully to our revenue in 2022, more heavily weighted towards the beginning of the year. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to deliver on our strategy is subject to a number of uncertainties, including, but not limited to, the effects of the COVID-19 pandemic, which remains unpredictable; the uncertainty regarding the amount and timing of future Veklury sales; the continuation of an uncertain global macroeconomic environment; our ability to realize the potential benefits of our acquisitions, collaborations or licensing arrangements; our ability to initiate, progress or complete clinical trials within currently anticipated timeframes, including as a result of any current or future holds on clinical trials; the possibility of unfavorable results from new and ongoing clinical trials; our ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; our ability to receive regulatory approvals in a timely manner or at all; market share and price erosion caused by the introduction of generics; loss of exclusivity of our products; higher than anticipated effects of the loss of exclusivity from Truvada and Atripla; slower than anticipated growth in Biktarvy, Trodelvy, Vemlidy and Cell Therapy products; inaccuracies in our patient start estimates; additional pricing pressures from payers and competitors; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; potential government actions that could have the effect of lowering prices; a larger-than anticipated shift in payer mix to a more highly discounted payer segment; and volatility in foreign currency exchange rates.</span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_1099511629448"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our revenues:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HCV</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,176&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,678&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,008&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,141&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,894&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,355&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HIV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIV product sales decreased by 4% to $16.3 billion in 2021, compared to $16.9 billion in 2020, due to the anticipated decline in sales volume of our Truvada (emtricitabine (&#8220;FTC&#8221;) and tenofovir disoproxil fumarate (&#8220;TDF&#8221;))-based products driven by the continued generic competition following the October 2020 loss of exclusivity of Truvada and Atripla in the United States. Truvada and Atripla product sales were $1.3 billion lower in 2021, compared to 2020. The decrease was also impacted by lower sales of Genvoya driven by decrease in volume worldwide primarily due to patients switching to Biktarvy. These declines were partially offset by an increase in Biktarvy product sales worldwide driven by higher demand, higher net average selling price driven by favorable changes in estimates of government rebates and discounts in the United States. We expect that our HIV business will continue to recover from the COVID-19 pandemic in 2022. We also expect the impact of the Truvada and Atripla loss of exclusivity will be largely behind us starting in the second quarter of 2022.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veklury product sales were $5.6 billion in 2021, compared to $2.8 billion in 2020. Veklury became commercially available in the third quarter of 2020, resulting in a partial year of sales in 2020. The increase was also attributable to higher hospital demand worldwide. Sales of Veklury are generally affected by COVID-19 related rates of infections, hospitalizations and vaccinations as well as the availability, uptake and effectiveness of alternative treatments for COVID-19. As a result, future sales of Veklury are difficult to predict.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HCV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HCV product sales decreased by 9% to $1.9 billion in 2021, compared to $2.1 billion in 2020, primarily due to lower demand driven by fewer patient starts worldwide due to the impact of the COVID-19 pandemic. The slight increase in HCV sales in Europe in 2021 was due to a favorable change in estimate of government rebates, which offset the revenue decrease associated with lower demand.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HBV / HDV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HBV and HDV product sales increased by 13% to $969 million in 2021, compared to $860 million in 2020, primarily due to higher Vemlidy product sales due to higher demand in all geographies, partially offset by lower Viread product sales in Other international locations. Hepcludex sales in 2021 were $37 million as launch activities continued across Europe following our first quarter 2021 acquisition of MYR.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cell Therapy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell Therapy product sales, which include Yescarta and Tecartus, increased by 43% to $871 million in 2021, compared to $607 million in 2020. The growth was primarily due to the July 2020 launch of Tecartus in the United States for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (&#8220;MCL&#8221;) and the December 2020 launch of Tecartus for MCL in Europe, resulting in partial year of sales in 2020. The increase was also driven by continued higher demand for Yescarta worldwide for LBCL and volume growth related to approval of Yescarta for FL in the United States in 2021.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trodelvy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trodelvy product sales increased to $380 million in 2021, compared to $49 million in 2020. We obtained Trodelvy through the fourth quarter 2020 acquisition of Immunomedics, resulting in a partial year of sales in 2020. In addition, 2021 revenues include continued uptake of Trodelvy following the full regulatory approval for metastatic TNBC in the United States and Europe and accelerated approval for metastatic UC in the United States.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales, which include AmBisome, Cayston, Jyseleca, Letairis, Ranexa and Zydelig, were $1.0 billion in 2021 and remained flat as compared to 2020. AmBisome sales volume increased due to higher demand in geographies outside the United States. The increase was mostly offset by lower Letairis sales in the United States, as anticipated, due to continued generic competition following the loss of exclusivity in 2019.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Gross-to-Net Deductions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record product sales net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales returns and other related costs. These deductions totaled $14.4 billion, or 35% of gross product sales in 2021, compared to $15.3 billion, or 39% of gross product sales in 2020. The reduction is driven by changes in product mix, primarily due to higher Veklury sales in 2021. Of the $14.4 billion in 2021, $12.6 billion, or 30% of gross product sales, was related to government and other rebates and chargebacks and $1.8 billion was related to cash discounts for prompt payment, distributor fees, sales returns and other related costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Exchange Impact</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our total product sales, 29% and 26% were generated outside the United States in 2021 and 2020, respectively. We generally face exposure to movements in foreign currency exchange rates, primarily in the Euro. We use foreign currency exchange contracts to hedge a portion of our foreign currency exposures. Foreign currency exchange, net of hedges, had a favorable impact on our total product sales of $141 million in 2021, based on a comparison using foreign currency exchange rates from 2020, largely driven by Euro-based product sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our product sales: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">HIV Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="57" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Descovy (FTC/TAF) Based Products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Descovy (FTC/TAF) Based Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,302&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,729&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,021&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="57" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Truvada (FTC/TDF) Based Products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Truvada (FTC/TDF) Based Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,897&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,828&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,315&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,651&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,565&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,811&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">HCV Products</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">HBV/HDV Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Cell Therapy Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Cell Therapy </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Other Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,176&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,008&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,894&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine FTC and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs and Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our costs and expenses: </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,601&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">-560 bps</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (&#8220;R&amp;D&#8221;) expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Gross Margin</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, product gross margin decreased to 75.6% as compared to 81.2% in 2020, primarily due to a $1.25 billion charge for a settlement related to bictegravir litigation as well as an increase of $848 million in acquisition-related expenses from amortization of finite-lived intangible assets and recognition of inventory step-up charges primarily driven by our acquisitions of Immunomedics and MYR. Product gross margin was also impacted by higher inventory write-down charges and changes in product mix. The increases were partially offset by lower royalty expenses due to lower sales of products containing emtricitabine and elvitegravir and the reversal of a previously recorded $175 million litigation accrual following a favorable court decision related to axicabtagene ciloleucel.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of clinical studies performed by contract research organizations, materials and supplies, payments under collaborative and other arrangements including milestone payments, licenses and fees, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations consisting of various support and infrastructure costs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our R&amp;D expenses by identifying the R&amp;D activities we anticipate will be performed during a given period and then prioritizing efforts based on scientific data, probability of technical and regulatory successful development, market potential, available human and capital resources and other considerations. We continually review our R&amp;D projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities that we believe will best support the long-term growth of our business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, R&amp;D expenses increased by $324 million compared to 2020, primarily due to the Arcus collaboration opt-in charge of $625 million, as well as higher investments in Trodelvy and magrolimab clinical activities. These increases were partially offset by (i) a decline of approximately $200 million in external expenses related to wind-down or completion of certain remdesivir clinical studies, (ii) $190 million (&#8364;160 million) charge recorded in 2020 in connection with the agreement to amend the existing arrangement with Galapagos for the commercialization and development of Jyseleca, and (iii) lower stock-based compensation expense. R&amp;D expenses for 2020 included accelerated stock-based compensation expenses of $166 million related to our acquisitions of Immunomedics and Forty Seven.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses reflect IPR&amp;D impairments as well as the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;D projects. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses of $177 million in 2021 were related to licensing, collaboration, investment and other arrangements we entered into during the year. Acquired IPR&amp;D expenses of $5.9 billion in 2020 were primarily related to our acquisition of Forty Seven as well as collaborations and other investments we entered into during the year with Arcus, Pionyr, Tango, Tizona and Jounce.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses relate to sales and marketing, finance, human resources, legal and other administrative activities, including information technology investments. SG&amp;A expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses and other general and administrative costs. SG&amp;A expenses also include the Branded Prescription Drug (&#8220;BPD&#8221;) fee. In the United States, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the BPD fee, which is estimated based on select government sales during the prior year as a percentage of total industry government sales. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, SG&amp;A expenses increased by $95 million compared to 2020, primarily due to an expense of $212&#160;million related to the donation of certain equity securities at fair value to the Gilead Foundation, a California nonprofit organization (the &#8220;Foundation&#8221;), and increased commercial activities, including higher promotional and marketing activities primarily driven by Trodelvy. SG&amp;A expenses for 2020 included accelerated stock-based compensation expense of $204 million related to our acquisitions of Immunomedics and Forty Seven, and a charge of $97 million related to a U.S. Department of Justice investigation, which was settled in the third quarter of 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense and Other Income (Expense), Net</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Interest expense and Other income (expense), net:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,001)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(984)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(639)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for 2021 increased by $17 million, or 2%, compared to 2020, primarily due to an increase in borrowing related to the fourth quarter 2020 acquisition of Immunomedics, partially offset by lower interest expense due to debt maturities and repayments.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Other income (expense), net for 2021, compared to 2020, primarily reflects lower unrealized losses from fair value adjustments of our investments in equity securities largely driven by our investment in Galapagos, partially offset by lower interest income. Changes in the fair value of equity securities resulted in net unrealized losses of $610 million and $1.7 billion for the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Income tax (expense) benefit:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,278&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate decreased in 2021, compared to 2020, primarily due to a $4.5 billion acquired IPR&amp;D charge recorded in connection with our acquisition of Forty Seven and $511 million of certain other acquired IPR&amp;D charges in 2020 that were non-deductible for tax purposes.</span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_1099511629466"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents, and marketable debt securities were $7.8 billion and $7.9 billion as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net income for non-cash items and changes in operating assets and liabilities. Cash provided by operating activities increased by $3.2 billion to $11.4 billion in 2021 compared to 2020. The increase was primarily due to revenue growth from sales of Veklury as well as higher collection of receivables in 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities primarily consists of purchases, sales and maturities of our marketable debt securities, capital expenditures, acquisitions, including IPR&amp;D, net of cash acquired, purchases of equity securities and other investments.&#160;Cash used in investing activities was $3.1 billion in 2021 compared to $14.6 billion in 2020. The decrease in cash used in investing activities was primarily due to a decrease in cash outflows related to acquisitions, including IPR&amp;D, net of cash acquired. We made a $1.2 billion payment in the first quarter of 2021 for our acquisition of MYR as compared to the $4.7 billion and $20.6 billion payments made in 2020 related to our acquisitions of Forty Seven and Immunomedics, respectively. The decrease was partially offset by net cash generated by investing activities in 2020 related to proceeds from sales and maturities of marketable debt securities used to partially fund these acquisitions. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities for the year ended December&#160;31, 2021 was $8.9 billion, compared to cash provided by financing activities of $770 million in 2020. In 2021, we utilized cash for $4.75 billion of debt repayments, $3.6 billion of dividend payments and $546 million of common stock repurchases. In 2020, we obtained $8.2 billion in proceeds from debt financing, net of issuance costs, to fund our fourth quarter 2020 acquisition of Immunomedics, partially offset by cash utilized for $3.4 billion of dividend payments, $2.5 billion of debt repayments and $1.6 billion of common stock repurchases. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and Credit Facilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our borrowings under various financing arrangements is included in Note 12. Debt and Credit Facilities of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K. We may choose to repay certain of our long-term debt obligations prior to maturity dates based on our assessment of current and long-term liquidity and capital requirements.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes and Term Loan </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we repaid $4.75 billion of debt, consisting of $3.75 billion senior unsecured notes and $1.0 billion on our senior unsecured term loan facility. We repaid $1.0 billion of senior unsecured notes due April 2021 in the first quarter of 2021 and $1.25 billion of senior unsecured notes due December 2021 in the third quarter of 2021. Additionally, we repaid $500 million of senior unsecured notes due upon maturity in September 2021. In October 2021, we exercised our option to call $500 million of senior unsecured floating rate notes and $500 million of 0.75% senior unsecured notes, both having a final maturity date of September 2023. These two early repayments totaling $1.0&#160;billion principal amount were made in the fourth quarter of 2021. In December 2021, we exercised our option to call $500 million of senior unsecured notes having a final maturity of March 2022. The notes were repaid in February 2022. No new debt was issued in 2021. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of December&#160;31, 2021 and 2020, we were not in violation of any covenants.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics, we assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust prior to our acquisition of Immunomedics. The liability related to future royalties was primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 6. Acquisitions of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we terminated our $2.5 billion five-year revolving credit facility maturing in May 2021 (the &#8220;2016 Revolving Credit Facility&#8221;) and entered into a new $2.5 billion five-year revolving credit facility maturing in June 2025 (the &#8220;2020 Revolving Credit Facility&#8221;). The 2020 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of December&#160;31, 2021 and 2020, there were no amounts outstanding under the 2020 Revolving Credit Facility. The 2020 Revolving Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default. As of December&#160;31, 2021, we were in compliance with all covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Return Program</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The details of our Stock Repurchase Programs and Dividends are included in Note 15. Stockholders&#8217; Equity of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (the &#8220;2016 Program&#8221;), under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion&#160;stock repurchase program (the &#8220;2020 Program&#8221;), which will commence upon the completion of the&#160;2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchased 8 million and 22 million shares of our common stock under the 2016 Program for $546 million and $1.6 billion in 2021 and 2020, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the remaining authorized repurchase amount from both programs was $6.3 billion.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We declared and paid quarterly cash dividends for an aggregate amount of $3.6 billion or $2.84 per share of our common stock and $3.4 billion or $2.72 per share of our common stock in 2021 and 2020, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;1, 2022, we announced that our Board of Directors declared a quarterly cash dividend increase of 2.8% from $0.71 to $0.73 per share of our common stock, with a payment date of March&#160;30, 2022 to all stockholders of record as of the close of business on March&#160;15, 2022. Future dividends are subject to declaration by our Board of Directors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Resources</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing capital resources, supplemented by cash flows generated from our operations, will be adequate to satisfy our capital needs for the foreseeable future. Our future capital requirements will depend on many factors, including but not limited to the following:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the commercial performance of our current and future products;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the progress and scope of our R&amp;D efforts, including preclinical studies and clinical trials;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the cost, timing and outcome of regulatory reviews;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the expansion of our sales and marketing capabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the possibility of acquiring additional manufacturing capabilities or office facilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the possibility of acquiring other companies or new products;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">debt service requirements;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the establishment of additional collaborative relationships with other companies; and</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">costs associated with the defense, settlement and adverse results of government investigations and litigation.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future require additional funding, which could be in the form of proceeds from equity or debt financings. If such funding is required, we cannot guarantee that it will be available to us on favorable terms, if at all. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually evaluate our liquidity and capital resources, including our access to external capital to ensure that we can adequately and efficiently finance our operations. As of December 31, 2021, our material cash requirements consisted primarily of the repayment of outstanding borrowings, the remaining obligations for the one-time repatriation transition tax from the Tax Cuts and Jobs Act, our settlement related to bictegravir litigation, purchases of inventory, operating leases obligations, capital expenditures and milestone and other payments related to our collaborative agreements. See Notes 11. Collaborations and Other Arrangements, 12. Debt and Credit Facilities, 13. Leases, 14. Commitments and Contingencies and 18. Income Taxes of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information. We anticipate our cash requirements related to capital expenditures will increase in 2022 as compared to the prior year as we work to expand our site infrastructure and capabilities. </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_52"></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES, ESTIMATES AND JUDGMENTS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations is based on our Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate and base our estimates on historical experience and on various other market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the following critical accounting policies reflect the more significant judgments and estimates used in the preparation of our Consolidated Financial Statements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government and Other Rebates and Chargebacks </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Revenues from product sales, net of these deductions, are recorded only to the extent a significant reversal of the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other rebates and chargebacks are subject to a complex estimation process, which requires significant judgment by management in part due to the lag between the date of the product sales and the date the related rebates or chargeback claims are settled. Government and other rebates and chargebacks include amounts payable to payers and healthcare providers under various programs, and may vary by product, by payer and by individual payer plans. For qualified programs that can purchase our products through wholesalers or other distributors at a lower contractual price, the wholesalers or distributors charge back to us the difference between their acquisition cost and the lower contractual price. Rebates and chargebacks are estimated primarily based on product sales, and expected payer mix and discount rates, which require significant estimates and judgment. Additionally, in developing our estimates of government and other rebates and chargebacks, we consider the following: </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">historical and estimated payer mix;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">statutory discount requirements and contractual terms;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">historical claims experience and processing time lags;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimated patient population;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">known market events or trends; </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market research;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">channel inventory data obtained from our major U.S. wholesalers; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other pertinent internal or external information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consolidated activities and ending balances in our government and other rebates and chargebacks accounts:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Decrease/(Increase) to Product Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2021 sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to sales prior to 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,594&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,691)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2020 sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to sales prior to 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,560)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,060)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in 2021 include the impact of $617 million for changes in estimates related to our 2020 product sales, primarily in the United States. In 2020, we had assumed higher rebate claims from government payer segments resulting in part from the COVID-19 pandemic and its anticipated impacts, which did not materialize.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess and update our estimates each reporting period to reflect actual claims and other current information. We believe the methodology that we use to estimate our government and other rebates and chargebacks is reasonable and appropriate given the current facts and circumstances. However, actual results may differ significantly from our estimates. Historically, our actual government and other rebates and chargebacks claimed for prior periods have varied by less than 5% from our estimates. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other chargebacks that are payable to our direct customers are classified as reductions of Accounts receivable in our Consolidated Balance Sheets and totaled $671 million and $552 million as of December&#160;31, 2021 and 2020, respectively. See Note 10. Other Financial Information of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information. Government and other rebates that are payable to third party payers and healthcare providers are generally recorded in Accrued government and other rebates on our Consolidated Balance Sheets and totaled $3.2 billion and $3.5 billion as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:8.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions and Valuation of Intangibles</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain judgments to determine whether transactions should be accounted for as acquisitions of assets or as business combinations. If it is determined that substantially all of the fair value of gross assets acquired in a transaction is concentrated in a single asset (or a group of similar assets), the transaction is treated as an acquisition of assets. We evaluate the inputs, processes, and outputs associated with the acquired set of activities and assets. If the assets in a transaction include an input and a substantive process that together significantly contribute to the ability to create outputs, the transaction is treated as an acquisition of a business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which requires that assets acquired and liabilities assumed generally be recorded at their fair values as of the acquisition date. Excess of consideration over the fair value of net assets acquired is recorded as goodwill. Estimating fair value requires us to make significant judgments and assumptions. We perform impairment testing of goodwill annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In transactions accounted for as acquisitions of assets, no goodwill is recorded and contingent consideration, such as payments upon achievement of various developmental, regulatory and commercial milestones, generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date are expensed unless there is an alternative future use. In addition, product development milestones are expensed upon achievement. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have acquired, and expect to continue to acquire, intangible assets through asset acquisitions or business combinations. The identifiable intangible assets are measured at their respective fair values as of the acquisition date. Intangible assets acquired through business combinations are subject to potential adjustments within the measurement period, which may be up to one year from the acquisition date. The fair values of the intangible assets are generally determined using a probability-weighted income approach that discounts expected future cash flows to present value. The estimated net cash flows are discounted using a discount rate that is based on the estimated weighted-average cost of capital for companies with profiles similar to our profile and represents the rate that market participants would use to value the intangible assets. The discounted cash flow models used in valuing these intangible assets require the use of significant estimates and assumptions including but not limited to:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification of product candidates with sufficient substance requiring separate recognition;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of projected future cash flows including revenues and operating profits related to the products or product candidates;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the probability of technical and regulatory success for unapproved product candidates considering their stages of development;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and resources needed to complete the development and approval of product candidates;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate discount rate;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the life of the potential commercialized products and associated risks, including the inherent difficulties and uncertainties in developing a product candidate such as obtaining FDA and other regulatory approvals; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the viability of and potential alternative treatments in any future target markets.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the fair values used to record intangible assets acquired are based upon reasonable estimates and assumptions given the facts and circumstances as of the related valuation dates. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment and Amortization of Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to IPR&amp;D projects acquired in a business combination are capitalized as indefinite-lived intangible assets until the completion or abandonment of the associated R&amp;D efforts. During the period the assets are considered indefinite-lived, they are not amortized. When development is successfully completed, which generally occurs when regulatory approval is obtained, the associated assets are deemed finite-lived and amortized over their respective estimated useful lives beginning at that point in time primarily on a straight-line basis. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, composed of IPR&amp;D projects acquired in a business combination that lack regulatory approval at the time of acquisition, are tested for impairment annually, whenever events or changes in circumstances indicate that it is more likely than not that the assets are impaired and upon regulatory approval. Estimates of fair value result from a complex series of judgments about future events and uncertainties and make assumptions at a point in time (acquisition date or subsequent impairment assessment date). Changes in estimates and assumptions, including the timing of product launch, pricing reductions, failure to obtain anticipated regulatory approval, deterioration in U.S. and global financial markets or other unanticipated events and circumstances, may decrease the projected cash flows or increase the discount rate and could potentially result in an impairment charge.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition. If the carrying value of an intangible asset exceeds its estimated fair value, an impairment charge is recorded to write down the intangible asset to its estimated fair value. For example, in 2019, we recognized an $800&#160;million impairment charge related to IPR&amp;D projects primarily for the treatment of indolent B-cell non-Hodgkin lymphoma due to changes in estimated market opportunities. A high rate of failure is inherent in the discovery and development of new products. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are also periodically reviewed for changes in facts or circumstances resulting in a reduction to the estimated useful life of the asset, requiring the acceleration of amortization.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9. Goodwill and Intangible Assets of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Contingencies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. The most significant of these are described in Note 14. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K. It is not possible to determine the outcome of these matters. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of the inherent uncertainty and unpredictability related to these matters, accruals are based on what we believe to be the best information available at the time of our assessment, including the legal facts and circumstances of the case, status of the proceedings, applicable law and the views of legal counsel. Upon the final resolution of such matters, it is possible that there may be a loss in excess of the amount recorded, and such amounts could have a material adverse effect on our results of operations, cash flows or financial position. We periodically reassess these matters when additional information becomes available and adjust our estimates and assumptions when facts and circumstances indicate the need for any changes. In the fourth quarter of 2021, we recorded an accrual of $1.25 billion in Accrued and other current liabilities on our Consolidated Balance Sheets for the settlement related to bictegravir litigation. See Note 14. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our income tax provision, including deferred tax assets and liabilities, based on significant management judgment. We evaluate the realization of our deferred tax assets each reporting period. We record a valuation allowance to reduce our deferred tax assets to the amounts that are more likely than not to be realized. We consider future taxable income, ongoing tax planning strategies and our historical financial performance in assessing the need for a valuation allowance. If we expect to realize deferred tax assets for which we have previously recorded a valuation allowance, we will reduce the valuation allowance in the period in which such determination is first made. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the United States and various foreign jurisdictions, including Ireland. Due to economic and political conditions, various countries are actively considering or have made changes to existing tax laws. We cannot predict the form or timing of potential legislative changes that could have a material adverse impact on our results of operations. In addition, significant judgment is required in determining our worldwide provision for income taxes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (&#8220;UTB&#8221;) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax (expense) benefit on our Consolidated Statements of Income. </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements issued nor adopted during the year ended December&#160;31, 2021 that are of significance to us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:60.75pt;text-align:justify;text-indent:-60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks that may result from changes in foreign currency exchange rates, interest rates, credit risks and market prices. To reduce certain of these risks, we enter into various types of foreign currency or interest rate derivative hedging transactions, follow investment guidelines and monitor outstanding receivables as part of our risk management program.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Exchange Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in more than 35 countries worldwide. As a result, our financial results could be significantly affected by factors such as changes in foreign currency exchange rates or weak economic conditions in the foreign markets in which we distribute our products. Our operating results are exposed to changes in foreign currency exchange rates between the U.S. dollar and various foreign currencies, the most significant of which is the Euro. When the U.S. dollar strengthens against these currencies, the relative value of sales made in the respective foreign currency decreases. Conversely, when the U.S. dollar weakens against these currencies, the relative value of such sales increase. Overall, we are a net receiver of foreign currencies and, therefore, we benefit from a weaker U.S. dollar and are adversely affected by a stronger U.S. dollar. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 26% of our product sales were denominated in foreign currencies during 2021. To partially mitigate the impact of changes in currency exchange rates on net cash flows from our foreign currency denominated sales, we may enter into foreign currency exchange forward or option contracts. We also hedge certain monetary assets and liabilities denominated in foreign currencies, which reduces but does not eliminate our exposure to currency fluctuations between the date a transaction is recorded and the date that cash is collected or paid. In general, the market risks of these contracts are offset by corresponding gains and losses on the transactions being hedged. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, we had open foreign currency forward contracts with notional amounts of $2.9 billion and $2.4 billion, respectively. A hypothetical 10% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December&#160;31, 2021 and 2020 would have resulted in a reduction in fair value of these contracts of approximately $333 million and $249 million, respectively, and if realized, would have negatively affected earnings over the remaining life of the contracts. The analysis does not consider the impact that hypothetical changes in foreign currency exchange rates would have on anticipated transactions that these foreign currency sensitive instruments were designed to offset.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of available-for-sale debt securities and our senior unsecured notes create an exposure to interest rate risk. With respect to our investment portfolio, we adhere to an investment policy that requires us to limit amounts invested in securities based on credit rating, maturity, industry group and investment type and issuer, except for securities issued by the U.S. government. The goals of our investment policy, in order of priority, are as follows: </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> safety and preservation of principal and diversification of risk; </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> liquidity of investments sufficient to meet cash flow requirements; and </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> a competitive after-tax rate of return. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the expected maturities and average interest rates of our interest-generating assets and interest-bearing liabilities as of December&#160;31, 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.515%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expected Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;Total Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior unsecured fixed rate notes, including current portion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Amounts represent principal balances. In addition to the senior unsecured fixed rate notes, we have a $2.5 billion five-year revolving credit facility that matures in June 2025. There were no amounts outstanding under the five-year revolving credit facility as of December&#160;31, 2021. See Note 12. Debt and Credit Facilities of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Price Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold shares of common stock of certain publicly traded biotechnology companies primarily in connection with license and collaboration agreements. These equity securities are measured at fair value with any changes in fair value recognized in earnings. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of these equity securities was approximately $1.8 billion and $2.4 billion as of December&#160;31, 2021 and 2020, respectively. Changes in fair value of these equity securities are impacted by the volatility of the stock market and changes in general economic conditions, among other factors. A hypothetical 20% increase or decrease in the stock prices of these equity securities would have increased or decreased their fair value as of December&#160;31, 2021 and 2020 by approximately $364 million and $478 million, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span><br/></span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_70"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December&#160;31, 2021, 2020 and 2019 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_73">Report of Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83MC9mcmFnOjRlMTVlZWIyODczYTQ5NTZiOTQ0YWVkZTQ4NGFiN2M5L3RhYmxlOjY0OTgzODk3NWYxZDRlYWViMzIzMTlmYWY3ZGNmYzVkL3RhYmxlcmFuZ2U6NjQ5ODM4OTc1ZjFkNGVhZWIzMjMxOWZhZjdkY2ZjNWRfMC0wLTEtMS05NzUxMC90ZXh0cmVnaW9uOjhjNjUwNjljODNlMjQyNGZiMzI3YjBhNWQzODZlNmEzXzU0OTc1NTgxMzkwNjg_d25c54c3-8fbf-4f02-ba1c-00db3101e9eb">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_73">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_73">50</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_76">Audited Consolidated Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_79">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_79">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_82">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_82">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_85">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_85">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_88">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_88">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_91">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_91">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_94">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_94">57</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Gilead Sciences, Inc.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Gilead Sciences, Inc. (the Company) as of December&#160;31, 2021 and 2020, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;23, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Government and commercial rebates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully described in Note 1, the Company estimates reductions to its revenues for amounts payable to payers and healthcare providers in the United States under various government and commercial rebate programs in the period that the related sales occur. Rebates may vary by product, payer and individual payer plans, some of which may not be known at the point of sale. Estimated reductions to revenue are based on product sales, historical and expected payer mix, discount rates, and various other estimated and actual data, adjusted for current period expectations.</span></div><div style="margin-bottom:12pt;margin-top:4.5pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s estimated reductions to revenue for rebates was complex and involved significant judgment, particularly in assessing the reasonableness of estimated payer mix applied to sales during the period. This estimate relies heavily on historical data that is adjusted for changes in payer mix expectations over time.</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4.5pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated and tested the design and operating effectiveness of the Company&#8217;s internal controls over management&#8217;s estimation and review of reductions from revenue for rebate programs, including controls to assess the payer mix assumption. We also tested the completeness and accuracy of data utilized in the controls, and the accuracy of calculations supporting management&#8217;s estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test management&#8217;s estimation methodology for determining the payer mix, our audit procedures included, among others, analytically evaluating management&#8217;s estimates, evaluating evidence contrary to the estimated amounts, performing a sensitivity analysis on the rates used in the estimates and performing a comparison of actual payments related to amounts accrued during the current and prior years.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Valuation of in-process research and development intangible assets acquired from Immunomedics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company&#8217;s in-process research and development (IPR&amp;D) intangible assets acquired in connection with the 2020 acquisition of Immunomedics, Inc. were $14.7 billion. As discussed in Note 1, intangible assets with indefinite useful lives related to purchased IPR&amp;D projects are measured at their respective fair values as of the acquisition date and are considered indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. The Company tests indefinite-lived intangible assets for impairment on an annual basis and in between annual tests if they become aware of any events or changes that would indicate the fair values of the assets are below their carrying amounts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the impairment test of the IPR&amp;D intangible assets acquired from Immunomedics was complex due to the significant judgment required in estimating their fair values. In particular, the fair value estimates required the use of valuation methodologies that were sensitive to significant assumptions (e.g., discount rate, probability of technical and regulatory success, addressable patient population, treatment duration and projected market share), which were affected by expected future market or economic conditions. </span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated and tested the design and operating effectiveness of the Company&#8217;s internal controls over the determination of the estimated fair value of the IPR&amp;D intangible assets acquired from Immunomedics. For example, we tested controls over management's review of the valuation methodologies and the significant assumptions used to develop the fair value estimates. We also tested management's controls to validate that the data used in the fair value estimates were complete and accurate. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the estimated fair value of the Company's IPR&amp;D intangible assets acquired from Immunomedics, our audit procedures, among others, included evaluating the Company's use of appropriate valuation methodologies with assistance from a valuation specialist, evaluating sensitivity analyses to determine which assumptions had the greatest impact on the overall determination of value, and testing the completeness and accuracy of the underlying data. Our audit procedures over the most significant assumptions included comparing the assumptions to current industry, market and economic trends, to historical results of the Company's business and other guideline companies within the same industry and to other relevant factors. For example, we evaluated the probability of technical and regulatory success by considering the phase of development of the clinical projects, and the Company's history of obtaining regulatory approval. In addition, we evaluated the expected addressable patient populations by comparing the Company&#8217;s estimates to external industry forecasts. </span></div></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83My9mcmFnOjlkYmU3ZjlkMDdmMTQ4MTFhODFhZWNlZjgzMDFhNDRiL3RleHRyZWdpb246OWRiZTdmOWQwN2YxNDgxMWE4MWFlY2VmODMwMWE0NGJfNTQ5NzU1ODE0NTYxNw_fdc33d8e-ad39-4b15-b2df-c4a107598ab9">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1988.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83My9mcmFnOjlkYmU3ZjlkMDdmMTQ4MTFhODFhZWNlZjgzMDFhNDRiL3RleHRyZWdpb246OWRiZTdmOWQwN2YxNDgxMWE4MWFlY2VmODMwMWE0NGJfNTQ5NzU1ODE0NTYxOA_9206e1f9-6c1e-4df2-8d8a-ffd9956dd615">San Jose, California</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2022</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_79"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC. </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNC0yLTEtMS0xMjE0MA_28939bc8-360a-4bbd-94b9-7e3279b23482">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNC00LTEtMS0xMjE0MA_168d7cb3-474e-4d33-bdd8-2be5677eb66d">5,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNS0yLTEtMS0xMjE0MA_342173c0-73ec-4c2e-96e1-5ad13e34753b">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNS00LTEtMS0xMjE0MA_a088a3a6-4e7e-43cd-b6b5-cc9cdb51054b">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNi0yLTEtMS0xMjE0MA_516f5860-617f-4083-9134-58d19f7554d3">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNi00LTEtMS0xMjE0MA_a505d8a2-b36f-4d31-b754-5c90c80ecbd7">4,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNy0yLTEtMS0xMjE0MA_a70bb646-3b03-4155-8326-535942408f70">1,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNy00LTEtMS0xMjE0MA_ff3e5391-9609-420a-b1bb-523823278433">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfOC0yLTEtMS0xMjE0MA_acb74504-69eb-4b85-af67-a299db4b5c51">2,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfOC00LTEtMS0xMjE0MA_fa0590a5-3c92-4230-8ab8-d519cb45f1f7">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfOS0yLTEtMS0xMjE0MA_434eb767-8949-4a58-b46e-6b61e61277b9">14,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfOS00LTEtMS0xMjE0MA_999d4a56-36bd-44c2-bf26-c738891f5bf0">15,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTAtMi0xLTEtMTIxNDA_dc7a1ad1-bbae-4058-a803-b518de11be37">5,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTAtNC0xLTEtMTIxNDA_f58af908-5b82-4965-b744-48eeb95535b3">4,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTEtMi0xLTEtMTIxNDA_58d952bd-fc4c-4b16-90cf-86e7d71e9cec">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTEtNC0xLTEtMTIxNDA_9b9cd04f-53b7-43ff-9009-5cc4d1e9773c">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTItMi0xLTEtMTIxNDA_c5236807-3d83-44f1-a7d0-416e51252b06">33,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTItNC0xLTEtMTIxNDA_6e47104e-9712-470b-b09b-2964ca6180ac">33,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTMtMi0xLTEtMTIxNDA_ba41d54d-b0fb-4e44-bcdf-0312a5ccb4d4">8,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTMtNC0xLTEtMTIxNDA_2e7f9794-2c34-4dde-9f31-3f2d595dd48d">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTQtMi0xLTEtMTIxNDA_fc618e8b-9921-4bc4-a9a3-19f8daf8c95e">4,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTQtNC0xLTEtMTIxNDA_0260c83a-d7d3-43c0-bc71-42b44fc1207c">5,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTUtMi0xLTEtMTIxNDA_f061996a-d519-43aa-bb25-b975074c8a87">67,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTUtNC0xLTEtMTIxNDA_7a6a65f1-00b0-493c-9bab-432754232222">68,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTgtMi0xLTEtMTIxNDA_899e6df7-bf8e-451b-8cd3-95bbb73aed97">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTgtNC0xLTEtMTIxNDA_5a0bcfa2-cb53-4219-8de4-49ca70293cd7">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued government and other rebates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="gild:AccruedGovernmentAndOtherRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTktMi0xLTEtMTIxNDA_7c4f6037-6cb0-4a91-8a36-c47b7f0f0648">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="gild:AccruedGovernmentAndOtherRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTktNC0xLTEtMTIxNDA_27c28934-e308-4d94-a2ad-d03e8cce2505">3,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjAtMi0xLTEtMTIxNDA_3ccad514-cc4f-411a-aed6-c657364ac10e">6,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjAtNC0xLTEtMTIxNDA_4823903a-88bd-46ec-b24b-70af8281603c">4,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt and other obligations, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjEtMi0xLTEtMTIxNDA_77ff1eac-035b-4982-9c29-2b91022e1c22">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjEtNC0xLTEtMTIxNDA_cd455780-4c93-439f-8c3c-d64341918f3e">2,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjItMi0xLTEtMTIxNDA_5ea7f7ce-6922-4369-844a-887491d96570">11,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjItNC0xLTEtMTIxNDA_a0f2ed74-68f7-4f15-aeda-a74a349bf32c">11,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjMtMi0xLTEtMTIxNDA_18793d24-fd46-4443-a126-f2c18e776d49">25,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjMtNC0xLTEtMTIxNDA_5fee0b5b-c00e-4b7a-b523-dda294c64ce0">28,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjQtMi0xLTEtMTIxNDA_7321422f-398a-4f26-a600-67ae9e4f04fe">4,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjQtNC0xLTEtMTIxNDA_668efb65-5a76-48ba-a7e2-c1e6e99c82e5">5,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjUtMi0xLTEtNzA3NTk_9e505394-5b6a-42de-8867-44523b0a8c43">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjUtNC0xLTEtNzA3NzY_134c288c-92e2-41b1-b269-6dcbec5e21f1">3,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjUtMi0xLTEtMTIxNDA_bdaf9822-4cc5-4375-bac8-0c060658085e">976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjUtNC0xLTEtMTIxNDA_7505dde3-ae32-407b-bb7a-b3c8145494d3">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjYtMi0xLTEtMTIxNDA_d4c2fcab-9c0b-4e70-8d48-1e74e7529474"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjYtNC0xLTEtMTIxNDA_977a7606-d9d3-47e4-9220-cc36b7ff705c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo4NTE5YmM0MmM4MmE0Zjg3YTUyODhiZjQyMGFkYWY5Zl8zMQ_599f69ee-34b7-4997-9577-3771ef7605a2"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo4NTE5YmM0MmM4MmE0Zjg3YTUyODhiZjQyMGFkYWY5Zl8zMQ_f34feac3-f0c4-407c-a9cc-01bc31a864a5">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo4NTE5YmM0MmM4MmE0Zjg3YTUyODhiZjQyMGFkYWY5Zl80NQ_2efac5d4-1070-4b2b-a67d-0f00ef16cea3"><ix:nonFraction unitRef="shares" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo4NTE5YmM0MmM4MmE0Zjg3YTUyODhiZjQyMGFkYWY5Zl80NQ_5486d027-4509-4829-b657-a7292c12b205">5</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo4NTE5YmM0MmM4MmE0Zjg3YTUyODhiZjQyMGFkYWY5Zl82Nw_58d1851f-912c-4cb6-af13-a85300970de8"><ix:nonFraction unitRef="shares" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo4NTE5YmM0MmM4MmE0Zjg3YTUyODhiZjQyMGFkYWY5Zl82Nw_92634f53-aebb-48ff-9248-9480bf09ae8b">no</ix:nonFraction></ix:nonFraction>ne outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMi0xLTEtMTIxNDA_4033250b-0dd2-4225-a468-a3bd287ae375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtNC0xLTEtMTIxNDA_9967b6ef-38a3-478b-8441-be2d54f13b88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF8yOA_6839cdbb-3d3f-40d8-900e-d9fb7b3c9f8f"><ix:nonFraction unitRef="usdPerShare" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF8yOA_f8c26046-c8ac-4a31-85e1-08e739f79a92">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF80Mg_1a63efec-8677-4fe4-8a76-df1d8b77a462"><ix:nonFraction unitRef="shares" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF80Mg_e57b97cb-41c1-4b16-9d75-7147b36a1f00">5,600</ix:nonFraction></ix:nonFraction> authorized; <ix:nonFraction unitRef="shares" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF81Nw_04305930-f24c-47e8-8611-3612958c9b90"><ix:nonFraction unitRef="shares" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF81Nw_0ea420cd-35bf-4098-99e8-6f52aca5e58f"><ix:nonFraction unitRef="shares" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF81Nw_3e27b6f4-1043-4df0-a96b-7e437aafe0cf"><ix:nonFraction unitRef="shares" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF81Nw_e8983144-fb39-464c-816a-17c5180ffaa6">1,254</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2021 and 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMi0xLTEtMTIxNDA_f8cd6dd9-c3ce-479d-8db0-5b8b3c3f58da">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktNC0xLTEtMTIxNDA_d0a81118-394e-421d-bd5c-2c8daf38ffbd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzAtMi0xLTEtMTIxNDA_3b1fcba0-beb5-4ba3-a29d-26a924d3beb9">4,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzAtNC0xLTEtMTIxNDA_359bdb98-5610-4ef2-8141-f5be67bdf1f0">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzEtMi0xLTEtMTIxNDA_b49b1de0-aa77-4019-bd97-6c0d1e5f3c11">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzEtNC0xLTEtMTIxNDA_1bc56eec-9356-4acf-8e9c-89b6e1e0dbe8">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzItMi0xLTEtMTIxNDA_bb22b1b4-aeb3-4903-a035-d249cbdf7458">16,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzItNC0xLTEtMTIxNDA_0c76f127-0b55-47dc-8cb7-173872f7089c">14,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Gilead stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzMtMi0xLTEtMTIxNDA_7fc24bb8-d50c-4fdd-98a6-e3107ded0137">21,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzMtNC0xLTEtMTIxNDA_4d72a38b-f66d-490e-82a8-05e27da572df">18,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzQtMi0xLTEtMTIxNDA_5145de7a-5aa3-4b4c-90cd-9fb5763b8653">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzQtNC0xLTEtMTIxNDA_af668807-3a14-4265-8d13-1f8c64801cfa">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzUtMi0xLTEtMTIxNDA_f78f3d60-a4ca-493f-ad8f-cb9a4dc6329e">21,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzUtNC0xLTEtMTIxNDA_85f2e534-1c6c-49df-8222-a295f4b2c494">18,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzYtMi0xLTEtMTIxNDA_4dd09549-2f36-4e35-a5da-ac54e2c143aa">67,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzYtNC0xLTEtMTIxNDA_6ff78528-2ce3-41e6-b3a5-4e3acdfa40d4">68,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC. </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4befd4212fc4248a63e9b436b533760_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMy0yLTEtMS0xMjE0MA_5ebd70c0-58d6-4bb1-9aa2-fe084b0a1c43">27,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c51a506a019465dba53c1f088a945dd_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMy00LTEtMS0xMjE0MA_7e884272-f9f9-4763-8a11-a26b1a3836b3">24,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i203243bdd8194063a5b0d20127c91ead_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMy02LTEtMS0xMjE0MA_8fe819f9-a1bc-4850-b195-496e4da719f9">22,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aad07ceecdc471a9ee9d0a50de54618_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNC0yLTEtMS0xMjE0MA_25123195-845a-4e2c-af7f-051bfb1d19f7">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c80ef090990421ba4cb204bcc7a4aed_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNC00LTEtMS0xMjE0MA_ff64c034-6397-400c-b706-875193818985">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f35d93745f44ac84aacec6dc9540d1_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNC02LTEtMS0xMjE0MA_91670cf2-dca3-41e3-b45b-f214083590f0">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNS0yLTEtMS0xMjE0MA_ff7f44ca-700b-4edb-9259-715134ad3e01">27,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNS00LTEtMS0xMjE0MA_d1ed0952-11f8-476b-ba76-485f08847081">24,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNS02LTEtMS0xMjE0MA_b4e490d3-d42a-4a0f-9baf-fd0b55c2fcdb">22,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNy0yLTEtMS0xMjE0MA_74148df6-d6a8-4fcb-9343-2428a67e9c6f">6,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNy00LTEtMS0xMjE0MA_1f3dfc1b-6453-40be-b386-ac12ea03d3fb">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNy02LTEtMS0xMjE0MA_5423225a-1079-49df-aabe-22c1baefafa4">4,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfOC0yLTEtMS0xMjE0MA_7cc6042c-fc89-4d9d-b456-abcee98fe8b6">5,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfOC00LTEtMS0xMjE0MA_0c5916f0-63ba-485f-bdd3-9a2e3da82a75">5,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfOC02LTEtMS0xMjE0MA_f0109506-b230-4c31-acd0-7f38d2a6fc9d">4,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="gild:ResearchAndDevelopmentInProcessIncludingImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfOS0yLTEtMS0xMjE0MA_1e975d66-9960-420d-9faf-ea273075f414">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="gild:ResearchAndDevelopmentInProcessIncludingImpairment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfOS00LTEtMS0xMjE0MA_3ad3791e-36ea-47a4-9b6d-a0a45c38ce4f">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="gild:ResearchAndDevelopmentInProcessIncludingImpairment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfOS02LTEtMS0xMjE0MA_d1577657-0356-474a-a0f0-9e0153424a27">5,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTAtMi0xLTEtMTIxNDA_54328236-6ffd-4d79-862e-645aa457f3fa">5,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTAtNC0xLTEtMTIxNDA_fd46c80c-7406-417a-bd4c-02ffcd3cafaa">5,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTAtNi0xLTEtMTIxNDA_ce00e218-4b19-4b16-9755-fd53e451196a">4,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTEtMi0xLTEtMTIxNDA_8340bbd3-27e7-4010-b879-450d6ca0fc1d">17,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTEtNC0xLTEtMTIxNDA_087587ed-c4cb-4d8b-b6b9-be81e3103ac9">20,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTEtNi0xLTEtMTIxNDA_83f7c113-83c4-4acb-96cf-5fda44ad4d0f">18,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTItMi0xLTEtMTIxNDA_1d42be18-473f-4eb3-97fc-b4698a5f8969">9,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTItNC0xLTEtMTIxNDA_60102a28-97cc-437c-97aa-ce35b8c2b9a7">4,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTItNi0xLTEtMTIxNDA_bb8c1b8f-63c5-4c09-9e3c-3514b359c67b">4,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTMtMi0xLTEtMTIxNDA_e86e369a-94e2-48cf-9bb4-499b98020360">1,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTMtNC0xLTEtMTIxNDA_98033442-680c-46ba-9ab6-01b407de4f93">984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTMtNi0xLTEtMTIxNDA_46eedad2-22f4-4745-8e7f-64ecaddb7717">995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTQtMi0xLTEtMTIxNDA_dba860ad-be89-4a82-a1d3-047f64367bb2">639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTQtNC0xLTEtMTIxNDA_740168dd-946b-451e-90e4-43bd59ab8726">1,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTQtNi0xLTEtMTIxNDA_c1a55473-3c21-418a-9183-218266730804">1,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTUtMi0xLTEtMTIxNDA_6bb17998-2e2a-451a-9cde-e79d9ab5e9ce">8,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTUtNC0xLTEtMTIxNDA_f732e7dd-2ed2-43d7-86ca-14fbf55d09f0">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTUtNi0xLTEtMTIxNDA_a4032ea3-2e3d-40d4-8c55-d7986dc09313">5,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTYtMi0xLTEtMTIxNDA_572581bb-6f75-4516-ac5f-52acb341c608">2,077</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTYtNC0xLTEtMTIxNDA_6a896311-8972-43ec-954c-59d77e3fe3c5">1,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTYtNi0xLTEtMTIxNDA_2934bee4-a3e5-4b21-bf95-108cb9b2f756">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTctMi0xLTEtMTIxNDA_48752ffa-62b8-445f-a014-79bfeb57b5e9">6,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTctNC0xLTEtMTIxNDA_a29e08bb-fd26-4b6e-9cb1-1f719e882a59">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTctNi0xLTEtMTIxNDA_9cad29a0-e125-4971-988b-a8c96302cfc4">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTgtMi0xLTEtMTIxNDA_d06262c2-a4ed-4a5e-85fb-d09dbbbf9f91">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTgtNC0xLTEtMTIxNDA_49e8a1f7-489f-4eaa-995c-30fc47841bbd">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTgtNi0xLTEtMTIxNDA_ac3df37c-a1e7-4bf5-99f4-b06fe761a1ba">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTktMi0xLTEtMTIxNDA_4d035083-75f9-4c53-8ca3-067bb21abdbe">6,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTktNC0xLTEtMTIxNDA_564c8740-2759-4cde-9706-636e6119d92d">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTktNi0xLTEtMTIxNDA_75966fcf-33a2-4d0f-aca7-ecf019810de9">5,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjAtMi0xLTEtMTIxNDA_f451b2d5-dff5-42b7-aee2-9e0ade70c961">4.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjAtNC0xLTEtMTIxNDA_bb894a0a-b337-47ba-a7b6-8739bc4a5872">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjAtNi0xLTEtMTIxNDA_07c678cc-c490-45b0-b781-e11dcb1486df">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjEtMi0xLTEtMTIxNDA_edf0c737-0c72-42a5-9086-6025aec472b1">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjEtNC0xLTEtMTIxNDA_9a729d9f-478e-40ae-8618-149e41c3b76b">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjEtNi0xLTEtMTIxNDA_ffbcc2a5-a295-461f-95b7-6366a189ab51">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjItMi0xLTEtMTIxNDA_901700f4-5b8d-43f5-920e-0b6418eae4d8">4.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjItNC0xLTEtMTIxNDA_488c9450-b9dd-4a19-b201-86cc053e239b">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjItNi0xLTEtMTIxNDA_ed4779fd-bb9b-4031-8dc0-c751bb10ed14">4.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjMtMi0xLTEtMTIxNDA_28e10d48-0e3e-477c-84b2-9065c362e132">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjMtNC0xLTEtMTIxNDA_f35b19a5-7c12-46aa-beb0-3802adf71e48">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjMtNi0xLTEtMTIxNDA_c0468eae-2296-4e41-96b1-08e250eba65c">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMi0yLTEtMS0xMjE0MA_48752ffa-62b8-445f-a014-79bfeb57b5e9">6,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMi00LTEtMS0xMjE0MA_a29e08bb-fd26-4b6e-9cb1-1f719e882a59">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMi02LTEtMS0xMjE0MA_9cad29a0-e125-4971-988b-a8c96302cfc4">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNC0yLTEtMS0xMjE0MA_224ca06f-04ef-49eb-84c9-67a5a1562658">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNC00LTEtMS0xMjE0MA_23b1248e-8580-403e-98df-97e95fc53fe4">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNC02LTEtMS0xMjE0MA_70a23d05-cf5d-475d-a3a4-6914044890e1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss), net of tax </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNi0yLTEtMS0xMjE0MA_2b0f06ae-cd22-43a3-ac87-4637d3385fda">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNi00LTEtMS0xMjE0MA_818baaab-5bae-463b-a645-6654f53ac0e4">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNi02LTEtMS0xMjE0MA_adca0572-d87d-4e13-857f-80ce4811be12">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income, net of tax </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNy0yLTEtMS0xMjE0MA_479ee4e8-e8ee-48f7-8d89-e1d062a9527f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNy00LTEtMS0xMjE0MA_1e96b240-5f12-48fc-bb6d-76c3e686c957">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNy02LTEtMS0xMjE0MA_f2fc6b16-a412-4f47-ad0b-69865aabdc18">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfOC0yLTEtMS0xMjE0MA_67ebdf88-c061-4051-9d00-5424ce6ae36f">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfOC00LTEtMS0xMjE0MA_7869f7a5-1db2-4c49-8730-74cbce7de540">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfOC02LTEtMS0xMjE0MA_92c92a0a-d06c-431e-99e2-d7d201bbc478">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss), net of tax </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTAtMi0xLTEtMTIxNDA_49782dd9-d655-4781-b71a-26ccc7e47f6b">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTAtNC0xLTEtMTIxNDA_d30c15f4-160b-4882-b789-91e595895704">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTAtNi0xLTEtMTIxNDA_d73bc5e8-710c-450a-8afc-7cc96ea90295">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income, net of tax </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTEtMi0xLTEtMTIxNDA_c95f91df-554c-4c79-8399-a1e91d1babd3">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTEtNC0xLTEtMTIxNDA_7dacc1d3-6d6f-437e-9810-76a16ebc4ff5">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTEtNi0xLTEtMTIxNDA_e761576b-d191-4662-9701-bc3810563c7e">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTItMi0xLTEtMTIxNDA_b911d015-e76b-44c9-a3df-09f0ba1b77d6">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTItNC0xLTEtMTIxNDA_093abef2-4776-4319-8fdf-411e0478f275">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTItNi0xLTEtMTIxNDA_367c4632-a51e-4855-b0d2-6b889e8ba785">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTMtMi0xLTEtMTIxNDA_87a89463-68f9-4f69-b619-659e3370dd82">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTMtNC0xLTEtMTIxNDA_5488c9a0-5d8f-4284-9234-8d3139099a06">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTMtNi0xLTEtMTIxNDA_8a495226-4337-4526-9f2a-2c243df2a22f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTQtMi0xLTEtMTIxNDA_47c32316-d28a-409a-9d5a-a73e20ad5bae">6,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTQtNC0xLTEtMTIxNDA_4ac4137b-e752-4827-a178-3a09f4c72795">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTQtNi0xLTEtMTIxNDA_ffbcfe17-bb56-4162-a1ff-5415b0596384">5,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTUtMi0xLTEtMTIxNDA_4caea9cf-df53-48f2-bf61-447b424b51cb">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTUtNC0xLTEtMTIxNDA_5d25d6ef-0d21-449a-a78e-cb73888e69e2">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTUtNi0xLTEtMTIxNDA_51e76f4c-6f5d-4d23-ab5f-d3252fe2e5ff">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTYtMi0xLTEtMTIxNDA_5d44ca22-a14c-4cbf-ba0c-a728ebb8b8ac">6,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTYtNC0xLTEtMTIxNDA_dd03d907-f867-4d3f-b817-c78ff6c25f05">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTYtNi0xLTEtMTIxNDA_3c40d3c0-8d14-480b-a6a0-493c7235f3bc">5,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC. </span></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income (Loss)</span></div></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8555f34a84a4c3887459093bd255d74_I20181231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtMi0xLTEtMTIxNDA_f49787c3-c7de-4bc8-b833-0c8ac7722be5">1,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8555f34a84a4c3887459093bd255d74_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtNC0xLTEtMTIxNDA_b9fd6a71-e22a-4097-ae07-bc969870f523">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7703ce81d19946348842d9982c50c0c4_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtNi0xLTEtMTIxNDA_4b7df92c-c70c-41ca-88e7-eb6a6bedb6a1">2,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id46d2d21dd6a43a89e740948d75f9380_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtOC0xLTEtMTIxNDA_67fd1c94-02ea-4f9a-91de-73f429fc7081">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7602de391c434d368154fe3329c135b4_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtMTAtMS0xLTEyMTQw_2a2d4961-06f5-49a2-84c2-529d9931e532">19,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i890acc6b92a24d29907006991e3f99d3_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtMTItMS0xLTEyMTQw_b6f8adb2-dd17-4d95-95e8-c1ad25d1244f">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8222e290a2284cb0bf64a4ac2b6995b5_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtMTQtMS0xLTEyMTQw_98fa632c-a7f8-4f5e-8534-2e9503164a06">21,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect from the adoption of new accounting standards </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie196e7c846694582b374a274089a496d_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTQtMTAtMS0xLTEyMTQw_33316bc7-c87b-45c2-8c10-11f5b5faaf47">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib588e93b222b4f21902099d1901de114_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTQtMTQtMS0xLTEyMTQw_8c1e2521-5b99-4127-96e9-41316be4730c">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3d1ac282964e3380614a0c573278a4_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTUtMTAtMS0xLTEyMTQw_aedf12d3-b79e-4a20-ad87-798421572c4b">5,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb1cc1349e424089965fc6662bf35a48_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTUtMTItMS0xLTEyMTQw_6f83b116-9c28-4087-bd4c-07aa492aee1c">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTUtMTQtMS0xLTEyMTQw_4f21f5f7-9264-4ac8-a2d2-6ad9a0c5a182">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01dacb3a581346e187edae0a347d2eeb_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTYtOC0xLTEtMTIxNDA_68983345-2204-4239-b8c9-31f157b012e5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTYtMTQtMS0xLTEyMTQw_39437252-99fe-46b9-a40f-9f6b4e830e00">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85a0c1ca4ff4429d9883b9d439e8e910_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTctMi0xLTEtMTIxNDA_6f9d08da-d716-49bc-b21c-a558999528b5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a8d6544a084df5b9c6407ecb2d93a0_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTctNi0xLTEtMTIxNDA_5ccfc5b8-b77b-4b28-810e-0c255103f7cf">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTctMTQtMS0xLTEyMTQw_85f3d648-8856-4b3d-892c-6cb24f71a093">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85a0c1ca4ff4429d9883b9d439e8e910_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTgtMi0xLTEtMTIxNDA_10074d67-90fb-4565-b774-00834d945531">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a8d6544a084df5b9c6407ecb2d93a0_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTgtNi0xLTEtMTIxNDA_c5e37dc7-aa32-48dc-8055-879bb0fdfcb3">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTgtMTQtMS0xLTEyMTQw_aa0ffc3f-10a9-4f25-866a-0394e04a3d1e">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a8d6544a084df5b9c6407ecb2d93a0_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTktNi0xLTEtMTIxNDA_5fedeb52-3c65-42a2-a1f0-0037ff4800c7">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTktMTQtMS0xLTEyMTQw_45d0ffbc-037f-420e-a4df-570bca829dce">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i85a0c1ca4ff4429d9883b9d439e8e910_D20190101-20191231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjAtMi0xLTEtMTIxNDA_d83cf83d-b30b-4233-b6a3-610620f8f2bf">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33a8d6544a084df5b9c6407ecb2d93a0_D20190101-20191231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjAtNi0xLTEtMTIxNDA_b6ba4586-5452-4100-bf04-342f36693483">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3d1ac282964e3380614a0c573278a4_D20190101-20191231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjAtMTAtMS0xLTEyMTQw_0b18d29d-4d49-4cf3-a76e-f4b646c616ab">1,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjAtMTQtMS0xLTEyMTQw_85f992d2-e22d-46a6-a44f-3097d27323b0">1,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjEtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjpiYmJhODdkNzYyOWM0MzEyYTFkNGZmYzg5NDdiZDcwOF8yNA_b498e656-e87c-4e0b-be01-ff13f5cf52c0">2.52</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3d1ac282964e3380614a0c573278a4_D20190101-20191231" decimals="-6" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjEtMTAtMS0xLTEyMTQw_11a2d645-fec8-4dce-8992-2afc1204881c">3,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjEtMTQtMS0xLTEyMTQw_eadfbca8-5c0a-4ad9-be61-63a041af1015">3,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4b5ab47f4054d119ad163b7730160e9_I20191231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItMi0xLTEtMTIxNDA_45786c0e-28f8-4970-818c-263c28b54678">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b5ab47f4054d119ad163b7730160e9_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItNC0xLTEtMTIxNDA_1024f864-3740-4c3c-bd20-1895cd180c42">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbd5347ef13d4d63a1e7031f22995187_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItNi0xLTEtMTIxNDA_e467733a-7d00-4a89-89ac-42595a27a24d">3,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9da767fe6764cc8955010ca3f076633_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItOC0xLTEtMTIxNDA_0112212e-13a9-41ca-8408-558785d6d753">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40b1731fe1b744a2b37e1b7157cc1c89_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItMTAtMS0xLTEyMTQw_da9bbeec-d5d8-409c-8b4a-2ddd9bb0e63c">19,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib64b3709e27d4ea2961642638f9cbf2c_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItMTItMS0xLTEyMTQw_3431d338-1239-42ae-83a5-66f7b3d2f237">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItMTQtMS0xLTEyMTQw_46ae2613-09e9-47ff-b847-77d99958b94f">22,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect from the adoption of new accounting standard </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1928c028f694d83885d06a82f22ca4d_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjMtMTAtMS0xLTEyMTQw_840d5c71-ac06-4755-a14d-40ec2289c35f">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac80893052fd42e9be5a92f71c18cdb2_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjMtMTQtMS0xLTEyMTQw_f73d91f9-cb61-4670-8d5c-485ba09b412c">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in noncontrolling interest </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1636d6a27341d4903b179394689324_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjQtMTItMS0xLTEyMTQw_8e729b40-7fc9-48de-af99-6767f28dbc73">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjQtMTQtMS0xLTEyMTQw_59c8809c-11c7-4fa4-8708-da8567596bea">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0fc16e772ac480c9e4ad4516e16c190_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjUtMTAtMS0xLTEyMTQw_38d4344f-192e-464b-a6a6-7f642861f31c">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1636d6a27341d4903b179394689324_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjUtMTItMS0xLTEyMTQw_ef94f776-4391-40ec-b5ed-1808a2909687">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjUtMTQtMS0xLTEyMTQw_e77623b0-6063-42a2-b04c-b7cbfbe36008">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc1931160c049e2b69a1fafb5719ec8_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtNi0xLTEtMTIxNDA_812403a6-959b-4c60-951f-8a2527f8600e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i851b03314d344a5e8ad436aa9235bf9c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtOC0xLTEtMTIxNDA_922e1e3a-d617-4b8e-9113-bed80fb13d33">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0fc16e772ac480c9e4ad4516e16c190_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtMTAtMS0xLTEyMTQw_2c71cb2d-b54e-4bcb-a799-96578a9ed76d">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtMTQtMS0xLTEyMTQw_5f5ca1c5-c954-4d7e-8dbe-442c4a37fffc">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f7ba76a51544cbd895730452d44bb48_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjctMi0xLTEtMTIxNDA_daab402d-e998-4a17-83f2-877f54ce9ed6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc1931160c049e2b69a1fafb5719ec8_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjctNi0xLTEtMTIxNDA_65aeb050-983d-4ff3-ae44-fd7b22a909ae">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjctMTQtMS0xLTEyMTQw_0f0ffd25-082a-4f37-8b45-a308336f229f">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f7ba76a51544cbd895730452d44bb48_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtMi0xLTEtMTIxNDA_ae669f2d-551e-4279-a9be-e728da63d994">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc1931160c049e2b69a1fafb5719ec8_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtNi0xLTEtMTIxNDA_03681be9-5cea-4bb2-a613-7f52ad332633">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtMTQtMS0xLTEyMTQw_426a6fa0-efa5-47c8-a458-2d31859e5a93">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc1931160c049e2b69a1fafb5719ec8_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjktNi0xLTEtMTIxNDA_471f077a-bc88-4872-aa53-af03d4e29d9c">642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjktMTQtMS0xLTEyMTQw_18a7401e-4c87-4dd9-9ba0-fc6c5ee38978">642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7f7ba76a51544cbd895730452d44bb48_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMi0xLTEtMTIxNDA_173145e5-aeee-4337-beff-fe9677af0298">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc1931160c049e2b69a1fafb5719ec8_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtNi0xLTEtMTIxNDA_82d228f9-011f-45d1-be77-1b7eb879582f">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0fc16e772ac480c9e4ad4516e16c190_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMTAtMS0xLTEyMTQw_4cd94d58-d564-4c5e-a016-fa45eb242f55">1,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMTQtMS0xLTEyMTQw_b14b1693-325e-417d-b882-bf0a714daa3c">1,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzEtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjoxM2ExYzUwYTNmNjI0Nzc1OTdjN2NiN2M2YjViNWQxZV8yNA_7c0b6bf4-c3e4-4942-a849-248e2213cebf">2.72</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0fc16e772ac480c9e4ad4516e16c190_D20200101-20201231" decimals="-6" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzEtMTAtMS0xLTEyMTQw_46a80ba0-fc34-426f-9575-4cb80cbec130">3,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzEtMTQtMS0xLTEyMTQw_0e909fbf-57d4-474e-9507-8ec59370959c">3,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0fd40f1bbe64b64bafc77d0138fdc55_I20201231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItMi0xLTEtMTIxNDA_ba735711-c542-4c98-b46a-913ba7bba195">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fd40f1bbe64b64bafc77d0138fdc55_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItNC0xLTEtMTIxNDA_ad6305b3-775b-4853-a70c-03edc0a3087c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9832261d41e74ecb88de8acbbbb81ca7_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItNi0xLTEtMTIxNDA_d7c40c02-a389-41c7-be01-716c0140d59e">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i803ae583deba4f7683154aaeec947d69_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItOC0xLTEtMTIxNDA_5f590a53-9f14-4117-9d3f-bc005659c6a1">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab9a9d73e541440bbe6a602affd5a7b0_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItMTAtMS0xLTEyMTQw_8d2a0724-c402-46a2-9a19-5a1bcb6810d0">14,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i124557415b5546be81b290394bba971e_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItMTItMS0xLTEyMTQw_8ade8c06-c29f-44fa-9265-72b7d1aecc72">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItMTQtMS0xLTEyMTQw_32f1535e-ec24-4793-a65d-18c2a12cc179">18,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81bd8c38c79a44cd82ea0da460afeda2_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjMtMTAtMS0xLTMxNDk4_9113bea7-522d-414c-a79b-c5ad5c99b389">6,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffaa88726d364819baced65640a14653_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjMtMTItMS0xLTMxNDk4_2728355d-4b34-46c7-a26b-ed7f9ecb9653">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjMtMTQtMS0xLTMxNDk4_23b047e1-56af-447c-b8a4-c06305d53519">6,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626caba187154b4d9558b2cc5d8c94d0_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjQtNi0xLTEtMzE0OTg_2c6aecf9-eff3-4c04-b8db-e4adb39067bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8023d2e7ae2f498fa0385be7010b4f25_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjQtOC0xLTEtMzE0OTg_c1b1c335-fa62-410f-b4a7-a51505a4f1a6">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81bd8c38c79a44cd82ea0da460afeda2_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjQtMTAtMS0xLTMxNDk4_187398f9-7075-4de8-9537-ddf4fb147a7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjQtMTQtMS0xLTMxNDk4_d9dcbc26-398c-4be0-ae6f-8cbf570c0ada">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b1ea74ddca943afada26dff9a0ef62b_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjUtMi0xLTEtMzE0OTg_2ecea73b-494b-446c-aca8-40a78e5cc107">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626caba187154b4d9558b2cc5d8c94d0_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjUtNi0xLTEtMzE0OTg_75015312-70aa-4703-a341-fa4601374585">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjUtMTQtMS0xLTMxNDk4_ab1a1f2f-a9cc-4d21-b85a-b042bf13192a">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b1ea74ddca943afada26dff9a0ef62b_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtMi0xLTEtMzE0OTg_aba3c028-9c92-4fdf-b9c0-67ffd99a147f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626caba187154b4d9558b2cc5d8c94d0_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtNi0xLTEtMzE0OTg_07a425b8-121d-4b04-86a3-e5af174d042e">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtMTQtMS0xLTMxNDk4_ce7f6ee0-4c4e-415b-8644-64967bf39203">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626caba187154b4d9558b2cc5d8c94d0_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjctNi0xLTEtMzE0OTg_df0cc97a-ccb1-41ab-84a8-76de333dc377">640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjctMTQtMS0xLTMxNDk4_6bf6e44c-6dd8-4b5c-b173-eef490a1cd6a">640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4b1ea74ddca943afada26dff9a0ef62b_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtMi0xLTEtMzE0OTg_c962df7b-f0a0-4a25-a364-9791cdd40b44">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i626caba187154b4d9558b2cc5d8c94d0_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtNi0xLTEtMzE0OTg_a043c3d1-a036-4b06-be5e-3339b3feb513">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81bd8c38c79a44cd82ea0da460afeda2_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtMTAtMS0xLTMxNDk4_f64af6af-f86a-4640-ae05-5513e4844542">664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtMTQtMS0xLTMxNDk4_34440d8d-3fbf-4368-8c8e-f41b0be44dce">692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjktMC0xLTEtMzE0OTgvdGV4dHJlZ2lvbjpkMDA2YWU5NWM2Njg0ZWFjOWZmYThlZDQzYzQwOGQ4Yl8xMDk5NTExNjI3ODE3_47dc81db-314c-4989-bfae-95c5e25dc197">2.84</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81bd8c38c79a44cd82ea0da460afeda2_D20210101-20211231" decimals="-6" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjktMTAtMS0xLTMxNDk4_c3caedc8-52e8-4eee-bec5-01713dee800d">3,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjktMTQtMS0xLTMxNDk4_a5b876f9-e440-432d-83e6-1271225bdbb5">3,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89cf74ab64a34cba879cbc8c8211ff81_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMi0xLTEtMzE0OTg_4fedf596-55f2-487f-ba95-60f153eb4682">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89cf74ab64a34cba879cbc8c8211ff81_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtNC0xLTEtMzE0OTg_3563f93a-1fe6-4b88-9aa2-f96fb83cb567">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d04ab1d0b074473902d53b2c6fa11cf_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtNi0xLTEtMzE0OTg_64800b67-d736-446a-b114-f9f223a02307">4,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ebb0b9dc1384269a861d7b5216e73fc_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtOC0xLTEtMzE0OTg_b145b05a-1b2a-494e-8195-384fade87951">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia37682e7f2e748009cff968cbeae3311_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMTAtMS0xLTMxNDk4_da04c6c8-373f-43f3-a611-ed93da2cc163">16,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93ce718fd81f499ba51f827334051126_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMTItMS0xLTMxNDk4_7ba32240-86c6-45d1-bca6-c1adefd225e7">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMTQtMS0xLTMxNDk4_e7bf2f76-cfc8-4664-82ac-3468d03e5ea5">21,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC. </span></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMy0yLTEtMS0xMjE0MA_48752ffa-62b8-445f-a014-79bfeb57b5e9">6,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMy00LTEtMS0xMjE0MA_a29e08bb-fd26-4b6e-9cb1-1f719e882a59">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMy02LTEtMS0xMjE0MA_9cad29a0-e125-4971-988b-a8c96302cfc4">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNS0yLTEtMS0xMjE0MA_d3865c05-07ce-480f-af57-4748062ffcdd">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNS00LTEtMS0xMjE0MA_a06552c1-9210-4647-9c83-4fc9d2b90aa8">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNS02LTEtMS0xMjE0MA_f22bbbd1-9cae-4f59-8833-c3bd8bbab26e">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNi0yLTEtMS0xMjE0MA_5129bb59-aea6-4703-a14f-2ddf9080dca3">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNi00LTEtMS0xMjE0MA_33e33f1f-9259-4d49-890f-d7820bf27e44">1,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNi02LTEtMS0xMjE0MA_a1b78afa-0c46-44d1-bb50-1a53ed1650a0">1,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNy0yLTEtMS0xMjE0MA_e1b9ab2e-ac10-410a-ad40-d0e06cd70854">635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNy00LTEtMS0xMjE0MA_3662b40a-bfb6-4ca3-b42f-d36ea2804b1a">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNy02LTEtMS0xMjE0MA_2ffffd5c-7429-4ac8-9b21-99ce9682abb1">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfOC0yLTEtMS0xMjE0MA_199eced0-2cef-48c5-8ada-c7d92cc58481">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfOC00LTEtMS0xMjE0MA_736befa4-f697-4040-afc2-1cb80de0e157">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfOC02LTEtMS0xMjE0MA_f778062b-29de-4009-b9ef-509fb0072a1b">2,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (gain) loss from equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfOS0yLTEtMS0xMjE0MA_93e41a1e-1f95-4c78-b9e5-1cc9a7d4fe24">610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfOS00LTEtMS0xMjE0MA_a3a380ff-73e8-4f95-8450-f8a4a1a9a669">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfOS02LTEtMS0xMjE0MA_0971662c-c98d-4471-b8d3-6eb8747d1280">1,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTAtMi0xLTEtMTIxNDA_d33684fd-5df7-4c0a-9fd5-8d5ced757bda">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTAtNC0xLTEtMTIxNDA_ebef8831-fb0f-4421-931c-1030d1d308d6">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTAtNi0xLTEtMTIxNDA_13b5c99c-96f2-4ed4-8267-c0a82b9a87ee">4,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTEtMi0xLTEtMTIxNDA_ba210b9f-2e7b-4e11-ac55-a4687b76125a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTEtNC0xLTEtMTIxNDA_b3296282-82df-4a92-bb4f-fd5206e37649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTEtNi0xLTEtMTIxNDA_0b30786c-8d76-4d12-a773-fc7a7e55720e">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-downs for slow-moving and excess raw material and work in process inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="gild:InventoryReserveForExcessRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTItMi0xLTEtMTIxNDA_9192e3db-a2df-4c49-a618-4756ae5e7822">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="gild:InventoryReserveForExcessRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTItNC0xLTEtMTIxNDA_88a43171-0eec-4d72-b51d-dc4784141761">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="gild:InventoryReserveForExcessRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTItNi0xLTEtMTIxNDA_f8f485ee-b1e2-4afe-a237-55123ab887f5">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTMtMi0xLTEtMTIxNDA_49465e11-4012-4ebc-a84c-f0bcbd836f11">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTMtNC0xLTEtMTIxNDA_c273080b-924f-4397-a562-334c5f31dd2f">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTMtNi0xLTEtMTIxNDA_96dd99e3-820e-4a7f-8bde-7a027b55e35d">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTUtMi0xLTEtMTIxNDA_6a68e56b-0da8-48b6-bd67-9cd26b56ee6e">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTUtNC0xLTEtMTIxNDA_c7484366-38f6-492a-b827-e1ec173b57be">1,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTUtNi0xLTEtMTIxNDA_192f9189-665e-41c4-acce-336fcb4697fc">218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTYtMi0xLTEtMTIxNDA_5207f8b7-729c-462c-8ddb-8e024daa7829">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTYtNC0xLTEtMTIxNDA_da73fa6b-f37b-484b-8cfe-1800fb775d06">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTYtNi0xLTEtMTIxNDA_55b600f2-7711-45d0-9c09-c3afa2a20585">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTctMi0xLTEtMTIxNDA_6557ae69-2a7e-4d2c-abb7-584b5d6ad3f7">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTctNC0xLTEtMTIxNDA_9278ea80-7150-4f07-b5ce-bb241b1f92b6">214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTctNi0xLTEtMTIxNDA_48d81933-41ac-4549-a4bc-0b1e0966c445">307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTgtMi0xLTEtMTIxNDA_7896d301-4988-40d8-ba60-de4c5ad13355">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTgtNC0xLTEtMTIxNDA_11ff5497-32df-48f9-a363-2e314e9ae6f8">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTgtNi0xLTEtMTIxNDA_b7031061-807f-42f3-bb72-5e763c176800">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTktMi0xLTEtMTIxNDA_b0573da1-dbcc-4262-b8f8-d3e468c6da2f">364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTktNC0xLTEtMTIxNDA_c82a40b3-14ee-4f7c-8176-e4e2c8df809b">778</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTktNi0xLTEtMTIxNDA_d9f3323b-56c7-4b0f-a26c-a8528449c126">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjAtMi0xLTEtMTIxNDA_79016d57-c692-4367-ab87-4b8c9d3f2954">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjAtNC0xLTEtMTIxNDA_514992a3-7e20-4bc6-93ec-fa3c5f689816">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjAtNi0xLTEtMTIxNDA_cfb97b1f-c9e4-4077-a251-6d4a5f4836fe">389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjEtMi0xLTEtMTIxNDA_54c6a486-41c5-43da-82e8-1b14a98d300c">11,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjEtNC0xLTEtMTIxNDA_9e6b0692-8ed3-48f8-aff7-ae7d24003dd5">8,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjEtNi0xLTEtMTIxNDA_6846c6dd-b9e4-4e61-8e69-4fc03f0e8aeb">9,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjQtMi0xLTEtMTIxNDA_45f25d45-9cc2-4fdd-afb2-7f122bb742c5">3,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjQtNC0xLTEtMTIxNDA_02a57391-4e7b-48f4-b8ba-69e4442286ce">20,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjQtNi0xLTEtMTIxNDA_c7d8f439-4430-4c4f-8ede-05d3d8c65426">30,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjUtMi0xLTEtMTIxNDA_9feed519-cccc-4929-a8e2-aaba428c369c">730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjUtNC0xLTEtMTIxNDA_b55115cc-bfea-4fc3-99a1-f2866154ce70">23,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjUtNi0xLTEtMTIxNDA_4cc79e23-51ac-45b9-9848-16c7a4b18e8d">7,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjYtMi0xLTEtMTIxNDA_8ab4cecb-9f69-4523-9640-7066c10c0925">2,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjYtNC0xLTEtMTIxNDA_84b5fce4-3212-47bc-b3a0-f736b081bd2e">9,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjYtNi0xLTEtMTIxNDA_53e2ac46-1ac3-4589-ad9e-ca3b8ce4b147">22,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, including in-process research and development, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjctMi0xLTEtMTIxNDA_6104bd80-952a-4d7d-a5d1-a7175d6820cf">1,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjctNC0xLTEtMTIxNDA_0dd1f126-e776-4b9e-a9e6-161043ed65e5">25,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjctNi0xLTEtMTIxNDA_80f3cd5d-73df-4160-a769-59d227a12e3a">4,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjgtMi0xLTEtMTIxNDA_54ecfbf8-92c2-4077-8f4f-674406a26a15">380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjgtNC0xLTEtMTIxNDA_01106c01-8d5e-4a48-8e90-a62eae0c7e34">455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjgtNi0xLTEtMTIxNDA_71b11598-0736-4e9c-a693-e1af307d12ed">1,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjktMi0xLTEtMTIxNDA_39b4d476-30fc-4a92-b708-1e2b54417316">579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjktNC0xLTEtMTIxNDA_16be836c-256a-4236-8ead-1e2b67ac351e">650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjktNi0xLTEtMTIxNDA_d1858555-bcd3-43bf-9854-d67f7decda06">825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzAtMi0xLTEtMTIxNDA_8aba5f1c-0f9e-4ff3-9b2b-9d6cb1a05fdd">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzAtNC0xLTEtMTIxNDA_2fa98dfb-d3cc-4cda-a27f-b595a573af3c">171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzAtNi0xLTEtMTIxNDA_9750804e-5998-4c0c-861b-cef5305f0b0c">434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in by investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzEtMi0xLTEtMTIxNDA_b5da0106-49a3-4e47-84f4-fbdde3f8bc88">3,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzEtNC0xLTEtMTIxNDA_87e6134b-6060-4a3b-95e6-4a3b1bd6506e">14,615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzEtNi0xLTEtMTIxNDA_ae76d583-013e-4b83-9527-4a744bf7072e">7,817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from debt financing, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzQtMi0xLTEtMTIxNDA_4f54b1fb-8281-4cc6-b837-9ff220d551d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzQtNC0xLTEtMTIxNDA_9026a569-bf58-4c6a-a789-e8f4c7aee1e7">8,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzQtNi0xLTEtMTIxNDA_4856ee76-9abe-4911-ba5a-125fc1f0e260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuances of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzUtMi0xLTEtMTIxNDA_32c33e78-5256-44e9-aefe-334bc905ad89">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzUtNC0xLTEtMTIxNDA_9c893aa5-76a3-4b5b-bd41-ca131cbf1f60">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzUtNi0xLTEtMTIxNDA_278b63f1-ef8b-4435-af73-1eccd5a96af5">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzYtMi0xLTEtMTIxNDA_e45d1534-d552-4013-9223-cf333effa759">546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzYtNC0xLTEtMTIxNDA_b65fc5e6-8cd8-4514-88c3-dfca74f90857">1,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzYtNi0xLTEtMTIxNDA_3aa07a87-2868-489b-8ea2-08d97c612a62">1,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of debt and other obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzctMi0xLTEtMTIxNDA_134b4c8e-366d-44f5-b058-fe4a93141b6f">4,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzctNC0xLTEtMTIxNDA_414b7073-bb46-4188-b2be-4d63a7881e8a">2,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzctNi0xLTEtMTIxNDA_f45890c0-9ef8-4811-a55b-47e3503294b7">2,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzgtMi0xLTEtMTIxNDA_0bcb49ff-040c-4510-9e4f-9c0574d911b6">3,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzgtNC0xLTEtMTIxNDA_d3002e66-542e-41ea-a196-e91bafb55e1c">3,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzgtNi0xLTEtMTIxNDA_91a1727a-1d7e-4a0b-a661-077bd119eb9d">3,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzktMi0xLTEtMTIxNDA_a59bc57f-2a40-430f-adec-b7ac1044c29f">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzktNC0xLTEtMTIxNDA_59643ab5-5a3a-4484-8c40-24d58fd03c2a">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzktNi0xLTEtMTIxNDA_4567a73e-488e-496e-b8b8-c99d0ccd06b3">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDAtMi0xLTEtMTIxNDA_3b5e52b0-a2c4-48bb-a58e-0af340df854e">8,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDAtNC0xLTEtMTIxNDA_98d55575-78be-4272-8240-2cb223cf9c61">770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDAtNi0xLTEtMTIxNDA_e6a20188-bcc3-48be-b017-dfce31022bac">7,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDEtMi0xLTEtMTIxNDA_f683b971-e07f-4830-8cd7-a079777cec16">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDEtNC0xLTEtMTIxNDA_937693cf-ca58-46fb-ba48-2761a2cdb1b9">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDEtNi0xLTEtMTIxNDA_ee964e35-fec8-45d6-af20-9968d773dca0">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDItMi0xLTEtMTIxNDA_9690e862-91b9-4a9b-abd2-59bf0d84f46d">659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDItNC0xLTEtMTIxNDA_2cb4c50a-7a0c-471f-9bb2-f271bace3a7a">5,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDItNi0xLTEtMTIxNDA_33805e9d-ae10-4fae-9aed-7c1c9c03c97e">6,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDMtMi0xLTEtMTIxNDA_16ac2b84-13e4-46ea-8387-4cdb532456e4"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDMtMi0xLTEtMTIxNDA_1e52130f-afcd-48b1-850a-d4df2e81a26c">5,997</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDMtNC0xLTEtMTIxNDA_8ed4cb46-ea40-46f0-9a23-38e9d3833b52">11,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8222e290a2284cb0bf64a4ac2b6995b5_I20181231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDMtNi0xLTEtMTIxNDA_fde0dfd6-9fc3-4952-ad15-efc48c591db8">17,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDQtMi0xLTEtMTIxNDA_cfb7e114-5617-42fa-afdd-ae97e8c4119a">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDQtNC0xLTEtMTIxNDA_16ac2b84-13e4-46ea-8387-4cdb532456e4"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDQtNC0xLTEtMTIxNDA_1e52130f-afcd-48b1-850a-d4df2e81a26c">5,997</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDQtNi0xLTEtMTIxNDA_c72e891b-ba7c-43d8-a004-cb99a1222f4a">11,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid, net of amounts capitalized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDctMi0xLTEtMTIxNDA_9155552f-8201-44e3-a63b-b115cd18a061">979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDctNC0xLTEtMTIxNDA_c824cd14-fd8a-46ff-9353-cbfb3711660d">951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDctNi0xLTEtMTIxNDA_7dd778a0-6f53-4698-9562-91dd1cf6a62a">982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDgtMi0xLTEtMTIxNDA_9f234fb6-5d11-4a61-9f91-aa39fad98086">2,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDgtNC0xLTEtMTIxNDA_e8108a6c-5387-43f9-9069-c223225d91e2">2,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDgtNi0xLTEtMTIxNDA_e37a5135-9c69-4b91-8afc-f67afa1f1b34">1,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_97"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5NDQ_63a2c092-8501-4fa8-862c-13da6b06c8dd" continuedAt="ib5eefea85a6b42b78926c5e0ac2b7073" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ib5eefea85a6b42b78926c5e0ac2b7073" continuedAt="ie294b54415c841099def641f84625455"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than <ix:nonFraction unitRef="country" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="INF" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMTA5OTUxMTY3OTc5Nw_a1fcc056-39fe-44dd-b0da-620af37da4cb">35</ix:nonFraction> countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketed products includes AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cayston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Emtriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(bulevirtide), Hepsera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jyseleca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (filgotinib), Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sovaldi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tybost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The approval status of Hepcludex and Jyseleca vary worldwide, and Hepcludex and Jyseleca are not approved in the United States. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the United States through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements. </span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MDk_1fb13489-a3ee-47a7-8f96-9fe39c6e74e4" continuedAt="i2c06f49b0a114398ad65edb03fdda069" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2c06f49b0a114398ad65edb03fdda069">We assess whether we are the primary beneficiary of a variable interest entity (&#8220;VIE&#8221;) at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</ix:continuation> We did not have any material VIEs as of December&#160;31, 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods in the Consolidated Financial Statements and accompanying notes to conform with the current presentation. Beginning 2020, acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expenses are reported separately from Research and development expenses on our Consolidated Statements of Income. Our Consolidated Statements of Income for the year ended December 31, 2019 was conformed to separately present acquired IPR&amp;D expenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI4ODk_2ae5253a-3836-4269-a9ce-c732cb64797c" continuedAt="i1600125628324b0e8d1ad0391e83865b" escape="true">Segment Information</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1600125628324b0e8d1ad0391e83865b">We have <ix:nonFraction unitRef="segment" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfNTQ5NzU1ODE4ODYyMQ_f5598217-ba18-42ec-bd88-e54b387e9abc">one</ix:nonFraction> operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business.</ix:continuation> See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5Mzk_846c3319-7486-40aa-87d9-aba68bf541f1" continuedAt="ie7ed6f170b324ed5b97196775f0b58a8" escape="true">Significant Accounting Policies, Estimates and Judgments </ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie7ed6f170b324ed5b97196775f0b58a8">The preparation of these Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and  expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease (&#8220;COVID-19&#8221;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ie294b54415c841099def641f84625455" continuedAt="ia965fe78df9d408aa0d6c03d94c25668"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MTA_c0089859-02cc-496b-9f8d-2962b7e04f0b" continuedAt="i5576b44ab0af482c8f29a249efe4eafb" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to the customer, or in certain cases, upon the corresponding sales by our customer to a third party. The revenues are recognized net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a financing component. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Deductions </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Rebates and Chargebacks</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other rebates and chargebacks include amounts payable to payers and healthcare providers under various programs, and may vary by product, by payer and individual payer plans. Rebates and chargebacks are based on contractual arrangements or statutory requirements which may vary by product, payer and individual payer plans. For qualified programs that can purchase our products through wholesalers or other distributors at a lower contractual price, the wholesalers or distributors charge back to us the difference between their acquisition cost and the lower contractual price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are estimated primarily based on product sales, and expected payer mix and discount rates, which require significant estimates and judgment. Additionally, in developing our estimates, we consider: historical and estimated payer mix; statutory discount requirements and contractual terms; historical claims experience and processing time lags; estimated patient population; known market events or trends; market research; channel inventory data obtained from our major U.S. wholesalers; and other pertinent internal or external information. We assess and update our estimates each reporting period to reflect actual claims and other current information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Government and other rebates that are payable to third party payers and healthcare providers are recorded in Accrued government and other rebates on our Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Discounts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Distributor Fees</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Allowance for Sales Returns</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the United States, we typically permit returns six months prior to and up to one year after the product expiration date. Outside the United States, returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Shipping and Handling</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling activities are considered to be fulfillment activities and not considered to be a separate performance obligation.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty, Contract and Other Revenues</span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5576b44ab0af482c8f29a249efe4eafb">Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ia965fe78df9d408aa0d6c03d94c25668" continuedAt="i14f15b2f9e9e4ea9a3ce794cb73e122a"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzMwMDc_59a2fff3-feb5-4c15-a732-0d52087dca4b" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of clinical studies performed by contract research organizations (&#8220;CROs&#8221;), materials and supplies, payments under collaborative and other arrangements including milestone payments, licenses and fees, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations consisting of various support and infrastructure costs. Milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of R&amp;D expenses.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We charge R&amp;D costs, including clinical study costs, to expense when incurred. Clinical study costs are a significant component of R&amp;D expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for R&amp;D services prior to the services being rendered are recorded as prepaid assets in our Consolidated Balance Sheets and are expensed as the services are provided.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfNTQ5NzU1ODE4ODkzMg_610ecf82-7720-4f21-a98b-5753203a3a88" continuedAt="ie3d2b31783724a25af1470074fba83b4" escape="true">Acquired In-Process Research and Development Expenses</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie3d2b31783724a25af1470074fba83b4">Acquired IPR&amp;D expenses reflect IPR&amp;D impairments as well as the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;D projects. The acquired IPR&amp;D is expensed on acquisition date. Future costs to develop these IPR&amp;D projects are recorded in Research and development expenses on our Consolidated Statements of Income as incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI4NzY_b59152e0-6b10-4d7e-9238-9f0c84a6cca2" continuedAt="i5de8558825d6416f9fd7ea32a6a0d424" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses relate to sales and marketing, finance, human resources, legal and other administrative activities. SG&amp;A expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs. SG&amp;A expenses also include the Branded Prescription Drug (&#8220;BPD&#8221;) fee. In the United States, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the BPD fee, which is estimated based on select government sales during the prior year as a percentage of total industry government sales.</span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5de8558825d6416f9fd7ea32a6a0d424">We expense the costs of advertising, including promotional expenses, as incurred.</ix:continuation> Advertising expenses were $<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMTI3MzE_92086ee9-f647-40ce-87a9-e8938e9c848c">735</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMTI3MzU_cc6e5d84-b152-4820-83bb-ee5a1d9fea1b">795</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMTI3NDI_8bd4a03b-d23d-42c8-a494-33ef9e0babee">784</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MTk_5bc1f486-c9f9-4eaa-ad76-544f5274349b" continuedAt="i027c3248f5a647bf964e7f6dfcd53436" escape="true">Cash and Cash Equivalents </ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i027c3248f5a647bf964e7f6dfcd53436">We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents.</ix:continuation> </span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI4OTI_7f7bf27a-30c2-45a9-be14-eeaaac685608" continuedAt="i0bcb9833d22141acbd4e8fe0b4b1d19a" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable and Non-Marketable Securities</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable debt securities are considered available-for-sale and carried at estimated fair values and reported in cash equivalents, short-term marketable debt securities or long-term marketable debt securities. Unrealized gains and losses on available-for-sale debt securities are excluded from net income and reported in Accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) as a separate component of stockholders&#8217; equity. Other income (expense), net, includes interest, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and expected credit losses, if any. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost bases. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in AOCI.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i14f15b2f9e9e4ea9a3ce794cb73e122a" continuedAt="i50ef7ccc33194104bf046bbaf7d4afc1"><ix:continuation id="i0bcb9833d22141acbd4e8fe0b4b1d19a"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable and Non-Marketable Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities, other than equity method investments, are recorded at fair market value if fair value is readily determinable, and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. We have elected the fair value option to account for our equity investments in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;) and Galapagos NV (&#8220;Galapagos&#8221;) over which we have significant influence. We believe the fair value option best reflects the underlying economics of these investments. See Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Certain investments in equity securities of non-public companies are accounted for using the equity method based on our ownership percentage and other factors that indicate we have significant influence over the investee. See Note 11. Collaborations and Other Arrangements for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in equity securities are recorded in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets. We regularly review our securities for indicators of impairment.</span></div></ix:continuation><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI4Nzc_b0c6a859-364d-4f5b-906a-80f7e8711191" continuedAt="ic7070b3740dc4108bc24eb5d801e33e9" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return.</span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic7070b3740dc4108bc24eb5d801e33e9">We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe.</ix:continuation> Additions to the allowance for credit losses, write-offs and recoveries of customer receivables were <ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfNTQ5NzU1ODE5NTc0OQ_0758e778-3b63-4ae8-a44a-27fb7e1a5dbe"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfNTQ5NzU1ODE5NTc0OQ_482d26fc-689a-45a4-9b62-08d5fface78d"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfNTQ5NzU1ODE5NTc0OQ_6bd2fb77-f007-4ebd-8e83-80d0507eab36">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t material for the years ended December&#160;31, 2021, 2020 and 2019.</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI4OTM_a62aeca9-df0d-4e99-974f-9149215dafa7" continuedAt="ife8ba2de012143bfb92ea671d6ed4891" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.</span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ife8ba2de012143bfb92ea671d6ed4891">When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i50ef7ccc33194104bf046bbaf7d4afc1" continuedAt="i3f71f6ee9fd3414ca90a0e59c84d6c6d"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5OTc_d3f89158-a0b2-4295-8e2f-8d2705a4d7b3" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. <ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="gild:PropertyPlantandEquipmentUsefulLivesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MTY_68274b4f-aed6-4636-93c4-59fe7ec68c58" continuedAt="i7bf79617a96349cca0e8cf8be956dd1a" escape="true">Estimated useful lives in years are generally as follows: </ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i7bf79617a96349cca0e8cf8be956dd1a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated&#160;Useful&#160;Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;<ix:nonNumeric contextRef="ib4576883c8c04416a8ac3190f1f6a401_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RhYmxlOmM5NTMzN2FlMmYwYzRmNjA5YzFmNTMxMWIwMTk2NWI0L3RhYmxlcmFuZ2U6Yzk1MzM3YWUyZjBjNGY2MDljMWY1MzExYjAxOTY1YjRfMS0xLTEtMS0xMjE0MC90ZXh0cmVnaW9uOjFjYzY4ZjhkN2I3NjQwMTE5NTRkMjFlNTU1YTBlZjdhXzE1_a552997f-9d0d-4661-8903-5d0a4e1c3676">35</ix:nonNumeric> years or useful&#160;life</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22f92d3d761342058252995e5000c7e3_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RhYmxlOmM5NTMzN2FlMmYwYzRmNjA5YzFmNTMxMWIwMTk2NWI0L3RhYmxlcmFuZ2U6Yzk1MzM3YWUyZjBjNGY2MDljMWY1MzExYjAxOTY1YjRfMi0xLTEtMS0xMjE0MC90ZXh0cmVnaW9uOmJiOWUyY2QwN2VmMjQ3N2NhOWMxNmNiNjczNzM5MmZmXzQ_51196a33-0522-4488-94d1-fb53776f3bf2">4</ix:nonNumeric>-<ix:nonNumeric contextRef="i187ee787664447d585348e1a2ab56b30_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RhYmxlOmM5NTMzN2FlMmYwYzRmNjA5YzFmNTMxMWIwMTk2NWI0L3RhYmxlcmFuZ2U6Yzk1MzM3YWUyZjBjNGY2MDljMWY1MzExYjAxOTY1YjRfMi0xLTEtMS0xMjE0MC90ZXh0cmVnaW9uOmJiOWUyY2QwN2VmMjQ3N2NhOWMxNmNiNjczNzM5MmZmXzc_6255a2af-30ea-4dd5-a264-d81268d758a3">10</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e6b53c8ca604244a32c0b5e15fd5c66_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RhYmxlOmM5NTMzN2FlMmYwYzRmNjA5YzFmNTMxMWIwMTk2NWI0L3RhYmxlcmFuZ2U6Yzk1MzM3YWUyZjBjNGY2MDljMWY1MzExYjAxOTY1YjRfMy0xLTEtMS0xMjE0MC90ZXh0cmVnaW9uOmU1NTM2MzI3MjViYzQxYmFiMGRiNjI0OWY5MTZkMDc4XzQ_1667b675-fccd-490e-9ead-ba0c563061da">3</ix:nonNumeric>-<ix:nonNumeric contextRef="ibdad0157d3ca4b4ab89aa860186ff56c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RhYmxlOmM5NTMzN2FlMmYwYzRmNjA5YzFmNTMxMWIwMTk2NWI0L3RhYmxlcmFuZ2U6Yzk1MzM3YWUyZjBjNGY2MDljMWY1MzExYjAxOTY1YjRfMy0xLTEtMS0xMjE0MC90ZXh0cmVnaW9uOmU1NTM2MzI3MjViYzQxYmFiMGRiNjI0OWY5MTZkMDc4Xzc_053c07cc-4cb0-4280-a661-d9a80f311624">15</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;useful&#160;life or lease&#160;term</span></td></tr></table></ix:continuation></div></ix:nonNumeric><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5NTQ_4b082052-39e6-4742-b63d-86d3aa016987" continuedAt="i3da55c3a906749c3800c4a237e7cf800" escape="true"><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at inception. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.</span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3da55c3a906749c3800c4a237e7cf800">As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability.</ix:continuation> </span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5NDg_4bbe4380-7758-4f03-a323-0a56f13de2c6" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period, which may be up to one year from the acquisition date, with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration, such as payments upon achievement of various developmental, regulatory and commercial milestones, generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are expensed as incurred on our Consolidated Statements of Income unless there is an alternative future use.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MzY_1ca37286-c661-43fb-a808-fdab8fa4651c" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may be subject to adjustment within the measurement period, which may be up to one year from the acquisition date. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. We do not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When development is successfully completed, which generally occurs when regulatory approval is obtained, the associated assets are deemed finite-lived and amortized over their respective estimated useful lives beginning at that point in time. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i3f71f6ee9fd3414ca90a0e59c84d6c6d" continuedAt="i1912b2daabfa40548f749e971225c8d4"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MzA_81ce0fe4-28d9-4cce-994b-172bae7b5fe7" continuedAt="i267d9051ec6a413bb301e815724af1f7" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i267d9051ec6a413bb301e815724af1f7">Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</ix:continuation> </span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MzE_2366eea8-b629-4c20-b8b1-1e78ce25fbaf" continuedAt="i25454594fd7c4d6a926e8b783bf8cdce" escape="true"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Contingent Consideration Resulting from a Business Combination</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value in Research and development expenses on our Consolidated Statements of Income until such time that the related product candidate receives marketing approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may differ from estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5ODc_0819fe33-e60a-4d9b-8e76-8ab50a3861e0" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. entity operations are recorded in the functional currency of each entity. Results of operations for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency rates. Assets and liabilities are translated using currency rates at period end. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Foreign currency transaction gains and losses are recorded in Other income (expense), net, on our Consolidated Statements of Income. Net foreign currency transaction gains and losses were not material for the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzMwMzU_71791f93-2f6e-4c72-b620-7d74a8f00db7" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value accounting for all financial and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5Mjg_b3828190-eae2-4d18-abe7-d932cba07928" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:4pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Unrealized changes in the fair value of derivatives designated as part of a hedge transaction are recorded in AOCI. The unrealized gains or losses in AOCI are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i1912b2daabfa40548f749e971225c8d4"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfNTQ5NzU1ODE4ODkzMw_a5b79eff-8a43-4928-8450-b609fc23f384" continuedAt="i14d0fa0cd9bf49ea9dd205494e12d7d8" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i14d0fa0cd9bf49ea9dd205494e12d7d8">We provide share-based compensation in the form of various types of equity-based awards, including restricted stock units (&#8220;RSU&#8221;s), performance share awards or units (&#8220;PSU&#8221;s) and stock options. Compensation expense is recognized on the Consolidated Statements of Income based on the estimated fair value of the award on the grant date. The estimated fair value of RSUs is based on the closing price of our common stock. For PSUs, depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. For stock option awards, estimated fair value is based on the Black-Scholes option valuation model.</ix:continuation> </span></div><ix:continuation id="i25454594fd7c4d6a926e8b783bf8cdce"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue the best estimate of loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time.</span></div></ix:continuation><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5ODk_ebf657f5-58c5-450b-963f-fdf0aebe86a8" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision is computed under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (&#8220;UTB&#8221;) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax (expense) benefit on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for the tax on Global Intangible Low-Taxed Income, enacted as part of the Tax Cuts and Jobs Act, as a component of tax expense in the period in which the tax is incurred.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Significant Accounting Policies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other significant accounting policies are described in the remaining appropriate Notes to the Consolidated Financial Statements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzIzMzk_85958979-d960-4066-b4be-65d1beb07d1e" continuedAt="i89e2d4cd70204c708fef67a45cabdcd4" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i89e2d4cd70204c708fef67a45cabdcd4" continuedAt="if28e36bf4b844a53b2205f62d3225d25"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenues </span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzIzNDE_9671d4d2-f8d8-486b-9402-d14d750b7343" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ab90c3fe714f4582356530234c3e60_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMi0xLTEtMTIxNDA_db6098e4-c8f7-4b0e-bd1c-d084c06fab06">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a627bb411ba4fa0a3e31a768339b2a0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtNC0xLTEtMTIxNDA_408c4a93-8988-45e9-95ff-e66818c97471">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b2ff7c2261943cab1a06f2276326cdf_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtNi0xLTEtMTIxNDA_aeef46d2-d884-43b5-9f18-eae6987a76e0">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id689626e4dac444288f45776a25c0250_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtOC0xLTEtMTIxNDA_7ddcca2a-3ffb-45a3-add9-bcb7d9f500ea">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc14ce605c54400c9ebe1fd7a321d9dd_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMTAtMS0xLTEyMTQw_5d7aac48-adb4-45ec-83ac-f96c380f01b1">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1051065ca69b4dd8bb278a9086b3981a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMTItMS0xLTEyMTQw_422ca86b-682f-4b17-860e-bc80f66dd728">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c1e93ba27243a0aec3ab8933b85547_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMTQtMS0xLTEyMTQw_043860f4-c86c-4e2b-a413-5b395e4a422f">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7be3325a864dcebdad2dd2a9d61b1d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMTYtMS0xLTEyMTQw_1b4e9024-0666-410b-b2a8-fd84d3e0ca6f">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8579426159424e1d88ee2838574cdf79_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMTgtMS0xLTEyMTQw_dd3589b7-0397-4b92-8658-6afc618387cd">501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16010a377327448d8c04798bd84bd4cd_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMjAtMS0xLTEyMTQw_86211175-bda7-43b1-b13c-895ebd489dc7">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b8647216f134ccfad7f18b6eeda9b4e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMjItMS0xLTEyMTQw_b861557a-f869-4b4c-8e0b-98347844d903">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bf76245cb82416b89541253976dc956_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMjQtMS0xLTEyMTQw_6e744c42-133c-4f08-b2eb-a58b26232be4">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5ed4771df344bf88d282203fb2c81a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMi0xLTEtMTIxNDA_3a2f97ed-78c3-4fcc-8935-077ce7c77982">7,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41a7b3cfd3a43729906149c4301f905_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtNC0xLTEtMTIxNDA_848db8fd-9bed-4839-9add-13ce34c9e970">969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81029626ddfb4f7bb7bcfe5c2fdfd743_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtNi0xLTEtMTIxNDA_1bfb594f-ae3d-49cb-a5c7-265f400a7ca4">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38b5f06b93954d2c8a448f52813c472b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtOC0xLTEtMTIxNDA_6220e768-3865-419c-9784-820eb5df110a">8,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e49c049a1ee4d1da001f9b14eede3d9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMTAtMS0xLTEyMTQw_c376f065-859b-41cb-8e64-e116f61dd3b0">6,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia257aaf476dc490ea9ce67b59628191f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMTItMS0xLTEyMTQw_2a6705ac-0898-4d4f-89d6-070cb01a71a1">735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i319aecbf35ee424caa4536ae8a070bd7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMTQtMS0xLTEyMTQw_a66da201-0481-43a9-a7ff-c753ca1eec56">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id923790754d142bc8a4cff9f0db14fea_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMTYtMS0xLTEyMTQw_02a0fbd2-1f24-438d-b892-2c24b74b39c4">7,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i004f42a19a0d4012ba76b651ac1781ad_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMTgtMS0xLTEyMTQw_e868ba9b-8feb-456d-a2f8-bb6823d76c16">4,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2e2462e823a488aadd395993cbcf54c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMjAtMS0xLTEyMTQw_170cf3e9-3ef7-4a2e-bc31-08750f4adf21">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3773b5856594296a0e0d5470b07272b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMjItMS0xLTEyMTQw_fc324cc5-c3f3-4a72-950d-8671e3599675">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb1ecc27305240afb7454391b76e7b3f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMjQtMS0xLTEyMTQw_019d6c93-8749-42fb-8bf8-8d9ac5851dd5">4,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955f95df25784bb981f16b33c53d7016_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMi0xLTEtMTIxNDA_4038194f-fe5d-4307-a4ce-01f19bd8ce21">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4364249c081e4a8299d35a203bc4202f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtNC0xLTEtMTIxNDA_47ef5c76-3238-4c5d-8763-1a1087b982f0">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15018f96b285492e9e58e9a7cf7f0920_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtNi0xLTEtMTIxNDA_6d3f9568-314c-4dab-9cde-bdd8d6f37880">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i943c0379de1a40db9377d8fb6d67ef66_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtOC0xLTEtMTIxNDA_1563d7d5-ca71-48e1-bf33-7c977032a3ac">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4554155264024aac9262c654e677f172_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMTAtMS0xLTEyMTQw_aaa0213a-55de-44a2-bf20-5071a3bcf0c5">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9044ed3ca9147dab388bcc7b177eecb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMTItMS0xLTEyMTQw_e365434c-c554-4121-b476-04bdfd7748f8">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07512868ee774a0cb3f3e62e504ffa2d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMTQtMS0xLTEyMTQw_3d389d5a-4d55-4831-b493-5a0d6562d13d">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83c30c6f5a8742afa25ed987810c2b23_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMTYtMS0xLTEyMTQw_a45492a1-d622-4604-aa48-f58c68f9f188">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a307049b7074acabfbc2358d76df30a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMTgtMS0xLTEyMTQw_966c0785-404d-48cd-978e-4db251e94129">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e743ecbe404abcad5a9fe1514264d3_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMjAtMS0xLTEyMTQw_c39b1874-2829-4a90-b9ba-c02b08ce84cf">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b1914f864b447d97ea0e13f1ce972d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMjItMS0xLTEyMTQw_3077d2ef-91b6-4a3d-9ac3-a954e936c76f">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a64962cf3bf49aa9644fc7d563ca33b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMjQtMS0xLTEyMTQw_75e8db3a-c6d9-47f1-9cf7-c106785f119b">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e847a9210e84d69b80c3e8dc9157357_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMi0xLTEtMTIxNDA_1fc14aa1-905e-4495-893b-4495a4799a2e">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief23171a182d4edda65a49c01d6e62a4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctNC0xLTEtMTIxNDA_df03a03d-7bbd-4819-9bf3-e893f0d59881">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823165f9f0194830b142fcc6bf699a90_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctNi0xLTEtMTIxNDA_17d8637c-8f42-4215-81c3-3d98ee9c9d81">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia58f199843b04c59b0faec348789a897_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctOC0xLTEtMTIxNDA_d4bc74b5-5bc5-48b1-bed8-a348bd307d51">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90cc329330df4a528c8cab6d9cd3edf1_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMTAtMS0xLTEyMTQw_1403dda5-92bc-438b-980a-027516b8150d">1,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479225886ad945e0b76b956d468e6f12_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMTItMS0xLTEyMTQw_8f656868-5cdc-4a5d-8451-bd0167d95f21">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fb52f7d4e44663ad1d8a82f09c8017_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMTQtMS0xLTEyMTQw_522d8416-c66e-4e77-9bee-1feec9298a67">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83c565a30a54c94b2209c76652e2a74_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMTYtMS0xLTEyMTQw_1e35965b-2081-4be1-a7ca-ba00d2299e02">1,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc63491101dd42d9a961519e1c143cee_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMTgtMS0xLTEyMTQw_fecd1a5a-3a89-4757-ae37-979a33bf2753">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67f5cfa462304b0ab9cbaf412e605c14_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMjAtMS0xLTEyMTQw_40e91295-655c-457c-8775-61e9aad11147">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i216a83afd3da4697ac13672ce7f19d1d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMjItMS0xLTEyMTQw_304fc3ce-40fe-49fa-ab1a-1423b225bf55">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabce25c37a564a34b5d87a9ca20dccaf_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMjQtMS0xLTEyMTQw_c3ffc184-94ce-4337-b57b-950c78353600">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ffde7221c6428c97f3d45227146507_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMi0xLTEtMTIxNDA_b8b552a8-54f5-4d27-b1ac-b4b9fa1b9e19">2,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50c2c139b864d0f9714887a2e19e6db_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtNC0xLTEtMTIxNDA_899c2862-9311-4985-b1bd-86a441000c8f">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb309902460441469df9d941328c83d3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtNi0xLTEtMTIxNDA_62c74d1a-3de1-4f9b-909c-46b335f49ded">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1dc009e9554fdd9f501b84f9a0359f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtOC0xLTEtMTIxNDA_14581c57-0eb8-4ed5-ac1e-a8fa2e046a10">2,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i936e4f60767e4e1b831396cbdc15a198_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMTAtMS0xLTEyMTQw_cc39c7e3-f7f0-453c-81f8-5ec28c1acb90">2,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a10f58aa8a4d788bb183517127b71a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMTItMS0xLTEyMTQw_05e25117-ff4d-4bf5-a1ed-f1e0e2a44f50">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba1f6a417454414a52eee67b903f766_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMTQtMS0xLTEyMTQw_1f4d89a6-d0ac-47d8-9ac1-96300905d370">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i578e91a5c0ef41cd8792efd4d19387a2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMTYtMS0xLTEyMTQw_c9506ea8-4e22-4101-960f-d5d29c964beb">3,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40d8621788548d7bf411858ff7ba95c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMTgtMS0xLTEyMTQw_426ac430-3b22-4f31-9353-b7b73399911e">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5afd54b578514567a98284af66dd6ac4_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMjAtMS0xLTEyMTQw_2fda4757-a50f-40bf-a91b-30f2d0d9cec6">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eb94cadea964808acc7aa15bff37b06_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMjItMS0xLTEyMTQw_bee4c96c-ca2c-450e-950a-1650400793dd">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf61ee83088444bebb4f09663550f050_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMjQtMS0xLTEyMTQw_edb08e91-79cd-46dd-b2db-644212d337e0">3,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d0947b224444048e064e12269cb830_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMi0xLTEtMTIxNDA_96575620-d494-4496-a67b-656e2003e56e">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia577fbe14a0c4e0d927470b3a7fbd587_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktNC0xLTEtMTIxNDA_150acc97-a871-491e-a1ce-1081d0eb043c">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i977d9314cc04434e91070353392923ff_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktNi0xLTEtMTIxNDA_c4208e9e-3fc0-4b1a-9d2d-7c73ca05121d">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d310b1fa75d4a7da984b20d948c2184_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktOC0xLTEtMTIxNDA_2a35cd69-0e79-4c86-b331-87c2b2a77c40">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbc93fa20d84074b84f54ab99be3ff8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMTAtMS0xLTEyMTQw_0c098ac3-8961-45d4-b2c5-aad0563995d4">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73de952e119a4e8193f9d06daafad3e6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMTItMS0xLTEyMTQw_d5ac1bda-b424-4bcf-a03c-3f0a35efde29">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a3692437a140df85ba1b362d2ab850_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMTQtMS0xLTEyMTQw_347616fa-b26a-4c08-b62a-375252d5feaa">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia94003099e5143b788e8be9985a431ba_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMTYtMS0xLTEyMTQw_7fb4fec2-f10d-41df-983d-51b9a1f9f227">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae5dc050b70c4243b5d650b622754554_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMTgtMS0xLTEyMTQw_7624b711-1d5f-4739-b424-d1ff867617f2">1,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3a4868171e44de9828b7b8b593f50c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMjAtMS0xLTEyMTQw_5a0c584c-464d-4924-bef7-f986e8a0fdf3">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e9af54cfc5343f9a51ab0c702ca66b2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMjItMS0xLTEyMTQw_9e74d043-aa11-4467-9a6d-039039c03e23">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00d8c27b3274579a8ddb2794664ce8c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMjQtMS0xLTEyMTQw_51da656f-ea52-4b46-99d6-540b29a5b44b">1,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925632f08b5b443abc506c4e0023ae1d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTItMS0xLTEyMTQw_97a86f83-e428-43d8-a52b-1781dd38a7e2">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i127c66e034bb456aac9234e1af982283_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTQtMS0xLTEyMTQw_43e529ce-4a8d-476d-88bb-7d8dcac745e1">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c935862970477fa978f1f0a2d5a975_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTYtMS0xLTEyMTQw_f2dbb477-645b-4963-abe2-ab9570e19237">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56588b2fbaa54723a442c57323d9358e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTgtMS0xLTEyMTQw_86334794-ee63-40e0-80ef-53ebfeef7fe2">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie911ed307ffe4eb880442fd8415ae516_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTEwLTEtMS0xMjE0MA_51dd5bd0-b8c6-418c-b0d8-76ba80dc9c63">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47483424d79343caad903d50f18fbc27_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTEyLTEtMS0xMjE0MA_af9ece42-a8c5-4d8f-8ce1-cdb94c6dc57e">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d5b07c3dba496b87eed5481cc9e061_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTE0LTEtMS0xMjE0MA_93b76bd9-4a13-4698-ba52-c03696051733">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6888f767fb5540a89c1b977dc34701f3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTE2LTEtMS0xMjE0MA_10b75ed3-da14-4537-ab8c-375d84276039">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcfe9bc16c64a6998c2ecc8a00a59a7_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTE4LTEtMS0xMjE0MA_d790d7d2-1e75-4361-ac03-f7c2fade9527">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab5c0a688812413b97b23617889fdc29_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTIwLTEtMS0xMjE0MA_0d5f859d-4112-4178-ab36-b7ecea9b76af">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3ab7f327aa411ca8cd78c5b9c55878_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTIyLTEtMS0xMjE0MA_c8cc9e16-d826-4809-809e-9cfb9e6f4c45">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f67d4b107054320b3c16b7722812905_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTI0LTEtMS0xMjE0MA_c3e794b2-49f2-41ed-aa9c-c3b652510c44">369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20615d735e3f4feb876b0d68cb833b1d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTItMS0xLTEyMTQw_e62fca8a-de3f-4bfb-8d9c-0a9311ead411">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafcee73041034a3bb538769755411935_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTQtMS0xLTEyMTQw_25625737-95a3-4003-8fd0-b9d5223cd64c">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e8a386144940089c04595189b92780_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTYtMS0xLTEyMTQw_6964576f-d44e-4063-807d-8e4ad243bd31">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida4bff1ec94d45e89d93a2f8a45a8829_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTgtMS0xLTEyMTQw_06b9db4e-2be3-48b2-b1b0-327e457b221b">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42c088f381c4f66821c3e14150643fd_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTEwLTEtMS0xMjE0MA_f606d7ef-a013-45a3-9195-9fe3d0825030">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a12972820c549f7975a5bf002bb6538_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTEyLTEtMS0xMjE0MA_a46048c2-307e-4643-9eb2-9b93c4bab092">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f2aad4ccbe4eb0b88c2df952d0f837_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTE0LTEtMS0xMjE0MA_9635cdc1-4ec9-4763-b090-d3476c63b666">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897e806822094d188dfde4952fccd379_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTE2LTEtMS0xMjE0MA_1c838587-bab5-4945-b324-977725e89ef3">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba451b80fc88410cb6da9b54c955e4ca_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTE4LTEtMS0xMjE0MA_64908823-b1f9-4746-a543-b3b3060f9309">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43aa85da84bc4a6aa2f0f6e6c94ce6ab_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTIwLTEtMS0xMjE0MA_4d88dd19-8e58-4e97-9909-980e180ab925">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic75353bae5a445d5bc123e7e2497e07f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTIyLTEtMS0xMjE0MA_a1cc1078-1336-417c-8559-e7fb3b3329d5">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacec9e096e3e44b99059f74fabeb6b7e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTI0LTEtMS0xMjE0MA_dc0616f5-11ba-49e6-a6d6-2e258697b760">2,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56fe44333d84038b5fbbdbcc054b3c6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTItMS0xLTU3NjQ1_949e6a24-ca89-419d-8fa3-c1b5dc8719b5">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53379b0e65dc4f64ae5b9bebdfe46157_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTQtMS0xLTU3NjQ1_64388488-abf1-48f7-b3a4-2c3442289ceb">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i893bbd6422a34883a23ca3d826e5330b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTYtMS0xLTU3NjQ1_b66d3ab1-f7cb-4d21-b0b5-eba0e99ce984">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448e732ad9d54ac69e5a1bd7cbe328c8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTgtMS0xLTU3NjQ1_3ce1ced9-ba69-40b3-985a-ec7df9bd6600">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia91566e38f88433997c0da1de1f66272_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTEwLTEtMS01NzY0NQ_2247160f-8ad2-4d89-a4a2-6d7df7c9fef6">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ff0ba8e2df54068b6656075016def3f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTEyLTEtMS01NzY0NQ_1ebe554a-a247-4445-b7ff-19d85e577001">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb20f84492cc40dc9b975458263e0c09_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTE0LTEtMS01NzY0NQ_4ae277b5-0997-4cc3-8f07-dfa23d824291">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f373d73c8b47b1b9b16c76da6f8272_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTE2LTEtMS01NzY0NQ_bf547c88-0b77-44c4-9c6c-713555d92a50">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0472aa0ea92940198b6e45b72223726e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTE4LTEtMS01NzY0NQ_9041ccdf-9107-4c53-8f90-610cc45424eb">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c4c20540eb44838445a3c3bf6934db_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTIwLTEtMS01NzY0NQ_47c832d7-ebac-4e1e-9cd3-3a6b3ab3ea67">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736248e52f04435497e629400596475c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTIyLTEtMS01NzY0NQ_8a0b6c13-a8d8-479f-b43b-5f03037f83eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83bcf63461a9483abe4dfe87ed5458a8_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTI0LTEtMS01NzY0NQ_9920af5e-41e6-4311-b464-ec569aa0fdf1">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faa4357e47d498d8cbb90bc8b52484f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTItMS0xLTEyMTQw_766fa455-8fec-4474-bda3-1ca3c79c5ab3">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i396c07fd8f3441388406ead2bb7d7a43_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTQtMS0xLTEyMTQw_60bd13fd-4885-4649-a806-8fc3348fe31c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i444aa902d7d24a6bb6ae1f79b9b2c713_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTYtMS0xLTEyMTQw_7db21286-5255-498a-9f46-84ac9bf2f679">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a837cfa59946e4a95ef8a3cda149f7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTgtMS0xLTEyMTQw_88a0b67d-c1f2-449e-9db9-c79383c892f6">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id88fe6e33c8e46bb9324f5323a45bae7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTEwLTEtMS0xMjE0MA_9a5d5679-1d9b-469b-80fc-a00567c640a5">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaecb4bf28d542abb8f6e6fd2b7265d3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTEyLTEtMS0xMjE0MA_9a4b8423-3d4c-46ea-8aa7-e77c2822cdfd">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if60bb22a46354d29b9219ed7fef954d0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTE0LTEtMS0xMjE0MA_c1a1683a-ba34-41a9-9d9e-ad8a902ee71b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f5a348b1384a0383f1142c48fbdfd1_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTE2LTEtMS0xMjE0MA_fa465ea9-3e90-463a-9320-a7472d84118b">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5c024b83bd4d2aa79c46874679d786_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTE4LTEtMS0xMjE0MA_87c81a98-4b93-40a4-822e-f9c39120662b">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504f85f6c7224b00875ce2499cf0be63_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTIwLTEtMS0xMjE0MA_492876a2-c332-4f90-afb7-810bc5df0768">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f908e96d164ff1b01f8baaa3fd197e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTIyLTEtMS0xMjE0MA_0eb2e998-401d-46bc-b3ad-0ee149bc2fdd">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia251084190c34f55a95d6b2d64e37c96_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTI0LTEtMS0xMjE0MA_cc84887e-23c8-490b-ae10-15e3ed3040e3">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HIV </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229cf3b61ba147a3bbcb87ad7c31cda8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTItMS0xLTEyMTQw_269fbe1b-fa2d-4db9-8935-a1ea9044847f">12,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac706cf047e462d9dfc15fd7dac6e57_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTQtMS0xLTEyMTQw_8dc11aee-fd7a-4ec3-9bfd-5528235ece3b">2,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3eb81dce73a4ed49c600ae52236de95_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTYtMS0xLTEyMTQw_bb689e0c-07e0-48dd-a816-7fdca87b4b34">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i618a49f5343d4aecbde299dd826aab16_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTgtMS0xLTEyMTQw_11c75797-5ad5-448d-98ee-92b94842d086">16,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dee7da238ca415a918de272a337f32d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTEwLTEtMS0xMjE0MA_8a3c9f5b-fd72-4c10-a1a6-7333eb06005a">13,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbaf6564706d428191f126d2bc0e85d9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTEyLTEtMS0xMjE0MA_c879acfb-923c-4f2c-bc83-0bafa9cb86d3">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie107375dab0449d29330362386bad92f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTE0LTEtMS0xMjE0MA_2c361419-67df-4619-bde7-3321fa2ffe4a">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaab2348e4b4632be02c7e9827151b6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTE2LTEtMS0xMjE0MA_b23877d3-ec6d-4f8a-a7a2-f4504d3aac6a">16,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e04004aaf38470babb8b33e23b0be74_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTE4LTEtMS0xMjE0MA_94acd3c4-b82f-4ce3-8e0f-1e401764371a">13,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3ea7d2e5d849d7a255cb4ca655164a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTIwLTEtMS0xMjE0MA_5821ed8a-673e-4095-9596-17781a1f91b0">2,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ace274ff98a410dba00afed59352d83_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTIyLTEtMS0xMjE0MA_9dcf7ef0-7c50-4a36-8ce6-df4a99ac94c1">811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i465510434439422dbfe78d94feefa0d9_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTI0LTEtMS0xMjE0MA_8c3e5b7f-1017-4e10-bd4f-7260ff45f532">16,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d552aa7c2b84ac880c86df8863dfdb2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTItMS0xLTk2NzI5_5a190b58-1456-459e-8fc1-54bc315c9416">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec344efbbcb4ac58cc8fa406d405f6c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTQtMS0xLTk2NzI5_9dc6b3f6-38ea-4110-870d-35c24581a3f1">1,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id54f9b7f9d7c4a1eafcfcbb1db87e3c7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTYtMS0xLTk2NzI5_51fca6df-8a01-4126-b820-01096c97909c">830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a47ad4a66a490c87ebcbdb533b3462_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTgtMS0xLTk2NzI5_e4ce5539-ffb6-4520-9c49-afe603be5571">5,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6ba686d4024e4cb3fe4e32aaa54c4a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTEwLTEtMS05NjcyOQ_68ae3548-8237-4423-95f6-091cbd29b414">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628f3e6013424bf6b278bfbb87d91521_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTEyLTEtMS05NjcyOQ_92294aed-3844-4842-a80f-e6ef096f7af9">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i099a39b4eb484948a229c49d6d7556b0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTE0LTEtMS05NjcyOQ_b7991e6c-e226-4f9e-b5f2-2c7604f640c7">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide13091f185d41cf95813a1577de725f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTE2LTEtMS05NjcyOQ_2c892e69-df4e-4b62-84c6-866b1a8e17a5">2,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee9158b1c9f74ee081ba38f7155459e2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTE4LTEtMS05NjcyOQ_73caba74-b036-41da-868b-ff32a7b08d61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief38edf0775b4b9ca4f0e44ff59522b2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTIwLTEtMS05NjcyOQ_a58c8512-f172-41a4-b2bb-f408cde87012">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf73a2b190f407094b4c112c16ea000_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTIyLTEtMS05NjcyOQ_3c932f5b-77f1-46c9-8fc2-085a8d692ff7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e97db273aa4eb795da9d6d163926de_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTI0LTEtMS05NjcyOQ_82443a0a-221b-4e1b-aa50-a981f6710101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ledipasvir/</span></div><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2c54277b224652bb5f481e8899b9e6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTItMS0xLTEyMTQw_ebf52dec-1302-42ec-9198-2dbbaa5b3288">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i941c012023db4169add7305278b25afb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTQtMS0xLTEyMTQw_72b49684-f016-4403-ad13-0fd36724add4">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b3da75ff53437da4d0ebb7b7fce5dc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTYtMS0xLTEyMTQw_657d6d2e-de2a-41a5-b3a0-a572db7c0ebf">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98d85f6a23645e7b3666fb72be32521_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTgtMS0xLTEyMTQw_4bcb6266-4ad8-4fa0-beb0-32634ebc96ab">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110bc03b8b9a4f39af6919c8022f5247_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTEwLTEtMS0xMjE0MA_9b7e3ce4-2920-4a0e-a7b8-8ca13e2045b6">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9461e732efa7439c98e730817b44bd6c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTEyLTEtMS0xMjE0MA_f497ba84-3f18-4f00-9757-a74e54a7a82a">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e0c50452714cc3bed41c678ceb7699_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTE0LTEtMS0xMjE0MA_e00a7539-930a-4249-af3f-348f1e96532e">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4a05a18dbff43cda41f2c88b1526af2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTE2LTEtMS0xMjE0MA_417808ce-d289-4312-8db0-8c97322abcc3">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071292c322124b9bbbf6c05bedcf533c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTE4LTEtMS0xMjE0MA_f3a59e15-b13f-456d-84ee-82ce1b09f73e">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6d911747d0e4dd896dcbd36aa8d64b6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTIwLTEtMS0xMjE0MA_48cf18d4-281d-4509-875f-01722e3e9d2a">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3db91593e7ae46df9458a6d27efd34e2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTIyLTEtMS0xMjE0MA_609244ba-0c20-4562-949e-707c4131175b">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice67dd103e8747c6a85c1155ca7fb3be_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTI0LTEtMS0xMjE0MA_5a790ac6-5a6f-4611-9c8f-fab79d1ba249">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72885015d43e44598a373a66ba3cd518_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTItMS0xLTEyMTQw_1e3e423e-95e6-458e-906a-b2d76bbf8fea">815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d706b9871c4ec09d84165adbfdc1bd_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTQtMS0xLTEyMTQw_7bd5f0da-13cb-4825-8be2-e14bfab208c0">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9744c1bb608145caa3c32e7f1f1e62c4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTYtMS0xLTEyMTQw_c0cd0083-aba5-45cc-a131-7338168df321">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf61fdee7ed484a8cf5ef1a28ae513c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTgtMS0xLTEyMTQw_db1e96f9-9097-457d-8950-84e6dddfaf39">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68f13d7d65f4a3f9d6b6fa6fe779f16_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTEwLTEtMS0xMjE0MA_f8a2311e-fdb1-4131-883b-afbe1544e4c4">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad62ec6434ec4a489357913014ef40c6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTEyLTEtMS0xMjE0MA_492d6b02-2bb8-42ce-96b8-43bee2d24a12">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632ecea3d6a14bcd8aba4b551ab1b109_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTE0LTEtMS0xMjE0MA_a9771c05-99fa-4334-a9ff-fbd70fe4aac6">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6977f8ca20334e9a848c24badc467c74_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTE2LTEtMS0xMjE0MA_1362fc4a-6fb3-4525-982e-672f4f86715f">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad186c8130da4cb0a163b46e15ef8e0e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTE4LTEtMS0xMjE0MA_8f629cb1-9f1d-4602-8ba9-e279ae3528be">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad332b2083f6422aa4d34ccad607df30_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTIwLTEtMS0xMjE0MA_c160b829-cb95-41c9-a56c-ac0c52bae887">553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic402cdf5c95049fab3f5cb084e3b4a9e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTIyLTEtMS0xMjE0MA_f026896a-2fcb-4ea2-8090-7ba73b831d69">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie91e317bcce84be491b677bb32bc6edd_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTI0LTEtMS0xMjE0MA_4e37a625-66ab-4bd8-a8b0-8473d6d6912c">1,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375f98b35c614e57bf7b3740ade479e6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTItMS0xLTEyMTQw_53ddfdd4-8ae9-4741-b19a-638faabb35a8">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee01bce4fff478da0c0d8e0717ceab3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTQtMS0xLTEyMTQw_9b818317-3396-4aa2-8bc7-fd004547e777">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19612080d7a04eb680dd7e62452339bd_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTYtMS0xLTEyMTQw_8de42229-1d86-4447-bd5a-8434e401c11f">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0528cba9d58149eeb50487d8e0d93ffa_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTgtMS0xLTEyMTQw_37648432-32d3-4ff2-8796-3401bc58d5fe">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id10376e1051b4ab49d4409daa6db3caf_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTEwLTEtMS0xMjE0MA_02ba0309-c802-4553-8c96-c8ab52ec59f1">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaccc6fe1894b406ea52f03be7d11f6d9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTEyLTEtMS0xMjE0MA_f31302b8-14c7-4834-b91f-0de046e787a2">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08fdcc10444240b5b0e2612cc6f7a33b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTE0LTEtMS0xMjE0MA_ff3724cc-6a54-4def-904b-8f9bcbb1099e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6778d1e87c764b129992c37e1b4c7453_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTE2LTEtMS0xMjE0MA_8c83b1aa-64d5-4f6b-a025-2aaf6e934bde">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a3a1f229ec4abb83405668328a28bc_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTE4LTEtMS0xMjE0MA_e5d3f7e5-104f-4499-815b-ff799147f1bd">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5ae4a747de409780ccfa5e25f24d81_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTIwLTEtMS0xMjE0MA_bc367c3c-712b-49ea-93c6-026c9a2e5c6b">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f226ca327245028082583aeea18794_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTIyLTEtMS0xMjE0MA_e14b72f6-d9d7-4d39-8ef7-059ba0d5befa">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic223455e19124079bccd18d5b6d19b66_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTI0LTEtMS0xMjE0MA_b9c7d6ee-33bf-4fc0-ad6b-50e56833b2fa">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729e30cec34d4651bcc4fffc012176bf_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTItMS0xLTEyMTQw_9bd1997a-7bf7-41d7-af6b-758217f8af23">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f528f5ab3e479f8750f39c2d1cda40_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTQtMS0xLTEyMTQw_f269e34e-eede-4495-ac3a-3ad5e487d07d">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c21b57a311843c7928c23075197493b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTYtMS0xLTEyMTQw_b69360d6-b7bc-44e3-a236-834db7030c62">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165baeb18574423899e97572f4ad2303_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTgtMS0xLTEyMTQw_02f4ea72-6d17-4a03-b6e8-4f59f7bbb501">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie276a8d1c5114e51906a50380e6079af_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTEwLTEtMS0xMjE0MA_97298a48-931e-4578-a531-58aaf57b0afe">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808173f115644f8887374d0ccd5b7c2b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTEyLTEtMS0xMjE0MA_4dd7cea1-ddbc-47f2-9955-064de089bd3a">414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af4bf5983dc4d368f5f7d4d273418b3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTE0LTEtMS0xMjE0MA_c85aa014-7040-4969-94b2-4972a21d2092">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47170c44772d4eca8e1e5e6506def2c6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTE2LTEtMS0xMjE0MA_075deae9-f3f5-47b1-b2b7-89299b2a5153">2,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51636ea5513d4d358e7a7b90f6dbbcd9_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTE4LTEtMS0xMjE0MA_f03cb18e-639f-48a7-803d-c36cdb4cf53c">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf522a1b7f6646bbabcc782e8dc1b51b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTIwLTEtMS0xMjE0MA_1363afda-bc40-4ad0-be7a-c3d51cf107c0">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fd3a2239f5b4e01a783ba6d8ec0df2b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTIyLTEtMS0xMjE0MA_13fed870-f638-411b-9a6d-c3028f21268d">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f8928add9a34ec3ad3f06c8d26024e0_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTI0LTEtMS0xMjE0MA_395faa65-b3df-4767-9f5a-28ba70a89c4b">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="27" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis Delta virus (&#8220;HDV&#8221;)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4a7b3c0e8c4e2a853a78f842c29fa7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTItMS0xLTI5NzA4_8c38ad69-c156-4379-82bb-fa7cc780bd00">384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4827aab7f394a64b3d94fcd0bb16303_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTQtMS0xLTI5NzA4_4eb61d03-a228-4e3e-b798-9f0e1da7c87c">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia26aa6ff603d43d18f70315e2b916968_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTYtMS0xLTI5NzA4_458c34d6-3465-4ba9-841a-5a60aa04f0a5">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871089dbd36740338ee626df7623365a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTgtMS0xLTI5NzA4_31ebd97b-3942-4d05-ac4a-ece9a5e61386">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b4e1408e03e47fb82f8f85c9eb666a6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTEwLTEtMS0yOTcwOA_dfb66970-6227-4b9e-8b42-7d82ba771a2d">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ce404a1df3479280a332700013fcf0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTEyLTEtMS0yOTcwOA_b70330fd-bc90-4810-8fab-0a214c28992b">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146057c31eb14e13a7a9e858bb60ead3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTE0LTEtMS0yOTcwOA_e3b7e277-bf42-4142-b193-840e0b25efb5">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ed2d462dfa849f6afe13f2ebcd6d4e9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTE2LTEtMS0yOTcwOA_6a0d574e-e8d0-43a8-9212-b1ccdb87a2e3">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1a81e689e545ee948a81eef2e1c110_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTE4LTEtMS0yOTcwOA_8beb39c3-1b71-4b2e-a42c-c463290648d0">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b28d7f764ed4df6a8fc6e996578f509_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTIwLTEtMS0yOTcwOA_f4be6c87-cff5-4405-ad5c-4695a1c46283">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2151dc48e6c947d99adf672da18b5df0_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTIyLTEtMS0yOTcwOA_eb1c453d-ffac-4b5d-9413-7a54b8c30cca">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb410dca7a24d078ff1663fdf12406a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTI0LTEtMS0yOTcwOA_8f0198bb-6f69-4d22-811d-7771ce704a20">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ea9f66d534416db1d7a1827cf95ef3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTItMS0xLTI5NzE4_7e7b2d6f-f1be-416a-b517-a1eff50c6a3d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1647c6936bc43fcbdf243a9abdc515c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTQtMS0xLTI5NzE4_95421fb6-28e5-4ec3-8cbb-34c2fef357a8">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aae349b58074fb090feca87f57d6a14_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTYtMS0xLTI5NzE4_ff31e210-6d81-4d71-895d-984e689b4f60">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ced3c15a03640a7835d719b1561a52c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTgtMS0xLTI5NzE4_a04dfbb1-067c-4763-a7a7-fc9b490c5a26">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73345ea2314645cfb8820974c816098d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTEwLTEtMS0yOTcxOA_0f303b7b-fdd7-43f7-87be-2420b425f2bc">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bd332574d544b2c82443ba3f73ee034_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTEyLTEtMS0yOTcxOA_8a05719a-42ab-4a44-9d97-3a331bdf2702">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91bc7aa72e1a4adf90ce08b4fc392bee_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTE0LTEtMS0yOTcxOA_91663bd3-7049-46aa-b5c6-7e908eab7b20">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb76b459c940c1b2329abee0b99396_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTE2LTEtMS0yOTcxOA_af0ce96b-32de-439e-8b89-0d7c022d41da">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09754db5820b49ccaccb7b061b0de557_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTE4LTEtMS0yOTcxOA_bc4e98c6-739f-4bcb-a369-24ee8d7b4f7c">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e265173cbd142768e582d998dc84774_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTIwLTEtMS0yOTcxOA_542f6d5d-196a-48cc-a82f-2d17fc218ea8">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172a3eda78c94e1a9b766caab41395d0_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTIyLTEtMS0yOTcxOA_c96ef750-ce19-4547-a22b-55eebe1278f8">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4459dfdc5346422aa45ece2ad20dbcf7_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTI0LTEtMS0yOTcxOA_77bf3a12-fb89-4c16-9474-f2965fe2a2e8">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieebec0082c664646b4c00fc161a76516_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTItMS0xLTI5NzM2_4af73a11-1e71-44c0-9273-0dd7bd13366c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7d099c53b1d444b94f937435b1658f9_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTQtMS0xLTI5NzM4_ac20e21a-8bf3-4467-90c4-670321fed51b">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ff0b32543a42a4abba6624736b33da_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTYtMS0xLTI5NzQw_4c522b38-5a8a-42c2-ac64-5904028347dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f1ebdb534d481b8b99013849133a98_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTgtMS0xLTI5NzQ2_9e9b6b45-06a8-4082-a291-ac9ac6b8d891">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970f012679314778a69b58c8c857088d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTEwLTEtMS0yOTczNA_291eca75-b4dc-4b9d-8938-2ab7162434ef">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff2b48995cec427d8433b77a188fc0e0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTEyLTEtMS0yOTc1Mg_488b3f71-7d55-47e1-a641-4fe2d4238e0c">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11fe2f0b1fc7469e95477b31fceb41b6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTE0LTEtMS0yOTc1NA_a4452a9d-44ca-453a-8b4d-37f9b84456b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f64c38e9ee4bb4a4adfed263dae20a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTE2LTEtMS0yOTc2MA_f64aa068-7ac6-4f42-b70d-5708d11cfae2">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4513c4c6a873402fb73e21a4c06e9516_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTE4LTEtMS0yOTc2Mg_cecaebbe-a9c7-4ca6-8562-ca0adda9d61d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3976c38729943bca9dadbf1a4d46799_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTIwLTEtMS0yOTc2NA_3661618a-8cbb-4a59-976c-317071a7400e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib547fcae84e34c80b007576498382eda_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTIyLTEtMS0yOTc2Ng_042b937f-d69b-47a1-93ec-97c848ea4b54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6cb120280c44aba952a2c8c31a2750_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTI0LTEtMS0yOTc3MA_431828d6-f12b-4057-acb1-af04aa952c85">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0079f3b20eae4a329e4b8ab2e229a710_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTItMS0xLTI5Nzcy_fc3c2233-fdbd-4471-b919-c3dde0fe31e3">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c533a97e93b4daea96b3f68f4b71cb1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTQtMS0xLTI5Nzc0_058f6d7b-7c8e-45fa-b6c3-47b2e6f40b4c">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i336a3356c30a4e60afd917f34ba87b7f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTYtMS0xLTI5Nzc2_ea42ae9f-efea-4a7c-b043-2d0d0f5ced69">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ab1d03e53b40818f7339579267f386_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTgtMS0xLTI5Nzc4_0c432c64-bc98-46f7-b448-f15efde15bf4">969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d26996cce54be89bc4f5b1de53509c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTEwLTEtMS0yOTc4MA_4436a839-ca35-4ed9-b54a-0bdf58ecb5a6">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73430cf69e6a4a81b0cb6ca9f2f1bcce_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTEyLTEtMS0yOTc4Ng_bd10a263-47cf-40c6-bab2-65c650f83654">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b4092e37bcc4090a2f341d283035c62_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTE0LTEtMS0yOTc5Mg_723d4ec3-ef3f-41a6-959b-9615ba857b4b">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8edb5cc13dcc444f8d32a508d719f99d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTE2LTEtMS0yOTc5OA_a6248f88-f3c4-4de5-b7eb-a194b7c2437b">860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72cab863f9944e49a8a3f6a212cfdf8_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTE4LTEtMS0yOTgwNA_e0e8d32a-8318-42e1-94d1-88392d398f91">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb6a7e8649e43ea9cb507ca4dfa26de_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTIwLTEtMS0yOTgxMA_4bebaaf0-1249-4aa1-9837-9564cc71c292">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24161ce3ce19498d973322014f5a38f9_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTIyLTEtMS0yOTgxMg_57d36e0e-1efb-45cd-a2e5-89a2bc5d3bd6">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ca7841873c343278c0054426a718e6c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTI0LTEtMS0yOTgxNA_9f40b359-7895-4d66-aa22-30544982948b">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id98a790faa824c7aa313d67d0d0d9def_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTItMS0xLTU3NzE3_1784b767-3104-4c89-82ee-722a61dc5c01">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd711f6c7d6a4b3caf2c838786295c50_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTQtMS0xLTU3NzE3_290e6191-4c8b-4a6b-bea6-2a6a89ce9b63">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b37a4b21504974b6a12ee7143b36f2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTYtMS0xLTU3NzE3_7698baeb-0773-46b3-8425-16288e2a8cbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2966258a34f945a6a240f933b9ea68a1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTgtMS0xLTU3NzE3_76953ac6-5dd9-46b2-b30d-8482a2110cc1">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacff29670a64fc3b828391eaad52b5c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTEwLTEtMS01NzcxNw_8cee0b69-0e82-45fc-a58a-624d60ea3d92">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51653a7404d243bbb8c6b8587d15c302_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTEyLTEtMS01NzcxNw_e1ed0717-7d6c-4502-8ccc-734e7e04083a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2206384caac54219b456deb7b0f73604_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTE0LTEtMS01NzcxNw_48dd9ea1-5eb7-49a6-b7a9-0c9b484c163a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i062b8b99606f460291f3600b276f88f9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTE2LTEtMS01NzcxNw_7fff3b5b-f154-4fc8-bab8-2ae550c52374">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65701b8285f24b0196e2fbb93db58af3_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTE4LTEtMS01NzcxNw_f77ac109-ac0e-420f-b409-d309b7297d22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2df490d82b849ba8e735ab25f5a83b8_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTIwLTEtMS01NzcxNw_343e5578-8d22-474f-b531-62dc857c4491">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c114e0218d342d9bb4a36cbb9d68b4d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTIyLTEtMS01NzcxNw_0febdf7c-9ff0-4b32-8724-e9389d107621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a119fbc00c649cd9b0a5f71bb9c51c3_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTI0LTEtMS01NzcxNw_7a2126a0-9fc0-46e2-8fa7-8cd286f43d66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9de5a23fb8f43d08be01ea9f3270bb5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTItMS0xLTEyMTQw_4e594508-6c48-41c0-8f08-3e56ebbea66b">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860b9ef8d88648b2bd14fdb1a1c02780_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTQtMS0xLTEyMTQw_355212e2-62d7-4d12-b166-cf30b76a17e2">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb532a2686334aa5bead08d5c4f00b78_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTYtMS0xLTEyMTQw_f720911f-c6e0-4391-bfaa-7dec4182e4cb">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic037528273e74f499033a150e619b4ff_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTgtMS0xLTEyMTQw_1dda6a76-b5d7-4632-b8f7-0f2732f3a257">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f699c45319641abb957b330b47c6d1f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTEwLTEtMS0xMjE0MA_b4eb91c8-4bb4-4805-b75e-d1c43cc6191a">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ff2ab162b88421d9ba989dd81c8eca5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTEyLTEtMS0xMjE0MA_9aa381db-8dff-4634-8911-6ce113c99380">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if208e11d45a94784a19929ca1f05b974_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTE0LTEtMS0xMjE0MA_d6455f80-03e6-405f-a8a5-6cc6710c7574">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic808e56b4fb14e02a5bc2f7449a1a9b4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTE2LTEtMS0xMjE0MA_e4f6517b-ae75-4eed-8e38-e84b50bce7c9">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba5b8558d6d4ff38879057fdcd4aea5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTE4LTEtMS0xMjE0MA_7f5abc17-e01b-458d-80d2-8e8f88601016">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8de715ffb064281b509585e98cc69f2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTIwLTEtMS0xMjE0MA_4029416e-34bd-4c89-b9ac-bcc601838a71">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92935c1825d54cbd8511cdb6abcb6c47_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTIyLTEtMS0xMjE0MA_2198b03f-0206-4725-a9be-a8198bb521f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3529227ebc7e4c039ce5ffffb338ca93_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTI0LTEtMS0xMjE0MA_977e385f-724a-4c73-bb51-e915f6dd0393">456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Cell Therapy </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea72c97e32144938bb26b805ed4c89b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTItMS0xLTEyMTQw_fa93e195-8786-4bb2-87cb-94ded7177937">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213cbdd848e94530b0d92ccdf1a75dfa_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTQtMS0xLTEyMTQw_e37d3ae1-5b10-4339-80b4-95405d3864d3">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5056823e9ae347a2933637a7bbe6b448_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTYtMS0xLTEyMTQw_241ee0d4-68d7-4050-8156-78ff4809f727">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4696f53ab1428d8c9d1112eeaa551e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTgtMS0xLTEyMTQw_104fda3d-994a-4270-9fde-56799f2cf835">871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c27d0f7d2c45fb98bdefdbb85bae75_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTEwLTEtMS0xMjE0MA_f61b9257-4583-4fb3-8f0a-b83dec250634">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ceb977bf93a41088454e4c206235415_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTEyLTEtMS0xMjE0MA_38a7b9f1-82c4-4442-8a23-055f2c188cb3">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ee0f595be264b08b8f9806028bf9b51_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTE0LTEtMS0xMjE0MA_b684ad34-2080-4f7b-82b5-73bc29d28a58">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09f0fd7313646458071d017d8175cb8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTE2LTEtMS0xMjE0MA_6d129da6-ef3e-45cc-b141-a4f7ad43d26e">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab8836d9a4ce4fc5ba393c942ed97e61_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTE4LTEtMS0xMjE0MA_6ca22f52-d7ec-45ab-a240-e5f7b62fa282">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaae822cf2d924f3ea765b050bbaa39b3_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTIwLTEtMS0xMjE0MA_01c0b877-deee-4024-aa61-3f8c1ae603fe">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i336854a9631445dfa14f917b4c21eb5e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTIyLTEtMS0xMjE0MA_abfbc839-15e5-4448-9629-2b123f5c15f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a0b5eb4e390464fb3247a2dcdbaebac_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTI0LTEtMS0xMjE0MA_a8f2bc18-bc17-4831-87e8-60b5ca6ded20">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e00b704a1f44803ada987adac8e13c0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTItMS0xLTEyMTQw_51f060a1-9e58-4004-8149-2b44d29741e7">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293b3b4563e14edfbe7fc51df8a013bf_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTQtMS0xLTEyMTQw_34e1b100-2c2b-4449-b09d-fe3e184661c8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7df84051b024c53a6a840e6cdfb14a4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTYtMS0xLTEyMTQw_484665c7-80d5-4009-933a-4a864c93936b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961b952327124924a5e23eb37b9e7069_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTgtMS0xLTEyMTQw_ea587ccc-002d-4aa8-a483-e85c53d85e9d">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137abd7ca81b458e88261321792ec71b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTEwLTEtMS0xMjE0MA_8f4f47a8-8d58-4f27-bc42-09672aa693ba">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i781c570cd3034947a327d3ee47e152fb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTEyLTEtMS0xMjE0MA_8d11b4c6-8af4-4af9-bb3e-c1d5f460a923">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f704090e060470bae3918d46cb8a9c8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTE0LTEtMS0xMjE0MA_f92152da-d922-4418-a3e1-17e0a3fffc2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a218e9a42374b4db9008f33b6126318_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTE2LTEtMS0xMjE0MA_186135ab-b79f-4425-8fda-70600a9a905b">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e25b298d34d4c5cb36e6a52a778cd3a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTE4LTEtMS0xMjE0MA_dc9c0665-ed8c-4385-b280-fb39412b7805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4403855d5dcd4d63b3eb5be25dbcfd64_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTIwLTEtMS0xMjE0MA_7d95b4ca-95c8-404e-ab17-05fc93c17808">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35e32326f834884ac9a61bb0b8b479c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTIyLTEtMS0xMjE0MA_7dbf5d39-2564-4d6f-b3c9-1280ff4af20c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65db5049fdd3411fb63e909ef2ec8e5a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTI0LTEtMS0xMjE0MA_4a4b704a-754a-42c8-b363-9c8c9c3ea1ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3938c584a5744b148070f5afb631ce36_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTItMS0xLTEyMTQw_6eb6a568-5e42-4d83-8363-4946df944fbf">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i713866d6cf0e4d8fb0f713df57c870bb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTQtMS0xLTEyMTQw_d8582bde-2844-46e4-a03d-70126c9b9fa2">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i681e654b253346a9b076a1bf6a0ca271_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTYtMS0xLTEyMTQw_65e2a30a-b8b9-410d-ac87-e101240835ec">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0f560cfb9a4aa2802a62ac6becbf6a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTgtMS0xLTEyMTQw_be6ce6d5-a919-4dcd-ba48-d43538464d53">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090096a8205c4fea847fc56558d9886b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTEwLTEtMS0xMjE0MA_e628afd3-1c78-448c-b1a9-f1b0a75ceca5">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9722c0087b814ddfb113130f0e25579a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTEyLTEtMS0xMjE0MA_643b8b87-ef39-4569-9ef8-f14fe016c957">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9900dfcf355e4c32bcfd2373bce186dc_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTE0LTEtMS0xMjE0MA_22a31864-3672-4eb8-8223-3bd141f31082">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie52246df773043eaa8b85b321512c538_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTE2LTEtMS0xMjE0MA_84cc44c3-2fba-4e5f-b454-2a943b510194">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3622a78565bc4859927f6689c3c01aa0_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTE4LTEtMS0xMjE0MA_3498c658-0c30-4911-8580-ecc5d7b11992">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92c7202f262d495b8e4e4a2f24623eba_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTIwLTEtMS0xMjE0MA_05d55bb9-d302-454a-b3fd-b7df08726526">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c9456ecdfe444ea9be0065da372c97_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTIyLTEtMS0xMjE0MA_bc0618e4-e69f-4dec-84d3-d7baaa662950">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0d01fa66074181a48c9de2389193a3_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTI0LTEtMS0xMjE0MA_8d055ca2-f071-4214-b8ea-eaa80434bf57">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib586d74aa0da4b4185dfddf3ded39f03_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTItMS0xLTEyMTQw_82df890c-21f4-4d2b-8c06-16da33515257">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia794817e23b245eea3847eac57b7d78b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTQtMS0xLTEyMTQw_fcf02c20-454e-4d1f-b2e6-4893a01a0bdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if987c46515874fb6a72a3a47e8e1d347_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTYtMS0xLTEyMTQw_cfc6c513-3c3e-43f2-acb2-a0cc499fd60c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e77e92b5ac4b18b7764f67456f114d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTgtMS0xLTEyMTQw_b925eb58-8e10-455a-8693-15433a5180ff">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21fe0e0298e4466c9ea8fc6c07e67b92_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTEwLTEtMS0xMjE0MA_71916091-af33-4c1c-8bb3-f05b8cc1014d">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7269f1f07c444f62b04e9950f4fb49eb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTEyLTEtMS0xMjE0MA_2d38fd4c-8a45-49fb-b00b-27e368b104d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1134f6515efc48459a0f5a14aacf594e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTE0LTEtMS0xMjE0MA_d06798e8-b2e6-4d1d-bff2-7bbc65506199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02940b7802cf4f7d9c2b6a7f03527332_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTE2LTEtMS0xMjE0MA_58e2e1f7-ab0a-44dc-b87d-ebc0398fb229">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5221e66f2614f1ebe73bce91d2dfe18_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTE4LTEtMS0xMjE0MA_ef91357a-1712-4681-9c3c-710dbfb5eb9e">618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac9cbee0c234416b4f8bf6424c7f023_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTIwLTEtMS0xMjE0MA_4f4131a9-3c28-48fe-8fe2-05e1cd6d0c2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f4fa85bcfe4c6183ce30b8e5b62370_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTIyLTEtMS0xMjE0MA_07846b46-6b70-431d-bd84-a2b13c582841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aea019cc63f4da6bd0e2026516da88a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTI0LTEtMS0xMjE0MA_068d0213-e2dd-46bb-9bad-2ca5cbbd5d2d">618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833b13271d42409cbfe54ea29a5832d9_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTItMS0xLTEyMTQw_bac1cc8b-8b4c-4eab-979e-ee536637e768">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43cf8de658eb444fb180c5e973190ced_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTQtMS0xLTEyMTQw_2fb0fedb-59ef-4bf5-94f3-41abac710986">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e2e3bf847e34446b91d9e3adb7b393a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTYtMS0xLTEyMTQw_dfe9aa1b-f7b4-4151-aed3-50beaf828df3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206db45c6dbf4ada8039f50d374ad057_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTgtMS0xLTEyMTQw_bd1779cd-d808-4e52-a419-d222a1d7ff67">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2747de847a5a4b9abe5da80ee4f4328b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTEwLTEtMS0xMjE0MA_0a20e662-5d2c-43df-a9f5-11baf72c8fad">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c35b4c8bdc540088472e6d5f39ad3af_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTEyLTEtMS0xMjE0MA_1e907704-404d-40bb-b8fe-66204f75e4e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8f38eb4cc941558bac08a5c690e998_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTE0LTEtMS0xMjE0MA_04206771-da3f-49e2-8c8d-173e8994f1cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dcff95b8dbf48c6be5de5c404ab2dc8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTE2LTEtMS0xMjE0MA_c37f6877-7cf2-49b9-bd2c-9816aee5b45a">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icec3ad77c73243afafa557c15ec72da5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTE4LTEtMS0xMjE0MA_891d8675-c3ac-4f4c-8bdb-d274b685ae19">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3eb32f54a11425b833021836e9f39f0_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTIwLTEtMS0xMjE0MA_b4ff1390-80dd-4b62-8046-70ceb19e9128">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01f488874b24cf494dc9072dca62c34_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTIyLTEtMS0xMjE0MA_cc3e2ebd-f4e5-4ab3-bb6f-d59ec7cfca21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9115ac2882474086a95ff0a92a7499_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTI0LTEtMS0xMjE0MA_a983d1dc-de6b-4546-813f-47a05474fed0">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ba2a5b00213403bba9525748da240d8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTItMS0xLTEyMTQw_311e80ad-53d5-4401-a069-9f1f5480a6ac">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d9039b4162443b796b32d897293cede_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTQtMS0xLTEyMTQw_800ebdb4-f63f-4644-a520-d547881871fd">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f0bdd9cdd64dc9b7e998b0c6c0cae5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTYtMS0xLTEyMTQw_2a6c9ec1-ccfd-4e66-8fc8-ef92528980e3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id619cc15e212429087aad1c7c9680827_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTgtMS0xLTEyMTQw_bc049652-974f-4f62-86be-33a5eb4c9232">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a1f18b294146738afbce7fb84f04c5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTEwLTEtMS0xMjE0MA_2fb74c75-34f1-4028-9b3f-38718f3d4cc5">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cde46ee36a2466ea21eb5d4fc29b9e0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTEyLTEtMS0xMjE0MA_a7cb4355-0176-4cff-ba6c-d05132b4ad2e">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f7a8cfea5e24a51b71987e1407913e6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTE0LTEtMS0xMjE0MA_a879f36b-5b45-4e90-bac0-514c181a7f13">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47da50f7e1714e2581271c261dcae57b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTE2LTEtMS0xMjE0MA_c0452bd3-73e4-49cc-a975-0eef75c9564c">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e531dc995d488b890a3208e0543ede_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTE4LTEtMS0xMjE0MA_79142bfc-fe26-4989-b12e-9576150f9101">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a0c129f84b440988cf1c09361bf9a8_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTIwLTEtMS0xMjE0MA_dbf6c590-c1df-40db-8fb3-6ea6910480aa">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aec4ea6992b43ce82e0f558dfd36b00_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTIyLTEtMS0xMjE0MA_7b6157e9-8146-42ca-87f8-3b191cad8b96">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d020553073843e5b6b7936014d32d7e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTI0LTEtMS0xMjE0MA_fff59d24-0a37-4b82-b3e8-fe185acd2c31">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bdf71c266dd49129cd99f86795f30f1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTItMS0xLTEyMTQw_de993d4e-36f1-447b-b151-649470dbd490">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedff3b1944b64c3f8541ba18488844a0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTQtMS0xLTEyMTQw_e4eccf55-2d93-4bd8-857e-3bd426d21def">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cae6eb7eace4771bc5b03cb7d5d7c3e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTYtMS0xLTEyMTQw_5b9eb143-9a54-470c-acfa-9aa85230b5fc">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieefadac07e0742a9bcc209927edca502_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTgtMS0xLTEyMTQw_3aa85882-bbc5-465d-b6ca-06a9a2693bea">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805cfc944d9648f5ab99fe13e0bd400c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTEwLTEtMS0xMjE0MA_58218693-a362-4a7d-9dad-22462a4020fb">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9340b12589ed4cf8870255d67072e0b2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTEyLTEtMS0xMjE0MA_d7c16ab4-cc07-4bf7-a15b-b4348ab70d0b">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if302e604d9c647f2aa117693d6731a70_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTE0LTEtMS0xMjE0MA_52b2628f-2eb7-475c-ada8-c33e3d0582fa">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f28249859146e18cebb4ada570cbe3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTE2LTEtMS0xMjE0MA_a20a6728-9bf4-4264-bc42-6090d06164f9">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269a61a8cdb949e899eeb283218bebe3_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTE4LTEtMS0xMjE0MA_e3eaf039-89ef-4ccd-8b34-2c8dd8b7aa9b">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec1ab3dfa64442192f0b94587b08674_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTIwLTEtMS0xMjE0MA_daa816e6-341c-48ef-8548-e03881656e77">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9783ccaee044c3192afdd2303af4975_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTIyLTEtMS0xMjE0MA_dd41f29e-8aa5-4a8d-8120-fad14dbb1e46">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8bb901328ad48a18b0d7ffb9e41d685_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTI0LTEtMS0xMjE0MA_8333e99a-88dc-45d0-bd56-4fb6d150ab97">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i080a4966175c497dae95d90a6ab9979c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTItMS0xLTEyMTQw_ba167c80-8f7c-40f8-be95-0561a61c8e80">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb880ef93270463586306266d0d1d82d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTQtMS0xLTEyMTQw_aea1e8db-7085-42a5-a810-769a8333aceb">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd188229a764f009b5c46cdd0daab4e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTYtMS0xLTEyMTQw_4fa80abd-e977-48e1-a90b-c398240e7d85">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade7fb25dc3444df929d6b582363121b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTgtMS0xLTEyMTQw_75fa4209-7fe0-4205-be93-8753d8f75a68">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c8b2e16b7a4af0bfd9779c4e42717f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTEwLTEtMS0xMjE0MA_4ed65857-8a19-4759-adab-1885defd846f">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a22b0fa2914e7a8689aaa9bb993522_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTEyLTEtMS0xMjE0MA_831c9791-5504-4338-acc0-e7fa590e7c74">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b2f4b1ba3c24bcc9400a0bac9f2f5d8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTE0LTEtMS0xMjE0MA_0d617541-48f2-4d4b-826f-f490fa3dc367">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec069c130bc64661af4695041ea3fcc3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTE2LTEtMS0xMjE0MA_1125560f-210d-47f6-9fdc-7fe3cbfe4a23">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf64712f0538422da3dddc8951a5c75a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTE4LTEtMS0xMjE0MA_f48a2ae4-afd6-4b78-9496-df20f7a9921f">1,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9206ff4ea2634a9b8710d3da4ab817eb_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTIwLTEtMS0xMjE0MA_9f94a6d6-bba0-4504-a6d9-f9a8ccadc7cb">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ac613e5c50a4f4685f5d72248c51ab0_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTIyLTEtMS0xMjE0MA_574e3fee-e1c4-4ed9-ad4e-55f08c180429">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b40444516934410acd5af26d4cc9cfa_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTI0LTEtMS0xMjE0MA_173b13bc-dd1b-470d-9071-ecfd2dd93908">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de92c1c900c41d58eaceb16cae8dab2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTItMS0xLTEyMTQw_07a09bce-83ca-416e-b41d-e00be90dca2b">19,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f7c42de6914a59a2ad2c63f6e1730b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTQtMS0xLTEyMTQw_41835e3d-4691-4de3-b69f-658147ce1158">4,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d6e05e9b75b4907bf54d729d73cccd2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTYtMS0xLTEyMTQw_d1200f5e-6d63-456f-9ff3-3381d4dc40df">3,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4befd4212fc4248a63e9b436b533760_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTgtMS0xLTEyMTQw_cad0dac5-5c3c-4129-a396-8b4fae5012e0">27,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a662c83a2aa4f978862cdbb062bd8a8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTEwLTEtMS0xMjE0MA_e7f99a3a-2e43-4bf5-9bf3-f30b93cd3bca">18,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a71363ffee44c8e958961f85ef4e870_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTEyLTEtMS0xMjE0MA_692959f1-bbb6-4301-9582-177801087158">3,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id771bf711f3a4abf927510c6700ba371_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTE0LTEtMS0xMjE0MA_3369645d-6797-42b0-b77a-18c43a68559e">2,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c51a506a019465dba53c1f088a945dd_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTE2LTEtMS0xMjE0MA_96f1c4dd-e94b-49c3-bb01-85fbe5085aec">24,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4949a1736044f93b646e6613b1043f2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTE4LTEtMS0xMjE0MA_9304d9c4-df2c-4133-a519-701af67d3679">16,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8462cf492cfc495cb1b6159e93665280_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTIwLTEtMS0xMjE0MA_10aa1aa8-2388-4447-bea1-35751c35b10c">3,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468ec8b3e2f040d686ff31e4dc41d689_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTIyLTEtMS0xMjE0MA_2761ec5c-e16e-413b-ac2e-4883e5ead56c">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i203243bdd8194063a5b0d20127c91ead_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTI0LTEtMS0xMjE0MA_9c4d183f-1d69-4df4-90dc-882f34ec31c1">22,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07489b4d42474f138fdfd6dfb3286ac4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTItMS0xLTEyMTQw_13239edc-7d60-4030-b308-b8c85a451579">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d6184cd0bd4777bb8666956ef185f3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTQtMS0xLTEyMTQw_e68e61eb-f7ed-41a1-985b-63a770877f2f">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb89a05869c84c4f8583d492d2024255_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTYtMS0xLTEyMTQw_516d751b-7c54-4327-b073-338e5c7cccc4">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aad07ceecdc471a9ee9d0a50de54618_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTgtMS0xLTEyMTQw_ab9e487c-89ca-4c83-b351-7a22dbc3d6a0">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ffea525fc61463397a9083c8c20ffd7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTEwLTEtMS0xMjE0MA_0cf5c565-8ce5-4d71-bc75-cb6daebc8d61">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc50225e8b064effa4994483dcb578e7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTEyLTEtMS0xMjE0MA_5f8db6b9-3274-4374-8896-8bb86bb1197f">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2623fb937a24938b56dcd468a751f90_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTE0LTEtMS0xMjE0MA_39eb346b-5b72-417e-ba7f-c0afb2173c9e">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c80ef090990421ba4cb204bcc7a4aed_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTE2LTEtMS0xMjE0MA_c6187629-5027-4298-a616-cb177977a3bd">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18a31f47fe134b108ed30bbed48a5c3f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTE4LTEtMS0xMjE0MA_66ec8beb-1e8f-4a2a-9558-abce5bd7997e">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db6ad4693a9411eaacfd1efa9b38245_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTIwLTEtMS0xMjE0MA_0c71bff3-c602-4125-b31f-a414f451e813">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307ad909b7ac4a7bad744035b5fdb3ee_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTIyLTEtMS0xMjE0MA_91d25fef-f154-4b97-adc3-473b55b98bd6">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f35d93745f44ac84aacec6dc9540d1_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTI0LTEtMS0xMjE0MA_19501dc7-7940-473f-8624-40734d6da50f">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc40e9061b2e4d7e8c573dcda94bbc8e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTItMS0xLTEyMTQw_35c27446-16de-4e98-a8a2-01e92b8fb002">19,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e77ce4e9354eee9898d81ad4e106f6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTQtMS0xLTEyMTQw_06112e8f-0055-4ee4-ab30-488ab44912d5">4,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466b9478bbef4388a85e27c598939910_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTYtMS0xLTEyMTQw_5db17c9d-3639-4462-b944-6b1bcb3fca2d">3,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTgtMS0xLTEyMTQw_29940594-d43d-4302-801b-6b4f74f08757">27,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cbf3bc1bc41429b801a094750174f13_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTEwLTEtMS0xMjE0MA_4b190bf7-2752-4411-b461-4992bbaebdd5">18,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb99587d2f584abeadc910467e333c6f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTEyLTEtMS0xMjE0MA_766f1d3d-cb55-40a3-b0f1-c8ba2e86ef80">4,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2eab591b3243489738a3ce929a3f56_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTE0LTEtMS0xMjE0MA_b9fdd58c-e2be-4f4e-9466-8eaaec28319c">2,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTE2LTEtMS0xMjE0MA_7bbb4e29-bcfe-46c9-9ce4-15538cb717c8">24,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad5223de57dd4696a199e9db73eaadcc_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTE4LTEtMS0xMjE0MA_7f63b8e3-b613-4bb1-a3b2-aac03983b31d">16,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5015e8cece1d484b8333c5dc5371eb78_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTIwLTEtMS0xMjE0MA_54f4c096-cf6d-47ce-b49e-c2f963e9e92e">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ff77f687774eab827d133749a17db9_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTIyLTEtMS0xMjE0MA_efd49aca-7680-4288-bbaf-758cfe935d1e">1,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTI0LTEtMS0xMjE0MA_5f45695c-42e9-487a-a6de-62a985b8c362">22,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#8220;Janssen&#8221;).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="if28e36bf4b844a53b2205f62d3225d25"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues From Major Customers</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzIzMzY_4602502d-643c-4f01-9e6b-121456f1ff4f" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id462101bfca04327af64a9543c8a833b_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzItMi0xLTEtMTIxNDA_727442ce-e201-493d-9906-d800ad08def1">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6af6e3232dc45a196b190b37e6c1439_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzItNC0xLTEtMTIxNDA_4896ae68-af75-467a-8db8-c49307f12ee7">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d6c7b10944a4914acc093ef93f55e30_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzItNi0xLTEtMTIxNDA_c31c09ab-b97f-410e-8adf-30d3d644efd6">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb1faac3f7f34f6cbdca10553062dea9_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzMtMi0xLTEtMTIxNDA_794db2b2-00c3-4746-bc25-64636f4c9e70">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b21d294f3d14aaa889eb58f573882e6_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzMtNC0xLTEtMTIxNDA_76d2bfb6-7e9d-4e4f-b500-c764cf65833b">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i19d534eb0c65483390415a8fdd2e4915_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzMtNi0xLTEtMTIxNDA_fc79f9b4-d330-4cc1-9d2f-2a6a8ae5165e">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ae8dc2f110f40cfbd42e80f081e08d8_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzQtMi0xLTEtMTIxNDA_d8cb6d1d-f409-445f-8b20-14a6e8a8a6e5">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i912278219236443aa0a53f2ed6c5335c_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzQtNC0xLTEtMTIxNDA_bf8d3b2b-ba3a-4398-87fb-630844d05aa2">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7a8bfac32dd43bdadd46b2b5c450cf9_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzQtNi0xLTEtMTIxNDA_33258f61-dac1-45ab-8935-36b07353b944">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues Recognized from Performance Obligations Satisfied in Prior Periods</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from performance obligations satisfied in prior years related to our revenue share with Janssen, as described in Note 11. Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzEwOTk1MTE2MzE3NzE_c3ef10ef-775f-4f87-b5b7-283b60e494ed">851</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzEwOTk1MTE2MzE3Nzg_364b3161-aea6-42fb-8e4f-bae41eff0e6c">841</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzkzNDU4NDg4NDM1MzY_9be329ba-8014-4dcd-8217-5aa6ff81b21b">741</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates related to sales made in prior years resulted in $<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzkzNDU4NDg4NDM0OTg_c5132e52-e8a9-4c8f-9fa4-d43e28b27205">856</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzkzNDU4NDg4NDM1MTI_d083e9e1-a3f1-4adb-a8cc-76033dbe5d92">101</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzkzNDU4NDg4NDM1NzI_b5d7cf5f-a289-400c-8a7b-e5a2698481b4">257</ix:nonFraction> million increase in revenues for the years ended December&#160;31, 2021, 2020 and 2019, respectively. This was primarily related to changes in estimates for accrued government and other rebates and allowances for sales returns upon product expiration.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzE4OTk_89dc9fc9-5b44-4806-96b6-c0376844debb">174</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzE5MDY_10a50ea4-36bf-43a8-b763-04d262d643dc">198</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were not material as of December&#160;31, 2021 and 2020, respectively. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div id="i72faa4a0a4974dcca6db2bf491b63d7a_103"></div><div style="-sec-extract:summary;margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzY4MjU_a0473cfb-2dee-408f-bd1c-b36dfdbf8bed" continuedAt="i4b13259c8ef54344a66fb1daec593bb2" escape="true">FAIR VALUE MEASUREMENTS </ix:nonNumeric></span></div><ix:continuation id="i4b13259c8ef54344a66fb1daec593bb2" continuedAt="i04b2542570224927a0ff08071a28e97d"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: </span></div><div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities; </span></div><div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and </span></div><div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities, and foreign currency exchange contracts are reported at their respective fair values on our Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Consolidated Balance Sheets. The remaining financial instruments are reported on our Consolidated Balance Sheets at amounts that approximate current fair values. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i04b2542570224927a0ff08071a28e97d" continuedAt="if734a4fdf2b645a196b0a5b1e48b04fb"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzY4Mzg_b46f93ac-c768-4650-bfaa-d958189101ac" escape="true"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8ec0117d844149bf15fb93a66a98b6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtMi0xLTEtMTIxNDA_c462e630-a1a8-4312-b95d-a84e01d5227d">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife19703a21e24deda943371d11289462_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtNC0xLTEtMTIxNDA_75dea9c1-089b-412f-bbaf-2c7f7b23b99e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fc481856f34a4dbd84bccfc4f900e8_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtNi0xLTEtMTIxNDA_fba17926-2576-4b49-86d4-f017b0f013c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c0246e87d7d4539b64d5bc5c091b3df_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtOC0xLTEtMTIxNDA_ea0a687d-197d-4fb8-91fa-2e80e41d0a32">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbc5fc480e4b4729b2803202c43ada08_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtMTAtMS0xLTEyMTQw_85a20025-694a-430b-a480-318723da65aa">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2286a95065594d6d9ca4944ff53d5394_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtMTItMS0xLTEyMTQw_64056525-829c-4b04-a402-bfbf68805527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0b2d20da4bd4cfbbc5ac7bff1a5b643_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtMTQtMS0xLTEyMTQw_f8e9e592-78ff-4c3e-a959-95d1c4148f1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e69d167f82a4883925ec64ac6b590dc_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtMTYtMS0xLTEyMTQw_ad8a9213-ed6b-4e40-be54-c9806f485a40">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf113888c5464692b6ffbe8e4a732bae_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMi0xLTEtNjE5MTM_c6835d15-633b-4b52-b4d6-bd1a014c5fef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if58ceba457fa41819c0289f982ba7126_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtNC0xLTEtNjE5MTM_5130652d-b070-4500-82e8-9b064b44289d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia353233b00564c41a4d9cd25abd93e70_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtNi0xLTEtNjE5MTM_34fce3ad-dc98-44f1-9289-c7fd361ac1ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb417101fed43a7b4ac1d574f6f9524_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtOC0xLTEtNjE5MTM_35978ed1-4aba-408e-a59b-81c01b084b6b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195c8db92c30457c89e804d5f743ea65_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTAtMS0xLTYxOTEz_414caf8b-3611-4e78-97e7-c078fc2e9b17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b07529177a4ad8898665bf99bb8bd4_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTItMS0xLTYxOTEz_b3ad8f04-c344-4122-a4ee-c98bfe87cdce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4694f2b970149499d768396c277556c_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTQtMS0xLTYxOTEz_3aedac9d-a55d-4d7e-b051-2359741bd240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7fd02cc204a4fcca4854f1cc54fdc75_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTYtMS0xLTYxOTEz_aada49a9-a1bc-4676-aafa-b4244463078e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9c593efcab48c292fef975883cb901_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtMi0xLTEtNjE5MTM_8670737d-a491-41c5-a6d5-ad482f0063cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f01b9dc465412898be06b78bed526e_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtNC0xLTEtNjE5MTM_eb64f42f-1015-4240-8fd7-a4b1ef83f091">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d0f95467284563a2793f3b45d55692_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtNi0xLTEtNjE5MTM_96394f54-3e86-4cf0-a41d-344cec88609d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if92ffa56cee1465981e8289446960059_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtOC0xLTEtNjE5MTM_e7e494c8-f6cf-4474-8fab-2a29a2fe1114">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ec023f9542416ab812e9b107619ed7_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtMTAtMS0xLTYxOTEz_4ae885da-da8b-4c6e-a388-2c3bd70a071a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec65128416ed4c2caa95ff502b873f17_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtMTItMS0xLTYxOTEz_7947b83c-5d25-4506-9382-9a2c75b7b6c4">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00702509b5b435495cf0ec01ce3bab9_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtMTQtMS0xLTYxOTEz_f41d0933-aac8-445f-81da-9938250c8e76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad92d842d244ddd8c185fba7ec11571_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtMTYtMS0xLTYxOTEz_e4083589-6951-4128-bede-f8483ce27e6f">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf683e991aa04e84b6b581929bc8a52d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMi0xLTEtMTIxNDA_bd203c20-b429-4f95-a2a0-4fdd612fc70c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678f3e8e9c0c4393bd7bbbd1dbc823bc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtNC0xLTEtMTIxNDA_26b79394-00fa-4235-856b-79df3c19a421">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17fc0330f5ae4c9aaf6ebfc057402b0e_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtNi0xLTEtMTIxNDA_51778c71-bc3e-4a69-9a13-b138e62f4c1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03cf8ed895c84bf6a0b0a590b3791db3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtOC0xLTEtMTIxNDA_2a279b53-8bc9-4ed8-9680-fb1e070cd983">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c6eb6568ed498290563719477a6d6c_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTAtMS0xLTEyMTQw_60899bbb-ea59-425c-b679-8f0aef136d97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0d3c79ea2c4c72810e8c002a5c14b1_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTItMS0xLTEyMTQw_ba5f9d35-94c6-4f4b-bc67-9f0c55c995f7">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6b42f3b50c40e7a356f40b566dd53a_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTQtMS0xLTEyMTQw_d01c8d77-5588-4db5-a3cc-acfa1756d168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bf4c1622964f4ba66d71293935d060_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTYtMS0xLTEyMTQw_c27787ab-4668-4411-9735-8a3944e72d57">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i946749b11bdc47e88afcab1bddcdef12_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtMi0xLTEtMTIxNDA_db736c3b-e588-48ce-8869-94eb6a22fa71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e50b420b9d24798a8608dae51733253_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtNC0xLTEtMTIxNDA_93f161fe-add1-4759-83bd-6f4379ce99bc">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb796c40fa2149c29dbc27aa4bb85775_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtNi0xLTEtMTIxNDA_a90414e7-d56d-4bb8-a06b-a8ddfd4a8c1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63935bd985224f0189d1730574c0313e_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtOC0xLTEtMTIxNDA_7e8af749-2434-44bb-9b11-ce94f99c75f4">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37ad7d3e58949e28ec38d38ed20873a_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtMTAtMS0xLTEyMTQw_7e2cead2-bb5b-4145-9cbc-317868fa5673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca1fc3df69c4ea6a527e5aadbaed99e_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtMTItMS0xLTEyMTQw_f74617e5-4d2d-40a1-9c7d-064ad071cccd">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314b3d48689b48a78390fdb9120b06f2_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtMTQtMS0xLTEyMTQw_abb4432c-8f2f-459e-ada2-27fcc6c294dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3331ea5fd3984313b34746715ba4ae93_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtMTYtMS0xLTEyMTQw_50b4bc04-0674-4d81-9d45-57baa08effdf">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25dc7b22e3f541188c657f4004692097_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktMi0xLTEtMTIxNDA_21ca8254-e6b1-444f-874f-2ec16349326d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8230e74cb644c5a3e520fc9a03f39e_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktNC0xLTEtMTIxNDA_eef40c1a-fadc-43c7-b648-2c3c4dc57e36">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152a4600edde4d04b65202787532de71_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktNi0xLTEtMTIxNDA_319a987a-0586-4e56-89ae-08a3bafa973f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5b6f43984b043f1838533b38d3e5e38_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktOC0xLTEtMTIxNDA_a1f48968-75f4-4f9f-aa15-844fcb3474bd">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i598fc7abce8f43bdaca52d6637a92fc4_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktMTAtMS0xLTEyMTQw_a3cc7f93-cd2b-4f51-b56d-8dd6fb5bd66f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6d92e9d06d49fa842aa61301fede5d_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktMTItMS0xLTEyMTQw_775c4fa9-9ab7-4a1e-8cca-1c178233058b">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i933d89b1d3e04e03901b0acbce724bc4_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktMTQtMS0xLTEyMTQw_76843ad6-130d-4b15-aa1c-34e494eb7bb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a96651d23b4cf0b0d1b40e9bd9a52b_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktMTYtMS0xLTEyMTQw_221b6b8e-c0a6-48d2-8007-1f15b2a44b39">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d25ed6103414d89dbd76e3f9e2cc5_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTItMS0xLTYxOTMx_0bef4768-539e-4b72-accf-df2fa08b91c4">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if793cdfa691a4047923ae5fbfa0651eb_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTQtMS0xLTYxOTMx_55bca449-da03-4f8b-8224-b46bedf260f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68f6c8a6e4b40be839701a8158a7994_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTYtMS0xLTYxOTMx_df5636ff-b3ef-462b-bdfe-77e2a28c9949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d5ef90d851431ea311b8514b301646_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTgtMS0xLTYxOTMx_9dec8803-3412-4d96-92c5-a283c1888f2d">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0099914e9b47e3b8c377d2d5605c48_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTEwLTEtMS02MTkzMQ_c9646773-8645-44cd-80d7-144929f3347d">4,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be17b88e76541728d2d52bc5c2c9912_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTEyLTEtMS02MTkzMQ_214e1c22-7d4d-4b8c-8b08-b917bc183f7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba9f036d1c6491b8d70e0393484bd55_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTE0LTEtMS02MTkzMQ_5093a627-180c-4065-a107-4ec226e36aa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31176ade8b484178bc6cd4473ef6e2aa_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTE2LTEtMS02MTkzMQ_bde5a8aa-6e2e-4478-93b8-9d951b5f7792">4,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67cdde391bee4e1aa62b4fe62d765eb8_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTItMS0xLTEyMTQw_7217b031-4d22-4b3d-ba34-1356a4cc7fe6">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i319991ed67fc46fe879ccb7ee406b2bf_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTQtMS0xLTEyMTQw_f1f618c1-566a-4d59-b6b3-100712460d72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ec4799858746d28f2672bb3328c313_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTYtMS0xLTEyMTQw_061567c6-aad9-4fcf-9697-7038e9ff5c9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie988bf37059d48c0bcc4ac229bbb92d1_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTgtMS0xLTEyMTQw_c9c1d850-ea09-40b2-98f3-7251944ff9c2">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7858389cba8440abda830a77b3c5dd7_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTEwLTEtMS0xMjE0MA_351621e4-cbc9-4156-9a6b-84481529d2cc">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a6c459ee244343821c1e3c44035a12_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTEyLTEtMS0xMjE0MA_4a5e0941-4e9b-423d-838a-1f41d50a5f58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d056305515d420da7c42e745bb193c1_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTE0LTEtMS0xMjE0MA_4853bc36-8faa-4164-be70-fdd40f92d3fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b510802aa0349f48dcb8a8e7cbf9a21_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTE2LTEtMS0xMjE0MA_fefd8991-b4a6-4fb2-aee3-fc4ef09ec619">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Arcus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c1b6d7dddb473ea3e00bef51b2e0f0_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTItMS0xLTg5NzAx_ff0ffeb1-97db-42b6-a7ab-b6bf450aaf50">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1c1f4de39c94a96aee95ff2f88a2128_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTQtMS0xLTg5NzE3_3182642e-415b-4772-96c0-8105c4a2fe6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib041556bab2d43ea87cd7b61b04e2646_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTYtMS0xLTg5NzE3_96635799-103d-415b-a56b-b686c69d155e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8fddfac82b4eac885606ee08c7a905_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTgtMS0xLTg5NzE3_633e91a1-90a5-404d-8dc7-4ed63a1b527d">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1be345220f478da51f25e82698124a_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTEwLTEtMS04OTcxNw_ad3774ed-fed7-43a1-a5d0-afd0fdbb6968">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic404165c5df74a6f8352e0db325e95c4_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTEyLTEtMS04OTcxNw_0802b1aa-34a6-4ae6-8b69-0129df42db9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i089e25d92ca54c8985ea2dec50042b89_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTE0LTEtMS04OTcxNw_fb3ad5cc-9aab-48d4-ac2b-2bb712ad89a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ada8ca7ebe9435e8e842501c7ad3ae3_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTE2LTEtMS04OTcxNw_fc80f699-9722-45c4-a431-f8a5043b121a">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016b509afd8947f3b511effbe125af0e_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTItMS0xLTEyMTQw_6ab85e54-de70-4b70-8b7d-8174439b6003">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71323cd5e83d4d6d87b2eed504ce751e_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTQtMS0xLTEyMTQw_122d4b20-2a36-40b3-9d36-92385c6f3f6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727438de14724066816f95ee9809e17d_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTYtMS0xLTEyMTQw_be71393d-e43d-496f-9967-a831ef3f0222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b832f22f4be4e61b0de45142590027e_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTgtMS0xLTEyMTQw_a7567971-6382-403b-8c7f-1449b8e373c3">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf631f09cad14340965003dda42b76f2_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTEwLTEtMS0xMjE0MA_6149bd62-dc90-476b-a576-25f253b93226">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic387fe29a75d489788a450be894254a2_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTEyLTEtMS0xMjE0MA_76cfe03c-bff2-40e9-b7e5-0d8153a9f410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2093e60191934786be5e9f3c4d997270_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTE0LTEtMS0xMjE0MA_a2784485-4558-432a-b2f5-959bba01a70e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1fae5ea08948ba843477c2e34181be_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTE2LTEtMS0xMjE0MA_a1cd4721-8c92-4239-b46d-0a64628133b0">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea29fc78efe4c18b496239d1891b476_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTItMS0xLTEyMTQw_32d3fd56-f085-46b9-9bef-b0cb8a3b359d">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9af306f4c8d042af84347454c60ca09d_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTQtMS0xLTEyMTQw_8aadbdcb-c459-4baf-89e2-98793e8c524e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a8909028d04fe1a126acdf567947cf_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTYtMS0xLTEyMTQw_f6c9bf65-47a8-4664-8a01-1bdda32b2928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c285b633ed488fbf315d7bcb4b9c40_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTgtMS0xLTEyMTQw_b6cc51ce-7bd1-4695-8cda-8311b25e36b9">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9869805732e4312926496da94a42e12_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTEwLTEtMS0xMjE0MA_162c6782-2ead-4f90-b7e8-bc7809691012">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92185773c58344ce928789fdf5535c76_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTEyLTEtMS0xMjE0MA_c2803d39-4706-454e-81c7-d04cc8374efc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0065f36a81224792b11e6b48f9770c23_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTE0LTEtMS0xMjE0MA_737561bb-67c1-4cf2-94af-933d6754883a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8ddd71ad6a4934a591d1a60321c3c2_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTE2LTEtMS0xMjE0MA_b334d9dc-a6ba-4bf3-9e50-e13c1dee0b6a">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id803bb97e7f740d6ad0af3395e67147d_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTItMS0xLTEyMTQw_dfe8510d-ad80-4f78-8128-033f1f15dd09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c806a171cbf4ef99d78d293d9736606_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTQtMS0xLTEyMTQw_399b4cb5-234d-403f-998d-3f79e3f2e0d4">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3167c1fc9a3e4a5788cfa0858e185c3c_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTYtMS0xLTEyMTQw_8dcb320d-916b-4d40-8ce6-dfc4f6900d37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideec20edc39c49fa90ed919a34d06198_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTgtMS0xLTEyMTQw_01e47f08-2b9a-4cf5-b581-ae1e0e715fa1">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271339ca119345d694d3d33dc37ebda3_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTEwLTEtMS0xMjE0MA_af6b8d3c-47b6-4e6a-a3cb-12cccff852cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fe215fd3514c48a9b0408fc2c8d430_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTEyLTEtMS0xMjE0MA_40edbd24-975e-4f47-8f99-35279e014411">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d5b54c27be44f58ad2ee7c5da2c1bc_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTE0LTEtMS0xMjE0MA_53a14a56-feb1-421c-a56c-f3a409bfe86c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7706841e6648cab9e75afad945d3ea_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTE2LTEtMS0xMjE0MA_4f2ea614-60c3-4aa6-b3cf-447135c8e345">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie627b2b228da4beaa2c490c412620ab6_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTItMS0xLTEyMTQw_23573df9-6c4a-4246-91ba-47d0e198bb07">6,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac8673365254bbdbf17e38b4c77bfd4_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTQtMS0xLTEyMTQw_e45af08b-bc1d-464a-b5e0-d2107a0021dc">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia43f9293bebd43209b55a1f81a2eb994_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTYtMS0xLTEyMTQw_26a7c68d-fee9-4807-b6e6-9ba72ba14f76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efa57e75bba46fa80520cf5680bd744_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTgtMS0xLTEyMTQw_9ba29771-469d-4d2b-9e42-ea416cf98dc6">8,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbab0dba432455d952aca9feddd5630_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTEwLTEtMS0xMjE0MA_cb80892e-a6c1-4f43-9bb3-1e945717df81">7,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee18145a966642cc8e1ce5da7d258519_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTEyLTEtMS0xMjE0MA_7eb3a212-2dc7-4ea8-8655-00916c87ef31">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb049a4497b4214bac4f90ea6d795dd_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTE0LTEtMS0xMjE0MA_6e404676-3ac7-4e1a-b1fa-1b5fa7ca6726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d09ac1c4594e0da8f577558b10d846_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTE2LTEtMS0xMjE0MA_fd70fed7-cedb-45ff-bed4-25a85acd3370">9,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ae968a144943c69767909be7df131b_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTItMS0xLTYwMzA1_75ac3e1a-96f2-4df4-9677-d80a9d7a11b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72ec7b074d434e8bbc8f74ca1c51fa6e_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTQtMS0xLTYwMzA1_679a24a0-3784-4efa-a46c-ab1433411930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba409e656a3f48ab972be2b06a795ed2_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTYtMS0xLTYwMzA1_49b91e4a-7436-4157-a384-710ab033a350">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77217ce37d644ed8b218aa4572cd4b7_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTgtMS0xLTYwMzA1_2c2d56c5-7085-4d33-8281-20e1545303e5">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bd3a01aa1b84a7f86ff1f7e00427920_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTEwLTEtMS02MDI4MQ_4d69a41b-9a08-4b00-b651-443043a79943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863d391d7654400d8d7b18b4f8ed2d6b_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTEyLTEtMS02MDI4MQ_896c56a5-ed57-4ab6-b0c4-998af9927d50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24b38f7656b4bdc843563195dcfddce_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTE0LTEtMS02MDI4MQ_84b9ad17-3717-475a-b2c7-670343be68c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bba9a34d1de4972a00d03116c7adcf1_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTE2LTEtMS02MDI4MQ_bce4183d-1977-489d-ad46-a1bac17ca473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea29fc78efe4c18b496239d1891b476_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTItMS0xLTEyMTQw_a684c7a6-9438-4670-86f8-4ba36f466e6a">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9af306f4c8d042af84347454c60ca09d_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTQtMS0xLTEyMTQw_90e742e0-1e69-434a-b659-97647155c341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a8909028d04fe1a126acdf567947cf_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTYtMS0xLTEyMTQw_45a44351-1213-45ba-a04a-0a9635407abe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c285b633ed488fbf315d7bcb4b9c40_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTgtMS0xLTEyMTQw_22566ca1-d251-4629-b6ff-7a367ed7c6eb">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9869805732e4312926496da94a42e12_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTEwLTEtMS0xMjE0MA_4b4fcaf0-4fb4-4bbb-94b3-512172b64d43">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92185773c58344ce928789fdf5535c76_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTEyLTEtMS0xMjE0MA_08b436de-4496-43ba-817c-04dd312b0897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0065f36a81224792b11e6b48f9770c23_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTE0LTEtMS0xMjE0MA_e711c6cd-2c07-4400-814b-2ef8721c7000">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8ddd71ad6a4934a591d1a60321c3c2_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTE2LTEtMS0xMjE0MA_b908dd88-4b54-4a05-921b-c73b59668c9c">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id803bb97e7f740d6ad0af3395e67147d_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTItMS0xLTEyMTQw_dc83d7a4-8e92-4b9a-83b2-8673eb9caf83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c806a171cbf4ef99d78d293d9736606_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTQtMS0xLTEyMTQw_7d9f5207-9ac9-47af-9bb9-c1372c0b9890">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3167c1fc9a3e4a5788cfa0858e185c3c_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTYtMS0xLTEyMTQw_29b08279-d7d9-46fa-84cb-700a0298a55d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideec20edc39c49fa90ed919a34d06198_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTgtMS0xLTEyMTQw_9e205242-2eff-4f99-b3e6-4a221009d826">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271339ca119345d694d3d33dc37ebda3_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTEwLTEtMS0xMjE0MA_471dceb4-ebaf-445b-bdee-fbe5bc0594e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fe215fd3514c48a9b0408fc2c8d430_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTEyLTEtMS0xMjE0MA_58f79be4-2c4e-47ee-9745-d700ae8ffb43">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d5b54c27be44f58ad2ee7c5da2c1bc_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTE0LTEtMS0xMjE0MA_b056517a-ff44-430f-90b3-5eb9cb8e1021">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7706841e6648cab9e75afad945d3ea_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTE2LTEtMS0xMjE0MA_09e8b016-0cd2-4a13-9ee5-f7443985c240">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie627b2b228da4beaa2c490c412620ab6_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTItMS0xLTEyMTQw_a29f9e18-019b-435e-8d59-5336f898b1f1">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac8673365254bbdbf17e38b4c77bfd4_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTQtMS0xLTEyMTQw_34d027d3-3daa-4dc8-832d-8711cd00bb05">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia43f9293bebd43209b55a1f81a2eb994_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTYtMS0xLTEyMTQw_f8a0aede-84d1-4224-acc7-e8de52de1d26">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efa57e75bba46fa80520cf5680bd744_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTgtMS0xLTEyMTQw_9ec9e35e-0713-450f-a73d-f863aad425f0">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbab0dba432455d952aca9feddd5630_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTEwLTEtMS0xMjE0MA_37858aa6-eae8-4f40-a73f-ad92c72f6b7d">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee18145a966642cc8e1ce5da7d258519_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTEyLTEtMS0xMjE0MA_73c7003c-3132-479c-ac71-4a204b4c05c1">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb049a4497b4214bac4f90ea6d795dd_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTE0LTEtMS0xMjE0MA_d40cc040-5d60-4df4-bcff-3204d545ad79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d09ac1c4594e0da8f577558b10d846_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTE2LTEtMS0xMjE0MA_d271c2e2-369b-44f9-84d6-6cc12a718579">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See Note 11. Collaborations and Other Arrangements for additional information.</span></div></ix:nonNumeric><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzY4NDE_78017401-9c2d-4563-9887-9260dce6ae63" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Consolidated Balance Sheets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5795fbc1c3341f29a10bb7056a260ae_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzEtMi0xLTEtMTIxNDA_0479b617-0cb8-48fb-a488-56c9f9753651">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeba2733f3294d8fbb36b69036097ed7_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzEtNC0xLTEtMTIxNDA_f36b926d-8e6a-469d-b9bb-0ae21061bf58">4,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537d6236c6684eb8b511aa68e41c2195_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzItMi0xLTEtMTIxNDA_3378ab17-99c0-45b9-aa43-79295ce0e96e">885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752e52cf961f4af794ad9d51504ea5ec_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzItNC0xLTEtMTIxNDA_87906d03-3a93-4534-b81d-89d68edc23d4">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9957ec642e74491187d1c03568dc54e8_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzMtMi0xLTEtMTIxNDA_1bcd9422-a898-44b8-8ddf-f38f3395719b">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82771ba0871b4c818fe4a95aad641c8f_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzMtNC0xLTEtMTIxNDA_cdec8d46-58d5-4b6d-a765-3eafce60b9e4">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13c72dd8cf642e199152f20a3bf4a87_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzQtMi0xLTEtMTIxNDA_58c6c785-d350-47e5-be92-4b70d76af8c8">5,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5c1170d657408696883656ec2bd949_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzQtNC0xLTEtMTIxNDA_1ce55392-9a20-46c9-90d4-9509f60de0c5">6,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of equity securities resulted in net unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzM4NDgyOTA3MDc2MTI_0e4bf323-8c78-4a96-8aa3-81b164894f20">610</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-8" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzM4NDgyOTA3MDc2NDU_7d5378fa-771d-4478-9ce7-af8cb484385c">1.7</ix:nonFraction> billion and net unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzkzNDU4NDg4Njk0NTU_12564fb2-0300-40e6-ab3c-0d428dd028ce">1.2</ix:nonFraction> billion for the years ended December&#160;31, 2021, 2020 and 2019 respectively, which were included in Other income (expense), net, on our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments and other equity investments without readily determinable fair values were $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzE4MTQxOTQxODkxMjY2_888ec231-1ea9-40aa-abc9-02ed3b2e8bbf">338</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzE4MTQxOTQxODkxMjc0_faa1341c-0684-4674-9f2b-c8f244a22a2f">262</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively, and were excluded from the above tables. These amounts were included in Other long-term assets on our Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transaction</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, we donated certain equity securities at fair value to the Gilead Foundation, a California nonprofit organization (the &#8220;Foundation&#8221;). The Foundation is a related party as certain officers of the company also serve as directors of the Foundation. The donation expense of $<ix:nonFraction unitRef="usd" contextRef="ic2adb19e0ca44d459898b6f842970ad2_D20210101-20211231" decimals="-6" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzQzOTgwNDY1MjU2OTQ_2100fd69-794d-4be8-8d1b-6b5ac625d5ce">212</ix:nonFraction>&#160;million was recorded within Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December 31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="if734a4fdf2b645a196b0a5b1e48b04fb"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of Level 2 investments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates (&#8220;LIBOR&#8221;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our aggregate short-term and long-term debt, determined using Level 2 inputs based on their quoted market values, were approximately $<ix:nonFraction unitRef="usd" contextRef="i67a406b4b0a049ffb974da9082946416_I20211231" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzUwNDI_25abd9db-6b53-4b9b-8438-a02a7a8a004c">28.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i3f6470cf7f5d4d0ebb2b950757008455_I20201231" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzUwNDk_2e0f6a64-5bef-48f7-ace1-83cf847f66a3">34.6</ix:nonFraction> billion as of December&#160;31, 2021 and 2020, respectively, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="i99fc02b86f154dc9aef67ccbad4572b3_I20211231" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzUxMDk_0c669660-2697-44ce-8690-3b30a783339c">25.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i10ea058e4eea4ab9a26e8149179fc6e7_I20201231" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzUxMTY_9494556f-2529-463b-abbb-6aff59640d42">30.3</ix:nonFraction> billion as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our first quarter 2021 acquisition of MYR, we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis, except for the liability for contingent consideration. The estimated fair value of the liability for contingent consideration was $<ix:nonFraction unitRef="usd" contextRef="i366d837490844422b12ca69c2324a42b_I20210304" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzY1OTcwNjk3ODgzODQ_bc47f63f-9905-488d-b6bd-74a4a6cab9fd">341</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iba409e656a3f48ab972be2b06a795ed2_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzkzNDU4NDg4Njg1NzU_2c717d75-404a-4093-b6f4-e74b000cab84">317</ix:nonFraction>&#160;million as of the acquisition date and December&#160;31, 2021, respectively. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex. See Note 6. Acquisitions for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;), we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis. The liability assumed related to the sale of future royalties is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to the sale of future royalties were $<ix:nonFraction unitRef="usd" contextRef="i601744dfe4a449f588dff2ea9f459c7a_I20211231" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzkzNDU4NDg4NjQ5ODE_3ddf76be-8a40-4175-9868-95dbb95fef57">1.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if747ff5ccb394525bf8dd861a2391455_I20201231" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzEwOTk1MTE2NjIwODE_9af40ae1-4060-40f3-bd1b-27abba196969">1.1</ix:nonFraction> billion as of December&#160;31, 2021 and 2020, respectively, and the carrying value was $<ix:nonFraction unitRef="usd" contextRef="if7987a3dc65e4b51a622b5dcbc55adcc_I20201231" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzE3MDQyNDMwMjY0MzA0_89be9f55-8ddb-44b3-aa5a-4b8bad734a32"><ix:nonFraction unitRef="usd" contextRef="i45bc386594ad4ae993ce88114eb4e62f_I20211231" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzE3MDQyNDMwMjY0MzA0_b102c19f-de0f-48cd-bba1-e84467db84f6">1.1</ix:nonFraction></ix:nonFraction> billion as of December&#160;31, 2021 and 2020. See Note 6. Acquisitions and Note 12. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, in connection with collaborations and other equity arrangements we entered into with Pionyr Immunotherapeutics Inc. (&#8220;Pionyr&#8221;) and Tizona Therapeutics, Inc. (&#8220;Tizona&#8221;), we also measured fair values of our exclusive options to acquire the remaining outstanding capital stock of Pionyr and Tizona on a nonrecurring basis. See Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we measured IPR&amp;D intangible assets acquired in connection with the acquisition of Kite Pharma, Inc. (&#8220;Kite&#8221;) at fair value on a nonrecurring basis, and recognized a pre-tax impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i347295d908ea47bd9ef9a8fa1edea941_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzU5ODY_1bebdf39-dd3f-486b-bfc9-f9ee1dafcf4e">800</ix:nonFraction> million. The fair values of the acquired IPR&amp;D assets are estimated based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements, and inputs include estimated revenues, costs, probability of technical and regulatory success and discount rates. Amounts capitalized as IPR&amp;D are subject to impairment testing until the completion or abandonment of the associated R&amp;D efforts. See Note 9. Goodwill and Intangible Assets for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy is to recognize transfers into or out of Level 3 classification as of the actual date of the event or change in circumstances that caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzExNjg_26f7661c-53f9-4dc1-9d28-71dae5a06d91" continuedAt="idfa2e545bbc54f14b94fccd97b952b7a" escape="true">AVAILABLE-FOR-SALE DEBT SECURITIES </ix:nonNumeric></span></div><ix:continuation id="idfa2e545bbc54f14b94fccd97b952b7a" continuedAt="ie96917d0734b44bf813c44ddb098eccb"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzExODk_5eb8f4bf-27fd-41da-93e3-786df7de0813" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2afdba519b8b455cbb7ae9cfc063ba8a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItMi0xLTEtMTIxNDA_8bb7112c-38e5-4e2c-a5a8-f4e15aac27cb">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2afdba519b8b455cbb7ae9cfc063ba8a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItNC0xLTEtMTIxNDA_2c95fb88-78f6-4234-80ba-4ca0b0e5f71f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2afdba519b8b455cbb7ae9cfc063ba8a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItNi0xLTEtMTIxNDA_a00ff8ec-a93a-4bbd-bfee-c68dea9af07d">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2afdba519b8b455cbb7ae9cfc063ba8a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItOC0xLTEtMTIxNDA_dc8d67b4-1400-4962-8592-432f1c9e3dcf">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie04ebb87f24d4c1dab5e3b201c5cb6ba_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItMTAtMS0xLTEyMTQw_c1aea899-d027-401c-acdc-dabf2dee35ea">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie04ebb87f24d4c1dab5e3b201c5cb6ba_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItMTItMS0xLTEyMTQw_947dcfda-d00d-41d8-b98d-f8592e40bdf1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie04ebb87f24d4c1dab5e3b201c5cb6ba_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItMTQtMS0xLTEyMTQw_42d84e10-6d72-40a5-974b-2e5148ec5eb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie04ebb87f24d4c1dab5e3b201c5cb6ba_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItMTYtMS0xLTEyMTQw_58e7c502-430c-4bab-8607-cadfe6ae8f27">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2cbea5bc7c4a8b854e2ea7a3ef27c1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMi0xLTEtNjE4NTU_f3b8cd19-ad64-4977-ab5d-7cf72413f113">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2cbea5bc7c4a8b854e2ea7a3ef27c1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtNC0xLTEtNjE4NTU_c1c228ae-2a6f-4ddd-85f5-4d3328d0fed3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2cbea5bc7c4a8b854e2ea7a3ef27c1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtNi0xLTEtNjE4NTU_3cdd1e76-e03e-4ee8-923a-29a3a4fa42a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2cbea5bc7c4a8b854e2ea7a3ef27c1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtOC0xLTEtNjE4NTU_97dc9927-1f90-42ce-a580-b54480b7db73">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd664388de741a283f40d467c2b991a_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTAtMS0xLTYxODU1_1a302771-a9a3-4043-ae9c-33f5f48ed6bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd664388de741a283f40d467c2b991a_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTItMS0xLTYxODU1_05225649-d936-4c2c-9f6a-5b7492a551bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd664388de741a283f40d467c2b991a_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTQtMS0xLTYxODU1_8b64310d-c8d2-4005-b820-b1fba61356b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd664388de741a283f40d467c2b991a_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTYtMS0xLTYxODU1_9e25c2d9-6c8c-4299-b321-faf9b3e3935f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic431d321c32f4a148e09f407728ba829_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtMi0xLTEtNjE4NTU_eabb76a8-a40e-40a6-9680-567bd1e16f02">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic431d321c32f4a148e09f407728ba829_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtNC0xLTEtNjE4NTU_d89ce2b8-c02e-4a60-a709-0a9109a58961">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic431d321c32f4a148e09f407728ba829_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtNi0xLTEtNjE4NTU_3f239abd-cb36-43f6-bd4d-6b4bb42a2ad9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic431d321c32f4a148e09f407728ba829_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtOC0xLTEtNjE4NTU_0966c6ab-a5a4-425f-9b17-e2adc786551a">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b2dfff9a8cf44d0a774eb9d6d1b49d3_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtMTAtMS0xLTYxODU1_efa6b81a-505d-4d9f-b8cf-63f1f9ae27b8">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b2dfff9a8cf44d0a774eb9d6d1b49d3_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtMTItMS0xLTYxODU1_491ade1e-c75d-4188-9832-8e8c051db288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b2dfff9a8cf44d0a774eb9d6d1b49d3_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtMTQtMS0xLTYxODU1_8ec80737-2515-40a1-af02-47ca0a306db4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b2dfff9a8cf44d0a774eb9d6d1b49d3_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtMTYtMS0xLTYxODU1_a837f6b4-9192-4919-bb91-ea54b0b7a884">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0e3695ed25418e9b23c7b9dfd2aae5_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMi0xLTEtMTIxNDA_7244e5fb-55db-4125-bee2-600a21cb2d9e">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0e3695ed25418e9b23c7b9dfd2aae5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtNC0xLTEtMTIxNDA_0aa52f7c-d9a9-452f-8725-18b1f28d9f2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0e3695ed25418e9b23c7b9dfd2aae5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtNi0xLTEtMTIxNDA_3c2b6cdc-0400-4be9-bee3-925c9f5d6f33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0e3695ed25418e9b23c7b9dfd2aae5_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtOC0xLTEtMTIxNDA_d1726309-911a-4f59-bc72-95c49454b865">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1287280e9a4deb8aa835abc6a56556_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTAtMS0xLTEyMTQw_745772a6-6524-4632-8d18-0ce7dd148ab5">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1287280e9a4deb8aa835abc6a56556_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTItMS0xLTEyMTQw_92d8317a-d01e-412a-8806-35da2d75018b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1287280e9a4deb8aa835abc6a56556_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTQtMS0xLTEyMTQw_aab3bc54-ca82-4868-99b8-b185bc6786ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1287280e9a4deb8aa835abc6a56556_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTYtMS0xLTEyMTQw_b097ad15-fef9-4447-a8b3-f137495dabcc">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d59af8c16674ee3b51662b5f23c4dd3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtMi0xLTEtMTIxNDA_b006eb41-d9e9-4f07-b564-049019a54f43">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d59af8c16674ee3b51662b5f23c4dd3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtNC0xLTEtMTIxNDA_2008fb77-4d74-4497-9989-6dc664329445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d59af8c16674ee3b51662b5f23c4dd3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtNi0xLTEtMTIxNDA_600f134d-0e6b-488c-8122-f91347dbef6a">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d59af8c16674ee3b51662b5f23c4dd3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtOC0xLTEtMTIxNDA_60ce2ab0-6355-45e2-b96a-987f4fd24102">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656a88d21ed14481983deda32ba5c61e_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtMTAtMS0xLTEyMTQw_3b6e0247-c0d6-4cd1-9218-518bf47c692d">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656a88d21ed14481983deda32ba5c61e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtMTItMS0xLTEyMTQw_a094bf45-91c7-4ebf-b361-bfb30351e966">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656a88d21ed14481983deda32ba5c61e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtMTQtMS0xLTEyMTQw_415a9e93-22d8-47d4-97c5-a0336813758b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656a88d21ed14481983deda32ba5c61e_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtMTYtMS0xLTEyMTQw_37aa5a9a-0394-4ab5-9e91-7f5435f1f045">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f871061a224dd98a831397d2bb871d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctMi0xLTEtMTIxNDA_a4f70542-85c3-45b3-9311-db23a9ee7cba">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f871061a224dd98a831397d2bb871d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctNC0xLTEtMTIxNDA_629b1c3e-f71a-4f39-9282-e6a0c7242a5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f871061a224dd98a831397d2bb871d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctNi0xLTEtMTIxNDA_1b73172f-b03a-4156-a82a-fa857d15b522">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f871061a224dd98a831397d2bb871d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctOC0xLTEtMTIxNDA_962ddf02-488c-47d2-bcf7-f4f5567f3656">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5683ccd60fc477ca7ea1aa59d4ccc1e_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctMTAtMS0xLTEyMTQw_38f7d33d-af50-40eb-a7ae-145e274892a9">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5683ccd60fc477ca7ea1aa59d4ccc1e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctMTItMS0xLTEyMTQw_02e29d9b-4a12-41ab-9eb7-a02dcf99ea65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5683ccd60fc477ca7ea1aa59d4ccc1e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctMTQtMS0xLTEyMTQw_e848dbe6-224f-4c23-bcdf-368512f426ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5683ccd60fc477ca7ea1aa59d4ccc1e_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctMTYtMS0xLTEyMTQw_cf52c05f-e287-487f-ba00-2b84b51a18cf">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtMi0xLTEtMTIxNDA_2b52ca30-f7ef-4360-8265-85907877b151">2,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtNC0xLTEtMTIxNDA_36897e5c-323f-4d3a-90b2-cb3b88ee2768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtNi0xLTEtMTIxNDA_e76109d6-6ad1-4109-9082-897d8195ff3a">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtOC0xLTEtMTIxNDA_a4fecbe9-b0a5-4f71-b700-7f4ded010237">2,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtMTAtMS0xLTEyMTQw_5d7a557d-81b0-41ff-a07f-de3307e54e40">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtMTItMS0xLTEyMTQw_5427752c-31da-41fb-845d-50acf4306089">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtMTQtMS0xLTEyMTQw_97455fda-708a-4317-94b8-d7fbe558e584">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtMTYtMS0xLTEyMTQw_9b306eee-7511-4ab5-905e-8a31875634a5">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzExNzk_9066c3d3-0321-49af-9e75-bc3dbb5db39f" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c0aae6ccc84b7db071d1c937c18fe9_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzEtMi0xLTEtMTIxNDA_10a8abd6-ec64-4ab9-a345-95cf612f16c8">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf1c274e36c24d35acaf02b87f54cdbc_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzEtNC0xLTEtMTIxNDA_0c12a767-4f6b-42e3-9ea6-1f1471675bc3">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a8e5050483425f801196f211abfa22_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzItMi0xLTEtMTIxNDA_d5d3aa2e-5b43-484f-aa57-b886cbb0cea6">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77bd1f1f55144c3b95b11c8a831313a_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzItNC0xLTEtMTIxNDA_f67bba2e-0f0c-4607-b39b-b14d947fd8dd">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba0806a7f7a4733846c919f29140932_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzMtMi0xLTEtMTIxNDA_299d67b2-df39-433f-9ff9-d41b0ad99a91">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade4a4ff784541f9894f489c3fb0b38b_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzMtNC0xLTEtMTIxNDA_b979ff2d-b1cb-48a0-8775-e0a7eddc4051">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzQtMi0xLTEtMTIxNDA_6eb98faf-97e2-44aa-88cc-9eee73804485">2,497</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzQtNC0xLTEtMTIxNDA_b8375400-2f9f-4686-bf27-c47a9b2df56b">2,026</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzExNDg_2ab21e8c-5f05-4bcf-a428-c4e954e867a2" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzItMi0xLTEtMTIxNDA_c35fcc77-7749-4c02-8123-9cdb2a8483d9">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzItNC0xLTEtMTIxNDA_6262a415-523d-47c2-84f4-8d66f28c857c">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzMtMi0xLTEtMTIxNDA_e38fea78-a135-4b4f-9d60-5197ba47993f">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzMtNC0xLTEtMTIxNDA_fea8af06-45f9-4932-abf6-f6e3d0946650">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="gild:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzQtMi0xLTEtMTIxNDA_4118827e-b08d-4c20-bd1e-80d27ba09984">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="gild:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzQtNC0xLTEtMTIxNDA_a63358c7-9dff-4e53-805f-6cce45bc874e">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzUtMi0xLTEtMTIxNDA_052127c6-934d-4e0f-8d78-09777b4ade1f">2,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzUtNC0xLTEtMTIxNDA_68db7ca7-5367-4bea-8fbf-6f0371ea3c45">2,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie96917d0734b44bf813c44ddb098eccb">We held a total of <ix:nonFraction unitRef="position" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2Xzc0Mg_561bc761-0e6a-41b8-a75a-622844d16bc0">534</ix:nonFraction> and <ix:nonFraction unitRef="position" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2Xzc0OQ_fa4fe044-de1d-4f41-b8da-67a84a7164fd">75</ix:nonFraction> positions which were in unrealized loss positions as of December&#160;31, 2021 and 2020, respectively. Aggregated gross unrealized losses on available-for-sale debt securities were not material for the years ended December&#160;31, 2021 and 2020. <ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzU0OTc1NTgxNDE5MTI_9b9e31bb-e24d-443d-b8a6-48076570c1f7"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzU0OTc1NTgxNDE5MTI_9df3b0b0-e629-4e9f-868e-37938d68d7bc"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzU0OTc1NTgxNDE5MTI_f0d6ed9a-bbed-493d-8c02-53778f45f1d8">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment was recognized for the years ended December&#160;31, 2021, 2020 and 2019.</ix:continuation> </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_109"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzI3ODg_cfc73ab8-c2a1-40f7-97b5-9bd2e1826710" continuedAt="i0a6f3b4933ba4e08ac12226cafb72dc9" escape="true">DERIVATIVE FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="i0a6f3b4933ba4e08ac12226cafb72dc9" continuedAt="i630cdc57ded641039840961cfe697951"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates, and as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges, and as a result, changes in their fair value are recorded in Other income (expense), net, on our Consolidated Statements of Income. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i630cdc57ded641039840961cfe697951" continuedAt="i431662d0f27043c8a6f7ec557b539558"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of <ix:nonNumeric contextRef="i37b11b51a2b54cf4a3a9e85b864611a7_D20210101-20211231" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzEzMjk_0289feac-fa79-4719-a8b8-75284fc5fb56">18</ix:nonNumeric> months or less. Upon executing a hedging contract and each reporting period thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in AOCI are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of December&#160;31, 2021 are expected to be reclassified to Product sales within <ix:nonNumeric contextRef="i37b11b51a2b54cf4a3a9e85b864611a7_D20210101-20211231" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzE3NDg_83df4234-3acc-4cb8-87cf-d384fb8ea976">12</ix:nonNumeric> months.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the years ended December&#160;31, 2021, 2020 and 2019 were included within Net cash provided by operating activities on our Consolidated Statements of Cash Flows.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had notional amounts on foreign currency exchange contracts outstanding of $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzE5OTM_95b4913b-a98a-40cc-aa3c-c6428c663420">2.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzIwMDA_0f4b4be3-7862-481f-ad19-1d89fc6cdcd6">2.4</ix:nonFraction> billion as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. <ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzI3NzI_450bfbd5-f9a6-4c1f-92f4-6834f0555de4" continuedAt="ifebde779eb3a48c69de712558c2db984" escape="true">The following table summarizes the classification and fair values of derivative instruments in our Consolidated Balance Sheets: </ix:nonNumeric></span></div><ix:continuation id="ifebde779eb3a48c69de712558c2db984"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5810a2be53eb4780af1fcce52fdb4182_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzQtNC0xLTEtMTIxNDA_147df8c2-22ad-4153-8a6f-a72039c8efba">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other&#160;current&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018037d6d5a34a678330d1e08439237d_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzQtOC0xLTEtMTIxNDA_b3073e7f-71ac-4486-af85-bc16887b0eee">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c8d27c7190478abd912de07485cf67_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzUtNC0xLTEtMTIxNDA_38c2c872-aeb3-4c46-b936-1c9525592337">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f32c2561ae4b3293149592ac05f4a5_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzUtOC0xLTEtMTIxNDA_8e11448f-d28e-4ad5-89d9-2428b2f0e7ef">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bc7259ae6041fbb19709a9cae25597_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzYtNC0xLTEtMTIxNDA_b82d18a9-9d67-468d-9994-5735f7c4ea2a">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bc7259ae6041fbb19709a9cae25597_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzYtOC0xLTEtMTIxNDA_8cc7b71d-c76a-4ca8-b68d-04b270f38357">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971521b0df674be6820599f3a1fc538a_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzgtNC0xLTEtMTIxNDA_83a90254-80f3-4ce1-b5fe-5665977a80db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other&#160;current&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf88e28a5724eb4a56d2dfc0bf0392f_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzgtOC0xLTEtMTIxNDA_b1fd5764-86a1-44ef-9c6a-8c91e2435e1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f76a18801e482ab060956da5e0577e_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzktNC0xLTEtMTIxNDA_4d8294c9-7eea-4bcf-8eb7-3d274c8e9bf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f76a18801e482ab060956da5e0577e_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzktOC0xLTEtMTIxNDA_c248854a-5316-4d9d-8204-ac233b658958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzEwLTQtMS0xLTEyMTQw_2319ad68-a91c-460b-bb3c-f0cfd8cb1c53">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzEwLTgtMS0xLTEyMTQw_6fbcd22e-8bbf-4bbc-9dc2-ed031b2fca61">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.339%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44df45962204ad590aa3deb292d480c_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzQtNC0xLTEtMTIxNDA_3f55287a-713c-41d8-989d-e19db02d2e14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other&#160;current&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef1ef2f4ad142b98639be3f14e6ee99_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzQtOC0xLTEtMTIxNDA_ca9d66a7-5621-43a9-abcf-f87c68f66135">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8547beeb32459aa1afd7e5ca598ef5_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzUtNC0xLTEtMTIxNDA_f3e7fa47-0c39-40b6-ad3a-eb18d737c341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2303cfde655d46948b6bf62eb15ca0de_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzUtOC0xLTEtMTIxNDA_0028863f-948f-45dd-bacb-941bb04f191c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea1ac770ed8451ab24e1400a67a9c3e_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzYtNC0xLTEtMTIxNDA_d6558305-3bf3-4cdc-aa65-6dbed5eda86f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea1ac770ed8451ab24e1400a67a9c3e_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzYtOC0xLTEtMTIxNDA_218c3402-b526-4ec0-ad7a-806f28633cb2">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id145919643ae4857950cf7eea0d60f0c_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzgtNC0xLTEtMTIxNDA_e49fb78a-78c4-43b7-ae22-c4a533885aef">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other&#160;current&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29ad5c6bdc744ae996da36f45e56366_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzgtOC0xLTEtMTIxNDA_6c074d8b-befa-4345-846d-614d5487a4a0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b12e0c7d5d4ac7972fa5266a3d7e8d_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzktNC0xLTEtMTIxNDA_d90ae51a-edbd-44ce-8c18-4518c4557545">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b12e0c7d5d4ac7972fa5266a3d7e8d_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzktOC0xLTEtMTIxNDA_f5d5c380-35e6-43b5-a081-68228e062f0d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzEwLTQtMS0xLTEyMTQw_5b117319-18ae-4f0b-a8a0-8f84cb99fb93">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzEwLTgtMS0xLTEyMTQw_cc423ff8-e5ee-4bdc-9a16-9cb5d41739e2">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i431662d0f27043c8a6f7ec557b539558"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzI3OTg_83d15b53-3cb6-40ab-bf00-aeb7a188ac2e" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Consolidated Financial Statements:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:76.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzMtMi0xLTEtMTIxNDA_c08e18e6-6a41-4500-8405-6abe39c899d4">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzMtNC0xLTEtMTIxNDA_4faf7304-636e-466d-8fcc-0dbc28da3a9f">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzMtNi0xLTEtMTIxNDA_2742e6d5-32de-4a08-a9c5-0fe0da896085">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from AOCI into Product sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzQtMi0xLTEtMTIxNDA_310254d1-706f-4844-9243-eb9419dba0e8">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzQtNC0xLTEtMTIxNDA_f416c261-4cd7-4fd6-8a3b-555c3fdbbfc3">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzQtNi0xLTEtMTIxNDA_829e004c-1539-4253-bc6a-c4b812f8a6e6">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzYtMi0xLTEtMTIxNDA_f1fccd47-973a-4aeb-bc06-e1e3785a60da">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzYtNC0xLTEtMTIxNDA_73be54d9-4271-4388-932c-038352fa8b55">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzYtNi0xLTEtMTIxNDA_87cadc29-3f10-4604-829b-41a598aface0">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Consolidated Statements of Income. There were <ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="INF" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzI1MTk_018ca302-d202-4b8a-9e69-50ae92281840"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="INF" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzI1MTk_857dc972-5b2f-4be8-a432-01aa22b1a911">no</ix:nonFraction></ix:nonFraction> discontinuances of cash flow hedges for the years presented.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, we only held foreign currency exchange contracts.&#160;<ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzI3Njg_f00eb1f4-e053-4081-afc9-22eb2417cf9b" continuedAt="i4bc20b0dddb54990ab92084b4b932021" escape="true">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Consolidated Balance Sheets:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i4bc20b0dddb54990ab92084b4b932021"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Offset on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received/Pledged</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount (Legal Offset)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzMtMi0xLTEtMTIxNDA_dd277a4b-3ecf-49ce-a8f7-b7b21ed00543">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzMtNC0xLTEtMTIxNDA_b877a4b8-9960-476c-92be-a40a2cfc8102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzMtNi0xLTEtMTIxNDA_c7b97523-6396-40c2-9192-fb5d31c8d05c">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzMtOC0xLTEtMTIxNDA_c62167a5-07f1-4261-8e05-c0bb5319bdc6">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzMtMTAtMS0xLTEyMTQw_8b42ad3e-77b6-4331-97cd-55e62e1a8f5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzMtMTItMS0xLTEyMTQw_0c19ba12-e7aa-4219-be42-43a40de8362a">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzQtMi0xLTEtMTIxNDA_ab757d03-6a4e-4c5b-a2df-1a48b72d82f1">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzQtNC0xLTEtMTIxNDA_c4799940-f121-4c2e-a24b-5f138f740fe5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzQtNi0xLTEtMTIxNDA_8a63b983-4e93-4308-9a68-03ee901058d6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzQtOC0xLTEtMTIxNDA_e156ca75-4448-447c-b433-51de01f32e0c">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzQtMTAtMS0xLTEyMTQw_a9ca3fbe-3106-43c6-b613-16bcaca4422b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzQtMTItMS0xLTEyMTQw_ff6ad16b-ec22-41e4-b5e4-04c9eaecd479">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzYtMi0xLTEtMTIxNDA_9eca1b84-e6eb-4da0-ac58-777e5c9247da">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzYtNC0xLTEtMTIxNDA_0db3a4d4-1f59-4b85-b17a-afbf428f372f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzYtNi0xLTEtMTIxNDA_6a4d174a-d4a3-4ddf-a7fb-6038f432a8ef">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzYtOC0xLTEtMTIxNDA_7677fb88-e851-4dff-aed8-6be17b9c4184">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzYtMTAtMS0xLTEyMTQw_1d5fea94-5aeb-434b-8ca3-6109d3f22e24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzYtMTItMS0xLTEyMTQw_b88d0cb5-d1e8-44c0-a9f1-cb1fda1b26ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzctMi0xLTEtMTIxNDA_856d6527-e968-487a-9c85-9a7f391ec180">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzctNC0xLTEtMTIxNDA_7c32f407-d7b7-4ed9-81aa-040407bd216b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzctNi0xLTEtMTIxNDA_6147b836-e484-41b5-bd63-b1ccb17d9bcc">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzctOC0xLTEtMTIxNDA_3e1699a1-c246-498d-a942-34d47c5b501d">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzctMTAtMS0xLTEyMTQw_cd57e27a-b0dd-4aef-ba66-2cde355b9aeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzctMTItMS0xLTEyMTQw_bef0c0ee-f295-4b17-8d09-7a6ebd8b21c1">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i72faa4a0a4974dcca6db2bf491b63d7a_112"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzEyNjk0_3161c759-0fee-45b3-bd1a-1a4e6ef7f238" continuedAt="i29251f62cabd4d82aa7a30870a552ca4" escape="true">ACQUISITIONS </ix:nonNumeric></span></div><ix:continuation id="i29251f62cabd4d82aa7a30870a552ca4" continuedAt="i4a865f88d7ac4c01b6135064f18ce220"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYR</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#8220;EMA&#8221;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Consolidated Financial Statements from the date of the acquisition. Acquisition-related expenses were not material for the year ended December&#160;31, 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate consideration for this acquisition of &#8364;<ix:nonFraction unitRef="eur" contextRef="i3154b2ea498c47eca679490b457a3b8c_D20210304-20210304" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM1NTg_4c982664-6058-4609-a663-ff3ff876e05b">1.3</ix:nonFraction> billion (or $<ix:nonFraction unitRef="usd" contextRef="i3154b2ea498c47eca679490b457a3b8c_D20210304-20210304" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM1NzU_dbc96857-cb9b-424e-96d7-f0ae59dfac83">1.6</ix:nonFraction> billion) primarily consisted of &#8364;<ix:nonFraction unitRef="eur" contextRef="i3154b2ea498c47eca679490b457a3b8c_D20210304-20210304" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM1OTE_734af2db-6433-40dd-9bbd-0656a40ede33">1.0</ix:nonFraction> billion (or $<ix:nonFraction unitRef="usd" contextRef="i3154b2ea498c47eca679490b457a3b8c_D20210304-20210304" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM2MDc_5ffe6698-d914-44cf-9528-7488a0ed8dcc">1.2</ix:nonFraction> billion) paid upon closing and contingent consideration of up to &#8364;<ix:nonFraction unitRef="eur" contextRef="i359a44a00217459b8f4262c8fc42c933_I20210304" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM2MjM_d8dac550-8b8f-4f30-bb2d-cec5390374c5">300</ix:nonFraction> million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $<ix:nonFraction unitRef="usd" contextRef="i366d837490844422b12ca69c2324a42b_I20210304" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM2NDA_bc47f63f-9905-488d-b6bd-74a4a6cab9fd">341</ix:nonFraction> million as of the acquisition date and was initially recorded in Other long-term obligations on our Consolidated Balance Sheets. In the second quarter of 2021, the balance was reclassified to Accrued and other current liabilities on our Consolidated Balance Sheets. The estimated fair value of this contingent liability was $<ix:nonFraction unitRef="usd" contextRef="iba409e656a3f48ab972be2b06a795ed2_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM5NzA_2c717d75-404a-4093-b6f4-e74b000cab84">317</ix:nonFraction>&#160;million as of December&#160;31, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be generally recognized at fair value as of the acquisition date. The fair value estimates for the assets acquired and liabilities assumed were based upon valuations using information known and knowable as of the date of this filing. Changes to these assumptions and estimates could cause an impact to the valuation of assets acquired, including intangible assets, goodwill and the related tax impacts of the acquisition, as well as legal and other contingencies. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i4a865f88d7ac4c01b6135064f18ce220" continuedAt="ib83368e481da439483c2d9f9767f3e6e"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzU0OTc1NTgyMDM2NjA_194bd33b-825b-45cc-969b-ce6301ff06af" continuedAt="ic93cfc478aba4cacb3ff9eeeea0a4945" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if51b044176e94e2bb20e9f08a40d5ebe_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzItMi0xLTEtNjI0OTY_68f40c03-5a67-4617-be7a-34ca9ba6b783">845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7c7aac8a2ee4a4ba775220f0d9f2cb3_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzMtMi0xLTEtNjI0OTY_5c40c5bc-77b9-4ef3-90b4-0fdbf3173bd2">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4935cfb394d8470eafcd34defaed7483_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzQtMi0xLTEtNjI0OTY_d57f4064-da84-4be3-bea0-958142e2fe74">513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4935cfb394d8470eafcd34defaed7483_I20210304" decimals="-6" sign="-" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzUtMi0xLTEtNjI0OTY_fb6e0727-8985-4c57-86f2-15db7569ccd5">187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4935cfb394d8470eafcd34defaed7483_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzYtMi0xLTEtNjI0OTY_d90b9573-e1b9-408b-871e-b0814af38dd9">1,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4935cfb394d8470eafcd34defaed7483_I20210304" decimals="-6" name="us-gaap:GoodwillGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzctMi0xLTEtNjI0OTY_ddd4af19-7c7c-4651-a039-6b8a73c9e498">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4935cfb394d8470eafcd34defaed7483_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzgtMi0xLTEtNjI0OTY_8aa38789-d843-4733-b329-9ec1ad7b6ca0">1,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $<ix:nonFraction unitRef="usd" contextRef="if51b044176e94e2bb20e9f08a40d5ebe_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzc2OTY1ODE0NjEzMDI_918a5fc8-f085-4285-abbe-ee622b20540f">845</ix:nonFraction> million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of <ix:nonFraction unitRef="number" contextRef="icb48d6051df7485eb73cdb8b7df0e985_I20210304" decimals="2" name="gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTYwOTA_75b3d72d-3d19-4907-8a85-63af774a810a">12</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of <ix:nonNumeric contextRef="i921b8d77d4f84f529ce58e9660da8dcf_D20210304-20210304" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTYwODc_4500dcbc-f692-4f23-a5b3-d2c42b542cf9">10</ix:nonNumeric> years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D consists of Hepcludex for HDV in all other regions without regulatory approval, including the United States. The estimated aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="ia2177833d44d42918c6ce32854820034_I20210304" decimals="-7" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTYxMDA_ec7113da-32f2-4cb3-81c1-505b7635418a">1.19</ix:nonFraction> billion as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to this asset and a discount rate of <ix:nonFraction unitRef="number" contextRef="i21ced31d30014719bdf7d7d18248633e_I20210304" decimals="2" name="gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTYxMDc_7cf00d5a-3a8e-4fd6-9b3c-30ee47364fce">12</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the more significant assumptions inherent in the development of intangible asset fair values include: estimates of projected future cash flows, including revenues and operating profits; probability of success; the discount rate selected; the life of the potential commercialized products and the risks related to the viability of and potential alternative treatments in any future target markets, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. See Note 3. Fair Value Measurements for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i4935cfb394d8470eafcd34defaed7483_I20210304" decimals="-6" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTY4ODI_76a3ed7e-bf6d-4028-84f0-942f44f278b1">226</ix:nonFraction> million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is <ix:nonFraction unitRef="usd" contextRef="ia9a673ba30ed4f0e806f09b015c95ec7_I20211231" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzU0OTc1NTgyMDM2ODE_3367018e-de8c-4b01-a550-8303ab5d8915">no</ix:nonFraction>t expected to be deductible for income tax purposes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the year ended December 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunomedics</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we completed the acquisition of Immunomedics, a company focused on the development of antibody-drug conjugate technology, for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i2cc76f278d7d430794fea351f77cb6c7_D20201023-20201023" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTc0OTI_9f72b4dc-8f65-4e63-a34d-1d7fc52de6b6">20.6</ix:nonFraction> billion. Upon closing, Immunomedics became a wholly-owned subsidiary of Gilead. The acquisition was financed with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $<ix:nonFraction unitRef="usd" contextRef="i1f5da942c50945a2940da6ebd718841a_D20200901-20200930" decimals="-8" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTc0OTk_08d2c7a3-d513-4a78-9121-b06730423686">1.0</ix:nonFraction> billion borrowing under a new senior unsecured term loan facility and cash on hand. In 2021, we repaid the borrowing under the senior unsecured term loan facility. See Note 12. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded share-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="icaf63b79601f41cbbbb79ce216ea77a9_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzkzNDU4NDg4OTU2Njk_2ca52252-dd25-4fb5-84f1-baf8399f84ec">289</ix:nonFraction> million related to the cash settlement of the accelerated share-based compensation expense attributable to the post-combination period, which was primarily recorded in Selling, general and administrative expenses and Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. We also recorded other acquisition-related expenses of $<ix:nonFraction unitRef="usd" contextRef="icaf63b79601f41cbbbb79ce216ea77a9_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzEwOTk1MTE2OTI4MzM_762ce030-3ac4-41b8-ad2d-8239da3d44e7">39</ix:nonFraction> million, primarily representing closing costs and related fees, in Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December 31, 2020. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ib83368e481da439483c2d9f9767f3e6e" continuedAt="ibe2474725f894f4dbb87321bcb5754ad"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Immunomedics was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be generally recognized at fair value as of the acquisition date. There were no material measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the year ended December 31, 2021. The fair value estimates for the assets acquired and liabilities assumed have been completed. </span></div><ix:continuation id="ic93cfc478aba4cacb3ff9eeeea0a4945"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzEtMi0xLTEtNjI2ODg_0d0351d2-8071-4704-ba57-d8de4a41966f">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzItMi0xLTEtNjI2ODg_351cf13e-7754-4dbf-914b-47d4a80e24bc">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d4bb748a364d08802e6d345ae95f56_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzQtMi0xLTEtNjI2ODg_c58f38dd-566d-4354-a2fe-b17e0566aa52">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48fbb200fd474e8c86b19b2980d80c7a_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzUtMi0xLTEtNjI2ODg_104da7ef-8591-4700-a7d0-c13294b1c9a9">15,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee6771abbf6845e9b749e3f2f831a535_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzYtMi0xLTEtNjI2ODg_eacfacfa-2f7f-46bd-9004-4d1bb13f2a66">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzctMi0xLTEtNjI2ODg_1253f3e4-4f8a-41d9-8fa7-ca26c71326bb">4,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023" decimals="-6" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzgtMi0xLTEtNjI2ODg_869f01eb-1307-426f-b4e3-ec5889c609b0">1,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023" decimals="-6" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzktMi0xLTEtNjI2ODg_be54b5bc-c583-4d2c-9d30-681fbab86d94">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzEwLTItMS0xLTYyNjg4_26a6786c-efb1-4bd4-ac40-1253bbbcff38">16,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023" decimals="-6" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzExLTItMS0xLTYyNjg4_010d7e44-611d-4beb-b89a-167ab1ede5e7">3,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzEyLTItMS0xLTYyNjg4_2e1d53ea-a09a-4ca4-a384-2df3b6f06bbd">20,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value step-up adjustment of $<ix:nonFraction unitRef="usd" contextRef="i2cc76f278d7d430794fea351f77cb6c7_D20201023-20201023" decimals="-6" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk3NDk_296d182a-b0fa-4621-8f9f-b79aba0b723c">881</ix:nonFraction> million, included in inventories of $<ix:nonFraction unitRef="usd" contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk3NTQ_e0e23b01-192f-4a42-b2b6-231dff31e198">946</ix:nonFraction>&#160;million as of the acquisition date, was primarily determined by the estimated selling price of finished inventory less the cost to complete the manufacturing process and selling effort. The step-up adjustment is recorded in Cost of goods sold on our Consolidated Statements of Income as the inventory is sold to customers and in Research and development expenses on our Consolidated Statements of Income for inventory used for clinical purposes.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $<ix:nonFraction unitRef="usd" contextRef="i40d4bb748a364d08802e6d345ae95f56_I20201023" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzc2OTY1ODE0NjA2Njc_18290be2-2f8e-40a8-af21-032a4d134db9">4.6</ix:nonFraction> billion represents the estimated fair value of Trodelvy for metastatic triple-negative breast cancer (&#8220;TNBC&#8221;) as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Trodelvy for metastatic TNBC and a discount rate of <ix:nonFraction unitRef="number" contextRef="i40d4bb748a364d08802e6d345ae95f56_I20201023" decimals="3" name="gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4MDc_d700496c-6194-4877-b837-03e424144557">7.0</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of <ix:nonNumeric contextRef="i4c0a66904d084d55b9dbeacaaa99fc01_D20201023-20201023" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4MTE_ca150fce-1250-4c13-8290-4d63091f9db2">12</ix:nonNumeric> years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D assets consist of Trodelvy for hormone receptor positive, human epidermal growth factor receptor 2 negative, metastatic breast cancer, Trodelvy for non-small cell lung cancer and Trodelvy for urothelial cancer (&#8220;UC&#8221;). The estimated aggregate fair value of&#160;$<ix:nonFraction unitRef="usd" contextRef="i48fbb200fd474e8c86b19b2980d80c7a_I20201023" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzkzNDU4NDg4ODYyMjY_0b26d06e-bf75-4bd6-b0d1-c4f1a3d8143a">15.8</ix:nonFraction> billion&#160;as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to these assets and a discount rate of <ix:nonFraction unitRef="number" contextRef="i48fbb200fd474e8c86b19b2980d80c7a_I20201023" decimals="3" name="gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4NTE_0b6ecafc-467d-4779-8665-0622be63bf0b">7.0</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value these intangible assets. Trodelvy for UC was granted accelerated approval by FDA in April 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4914efbe4a514e3a9b1e8ce1c3d1f7a8_I20210430" decimals="-8" sign="-" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4MjY_4198f800-0704-4983-a6b7-49b304e53af5"><ix:nonFraction unitRef="usd" contextRef="iea54bfd7cd894da1a9dc4dab9d27fd06_I20210430" decimals="-8" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4MjY_7f46a8a6-e3bc-4a3d-8aab-2e53bfc496ae">1.0</ix:nonFraction></ix:nonFraction> billion was reclassified to finite-lived intangibles from IPR&amp;D. See Note 9. Goodwill and Intangible Assets for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the more significant assumptions inherent in the development of intangible asset fair values include: the amount and timing of projected future cash flows (including revenue, cost of sales, research and development costs, and sales and marketing expenses); probability of success; the discount rate selected to measure the inherent risk of future cash flows; the assessment of the asset&#8217;s life cycle and the competitive trends impacting the asset, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recorded an intangible asset related to a license and supply agreement with a third party, which was entered into by Immunomedics prior to the acquisition. Under the agreement, the third party was granted an exclusive license to develop and commercialize Trodelvy in certain territories in Asia and make certain sales milestones and royalty payments to us. The acquisition date fair value of $<ix:nonFraction unitRef="usd" contextRef="iee6771abbf6845e9b749e3f2f831a535_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4Mzg_eacfacfa-2f7f-46bd-9004-4d1bb13f2a66">175</ix:nonFraction> million was determined by estimating the probability-weighted net cash flows attributable to the outlicense and a discount rate of <ix:nonFraction unitRef="number" contextRef="iee6771abbf6845e9b749e3f2f831a535_I20201023" decimals="3" name="gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4NDc_c3dfd0f8-84f6-4ddd-b087-82eb29925813">7.0</ix:nonFraction>%. The discount rate represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of <ix:nonNumeric contextRef="i8e4d4939ae6f4eacb0ac9fcf29a6a86b_D20201023-20201023" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4NTU_bcc54671-9005-446b-b13d-8f3a0fb1a92a">15</ix:nonNumeric> years on a straight-line basis. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ibe2474725f894f4dbb87321bcb5754ad" continuedAt="i9d829c21850e484cbae7f8a46357d460"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of Immunomedics.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust (&#8220;RPI&#8221;), prior to our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The acquisition date fair value of the liability was estimated as $<ix:nonFraction unitRef="usd" contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023" decimals="-8" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzc2OTY1ODE0NjA2NzU_9e242cac-3cce-4421-ad1f-62d9b1f04c1a">1.1</ix:nonFraction> billion, which was primarily determined based on current estimates of future royalty payments to RPI over the life of the arrangement using the real options method and an effective annual interest rate of <ix:nonFraction unitRef="number" contextRef="i2cc576f3ddae4cccba9f06dea7d86258_I20201023" decimals="3" name="gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4ODU_88083ac6-1ccc-4b86-8e9f-027febd3e53b">2.5</ix:nonFraction>%. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over <ix:nonFraction unitRef="number" contextRef="i17b0826d35c24c928061c1e5a0cc3d90_I20201023" decimals="0" name="gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4ODk_65487143-e0db-46c7-9f8c-5cdcc48e500f">16</ix:nonFraction> years. The estimated timing and amount of future expected royalty payments over the estimated term will be re-assessed each reporting period. The impact from changes in estimates will be recognized in the liability and the related interest expense prospectively. The inputs used for valuation of this liability are unobservable and are considered Level 3 under the fair value measurement and disclosure guidance. See Note 3. Fair Value Measurements for additional information. The liability related to future royalties was categorized as debt and primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 12. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The&#160;excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023" decimals="-8" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzE2NDkyNjc1MDY0Nzk_9a484348-7ed0-43c8-b31b-a0f89146afd7">4.0</ix:nonFraction> billion was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for Immunomedics is <ix:nonFraction unitRef="usd" contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzU0OTc1NTgyMDM2OTM_634ba329-eb89-4ace-9670-9c4a5554931f">no</ix:nonFraction>t expected to be deductible for income tax purposes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forty Seven, Inc. (&#8220;Forty Seven&#8221;) </span></div></ix:continuation><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9d829c21850e484cbae7f8a46357d460">In the second quarter of 2020, we completed the acquisition of Forty Seven, a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for total consideration of $<ix:nonFraction unitRef="usd" contextRef="ic064b955d17a405a8e93d4ced0a24b8b_D20200407-20200407" decimals="-8" name="gild:PaymentsToAcquireAssetsNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTgzNjk_c3564615-2336-49a2-9852-1969ecd355a6">4.7</ix:nonFraction> billion, net of acquired cash. Upon closing, Forty Seven became a wholly-owned subsidiary of Gilead. We accounted for the transaction as an asset acquisition since the lead asset, magrolimab, represented substantially all the fair value of the gross assets acquired. During the year ended December 31, 2020, we recorded a $<ix:nonFraction unitRef="usd" contextRef="if390b664ad9b4a3fa1db0cce3b5ead91_D20200101-20201231" decimals="-8" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTg0MDM_a5c05dc1-f90c-4cfd-8827-8b2a7b3164c2">4.5</ix:nonFraction> billion charge representing an acquired IPR&amp;D asset with no alternative future use in Acquired in-process research and development expenses, and stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="ic616f3942a304ac4ab23e63afeed5a7d_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTg0MDY_4e352571-745e-4fa9-b3e7-3b7a8471cd8d">144</ix:nonFraction> million primarily in Research and development expenses on our Consolidated Statements of Income.</ix:continuation> </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_115"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzg1Mw_0ec24f48-4fea-45c3-8593-933b606e5071" continuedAt="i4644e66dd5034a15aa55382cbbdefcef" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i4644e66dd5034a15aa55382cbbdefcef"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzg1Ng_49668cf7-775b-4846-8b79-6321bf463089" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzItMi0xLTEtMTIxNDA_eae505e3-7b13-4d6b-a296-929c3c6c7316">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzItNC0xLTEtMTIxNDA_80fd503a-d0b1-42d6-96ed-e4a64535a5c2">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzMtMi0xLTEtMTIxNDA_608b1f80-76f8-4bdd-a59e-77357991182b">590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzMtNC0xLTEtMTIxNDA_683c8ef6-c492-4f79-b6b7-4f96534d989c">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzQtMi0xLTEtMTIxNDA_d67b817f-8008-44cb-866c-10f00024c7e2">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzQtNC0xLTEtMTIxNDA_e6639eab-eda5-49be-888f-4cb109853c8f">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799ec7afbe884df09fd62386211ca69c_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzUtMi0xLTEtMTIxNDA_1f01344e-34a8-4d6e-b1b7-7c2e10be06b9">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb077705a6144313995575f715ac8647_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzUtNC0xLTEtMTIxNDA_136449b7-348a-4441-b970-f0f3fc645603">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzgtMi0xLTEtMTIxNDA_6d05d9c7-1393-4522-82cc-e7da946d5812">1,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzgtNC0xLTEtMTIxNDA_42d697a7-bd6c-4848-bc51-33e8518d8a75">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzktMi0xLTEtMTIxNDA_b85926f5-7db7-49c0-97d4-e7fd77a26920">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzktNC0xLTEtMTIxNDA_a6117921-6a53-49ad-9086-31dd67caf384">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799ec7afbe884df09fd62386211ca69c_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzEwLTItMS0xLTEyMTQw_3e2b04ed-8489-4beb-a8f9-4bd418b93590">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb077705a6144313995575f715ac8647_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzEwLTQtMS0xLTEyMTQw_5c3cc36f-03cb-4997-ab2a-0503bf2dab60">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported as Other long-term assets primarily consisted of raw materials as of December&#160;31, 2021 and 2020. Total inventories as of December&#160;31, 2021 and 2020 include $<ix:nonFraction unitRef="usd" contextRef="i9130594e600c402b8c0b978840773abf_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzEzNzQzODk1MzUyMzM4_b7cb2558-318d-474a-a692-f462ae69b2dd">294</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2809f8582076480fa7e0927fefc603b7_I20201231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzEzNzQzODk1MzUyMzg2_5c9a4fae-d84b-4351-a739-ab4b753c8fdc">797</ix:nonFraction>&#160;million, respectively, of fair value adjustments resulting from the Immunomedics acquisition. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventory write-down charges were $<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzkzNDU4NDg4NDA2MzI_b52c3fb3-e40e-4c4f-aecd-f3e9697d1938">228</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzkzNDU4NDg4NDA5MDY_c9f07d81-e88d-4248-8cdc-246467ecaded">86</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzkzNDU4NDg4NDA5MTQ_375ea94d-88cf-45cd-8cd8-8076f2e803e1">649</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. During the year ended December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="ie9515dcb5dcd4ed096a37c411b6c94a8_D20190101-20191231" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzM4NDgyOTA2OTkyMDc_5ae3e29d-ce92-4e1a-a516-d3e6abffec39">547</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzkzNDU4NDg4NDA5OTc_375ea94d-88cf-45cd-8cd8-8076f2e803e1">649</ix:nonFraction> million inventory write-down charges was related to slow-moving and excess raw material and work in process inventory primarily due to lower long-term demand for our HCV products.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 8. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0Xzc2MA_71d4da9e-40b2-4eca-b03b-de979c3e46e4" continuedAt="ideeb7c157ab64396882ae0f0e472cf26" escape="true">PROPERTY, PLANT AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="ideeb7c157ab64396882ae0f0e472cf26"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0Xzc0OQ_955145b0-34cd-44cc-af55-e22416769bc4" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Property, plant and equipment, net: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzItMi0xLTEtMTIxNDA_4db5a2d2-f07b-4ba5-b27f-5fb79909b658">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzItNC0xLTEtMTIxNDA_38f498f5-16c7-496c-9c64-cae5b7faf0e6">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements (including leasehold improvements)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzMtMi0xLTEtMTIxNDA_598a4045-37fa-4d13-a2a8-fe1ae91d0111">3,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzMtNC0xLTEtMTIxNDA_c261c68f-b46b-419d-b98f-44c2325722fe">3,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzQtMi0xLTEtMTIxNDA_9a09da01-bfbd-4162-afa2-4987a49aed3f">952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzQtNC0xLTEtMTIxNDA_35d4c9e5-d02d-4ad9-8af8-4bbedb2e8424">904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzUtMi0xLTEtMTIxNDA_b846ea0c-db89-4bee-b687-360a06b038ee">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzUtNC0xLTEtMTIxNDA_d85e725c-d511-4737-bf8c-408ed313f3f9">793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzYtMi0xLTEtMTIxNDA_74a45f3a-25a4-4112-8417-3135b825b175">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzYtNC0xLTEtMTIxNDA_f55922a4-06c6-41ab-b91f-e00c7d5da59f">856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzctMi0xLTEtMTIxNDA_29e5f838-9a4a-4a1f-a1cd-a8eb7b789ff2">7,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzctNC0xLTEtMTIxNDA_091eb6b5-e26e-4fb7-84af-de11d953a1de">6,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzgtMi0xLTEtMTIxNDA_ce731bb3-3085-49bc-a8d4-4baa9ef3328c">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzgtNC0xLTEtMTIxNDA_e5ff2332-b8ec-41a2-9b3b-66f357974d7c">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzktMi0xLTEtMTIxNDA_e87d50ae-b271-43c1-aee3-117fae3920b2">5,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzktNC0xLTEtMTIxNDA_8ba84aa3-b582-4ec0-8378-c3e94318f8c2">4,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had unamortized capitalized software costs, included in Office, computer equipment and other, of $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0XzE4Nw_d8de61f5-837a-4640-bf97-da79d4ec7723">131</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0XzE5NA_17c12b3b-5cd4-4ff9-95ec-657c0cdd7df9">124</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively. Capitalized interest on construction in progress is included in Property, plant and equipment, net on our Consolidated Balance Sheets. Interest capitalized in 2021 and 2020 was not material.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net book value of our property, plant and equipment in the United States was $<ix:nonFraction unitRef="usd" contextRef="i0ac72ff3c91e41dda636f4481b43d8d8_I20211231" decimals="-8" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0XzUyMg_0099281d-d803-4d22-8c8c-f33a70bdd7eb">4.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if86d40bd14d6458096e0c4c590a93b2d_I20201231" decimals="-8" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0XzQ5NDc4MDIzMjYwNzc_148203cd-9e5d-4212-942f-9ce1370b4382">4.0</ix:nonFraction> billion as of December&#160;31, 2021 and 2020, respectively. The corresponding amount in international locations was $<ix:nonFraction unitRef="usd" contextRef="i954f79dbc23344e2bc4a6cc0b85ebc55_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0XzYyMA_744436b4-8dc3-4b04-a5bf-f2f84acddfa2">963</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0d05732d25884b3886f2b6eb46e0c7a2_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0XzQ5NDc4MDIzMjYwODQ_1c6f32b2-fa84-4531-8f09-9f1523b34ca3">940</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively. All individual international locations accounted for less than 10% of the total balances.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzI5Mzk_55edd9fa-3c24-4ab3-af99-8e32f04bb02b" continuedAt="ifc23c58f07c543c8a747abfb349babe3" escape="true">GOODWILL AND INTANGIBLE ASSETS </ix:nonNumeric></span></div><ix:continuation id="ifc23c58f07c543c8a747abfb349babe3" continuedAt="i6b1f3af545834019b51227c3147f4356"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzI5MTk_4ec9d75c-3281-4af9-b65e-5f884d6bc616" escape="true"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of Goodwill:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzEtMi0xLTEtMTIxNDA_69c4f0a2-9f71-4c83-b761-d0b5c3015071">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzItNC0xLTEtOTkyNzM_b92fb2c6-7425-4adb-8890-fc172e61735a">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzItMi0xLTEtMTIxNDA_bac71c63-4ca0-416f-9c9c-bd575f7e6147">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzMtNC0xLTEtOTkyODc_d4eb9404-0295-4db3-8cbe-f3aab6d82ded">3,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzMtMi0xLTEtNjM4MTc_e24675b0-9247-40af-837e-b48bec04e8f0">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzQtNC0xLTEtOTkzMDM_9ed0f71e-3ad4-4d3e-8880-b972d1708820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzMtMi0xLTEtMTIxNDA_4502a415-8ebb-40ce-b4c0-971e5a8a1108">8,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzUtNC0xLTEtOTkyOTA_25ecdd01-ff47-4706-a2f4-fe1a33a97af2">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an annual goodwill impairment assessment in the fourth quarter or earlier if impairment indicators exist. As of December&#160;31, 2021, there were <ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzI0NA_a25514ee-913f-4bff-beed-ac7ed80d0a25">no</ix:nonFraction> accumulated goodwill impairment losses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzI5MTQ_27e7171d-bffe-469b-8335-0b82c62ac071" continuedAt="i3dfcb78a59654b80938b3acf40b671e5" escape="true"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzI5NDk_f7d548e4-42c5-44cf-9b4b-61e430d245a6" continuedAt="i55bb1aeef55542b48b28d9265861ce3e" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5cf4e62a72481988dcf8c0806f41bf_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtMi0xLTEtMTIxNDA_e9d02b91-f158-488f-8149-6363b148d078">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e5cf4e62a72481988dcf8c0806f41bf_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtNC0xLTEtMTIxNDA_08b4407b-b312-4fc1-9ad7-137c192b76d4">5,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5cf4e62a72481988dcf8c0806f41bf_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtNi0xLTEtMTIxNDA_840a3a32-dea3-47b0-a430-1e8eaea5fdb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5cf4e62a72481988dcf8c0806f41bf_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtOC0xLTEtMTIxNDA_208df603-cf78-4cf3-9114-badf05a9bdb7">5,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7db52d1e4a414281cb490a081d6dfc_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtMTAtMS0xLTEyMTQw_686576e8-6d9e-4be1-80e1-b558d677a795">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a7db52d1e4a414281cb490a081d6dfc_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtMTItMS0xLTEyMTQw_5ea2527a-d776-4208-8e68-f32e6a3e740d">4,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7db52d1e4a414281cb490a081d6dfc_I20201231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtMTQtMS0xLTEyMTQw_759b9284-7962-48a8-ba99-7c5945a88316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7db52d1e4a414281cb490a081d6dfc_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtMTYtMS0xLTEyMTQw_e7593475-e35e-4be4-aef9-303e705f2087">5,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2781ca10ac41f5983b9e118c2abf70_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtMi0xLTEtMTIxNDA_af1db4b6-947f-4c01-9f58-8be00419f88a">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c2781ca10ac41f5983b9e118c2abf70_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtNC0xLTEtMTIxNDA_99719588-00e8-4815-86c5-82303a5d904f">1,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2781ca10ac41f5983b9e118c2abf70_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtNi0xLTEtMTIxNDA_0e9d9e34-c200-426a-85ff-1a4d42f93cc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2781ca10ac41f5983b9e118c2abf70_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtOC0xLTEtMTIxNDA_6207b285-4bb7-4ff7-9fad-659f1a327968">5,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ad0c1f171b4177b15cd5e56d09b6c1_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtMTAtMS0xLTEyMTQw_dda84990-51d6-4b5a-98c7-1c64ffb8bafc">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1ad0c1f171b4177b15cd5e56d09b6c1_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtMTItMS0xLTEyMTQw_d4ccc2a7-65ee-4afd-9d3c-abdd7f770ce1">1,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ad0c1f171b4177b15cd5e56d09b6c1_I20201231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtMTQtMS0xLTEyMTQw_b5fca952-16c6-460c-9875-c5891e0dfb08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ad0c1f171b4177b15cd5e56d09b6c1_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtMTYtMS0xLTEyMTQw_a4aade33-0f25-4b5f-af95-444f95a95d94">5,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf491080c57475991aa98abcc4fbcc0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtMi0xLTEtMTIxNDA_18ba820e-5d67-4a84-84d9-da445e33d050">5,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaf491080c57475991aa98abcc4fbcc0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtNC0xLTEtMTIxNDA_49b8e3cd-62e0-465d-9aee-47636675e0be">507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf491080c57475991aa98abcc4fbcc0_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtNi0xLTEtMTIxNDA_e5c8c71b-4c37-4667-aae1-477f6638092d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf491080c57475991aa98abcc4fbcc0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtOC0xLTEtMTIxNDA_1ab92e1e-06b9-4719-b54a-9b289bb49f01">5,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bdf2ca12670410281b8c08d6e3e7fcc_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtMTAtMS0xLTEyMTQw_30f06f6f-66d3-4a7e-a52e-553f56591438">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bdf2ca12670410281b8c08d6e3e7fcc_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtMTItMS0xLTEyMTQw_13eee71e-a8fd-4e3f-8b6b-fba473661494">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bdf2ca12670410281b8c08d6e3e7fcc_I20201231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtMTQtMS0xLTEyMTQw_14997a01-c9ec-4a7b-9f07-d7bfb0370b32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bdf2ca12670410281b8c08d6e3e7fcc_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtMTYtMS0xLTEyMTQw_5cdd9b1b-e4bc-4a0d-8ca4-e295e6bbfc08">4,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f8421f3e1d46c38dbaab52dda2ef27_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMi0xLTEtNjM5NzA_d5b6255c-ab0c-402f-91d8-4629959f5923">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1f8421f3e1d46c38dbaab52dda2ef27_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtNC0xLTEtNjM5NzA_732abc2d-a011-4b54-8f33-470b2ece0d63">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f8421f3e1d46c38dbaab52dda2ef27_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtNi0xLTEtNjM5NzA_00f548f1-6c6e-4947-a537-b3d4e80ef3cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f8421f3e1d46c38dbaab52dda2ef27_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtOC0xLTEtNjM5NzA_52971745-cd07-4476-a482-c12a069dd566">773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf23ded0c1324053bcaf589d66627968_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTAtMS0xLTYzOTcw_80a995cb-18ea-46b0-8f14-a34b53cea8b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf23ded0c1324053bcaf589d66627968_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTItMS0xLTYzOTcw_559fe069-c6b0-4a97-b1c5-71df0cbcd4cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf23ded0c1324053bcaf589d66627968_I20201231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTQtMS0xLTYzOTcw_fefce2d0-8e4d-4894-bf41-1aa1dc6f9b22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf23ded0c1324053bcaf589d66627968_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTYtMS0xLTYzOTcw_74274c0b-822c-4871-8692-623bdce33bc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30947e974d8c479392d193aad7a782fd_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMi0xLTEtMTIxNDA_165793ff-6cd9-4b6f-bb05-6f30d7da469a">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30947e974d8c479392d193aad7a782fd_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtNC0xLTEtMTIxNDA_6d787041-0a7d-466c-b24a-37a66a386f93">650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30947e974d8c479392d193aad7a782fd_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtNi0xLTEtMTIxNDA_36277e03-ba7a-42e7-aac0-82a96fd28263">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30947e974d8c479392d193aad7a782fd_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtOC0xLTEtMTIxNDA_799f4c51-98ff-4a23-b6ce-9bb41c44aed7">961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94d5c1399f498a9997b438dd170d14_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTAtMS0xLTEyMTQw_d09cea8e-7151-4eff-b5be-948b75da1092">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d94d5c1399f498a9997b438dd170d14_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTItMS0xLTEyMTQw_1a84ff8b-3aef-48d9-a390-d157b5625c04">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d94d5c1399f498a9997b438dd170d14_I20201231" decimals="-6" sign="-" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTQtMS0xLTEyMTQw_8162bf83-e188-49bc-91eb-a1fa4bf029c9">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94d5c1399f498a9997b438dd170d14_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTYtMS0xLTEyMTQw_d9371bd1-a575-4d6b-a892-99691ae3052b">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctMi0xLTEtMTIxNDA_e86b9e95-892a-447f-a981-7841c6d7167e">25,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctNC0xLTEtMTIxNDA_80e4c4e5-025d-415b-a173-e17c240cf174">8,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctNi0xLTEtMTIxNDA_7f7466a0-9754-4cb6-823c-a82c0bbdc2c3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctOC0xLTEtMTIxNDA_502edf7f-5d4f-4b7a-bea8-20c91ef8d67d">17,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctMTAtMS0xLTEyMTQw_5ffff38c-7805-4ef4-9475-5f3fa761c4f6">22,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctMTItMS0xLTEyMTQw_73950f6c-8063-4d41-a976-06ebd8c64ee6">6,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" sign="-" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctMTQtMS0xLTEyMTQw_70258890-705a-4bbe-9469-de1e0a612020">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctMTYtMS0xLTEyMTQw_ac18ca2c-345b-4a98-a185-80da464c8f85">16,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f89193810b43f085be64ba7f474b2d_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzgtMi0xLTEtMTIxNDA_c8320b84-e6a1-49a3-9b19-5cec54c5bef5">15,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f89193810b43f085be64ba7f474b2d_I20211231" decimals="-6" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzgtNi0xLTEtMTIxNDA_230bc1e5-180d-4404-8c60-eafaec8e04f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f89193810b43f085be64ba7f474b2d_I20211231" decimals="-6" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzgtOC0xLTEtMTIxNDA_6c0a1a7e-630c-4dfc-8e6c-6cb40502a1b1">15,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4094fc9d8da341cea659d729c71c046d_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzgtMTAtMS0xLTEyMTQw_ca9520b2-df5c-4b9f-8df0-0a4e35ae49e4">16,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4094fc9d8da341cea659d729c71c046d_I20201231" decimals="-6" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzgtMTQtMS0xLTEyMTQw_4a7231b0-a849-44c4-8092-d5c0f25fa659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4094fc9d8da341cea659d729c71c046d_I20201231" decimals="-6" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzgtMTYtMS0xLTEyMTQw_f5550a84-f6c1-483c-983d-3f91165e8316">16,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktMi0xLTEtMTIxNDA_5dfa1538-be9c-4777-afa4-d38c1ea4d3c2">41,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktNC0xLTEtMTIxNDA_56cb9011-5e74-49a7-97eb-7fe437e6ec01">8,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktNi0xLTEtMTIxNDA_2d896566-0811-4dbd-a870-9c82a5f25fa9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktOC0xLTEtMTIxNDA_30cc9d6b-ca0b-43c5-a61f-19df7aac74eb">33,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktMTAtMS0xLTEyMTQw_9aa31362-dec3-4e4b-90fb-e60a47204d12">39,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktMTItMS0xLTEyMTQw_f726dad8-fa72-4a27-ad2a-651cabfb0113">6,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" sign="-" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktMTQtMS0xLTEyMTQw_6f3c0962-6792-4a17-9ab9-0603ca105c78">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktMTYtMS0xLTEyMTQw_1a7a2de9-5ed2-421a-b31d-11dc51ca560b">33,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes $<ix:nonFraction unitRef="usd" contextRef="ic1d241566dd94df38a909334019a059a_I20210331" decimals="-6" sign="-" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MDY4ODA_852e8cde-d13f-4acb-8f3c-18a88d8f6f12"><ix:nonFraction unitRef="usd" contextRef="i6252373178cb4cf6833d9fea5111db48_I20210331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MDY4ODA_d1a66762-e464-4b3b-b853-3536fff9564d">910</ix:nonFraction></ix:nonFraction>&#160;million reclassified in the first quarter of 2021 from indefinite-lived assets - IPR&amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes Trodelvy for metastatic TNBC and Trodelvy for use in adult patients with locally advanced or metastatic UC. The amount related to UC of $<ix:nonFraction unitRef="usd" contextRef="i4914efbe4a514e3a9b1e8ce1c3d1f7a8_I20210430" decimals="-8" sign="-" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MDY4OTU_3441c6c0-c3fd-4288-adf1-1b91b5746476"><ix:nonFraction unitRef="usd" contextRef="iea54bfd7cd894da1a9dc4dab9d27fd06_I20210430" decimals="-8" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MDY4OTU_352387f8-ec7d-4875-b249-57e2b0602092">1.0</ix:nonFraction></ix:nonFraction> billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;D upon the accelerated approval by FDA in April 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $<ix:nonFraction unitRef="usd" contextRef="i034b60a8653f4767b2a7133e87e4160c_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MDc5ODk_c4c31fa6-1655-48ed-a206-cf2e64e0750f"><ix:nonFraction unitRef="usd" contextRef="i30947e974d8c479392d193aad7a782fd_I20211231" decimals="-6" sign="-" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MDc5ODk_f6bc5978-e79b-4e3a-bafa-9db1f3e430d4">200</ix:nonFraction></ix:nonFraction> million was reclassified to finite-lived assets in the fourth quarter of 2021.</span></div></ix:nonNumeric></ix:nonNumeric><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i3dfcb78a59654b80938b3acf40b671e5" continuedAt="id9e02e6de22d4f09840967a726e2c950"><ix:continuation id="i55bb1aeef55542b48b28d9265861ce3e" continuedAt="if61f7afa55b64b18a38fcd9abc109bbe">(4)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="id9e02e6de22d4f09840967a726e2c950"><ix:continuation id="if61f7afa55b64b18a38fcd9abc109bbe">&#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes IPR&amp;D from our 2021 acquisition of MYR and remaining IPR&amp;D from our 2020 acquisition of Immunomedics. Gross carrying amount as of December&#160;31, 2020 includes IPR&amp;D from our 2020 acquisition of Immunomedics and remaining IPR&amp;D from our 2017 acquisition of Kite.</ix:continuation></ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i808afce6234d4f44b02493f616cfcdad_D20210101-20211231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzYzNQ_35aefad1-7edb-4667-aa9e-5e1d8b158339">1.7</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i157409bb1ea342b2a3f94ed6091834b3_D20200101-20201231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzYzOQ_1b0fbfa1-c55b-4e59-a6b1-9a4961ddb4c1">1.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i4e62f0a33b96429bb3fe4df85eb86fd7_D20190101-20191231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzY0Ng_ccd03ac0-52f8-46bb-92cf-e641bffc8e4b">1.1</ix:nonFraction> billion for the years ended December&#160;31, 2021, 2020 and 2019, respectively, and is primarily included in Cost of goods sold on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts capitalized as IPR&amp;D are subject to impairment testing until the completion or abandonment of the associated R&amp;D efforts</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we performed a qualitative assessment of our IPR&amp;D intangible asset obtained in connection with our first quarter 2021 acquisition of MYR and did not identify any indicators of impairment.</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, 2020 and 2019, we performed quantitative impairment testing of our IPR&amp;D intangible assets, other than the MYR asset described above, using a probability-weighted income approach that discounts expected future cash flows to present value using discount rates of <ix:nonFraction unitRef="number" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="3" name="gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MTg4MDU_5ab37d07-ec15-476a-8c5c-b9d3ae58b046">6.5</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="3" name="gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzkzNDU4NDg4NTU0MzA_69924854-c073-4a82-abe9-552f72703c35">8.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231" decimals="3" name="gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzkzNDU4NDg4NTU0Mzg_20c26542-8b92-433e-8482-6f984ef9d0c1">9.5</ix:nonFraction>%, respectively</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rates are based on the estimated weighted-average cost of capital for companies with profiles similar to our profile and represents the rate that market participants would use to value the intangible assets. The discounted cash flow models used in valuing these intangible assets also require the use of Level 3 fair value measurements and inputs including estimated revenues, costs, and probability of technical and regulatory success. <ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzU0OTc1NTgxNjIzMDc_48279e86-3fe5-4890-ba44-dcaf12435b18"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzU0OTc1NTgxNjIzMDc_4df6a240-fe27-400c-a1c0-948d8c3e6bdd">No</ix:nonFraction></ix:nonFraction> IPR&amp;D impairment charges were recorded in 2021 and 2020. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i6b1f3af545834019b51227c3147f4356"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we lowered our estimated revenues related to our IPR&amp;D intangible asset - axicabtagene ciloleucel for the treatment of indolent B-cell non-Hodgkin lymphoma due to changes in the estimated market opportunities as new therapies or combinations of existing therapies were approved. The lower estimated revenues reduced the fair value of the IPR&amp;D intangible assets below carrying value resulting in the recognition of an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i347295d908ea47bd9ef9a8fa1edea941_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MTQ3NDk_1bebdf39-dd3f-486b-bfc9-f9ee1dafcf4e">800</ix:nonFraction> million, which was recorded within Acquired in-process research and development expenses on our Consolidated Statements of Income.</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzI5MjI_c5ba2f3d-b61e-41fa-9809-84d98e7ef6e7" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2021:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzEtMi0xLTEtMTIxNDA_b750f926-196a-403f-84b5-67b39f510f5c">1,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzItMi0xLTEtMTIxNDA_ebe28946-49ca-4390-998f-40a00d60ee73">1,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzMtMi0xLTEtMTIxNDA_bd5673a6-273d-4093-8842-1d52c360e1b5">1,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzQtMi0xLTEtMTIxNDA_e6b9e6fe-6478-442e-9e8e-11233dabb361">1,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzUtMi0xLTEtMTIxNDA_f0f4f44f-1724-4399-b975-e49ebcf9ffb7">1,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzYtMi0xLTEtMTIxNDA_3c03b2d2-53ee-4fcb-819a-881a45e310f0">8,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzctMi0xLTEtMTIxNDA_3f65f729-28f1-4d4b-8ffb-4688b6b93feb">17,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i72faa4a0a4974dcca6db2bf491b63d7a_124"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90ZXh0cmVnaW9uOjc0ODdmYjEzZTYwNjQzNjJiNmZmM2UwMWYwMDM4YzVmXzIwNQ_f9031ce0-9fd3-48b9-b1a7-96be85e0cd68" continuedAt="i550516fd7ad04e5387b60888ba59bc55" escape="true">OTHER FINANCIAL INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i550516fd7ad04e5387b60888ba59bc55"><div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90ZXh0cmVnaW9uOjc0ODdmYjEzZTYwNjQzNjJiNmZmM2UwMWYwMDM4YzVmXzIwOQ_fbc2d76a-eba2-40ed-9f17-b3c408220275" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net: </span></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzItMi0xLTEtMTIxNDA_52cb5d84-4652-41fd-b2f7-c0c209702bcd">5,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzItNC0xLTEtMTIxNDA_e595cda6-7e27-4fc5-b12e-8fe3173212d0">5,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzMtMi0xLTEtMTIxNDA_e5256ea7-d8e1-4a06-b325-038fa25a4e13">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzMtNC0xLTEtMTIxNDA_1080a7a7-fae2-4b7e-9b00-bdf40c4b3c15">552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzQtMi0xLTEtMTIxNDA_54af22ae-04e6-4c6b-a2dc-de92b20a002a">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzQtNC0xLTEtMTIxNDA_9cb2a3ad-10c5-460e-bc0f-466c68975de5">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzUtMi0xLTEtMTIxNDA_8845d98d-f54f-4ba4-9cfd-2d5f9801b753">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzUtNC0xLTEtMTIxNDA_dcfe2902-e004-455e-8cfd-1dd35f5c77c4">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzYtMi0xLTEtMTIxNDA_c35eca51-f2f4-4678-97e9-9877224e0402">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzYtNC0xLTEtMTIxNDA_8db9fea2-84fc-4084-8f59-93a2bade2021">4,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued and other current liabilities</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90ZXh0cmVnaW9uOjc0ODdmYjEzZTYwNjQzNjJiNmZmM2UwMWYwMDM4YzVmXzIxNA_f62999e6-74e1-48e0-89a4-3afb44b0c796" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Accrued and other current liabilities:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzItMi0xLTEtMTIxNDA_c2e778e7-08d6-483a-865d-85f3a613612c">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzItNC0xLTEtMTIxNDA_ac7a3a2d-8abf-43c1-bf19-d46575cafcb1">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzMtMi0xLTEtMTIxNDA_9fc5fdaf-4d3c-460d-bd83-6f218eebba64">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzMtNC0xLTEtMTIxNDA_f4d4fc72-1a6b-4233-87e1-d94811629afe">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzQtMi0xLTEtMTIxNDA_d3e63481-b470-4eaa-8c7e-2bc43f3f2c4d">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzQtNC0xLTEtMTIxNDA_9c00b022-2c17-483a-b4c4-e8dfb32151a6">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for settlement related to bictegravir litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzUtMi0xLTEtOTU4NDc_63d9e471-3bde-4157-bcd1-dd0c96efc52b">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzUtNC0xLTEtOTU4NDc_5a6e8335-2147-485f-bad4-eb411b068321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzUtMi0xLTEtMTIxNDA_20ee1843-a9a0-417c-b10e-34bb2eb45764">2,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzUtNC0xLTEtMTIxNDA_f089e147-8569-4521-86b2-b49bc1ab2c24">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzYtMi0xLTEtMTIxNDA_09e596d9-8713-4e4c-b2ad-e73972aba7d9">6,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzYtNC0xLTEtMTIxNDA_fd7959d2-7330-45de-9c68-72f9f5f8712d">4,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See Note 14. Commitments and Contingencies for additional information.</span></div></ix:nonNumeric></ix:continuation><div id="i72faa4a0a4974dcca6db2bf491b63d7a_127"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="gild:CollaborativeAndOtherArrangementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM1Mjg5_cd926421-d05f-4580-8b51-7792382c0bd6" continuedAt="i9534d561d901481094dde7a6b63e6695" escape="true">COLLABORATIONS AND OTHER ARRANGEMENTS </ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9534d561d901481094dde7a6b63e6695" continuedAt="i1074cd85afbc43718f70c1759e3f3f53">We enter into licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements and cost-sharing arrangements. We also have equity investments in third parties focused on the development and commercialization of products and product candidates. </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i1074cd85afbc43718f70c1759e3f3f53" continuedAt="i01cff8cf92004cf2857f1c5a9b0824de"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merck &amp; Co, Inc. (&#8220;Merck&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2021, we entered into a license and collaboration agreement with Merck Sharp &amp; Dohme Corp., a subsidiary of Merck to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#8217;s investigational capsid inhibitor, lenacapavir, and Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration will initially focus on long-acting oral and injectable formulations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Gilead and Merck will share global development and commercialization costs at <ix:nonFraction unitRef="number" contextRef="iaaddd81bb83f462cae89580391426788_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDM5MTA_764fc7dc-d3f2-4fdc-a997-eda99bb939d0">60</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i55469af46ac6444babd1103f64cce260_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDM5MTg_f2ce3e41-3bb8-457a-8bee-77ede232d3a8">40</ix:nonFraction>%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, Gilead would lead commercialization in the United States, and Merck would lead commercialization in the European Union (&#8220;EU&#8221;) and rest of the world. For long-acting injectable products, if approved, Merck would lead commercialization in the United States and Gilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, Gilead and Merck would jointly promote the combination products in the United States and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $<ix:nonFraction unitRef="usd" contextRef="ie62b8bd54ac5417b86b9d244cf6f31e4_D20210313-20210313" decimals="-8" name="gild:CollaborationArrangementNetProductSalesThreshold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDQ2MDQ_51964d29-fd11-4b97-91b3-2090f45ffd65">2.0</ix:nonFraction> billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to <ix:nonFraction unitRef="number" contextRef="ie62b8bd54ac5417b86b9d244cf6f31e4_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalProductRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDQ3MTg_1ce33064-5009-4d73-86fc-8b7ba561b1cd">65</ix:nonFraction>% for any revenues above the threshold for such calendar year. Upon passing $<ix:nonFraction unitRef="usd" contextRef="i1366e28f1db34aa6adddcb7dc9cc3fe0_D20210313-20210313" decimals="-8" name="gild:CollaborationArrangementNetProductSalesThreshold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDQ3OTY_ec02d0df-2785-4d0d-a749-45c9407e7d30">3.5</ix:nonFraction> billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to <ix:nonFraction unitRef="number" contextRef="ie62b8bd54ac5417b86b9d244cf6f31e4_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalProductRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDQ5MTY_1ce33064-5009-4d73-86fc-8b7ba561b1cd">65</ix:nonFraction>% for any revenues above the threshold for such calendar year. Reimbursements of research and development costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Income. Expenses recognized under the agreement were not material for the year ended December 31, 2021. <ix:nonFraction unitRef="usd" contextRef="i0358f4e9723644c2ad88455c39676410_D20210101-20211231" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDUxNTQ_ecb3b355-4d0f-4290-b71f-f430d5278182">No</ix:nonFraction> revenues have been recognized under the agreement for the year ended December 31, 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also have the option to license certain of Merck&#8217;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#8217;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first <ix:nonNumeric contextRef="iaaddd81bb83f462cae89580391426788_D20210313-20210313" name="gild:CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzU0OTc1NTgzMzE5MzA_1962851a-6bdb-43cd-a94e-3295b294c814">five years</ix:nonNumeric> after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out, in which case the non-exercising company will be paid a royalty.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Merck announced the decision of the parties to stop all dosing of participants in the Phase 2 clinical study evaluating an oral-weekly combination treatment regimen of lenacapavir and islatravir following the decision of FDA to place clinical holds on the investigational new drug applications for certain formulations of islatravir. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arcus</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2020, we entered into a transaction with Arcus, a publicly traded oncology-focused biopharmaceutical company, which included entry into an option, license and collaboration agreement (the &#8220;Collaboration Agreement&#8221;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the &#8220;Stock Purchase Agreements&#8221;). In accordance with the terms of the Collaboration Agreement and Stock Purchase Agreements, which closed on July 13, 2020, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM1NTE_9bf213b3-68d6-4502-b8cd-42c4dd51d15a">175</ix:nonFraction> million and acquired approximately <ix:nonFraction unitRef="shares" contextRef="ieb4c98e8e51d40a1b47f8612c6763bdb_I20200713" decimals="-5" name="gild:InvestmentOwnedBalanceAdditionalShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM1ODI_9dfd1e42-87b4-41ce-97ba-b9f80bc46e78">6.0</ix:nonFraction>&#160;million shares of Arcus common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM2MzM_57814447-af97-45e3-b511-c05590780b7f">200</ix:nonFraction> million. Of the total $<ix:nonFraction unitRef="usd" contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713" decimals="-6" name="gild:TotalUpfrontPaymentsMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM2NDU_07429dba-5c0d-49f3-ac63-749fc88d5e13">391</ix:nonFraction> million initial cash payments, including transactional costs, made under the agreements, we recorded $<ix:nonFraction unitRef="usd" contextRef="ieb4c98e8e51d40a1b47f8612c6763bdb_I20200713" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM3NDg_4628d0fe-2d28-4bf9-8cfe-a9b6b67ddf2b">135</ix:nonFraction> million as an equity investment which was calculated based on Arcus&#8217; closing stock price on the closing date of the transaction. The remaining $<ix:nonFraction unitRef="usd" contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM4OTQ_bcc2cfad-b2cd-4dc5-a53f-112acf22bec0">256</ix:nonFraction> million was attributed to (i) the acquired license and option rights of $<ix:nonFraction unitRef="usd" contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM5NTg_ebf6b921-493f-4edb-87a5-3d400404bf78">175</ix:nonFraction> million representing IPR&amp;D assets with no alternative future use, (ii) $<ix:nonFraction unitRef="usd" contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713" decimals="-6" sign="-" name="gild:IssuanceDiscountPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjQwMjE_ffbe2da9-400b-4719-9275-bee2d6fc78de">65</ix:nonFraction> million of an issuance premium for the equity purchase and (iii) $<ix:nonFraction unitRef="usd" contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713" decimals="-6" name="gild:PaymentsForDirectTransactionalExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjQwNzY_23ad27aa-3b08-474d-86a4-5ec49260572f">16</ix:nonFraction> million of direct transactional costs. These amounts were expensed as Acquired in-process research and development expenses during the year ended December 31, 2020 on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Stock Purchase Agreements, we have the right to purchase additional shares of Arcus from Arcus over the <ix:nonNumeric contextRef="i123ae893a43346c69c0dbe160845d982_D20200713-20200713" name="gild:EquitySecuritiesFVNIPurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzU0OTc1NTgzMzE5MzI_03e7239c-2475-4357-abfa-d99f9a0c5ad7">five-year</ix:nonNumeric> period beginning on the closing of the Stock Purchase Agreements, up to a maximum of <ix:nonFraction unitRef="number" contextRef="i123ae893a43346c69c0dbe160845d982_D20200713-20200713" decimals="2" name="gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3ODczOTc_2afe01ea-f9c6-4219-a0df-8646d50e08b2">35</ix:nonFraction>% of the outstanding voting stock. We are subject to a <ix:nonNumeric contextRef="i123ae893a43346c69c0dbe160845d982_D20200713-20200713" name="gild:EquitySecuritiesFVNIRestrictionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzU0OTc1NTgzMzE5MzE_9e273ed6-76f0-4c8c-a537-aedf136190e8">three-year</ix:nonNumeric> standstill, restricting our ability to acquire voting stock of Arcus exceeding more than <ix:nonFraction unitRef="number" contextRef="i123ae893a43346c69c0dbe160845d982_D20200713-20200713" decimals="2" name="gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3ODc0MDc_2afe01ea-f9c6-4219-a0df-8646d50e08b2">35</ix:nonFraction>% of the then-issued and outstanding voting stock of Arcus, subject to certain exceptions. Additionally, we agreed not to dispose of any equity securities of Arcus prior to the second anniversary of the closing of the Stock Purchase Agreements without the prior consent of Arcus, subject to certain exceptions. On May 29, 2020, in a separate secondary equity offering, we acquired <ix:nonFraction unitRef="shares" contextRef="i30f6211f84014d5fb004dbfaa00c87ea_I20200529" decimals="-5" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDA3Mjk_ebbaf299-0e5d-4581-bf8e-14ff946f824c">2.2</ix:nonFraction>&#160;million shares of common stock of Arcus for approximately $<ix:nonFraction unitRef="usd" contextRef="ia724223fb3ac4ac189bcbeacf8570846_D20200529-20200529" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDA3NDc_16cc0bbd-f606-4ca4-b81f-a26e00ead497">61</ix:nonFraction> million. In the first quarter of 2021, we also acquired approximately <ix:nonFraction unitRef="shares" contextRef="i097284d2fd8842978d347c1888e015ca_D20210101-20210331" decimals="-5" name="gild:EquitySecuritiesFVNISharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3ODc0MjY_6fb19b5b-4ed0-4446-8adb-90a73fd16774">5.7</ix:nonFraction>&#160;million additional shares of Arcus common stock for $<ix:nonFraction unitRef="usd" contextRef="i097284d2fd8842978d347c1888e015ca_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3ODc0MzY_2c735839-1f87-42d3-b869-d820a85080af">220</ix:nonFraction> million. As a result, we currently own a total of <ix:nonFraction unitRef="shares" contextRef="i2ef41f89acb2446a8d12c64235b715ba_I20211231" decimals="-5" name="gild:EquitySecuritiesFVNIShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3ODc0NDI_e5d94c6e-d6a5-40c3-8d6c-36ba2be33b12">13.8</ix:nonFraction>&#160;million shares of Arcus, which represented approximately <ix:nonFraction unitRef="number" contextRef="i7c0c8d8e8e5041718f4702400109bd45_I20210208" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3ODc0NTM_ca863a09-9c75-4146-900f-b9a5fe527c71">19.5</ix:nonFraction>% of the issued and outstanding voting stock of Arcus immediately following the closing of the first quarter 2021 transaction. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i01cff8cf92004cf2857f1c5a9b0824de" continuedAt="idf4f5cd9f04e436ca1750e2171da1704"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Collaboration Agreement, Gilead had the right to opt in to all current and future clinical-stage product candidates for up to <ix:nonNumeric contextRef="i1ed865dca089431bac2babc189c7b73e_D20200527-20200527" name="gild:CollaborativeAgreementOptInTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzU0OTc1NTgzMzE5MzM_07afab4f-408e-43ed-8c0d-4719e4dd4e5a">ten years</ix:nonNumeric> following the closing of the transaction. In November 2021, we exercised our options to <ix:nonFraction unitRef="program" contextRef="i6a21258292b74537b89e8497e7a5f1a1_I20211118" decimals="INF" name="gild:NumberOfClinicalStageProgramsWithExercisedOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzU0OTc1NTgzMzE5NjA_9d2de1a2-db29-4516-ba45-e85bf9dd2fec">three</ix:nonFraction> of Arcus&#8217; clinical stage programs and amended the Collaboration Agreement. The option exercise and amendment transaction closed in December 2021, triggering collaboration opt-in payments of $<ix:nonFraction unitRef="usd" contextRef="i7fffbc21fc7d4b79950ac95fd954ed10_D20211221-20211221" decimals="-6" name="gild:PaymentsToOptInTheCollaborativeAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEwMDU_f52edeec-1a25-48cd-982c-163ac6006bcd">725</ix:nonFraction> million and waiving the $<ix:nonFraction unitRef="usd" contextRef="if55eb0ad124b4e9881655f8d21b1defb_I20200713" decimals="-6" name="gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEwMjM_fd5ddfbb-1401-44e8-b8d1-730d54f067d0">100</ix:nonFraction> million option continuation payment which would have been due to Arcus in the third quarter of 2022. The net option charge of $<ix:nonFraction unitRef="usd" contextRef="ib55eff2de05b4735962a5178e2d0c136_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwMDg4OTU_fc700c57-c907-47d2-8beb-3b604f9de495">625</ix:nonFraction> million was recorded within Research and development expenses on our Consolidated Statements of Income for the year ended December&#160;31, 2021. The collaboration opt-in payments of $<ix:nonFraction unitRef="usd" contextRef="i7fffbc21fc7d4b79950ac95fd954ed10_D20211221-20211221" decimals="-6" name="gild:PaymentsToOptInTheCollaborativeAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3MDQyNDMwNDUyNzM4_f52edeec-1a25-48cd-982c-163ac6006bcd">725</ix:nonFraction> million were recorded in Accrued and other current liabilities on our Consolidated Balance Sheets as of December&#160;31, 2021 and paid to Arcus in January 2022. Our payments to Arcus will be included within Net cash provided by investing activities on our Consolidated Statements of Cash Flows in the first quarter of 2022. Under the amended Collaboration Agreement, the companies will co-develop and share the global costs related to these clinical programs. If the optioned molecules achieve regulatory approval, the companies will co-commercialize and equally share profits in the U.S. Gilead will hold exclusive commercialization rights outside the U.S., subject to any rights of Arcus&#8217;s existing collaboration partners, and will pay to Arcus tiered royalties as a percentage of net sales ranging from the mid-teens and low twenties. Under the Collaboration Agreement, we may also pay an additional $<ix:nonFraction unitRef="usd" contextRef="if55eb0ad124b4e9881655f8d21b1defb_I20200713" decimals="-6" name="gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjM0NDg1OTc_fd5ddfbb-1401-44e8-b8d1-730d54f067d0">100</ix:nonFraction> million at our option on each of the fourth, sixth and eighth anniversaries of the agreement, unless terminated early, to maintain the rights to opt-in to future Arcus programs for the duration of the contact term. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected and applied the fair value option to account for our equity investment in Arcus whereby the investment is marked to market each reporting period based on the market price of Arcus shares. We believe the fair value option best reflects the underlying economics of the investment. During the years ended December&#160;31, 2021 and 2020, we recorded pre-tax</span><span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrealized gains of</span><span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ib55eff2de05b4735962a5178e2d0c136_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNTgxMDM_27c5239d-ce41-4a20-8889-2bd561a78c96">127</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i91b41bd2879340d590e60e9612a0f797_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNTgxMDc_0c147255-58f8-486a-8594-cd3f907129ad">80</ix:nonFraction> million, respectively, related to our investment in Arcus in Other income (expense), net on our Consolidated Statements of Income. We initially recorded our equity investments in Arcus in Other long-term assets on our Consolidated Balance Sheets as the investments were subject to contractual lock-up provisions for a period of two years from the closing date of the Stock Purchase Agreements, subject to certain conditions. In the third quarter of 2021, we reclassified our equity investments in Arcus to Prepaid and other current assets on our Consolidated Balance Sheets as the contractual lock-up provisions are expected to expire in July 2022. Our equity investment in Arcus was $<ix:nonFraction unitRef="usd" contextRef="ide14895bf0d94cfda60b8f404be8046a_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MzE5MTY_21624019-9ac0-4fbf-b69b-73afa4768fbc">559</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5dbdcfe118594570aa52cb141478f07d_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MzM5NDE_44d76466-58fd-42c1-9e97-8d35acc5b992">212</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pionyr</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, we entered into a transaction with Pionyr, a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate merger agreements, one contemplating the initial acquisition of a <ix:nonFraction unitRef="number" contextRef="if414b8855b364ef693704d5b8001f3de_I20200619" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjM0MzU4OTY_b9b1efda-c401-46cd-8831-72a69b04ed20">49.9</ix:nonFraction>% equity interest in Pionyr, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (together, the &#8220;Pionyr Merger and Option Agreements&#8221;) and a research and development service agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2020, we closed the transaction and made cash payments of $<ix:nonFraction unitRef="usd" contextRef="i2e1550a829c24cdb927d71b758e41d28_D20200713-20200713" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEwNTk_16b67255-bb10-40bc-a666-e616019bd573">269</ix:nonFraction> million. We account for our investment in Pionyr using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Pionyr. Our investment in Pionyr, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Pionyr's net assets at transaction closing. We determined that the resulting basis difference primarily relates to Pionyr&#8217;s IPR&amp;D which has no alternative future use and that Pionyr is not a business as defined in ASC 805, &#8220;Business Combinations.&#8221; As a result, we immediately recorded a charge for this basis difference of $<ix:nonFraction unitRef="usd" contextRef="if7c095b57994471c805950b5c5648d45_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEwNDE_a294c246-5904-49c8-8619-ebce04639e20">215</ix:nonFraction> million in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. The carrying value of our equity method investment in Pionyr was <ix:nonFraction unitRef="usd" contextRef="iade36ecd4b2f43d18bc13b3efe3cfbb6_I20201231" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNDE0MTI_92071be1-4ab2-4054-9451-afe7feb6f968"><ix:nonFraction unitRef="usd" contextRef="i440f8eb082024226b3b774d89e0637e0_I20211231" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNDE0MTI_f530b755-7fe9-4ffb-b5c3-99309a9739bf">zero</ix:nonFraction></ix:nonFraction> as of December&#160;31, 2021 and 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Pionyr is approximately $<ix:nonFraction unitRef="usd" contextRef="i4ffb74e13be94db9b8207cb1d854b5c7_I20200713" decimals="-6" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEwOTI_01323ac7-ab01-4423-94be-22fda457d545">70</ix:nonFraction> million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount is recorded in Other long-term assets on our Consolidated Balance Sheets. We may choose to exercise our exclusive option to purchase the remaining equity interest from Pionyr&#8217;s current shareholders for a $<ix:nonFraction unitRef="usd" contextRef="i4ffb74e13be94db9b8207cb1d854b5c7_I20200713" decimals="-6" name="gild:EquityMethodInvestmentOptionExerciseFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDExMDc_3d814ca0-674a-4687-9a47-7c08bcc68669">315</ix:nonFraction> million option exercise fee and up to $<ix:nonFraction unitRef="usd" contextRef="i4ffb74e13be94db9b8207cb1d854b5c7_I20200713" decimals="-8" name="gild:PotentialFutureMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDExMjI_2d5bcd5c-caf9-48b3-83f6-a250a06a2252">1.2</ix:nonFraction> billion in potential future milestone payments upon achievement of certain development and regulatory milestones. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Pionyr. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the research and development service agreement, we made an initial cash funding of $<ix:nonFraction unitRef="usd" contextRef="i6d004159e86645f4b54571d61ef34b7a_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDExNDc_76cdac37-5f05-46d7-ab72-4265f648903b">80</ix:nonFraction> million and recorded a charge in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. In addition, we committed to provide additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="ifb5f6c23a9644726bde59d143b28193d_I20200713" decimals="-6" name="gild:ResearchAndDevelopmentFutureMaximumPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDExNjI_f91137f9-ba8e-431e-986a-d7cfad486fb1">115</ix:nonFraction> million to Pionyr upon achievement of certain development milestones. We accrued $<ix:nonFraction unitRef="usd" contextRef="id404a80a80e44a99a559bfcef8dd06bd_D20210101-20210331" decimals="-6" name="gild:PaymentsForResearchAndDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDExNzY_d04bdd38-8c8d-4a73-82d1-d01f3f4667a2">70</ix:nonFraction> million in milestone payments, related to the initiation of two Phase 1 studies, with a charge to Research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020, and the payment was made in the first quarter of 2021. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="idf4f5cd9f04e436ca1750e2171da1704" continuedAt="i0cdceda2809641449fba3d06629a9552"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tizona</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, we entered into a transaction with Tizona, a privately held company developing cancer immunotherapies, which included entry into two separate merger agreements, one contemplating the initial acquisition of a <ix:nonFraction unitRef="number" contextRef="i697aa6050edb4e629c83ae942ed52f29_I20200717" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjM0MzU5MDQ_85798bd0-6ff7-48b9-af68-268fe6746117">49.9</ix:nonFraction>% equity interest in Tizona, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Tizona (together, the &#8220;Tizona Merger and Option Agreements&#8221;) and a development agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, we closed the transaction with Tizona and made cash payments of $<ix:nonFraction unitRef="usd" contextRef="i397dc877c7694d19958b40ce06f66597_D20200825-20200825" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEzMTY_98d58f86-f953-4206-873c-6c9b16546211">302</ix:nonFraction> million to Tizona&#8217;s shareholders in accordance with the terms of the Tizona Merger and Option Agreements. We account for our investment in Tizona using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Tizona. Our investment in Tizona, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Tizona&#8217;s net assets at transaction closing. We determined that the resulting basis difference primarily relates to Tizona&#8217;s IPR&amp;D with no alternative future use and that Tizona is not a business as defined in ASC 805, &#8220;Business Combinations.&#8221; As a result, during the year ended December 31, 2020, we immediately recorded a charge for this basis difference of $<ix:nonFraction unitRef="usd" contextRef="i49d256c267ef40f8ab7c6c8aa7a19bf9_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEzMzQ_5335e87c-61a6-4873-a919-4a5d65f44627">272</ix:nonFraction> million in Acquired in-process research and development expenses on our Consolidated Statements of Income. The carrying value of our equity method investment in Tizona was <ix:nonFraction unitRef="usd" contextRef="i9b799eb641ab49b28bf86c39cc6029ff_I20201231" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNDE0Mjk_5edb840a-cbd8-4920-9a7f-ec3e98c43f0a"><ix:nonFraction unitRef="usd" contextRef="i2b9c16a178a84867be9f2a8338568380_I20211231" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNDE0Mjk_75a39f81-ec2e-476d-86f3-6536de0f64f4">zero</ix:nonFraction></ix:nonFraction> as of December&#160;31, 2021 and 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Tizona is approximately $<ix:nonFraction unitRef="usd" contextRef="ib17c6ee7308a4338b6c4a503ef2f8d57_I20200825" decimals="-6" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEzNTE_819ca1ee-36b1-486c-a578-4ed8ca303769">41</ix:nonFraction> million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount is recorded in Other long-term assets on our Consolidated Balance Sheets. We may choose to exercise our exclusive option to purchase the remaining equity interest from Tizona&#8217;s current shareholders for a $<ix:nonFraction unitRef="usd" contextRef="ib17c6ee7308a4338b6c4a503ef2f8d57_I20200825" decimals="-6" name="gild:EquityMethodInvestmentOptionExerciseFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MzQyMzk_c10d7efc-1daf-4d2b-9f4f-ef00a3961bc7">100</ix:nonFraction> million option exercise fee and up to $<ix:nonFraction unitRef="usd" contextRef="i6db4377ec93e4d7bbbe59b9ebfaba7ca_I20200825" decimals="-8" name="gild:EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEzNjk_98c72c81-17ec-442b-af71-a63e18cb79e5">1.2</ix:nonFraction> billion in potential future milestone payments upon achievement of certain development and regulatory milestones. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Tizona. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the development agreement, we committed to provide funding to Tizona of $<ix:nonFraction unitRef="usd" contextRef="i339e56a5445e42a7bd636e9572986490_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEzODc_26b99207-de8b-4800-a951-532f89947703">115</ix:nonFraction> million, which was recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tango Therapeutics, Inc. (&#8220;Tango&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2020, we entered into a transaction with Tango, a privately held company pursuing innovative targeted immune evasion therapies for patients with cancer through its proprietary, CRISPR-enabled functional genomics target discovery platform, which included entry into an amended and restated research collaboration and license agreement and a stock purchase agreement (together, the &#8220;Tango Collaboration and Stock Purchase Agreements&#8221;). </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE0Njk_7661042b-668b-49a6-a321-21116dae7efe">125</ix:nonFraction> million and a $<ix:nonFraction unitRef="usd" contextRef="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817" decimals="-6" name="gild:CashPaymentsMadeRelatedToEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE0ODQ_bfe89be2-c719-4571-aac7-642352f2cf59">20</ix:nonFraction> million equity investment in Tango. During the year ended December 31, 2020, we recorded the $<ix:nonFraction unitRef="usd" contextRef="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE1MTE_16a71bb6-14e2-41f5-9caf-9c258d8a974e">125</ix:nonFraction> million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income. In the third quarter of 2021, we made an additional $<ix:nonFraction unitRef="usd" contextRef="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE1Mjk_f0096ac0-613d-409d-aada-277e32f6d7d5">13</ix:nonFraction> million equity investment. Tango became a publicly traded company in the third quarter of 2021, and accordingly our equity investment is recorded in Prepaid and other current assets on our Consolidated Balance Sheets at fair market value as of December&#160;31, 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tango Collaboration and Stock Purchase Agreements, Gilead has the right to option up to <ix:nonFraction unitRef="program" contextRef="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817" decimals="INF" name="gild:NumberOfPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjM0MzU5MDk_70d999c6-e894-4070-998c-c3172d7ab376">15</ix:nonFraction> programs over the <ix:nonNumeric contextRef="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817" name="gild:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzU0OTc1NTgzMzE5ODA_293b516a-ebd2-4580-ba87-e2bd6fbf2a88">seven-year</ix:nonNumeric> collaboration for up to $<ix:nonFraction unitRef="usd" contextRef="i218f3bf11f8c42b7b70c818ee6cc5f8f_D20200817-20200817" decimals="-6" name="gild:EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE1NTM_0b906424-bde5-456a-8c0f-3b5fbd118946">410</ix:nonFraction> million per program in opt-in, extension and milestone payments. For the products that Tango opts to co-develop and co-promote, the parties will equally split profits and losses, as well as development costs in the U.S. For products that Tango does not opt to co-develop and co-promote, we will pay Tango up to low double-digit tiered royalties on net sales. We will provide Tango milestone payments and royalties on sales outside of the U.S. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jounce Therapeutics, Inc. (&#8220;Jounce&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, we entered into a transaction with Jounce, a publicly traded company developing novel cancer immunotherapies, which included entry into license, registration rights and stock purchase agreements (together, &#8220;Jounce License and Stock Purchase Agreement&#8221;). In October 2020, we closed this transaction and made a total payment of $<ix:nonFraction unitRef="usd" contextRef="i6623efe8bef84a7791fcfec2fcc2f16b_D20201001-20201031" decimals="-6" name="gild:TotalUpfrontPaymentsMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE1NzA_40ee5e69-f421-4cf8-b606-1902f65646fb">120</ix:nonFraction> million. We recorded $<ix:nonFraction unitRef="usd" contextRef="icb7bf0dc4a3e43daaefa71f64c8916e5_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjY3MTE_6e202f2d-ce9a-4578-a4ab-68e2ac8d8351">64</ix:nonFraction> million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income and $<ix:nonFraction unitRef="usd" contextRef="i6623efe8bef84a7791fcfec2fcc2f16b_D20201001-20201031" decimals="-6" name="gild:CashPaymentsMadeRelatedToEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE1ODg_604536e0-3518-4901-9514-401dfc4f5b05">56</ix:nonFraction> million as an equity investment in Other long-term assets on our Consolidated Balance Sheets, representing approximately <ix:nonFraction unitRef="number" contextRef="i9750074cced84b80b470f7d052116226_I20201031" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE1OTQ_bf43df15-6de1-4829-87cd-9f703b7abce3">14</ix:nonFraction>% of the issued and outstanding voting stock of Jounce immediately following the transaction, which was calculated based on Jounce&#8217;s closing stock price on the closing date of the transaction. As of December&#160;31, 2021, Jounce was eligible to receive from us up to $<ix:nonFraction unitRef="usd" contextRef="i85f6aa2b44894183be1329a1fd12b947_I20211231" decimals="-6" name="gild:PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE2NjE_abdb173a-75ec-4626-a5f4-68ee790a340b">660</ix:nonFraction> million in future potential clinical, regulatory and commercial milestone payments upon achievement of certain milestones, and royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i0cdceda2809641449fba3d06629a9552" continuedAt="if1ec7d49dff94702b18c88f36a130985"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Galapagos</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Filgotinib Collaboration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we closed a license and collaboration agreement with Galapagos, a clinical-stage biotechnology company based in Belgium, for the development and commercialization of filgotinib, a JAK1-selective inhibitor being evaluated for inflammatory disease indications (the &#8220;filgotinib agreement&#8221;). Upon closing, we made an upfront license fee payment and an equity investment in Galapagos by subscribing for <ix:nonFraction unitRef="shares" contextRef="i4143eccc523441058a76f70c0b3fe14a_I20160119" decimals="-5" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE0MDU4_49d55973-dd63-48d9-a5ac-bdcd5f2807a1">6.8</ix:nonFraction> million new ordinary shares of Galapagos at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i4143eccc523441058a76f70c0b3fe14a_I20160119" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE0MTA4_976305e6-e1f6-427c-89ef-ae365ba5bfbb">58</ix:nonFraction> per share. We amended the terms of the agreement in 2019, 2020 and 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the filgotinib agreement, as amended in 2019 (the &#8220;2019 Agreement&#8221;), we obtained an exclusive, worldwide, royalty-bearing, sublicensable license for filgotinib and products containing filgotinib. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, following a Type A meeting with FDA to discuss the points raised in the Complete Response Letter related to the New Drug Application for filgotinib in the treatment of rheumatoid arthritis, Gilead and Galapagos agreed to amend the 2019 Agreement to allow Galapagos to assume development, manufacturing, commercialization and certain other rights for filgotinib in Europe which the parties reflected in an amendment to the 2019 Agreement in December 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning on January 1, 2021, Galapagos bore the development costs for certain studies, in lieu of the equal cost split contemplated by the 2019 Agreement. The parties transferred filgotinib&#8217;s marketing authorizations in the EU and Great Britain to Galapagos in December 2021. As of January 1, 2022, all commercial economics on filgotinib in Europe transferred to Galapagos, subject to payment of tiered royalties of <ix:nonFraction unitRef="number" contextRef="i38d8e949cd7d431c99be65bf7f658b30_I20201215" decimals="2" name="gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2Mzcw_77a45880-ac7a-4f72-9d3b-1256c1ae71c3">8</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i38d8e949cd7d431c99be65bf7f658b30_I20201215" decimals="2" name="gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2Mzc2_1950e8d4-04c9-42fc-95c7-327892563e25">15</ix:nonFraction>% of net sales in Europe to Gilead, starting in 2024. In connection with the amendments to the 2019 Agreement, Gilead agreed to irrevocably pay Galapagos &#8364;<ix:nonFraction unitRef="eur" contextRef="i38d8e949cd7d431c99be65bf7f658b30_I20201215" decimals="-6" name="gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NTMx_1790dc9f-ddaa-4f35-8f78-81513ed06102">160</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="ibfef5580108a40bb81fbb13f508788a2_I20191231" decimals="-6" name="gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NTUy_36c5154e-2a3e-47f1-8fdc-aef0d650c4ee">190</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is subject to certain adjustments for higher-than-budgeted development costs. Of this total amount, Gilead paid &#8364;<ix:nonFraction unitRef="eur" contextRef="i67c0a0b9d43540d6bb4a7d7d6f17ebcc_D20210101-20210131" decimals="-6" name="gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2Njc1_030a0665-a96b-485e-95fb-dd8c4d5dec11">35</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="i67c0a0b9d43540d6bb4a7d7d6f17ebcc_D20210101-20210131" decimals="-6" name="gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2Njk2_84e5b34e-1ab4-4976-8ccc-fbfab21824ea">43</ix:nonFraction> million) in January 2021 and paid an additional &#8364;<ix:nonFraction unitRef="eur" contextRef="i67e54ce58cd24263aa47b0dc690946cc_I20210430" decimals="-6" name="gild:AdjustmentsOfBudgetedDevelopmentCostsPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NzQz_b2718b13-77f5-4dd6-b94d-0cc5ed6bfaa6">75</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="i67e54ce58cd24263aa47b0dc690946cc_I20210430" decimals="-6" name="gild:AdjustmentsOfBudgetedDevelopmentCostsPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NzY0_536a1927-b2c8-408c-8302-bd10899305da">88</ix:nonFraction> million) in April 2021 and will pay &#8364;<ix:nonFraction unitRef="eur" contextRef="i97319e361fc94cc9a211d39a12605abd_I20211231" decimals="-6" name="gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2Nzg5_58b1a5c3-4fca-4825-b69f-99e2b29847e9">50</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="i97319e361fc94cc9a211d39a12605abd_I20211231" decimals="-6" name="gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2ODEw_d8646399-f3a2-4741-b523-c5068a73279c">60</ix:nonFraction> million) in 2022. We accrued the full amount of this liability with a charge to Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. In addition, Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Collaboration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In&#160;August 2019, we closed an option, license and collaboration Agreement (the &#8220;Galapagos Collaboration Agreement&#8221;) and a subscription agreement (the &#8220;Galapagos Subscription Agreement&#8221;), each with Galapagos, pursuant to which the parties entered into a global collaboration that covers Galapagos&#8217; current and future product portfolio (other than filgotinib). Upon closing, we paid $<ix:nonFraction unitRef="usd" contextRef="i696425f28417451f92ec8151983911c1_D20190801-20190831" decimals="-7" name="gild:PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3NTUz_3ed08ae0-753a-4515-b9c2-2e8005b6c886">5.05</ix:nonFraction> billion for the license and option rights and for <ix:nonFraction unitRef="shares" contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831" decimals="-5" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3NTk4_6f844abc-16b7-494c-9a55-e3c85f2c4c2c">6.8</ix:nonFraction> million new ordinary shares of Galapagos at a subscription price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3NjYx_90a3d0c7-2630-470c-bc23-1f4862e1bc75">140.59</ix:nonFraction> per share with a fair value of $<ix:nonFraction unitRef="usd" contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831" decimals="-7" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3Njk1_5b647fd4-5e23-41ed-b2e6-8d4180dc804e">1.13</ix:nonFraction> billion, which included an issuance discount of $<ix:nonFraction unitRef="usd" contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831" decimals="-6" name="gild:Issuancediscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3NzM4_93fed1d6-6450-44f7-a085-32a6f1f594e7">63</ix:nonFraction> million calculated based on Galapagos&#8217; closing stock price on the date of closing of the Galapagos Subscription Agreement. The remaining $<ix:nonFraction unitRef="usd" contextRef="i7927d3d1315d45eab4bbe1b07f2029c6_D20190101-20191231" decimals="-7" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3ODcw_5596c32f-0e0e-4620-ad0d-6dcc59b20cc5">3.92</ix:nonFraction> billion of the payment was recorded within Acquired in-process research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2019. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Galapagos Subscription Agreement, we were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by Galapagos sufficient to bring the number of shares owned by us to <ix:nonFraction unitRef="number" contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831" decimals="3" name="gild:MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4MjIz_e964d399-7247-48ef-af16-f8f607a62455">29.9</ix:nonFraction>% of the issued and outstanding shares at the time of our exercises. In 2019, we exercised a warrant to subscribe for <ix:nonFraction unitRef="shares" contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831" decimals="-5" name="gild:InvestmentOwnedBalanceAdditionalShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4MzQy_abdc39b3-71ab-489a-b6c1-8417d5c2c01d">2.6</ix:nonFraction> million ordinary shares of Galapagos at &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4Mzc3_90a3d0c7-2630-470c-bc23-1f4862e1bc75">140.59</ix:nonFraction> per share and purchased shares on the open market with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831" decimals="-6" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4NDYy_1befe1d3-7171-411f-9961-f6c1026cd8c8">586</ix:nonFraction> million, which brought the number of shares owned by us to <ix:nonFraction unitRef="shares" contextRef="ib85c08bffd6947139520ddf1b963fae1_I20191231" decimals="-5" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4NTE2_48b35c81-02d0-4c8e-9752-4aae2e31ea59">16.7</ix:nonFraction> million or approximately <ix:nonFraction unitRef="number" contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4NTM2_12d51d33-4055-4755-be88-21cf4fdf7fe3">25.8</ix:nonFraction>% of the shares then issued and outstanding. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a <ix:nonNumeric contextRef="i696425f28417451f92ec8151983911c1_D20190801-20190831" name="gild:StandstillRestrictingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM1Mjkz_4dc0e383-a66b-4187-9fb2-b121b20e00b6">10-year</ix:nonNumeric> standstill restricting our ability to acquire voting securities of Galapagos exceeding more than <ix:nonFraction unitRef="number" contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831" decimals="3" name="gild:MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4ODY1_2eb37151-a10e-465d-827f-0b05063fe119">29.9</ix:nonFraction>% of the then-issued and outstanding voting securities of Galapagos. We agreed not to, without the prior consent of Galapagos, dispose of any equity securities of Galapagos prior to the second anniversary of the closing of the Galapagos Subscription Agreement or dispose of any equity securities of Galapagos thereafter until the fifth anniversary of the closing of the Galapagos Subscription Agreement, if after such disposal we would own less than <ix:nonFraction unitRef="number" contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831" decimals="3" name="gild:MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE5MzE2_93ef6044-6975-4a62-9d51-fb18b4da5e1e">20.1</ix:nonFraction>% of the then-issued and outstanding voting securities of Galapagos, subject to certain exceptions and termination events. In April 2021, we amended the Galapagos Subscription Agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024. We have two designees appointed to Galapagos&#8217; board of directors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The initial contractual lock-up provision for certain Galapagos shares was due to expire in August 2021. As such, $<ix:nonFraction unitRef="usd" contextRef="i2011c1fa80f041a5b06d24015e3d5227_I20201231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwMDY1Njg_315f0a22-75d5-48fd-96f3-6f33c2e536a6">351</ix:nonFraction> million was included within Prepaid and other current assets on our Consolidated Balance Sheets and the remainder of $<ix:nonFraction unitRef="usd" contextRef="i2011c1fa80f041a5b06d24015e3d5227_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwMDY1ODI_c86c99f5-0fbb-49d4-b497-d76d003025bb">1.3</ix:nonFraction> billion was included within Other long-term assets on our Consolidated Balance Sheets as of December&#160;31, 2020. Subsequent to the extension of the contractual lock-up period, all of our equity investment in Galapagos was classified to Other long-term assets on our Consolidated Balance Sheets, and was $<ix:nonFraction unitRef="usd" contextRef="ia9a5706c39e84b85ac9e1d0f522c9890_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzk4OTU2MDQ4MjY0NzU_54a22ef4-57b3-4cf0-a22f-1464beef1c39">931</ix:nonFraction> million as of December&#160;31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="if1ec7d49dff94702b18c88f36a130985" continuedAt="iefc15d0f419047848a124f762e8fe805"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos&#8217; shares. We believe the fair value option best reflects the underlying economics of the investment. During the years ended December&#160;31, 2021, 2020 and 2019, we recorded pre-tax</span><span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrealized losses of</span><span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i4db427db2e8f4ebfa1972445ce88c38c_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIwMjE4_46a663aa-ff64-41fe-adae-418e610f1b16">717</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6db86d92098f4af891245ad653df5061_D20200101-20201231" decimals="-8" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwMTQ2MzA_ba0538ad-bcf9-49d9-b7f7-bc27914f7b7e">1.8</ix:nonFraction> billion and a pre-tax unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="i6db86d92098f4af891245ad653df5061_D20200101-20201231" decimals="-8" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNTc2NjY_1ea14187-d52f-4921-bf5d-73127fb26e17">1.2</ix:nonFraction> billion, respectively, related to our investment in Galapagos in Other income (expense), net on our Consolidated Statements of Income due to changes in Galapagos&#8217; stock price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Galapagos Collaboration Agreement, we had an exclusive license for the development and commercialization of GLPG-1690, a late-stage candidate for idiopathic pulmonary fibrosis, in our territories and had an option to participate in the development and commercialization of Galapagos&#8217; other current and future clinical programs that have entered clinical development during the first ten years of the collaboration, subject to extension in certain circumstances. Gilead and Galapagos terminated the Phase 3 clinical studies with GLPG-1690 in February 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to all other programs in Galapagos&#8217; current and future pipeline, if we exercise our option to a program, we will pay a $<ix:nonFraction unitRef="usd" contextRef="i7372c5e4ed6845fca519e44a4bb17431_I20190831" decimals="-6" name="gild:PotentialOptionExerciseFeePerProgram" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxMzEw_1969d997-2150-4524-b616-9d4b623421f6">150</ix:nonFraction> million option exercise fee per program. In addition, Galapagos will receive tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="i7372c5e4ed6845fca519e44a4bb17431_I20190831" decimals="2" name="gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxNDEy_f24a4620-78d6-40a4-ac6d-1013c852606d">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i7372c5e4ed6845fca519e44a4bb17431_I20190831" decimals="2" name="gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxNDE4_907868f0-c303-4bbc-a316-de49f9680529">24</ix:nonFraction>% on net sales in our territories of each Galapagos product optioned by us. If we exercise our option for a program, the parties will share equally in development costs and mutually agreed commercialization costs incurred subsequent to our exercise of the option. We may terminate the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Janssen</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Complera/Eviplera and Odefsey</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, we entered into a license and collaboration agreement with Janssen, formerly Tibotec Pharmaceuticals, to develop and commercialize a fixed-dose combination of our Truvada and Janssen&#8217;s non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011 and is sold under the brand name Complera in the U.S. and Eviplera in the EU.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen&#8217;s rilpivirine and our emtricitabine and tenofovir alafenamide (&#8220;Odefsey&#8221;).</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party&#8217;s component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen&#8217;s share of revenues, including up to <ix:nonFraction unitRef="number" contextRef="i5dad1dfaca274c1799a38e45db78a46f_I20141231" decimals="2" name="gild:PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI0MjM5_03ea9333-b71e-406b-9132-3b43163f741c">30</ix:nonFraction>% in major markets. Sales of these products are included in Product sales and Janssen&#8217;s share of revenues is included in Cost of goods sold on our Consolidated Statements of Income. Cost of goods sold relating to Janssen&#8217;s share was $<ix:nonFraction unitRef="usd" contextRef="i45c072246c2f4e6d946c5c5570d2fed8_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA4MzE4ODI_7b49692a-43e8-42d7-909d-595d1039f341">530</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6ce860376b2440a786d96346e8ce0f89_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI0NDQ2_093c6a3c-d729-43b5-94ee-d6e8f2e00d48">570</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i578443185f7749589002f4f312b78678_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI0NDUw_87d142b4-7b83-4558-b71b-3b5097e1e7b0">574</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products, in which case Janssen has the right to become the selling party for such country if the product has launched but has been on the market for fewer than <ix:nonNumeric contextRef="i0dba157973574ff69d357c2d296e62e9_D20140101-20141231" name="gild:CollaborativeAgreementProductMarketPeriodSubjectToTermination" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjM0MzU5OTU_5a90cfe6-3a22-49ee-aeef-d433f7b35c85">10</ix:nonNumeric> years.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symtuza</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen&#8217;s darunavir and our cobicistat, emtricitabine and tenofovir alafenamide (&#8220;Gilead Compounds&#8221;). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the Gilead Compounds and are the exclusive supplier of the Gilead Compounds. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Symtuza. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="iefc15d0f419047848a124f762e8fe805" continuedAt="i7e5590efda8a49188033fc2e5c0b60f8"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party&#8217;s component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Income primarily because we supply the Gilead Compounds to Janssen for Symtuza.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than <ix:nonNumeric contextRef="i0dba157973574ff69d357c2d296e62e9_D20140101-20141231" name="gild:CollaborativeAgreementProductMarketPeriodSubjectToTermination" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjM0MzYwMDA_5a90cfe6-3a22-49ee-aeef-d433f7b35c85">10</ix:nonNumeric> years. Janssen may also terminate the entire agreement without cause. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Japan Tobacco, Inc. (&#8220;Japan Tobacco&#8221;) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2005, Japan Tobacco granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Income. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Income. Royalty expenses recognized were $<ix:nonFraction unitRef="usd" contextRef="i58b324bcac2249b5930ebbcdea8ee4c1_D20210101-20211231" decimals="-6" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA4MzE5MDM_976ea28a-5d3d-495c-b534-3e618527ee5b">250</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3bdde946e55442a1aa5d7882ec1e7427_D20200101-20201231" decimals="-6" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI4NDY1_d8d66a66-4753-4742-a7ee-f214e8861af9">291</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i00e7665e176c479ea7bb308c8eeca6b6_D20190101-20191231" decimals="-6" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI4NDY5_095c85bf-1903-4f66-a9e6-67d159f228da">358</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 agreement, we paid Japan Tobacco $<ix:nonFraction unitRef="usd" contextRef="i2d244f0e9b79475cb0ba4b314b832cfe_D20181201-20181231" decimals="-6" name="gild:InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI4OTg1_14b80878-6801-4500-9497-67f41b9a23b0">559</ix:nonFraction> million in cash and recognized an intangible asset of $<ix:nonFraction unitRef="usd" contextRef="i2d244f0e9b79475cb0ba4b314b832cfe_D20181201-20181231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI5MTIx_d52e69a8-40fd-4228-a159-b27499e49183">550</ix:nonFraction> million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over <ix:nonNumeric contextRef="i2d244f0e9b79475cb0ba4b314b832cfe_D20181201-20181231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI5MzQz_eb4a4921-9813-44a4-80e4-c2133c9c7b1d">nine years</ix:nonNumeric>, representing the period over which the majority of the benefits are expected to be derived from the applicable products in our HIV portfolio. The amortization expense is classified as selling expense and recorded as Selling, general and administrative expenses on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gadeta B.V. (&#8220;Gadeta&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we entered into a collaboration arrangement with Gadeta and made a purchase of equity in Gadeta from Gadeta&#8217;s shareholders. We determined that Gadeta was a VIE, and we were its primary beneficiary because we had the power to direct the activities of Gadeta that most significantly impact its economic performance. Upon the initial consolidation of Gadeta, we recorded $<ix:nonFraction unitRef="usd" contextRef="ie60c8cd3db5843dc97136850ade2673e_I20180731" decimals="-6" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzMwMjQ4_8668003f-c14d-4465-aebc-f7469767b933">82</ix:nonFraction> million to Noncontrolling interest, primarily reflecting acquired intangible assets related to IPR&amp;D, on our Consolidated Balance Sheets. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we effectively terminated the agreement with Gadeta. Upon the effective termination, we ceased to have a controlling interest and deconsolidated this VIE by removing the related net assets and noncontrolling interest of $<ix:nonFraction unitRef="usd" contextRef="i0ba0c9e44c9746718a04e414e6de9857_I20191231" decimals="-6" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzMwNTkx_9d309eed-d8a4-4e4b-9779-7edf158e3b25">82</ix:nonFraction> million from our Consolidated Balance Sheets. The net loss from the deconsolidation was not material.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Collaboration Arrangements That Are Not Individually Significant </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, 2020 and 2019, we entered into several collaborations, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements of $<ix:nonFraction unitRef="usd" contextRef="i5beb0d51c4e54f94969f8c6cd1ba0419_D20210101-20211231" decimals="-6" name="gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM0MTA4_1e35fc37-e05e-449d-92a2-e48fed4d330f">177</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8e25b453d1fa4d85a5dca483e607e4d9_D20200101-20201231" decimals="-6" name="gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjMyOTQ1MDc_e7b7e7f2-e735-4c88-bdf0-acc382b1b13d">129</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icde588c2a460402c9deeff992fa80573_D20190101-20191231" decimals="-6" name="gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjMyOTQ1MTE_65e5f47c-5077-4c41-8b6b-71b0512bafa6">331</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively, within Acquired in-process research and development expenses on our Consolidated Statements of Income. Cash payments for our equity investments, other than those noted above, during the years ended December&#160;31, 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i5beb0d51c4e54f94969f8c6cd1ba0419_D20210101-20211231" decimals="-6" name="gild:CashPaymentsMadeRelatedToEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM0MzM1_a3c31b86-c9fa-4bf5-b981-72e96f032b49">147</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8e25b453d1fa4d85a5dca483e607e4d9_D20200101-20201231" decimals="-6" name="gild:CashPaymentsMadeRelatedToEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM0MzM5_d8dd2353-3ca3-4df9-9247-7bdf3db4c409">72</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icde588c2a460402c9deeff992fa80573_D20190101-20191231" decimals="-6" name="gild:CashPaymentsMadeRelatedToEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM0MzQ2_e959091a-5991-4970-ba78-f9279bcda94c">118</ix:nonFraction> million, respectively, which were primarily recorded within Prepaid and other current assets and Other long-term assets on our Consolidated Balance Sheets. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7e5590efda8a49188033fc2e5c0b60f8">Under the financial terms of these arrangements, we may be required to make payments upon achievement of various developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Consolidated Statements of Income when the corresponding events become probable. In connection with the regulatory approvals, milestone payments made will be capitalized as intangible assets and will be amortized to Cost of goods sold through the terms of these collaboration arrangements. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty.</ix:continuation> </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_130"></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2ODc_b609255d-0d88-42f1-9ddd-05d9ac99eac5" continuedAt="i947d0dd8aba7405dadca87a66f207864" escape="true">DEBT AND CREDIT FACILITIES</ix:nonNumeric></span></div><ix:continuation id="i947d0dd8aba7405dadca87a66f207864" continuedAt="ia351f2e86d9c45018c3047f881babae3"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2NjQ_842fe4ce-ce42-45fd-9fbe-94df663ca222" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88553ac9d9624f42958c6f396678542b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzQtNi0xLTEtMTIxNDA_4b3cd12c-8016-4f16-baba-8133bd9ee120">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88553ac9d9624f42958c6f396678542b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzQtOC0xLTEtMTIxNDA_fc1eeeb5-7634-4851-9a72-f1695be3d811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4800b053ef3c4136a3cc63c8103e707a_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzQtMTAtMS0xLTEyMTQw_38d3e032-f5c7-4b58-82cf-2f71ce41af2d">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + <ix:nonFraction unitRef="number" contextRef="i15ff3826397c4b51af10501cdfc1ffbd_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzUtNi0xLTEtMTIxNDAvdGV4dHJlZ2lvbjpkZDAwMzZhZjQwNTE0MWQ1YTJhNjM2MDU0ZDQ4MmIxZV8yMA_b27a6d93-0264-4bd1-bfcb-b72cfd0bd4ac">0.15</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90520151d5e45a5b3bafe9e36c40ab1_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzUtOC0xLTEtMTIxNDA_54b67149-7787-4fb8-8013-77c5addec42a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbd11fa3c26e4fd38091c2e840bb69d9_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzUtMTAtMS0xLTEyMTQw_02de088f-b6a6-4282-a1f9-956b9ddc1ae9">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if49d256ecf4c4fccb417a3006ed896b7_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzYtNi0xLTEtMTIxNDA_4ef552c0-625a-4a4f-90c6-6cfeb532aee7">4.40</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49d256ecf4c4fccb417a3006ed896b7_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzYtOC0xLTEtMTIxNDA_6336878b-e390-4e66-80ed-f19780024217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d9c33739db4dc08bf4edd765bd7407_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzYtMTAtMS0xLTEyMTQw_6da07ff8-7a23-4f15-945e-b356c211e620">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if32ef749e53840578fa5654cc25b8c69_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzctNi0xLTEtMTIxNDA_ae475008-abbf-4f64-a476-5737f15a28b2">1.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if32ef749e53840578fa5654cc25b8c69_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzctOC0xLTEtMTIxNDA_187dd779-e7c7-4304-b249-c6f64b658975">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43afc0414e494b869b770762bc4d9a52_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzctMTAtMS0xLTEyMTQw_1ceb2caf-833c-495a-9311-f28d2b1a6f03">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51ed2cd34ce84554940fc25d819f2777_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzgtNi0xLTEtMTIxNDA_90699933-44cc-41c3-b61d-44ad2e3b8dd1">3.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ed2cd34ce84554940fc25d819f2777_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzgtOC0xLTEtMTIxNDA_cddf2c38-a653-48d3-8547-e7d3b244155d">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab69215b4e64f54a4722114423cf768_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzgtMTAtMS0xLTEyMTQw_5595a618-d0ad-4900-a65f-577d73880b86">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia79e2cc5633d4132a25a764b4a709783_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzktNi0xLTEtMTIxNDA_cb3f14c6-ac75-42b8-9e46-ba46b82872c2">2.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia79e2cc5633d4132a25a764b4a709783_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzktOC0xLTEtMTIxNDA_e5c180f9-0b81-4699-ad13-baea263a4e39">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6efa694deb2427e8f5f99cf4f174aa3_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzktMTAtMS0xLTEyMTQw_08955d50-8157-43b1-aff8-65124a5b2e52">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + <ix:nonFraction unitRef="number" contextRef="i4db7fc21d050453fb55088da46769875_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEwLTYtMS0xLTEyMTQwL3RleHRyZWdpb246NGU5OWRlNTFhMWYxNDcyOTg1NTM5NTBiZDAzZTIyYWVfMjA_829ec86b-1268-4ed5-9c83-1eaca27a63af">0.52</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57ff25bef0d4bf4a3e07a11a72aa1c4_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEwLTgtMS0xLTEyMTQw_434a5cc5-eb03-4cdf-b8ac-645893ec8204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fe7b7bd7a749eca2309daea67e59ca_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEwLTEwLTEtMS0xMjE0MA_9f2544c9-c6ba-4002-bca0-f1d7e2cafaf8">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff239ca5ea6542a1b65cc0ff2d9218fd_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzExLTYtMS0xLTEyMTQw_ff076239-5ae5-4978-996b-693bcb4b33d9">0.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff239ca5ea6542a1b65cc0ff2d9218fd_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzExLTgtMS0xLTEyMTQw_ff1b2a94-3522-4301-aa8f-e54e27397065">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f46a74be3740deb3686fa5d733f011_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzExLTEwLTEtMS0xMjE0MA_ba7aae20-36f4-4e64-bca3-fe1dc649d9a4">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dea7ef2353348b9b97eb413fb4c0d7b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEyLTgtMS0xLTEyMTQw_b9791fba-1861-4263-a272-b50f7bad2c3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85abfdacc7a34da5888f65dc84ca6fca_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEyLTEwLTEtMS0xMjE0MA_fa67e811-081e-470c-8c8f-e855525bd80e">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20a94020fb22453791fa3f7a17071381_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEzLTYtMS0xLTEyMTQw_23de4d7b-ca7e-4011-892d-c1a3de21dc24">3.70</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a94020fb22453791fa3f7a17071381_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEzLTgtMS0xLTEyMTQw_5ad840bb-3d2a-4b3f-ad5f-3b4f8cd9874d">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44be2f180cd740a2817d4a90b827ce9c_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEzLTEwLTEtMS0xMjE0MA_a30f5f8b-dce3-4933-9f6a-2bfbcb99b763">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5f33f1a524c46ef989dcaf10d803a74_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE0LTYtMS0xLTEyMTQw_79616797-2071-4f24-9bf8-cac8225e0e0a">3.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5f33f1a524c46ef989dcaf10d803a74_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE0LTgtMS0xLTEyMTQw_63f26b62-0d6a-4bbe-be6a-9cd90d60b724">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05fed16be294c6fb4bbc7419f3eaef4_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE0LTEwLTEtMS0xMjE0MA_cd26ef0e-5d42-48d0-bed0-d2391bd3e440">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e4a183e1199483b92ed085372e796c5_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE1LTYtMS0xLTEyMTQw_67b1ec99-3b86-4a5c-828c-87c260816f5f">3.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4a183e1199483b92ed085372e796c5_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE1LTgtMS0xLTEyMTQw_6e0a326b-aa93-4ca5-8cea-9222654abd31">2,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb302b98be6d4fe8bcaa37065ebb5a54_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE1LTEwLTEtMS0xMjE0MA_ba722c59-0703-4507-bd65-3527ebcc098c">2,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib60a477703704a5b8d5fee9be6c07b0f_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE2LTYtMS0xLTEyMTQw_b96eef04-52f0-47e3-bb43-5fb34c4c35ff">2.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib60a477703704a5b8d5fee9be6c07b0f_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE2LTgtMS0xLTEyMTQw_55ef91f7-e86f-4eaa-8bd0-2e256d3f6e9a">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d459efd6b0147f8b01649f355747ec3_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE2LTEwLTEtMS0xMjE0MA_d926c0c1-697e-4f8a-bb39-52407b95e2ed">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5fc6d5d4b12c47c9a6edd38827bfbdce_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE3LTYtMS0xLTEyMTQw_9a77c4dd-328d-42c7-827d-ea1ec0e09efe">1.20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc6d5d4b12c47c9a6edd38827bfbdce_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE3LTgtMS0xLTEyMTQw_98ccafa3-d133-4c24-b312-694efbc8b7a2">746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa4722d53ca492d86cb72a4394bdad1_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE3LTEwLTEtMS0xMjE0MA_b4106f51-7954-4907-88d7-c859a97cb0a9">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ee4ce7cca0b42fc81e5cae1b1b19a25_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE4LTYtMS0xLTEyMTQw_6ae212ea-b00e-4c68-95c1-5217efd98e26">1.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee4ce7cca0b42fc81e5cae1b1b19a25_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE4LTgtMS0xLTEyMTQw_61a99cd2-77fa-4036-bc84-9586473fa7c1">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c38cd0fcf7429e905732a6030b0115_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE4LTEwLTEtMS0xMjE0MA_cc97f245-b24c-4b8d-9cb7-ef8b9f895bb0">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99ac4c08ddd043138479c7a929366808_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE5LTYtMS0xLTEyMTQw_c7f0160c-1a5d-4d3e-b444-3cf3046fcda6">4.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ac4c08ddd043138479c7a929366808_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE5LTgtMS0xLTEyMTQw_21ccc378-04f1-42ec-a9b6-70a04e785c60">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7107a8f3798a4b4f85c5c3934cc538a6_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE5LTEwLTEtMS0xMjE0MA_e81655d9-3757-476f-a8e8-8eb0c1b47f52">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42c4206352ed45c49b1ffe6a976a0723_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIwLTYtMS0xLTEyMTQw_a15a25f5-6797-4042-8d9f-423e5d8c0414">4.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c4206352ed45c49b1ffe6a976a0723_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIwLTgtMS0xLTEyMTQw_f14947d9-be96-4620-9325-fff55c7dc2be">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i067ec910ab5441abb89d5d73967bc967_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIwLTEwLTEtMS0xMjE0MA_2c8068cb-656b-4980-8a1c-6455e6b32848">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738af8e5e5d481482a0aff98aacdf90_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIxLTYtMS0xLTEyMTQw_b9976d89-c157-4309-a23d-5823f88f09b6">2.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738af8e5e5d481482a0aff98aacdf90_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIxLTgtMS0xLTEyMTQw_1b0c4092-a347-4409-9b36-c3078bbec19e">987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d50e8b499914bcd8bf4ea2da01301ea_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIxLTEwLTEtMS0xMjE0MA_369b0ef2-a5b7-40d0-aeb5-6ab4ccf1747a">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i671b7a2302524fd38cee3f6ff2f98b3c_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIyLTYtMS0xLTEyMTQw_1ca9506b-2ba4-48e3-8399-85281db38305">5.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i671b7a2302524fd38cee3f6ff2f98b3c_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIyLTgtMS0xLTEyMTQw_c37e92c8-58d4-4b4c-a461-b44ff9a667c5">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78530d2e8d6b45118714c099f29d8e67_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIyLTEwLTEtMS0xMjE0MA_c9881492-e30d-421c-afc1-0dc3c43985c3">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00e1ab6155ce4b2ca7387b0e499b13ca_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIzLTYtMS0xLTEyMTQw_e9e75488-e9d4-4638-bcc3-61241f3dbf9d">4.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e1ab6155ce4b2ca7387b0e499b13ca_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIzLTgtMS0xLTEyMTQw_4fbba01e-c2a4-4966-a1c7-f98448750317">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8027a7afa87d4545a246f3cfa058ecc1_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIzLTEwLTEtMS0xMjE0MA_3a3d6775-511f-4f53-b39f-773c523a07a7">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i775bc80f0b4046eb933f175fa23054be_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI0LTYtMS0xLTEyMTQw_9bbcea90-d5d0-49eb-84ae-b077b76511dc">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775bc80f0b4046eb933f175fa23054be_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI0LTgtMS0xLTEyMTQw_91eb6b91-2e51-4b48-961d-edf9f0fce1fd">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i600f96952ca74888901fe56db25f0a9f_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI0LTEwLTEtMS0xMjE0MA_29a7724f-0580-43f8-8bbd-d2c69f8b1691">1,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80a1b0b283de4323a915636bf3154c0b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI1LTYtMS0xLTEyMTQw_7a6f599f-ea60-4923-85b8-61292d04b83c">4.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a1b0b283de4323a915636bf3154c0b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI1LTgtMS0xLTEyMTQw_23f2f9d4-d432-46b4-b730-a0953e519ba7">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e9c5b3387647bbbf9a05d29bc125b0_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI1LTEwLTEtMS0xMjE0MA_edf8c2e6-8eea-4d04-9788-10a0c7231b0a">2,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i48f7619e739144e8ad45877990dc8b4d_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI2LTYtMS0xLTEyMTQw_5cd6206b-a024-46d3-9f22-d990e85c05f8">4.15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f7619e739144e8ad45877990dc8b4d_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI2LTgtMS0xLTEyMTQw_7f091916-f0b4-49bf-9cd5-467dbc518665">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6efa1b3c097d4e8bbb0044de2e0eb97e_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI2LTEwLTEtMS0xMjE0MA_f70cbc7f-f305-457e-ae19-904886f00d15">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00f996e674334831a4b702a6dab1227c_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI3LTYtMS0xLTEyMTQw_4f86037a-553b-4c54-bcf2-e9822dd06125">2.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f996e674334831a4b702a6dab1227c_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI3LTgtMS0xLTEyMTQw_6f881b8d-63ab-4e45-8eb8-d34da28f0979">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8731d482f54944dcbc86441135f6aadf_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI3LTEwLTEtMS0xMjE0MA_999dc90a-6f0d-44e3-aba6-138825e6c6f7">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes and term loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30937e6ac3d4bb5a4c2184d7905886c_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI4LTgtMS0xLTEyMTQw_a9e1e180-0ba0-45fd-a796-ace3c0483147">25,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i452b8349934f45998316aa6b615f395c_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI4LTEwLTEtMS0xMjE0MA_38fa3162-b5d1-41cc-b3be-d7128159e797">30,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9268c9e7d32a4d089a0df68305d6cdd8_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI5LTgtMS0xLTEyMTQw_bccd36ff-99e9-485e-a668-8caf989a963d">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icde2c819b2eb481a82769fd804c55108_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI5LTEwLTEtMS0xMjE0MA_e967c4f5-34cf-424c-bd30-ccbb1c20d704">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzMwLTgtMS0xLTEyMTQw_bbce3eb5-675f-4f35-b802-403513bef0e4">26,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzMwLTEwLTEtMS0xMjE0MA_03aa9a1d-5382-452b-81c5-35a56745656e">31,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt and other obligations, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzMxLTgtMS0xLTEyMTQw_e184d12b-8dfb-4073-b84c-2c616173b153">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzMxLTEwLTEtMS0xMjE0MA_837a5937-0e6d-4eaa-ade7-9966e119a1a1">2,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzMyLTgtMS0xLTEyMTQw_3815efb0-7565-40d5-9802-a0369003ae9c">25,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzMyLTEwLTEtMS0xMjE0MA_02efbb88-1878-4e34-b9c2-47432ce849fd">28,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes and Term Loan Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we repaid $<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-7" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzgyNDYzMzcyNTA0MTc_9f07faf4-f3a1-4d8b-8975-6225a80b342d">4.75</ix:nonFraction> billion of debt, consisting of $<ix:nonFraction unitRef="usd" contextRef="idb910542d9424ab9b95e5810565ad466_D20210101-20211231" decimals="-7" name="us-gaap:RepaymentsOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTQ3MjA_90dace5e-4974-4f13-b631-13641ac303bd">3.75</ix:nonFraction> billion senior unsecured notes and $<ix:nonFraction unitRef="usd" contextRef="iebf9a43b220342c69783776e723e023f_D20210101-20211231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzgyNDYzMzcyNTAzOTk_661616c3-c4ab-44d5-a7be-0f6ea39d98df">1.0</ix:nonFraction> billion of our senior unsecured term loan facility. We repaid $<ix:nonFraction unitRef="usd" contextRef="i81f6869ed0c24ce4871816f7d2e7cb43_D20210101-20210331" decimals="-8" name="us-gaap:RepaymentsOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTM4NDU_c1ce5748-7361-4cb0-9ff7-78b8e1327645">1.0</ix:nonFraction> billion of senior unsecured notes due April 2021 in the first quarter of 2021 and $<ix:nonFraction unitRef="usd" contextRef="iba530d87b0864376a38558b02d16b8c3_D20210701-20210930" decimals="-7" name="us-gaap:RepaymentsOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTM4NTI_95e2f4da-80eb-4b7b-8404-32c32a2f453c">1.25</ix:nonFraction> billion of senior unsecured notes due December 2021 in the third quarter of 2021. Additionally, we repaid $<ix:nonFraction unitRef="usd" contextRef="i4a350670d64d4f1e800774de0810abc7_D20210901-20210930" decimals="-6" name="us-gaap:RepaymentsOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTM4NjE_62e58ef7-6f9b-45f7-bc3c-c84c1b2e21f7">500</ix:nonFraction> million of senior unsecured floating rate notes due upon maturity in September 2021. In October 2021, we exercised our option to call $<ix:nonFraction unitRef="usd" contextRef="id678a65bd8bf4578bec8bbcc0aa50cc6_D20211001-20211031" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTM4NzM_12d7d6ec-33a6-4315-bc37-5d6e9ab36026">500</ix:nonFraction> million of senior unsecured floating rate notes and $<ix:nonFraction unitRef="usd" contextRef="if2318fc40c5a4044a5e207e06b104152_D20211001-20211031" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTM4Nzg_a38a6ca1-6dc8-491c-8b6d-c554a2e42c67">500</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="iff239ca5ea6542a1b65cc0ff2d9218fd_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2Xzc2OTY1ODE0Mzc2MzY_ef83971e-093a-43d2-97d5-f8a04ad66a6e">0.75</ix:nonFraction>% senior unsecured notes, both having a final maturity date of September 2023. These <ix:nonFraction unitRef="repayment" contextRef="ide0591f02f274c108fd4f307409ea95c_D20211001-20211231" decimals="INF" name="gild:NumberOfEarlyRepaymentsOfLongTermDebt" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU0OTc1NTgxODE1NDg_9af9bf13-4312-4c22-9332-d407df6fa57d">two</ix:nonFraction> early repayments totaling $<ix:nonFraction unitRef="usd" contextRef="ide0591f02f274c108fd4f307409ea95c_D20211001-20211231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzgyNDYzMzcyNTA0NTM_7551c76d-87d7-4187-ba76-f6911b8d4e91">1.0</ix:nonFraction>&#160;billion principal amount were made in the fourth quarter of 2021. In December 2021, we exercised our option to call $<ix:nonFraction unitRef="usd" contextRef="i2149910737774396859ee858a7be3b62_D20211201-20211231" decimals="-6" name="us-gaap:RepaymentsOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTQyNjg_a55b278f-e100-4bc7-8b13-5d24de68c999">500</ix:nonFraction> million of senior unsecured notes having a final maturity of March 2022. The notes were repaid in February 2022. <ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="INF" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIzNjM5NTAwMDQwMDcw_30f593b7-700e-4238-a5a7-aa404d0afd33">No</ix:nonFraction> new debt was issued in 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ia351f2e86d9c45018c3047f881babae3" continuedAt="i64b69775c92245be8b787d60c038747e"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our senior unsecured fixed rate notes may be redeemed at our option at a redemption price equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="idb910542d9424ab9b95e5810565ad466_D20210101-20211231" decimals="3" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzEyMTc_9e019f79-4c2e-484b-8b52-d7b73be72276">100</ix:nonFraction>% of the principal amount of the notes to be redeemed and (ii) the sum, as determined by an independent investment banker, of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium as defined in the indenture. The senior unsecured fixed rate notes also have a call feature, exercisable at our option, to redeem the notes at par in whole, or in part, on dates ranging from <ix:nonNumeric contextRef="i23a0d3b2005a437792898712c9d8fd19_D20210101-20211231" name="gild:DebtInstrumentCallFeaturePeriodBeforeMaturity" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzE4MDY_c3e93f22-6ecd-4cd9-b073-6e1a9cd67108">one month</ix:nonNumeric> to <ix:nonNumeric contextRef="i42858b3c72b14dd29fd0366fad42b66d_D20210101-20211231" name="gild:DebtInstrumentCallFeaturePeriodBeforeMaturity" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzE4MTI_4a84a2f2-9785-4d6a-8494-ec68949c8762">two years</ix:nonNumeric> prior to maturity. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption. The $<ix:nonFraction unitRef="usd" contextRef="iff239ca5ea6542a1b65cc0ff2d9218fd_I20211231" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzE2NDkyNjc0ODQ3Mzc_5577b192-554b-4272-bf5f-7611b04a76a7">1.5</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="iff239ca5ea6542a1b65cc0ff2d9218fd_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2Xzc2OTY1ODE0Mzc2MzA_ef83971e-093a-43d2-97d5-f8a04ad66a6e">0.75</ix:nonFraction>% senior unsecured notes due September 2023 also have a call feature, exercisable at our option, to redeem the notes at par, in whole or in part, after September 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of the occurrence of a change in control and a downgrade in the rating of our senior unsecured notes below investment grade by Moody&#8217;s Investors Service, Inc. and S&amp;P Global Ratings, the holders may require us to purchase all or a portion of their notes at a price equal to <ix:nonFraction unitRef="number" contextRef="idb910542d9424ab9b95e5810565ad466_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzI0MDA_d58ab0d2-9a17-4624-a89f-e16c79bd416d">101</ix:nonFraction>% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest to the date of repurchase. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of December&#160;31, 2021 and 2020, we were not in violation of any covenants.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a commitment letter with a group of institutional lenders to provide for a <ix:nonNumeric contextRef="i9b6ed812482443698e8524ebc5028ef4_D20200901-20200930" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2NzU_e13ca8f2-0849-4e96-9cab-8ba88da6b18b">three-year</ix:nonNumeric> senior unsecured term loan facility in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i3e04a1496e924fd6aaa5cf09f6d3974b_I20200930" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzI4Nzg_b5ec3789-faa9-47ba-b924-5e895d74eb00">1.0</ix:nonFraction>&#160;billion. In October 2020, in connection with our acquisition of Immunomedics, we entered into a term loan credit agreement (the &#8220;Term Loan Facility&#8221;) and borrowed an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ib86f88f4366542d4b2110433d8eb2472_I20201031" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzMxMDQ_134cc8f5-8627-4147-9941-dc930062c521">1.0</ix:nonFraction>&#160;billion. In 2021, we repaid $<ix:nonFraction unitRef="usd" contextRef="iebf9a43b220342c69783776e723e023f_D20210101-20211231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTQ3ODk_661616c3-c4ab-44d5-a7be-0f6ea39d98df">1.0</ix:nonFraction> billion principal amount outstanding under the Term Loan Facility which was due upon maturity in October 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics, we assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI, prior to our acquisition of Immunomedics. The liability related to future royalties was primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 6. Acquisitions for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revolving Credit Facilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we terminated our $<ix:nonFraction unitRef="usd" contextRef="i6a0dca0a129d4621881c8db9cee9561b_I20160531" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzEwOTk1MTE2NjQ2NDE_0af1ce89-5650-417c-a73a-2efe33b5f5e0">2.5</ix:nonFraction> billion <ix:nonNumeric contextRef="i424653e19ba342da9528563065ececec_D20160531-20160531" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU0OTc1NTgxODE1NTc_174dcad7-9146-4240-b841-9ea833036811">five-year</ix:nonNumeric> revolving credit facility maturing in May 2021 (the &#8220;2016 Revolving Credit Facility&#8221;) and entered into a new $<ix:nonFraction unitRef="usd" contextRef="iebfeba12e19f4f08b20c868b3c5aae4f_I20200630" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzEwOTk1MTE2NjQ2NzA_a7581910-204c-4b40-abe4-ba5d05d5c713">2.5</ix:nonFraction> billion <ix:nonNumeric contextRef="ibc9ab8f16b194dca9d59c47d3bca5701_D20200601-20200630" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU0OTc1NTgxODE1NTY_2ced2916-a42a-4797-8c3a-465bc3aa8dd8">five-year</ix:nonNumeric> revolving credit facility maturing in June 2025 (the &#8220;2020 Revolving Credit Facility&#8221;). The 2020 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of December&#160;31, 2021 and 2020, there were <ix:nonFraction unitRef="usd" contextRef="ie345d4f41b194bbebb717ccc62b975f2_I20201231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzEwOTk1MTE2NjQ2NTU_39aa6f2e-ba40-4d1a-8e28-e3a47daa1f14"><ix:nonFraction unitRef="usd" contextRef="i811b6102317d403db8c7febef98c0b3d_I20211231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzEwOTk1MTE2NjQ2NTU_ea0ce473-1613-473d-928b-ee816dc8c2e6">no</ix:nonFraction></ix:nonFraction> amounts outstanding under the 2020 Revolving Credit facility.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Revolving Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default. As of December&#160;31, 2021, we were in compliance with all covenants. Loans under the 2020 Revolving Credit Facility bear interest at either (i) the Eurodollar Rate plus the Applicable Percentage, or (ii) the Base Rate plus the Applicable Percentage, each as defined in the 2020 Revolving Credit Facility agreement. We may terminate or reduce the commitments, and may prepay any loans under the credit facility in whole or in part at any time without premium or penalty.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Maturities of Financing Obligations</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2ODA_34765bed-c924-4805-b5d3-5cb8cd1818aa" escape="true"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate future principal maturities of our senior unsecured notes as of December&#160;31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzEtMi0xLTEtMTIxNDA_873afb90-cc4a-4b73-963f-fb7e5b1436f6">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzItMi0xLTEtMTIxNDA_42fa73e7-4719-408a-b659-be8e37837e65">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzMtMi0xLTEtMTIxNDA_a5d50c6f-10ca-4a9e-91c0-2d491db5c42e">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzQtMi0xLTEtMTIxNDA_d35c9614-fc83-4eda-91f5-7c1b522d4e9d">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzUtMi0xLTEtMTIxNDA_25abca2f-81c5-42d6-ab5a-4ee6249655ca">2,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzYtMi0xLTEtMTIxNDA_66e3a622-39d0-4b52-8b1a-169497f00526">15,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzctMi0xLTEtMTIxNDA_44c842ba-657f-45e3-8f27-3684cd3bcaa5">25,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div></ix:continuation><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i64b69775c92245be8b787d60c038747e">Interest expense on our debt and credit facilities related to the contractual coupon rates and amortization of the debt discount and issuance costs was $<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:InterestExpenseLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2MTY_3862f767-4bd5-4001-a6fc-16d14bc03dbc"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2MTY_76c863bc-f858-47a2-ae01-7aff6ee45f09"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2MTY_88aac6a2-30c6-4579-9eda-dd62d97f7fa7">1.0</ix:nonFraction></ix:nonFraction></ix:nonFraction> billion in 2021, 2020 and 2019.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzg4Ng_e8ccf249-8647-44f5-a08a-a58220465161" continuedAt="ie3ab820b39254afe9313b9612f488165" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="ie3ab820b39254afe9313b9612f488165"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases consist primarily of properties and equipment for our administrative, manufacturing and R&amp;D activities. Some of our leases include options to extend the terms for up to <ix:nonNumeric contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzIwMg_6fbcda29-cc43-4625-a6c9-1f19f2fa1b02">15</ix:nonNumeric> years and some include options to terminate the lease within <ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseOptionToTerminate" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzIxOTkwMjMyNTY2Mjk_4c849f7f-a382-439f-8b97-6f250c34829a">one year</ix:nonNumeric> after the lease commencement date. As of December&#160;31, 2021 and 2020, we did not have material finance leases. Operating lease expense, including variable costs and short-term leases, was $<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzQzMw_d962d120-4c09-4960-9a40-5c11105026ea">156</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzQ0MA_88d4be26-d392-4eb9-b00c-b090b0ae4ad7">171</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzI3NDg3NzkwNzAzOTA_7563ce5c-da3b-4730-a176-6ef751b26262">162</ix:nonFraction> million in 2021, 2020 and 2019, respectively. </span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzg4NA_4da862b7-8451-4386-9b4f-eb91b85378a8" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balance sheet and other information related to our operating leases:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.109%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except weighted average amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_bf1a57bf-a703-4b3f-bc9b-0294a5049060"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_c74f8a0a-3c1e-43dc-9a44-91448c3a81f3">Other long-term assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItNC0xLTEtMTIxNDA_7d043954-64b6-4a85-b9c9-5eb001df7214">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItNi0xLTEtMTIxNDA_44c40ad7-f528-4133-9bd4-1b628ffe8f0d">646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_3f97a2d5-98a1-46a4-8619-f3becdea71f5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_c90d340b-270c-4dd6-bbe4-3b313ad42434">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtNC0xLTEtMTIxNDA_727d0cab-71da-4e1c-aee4-a1629a8f2823">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtNi0xLTEtMTIxNDA_1ff9f279-1277-44f9-bece-e256026d7d98">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_511d014a-a5ee-4a2c-a65f-0d75ca7b60e9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_7e2903b1-a222-4253-bf44-fbb3ee9aa161">Other long-term obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtNC0xLTEtMTIxNDA_8098ca2e-406c-4012-b83c-4d7a02925557">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtNi0xLTEtMTIxNDA_2c7f0e3f-e392-4a76-806b-c946f68a93d0">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzUtNC0xLTEtMTIxNDA_4981a080-cf21-464c-bcd5-55aa3fda447f">8.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzUtNi0xLTEtMTIxNDA_28565fd4-4785-4711-9e10-433c307342e0">8.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzYtNC0xLTEtMTIxNDA_96c5f623-d6d5-474c-9a3d-7e3f96e5d27f">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzYtNi0xLTEtMTIxNDA_cbc66691-0b84-4410-b670-77b83cea25a2">3.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to our operating leases:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTo1NjUxYzlhOTRjMzg0ZmNlYjIwZjE5NTdlODhmYmY2Mi90YWJsZXJhbmdlOjU2NTFjOWE5NGMzODRmY2ViMjBmMTk1N2U4OGZiZjYyXzItMi0xLTEtMTIxNDA_a523ad3d-0a5c-43db-b9df-0336c5d35831">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTo1NjUxYzlhOTRjMzg0ZmNlYjIwZjE5NTdlODhmYmY2Mi90YWJsZXJhbmdlOjU2NTFjOWE5NGMzODRmY2ViMjBmMTk1N2U4OGZiZjYyXzItNC0xLTEtMTIxNDA_4d5b8032-3e5a-4fe5-82c1-52d84aefb273">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTo1NjUxYzlhOTRjMzg0ZmNlYjIwZjE5NTdlODhmYmY2Mi90YWJsZXJhbmdlOjU2NTFjOWE5NGMzODRmY2ViMjBmMTk1N2U4OGZiZjYyXzMtMi0xLTEtMTIxNDA_fe21b4b2-8afb-4cc1-87bd-171b9c599af9">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTo1NjUxYzlhOTRjMzg0ZmNlYjIwZjE5NTdlODhmYmY2Mi90YWJsZXJhbmdlOjU2NTFjOWE5NGMzODRmY2ViMjBmMTk1N2U4OGZiZjYyXzMtNC0xLTEtMTIxNDA_6615068c-8d7a-4eff-af5c-428734fa712e">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzg4NQ_27f549e2-06f0-40ae-afa8-674cb346b45f" escape="true"><div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzEtMi0xLTEtMTIxNDA_44dec94e-5241-46ce-98a6-d2a6c574465b">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzItMi0xLTEtMTIxNDA_b5e69769-28ac-4019-94ea-df5b725c7061">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzMtMi0xLTEtMTIxNDA_ec7177a8-0be7-4501-9d2d-651f9a876ac6">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzQtMi0xLTEtMTIxNDA_940624c8-d1eb-445e-a6c6-73929214e50e">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzUtMi0xLTEtMTIxNDA_2c46b73b-a8a6-4dbe-87bc-c0a7cf81aa50">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzYtMi0xLTEtMTIxNDA_0105a35f-74b3-4192-8cea-a556582a6de7">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzctMi0xLTEtMTIxNDA_2caa48f4-8f7c-451f-a0be-d0394de78951">677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzgtMi0xLTEtMTIxNDA_c685bbd8-9d76-47c6-98b3-c8bc20cc02f3">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total discounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzktMi0xLTEtMTIxNDA_d4c19113-4d6d-4ff8-9697-57824bb86314">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i72faa4a0a4974dcca6db2bf491b63d7a_139"></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI1NTU4_98b3a623-14d4-4ed8-9baf-3c82e8c2534a" continuedAt="i69258cac753544ada06b07400424b6d5" escape="true">COMMITMENTS AND CONTINGENCIES </ix:nonNumeric></span></div><ix:continuation id="i69258cac753544ada06b07400424b6d5" continuedAt="i6f82b1ee855e4cd49f8e5b4678421b66"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2021, we reversed a $<ix:nonFraction unitRef="usd" contextRef="i3a0a5d98945240a491ca261188cf0b76_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzEwOTk1MTE3ODQ4MjI_fe409b27-9260-473a-bd47-0e35b3f89f65">175</ix:nonFraction> million previously recorded litigation accrual following a favorable court decision for the litigation related to axicabtagene ciloleucel described below. In the fourth quarter of 2021, we recorded an accrual of $<ix:nonFraction unitRef="usd" contextRef="i3f4cd81637934eb4bfcfc5bb4da29021_D20211001-20211231" decimals="-7" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI3NDg3NzkyMjUwNzQ_fac5c1b1-1c3c-45f8-bbd4-938e9441ffad">1.25</ix:nonFraction> billion in Accrued and other current liabilities on our Consolidated Balance Sheets for the settlement related to bictegravir litigation described below.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i6f82b1ee855e4cd49f8e5b4678421b66" continuedAt="icad0081866264bbe867a375b6181342d"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concludes the inter partes review that it has initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#8217;s patent invalid. In July 2021, the University appealed this decision. The litigation in the U.S. District Court will remain stayed through the appeal proceedings.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with NuCana plc. (&#8220;NuCana&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuCana has obtained European Patent No. 2,955,190 (the &#8220;EP &#8217;190 patent&#8221;) that allegedly covers sofosbuvir. In opposition proceedings before the European Patent Office (&#8220;EPO&#8221;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#8217;190 patent in amended form. We believe that the amended EP &#8217;190 patent claims are invalid. Subsequently, we initiated proceedings to invalidate the UK counterpart of the EP &#8217;190 patent in the High Court of England &amp; Wales. In March 2021, NuCana filed a counterclaim against us in the High Court of England &amp; Wales alleging patent infringement of the UK counterpart and seeking damages and other relief. In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#252;sseldorf alleging patent infringement of the German counterpart of the EP &#8217;190 patent and seeking damages and injunctive relief. The hearing date for the German NuCana case has been scheduled for May 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hearing date for the UK NuCana case has been scheduled for January 2023.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Axicabtagene Ciloleucel</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#8220;&#8217;190 patent&#8221;). A jury trial was held on the &#8217;190 patent, and in December 2019, the jury found that the asserted claims of the &#8217;190 patent were valid, and that we willfully infringed the asserted claims of the &#8217;190 patent. The jury also awarded Juno damages in amounts of $<ix:nonFraction unitRef="usd" contextRef="i06eb7508edc54e1d963da3d320aa56cd_D20191201-20191231" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzEwOTk1MTE3ODQxMzU_06f31cd4-2f5b-4e2f-9abe-cc18357028b1">585</ix:nonFraction> million in an upfront payment and a <ix:nonFraction unitRef="number" contextRef="i06eb7508edc54e1d963da3d320aa56cd_D20191201-20191231" decimals="3" name="gild:JudgmentRoyaltyRateFromOctober2017" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzM0NjM0NjE2NDQ2ODE0_690ee76e-4415-4608-85cd-9c7ed648edbe">27.6</ix:nonFraction>% running royalty from October 2017 through the date of the jury&#8217;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#8217;s verdict, enhanced the past damages by <ix:nonFraction unitRef="number" contextRef="i0515ea18ac744e009b23a9242a725ab9_I20200430" decimals="2" name="gild:JudgmentEnhancedDamagesOnPastSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzEwOTk1MTE3ODQxNjM_30b1d62c-4ed4-45d9-8cb0-7c07097a1753">50</ix:nonFraction>% and maintained the royalties on future Yescarta sales at <ix:nonFraction unitRef="number" contextRef="i0515ea18ac744e009b23a9242a725ab9_I20200430" decimals="3" name="gild:JudgmentRoyaltyRateOnFutureSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzM0NjM0NjE2NDQ2ODIz_18798061-80ad-48c7-a019-aad774ff0529">27.6</ix:nonFraction>%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge, and in July 2021, the appeals court heard oral arguments. In August 2021, the Court of Appeals for the Federal Circuit (the &#8220;CAFC&#8221;) reversed the jury verdict, finding the asserted claims of Juno&#8217;s patent invalid. In October 2021, Juno filed a petition for rehearing with the CAFC. In January 2022, the CAFC denied Juno&#8217;s petition for rehearing. We believe that the likelihood of a material adverse outcome in this matter is remote.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Bictegravir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV Healthcare Company (&#8220;VHC&#8221;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes VHC&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;) covering VHC&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#8217;385 patent. In its lawsuit, VHC was seeking billions of dollars for alleged damages comprised of VHC&#8217;s lost profits and a royalty on U.S. sales of bictegravir from launch through the trial. In addition, should a court find that we are liable for infringement, we also expected VHC to seek a royalty on U.S. sales after the trial.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="icad0081866264bbe867a375b6181342d" continuedAt="i0a6fb467c9a44b7985867d4b288f4d64"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, VHC also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound infringes VHC&#8217;s Canadian Patent No. 2,606,282 (the &#8220;&#8217;282 patent&#8221;), which was issued to Shionogi &amp; Co. Ltd. and VHC. The &#8217;282 patent is the compound patent covering VHC&#8217;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#8217;282 patent. In November and December 2019, VHC filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206; in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 and 1363875. These patents all relate to molecules that VHC claims would act as integrase inhibitors. We believe that bictegravir does not infringe any valid claims of VHC&#8217;s patents and have prevailed in court proceedings to date in Canada and Germany. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2022, Gilead reached an agreement (the &#8220;Settlement&#8221;) with VHC, ViiV Healthcare UK (No.3) Limited, ViiV Healthcare UK Limited, Shionogi &amp; Co., Ltd. and GlaxoSmithKline Mercury Limited (collectively, &#8220;ViiV&#8221;) for a global resolution of all pending or potential claims related to Gilead&#8217;s sales of Biktarvy, including the litigation pending in the U.S. District Court of Delaware and other jurisdictions outside the United States as described above. In February 2022, the lawsuit pending in the United States was dismissed as well as the lawsuits in Canada, France, Ireland, the UK, Australia, Japan and Korea.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Settlement, ViiV grants Gilead a broad worldwide license and covenant not to sue relating to any past, present or future development or commercialization of bictegravir. In connection with the Settlement, Gilead (1) made a one-time payment to ViiV of $<ix:nonFraction unitRef="usd" contextRef="i58312b3302b9493cb83df643b7d08e9a_D20220101-20220331" decimals="-7" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI3NDg3NzkyMjk1OTI_332c3c74-7c39-4a6f-a603-b1d1363d511e">1.25</ix:nonFraction> billion in the first quarter of 2022, and (2) will provide ViiV an ongoing royalty at a rate of <ix:nonFraction unitRef="number" contextRef="i265d4a6f0a374d1dab17e075aed111ab_D20220201-20220201" decimals="2" name="gild:LossContingencyRoyaltyPercentageOnFutureSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzEwOTk1MTE3ODQxMTk_40603967-ad3a-4c24-9416-6cb02d770af2">3</ix:nonFraction>% on future sales of Biktarvy and the bictegravir component of bictegravir-containing products in the United States until October 5, 2027. In connection with the Settlement, Gilead recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i3f4cd81637934eb4bfcfc5bb4da29021_D20211001-20211231" decimals="-7" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzEwOTk1MTE3ODMyOTg_fac5c1b1-1c3c-45f8-bbd4-938e9441ffad">1.25</ix:nonFraction> billion to Cost of goods sold on our Consolidated Statements of Income in the fourth quarter of 2021.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine or tenofovir disoproxil fumarate (&#8220;TDF&#8221;) prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the U.S. Court of Federal Claims, alleging violations of <ix:nonFraction unitRef="agreement" contextRef="ib937eacd40624de4b33e1818017eaa04_I20200430" decimals="INF" name="gild:LossContingencyMaterialTransferAgreementsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3Mjc_31ac2e78-aa0d-444c-ae5c-1b8690cf59f9">four</ix:nonFraction> material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and a clinical trial agreement (&#8220;CTA&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Court of Federal Claims has been set for June 2022, and a trial date for the lawsuit in the District Court of Delaware has been set for May 2023.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in December 2019, we received letters from Lupin Ltd., Apotex Inc., Shilpa Medicare Ltd. (&#8220;Shilpa&#8221;), Sunshine Lake Pharma Co. Ltd. (&#8220;Sunshine Lake&#8221;), Laurus Labs, Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (collectively, &#8220;Generic Manufacturers&#8221;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our TAF-containing products. Between them, these Generic Manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. The Generic Manufacturers have challenged the validity of <ix:nonFraction unitRef="patent" contextRef="i7a0546071ccb452889c1fb141764dfef_D20191201-20191231" decimals="INF" name="gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3NDA_42502e0f-fc9b-4d7d-bbfd-1bd34604451f">two</ix:nonFraction> to <ix:nonFraction unitRef="patent" contextRef="i7a0546071ccb452889c1fb141764dfef_D20191201-20191231" decimals="INF" name="gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3MzQ_a16007d1-964d-4f6b-b5d5-1c85361612a6">four</ix:nonFraction> patents listed on the Orange Book and associated with TAF. We filed lawsuits against the Generic Manufacturers, and we intend to enforce and defend our intellectual property. In November 2021, we reached an agreement with Shilpa to resolve the lawsuit against Shilpa. In addition, in January 2022, we reached an agreement with Sunshine Lake to resolve the lawsuit against Sunshine Lake. The settlement agreements have been filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i0a6fb467c9a44b7985867d4b288f4d64" continuedAt="i8ca0a5854d22480ab17e12b9ffbf88a8"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we received a letter from Lupin Ltd. (&#8220;Lupin&#8221;) indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen, filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Lupin asserting infringement of <ix:nonFraction unitRef="patent" contextRef="i0639e3db3b664793a6beb77eb685f7b0_D20211001-20211031" decimals="INF" name="gild:LossContingencyAdditionalPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzE2NDkyNjc2MTMyNzg_14c320c1-2f48-4796-b370-af9410d44072">two</ix:nonFraction> additional patents in the same court. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. An appeal hearing originally scheduled for July 2021 has been canceled and a new date has not yet been set by the EPO.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. <ix:nonFraction unitRef="opposingparty" contextRef="i1f23bfe0992f40f3b1234a110848985b_I20191231" decimals="INF" name="gild:LossContingencyPartiesAppealedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3NDY_909d551f-6efa-43a8-9244-900efb32cd8d">Two</ix:nonFraction> of the original opposing parties have appealed, requesting full revocation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. <ix:nonFraction unitRef="opposingparty" contextRef="ie0d5cca66648457e8765b48c19c1fe65_I20191231" decimals="INF" name="gild:LossContingencyPartiesAppealedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3NTQ_921b6489-c117-464e-971e-364d6c033fdc">Three</ix:nonFraction> parties have appealed this decision. The appeal hearing was held in March 2021, and the validity of all claims were upheld.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. <ix:nonFraction unitRef="opposingparty" contextRef="if8a659c08da049ae986c9c29e62e00e4_I20191231" decimals="INF" name="gild:LossContingencyPartiesAppealedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3NjI_2c3a4de7-9e17-4298-9a08-1745b5c9e9b8">Three</ix:nonFraction> parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, <ix:nonFraction unitRef="party" contextRef="i225c85c01cb74eef9ba4b88802d3cdf6_D20160101-20161231" decimals="INF" name="gild:LossContingencyPartiesFilingOppositionNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3NzA_dd6e43b9-e9c1-4bf4-b582-f8755a9d399f">three</ix:nonFraction> parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. <ix:nonFraction unitRef="opposingparty" contextRef="ifa3f8743db084c41b63d403832f512f3_I20191231" decimals="INF" name="gild:LossContingencyPartiesAppealedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3NzY_26413441-4a6d-4ce3-b17a-fb7bb884194b">Two</ix:nonFraction> parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the EU could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We (along with Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and Johnson &amp; Johnson, Inc.) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes&#8212;one of direct purchasers consisting largely of wholesalers, and another of indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the fall of 2021, several plaintiffs filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the putative classes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These cases have been coordinated with the class actions. Trial is set for March 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we, along with generic manufacturers Cipla Ltd. and Cipla USA Inc. (together, &#8220;Cipla&#8221;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and Cipla, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we along with BMS and Teva Pharmaceutical Industries Ltd. were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i8ca0a5854d22480ab17e12b9ffbf88a8" continuedAt="iaa181336ce364fe1874388e75482dbc5"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i327f548a38ab4392948582ff7fef469a_D20210101-20211231" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3ODI_0b29e98e-811f-4ed8-830f-900a7b76ddde">one</ix:nonFraction> class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Maryland, Missouri and New Jersey, involve more than <ix:nonFraction unitRef="plaintiff" contextRef="i327f548a38ab4392948582ff7fef469a_D20210101-20211231" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzkzNDU4NDkwMDc3MDM_aeccc9d1-8108-4d00-92ad-808f08f55639">27,000</ix:nonFraction> plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead&#8217;s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The relator seeks all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="plaintiff" contextRef="i25a9bfaaa2514554b1836ba98b4643cb_D20200401-20200430" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3OTc_e5691bee-dbf9-4e38-9e36-563516ee87a9">Two</ix:nonFraction> former employees filed a qui tam lawsuit against Gilead in April 2020 in California state court. Following the California Attorney General&#8217;s Office&#8217;s decision not to intervene, relators served Gilead with their complaint in August 2020. The complaint alleges violations of the California False Claims Act (&#8220;CFCA&#8221;) and employment law claims. Relators seek all available relief under the CFCA. In December 2021, Gilead and relators executed a settlement agreement to resolve the lawsuit, and in February 2022, the court issued an order dismissing the lawsuit with prejudice.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement does not have a material impact to our Consolidated Financial Statements. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice Advocates, LLC (&#8220;Health Choice&#8221;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#8217;s dismissal.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. In September 2021, the Texas Court of Appeals for the Sixth Court Appeals District granted our request to stay the Texas litigation. The case is stayed pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="iaa181336ce364fe1874388e75482dbc5" continuedAt="i3e6ed0e007104865a1df6ced14a8c6f2">Other Commitments </ix:continuation></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3e6ed0e007104865a1df6ced14a8c6f2">In the normal course of business, we enter into firm purchase commitments related to inventory. As of December&#160;31, 2021, these commitments for the next five years were approximately $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-8" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI1NDI1_7a5de6b3-8ed4-42bd-a1b6-dd3b04d8c6ce">1.1</ix:nonFraction> billion in 2022, $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI1NDM1_a78c306b-55ce-4104-bd73-f0cd266c3982">450</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI1NDQ1_01b9f1b5-48a2-4c70-928f-5f5207bc23c0">243</ix:nonFraction> million in 2024, $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI1NDU1_31fb49cf-2446-4381-9f20-59c8baffadff">60</ix:nonFraction> million in 2025 and $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI1NDY4_3bf24535-e061-48eb-9825-850d20220ed2">31</ix:nonFraction> million in 2026.</ix:continuation>  </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_142"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzI3NDc_6c6790fc-f4c7-4c9f-a829-681bda8c262b" continuedAt="iad67dc5e98164dce90854eedaddc2e28" escape="true">STOCKHOLDERS&#8217; EQUITY </ix:nonNumeric></span></div><ix:continuation id="iad67dc5e98164dce90854eedaddc2e28" continuedAt="ic83716d3e8bc41afa2078ba8f5721da0"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $<ix:nonFraction unitRef="usd" contextRef="i3d943fc6896d42a2a402f7355165d0db_I20160331" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzEwNA_299ea398-6002-4f52-a461-7a878a0b19f4">12.0</ix:nonFraction> billion stock repurchase program (&#8220;2016 Program&#8221;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $<ix:nonFraction unitRef="usd" contextRef="ia0ac11cc10c94ff59a93bc7def17ae5b_I20200331" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzM2Nw_6e1a19a2-d32d-4594-b016-81a32e56c3d7">5.0</ix:nonFraction> billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), which will commence upon the completion of the 2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the remaining authorized repurchase amount under both programs was $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzYzNQ_3c30f596-d5c3-46a4-9d4f-d736bff84b32">6.3</ix:nonFraction> billion.</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzI3NzU_360f1ede-8e14-4c20-abf1-4406129677cf" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock repurchases under the 2016 Program:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased and retired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88ed2a00d0174820ad767760e9f24578_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzItMi0xLTEtMTIxNDA_5cfbc1f2-0db3-45cd-9b2f-f349e12baf43">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a679c0b45db4ea5bbb87a138014433a_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzItNC0xLTEtMTIxNDA_ec481fdc-1104-419a-b989-392c7f6fa909">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic28e0d3d171544a895828b1b399da271_D20190101-20191231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzItNi0xLTEtMTIxNDA_1712a4fc-7e7a-4623-bca6-0bda37afa19f">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzMtMi0xLTEtMTIxNDA_bf739ddf-ba94-4f60-aede-4dac6e20fea9">546</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzMtNC0xLTEtMTIxNDA_466f9ca4-7da7-4b24-922b-120f52ac7dc8">1,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzMtNi0xLTEtMTIxNDA_e23aacac-5864-41b2-9eeb-7a94104a3e49">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzQtMi0xLTEtMTIxNDA_c4963ba4-16fc-4e83-9d11-d62c641cff7d">66.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzQtNC0xLTEtMTIxNDA_68810e53-22af-49fc-a927-9e1e262e2f22">70.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzQtNi0xLTEtMTIxNDA_9a9c97ed-1d40-44e4-9e7a-b8e925466c9c">66.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to repurchases from the 2016 Program and 2020 Program, we repurchased shares of common stock withheld by us from employee restricted stock awards to satisfy our applicable tax withholding obligations. These shares are excluded from the table above. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the par value method of accounting for our stock repurchases. Under the par value method, common stock is first charged with the par value of the shares involved. The excess of the cost of shares acquired over the par value is allocated to additional paid-in capital based on an estimated average sales price per issued share with the excess amounts charged to retained earnings. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:DividendsDeclaredTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzI3NTI_0fe5578f-c75c-4359-980c-20bae51c6ca6" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash dividends declared on our common stock:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8488cd00ad754d66a2f89c28ef0113ca_D20210101-20210331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzItMi0xLTEtMTIxNDA_2b33d1f6-8f00-4a85-a67c-8d580e761750">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8488cd00ad754d66a2f89c28ef0113ca_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzItNC0xLTEtMTIxNDA_c45f33f4-ce06-4c53-b653-20ae2ceb5a2b">906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23e97ce3ab7e42c8b5eddc72bc3e2957_D20200101-20200331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzItNi0xLTEtMTIxNDA_91378248-193c-4b1a-b5de-3f0a95078020">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23e97ce3ab7e42c8b5eddc72bc3e2957_D20200101-20200331" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzItOC0xLTEtMTIxNDA_1cbf16a3-0122-492c-9f41-24c6605f47cc">867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee9756a76bba457e81595f5fdbe576fc_D20210401-20210630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzMtMi0xLTEtMTIxNDA_09434562-f2d3-47c4-a273-70f258e18004">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee9756a76bba457e81595f5fdbe576fc_D20210401-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzMtNC0xLTEtMTIxNDA_6bdfe8a5-e4f5-4f55-aac3-c828b583e8fd">903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9cc38953c3ec4d0c9b3cbf82dde62ac8_D20200401-20200630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzMtNi0xLTEtMTIxNDA_dd9e8a9b-9493-484f-b5e8-0fe634e88081">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc38953c3ec4d0c9b3cbf82dde62ac8_D20200401-20200630" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzMtOC0xLTEtMTIxNDA_bc8d4fff-a3e1-4388-b4ec-519def1e13ed">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5501384b52f44d51a145ef3f4f3e7ca5_D20210701-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzQtMi0xLTEtMTIxNDA_f5598d8f-2a70-4994-8f83-5b2070bb311e">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5501384b52f44d51a145ef3f4f3e7ca5_D20210701-20210930" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzQtNC0xLTEtMTIxNDA_6d389007-b20d-4775-af99-cb451ccfc266">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bea2cadcf9646f58956abc926e1586f_D20200701-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzQtNi0xLTEtMTIxNDA_32f78750-6954-46a0-9e4a-243c087949cd">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bea2cadcf9646f58956abc926e1586f_D20200701-20200930" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzQtOC0xLTEtMTIxNDA_be600a4e-1e2d-49fe-817c-cc4f89b405d3">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6d11aa8c23bc48e69c02c674ce48e4b1_D20211001-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzUtMi0xLTEtMTIxNDA_432accea-df8d-4a2d-9db8-b9dbcdce49b0">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d11aa8c23bc48e69c02c674ce48e4b1_D20211001-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzUtNC0xLTEtMTIxNDA_d26b9b1a-e60f-4cdc-9e7f-43a2b27b0356">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bf6d6d327dd4e03a5847141baa75c2b_D20201001-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzUtNi0xLTEtMTIxNDA_25dd5a9c-82d2-47f7-a15c-5f4d39239b88">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf6d6d327dd4e03a5847141baa75c2b_D20201001-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzUtOC0xLTEtMTIxNDA_27937fe8-74d3-4c66-aa98-aca5625fef72">865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzYtMi0xLTEtMTIxNDA_8355f299-0dc8-4c8e-aea1-4cda979bc5b7">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzYtNC0xLTEtMTIxNDA_52efeec6-8e58-467c-b541-ff303436e379">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzYtNi0xLTEtMTIxNDA_3127e184-cf71-4b61-9fae-d6abe81ba7db">2.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzYtOC0xLTEtMTIxNDA_92c32d0b-a6b1-40d4-82bf-7ea156232e42">3,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted stock and performance share awards or units have dividend equivalent rights entitling holders to dividend equivalents to be paid upon vesting for each share of the underlying unit.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;1, 2022, we announced that our Board of Directors declared a quarterly cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3ea289ffec3b458087dccbfc47e573d0_D20220201-20220201" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzE3MjU_f966a5a2-04a0-492a-bd72-c3ffa424000f">0.73</ix:nonFraction> per share of our common stock, with a payment date of March&#160;30, 2022 to all stockholders of record as of the close of business on March&#160;15, 2022. Future dividends are subject to declaration by our Board of Directors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="shares" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzE5NDY_35d6aa46-8417-4803-a174-8b69e63313f1">5</ix:nonFraction> million shares of authorized preferred stock issuable in series. Our Board is authorized to determine the designation, powers, preferences and rights of any such series. There was <ix:nonFraction unitRef="shares" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzIxMjE_3fcd5840-aa10-4593-a882-ef097733b894"><ix:nonFraction unitRef="shares" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzIxMjE_a3fa4fe6-461b-4b70-a6f7-db09498939ef">no</ix:nonFraction></ix:nonFraction> preferred stock outstanding as of December&#160;31, 2021 and 2020. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ic83716d3e8bc41afa2078ba8f5721da0"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income </span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzI3NDY_49c8947a-3af2-4b5f-9add-a6f8985b4992" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf763f4ea7f4880a47f0e6a403877f4_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEtMi0xLTEtMTIxNDA_bac32f95-f3ad-40a1-9424-e78ac59307eb">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff25d3116ceb4bbab1c6c9c8d145401c_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEtNC0xLTEtMTIxNDA_57bf4915-bc3f-45b5-a7d4-9822ff9e6e23">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9f1e0014a754c4cb3066bf85c4a2570_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEtNi0xLTEtMTIxNDA_cc976abb-9a1c-43c0-8f36-2e63dbaa5ed6">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id46d2d21dd6a43a89e740948d75f9380_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEtOC0xLTEtMTIxNDA_2a02fd32-9408-46e2-a32b-319fe059fbd4">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa632be9dee643cc918655e93fa6c0f6_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzItMi0xLTEtMTIxNDA_a999a4fb-a63a-4317-ab3e-4a0c20044026">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba6a2a2d50c4a6db88d7c68e239a2b0_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzItNC0xLTEtMTIxNDA_a54ef9f0-9f90-4f51-9b6a-69ebfc501d45">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39bec68158bd4af6bb2c347ac792a9ae_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzItNi0xLTEtMTIxNDA_df01809f-77fc-4446-8e6d-96bf776e52bf">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01dacb3a581346e187edae0a347d2eeb_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzItOC0xLTEtMTIxNDA_f12bdca1-98c7-4e35-ad46-313f95b93d26">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa632be9dee643cc918655e93fa6c0f6_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzMtMi0xLTEtMTIxNDA_4c888690-057a-4cbf-9c1c-1bc8cca8b20d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ba6a2a2d50c4a6db88d7c68e239a2b0_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzMtNC0xLTEtMTIxNDA_ff0e8a1b-f4ff-4337-a2d4-03bab0e266ae">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39bec68158bd4af6bb2c347ac792a9ae_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzMtNi0xLTEtMTIxNDA_8c900147-b457-4c4f-b8eb-90ab95971a30">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01dacb3a581346e187edae0a347d2eeb_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzMtOC0xLTEtMTIxNDA_66557424-7ff4-4ddb-8b4d-9039c2466d6d">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa632be9dee643cc918655e93fa6c0f6_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzQtMi0xLTEtMTIxNDA_d73ad2e1-92dd-4612-bd2e-1e8112fd2f31">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba6a2a2d50c4a6db88d7c68e239a2b0_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzQtNC0xLTEtMTIxNDA_a3575cd5-1532-4667-a816-849f424a8f63">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39bec68158bd4af6bb2c347ac792a9ae_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzQtNi0xLTEtMTIxNDA_a2fcf9d6-0f11-4690-9047-2111fc26c40d">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01dacb3a581346e187edae0a347d2eeb_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzQtOC0xLTEtMTIxNDA_2efbab8d-79b1-4b66-829b-3fd90c812029">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f580454e7604d7785de9823f350085c_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzUtMi0xLTEtMTIxNDA_b6519452-e3d1-4c45-88d4-5dc2039e036a">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031ae4d8e4484c4e9b1cadccb6c88ff9_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzUtNC0xLTEtMTIxNDA_aaf728c7-fe90-41f4-a256-9498d472c464">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7baa42c3821a4c50ae27b170e3c7858f_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzUtNi0xLTEtMTIxNDA_5b676132-1dec-4b13-988d-32e014b31d3b">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9da767fe6764cc8955010ca3f076633_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzUtOC0xLTEtMTIxNDA_d344a1d9-6ab9-4717-879e-e317cd3e50ed">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74a7063cdae7438bb8481aee4e692325_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzYtMi0xLTEtMTIxNDA_cf47ce1e-4234-41f4-85a9-b1cdbedacebf">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i193cbc90df134a0d9735d84dde8ed9ec_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzYtNC0xLTEtMTIxNDA_b460e081-91b6-4bbc-bad7-da10359dad6f">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d96d9b09d2a48cfa30e6bf373b5f762_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzYtNi0xLTEtMTIxNDA_a96a750f-2d65-4dda-9e8e-c469369686c8">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i851b03314d344a5e8ad436aa9235bf9c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzYtOC0xLTEtMTIxNDA_5838a042-b707-497f-bd28-3d1b33a80fd9">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a7063cdae7438bb8481aee4e692325_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzctMi0xLTEtMTIxNDA_b12998b9-ae17-4dea-95d3-77590327f09d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i193cbc90df134a0d9735d84dde8ed9ec_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzctNC0xLTEtMTIxNDA_6db2ac8b-5e94-4f14-9c40-92e9b578d392">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d96d9b09d2a48cfa30e6bf373b5f762_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzctNi0xLTEtMTIxNDA_0a75edd4-0cf3-481a-9df5-669f2818b8cf">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i851b03314d344a5e8ad436aa9235bf9c_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzctOC0xLTEtMTIxNDA_ce09dfc3-a649-442b-9854-058cea099dd5">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74a7063cdae7438bb8481aee4e692325_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzgtMi0xLTEtMTIxNDA_52102296-2876-45b5-8b95-afcec7a5feeb">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i193cbc90df134a0d9735d84dde8ed9ec_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzgtNC0xLTEtMTIxNDA_16db38d0-11f6-4b5b-91b0-1851a70132ac">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d96d9b09d2a48cfa30e6bf373b5f762_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzgtNi0xLTEtMTIxNDA_20dadff1-e660-4434-9b4c-70b3c88a59f9">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i851b03314d344a5e8ad436aa9235bf9c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzgtOC0xLTEtMTIxNDA_cd565ac9-b081-4aee-a874-3e7ca69c32a8">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb145868ff1249dab7c2d803aac491ec_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzktMi0xLTEtMTIxNDA_c99e45b8-4fcd-423e-a0e1-79137d473c00">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie75f65899cfb4ee38ea27dd37daca0ee_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzktNC0xLTEtMTIxNDA_11ca03f1-f497-453f-b1d1-1b036ec8fbf4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0afde8034f24eb688bd439bf07e61b4_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzktNi0xLTEtMTIxNDA_f8cf1266-f22d-4c87-ab3e-841dfff33a73">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i803ae583deba4f7683154aaeec947d69_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzktOC0xLTEtMTIxNDA_c3622635-2e67-4e15-bd8c-c626909b32cb">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5240156832f4cc8ba8aa92faeec8f85_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEwLTItMS0xLTEyMTQw_f7d47890-1da4-4536-8dcd-21b1580e40b6">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9d19504e53c460ebb2acf511d875bc6_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEwLTQtMS0xLTEyMTQw_0cd9a320-6165-43e3-ab3f-a9e105987ce6">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a09a18820154418b65c5db65a9e8ef6_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEwLTYtMS0xLTEyMTQw_81598644-bc44-45bf-98e7-79c225a6abd8">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8023d2e7ae2f498fa0385be7010b4f25_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEwLTgtMS0xLTEyMTQw_3c3917bb-4c89-485e-b1e0-19a9d08e8f73">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5240156832f4cc8ba8aa92faeec8f85_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzExLTItMS0xLTEyMTQw_dcb5cb2b-91da-461c-b23d-23e7b1657a7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d19504e53c460ebb2acf511d875bc6_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzExLTQtMS0xLTEyMTQw_ae5abcdc-c102-46a2-a59c-d28add030852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a09a18820154418b65c5db65a9e8ef6_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzExLTYtMS0xLTEyMTQw_6498dc4c-7ef7-4438-932c-c3e50223161b">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8023d2e7ae2f498fa0385be7010b4f25_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzExLTgtMS0xLTEyMTQw_d03e4590-8e6e-4331-bb17-ea62b8135ff4">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5240156832f4cc8ba8aa92faeec8f85_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEyLTItMS0xLTEyMTQw_7aa10595-980b-442b-954d-5c18fa570c37">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9d19504e53c460ebb2acf511d875bc6_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEyLTQtMS0xLTEyMTQw_82a53782-e4d2-47f8-af9f-9557f2af7fcb">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a09a18820154418b65c5db65a9e8ef6_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEyLTYtMS0xLTEyMTQw_ec4000dc-e270-4ae7-9607-ce314323ab49">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8023d2e7ae2f498fa0385be7010b4f25_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEyLTgtMS0xLTEyMTQw_b2c0129f-d6b3-4c0a-ba8e-16cddbce80b5">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaea04c5cb73429c92a11dfc633c9a7e_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEzLTItMS0xLTEyMTQw_9f5f8c98-4284-4403-832d-68ef7537fd1b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf9f4f8bc79c4814960889868046cc5f_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEzLTQtMS0xLTEyMTQw_a83fd778-fa12-4eee-8c93-22a13eadcfb2">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a1104220914dc19840bbf261ce2cf7_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEzLTYtMS0xLTEyMTQw_e4f8e9fd-b785-4517-ab88-aac95ed39da2">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ebb0b9dc1384269a861d7b5216e73fc_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEzLTgtMS0xLTEyMTQw_29df2011-d743-4df3-83d7-afe055ab0e5e">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts reclassified to net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Consolidated Statements of Income. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net, on our Consolidated Statements of Income. The income tax impact allocated to each component of other comprehensive income was not material for the periods presented.</span></div></ix:continuation><div id="i72faa4a0a4974dcca6db2bf491b63d7a_145"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzEwMzk2_b9e9e67f-a560-42ed-aeb8-911f785603a3" continuedAt="i81897aa3820e4c6ba8c0739456381102" escape="true">EMPLOYEE BENEFITS </ix:nonNumeric></span></div><ix:continuation id="i81897aa3820e4c6ba8c0739456381102" continuedAt="i590e735d791b41689f7ec5e20f001d46"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2004, our stockholders approved and we adopted the Gilead Sciences, Inc. 2004 Equity Incentive Plan (as amended, the &#8220;2004 Plan&#8221;). The 2004 Plan authorized the issuance of a total of <ix:nonFraction unitRef="shares" contextRef="ica652e76a6974f3cb7f5a6d0f8d94017_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzg0Ng_ead2db80-ebcd-4865-997a-361e1f0fbb84">309</ix:nonFraction> million&#160;shares of common stock. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the Forty Seven acquisition, we assumed the Forty Seven, Inc. 2018 Equity Incentive Plan, which we subsequently amended and restated as the Gilead Sciences, Inc. 2018 Equity Incentive Plan (as amended and restated, the &#8220;2018 Plan&#8221;). The aggregate amount of shares that may be issued under the 2018 Plan on or after the assumption date will not exceed <ix:nonFraction unitRef="shares" contextRef="ib59a14c778a94c75975c4acb8a10179d_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzEyMzY_85ed96ee-376f-46ea-90d4-639e6da10b3c"><ix:nonFraction unitRef="shares" contextRef="ib59a14c778a94c75975c4acb8a10179d_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzU0OTc1NTgxNTAzNTc_dede91fa-e35a-4131-a838-c8d7e5d527d2">12</ix:nonFraction></ix:nonFraction>&#160;million shares. As part of the Immunomedics acquisition, we assumed the Immunomedics Amended and Restated 2014 Long-Term Incentive Plan (the &#8220;Immunomedics Plan&#8221; and referred together with the 2004 Plan and 2018 Plan as the &#8220;Plans&#8221;), which we subsequently merged into the 2004 Plan. The aggregate amount of shares that may be issued under the Immunomedics Plan on or after the assumption date will not exceed <ix:nonFraction unitRef="shares" contextRef="iba210e1a3e384daca10160c7ffbc3ee5_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzE2Mzk_5313766d-df17-4ab8-bad6-40475c8033db">26</ix:nonFraction>&#160;million shares. See Note 6. Acquisitions for additional information on the settlement of stock awards.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plans are broad based incentive plans that provide for the grant of equity-based awards, including stock options, restricted stock units, restricted stock awards and performance share awards, to employees, directors and consultants. As of December&#160;31, 2021, a total of <ix:nonFraction unitRef="shares" contextRef="ica652e76a6974f3cb7f5a6d0f8d94017_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzE5OTU_3f8ef2f7-a8ce-40d8-9d2a-c8740b8b8751">82</ix:nonFraction>&#160;million shares remain available for future grant under the Plans. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plans provide for option grants designated as either non-qualified or incentive stock options. All stock options granted after January&#160;1, 2006 have been non-qualified stock options. Employee stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIzMDE_e5e44bde-010a-4057-a014-5f91fdc040cb">three</span> or <ix:nonNumeric contextRef="i63aedd4c33d5433b8067d84fd5b6f093_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIzMDc_8cf4d167-f296-492c-a567-2f59d50a2066">four years</ix:nonNumeric>. All options are exercisable over a period not to exceed the contractual term of <ix:nonNumeric contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIzOTE_ad015a0d-8b6a-42c3-b033-ac3dca0b3460">ten years</ix:nonNumeric> from the date the stock options are issued and are granted at prices not less than the fair market value of our common stock on the grant date. Stock option exercises are settled with common stock from the Plans&#8217; previously authorized and available pool of shares. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i590e735d791b41689f7ec5e20f001d46" continuedAt="i40dd8fe46d4242ec9acbc9a92d8d7790"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzEwMzc2_29cfc6f2-b0a3-4e5d-9965-3192b51159c2" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity and related information under our stock option plans. All option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price<br/>(in dollars)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average <br/>Remaining <br/>Contractual Term <br/>(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>&#160;Intrinsic <br/>Value <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0729bf1c13614c1dbd5464ad3b216cd1_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzEtMi0xLTEtMTIxNDA_732bbe87-96d1-4f58-a5c1-d4c77012c01b">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0729bf1c13614c1dbd5464ad3b216cd1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzEtNC0xLTEtMTIxNDA_15e17086-28bb-49db-b482-5f5386963f27">69.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzItMi0xLTEtMTIxNDA_7695cde6-4030-46a4-912a-9d0d9fb20fb4">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzItNC0xLTEtMTIxNDA_0b24dcc7-8de9-4138-8e34-44657835267d">64.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzMtMi0xLTEtMTIxNDA_12a0c3b4-6012-4479-82d1-e3b5a56a3745">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzMtNC0xLTEtMTIxNDA_e82d36ce-49d5-4b0b-a272-4a8e32461d60">67.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzQtMi0xLTEtMTIxNDA_d479a9c0-934f-48d9-952f-c70cbeef400f">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzQtNC0xLTEtMTIxNDA_8475d247-cbbf-4ac6-9283-0eed66b84315">82.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzUtMi0xLTEtMTIxNDA_a2e53f00-cd3f-406d-8c6e-964d5078e8ba">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzUtNC0xLTEtMTIxNDA_75cf724c-daf9-4656-b6f5-c400354f7920">37.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i354b6ee389b345259779247e1761d741_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzYtMi0xLTEtMTIxNDA_a6bce2e5-2287-44cf-9a31-eea9d4dd2e3a">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i354b6ee389b345259779247e1761d741_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzYtNC0xLTEtMTIxNDA_777ce429-41ce-4bb7-b4b8-339dd251e613">70.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzYtNi0xLTEtMTIxNDA_002c31ce-553d-4e54-99cc-8025e9338036">5.34</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i354b6ee389b345259779247e1761d741_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzYtOC0xLTEtMTIxNDA_5fea69ac-6080-4af8-808e-4efcaed7f6d8">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i354b6ee389b345259779247e1761d741_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzctMi0xLTEtMTIxNDA_e1834fe2-0a69-4487-8fb2-c87c31f3d3eb">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i354b6ee389b345259779247e1761d741_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzctNC0xLTEtMTIxNDA_211d6707-f05b-4bc0-b884-eb4a9f6af813">72.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzctNi0xLTEtMTIxNDA_19dd13c5-d01d-4456-bbc7-5f19f56abbc9">3.67</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i354b6ee389b345259779247e1761d741_I20211231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzctOC0xLTEtMTIxNDA_8d85792a-184a-4694-a039-8213ff072185">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest, net of estimated forfeitures as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i354b6ee389b345259779247e1761d741_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzgtMi0xLTEtMTIxNDA_ba4f7b0c-063b-4b84-9c2c-53d67e8d9875">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i354b6ee389b345259779247e1761d741_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzgtNC0xLTEtMTIxNDA_a1798403-71f6-4812-9752-3861b1af857e">67.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzgtNi0xLTEtMTIxNDA_0469ffe9-66a4-4451-b8e1-671eb4ff655f">8.61</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i354b6ee389b345259779247e1761d741_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzgtOC0xLTEtMTIxNDA_2ddb48c8-02d1-41de-80ca-cdcd689341e1">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable. Total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYwMjE_26ce7823-1600-42d3-9094-88427db70bf0">48</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i978af2e4f66d4a0598365cc6a4df3a60_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc1OTA_0ad8d285-20b8-4c67-8bf0-c34d35d25afc">179</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8ac2832a817c4b079e7e753df575c2fd_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc1OTg_23a4d3b6-9ad7-4521-ab3b-a853bf5e2474">209</ix:nonFraction> million for 2021, 2020 and 2019, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of the stock options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYwMzk_ddde78ba-0980-4faf-8782-0251cae0bb7a">10.05</ix:nonFraction> per share, $<ix:nonFraction unitRef="usdPerShare" contextRef="i978af2e4f66d4a0598365cc6a4df3a60_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc2NDg_ec62a6f6-d88c-47c6-aeea-07f763dec534">11.69</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="i8ac2832a817c4b079e7e753df575c2fd_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc2NjY_8552d799-e6f7-4b61-8bc4-ee445606d3d5">12.15</ix:nonFraction> per share for 2021, 2020 and 2019, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i354b6ee389b345259779247e1761d741_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYwNDg_12589f07-0a10-40d4-a4f6-79746e08273e">47</ix:nonFraction> million of unrecognized compensation cost related to stock options, which is expected to be recognized over an estimated weighted-average period of <ix:nonNumeric contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYwNTY_754b9c0a-8822-4703-b3e3-9dbbe0a0a06f">2.3</ix:nonNumeric> years.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock and Performance Share Awards</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant time-based RSUs to certain employees as part of our annual employee equity compensation review program as well as to new hire employees and to non-employee members of our Board. RSUs are share-based awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. RSUs generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzM4OTI_528fb9fb-324d-4172-b895-26994db1e7b3">three</span> or <ix:nonNumeric contextRef="iea60cbe1d7984731a8c9400ef7641432_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzM4OTg_f4210a8e-ec5a-4d81-b9de-925b976e753a">four years</ix:nonNumeric> from the date of grant. The fair value of an RSU is equal to the closing price of our common stock on the grant date. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant PSUs which vest upon the achievement of specified market or performance goals, which could include achieving a total shareholder return compared to a pre-determined peer group or achieving revenue targets. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from <ix:nonFraction unitRef="number" contextRef="i6305a82bd394408e9eb61ee6d9a6b096_I20211231" decimals="INF" name="gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzQzNzI_0bbe79d8-adf9-411e-94bd-782101080adf">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="icec935a6b97544d6a97b10b0c0f9a6b1_I20211231" decimals="INF" name="gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzQzNzg_3dddbf38-3162-435e-9e6e-90623403058f">200</ix:nonFraction>%, and these awards generally vest only when a committee (or subcommittee) of our Board has determined that the specified market and performance goals have been achieved. The fair value of each PSU is estimated at the date of grant or when performance objectives are defined for the grants. Depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have also granted other PSUs to certain of our employees under the 2004 Plan. The vesting of these awards is subject to the achievement of specified individual performance goals, typically within a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzUwNzA_664e182d-33f3-4d5a-92ea-3c6d4ced19cd">one</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzUwNzY_9109fd84-6601-41a5-b36b-3897b4762db9">two</span> year period. The fair value of such an award is equal to the closing price of our common stock on the grant date.</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzEwMzk4_246b8703-11ac-4b35-90dc-e6cd555385df" continuedAt="i93b952b5c6d24430abb162f98f3c30a9" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU and PSU activity and related information:</span></div><div style="margin-top:4.5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e0958f8c926485eae5d31e7b78ed257_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzItMi0xLTEtMTIxNDA_ac0cb69c-4012-47d9-bcaa-af9391b3ccda">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e0958f8c926485eae5d31e7b78ed257_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzItNC0xLTEtMTIxNDA_0ef6ae3b-b365-44ff-8dfa-67308e4d56d0">69.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35a87915496f4f0f918d93a07f297c71_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzItNi0xLTEtMTIxNDA_10493a7f-3f07-4f3d-a4df-5429ae4a96ef">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i35a87915496f4f0f918d93a07f297c71_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzItOC0xLTEtMTIxNDA_d9d9a555-943a-4b2d-861c-bc2236841c64">84.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzMtMi0xLTEtMTIxNDA_79369d6e-b812-4133-9a70-f53c4e6d1f26">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzMtNC0xLTEtMTIxNDA_424db7d5-6a3b-4976-ac4d-bb3cdd3ccd2d">65.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzMtNi0xLTEtMTIxNDA_f4a015ea-f848-40f0-8160-bda02fafb1a9">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzMtOC0xLTEtMTIxNDA_4e8b8763-7ba8-426e-9d11-072033cf98ec">71.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzQtMi0xLTEtMTIxNDA_b600b0d8-55db-4c5c-b72e-80ede7efd430">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzQtNC0xLTEtMTIxNDA_299d969e-edec-4e7e-9959-91b0884c55c6">70.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzQtNi0xLTEtMTIxNDA_29a62437-cf4b-4262-953b-a3365dd2e1e3">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzQtOC0xLTEtMTIxNDA_44267b64-8a06-4bc3-b8e0-74ee311bc61c">88.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzUtMi0xLTEtMTIxNDA_733704ce-df08-4bd6-91a8-c3423f5fd37b">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzUtNC0xLTEtMTIxNDA_5ae65522-f945-46de-8670-eeaf2490c1c9">67.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzUtNi0xLTEtMTIxNDA_8e985dde-c446-4a14-b6e4-622ffecf2003">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzUtOC0xLTEtMTIxNDA_09471bb0-42cd-4dfe-99e0-689e31b74499">78.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17e83904e7c84fe4ba24ed426244affb_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzYtMi0xLTEtMTIxNDA_1d206b08-1750-4989-9dd2-242de894fc64">20.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17e83904e7c84fe4ba24ed426244affb_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzYtNC0xLTEtMTIxNDA_8b7719fa-616c-4030-934e-4663ccb766e1">67.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12f8795691e94495b697bd3ee9e10a01_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzYtNi0xLTEtMTIxNDA_2cd35290-7426-499f-9b23-9a3979cc2d89">0.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12f8795691e94495b697bd3ee9e10a01_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzYtOC0xLTEtMTIxNDA_34a3b535-4018-49a3-ae98-3a0ea9102c40">79.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i93b952b5c6d24430abb162f98f3c30a9" continuedAt="i8c617cc7588842a5bd95596af8d9e8bd">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i8c617cc7588842a5bd95596af8d9e8bd"> &#160;&#160;&#160;&#160;Weighted-average grant-date fair value per share excludes shares related to grants that currently have no grant date as the performance objectives have not yet been defined.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i40dd8fe46d4242ec9acbc9a92d8d7790" continuedAt="iff9da0b30bd04ac1a8d55ae9a417c376"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYwOTc_b1d94718-8976-4ae3-a271-4500bf2120d7">65.42</ix:nonFraction> per share, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1f4fbfc0f6ca4a74b926e26a7212b4d4_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc3NDk_7712e100-fb32-405d-a8c5-52c24b449504">70.94</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="i092e7210064445688e64ea085cde62b9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc3Njc_29f27f32-6190-4ed7-84e2-cdb2155aa3d5">64.31</ix:nonFraction> per share for 2021, 2020 and 2019, respectively. The weighted-average grant date fair value of PSUs granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxMTI_4e8b8763-7ba8-426e-9d11-072033cf98ec">71.31</ix:nonFraction> per share, $<ix:nonFraction unitRef="usdPerShare" contextRef="i597fc5ca87d64f79987a4deb4814a2cc_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc4NTQ_5da4869b-3231-4a5b-a5c5-887d0e14d7db">83.64</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="ibb8bcd0d8ecf4205b8fe6029870b6fba_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc4NzE_f61064c2-4b09-4f5c-a27c-a06b6b3283ea">68.30</ix:nonFraction> per share for 2021, 2020 and 2019, respectively. The total grant date fair value of our vested RSUs and PSUs was $<ix:nonFraction unitRef="usd" contextRef="i5f4b7466ad0243e69a21d012954cb83e_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxMjc_c42d7d84-b26d-402c-aa5e-c23828f0f247">503</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i27e180b4cd6e425b8489f50bc779226d_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc4MTU_0bb5d6fa-4c91-48c3-bbc6-826b6778994b">479</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74136efa08b74a10bd1a8c546eacd605_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc4MjI_07283c78-3cbe-4e36-918d-30ee6c04961c">450</ix:nonFraction> million for 2021, 2020 and 2019, respectively, and total fair value as of the respective vesting dates was $<ix:nonFraction unitRef="usd" contextRef="i7bc9c86928c74673ab301285440c1661_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxNDM_5beb7726-0c3b-4e27-8cf0-df59eeb89914">471</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if0c35aff509b4c369b6860cf48fb5cac_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc5NTE_dd718b8b-5841-489d-86c8-0567056603a0">459</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1b1a7a2d096046eea14fab1d821f637f_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc5NTg_4edb61e5-076d-4906-90c8-195d4be54b4f">372</ix:nonFraction> million for 2021, 2020 and 2019, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="iff82fe9d37f642f6bd89267088886a42_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxNTE_242c0e08-9589-442e-b7d1-740ff94a55e6">917</ix:nonFraction> million of unrecognized compensation cost related to unvested RSUs and PSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="icad35ac1806e4f21a40d3a0946de361d_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxNjA_d61f5868-0c02-4a46-b2a6-572ed692eb67">2.2</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the &#8220;ESPP&#8221;), employees can purchase shares of our common stock based on a percentage of their compensation subject to certain limits. The purchase price per share is equal to the lower of <ix:nonFraction unitRef="number" contextRef="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzY0NDA_24c132d8-098e-427f-95e3-2e40a5752021">85</ix:nonFraction>% of the fair market value of our common stock on the offering date or the purchase date. The ESPP offers a six-month look-back feature as well as an automatic reset feature that provides for an offering period to be reset to a new lower-priced offering if the offering price of the new offering period is less than that of the current offering period. ESPP purchases are settled with common stock from the ESPP&#8217;s previously authorized and available pool of shares. During 2021, <ix:nonFraction unitRef="shares" contextRef="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxODE_1b62caf9-429f-4594-9b01-13a73d2cf0b5">2</ix:nonFraction> million shares were issued under the ESPP for $<ix:nonFraction unitRef="usd" contextRef="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxODk_420eb0d4-2229-419e-b892-40699086b6c8">111</ix:nonFraction> million. A total of <ix:nonFraction unitRef="shares" contextRef="ife2e5f0230844117bbb72a6267db6609_I20211231" decimals="-6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxOTc_19343e8b-70a0-4a58-9a17-fe088094504e">79</ix:nonFraction> million shares of common stock have been authorized for issuance under the ESPP, and there were <ix:nonFraction unitRef="shares" contextRef="ife2e5f0230844117bbb72a6267db6609_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYyMDU_fdfbd7a8-8f70-4559-9aae-3a49951a6093">5</ix:nonFraction> million shares available for issuance under the ESPP as of December&#160;31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzEwMzc4_4567c3b1-1411-490b-b809-d749b40512be" continuedAt="i1fa1a4bd2ca141f985654af1bb716c68" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock-based compensation expenses included on our Consolidated Statements of Income:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808afce6234d4f44b02493f616cfcdad_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzItMi0xLTEtMTIxNDA_b6952758-2c1a-4048-b6e2-6ec4c510170c">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157409bb1ea342b2a3f94ed6091834b3_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzItNC0xLTEtMTIxNDA_ef051375-2b3d-4cc5-9647-2e114f5e61f6">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e62f0a33b96429bb3fe4df85eb86fd7_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzItNi0xLTEtMTIxNDA_f28230f7-2c40-4f79-a8e7-c09cc8feaa0d">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63775c3a22e4db9805ee00e5e0ad2f7_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzMtMi0xLTEtMTIxNDA_de47f3ab-7ace-450b-a405-1a2801e60767">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ace142a66d4ef093c014ea5eb86836_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzMtNC0xLTEtMTIxNDA_179b0e19-d5ad-4009-94a4-16eaecaf7e55">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6851218a40374235b12bad014064a29d_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzMtNi0xLTEtMTIxNDA_6f864295-0575-4e5f-921d-3a3965961f2e">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ee369dd27f4f9fa86ebb38e3b71a65_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzQtMi0xLTEtMTIxNDA_d0a49b15-52c6-4eb8-8a80-665780dc8ebf">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94fdbc3b74014794bf026a159fb15aa2_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzQtNC0xLTEtMTIxNDA_c2560d7e-a3bb-4f9a-a0c9-5d6edfff87eb">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d0883810134f519ae9afb0d14ed77a_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzQtNi0xLTEtMTIxNDA_23daf278-4ee9-45ed-bc44-0e31274e8b48">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in total costs and expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzUtMi0xLTEtMTIxNDA_916c6736-0677-45d1-a1e9-5ec431ed897f">635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzUtNC0xLTEtMTIxNDA_14300e5c-710e-4698-8aec-0eb15f936f14">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzUtNi0xLTEtMTIxNDA_aee6d8f7-f3e6-4750-84f0-afdc84cf39f4">636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzYtMi0xLTEtMTIxNDA_7036a8cc-67d9-433a-ab3b-e021945b4607">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzYtNC0xLTEtMTIxNDA_5c3b72c7-58aa-493c-9a09-de4a610af8d8">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzYtNi0xLTEtMTIxNDA_ad69581b-83f7-4e37-9da9-34fa85807690">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzctMi0xLTEtMTIxNDA_87fc1ec2-e486-4bdc-95c7-70ef0a020fc1">535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzctNC0xLTEtMTIxNDA_9a76a677-e306-4437-a14c-5c3cd98568b5">854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzctNi0xLTEtMTIxNDA_1aebb835-34d5-43e7-a0c7-5a0b8e90f002">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Pre-tax stock-based compensation expense for the year ended December&#160;31, 2020 of $<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-8" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzE2NDkyNjc0NTMxNDQ_e43c177b-8853-4003-b3a4-1733437700b2">1.1</ix:nonFraction> billion included $<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzI3NDg3NzkwODAxNjk_7b2acaca-4654-4c49-82f3-d9a7cd5b0aa7">643</ix:nonFraction> million non-cash stock-based expense and $<ix:nonFraction unitRef="usd" contextRef="icaf63b79601f41cbbbb79ce216ea77a9_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzczOTQ_2ca52252-dd25-4fb5-84f1-baf8399f84ec">289</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic616f3942a304ac4ab23e63afeed5a7d_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzc0MDE_4e352571-745e-4fa9-b3e7-3b7a8471cd8d">144</ix:nonFraction> million of accelerated post-acquisition stock-based expense related to the acquisitions of Immunomedics and Forty Seven, respectively. See Note 6. Acquisitions for additional information.</span></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><ix:continuation id="i1fa1a4bd2ca141f985654af1bb716c68"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Income tax effect for the year ended December&#160;31, 2019 included a $<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzc2MzE_802ed541-5024-4b57-af4a-2650855ce9e7">114</ix:nonFraction> million income tax expense following the U.S. Court of Appeals decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Altera Corp v. Commissioner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, which requires related parties in an intercompany cost sharing arrangement to share expenses related to stock-based compensation.</span></ix:continuation><span style="color:#6d6d6d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is recognized as expense over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of options granted under our Plans and purchases under our ESPP were estimated at grant or purchase dates using a Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including expected stock price volatility and expected award life. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="iff9da0b30bd04ac1a8d55ae9a417c376"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="gild:ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzEwMzkx_96936c7d-a86f-44c8-aba0-a5ff1c0e7303" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the following assumptions to calculate the estimated fair value of the awards: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzMtMi0xLTEtMTIxNDA_6700676b-3b04-4099-94a6-6d3cb5271e01">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i978af2e4f66d4a0598365cc6a4df3a60_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzMtNC0xLTEtMTIxNDA_16a8f6ae-1f80-4e2d-b660-d1ee1d71bd4a">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ac2832a817c4b079e7e753df575c2fd_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzMtNi0xLTEtMTIxNDA_cf4f5bf0-866e-4e6e-9f0e-c0a2f94b9569">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzQtMi0xLTEtMTIxNDA_9fa86b15-eac7-493b-ad25-8a17ea469676">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i490b5d2fa50a4d27ba621c355f27e7c5_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzQtNC0xLTEtMTIxNDA_5b10a3b2-2b21-4931-a8c3-c56ed15aa7e4">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7bea36ad4f2b4224bf60b33eecac3150_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzQtNi0xLTEtMTIxNDA_4aca5d58-f450-41f3-9e10-34c1c0c01ad6">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzYtMi0xLTEtMTIxNDA_705caa0d-4ab7-44b6-bd86-6a8b9cfebb10">5.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i978af2e4f66d4a0598365cc6a4df3a60_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzYtNC0xLTEtMTIxNDA_7ffa9b6f-0bbf-435e-a42b-5d8413340757">5.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ac2832a817c4b079e7e753df575c2fd_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzYtNi0xLTEtMTIxNDA_accea282-f650-4700-b4ae-a13b14bd2ba9">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzctMi0xLTEtMTIxNDA_32ba45ae-1aa0-4de3-a807-b2bac617b8c2">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i490b5d2fa50a4d27ba621c355f27e7c5_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzctNC0xLTEtMTIxNDA_81581f76-335b-4bfe-b069-d7658fea6687">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7bea36ad4f2b4224bf60b33eecac3150_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzctNi0xLTEtMTIxNDA_27bce300-e550-408a-a104-90b3945476cf">0.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzktMi0xLTEtMTIxNDA_61fc4229-2cf8-472e-842f-a5a871511455">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i978af2e4f66d4a0598365cc6a4df3a60_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzktNC0xLTEtMTIxNDA_4982b092-54ed-4f49-8359-3f96d2d25a21">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ac2832a817c4b079e7e753df575c2fd_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzktNi0xLTEtMTIxNDA_4001de47-83fc-4cfa-939d-80aae3112075">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzEwLTItMS0xLTEyMTQw_fa54b83e-0add-4f39-9a17-eb9ad93647ae">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i490b5d2fa50a4d27ba621c355f27e7c5_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzEwLTQtMS0xLTEyMTQw_fd69ce93-fcba-4b3b-a779-514224167f32">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7bea36ad4f2b4224bf60b33eecac3150_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzEwLTYtMS0xLTEyMTQw_49c426df-c977-4131-b150-cc3434d20ae1">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzExLTItMS0xLTEyMTQw_2b208d10-d6cd-4000-a51a-31ace5ba7893">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzExLTQtMS0xLTEyMTQw_09588f93-05f9-4505-9671-8a0b21c65555">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzExLTYtMS0xLTEyMTQw_ed8b5d9d-1897-424e-9e8b-12a48c824cd1">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted was calculated using the single option approach. We use a blend of historical volatility along with implied volatility for traded options on our common stock to determine our expected volatility. The expected term of stock-based awards represents the weighted-average period the awards are expected to remain outstanding. We estimate the weighted-average expected term based on historical cancellation and historical exercise data related to our stock options as well as the contractual term and vesting terms of the awards. The risk-free interest rate is based upon observed interest rates appropriate for the term of the stock-based awards. The dividend yield is based on our history and expectation of dividend payouts. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Compensation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a retirement saving plan under which eligible U.S. employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (the Gilead Sciences 401k Plan). In certain foreign subsidiaries, we maintain defined benefit plans as required by local regulatory requirements. Our total matching contribution expense under the Gilead Sciences 401k Plan and other defined benefit plans was $<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYyMzg_3f6fb4ac-8bb0-4665-ab9c-8a837a59ba38">166</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc5OTc_0240eef8-97ab-4d88-83e0-a69f4b9559d2">144</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDgwMDQ_240ffb51-427b-4eda-9786-7d94d4e9d2e3">110</ix:nonFraction> million during 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a deferred compensation plan under which our directors and key employees may defer compensation. Amounts deferred by participants are deposited into a rabbi trust. The total assets and liabilities associated with the deferred compensation plan were $<ix:nonFraction unitRef="usd" contextRef="i90c285b633ed488fbf315d7bcb4b9c40_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjc1OTc_b6cc51ce-7bd1-4695-8cda-8311b25e36b9">261</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifd8ddd71ad6a4934a591d1a60321c3c2_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjc2MDI_b334d9dc-a6ba-4bf3-9e50-e13c1dee0b6a">218</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively.</span></div></ix:continuation><div id="i72faa4a0a4974dcca6db2bf491b63d7a_148"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90ZXh0cmVnaW9uOmY5YTI4NTYxYmJkYzRiZDE5YjBjNTFmMzNhMzkxYTQ2Xzk2Mg_0063a44a-e11b-47fd-ab10-246fac811c2d" continuedAt="i8834e924bae244c8a835ea173e965438" escape="true">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</ix:nonNumeric></span></div><ix:continuation id="i8834e924bae244c8a835ea173e965438"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock method.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common shareholders because their effect would have been antidilutive were <ix:nonFraction unitRef="shares" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90ZXh0cmVnaW9uOmY5YTI4NTYxYmJkYzRiZDE5YjBjNTFmMzNhMzkxYTQ2Xzc4Mw_18588003-0847-4535-ae3e-b7e9187c9f23">15</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90ZXh0cmVnaW9uOmY5YTI4NTYxYmJkYzRiZDE5YjBjNTFmMzNhMzkxYTQ2XzIxOTkwMjMyNTY1NTM_7dc73112-f025-4d56-bfdb-44b4f7cfc3a6">13</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90ZXh0cmVnaW9uOmY5YTI4NTYxYmJkYzRiZDE5YjBjNTFmMzNhMzkxYTQ2XzIxOTkwMjMyNTY1NTk_045a69df-d6dc-4b92-9942-de41c18e8ba7">14</ix:nonFraction> million during 2021, 2020 and 2019, respectively.</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90ZXh0cmVnaW9uOmY5YTI4NTYxYmJkYzRiZDE5YjBjNTFmMzNhMzkxYTQ2Xzk3MQ_e4495827-72d1-4422-b85c-e4bae542919b" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzItMi0xLTEtMTIxNDA_c15b37d5-937e-4653-ac08-5bc65a955290">6,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzItNC0xLTEtMTIxNDA_8e033343-f34e-4c9a-84c7-7c0d0e29ba65">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzItNi0xLTEtMTIxNDA_6e26a8f1-6e99-4e9e-a024-e2d490df86b5">5,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzMtMi0xLTEtMTIxNDA_ef43602e-1dab-41bc-b513-bdce0cc162e8">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzMtNC0xLTEtMTIxNDA_d02244cc-a4ea-48e8-a41d-fc457d780973">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzMtNi0xLTEtMTIxNDA_e6a3fe3b-d9e4-4822-a080-2c7e31bc82d4">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzQtMi0xLTEtMTIxNDA_c71ee2c0-bf00-4846-990b-89a8391f2a53">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzQtNC0xLTEtMTIxNDA_ae73062b-f054-4036-a1d2-031d4267a8d1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzQtNi0xLTEtMTIxNDA_79e520d3-2730-4874-bd10-6b3295b012dc">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzUtMi0xLTEtMTIxNDA_caa9d450-8268-419a-a5dc-9931a84888ab">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzUtNC0xLTEtMTIxNDA_223573d3-e9a6-45cf-8aba-18229b7194ad">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzUtNi0xLTEtMTIxNDA_251e6e6c-76f5-4f2a-af8b-fc59a5ff9109">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzYtMi0xLTEtMTIxNDA_f451b2d5-dff5-42b7-aee2-9e0ade70c961">4.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzYtNC0xLTEtMTIxNDA_bb894a0a-b337-47ba-a7b6-8739bc4a5872">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzYtNi0xLTEtMTIxNDA_07c678cc-c490-45b0-b781-e11dcb1486df">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzctMi0xLTEtMTIxNDA_901700f4-5b8d-43f5-920e-0b6418eae4d8">4.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzctNC0xLTEtMTIxNDA_488c9450-b9dd-4a19-b201-86cc053e239b">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzctNi0xLTEtMTIxNDA_ed4779fd-bb9b-4031-8dc0-c751bb10ed14">4.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzQ4OTE_b240e650-e85c-44b6-9ac7-1eb525a22a03" continuedAt="ic9fa19d56c78400e9889e090abba5114" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="ic9fa19d56c78400e9889e090abba5114" continuedAt="i52ab1c6c78b14a0f8294e3eb9536846f"><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzQ4ODQ_f6fbd486-0da8-4066-93ca-b540fa5ba82b" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes consists of the following:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzItMi0xLTEtMTIxNDA_c02abafe-4978-45d0-8b8d-b082957b906b">8,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzItNC0xLTEtMTIxNDA_d78a6b06-b097-4c3b-bc27-9463a69e6ead">2,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzItNi0xLTEtMTIxNDA_27896a6c-a4a5-42e5-89f9-be9ae19f22c9">4,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzMtMi0xLTEtMTIxNDA_d44cc193-bb93-409f-ad70-c1a05717eff7">309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzMtNC0xLTEtMTIxNDA_3743b2a1-dcb9-4228-9bfa-5120cd092bf8">836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzMtNi0xLTEtMTIxNDA_50481489-f1e4-47a1-91ca-c594ceacc3be">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzQtMi0xLTEtMTIxNDA_d2c2e1c9-ccd6-4d83-abf4-a3db68b09562">8,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzQtNC0xLTEtMTIxNDA_184cf0fc-8539-4b08-884b-4d39c0d2a7d3">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzQtNi0xLTEtMTIxNDA_95e05016-e774-4f73-8597-fa1a7b6ed7b8">5,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzQ4OTI_3bb581f8-067f-40f7-877b-e8a057e752dd" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Income tax (expense) benefit consists of the following:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzMtMi0xLTEtMTIxNDA_f3d2982b-4c8c-4917-8efc-ac9c37f62270">1,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzMtNC0xLTEtMTIxNDA_b7acbbe5-da0e-4230-ac98-c950633b9e3e">1,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzMtNi0xLTEtMTIxNDA_8a7386a4-ad96-4c49-a79e-c304b7f3627c">1,646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzQtMi0xLTEtMTIxNDA_fa811547-5288-447c-8087-30ea7d37c651">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzQtNC0xLTEtMTIxNDA_f26c6d11-52bd-4a45-a3d4-ee6f0895b9af">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzQtNi0xLTEtMTIxNDA_16a748b0-d9b0-46f1-b20f-4265e78e0fc7">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzUtMi0xLTEtMTIxNDA_978b6478-8097-4aae-84ee-8e632b97888e">1,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzUtNC0xLTEtMTIxNDA_ce37c470-7503-4a24-b05b-05e25c735e72">1,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzUtNi0xLTEtMTIxNDA_64a6325d-735e-4225-9077-bb0a60c81229">803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzctMi0xLTEtMTIxNDA_88f97844-6355-498b-aad1-6cfe632792ff">228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzctNC0xLTEtMTIxNDA_30c8efcb-8c9e-4048-92d0-a6faa233f7cf">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzctNi0xLTEtMTIxNDA_63123bea-9f36-489b-ac8a-82d3a8b7effa">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzgtMi0xLTEtMTIxNDA_fff4e8e4-9540-4ad7-ac1a-68a03f898c11">185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzgtNC0xLTEtMTIxNDA_29a5fd59-1902-4b16-a7ac-677c249a4773">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzgtNi0xLTEtMTIxNDA_27e9dd2f-6988-4df3-9228-8f19943fa72a">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzktMi0xLTEtMTIxNDA_3923c5bc-87b2-40b2-b5a3-27559431cc19">413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzktNC0xLTEtMTIxNDA_0ac2ea67-af0b-4634-a5b0-16644178d5be">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzktNi0xLTEtMTIxNDA_b6f4d91c-fd74-489a-b0bf-5933453826bc">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzExLTItMS0xLTEyMTQw_996395e6-d869-4b11-9a4e-01e2bb43ce43">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzExLTQtMS0xLTEyMTQw_86660afe-e094-4bc5-8989-0522f395ecb0">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzExLTYtMS0xLTEyMTQw_13ae7bd6-d442-458d-8c98-229b2891eae6">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzEyLTItMS0xLTEyMTQw_69a8cc62-4a6f-446e-8f15-cd597906ca10">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzEyLTQtMS0xLTEyMTQw_8a65cdde-ddda-42bf-a64d-453a7efd802d">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzEyLTYtMS0xLTEyMTQw_9a41804f-3ed9-4f85-a0a7-633cba26fca6">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzEzLTItMS0xLTEyMTQw_6ce186da-9a21-42d7-98c4-99629960da3e">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzEzLTQtMS0xLTEyMTQw_9db51a47-5c50-45d7-ad78-c7d3cccd5188">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzEzLTYtMS0xLTEyMTQw_27e9319e-6c39-4c65-ae85-f3e9ef2c8ad1">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzE0LTItMS0xLTEyMTQw_9a9ce1c7-1646-4fd0-8b4f-b4f8ee4b150d">2,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzE0LTQtMS0xLTEyMTQw_762838af-9c60-4c9e-9c4f-dc21a6098b94">1,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzE0LTYtMS0xLTEyMTQw_d0faeb43-a966-4ad7-830d-f0ddb55cebce">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 income tax benefit included a $<ix:nonFraction unitRef="usd" contextRef="ie16d6139caf042729e09c331c0223fee_D20190101-20191231" decimals="-8" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjUyNDk_d8332c90-b5d2-4c3b-8e5f-0876ebf42389">1.2</ix:nonFraction> billion deferred tax benefit related to intangible asset transfers from a foreign subsidiary to Ireland and the United States. In the fourth quarter of 2019, we completed an intra-entity asset transfer of certain intangible assets from a foreign subsidiary to Ireland. The transaction resulted in a step-up of the Irish tax-deductible basis in the transferred assets, and accordingly, created a temporary difference where the tax basis exceeded the financial statement basis of such intangible assets. As a result, we recognized a deferred tax asset of $<ix:nonFraction unitRef="usd" contextRef="i49ab5beb24194822982742d602f870c9_I20191231" decimals="-8" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjUyODM_e7a3a3c7-5299-460a-8641-968aedbde451">1.2</ix:nonFraction> billion on our Consolidated Financial Statements. We expect to be able to realize the deferred tax asset resulting from this intra-entity asset transfer. The impact of the intangible asset transfer from a foreign subsidiary to the United States was not material.</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzQ4NzI_2f148eae-2ff2-4996-849d-0f5efe83f390" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the federal statutory tax rate applied to income before income taxes and our effective tax rate is summarized as follows:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzItMi0xLTEtMTIxNDA_949899c6-6961-4506-a96f-5ccf94d083b8">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzItNC0xLTEtMTIxNDA_68edca6d-b1c5-45f3-82c6-3c776862572f">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzItNi0xLTEtMTIxNDA_9be67080-fe20-40a6-be89-19e8b707a468">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzMtMi0xLTEtMTIxNDA_4a3a492e-6994-493c-9d74-b46ea154f491">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzMtNC0xLTEtMTIxNDA_307dd91b-454f-44fc-ba7e-f89f9c194ffc">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzMtNi0xLTEtMTIxNDA_9932fc41-82f1-4b5a-8c6e-75524c32f625">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at different rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzQtMi0xLTEtMTIxNDA_44d3003f-779f-4f7f-86a5-7e1bf43f0404">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzQtNC0xLTEtMTIxNDA_98d509f0-c0b3-4507-ac48-362a0334f5c4">10.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzQtNi0xLTEtMTIxNDA_7b0b43c9-cec6-440d-b38e-25792b35d817">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzUtMi0xLTEtMTIxNDA_b371d939-1bfb-4666-9a53-8a94524de130">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzUtNC0xLTEtMTIxNDA_3ae362cd-c1ad-49e6-a8b3-c90b259befcf">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzUtNi0xLTEtMTIxNDA_5241342b-853a-439b-b2ba-dd5d86d56cea">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US tax on foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzYtMi0xLTEtMTIxNDA_7f4170d8-d57c-4fd2-8891-a56dd8850543">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzYtNC0xLTEtMTIxNDA_f2edff33-7fb6-48c0-9b8f-d7c43d14e9a3">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzYtNi0xLTEtMTIxNDA_18e94590-d512-46cc-9922-11b0dfa71294">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzctMi0xLTEtOTY2OTc_f102d5fb-500b-47c1-ac17-b94b572583c0">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzctNC0xLTEtOTY2OTc_e2cb3508-0683-440c-80fd-1d24a76435ab">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzctNi0xLTEtOTY2OTc_69306f60-5770-4138-b5b7-c7ec1372d9b7">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax - intra-entity transfer of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzctMi0xLTEtMTIxNDA_27d07d4c-03a0-4766-9608-47b5586c4ae0">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzctNC0xLTEtMTIxNDA_d76debdd-f115-4e34-8a1a-efaa3723f4fd">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzctNi0xLTEtMTIxNDA_0cb14536-cd71-4f1d-9407-cbcf051f343a">24.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of tax examinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzgtMi0xLTEtMTIxNDA_cee35c6e-5f7a-4fec-b5e4-552c44e5f088">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzgtNC0xLTEtMTIxNDA_f9646520-aa1d-487f-b014-45e003f62d18">10.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzgtNi0xLTEtMTIxNDA_24dc3b72-e5da-4892-a3ea-18c18edf8075">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D and related charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzktMi0xLTEtMTIxNDA_8c4db68b-e369-44f2-983a-b1c3b3cd547e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzktNC0xLTEtMTIxNDA_5abc821a-5921-45dc-a78d-847ad65c5f0f">56.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzktNi0xLTEtMTIxNDA_fa0fd5e8-3319-4199-a342-afa672c7a990">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEwLTItMS0xLTEyMTQw_0df697d6-75f0-4baf-b07f-bdd896e5e7f1">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEwLTQtMS0xLTEyMTQw_81c017d0-73f4-4003-a365-91ae260cc213">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEwLTYtMS0xLTEyMTQw_601dbf94-e878-4313-b0df-cc526612653c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable unrealized (gain)  loss on investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzExLTItMS0xLTEyMTQw_8cac1e0e-be37-42ee-99cf-e5eb620adeb6">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzExLTQtMS0xLTEyMTQw_08f8e7b0-704b-4033-9549-bf4eed61339e">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzExLTYtMS0xLTEyMTQw_e68a25e0-7e2b-4a03-8bcc-ca1a65dc3c10">5.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEyLTItMS0xLTEyMTQw_5a651de8-f45e-4e53-9afd-9a75586a0ce9">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEyLTQtMS0xLTEyMTQw_633b6f7a-0fb3-415a-8e25-ac6daa0c3dff">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEyLTYtMS0xLTEyMTQw_a72ea971-c712-47b9-9e79-3d560b36fa6f">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEzLTItMS0xLTEyMTQw_66b7dd48-cd67-4bff-8a8e-dbf14094a79c">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEzLTQtMS0xLTEyMTQw_dee11782-794c-4c7a-812d-8f832ccc396f">94.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEzLTYtMS0xLTEyMTQw_8a626d00-a946-4bb9-a9bf-0927ae2aba3a">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i52ab1c6c78b14a0f8294e3eb9536846f" continuedAt="i29cd245a9f5e4b868ce53af94e9d730f"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzQ4NjY_0e435777-8090-4a07-bdaf-f12faccf4cfe" continuedAt="ie0b8e222b37044f2a4d03fc485062fe3" escape="true">Significant components of our deferred tax assets and liabilities are as follows:</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:center"><ix:continuation id="ie0b8e222b37044f2a4d03fc485062fe3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzMtMi0xLTEtMTIxNDA_af947029-07dc-4a65-9225-c339efd5ae6a">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzMtNC0xLTEtMTIxNDA_7cd234bd-6ad8-467f-bc5d-e0d1b6be02a1">587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzQtMi0xLTEtMTIxNDA_d42f5dc0-3229-41f9-8e8c-f0262f8b2b06">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzQtNC0xLTEtMTIxNDA_33c85f1d-7d6b-47e3-95b9-442ff87f7ed5">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals not currently deductible</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzUtMi0xLTEtMTIxNDA_cd1a185f-1d10-4f69-b598-945cf2772f3c">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzUtNC0xLTEtMTIxNDA_961f9cf1-91c2-43f3-bc50-c42d47dba594">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of tax basis over book basis of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzYtMi0xLTEtMTIxNDA_dbf496a9-a3a7-4c2b-a390-6451a2d638d7">1,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzYtNC0xLTEtMTIxNDA_c7159469-78ec-4477-9294-9808aec40edf">1,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront and milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="gild:DeferredTaxAssetsUpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzctMi0xLTEtMTIxNDA_36fdd640-eb35-41d7-a924-3e09448c284c">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="gild:DeferredTaxAssetsUpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzctNC0xLTEtMTIxNDA_5d1ee3f3-371b-403c-93d6-56abf4d869e0">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzgtMi0xLTEtMTIxNDA_a9f686e9-577e-4755-945b-2465399bf47e">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzgtNC0xLTEtMTIxNDA_5234347a-bc9c-4220-83e4-5f911e5a71eb">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzktMi0xLTEtMTIxNDA_990e0c44-b01f-458f-bb60-879480783c0c">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzktNC0xLTEtMTIxNDA_669d381b-995b-413c-8908-64eb9ab180a7">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzEwLTItMS0xLTEyMTQw_f87e17c6-7d18-4417-b7f0-f7e7a4c1f7b7">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzEwLTQtMS0xLTEyMTQw_c628a2c9-ee0b-4bbd-8d89-14967d9e1ac0">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzExLTItMS0xLTEyMTQw_9ac4c7dc-6df7-4b8e-a44b-1a12511b3bac">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzExLTQtMS0xLTEyMTQw_71f79ca3-a9a6-4b8d-aecb-3d8b9764a3fb">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzEyLTItMS0xLTEyMTQw_693c0309-039c-42b1-b290-5434ad5922fa">4,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzEyLTQtMS0xLTEyMTQw_f7c3eb91-228f-450c-99ba-6aef00321ef3">4,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzEzLTItMS0xLTEyMTQw_f377ac7d-9cd5-4684-8ce6-393f56106f3e">520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzEzLTQtMS0xLTEyMTQw_40d0759a-12ef-4fad-99bd-0a37cd196a68">398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE0LTItMS0xLTEyMTQw_688a7d92-35a0-4532-9bbc-4f3c32765f9b">4,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE0LTQtMS0xLTEyMTQw_5adc65c2-56ca-4581-8dba-8b517e969003">3,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE2LTItMS0xLTEyMTQw_1a3904b8-1c7a-41cb-bbb8-8cbfde2c6575">227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE2LTQtMS0xLTEyMTQw_d097173a-9faf-4f27-af82-b3a8cfc15222">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of book basis over tax basis of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE3LTItMS0xLTEyMTQw_5773e126-2d27-4de3-8047-1657aad5fd80">6,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE3LTQtMS0xLTEyMTQw_a4505619-058d-4466-9bca-054bcf462675">6,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE4LTItMS0xLTEyMTQw_be9e7a35-0b19-4ef7-a85a-a5ff6c6ad244">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE4LTQtMS0xLTEyMTQw_be0097d6-4045-41af-80a0-a91817db7fd2">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE5LTItMS0xLTEyMTQw_e37947d7-7abb-4a27-972a-1db1e41b17e0">7,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE5LTQtMS0xLTEyMTQw_980774c5-8145-462e-bfef-d7f430b62ff5">6,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzIwLTItMS0xLTEyMTQw_08c7ff38-a359-4b31-b99e-4ded9e30b404">3,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzIwLTQtMS0xLTEyMTQw_ef3adb8c-7aa4-4051-b785-c17e160dc7fb">2,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance was $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzI3NDg3NzkwNzgxOTA_d1e320fb-58d2-4452-b849-dba78a47dc72">520</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzI3NDg3NzkwNzc2Njg_99f0f270-5ffb-44ea-afeb-2f5e588c1926">398</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively. The increase of our valuation allowance in 2021 was primarily related to California research and development tax credits.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance was $<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzI3NDg3NzkwNzY1MjE_99f0f270-5ffb-44ea-afeb-2f5e588c1926">398</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzI3NDg3NzkwNzY4NTI_b1d2aba1-a1fa-4bc8-bcd6-950ee228e6af">217</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. The increase of our valuation allowance in 2020 was primarily related to acquired attributes related to Forty Seven and Immunomedics acquisitions, and capital losses related to our equity method investments.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had U.S. federal net operating loss and tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i77335a2113da496c800ece78587ef758_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA1Njk_0ab88546-4494-4b7a-aa20-3a92f3987440">250</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i77335a2113da496c800ece78587ef758_I20211231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA1Nzg_4b1245b1-55a2-4f7c-b62b-e5ddd31b9067">8</ix:nonFraction> million, respectively, which will start to expire in 2022, if not utilized. In addition, we had state net operating loss and tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ie33787d4b92844f0b3f49ee4b16ba703_I20211231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA1ODc_da40eda2-459b-41ba-a1cd-0a231b933845">2.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie33787d4b92844f0b3f49ee4b16ba703_I20211231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA1OTk_b95c537a-aa6c-4fa2-974a-d6decede9b6f">768</ix:nonFraction> million, respectively. The state net operating loss and state tax credit carryforwards will start to expire in 2022 if not utilized.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of net operating losses and tax credits may be subject to an annual limitation due to ownership change limitations provided in the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file federal, state and foreign income tax returns in the United States and in many foreign jurisdictions. For federal income tax purposes, the statute of limitations is open for 2016 and onwards and 2013 and onwards for California income tax purposes. For certain acquired entities, the statute of limitations is open for all years from inception due to our utilization of their net operating losses and credits carried over from prior years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service and Irish tax authorities for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.</span><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i29cd245a9f5e4b868ce53af94e9d730f"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total unrecognized tax benefits, $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA2MTE_180c1b18-ca08-4a6d-a1bc-78fe215f1173">800</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-8" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA2MDc_bb4a0106-7dbe-47ce-bac5-555cb36f8f7b">1.2</ix:nonFraction> billion as of December&#160;31, 2021 and 2020, respectively, if recognized, would reduce our effective tax rate in the period of recognition. Interest and penalties related to unrecognized tax benefits included income tax expense of $<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzkzNDU4NDg4NDc3MDM_48cfe713-0c30-4093-a29a-b4942bcc2cf0">41</ix:nonFraction> million, income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA2MTk_1c64bd4e-ecf6-4d3f-bdd5-6548586738a5">82</ix:nonFraction> million and income tax expense of $<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzkzNDU4NDg4NDk3MzI_ef85dcf6-802f-4cab-bb87-b5df9f58a0b7">105</ix:nonFraction> million on our Consolidated Statements of Income for the years ended December&#160;31, 2021, 2020 and 2019 respectively. Accrued interest and penalties related to unrecognized tax benefits were $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA2NDI_441ef70e-37bf-46bf-9696-1f39a4164a08">218</ix:nonFraction> million</span><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA2Mzg_8ff2489a-0d1d-4cc4-a707-9741b89dcfdb">177</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we believe that it is reasonably possible that our unrecognized tax benefits will decrease by approximately $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzEwOTk1MTE2MzkzMzg_d19c0cae-5953-40ed-a133-a86a68338b80">100</ix:nonFraction> million in the next 12 months due to potential settlements with various taxing authorities.</span></div><ix:nonNumeric contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzQ4OTY_11befe19-0a8a-4a67-993c-311a3ec1cad8" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our total gross unrecognized tax benefits:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzItMi0xLTEtMTIxNDA_e04ce945-b37d-4a1a-acbe-d73d5ff0df21">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzItNC0xLTEtMTIxNDA_1ecd07ea-b35b-4902-870d-f233e1f6f2e5">2,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8222e290a2284cb0bf64a4ac2b6995b5_I20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzItNi0xLTEtMTIxNDA_a28c02d0-feba-4c34-873a-2143069a1f4a">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzQtMi0xLTEtMTIxNDA_abfa89a4-10c1-4762-8621-0b0766dc8cc4">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzQtNC0xLTEtMTIxNDA_25c6b91b-0b91-4183-af3f-d1002c5f9c95">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzQtNi0xLTEtMTIxNDA_cbfbd56c-0f9a-40a4-bf6e-db9e7fe0daf3">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzUtMi0xLTEtMTIxNDA_91465122-2084-44de-8810-108fa6657c75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzUtNC0xLTEtMTIxNDA_ac76726d-2f8b-456c-aa2d-e7c2b11b8ce6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzUtNi0xLTEtMTIxNDA_a593c3c0-bab0-446c-9522-c86feaff23db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzctMi0xLTEtMTIxNDA_19df6009-e380-49f2-9e92-082a5079645b">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzctNC0xLTEtMTIxNDA_aeb3ce6c-924b-4bb6-a6e4-286fe8da7aa9">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzctNi0xLTEtMTIxNDA_76f75e73-1292-4cea-bfae-42b23b342104">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzgtMi0xLTEtMTIxNDA_ea4364ea-ccff-4b1f-89fe-583a67565295">179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzgtNC0xLTEtMTIxNDA_06b9cf98-4661-4281-bdf1-4d14fa91d00d">481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzgtNi0xLTEtMTIxNDA_cbfd4d45-9d6a-44b5-9f7f-d02065777765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzktMi0xLTEtMTIxNDA_7b5eba7d-195a-47ed-b0b3-e043d4dd0df5">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzktNC0xLTEtMTIxNDA_1e30881d-6c88-41fd-8232-bc01aa23648d">454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzktNi0xLTEtMTIxNDA_c56250f0-8097-4398-8ffb-45fb4cc14455">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzEwLTItMS0xLTEyMTQw_f3ddf463-5961-4bf8-b45e-0d49e340a149">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzEwLTQtMS0xLTEyMTQw_3c9e15ed-bb95-492a-b98f-4b292303fdf5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzEwLTYtMS0xLTEyMTQw_4771a3db-a2cd-4b8c-8f58-cb8273dac5d3">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzExLTItMS0xLTEyMTQw_05a26092-66fd-4a98-a910-5658d544ec70">1,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzExLTQtMS0xLTEyMTQw_d4188d45-4ac7-4ae0-9eb8-2f06afcc63bf">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzExLTYtMS0xLTEyMTQw_7664c8fd-ecd3-4c3e-b50e-8101805ffa12">2,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Tax Cuts and Jobs Act, we recorded a federal income tax payable for transition tax on the mandatory deemed repatriation of foreign earnings that is payable over an eight-year period. As of December&#160;31, 2021 and 2020, we have accrued $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-8" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzkzNDU4NDg4NDg5MDY_f1f90031-9d12-47af-8f71-a3cf124b8089">4.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231" decimals="-8" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzkzNDU4NDg4NDg5MjU_8c8d372e-4c86-45a9-af3d-f096bd3da603">4.5</ix:nonFraction> billion, respectively, for transition tax. Of the amounts accrued as of December&#160;31, 2021, approximately $<ix:nonFraction unitRef="usd" contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231" decimals="-6" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzkzNDU4NDg4NDg5NDM_22daf962-7a8a-4a56-b829-211d4597b5d2">473</ix:nonFraction> million is expected to be paid within one year.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Gilead Sciences, Inc. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Gilead Sciences, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Gilead Sciences, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2021, based on the COSO criteria.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2021 and 2020, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2021, and the related notes and our report dated February&#160;23, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion</span><span style="color:#b6b6b6;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Evaluation of Disclosure Controls and Procedures </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation as of December&#160;31, 2021 was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our &#8220;disclosure controls and procedures,&#8221; which are defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as controls and other procedures of a company that are designed to ensure that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to the company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December&#160;31, 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Management&#8217;s Report on Internal Control over Financial Reporting </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule&#160;13a-15(f) and 15d-15(f) of the Exchange Act. Our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of financial statements for external purposes in accordance with generally accepted accounting principles. All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable assurance that the objectives of the internal control system are met. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting, based on criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in its 2013 Internal Control-Integrated Framework. Based on our evaluation, we concluded that our internal control over financial reporting was effective as of December&#160;31, 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm, Ernst&#160;&amp; Young LLP, has audited our Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K and have issued a report on our internal control over financial reporting as of December&#160;31, 2021. Its report on the audit of internal control over financial reporting appears above. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Changes in Internal Control over Financial Reporting </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, has evaluated any changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2021, and has concluded that there was no change during such quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_166"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_1732"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_169"></div><div style="margin-top:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_172"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item concerning our directors and executive officers is incorporated by reference to the sections of our Definitive Proxy Statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with our 2022 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;) under the headings &#8220;The Gilead Board of Directors - Nominees,&#8221; &#8220;Board Structure,&#8221; &#8220;Executive Officers,&#8221; and, if applicable, &#8220;Delinquent Section&#160;16(a) Reports.&#8221; </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our written Code of Ethics applies to all of our directors and employees, including our executive officers, including without limitation our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. The Code of Ethics is available on our website at www.gilead.com in the &#8220;Investors&#8221; section under &#8220;Corporate Governance.&#8221; We intend to disclose future amendments to certain provisions of the Code of Ethics, and waivers of the Code of Ethics granted to executive officers and directors, on the website within four business days following the date of the amendment or waiver.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the sections of the Proxy Statement under the headings &#8220;Executive Compensation,&#8221; &#8220;Committees of our Board of Directors,&#8221; &#8220;Compensation and Talent Committee Report,&#8221; and &#8220;Compensation of Non-Employee Board Members.&#8221; </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_178"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to Item 5 of our Annual Report on Form 10-K under the heading &#8220;Equity Compensation Plan Information&#8221; and the section of the Proxy Statement under the heading &#8220;Security Ownership of Certain Beneficial Owners and Management.&#8221;</span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_181"></div><div style="margin-top:13.5pt;padding-left:60.75pt;text-align:justify;text-indent:-60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the sections of the Proxy Statement under the headings &#8220;The Gilead Board of Directors,&#8221; and &#8220;Board Processes.&#8221; </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_184"></div><div style="margin-top:13.5pt;padding-left:60.75pt;text-align:justify;text-indent:-60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL ACCOUNTANT FEES AND SERVICES </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the section&#160;of the Proxy Statement under the heading &#8220;Principal Accountant Fees and Services.&#8221; </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_187"></div><div style="margin-top:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV </span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_190"></div><div style="margin-top:13.5pt;padding-left:60.75pt;text-align:justify;text-indent:-60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_193"></div><div style="-sec-extract:summary;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The following documents are filed as part of this Annual Report on Form&#160;10-K: </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Index list to Consolidated Financial Statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_73">Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_73">50</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_76">Audited Consolidated Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_79">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_79">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_82">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_82">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_85">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_85">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_88">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_88">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_91">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_91">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_94">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_94">57</a></span></div></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) All other schedules are omitted because they are not required or the required information is included in the financial statements or notes thereto. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Exhibits.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed herewith or incorporated by reference:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit<br/>Footnote</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000095010320017822/dp136480_ex0201.htm">Agreement and Plan of Merger, dated September 13, 2020, among Immunomedics, Inc., Gilead Sciences, Inc. and Maui Merger Sub, Inc</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920027472/tm2011253d2_ex2-1.htm">.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920027472/tm2011253d2_ex2-1.htm">Agreement and Plan of Merger, by and among Forty Seven, Inc., Registrant and Toro Merger Sub, Inc., dated March 1, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d2.htm">Restated Certificate of Incorporation of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d3.htm">Amended and Restated Bylaws of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex41.htm">Indenture related to Senior Notes, dated as of March&#160;30, 2011, between Registrant and Wells Fargo, National Association, as Trustee</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex42.htm">First Supplemental Indenture related to Senior Notes, dated as of March 30, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including form of Senior Notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511339157/d269235dex41.htm">Second Supplemental Indenture related to Senior Notes, dated as of December 13, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511339157/d269235dex41.htm">Form of 2041 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm">Third Supplemental Indenture related to Senior Notes, dated as of March 7, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2024 Note</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm"> a</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm">nd</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm"> Form of 2044 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm">Fourth Supplemental Indenture related to Senior Notes, dated as of November 17, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm">Form of 2025 Note</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm"> and</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm"> Form of 2045 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312515319560/d68529dex41.htm">Fifth Supplemental Indenture, dated as of September 14, 2015, between Registrant and Wells Fargo Bank, National Association, as Trustee (including </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312515319560/d68529dex41.htm">Form of 2026 Note, Form of 2035 Note and Form of 2046 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312516714926/d259911dex41.htm">Sixth Supplemental Indenture, dated as of September 20, 2016, between Registrant and Wells Fargo Bank, National Association, as Trustee (including </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312516714926/d259911dex41.htm">Form of 2023 Note, Form of 2027 Note, Form of 2036 Note and Form of 2047 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm">Eighth Supplemental Indenture, dated as of September 30, 2020, between the </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm">Registrant</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm"> and Wells Fargo Bank, National Association, as Trustee (including form of notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/gild2019form10-kex49.htm">Description of Registrant&#8217;s Securities</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(12)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312517168672/d396034dex101.htm">Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000008/gild20ormex102amendmentto2.htm">Amendment No. 1 to Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1042.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex104.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex105.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex105.htm"> in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex1072021employe.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312509165506/dex1019.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2009 through 2012)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1043.htm">Form of non-employee director stock option agreement (U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1044.htm">Form of non-employee director stock option agreement (non-U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209514000038/ex1045-stockoptionagreement.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2014 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm"> in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(22)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.13*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants commencing in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.14*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1012.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1013.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1013.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1013.htm"> in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.16*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10162021psuagr.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1015.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1017.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1017.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1017.htm"> in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.19*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10192021psuagr.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1057.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1017.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.22*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1020.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1024.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.24*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10242021employ.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(22)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.25*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm">Form of non-employee director restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants commencing in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(22)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.26*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10272018eq.htm">Gilead Sciences, Inc. 2018 Equity Incentive Plan, amended and restated April 7, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(23) </span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.27*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000015/exhibit101-espp.htm">Gilead Sciences, Inc. Employee Stock Purchase Plan, amended and restated January 22, 2015</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.28*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1020.htm">Gilead Sciences, Inc. 2005 Deferred Compensation Plan, amended and restated April 19, 2016</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(22)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.29*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1030severa.htm">Gilead Sciences, Inc. Severance Plan, amended and restated May 5, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.30*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1028.htm">Gilead Sciences, Inc. Corporate Annual Incentive Plan, amended and restated January 1, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.31*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465918072098/a18-41320_1ex99d2.htm">Offer Letter between Registrant and Daniel O&#8217;Day, dated November 30, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.32*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1027.htm">Stock option agreement for Daniel O&#8217;Day under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.33*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1028.htm">Performance share award agreement for Daniel O&#8217;Day (for TSR Goals in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.34*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1029.htm">Performance share award agreement for Daniel O&#8217;Day (for Revenue Goals in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.35*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1029.htm">Form of restricted stock unit issuance agreement for Daniel O&#8217;Day (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.36*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1026.htm">Offer Letter between Registrant and Johanna Mercier, dated May 21, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(22)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.37*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1043housin.htm">Letter Agreement between Registrant and Johanna Mercier, dated May 4, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.38*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1040.htm">Global stock option agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1041.htm">Restricted stock unit issuance agreement for Johanna Mercier (for Performance Objectives in 2019-2020) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.40*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1042.htm">Global restricted stock unit issuance agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.41*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1043.htm">Offer Letter between Registrant and Merdad Parsey, dated September 29, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.42*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1044.htm">Global stock option agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.43*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1045.htm">Global restricted stock unit issuance agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(25)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.44*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Indemnity Agreement entered into between Registrant and its directors and executive officers</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(25)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.45*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(26)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.46*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312507041203/dex103.htm">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees (revised September&#160;2006)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(27)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amendment Agreement, dated October&#160;25, 1993, between Registrant, the Institute of Organic Chemistry and Biochemistry (IOCB) and Rega Stichting v.z.w. (REGA), together with the following exhibits: the License Agreement, dated December&#160;15, 1991, between Registrant, IOCB and REGA (the 1991 License Agreement); the License Agreement, dated October&#160;15, 1992, between Registrant, IOCB and REGA (the October 1992 License Agreement); and the License Agreement, dated December&#160;1, 1992, between Registrant, IOCB and REGA (the December 1992 License Agreement)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(28)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000091205701007841/a2041233zex-10_13.txt">Amendment Agreement between Registrant and IOCB/REGA, dated December&#160;27, 2000, amending the 1991 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(29)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312506223996/dex103.htm">Sixth Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated August&#160;18, 2006, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(30)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000046/q313form10-qxexhibit1078.htm">Seventh Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated July 1, 2013, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(31)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.51</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022622/000091205799003190/0000912057-99-003190.txt">Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University, dated May&#160;6, 1999</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(32)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Royalty Sale Agreement by and among Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;18, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(32)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Amended and Restated License Agreement by and between Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;21, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(33)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.54</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1042.htm">Amended and Restated EVG License Agreement by and between Japan Tobacco Inc. and Registrant, dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(33)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.55</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1043.htm">Master Agreement by and between Registrant, Gilead Sciences K.K. and Japan Tobacco Inc., dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(34)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000008/ex1076-arcollaborationagre.htm">Amended and Restated Collaboration Agreement by and among Registrant, Gilead Sciences Ireland UC (formerly Gilead Sciences Limited) and Janssen R&amp;D Ireland, dated December 23, 2014</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(35)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1510580/000119312514239257/d705296dex1017.htm">License Agreement by and among Kite Pharma, Inc., Cabaret Biotech Ltd. and Dr. Zelig Eshhar, dated December 12, 2013</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.58</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1050.htm">Option, License and Collaboration Agreement by and between Galapagos NV and Registrant, dated July 14, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">21.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2021form10-kexhibit211.htm">Subsidiaries of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2021form10-kexhibit231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">24.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i72faa4a0a4974dcca6db2bf491b63d7a_199">Power of Attorney (included on the signature page of this report)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2021form10-kexhibit311.htm">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2021form10-kexhibit312.htm">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">32***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2021form10-kexhibit32.htm">Certifications of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.INS**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.SCH**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.CAL**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.DEF**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.LAB**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.PRE**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">Cover Page Interactive Data File, formatted in Inline XBRL (included as Exhibit 101)</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 14, 2020, and incorporated herein by reference.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on March 2, 2020, and incorporated herein by reference.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 9, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on April&#160;1, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 13, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on March 7, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on November 17, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 14, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 20, 2016, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 12, 2017, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(13)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(16)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(17)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(18)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(19)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2009, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(20)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, and incorporated herein by reference</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(21)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(22)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(23)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 8, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(24)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 10, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(25)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Registration Statement on Form S-1 (No. 33-55680), as amended, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(26)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(27)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended March&#160;31, 1994, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(28)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2000, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(29)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(30)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(31)&#160;&#160;&#160;&#160;Filed as an exhibit to Triangle Pharmaceuticals, Inc.&#8217;s Quarterly Report on Form 10-Q/A filed on November&#160;3, 1999, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(32)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2005, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(33)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Amendment No. 1 to Annual Report on Form 10-K/A filed on April 18, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(34)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(35)&#160;&#160;&#160;&#160;Filed as an exhibit to Kite Pharma, Inc.&#8217;s Registration Statement on Form S-1/A (No. 333-196081) filed on June 17, 2014, and incorporated herein by reference.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with an asterisk (the Mark). This Exhibit has been filed separately with the Secretary of the Securities and Exchange Commission without the Mark pursuant to Registrant&#8217;s Application Requesting Confidential Treatment under Rule 24b-2 under the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with the Mark because the identified confidential portions are (i) not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_196"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i72faa4a0a4974dcca6db2bf491b63d7a_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.859%"><tr><td style="width:1.0%"></td><td style="width:10.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILEAD SCIENCES, INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daniel P. O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Day</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</span></div></td></tr></table></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel P. O&#8217;Day and Brett A. Pletcher, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel P. O&#8217;Day</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew D. Dickinson</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DIANE E. WILFONG</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diane E. Wilfong</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;JACQUELINE K. BARTON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline K. Barton, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;JEFFREY A. BLUESTONE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey A. Bluestone, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;SANDRA J. HORNING</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra J. Horning, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;KELLY A. KRAMER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly A. Kramer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;KEVIN E. LOFTON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin E. Lofton</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;HARISH MANWANI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harish Manwani</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JAVIER J. RODRIGUEZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Javier J. Rodriguez</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;ANTHONY WELTERS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthony Welters</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>gild2021form10-kexhibit211.htm
<DESCRIPTION>EXHIBIT 21.1 LISTING OF SUBSIDIARIES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id7272b4784b5439d8791b1812831e68d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.903%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUBSIDIARIES OF GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(as of December 31, 2021)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NAME OF SUBSIDIARY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COUNTRY OF FORMATION</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asegua Therapeutics LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forty Seven, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forty Seven Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Alberta, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Apollo, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Biopharmaceutics US LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Calistoga, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Connecticut, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Pharmasset LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Holding, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunomedics, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IBC Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">neoKite, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Argentina S.R.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cytopia Pty. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Pty. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences YM Australia Pty. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">YM BioSciences Australia Pty. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences GesmbH.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Belgium BVBA</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Farmac&#234;utica do Brasil Ltda.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Alberta ULC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Canada, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead YM ULC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fosun Pharma Kite Biotechnology Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences (Shanghai) Consulting Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Hangzhou Pharmaceutical Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Colombia S.A.S.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Columbia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences s.r.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EpiTherapeutics ApS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Denmark ApS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Finland Oy</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences SAS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MYR Pharmaceuticals France SAS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunomedics GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MYR GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Hellas EPE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Hong Kong Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.903%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUBSIDIARIES OF GILEAD SCIENCES, INC. (continued)</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(as of December 31, 2021)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NAME OF SUBSIDIARY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COUNTRY OF FORMATION</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences India Private Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Apollo Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Biopharmaceutics Ireland UC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Ireland Research UC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Oncology Ireland UC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Ireland Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Therapeutics A1 Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Therapeutics A2 Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Israel Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences S.r.l.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences KK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Luxembourg S.a.r.l.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Malaysia Sdn. Bhd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Mexico S. de R.L. de C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Netherlands BV</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma EU B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KP EU C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences (NZ)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Norway AS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Americas S. de R.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Poland Sp. z o.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Lda.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences (GSR) S.R.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Russia LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Singapore Pte. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Slovakia s.r.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences South Africa (Pty) Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Korea Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences S.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Sweden AB</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Switzerland Sarl</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gilead Sciences Ilac Ticaret Limited Sirketi</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Europe Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences International Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>gild2021form10-kexhibit231.htm
<DESCRIPTION>EXHIBIT 23.1 CONSENT OF INDEPENDANT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3edede1781d644a1b58b7176da00abfd_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 33-81670, 33-46058, 333-58893, 333-84719, 333-117480, 333-126012, 333-135412, 333-143920, 333-151624, 333-161069, 333-163871, 333-207813, 333-219772, 333-223248, 333-238525 and 333-249836) pertaining to the Employee Stock Purchase Plan, the International Employee Stock Purchase Plan, the 2004 Equity Incentive Plan and the 2018 Equity Incentive Plan of Gilead Sciences, Inc. and the Amended &#38; Restated 2014 Long-Term Incentive Plan of Immunomedics, Inc., and the Registration Statement on Form S-3 (No. 333-242321) of Gilead Sciences, Inc. and in the related Prospectuses, as applicable, of our reports dated February&#160;23, 2022, with respect to the consolidated financial statements of Gilead Sciences, Inc., and the effectiveness of internal control over financial reporting of Gilead Sciences, Inc., included in this Annual Report (Form 10-K) for the year ended December&#160;31, 2021.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2022</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>gild2021form10-kexhibit311.htm
<DESCRIPTION>SECTION 302 CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icf661819a0e842e88739c28fae35bae6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel P. O&#8217;Day, certify that&#58;</font></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this annual report on Form 10-K of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O&#8217;Day<br>Chairman and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>gild2021form10-kexhibit312.htm
<DESCRIPTION>SECTION 302 CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if7fabf7bbe8245ffb1912210cd96fccb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Andrew D. Dickinson, certify that&#58;</font></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this annual report on Form 10-K of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:24.75pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>gild2021form10-kexhibit32.htm
<DESCRIPTION>SECTION 906 CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4f4514233d0c43188b70ff4127653198_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Exhibit 32</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. &#167; 1350, as adopted), Daniel P. O&#8217;Day, the Chairman and Chief Executive Officer of Gilead Sciences, Inc. (the Company), and Andrew D. Dickinson, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge&#58; </font></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Annual Report on Form&#160;10-K for the annual period ended December&#160;31, 2021 (the Report) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;23, 2022 </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:47.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O&#8217;Day<br>Chairman and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>gild-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4eb1680c-5761-45c7-95ef-3c78b834062a,g:a0cedc55-fc60-4d3f-bea8-ef196ffaa864-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gild="http://www.gilead.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gilead.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.gilead.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.gilead.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.gilead.com/role/ConsolidatedStatementsofIncome">
        <link:definition>1003005 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1004006 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1006008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.gilead.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1007009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.gilead.com/role/Revenues">
        <link:definition>2105102 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.gilead.com/role/RevenuesTables">
        <link:definition>2306302 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDisaggregationofRevenuesDetails" roleURI="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails">
        <link:definition>2407402 - Disclosure - Revenues - Disaggregation of Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesSummarizedRevenuesfromMajorCustomersDetails" roleURI="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails">
        <link:definition>2408403 - Disclosure - Revenues - Summarized Revenues from Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.gilead.com/role/RevenuesNarrativeDetails">
        <link:definition>2409404 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.gilead.com/role/FairValueMeasurements">
        <link:definition>2110103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.gilead.com/role/FairValueMeasurementsTables">
        <link:definition>2311303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails">
        <link:definition>2412405 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails" roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails">
        <link:definition>2413406 - Disclosure - Fair Value Measurements - Summary of Classification on Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>2414407 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecurities" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecurities">
        <link:definition>2115104 - Disclosure - Available-for-Sale Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesTables" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables">
        <link:definition>2316304 - Disclosure - Available-for-Sale Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
        <link:definition>2417408 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>2418409 - Disclosure - Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails">
        <link:definition>2419410 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesAdditionalInformationDetails" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails">
        <link:definition>2420411 - Disclosure - Available-for-Sale Debt Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.gilead.com/role/DerivativeFinancialInstruments">
        <link:definition>2121105 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>2322305 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsAdditionalInformationDetails" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>2423412 - Disclosure - Derivative Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
        <link:definition>2424413 - Disclosure - Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails">
        <link:definition>2425414 - Disclosure - Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails">
        <link:definition>2426415 - Disclosure - Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.gilead.com/role/Acquisitions">
        <link:definition>2127106 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.gilead.com/role/AcquisitionsTables">
        <link:definition>2328306 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.gilead.com/role/AcquisitionsNarrativeDetails">
        <link:definition>2429416 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2430417 - Disclosure - Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.gilead.com/role/Inventories">
        <link:definition>2131107 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.gilead.com/role/InventoriesTables">
        <link:definition>2332307 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofinventoriesDetails" roleURI="http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails">
        <link:definition>2433418 - Disclosure - Inventories - Schedule of inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.gilead.com/role/InventoriesNarrativeDetails">
        <link:definition>2434419 - Disclosure - Inventories - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.gilead.com/role/PropertyPlantandEquipment">
        <link:definition>2135108 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentTables">
        <link:definition>2336308 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>2437420 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNarrativeDetails" roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails">
        <link:definition>2438421 - Disclosure - Property, Plant and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssets">
        <link:definition>2139109 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2340309 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsGoodwillDetails" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails">
        <link:definition>2441422 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails">
        <link:definition>2442423 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails">
        <link:definition>2443424 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1">
        <link:definition>2443424 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails">
        <link:definition>2444425 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.gilead.com/role/OtherFinancialInformation">
        <link:definition>2145110 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.gilead.com/role/OtherFinancialInformationTables">
        <link:definition>2346310 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccountsReceivableNetDetails" roleURI="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails">
        <link:definition>2447426 - Disclosure - Other Financial Information - Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationOtherAccruedLiabilitiesDetails" roleURI="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails">
        <link:definition>2448427 - Disclosure - Other Financial Information - Other Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangements" roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangements">
        <link:definition>2149111 - Disclosure - Collaborations and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsDetails" roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails">
        <link:definition>2450428 - Disclosure - Collaborations and Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilities" roleURI="http://www.gilead.com/role/DebtandCreditFacilities">
        <link:definition>2151112 - Disclosure - Debt and Credit Facilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilitiesTables" roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesTables">
        <link:definition>2352311 - Disclosure - Debt and Credit Facilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails">
        <link:definition>2453429 - Disclosure - Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilitiesNarrativeDetails" roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails">
        <link:definition>2454430 - Disclosure - Debt and Credit Facilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails">
        <link:definition>2455431 - Disclosure - Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.gilead.com/role/Leases">
        <link:definition>2156113 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.gilead.com/role/LeasesTables">
        <link:definition>2357312 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.gilead.com/role/LeasesNarrativeDetails">
        <link:definition>2458432 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalanceSheetLocationDetailDetails" roleURI="http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails">
        <link:definition>2459433 - Disclosure - Leases - Balance Sheet Location Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalInformationRelatedtoLeasesDetails" roleURI="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails">
        <link:definition>2460434 - Disclosure - Leases - Supplemental Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails">
        <link:definition>2461435 - Disclosure - Leases - Summary of Operating Lease Liabilities Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1">
        <link:definition>2461435 - Disclosure - Leases - Summary of Operating Lease Liabilities Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.gilead.com/role/CommitmentsandContingencies">
        <link:definition>2162114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.gilead.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2463436 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.gilead.com/role/StockholdersEquity">
        <link:definition>2164115 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.gilead.com/role/StockholdersEquityTables">
        <link:definition>2365313 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRepurchasesofCommonStockDetails" roleURI="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails">
        <link:definition>2466437 - Disclosure - Stockholders' Equity - Repurchases of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDividendsDetails" roleURI="http://www.gilead.com/role/StockholdersEquityDividendsDetails">
        <link:definition>2467438 - Disclosure - Stockholders' Equity - Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPreferredStockDetails" roleURI="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails">
        <link:definition>2468439 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>2469440 - Disclosure - Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefits" roleURI="http://www.gilead.com/role/EmployeeBenefits">
        <link:definition>2170116 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsTables" roleURI="http://www.gilead.com/role/EmployeeBenefitsTables">
        <link:definition>2371314 - Disclosure - Employee Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsNarrativeDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails">
        <link:definition>2472441 - Disclosure - Employee Benefits - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsStockOptionsDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails">
        <link:definition>2473442 - Disclosure - Employee Benefits - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails">
        <link:definition>2474443 - Disclosure - Employee Benefits - Restricted Stock and Performance Share Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsSummaryofStockBasedCompensationDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails">
        <link:definition>2475444 - Disclosure - Employee Benefits - Summary of Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails">
        <link:definition>2476445 - Disclosure - Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareAttributabletoGileadCommonShareholders" roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders">
        <link:definition>2177117 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareAttributabletoGileadCommonShareholdersTables" roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables">
        <link:definition>2378315 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails" roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails">
        <link:definition>2479446 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails" roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails">
        <link:definition>2480447 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.gilead.com/role/IncomeTaxes">
        <link:definition>2181118 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.gilead.com/role/IncomeTaxesTables">
        <link:definition>2382316 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>2483448 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails">
        <link:definition>2484449 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails">
        <link:definition>2485450 - Disclosure - Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2486451 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" roleURI="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails">
        <link:definition>2487452 - Disclosure - Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.gilead.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2488453 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="gild_CollaborativeandOtherArrangementsAbstract" abstract="true" name="CollaborativeandOtherArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_CollaborativeAndOtherArrangementsTextBlock" abstract="false" name="CollaborativeAndOtherArrangementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gild_ScheduleofInventoryLineItems" abstract="true" name="ScheduleofInventoryLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" abstract="false" name="AdjustmentsOfBudgetedDevelopmentCostsPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HepcludexMember" abstract="true" name="HepcludexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ArcusStockPurchaseAgreementMember" abstract="true" name="ArcusStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" abstract="false" name="MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" abstract="false" name="UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CollaborativeAgreementOptInTerm" abstract="false" name="CollaborativeAgreementOptInTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" abstract="false" name="PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AmerisourcebergenCorpMember" abstract="true" name="AmerisourcebergenCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsRanexaMember" abstract="true" name="OtherProductsRanexaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2026ExpirationMember" abstract="true" name="EuropeanPatentClaims2026ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_JudgmentRoyaltyRateFromOctober2017" abstract="false" name="JudgmentRoyaltyRateFromOctober2017" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_DeferredIncomeTaxExpenseBenefitComponentAxis" abstract="true" name="DeferredIncomeTaxExpenseBenefitComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinApril2024Member" abstract="true" name="SeniorUnsecuredNotesDueinApril2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2024ExpirationMember" abstract="true" name="EuropeanPatentClaims2024ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A2016StockRepurchaseProgramMember" abstract="true" name="A2016StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_ProductsOtherHIVMember" abstract="true" name="ProductsOtherHIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" abstract="true" name="MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherHCVMember" abstract="true" name="OtherHCVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FairValueatGrantDateMember" abstract="true" name="FairValueatGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2032ExpirationMember" abstract="true" name="EuropeanPatentClaims2032ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" abstract="false" name="PropertyPlantandEquipmentUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gild_InventoryReserveForExcessRawMaterials" abstract="false" name="InventoryReserveForExcessRawMaterials" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AgreementWithJapanTobaccoIncMember" abstract="true" name="AgreementWithJapanTobaccoIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinFebruary2025Member" abstract="true" name="SeniorUnsecuredNotesDueinFebruary2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ForeignCurrencyDerivativeContractsMember" abstract="true" name="ForeignCurrencyDerivativeContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductSalesMember" abstract="true" name="HIVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" abstract="true" name="JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ResearchAndDevelopmentInProcessIncludingImpairment" abstract="false" name="ResearchAndDevelopmentInProcessIncludingImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" abstract="true" name="UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_OtherCollaborationArrangementsMember" abstract="true" name="OtherCollaborationArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MerckMember" abstract="true" name="MerckMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PotentialFutureMilestonePaymentsMaximum" abstract="false" name="PotentialFutureMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_FortySevenIncMember" abstract="true" name="FortySevenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ScheduleOfInventoriesLineItems" abstract="true" name="ScheduleOfInventoriesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" abstract="true" name="LicenseRegistrationRightsAndStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" abstract="false" name="EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2035Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2027Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_TizonaMergerAndOptionAgreementsMember" abstract="true" name="TizonaMergerAndOptionAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MckessonCorpMember" abstract="true" name="MckessonCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ResidentialMortgageAndAssetBackedSecuritiesMember" abstract="true" name="ResidentialMortgageAndAssetBackedSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsGrossReclassified" abstract="false" name="FiniteLivedIntangibleAssetsGrossReclassified" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ImmunomedicsIncMember" abstract="true" name="ImmunomedicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PaymentsToAcquireAssetsNetOfCashAcquired" abstract="false" name="PaymentsToAcquireAssetsNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_TotalFairValueAxis" abstract="true" name="TotalFairValueAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_PubliclyAnnouncedProgramMember" abstract="true" name="PubliclyAnnouncedProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorNotesAndMediumTermNotesMember" abstract="true" name="SeniorNotesAndMediumTermNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueApril2021Member" abstract="true" name="SeniorUnsecuredNotesDueApril2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MYRGmbHMember" abstract="true" name="MYRGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" abstract="false" name="EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_MarketableSecuritiesNoncurrentMember" abstract="true" name="MarketableSecuritiesNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PaymentsForResearchAndDevelopmentMilestones" abstract="false" name="PaymentsForResearchAndDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_PionyrImmunotherapeuticsIncMember" abstract="true" name="PionyrImmunotherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_GileadFoundationMember" abstract="true" name="GileadFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CellTherapyProductsTotalCellTherapyProductSalesMember" abstract="true" name="CellTherapyProductsTotalCellTherapyProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" abstract="false" name="TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_GileadSciencesInc2018EquityIncentivePlanMember" abstract="true" name="GileadSciencesInc2018EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" abstract="true" name="FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PaymentsForDirectTransactionalExpense" abstract="false" name="PaymentsForDirectTransactionalExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2026Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsGenvoyaMember" abstract="true" name="HIVProductsGenvoyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsStribildMember" abstract="true" name="HIVProductsStribildMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" abstract="true" name="FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IntangibleAssetTransferMember" abstract="true" name="IntangibleAssetTransferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" abstract="false" name="CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" abstract="false" name="BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductVireadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2022Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" abstract="true" name="UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_HIVProductsAtriplaMember" abstract="true" name="HIVProductsAtriplaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquityMethodInvestmentOptionExerciseFee" abstract="false" name="EquityMethodInvestmentOptionExerciseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_InvestmentOwnedBalanceAdditionalShares" abstract="false" name="InvestmentOwnedBalanceAdditionalShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gild_KitePharmaIncMember" abstract="true" name="KitePharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" abstract="false" name="PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" abstract="false" name="InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_DeferredTaxAssetsUpfrontAndMilestonePayments" abstract="false" name="DeferredTaxAssetsUpfrontAndMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_GalapagosMember" abstract="true" name="GalapagosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsOdefseyMember" abstract="true" name="HIVProductsOdefseyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IssuanceDiscountPremium" abstract="false" name="IssuanceDiscountPremium" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HCVProductsLedipasvirSofosbuvirMember" abstract="true" name="HCVProductsLedipasvirSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DeferredIncomeTaxExpenseBenefitComponentDomain" abstract="true" name="DeferredIncomeTaxExpenseBenefitComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AccruedGovernmentAndOtherRebates" abstract="false" name="AccruedGovernmentAndOtherRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_PionyrMergerAndOptionAgreementsMember" abstract="true" name="PionyrMergerAndOptionAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_NumberOfPrograms" abstract="false" name="NumberOfPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_GalapagosSubscriptionAgreementMember" abstract="true" name="GalapagosSubscriptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CreditFacilityDueMay2021Member" abstract="true" name="CreditFacilityDueMay2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" abstract="false" name="PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_A260SeniorUnsecuredNotesDueOctober2040Member" abstract="true" name="A260SeniorUnsecuredNotesDueOctober2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_A165SeniorUnsecuredNotesDueOctober2030Member" abstract="true" name="A165SeniorUnsecuredNotesDueOctober2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_TotalGrantDateFairValueDomain" abstract="true" name="TotalGrantDateFairValueDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_LossContingencyRoyaltyPercentageOnFutureSales" abstract="false" name="LossContingencyRoyaltyPercentageOnFutureSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_OtherProductsLetairisMember" abstract="true" name="OtherProductsLetairisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" abstract="false" name="PotentialSalesBasedTieredRoyaltiesHighEndPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" abstract="false" name="CollaborativeAgreementProductMarketPeriodSubjectToTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2046Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_JanssenPharmaceuticalsMember" abstract="true" name="JanssenPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A120SeniorUnsecuredNotesDueOctober2027Member" abstract="true" name="A120SeniorUnsecuredNotesDueOctober2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ViiVHealthcareCompanyMember" abstract="true" name="ViiVHealthcareCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PaymentsToOptInTheCollaborativeAgreement" abstract="false" name="PaymentsToOptInTheCollaborativeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_IntangibleAssetSofosbuvirMember" abstract="true" name="IntangibleAssetSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" abstract="false" name="IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNISharesAcquired" abstract="false" name="EquitySecuritiesFVNISharesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gild_GadetaBVCollaborationArrangementMember" abstract="true" name="GadetaBVCollaborationArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_TrodelvyMember" abstract="true" name="TrodelvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ResearchAndDevelopmentServiceAgreementMember" abstract="true" name="ResearchAndDevelopmentServiceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" abstract="false" name="MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" abstract="false" name="CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gild_OtherProductsYescartaMember" abstract="true" name="OtherProductsYescartaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PreExposureProphylaxisMember" abstract="true" name="PreExposureProphylaxisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AccountsReceivableChargebacksCurrent" abstract="false" name="AccountsReceivableChargebacksCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2022Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsCompleraEvipleraMember" abstract="true" name="HIVProductsCompleraEvipleraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PotentialOptionExerciseFeePerProgram" abstract="false" name="PotentialOptionExerciseFeePerProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueDecember2021Member" abstract="true" name="SeniorUnsecuredNotesDueDecember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_RoyaltyContractAndOtherMember" abstract="true" name="RoyaltyContractAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsZydeligMember" abstract="true" name="OtherProductsZydeligMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" abstract="true" name="ThreeYearSeniorUnsecuredTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2036Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_VariableTermLoanNoteDueOctober2023Member" abstract="true" name="VariableTermLoanNoteDueOctober2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HCVProductsSofosbuvirVelpatasvirMember" abstract="true" name="HCVProductsSofosbuvirVelpatasvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" abstract="true" name="ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyMaterialTransferAgreementsNumber" abstract="false" name="LossContingencyMaterialTransferAgreementsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_OtherInternationalMember" abstract="true" name="OtherInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIShares" abstract="false" name="EquitySecuritiesFVNIShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" abstract="false" name="EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_InventoryWritedownsforExcessRawMaterialsMember" abstract="true" name="InventoryWritedownsforExcessRawMaterialsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_JudgmentEnhancedDamagesOnPastSales" abstract="false" name="JudgmentEnhancedDamagesOnPastSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" abstract="false" name="AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HCVProductSalesMember" abstract="true" name="HCVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_TotalUpfrontPaymentsMade" abstract="false" name="TotalUpfrontPaymentsMade" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_JudgmentRoyaltyRateOnFutureSales" abstract="false" name="JudgmentRoyaltyRateOnFutureSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" abstract="false" name="AcquiredFiniteLivedIntangibleAssetsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" abstract="false" name="PaymentForAdjustmentsOfBudgetedDevelopmentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ProductsRevenueShareSymtuzaMember" abstract="true" name="ProductsRevenueShareSymtuzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AxicabtageneCiloleucelDLBCLMember" abstract="true" name="AxicabtageneCiloleucelDLBCLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_GalapagosCollaborationAgreementMember" abstract="true" name="GalapagosCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsBiktarvyMember" abstract="true" name="HIVProductsBiktarvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" abstract="false" name="DebtInstrumentCallFeaturePeriodBeforeMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinFebruary2045Member" abstract="true" name="SeniorUnsecuredNotesDueinFebruary2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_JounceTherapeuticsIncMember" abstract="true" name="JounceTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_VekluryMember" abstract="true" name="VekluryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_ProductLiabilityMember" abstract="true" name="ProductLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_RestrictedStockandPerformanceShareAwardsMember" abstract="true" name="RestrictedStockandPerformanceShareAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_InjectableFormulationProductMember" abstract="true" name="InjectableFormulationProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" abstract="false" name="PotentialSalesBasedTieredRoyaltyLowEndPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" abstract="true" name="A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" abstract="false" name="EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_QuiTamMember" abstract="true" name="QuiTamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CreditFacilityDueJune2025Member" abstract="true" name="CreditFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" abstract="true" name="A075SeniorUnsecuredNotesDueInSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2027ExpirationMember" abstract="true" name="EuropeanPatentClaims2027ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" abstract="true" name="AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_Issuancediscount" abstract="false" name="Issuancediscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_DeferredCompensationPlanMember" abstract="true" name="DeferredCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OralFormulationProductMember" abstract="true" name="OralFormulationProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_TangoTherapeuticsIncMember" abstract="true" name="TangoTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIRestrictionPeriod" abstract="false" name="EquitySecuritiesFVNIRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_ArcusBiosciencesIncMember" abstract="true" name="ArcusBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_LossContingencyPartiesAppealedNumber" abstract="false" name="LossContingencyPartiesAppealedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_A280SeniorUnsecuredNotesDueOctober2050Member" abstract="true" name="A280SeniorUnsecuredNotesDueOctober2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AccountsReceivableCashDiscountsAndOtherCurrent" abstract="false" name="AccountsReceivableCashDiscountsAndOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CollaborationArrangementPercentOfGlobalProductRevenues" abstract="false" name="CollaborationArrangementPercentOfGlobalProductRevenues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_OtherProductsOtherMember" abstract="true" name="OtherProductsOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" abstract="false" name="PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A2020StockRepurchaseProgramMember" abstract="true" name="A2020StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2047Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ResearchAndDevelopmentFutureMaximumPayments" abstract="false" name="ResearchAndDevelopmentFutureMaximumPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HIVProductsDescovyMember" abstract="true" name="HIVProductsDescovyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_TizonaTherapeuticsIncMember" abstract="true" name="TizonaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueDecember2041Member" abstract="true" name="SeniorUnsecuredNotesDueDecember2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_NumberOfEarlyRepaymentsOfLongTermDebt" abstract="false" name="NumberOfEarlyRepaymentsOfLongTermDebt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_NumberOfClinicalStageProgramsWithExercisedOptions" abstract="false" name="NumberOfClinicalStageProgramsWithExercisedOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_OtherProductsTotalOtherProductSalesMember" abstract="true" name="OtherProductsTotalOtherProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinApril2044Member" abstract="true" name="SeniorUnsecuredNotesDueinApril2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FairValueatVestingDateMember" abstract="true" name="FairValueatVestingDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" abstract="false" name="LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" abstract="false" name="LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_OtherProductsAmBisomeMember" abstract="true" name="OtherProductsAmBisomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesDonationMember" abstract="true" name="EquitySecuritiesDonationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_StandstillRestrictingTerm" abstract="false" name="StandstillRestrictingTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIPurchasePeriod" abstract="false" name="EquitySecuritiesFVNIPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" abstract="true" name="ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsTruvadaMember" abstract="true" name="HIVProductsTruvadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2023Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MarketableSecuritiesCurrentMember" abstract="true" name="MarketableSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DevelopmentAgreementMember" abstract="true" name="DevelopmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CashPaymentsMadeRelatedToEquityInvestments" abstract="false" name="CashPaymentsMadeRelatedToEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" abstract="true" name="AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ScheduleofInventoryTable" abstract="true" name="ScheduleofInventoryTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_CellTherapyProductsTecartusMember" abstract="true" name="CellTherapyProductsTecartusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" abstract="false" name="LossContingencyAdditionalPatentsAllegedlyInfringedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_GileadSciencesInc2004EquityIncentivePlanMember" abstract="true" name="GileadSciencesInc2004EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ArcusCollaborationAgreementMember" abstract="true" name="ArcusCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyPartiesFilingOppositionNumber" abstract="false" name="LossContingencyPartiesFilingOppositionNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_CollaborationArrangementNetProductSalesThreshold" abstract="false" name="CollaborationArrangementNetProductSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>gild-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4eb1680c-5761-45c7-95ef-3c78b834062a,g:a0cedc55-fc60-4d3f-bea8-ef196ffaa864-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_91790918-88ba-4cab-b0f8-b0d85ea3f5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bb0ba949-691c-4c5f-b3cd-48aaa76e2bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_91790918-88ba-4cab-b0f8-b0d85ea3f5c0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bb0ba949-691c-4c5f-b3cd-48aaa76e2bff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_e7462be6-a798-46e9-a02e-d2621820d42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_91790918-88ba-4cab-b0f8-b0d85ea3f5c0" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_e7462be6-a798-46e9-a02e-d2621820d42c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_128078da-1e4e-49cb-8e66-284797a57158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_91790918-88ba-4cab-b0f8-b0d85ea3f5c0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_128078da-1e4e-49cb-8e66-284797a57158" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0ed458c3-3f8e-442f-864d-add62e11269c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_91790918-88ba-4cab-b0f8-b0d85ea3f5c0" xlink:to="loc_us-gaap_InventoryNet_0ed458c3-3f8e-442f-864d-add62e11269c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_633fe153-b1a5-41e7-b11b-c43eb4ec3a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_91790918-88ba-4cab-b0f8-b0d85ea3f5c0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_633fe153-b1a5-41e7-b11b-c43eb4ec3a2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_127c847c-ce46-4549-bd5f-ddd765a1c46b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac3806ab-8426-4ca9-adae-448cbab7aa71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_127c847c-ce46-4549-bd5f-ddd765a1c46b" xlink:to="loc_us-gaap_StockholdersEquity_ac3806ab-8426-4ca9-adae-448cbab7aa71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0f51a7b6-41ff-44f6-9319-eece95f5bd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_127c847c-ce46-4549-bd5f-ddd765a1c46b" xlink:to="loc_us-gaap_MinorityInterest_0f51a7b6-41ff-44f6-9319-eece95f5bd7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6639706-96c5-428e-bb8b-a5db7f741392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_765e2e8c-7c42-4e7a-b8e3-13f293bfbf65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6639706-96c5-428e-bb8b-a5db7f741392" xlink:to="loc_us-gaap_LiabilitiesCurrent_765e2e8c-7c42-4e7a-b8e3-13f293bfbf65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c0ecf82d-e417-4277-a005-ffb14d339f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6639706-96c5-428e-bb8b-a5db7f741392" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c0ecf82d-e417-4277-a005-ffb14d339f29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_db8815c6-f377-4858-9882-f4f30b55b446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6639706-96c5-428e-bb8b-a5db7f741392" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_db8815c6-f377-4858-9882-f4f30b55b446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_df3d9d08-6980-41db-8d6f-c9e055b5f3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6639706-96c5-428e-bb8b-a5db7f741392" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_df3d9d08-6980-41db-8d6f-c9e055b5f3ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4cbcaad7-a172-442a-b257-da84582f29d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6639706-96c5-428e-bb8b-a5db7f741392" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4cbcaad7-a172-442a-b257-da84582f29d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ed95b81-fab7-4f39-8376-6a1d348a62d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6639706-96c5-428e-bb8b-a5db7f741392" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ed95b81-fab7-4f39-8376-6a1d348a62d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d92c13a3-9d0b-4433-856e-9b551960e1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6639706-96c5-428e-bb8b-a5db7f741392" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d92c13a3-9d0b-4433-856e-9b551960e1ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3ab4bc6a-8a58-4e4d-a9fb-d5e3d6bde127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_92548c82-5774-4af5-856c-b78582f36478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3ab4bc6a-8a58-4e4d-a9fb-d5e3d6bde127" xlink:to="loc_us-gaap_AccountsPayableCurrent_92548c82-5774-4af5-856c-b78582f36478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedGovernmentAndOtherRebates_8e8a1785-42c2-4a23-a211-f431723a660a" xlink:href="gild-20211231.xsd#gild_AccruedGovernmentAndOtherRebates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3ab4bc6a-8a58-4e4d-a9fb-d5e3d6bde127" xlink:to="loc_gild_AccruedGovernmentAndOtherRebates_8e8a1785-42c2-4a23-a211-f431723a660a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_17e77b1b-6fbd-4351-a502-5989a05c0254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3ab4bc6a-8a58-4e4d-a9fb-d5e3d6bde127" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_17e77b1b-6fbd-4351-a502-5989a05c0254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_38fdbdea-4493-4d96-bd2f-dfe05341a768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3ab4bc6a-8a58-4e4d-a9fb-d5e3d6bde127" xlink:to="loc_us-gaap_DebtCurrent_38fdbdea-4493-4d96-bd2f-dfe05341a768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_22bc1f31-1c3c-414e-9660-affd20223e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d421432a-f165-4e63-8898-66331c0e0932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_22bc1f31-1c3c-414e-9660-affd20223e73" xlink:to="loc_us-gaap_AssetsCurrent_d421432a-f165-4e63-8898-66331c0e0932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6261556c-7354-4c26-a8fe-c6f81f65e152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_22bc1f31-1c3c-414e-9660-affd20223e73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6261556c-7354-4c26-a8fe-c6f81f65e152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_6a4d5bde-876f-4d5a-93e3-324970c911d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_22bc1f31-1c3c-414e-9660-affd20223e73" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_6a4d5bde-876f-4d5a-93e3-324970c911d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_13e8eb5a-7e53-4a1c-beb9-febf0affceec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_22bc1f31-1c3c-414e-9660-affd20223e73" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_13e8eb5a-7e53-4a1c-beb9-febf0affceec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_483570c7-38b4-4c9d-99ee-e00633995fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_22bc1f31-1c3c-414e-9660-affd20223e73" xlink:to="loc_us-gaap_Goodwill_483570c7-38b4-4c9d-99ee-e00633995fd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_245d5d5e-617d-4691-93eb-75ffacfcf78d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_22bc1f31-1c3c-414e-9660-affd20223e73" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_245d5d5e-617d-4691-93eb-75ffacfcf78d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_46965d76-31a2-451c-b4d0-69389c0c765b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9fb526ea-1ef0-4f6f-a479-ae8d84eb6d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_46965d76-31a2-451c-b4d0-69389c0c765b" xlink:to="loc_us-gaap_PreferredStockValue_9fb526ea-1ef0-4f6f-a479-ae8d84eb6d56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e8ece887-5b3a-46b4-b18d-5dcc7fa3856e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_46965d76-31a2-451c-b4d0-69389c0c765b" xlink:to="loc_us-gaap_CommonStockValue_e8ece887-5b3a-46b4-b18d-5dcc7fa3856e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2822d340-8a45-4ac7-ae34-a0ee18d0b5db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_46965d76-31a2-451c-b4d0-69389c0c765b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2822d340-8a45-4ac7-ae34-a0ee18d0b5db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b7b44a4-259c-4eab-a0ca-6d56da49d7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_46965d76-31a2-451c-b4d0-69389c0c765b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b7b44a4-259c-4eab-a0ca-6d56da49d7c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d364b88-6e13-4890-b224-9b9ca249d936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_46965d76-31a2-451c-b4d0-69389c0c765b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d364b88-6e13-4890-b224-9b9ca249d936" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_db2f1388-8c43-4802-9471-814566f822ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84305d65-ace2-4e51-9d1b-4a4818b55f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_db2f1388-8c43-4802-9471-814566f822ee" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84305d65-ace2-4e51-9d1b-4a4818b55f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_af217d0e-9138-418f-8afa-683c21d0dea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_db2f1388-8c43-4802-9471-814566f822ee" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_af217d0e-9138-418f-8afa-683c21d0dea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b9f207a1-8a42-47d6-b845-0277cc1ec0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_103f93df-cec1-4aad-9b84-cbaf976994c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b9f207a1-8a42-47d6-b845-0277cc1ec0e3" xlink:to="loc_us-gaap_CostsAndExpenses_103f93df-cec1-4aad-9b84-cbaf976994c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d7d5970-c5a9-44c2-b734-f9e77b5386bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b9f207a1-8a42-47d6-b845-0277cc1ec0e3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d7d5970-c5a9-44c2-b734-f9e77b5386bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6492b689-4537-4a50-b86d-082e6cd2d1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b2ea4b86-f4d8-4dcb-a59c-5da3f0940ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6492b689-4537-4a50-b86d-082e6cd2d1a5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b2ea4b86-f4d8-4dcb-a59c-5da3f0940ba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_73e17987-d423-419a-9270-a60d7423f624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6492b689-4537-4a50-b86d-082e6cd2d1a5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_73e17987-d423-419a-9270-a60d7423f624" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d346067a-cb5a-4987-a20d-4d9f3d4f9807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6492b689-4537-4a50-b86d-082e6cd2d1a5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d346067a-cb5a-4987-a20d-4d9f3d4f9807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment_666aa4b8-eda6-4ead-a803-f4a187b97d45" xlink:href="gild-20211231.xsd#gild_ResearchAndDevelopmentInProcessIncludingImpairment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6492b689-4537-4a50-b86d-082e6cd2d1a5" xlink:to="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment_666aa4b8-eda6-4ead-a803-f4a187b97d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2f028877-2aae-4a68-a61e-7013bb420d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4da38703-b5ed-4d18-8e8a-45c629dcceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2f028877-2aae-4a68-a61e-7013bb420d08" xlink:to="loc_us-gaap_OperatingIncomeLoss_4da38703-b5ed-4d18-8e8a-45c629dcceaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_00e628dd-4476-4748-8aac-c992be09cb73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2f028877-2aae-4a68-a61e-7013bb420d08" xlink:to="loc_us-gaap_InterestExpense_00e628dd-4476-4748-8aac-c992be09cb73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_af5fc9e5-4cf9-42d0-ae56-a0c6ee973957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2f028877-2aae-4a68-a61e-7013bb420d08" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_af5fc9e5-4cf9-42d0-ae56-a0c6ee973957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5557ee08-244a-487e-a66d-6f7cc692bde6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_aa43a49b-176e-47d9-8c22-e70cc445cf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5557ee08-244a-487e-a66d-6f7cc692bde6" xlink:to="loc_us-gaap_ProfitLoss_aa43a49b-176e-47d9-8c22-e70cc445cf9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ea7aff5a-98c3-4b5b-a0a9-17d2e0dbdf94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5557ee08-244a-487e-a66d-6f7cc692bde6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ea7aff5a-98c3-4b5b-a0a9-17d2e0dbdf94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6bb48915-b97b-4c23-9bb3-65cca0cf1d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_dcf3f012-35ac-4d0d-a1aa-719504937462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6bb48915-b97b-4c23-9bb3-65cca0cf1d82" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_dcf3f012-35ac-4d0d-a1aa-719504937462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_31704822-4f09-4461-b6d8-fe076bb29b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6bb48915-b97b-4c23-9bb3-65cca0cf1d82" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_31704822-4f09-4461-b6d8-fe076bb29b79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_468cc3b2-a881-48ff-b249-802bbb5fcc24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2ad7bb8d-502b-4aef-9f73-da03d7eb8696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_468cc3b2-a881-48ff-b249-802bbb5fcc24" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2ad7bb8d-502b-4aef-9f73-da03d7eb8696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_005cd2f4-7382-4055-b05c-105fd3b48ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_468cc3b2-a881-48ff-b249-802bbb5fcc24" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_005cd2f4-7382-4055-b05c-105fd3b48ccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e3ac16b1-5538-4ba8-aeb0-df683f9d2759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5bcd4a12-8565-4e65-9dcf-7bd71120b28a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e3ac16b1-5538-4ba8-aeb0-df683f9d2759" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5bcd4a12-8565-4e65-9dcf-7bd71120b28a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6cae5c64-e0b6-411a-b0da-ce22ba780929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e3ac16b1-5538-4ba8-aeb0-df683f9d2759" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6cae5c64-e0b6-411a-b0da-ce22ba780929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0e51d20a-1fb9-4825-a750-7ecb28756fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e3ac16b1-5538-4ba8-aeb0-df683f9d2759" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0e51d20a-1fb9-4825-a750-7ecb28756fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a02c78c0-fd99-4e13-8803-53bbf70eb68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_afd4377b-9b4c-4856-ade7-64c3868b2b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a02c78c0-fd99-4e13-8803-53bbf70eb68b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_afd4377b-9b4c-4856-ade7-64c3868b2b35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_588bf8eb-d216-40d2-8e70-2d7967609275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a02c78c0-fd99-4e13-8803-53bbf70eb68b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_588bf8eb-d216-40d2-8e70-2d7967609275" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c95a253c-6f65-4198-ba3e-6947ab3c6364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ae567386-7140-4484-ba0d-fa848fd6124f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c95a253c-6f65-4198-ba3e-6947ab3c6364" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ae567386-7140-4484-ba0d-fa848fd6124f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1ede87a3-cfeb-4083-b784-f00237ad0057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c95a253c-6f65-4198-ba3e-6947ab3c6364" xlink:to="loc_us-gaap_ProfitLoss_1ede87a3-cfeb-4083-b784-f00237ad0057" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b13908c9-88fa-473e-9c71-d3102cd1c2be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_d514f788-a8dd-416b-ad93-10d58754e5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b13908c9-88fa-473e-9c71-d3102cd1c2be" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_d514f788-a8dd-416b-ad93-10d58754e5c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3f03f7ad-bec2-44e0-936b-0c0087b8a08b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b13908c9-88fa-473e-9c71-d3102cd1c2be" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3f03f7ad-bec2-44e0-936b-0c0087b8a08b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0d509a4b-bf68-4b57-86f2-f1926317194f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b13908c9-88fa-473e-9c71-d3102cd1c2be" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0d509a4b-bf68-4b57-86f2-f1926317194f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_b1fe9110-8e92-4f52-b881-4c10996184be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b13908c9-88fa-473e-9c71-d3102cd1c2be" xlink:to="loc_us-gaap_RepaymentsOfDebt_b1fe9110-8e92-4f52-b881-4c10996184be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_4a4df7dc-f6d8-4117-8f4b-b3d760838583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b13908c9-88fa-473e-9c71-d3102cd1c2be" xlink:to="loc_us-gaap_PaymentsOfDividends_4a4df7dc-f6d8-4117-8f4b-b3d760838583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b19bf147-8ebf-486a-b50d-5c83a8db77f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b13908c9-88fa-473e-9c71-d3102cd1c2be" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b19bf147-8ebf-486a-b50d-5c83a8db77f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4c3fdf8-19a8-4c31-b7be-84131fbe694f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c1d4581e-4e04-4916-9702-eb3deec8d645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4c3fdf8-19a8-4c31-b7be-84131fbe694f" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c1d4581e-4e04-4916-9702-eb3deec8d645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_527cff4d-6a17-4f21-8b87-a2ad6c18aef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4c3fdf8-19a8-4c31-b7be-84131fbe694f" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_527cff4d-6a17-4f21-8b87-a2ad6c18aef9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_4088ded6-b06c-442b-a900-2827284b77de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4c3fdf8-19a8-4c31-b7be-84131fbe694f" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_4088ded6-b06c-442b-a900-2827284b77de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f3d6fe2d-bd9d-4210-a271-f519837d3c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4c3fdf8-19a8-4c31-b7be-84131fbe694f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f3d6fe2d-bd9d-4210-a271-f519837d3c1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_339b4cc1-eb73-4181-acb5-d334efcae49c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4c3fdf8-19a8-4c31-b7be-84131fbe694f" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_339b4cc1-eb73-4181-acb5-d334efcae49c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c269c079-ce43-4882-9e5e-4e16f0bf8e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4c3fdf8-19a8-4c31-b7be-84131fbe694f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c269c079-ce43-4882-9e5e-4e16f0bf8e79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a8d663a6-f8f4-4ab3-9381-0fa7e0da3bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4c3fdf8-19a8-4c31-b7be-84131fbe694f" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a8d663a6-f8f4-4ab3-9381-0fa7e0da3bef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c08b6094-7389-4221-8b16-8d623b8e8a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a4866f14-a38e-46c1-81e2-b4106a7862b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c08b6094-7389-4221-8b16-8d623b8e8a2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a4866f14-a38e-46c1-81e2-b4106a7862b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cfbad760-950f-4d4e-bfbf-b10b7b8de36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c08b6094-7389-4221-8b16-8d623b8e8a2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cfbad760-950f-4d4e-bfbf-b10b7b8de36b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e7c8fcec-7257-4bdf-9cc5-50998f652c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c08b6094-7389-4221-8b16-8d623b8e8a2c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e7c8fcec-7257-4bdf-9cc5-50998f652c47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa416e4c-4bc6-47a9-b89d-5f1ff6e3ffa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c08b6094-7389-4221-8b16-8d623b8e8a2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa416e4c-4bc6-47a9-b89d-5f1ff6e3ffa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_22e51278-75fe-4ea7-86a9-cfe1eca4c5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_ProfitLoss_22e51278-75fe-4ea7-86a9-cfe1eca4c5c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e0d54779-5585-45a2-9cd2-3e5411cf1c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_Depreciation_e0d54779-5585-45a2-9cd2-3e5411cf1c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_892fb6bb-0e96-4093-8970-80407ee9fdce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_AdjustmentForAmortization_892fb6bb-0e96-4093-8970-80407ee9fdce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_20014859-bc89-4cb2-8ff7-744b2151c7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_ShareBasedCompensation_20014859-bc89-4cb2-8ff7-744b2151c7a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_784dc4e8-4fe7-41ee-838a-8f87578d19f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_784dc4e8-4fe7-41ee-838a-8f87578d19f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_7de8f660-d2cd-4343-84d3-f007c78c85fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_7de8f660-d2cd-4343-84d3-f007c78c85fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_7002c940-23a1-4030-a61d-ab02d9d822c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_7002c940-23a1-4030-a61d-ab02d9d822c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_11690ea9-dc2a-49df-9fac-6a52ebf05f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_11690ea9-dc2a-49df-9fac-6a52ebf05f8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryReserveForExcessRawMaterials_38cff93f-f8a9-4825-9540-ee8973b46729" xlink:href="gild-20211231.xsd#gild_InventoryReserveForExcessRawMaterials"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_gild_InventoryReserveForExcessRawMaterials_38cff93f-f8a9-4825-9540-ee8973b46729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e843292d-554d-4ba1-96b0-3e95360a8b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e843292d-554d-4ba1-96b0-3e95360a8b9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4178b0b8-80fe-4e97-aa4f-abb28627e9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4178b0b8-80fe-4e97-aa4f-abb28627e9d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9ce6a9b2-c46f-4491-b689-f76f263f1469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9ce6a9b2-c46f-4491-b689-f76f263f1469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ba48cca9-a9ff-4924-a583-b39406225ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ba48cca9-a9ff-4924-a583-b39406225ea5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_05ee7773-576c-4ac0-b9a5-0a7983394f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_05ee7773-576c-4ac0-b9a5-0a7983394f20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_8b6cf325-925a-4893-a076-88aec703dc70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_8b6cf325-925a-4893-a076-88aec703dc70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1e45317d-aaa7-4950-b985-b35319efee13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c7bbc5c-2590-4b0b-aa35-e3f41809fceb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1e45317d-aaa7-4950-b985-b35319efee13" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_39b82552-3d8e-4ddc-b365-7e72bac3645b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_e7d4f8a1-f8f9-4f42-87ca-f39d3a8638cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_39b82552-3d8e-4ddc-b365-7e72bac3645b" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_e7d4f8a1-f8f9-4f42-87ca-f39d3a8638cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1f2a92cb-5ff7-407d-b4f5-0b2fcd429f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_39b82552-3d8e-4ddc-b365-7e72bac3645b" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1f2a92cb-5ff7-407d-b4f5-0b2fcd429f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d2e6b1f-ae1b-4213-84f2-ecfd886f308d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_39b82552-3d8e-4ddc-b365-7e72bac3645b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d2e6b1f-ae1b-4213-84f2-ecfd886f308d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_866b46ab-7182-4c24-b975-4f76fe58c86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_b68013fb-f518-4e43-bc21-298e39c1b48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_866b46ab-7182-4c24-b975-4f76fe58c86b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_b68013fb-f518-4e43-bc21-298e39c1b48a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_eab90c59-9bf8-4f1d-b9b4-b554504d2ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_866b46ab-7182-4c24-b975-4f76fe58c86b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_eab90c59-9bf8-4f1d-b9b4-b554504d2ad9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_3b55e787-436d-41e3-9b29-6d0998d6f48b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_866b46ab-7182-4c24-b975-4f76fe58c86b" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_3b55e787-436d-41e3-9b29-6d0998d6f48b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ac0949d7-9d97-4f2b-9b4e-830e88dd4a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a61bf26e-aeb4-44bc-9402-7dec64048671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ac0949d7-9d97-4f2b-9b4e-830e88dd4a52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a61bf26e-aeb4-44bc-9402-7dec64048671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3a18e280-a379-43a4-b372-4ae7088204e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ac0949d7-9d97-4f2b-9b4e-830e88dd4a52" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3a18e280-a379-43a4-b372-4ae7088204e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3eb660a3-d43a-4138-8802-eef9cabc4a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ac0949d7-9d97-4f2b-9b4e-830e88dd4a52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3eb660a3-d43a-4138-8802-eef9cabc4a20" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3eb99fdd-401e-4283-a290-4b4e8bba16ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5e20a519-7df3-474a-8576-ac830392aa65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3eb99fdd-401e-4283-a290-4b4e8bba16ae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5e20a519-7df3-474a-8576-ac830392aa65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ed486f76-11f8-4609-b036-069999e24df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3eb99fdd-401e-4283-a290-4b4e8bba16ae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ed486f76-11f8-4609-b036-069999e24df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_9c349eb8-9bd8-47de-8d6d-13c9307b723c" xlink:href="gild-20211231.xsd#gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3eb99fdd-401e-4283-a290-4b4e8bba16ae" xlink:to="loc_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_9c349eb8-9bd8-47de-8d6d-13c9307b723c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8515583c-d8a7-426b-8b24-57a4d0a8b138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8571183b-ffee-4863-afb5-88cd08adee55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8515583c-d8a7-426b-8b24-57a4d0a8b138" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8571183b-ffee-4863-afb5-88cd08adee55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_606c3f54-58cc-452e-a629-eda4c039a966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8515583c-d8a7-426b-8b24-57a4d0a8b138" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_606c3f54-58cc-452e-a629-eda4c039a966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_67080453-4c7f-4da4-a642-39ddc87b30fd" xlink:href="gild-20211231.xsd#gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8515583c-d8a7-426b-8b24-57a4d0a8b138" xlink:to="loc_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_67080453-4c7f-4da4-a642-39ddc87b30fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_024afa2b-25bc-4d01-a3c4-e62ec0729ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_dd8f0d4e-71b3-4748-87ec-cc0bc0ec3d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_024afa2b-25bc-4d01-a3c4-e62ec0729ce4" xlink:to="loc_us-gaap_DerivativeAssets_dd8f0d4e-71b3-4748-87ec-cc0bc0ec3d6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_022a8a6b-207c-46ab-937d-acfb7029905e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_024afa2b-25bc-4d01-a3c4-e62ec0729ce4" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_022a8a6b-207c-46ab-937d-acfb7029905e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_c46c06cb-23a5-44f2-8c73-676bcfa827dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_024afa2b-25bc-4d01-a3c4-e62ec0729ce4" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_c46c06cb-23a5-44f2-8c73-676bcfa827dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_874a0bb6-4530-4f45-b9a8-6343856146a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_c92440e3-725a-425f-bde8-fd0461787d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_874a0bb6-4530-4f45-b9a8-6343856146a2" xlink:to="loc_us-gaap_DerivativeLiabilities_c92440e3-725a-425f-bde8-fd0461787d04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_329355e4-e980-4475-b43b-5c0e85275645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_874a0bb6-4530-4f45-b9a8-6343856146a2" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_329355e4-e980-4475-b43b-5c0e85275645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_6b8d4ed5-76c2-4636-81b5-ca6e45a79e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_874a0bb6-4530-4f45-b9a8-6343856146a2" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_6b8d4ed5-76c2-4636-81b5-ca6e45a79e72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_7326345e-a4b7-4a49-b81b-a87676802d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_b2b8ffe7-a04e-4103-9e2c-6a92082a8596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_7326345e-a4b7-4a49-b81b-a87676802d17" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_b2b8ffe7-a04e-4103-9e2c-6a92082a8596" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_38da6a65-7815-4fa0-b292-13e456448ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_7326345e-a4b7-4a49-b81b-a87676802d17" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_38da6a65-7815-4fa0-b292-13e456448ea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_b7a38762-e7c8-4007-9bc4-7de4941603ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_13fdb82f-9c7a-4ac6-9002-dca3e5c7fbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_b7a38762-e7c8-4007-9bc4-7de4941603ff" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_13fdb82f-9c7a-4ac6-9002-dca3e5c7fbdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_d268759c-506f-4a61-8ef9-d22058b1eab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_b7a38762-e7c8-4007-9bc4-7de4941603ff" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_d268759c-506f-4a61-8ef9-d22058b1eab5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_170ca84c-842e-43e1-a3e4-4412286a0d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_75792337-08be-4e4f-a364-28674e27188b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_170ca84c-842e-43e1-a3e4-4412286a0d7d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_75792337-08be-4e4f-a364-28674e27188b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_4ebcef6a-8557-4728-874b-948d5cc07915" xlink:href="gild-20211231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_170ca84c-842e-43e1-a3e4-4412286a0d7d" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_4ebcef6a-8557-4728-874b-948d5cc07915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f9c2f5ab-c517-4b19-b3f4-2967bc37444e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_170ca84c-842e-43e1-a3e4-4412286a0d7d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f9c2f5ab-c517-4b19-b3f4-2967bc37444e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_02b3aba9-fec2-44e3-a60e-b01a50421671" xlink:href="gild-20211231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_170ca84c-842e-43e1-a3e4-4412286a0d7d" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_02b3aba9-fec2-44e3-a60e-b01a50421671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_3fd28705-527c-4784-8045-3e95096adfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_170ca84c-842e-43e1-a3e4-4412286a0d7d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_3fd28705-527c-4784-8045-3e95096adfd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_694612a3-d75f-4154-80a9-c46bc57294a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_170ca84c-842e-43e1-a3e4-4412286a0d7d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_694612a3-d75f-4154-80a9-c46bc57294a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e14de180-fda6-41fa-b82f-cf19919b3cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_170ca84c-842e-43e1-a3e4-4412286a0d7d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e14de180-fda6-41fa-b82f-cf19919b3cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_f21a7003-a542-4791-a870-2658ba1a3dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_166bf497-5fce-476e-b911-35fa3c342024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_f21a7003-a542-4791-a870-2658ba1a3dfd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_166bf497-5fce-476e-b911-35fa3c342024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_9de98197-53cf-49b2-af24-7062a84257e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_f21a7003-a542-4791-a870-2658ba1a3dfd" xlink:to="loc_us-gaap_GoodwillGross_9de98197-53cf-49b2-af24-7062a84257e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_679a8b13-fe9b-49f4-a6e4-129f1655b415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_831954d3-51f9-45e2-92b7-1000697315d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_679a8b13-fe9b-49f4-a6e4-129f1655b415" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_831954d3-51f9-45e2-92b7-1000697315d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_39fd2d8f-4127-4442-995f-62a286c290a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_679a8b13-fe9b-49f4-a6e4-129f1655b415" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_39fd2d8f-4127-4442-995f-62a286c290a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7b14e82e-0b8b-49ea-8f66-3933539c3eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_d79d17c7-86c7-47c8-a862-9bae1f38cf08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7b14e82e-0b8b-49ea-8f66-3933539c3eb4" xlink:to="loc_us-gaap_Land_d79d17c7-86c7-47c8-a862-9bae1f38cf08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_15c278e6-33b7-4859-8f80-d65613d84744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7b14e82e-0b8b-49ea-8f66-3933539c3eb4" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_15c278e6-33b7-4859-8f80-d65613d84744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_11ae843e-b88f-4905-9027-84c4dacba0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7b14e82e-0b8b-49ea-8f66-3933539c3eb4" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_11ae843e-b88f-4905-9027-84c4dacba0c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_d875f26b-31e0-47d5-806d-c2d5a76b411d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7b14e82e-0b8b-49ea-8f66-3933539c3eb4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_d875f26b-31e0-47d5-806d-c2d5a76b411d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_d5068424-0a00-4e28-b556-404e7617e633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7b14e82e-0b8b-49ea-8f66-3933539c3eb4" xlink:to="loc_us-gaap_ConstructionInProgressGross_d5068424-0a00-4e28-b556-404e7617e633" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_87fea731-40be-48a3-9d6f-22a774e505bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75f430a3-c0ff-4338-a1ae-2fc706ac9341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_87fea731-40be-48a3-9d6f-22a774e505bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75f430a3-c0ff-4338-a1ae-2fc706ac9341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6159d64d-4107-4740-9a03-a136ba6008e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_87fea731-40be-48a3-9d6f-22a774e505bf" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6159d64d-4107-4740-9a03-a136ba6008e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_d2e43f32-8675-4206-8e88-e43a69b143a7" xlink:href="gild-20211231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_87fea731-40be-48a3-9d6f-22a774e505bf" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_d2e43f32-8675-4206-8e88-e43a69b143a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_717cfe88-6597-475a-95dc-719d84a23b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0cb53a15-b3fb-47ef-805b-15cf99d4b221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_717cfe88-6597-475a-95dc-719d84a23b3d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0cb53a15-b3fb-47ef-805b-15cf99d4b221" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_00f38a6b-af0d-4e3b-bf40-c40bffddd6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_717cfe88-6597-475a-95dc-719d84a23b3d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_00f38a6b-af0d-4e3b-bf40-c40bffddd6c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_611ccdf2-74af-430a-aae1-bd65e9b79286" xlink:href="gild-20211231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_717cfe88-6597-475a-95dc-719d84a23b3d" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_611ccdf2-74af-430a-aae1-bd65e9b79286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_d068634a-46f6-4ac6-a6c9-266378ff87b8" xlink:href="gild-20211231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_05f262a4-8f2d-44b5-86db-9c2c21969d09" xlink:href="gild-20211231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_d068634a-46f6-4ac6-a6c9-266378ff87b8" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_05f262a4-8f2d-44b5-86db-9c2c21969d09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_be6f63f4-d5b1-46eb-9965-c87545b9497d" xlink:href="gild-20211231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_d068634a-46f6-4ac6-a6c9-266378ff87b8" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_be6f63f4-d5b1-46eb-9965-c87545b9497d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_20e78b45-1d92-4473-a589-f40e0fea3a64" xlink:href="gild-20211231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fb190bc3-d2cf-4e38-ad60-c5076a83c40a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_20e78b45-1d92-4473-a589-f40e0fea3a64" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fb190bc3-d2cf-4e38-ad60-c5076a83c40a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_a5c4bd7d-1863-435f-b70e-40c8d6fc4c1d" xlink:href="gild-20211231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_20e78b45-1d92-4473-a589-f40e0fea3a64" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_a5c4bd7d-1863-435f-b70e-40c8d6fc4c1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_281e4201-1910-45fb-bd42-758692febb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2bfe97a7-6335-44db-b65d-3593ec52c685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_281e4201-1910-45fb-bd42-758692febb2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2bfe97a7-6335-44db-b65d-3593ec52c685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_71e10af4-eaa0-4152-a0e6-3723cfb3f429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_281e4201-1910-45fb-bd42-758692febb2b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_71e10af4-eaa0-4152-a0e6-3723cfb3f429" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="gild-20211231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_70f35e8a-8796-4d4e-88ed-6ea00a66eb42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9d4ecb3a-a158-433c-a72c-332aeb9b24ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_70f35e8a-8796-4d4e-88ed-6ea00a66eb42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9d4ecb3a-a158-433c-a72c-332aeb9b24ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_4f14cc71-a443-4d18-9b8b-f8925891e197" xlink:href="gild-20211231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_70f35e8a-8796-4d4e-88ed-6ea00a66eb42" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_4f14cc71-a443-4d18-9b8b-f8925891e197" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_23d7c849-23a1-4e8b-a351-307d2a153b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_42784993-b5e5-413e-bfc7-4b80f6b11659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_23d7c849-23a1-4e8b-a351-307d2a153b1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_42784993-b5e5-413e-bfc7-4b80f6b11659" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_28902b84-2a96-4759-8710-919e70d15667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_23d7c849-23a1-4e8b-a351-307d2a153b1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_28902b84-2a96-4759-8710-919e70d15667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6c900f67-578e-42f4-aaef-d5e8f97e6129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_23d7c849-23a1-4e8b-a351-307d2a153b1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6c900f67-578e-42f4-aaef-d5e8f97e6129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cfb38442-1b41-4b10-9d0e-271537e85543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_23d7c849-23a1-4e8b-a351-307d2a153b1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cfb38442-1b41-4b10-9d0e-271537e85543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_081b46ca-d1b9-4c9b-ac42-740996745df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_23d7c849-23a1-4e8b-a351-307d2a153b1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_081b46ca-d1b9-4c9b-ac42-740996745df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_dc541ba0-0934-4ad1-b99f-758fc39bb9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_23d7c849-23a1-4e8b-a351-307d2a153b1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_dc541ba0-0934-4ad1-b99f-758fc39bb9f7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#OtherFinancialInformationAccountsReceivableNetDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5bddff91-7b58-4900-a33b-b5b61f7fc491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_6c92dc5f-90d2-4f9c-a661-7b06736e8d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_5bddff91-7b58-4900-a33b-b5b61f7fc491" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_6c92dc5f-90d2-4f9c-a661-7b06736e8d78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_5974506a-4db4-4353-8083-ae9bfe693365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_5bddff91-7b58-4900-a33b-b5b61f7fc491" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_5974506a-4db4-4353-8083-ae9bfe693365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_1eca6c95-3885-4ff2-b890-8a6ddc7182ed" xlink:href="gild-20211231.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_5bddff91-7b58-4900-a33b-b5b61f7fc491" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_1eca6c95-3885-4ff2-b890-8a6ddc7182ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_b980d820-1688-47c1-85c0-12666292b832" xlink:href="gild-20211231.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_5bddff91-7b58-4900-a33b-b5b61f7fc491" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_b980d820-1688-47c1-85c0-12666292b832" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#OtherFinancialInformationOtherAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e41cb7da-7445-4a8a-8db7-d02062701d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_1c0aa147-820c-47e2-b063-dccffe8bb6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e41cb7da-7445-4a8a-8db7-d02062701d20" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_1c0aa147-820c-47e2-b063-dccffe8bb6dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5f7d93c5-c7fa-41ca-a279-06b261a89440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e41cb7da-7445-4a8a-8db7-d02062701d20" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5f7d93c5-c7fa-41ca-a279-06b261a89440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_15b11f0e-2468-487e-a872-60d4d4aac02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e41cb7da-7445-4a8a-8db7-d02062701d20" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_15b11f0e-2468-487e-a872-60d4d4aac02c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_37ae81eb-5664-4e82-a66c-7a958fecd03a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e41cb7da-7445-4a8a-8db7-d02062701d20" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_37ae81eb-5664-4e82-a66c-7a958fecd03a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_4cfd1403-f9be-43d5-919f-1b25d168da3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e41cb7da-7445-4a8a-8db7-d02062701d20" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_4cfd1403-f9be-43d5-919f-1b25d168da3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_19ed811a-9d42-4c8e-a49a-20a9fb2ee83e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f02f40df-162c-4153-b5d6-e3009a125582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_19ed811a-9d42-4c8e-a49a-20a9fb2ee83e" xlink:to="loc_us-gaap_LongTermDebtCurrent_f02f40df-162c-4153-b5d6-e3009a125582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6be2f34a-8701-42db-8caa-b9a51825b77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_19ed811a-9d42-4c8e-a49a-20a9fb2ee83e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6be2f34a-8701-42db-8caa-b9a51825b77a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b3c26dab-8016-4fa0-8525-b07f65cc5249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_94db959a-ed07-406f-90e0-c377dd65e033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b3c26dab-8016-4fa0-8525-b07f65cc5249" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_94db959a-ed07-406f-90e0-c377dd65e033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c4a3921a-8ca3-4b5b-9df8-1ed5920fe82f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b3c26dab-8016-4fa0-8525-b07f65cc5249" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c4a3921a-8ca3-4b5b-9df8-1ed5920fe82f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8c7f298a-5303-4b11-b52a-d2288b3f718e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b3c26dab-8016-4fa0-8525-b07f65cc5249" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8c7f298a-5303-4b11-b52a-d2288b3f718e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_50cb8154-7e9c-4ef4-9d15-1a07ec3508aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b3c26dab-8016-4fa0-8525-b07f65cc5249" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_50cb8154-7e9c-4ef4-9d15-1a07ec3508aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_5226b8bc-b450-450c-9dc0-ed6dfad97b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b3c26dab-8016-4fa0-8525-b07f65cc5249" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_5226b8bc-b450-450c-9dc0-ed6dfad97b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ae64c6df-53f0-403a-8bd1-4a245635b580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b3c26dab-8016-4fa0-8525-b07f65cc5249" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ae64c6df-53f0-403a-8bd1-4a245635b580" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c06f9f1-2329-4acd-96b1-a6a4d0e74030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_521a23b6-02ef-4d00-9600-e9825cc1cc71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c06f9f1-2329-4acd-96b1-a6a4d0e74030" xlink:to="loc_us-gaap_OperatingLeaseLiability_521a23b6-02ef-4d00-9600-e9825cc1cc71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8d960091-efcb-4481-a8c4-3b52cefe7108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c06f9f1-2329-4acd-96b1-a6a4d0e74030" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8d960091-efcb-4481-a8c4-3b52cefe7108" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" xlink:type="simple" xlink:href="gild-20211231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d282f7c-44f5-45fd-9b58-b2c2b8bbdcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2d88e3b8-59c0-4bae-868d-aee1756bab1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d282f7c-44f5-45fd-9b58-b2c2b8bbdcb9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2d88e3b8-59c0-4bae-868d-aee1756bab1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4209b37c-61c5-4204-80f6-13e7add39d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d282f7c-44f5-45fd-9b58-b2c2b8bbdcb9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4209b37c-61c5-4204-80f6-13e7add39d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_951f17c5-fffb-4891-97fb-29b612d3d3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d282f7c-44f5-45fd-9b58-b2c2b8bbdcb9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_951f17c5-fffb-4891-97fb-29b612d3d3ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0f041bea-fdae-4acd-8a62-8a4b2a67a560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d282f7c-44f5-45fd-9b58-b2c2b8bbdcb9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0f041bea-fdae-4acd-8a62-8a4b2a67a560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fd2aa368-3758-4f70-a27c-1447d1af7981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d282f7c-44f5-45fd-9b58-b2c2b8bbdcb9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fd2aa368-3758-4f70-a27c-1447d1af7981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7c03a402-cc51-4ba4-acc6-ad321a992e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d282f7c-44f5-45fd-9b58-b2c2b8bbdcb9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7c03a402-cc51-4ba4-acc6-ad321a992e80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7100e538-eb12-4fb3-865f-d2e41f133c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6c488917-3f1e-411f-964e-b475540d7132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7100e538-eb12-4fb3-865f-d2e41f133c2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6c488917-3f1e-411f-964e-b475540d7132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_679868b5-c959-4936-ad9d-dde6c500372e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7100e538-eb12-4fb3-865f-d2e41f133c2e" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_679868b5-c959-4936-ad9d-dde6c500372e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefitsSummaryofStockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_fff89416-8b43-4ffe-914b-fa9d421fe5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e71ef90e-9a64-4442-a82e-cae126301eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_fff89416-8b43-4ffe-914b-fa9d421fe5cc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e71ef90e-9a64-4442-a82e-cae126301eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a3385967-07f5-423f-b3d8-e4346c754ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_fff89416-8b43-4ffe-914b-fa9d421fe5cc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a3385967-07f5-423f-b3d8-e4346c754ca9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6450dc71-a81a-41ab-bd27-76ec58813238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32151bc6-9b95-4c85-8aa7-8a59ce0bbb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6450dc71-a81a-41ab-bd27-76ec58813238" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32151bc6-9b95-4c85-8aa7-8a59ce0bbb0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_255d12ec-f801-442f-aa6e-d989bf902d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6450dc71-a81a-41ab-bd27-76ec58813238" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_255d12ec-f801-442f-aa6e-d989bf902d5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7085630-d0a5-4f1b-b3e5-0cd46c7bf6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7ced79b7-228e-4612-94f4-2c64ffe6010b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7085630-d0a5-4f1b-b3e5-0cd46c7bf6e9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7ced79b7-228e-4612-94f4-2c64ffe6010b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ff888a94-354e-4b89-9935-47c95e3668f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7085630-d0a5-4f1b-b3e5-0cd46c7bf6e9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ff888a94-354e-4b89-9935-47c95e3668f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_e5f8b7e0-0b6d-42ac-892f-2c4368c241af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_d30bcb88-ccad-47d8-8321-56790c020c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_e5f8b7e0-0b6d-42ac-892f-2c4368c241af" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_d30bcb88-ccad-47d8-8321-56790c020c2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_48f36d72-d5c5-4b9f-8997-83323f4d0897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_e5f8b7e0-0b6d-42ac-892f-2c4368c241af" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_48f36d72-d5c5-4b9f-8997-83323f4d0897" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_17957fe1-3aa6-478a-94e1-c7e0b6cf9354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ab4c243b-9644-45fb-802c-e2ea2779676c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_17957fe1-3aa6-478a-94e1-c7e0b6cf9354" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ab4c243b-9644-45fb-802c-e2ea2779676c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_01e1eca7-8679-4a3c-986b-227c83028ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_17957fe1-3aa6-478a-94e1-c7e0b6cf9354" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_01e1eca7-8679-4a3c-986b-227c83028ca8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_856b8cff-6f3e-4cd0-9630-b633788eef1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_ecd7751a-b89f-4f20-b55e-03453ddcae8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_856b8cff-6f3e-4cd0-9630-b633788eef1d" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_ecd7751a-b89f-4f20-b55e-03453ddcae8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_ea60052f-62f3-4931-b71e-7f1deb57e7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_856b8cff-6f3e-4cd0-9630-b633788eef1d" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_ea60052f-62f3-4931-b71e-7f1deb57e7c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_ba29533b-404c-4269-8f2f-6be19523af5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_856b8cff-6f3e-4cd0-9630-b633788eef1d" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_ba29533b-404c-4269-8f2f-6be19523af5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_ab6814c8-11bd-42b9-9988-d343c0482b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ae801346-db19-476a-bfc0-caaab601bf83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_ab6814c8-11bd-42b9-9988-d343c0482b16" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ae801346-db19-476a-bfc0-caaab601bf83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8049f9aa-b9e8-4092-b03e-28647293d0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_ab6814c8-11bd-42b9-9988-d343c0482b16" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8049f9aa-b9e8-4092-b03e-28647293d0f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_bf7f2839-2fd3-44fb-87d2-7216b8b08761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_bf7f2839-2fd3-44fb-87d2-7216b8b08761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_bd96d76d-2855-4f88-9821-17c2d4bf2127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_bd96d76d-2855-4f88-9821-17c2d4bf2127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_082bdd46-1b46-4203-8e60-b521f4795e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_082bdd46-1b46-4203-8e60-b521f4795e2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_f7d183d4-b610-495f-9f58-42515250d212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_f7d183d4-b610-495f-9f58-42515250d212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_cbba75e1-b5e4-48ca-a47e-3b8a64bd99be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_cbba75e1-b5e4-48ca-a47e-3b8a64bd99be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8df3ad10-ce68-4605-b9ba-abb3d31c1ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8df3ad10-ce68-4605-b9ba-abb3d31c1ca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_92e083a8-9566-449b-b9af-6bcec8ae7c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_92e083a8-9566-449b-b9af-6bcec8ae7c17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_03ceaa1e-41b9-456f-bdb9-0d481076736f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_03ceaa1e-41b9-456f-bdb9-0d481076736f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b7351837-306d-4d28-96dc-5bd5d57a0b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b7351837-306d-4d28-96dc-5bd5d57a0b24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a55571c9-26bc-4284-a26b-520937b59e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a55571c9-26bc-4284-a26b-520937b59e5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_c2dcf1ca-b5fb-4aff-8251-f3daefd859ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_c2dcf1ca-b5fb-4aff-8251-f3daefd859ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_6de2a602-cdf8-41de-9c1e-067780bcce69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b13f9ff-f00e-49b2-b6f5-abbb12c00c32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_6de2a602-cdf8-41de-9c1e-067780bcce69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f0d38a0e-8acf-48ed-a5bb-ffc1c42ab2af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e2f3fe19-99f2-4056-933f-473f76417606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0d38a0e-8acf-48ed-a5bb-ffc1c42ab2af" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e2f3fe19-99f2-4056-933f-473f76417606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_c14ee9ec-198b-400f-9969-bd1485ea57f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0d38a0e-8acf-48ed-a5bb-ffc1c42ab2af" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_c14ee9ec-198b-400f-9969-bd1485ea57f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0c295891-e3f5-4b16-b93f-740669556b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0d38a0e-8acf-48ed-a5bb-ffc1c42ab2af" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0c295891-e3f5-4b16-b93f-740669556b12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_12b3a19d-b4e3-441a-b3a5-ef187437cfa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0d38a0e-8acf-48ed-a5bb-ffc1c42ab2af" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_12b3a19d-b4e3-441a-b3a5-ef187437cfa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fa07a99c-4ce4-4a26-885c-bf97c7311e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0d38a0e-8acf-48ed-a5bb-ffc1c42ab2af" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fa07a99c-4ce4-4a26-885c-bf97c7311e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_9d5d5b94-bfde-49f4-aa7d-b83f87c23346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0d38a0e-8acf-48ed-a5bb-ffc1c42ab2af" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_9d5d5b94-bfde-49f4-aa7d-b83f87c23346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_8712ce61-e3bd-42b7-92bd-c09fffe6d9c9" xlink:href="gild-20211231.xsd#gild_DeferredTaxAssetsUpfrontAndMilestonePayments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0d38a0e-8acf-48ed-a5bb-ffc1c42ab2af" xlink:to="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_8712ce61-e3bd-42b7-92bd-c09fffe6d9c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_1dda45bb-1f7c-413d-90b9-7fcb82ef23d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0d38a0e-8acf-48ed-a5bb-ffc1c42ab2af" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_1dda45bb-1f7c-413d-90b9-7fcb82ef23d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_b0eb823a-af73-4571-b2c1-bbd102509dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f0d38a0e-8acf-48ed-a5bb-ffc1c42ab2af" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_b0eb823a-af73-4571-b2c1-bbd102509dcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_307fe126-519b-4438-b6ca-55b4b9625299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cddc769a-8140-42d9-bbde-ba17bc3f0073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_307fe126-519b-4438-b6ca-55b4b9625299" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cddc769a-8140-42d9-bbde-ba17bc3f0073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_108d013c-c6da-4209-9b0e-d2fbb1bbbe5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_307fe126-519b-4438-b6ca-55b4b9625299" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_108d013c-c6da-4209-9b0e-d2fbb1bbbe5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_0df93c6b-a0ea-4de3-9349-665d236d47f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_307fe126-519b-4438-b6ca-55b4b9625299" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_0df93c6b-a0ea-4de3-9349-665d236d47f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8743c39d-cec2-4340-aaca-feabdb9c48d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f8268cf4-772d-48ff-8ec3-144c595e50ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_8743c39d-cec2-4340-aaca-feabdb9c48d6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f8268cf4-772d-48ff-8ec3-144c595e50ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4e88f43c-ccbe-48f1-ae51-e2ad649da001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_8743c39d-cec2-4340-aaca-feabdb9c48d6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4e88f43c-ccbe-48f1-ae51-e2ad649da001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_77f4d45a-6478-4f16-9fe8-07ba5decb8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a11c7044-2024-45ea-b1d5-856cb8526c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_77f4d45a-6478-4f16-9fe8-07ba5decb8ac" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_a11c7044-2024-45ea-b1d5-856cb8526c4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b556ec29-4bfd-4d00-9bd2-e7d1aa053762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_77f4d45a-6478-4f16-9fe8-07ba5decb8ac" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_b556ec29-4bfd-4d00-9bd2-e7d1aa053762" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>gild-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4eb1680c-5761-45c7-95ef-3c78b834062a,g:a0cedc55-fc60-4d3f-bea8-ef196ffaa864-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofIncome" xlink:type="extended" id="if0b6020b2bdd4eef9e67a4f829aec6f4_ConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a32004a4-591a-4e83-98cc-37acc6db2d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_RevenuesAbstract_a32004a4-591a-4e83-98cc-37acc6db2d10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09a8221c-0b18-4c06-b031-331268767059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_a32004a4-591a-4e83-98cc-37acc6db2d10" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09a8221c-0b18-4c06-b031-331268767059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_601bb89e-6d8f-4c82-b3e5-510156f0417e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_601bb89e-6d8f-4c82-b3e5-510156f0417e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_299501ac-8333-44b4-97d9-4f4251c98e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_299501ac-8333-44b4-97d9-4f4251c98e6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment_e0715240-4df1-4fbe-8093-95e0bdc06ba2" xlink:href="gild-20211231.xsd#gild_ResearchAndDevelopmentInProcessIncludingImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:to="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment_e0715240-4df1-4fbe-8093-95e0bdc06ba2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_299b7c77-a74f-47e2-b858-6165283cd8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_299b7c77-a74f-47e2-b858-6165283cd8a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c89d5f64-a81c-4d00-ac01-12b4f46a1641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:to="loc_us-gaap_CostsAndExpenses_c89d5f64-a81c-4d00-ac01-12b4f46a1641" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_505e8ff4-f28f-4655-ba58-6ca693605970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_OperatingIncomeLoss_505e8ff4-f28f-4655-ba58-6ca693605970" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_cc3d8e7a-e6e1-491f-b89e-88fc5004c0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_InterestExpense_cc3d8e7a-e6e1-491f-b89e-88fc5004c0e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_708a5bab-68d4-4a81-99fb-4e33e9c2187d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_708a5bab-68d4-4a81-99fb-4e33e9c2187d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7dadf185-d43f-4959-8727-ccfdebeace32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7dadf185-d43f-4959-8727-ccfdebeace32" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5276b889-db62-4c90-8084-6c201c6726c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5276b889-db62-4c90-8084-6c201c6726c6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_eb785c7c-5cd1-4d37-a9e2-4c3b62688db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_ProfitLoss_eb785c7c-5cd1-4d37-a9e2-4c3b62688db1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d9d5c18f-1c34-4156-b0ba-9e0f233df693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d9d5c18f-1c34-4156-b0ba-9e0f233df693" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aac35409-61ec-477f-9623-d41c0ad781c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_NetIncomeLoss_aac35409-61ec-477f-9623-d41c0ad781c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c4e91619-b74f-4a46-b8a8-e8a67c489672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_EarningsPerShareBasic_c4e91619-b74f-4a46-b8a8-e8a67c489672" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e1de03d1-45bc-4914-bade-13f0c2812d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e1de03d1-45bc-4914-bade-13f0c2812d2c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1fc7bf43-4e41-4f7e-a1df-b4a64317eabb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1fc7bf43-4e41-4f7e-a1df-b4a64317eabb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6080d545-afd0-4af6-8697-35d990c5166d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6080d545-afd0-4af6-8697-35d990c5166d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2d3ce795-a3b8-4688-bd68-2b41e949b2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_StatementTable_2d3ce795-a3b8-4688-bd68-2b41e949b2e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5437ff1b-0153-4d41-878a-25ff7c44abd5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2d3ce795-a3b8-4688-bd68-2b41e949b2e0" xlink:to="loc_srt_ProductOrServiceAxis_5437ff1b-0153-4d41-878a-25ff7c44abd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5437ff1b-0153-4d41-878a-25ff7c44abd5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5437ff1b-0153-4d41-878a-25ff7c44abd5" xlink:to="loc_srt_ProductsAndServicesDomain_5437ff1b-0153-4d41-878a-25ff7c44abd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73be9344-c14d-4f21-aee6-61788e2ac6bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5437ff1b-0153-4d41-878a-25ff7c44abd5" xlink:to="loc_srt_ProductsAndServicesDomain_73be9344-c14d-4f21-aee6-61788e2ac6bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_aef875d9-e3ec-403f-90b3-bc446b1f3360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_73be9344-c14d-4f21-aee6-61788e2ac6bc" xlink:to="loc_us-gaap_ProductMember_aef875d9-e3ec-403f-90b3-bc446b1f3360" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_6ee3be36-cf63-4b17-bca7-9e098390d032" xlink:href="gild-20211231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_73be9344-c14d-4f21-aee6-61788e2ac6bc" xlink:to="loc_gild_RoyaltyContractAndOtherMember_6ee3be36-cf63-4b17-bca7-9e098390d032" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i4e90ef656b524c05a73f338acc1ccfc5_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5d3e8066-7799-4fde-87f8-6fa9971abf14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5d3e8066-7799-4fde-87f8-6fa9971abf14" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_db38f91d-0bb7-4903-907d-5a30e4c24403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_db38f91d-0bb7-4903-907d-5a30e4c24403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_717d859e-5534-461a-b1b8-df2aef45b23b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_717d859e-5534-461a-b1b8-df2aef45b23b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_d9521b73-afc6-41fd-9588-bdbf1b642a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_d9521b73-afc6-41fd-9588-bdbf1b642a47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9e034b8e-2d28-452b-92bf-db144a3a7dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_ProfitLoss_9e034b8e-2d28-452b-92bf-db144a3a7dd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f7d88cef-32f4-416c-8c75-3dfe82a02c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f7d88cef-32f4-416c-8c75-3dfe82a02c6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_404cf54c-c804-4535-a2d2-b91b631e6a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_404cf54c-c804-4535-a2d2-b91b631e6a33" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_276c8936-55f9-4f1e-aa84-318cc2953f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_276c8936-55f9-4f1e-aa84-318cc2953f2d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_12e34418-09e5-475e-8142-ac58be42e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_12e34418-09e5-475e-8142-ac58be42e84c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7fd48bd6-4345-45e4-bd23-0cf91a0e9df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7fd48bd6-4345-45e4-bd23-0cf91a0e9df5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f99c7d4-6603-45ee-acc9-5fab73651e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f99c7d4-6603-45ee-acc9-5fab73651e56" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_129c4c0f-43d4-43a2-a2f9-9545770611de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_129c4c0f-43d4-43a2-a2f9-9545770611de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_6619b381-f590-4979-9591-04feecdfe735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_6619b381-f590-4979-9591-04feecdfe735" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_59b273db-b13c-43e4-9af2-d52667d3d9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_Dividends_59b273db-b13c-43e4-9af2-d52667d3d9ed" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f630595a-1b75-43f2-85c2-ca1512641f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2bfdab23-fd5e-42d8-aadc-d1173c2ea987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c0e0cd65-707b-4287-91e4-67e21ec50d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5d3e8066-7799-4fde-87f8-6fa9971abf14" xlink:to="loc_us-gaap_StatementTable_c0e0cd65-707b-4287-91e4-67e21ec50d68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_32956085-8195-429d-a933-7962318a385c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c0e0cd65-707b-4287-91e4-67e21ec50d68" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_32956085-8195-429d-a933-7962318a385c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_32956085-8195-429d-a933-7962318a385c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32956085-8195-429d-a933-7962318a385c" xlink:to="loc_us-gaap_EquityComponentDomain_32956085-8195-429d-a933-7962318a385c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32956085-8195-429d-a933-7962318a385c" xlink:to="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6978b0bb-c77c-4e29-a52f-ff98dbb0f6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:to="loc_us-gaap_CommonStockMember_6978b0bb-c77c-4e29-a52f-ff98dbb0f6f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_97282e71-c86f-4f21-864b-02e56ec57996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_97282e71-c86f-4f21-864b-02e56ec57996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bbfddce5-5ea0-4ace-ba6c-f64f9db40cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bbfddce5-5ea0-4ace-ba6c-f64f9db40cb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d2ca4b2d-5eab-44b2-b3e1-f1d4299af97b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:to="loc_us-gaap_RetainedEarningsMember_d2ca4b2d-5eab-44b2-b3e1-f1d4299af97b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e7c40d2f-1d74-455b-93e5-cf55c7fa1ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e7c40d2f-1d74-455b-93e5-cf55c7fa1ae9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_623df719-4b7c-4502-9098-1b3502364160" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c0e0cd65-707b-4287-91e4-67e21ec50d68" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_623df719-4b7c-4502-9098-1b3502364160" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_623df719-4b7c-4502-9098-1b3502364160_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_623df719-4b7c-4502-9098-1b3502364160" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_623df719-4b7c-4502-9098-1b3502364160_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7484974e-285e-49a7-bc55-1f0a52e13da7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_623df719-4b7c-4502-9098-1b3502364160" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7484974e-285e-49a7-bc55-1f0a52e13da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6b0285c8-4794-4f4e-9c7d-9fc83441f991" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7484974e-285e-49a7-bc55-1f0a52e13da7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6b0285c8-4794-4f4e-9c7d-9fc83441f991" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="if94f2e618a814d989d7af68a1ff6cd7e_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:href="gild-20211231.xsd#gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_f17abfa2-c2c2-4d23-8875-543398907c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_f17abfa2-c2c2-4d23-8875-543398907c0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8f765b7c-9b2e-4cf9-bbe5-802f1359c35c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8f765b7c-9b2e-4cf9-bbe5-802f1359c35c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_770afaed-304f-48b5-8ae4-8d0b3e3fc333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:to="loc_us-gaap_AdvertisingExpense_770afaed-304f-48b5-8ae4-8d0b3e3fc333" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_a2fcb468-d56c-4897-ab03-2edc8a4010d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_a2fcb468-d56c-4897-ab03-2edc8a4010d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2d56f95d-df28-4cb1-b8c5-9439c41e0667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2d56f95d-df28-4cb1-b8c5-9439c41e0667" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SummaryOfSignificantAccountingPoliciesTable_bc7157a9-5237-4774-9742-fab2f98d5cf7" xlink:href="gild-20211231.xsd#gild_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:to="loc_gild_SummaryOfSignificantAccountingPoliciesTable_bc7157a9-5237-4774-9742-fab2f98d5cf7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3bc28df8-d0b9-453d-ae8f-3f38b5104f3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_bc7157a9-5237-4774-9742-fab2f98d5cf7" xlink:to="loc_srt_RangeAxis_3bc28df8-d0b9-453d-ae8f-3f38b5104f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3bc28df8-d0b9-453d-ae8f-3f38b5104f3c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3bc28df8-d0b9-453d-ae8f-3f38b5104f3c" xlink:to="loc_srt_RangeMember_3bc28df8-d0b9-453d-ae8f-3f38b5104f3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a24bcb04-ce9e-4750-b183-29740e392133" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3bc28df8-d0b9-453d-ae8f-3f38b5104f3c" xlink:to="loc_srt_RangeMember_a24bcb04-ce9e-4750-b183-29740e392133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_13f04e7f-9a90-4e8a-a4f4-b23e8e3ac4a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a24bcb04-ce9e-4750-b183-29740e392133" xlink:to="loc_srt_MinimumMember_13f04e7f-9a90-4e8a-a4f4-b23e8e3ac4a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4052e09-6ec6-4ea7-94c3-612c3605e8b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a24bcb04-ce9e-4750-b183-29740e392133" xlink:to="loc_srt_MaximumMember_a4052e09-6ec6-4ea7-94c3-612c3605e8b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d409b165-b6f6-44a9-8123-86322e6d79fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_bc7157a9-5237-4774-9742-fab2f98d5cf7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d409b165-b6f6-44a9-8123-86322e6d79fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d409b165-b6f6-44a9-8123-86322e6d79fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d409b165-b6f6-44a9-8123-86322e6d79fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d409b165-b6f6-44a9-8123-86322e6d79fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b88b623-abd3-42ff-9eb3-6c276bb22009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d409b165-b6f6-44a9-8123-86322e6d79fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b88b623-abd3-42ff-9eb3-6c276bb22009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_36eceb30-326a-4b01-956d-9f6e09abad7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b88b623-abd3-42ff-9eb3-6c276bb22009" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_36eceb30-326a-4b01-956d-9f6e09abad7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_0901708a-386d-4808-93d9-498bbe42d227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b88b623-abd3-42ff-9eb3-6c276bb22009" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_0901708a-386d-4808-93d9-498bbe42d227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2711dd13-849e-443f-9a9b-dfec72a9d287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b88b623-abd3-42ff-9eb3-6c276bb22009" xlink:to="loc_us-gaap_ComputerEquipmentMember_2711dd13-849e-443f-9a9b-dfec72a9d287" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#RevenuesDisaggregationofRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="extended" id="i33dd85089fdc44259f895983979a5a53_RevenuesDisaggregationofRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6eb8d3f1-e954-4576-aa16-8a3ad1d9bc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c2dd157-3a68-4b2e-a749-aa65c330ff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6eb8d3f1-e954-4576-aa16-8a3ad1d9bc9a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c2dd157-3a68-4b2e-a749-aa65c330ff2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_306ef94d-93b8-407e-8c07-91f3c00098ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6eb8d3f1-e954-4576-aa16-8a3ad1d9bc9a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_306ef94d-93b8-407e-8c07-91f3c00098ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8be6c2f5-7bda-49fc-aae3-ec0245ade4b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_306ef94d-93b8-407e-8c07-91f3c00098ae" xlink:to="loc_srt_ProductOrServiceAxis_8be6c2f5-7bda-49fc-aae3-ec0245ade4b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8be6c2f5-7bda-49fc-aae3-ec0245ade4b1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8be6c2f5-7bda-49fc-aae3-ec0245ade4b1" xlink:to="loc_srt_ProductsAndServicesDomain_8be6c2f5-7bda-49fc-aae3-ec0245ade4b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1392908-781c-4c88-88c4-aaccf515445c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8be6c2f5-7bda-49fc-aae3-ec0245ade4b1" xlink:to="loc_srt_ProductsAndServicesDomain_f1392908-781c-4c88-88c4-aaccf515445c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1392908-781c-4c88-88c4-aaccf515445c" xlink:to="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:href="gild-20211231.xsd#gild_HIVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsAtriplaMember_347842b4-7661-489c-b91f-bdbf6e7cabeb" xlink:href="gild-20211231.xsd#gild_HIVProductsAtriplaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsAtriplaMember_347842b4-7661-489c-b91f-bdbf6e7cabeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_cbb23c70-cc1b-45ed-aaa7-2b8bb0347bbe" xlink:href="gild-20211231.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsBiktarvyMember_cbb23c70-cc1b-45ed-aaa7-2b8bb0347bbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_0c81105d-b89f-4d28-98dc-31da43a631c9" xlink:href="gild-20211231.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_0c81105d-b89f-4d28-98dc-31da43a631c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_90cf635f-c971-4993-8511-f831bc64d98d" xlink:href="gild-20211231.xsd#gild_HIVProductsDescovyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsDescovyMember_90cf635f-c971-4993-8511-f831bc64d98d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_964e3a59-cd0e-4d02-9c4d-5bb2c5517bcd" xlink:href="gild-20211231.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsGenvoyaMember_964e3a59-cd0e-4d02-9c4d-5bb2c5517bcd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_3213ddad-870c-4fe1-97c9-b4a1f665279a" xlink:href="gild-20211231.xsd#gild_HIVProductsOdefseyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsOdefseyMember_3213ddad-870c-4fe1-97c9-b4a1f665279a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_aa376418-8e8f-4fd5-a0e3-282e82bfd18f" xlink:href="gild-20211231.xsd#gild_HIVProductsStribildMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsStribildMember_aa376418-8e8f-4fd5-a0e3-282e82bfd18f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_72d715ec-ad6e-4d51-a3dd-f91f56d5ef8c" xlink:href="gild-20211231.xsd#gild_HIVProductsTruvadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsTruvadaMember_72d715ec-ad6e-4d51-a3dd-f91f56d5ef8c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_2aa9f730-4701-40ed-919e-8041f909eecb" xlink:href="gild-20211231.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_2aa9f730-4701-40ed-919e-8041f909eecb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_292f94a4-aae5-48c3-8328-353a36677c39" xlink:href="gild-20211231.xsd#gild_ProductsOtherHIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_ProductsOtherHIVMember_292f94a4-aae5-48c3-8328-353a36677c39" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember_73dcdae7-da54-40f6-9d40-516c69188611" xlink:href="gild-20211231.xsd#gild_VekluryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_VekluryMember_73dcdae7-da54-40f6-9d40-516c69188611" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_335a87e5-e6b3-4975-8cec-7d89247a8c1e" xlink:href="gild-20211231.xsd#gild_HCVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_HCVProductSalesMember_335a87e5-e6b3-4975-8cec-7d89247a8c1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_9cbb9c7d-0fdf-43cd-8007-5ed2a1590f18" xlink:href="gild-20211231.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_335a87e5-e6b3-4975-8cec-7d89247a8c1e" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_9cbb9c7d-0fdf-43cd-8007-5ed2a1590f18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_7ae85b20-300f-4405-a279-694032a386b4" xlink:href="gild-20211231.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_335a87e5-e6b3-4975-8cec-7d89247a8c1e" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_7ae85b20-300f-4405-a279-694032a386b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHCVMember_1cd90462-94a4-43fd-a154-88f701430e76" xlink:href="gild-20211231.xsd#gild_OtherHCVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_335a87e5-e6b3-4975-8cec-7d89247a8c1e" xlink:to="loc_gild_OtherHCVMember_1cd90462-94a4-43fd-a154-88f701430e76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_0f9ef6d3-37b7-4294-a593-985058ef7413" xlink:href="gild-20211231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_0f9ef6d3-37b7-4294-a593-985058ef7413" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_8a3445db-9356-48b5-9c5d-b12f391a1339" xlink:href="gild-20211231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_0f9ef6d3-37b7-4294-a593-985058ef7413" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_8a3445db-9356-48b5-9c5d-b12f391a1339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_a0a06e6e-9bdf-49db-a26b-6ce30fe69a42" xlink:href="gild-20211231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_0f9ef6d3-37b7-4294-a593-985058ef7413" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_a0a06e6e-9bdf-49db-a26b-6ce30fe69a42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_83a48084-fc9b-449a-942e-1a7bd6a2d8b7" xlink:href="gild-20211231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_0f9ef6d3-37b7-4294-a593-985058ef7413" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_83a48084-fc9b-449a-942e-1a7bd6a2d8b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_40193d41-d10c-43af-b725-2e107b19812f" xlink:href="gild-20211231.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_40193d41-d10c-43af-b725-2e107b19812f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_faa409dd-b224-4ffb-826b-069fc85f6748" xlink:href="gild-20211231.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_40193d41-d10c-43af-b725-2e107b19812f" xlink:to="loc_gild_CellTherapyProductsTecartusMember_faa409dd-b224-4ffb-826b-069fc85f6748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsYescartaMember_dc099a71-9bfd-4c31-afb5-5c22d93bd77b" xlink:href="gild-20211231.xsd#gild_OtherProductsYescartaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_40193d41-d10c-43af-b725-2e107b19812f" xlink:to="loc_gild_OtherProductsYescartaMember_dc099a71-9bfd-4c31-afb5-5c22d93bd77b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_8865fb5e-80de-4448-98ec-edcc3d52a305" xlink:href="gild-20211231.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_TrodelvyMember_8865fb5e-80de-4448-98ec-edcc3d52a305" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:href="gild-20211231.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_7565c889-cd4a-428e-8cd5-b4df0c8c4710" xlink:href="gild-20211231.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:to="loc_gild_OtherProductsAmBisomeMember_7565c889-cd4a-428e-8cd5-b4df0c8c4710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_db90e806-9685-4423-85cb-e0b63e624874" xlink:href="gild-20211231.xsd#gild_OtherProductsLetairisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:to="loc_gild_OtherProductsLetairisMember_db90e806-9685-4423-85cb-e0b63e624874" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsRanexaMember_fdbd170e-1f95-44de-b12f-40d1cc41e598" xlink:href="gild-20211231.xsd#gild_OtherProductsRanexaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:to="loc_gild_OtherProductsRanexaMember_fdbd170e-1f95-44de-b12f-40d1cc41e598" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsZydeligMember_0359e329-1872-412d-908f-a74a68cf4ae6" xlink:href="gild-20211231.xsd#gild_OtherProductsZydeligMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:to="loc_gild_OtherProductsZydeligMember_0359e329-1872-412d-908f-a74a68cf4ae6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_e46e13a5-2670-457f-be42-ad73e285002c" xlink:href="gild-20211231.xsd#gild_OtherProductsOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:to="loc_gild_OtherProductsOtherMember_e46e13a5-2670-457f-be42-ad73e285002c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_84f85015-e54e-4750-8638-190a2f2ee2df" xlink:href="gild-20211231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1392908-781c-4c88-88c4-aaccf515445c" xlink:to="loc_gild_RoyaltyContractAndOtherMember_84f85015-e54e-4750-8638-190a2f2ee2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0137e542-62e8-4f3f-a65d-b6bd3d5a695a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_306ef94d-93b8-407e-8c07-91f3c00098ae" xlink:to="loc_srt_StatementGeographicalAxis_0137e542-62e8-4f3f-a65d-b6bd3d5a695a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0137e542-62e8-4f3f-a65d-b6bd3d5a695a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0137e542-62e8-4f3f-a65d-b6bd3d5a695a" xlink:to="loc_srt_SegmentGeographicalDomain_0137e542-62e8-4f3f-a65d-b6bd3d5a695a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c65dce8f-93a7-46e4-881e-03d9d6f283aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0137e542-62e8-4f3f-a65d-b6bd3d5a695a" xlink:to="loc_srt_SegmentGeographicalDomain_c65dce8f-93a7-46e4-881e-03d9d6f283aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9ef47f6d-0555-4358-8781-6992a03fbaee" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c65dce8f-93a7-46e4-881e-03d9d6f283aa" xlink:to="loc_country_US_9ef47f6d-0555-4358-8781-6992a03fbaee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_5ea9ac3f-f108-49b1-aebe-decc14f8dbec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c65dce8f-93a7-46e4-881e-03d9d6f283aa" xlink:to="loc_srt_EuropeMember_5ea9ac3f-f108-49b1-aebe-decc14f8dbec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_493c3505-caaa-404d-af89-92bab5b53fde" xlink:href="gild-20211231.xsd#gild_OtherInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c65dce8f-93a7-46e4-881e-03d9d6f283aa" xlink:to="loc_gild_OtherInternationalMember_493c3505-caaa-404d-af89-92bab5b53fde" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#RevenuesSummarizedRevenuesfromMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="extended" id="i766a1b0cd9ed4d14b12b328773ae952d_RevenuesSummarizedRevenuesfromMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_102eb3f7-01ee-426c-a8bb-d6e6f4dc421d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_833c695a-9923-4ae5-b5a5-3a306bab1b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_102eb3f7-01ee-426c-a8bb-d6e6f4dc421d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_833c695a-9923-4ae5-b5a5-3a306bab1b16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ffbc0d94-6b6b-43ed-9c4e-184404f58235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_102eb3f7-01ee-426c-a8bb-d6e6f4dc421d" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ffbc0d94-6b6b-43ed-9c4e-184404f58235" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1feb23ff-b575-4cd5-97da-091f816e25a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ffbc0d94-6b6b-43ed-9c4e-184404f58235" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1feb23ff-b575-4cd5-97da-091f816e25a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1feb23ff-b575-4cd5-97da-091f816e25a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1feb23ff-b575-4cd5-97da-091f816e25a5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1feb23ff-b575-4cd5-97da-091f816e25a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2823a0a1-4cbb-4fbb-9023-23ffb4a0e982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1feb23ff-b575-4cd5-97da-091f816e25a5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2823a0a1-4cbb-4fbb-9023-23ffb4a0e982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_3af93181-1902-4775-a8a9-4410f3cd341e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2823a0a1-4cbb-4fbb-9023-23ffb4a0e982" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_3af93181-1902-4775-a8a9-4410f3cd341e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_08d25965-e559-4fa4-afcc-7b02e8d4ada7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ffbc0d94-6b6b-43ed-9c4e-184404f58235" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_08d25965-e559-4fa4-afcc-7b02e8d4ada7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_08d25965-e559-4fa4-afcc-7b02e8d4ada7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_08d25965-e559-4fa4-afcc-7b02e8d4ada7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_08d25965-e559-4fa4-afcc-7b02e8d4ada7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3c15fcb0-88b3-4085-aab8-86d34816273a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_08d25965-e559-4fa4-afcc-7b02e8d4ada7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3c15fcb0-88b3-4085-aab8-86d34816273a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_11cc303a-ad2b-48ae-957d-8b4e08fd0727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3c15fcb0-88b3-4085-aab8-86d34816273a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_11cc303a-ad2b-48ae-957d-8b4e08fd0727" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_872359cf-f507-4e7e-89ec-eca689728e7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ffbc0d94-6b6b-43ed-9c4e-184404f58235" xlink:to="loc_srt_MajorCustomersAxis_872359cf-f507-4e7e-89ec-eca689728e7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_872359cf-f507-4e7e-89ec-eca689728e7d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_872359cf-f507-4e7e-89ec-eca689728e7d" xlink:to="loc_srt_NameOfMajorCustomerDomain_872359cf-f507-4e7e-89ec-eca689728e7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_37022a98-0274-42a6-b35e-38afa6897378" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_872359cf-f507-4e7e-89ec-eca689728e7d" xlink:to="loc_srt_NameOfMajorCustomerDomain_37022a98-0274-42a6-b35e-38afa6897378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_8e0ff66d-1c0d-4901-8985-565b4c2e87b7" xlink:href="gild-20211231.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_37022a98-0274-42a6-b35e-38afa6897378" xlink:to="loc_gild_AmerisourcebergenCorpMember_8e0ff66d-1c0d-4901-8985-565b4c2e87b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_65e7ef37-d273-42cb-a13e-515ce087e553" xlink:href="gild-20211231.xsd#gild_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_37022a98-0274-42a6-b35e-38afa6897378" xlink:to="loc_gild_CardinalHealthIncMember_65e7ef37-d273-42cb-a13e-515ce087e553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_6251fa9d-20fe-4810-8bf0-c059a7fe104d" xlink:href="gild-20211231.xsd#gild_MckessonCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_37022a98-0274-42a6-b35e-38afa6897378" xlink:to="loc_gild_MckessonCorpMember_6251fa9d-20fe-4810-8bf0-c059a7fe104d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended" id="i8cf7b924dce44183ac8749b452dee8ff_FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8de7bf23-49d8-46f1-8924-3465a261c601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6f246a97-2f88-4b24-9f6c-1ea4faa044e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8de7bf23-49d8-46f1-8924-3465a261c601" xlink:to="loc_us-gaap_AssetsAbstract_6f246a97-2f88-4b24-9f6c-1ea4faa044e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a638cece-42fc-4d9f-aa50-669e02176002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6f246a97-2f88-4b24-9f6c-1ea4faa044e8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a638cece-42fc-4d9f-aa50-669e02176002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_cbe8dafb-78b0-408a-aa08-15eb4f077287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6f246a97-2f88-4b24-9f6c-1ea4faa044e8" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_cbe8dafb-78b0-408a-aa08-15eb4f077287" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_d75be06e-25aa-4ad1-9b83-bc4033235a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6f246a97-2f88-4b24-9f6c-1ea4faa044e8" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_d75be06e-25aa-4ad1-9b83-bc4033235a16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_de976bfa-4c33-4567-b806-ee2808ab4d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6f246a97-2f88-4b24-9f6c-1ea4faa044e8" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_de976bfa-4c33-4567-b806-ee2808ab4d9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_98e74709-dfa4-4d2e-a925-40c233652d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8de7bf23-49d8-46f1-8924-3465a261c601" xlink:to="loc_us-gaap_LiabilitiesAbstract_98e74709-dfa4-4d2e-a925-40c233652d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f3c1a49a-5567-4171-bba3-0c6b5818700e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_98e74709-dfa4-4d2e-a925-40c233652d39" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f3c1a49a-5567-4171-bba3-0c6b5818700e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_744da5f0-8ee4-45d9-bec3-051f1e6b2600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_98e74709-dfa4-4d2e-a925-40c233652d39" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_744da5f0-8ee4-45d9-bec3-051f1e6b2600" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_cb425d0d-8e2a-402a-ba95-601864b21e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_98e74709-dfa4-4d2e-a925-40c233652d39" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_cb425d0d-8e2a-402a-ba95-601864b21e77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0a9e4175-faeb-4464-aa86-7b2f4a868c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_98e74709-dfa4-4d2e-a925-40c233652d39" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0a9e4175-faeb-4464-aa86-7b2f4a868c85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8de7bf23-49d8-46f1-8924-3465a261c601" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_096ede4f-84c0-48c4-820f-3cb4832fa6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_096ede4f-84c0-48c4-820f-3cb4832fa6b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_096ede4f-84c0-48c4-820f-3cb4832fa6b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_096ede4f-84c0-48c4-820f-3cb4832fa6b1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_096ede4f-84c0-48c4-820f-3cb4832fa6b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_37316d9c-ebf2-4b61-9845-a6134b022041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_096ede4f-84c0-48c4-820f-3cb4832fa6b1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_37316d9c-ebf2-4b61-9845-a6134b022041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8b69a5b5-e0c5-4fd7-8cac-f99ffe0ef173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_37316d9c-ebf2-4b61-9845-a6134b022041" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8b69a5b5-e0c5-4fd7-8cac-f99ffe0ef173" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c48099aa-04c0-4855-b52d-96ab9d45bb40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c48099aa-04c0-4855-b52d-96ab9d45bb40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c48099aa-04c0-4855-b52d-96ab9d45bb40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c48099aa-04c0-4855-b52d-96ab9d45bb40" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c48099aa-04c0-4855-b52d-96ab9d45bb40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d47c09f1-d54a-40fe-b946-902c7c71d725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c48099aa-04c0-4855-b52d-96ab9d45bb40" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d47c09f1-d54a-40fe-b946-902c7c71d725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3d4c6f52-bf9b-46ef-9862-4927200b7eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d47c09f1-d54a-40fe-b946-902c7c71d725" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3d4c6f52-bf9b-46ef-9862-4927200b7eb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d83c56b0-5fcd-4c32-b1ca-49571e12d686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d47c09f1-d54a-40fe-b946-902c7c71d725" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d83c56b0-5fcd-4c32-b1ca-49571e12d686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0bf381b8-20fd-4091-9105-35c8d24f26aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d47c09f1-d54a-40fe-b946-902c7c71d725" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0bf381b8-20fd-4091-9105-35c8d24f26aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a48a847d-a4d4-487f-a16e-a358fb2da1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a48a847d-a4d4-487f-a16e-a358fb2da1bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a48a847d-a4d4-487f-a16e-a358fb2da1bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a48a847d-a4d4-487f-a16e-a358fb2da1bd" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a48a847d-a4d4-487f-a16e-a358fb2da1bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1661539c-4ffa-48a5-8d2c-6448b13e65ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a48a847d-a4d4-487f-a16e-a358fb2da1bd" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1661539c-4ffa-48a5-8d2c-6448b13e65ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b05d7a8f-a1b0-45ee-8126-81fa54ae517b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1661539c-4ffa-48a5-8d2c-6448b13e65ed" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b05d7a8f-a1b0-45ee-8126-81fa54ae517b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1a6888f5-05dc-41c2-be59-7d3b0acc2e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b05d7a8f-a1b0-45ee-8126-81fa54ae517b" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1a6888f5-05dc-41c2-be59-7d3b0acc2e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1ff744a0-63ca-49cb-aaac-61dcc9812e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1ff744a0-63ca-49cb-aaac-61dcc9812e8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ff744a0-63ca-49cb-aaac-61dcc9812e8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1ff744a0-63ca-49cb-aaac-61dcc9812e8a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ff744a0-63ca-49cb-aaac-61dcc9812e8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1ff744a0-63ca-49cb-aaac-61dcc9812e8a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_03df277e-8485-4315-98cc-988fa430729f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_03df277e-8485-4315-98cc-988fa430729f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cd7ec023-d1a8-4c10-9302-b5047c618b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cd7ec023-d1a8-4c10-9302-b5047c618b61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_270bd51d-fb55-41d9-ac55-b6d7108b3b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_270bd51d-fb55-41d9-ac55-b6d7108b3b53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_969970f6-adcc-4357-aa16-b8cb24657454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_969970f6-adcc-4357-aa16-b8cb24657454" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_50cfcf2c-7e06-4c51-b106-b5d5ef5cfb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_50cfcf2c-7e06-4c51-b106-b5d5ef5cfb46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_420f1987-060c-4350-a215-2366e7a5e699" xlink:href="gild-20211231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_420f1987-060c-4350-a215-2366e7a5e699" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7100b04a-8116-4140-9a78-3a3d4934f75e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7100b04a-8116-4140-9a78-3a3d4934f75e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_4b60b299-83bc-4014-8f31-27d96c9a3796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_EquitySecuritiesMember_4b60b299-83bc-4014-8f31-27d96c9a3796" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_644281ee-b104-4616-8398-1c5b22a77c95" xlink:href="gild-20211231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_gild_DeferredCompensationPlanMember_644281ee-b104-4616-8398-1c5b22a77c95" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_2193e25d-e8d3-461b-8eb9-7d0478348580" xlink:href="gild-20211231.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_2193e25d-e8d3-461b-8eb9-7d0478348580" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_096d0198-b401-4133-a2cf-e6c62dd69143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_096d0198-b401-4133-a2cf-e6c62dd69143" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_096d0198-b401-4133-a2cf-e6c62dd69143_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_096d0198-b401-4133-a2cf-e6c62dd69143" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_096d0198-b401-4133-a2cf-e6c62dd69143_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a58c7826-fab8-44b3-b136-2652a85eeda7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_096d0198-b401-4133-a2cf-e6c62dd69143" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a58c7826-fab8-44b3-b136-2652a85eeda7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_21ab4b45-adc2-44e3-9b37-ab7a7ba11b0e" xlink:href="gild-20211231.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a58c7826-fab8-44b3-b136-2652a85eeda7" xlink:to="loc_gild_MYRGmbHMember_21ab4b45-adc2-44e3-9b37-ab7a7ba11b0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2de7f2a8-f12e-4496-8a7c-517fa2416636" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2de7f2a8-f12e-4496-8a7c-517fa2416636" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2de7f2a8-f12e-4496-8a7c-517fa2416636_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2de7f2a8-f12e-4496-8a7c-517fa2416636" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2de7f2a8-f12e-4496-8a7c-517fa2416636_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_193c23f1-7422-4a45-aa07-2d4af79a058d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2de7f2a8-f12e-4496-8a7c-517fa2416636" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_193c23f1-7422-4a45-aa07-2d4af79a058d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_78cedae9-e669-4b6e-94f8-67b7f776628b" xlink:href="gild-20211231.xsd#gild_GalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_193c23f1-7422-4a45-aa07-2d4af79a058d" xlink:to="loc_gild_GalapagosMember_78cedae9-e669-4b6e-94f8-67b7f776628b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_ae1a68ea-be3d-41d9-b1c8-ccbb24b1d724" xlink:href="gild-20211231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_193c23f1-7422-4a45-aa07-2d4af79a058d" xlink:to="loc_gild_ArcusBiosciencesIncMember_ae1a68ea-be3d-41d9-b1c8-ccbb24b1d724" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails" xlink:type="extended" id="i39c1dd0e0f72415fbb345fbc01f2f388_FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_90d8de9e-82d0-4640-b02a-2067f41aee77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_77f03127-14bc-44d7-8207-4df6b1c87cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_90d8de9e-82d0-4640-b02a-2067f41aee77" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_77f03127-14bc-44d7-8207-4df6b1c87cc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b1ef6c96-7f77-4ff8-b160-e0e073afb696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_90d8de9e-82d0-4640-b02a-2067f41aee77" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b1ef6c96-7f77-4ff8-b160-e0e073afb696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b5bf7c2-4b8a-4b8f-b957-794eff7a787a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_90d8de9e-82d0-4640-b02a-2067f41aee77" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b5bf7c2-4b8a-4b8f-b957-794eff7a787a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3257c88d-feb0-4407-87c4-1c55cfbef7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b5bf7c2-4b8a-4b8f-b957-794eff7a787a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3257c88d-feb0-4407-87c4-1c55cfbef7a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3257c88d-feb0-4407-87c4-1c55cfbef7a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3257c88d-feb0-4407-87c4-1c55cfbef7a1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3257c88d-feb0-4407-87c4-1c55cfbef7a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8be5ed98-1387-49f6-8f39-e319e90d9cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3257c88d-feb0-4407-87c4-1c55cfbef7a1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8be5ed98-1387-49f6-8f39-e319e90d9cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_5c0d952a-c6b3-4d48-9fba-cbc3b3cb8e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8be5ed98-1387-49f6-8f39-e319e90d9cef" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_5c0d952a-c6b3-4d48-9fba-cbc3b3cb8e7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_875f9b6c-f427-4bf5-bc7d-c5c1be1663c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8be5ed98-1387-49f6-8f39-e319e90d9cef" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_875f9b6c-f427-4bf5-bc7d-c5c1be1663c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_eafca7f7-4bd0-4dac-8cbd-f0195e67502c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8be5ed98-1387-49f6-8f39-e319e90d9cef" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_eafca7f7-4bd0-4dac-8cbd-f0195e67502c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_550aa7e4-3e73-4522-9ca4-38a242d0f6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b5bf7c2-4b8a-4b8f-b957-794eff7a787a" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_550aa7e4-3e73-4522-9ca4-38a242d0f6ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_550aa7e4-3e73-4522-9ca4-38a242d0f6ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_550aa7e4-3e73-4522-9ca4-38a242d0f6ff" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_550aa7e4-3e73-4522-9ca4-38a242d0f6ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5a628b64-bfea-4b81-9d40-f11df01bb338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_550aa7e4-3e73-4522-9ca4-38a242d0f6ff" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5a628b64-bfea-4b81-9d40-f11df01bb338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_6e2a113f-cdea-4362-b30b-37a73a79ac95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5a628b64-bfea-4b81-9d40-f11df01bb338" xlink:to="loc_us-gaap_EquitySecuritiesMember_6e2a113f-cdea-4362-b30b-37a73a79ac95" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" id="i91ba3ba477b4412ebc7460122da1864b_FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_7059687c-7df0-4fc1-92fd-5bcc5642f2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_7059687c-7df0-4fc1-92fd-5bcc5642f2ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_93009c89-a803-43b2-bde9-e3acc50f47d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_93009c89-a803-43b2-bde9-e3acc50f47d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_837275ac-d92f-4874-b18a-163da1388bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_837275ac-d92f-4874-b18a-163da1388bd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_868a4f9b-74bd-4b5e-9407-24958f6f75a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_868a4f9b-74bd-4b5e-9407-24958f6f75a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_8975e19c-c0f4-47d8-a0f0-53eec08fb7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_LongTermDebtFairValue_8975e19c-c0f4-47d8-a0f0-53eec08fb7a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a6ec6399-2d23-486f-be69-9f3a6ddc00a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a6ec6399-2d23-486f-be69-9f3a6ddc00a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_72b4f9d7-abbe-48a1-b539-852814c6dc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_72b4f9d7-abbe-48a1-b539-852814c6dc6c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_e85378c8-181f-443c-a267-fa2facdfd633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_e85378c8-181f-443c-a267-fa2facdfd633" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2dacddd8-d2e2-466d-96a6-54ad2595ffd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2dacddd8-d2e2-466d-96a6-54ad2595ffd5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_04c5e829-e5f7-4ff3-bde3-7f06848d771d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_04c5e829-e5f7-4ff3-bde3-7f06848d771d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04c5e829-e5f7-4ff3-bde3-7f06848d771d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_04c5e829-e5f7-4ff3-bde3-7f06848d771d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04c5e829-e5f7-4ff3-bde3-7f06848d771d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3d70eb29-ac05-441e-986e-35e9770717b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_04c5e829-e5f7-4ff3-bde3-7f06848d771d" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3d70eb29-ac05-441e-986e-35e9770717b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04319fdd-3947-4fdd-8466-0e232bd83b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3d70eb29-ac05-441e-986e-35e9770717b3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04319fdd-3947-4fdd-8466-0e232bd83b38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_12fa33f9-c703-4f03-a698-651a3416f43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04319fdd-3947-4fdd-8466-0e232bd83b38" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_12fa33f9-c703-4f03-a698-651a3416f43f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_26e936a6-9936-44e6-bdbe-b5c80d920fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04319fdd-3947-4fdd-8466-0e232bd83b38" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_26e936a6-9936-44e6-bdbe-b5c80d920fce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a29e832-9a5f-41a3-9c77-511dcca8f65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a29e832-9a5f-41a3-9c77-511dcca8f65c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0a29e832-9a5f-41a3-9c77-511dcca8f65c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a29e832-9a5f-41a3-9c77-511dcca8f65c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0a29e832-9a5f-41a3-9c77-511dcca8f65c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2528411-31ad-4d93-a6d1-ee60bda05239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a29e832-9a5f-41a3-9c77-511dcca8f65c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2528411-31ad-4d93-a6d1-ee60bda05239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_58198514-51d3-44ae-8900-a439906c862c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2528411-31ad-4d93-a6d1-ee60bda05239" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_58198514-51d3-44ae-8900-a439906c862c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c4dec1ae-81a2-4953-995b-8bc18fce4f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2528411-31ad-4d93-a6d1-ee60bda05239" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c4dec1ae-81a2-4953-995b-8bc18fce4f16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1c5a187f-11a6-4e26-bb0b-457c4d60ec5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1c5a187f-11a6-4e26-bb0b-457c4d60ec5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1c5a187f-11a6-4e26-bb0b-457c4d60ec5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1c5a187f-11a6-4e26-bb0b-457c4d60ec5a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1c5a187f-11a6-4e26-bb0b-457c4d60ec5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9758d425-8263-44e0-aa7a-ee384ca5c737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1c5a187f-11a6-4e26-bb0b-457c4d60ec5a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9758d425-8263-44e0-aa7a-ee384ca5c737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesDonationMember_a78210ac-23df-4678-a6d9-79fc85139e63" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesDonationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9758d425-8263-44e0-aa7a-ee384ca5c737" xlink:to="loc_gild_EquitySecuritiesDonationMember_a78210ac-23df-4678-a6d9-79fc85139e63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_83464f72-1005-4ce9-adae-5b7b505d0414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_83464f72-1005-4ce9-adae-5b7b505d0414" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_83464f72-1005-4ce9-adae-5b7b505d0414_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_83464f72-1005-4ce9-adae-5b7b505d0414" xlink:to="loc_us-gaap_RelatedPartyDomain_83464f72-1005-4ce9-adae-5b7b505d0414_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_de308cdd-3dad-4137-84b5-a2f6fd0571d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_83464f72-1005-4ce9-adae-5b7b505d0414" xlink:to="loc_us-gaap_RelatedPartyDomain_de308cdd-3dad-4137-84b5-a2f6fd0571d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadFoundationMember_50e0b0bd-c67c-42dc-ac1a-ac1606bf7635" xlink:href="gild-20211231.xsd#gild_GileadFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_de308cdd-3dad-4137-84b5-a2f6fd0571d7" xlink:to="loc_gild_GileadFoundationMember_50e0b0bd-c67c-42dc-ac1a-ac1606bf7635" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1d5e3035-f290-4868-bf5c-e886d3d041b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1d5e3035-f290-4868-bf5c-e886d3d041b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d5e3035-f290-4868-bf5c-e886d3d041b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d5e3035-f290-4868-bf5c-e886d3d041b5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d5e3035-f290-4868-bf5c-e886d3d041b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd615f7e-c6a2-45f3-a824-094fe6bc4f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d5e3035-f290-4868-bf5c-e886d3d041b5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd615f7e-c6a2-45f3-a824-094fe6bc4f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_c9d08c30-bff8-4dfd-9ab9-46c18afe7504" xlink:href="gild-20211231.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd615f7e-c6a2-45f3-a824-094fe6bc4f58" xlink:to="loc_gild_MYRGmbHMember_c9d08c30-bff8-4dfd-9ab9-46c18afe7504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_464d3d77-9495-4b0e-8e10-062431a28565" xlink:href="gild-20211231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd615f7e-c6a2-45f3-a824-094fe6bc4f58" xlink:to="loc_gild_ImmunomedicsIncMember_464d3d77-9495-4b0e-8e10-062431a28565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_KitePharmaIncMember_5da24403-901c-4cff-8466-ce5add3a5a86" xlink:href="gild-20211231.xsd#gild_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd615f7e-c6a2-45f3-a824-094fe6bc4f58" xlink:to="loc_gild_KitePharmaIncMember_5da24403-901c-4cff-8466-ce5add3a5a86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80bb84f0-264c-4165-b9c4-40b57c093b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80bb84f0-264c-4165-b9c4-40b57c093b6b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_80bb84f0-264c-4165-b9c4-40b57c093b6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80bb84f0-264c-4165-b9c4-40b57c093b6b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_80bb84f0-264c-4165-b9c4-40b57c093b6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_248292e5-caeb-4f18-ab64-2833c9c633dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80bb84f0-264c-4165-b9c4-40b57c093b6b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_248292e5-caeb-4f18-ab64-2833c9c633dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_179ac6ba-ea0b-486c-8768-575a4f4a112a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_248292e5-caeb-4f18-ab64-2833c9c633dc" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_179ac6ba-ea0b-486c-8768-575a4f4a112a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_713ecd8d-5a90-4fff-8b1e-f67c04b5f386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_248292e5-caeb-4f18-ab64-2833c9c633dc" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_713ecd8d-5a90-4fff-8b1e-f67c04b5f386" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended" id="ib96b26beacb54811bc1bffde8abfaf73_AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5bb462c2-fd26-4ede-90ea-2ab78e2c890b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4e96f9d9-3c51-43d6-ad44-00745a63e970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5bb462c2-fd26-4ede-90ea-2ab78e2c890b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4e96f9d9-3c51-43d6-ad44-00745a63e970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f859207a-9d90-498f-aaa6-884814deb76c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5bb462c2-fd26-4ede-90ea-2ab78e2c890b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f859207a-9d90-498f-aaa6-884814deb76c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e76334d-9e15-4197-a461-a4f3e38059ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5bb462c2-fd26-4ede-90ea-2ab78e2c890b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e76334d-9e15-4197-a461-a4f3e38059ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_72c4ba86-9b08-4f63-8c2c-32aedfdf094f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5bb462c2-fd26-4ede-90ea-2ab78e2c890b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_72c4ba86-9b08-4f63-8c2c-32aedfdf094f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_953e6690-e084-45b0-a567-e640b3c2a5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5bb462c2-fd26-4ede-90ea-2ab78e2c890b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_953e6690-e084-45b0-a567-e640b3c2a5e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_abecfcf7-10dc-4a39-a2d3-10ce2b3fcf27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_953e6690-e084-45b0-a567-e640b3c2a5e2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_abecfcf7-10dc-4a39-a2d3-10ce2b3fcf27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_abecfcf7-10dc-4a39-a2d3-10ce2b3fcf27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_abecfcf7-10dc-4a39-a2d3-10ce2b3fcf27" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_abecfcf7-10dc-4a39-a2d3-10ce2b3fcf27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_abecfcf7-10dc-4a39-a2d3-10ce2b3fcf27" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f183018c-0e2c-4ba2-a1e7-011f99dee458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f183018c-0e2c-4ba2-a1e7-011f99dee458" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5c9b6b22-1b06-4a79-a5e0-807ce6bffe4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5c9b6b22-1b06-4a79-a5e0-807ce6bffe4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_62ba527a-f1a6-412b-b25f-6b413b70883a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_62ba527a-f1a6-412b-b25f-6b413b70883a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0f482c01-5a7d-4054-a702-6b021f9c5eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0f482c01-5a7d-4054-a702-6b021f9c5eb8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e0f8e335-a021-4733-a947-f28902d3258d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e0f8e335-a021-4733-a947-f28902d3258d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_f8973a51-0c52-4458-bd9e-ff3ce9aab2c2" xlink:href="gild-20211231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_f8973a51-0c52-4458-bd9e-ff3ce9aab2c2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended" id="id99d4223f4d041829f963dd7ba9a0161_AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d476a739-a163-4e9d-819f-c932e08058dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6e67aa87-c66d-4d78-b7df-02797c212949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d476a739-a163-4e9d-819f-c932e08058dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6e67aa87-c66d-4d78-b7df-02797c212949" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_34052fba-6e28-4f5e-bae9-59245b223c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d476a739-a163-4e9d-819f-c932e08058dd" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_34052fba-6e28-4f5e-bae9-59245b223c75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0515563b-0735-41f7-b532-8df54ff02f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_34052fba-6e28-4f5e-bae9-59245b223c75" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0515563b-0735-41f7-b532-8df54ff02f5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0515563b-0735-41f7-b532-8df54ff02f5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0515563b-0735-41f7-b532-8df54ff02f5b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0515563b-0735-41f7-b532-8df54ff02f5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_613018ca-b60f-4a23-8fce-938948105e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0515563b-0735-41f7-b532-8df54ff02f5b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_613018ca-b60f-4a23-8fce-938948105e29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_5c87e2b1-c8ad-45e2-8ce4-8affcbd55560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_613018ca-b60f-4a23-8fce-938948105e29" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_5c87e2b1-c8ad-45e2-8ce4-8affcbd55560" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_75c231bf-b267-4cee-b84b-cd81fd5fb076" xlink:href="gild-20211231.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_613018ca-b60f-4a23-8fce-938948105e29" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_75c231bf-b267-4cee-b84b-cd81fd5fb076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_e374abc4-6a31-45a6-85d4-2767bdd35a83" xlink:href="gild-20211231.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_613018ca-b60f-4a23-8fce-938948105e29" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_e374abc4-6a31-45a6-85d4-2767bdd35a83" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DerivativeFinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended" id="i45fdd2362e70479ca339bbd3553a7ca2_DerivativeFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0cc00b0f-ac1d-46ad-a21f-733685c13f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_0cfe8ad6-fab4-4fe9-a94f-2a73b711d452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0cc00b0f-ac1d-46ad-a21f-733685c13f37" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_0cfe8ad6-fab4-4fe9-a94f-2a73b711d452" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_c6fdfad6-1e31-4948-b3a9-8aae8ebd754b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0cc00b0f-ac1d-46ad-a21f-733685c13f37" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_c6fdfad6-1e31-4948-b3a9-8aae8ebd754b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_be10e06f-d779-4c71-93f1-3be5e8b570e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0cc00b0f-ac1d-46ad-a21f-733685c13f37" xlink:to="loc_us-gaap_DerivativeNotionalAmount_be10e06f-d779-4c71-93f1-3be5e8b570e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_5a722b6b-523d-4a4a-add6-d15ced97c5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0cc00b0f-ac1d-46ad-a21f-733685c13f37" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_5a722b6b-523d-4a4a-add6-d15ced97c5ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_b3892069-42b4-42bc-98fa-76d21c26c420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0cc00b0f-ac1d-46ad-a21f-733685c13f37" xlink:to="loc_us-gaap_DerivativeTable_b3892069-42b4-42bc-98fa-76d21c26c420" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_21711521-843b-4654-8b88-143a719ec6f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b3892069-42b4-42bc-98fa-76d21c26c420" xlink:to="loc_srt_RangeAxis_21711521-843b-4654-8b88-143a719ec6f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_21711521-843b-4654-8b88-143a719ec6f9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_21711521-843b-4654-8b88-143a719ec6f9" xlink:to="loc_srt_RangeMember_21711521-843b-4654-8b88-143a719ec6f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52210409-4aa5-4479-8434-304c65e3155b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_21711521-843b-4654-8b88-143a719ec6f9" xlink:to="loc_srt_RangeMember_52210409-4aa5-4479-8434-304c65e3155b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_11dea193-54ac-44ad-a193-0b3079265c7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52210409-4aa5-4479-8434-304c65e3155b" xlink:to="loc_srt_MaximumMember_11dea193-54ac-44ad-a193-0b3079265c7e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended" id="if769d560d8c4474496b6dc1e8b043b15_DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_338ddcd4-5dc5-4bc8-848b-64c36901bb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_c9c57827-cd10-49a2-9803-6c5b42f0fd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_338ddcd4-5dc5-4bc8-848b-64c36901bb5e" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_c9c57827-cd10-49a2-9803-6c5b42f0fd1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_9503d90d-e119-4ce4-9361-d91ec7b9d5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_338ddcd4-5dc5-4bc8-848b-64c36901bb5e" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_9503d90d-e119-4ce4-9361-d91ec7b9d5bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7fcd35e3-0810-487e-ac3a-eb5a011f5a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_338ddcd4-5dc5-4bc8-848b-64c36901bb5e" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7fcd35e3-0810-487e-ac3a-eb5a011f5a13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b79cbc2f-85b2-4dae-8505-8ba24d41fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7fcd35e3-0810-487e-ac3a-eb5a011f5a13" xlink:to="loc_us-gaap_HedgingDesignationAxis_b79cbc2f-85b2-4dae-8505-8ba24d41fc0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b79cbc2f-85b2-4dae-8505-8ba24d41fc0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_b79cbc2f-85b2-4dae-8505-8ba24d41fc0f" xlink:to="loc_us-gaap_HedgingDesignationDomain_b79cbc2f-85b2-4dae-8505-8ba24d41fc0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ba72200c-92cd-45f0-83a9-9cd6fce5f8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_b79cbc2f-85b2-4dae-8505-8ba24d41fc0f" xlink:to="loc_us-gaap_HedgingDesignationDomain_ba72200c-92cd-45f0-83a9-9cd6fce5f8c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_762c8ba2-b657-481e-b2db-37d1ad5b2624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ba72200c-92cd-45f0-83a9-9cd6fce5f8c5" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_762c8ba2-b657-481e-b2db-37d1ad5b2624" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_9f7cdb03-9f0a-4ddd-a4c5-8d5fca2e47bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ba72200c-92cd-45f0-83a9-9cd6fce5f8c5" xlink:to="loc_us-gaap_NondesignatedMember_9f7cdb03-9f0a-4ddd-a4c5-8d5fca2e47bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_95b6c303-e226-4b9b-888a-8fb2ce0f561e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7fcd35e3-0810-487e-ac3a-eb5a011f5a13" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_95b6c303-e226-4b9b-888a-8fb2ce0f561e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_95b6c303-e226-4b9b-888a-8fb2ce0f561e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_95b6c303-e226-4b9b-888a-8fb2ce0f561e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_95b6c303-e226-4b9b-888a-8fb2ce0f561e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3082a8f9-9faa-4d77-9ee7-a82ef8b323d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_95b6c303-e226-4b9b-888a-8fb2ce0f561e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3082a8f9-9faa-4d77-9ee7-a82ef8b323d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0e8a252d-3509-4c33-b4bb-8a48d386f852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3082a8f9-9faa-4d77-9ee7-a82ef8b323d9" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0e8a252d-3509-4c33-b4bb-8a48d386f852" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_8ae0af86-63da-4cad-b741-f11145c1c36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3082a8f9-9faa-4d77-9ee7-a82ef8b323d9" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_8ae0af86-63da-4cad-b741-f11145c1c36e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_48cacab7-b97b-4f9e-94f5-196800b6600b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3082a8f9-9faa-4d77-9ee7-a82ef8b323d9" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_48cacab7-b97b-4f9e-94f5-196800b6600b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_24a12c0d-0717-4c58-ac58-cd811b8afbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3082a8f9-9faa-4d77-9ee7-a82ef8b323d9" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_24a12c0d-0717-4c58-ac58-cd811b8afbbf" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="i8ef6284602e341019f48a96c2facad5a_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2867f596-6b1c-485d-88cb-8bed2d443a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2867f596-6b1c-485d-88cb-8bed2d443a26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_d119403e-beeb-4dd2-84f5-12b4400732d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_d119403e-beeb-4dd2-84f5-12b4400732d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d7e9a043-2b2a-4189-b4a8-92d7108ee7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d7e9a043-2b2a-4189-b4a8-92d7108ee7a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3c7b33bf-b47a-48a0-9c48-2e705f93335b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3c7b33bf-b47a-48a0-9c48-2e705f93335b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_6517d3e6-9ae1-45ed-846d-2e8118cc1bd4" xlink:href="gild-20211231.xsd#gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_6517d3e6-9ae1-45ed-846d-2e8118cc1bd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_09d69570-b2ff-47cf-a26d-4049a3740300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_09d69570-b2ff-47cf-a26d-4049a3740300" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_9c20ad82-3e4b-4874-a1dd-c296ebb0b0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_9c20ad82-3e4b-4874-a1dd-c296ebb0b0f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_4fa6c094-7d6f-4b9e-9279-858cc07eec72" xlink:href="gild-20211231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_4fa6c094-7d6f-4b9e-9279-858cc07eec72" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_05b9f212-eea2-4a83-8040-8c413bb49ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_GoodwillGross_05b9f212-eea2-4a83-8040-8c413bb49ca1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_7c559c3b-10f7-404f-9772-a926afa76ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_7c559c3b-10f7-404f-9772-a926afa76ad0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_2ba047a0-0eb4-4ee9-84ca-728a6cc43772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_2ba047a0-0eb4-4ee9-84ca-728a6cc43772" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_9e3f3391-1f9c-4192-ad2a-9dc85f3fa8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_9e3f3391-1f9c-4192-ad2a-9dc85f3fa8cf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a51b0a62-2a3b-4e3a-884f-2155826b59e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a51b0a62-2a3b-4e3a-884f-2155826b59e3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_21fc5d6b-4623-4224-9e82-d9fa2920938b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_21fc5d6b-4623-4224-9e82-d9fa2920938b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_380efe97-26bf-4eb9-bcac-2397aef70354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_380efe97-26bf-4eb9-bcac-2397aef70354" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_fd443a2b-12c3-404b-bdc3-10bbd5c6d31b" xlink:href="gild-20211231.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_fd443a2b-12c3-404b-bdc3-10bbd5c6d31b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_c366458a-e5a5-4f66-a7df-01fedf76e997" xlink:href="gild-20211231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_c366458a-e5a5-4f66-a7df-01fedf76e997" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_4da51c95-56e9-4216-bf32-f4a8376d54b5" xlink:href="gild-20211231.xsd#gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_4da51c95-56e9-4216-bf32-f4a8376d54b5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired_fefd4935-0944-4958-8f4d-b926c8169a8c" xlink:href="gild-20211231.xsd#gild_PaymentsToAcquireAssetsNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired_fefd4935-0944-4958-8f4d-b926c8169a8c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ad979bdf-8d83-4c32-add0-13d444175be1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ad979bdf-8d83-4c32-add0-13d444175be1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b60f2e49-f63b-4b5e-b276-de837798b07e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b60f2e49-f63b-4b5e-b276-de837798b07e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b60f2e49-f63b-4b5e-b276-de837798b07e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b60f2e49-f63b-4b5e-b276-de837798b07e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b60f2e49-f63b-4b5e-b276-de837798b07e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ea9eca3-4e19-4dde-83a8-3accb9942955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b60f2e49-f63b-4b5e-b276-de837798b07e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ea9eca3-4e19-4dde-83a8-3accb9942955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_b15b4e64-9ea0-4b4e-803d-473fb62c5628" xlink:href="gild-20211231.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ea9eca3-4e19-4dde-83a8-3accb9942955" xlink:to="loc_gild_MYRGmbHMember_b15b4e64-9ea0-4b4e-803d-473fb62c5628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_1ee8a847-0fd0-4980-8ee7-3b30889f1d75" xlink:href="gild-20211231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ea9eca3-4e19-4dde-83a8-3accb9942955" xlink:to="loc_gild_ImmunomedicsIncMember_1ee8a847-0fd0-4980-8ee7-3b30889f1d75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_b354a1fd-ab29-4b1d-810b-3e82ac9ac2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_AssetAcquisitionAxis_b354a1fd-ab29-4b1d-810b-3e82ac9ac2c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b354a1fd-ab29-4b1d-810b-3e82ac9ac2c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_b354a1fd-ab29-4b1d-810b-3e82ac9ac2c6" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b354a1fd-ab29-4b1d-810b-3e82ac9ac2c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_0ecc8855-a1cc-433f-9674-214c6f514607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_b354a1fd-ab29-4b1d-810b-3e82ac9ac2c6" xlink:to="loc_us-gaap_AssetAcquisitionDomain_0ecc8855-a1cc-433f-9674-214c6f514607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_a20094ca-f94d-47cd-9856-3ebb0c98d855" xlink:href="gild-20211231.xsd#gild_FortySevenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_0ecc8855-a1cc-433f-9674-214c6f514607" xlink:to="loc_gild_FortySevenIncMember_a20094ca-f94d-47cd-9856-3ebb0c98d855" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66310901-c5c2-4eae-be02-ab93687c1f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66310901-c5c2-4eae-be02-ab93687c1f37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66310901-c5c2-4eae-be02-ab93687c1f37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66310901-c5c2-4eae-be02-ab93687c1f37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66310901-c5c2-4eae-be02-ab93687c1f37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cf7dda9-57b1-48fd-8f3a-9dee8d16441c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66310901-c5c2-4eae-be02-ab93687c1f37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cf7dda9-57b1-48fd-8f3a-9dee8d16441c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_d33f455b-3f2a-41f1-b54e-5123e07c11a6" xlink:href="gild-20211231.xsd#gild_HepcludexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cf7dda9-57b1-48fd-8f3a-9dee8d16441c" xlink:to="loc_gild_HepcludexMember_d33f455b-3f2a-41f1-b54e-5123e07c11a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_c8877a8b-d4c9-4d85-95cb-904bdaeb4e9a" xlink:href="gild-20211231.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cf7dda9-57b1-48fd-8f3a-9dee8d16441c" xlink:to="loc_gild_TrodelvyMember_c8877a8b-d4c9-4d85-95cb-904bdaeb4e9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_89e5d07c-ea84-43d8-b4ad-792fbe1537ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cf7dda9-57b1-48fd-8f3a-9dee8d16441c" xlink:to="loc_us-gaap_LicensingAgreementsMember_89e5d07c-ea84-43d8-b4ad-792fbe1537ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bd60e406-bd0d-44c1-8125-a1b167ead87f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bd60e406-bd0d-44c1-8125-a1b167ead87f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bd60e406-bd0d-44c1-8125-a1b167ead87f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bd60e406-bd0d-44c1-8125-a1b167ead87f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bd60e406-bd0d-44c1-8125-a1b167ead87f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_19a68278-fb36-4358-aabb-5e461e2a843a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bd60e406-bd0d-44c1-8125-a1b167ead87f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_19a68278-fb36-4358-aabb-5e461e2a843a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_3d52ae24-0e95-46c1-9e06-2b40c32c211b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_19a68278-fb36-4358-aabb-5e461e2a843a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_3d52ae24-0e95-46c1-9e06-2b40c32c211b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_967c932c-3b48-4fff-a746-22dd44a45921" xlink:href="gild-20211231.xsd#gild_HepcludexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_19a68278-fb36-4358-aabb-5e461e2a843a" xlink:to="loc_gild_HepcludexMember_967c932c-3b48-4fff-a746-22dd44a45921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d9a36e53-bcd9-4935-81bc-2def9fcffc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_DebtInstrumentAxis_d9a36e53-bcd9-4935-81bc-2def9fcffc43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d9a36e53-bcd9-4935-81bc-2def9fcffc43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d9a36e53-bcd9-4935-81bc-2def9fcffc43" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d9a36e53-bcd9-4935-81bc-2def9fcffc43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5f98e8f4-29b2-4ca2-a508-9201de1ca24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d9a36e53-bcd9-4935-81bc-2def9fcffc43" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5f98e8f4-29b2-4ca2-a508-9201de1ca24a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_abfa1d92-7fad-48c2-b250-c074fcb63ed4" xlink:href="gild-20211231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f98e8f4-29b2-4ca2-a508-9201de1ca24a" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_abfa1d92-7fad-48c2-b250-c074fcb63ed4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ffddc420-4f55-4a6f-9dd6-280f45d8cbab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ffddc420-4f55-4a6f-9dd6-280f45d8cbab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ffddc420-4f55-4a6f-9dd6-280f45d8cbab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ffddc420-4f55-4a6f-9dd6-280f45d8cbab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ffddc420-4f55-4a6f-9dd6-280f45d8cbab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9eafa6b2-c09c-4064-bcdf-f20f23107c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ffddc420-4f55-4a6f-9dd6-280f45d8cbab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9eafa6b2-c09c-4064-bcdf-f20f23107c08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_ad641c92-add7-4b01-aca8-3c399aa152ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9eafa6b2-c09c-4064-bcdf-f20f23107c08" xlink:to="loc_us-gaap_MediumTermNotesMember_ad641c92-add7-4b01-aca8-3c399aa152ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6bc068f4-7538-49f9-82b7-56564c86f95e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6bc068f4-7538-49f9-82b7-56564c86f95e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6bc068f4-7538-49f9-82b7-56564c86f95e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6bc068f4-7538-49f9-82b7-56564c86f95e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6bc068f4-7538-49f9-82b7-56564c86f95e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_fafd1a75-8373-4839-87bd-685a5b35e03e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6bc068f4-7538-49f9-82b7-56564c86f95e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_fafd1a75-8373-4839-87bd-685a5b35e03e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4415fa7f-f828-4934-9a54-00b3e9ac66d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fafd1a75-8373-4839-87bd-685a5b35e03e" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4415fa7f-f828-4934-9a54-00b3e9ac66d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3685b828-eecd-4c8f-844e-deb4d22f4d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fafd1a75-8373-4839-87bd-685a5b35e03e" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3685b828-eecd-4c8f-844e-deb4d22f4d16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_99a80c73-f580-447e-83f6-12404240f8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fafd1a75-8373-4839-87bd-685a5b35e03e" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_99a80c73-f580-447e-83f6-12404240f8cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f6d5bcdc-6aef-4ea0-8ce4-041915040d93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_srt_RangeAxis_f6d5bcdc-6aef-4ea0-8ce4-041915040d93" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6d5bcdc-6aef-4ea0-8ce4-041915040d93_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f6d5bcdc-6aef-4ea0-8ce4-041915040d93" xlink:to="loc_srt_RangeMember_f6d5bcdc-6aef-4ea0-8ce4-041915040d93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_074e51f4-7878-4037-86b2-a6183dbd9b20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f6d5bcdc-6aef-4ea0-8ce4-041915040d93" xlink:to="loc_srt_RangeMember_074e51f4-7878-4037-86b2-a6183dbd9b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e161db4b-d492-4d4f-9d16-be9dd60a3a62" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_074e51f4-7878-4037-86b2-a6183dbd9b20" xlink:to="loc_srt_MaximumMember_e161db4b-d492-4d4f-9d16-be9dd60a3a62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11136fb9-fc16-49b4-b106-847d9f6ec5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11136fb9-fc16-49b4-b106-847d9f6ec5bc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11136fb9-fc16-49b4-b106-847d9f6ec5bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11136fb9-fc16-49b4-b106-847d9f6ec5bc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11136fb9-fc16-49b4-b106-847d9f6ec5bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c303b906-08ec-40aa-94f0-5028de9ac723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11136fb9-fc16-49b4-b106-847d9f6ec5bc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c303b906-08ec-40aa-94f0-5028de9ac723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d68dc5c6-5427-43ab-8111-d17b75feb23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c303b906-08ec-40aa-94f0-5028de9ac723" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d68dc5c6-5427-43ab-8111-d17b75feb23a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_350c695e-3adb-4743-8861-9065f5549b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_350c695e-3adb-4743-8861-9065f5549b71" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_350c695e-3adb-4743-8861-9065f5549b71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_350c695e-3adb-4743-8861-9065f5549b71" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_350c695e-3adb-4743-8861-9065f5549b71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_046131ab-3c6a-4e53-aed9-6fe34a64bd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_350c695e-3adb-4743-8861-9065f5549b71" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_046131ab-3c6a-4e53-aed9-6fe34a64bd6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a3e0a2f2-da06-4ac4-947a-dd5324064461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_046131ab-3c6a-4e53-aed9-6fe34a64bd6b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a3e0a2f2-da06-4ac4-947a-dd5324064461" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i2fed2ee1a71f4e8faf6ff69f39906a64_AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c8a1eb0f-7155-4510-b48e-ae510c7a0a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c8a1eb0f-7155-4510-b48e-ae510c7a0a0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1b02d385-5e6a-4337-804d-06f84b6984dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1b02d385-5e6a-4337-804d-06f84b6984dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_2666c748-7953-4847-a7e2-6c2842b39a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_2666c748-7953-4847-a7e2-6c2842b39a3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_81e3fb5f-fb78-47bc-beee-debb6217645f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_2666c748-7953-4847-a7e2-6c2842b39a3a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_81e3fb5f-fb78-47bc-beee-debb6217645f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a9f2c530-668f-463f-b274-004ce80534f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_2666c748-7953-4847-a7e2-6c2842b39a3a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a9f2c530-668f-463f-b274-004ce80534f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d4542ad3-47c4-48a3-b3bb-0a1241ce8958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d4542ad3-47c4-48a3-b3bb-0a1241ce8958" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_7f6ee244-ebb7-4ba8-9586-53d08622a5db" xlink:href="gild-20211231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_7f6ee244-ebb7-4ba8-9586-53d08622a5db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_11c8286b-10ee-45ce-ab3d-c59ef7a0450c" xlink:href="gild-20211231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_11c8286b-10ee-45ce-ab3d-c59ef7a0450c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_22af0a33-6626-411e-ab8c-5ebbb238085b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_22af0a33-6626-411e-ab8c-5ebbb238085b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_e3bde7c8-9a9f-443e-9ca5-e7e68241677e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_GoodwillGross_e3bde7c8-9a9f-443e-9ca5-e7e68241677e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b1b3b7ad-dd2e-4031-850a-307b885dd6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b1b3b7ad-dd2e-4031-850a-307b885dd6f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4b956db-4b6c-4bb9-b5d2-e0a9c113c842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4b956db-4b6c-4bb9-b5d2-e0a9c113c842" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f39cf471-4263-475e-aa12-c64656a71f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4b956db-4b6c-4bb9-b5d2-e0a9c113c842" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f39cf471-4263-475e-aa12-c64656a71f64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f39cf471-4263-475e-aa12-c64656a71f64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f39cf471-4263-475e-aa12-c64656a71f64" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f39cf471-4263-475e-aa12-c64656a71f64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3f38c70-f02d-4980-8e33-ceb9d07674d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f39cf471-4263-475e-aa12-c64656a71f64" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3f38c70-f02d-4980-8e33-ceb9d07674d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_f9288f6f-a73f-4d2c-8e7a-7c1bc7d131a5" xlink:href="gild-20211231.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3f38c70-f02d-4980-8e33-ceb9d07674d7" xlink:to="loc_gild_MYRGmbHMember_f9288f6f-a73f-4d2c-8e7a-7c1bc7d131a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_9ce59465-a545-49c8-ab05-1fa22bcbefe9" xlink:href="gild-20211231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3f38c70-f02d-4980-8e33-ceb9d07674d7" xlink:to="loc_gild_ImmunomedicsIncMember_9ce59465-a545-49c8-ab05-1fa22bcbefe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00a121ac-d725-4fe3-b1a5-a70e764d03d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4b956db-4b6c-4bb9-b5d2-e0a9c113c842" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00a121ac-d725-4fe3-b1a5-a70e764d03d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_00a121ac-d725-4fe3-b1a5-a70e764d03d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00a121ac-d725-4fe3-b1a5-a70e764d03d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_00a121ac-d725-4fe3-b1a5-a70e764d03d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_37426307-2818-4864-90b3-6e08a1423f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00a121ac-d725-4fe3-b1a5-a70e764d03d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_37426307-2818-4864-90b3-6e08a1423f33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_97d2d518-7cb1-4634-b4f4-c25a96b1bf09" xlink:href="gild-20211231.xsd#gild_HepcludexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_37426307-2818-4864-90b3-6e08a1423f33" xlink:to="loc_gild_HepcludexMember_97d2d518-7cb1-4634-b4f4-c25a96b1bf09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_60d4a004-2c70-474e-ad9c-09a5035b6d18" xlink:href="gild-20211231.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_37426307-2818-4864-90b3-6e08a1423f33" xlink:to="loc_gild_TrodelvyMember_60d4a004-2c70-474e-ad9c-09a5035b6d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_52720381-4568-432e-bd09-702c164776b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_37426307-2818-4864-90b3-6e08a1423f33" xlink:to="loc_us-gaap_LicensingAgreementsMember_52720381-4568-432e-bd09-702c164776b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f672b722-4e9d-4b3b-a41f-5708d4bb2d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4b956db-4b6c-4bb9-b5d2-e0a9c113c842" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f672b722-4e9d-4b3b-a41f-5708d4bb2d7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f672b722-4e9d-4b3b-a41f-5708d4bb2d7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f672b722-4e9d-4b3b-a41f-5708d4bb2d7d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f672b722-4e9d-4b3b-a41f-5708d4bb2d7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8630329c-8f66-4f2f-ac5f-4c0934f645fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f672b722-4e9d-4b3b-a41f-5708d4bb2d7d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8630329c-8f66-4f2f-ac5f-4c0934f645fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8419e7da-463a-46b2-8109-31d18555159f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8630329c-8f66-4f2f-ac5f-4c0934f645fd" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8419e7da-463a-46b2-8109-31d18555159f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#InventoriesScheduleofinventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails" xlink:type="extended" id="i3cd534e82a8f4726b95c65ac1c07aeb6_InventoriesScheduleofinventoriesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:href="gild-20211231.xsd#gild_ScheduleofInventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_cf292bf0-3e29-4b5a-9aa9-289061d228f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_cf292bf0-3e29-4b5a-9aa9-289061d228f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_183a2af1-75ee-40cc-9c88-6a353b7b22f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_183a2af1-75ee-40cc-9c88-6a353b7b22f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_77e4a581-722e-4bef-9355-7a6790f3cb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_77e4a581-722e-4bef-9355-7a6790f3cb31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_96f19233-ab26-4341-9f60-65e39eb6c1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:to="loc_us-gaap_InventoryNet_96f19233-ab26-4341-9f60-65e39eb6c1b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_d0b64011-fdca-4cbc-b2ce-6f5cb0a69f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:to="loc_us-gaap_InventoryNoncurrent_d0b64011-fdca-4cbc-b2ce-6f5cb0a69f96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable_d4710eaa-1e3a-4b93-b74c-c7ba9934191b" xlink:href="gild-20211231.xsd#gild_ScheduleofInventoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:to="loc_gild_ScheduleofInventoryTable_d4710eaa-1e3a-4b93-b74c-c7ba9934191b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_37a1f9be-6f41-4f1a-b877-6da5eb987158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_ScheduleofInventoryTable_d4710eaa-1e3a-4b93-b74c-c7ba9934191b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_37a1f9be-6f41-4f1a-b877-6da5eb987158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_37a1f9be-6f41-4f1a-b877-6da5eb987158_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_37a1f9be-6f41-4f1a-b877-6da5eb987158" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_37a1f9be-6f41-4f1a-b877-6da5eb987158_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4d675894-3364-473b-8b9d-cb083eab316f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_37a1f9be-6f41-4f1a-b877-6da5eb987158" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4d675894-3364-473b-8b9d-cb083eab316f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsTotalMember_68db28cf-17e6-42b5-b292-8325e2a33966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4d675894-3364-473b-8b9d-cb083eab316f" xlink:to="loc_us-gaap_AssetsTotalMember_68db28cf-17e6-42b5-b292-8325e2a33966" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i6d344323ab624ba295321ae913112f47_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleOfInventoriesLineItems_2f2aea67-fc57-4adf-8346-5c9a45a2ea02" xlink:href="gild-20211231.xsd#gild_ScheduleOfInventoriesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2b27e2e6-33cc-4311-86bf-86ba8fed7def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleOfInventoriesLineItems_2f2aea67-fc57-4adf-8346-5c9a45a2ea02" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2b27e2e6-33cc-4311-86bf-86ba8fed7def" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_35c1d754-1926-495e-ab85-9347bcf39d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleOfInventoriesLineItems_2f2aea67-fc57-4adf-8346-5c9a45a2ea02" xlink:to="loc_us-gaap_InventoryWriteDown_35c1d754-1926-495e-ab85-9347bcf39d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable_5bd41101-4c4e-4b36-96cf-90cdefd4d371" xlink:href="gild-20211231.xsd#gild_ScheduleofInventoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gild_ScheduleOfInventoriesLineItems_2f2aea67-fc57-4adf-8346-5c9a45a2ea02" xlink:to="loc_gild_ScheduleofInventoryTable_5bd41101-4c4e-4b36-96cf-90cdefd4d371" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_8b75dad1-e82d-4ac2-b583-6ef008b2988f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_ScheduleofInventoryTable_5bd41101-4c4e-4b36-96cf-90cdefd4d371" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_8b75dad1-e82d-4ac2-b583-6ef008b2988f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_8b75dad1-e82d-4ac2-b583-6ef008b2988f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_8b75dad1-e82d-4ac2-b583-6ef008b2988f" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_8b75dad1-e82d-4ac2-b583-6ef008b2988f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_eeb3bdae-0e3e-49bd-90cb-1b2614652dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_8b75dad1-e82d-4ac2-b583-6ef008b2988f" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_eeb3bdae-0e3e-49bd-90cb-1b2614652dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryWritedownsforExcessRawMaterialsMember_293d77e9-ddbe-4b8b-9433-f5c86243860b" xlink:href="gild-20211231.xsd#gild_InventoryWritedownsforExcessRawMaterialsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_eeb3bdae-0e3e-49bd-90cb-1b2614652dc7" xlink:to="loc_gild_InventoryWritedownsforExcessRawMaterialsMember_293d77e9-ddbe-4b8b-9433-f5c86243860b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_517eb80d-b92f-4039-b119-39af6bb9e448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_ScheduleofInventoryTable_5bd41101-4c4e-4b36-96cf-90cdefd4d371" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_517eb80d-b92f-4039-b119-39af6bb9e448" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_517eb80d-b92f-4039-b119-39af6bb9e448_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_517eb80d-b92f-4039-b119-39af6bb9e448" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_517eb80d-b92f-4039-b119-39af6bb9e448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_124d6f2e-9ece-4163-b986-b991038728e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_517eb80d-b92f-4039-b119-39af6bb9e448" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_124d6f2e-9ece-4163-b986-b991038728e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_9255aa8e-087f-4e5e-9749-d91091b6345b" xlink:href="gild-20211231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_124d6f2e-9ece-4163-b986-b991038728e0" xlink:to="loc_gild_ImmunomedicsIncMember_9255aa8e-087f-4e5e-9749-d91091b6345b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended" id="icc415184591b4fb68988bab9e86d2ef8_PropertyPlantandEquipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c918a352-56f7-469e-ac74-f70174526dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_7edd0761-c7d3-404b-a9f0-ddf0e06c042d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c918a352-56f7-469e-ac74-f70174526dda" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_7edd0761-c7d3-404b-a9f0-ddf0e06c042d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c1bc09c9-eb1e-46b1-8169-3c8f57ef8188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c918a352-56f7-469e-ac74-f70174526dda" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c1bc09c9-eb1e-46b1-8169-3c8f57ef8188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91829d4b-039a-46e7-bde6-02b386f00af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c918a352-56f7-469e-ac74-f70174526dda" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91829d4b-039a-46e7-bde6-02b386f00af5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e1411997-d7dd-47b2-a423-1f1881f4a0ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91829d4b-039a-46e7-bde6-02b386f00af5" xlink:to="loc_srt_StatementGeographicalAxis_e1411997-d7dd-47b2-a423-1f1881f4a0ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e1411997-d7dd-47b2-a423-1f1881f4a0ba_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e1411997-d7dd-47b2-a423-1f1881f4a0ba" xlink:to="loc_srt_SegmentGeographicalDomain_e1411997-d7dd-47b2-a423-1f1881f4a0ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0b493100-5710-4fcb-8c71-b866314582b3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e1411997-d7dd-47b2-a423-1f1881f4a0ba" xlink:to="loc_srt_SegmentGeographicalDomain_0b493100-5710-4fcb-8c71-b866314582b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_abdf63d5-0857-40e5-8a1c-b7082797238a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0b493100-5710-4fcb-8c71-b866314582b3" xlink:to="loc_country_US_abdf63d5-0857-40e5-8a1c-b7082797238a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_911c6446-cc56-4d53-902a-4a1f298eef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0b493100-5710-4fcb-8c71-b866314582b3" xlink:to="loc_us-gaap_NonUsMember_911c6446-cc56-4d53-902a-4a1f298eef3f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended" id="i7550ac997df346f98f6136cde744647e_GoodwillandIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d88235fe-7ad7-4e53-978c-33b60ee673be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ef453feb-963f-4c9d-a378-9e89e8e5f372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d88235fe-7ad7-4e53-978c-33b60ee673be" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ef453feb-963f-4c9d-a378-9e89e8e5f372" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c9ff5974-0177-4b6a-989b-c987320659a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d88235fe-7ad7-4e53-978c-33b60ee673be" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c9ff5974-0177-4b6a-989b-c987320659a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_ec5fb33b-947a-40f4-a111-c6995ff424d1" xlink:href="gild-20211231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d88235fe-7ad7-4e53-978c-33b60ee673be" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_ec5fb33b-947a-40f4-a111-c6995ff424d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6be09510-5195-4b5d-85c3-c5425c1dd21b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d88235fe-7ad7-4e53-978c-33b60ee673be" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6be09510-5195-4b5d-85c3-c5425c1dd21b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6762c520-e1a3-4c5d-a1a1-0e13612d2470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d88235fe-7ad7-4e53-978c-33b60ee673be" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6762c520-e1a3-4c5d-a1a1-0e13612d2470" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8f8c65f3-81ad-4fe6-9a70-1470ab870204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6762c520-e1a3-4c5d-a1a1-0e13612d2470" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8f8c65f3-81ad-4fe6-9a70-1470ab870204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8f8c65f3-81ad-4fe6-9a70-1470ab870204_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8f8c65f3-81ad-4fe6-9a70-1470ab870204" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8f8c65f3-81ad-4fe6-9a70-1470ab870204_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ab37cd58-d26c-434e-9fa6-2f4becb8ecec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8f8c65f3-81ad-4fe6-9a70-1470ab870204" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ab37cd58-d26c-434e-9fa6-2f4becb8ecec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_744eddc2-fa32-4e9d-a170-58d37afd2530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ab37cd58-d26c-434e-9fa6-2f4becb8ecec" xlink:to="loc_us-gaap_CostOfSalesMember_744eddc2-fa32-4e9d-a170-58d37afd2530" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_580fea45-79e8-46d9-9487-d3b23ebaebcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6762c520-e1a3-4c5d-a1a1-0e13612d2470" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_580fea45-79e8-46d9-9487-d3b23ebaebcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_580fea45-79e8-46d9-9487-d3b23ebaebcc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_580fea45-79e8-46d9-9487-d3b23ebaebcc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_580fea45-79e8-46d9-9487-d3b23ebaebcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f577a4da-2a21-44ec-a6c7-6fe669afc913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_580fea45-79e8-46d9-9487-d3b23ebaebcc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f577a4da-2a21-44ec-a6c7-6fe669afc913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_KitePharmaIncMember_0ad96481-0d9e-4530-acd5-be43d734762d" xlink:href="gild-20211231.xsd#gild_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f577a4da-2a21-44ec-a6c7-6fe669afc913" xlink:to="loc_gild_KitePharmaIncMember_0ad96481-0d9e-4530-acd5-be43d734762d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended" id="ia244faae37214af292f123145fee09cb_GoodwillandIntangibleAssetsIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fde22e23-8401-43bd-b5b7-04597d76d606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fde22e23-8401-43bd-b5b7-04597d76d606" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d76a7b7f-76e3-4a4a-9385-c1825396b66e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fde22e23-8401-43bd-b5b7-04597d76d606" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d76a7b7f-76e3-4a4a-9385-c1825396b66e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cf9eacdb-e72e-4c92-adc4-f699ef83a3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fde22e23-8401-43bd-b5b7-04597d76d606" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cf9eacdb-e72e-4c92-adc4-f699ef83a3ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_939ca16d-55c0-45d9-9f15-38945f2895dc" xlink:href="gild-20211231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fde22e23-8401-43bd-b5b7-04597d76d606" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_939ca16d-55c0-45d9-9f15-38945f2895dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_363b949e-d286-4d97-a08c-50af8769f59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fde22e23-8401-43bd-b5b7-04597d76d606" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_363b949e-d286-4d97-a08c-50af8769f59d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d9214f57-978d-40da-ab2a-9d225573d07e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d9214f57-978d-40da-ab2a-9d225573d07e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5a6487e0-39ce-4ad8-a1ea-cb3b130d771d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d9214f57-978d-40da-ab2a-9d225573d07e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5a6487e0-39ce-4ad8-a1ea-cb3b130d771d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ca2b48c2-074e-4d4f-a186-106039b3222e" xlink:href="gild-20211231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d9214f57-978d-40da-ab2a-9d225573d07e" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ca2b48c2-074e-4d4f-a186-106039b3222e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_50d26ff2-28f5-4d1e-9158-9d1e8173c764" xlink:href="gild-20211231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d9214f57-978d-40da-ab2a-9d225573d07e" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_50d26ff2-28f5-4d1e-9158-9d1e8173c764" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cef93494-ab8a-4417-ac79-06576c8e23b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cef93494-ab8a-4417-ac79-06576c8e23b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_76454827-d608-41db-8e7c-8c23a23a4c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cef93494-ab8a-4417-ac79-06576c8e23b3" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_76454827-d608-41db-8e7c-8c23a23a4c8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ec01c8dc-639f-4605-b212-26f0808d76c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_9565d2f9-0ea7-4dda-95d5-841470df9464" xlink:href="gild-20211231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cef93494-ab8a-4417-ac79-06576c8e23b3" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_9565d2f9-0ea7-4dda-95d5-841470df9464" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f14bc4fa-3a6f-40ea-8c8a-970886e46050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cef93494-ab8a-4417-ac79-06576c8e23b3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f14bc4fa-3a6f-40ea-8c8a-970886e46050" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_4efd8ee5-d25b-4569-ad74-1dbd36ca9d83" xlink:href="gild-20211231.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_4efd8ee5-d25b-4569-ad74-1dbd36ca9d83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4628d750-68f9-4a06-b922-96a1fccd17ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4628d750-68f9-4a06-b922-96a1fccd17ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baedc38f-d0cd-4726-af3e-d2021bf5246f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baedc38f-d0cd-4726-af3e-d2021bf5246f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23ddbd7d-6e32-4483-92ce-796f1f11497a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baedc38f-d0cd-4726-af3e-d2021bf5246f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23ddbd7d-6e32-4483-92ce-796f1f11497a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_23ddbd7d-6e32-4483-92ce-796f1f11497a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23ddbd7d-6e32-4483-92ce-796f1f11497a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_23ddbd7d-6e32-4483-92ce-796f1f11497a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23ddbd7d-6e32-4483-92ce-796f1f11497a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_9504462b-d9cb-4064-8e6b-0b8cca59ddbe" xlink:href="gild-20211231.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_9504462b-d9cb-4064-8e6b-0b8cca59ddbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneCiloleucelDLBCLMember_592d03ee-3a56-4516-ba06-810a6a5cbd41" xlink:href="gild-20211231.xsd#gild_AxicabtageneCiloleucelDLBCLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:to="loc_gild_AxicabtageneCiloleucelDLBCLMember_592d03ee-3a56-4516-ba06-810a6a5cbd41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_ce54df69-1c4a-4335-9e3a-e4cae787885c" xlink:href="gild-20211231.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:to="loc_gild_TrodelvyMember_ce54df69-1c4a-4335-9e3a-e4cae787885c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_c856d69c-3447-4504-a1b5-835bcd73785d" xlink:href="gild-20211231.xsd#gild_HepcludexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:to="loc_gild_HepcludexMember_c856d69c-3447-4504-a1b5-835bcd73785d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_de8e2688-96b0-4ef4-b15c-0269530deea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_de8e2688-96b0-4ef4-b15c-0269530deea1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_9ad4fdf0-445d-4646-b2c3-89a42e215035" xlink:href="gild-20211231.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:to="loc_gild_CellTherapyProductsTecartusMember_9ad4fdf0-445d-4646-b2c3-89a42e215035" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bdcf75b-34bb-43c1-a644-93573cfea2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baedc38f-d0cd-4726-af3e-d2021bf5246f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bdcf75b-34bb-43c1-a644-93573cfea2cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8bdcf75b-34bb-43c1-a644-93573cfea2cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bdcf75b-34bb-43c1-a644-93573cfea2cb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8bdcf75b-34bb-43c1-a644-93573cfea2cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b1679243-94e2-4162-be76-d84c388c5c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bdcf75b-34bb-43c1-a644-93573cfea2cb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b1679243-94e2-4162-be76-d84c388c5c99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_77c9b5c6-5334-4541-b22c-119c79fb974f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b1679243-94e2-4162-be76-d84c388c5c99" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_77c9b5c6-5334-4541-b22c-119c79fb974f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended" id="i2e19eef4d6ca4f15bce3141b299afbac_CollaborationsandOtherArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_2b47f890-8ff0-46df-a125-72691bece935" xlink:href="gild-20211231.xsd#gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_2b47f890-8ff0-46df-a125-72691bece935" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementNetProductSalesThreshold_e402106e-0899-42e3-a7eb-74fc8d6e7472" xlink:href="gild-20211231.xsd#gild_CollaborationArrangementNetProductSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborationArrangementNetProductSalesThreshold_e402106e-0899-42e3-a7eb-74fc8d6e7472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_0b9066d7-bdf2-4ef8-a7d9-17fd47c1abd3" xlink:href="gild-20211231.xsd#gild_CollaborationArrangementPercentOfGlobalProductRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_0b9066d7-bdf2-4ef8-a7d9-17fd47c1abd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a44216c1-dc78-4949-b8de-68d2b0326a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a44216c1-dc78-4949-b8de-68d2b0326a8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_a89c2788-4e3c-44ba-b0af-6542165e8a83" xlink:href="gild-20211231.xsd#gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_a89c2788-4e3c-44ba-b0af-6542165e8a83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_2bff0a70-7dc9-4a8a-a859-c790e9c65c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_2bff0a70-7dc9-4a8a-a859-c790e9c65c3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InvestmentOwnedBalanceAdditionalShares_578cb583-7a17-4686-a66a-4cff48d9c8b5" xlink:href="gild-20211231.xsd#gild_InvestmentOwnedBalanceAdditionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_InvestmentOwnedBalanceAdditionalShares_578cb583-7a17-4686-a66a-4cff48d9c8b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_6cb999a0-457c-4ad0-af3c-e6d7f8be0a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_6cb999a0-457c-4ad0-af3c-e6d7f8be0a1c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_406662cc-fcd1-47f2-9157-5d4ce8679a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalUpfrontPaymentsMade_dd695499-9c18-489b-a5ba-b01d837338de" xlink:href="gild-20211231.xsd#gild_TotalUpfrontPaymentsMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_TotalUpfrontPaymentsMade_dd695499-9c18-489b-a5ba-b01d837338de" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a3582717-bac3-49f6-baa4-408afbc0d124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a3582717-bac3-49f6-baa4-408afbc0d124" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_8d15ec16-43a5-443b-a760-3312b5613dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_8d15ec16-43a5-443b-a760-3312b5613dba" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IssuanceDiscountPremium_1484c534-10b6-4f3a-924a-e18dd43454c3" xlink:href="gild-20211231.xsd#gild_IssuanceDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_IssuanceDiscountPremium_1484c534-10b6-4f3a-924a-e18dd43454c3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForDirectTransactionalExpense_7571b644-622d-48ea-bdcb-036d1d347a49" xlink:href="gild-20211231.xsd#gild_PaymentsForDirectTransactionalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PaymentsForDirectTransactionalExpense_7571b644-622d-48ea-bdcb-036d1d347a49" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod_0096bdfd-90be-4f1d-bbba-31204b36a0eb" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNIPurchasePeriod_0096bdfd-90be-4f1d-bbba-31204b36a0eb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_54b7eb08-605d-4d67-b248-7216892bd72f" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_54b7eb08-605d-4d67-b248-7216892bd72f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_936b7c23-2675-4502-98a7-46e2f063f643" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_936b7c23-2675-4502-98a7-46e2f063f643" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_57002351-337c-45de-972f-8d703cabcc86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_57002351-337c-45de-972f-8d703cabcc86" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNISharesAcquired_55d3f999-0eae-44f7-877a-f7054dbc32d7" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNISharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNISharesAcquired_55d3f999-0eae-44f7-877a-f7054dbc32d7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIShares_c3f44afc-1ae8-4078-b27e-ef2e2fcde14b" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNIShares_c3f44afc-1ae8-4078-b27e-ef2e2fcde14b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_87ed8320-fd2d-4f5f-a924-edc3b2a11156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_87ed8320-fd2d-4f5f-a924-edc3b2a11156" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementOptInTerm_a165f393-2fae-4080-a550-dd24e0f7a947" xlink:href="gild-20211231.xsd#gild_CollaborativeAgreementOptInTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborativeAgreementOptInTerm_a165f393-2fae-4080-a550-dd24e0f7a947" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions_14c47299-501a-4727-86fb-2add4e432206" xlink:href="gild-20211231.xsd#gild_NumberOfClinicalStageProgramsWithExercisedOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions_14c47299-501a-4727-86fb-2add4e432206" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToOptInTheCollaborativeAgreement_87f789bc-6d80-4b3b-a12c-b7ecb11474cb" xlink:href="gild-20211231.xsd#gild_PaymentsToOptInTheCollaborativeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PaymentsToOptInTheCollaborativeAgreement_87f789bc-6d80-4b3b-a12c-b7ecb11474cb" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_644f595c-7809-4f2b-ad8c-a232b8d9fc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_644f595c-7809-4f2b-ad8c-a232b8d9fc3e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a9bf5439-3326-4a21-a39d-4a18382345a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_EquityMethodInvestments_a9bf5439-3326-4a21-a39d-4a18382345a6" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_7ebf8a76-651c-4b8b-9e72-f59a05ff9769" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_7ebf8a76-651c-4b8b-9e72-f59a05ff9769" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_c655f655-3803-4c74-a169-1b43b72208aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_c655f655-3803-4c74-a169-1b43b72208aa" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_2acadff2-831b-420d-b681-3af045692e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_2acadff2-831b-420d-b681-3af045692e53" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeArrangementTerm_738e8af9-8414-4ced-899b-b88f3ec00b0d" xlink:href="gild-20211231.xsd#gild_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborativeArrangementTerm_738e8af9-8414-4ced-899b-b88f3ec00b0d" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4f423443-7915-406b-b65d-5b5430fde839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4f423443-7915-406b-b65d-5b5430fde839" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_df4eb310-90fb-4b26-a4bf-544eef7e2f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_SharePrice_df4eb310-90fb-4b26-a4bf-544eef7e2f5c" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_87539394-4fb7-4d4c-8a9f-8b0daa7834df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_87539394-4fb7-4d4c-8a9f-8b0daa7834df" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_5cd7413d-5661-407d-8275-797b74a0dc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_5cd7413d-5661-407d-8275-797b74a0dc43" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionExerciseFee_5b02183b-fe85-46d3-9494-82186fc69a8e" xlink:href="gild-20211231.xsd#gild_EquityMethodInvestmentOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquityMethodInvestmentOptionExerciseFee_5b02183b-fe85-46d3-9494-82186fc69a8e" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum_9fd78b79-4491-43f9-ad93-70f1de345be2" xlink:href="gild-20211231.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PotentialFutureMilestonePaymentsMaximum_9fd78b79-4491-43f9-ad93-70f1de345be2" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentFutureMaximumPayments_0b317122-6cbd-4fc4-b5da-19627db12f9f" xlink:href="gild-20211231.xsd#gild_ResearchAndDevelopmentFutureMaximumPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_ResearchAndDevelopmentFutureMaximumPayments_0b317122-6cbd-4fc4-b5da-19627db12f9f" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForResearchAndDevelopmentMilestones_4f4dab8e-6fce-4ea6-86f9-3916ef1f0b32" xlink:href="gild-20211231.xsd#gild_PaymentsForResearchAndDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PaymentsForResearchAndDevelopmentMilestones_4f4dab8e-6fce-4ea6-86f9-3916ef1f0b32" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_3effca2d-a231-40ce-8068-d8adb68961ef" xlink:href="gild-20211231.xsd#gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_3effca2d-a231-40ce-8068-d8adb68961ef" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_97177515-691c-4099-8fa8-6820f8ab6e68" xlink:href="gild-20211231.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_97177515-691c-4099-8fa8-6820f8ab6e68" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfPrograms_93256f0a-d8ec-4d0d-8802-ac8c81de1cb1" xlink:href="gild-20211231.xsd#gild_NumberOfPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_NumberOfPrograms_93256f0a-d8ec-4d0d-8802-ac8c81de1cb1" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_dbdff62c-bac2-4bff-898c-91da45aed74d" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_dbdff62c-bac2-4bff-898c-91da45aed74d" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_73fb74a2-d02c-4aec-b74b-7a6829e4285e" xlink:href="gild-20211231.xsd#gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_73fb74a2-d02c-4aec-b74b-7a6829e4285e" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_6f3a70a6-57a0-4ff7-a80f-7481d01e3cdb" xlink:href="gild-20211231.xsd#gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_6f3a70a6-57a0-4ff7-a80f-7481d01e3cdb" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_3b6aedcb-08bf-4302-91ae-bbc2995a151f" xlink:href="gild-20211231.xsd#gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_3b6aedcb-08bf-4302-91ae-bbc2995a151f" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_1e9a6256-781d-4efa-a994-b29eb165472c" xlink:href="gild-20211231.xsd#gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_1e9a6256-781d-4efa-a994-b29eb165472c" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_9f8380a1-75cb-4423-a71a-cf35052f7f31" xlink:href="gild-20211231.xsd#gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_9f8380a1-75cb-4423-a71a-cf35052f7f31" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_ae1d4f34-ccd4-4c08-b22c-464c029fb03e" xlink:href="gild-20211231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_ae1d4f34-ccd4-4c08-b22c-464c029fb03e" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_8b35a995-d41e-434b-9170-f47f1f76d5d7" xlink:href="gild-20211231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_8b35a995-d41e-434b-9170-f47f1f76d5d7" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_946015a5-c96f-439d-9bfe-b296c4be27de" xlink:href="gild-20211231.xsd#gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_946015a5-c96f-439d-9bfe-b296c4be27de" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Issuancediscount_d7c631a2-2303-4d80-bb04-8905041c1d87" xlink:href="gild-20211231.xsd#gild_Issuancediscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_Issuancediscount_d7c631a2-2303-4d80-bb04-8905041c1d87" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_7db5bc69-e552-49dd-b563-7be7ce8cee25" xlink:href="gild-20211231.xsd#gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_7db5bc69-e552-49dd-b563-7be7ce8cee25" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_StandstillRestrictingTerm_9cba6034-a257-4aa7-85de-84162368b56f" xlink:href="gild-20211231.xsd#gild_StandstillRestrictingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_StandstillRestrictingTerm_9cba6034-a257-4aa7-85de-84162368b56f" xlink:type="arc" order="52"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_69f1576d-f288-4737-a327-8051d6bcae90" xlink:href="gild-20211231.xsd#gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_69f1576d-f288-4737-a327-8051d6bcae90" xlink:type="arc" order="53"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fac5a26f-279e-41f5-bfe9-10cb8ea326a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fac5a26f-279e-41f5-bfe9-10cb8ea326a2" xlink:type="arc" order="54"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4d83e707-f070-4191-a50c-803fbe88d10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4d83e707-f070-4191-a50c-803fbe88d10b" xlink:type="arc" order="55"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialOptionExerciseFeePerProgram_d1053591-b785-4949-b650-35748dd77bd1" xlink:href="gild-20211231.xsd#gild_PotentialOptionExerciseFeePerProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PotentialOptionExerciseFeePerProgram_d1053591-b785-4949-b650-35748dd77bd1" xlink:type="arc" order="56"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_cb122b5f-8e94-4929-8659-52208ac432e3" xlink:href="gild-20211231.xsd#gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_cb122b5f-8e94-4929-8659-52208ac432e3" xlink:type="arc" order="57"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_87cf2c23-5a13-4ac3-8675-49029bae544b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_87cf2c23-5a13-4ac3-8675-49029bae544b" xlink:type="arc" order="58"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_2460ab27-4965-4b63-9a09-1f82dc0370c2" xlink:href="gild-20211231.xsd#gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_2460ab27-4965-4b63-9a09-1f82dc0370c2" xlink:type="arc" order="59"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_f4756f7b-33aa-486b-b653-a621055d8da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_RoyaltyExpense_f4756f7b-33aa-486b-b653-a621055d8da2" xlink:type="arc" order="60"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_9af5d3e1-9dcd-4a0d-a2e1-2d49e31fef30" xlink:href="gild-20211231.xsd#gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_9af5d3e1-9dcd-4a0d-a2e1-2d49e31fef30" xlink:type="arc" order="61"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_5d133c72-75bf-42a9-9335-031f21795167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_5d133c72-75bf-42a9-9335-031f21795167" xlink:type="arc" order="62"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_33cac58d-3f71-459a-92d9-413a158be30f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_33cac58d-3f71-459a-92d9-413a158be30f" xlink:type="arc" order="63"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_13c3dfc2-65da-4f7e-907b-bbcf6851f8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_13c3dfc2-65da-4f7e-907b-bbcf6851f8b8" xlink:type="arc" order="64"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_183ff308-998d-4883-bb1e-5cf46fa14144" xlink:href="gild-20211231.xsd#gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_183ff308-998d-4883-bb1e-5cf46fa14144" xlink:type="arc" order="65"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1c141efc-ae30-41cc-a393-950008368f6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1c141efc-ae30-41cc-a393-950008368f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1c141efc-ae30-41cc-a393-950008368f6e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1c141efc-ae30-41cc-a393-950008368f6e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1c141efc-ae30-41cc-a393-950008368f6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1c141efc-ae30-41cc-a393-950008368f6e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_21ef9332-e5c4-47ad-ae57-32e0c77655db" xlink:href="gild-20211231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:to="loc_gild_ArcusBiosciencesIncMember_21ef9332-e5c4-47ad-ae57-32e0c77655db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrImmunotherapeuticsIncMember_d675901d-330f-4c58-86ef-55f9e463c0f1" xlink:href="gild-20211231.xsd#gild_PionyrImmunotherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:to="loc_gild_PionyrImmunotherapeuticsIncMember_d675901d-330f-4c58-86ef-55f9e463c0f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaTherapeuticsIncMember_4a471b17-bd47-4354-8d7b-ae30c7b07058" xlink:href="gild-20211231.xsd#gild_TizonaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:to="loc_gild_TizonaTherapeuticsIncMember_4a471b17-bd47-4354-8d7b-ae30c7b07058" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember_5c10e5d1-826f-4aaa-937e-cb171c233898" xlink:href="gild-20211231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:to="loc_gild_TangoTherapeuticsIncMember_5c10e5d1-826f-4aaa-937e-cb171c233898" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember_bb437695-621e-4ef5-9d34-0b1686a82de3" xlink:href="gild-20211231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:to="loc_gild_JounceTherapeuticsIncMember_bb437695-621e-4ef5-9d34-0b1686a82de3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_bad7d4f6-3638-4b77-84df-e7890f8cbca0" xlink:href="gild-20211231.xsd#gild_GalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:to="loc_gild_GalapagosMember_bad7d4f6-3638-4b77-84df-e7890f8cbca0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fc0c5e64-652f-4183-b14c-c5486f265b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fc0c5e64-652f-4183-b14c-c5486f265b04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc0c5e64-652f-4183-b14c-c5486f265b04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc0c5e64-652f-4183-b14c-c5486f265b04" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc0c5e64-652f-4183-b14c-c5486f265b04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc0c5e64-652f-4183-b14c-c5486f265b04" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_40a35c0a-75d4-440c-bb1b-b61c92011541" xlink:href="gild-20211231.xsd#gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_40a35c0a-75d4-440c-bb1b-b61c92011541" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_2c5a0738-460f-4281-ba61-2e72f4c1d29d" xlink:href="gild-20211231.xsd#gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_2c5a0738-460f-4281-ba61-2e72f4c1d29d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementMember_24d7d749-2486-452b-9ae8-0ff950933770" xlink:href="gild-20211231.xsd#gild_ArcusCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_ArcusCollaborationAgreementMember_24d7d749-2486-452b-9ae8-0ff950933770" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember_c44b6ad1-64bc-48f3-a51e-6d2484e63d98" xlink:href="gild-20211231.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_ArcusStockPurchaseAgreementMember_c44b6ad1-64bc-48f3-a51e-6d2484e63d98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrMergerAndOptionAgreementsMember_dffbb22b-540a-4bab-9f8e-5add3b0c8bf7" xlink:href="gild-20211231.xsd#gild_PionyrMergerAndOptionAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_PionyrMergerAndOptionAgreementsMember_dffbb22b-540a-4bab-9f8e-5add3b0c8bf7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentServiceAgreementMember_8eeb753b-b0b0-488b-852b-14ee9407c108" xlink:href="gild-20211231.xsd#gild_ResearchAndDevelopmentServiceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_ResearchAndDevelopmentServiceAgreementMember_8eeb753b-b0b0-488b-852b-14ee9407c108" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaMergerAndOptionAgreementsMember_371e6eb3-0b10-436e-a37d-add1416990fc" xlink:href="gild-20211231.xsd#gild_TizonaMergerAndOptionAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_TizonaMergerAndOptionAgreementsMember_371e6eb3-0b10-436e-a37d-add1416990fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JanssenPharmaceuticalsMember_c5c7e994-ed2d-4b38-ac81-559cdd9d3b63" xlink:href="gild-20211231.xsd#gild_JanssenPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_JanssenPharmaceuticalsMember_c5c7e994-ed2d-4b38-ac81-559cdd9d3b63" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_bb1b4112-5541-47e0-abff-0dd33f4c8ae0" xlink:href="gild-20211231.xsd#gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_bb1b4112-5541-47e0-abff-0dd33f4c8ae0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_36be589b-afbf-45c2-b9da-b3d662b8663d" xlink:href="gild-20211231.xsd#gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_36be589b-afbf-45c2-b9da-b3d662b8663d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosSubscriptionAgreementMember_062048ad-8864-41fb-869d-bd11bb3de5da" xlink:href="gild-20211231.xsd#gild_GalapagosSubscriptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_GalapagosSubscriptionAgreementMember_062048ad-8864-41fb-869d-bd11bb3de5da" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosCollaborationAgreementMember_b780b5ce-6ffb-4571-85b2-0b920bf8b44c" xlink:href="gild-20211231.xsd#gild_GalapagosCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_GalapagosCollaborationAgreementMember_b780b5ce-6ffb-4571-85b2-0b920bf8b44c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DevelopmentAgreementMember_59207bfd-8da5-4450-b672-5e763f1fe43d" xlink:href="gild-20211231.xsd#gild_DevelopmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_DevelopmentAgreementMember_59207bfd-8da5-4450-b672-5e763f1fe43d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_599ff833-8dd4-4628-b3c0-5aca49e8e5bc" xlink:href="gild-20211231.xsd#gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_599ff833-8dd4-4628-b3c0-5aca49e8e5bc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_4133c024-fcdd-4a8d-ae18-c237ebff6d86" xlink:href="gild-20211231.xsd#gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_4133c024-fcdd-4a8d-ae18-c237ebff6d86" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AgreementWithJapanTobaccoIncMember_99328b55-c82b-470f-b989-51b4a6498363" xlink:href="gild-20211231.xsd#gild_AgreementWithJapanTobaccoIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_AgreementWithJapanTobaccoIncMember_99328b55-c82b-470f-b989-51b4a6498363" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GadetaBVCollaborationArrangementMember_20743986-ec09-41c0-8652-c4ef77d845aa" xlink:href="gild-20211231.xsd#gild_GadetaBVCollaborationArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_GadetaBVCollaborationArrangementMember_20743986-ec09-41c0-8652-c4ef77d845aa" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember_313dcbd3-b386-4fc1-ad87-6f1d9b480f34" xlink:href="gild-20211231.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_OtherCollaborationArrangementsMember_313dcbd3-b386-4fc1-ad87-6f1d9b480f34" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_41ef0166-31c3-4c2b-9cbb-3f8776e89164" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_srt_OwnershipAxis_41ef0166-31c3-4c2b-9cbb-3f8776e89164" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_41ef0166-31c3-4c2b-9cbb-3f8776e89164_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_41ef0166-31c3-4c2b-9cbb-3f8776e89164" xlink:to="loc_srt_OwnershipDomain_41ef0166-31c3-4c2b-9cbb-3f8776e89164_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_073ce8f6-c81b-40de-aace-ac3c2a0251a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_41ef0166-31c3-4c2b-9cbb-3f8776e89164" xlink:to="loc_srt_OwnershipDomain_073ce8f6-c81b-40de-aace-ac3c2a0251a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_d01af766-9f54-47d2-8399-781fb9e6e038" xlink:href="gild-20211231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_073ce8f6-c81b-40de-aace-ac3c2a0251a6" xlink:to="loc_gild_ArcusBiosciencesIncMember_d01af766-9f54-47d2-8399-781fb9e6e038" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember_8d6b5112-94a7-4cc5-b9a2-bd6c32caf6ef" xlink:href="gild-20211231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_073ce8f6-c81b-40de-aace-ac3c2a0251a6" xlink:to="loc_gild_TangoTherapeuticsIncMember_8d6b5112-94a7-4cc5-b9a2-bd6c32caf6ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember_b344d828-60ea-410b-ac7c-52dd2484154f" xlink:href="gild-20211231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_073ce8f6-c81b-40de-aace-ac3c2a0251a6" xlink:to="loc_gild_JounceTherapeuticsIncMember_b344d828-60ea-410b-ac7c-52dd2484154f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_deb25dbb-74aa-42a1-97fa-a263db72431f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_dei_LegalEntityAxis_deb25dbb-74aa-42a1-97fa-a263db72431f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_deb25dbb-74aa-42a1-97fa-a263db72431f_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_deb25dbb-74aa-42a1-97fa-a263db72431f" xlink:to="loc_dei_EntityDomain_deb25dbb-74aa-42a1-97fa-a263db72431f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5cf0104e-8fe4-475c-88d3-3bcc7eb685af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_deb25dbb-74aa-42a1-97fa-a263db72431f" xlink:to="loc_dei_EntityDomain_5cf0104e-8fe4-475c-88d3-3bcc7eb685af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckMember_40e07281-9168-4aa5-9aa1-cd0eb31313d3" xlink:href="gild-20211231.xsd#gild_MerckMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5cf0104e-8fe4-475c-88d3-3bcc7eb685af" xlink:to="loc_gild_MerckMember_40e07281-9168-4aa5-9aa1-cd0eb31313d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c17bde3-ad09-471b-a082-3af42093772d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_srt_ProductOrServiceAxis_8c17bde3-ad09-471b-a082-3af42093772d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c17bde3-ad09-471b-a082-3af42093772d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8c17bde3-ad09-471b-a082-3af42093772d" xlink:to="loc_srt_ProductsAndServicesDomain_8c17bde3-ad09-471b-a082-3af42093772d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_65ded896-8e15-4681-afb5-9460d6929b90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8c17bde3-ad09-471b-a082-3af42093772d" xlink:to="loc_srt_ProductsAndServicesDomain_65ded896-8e15-4681-afb5-9460d6929b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OralFormulationProductMember_f5479836-1b67-4334-8f8f-93f7fef0479e" xlink:href="gild-20211231.xsd#gild_OralFormulationProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_65ded896-8e15-4681-afb5-9460d6929b90" xlink:to="loc_gild_OralFormulationProductMember_f5479836-1b67-4334-8f8f-93f7fef0479e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InjectableFormulationProductMember_ae862e13-8e56-46c9-b14f-f1709d6c4461" xlink:href="gild-20211231.xsd#gild_InjectableFormulationProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_65ded896-8e15-4681-afb5-9460d6929b90" xlink:to="loc_gild_InjectableFormulationProductMember_ae862e13-8e56-46c9-b14f-f1709d6c4461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_905dc90a-544e-4a47-b01b-0bdb25ae89de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_srt_RangeAxis_905dc90a-544e-4a47-b01b-0bdb25ae89de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_905dc90a-544e-4a47-b01b-0bdb25ae89de_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_905dc90a-544e-4a47-b01b-0bdb25ae89de" xlink:to="loc_srt_RangeMember_905dc90a-544e-4a47-b01b-0bdb25ae89de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab1657cb-53f6-4613-ac8b-3eac258a4423" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_905dc90a-544e-4a47-b01b-0bdb25ae89de" xlink:to="loc_srt_RangeMember_ab1657cb-53f6-4613-ac8b-3eac258a4423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_45dd2687-6e77-4968-8a07-911bc9e3925a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ab1657cb-53f6-4613-ac8b-3eac258a4423" xlink:to="loc_srt_MaximumMember_45dd2687-6e77-4968-8a07-911bc9e3925a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="extended" id="i7e550de57ea345959caf51ea2fa6094a_DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_142e854f-3231-4d77-9a50-e4dd78dbdc97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_142e854f-3231-4d77-9a50-e4dd78dbdc97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_beb53e40-1021-4c6b-b5c7-307e85596705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_beb53e40-1021-4c6b-b5c7-307e85596705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_84731526-c462-42c0-ba40-f3760984570d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:to="loc_us-gaap_LongTermDebt_84731526-c462-42c0-ba40-f3760984570d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_67ba9f72-5bdd-4b8e-92a1-2b8c59dd96ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:to="loc_us-gaap_LongTermDebtCurrent_67ba9f72-5bdd-4b8e-92a1-2b8c59dd96ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b7d75f7b-43f5-4e25-9226-751f63587dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b7d75f7b-43f5-4e25-9226-751f63587dac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7d4490fd-88e7-413d-b507-87c25e6403de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:to="loc_us-gaap_DebtInstrumentTable_7d4490fd-88e7-413d-b507-87c25e6403de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_79655a26-2d28-4905-85cb-7cf9ee0971dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7d4490fd-88e7-413d-b507-87c25e6403de" xlink:to="loc_us-gaap_VariableRateAxis_79655a26-2d28-4905-85cb-7cf9ee0971dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_79655a26-2d28-4905-85cb-7cf9ee0971dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_79655a26-2d28-4905-85cb-7cf9ee0971dc" xlink:to="loc_us-gaap_VariableRateDomain_79655a26-2d28-4905-85cb-7cf9ee0971dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_41e37914-f251-4c5e-bb99-eeb89a16cb82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_79655a26-2d28-4905-85cb-7cf9ee0971dc" xlink:to="loc_us-gaap_VariableRateDomain_41e37914-f251-4c5e-bb99-eeb89a16cb82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_3e556577-d00a-489f-8ce5-731d82e4da1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_41e37914-f251-4c5e-bb99-eeb89a16cb82" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_3e556577-d00a-489f-8ce5-731d82e4da1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3b10a342-b2ac-4bb4-a113-93a6ebdc1144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7d4490fd-88e7-413d-b507-87c25e6403de" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3b10a342-b2ac-4bb4-a113-93a6ebdc1144" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3b10a342-b2ac-4bb4-a113-93a6ebdc1144_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3b10a342-b2ac-4bb4-a113-93a6ebdc1144" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3b10a342-b2ac-4bb4-a113-93a6ebdc1144_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bc4e2769-d9fb-4eb2-98d1-6708f7cad5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3b10a342-b2ac-4bb4-a113-93a6ebdc1144" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bc4e2769-d9fb-4eb2-98d1-6708f7cad5ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember_52bc580b-2496-4825-b25c-6455a082ab13" xlink:href="gild-20211231.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bc4e2769-d9fb-4eb2-98d1-6708f7cad5ad" xlink:to="loc_gild_SeniorNotesAndMediumTermNotesMember_52bc580b-2496-4825-b25c-6455a082ab13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_15c81179-15f5-441c-8649-0c7a7ff6121c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_52bc580b-2496-4825-b25c-6455a082ab13" xlink:to="loc_us-gaap_SeniorNotesMember_15c81179-15f5-441c-8649-0c7a7ff6121c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_58152691-8b6b-4a46-bd12-42ae22c79c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_52bc580b-2496-4825-b25c-6455a082ab13" xlink:to="loc_us-gaap_MediumTermNotesMember_58152691-8b6b-4a46-bd12-42ae22c79c50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_ff86166e-d561-4916-bc3d-9d87676a341f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bc4e2769-d9fb-4eb2-98d1-6708f7cad5ad" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_ff86166e-d561-4916-bc3d-9d87676a341f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fc3b50cb-b74f-42e4-af8d-58ee8d15ab1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7d4490fd-88e7-413d-b507-87c25e6403de" xlink:to="loc_us-gaap_DebtInstrumentAxis_fc3b50cb-b74f-42e4-af8d-58ee8d15ab1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fc3b50cb-b74f-42e4-af8d-58ee8d15ab1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fc3b50cb-b74f-42e4-af8d-58ee8d15ab1e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fc3b50cb-b74f-42e4-af8d-58ee8d15ab1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fc3b50cb-b74f-42e4-af8d-58ee8d15ab1e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueApril2021Member_4b2cc6b7-fd54-435c-808d-5ea6c691ac0f" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueApril2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueApril2021Member_4b2cc6b7-fd54-435c-808d-5ea6c691ac0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_240308e2-256f-4499-8e22-190d7b293592" xlink:href="gild-20211231.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_240308e2-256f-4499-8e22-190d7b293592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2021Member_cf53adb9-43af-4866-89dd-f22e85a3771d" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueDecember2021Member_cf53adb9-43af-4866-89dd-f22e85a3771d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_4e8a387e-2735-4f66-9ac2-2ff02d84ac8c" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_4e8a387e-2735-4f66-9ac2-2ff02d84ac8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member_125a8434-fd7f-400b-a355-35687621908d" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member_125a8434-fd7f-400b-a355-35687621908d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member_2fd38492-d1cd-40b7-ab64-ad5be12bd4f5" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member_2fd38492-d1cd-40b7-ab64-ad5be12bd4f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_43a61bdc-a046-4e56-91e7-f5019a17619e" xlink:href="gild-20211231.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_43a61bdc-a046-4e56-91e7-f5019a17619e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_c358ed19-0190-440a-a460-3b8845428136" xlink:href="gild-20211231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_c358ed19-0190-440a-a460-3b8845428136" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member_7394a345-89d2-4265-a31b-726a936f117e" xlink:href="gild-20211231.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_VariableTermLoanNoteDueOctober2023Member_7394a345-89d2-4265-a31b-726a936f117e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2024Member_0fa9e812-1f7f-49e5-8f07-0307e5160e4b" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinApril2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinApril2024Member_0fa9e812-1f7f-49e5-8f07-0307e5160e4b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member_25b77e60-4afe-4839-bcd3-f43141db29c9" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member_25b77e60-4afe-4839-bcd3-f43141db29c9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member_95b90938-0e60-4636-94b3-19dc81656fb9" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member_95b90938-0e60-4636-94b3-19dc81656fb9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member_805a91f9-cc63-4641-9aeb-f092d11aec4c" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member_805a91f9-cc63-4641-9aeb-f092d11aec4c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_ac58d370-f758-421c-91e3-d93963cc640b" xlink:href="gild-20211231.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_ac58d370-f758-421c-91e3-d93963cc640b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_54b1f51d-9132-4839-a0ff-64305fa8944b" xlink:href="gild-20211231.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_54b1f51d-9132-4839-a0ff-64305fa8944b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member_63218670-650b-4dc7-a64a-12ddf70d682a" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member_63218670-650b-4dc7-a64a-12ddf70d682a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member_d4fa7489-0b92-42d4-a66e-4369e848a4d4" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member_d4fa7489-0b92-42d4-a66e-4369e848a4d4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_5bf0416d-ad45-4beb-8360-8befe072a7ab" xlink:href="gild-20211231.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_5bf0416d-ad45-4beb-8360-8befe072a7ab" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2041Member_ebe6310f-e33d-45a1-a26f-37c52e049ede" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueDecember2041Member_ebe6310f-e33d-45a1-a26f-37c52e049ede" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2044Member_c73c9ddf-fda2-47dd-8952-6af2e16b19ee" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinApril2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinApril2044Member_c73c9ddf-fda2-47dd-8952-6af2e16b19ee" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member_c91e2e99-1e9d-4929-b053-1ffbb7c75418" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member_c91e2e99-1e9d-4929-b053-1ffbb7c75418" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member_9f6bc481-864c-4385-956c-ffff7dd20e4b" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member_9f6bc481-864c-4385-956c-ffff7dd20e4b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member_3d0932e9-dcdc-4f9b-aa5b-21734fb44636" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member_3d0932e9-dcdc-4f9b-aa5b-21734fb44636" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_16bbe74c-8ecc-4552-8e62-4ff66b2e6f54" xlink:href="gild-20211231.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_16bbe74c-8ecc-4552-8e62-4ff66b2e6f54" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DebtandCreditFacilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="extended" id="ief06412805d644f19c386df127ded481_DebtandCreditFacilitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ab04b3f8-b99d-4735-812a-fd9d6a701211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ab04b3f8-b99d-4735-812a-fd9d6a701211" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_c5f729e9-8a2d-4c19-8dda-b621a617525b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_c5f729e9-8a2d-4c19-8dda-b621a617525b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e941376c-cb05-496b-9203-34a3bcea09f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e941376c-cb05-496b-9203-34a3bcea09f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfEarlyRepaymentsOfLongTermDebt_722250ac-6e36-4107-b461-fbe02b098821" xlink:href="gild-20211231.xsd#gild_NumberOfEarlyRepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_gild_NumberOfEarlyRepaymentsOfLongTermDebt_722250ac-6e36-4107-b461-fbe02b098821" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_da3cf407-14ed-46b7-8f62-ff1513f790e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_da3cf407-14ed-46b7-8f62-ff1513f790e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_0da13501-d96a-40d4-8b6c-749d1fb4166a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_0da13501-d96a-40d4-8b6c-749d1fb4166a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_e363e269-4607-47b9-acfc-9ff0678d5725" xlink:href="gild-20211231.xsd#gild_DebtInstrumentCallFeaturePeriodBeforeMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_e363e269-4607-47b9-acfc-9ff0678d5725" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9ad8cf39-0407-469e-af97-1aa2ee4f1f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9ad8cf39-0407-469e-af97-1aa2ee4f1f8d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b63b3f85-8f33-4887-9911-29f6dc339468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_LongTermDebt_b63b3f85-8f33-4887-9911-29f6dc339468" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_d0067ffb-d833-4e20-a070-64b3b1178a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_DebtInstrumentTerm_d0067ffb-d833-4e20-a070-64b3b1178a90" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ba6380fd-ea86-483e-9414-8118ee398195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ba6380fd-ea86-483e-9414-8118ee398195" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c9d0cfbc-3e02-4f1e-b785-d9aca14e7e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c9d0cfbc-3e02-4f1e-b785-d9aca14e7e1f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_54c75c7e-e243-4b0b-a1b2-898f42bee4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_LineOfCredit_54c75c7e-e243-4b0b-a1b2-898f42bee4e2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt_0e677c3c-406d-4e31-ae78-727578c5a7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_InterestExpenseLongTermDebt_0e677c3c-406d-4e31-ae78-727578c5a7c9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a7ce754b-1c29-4792-8b47-91974f4850d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:to="loc_us-gaap_DebtInstrumentAxis_a7ce754b-1c29-4792-8b47-91974f4850d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7ce754b-1c29-4792-8b47-91974f4850d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a7ce754b-1c29-4792-8b47-91974f4850d2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7ce754b-1c29-4792-8b47-91974f4850d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a7ce754b-1c29-4792-8b47-91974f4850d2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueApril2021Member_534c9c17-4dd5-449e-907c-26e1a19c1f4d" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueApril2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_SeniorUnsecuredNotesDueApril2021Member_534c9c17-4dd5-449e-907c-26e1a19c1f4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2021Member_23c54159-9482-4641-9ebd-5731366db3b0" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_SeniorUnsecuredNotesDueDecember2021Member_23c54159-9482-4641-9ebd-5731366db3b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_36810930-cfc3-4a81-88e4-efb458bb621a" xlink:href="gild-20211231.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_36810930-cfc3-4a81-88e4-efb458bb621a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_3d8aba5c-8eef-4982-b6d8-02141a2c4a98" xlink:href="gild-20211231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_3d8aba5c-8eef-4982-b6d8-02141a2c4a98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_b18dd89d-2e67-44ef-a0ae-d81123b200b4" xlink:href="gild-20211231.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_b18dd89d-2e67-44ef-a0ae-d81123b200b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_fd6fa795-cac6-4139-a4d6-5dcd2dd739c6" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_fd6fa795-cac6-4139-a4d6-5dcd2dd739c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_10ab707c-8c4c-434e-9a3b-15bbc1281e48" xlink:href="gild-20211231.xsd#gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_10ab707c-8c4c-434e-9a3b-15bbc1281e48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_fa305822-be04-4278-96e8-c50e6ccd86c9" xlink:href="gild-20211231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_fa305822-be04-4278-96e8-c50e6ccd86c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueMay2021Member_8ae60668-2d33-4d81-b822-9574ab133cac" xlink:href="gild-20211231.xsd#gild_CreditFacilityDueMay2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_CreditFacilityDueMay2021Member_8ae60668-2d33-4d81-b822-9574ab133cac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_c8ba16b5-59fb-41e0-963a-da6bbef03a1c" xlink:href="gild-20211231.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_CreditFacilityDueJune2025Member_c8ba16b5-59fb-41e0-963a-da6bbef03a1c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member_086101d2-d14e-464b-b27b-124eeddb4fb6" xlink:href="gild-20211231.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_VariableTermLoanNoteDueOctober2023Member_086101d2-d14e-464b-b27b-124eeddb4fb6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_231748b8-a16e-47b3-b385-d74cee6e2790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_231748b8-a16e-47b3-b385-d74cee6e2790" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_231748b8-a16e-47b3-b385-d74cee6e2790_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_231748b8-a16e-47b3-b385-d74cee6e2790" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_231748b8-a16e-47b3-b385-d74cee6e2790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_83798fd6-e8a1-4eb8-8d4e-b0cf1b6d72e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_231748b8-a16e-47b3-b385-d74cee6e2790" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_83798fd6-e8a1-4eb8-8d4e-b0cf1b6d72e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_839e8c07-388d-43c1-8df8-a8572697ec33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_83798fd6-e8a1-4eb8-8d4e-b0cf1b6d72e9" xlink:to="loc_us-gaap_SeniorNotesMember_839e8c07-388d-43c1-8df8-a8572697ec33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_7aba82be-3e1b-4266-80d2-55e7f4131d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_83798fd6-e8a1-4eb8-8d4e-b0cf1b6d72e9" xlink:to="loc_us-gaap_MediumTermNotesMember_7aba82be-3e1b-4266-80d2-55e7f4131d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_9fe2ea3d-5b7f-48a7-bc3c-4ded0e8a2494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_83798fd6-e8a1-4eb8-8d4e-b0cf1b6d72e9" xlink:to="loc_us-gaap_LineOfCreditMember_9fe2ea3d-5b7f-48a7-bc3c-4ded0e8a2494" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dba785ca-2741-4dbe-a5a1-e154c3fad961" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:to="loc_srt_RangeAxis_dba785ca-2741-4dbe-a5a1-e154c3fad961" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dba785ca-2741-4dbe-a5a1-e154c3fad961_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dba785ca-2741-4dbe-a5a1-e154c3fad961" xlink:to="loc_srt_RangeMember_dba785ca-2741-4dbe-a5a1-e154c3fad961_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_745411e6-9983-4050-b68a-8b14ba7639e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dba785ca-2741-4dbe-a5a1-e154c3fad961" xlink:to="loc_srt_RangeMember_745411e6-9983-4050-b68a-8b14ba7639e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0182f29b-72b3-4500-a081-cc39ace6a8ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_745411e6-9983-4050-b68a-8b14ba7639e8" xlink:to="loc_srt_MinimumMember_0182f29b-72b3-4500-a081-cc39ace6a8ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c630478-afc7-4abd-aee9-21bb4fa254a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_745411e6-9983-4050-b68a-8b14ba7639e8" xlink:to="loc_srt_MaximumMember_0c630478-afc7-4abd-aee9-21bb4fa254a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_3091e1cc-b8c4-4808-b9e2-6144eda2a452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:to="loc_us-gaap_CreditFacilityAxis_3091e1cc-b8c4-4808-b9e2-6144eda2a452" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3091e1cc-b8c4-4808-b9e2-6144eda2a452_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_3091e1cc-b8c4-4808-b9e2-6144eda2a452" xlink:to="loc_us-gaap_CreditFacilityDomain_3091e1cc-b8c4-4808-b9e2-6144eda2a452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_19580bf8-93a5-440a-8a4b-687a861abbab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_3091e1cc-b8c4-4808-b9e2-6144eda2a452" xlink:to="loc_us-gaap_CreditFacilityDomain_19580bf8-93a5-440a-8a4b-687a861abbab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8571738b-4ea3-4a41-9393-13b1b88aaaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_19580bf8-93a5-440a-8a4b-687a861abbab" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8571738b-4ea3-4a41-9393-13b1b88aaaf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b88a3c5f-3641-4fb9-a997-6e7c17deafd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b88a3c5f-3641-4fb9-a997-6e7c17deafd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b88a3c5f-3641-4fb9-a997-6e7c17deafd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b88a3c5f-3641-4fb9-a997-6e7c17deafd2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b88a3c5f-3641-4fb9-a997-6e7c17deafd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ad90a481-77ae-4194-8043-e8c003bc9857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b88a3c5f-3641-4fb9-a997-6e7c17deafd2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ad90a481-77ae-4194-8043-e8c003bc9857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e041f04f-3397-4d6c-9031-508386afbf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ad90a481-77ae-4194-8043-e8c003bc9857" xlink:to="loc_us-gaap_SubsequentEventMember_e041f04f-3397-4d6c-9031-508386afbf06" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="extended" id="i8523ec5cbff54970aa143051c6e5226b_DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ca18a23d-1bf5-443e-804a-02e57717f4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ca18a23d-1bf5-443e-804a-02e57717f4f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_98955ce4-8ebc-476e-99e2-e91ba918ae8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_98955ce4-8ebc-476e-99e2-e91ba918ae8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8911c832-619b-409b-bf59-a60d5413d492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8911c832-619b-409b-bf59-a60d5413d492" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6a1b223d-09ff-4937-8247-c73ed5bdb117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6a1b223d-09ff-4937-8247-c73ed5bdb117" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a332d9a5-e9e5-4cea-a70b-db5f268ee159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a332d9a5-e9e5-4cea-a70b-db5f268ee159" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6db925b8-49b2-4f8e-9fe7-9cb6432bd353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6db925b8-49b2-4f8e-9fe7-9cb6432bd353" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5f97d897-3d3c-4d4d-a6e4-749aaf0e61fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebt_5f97d897-3d3c-4d4d-a6e4-749aaf0e61fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ea4c4307-bab8-445c-8a13-51e327a42dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_DebtInstrumentTable_ea4c4307-bab8-445c-8a13-51e327a42dbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_77291d31-5f75-4b1d-823e-0ea8aaae08db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ea4c4307-bab8-445c-8a13-51e327a42dbb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_77291d31-5f75-4b1d-823e-0ea8aaae08db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_77291d31-5f75-4b1d-823e-0ea8aaae08db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_77291d31-5f75-4b1d-823e-0ea8aaae08db" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_77291d31-5f75-4b1d-823e-0ea8aaae08db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba8c498f-0910-448d-b299-4e532d3a08c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_77291d31-5f75-4b1d-823e-0ea8aaae08db" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba8c498f-0910-448d-b299-4e532d3a08c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_efcfd4d3-1da0-42b9-8ef0-8c13ee47b378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba8c498f-0910-448d-b299-4e532d3a08c0" xlink:to="loc_us-gaap_SeniorNotesMember_efcfd4d3-1da0-42b9-8ef0-8c13ee47b378" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i537cf8c1ec8246d59b2f073e25cac949_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_ddb0b0e2-b413-4c3f-96ee-ded4b46a0b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_ddb0b0e2-b413-4c3f-96ee-ded4b46a0b16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_c0cabaae-239b-4405-8dcf-78e61d29a353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_c0cabaae-239b-4405-8dcf-78e61d29a353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_22471570-4584-43ff-9c3b-3bab1e00ab69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_22471570-4584-43ff-9c3b-3bab1e00ab69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017_26c52118-ca74-456b-8aa4-d6cb5f19a5e0" xlink:href="gild-20211231.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_JudgmentRoyaltyRateFromOctober2017_26c52118-ca74-456b-8aa4-d6cb5f19a5e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales_052a2194-4b1f-4491-b51d-57a887eaf74f" xlink:href="gild-20211231.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_JudgmentEnhancedDamagesOnPastSales_052a2194-4b1f-4491-b51d-57a887eaf74f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales_04b29ee5-f29f-466e-ba88-cb0127c3eddb" xlink:href="gild-20211231.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_JudgmentRoyaltyRateOnFutureSales_04b29ee5-f29f-466e-ba88-cb0127c3eddb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_e27ec9ca-3bd6-4953-93a6-07948a7a0426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_e27ec9ca-3bd6-4953-93a6-07948a7a0426" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyRoyaltyPercentageOnFutureSales_1a4ac0a6-fd6b-4e3c-a56c-062e638c092a" xlink:href="gild-20211231.xsd#gild_LossContingencyRoyaltyPercentageOnFutureSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyRoyaltyPercentageOnFutureSales_1a4ac0a6-fd6b-4e3c-a56c-062e638c092a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber_1375a5cf-c4a9-484f-b568-084b1a657015" xlink:href="gild-20211231.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyMaterialTransferAgreementsNumber_1375a5cf-c4a9-484f-b568-084b1a657015" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_f10f691c-0702-426d-8ac1-c676b6ee5e13" xlink:href="gild-20211231.xsd#gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_f10f691c-0702-426d-8ac1-c676b6ee5e13" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_396d7899-9eb1-4a02-93eb-965d4ece0181" xlink:href="gild-20211231.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_396d7899-9eb1-4a02-93eb-965d4ece0181" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_bef34116-9080-49c2-a541-f2f1bc246a58" xlink:href="gild-20211231.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_bef34116-9080-49c2-a541-f2f1bc246a58" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber_4d5f3ac0-a4af-414c-82dd-8267e8f8b3cf" xlink:href="gild-20211231.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyPartiesAppealedNumber_4d5f3ac0-a4af-414c-82dd-8267e8f8b3cf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesFilingOppositionNumber_f4020d78-f1ce-4598-a89a-e801a2c6b6e1" xlink:href="gild-20211231.xsd#gild_LossContingencyPartiesFilingOppositionNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyPartiesFilingOppositionNumber_f4020d78-f1ce-4598-a89a-e801a2c6b6e1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_d3dcba1f-1404-484c-b33f-8a9a12b309e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_d3dcba1f-1404-484c-b33f-8a9a12b309e8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_3a8ebdc5-f840-4231-bbe5-a475aaa0b9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_3a8ebdc5-f840-4231-bbe5-a475aaa0b9a4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_1504878f-9f6b-4852-8eb5-a970aef6ccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_1504878f-9f6b-4852-8eb5-a970aef6ccb3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_cb8f9e61-6ab1-45f2-a0a0-2721cb2fde07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_cb8f9e61-6ab1-45f2-a0a0-2721cb2fde07" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_85681c75-9b89-4f69-8b40-873212e041e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_85681c75-9b89-4f69-8b40-873212e041e5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_0b86d188-cc89-4f85-a20e-1ea9d2857762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_0b86d188-cc89-4f85-a20e-1ea9d2857762" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_82693326-ba3e-4584-b7ad-27c8fc1ed835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_82693326-ba3e-4584-b7ad-27c8fc1ed835" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_8e3e8fdd-70eb-4570-9346-28150d6a3ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_OtherCommitmentsTable_8e3e8fdd-70eb-4570-9346-28150d6a3ab1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_52b16157-1d05-4ebf-836b-ac6f6f183553" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8e3e8fdd-70eb-4570-9346-28150d6a3ab1" xlink:to="loc_srt_LitigationCaseAxis_52b16157-1d05-4ebf-836b-ac6f6f183553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_52b16157-1d05-4ebf-836b-ac6f6f183553_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_52b16157-1d05-4ebf-836b-ac6f6f183553" xlink:to="loc_srt_LitigationCaseTypeDomain_52b16157-1d05-4ebf-836b-ac6f6f183553_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_52b16157-1d05-4ebf-836b-ac6f6f183553" xlink:to="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember_30cc75fa-0bde-447a-9288-b0dd5f64d2f8" xlink:href="gild-20211231.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_ViiVHealthcareCompanyMember_30cc75fa-0bde-447a-9288-b0dd5f64d2f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_d9bd3e5a-2d04-4a02-af0d-0db522659beb" xlink:href="gild-20211231.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_d9bd3e5a-2d04-4a02-af0d-0db522659beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember_86e5b56a-1937-4772-81e2-227427cb45be" xlink:href="gild-20211231.xsd#gild_PreExposureProphylaxisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_PreExposureProphylaxisMember_86e5b56a-1937-4772-81e2-227427cb45be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2024ExpirationMember_8e85c7ca-3428-47fc-a042-e4ba82c4a2e0" xlink:href="gild-20211231.xsd#gild_EuropeanPatentClaims2024ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_EuropeanPatentClaims2024ExpirationMember_8e85c7ca-3428-47fc-a042-e4ba82c4a2e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2026ExpirationMember_8d1c7bd5-1425-469a-8520-4ecc1e57c61a" xlink:href="gild-20211231.xsd#gild_EuropeanPatentClaims2026ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_EuropeanPatentClaims2026ExpirationMember_8d1c7bd5-1425-469a-8520-4ecc1e57c61a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember_161aa991-3d26-44a7-8787-84d1389d5ab5" xlink:href="gild-20211231.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_EuropeanPatentClaims2032ExpirationMember_161aa991-3d26-44a7-8787-84d1389d5ab5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2027ExpirationMember_1b4b684b-af96-4ec3-8b63-31deba103e31" xlink:href="gild-20211231.xsd#gild_EuropeanPatentClaims2027ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_EuropeanPatentClaims2027ExpirationMember_1b4b684b-af96-4ec3-8b63-31deba103e31" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember_4f259cd4-4f01-4e9b-8e61-c4a66a4e1d9f" xlink:href="gild-20211231.xsd#gild_ProductLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_ProductLiabilityMember_4f259cd4-4f01-4e9b-8e61-c4a66a4e1d9f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_QuiTamMember_9d6902fa-1ccf-4eee-9a88-b45022128b83" xlink:href="gild-20211231.xsd#gild_QuiTamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_QuiTamMember_9d6902fa-1ccf-4eee-9a88-b45022128b83" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2356c026-5ffb-4de7-8356-8d573e8d392b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8e3e8fdd-70eb-4570-9346-28150d6a3ab1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2356c026-5ffb-4de7-8356-8d573e8d392b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2356c026-5ffb-4de7-8356-8d573e8d392b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2356c026-5ffb-4de7-8356-8d573e8d392b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2356c026-5ffb-4de7-8356-8d573e8d392b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_05c5867a-1186-48bb-aeff-1c975f561d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2356c026-5ffb-4de7-8356-8d573e8d392b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_05c5867a-1186-48bb-aeff-1c975f561d49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ef8c6f09-00ab-4bbc-bf12-7bdc93234782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_05c5867a-1186-48bb-aeff-1c975f561d49" xlink:to="loc_us-gaap_SubsequentEventMember_ef8c6f09-00ab-4bbc-bf12-7bdc93234782" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_abb62fb1-caff-4c98-ad2a-d7b82722b146" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8e3e8fdd-70eb-4570-9346-28150d6a3ab1" xlink:to="loc_srt_StatementScenarioAxis_abb62fb1-caff-4c98-ad2a-d7b82722b146" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_abb62fb1-caff-4c98-ad2a-d7b82722b146_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_abb62fb1-caff-4c98-ad2a-d7b82722b146" xlink:to="loc_srt_ScenarioUnspecifiedDomain_abb62fb1-caff-4c98-ad2a-d7b82722b146_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5774abda-3009-4e30-a4ae-4bb6aedbbd3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_abb62fb1-caff-4c98-ad2a-d7b82722b146" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5774abda-3009-4e30-a4ae-4bb6aedbbd3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_bed91208-b531-4ad8-87de-abee7ed6942f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_5774abda-3009-4e30-a4ae-4bb6aedbbd3c" xlink:to="loc_srt_ScenarioForecastMember_bed91208-b531-4ad8-87de-abee7ed6942f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#StockholdersEquityRepurchasesofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="extended" id="ibecc69a53dac44bbb95acfca3e3f282d_StockholdersEquityRepurchasesofCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fdce29a2-1bc0-4f1d-9266-5bad860d9163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fdce29a2-1bc0-4f1d-9266-5bad860d9163" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b51c6070-3daa-49ed-99de-8e78382e04fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b51c6070-3daa-49ed-99de-8e78382e04fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5fc9686f-9a28-4b57-9f74-daeb88c30477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5fc9686f-9a28-4b57-9f74-daeb88c30477" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_98cc439c-e5ad-472b-abf3-43016d3fe7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_98cc439c-e5ad-472b-abf3-43016d3fe7e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_bb45d573-52ba-4ab2-8bc0-0443748b4e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_bb45d573-52ba-4ab2-8bc0-0443748b4e70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a21cec8d-c0d5-4240-b765-3ccbe239f934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a21cec8d-c0d5-4240-b765-3ccbe239f934" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_8238799b-302b-4fba-921c-2963d0a8621a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a21cec8d-c0d5-4240-b765-3ccbe239f934" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_8238799b-302b-4fba-921c-2963d0a8621a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_8238799b-302b-4fba-921c-2963d0a8621a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_8238799b-302b-4fba-921c-2963d0a8621a" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_8238799b-302b-4fba-921c-2963d0a8621a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f2b8d3fd-53ab-4b08-b7cb-9b244765fe6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_8238799b-302b-4fba-921c-2963d0a8621a" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f2b8d3fd-53ab-4b08-b7cb-9b244765fe6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember_581c015c-ea60-4de8-a74c-76eb200f6495" xlink:href="gild-20211231.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f2b8d3fd-53ab-4b08-b7cb-9b244765fe6c" xlink:to="loc_gild_A2016StockRepurchaseProgramMember_581c015c-ea60-4de8-a74c-76eb200f6495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember_d6355de1-d710-488b-b909-ccdeb62ee161" xlink:href="gild-20211231.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f2b8d3fd-53ab-4b08-b7cb-9b244765fe6c" xlink:to="loc_gild_A2020StockRepurchaseProgramMember_d6355de1-d710-488b-b909-ccdeb62ee161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PubliclyAnnouncedProgramMember_2f9b141c-b20a-412f-a37c-fc5fce786ce1" xlink:href="gild-20211231.xsd#gild_PubliclyAnnouncedProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f2b8d3fd-53ab-4b08-b7cb-9b244765fe6c" xlink:to="loc_gild_PubliclyAnnouncedProgramMember_2f9b141c-b20a-412f-a37c-fc5fce786ce1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#StockholdersEquityDividendsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="extended" id="ifd00b4cac1424986af3ef14b7263e7ff_StockholdersEquityDividendsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_919188aa-b33d-4aa7-a25a-328499b03974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_9019b0fd-f4b3-472e-b6cb-313acd80f3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_919188aa-b33d-4aa7-a25a-328499b03974" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_9019b0fd-f4b3-472e-b6cb-313acd80f3d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_7da12d0f-11da-498e-9e49-09c71b6106b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_919188aa-b33d-4aa7-a25a-328499b03974" xlink:to="loc_us-gaap_DividendsCommonStockCash_7da12d0f-11da-498e-9e49-09c71b6106b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f1cc34e0-b352-40e7-828a-34e75dc815dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_919188aa-b33d-4aa7-a25a-328499b03974" xlink:to="loc_us-gaap_SubsequentEventTable_f1cc34e0-b352-40e7-828a-34e75dc815dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_55d6b76e-c6a4-4edb-be0a-3023120cb8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f1cc34e0-b352-40e7-828a-34e75dc815dd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_55d6b76e-c6a4-4edb-be0a-3023120cb8c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_55d6b76e-c6a4-4edb-be0a-3023120cb8c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_55d6b76e-c6a4-4edb-be0a-3023120cb8c5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_55d6b76e-c6a4-4edb-be0a-3023120cb8c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_efff6c99-3693-4e6d-9fd7-415c6c23a36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_55d6b76e-c6a4-4edb-be0a-3023120cb8c5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_efff6c99-3693-4e6d-9fd7-415c6c23a36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e1690ae1-d95e-4dc3-9f5e-4a4bf242f90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_efff6c99-3693-4e6d-9fd7-415c6c23a36f" xlink:to="loc_us-gaap_SubsequentEventMember_e1690ae1-d95e-4dc3-9f5e-4a4bf242f90d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="i3edfb06274e241268a2b416a7c8a92a1_StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_eb60bcff-f3b6-44b0-b15f-bd7ad549363e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_eb60bcff-f3b6-44b0-b15f-bd7ad549363e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8d117f2-e8d1-46e6-ac38-1b6002065d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8d117f2-e8d1-46e6-ac38-1b6002065d46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_4e5d3d5e-1787-4aa1-8619-90dda9d32080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_4e5d3d5e-1787-4aa1-8619-90dda9d32080" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6cff41a8-034b-4999-9753-c00ed2da6c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6cff41a8-034b-4999-9753-c00ed2da6c45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b45dd90b-ff75-47f3-a2a3-d1d8530de015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b45dd90b-ff75-47f3-a2a3-d1d8530de015" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_275d36ba-4c3d-4335-8d3e-a0ef14a55474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0548bedb-4578-43cc-a394-9f41bcd698a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_eb60bcff-f3b6-44b0-b15f-bd7ad549363e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0548bedb-4578-43cc-a394-9f41bcd698a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_84374d64-dd2a-4788-a65a-ebe9ac8616ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0548bedb-4578-43cc-a394-9f41bcd698a4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_84374d64-dd2a-4788-a65a-ebe9ac8616ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_84374d64-dd2a-4788-a65a-ebe9ac8616ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_84374d64-dd2a-4788-a65a-ebe9ac8616ed" xlink:to="loc_us-gaap_EquityComponentDomain_84374d64-dd2a-4788-a65a-ebe9ac8616ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_34cf9bf5-0a47-4d4b-8607-a7865ed98f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_84374d64-dd2a-4788-a65a-ebe9ac8616ed" xlink:to="loc_us-gaap_EquityComponentDomain_34cf9bf5-0a47-4d4b-8607-a7865ed98f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_01c45385-12d8-4c8e-9933-568b03da433d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_34cf9bf5-0a47-4d4b-8607-a7865ed98f5a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_01c45385-12d8-4c8e-9933-568b03da433d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_0c3d3e88-79a1-4c03-806a-b117f513fd81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_01c45385-12d8-4c8e-9933-568b03da433d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_0c3d3e88-79a1-4c03-806a-b117f513fd81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cc58afd5-2b84-4e1c-b74f-f82b6d6d5279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_01c45385-12d8-4c8e-9933-568b03da433d" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cc58afd5-2b84-4e1c-b74f-f82b6d6d5279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_aee5f457-e8a6-4a9f-a3e6-6970d4a67664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_01c45385-12d8-4c8e-9933-568b03da433d" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_aee5f457-e8a6-4a9f-a3e6-6970d4a67664" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="extended" id="ied38bb2a90384ef991e77be166e27e40_EmployeeBenefitsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a4b0e4af-fcfe-4f48-ad94-0000d6821f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a4b0e4af-fcfe-4f48-ad94-0000d6821f97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_94c61b75-56b4-4131-aef7-f10eb4a75b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_94c61b75-56b4-4131-aef7-f10eb4a75b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3ed2b3b2-8200-4f83-8266-4dfa66a5fead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3ed2b3b2-8200-4f83-8266-4dfa66a5fead" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_794c8e30-bed5-41e1-8e58-90f10f7f7a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_794c8e30-bed5-41e1-8e58-90f10f7f7a74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e45e53f9-2124-42de-9dc4-c59e2ad465a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e45e53f9-2124-42de-9dc4-c59e2ad465a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4c769ec2-d581-4e51-ab6e-4308876513fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4c769ec2-d581-4e51-ab6e-4308876513fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e8caab7c-0958-4943-b9d5-95e54400146d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e8caab7c-0958-4943-b9d5-95e54400146d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_884b390e-e29b-48f2-b9a0-f34ae61b4f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_884b390e-e29b-48f2-b9a0-f34ae61b4f34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_441b33fa-4ba8-4941-a935-07b21498d62b" xlink:href="gild-20211231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_441b33fa-4ba8-4941-a935-07b21498d62b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8161ce28-d471-4726-8e64-50e6879ca28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8161ce28-d471-4726-8e64-50e6879ca28c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_232d21dd-b9c6-4eeb-8e39-4def4c797b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_232d21dd-b9c6-4eeb-8e39-4def4c797b60" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5beb3df1-461b-40f3-952d-61c8bd0eb072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5beb3df1-461b-40f3-952d-61c8bd0eb072" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_dd1eccbd-c84a-4201-9036-85fdae084eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_dd1eccbd-c84a-4201-9036-85fdae084eed" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d8d84e80-e771-443d-a4bc-963f5dd97507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d8d84e80-e771-443d-a4bc-963f5dd97507" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c093bbfb-b07c-4de8-8d5f-e892fec5d3df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c093bbfb-b07c-4de8-8d5f-e892fec5d3df" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_fc19742e-5f6a-431f-86ee-3c781ff58aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_fc19742e-5f6a-431f-86ee-3c781ff58aae" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_cd9d68d8-07b7-4c41-91e7-35fb64abd279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_cd9d68d8-07b7-4c41-91e7-35fb64abd279" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalFairValueAxis_6c806132-6125-4625-83c3-0c59763ed911" xlink:href="gild-20211231.xsd#gild_TotalFairValueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_gild_TotalFairValueAxis_6c806132-6125-4625-83c3-0c59763ed911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalGrantDateFairValueDomain_6c806132-6125-4625-83c3-0c59763ed911_default" xlink:href="gild-20211231.xsd#gild_TotalGrantDateFairValueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_TotalFairValueAxis_6c806132-6125-4625-83c3-0c59763ed911" xlink:to="loc_gild_TotalGrantDateFairValueDomain_6c806132-6125-4625-83c3-0c59763ed911_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalGrantDateFairValueDomain_1678cfba-ecfb-4c4c-90f7-71258291b445" xlink:href="gild-20211231.xsd#gild_TotalGrantDateFairValueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_TotalFairValueAxis_6c806132-6125-4625-83c3-0c59763ed911" xlink:to="loc_gild_TotalGrantDateFairValueDomain_1678cfba-ecfb-4c4c-90f7-71258291b445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueatGrantDateMember_b001dcc1-10ea-42cc-a6ec-b0df8e93969f" xlink:href="gild-20211231.xsd#gild_FairValueatGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_TotalGrantDateFairValueDomain_1678cfba-ecfb-4c4c-90f7-71258291b445" xlink:to="loc_gild_FairValueatGrantDateMember_b001dcc1-10ea-42cc-a6ec-b0df8e93969f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueatVestingDateMember_625c8695-0757-446b-a59b-365d17c2c85b" xlink:href="gild-20211231.xsd#gild_FairValueatVestingDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_TotalGrantDateFairValueDomain_1678cfba-ecfb-4c4c-90f7-71258291b445" xlink:to="loc_gild_FairValueatVestingDateMember_625c8695-0757-446b-a59b-365d17c2c85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_36b034b0-d63f-4910-b2ab-6c9961220b54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_36b034b0-d63f-4910-b2ab-6c9961220b54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_36b034b0-d63f-4910-b2ab-6c9961220b54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_36b034b0-d63f-4910-b2ab-6c9961220b54" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_36b034b0-d63f-4910-b2ab-6c9961220b54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_394b77fc-b7cd-4f76-b982-2d09ee060b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_36b034b0-d63f-4910-b2ab-6c9961220b54" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_394b77fc-b7cd-4f76-b982-2d09ee060b47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_851524b6-cc42-449c-ab90-633ee86ff55f" xlink:href="gild-20211231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_394b77fc-b7cd-4f76-b982-2d09ee060b47" xlink:to="loc_gild_DeferredCompensationPlanMember_851524b6-cc42-449c-ab90-633ee86ff55f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a46f327b-6000-42c1-beb4-c5064fa8612d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a46f327b-6000-42c1-beb4-c5064fa8612d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a46f327b-6000-42c1-beb4-c5064fa8612d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a46f327b-6000-42c1-beb4-c5064fa8612d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a46f327b-6000-42c1-beb4-c5064fa8612d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c948ec9-1739-46f7-80ec-a032660ad15e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a46f327b-6000-42c1-beb4-c5064fa8612d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c948ec9-1739-46f7-80ec-a032660ad15e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9777444c-2e39-422f-a93b-8ff1fa971dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c948ec9-1739-46f7-80ec-a032660ad15e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9777444c-2e39-422f-a93b-8ff1fa971dc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3ce8bd2c-e622-431b-9869-90aab15c7862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_AwardTypeAxis_3ce8bd2c-e622-431b-9869-90aab15c7862" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ce8bd2c-e622-431b-9869-90aab15c7862_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3ce8bd2c-e622-431b-9869-90aab15c7862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ce8bd2c-e622-431b-9869-90aab15c7862_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3ce8bd2c-e622-431b-9869-90aab15c7862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d02c0f39-bee9-4614-9313-ce411a247079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d02c0f39-bee9-4614-9313-ce411a247079" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6c485832-3b7b-4f28-a20a-896ea5963f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6c485832-3b7b-4f28-a20a-896ea5963f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a24a940e-fec8-4552-873b-dccae2f7df61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:to="loc_us-gaap_PerformanceSharesMember_a24a940e-fec8-4552-873b-dccae2f7df61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RestrictedStockandPerformanceShareAwardsMember_34e1c3b5-7d0c-4f45-ae43-ee8822376396" xlink:href="gild-20211231.xsd#gild_RestrictedStockandPerformanceShareAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:to="loc_gild_RestrictedStockandPerformanceShareAwardsMember_34e1c3b5-7d0c-4f45-ae43-ee8822376396" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ecc7ef4c-de57-4751-bc3a-5f5edbb2af27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:to="loc_us-gaap_EmployeeStockMember_ecc7ef4c-de57-4751-bc3a-5f5edbb2af27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c465520-715e-4621-8c1c-80bb9fc2eccf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_srt_RangeAxis_7c465520-715e-4621-8c1c-80bb9fc2eccf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c465520-715e-4621-8c1c-80bb9fc2eccf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7c465520-715e-4621-8c1c-80bb9fc2eccf" xlink:to="loc_srt_RangeMember_7c465520-715e-4621-8c1c-80bb9fc2eccf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9acf32a3-febc-4a18-b5e9-e563ea41d646" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7c465520-715e-4621-8c1c-80bb9fc2eccf" xlink:to="loc_srt_RangeMember_9acf32a3-febc-4a18-b5e9-e563ea41d646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f4d7091e-1f90-40e0-acbe-37700ace2123" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9acf32a3-febc-4a18-b5e9-e563ea41d646" xlink:to="loc_srt_MinimumMember_f4d7091e-1f90-40e0-acbe-37700ace2123" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019f43c7-73c7-40d4-9623-1c98a962b894" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9acf32a3-febc-4a18-b5e9-e563ea41d646" xlink:to="loc_srt_MaximumMember_019f43c7-73c7-40d4-9623-1c98a962b894" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_69f2dba4-3d00-42b2-aabf-1e7b26c47857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_PlanNameAxis_69f2dba4-3d00-42b2-aabf-1e7b26c47857" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_69f2dba4-3d00-42b2-aabf-1e7b26c47857_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_69f2dba4-3d00-42b2-aabf-1e7b26c47857" xlink:to="loc_us-gaap_PlanNameDomain_69f2dba4-3d00-42b2-aabf-1e7b26c47857_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_17bb28cd-e2d1-4b2d-9470-c04f1d2c0590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_69f2dba4-3d00-42b2-aabf-1e7b26c47857" xlink:to="loc_us-gaap_PlanNameDomain_17bb28cd-e2d1-4b2d-9470-c04f1d2c0590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2004EquityIncentivePlanMember_40dd0aa0-2983-48b5-bc09-3fa1fbb5be77" xlink:href="gild-20211231.xsd#gild_GileadSciencesInc2004EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_17bb28cd-e2d1-4b2d-9470-c04f1d2c0590" xlink:to="loc_gild_GileadSciencesInc2004EquityIncentivePlanMember_40dd0aa0-2983-48b5-bc09-3fa1fbb5be77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2018EquityIncentivePlanMember_772e638f-487b-4b73-b5be-48e3927f5164" xlink:href="gild-20211231.xsd#gild_GileadSciencesInc2018EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_17bb28cd-e2d1-4b2d-9470-c04f1d2c0590" xlink:to="loc_gild_GileadSciencesInc2018EquityIncentivePlanMember_772e638f-487b-4b73-b5be-48e3927f5164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_ea717ea2-9c7a-4d76-b8df-c1baab78ef55" xlink:href="gild-20211231.xsd#gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_17bb28cd-e2d1-4b2d-9470-c04f1d2c0590" xlink:to="loc_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_ea717ea2-9c7a-4d76-b8df-c1baab78ef55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fffb5ed8-6a71-4b24-9dfc-2bb80819f675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fffb5ed8-6a71-4b24-9dfc-2bb80819f675" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fffb5ed8-6a71-4b24-9dfc-2bb80819f675_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fffb5ed8-6a71-4b24-9dfc-2bb80819f675" xlink:to="loc_us-gaap_ClassOfStockDomain_fffb5ed8-6a71-4b24-9dfc-2bb80819f675_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0546a7c3-d432-405b-9dcf-ec2f046fc4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fffb5ed8-6a71-4b24-9dfc-2bb80819f675" xlink:to="loc_us-gaap_ClassOfStockDomain_0546a7c3-d432-405b-9dcf-ec2f046fc4fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_55516d9a-29ca-446f-a300-2b4a39fbe881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0546a7c3-d432-405b-9dcf-ec2f046fc4fd" xlink:to="loc_us-gaap_CommonStockMember_55516d9a-29ca-446f-a300-2b4a39fbe881" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_25b51fd8-a476-4b0b-a148-d9edf8be5914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_25b51fd8-a476-4b0b-a148-d9edf8be5914" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_25b51fd8-a476-4b0b-a148-d9edf8be5914_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_25b51fd8-a476-4b0b-a148-d9edf8be5914" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_25b51fd8-a476-4b0b-a148-d9edf8be5914_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8592f4d6-042b-4c4a-9ee9-e3d99d8b61a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_25b51fd8-a476-4b0b-a148-d9edf8be5914" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8592f4d6-042b-4c4a-9ee9-e3d99d8b61a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d14ab2dc-0256-4b5b-82a5-c082d66f6cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8592f4d6-042b-4c4a-9ee9-e3d99d8b61a0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d14ab2dc-0256-4b5b-82a5-c082d66f6cea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_87c6a384-a16c-41ef-973e-e434f9702703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d14ab2dc-0256-4b5b-82a5-c082d66f6cea" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_87c6a384-a16c-41ef-973e-e434f9702703" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefitsStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="extended" id="ie392ea2402924017a4b800d59e4c9af6_EmployeeBenefitsStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_617a4105-c3b3-4081-bb80-7dd1ccd2ac40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_617a4105-c3b3-4081-bb80-7dd1ccd2ac40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3cc74ee0-7a8e-4b07-bc0b-e2a20d944507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3cc74ee0-7a8e-4b07-bc0b-e2a20d944507" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1bf2c4f6-e833-403b-9465-b3b7700a6042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1bf2c4f6-e833-403b-9465-b3b7700a6042" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9413e618-0b9c-45d8-8512-8fb62281a166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9413e618-0b9c-45d8-8512-8fb62281a166" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_70a84405-ffcb-409e-ab43-faaa73dd500d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_70a84405-ffcb-409e-ab43-faaa73dd500d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_462a0176-7c40-414f-bb96-201053367bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b5ecfcee-dbe4-4f58-b32c-3eb33c09e43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b5ecfcee-dbe4-4f58-b32c-3eb33c09e43c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e41ea7e8-c472-4d0f-9712-2e9af5bead0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e41ea7e8-c472-4d0f-9712-2e9af5bead0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:href="gild-20211231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be958ec7-270b-41c8-890a-ca8b600da8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be958ec7-270b-41c8-890a-ca8b600da8ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20848b4d-a03c-4bd2-a4b4-7fbdb80d8e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20848b4d-a03c-4bd2-a4b4-7fbdb80d8e76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cf5a4998-fc58-4e5d-aa34-372c60334594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cf5a4998-fc58-4e5d-aa34-372c60334594" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_94015f30-cad6-4199-9490-971994e23cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_94015f30-cad6-4199-9490-971994e23cc2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6a58ae2e-3bb4-496f-a00a-be6c03c40804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6a58ae2e-3bb4-496f-a00a-be6c03c40804" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95fe14d7-5ea0-4c53-86a8-a787db4852b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5713f264-9c03-4ccd-bb02-00e145f151a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5713f264-9c03-4ccd-bb02-00e145f151a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_51c9000f-2836-4caf-810b-4da157dfcf64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_51c9000f-2836-4caf-810b-4da157dfcf64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e24c02d6-50e2-4751-8b0e-e45adddf8ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e24c02d6-50e2-4751-8b0e-e45adddf8ece" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_91cc94e3-dd17-4863-8423-f7f3a5530bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e24c02d6-50e2-4751-8b0e-e45adddf8ece" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_91cc94e3-dd17-4863-8423-f7f3a5530bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21bff5c9-ed6b-4f3e-a220-5a6c82b9cf79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e24c02d6-50e2-4751-8b0e-e45adddf8ece" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21bff5c9-ed6b-4f3e-a220-5a6c82b9cf79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7158f921-b5b2-48d0-9f8f-43f85b1c0108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e24c02d6-50e2-4751-8b0e-e45adddf8ece" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7158f921-b5b2-48d0-9f8f-43f85b1c0108" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_0518ede9-6fb1-4420-a23a-b6cb8deafe32" xlink:href="gild-20211231.xsd#gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_0518ede9-6fb1-4420-a23a-b6cb8deafe32" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2a4afa35-9987-41a5-a79c-c63738adf61c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_0518ede9-6fb1-4420-a23a-b6cb8deafe32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2a4afa35-9987-41a5-a79c-c63738adf61c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7b052e42-dd63-49fc-9951-a8b104fd368c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_0518ede9-6fb1-4420-a23a-b6cb8deafe32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7b052e42-dd63-49fc-9951-a8b104fd368c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4615cc75-5e6f-4238-a833-4c96eb48d4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_0518ede9-6fb1-4420-a23a-b6cb8deafe32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4615cc75-5e6f-4238-a833-4c96eb48d4cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0849a864-5686-4307-a2c3-04ee83af05e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0849a864-5686-4307-a2c3-04ee83af05e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a1f37ea7-797f-406e-889a-9a3aec409f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0849a864-5686-4307-a2c3-04ee83af05e6" xlink:to="loc_us-gaap_AwardTypeAxis_a1f37ea7-797f-406e-889a-9a3aec409f04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1f37ea7-797f-406e-889a-9a3aec409f04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a1f37ea7-797f-406e-889a-9a3aec409f04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1f37ea7-797f-406e-889a-9a3aec409f04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13c96ae3-8359-47b8-9c0e-4e3e9d3df6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a1f37ea7-797f-406e-889a-9a3aec409f04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13c96ae3-8359-47b8-9c0e-4e3e9d3df6a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1325f4ca-37b8-44b9-ab9c-db45e58e6e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13c96ae3-8359-47b8-9c0e-4e3e9d3df6a0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1325f4ca-37b8-44b9-ab9c-db45e58e6e72" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails" xlink:type="extended" id="i1c14655b09d74a39a976e36d2e46f38b_EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e64cc8a-5853-43dd-873b-5097b09766ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e64cc8a-5853-43dd-873b-5097b09766ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40f7bdc0-7303-40da-b41e-8357dcfb2b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40f7bdc0-7303-40da-b41e-8357dcfb2b4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0e0cfccd-35d8-49be-b5f0-78bb9c30f152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0e0cfccd-35d8-49be-b5f0-78bb9c30f152" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e0f3e983-833c-41c9-9b45-f80a2da54620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e0f3e983-833c-41c9-9b45-f80a2da54620" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5d1acbce-fbcd-4566-9f92-6de897d56275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5d1acbce-fbcd-4566-9f92-6de897d56275" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5dcf121-509c-4f40-aa29-5dc3779ba634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:href="gild-20211231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e64cc8a-5853-43dd-873b-5097b09766ed" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fed18151-ece5-49d7-80f9-d44da9980ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fed18151-ece5-49d7-80f9-d44da9980ab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78451bcf-287f-4451-97c1-2c8dcd17bb74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78451bcf-287f-4451-97c1-2c8dcd17bb74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_72998906-a2c0-43d6-89c2-76720e0c307f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_72998906-a2c0-43d6-89c2-76720e0c307f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9cdf4698-7664-42ce-b228-08bafc7a7262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9cdf4698-7664-42ce-b228-08bafc7a7262" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08ee6f26-f3c9-45e3-a5b5-cf99bfbbbdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4140dc13-de0e-4ba8-8683-8348d1cfcbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e64cc8a-5853-43dd-873b-5097b09766ed" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4140dc13-de0e-4ba8-8683-8348d1cfcbe4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_24b8a9b0-5498-43bf-acdd-64859da46887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4140dc13-de0e-4ba8-8683-8348d1cfcbe4" xlink:to="loc_us-gaap_AwardTypeAxis_24b8a9b0-5498-43bf-acdd-64859da46887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24b8a9b0-5498-43bf-acdd-64859da46887_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_24b8a9b0-5498-43bf-acdd-64859da46887" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24b8a9b0-5498-43bf-acdd-64859da46887_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf2431b4-d632-4323-b156-415cb192b24e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_24b8a9b0-5498-43bf-acdd-64859da46887" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf2431b4-d632-4323-b156-415cb192b24e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_53e19828-098c-4188-9454-bbee0e1c24e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf2431b4-d632-4323-b156-415cb192b24e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_53e19828-098c-4188-9454-bbee0e1c24e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f4fb3898-b77e-40f8-a9f9-af55cb752f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf2431b4-d632-4323-b156-415cb192b24e" xlink:to="loc_us-gaap_PerformanceSharesMember_f4fb3898-b77e-40f8-a9f9-af55cb752f3c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefitsSummaryofStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="extended" id="ia622cefc9bf448718d8c13d43503f524_EmployeeBenefitsSummaryofStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_75f6d50c-66bf-47d2-b350-f9226095b8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_75f6d50c-66bf-47d2-b350-f9226095b8c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ecfbd12c-d81d-4419-b7e1-73e3275d8f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ecfbd12c-d81d-4419-b7e1-73e3275d8f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a5bc77ac-f385-46fc-8b7c-cbe19197ad20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a5bc77ac-f385-46fc-8b7c-cbe19197ad20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4db7906c-5894-407d-8aa2-b2e0ea3ae35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_ShareBasedCompensation_4db7906c-5894-407d-8aa2-b2e0ea3ae35a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c7e61b10-1e5e-4d6b-8511-954e1804c4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c7e61b10-1e5e-4d6b-8511-954e1804c4c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_c13ebcf6-e690-414e-a315-bf310a6a7e45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_c13ebcf6-e690-414e-a315-bf310a6a7e45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a0d3eca5-2167-446c-b5ad-d85c668788ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a0d3eca5-2167-446c-b5ad-d85c668788ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b1c0c4ef-7653-496a-8525-0e8f2e0f4994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a0d3eca5-2167-446c-b5ad-d85c668788ec" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b1c0c4ef-7653-496a-8525-0e8f2e0f4994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b1c0c4ef-7653-496a-8525-0e8f2e0f4994_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b1c0c4ef-7653-496a-8525-0e8f2e0f4994" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b1c0c4ef-7653-496a-8525-0e8f2e0f4994_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4612e89f-3824-4cf1-aa17-2041a115f46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b1c0c4ef-7653-496a-8525-0e8f2e0f4994" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4612e89f-3824-4cf1-aa17-2041a115f46e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_e09c20a2-8835-4c23-b558-6521bfa660db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4612e89f-3824-4cf1-aa17-2041a115f46e" xlink:to="loc_us-gaap_CostOfSalesMember_e09c20a2-8835-4c23-b558-6521bfa660db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8ba5238c-5486-43d0-9614-f64d39e867ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4612e89f-3824-4cf1-aa17-2041a115f46e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8ba5238c-5486-43d0-9614-f64d39e867ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a8f11fd7-6a30-49b5-a099-b025e7d0c726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4612e89f-3824-4cf1-aa17-2041a115f46e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a8f11fd7-6a30-49b5-a099-b025e7d0c726" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c483a2a1-e3aa-478f-b1d7-c4abd0da6594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a0d3eca5-2167-446c-b5ad-d85c668788ec" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c483a2a1-e3aa-478f-b1d7-c4abd0da6594" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c483a2a1-e3aa-478f-b1d7-c4abd0da6594_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c483a2a1-e3aa-478f-b1d7-c4abd0da6594" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c483a2a1-e3aa-478f-b1d7-c4abd0da6594_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c7aa111f-8546-4ac5-8871-e1cd9d76ca1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c483a2a1-e3aa-478f-b1d7-c4abd0da6594" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c7aa111f-8546-4ac5-8871-e1cd9d76ca1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_1c5b977f-5895-41ef-9d75-49b06137f5ca" xlink:href="gild-20211231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c7aa111f-8546-4ac5-8871-e1cd9d76ca1a" xlink:to="loc_gild_ImmunomedicsIncMember_1c5b977f-5895-41ef-9d75-49b06137f5ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_8fc6becf-c229-4923-b763-3b7f72c0a72c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a0d3eca5-2167-446c-b5ad-d85c668788ec" xlink:to="loc_us-gaap_AssetAcquisitionAxis_8fc6becf-c229-4923-b763-3b7f72c0a72c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_8fc6becf-c229-4923-b763-3b7f72c0a72c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_8fc6becf-c229-4923-b763-3b7f72c0a72c" xlink:to="loc_us-gaap_AssetAcquisitionDomain_8fc6becf-c229-4923-b763-3b7f72c0a72c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_21d501a5-81f7-43bc-9608-9916b86c6219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_8fc6becf-c229-4923-b763-3b7f72c0a72c" xlink:to="loc_us-gaap_AssetAcquisitionDomain_21d501a5-81f7-43bc-9608-9916b86c6219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_6e214cfd-a38b-4f59-ae33-3b8f1074b297" xlink:href="gild-20211231.xsd#gild_FortySevenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_21d501a5-81f7-43bc-9608-9916b86c6219" xlink:to="loc_gild_FortySevenIncMember_6e214cfd-a38b-4f59-ae33-3b8f1074b297" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="extended" id="if0c6ad4785c240dd847910fc086f3fff_EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d119baaa-06ff-4a21-a6fc-538b955ca59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6ee86b2b-ccf3-4105-9985-9019c3a3b61c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d119baaa-06ff-4a21-a6fc-538b955ca59a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6ee86b2b-ccf3-4105-9985-9019c3a3b61c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1ab3f10-d6f5-42de-a382-9eea6e1b6e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d119baaa-06ff-4a21-a6fc-538b955ca59a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1ab3f10-d6f5-42de-a382-9eea6e1b6e75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_68114e9e-0249-4717-95ff-a2d28bd4ade2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d119baaa-06ff-4a21-a6fc-538b955ca59a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_68114e9e-0249-4717-95ff-a2d28bd4ade2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ef5c677-2840-40ba-8b38-4c7981eff8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d119baaa-06ff-4a21-a6fc-538b955ca59a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ef5c677-2840-40ba-8b38-4c7981eff8bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5cbc603-4b6b-4143-9537-e2ddfd103e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d119baaa-06ff-4a21-a6fc-538b955ca59a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5cbc603-4b6b-4143-9537-e2ddfd103e73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8e5e2ace-5c06-4771-83a8-ab1eb2712d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5cbc603-4b6b-4143-9537-e2ddfd103e73" xlink:to="loc_us-gaap_AwardTypeAxis_8e5e2ace-5c06-4771-83a8-ab1eb2712d0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5e2ace-5c06-4771-83a8-ab1eb2712d0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8e5e2ace-5c06-4771-83a8-ab1eb2712d0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e5e2ace-5c06-4771-83a8-ab1eb2712d0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe80bfe5-1fb1-4e1d-8e8c-3c7627000453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8e5e2ace-5c06-4771-83a8-ab1eb2712d0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe80bfe5-1fb1-4e1d-8e8c-3c7627000453" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5711cc9-345d-48c3-9f7f-51057487420f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe80bfe5-1fb1-4e1d-8e8c-3c7627000453" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5711cc9-345d-48c3-9f7f-51057487420f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4bd5ac54-d445-46f5-85d2-ee7a032ced4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe80bfe5-1fb1-4e1d-8e8c-3c7627000453" xlink:to="loc_us-gaap_EmployeeStockMember_4bd5ac54-d445-46f5-85d2-ee7a032ced4a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i824a260a547b4721bd3358ef39294d08_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0a297f49-e7db-4ad9-9808-4a4d1f65d1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0a297f49-e7db-4ad9-9808-4a4d1f65d1a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4a7ac762-8458-4d0f-bdfc-8ac8b02d7c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4a7ac762-8458-4d0f-bdfc-8ac8b02d7c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_52b5048e-a55c-49c4-bdff-df24ef3e3125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_52b5048e-a55c-49c4-bdff-df24ef3e3125" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_aeb28c55-c943-49aa-9afa-9f4c7a825a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_aeb28c55-c943-49aa-9afa-9f4c7a825a37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_84d68984-e367-4599-8fe9-9a115cecd243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_84d68984-e367-4599-8fe9-9a115cecd243" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_92b2e686-eb15-4750-982e-6aba3f4f7df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_92b2e686-eb15-4750-982e-6aba3f4f7df5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_dc9073ec-2cd9-4dda-9bd4-559c2b18ac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_dc9073ec-2cd9-4dda-9bd4-559c2b18ac8a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_5eb22eab-bc82-4dbe-b5e6-27620ca09138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_5eb22eab-bc82-4dbe-b5e6-27620ca09138" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_92848938-ebe4-4b7a-bcf7-c4e5023061f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_92848938-ebe4-4b7a-bcf7-c4e5023061f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_4077f62b-8f44-4823-bf30-0103b81c6bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_4077f62b-8f44-4823-bf30-0103b81c6bb7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_d57b3fce-e513-40af-a96d-25272f2093e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_d57b3fce-e513-40af-a96d-25272f2093e9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_44179258-169c-4e71-a750-069516e4a800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_44179258-169c-4e71-a750-069516e4a800" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_e4bef188-970c-42a2-b822-bb84390160a2" xlink:href="gild-20211231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_44179258-169c-4e71-a750-069516e4a800" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_e4bef188-970c-42a2-b822-bb84390160a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_e4bef188-970c-42a2-b822-bb84390160a2_default" xlink:href="gild-20211231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_e4bef188-970c-42a2-b822-bb84390160a2" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_e4bef188-970c-42a2-b822-bb84390160a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_5a413c71-7a5e-40cc-84d1-945a71050d05" xlink:href="gild-20211231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_e4bef188-970c-42a2-b822-bb84390160a2" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_5a413c71-7a5e-40cc-84d1-945a71050d05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetTransferMember_4af77d59-e096-408b-ae22-cdceb3cf57d7" xlink:href="gild-20211231.xsd#gild_IntangibleAssetTransferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_5a413c71-7a5e-40cc-84d1-945a71050d05" xlink:to="loc_gild_IntangibleAssetTransferMember_4af77d59-e096-408b-ae22-cdceb3cf57d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_32947952-126b-4e3f-9f69-5fde3c6fe157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_44179258-169c-4e71-a750-069516e4a800" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_32947952-126b-4e3f-9f69-5fde3c6fe157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_32947952-126b-4e3f-9f69-5fde3c6fe157_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_32947952-126b-4e3f-9f69-5fde3c6fe157" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_32947952-126b-4e3f-9f69-5fde3c6fe157_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_259239b8-4929-4dd6-b67b-416f02f3e805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_32947952-126b-4e3f-9f69-5fde3c6fe157" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_259239b8-4929-4dd6-b67b-416f02f3e805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_aaaf6551-ed76-4c5a-bb83-de0ab545cfca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_259239b8-4929-4dd6-b67b-416f02f3e805" xlink:to="loc_us-gaap_DomesticCountryMember_aaaf6551-ed76-4c5a-bb83-de0ab545cfca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f8ec6128-2b36-468c-b31a-ce4f7159c581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_259239b8-4929-4dd6-b67b-416f02f3e805" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f8ec6128-2b36-468c-b31a-ce4f7159c581" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>gild-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4eb1680c-5761-45c7-95ef-3c78b834062a,g:a0cedc55-fc60-4d3f-bea8-ef196ffaa864-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_gild_ScheduleofInventoryLineItems_a777c33b-8edd-47d9-8b94-3eec30b58a48_terseLabel_en-US" xlink:label="lab_gild_ScheduleofInventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Line Items]</link:label>
    <link:label id="lab_gild_ScheduleofInventoryLineItems_label_en-US" xlink:label="lab_gild_ScheduleofInventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Line Items]</link:label>
    <link:label id="lab_gild_ScheduleofInventoryLineItems_documentation_en-US" xlink:label="lab_gild_ScheduleofInventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Disclosure of information about inventory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryLineItems" xlink:href="gild-20211231.xsd#gild_ScheduleofInventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ScheduleofInventoryLineItems" xlink:to="lab_gild_ScheduleofInventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_be743599-5b57-4218-b60c-daee4c12f89b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_2f7f62ee-a6e2-4a3d-a98e-b5e5113e14b2_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_08db975a-6bbf-4ee4-82ff-da7875808cfe_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_6ca8eeab-cd12-44cf-bbde-34feeebe1649_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed, scenario two</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_label_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_documentation_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:href="gild-20211231.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:to="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_18806d0c-79ff-4700-9b2a-89d841c10396_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70801fea-7dd0-430c-92dd-d5c55864762b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_7c166eba-7ade-41cd-a5cc-610b557abe24_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_4cc799fc-f858-4b3b-a412-a6be75eee049_terseLabel_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Running royalty rate on future sales</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_label_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate on Future Sales</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_documentation_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate on Future Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales" xlink:href="gild-20211231.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentRoyaltyRateOnFutureSales" xlink:to="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a8a51818-1aed-4c5c-acc6-33d1f23f1556_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_7ef78cd4-8b4e-45e0-8d01-8988e6ebcf88_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_2b3ba6a8-2f3d-4e79-9a7f-67fbc1e8fe68_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_4e2da35c-da24-4481-a4b5-ec01b0a1543a_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_14071abc-8313-4223-903a-dcace96d89a8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_aea532c7-74b4-4dde-8f12-fd8350113e46_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_c2ce0e7c-c1a0-4f75-8092-f447469b8678_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_18511f13-1e6f-4660-9559-460b65da4d0b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4c64ea9d-d225-46eb-a24b-7af2da16654c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_3cf8473e-cc7e-4f06-8c30-a974ef701f13_terseLabel_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:href="gild-20211231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:to="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2714c60e-d007-4b76-a089-dd7b0fd941a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_c0e8e3cf-451d-479f-af7b-80421e2902ec_terseLabel_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 stock repurchase program</link:label>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_label_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember" xlink:href="gild-20211231.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A2020StockRepurchaseProgramMember" xlink:to="lab_gild_A2020StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_803b9bf6-96d4-4d57-9d4a-5ae76e8fa86b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a0fa973d-3cbc-4b99-956e-81836b30f282_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_2f1e40a9-5763-4796-b5b0-5bda5b121bc4_terseLabel_en-US" xlink:label="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties, measurement Input</link:label>
    <link:label id="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_label_en-US" xlink:label="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Future Royalties, Liability, Measurement Input</link:label>
    <link:label id="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Future Royalties, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:href="gild-20211231.xsd#gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:to="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsYescartaMember_23cc613d-6322-4f5b-ac45-5d9ba8d8bd09_terseLabel_en-US" xlink:label="lab_gild_OtherProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yescarta</link:label>
    <link:label id="lab_gild_OtherProductsYescartaMember_label_en-US" xlink:label="lab_gild_OtherProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Yescarta [Member]</link:label>
    <link:label id="lab_gild_OtherProductsYescartaMember_documentation_en-US" xlink:label="lab_gild_OtherProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Yescarta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsYescartaMember" xlink:href="gild-20211231.xsd#gild_OtherProductsYescartaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsYescartaMember" xlink:to="lab_gild_OtherProductsYescartaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_6f75a890-2c71-4ef4-8456-f6810748451b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued repatriation of foreign earnings</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_KitePharmaIncMember_1024fe4a-1007-4cff-ad4a-838b7a8ed019_terseLabel_en-US" xlink:label="lab_gild_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma, Inc.</link:label>
    <link:label id="lab_gild_KitePharmaIncMember_label_en-US" xlink:label="lab_gild_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma, Inc. [Member]</link:label>
    <link:label id="lab_gild_KitePharmaIncMember_documentation_en-US" xlink:label="lab_gild_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_KitePharmaIncMember" xlink:href="gild-20211231.xsd#gild_KitePharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_KitePharmaIncMember" xlink:to="lab_gild_KitePharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fd5b497-3530-40aa-a9d8-106dfcfb6f3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d3719de0-4468-4732-8f87-453c2a4b2ae9_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_72a2904f-cffb-4c6e-8d98-2e432c705943_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_05f1a6c4-ea52-4580-aeed-a88ab52523b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InjectableFormulationProductMember_777dc42c-7bd0-4f6d-a13d-dedb59b17f31_terseLabel_en-US" xlink:label="lab_gild_InjectableFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation Product</link:label>
    <link:label id="lab_gild_InjectableFormulationProductMember_label_en-US" xlink:label="lab_gild_InjectableFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation Product [Member]</link:label>
    <link:label id="lab_gild_InjectableFormulationProductMember_documentation_en-US" xlink:label="lab_gild_InjectableFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InjectableFormulationProductMember" xlink:href="gild-20211231.xsd#gild_InjectableFormulationProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InjectableFormulationProductMember" xlink:to="lab_gild_InjectableFormulationProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_292a324c-5f2e-4feb-ba02-56988aadde13_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_09f114a2-26ea-43a4-afc5-beaa42fcf566_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility:</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d32b38ba-b1de-4adc-99f6-48ec54b2e113_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_fa182ded-775e-43a1-85c3-e0470adbbfa4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of book basis over tax basis of intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_66a8b23a-80d3-46c8-b32c-4e6d04c55006_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_773f034b-abdb-4d1c-a795-31fbb98a5363_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_02cabebe-d2a3-4b58-ac0a-9f210ccb8c74_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_ad7b546d-8376-439c-935f-94de521a7e94_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_b109f507-4444-4e87-8875-7d94b132d5e4_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_125b52bd-b94b-4913-926b-60015ab8baf9_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_bac6cffc-9d4a-4737-923a-47d49f57e73f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ae6460a3-f819-4fc7-a25f-e81d35ab7973_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b6590196-ad1b-470d-85cd-c3f4b5d933f8_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amortization expense related to finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_4f050735-52e8-4f5e-8214-1b99bd9fd50b_terseLabel_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus collaboration agreement and stock purchase agreements</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_label_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement and Stock Purchase Agreements [Member]</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_documentation_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement and Stock Purchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:href="gild-20211231.xsd#gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:to="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_92fed94a-3bf7-4fa1-a006-f6a14f5d866f_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of finite-lived intangible asset acquired</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c0ae4ef8-7504-414b-91f1-3257c87e9515_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_12ecb594-0321-4240-85ea-3d88d062f2be_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_694212ad-b44f-43df-9cb7-92a350dad906_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Collateral Received/Pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Obligation to Return Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c3d152d5-6ace-4bf7-806c-dcdc9c4469c9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_286ce54f-d0a0-454d-86bf-49fb9dd35f93_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ed873eee-392c-43da-a619-aa6d8b59b23d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_090a2c06-8e99-4972-9222-deeaf86d65a3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d34ea5f4-63c1-4078-91e2-e5ddd7382436_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_8f4716bd-ed9b-4ab7-b456-12eb47789478_terseLabel_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmBisome</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_label_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_documentation_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember" xlink:href="gild-20211231.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsAmBisomeMember" xlink:to="lab_gild_OtherProductsAmBisomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_45f385df-4da8-4de1-9937-ee2a5153aa82_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_cb3fee46-d3d4-4db2-8f36-2dd5099a555b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_6371b03b-29a3-4d8b-9963-4c598eaaa24a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_c91d0ca7-2f40-4ef5-82fb-f787e9816ce2_terseLabel_en-US" xlink:label="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in millions)</link:label>
    <link:label id="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_label_en-US" xlink:label="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:href="gild-20211231.xsd#gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_cbc73711-60b8-43ac-af25-4f84fa72b274_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24aeb348-d439-490a-83fe-b6c96a3f4f08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5af06627-2d8e-4234-b6a1-5a6cb1c4b3a2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_d5be4085-fd85-4685-af1b-697146768d1d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt Securities at Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_ca874c43-4d24-424d-9437-47d35e6c1fa4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_e223f0c3-6e46-4bd5-b222-dfe6cfd792be_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d4ff982e-f81a-47fd-a302-83ad47b61461_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_20ecd48b-8dc9-446d-83f2-64653b88691b_terseLabel_en-US" xlink:label="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit) Component [Domain]</link:label>
    <link:label id="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_label_en-US" xlink:label="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit) Component [Domain]</link:label>
    <link:label id="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_documentation_en-US" xlink:label="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Deferred Income Tax Expense (Benefit) Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain" xlink:href="gild-20211231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain" xlink:to="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_53756f21-fcb8-492c-8da2-2ca6c10c61e1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeArrangementTerm_2a536985-11ae-42a7-b61c-d1b7818a0899_terseLabel_en-US" xlink:label="lab_gild_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration term</link:label>
    <link:label id="lab_gild_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_gild_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_gild_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_gild_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeArrangementTerm" xlink:href="gild-20211231.xsd#gild_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeArrangementTerm" xlink:to="lab_gild_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_f9cbb338-33e3-4f71-82ea-0de6189549d8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_4b4f6a5d-4d16-4c64-9433-93e630c52b8f_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits that is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0b2bec0c-5426-466f-bee2-70ead59b3d04_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_9268f023-af9d-4c1f-8361-9b63da759b76_terseLabel_en-US" xlink:label="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions to Calculate the Estimated Fair Value of Awards</link:label>
    <link:label id="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options and Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and ESPP, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="gild-20211231.xsd#gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_e079c2a4-75f7-4923-b4fc-db2d73d2387d_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MckessonCorpMember_03eb0d15-e24d-4203-a362-8164401088c3_terseLabel_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_gild_MckessonCorpMember_label_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:label id="lab_gild_MckessonCorpMember_documentation_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember" xlink:href="gild-20211231.xsd#gild_MckessonCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MckessonCorpMember" xlink:to="lab_gild_MckessonCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_6a4ba0d8-ce07-46c8-b30b-ebe62dcc65db_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5c873a61-a4e8-4623-b397-77ce2ce114d0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_20852006-9265-4625-bd67-ddd5ca0d7d9c_terseLabel_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of tiered royalties, high-end percentage</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_label_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalties High-end, Percentage</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_documentation_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalties High-end, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:href="gild-20211231.xsd#gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:to="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_38d68b4b-3aa6-485f-81d2-b078be986730_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: chargebacks</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent" xlink:href="gild-20211231.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableChargebacksCurrent" xlink:to="lab_gild_AccountsReceivableChargebacksCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_5c092c0b-4cb7-4d39-8ae8-4638f124445c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares (in millions)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember_c4a9b279-cf92-459d-a410-3b504ddc8679_terseLabel_en-US" xlink:label="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember_label_en-US" xlink:label="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences, Inc. 2018 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences, Inc. 2018 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2018EquityIncentivePlanMember" xlink:href="gild-20211231.xsd#gild_GileadSciencesInc2018EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GileadSciencesInc2018EquityIncentivePlanMember" xlink:to="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a718278d-1e7c-44b6-8119-c9a5584975fe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_981ec1a6-c2cb-46e0-ba64-3722d34f5c43_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restriction period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restriction Period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:to="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e9611c8d-2e6e-46d8-8abe-c35022a1183f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ecf7f7b2-458e-4e16-8240-32da182f1662_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_6e059026-93db-442d-b6ff-5afc6035f190_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c6340883-7406-4be4-99ae-900b5544ae08_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_7352291d-e244-4748-b3bd-ae64f2456b47_terseLabel_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genvoya</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_label_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember" xlink:href="gild-20211231.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsGenvoyaMember" xlink:to="lab_gild_HIVProductsGenvoyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialOptionExerciseFeePerProgram_2d814894-642a-4166-bb51-343b24ca52ad_terseLabel_en-US" xlink:label="lab_gild_PotentialOptionExerciseFeePerProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential option exercise fee</link:label>
    <link:label id="lab_gild_PotentialOptionExerciseFeePerProgram_label_en-US" xlink:label="lab_gild_PotentialOptionExerciseFeePerProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Option Exercise Fee Per Program</link:label>
    <link:label id="lab_gild_PotentialOptionExerciseFeePerProgram_documentation_en-US" xlink:label="lab_gild_PotentialOptionExerciseFeePerProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Option Exercise Fee Per Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialOptionExerciseFeePerProgram" xlink:href="gild-20211231.xsd#gild_PotentialOptionExerciseFeePerProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialOptionExerciseFeePerProgram" xlink:to="lab_gild_PotentialOptionExerciseFeePerProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_13db793d-664e-4581-ac33-909fb354afcc_terseLabel_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for adjustments of budgeted development costs in 2022</link:label>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months</link:label>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_documentation_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:href="gild-20211231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:to="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6bd28ddc-5148-47b7-8afc-aa752fa45460_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_72e7f7bd-2878-447a-8241-35ad55325229_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to Gilead common stockholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_6eac7322-ad6b-4321-bac4-2a514c916399_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_101e50e3-3e40-4605-a419-256576990add_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2041Member_76cac6ed-44e2-4792-9efa-1d98df88dca8_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due in December 2041</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2041Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2041Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cabc76b3-ceeb-41a2-bd47-4a971aec6b15_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e5f59eec-0afc-4c90-abcb-cbea35f18ff3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1a173bd4-50b2-4f55-899b-bc7d8d1fdc06_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_a42bf766-0ad3-43a7-844f-60cd7e173379_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_cee34e9f-67c7-4597-b0b5-509bebaf88aa_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized&#160;Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_4fc05256-045f-418b-835a-961e3abc971b_terseLabel_en-US" xlink:label="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the "2020 Fixed Rate Notes"</link:label>
    <link:label id="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_label_en-US" xlink:label="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Rate Senior Unsecured Note Issued September 2020 [Member]</link:label>
    <link:label id="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_documentation_en-US" xlink:label="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Rate Senior Unsecured Note Issued September 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:href="gild-20211231.xsd#gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:to="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ScheduleofInventoryTable_4901c7a9-cdea-406b-838f-e3e020f46b51_terseLabel_en-US" xlink:label="lab_gild_ScheduleofInventoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Table]</link:label>
    <link:label id="lab_gild_ScheduleofInventoryTable_label_en-US" xlink:label="lab_gild_ScheduleofInventoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Table]</link:label>
    <link:label id="lab_gild_ScheduleofInventoryTable_documentation_en-US" xlink:label="lab_gild_ScheduleofInventoryTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about inventory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable" xlink:href="gild-20211231.xsd#gild_ScheduleofInventoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ScheduleofInventoryTable" xlink:to="lab_gild_ScheduleofInventoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_9fc144eb-70a4-414d-be46-fe5927c10533_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value step-up adjustment of inventories acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_518e6454-802b-4c8c-95f2-e4dde1d996ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_bd72a8c7-ab4b-495f-ba89-c28f93439b35_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect from the adoption of new accounting standard</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_c8fedb24-6707-465d-b4f5-bc4c650a1504_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_bfcadd2b-0678-40b2-8afc-e032f883e256_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_b7e626bc-be04-4580-a985-4d919183fb18_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_2aa3e993-bd33-485e-90e1-cbcf745cf25e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts of Recognized Assets/Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_a43f0303-3e40-4439-aecd-8e9485b040e9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_2973f37f-e04d-40c5-8883-756f086a4f16_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time estimate for gains (losses) to be reclassified from AOCI to product sales</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2234f5ee-2a49-40d2-9ab2-7a9068ee24e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_72b33620-41bb-46ff-9ac2-e3fc9db34f44_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments, year one</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_e9bc5423-84da-444f-8fd4-109e5907771f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_8504cd6f-fc1b-4d11-91b8-fc2154506eaf_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TrodelvyMember_17746f4f-d63a-44a8-9411-9fcb6cede860_terseLabel_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:label id="lab_gild_TrodelvyMember_afdfa2a0-e72a-46cf-a40b-1a45371455bf_verboseLabel_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - Trodelvy</link:label>
    <link:label id="lab_gild_TrodelvyMember_label_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy [Member]</link:label>
    <link:label id="lab_gild_TrodelvyMember_documentation_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember" xlink:href="gild-20211231.xsd#gild_TrodelvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TrodelvyMember" xlink:to="lab_gild_TrodelvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_6437acfb-f632-44ef-803b-2892de289620_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_7a557b5e-2dc0-4d2e-bd43-c0a12ecad694_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_36a286f6-2042-4a74-aaf8-89035626d474_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_4a1d7d88-e9e5-4435-9cfe-dc1837199087_terseLabel_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_label_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_documentation_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract" xlink:href="gild-20211231.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract" xlink:to="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_290eaa22-3eee-4dd9-aeef-d2524aebe315_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dd9b754b-f842-461e-9c62-eb135e7ecd40_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_24c4fee9-b707-4a9e-a3a0-381a58f44fbd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_963e77c9-b2d6-4801-8daa-f77f3dedd175_terseLabel_en-US" xlink:label="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential payment for adjustments of budgeted development costs</link:label>
    <link:label id="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_label_en-US" xlink:label="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Payment for Adjustments of Budgeted Development Costs</link:label>
    <link:label id="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_documentation_en-US" xlink:label="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Payment for Adjustments of Budgeted Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:href="gild-20211231.xsd#gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:to="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ff768078-749c-4630-99b2-cdf7848b174d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_7bb8a0ec-e7fa-4b5b-beae-522beb60b81a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6f61f66b-c3ad-4fcb-ba4a-ddbc13bfc7b5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0006385-461f-4c04-8015-f10ce0910e7f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_5ffd8047-9be7-4186-9b94-fb2aabc1acb1_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_f677bd06-9a6f-445a-afdf-f3077e08a458_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_e736468c-3d6b-4c9f-8a96-da4f5b75bf5f_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20211231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_b0077c3d-a061-4ab5-a046-02a385f8f1ea_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81b306b7-1926-4efc-8227-0666d3cd1cb0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_95ecf7d9-9d02-4400-b9d2-5e90f0d365c0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_29662e29-d9e2-4f1f-a06c-08b3daf5520c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member_770cef53-2367-416b-9147-70f706f32eac_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due in March 2027</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2027 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b15b283a-17b3-470f-a819-478e6455b005_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ab52e72a-ddbd-4d6b-94e1-74f8d8ba6f76_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_24587b0c-7fd3-440a-b030-b709ec1fb975_terseLabel_en-US" xlink:label="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid</link:label>
    <link:label id="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_label_en-US" xlink:label="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Consideration for Acquisition of Rights to Market and Distribute Certain Products in Japan</link:label>
    <link:label id="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_documentation_en-US" xlink:label="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial consideration for acquisition of rights to market and distribute certain products in Japan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" xlink:href="gild-20211231.xsd#gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" xlink:to="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2a15491c-1bb3-41b7-8daa-b6dafde8da1b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_a5fbfbe6-ca98-4cb4-94ac-693e705e5441_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_fad4b973-7987-4c56-a8d8-cba7e85b7ddd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherInternationalMember_2d67f7e7-3b84-4992-bec4-4999cacaf26a_terseLabel_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International</link:label>
    <link:label id="lab_gild_OtherInternationalMember_label_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:label id="lab_gild_OtherInternationalMember_documentation_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember" xlink:href="gild-20211231.xsd#gild_OtherInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherInternationalMember" xlink:to="lab_gild_OtherInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_9c05987f-2043-43f6-bc71-fdbc114177d0_terseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets (and liabilities), net</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_label_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_documentation_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:href="gild-20211231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:to="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_31a1991e-8039-414e-9473-07ed514042bb_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_40a6ecac-19d4-4914-b773-c4270fdfc683_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ae145eed-3f95-46d5-b573-21ae2f68f40c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_f4768221-3787-43c7-ad1b-eb4d5ab0f12b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Repurchases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_68c233d4-3e4b-4659-8325-69a96fe67a12_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2b97a04d-12fa-44f3-bb59-b90656f1310d_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_e5758fe9-85af-4087-9ff2-70ee477077e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_caa3e182-6e69-421a-919f-6caebc6239b6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPartiesFilingOppositionNumber_90226ce2-572c-42bd-9a3b-b4ce2ff18685_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parties filing opposition</link:label>
    <link:label id="lab_gild_LossContingencyPartiesFilingOppositionNumber_label_en-US" xlink:label="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Filing Opposition, Number</link:label>
    <link:label id="lab_gild_LossContingencyPartiesFilingOppositionNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Filing Opposition, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesFilingOppositionNumber" xlink:href="gild-20211231.xsd#gild_LossContingencyPartiesFilingOppositionNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPartiesFilingOppositionNumber" xlink:to="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_06743551-bf67-45cf-9097-f33aade4aacf_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_50755540-3f44-435d-8f0e-bae17a7a8e61_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TizonaMergerAndOptionAgreementsMember_d724f339-148b-4d63-b75d-be5228f6718a_terseLabel_en-US" xlink:label="lab_gild_TizonaMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona merger and option agreements</link:label>
    <link:label id="lab_gild_TizonaMergerAndOptionAgreementsMember_label_en-US" xlink:label="lab_gild_TizonaMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona Merger and Option Agreements [Member]</link:label>
    <link:label id="lab_gild_TizonaMergerAndOptionAgreementsMember_documentation_en-US" xlink:label="lab_gild_TizonaMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona Merger and Option Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaMergerAndOptionAgreementsMember" xlink:href="gild-20211231.xsd#gild_TizonaMergerAndOptionAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TizonaMergerAndOptionAgreementsMember" xlink:to="lab_gild_TizonaMergerAndOptionAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a5e21f65-9102-4845-80b9-c98856664409_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_d9876f06-9369-4aab-948b-8bf198774399_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tecartus</link:label>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Tecartus [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Tecartus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember" xlink:href="gild-20211231.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsTecartusMember" xlink:to="lab_gild_CellTherapyProductsTecartusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6bdf79c7-be1b-47e9-8d5c-a2f87d66527a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InventoryWritedownsforExcessRawMaterialsMember_0445dbdb-a607-44a2-aa68-404efcf77ad0_terseLabel_en-US" xlink:label="lab_gild_InventoryWritedownsforExcessRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-downs for Excess Raw Materials</link:label>
    <link:label id="lab_gild_InventoryWritedownsforExcessRawMaterialsMember_label_en-US" xlink:label="lab_gild_InventoryWritedownsforExcessRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-downs for Excess Raw Materials [Member]</link:label>
    <link:label id="lab_gild_InventoryWritedownsforExcessRawMaterialsMember_documentation_en-US" xlink:label="lab_gild_InventoryWritedownsforExcessRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-downs for Excess Raw Materials [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryWritedownsforExcessRawMaterialsMember" xlink:href="gild-20211231.xsd#gild_InventoryWritedownsforExcessRawMaterialsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InventoryWritedownsforExcessRawMaterialsMember" xlink:to="lab_gild_InventoryWritedownsforExcessRawMaterialsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50126f83-11b5-4939-a7d9-26e4e94b6df0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_ebecb00d-07e4-4b11-9876-52aa22ae61f9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7f12d745-a021-497b-b2ed-72f110f40ec9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and income tax penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_96f94b90-9d59-40d4-917e-3fec04789b19_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_29627a2f-6125-4f01-aa1d-65fcf8b44b19_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_da41ca40-3c36-4d32-9376-529de6695136_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_ec7a110d-495f-46f7-ba2b-91331ccb6286_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. government securities</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ab8514f5-2e81-40a7-917d-c8db63cc4d9e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_24ef2023-a16b-4b66-b250-c1c0da5cd902_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense following U.S. Court of Appeals decision</link:label>
    <link:label id="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_label_en-US" xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Adjustments, Settlements, and Unusual Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_506d2691-d1bc-462c-afcd-dddf319a8dbd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_497c5e53-40da-434d-9086-681d6b33ac33_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total discounted lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_e9f333cf-8f94-4c64-b6d5-648f23ff6c44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU and PSU Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d7181dfa-8177-4085-b79f-c7db5172f177_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2c3e49c7-22ae-46d6-a0fd-9a79bd15b499_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December&#160;31, 2021 and 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2027ExpirationMember_74bd3ac6-c145-457d-9948-642d3949338e_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2027ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2027 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2027ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2027ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2027 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2027ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2027ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2027 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2027ExpirationMember" xlink:href="gild-20211231.xsd#gild_EuropeanPatentClaims2027ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2027ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2027ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_72338f4a-2fc0-48fd-bb84-c3ba918e089c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a2f8e03c-7611-4678-88d6-f653bc192246_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ef17839d-923a-4a6d-ab89-a3b38c965616_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_cf975556-4009-4c56-824b-3f7217c35733_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2024ExpirationMember_191842f9-f062-4324-965c-dce282dd45f8_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2024ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2024 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2024ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2024ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2024 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2024ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2024ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2024 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2024ExpirationMember" xlink:href="gild-20211231.xsd#gild_EuropeanPatentClaims2024ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2024ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2024ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_874ca146-17d7-4a6b-ac88-b2089b9251e7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementNetProductSalesThreshold_5cde1212-fdd5-4d58-a08f-c175c8611e44_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales threshold</link:label>
    <link:label id="lab_gild_CollaborationArrangementNetProductSalesThreshold_label_en-US" xlink:label="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Net Product Sales Threshold</link:label>
    <link:label id="lab_gild_CollaborationArrangementNetProductSalesThreshold_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Net Product Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementNetProductSalesThreshold" xlink:href="gild-20211231.xsd#gild_CollaborationArrangementNetProductSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementNetProductSalesThreshold" xlink:to="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_c48bab46-dc60-4a99-9837-9360489dea66_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_1711cb18-8c55-4278-aa9e-7fa2fbe5af6a_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_f4a6edea-75ad-45c8-9303-0f3e9e0b5213_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsAtriplaMember_260ef6c3-3888-48af-9dfc-e5f8f5c11694_terseLabel_en-US" xlink:label="lab_gild_HIVProductsAtriplaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Atripla</link:label>
    <link:label id="lab_gild_HIVProductsAtriplaMember_label_en-US" xlink:label="lab_gild_HIVProductsAtriplaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Atripla [Member]</link:label>
    <link:label id="lab_gild_HIVProductsAtriplaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsAtriplaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Atripla [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsAtriplaMember" xlink:href="gild-20211231.xsd#gild_HIVProductsAtriplaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsAtriplaMember" xlink:to="lab_gild_HIVProductsAtriplaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_ba3b6ebf-3968-48ea-b394-b8225ad214c6_terseLabel_en-US" xlink:label="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax positions related to prior years:</link:label>
    <link:label id="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_label_en-US" xlink:label="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Prior Period Tax Positions [Abstract]</link:label>
    <link:label id="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_documentation_en-US" xlink:label="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" xlink:href="gild-20211231.xsd#gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" xlink:to="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_2aa0f90b-2af6-4a8b-a569-287f637c2005_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccruedGovernmentAndOtherRebates_aa1184c7-6850-47cd-8a5f-04376d398a67_terseLabel_en-US" xlink:label="lab_gild_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued government and other rebates</link:label>
    <link:label id="lab_gild_AccruedGovernmentAndOtherRebates_label_en-US" xlink:label="lab_gild_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government And Other Rebates</link:label>
    <link:label id="lab_gild_AccruedGovernmentAndOtherRebates_documentation_en-US" xlink:label="lab_gild_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government And Other Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedGovernmentAndOtherRebates" xlink:href="gild-20211231.xsd#gild_AccruedGovernmentAndOtherRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccruedGovernmentAndOtherRebates" xlink:to="lab_gild_AccruedGovernmentAndOtherRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_c46be56b-aa83-416e-b661-68d6f1fd6577_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1d77fea9-db95-429c-84b1-f6b500bdf3ad_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_5eb7549b-7729-4bde-9f7d-142da671f8a1_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_05454029-7c96-41c9-9b0e-1a44e1355cc2_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of stock options and equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member_a358f711-88c6-46cf-ade6-3999623f01f8_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due in March 2022</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2022 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_340db626-7cd3-4b68-a4cf-d8f9778f9a9d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeAndOtherArrangementsTextBlock_c5428f01-988a-4c04-adfa-5e59a6dd2b9c_terseLabel_en-US" xlink:label="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements</link:label>
    <link:label id="lab_gild_CollaborativeAndOtherArrangementsTextBlock_label_en-US" xlink:label="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative And Other Arrangements [Text Block]</link:label>
    <link:label id="lab_gild_CollaborativeAndOtherArrangementsTextBlock_documentation_en-US" xlink:label="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:href="gild-20211231.xsd#gild_CollaborativeAndOtherArrangementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:to="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c8fc2f9e-4835-4aa5-8164-0f1d34e9fe41_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_4d78ccad-1aae-4df4-bf1b-4ad134ee8067_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_b55c4c19-8366-4931-9b67-bc20550e01f5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2618e3ef-22bf-475e-b7ee-a69541811ebd_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_7824cc19-d54c-44cb-a981-f244ac35adb4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gain) loss from equity securities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b89ddaf6-4913-4c0b-a89c-3fbeafc973f5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_9e721b92-3696-43d1-9712-3b230729877e_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_00e0b931-3fc9-4c19-b5d9-8fa565780072_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_13c68eed-4e7f-48ae-8251-44ade6190492_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_68321992-4917-4227-ad0f-31c39c3b4740_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a4e3201f-4957-4a76-b1b1-9dcceede872b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8a36021-791b-412d-b545-a80079f99cd6_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b086b93a-1896-45c1-983c-393b521165d7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_2a430920-0cf8-40e1-939d-e4befeefb09b_terseLabel_en-US" xlink:label="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax positions related to current year:</link:label>
    <link:label id="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_label_en-US" xlink:label="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Current Period Tax Positions [Abstract]</link:label>
    <link:label id="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_documentation_en-US" xlink:label="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" xlink:href="gild-20211231.xsd#gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" xlink:to="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_3971949a-51f7-46fd-87f6-67b4a93fc2e5_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassified intangible assets</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross, Reclassified</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross, Reclassified</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:href="gild-20211231.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:to="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_1b7bba65-4a1d-499e-8331-d7d87c5e4809_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_c15e449d-e357-4554-9e58-b402aced6f6c_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Dividends Declared</link:label>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Declared [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:to="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f4dda520-2d77-4b15-94b6-8023e9fec35d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_42156610-af76-44be-b728-1b47a9e5fba0_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe80252c-7a71-4907-a6ff-76cec25da270_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_e2698ff7-5fd0-4c2b-b3bd-9b3c15adfe50_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and other credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_62ee283e-6d45-4906-9d2d-1325fcc85dd0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_ad23bc06-0c32-4916-b847-3d415a5bd701_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_1770edfc-a8a2-42aa-96d4-94309d69c01b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_6e0fb15d-1f48-4652-8933-c748fb93674a_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable debt securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember" xlink:href="gild-20211231.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesCurrentMember" xlink:to="lab_gild_MarketableSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_3059b59c-f782-4db8-8a77-ba998c278095_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member_c01a4767-897a-470a-86f2-a697df88f16b_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due in March 2026</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2026 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_689ddd5b-41a7-40ff-91c1-e6c4d258cc9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_543500e0-ed0a-417a-b2d7-ef5dff862820_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48f24fff-615e-49cf-82dd-13de2b81fdf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9dc37621-5fbe-4e6b-9790-d627386b7bce_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_VekluryMember_d200c153-196b-4dee-9ae9-1fe5710351bc_terseLabel_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:label id="lab_gild_VekluryMember_label_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury [Member]</link:label>
    <link:label id="lab_gild_VekluryMember_documentation_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember" xlink:href="gild-20211231.xsd#gild_VekluryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_VekluryMember" xlink:to="lab_gild_VekluryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d01d89d7-923a-4ab1-8531-203f0bfbe7c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_09b2e500-788d-4a5b-9705-ecae6daa49ed_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_87b1a7d3-9af7-4273-b6a2-80ddfbb2abbb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f7da7506-5db0-4964-b813-4f0a7bcfa2b3_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_94aa654a-c50d-42ea-a7bc-b814d582564c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d830f08e-5968-4948-b1b8-7ce33c210d28_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FortySevenIncMember_8cd5f9f6-c39a-420d-82ef-7b0ced08daf9_terseLabel_en-US" xlink:label="lab_gild_FortySevenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Seven, Inc.</link:label>
    <link:label id="lab_gild_FortySevenIncMember_label_en-US" xlink:label="lab_gild_FortySevenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Seven, Inc. [Member]</link:label>
    <link:label id="lab_gild_FortySevenIncMember_documentation_en-US" xlink:label="lab_gild_FortySevenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Seven, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember" xlink:href="gild-20211231.xsd#gild_FortySevenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FortySevenIncMember" xlink:to="lab_gild_FortySevenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_501eed42-7f8c-406e-8139-409af7cab080_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt and other obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5b9f45ce-af17-4abd-96f4-cb859409394b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_3f005c98-b823-4f60-bf65-e1dbb488a52b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsOtherHIVMember_dba1124f-fb10-4870-a280-c3c43c0643bd_terseLabel_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HIV</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_label_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_documentation_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember" xlink:href="gild-20211231.xsd#gild_ProductsOtherHIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsOtherHIVMember" xlink:to="lab_gild_ProductsOtherHIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_be277b6f-4b24-460c-9bae-825e5a26de3e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-taxable unrealized (gain) loss on investment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_947b54cd-53db-45fa-9280-aebf4f0633ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased and retired (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_c1d20aeb-5019-4f32-94c7-b479e6eb35e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage of principal amount repurchased</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_32bb668e-c544-4210-9947-905e68572b6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_4b88193a-6835-4b23-b324-add6d2a46137_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In Process Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_7ce6f07a-dfed-4b03-a845-d7c3f30ae4f8_terseLabel_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 stock repurchase program</link:label>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_label_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember" xlink:href="gild-20211231.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A2016StockRepurchaseProgramMember" xlink:to="lab_gild_A2016StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0b608703-9b21-4a78-a161-a4b4cdbf85cb_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_c5e9a6fe-0148-40a7-a7bb-6be1de051ba0_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06ca4de5-cb6e-4ff9-a5df-bc24557616ae_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_9460b800-458e-4d74-91fe-3d005437f6af_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investment of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1d10551e-4fd0-4220-82cb-70b2a8ca722e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_fa29f2ca-7d94-4dac-bbef-d28077ae4214_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsZydeligMember_dc942625-1719-450c-bec2-76fe54fa661c_terseLabel_en-US" xlink:label="lab_gild_OtherProductsZydeligMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zydelig</link:label>
    <link:label id="lab_gild_OtherProductsZydeligMember_label_en-US" xlink:label="lab_gild_OtherProductsZydeligMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Zydelig [Member]</link:label>
    <link:label id="lab_gild_OtherProductsZydeligMember_documentation_en-US" xlink:label="lab_gild_OtherProductsZydeligMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Zydelig [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsZydeligMember" xlink:href="gild-20211231.xsd#gild_OtherProductsZydeligMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsZydeligMember" xlink:to="lab_gild_OtherProductsZydeligMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_0a4d2804-1fff-4af7-9715-cf15184f50c0_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in, extension and milestone payments</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:to="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a78c430f-4c20-47d9-a40b-a69abfa521e5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5bab09fb-09c1-47f1-933d-c0852ed9995d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d9efb30c-5602-4ad2-8e04-a96c4e67228f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Aggregate Future Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_4dc45cad-bcd3-408b-ba17-72ea918ef691_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Revenues from Major Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_27754374-e201-4876-a706-8bfe7d1d049d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gilead stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_671b489a-80a5-4cc1-b709-b36844ffca2d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_af617a86-a6f3-40c4-bdf9-fef434671091_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3da1c390-5097-4580-990d-d606c13af17f_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal:</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_aeba09ba-aea7-46bb-aa0b-eda44512f802_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_a8f4a2df-8ef9-49ad-a72d-c82c6a3432d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_adb4ecc0-578d-49c8-934b-66cbfcf05e78_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_21cc1dda-f2d7-492e-9e00-06a070bddee8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_8419318f-0386-4fb7-b5d0-7de3182ebe3d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized from performance obligations satisfied in prior years</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_7564d141-3ba5-442c-8b0f-4d8d12dfdf0c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_39d2021a-4fb1-40c9-972b-33b5ab44ddac_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and land improvements</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a8834d83-1b4d-4847-af81-ef7b686eb9e7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities - noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d1523d63-916b-47e4-9f0e-5468fc3ac75a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_7443f577-4da1-4a52-944c-79c7ea096d6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_cddfc5b0-3027-4573-8e11-228951c05b10_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsAbstract" xlink:to="lab_us-gaap_DerivativeAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_50c3f7e9-3429-4243-9477-fa0c5a70c44b_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_d8a3783e-358e-49cf-9cc9-31c594ab81b7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a89cdd5c-2dec-411e-8940-0ff013a2c34c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_42779210-fc24-43c4-8d27-739e06ba8d1f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c1fcc2e1-53cf-4b95-bbe6-ce4a324bc03d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Fair Values of Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_e1d862b0-576d-4e3a-b2eb-34cae4b002e8_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional option fee on fourth, sixth, and eighth anniversaries</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:to="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_d9922fb1-0162-4b03-9ccc-4d83b0a90af9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_ffc14b0f-052d-49a9-8b1c-080e0453572c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0e483e39-4142-4b63-b052-bd321f914b85_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_62ff142f-2559-48b8-9f66-46a2d487a178_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_fe340214-6828-4702-86a9-df549d848918_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8141696c-dab3-453f-94b9-3f6cddec49bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_a87bdff4-ccc1-4baa-a902-afec7ff35b3e_terseLabel_en-US" xlink:label="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum ownership percentage</link:label>
    <link:label id="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_label_en-US" xlink:label="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</link:label>
    <link:label id="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_documentation_en-US" xlink:label="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:href="gild-20211231.xsd#gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:to="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_682bbd61-81d0-4ee3-a267-d4e2fb0ba894_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a99c7344-a5a1-439e-a6fb-a7cd66694a4d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_51d781fe-6cef-4a26-ac9b-0e7b7cdaed9f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_cdba1c77-7d3f-42a2-982a-b0dac7556efe_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6a0cfd89-8d29-4fa7-a849-c51be27e0df4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9a3b907f-3f19-49b4-bec0-69a04209d91b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d58d360d-8267-4961-a1fe-840364af964c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b995e14b-a717-4b98-bad9-ae889b559c60_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_51b7c93e-b70f-4315-8283-b7df764a132f_terseLabel_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhanced damages on past sales</link:label>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_label_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Enhanced Damages On Past Sales</link:label>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_documentation_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Enhanced Damages On Past Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales" xlink:href="gild-20211231.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentEnhancedDamagesOnPastSales" xlink:to="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2fec58c4-676d-4ae1-8d28-c19f4b9b0228_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0b0f8449-8b18-4cf0-b545-e1743bab7aef_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_333d4459-19d3-46b2-acb5-7c2479cd557e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f93b0011-6e6b-4313-8bc6-915e68e9f932_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_60c5b38f-c36e-4fdb-a378-708415e5198b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_25f80a25-e3cb-4a82-8ea4-104525f802b2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36b46da6-36bb-4714-ba0e-7568c811db06_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5e7cda1e-019f-4ae7-a21f-3801fb1abd32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_5d0cf6d5-62e0-489b-8f64-d3b4789055f9_terseLabel_en-US" xlink:label="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jounce license and stock purchase agreement</link:label>
    <link:label id="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_label_en-US" xlink:label="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Registration Rights and Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Registration Rights and Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:href="gild-20211231.xsd#gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:to="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_78a13ea2-d653-43ae-86a7-1f50d293d98e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_bc3eaecf-e502-4b78-9e96-b4d3226c2c15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Repurchases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2c937a16-faea-4e03-baba-41156530e57c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_4422d973-d932-476d-97ab-0f0b5ab182f1_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5df6dd55-b1a8-4ad9-a74c-39308d6fb763_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e10fa100-1bab-4cb7-a1d1-faa5fb62cf3d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_6ddb11e8-4157-4387-95b4-f25ebbb86808_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_bdc99ffb-ff2f-4b42-86c9-43148a345ef9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_94b94bc6-9631-4ef3-af04-90c2d1633e0d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_795ebcb9-149d-411b-a22a-46fbcb343ad0_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option period to license certain inhibitors</link:label>
    <link:label id="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_label_en-US" xlink:label="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period</link:label>
    <link:label id="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:href="gild-20211231.xsd#gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:to="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3eea11fd-d9f0-4e4f-bd47-ae6e0d9c70f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4fb7b63a-0034-4258-90f8-e0e492609bf5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f9c33a28-10e7-4de1-9402-da64343da4b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_4bc84cba-7f05-4ddd-aa66-7f35519cf258_terseLabel_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract" xlink:href="gild-20211231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherFinancialInformationAbstract" xlink:to="lab_gild_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_c9bcd34d-d52e-46a4-85c5-4f55dea8f4de_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_3eff2fd5-76e0-46c4-8d8a-4f6c7061faa5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_188ebf5d-4dab-433d-9aee-dfba525b737c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_59b358ee-f669-4855-9a04-db7545735024_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_172a36e3-089b-47ce-83ee-4e43c4befc0c_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Purchase Period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:to="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_0341dd3c-1c90-40ff-92a7-19fef3507254_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments, year five</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_7ca00f1c-9cc4-4ae0-ae75-bec8f2da5bf2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b56f04c1-c0b1-4925-9a5a-7f8b7bca0ab2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3c05c95c-666d-4bb7-85d7-2c3b81fcd3e2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e6e8b4f6-bc2b-41d6-9448-7b80a416334f_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_cda0e1d3-fe25-4f8b-a8cb-c4dde8559d3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1265f899-db85-4c57-b7c0-5bdbf94701e2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_cf3e5b3a-aa0d-46c3-8900-d6f8cd369285_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_b5948cd4-40ce-4487-aa2c-8b350d31026d_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e550a210-ef93-4ff5-9c81-d8ddfe46c55b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_b5d6c7c1-b930-48a9-9492-bc1168229bd9_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies, Estimates and Judgments</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bd2fdbb4-13f6-4a3a-947b-f8b532c380b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_43a69632-0d19-436e-814d-80c100b9bc2e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_6db2e031-61d0-4635-82b1-07b59ed0f2fd_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ca177468-fc94-408c-8066-2e1955b99db8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_298fd34a-7ca2-441e-94df-b3ad762a7b44_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of tax examinations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_6475aeec-c37b-4689-acbf-0a1af627346b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9d5dddff-c567-4a05-afe2-05fe51040575_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment_b2a03518-1f6b-4652-af27-00e5de9bf492_terseLabel_en-US" xlink:label="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development expenses</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment_label_en-US" xlink:label="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process, Including Impairment</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment_documentation_en-US" xlink:label="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process, Including Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment" xlink:href="gild-20211231.xsd#gild_ResearchAndDevelopmentInProcessIncludingImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment" xlink:to="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_27dd6423-3ce3-464a-82df-b2baf3fe4c7b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2021Member_e8613471-9e43-4178-a54f-bd16eef13600_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% Senior Unsecured Notes Due In December 2021</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2021Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due December 2021 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2021Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due December 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2021Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueDecember2021Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueDecember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_bef67f72-6925-494c-bc46-d85b30f17e4d_terseLabel_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_label_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_documentation_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember" xlink:href="gild-20211231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusBiosciencesIncMember" xlink:to="lab_gild_ArcusBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c690b29-9b42-4912-99f6-aa67605d58bf_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_288f9693-45b9-409d-bdbd-51358a72a523_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialFutureMilestonePaymentsMaximum_b8d109cd-b8bb-477d-972f-6572bf43dd49_terseLabel_en-US" xlink:label="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential future milestone payments</link:label>
    <link:label id="lab_gild_PotentialFutureMilestonePaymentsMaximum_label_en-US" xlink:label="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments, Maximum</link:label>
    <link:label id="lab_gild_PotentialFutureMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum" xlink:href="gild-20211231.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialFutureMilestonePaymentsMaximum" xlink:to="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_70e76108-e1fe-4897-a8cc-dfd641752a55_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount (Legal Offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_ae78cce1-4b63-4a42-a7ac-a604b9f76d7e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term extension</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c073b37d-36c9-40ab-8855-31500cef3885_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent_59dd4058-36ce-4987-b88b-ae916d19b873_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for settlement related to bictegravir litigation</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6df1bb9e-a1dd-44ba-ad73-eed98d88223b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1a2cf66-de06-4e9e-88b1-4fdcf9f65ee8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsDescovyMember_5725208d-9d18-444a-b127-9fce8e9ae116_terseLabel_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Descovy</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_label_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember" xlink:href="gild-20211231.xsd#gild_HIVProductsDescovyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsDescovyMember" xlink:to="lab_gild_HIVProductsDescovyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseLongTermDebt_a48ca578-7b69-47e2-95bc-b7d8b1cd39cd_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseLongTermDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseLongTermDebt" xlink:to="lab_us-gaap_InterestExpenseLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_6200613e-9ff0-4a6d-aa45-9e0133a4aeaa_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ImmunomedicsIncMember_615b4574-ace9-4917-b738-300b50cf4795_terseLabel_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc.</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_label_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. [Member]</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_documentation_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. (&#8220;Immunomedics&#8221;), a leading company in antibody-drug conjugate (&#8220;ADC&#8221;) technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember" xlink:href="gild-20211231.xsd#gild_ImmunomedicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ImmunomedicsIncMember" xlink:to="lab_gild_ImmunomedicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquityMethodInvestmentOptionExerciseFee_a6c30560-e17a-4988-a5a1-352536b83938_terseLabel_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_gild_EquityMethodInvestmentOptionExerciseFee_label_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Option Exercise Fee</link:label>
    <link:label id="lab_gild_EquityMethodInvestmentOptionExerciseFee_documentation_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionExerciseFee" xlink:href="gild-20211231.xsd#gild_EquityMethodInvestmentOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquityMethodInvestmentOptionExerciseFee" xlink:to="lab_gild_EquityMethodInvestmentOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_dcc27631-550d-45b8-8a4c-960e17ee0474_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_dff0103d-f23a-4b83-8033-dc200b206c26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_e339b88b-0496-4728-88f3-3b8c6ab709dc_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Information Related to Operating Leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AuditInformationAbstract_label_en-US" xlink:label="lab_gild_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_gild_AuditInformationAbstract_documentation_en-US" xlink:label="lab_gild_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AuditInformationAbstract" xlink:href="gild-20211231.xsd#gild_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AuditInformationAbstract" xlink:to="lab_gild_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_63cb22fb-9107-46fd-9042-91a4c35e30f7_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_bb0634e0-724b-45c4-a066-31d7c299e1a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_eed222e4-9389-4168-82ef-55fe8c79cca4_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_32671566-be88-45b5-acb1-12abac31dd92_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate of acquired IPR&amp;D</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired, Discount Rate</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:href="gild-20211231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AxicabtageneCiloleucelDLBCLMember_47b4a2e5-8d3d-48db-8659-d1c2f8900eb9_terseLabel_en-US" xlink:label="lab_gild_AxicabtageneCiloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - axicabtagene ciloleucel</link:label>
    <link:label id="lab_gild_AxicabtageneCiloleucelDLBCLMember_label_en-US" xlink:label="lab_gild_AxicabtageneCiloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Axicabtagene Ciloleucel (DLBCL) [Member]</link:label>
    <link:label id="lab_gild_AxicabtageneCiloleucelDLBCLMember_documentation_en-US" xlink:label="lab_gild_AxicabtageneCiloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneCiloleucelDLBCLMember" xlink:href="gild-20211231.xsd#gild_AxicabtageneCiloleucelDLBCLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AxicabtageneCiloleucelDLBCLMember" xlink:to="lab_gild_AxicabtageneCiloleucelDLBCLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_16e6f387-2724-4fbb-89b2-baedb46c8880_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResearchAndDevelopmentServiceAgreementMember_bd124db1-321c-4413-9253-5608d9b2e2c9_terseLabel_en-US" xlink:label="lab_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development service agreement</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentServiceAgreementMember_label_en-US" xlink:label="lab_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Service Agreement [Member]</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentServiceAgreementMember_documentation_en-US" xlink:label="lab_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Service Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:href="gild-20211231.xsd#gild_ResearchAndDevelopmentServiceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:to="lab_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_23156434-671f-49d7-9f83-ce0889714788_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Collateral Received/Pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Right to Reclaim Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_528b5267-e80b-4e30-85f3-81931bff62a8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign-derived intangible income deduction</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DevelopmentAgreementMember_9f36a090-dea7-45dd-97e2-0953257bc0e9_terseLabel_en-US" xlink:label="lab_gild_DevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development agreement</link:label>
    <link:label id="lab_gild_DevelopmentAgreementMember_label_en-US" xlink:label="lab_gild_DevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreement [Member]</link:label>
    <link:label id="lab_gild_DevelopmentAgreementMember_documentation_en-US" xlink:label="lab_gild_DevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DevelopmentAgreementMember" xlink:href="gild-20211231.xsd#gild_DevelopmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DevelopmentAgreementMember" xlink:to="lab_gild_DevelopmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_16390881-17f4-4189-bf6d-4b0d48ec967a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable and Non-Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_c1c1de17-7067-4885-952e-312fa2a995de_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill expected to be deductible for tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f73415d-81d5-4538-b305-ab2f00142e2a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3704d875-26bd-4a8b-bb68-cda9fad16168_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_6f8cb490-5f76-4b62-b5f7-a57f22e8397f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member_6f33ec42-43d0-4953-acad-5907072a561e_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due in September 2023</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JounceTherapeuticsIncMember_ec9a4295-45b1-4cfd-a111-faac089b13c7_terseLabel_en-US" xlink:label="lab_gild_JounceTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jounce</link:label>
    <link:label id="lab_gild_JounceTherapeuticsIncMember_label_en-US" xlink:label="lab_gild_JounceTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jounce Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_JounceTherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_JounceTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jounce Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember" xlink:href="gild-20211231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JounceTherapeuticsIncMember" xlink:to="lab_gild_JounceTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_081d5657-3ba0-4e21-94fe-d2afaa0b1cd2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office, computer equipment and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5b3f1425-f970-4736-a97d-fdd70beedf83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_28b70d0b-1e92-46c1-865e-47cd7532015d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_08cc8adf-10f8-4ee5-a9c1-359f714eeaa3_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember" xlink:href="gild-20211231.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2032ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_0caed5fa-7d58-4b2d-a2d6-5d1997add51c_terseLabel_en-US" xlink:label="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront collaboration expenses</link:label>
    <link:label id="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_label_en-US" xlink:label="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant</link:label>
    <link:label id="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_documentation_en-US" xlink:label="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:href="gild-20211231.xsd#gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:to="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_cd58afd2-a71e-449c-80eb-d2ca78c037ff_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_23f64bdc-a9fe-4929-a7e2-15918a577625_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing under the senior unsecured term loan facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_204baafb-0e96-4453-b7a3-81b2bba42342_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_0d9fcdcf-9c5f-454c-90ad-3c1c438e380b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_73834eab-a0c1-4f31-98f9-9f3f4ecf216e_terseLabel_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_label_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_documentation_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:href="gild-20211231.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:to="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_15202767-ba1b-4c53-aa3a-f3eb3779d4dd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_NumberOfPrograms_2d9c1261-5f65-4a47-a7e1-f138db364d35_terseLabel_en-US" xlink:label="lab_gild_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of programs</link:label>
    <link:label id="lab_gild_NumberOfPrograms_label_en-US" xlink:label="lab_gild_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Programs</link:label>
    <link:label id="lab_gild_NumberOfPrograms_documentation_en-US" xlink:label="lab_gild_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfPrograms" xlink:href="gild-20211231.xsd#gild_NumberOfPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_NumberOfPrograms" xlink:to="lab_gild_NumberOfPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ead5c8c6-b344-4431-a975-053b1bbc7f93_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member_d817dc83-33f1-4e3b-aa7e-f6fb199421d1_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due in March 2047</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2047 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2044Member_260a9f5c-b341-4b18-809e-a1acebcf1b48_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due in April 2044</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2044Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in April 2044 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2044Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in April 2044 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinApril2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_71d53aa1-5d73-4865-81d2-f195440c8166_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_e8292858-e46b-416e-844d-6d3709a83065_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_ab7d9d72-f75c-4f1b-a4db-922bd1fe515c_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a116f685-4a9f-4d8f-a2d0-1e7c19cfac7f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8adc7ad2-d63d-4be4-979f-6681c453bb60_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_fb10d19b-76b6-4a81-ad82-fff168f5207b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_2e9738fe-b77c-4d45-a6c7-5f58d916eb24_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments, year four</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7ffac36f-389f-4caf-a8f4-5f368967edba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2e725979-237b-4884-be1f-c9df7025f5aa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and other credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_0455b3aa-e692-4a99-943e-9a9ef8b2102f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5c20aad3-34c0-4483-8ada-36857e8ce023_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_366a776d-ba67-4a0c-b4ea-a1ee833cf883_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of unsecured debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Unsecured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues_62828b87-4982-4657-b673-670e3da9460f_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of global product revenues</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues_label_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Product Revenues</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Product Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:href="gild-20211231.xsd#gild_CollaborationArrangementPercentOfGlobalProductRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:to="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_81e1ea51-30b2-4027-9700-bfe4c359734c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D and related charges</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_41cc74bd-58bf-4062-97ae-622e88a881be_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f59c2b67-9d8b-4af4-84fb-025172959887_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PionyrMergerAndOptionAgreementsMember_27106f1a-36f9-4500-896f-8976de066658_terseLabel_en-US" xlink:label="lab_gild_PionyrMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr merger and option agreements</link:label>
    <link:label id="lab_gild_PionyrMergerAndOptionAgreementsMember_label_en-US" xlink:label="lab_gild_PionyrMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Merger and Option Agreements [Member]</link:label>
    <link:label id="lab_gild_PionyrMergerAndOptionAgreementsMember_documentation_en-US" xlink:label="lab_gild_PionyrMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Merger and Option Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrMergerAndOptionAgreementsMember" xlink:href="gild-20211231.xsd#gild_PionyrMergerAndOptionAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PionyrMergerAndOptionAgreementsMember" xlink:to="lab_gild_PionyrMergerAndOptionAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PubliclyAnnouncedProgramMember_937dc59e-4994-4450-bfc1-2f757c182f76_terseLabel_en-US" xlink:label="lab_gild_PubliclyAnnouncedProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly announced program</link:label>
    <link:label id="lab_gild_PubliclyAnnouncedProgramMember_label_en-US" xlink:label="lab_gild_PubliclyAnnouncedProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly Announced Program [Member]</link:label>
    <link:label id="lab_gild_PubliclyAnnouncedProgramMember_documentation_en-US" xlink:label="lab_gild_PubliclyAnnouncedProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly Announced Program(s)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PubliclyAnnouncedProgramMember" xlink:href="gild-20211231.xsd#gild_PubliclyAnnouncedProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PubliclyAnnouncedProgramMember" xlink:to="lab_gild_PubliclyAnnouncedProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_f998c1d0-fccc-472c-9ddb-1295856c18c3_terseLabel_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes And Medium-Term Notes</link:label>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_label_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes And Medium-Term Notes [Member]</link:label>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_documentation_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes And Medium-Term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember" xlink:href="gild-20211231.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember" xlink:to="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e87c6810-be73-45be-8554-147ac589bf39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future Amortization Expense of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_f47e7ce7-a88b-4645-817c-e07d57942453_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b48815fe-53d2-44ba-9ed6-f7a99f9652ac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_5fc99ba6-04e4-43fd-942a-657fb235a606_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_6d2d7352-ad13-4a39-8ba1-28c038416010_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_38d4f90a-d8db-4454-aadf-f12922c166a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_bfe88125-7733-43b8-a56b-e624e2f592a1_terseLabel_en-US" xlink:label="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics Plan</link:label>
    <link:label id="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_label_en-US" xlink:label="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics Amended and Restated 2014 Long-Term Incentive Plan [Member]</link:label>
    <link:label id="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_documentation_en-US" xlink:label="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics Amended and Restated 2014 Long-Term Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" xlink:href="gild-20211231.xsd#gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" xlink:to="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_d3f2d075-cab0-4d58-ac0b-63f36ca3cafd_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign income tax expense (benefit), continuing operations</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductSalesMember_b02a5080-8e71-49c3-8ceb-104ad8b9b9e1_terseLabel_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HCV</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_label_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember" xlink:href="gild-20211231.xsd#gild_HCVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductSalesMember" xlink:to="lab_gild_HCVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIShares_3052e2f3-0986-47fd-b6b9-8b5a6cdcde43_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIShares_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIShares_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIShares" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIShares" xlink:to="lab_gild_EquitySecuritiesFVNIShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_3bbe6716-c345-4cc8-a40e-f46df2f2fe15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_550af8e3-5338-4c31-8e16-15c919d39352_terseLabel_en-US" xlink:label="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for license and option rights</link:label>
    <link:label id="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_label_en-US" xlink:label="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for License, Option Rights and Equity Investments Upon Closing</link:label>
    <link:label id="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_documentation_en-US" xlink:label="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">payment for license, option rights and equity investments upon closing of collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" xlink:href="gild-20211231.xsd#gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" xlink:to="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CreditFacilityDueMay2021Member_83b2b75d-1e87-43f6-bb97-f527f184d628_terseLabel_en-US" xlink:label="lab_gild_CreditFacilityDueMay2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 revolving credit facility</link:label>
    <link:label id="lab_gild_CreditFacilityDueMay2021Member_label_en-US" xlink:label="lab_gild_CreditFacilityDueMay2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due May 2021 [Member]</link:label>
    <link:label id="lab_gild_CreditFacilityDueMay2021Member_documentation_en-US" xlink:label="lab_gild_CreditFacilityDueMay2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due May 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueMay2021Member" xlink:href="gild-20211231.xsd#gild_CreditFacilityDueMay2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CreditFacilityDueMay2021Member" xlink:to="lab_gild_CreditFacilityDueMay2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4df63379-a2a7-4d25-8ee2-6ba09edc06d4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cfff4277-16fd-451a-8d63-7a6ad82f62af_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_d55f7ec0-b4c9-40db-a416-385243b002c9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_a0759a7c-7567-40d2-a1a5-6efaf9a62f0c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, noncurrent, statement of financial position, extensible enumeration</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_40dcaf68-d1ec-4822-a0ad-0de220db4f8a_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_1bf8dfab-aa9b-45a0-ab61-dcb24b165d90_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in unrealized loss positions, number of positions (securities)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_d0a2f703-6b9d-4a16-918c-8706eae5c89c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FairValueatVestingDateMember_e267e18d-2454-4e9e-9281-5e3601711221_terseLabel_en-US" xlink:label="lab_gild_FairValueatVestingDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at vesting date</link:label>
    <link:label id="lab_gild_FairValueatVestingDateMember_label_en-US" xlink:label="lab_gild_FairValueatVestingDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value at Vesting Date [Member]</link:label>
    <link:label id="lab_gild_FairValueatVestingDateMember_documentation_en-US" xlink:label="lab_gild_FairValueatVestingDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value at Vesting Date [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueatVestingDateMember" xlink:href="gild-20211231.xsd#gild_FairValueatVestingDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FairValueatVestingDateMember" xlink:to="lab_gild_FairValueatVestingDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CardinalHealthIncMember_34e9cfbc-81f2-4676-b9e4-52f378403c8b_terseLabel_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_label_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember" xlink:href="gild-20211231.xsd#gild_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CardinalHealthIncMember" xlink:to="lab_gild_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_0ef8ff01-99f6-4038-b967-1875b185dc2d_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d5781163-f211-4972-9950-06882b61668f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6b6bdfcf-432f-4372-bc8e-65c2b35982ec_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_62c627d3-15f3-498a-9a3f-f3966c619f8a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_b02b8a44-7480-4db2-9dc5-b0dd06440597_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AgreementWithJapanTobaccoIncMember_27245c8d-6e45-4d9f-82bd-df98345368ec_terseLabel_en-US" xlink:label="lab_gild_AgreementWithJapanTobaccoIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan tobacco</link:label>
    <link:label id="lab_gild_AgreementWithJapanTobaccoIncMember_label_en-US" xlink:label="lab_gild_AgreementWithJapanTobaccoIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with Japan Tobacco, Inc. [Member]</link:label>
    <link:label id="lab_gild_AgreementWithJapanTobaccoIncMember_documentation_en-US" xlink:label="lab_gild_AgreementWithJapanTobaccoIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with Japan Tobacco, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AgreementWithJapanTobaccoIncMember" xlink:href="gild-20211231.xsd#gild_AgreementWithJapanTobaccoIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AgreementWithJapanTobaccoIncMember" xlink:to="lab_gild_AgreementWithJapanTobaccoIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepcludexMember_8f5cf4b7-30ed-4123-a31b-3d0d8ef024b6_verboseLabel_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex</link:label>
    <link:label id="lab_gild_HepcludexMember_60964e35-4cec-4d00-a62d-c851707cb2c8_terseLabel_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - Hepcludex</link:label>
    <link:label id="lab_gild_HepcludexMember_label_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex [Member]</link:label>
    <link:label id="lab_gild_HepcludexMember_documentation_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember" xlink:href="gild-20211231.xsd#gild_HepcludexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepcludexMember" xlink:to="lab_gild_HepcludexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_a59b41a0-b78b-4323-92aa-459bc87596bc_terseLabel_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ledipasvir/Sofosbuvir</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_label_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:href="gild-20211231.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:to="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_c770fd0c-7781-4b17-afb1-07fd8c1d75e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_ba91dabb-e6fe-40e5-af0e-2dbd48ac2572_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_66844e04-8716-4be6-b076-c2e19b13f7db_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_24c0863f-3602-4a44-8b13-921d0412a28a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_3a9040a4-cd9f-4c89-b540-cab965ddadcf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_773f4965-8789-419b-a809-e813369ecd79_terseLabel_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_label_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050 [Member]</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_documentation_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:href="gild-20211231.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:to="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4d4f60e4-8572-42d8-80fb-bfb379e70970_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_18b4c79f-e7c8-4478-bf73-1b604b04b713_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_0d08e9aa-d320-4905-81e7-54cd86874a64_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_223d74f3-f2ea-46d3-9cd6-9336a2e7c8a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_ec85ac58-9bf6-4852-8bd6-2c1870b1e781_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR rate</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_9864f9c0-fbc9-4ee2-babe-d06bd0e03545_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_98e3a4e3-8d54-4987-a502-459e3010f129_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5aa3753b-e05d-48b1-92e1-a1512976ff20_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_219982ba-5608-426b-8417-49f24ddb2389_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f7bdd27f-e809-4442-a5b4-ab7b55b1f6eb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c244f568-b9e9-4fc0-ac5c-f118dd2b1e90_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6a6c08a8-9db7-462e-91ea-5bd61d0ecdab_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fabf586c-f2e8-49cb-a520-7932d9ddbba8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_6af25bc6-cb02-4242-ace6-14322166d97a_terseLabel_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payout percentage</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_label_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_documentation_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:href="gild-20211231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:to="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_e30d3d24-3508-4adc-bd9c-6a1417d7cb66_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire in process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_142af2fa-63d0-4040-b9e5-63c63dade449_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeAgreementOptInTerm_67c77c9e-0932-4eee-b0f2-1510e462ce99_terseLabel_en-US" xlink:label="lab_gild_CollaborativeAgreementOptInTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in term</link:label>
    <link:label id="lab_gild_CollaborativeAgreementOptInTerm_label_en-US" xlink:label="lab_gild_CollaborativeAgreementOptInTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Opt-In Term</link:label>
    <link:label id="lab_gild_CollaborativeAgreementOptInTerm_documentation_en-US" xlink:label="lab_gild_CollaborativeAgreementOptInTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Opt-In Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementOptInTerm" xlink:href="gild-20211231.xsd#gild_CollaborativeAgreementOptInTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeAgreementOptInTerm" xlink:to="lab_gild_CollaborativeAgreementOptInTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8678fcc7-0610-4900-be8b-aafdf68a13de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_a0aaf947-b5ec-440a-b939-3c50f68e0dbb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_a7c54f9d-6021-48fa-bce9-77f355dd3811_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_76f0d744-afc8-45bc-8e17-8eb6c8e3af1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity Under Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_869b172b-88db-42c1-a7f4-0c02aba2f506_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TizonaTherapeuticsIncMember_01dc3847-f6f7-4c06-9043-3fee08412028_terseLabel_en-US" xlink:label="lab_gild_TizonaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona</link:label>
    <link:label id="lab_gild_TizonaTherapeuticsIncMember_label_en-US" xlink:label="lab_gild_TizonaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_TizonaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_TizonaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaTherapeuticsIncMember" xlink:href="gild-20211231.xsd#gild_TizonaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TizonaTherapeuticsIncMember" xlink:to="lab_gild_TizonaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member_e3a98d14-0502-452c-8a2e-0c91d93ca12d_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due in March 2046</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2046 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2046</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c30bd147-e74c-4080-b89f-67549d451d2a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsLetairisMember_38b5c011-8272-476f-96cb-fa0bb858223e_terseLabel_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letairis</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_label_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_documentation_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember" xlink:href="gild-20211231.xsd#gild_OtherProductsLetairisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsLetairisMember" xlink:to="lab_gild_OtherProductsLetairisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_d653dff2-daf8-4d80-b97c-361919560f41_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_de9cd24b-d0e0-4348-b474-dcc2640bd21a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JanssenPharmaceuticalsMember_c6bb555a-1b58-4d5e-af9e-c9ef8c54704c_terseLabel_en-US" xlink:label="lab_gild_JanssenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen pharmaceuticals</link:label>
    <link:label id="lab_gild_JanssenPharmaceuticalsMember_label_en-US" xlink:label="lab_gild_JanssenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals [Member]</link:label>
    <link:label id="lab_gild_JanssenPharmaceuticalsMember_documentation_en-US" xlink:label="lab_gild_JanssenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the collaboration with Janssen Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JanssenPharmaceuticalsMember" xlink:href="gild-20211231.xsd#gild_JanssenPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JanssenPharmaceuticalsMember" xlink:to="lab_gild_JanssenPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42ca20ca-7be2-48b0-b765-f1b821c03d09_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_b871dc07-0c32-4d59-9008-a00ab3ed585f_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_66a8a18f-1532-45ac-b02e-119a71c59aa4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_07402d06-9559-41f1-9922-3a65c7f326b3_terseLabel_en-US" xlink:label="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_label_en-US" xlink:label="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year 5</link:label>
    <link:label id="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_documentation_en-US" xlink:label="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year 5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:href="gild-20211231.xsd#gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:to="lab_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_edf8a2d4-db63-4426-ad18-529aec835df6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4edd6300-21e5-49f4-b012-939bb9b8a9e0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9eb4c592-fce8-445b-8808-2e0f0010ac13_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_23d0ea5b-325a-41fc-9804-b953550c20dc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_b2171d0b-0385-48b9-a1b5-4aec60456d56_terseLabel_en-US" xlink:label="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% LIBOR Senior Unsecured Notes Due September 2021</link:label>
    <link:label id="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_label_en-US" xlink:label="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% LIBOR Senior Unsecured Notes Due September 2021 [Member]</link:label>
    <link:label id="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_documentation_en-US" xlink:label="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% LIBOR Senior Unsecured Notes Due September 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:href="gild-20211231.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:to="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9b7e2af8-a66f-4d22-a92f-2683a6328b11_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5106f510-14f2-4ae0-95f2-831b3c0ca7df_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years:</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d1587956-9f82-42ce-969c-aff10f9cf7cb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_66a52c15-ace0-4017-8126-bb631e085aae_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_eb6e4984-a82a-465f-ba88-429dd89c6e12_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parties appealed</link:label>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_label_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Appealed, Number</link:label>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Appealed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber" xlink:href="gild-20211231.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPartiesAppealedNumber" xlink:to="lab_gild_LossContingencyPartiesAppealedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_69902981-065f-459f-8ae4-468bac4e504d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_de20bfdd-511d-44a3-a0df-0f23b3a7818a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ee75915f-85df-45c3-aecd-a3ee972e3358_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_089b1e5b-05a8-4e81-990a-cd631c58ef07_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GalapagosSubscriptionAgreementMember_ffb7d1ca-93e9-4924-a811-ededa1204094_terseLabel_en-US" xlink:label="lab_gild_GalapagosSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos subscription agreement</link:label>
    <link:label id="lab_gild_GalapagosSubscriptionAgreementMember_label_en-US" xlink:label="lab_gild_GalapagosSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos Subscription Agreement [Member]</link:label>
    <link:label id="lab_gild_GalapagosSubscriptionAgreementMember_documentation_en-US" xlink:label="lab_gild_GalapagosSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosSubscriptionAgreementMember" xlink:href="gild-20211231.xsd#gild_GalapagosSubscriptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GalapagosSubscriptionAgreementMember" xlink:to="lab_gild_GalapagosSubscriptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c5e340f8-f39b-4902-bd98-846e2df0a4c7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b610b480-820b-48a8-8809-9635d799d8fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_0e76d6dd-68d4-4225-b32c-9f89f961a2e9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_f06f030c-2fe6-41a7-98f7-0bad295e92ba_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_17feea0d-4d7b-4f36-8d2e-0ba74c3ae2b7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d660c924-3bc2-4901-b4d3-f6a743db57e3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_91ae9823-7955-458b-85b2-8f7fc8ad77dc_terseLabel_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir/Velpatasvir</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_label_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:href="gild-20211231.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:to="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_c488c5af-3e9e-405b-8aa1-e147a7bec00b_terseLabel_en-US" xlink:label="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage</link:label>
    <link:label id="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_label_en-US" xlink:label="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</link:label>
    <link:label id="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_documentation_en-US" xlink:label="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:href="gild-20211231.xsd#gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:to="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_aacb51cf-5a2f-4d07-889a-d01fcf49e401_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4e75db45-3dd4-404d-bb39-6bcefdc10b4b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_62efc945-5110-4e23-bb34-275e109269c7_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_29730558-e599-4759-ab7e-9588225b991d_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GadetaBVCollaborationArrangementMember_d07d222b-6adb-43e3-b05b-36308e72620f_terseLabel_en-US" xlink:label="lab_gild_GadetaBVCollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gadeta collaboration arrangement</link:label>
    <link:label id="lab_gild_GadetaBVCollaborationArrangementMember_label_en-US" xlink:label="lab_gild_GadetaBVCollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gadeta B.V. Collaboration Arrangement [Member]</link:label>
    <link:label id="lab_gild_GadetaBVCollaborationArrangementMember_documentation_en-US" xlink:label="lab_gild_GadetaBVCollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gadeta B.V. Collaboration Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GadetaBVCollaborationArrangementMember" xlink:href="gild-20211231.xsd#gild_GadetaBVCollaborationArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GadetaBVCollaborationArrangementMember" xlink:to="lab_gild_GadetaBVCollaborationArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4f2dac85-a3ef-40a0-b5f5-99e16ea1906f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right-of-use asset, statement of financial position, extensible enumeration</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_e51d0310-de02-4dd3-a87e-7a97f52f2b46_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ed50e58a-3bea-41af-9035-cc467f5df1c3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings at different rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RestrictedStockandPerformanceShareAwardsMember_88d0d64d-6c4d-415f-8106-4236fe5880c2_terseLabel_en-US" xlink:label="lab_gild_RestrictedStockandPerformanceShareAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock and performance share awards</link:label>
    <link:label id="lab_gild_RestrictedStockandPerformanceShareAwardsMember_label_en-US" xlink:label="lab_gild_RestrictedStockandPerformanceShareAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Performance Share Awards [Member]</link:label>
    <link:label id="lab_gild_RestrictedStockandPerformanceShareAwardsMember_documentation_en-US" xlink:label="lab_gild_RestrictedStockandPerformanceShareAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Performance Share Awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RestrictedStockandPerformanceShareAwardsMember" xlink:href="gild-20211231.xsd#gild_RestrictedStockandPerformanceShareAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RestrictedStockandPerformanceShareAwardsMember" xlink:to="lab_gild_RestrictedStockandPerformanceShareAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_a221edc5-770d-4cd6-85b4-cde10718018b_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_f5fe34b7-0547-461d-b9f8-164a6667a3ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bf498139-e01a-424a-bf21-48f3f3c4fc7c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_f69d2c9b-2e25-49bb-95fa-7495bb500341_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3d8c2d27-b3ca-468a-bdee-db9892603f57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification and Fair Value of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_65e8643c-7463-421a-a3be-6e8716b8bd98_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office, computer equipment and other</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_abeb66c5-5028-40c6-8c7e-104debfb5f58_terseLabel_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, contract and other revenues</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_label_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_documentation_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember" xlink:href="gild-20211231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RoyaltyContractAndOtherMember" xlink:to="lab_gild_RoyaltyContractAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_2d6f4f98-b0d1-4842-ab9f-a043b1b1e3e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount reversed against previously recorded litigation accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_e22dd1ee-33a2-46ad-a83f-84e57d2106d2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_8c807089-40b0-4f09-9d0a-4113a7af8348_terseLabel_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - sofosbuvir</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_label_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset - Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember" xlink:href="gild-20211231.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IntangibleAssetSofosbuvirMember" xlink:to="lab_gild_IntangibleAssetSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_28cbd502-bb56-407d-ba93-db70d6601860_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_aaae3c3a-ca2c-4dc6-a2b7-c6841a3fcf8b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_30ed5c58-ae42-4f1c-b8e8-9d537431cdc3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_16e077d9-90a9-40ef-a3a4-c50c460cffe0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7620c711-ebe8-4ab7-8699-edbe1d8db0ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_81bfcd67-a1e4-4dd1-b735-2346c15b7e47_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c9d8ece5-9d35-4afa-97ef-7054baaf32d8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member_426a6047-548c-4e78-8272-bf049411cb21_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due in September 2022</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2022 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9ffe8be5-9bd2-4070-9112-436e485c07b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ccd7ae3d-bc4d-4d20-a79c-1b6a2da130b3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_067545ca-35a9-4eeb-81b3-37111bab3edd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_149f102d-e2b8-4f93-b523-99a70e394da1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e3bca24b-f11c-4228-96de-262d6e62af3a_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_aa96abd3-0873-4948-b086-b3461ebf1862_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_060977b6-8d1d-4bff-a390-b140877e1fdd_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_6bedbcad-ad37-4a37-a8fa-642a5d603e83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contractual Maturities of Financing Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_62ffc72f-407a-4637-ae33-5df19070e052_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cell Therapy</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:href="gild-20211231.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:to="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_a993bd32-38c1-44b0-9e7d-ad4a9605ff53_terseLabel_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of material transfer agreements</link:label>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_label_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Material Transfer Agreements, Number</link:label>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Material Transfer Agreements, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:href="gild-20211231.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:to="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusCollaborationAgreementMember_0b08bb6e-ff1f-4a1e-b524-975a2c5094d6_terseLabel_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus collaboration agreement</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementMember" xlink:href="gild-20211231.xsd#gild_ArcusCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusCollaborationAgreementMember" xlink:to="lab_gild_ArcusCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_75cd3a60-08bd-48a0-b84f-cc59b449f1bd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_50eade4b-4c0f-4d01-bf5e-2f5eddbc748a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_fc64a15f-a892-4c57-b2a3-07ab66f189ae_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f88f4aff-1c04-4f4f-998a-34d8485d903f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_785adf39-f2ae-480e-867d-6aeade47e6ec_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest in variable interest entity</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest in Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:to="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8bee4884-2073-4534-a968-02150231e8b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_9ab5fdd7-330a-419b-bdb4-fd0c27e9026e_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_3d0a16a2-3522-49c6-bd97-828233811406_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HB/HDV</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Other [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:href="gild-20211231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2bb4f95e-fc0f-4a28-b30f-9b886ba16d2f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_dc3030b1-23e2-4133-8149-9e7525df1311_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5ee7e631-8cd9-42bd-a3f6-c0bc09d7f32d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_5ec6647c-7cc5-4332-90ca-667ad9f98278_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Classification of Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_2c5fadbd-599c-492f-93c6-bb3d53aa35bc_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed, scenario one</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_label_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario One</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_documentation_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:href="gild-20211231.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:to="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IntangibleAssetTransferMember_fd1b7fef-c92b-49bc-a75d-bad78ca5e5f2_terseLabel_en-US" xlink:label="lab_gild_IntangibleAssetTransferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Transfer</link:label>
    <link:label id="lab_gild_IntangibleAssetTransferMember_label_en-US" xlink:label="lab_gild_IntangibleAssetTransferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Transfer [Member]</link:label>
    <link:label id="lab_gild_IntangibleAssetTransferMember_documentation_en-US" xlink:label="lab_gild_IntangibleAssetTransferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Transfer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetTransferMember" xlink:href="gild-20211231.xsd#gild_IntangibleAssetTransferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IntangibleAssetTransferMember" xlink:to="lab_gild_IntangibleAssetTransferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_95eace2c-1295-447a-ad35-6f13040e18b4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ec5a6121-f0bd-44fb-8c20-0cfc7ca8c46a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResearchAndDevelopmentFutureMaximumPayments_ffaef8a6-6108-4329-ad14-4c3a31808df5_terseLabel_en-US" xlink:label="lab_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development future maximum payments</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentFutureMaximumPayments_label_en-US" xlink:label="lab_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Future Maximum Payments</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentFutureMaximumPayments_documentation_en-US" xlink:label="lab_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Future Maximum Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:href="gild-20211231.xsd#gild_ResearchAndDevelopmentFutureMaximumPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:to="lab_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_2ba25867-834e-47cc-98e0-94c7e3da45f6_terseLabel_en-US" xlink:label="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call feature, period prior to maturity</link:label>
    <link:label id="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_label_en-US" xlink:label="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Call Feature, Period Before Maturity</link:label>
    <link:label id="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_documentation_en-US" xlink:label="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Call Feature, Period Before Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:href="gild-20211231.xsd#gild_DebtInstrumentCallFeaturePeriodBeforeMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:to="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_53daf747-e8d7-4ad1-a5f3-4dff5086b07a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of vested stock awards as of vesting date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ea2b94b8-a032-4cc4-8a45-f1aef7278ce3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MerckMember_d347f52f-150b-46a1-b608-904a40b44464_terseLabel_en-US" xlink:label="lab_gild_MerckMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_gild_MerckMember_label_en-US" xlink:label="lab_gild_MerckMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_gild_MerckMember_documentation_en-US" xlink:label="lab_gild_MerckMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckMember" xlink:href="gild-20211231.xsd#gild_MerckMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MerckMember" xlink:to="lab_gild_MerckMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_03ca1e8a-10f3-4099-98f9-8bf3be45dcdf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4acc5010-f1ea-4790-b77b-600783a25a2a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_2b6433a2-4be3-40e6-a9dd-8ff50cadaab6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_2979438a-97c5-461a-9ab5-49813e42f061_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_bc16f138-8513-4ca5-b00b-9561e0855e86_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductSalesMember_7f081f1a-910e-486e-820e-d8437b3dd38b_terseLabel_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HIV</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_label_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember" xlink:href="gild-20211231.xsd#gild_HIVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductSalesMember" xlink:to="lab_gild_HIVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_963c1ac0-b4ac-42d1-99fe-f0ec923dc356_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c638f421-4aba-4e80-bf56-3c2fd24851ed_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_4d530ebe-3a53-4e37-a65a-84d9191dae9c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_27a50ad9-671c-400d-8d2a-0b3d2f670dc8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_80d522f0-6c5f-488d-b4bc-5e127b55cfb3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_868a7f59-6de8-4aed-ad98-f7875a2a7c95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d4ab6dbe-22bd-4d4f-b4c2-f9fa4cf11594_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember_13fa4c32-84d6-4d7a-83b4-887ed72b8e33_terseLabel_en-US" xlink:label="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Plan</link:label>
    <link:label id="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember_label_en-US" xlink:label="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences, Inc. 2004 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences, Inc. 2004 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2004EquityIncentivePlanMember" xlink:href="gild-20211231.xsd#gild_GileadSciencesInc2004EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GileadSciencesInc2004EquityIncentivePlanMember" xlink:to="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f12e314a-d93b-4340-abc1-651b2d582067_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_6ec2b117-a663-436f-aa42-87cfe90df8ad_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f3572603-7d62-4907-8486-d5f99510cbe2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsRanexaMember_6d281ecf-a723-4bcf-a3e6-34d92ab8e34f_terseLabel_en-US" xlink:label="lab_gild_OtherProductsRanexaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranexa</link:label>
    <link:label id="lab_gild_OtherProductsRanexaMember_label_en-US" xlink:label="lab_gild_OtherProductsRanexaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Ranexa [Member]</link:label>
    <link:label id="lab_gild_OtherProductsRanexaMember_documentation_en-US" xlink:label="lab_gild_OtherProductsRanexaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Ranexa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsRanexaMember" xlink:href="gild-20211231.xsd#gild_OtherProductsRanexaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsRanexaMember" xlink:to="lab_gild_OtherProductsRanexaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e3050147-99db-48ef-99fb-7cdcbbde2d1c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_15044632-8ece-4bb9-a32c-ee55b601e4d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_775c3945-9a88-4bb8-8494-f93746b94425_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_430d1520-b85a-4df4-bd20-bfe54d556577_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_50010a99-a551-44a7-b935-3edf18b4d55b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56b64cb9-b182-4fa8-96ae-a5a03ef1dda9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_84404773-528b-44ac-8a0a-c48f96102859_terseLabel_en-US" xlink:label="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period subject to termination</link:label>
    <link:label id="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_label_en-US" xlink:label="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Product Market Period Subject To Termination</link:label>
    <link:label id="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_documentation_en-US" xlink:label="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Product Market Period Subject To Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" xlink:href="gild-20211231.xsd#gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" xlink:to="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_995ec5b0-2435-46d2-86ef-5fc30092bb78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b97d7b15-d15f-45ca-9b62-b014c7c71502_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_5d0aa5f4-935c-4047-92d6-e8b3b076e6ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_a03c90c6-3895-401c-9349-eb37ef28159f_terseLabel_en-US" xlink:label="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of goods less specified amount, maximum percentage</link:label>
    <link:label id="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_label_en-US" xlink:label="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price of Goods Less Specified Amount, Maximum Percentage</link:label>
    <link:label id="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_documentation_en-US" xlink:label="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price of Goods Less Specified Amount, Maximum Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" xlink:href="gild-20211231.xsd#gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" xlink:to="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_292d0746-1b8b-4a28-92b8-f68717cf4803_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued repatriation of foreign earnings, expected to be paid</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_6fe64376-3ee6-4dac-ab77-129be240b15e_terseLabel_en-US" xlink:label="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2019 agreement</link:label>
    <link:label id="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_label_en-US" xlink:label="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Filgotinib License and Collaboration Agreement in December 2020 [Member]</link:label>
    <link:label id="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_documentation_en-US" xlink:label="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Filgotinib License and Collaboration Agreement in December 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:href="gild-20211231.xsd#gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:to="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_61396611-4b51-4854-98a7-6b6962f081be_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3a013163-8fbc-49d7-8839-aace7532a1a9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3e1ce46d-b812-4e5a-81f5-c79ce1ac61c5_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c8ae2aec-fbae-4cf7-8d60-4e782f3182da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_4ce53076-3470-488f-b519-36d44663f729_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20211231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_66ff1904-a526-40ff-b9f8-8469e79a9eb6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_1e7da617-cad6-4278-89f4-80fa10330c48_terseLabel_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_label_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_documentation_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember" xlink:href="gild-20211231.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmerisourcebergenCorpMember" xlink:to="lab_gild_AmerisourcebergenCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_eae81afe-8926-497b-b5e4-4eeb8566f8dd_terseLabel_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus stock purchase agreement</link:label>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_label_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember" xlink:href="gild-20211231.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusStockPurchaseAgreementMember" xlink:to="lab_gild_ArcusStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_4890f141-02ee-495a-b76f-f7974985761b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_35d36ceb-4c07-4ad9-b0d8-16d413dfae6d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsOtherMember_ccd3dcc6-cf4d-4d26-abca-4b360ace5915_terseLabel_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_label_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_documentation_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember" xlink:href="gild-20211231.xsd#gild_OtherProductsOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsOtherMember" xlink:to="lab_gild_OtherProductsOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_636e54d0-0946-4ee9-a06c-a544419d6306_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions_afb45ea6-5516-496b-bd1c-11b8be05b853_terseLabel_en-US" xlink:label="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical stage programs with exercise options</link:label>
    <link:label id="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions_label_en-US" xlink:label="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Stage Programs With Exercised Options</link:label>
    <link:label id="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions_documentation_en-US" xlink:label="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Stage Programs With Exercised Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:href="gild-20211231.xsd#gild_NumberOfClinicalStageProgramsWithExercisedOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:to="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ca3f4504-d050-4b6e-b6da-deead8cba9ca_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_33c3cb0e-04a5-4590-abae-bb910ba7a7ca_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire shares</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_45b65196-c584-476c-98f9-8876cd54c668_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign:</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1fb2cdf4-674a-4068-9c65-4be8391b095c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Contingent Consideration Resulting from a Business Combination and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member_bf8d9899-ca1d-490a-ba0d-4df855b6d871_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due in February 2045</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in February 2045 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in February 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_985ec874-2dc1-4352-9d6f-4a8ab50ee85b_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_4388d46c-edc3-4f28-9922-9aaa3da139d2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_c3c15fbe-03e2-4916-ab92-06055d2e9330_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f5e6e1bc-0ac7-4db0-8713-2f151a33bb34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_bc2d72de-f4da-427c-9f55-9a32105392e1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6994359c-ddf6-4833-a3bb-720954e55d1e_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_b7bebf04-a83d-4a7f-b7c7-4bcd5db87356_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FairValueatGrantDateMember_ecd0141c-5eb9-4d0c-9d69-d1141212cef3_terseLabel_en-US" xlink:label="lab_gild_FairValueatGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at grant date</link:label>
    <link:label id="lab_gild_FairValueatGrantDateMember_label_en-US" xlink:label="lab_gild_FairValueatGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value at Grant Date [Member]</link:label>
    <link:label id="lab_gild_FairValueatGrantDateMember_documentation_en-US" xlink:label="lab_gild_FairValueatGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value at Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueatGrantDateMember" xlink:href="gild-20211231.xsd#gild_FairValueatGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FairValueatGrantDateMember" xlink:to="lab_gild_FairValueatGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_12c5bb15-3dea-4e59-9fca-9b9491bf3d15_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ScheduleOfInventoriesLineItems_316ea6a3-5e3d-4bfc-8fb9-0f4a42fe6025_terseLabel_en-US" xlink:label="lab_gild_ScheduleOfInventoriesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Line Items]</link:label>
    <link:label id="lab_gild_ScheduleOfInventoriesLineItems_label_en-US" xlink:label="lab_gild_ScheduleOfInventoriesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories [Line Items]</link:label>
    <link:label id="lab_gild_ScheduleOfInventoriesLineItems_documentation_en-US" xlink:label="lab_gild_ScheduleOfInventoriesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleOfInventoriesLineItems" xlink:href="gild-20211231.xsd#gild_ScheduleOfInventoriesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ScheduleOfInventoriesLineItems" xlink:to="lab_gild_ScheduleOfInventoriesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b00690eb-170c-40a3-beec-33029ead7519_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0035847f-3bfc-4a64-8c47-8b7f53069a06_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsToOptInTheCollaborativeAgreement_ba0a782d-0c89-4bb1-b5c6-69228ba50169_terseLabel_en-US" xlink:label="lab_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration opt-in payments</link:label>
    <link:label id="lab_gild_PaymentsToOptInTheCollaborativeAgreement_label_en-US" xlink:label="lab_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Opt-In The Collaborative Agreement</link:label>
    <link:label id="lab_gild_PaymentsToOptInTheCollaborativeAgreement_documentation_en-US" xlink:label="lab_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Opt-In The Collaborative Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:href="gild-20211231.xsd#gild_PaymentsToOptInTheCollaborativeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:to="lab_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_07232203-64d2-434b-b0a8-aaaacf84bf48_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1a95f64b-fd83-409d-99c9-1beb85b26e6d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_4a5ca893-a264-4861-9973-a352baf3ba21_terseLabel_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_label_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030 [Member]</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_documentation_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:href="gild-20211231.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:to="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_be4b25d7-233f-47e7-ad17-373bbc41bd9c_terseLabel_en-US" xlink:label="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for adjustments of budgeted development costs</link:label>
    <link:label id="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_label_en-US" xlink:label="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Adjustments of Budgeted Development Costs</link:label>
    <link:label id="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_documentation_en-US" xlink:label="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Adjustments of Budgeted Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:href="gild-20211231.xsd#gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:to="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_f7279acd-3a9f-4354-b5ce-f89afc269494_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_f04ae42b-3144-447c-b48d-e59ea72de4ea_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax expense (benefit), continuing operations</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired_02f1f9c0-9aa4-48af-a746-372222fa8a0c_terseLabel_en-US" xlink:label="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration, net of acquired cash</link:label>
    <link:label id="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired_label_en-US" xlink:label="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Assets, Net Of Cash Acquired</link:label>
    <link:label id="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired_documentation_en-US" xlink:label="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Assets, Net Of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:href="gild-20211231.xsd#gild_PaymentsToAcquireAssetsNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:to="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_71be75f7-46bc-4c39-baa6-f2a517fff9db_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2819820b-e6b7-4857-9045-c1eb85a5eca4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_VariableTermLoanNoteDueOctober2023Member_f1a69385-83d7-4f94-8253-f5d1b209ac95_terseLabel_en-US" xlink:label="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Term Loan Note Due October 2023</link:label>
    <link:label id="lab_gild_VariableTermLoanNoteDueOctober2023Member_label_en-US" xlink:label="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Term Loan Note Due October 2023 [Member]</link:label>
    <link:label id="lab_gild_VariableTermLoanNoteDueOctober2023Member_documentation_en-US" xlink:label="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Term Loan Note Due October 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member" xlink:href="gild-20211231.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_VariableTermLoanNoteDueOctober2023Member" xlink:to="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_c371e0a7-9b80-467d-a34c-3f88482a49af_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_16545110-d19a-4c0b-8f6d-754e381d66bf_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3b447035-a868-4f91-b2c6-2539e1694ee7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsForDirectTransactionalExpense_880eaa65-01e3-4f40-a4ba-1faafab0a949_terseLabel_en-US" xlink:label="lab_gild_PaymentsForDirectTransactionalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct transactional costs</link:label>
    <link:label id="lab_gild_PaymentsForDirectTransactionalExpense_label_en-US" xlink:label="lab_gild_PaymentsForDirectTransactionalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Direct Transactional Expense</link:label>
    <link:label id="lab_gild_PaymentsForDirectTransactionalExpense_documentation_en-US" xlink:label="lab_gild_PaymentsForDirectTransactionalExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Direct Transactional Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForDirectTransactionalExpense" xlink:href="gild-20211231.xsd#gild_PaymentsForDirectTransactionalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsForDirectTransactionalExpense" xlink:to="lab_gild_PaymentsForDirectTransactionalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_127259a0-e58b-4878-8bcc-1d44cc0445bd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9728dd37-e685-4836-9027-a58cac0c8528_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_92201a41-55bc-4385-8eab-a025b7e73b30_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ed264761-9e03-4dcd-b073-066fd80a0663_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_44388ef5-288b-4aa0-a3e4-cebaf00bdfd7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d593a2e2-a553-4711-bc1e-6fe7d7ebbd52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsTotalMember_f0bdfb98-20db-4d70-90cd-ef8e8d9659b7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsTotalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsTotalMember_label_en-US" xlink:label="lab_us-gaap_AssetsTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Total [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsTotalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsTotalMember" xlink:to="lab_us-gaap_AssetsTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_938bade6-f37d-4d79-ba65-5a8187e135fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_31234954-b1f8-4c9b-b9c4-8f9a289c58f4_terseLabel_en-US" xlink:label="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional patents allegedly infringed</link:label>
    <link:label id="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Additional Patents Allegedly Infringed, Number</link:label>
    <link:label id="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Additional Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:href="gild-20211231.xsd#gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:to="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c6cb3d6c-e792-4ffc-ba2b-ae5d5b57f546_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3b510d8b-8aa4-4db7-9791-ca6b4e64d349_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_6263a8b2-2139-4ede-a78d-936cbe04afed_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount (Legal Offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_f269d1e9-5118-4f6c-b58c-ada9cd64632d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock_46f31859-7e8e-4c06-8853-5ed2d9a59d78_terseLabel_en-US" xlink:label="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Life</link:label>
    <link:label id="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock_label_en-US" xlink:label="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant and Equipment Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock_documentation_en-US" xlink:label="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Lives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" xlink:href="gild-20211231.xsd#gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" xlink:to="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_de3a7ed5-47b9-470b-a0a9-77f43cdc8be1_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_8919bcb6-cc67-4e37-b683-fa4f45dcabca_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State:</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4a385a56-1fc6-4344-8487-29f8d5c16353_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share Attributable to Gilead Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_374a1f38-c58c-4254-bbf1-4ae4e5ad5cd6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2024Member_9e8ea3f5-f5b8-4987-8da9-1cbdc809bb9c_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due in April 2024</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2024Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in April 2024 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2024Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in April 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinApril2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_e0db243e-1745-4170-b82e-4f739afbb727_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_b104cc09-3c96-43c2-9f7e-85fa32621bb8_terseLabel_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue share - Symtuza</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_label_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_documentation_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:href="gild-20211231.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:to="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_adfa94fb-433c-4a2b-a950-fab745878bbe_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fbfe8505-cfc6-4527-ba74-931a28c4a43f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_caec897f-0bb2-4c93-a7f9-cc4cce10719d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts outstanding under the facility</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90b6f09b-1c2d-460d-9b32-dc8b68d30c86_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_aaf8fb02-c585-4d99-8c65-f5c8799f1f4e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsTruvadaMember_c8acbfe8-c327-48f3-aeae-9ebd59b0437f_terseLabel_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Truvada</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_label_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember" xlink:href="gild-20211231.xsd#gild_HIVProductsTruvadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsTruvadaMember" xlink:to="lab_gild_HIVProductsTruvadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_4ceb4787-e2ec-437d-89f2-aac203e1c445_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2835c547-59f8-471b-9fcc-7cd7d4a3361f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_471947e1-1578-4c06-847c-0e31fb4194e1_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_b7a477a9-3faf-4b08-ad53-c64c157b7d5d_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_ce9f877a-4c11-4d61-a016-4c2bf47c7b1a_terseLabel_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_label_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040 [Member]</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_documentation_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:href="gild-20211231.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:to="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MYRGmbHMember_3b99fa99-1c50-40d0-99c9-806c8f578b7a_terseLabel_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR</link:label>
    <link:label id="lab_gild_MYRGmbHMember_label_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH [Member]</link:label>
    <link:label id="lab_gild_MYRGmbHMember_documentation_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH (&#8220;MYR&#8221;), a German biotechnology company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember" xlink:href="gild-20211231.xsd#gild_MYRGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MYRGmbHMember" xlink:to="lab_gild_MYRGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_QuiTamMember_f4f36080-c4a7-40f1-94c2-308fc3de5cfc_terseLabel_en-US" xlink:label="lab_gild_QuiTamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qui Tam</link:label>
    <link:label id="lab_gild_QuiTamMember_label_en-US" xlink:label="lab_gild_QuiTamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qui Tam [Member]</link:label>
    <link:label id="lab_gild_QuiTamMember_documentation_en-US" xlink:label="lab_gild_QuiTamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qui Tam</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_QuiTamMember" xlink:href="gild-20211231.xsd#gild_QuiTamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_QuiTamMember" xlink:to="lab_gild_QuiTamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6f2367f3-201c-4282-88e9-1e86c92cd29d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_92bdc9d9-c189-4fc0-977e-fd82e29d6c05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated stock-based expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Accelerated Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6d1db638-9e12-438c-9771-f2c7006c1aff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, including in-process research and development, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_63bf1427-aa09-4158-bffa-5a3709fbd489_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_b97b8a92-25ae-4446-b379-15dc825a36f1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Credit Facilities</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6a0b67af-8c7f-4afb-8f26-66d1a3dc2878_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4328c3fa-c830-469b-a8ed-601dc0d0040e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of tax basis over book basis of intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_a80552c8-39ca-498c-936b-b95a4834c636_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4b7ec764-83cf-4d21-916a-7b8f69a7f29a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_fccb9799-4a6c-4ad4-9fac-06aa100fe51d_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_33e6a252-19e6-4ec2-8bf5-419f83158fbc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_d11d8bfa-7e66-4c8f-932c-93e0f6f5e571_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductLiabilityMember_22e5c121-93f7-4814-8a2f-ca848e0e529e_terseLabel_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_gild_ProductLiabilityMember_label_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Member]</link:label>
    <link:label id="lab_gild_ProductLiabilityMember_documentation_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember" xlink:href="gild-20211231.xsd#gild_ProductLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductLiabilityMember" xlink:to="lab_gild_ProductLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_15ce3e4b-1561-4265-8818-7575c8ce3560_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Donation expense</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_21a6c6e0-11af-4b06-a67d-1aee75106dd0_terseLabel_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of tiered royalties, low-end percentage</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_label_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalty, Low-end, Percentage</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_documentation_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalty, Low-end, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:href="gild-20211231.xsd#gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:to="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_1009ef9e-d73f-4876-80e4-1889e2dfa1c5_terseLabel_en-US" xlink:label="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharp &amp; Dohme Corp</link:label>
    <link:label id="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharp &amp; Dohme Corp License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharp &amp; Dohme Corp License And Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:href="gild-20211231.xsd#gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:to="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_33b683fc-4fe5-463b-83f0-516caf1b197c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_f19eebcb-46b0-4403-bb3c-4ba5baf67d9e_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_3b4f0461-c767-4853-94ea-786984bf080d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill resulting from acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fa838354-1304-4642-a7ce-83e05c8fafc0_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_4a6e9212-e4dc-4244-8dcb-9f305f9798ff_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9b8f6649-7edf-4cd0-b23b-2436fcaf3629_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_51c72d37-484c-4c32-a4ff-8542e589da3e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueApril2021Member_dd0a6e84-b548-451a-9b84-a5e1cca210f8_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueApril2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due in April 2021</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueApril2021Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueApril2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due April 2021 Member</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueApril2021Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueApril2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due April 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueApril2021Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueApril2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueApril2021Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueApril2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_16bc8838-8aff-451e-8c52-d0bb9ebf5754_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_15c44846-06d5-4b62-920f-6043b96a592e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_c148f242-3ae2-4eac-9a17-c7e0b5ab0a9c_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowances for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_f8431acf-d3c6-44f8-a863-ac1d2b6370e9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt financing, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_14c42ae7-52ee-40f1-87f7-70706adc6f3c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-downs</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MediumTermNotesMember_a2b92d0a-3de0-46ff-bd61-9e199b7e78eb_terseLabel_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term notes</link:label>
    <link:label id="lab_us-gaap_MediumTermNotesMember_label_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MediumTermNotesMember" xlink:to="lab_us-gaap_MediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_2c766188-9ed1-4a34-8b43-f32e1c3d9a21_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_0ffc54fd-6d98-4ac2-a5e4-bae94d927b6b_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HBV/HDV</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:href="gild-20211231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_b5468877-f211-44f8-895d-502d491d700c_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash discounts and other</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:href="gild-20211231.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:to="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_c32bfa99-a346-49a4-80c7-b24f063ec1bd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issued</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_13222897-4dd1-4902-9779-071f1d039d8a_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_769a2976-330a-4cae-a404-8707a6fe42fe_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_36b647bd-bd0f-47b6-8d77-fbc3eac0af23_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investment of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_730d1661-6407-4a72-9610-ea260d7f0daa_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5c721bf8-375d-4bb6-91d2-fd4551dfdcc0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_73ba16ca-581f-41ed-9e53-7cf2a86e1924_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0c88010a-02f7-4ca7-825f-de52735ab770_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_cf994861-c156-42e5-b078-59d552d950b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4b13f356-a1c6-4760-8497-a96bf45f7164_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_39081963-c0d1-4c36-bd99-a3f6602f0d58_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments, year three</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b6ff60e5-f114-46a2-8abe-6005b82cd59b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_f8b25d63-4a9e-4bc2-86a9-5d4883b1bbe4_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_8a032201-aa7e-4c0d-bd78-27d76b28e541_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value&#160;</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_1a98d235-8fac-40d6-be08-3a4c2320ed6e_netLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_97a07895-c939-4786-8bba-49e6f6326b84_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_dd2b1e1e-4042-4eb5-8f49-c5ec71b2849a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_f9320b13-bd9e-46c9-b222-fe4a0d25da27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member_875a1af0-da19-40e8-9046-2cbfc60f4d1d_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due in September 2036</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2036 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IssuanceDiscountPremium_35f0513b-b69e-4d48-87ce-9a72be98d7f7_terseLabel_en-US" xlink:label="lab_gild_IssuanceDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance discount (premium)</link:label>
    <link:label id="lab_gild_IssuanceDiscountPremium_label_en-US" xlink:label="lab_gild_IssuanceDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Discount (Premium)</link:label>
    <link:label id="lab_gild_IssuanceDiscountPremium_documentation_en-US" xlink:label="lab_gild_IssuanceDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IssuanceDiscountPremium" xlink:href="gild-20211231.xsd#gild_IssuanceDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IssuanceDiscountPremium" xlink:to="lab_gild_IssuanceDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_255892e9-4970-4ce7-b3c5-f768c6f172b2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_79578a86-68d6-4c0d-a5f7-0a691c9db97a_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ed623623-6092-4385-b697-fea7fb48dbf3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock&#160;</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_250f5e54-690a-4629-8e27-d1874a4a10f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_ff045c79-e20e-45e2-8d7b-39dc65634f5a_totalLabel_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Indefinite Lived Intangible Assets Excluding Goodwill</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_documentation_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="gild-20211231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8d8b7c7a-810f-4e7b-b066-3366c27d098d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e090d81e-2eb8-4685-960b-95f75a79319e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cd6ab1c4-fe78-4534-9ca0-40d0ffd1d73b_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_4d392293-fd2f-4fa2-8b5c-2a5e648e2253_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_144f4de6-7b8b-429d-9446-7d0ef2681b68_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_b8d2d435-a154-4dad-bea7-6ca8e9e59915_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ce7ab482-2411-4a11-9a93-ddc7f89e8823_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member_60bda011-a5c5-4d9b-ad6d-58f98edc36e4_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due in February 2025</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in February 2025 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in February 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_e005c494-c8d6-4bf4-bd5c-6ec9a9a14b9e_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7f18eafd-afb2-4f48-b086-8fbc33d1a500_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_3f23f5db-e542-402a-bc86-dcd003cd09e5_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_2839f6ea-cc21-4c4c-987c-4d3678051bd8_terseLabel_en-US" xlink:label="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate of finite-lived intangible asset acquired</link:label>
    <link:label id="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_label_en-US" xlink:label="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_documentation_en-US" xlink:label="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:href="gild-20211231.xsd#gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:to="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_c4757c47-3405-4a7e-b0fb-70973219c5f6_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable debt securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:href="gild-20211231.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:to="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_88f4067b-bd1e-4ace-99cd-88814ff4eff2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales_55e339a4-39ab-4e47-a50c-8483535ba867_terseLabel_en-US" xlink:label="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage on future sales</link:label>
    <link:label id="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales_label_en-US" xlink:label="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Royalty Percentage On Future Sales</link:label>
    <link:label id="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales_documentation_en-US" xlink:label="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Royalty Percentage On Future Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyRoyaltyPercentageOnFutureSales" xlink:href="gild-20211231.xsd#gild_LossContingencyRoyaltyPercentageOnFutureSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyRoyaltyPercentageOnFutureSales" xlink:to="lab_gild_LossContingencyRoyaltyPercentageOnFutureSales" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsForResearchAndDevelopmentMilestones_dfe56922-4248-47f7-8c8b-c0376ed1e84e_terseLabel_en-US" xlink:label="lab_gild_PaymentsForResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments made for research and development milestones</link:label>
    <link:label id="lab_gild_PaymentsForResearchAndDevelopmentMilestones_label_en-US" xlink:label="lab_gild_PaymentsForResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Research and Development Milestones</link:label>
    <link:label id="lab_gild_PaymentsForResearchAndDevelopmentMilestones_documentation_en-US" xlink:label="lab_gild_PaymentsForResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Research and Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForResearchAndDevelopmentMilestones" xlink:href="gild-20211231.xsd#gild_PaymentsForResearchAndDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsForResearchAndDevelopmentMilestones" xlink:to="lab_gild_PaymentsForResearchAndDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_d9016817-7e5c-4193-9f25-530b0b2cafc8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7a14cf66-be3f-4edb-9ab4-1074f09b130f_verboseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_ec943947-841a-42c7-96a1-cd66f2a80e2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6d70b4a5-aa7c-4d4d-8d74-e40001f7561b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, current, statement of financial position, extensible enumeration</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_552b8ed7-97f9-4caf-abb5-d4d784d42586_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding notional amounts on foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_6bd748e3-0453-49c2-aabb-da1f12656bec_terseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_731ea6ad-ad74-4d4a-8dac-57053ba6b066_negatedTerseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_label_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_documentation_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:href="gild-20211231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:to="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_211e2938-d55e-404f-91da-26ab7ebb785b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_49675f3c-536d-45d9-ab3d-3ca998eaad33_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2633e4b1-973d-42cc-8a0b-4930db2cdf88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ac84ab66-05d4-44ee-9a84-fa1264685b0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6e54939a-afe1-4f32-8ca4-1c27b2aaf957_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_fb17e70e-b1d5-4a8f-895c-43dd3ce93013_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_89779d25-76f0-4cf4-83f9-09105b79b8a4_terseLabel_en-US" xlink:label="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tango collaboration and stock purchase agreement</link:label>
    <link:label id="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_label_en-US" xlink:label="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Research Collaboration and License Agreement and Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Research Collaboration and License Agreement and Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:href="gild-20211231.xsd#gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:to="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_871955d4-ca93-4ca0-a64d-6d97b044a3aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e8a1aa8c-c35c-4125-810a-7610e87b6724_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_54b006cf-d3ef-47cf-9639-23b80c5ee58a_terseLabel_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 revolving credit facility</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_label_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member" xlink:href="gild-20211231.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CreditFacilityDueJune2025Member" xlink:to="lab_gild_CreditFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1efa3ce2-cf6b-4234-a7b4-3dfe63092372_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0ba144f8-720d-4736-ae59-2d7914a10e83_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1d2b670c-cedc-462a-b73f-47667fa34a82_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_9c6b4afd-b64d-43ea-a88e-55b3dc586a9c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_56983b76-ce55-4608-90b0-e9f99332f814_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member_66cfe72b-671a-472e-accd-3573d3a82b4b_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due in September 2035</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2035 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2035</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_3e005525-e467-4a1f-bd1c-90e2a8445fa7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_bd4c4183-5127-4466-8788-4f0500b94aae_terseLabel_en-US" xlink:label="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_label_en-US" xlink:label="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Upfront and Milestone Payments</link:label>
    <link:label id="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_documentation_en-US" xlink:label="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Upfront and Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:href="gild-20211231.xsd#gild_DeferredTaxAssetsUpfrontAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:to="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b5ea5829-7ce7-42cf-a50d-adfb88ee8479_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated OCI by Component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_a86f48a3-0a5f-4048-b794-d87f22b7c5fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8eed0384-7a9c-4f3c-94c5-7049de9f9be0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_2a1466ac-8771-4ec3-adcb-c3c234ff666b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2026ExpirationMember_951d6f0d-2b73-4224-a68c-d1d8ed4bad08_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2026ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2026 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2026ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2026ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2026 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2026ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2026ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2026 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2026ExpirationMember" xlink:href="gild-20211231.xsd#gild_EuropeanPatentClaims2026ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2026ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2026ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNISharesAcquired_031428f8-8fa9-4454-8b0d-339d3767eb08_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares acquired (in shares)</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNISharesAcquired_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares Acquired</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNISharesAcquired_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNISharesAcquired" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNISharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNISharesAcquired" xlink:to="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_be8d7f90-f0c7-480e-848a-3c12a3a5b01f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_1e56fecf-a76c-4a4a-a63d-7cf81ff65eb8_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outlicense contract</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_83456cf4-422a-4f74-b975-7dce3433c287_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4e08df47-9108-45d5-a975-7e7e74087e0a_terseLabel_en-US" xlink:label="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="gild-20211231.xsd#gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0712a2b4-f72c-4e7c-a485-3e3e5965be7b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2edd03c1-d226-4611-b43b-b90d95509108_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_2421df29-1e7a-4966-8382-ed3f29a1c469_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_71a3858e-03e0-4921-8844-ccbd1a0b19ea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3eed0951-2358-49e2-96d5-b5d495917374_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9191ba2a-9200-4f2b-aace-b03574840b03_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_94c28fd5-ddeb-48a6-b020-33dd8b65e32a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognized</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5a41d9cb-1838-42d4-9a88-2b26ddda6c18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate:</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_d766b18c-3d31-46e8-bcb5-f5abd5ce59fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Effect of Foreign Currency Exchange Contracts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_9248cb3e-f2e0-4334-abb9-81772cfc9fe1_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8805fd85-1fbc-409b-97fe-f4d29dd8953e_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_9ec3b8ae-08a0-438c-9e6d-b67ec6a73a5b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_e72f42b6-0c09-4be1-a3b1-53ec5691b345_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a5344d4b-e79a-4514-8dd6-7b1abe487700_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_b6e4f4b3-e48c-402b-a55e-2dacfdfbf2ae_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized capitalized software costs</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_46cc94d3-22cd-41aa-ad34-7c382aa2c19a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5091dfe4-7293-44fd-958e-ef3ac722a876_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eba68fb7-9f98-4f18-b1d2-00dc24bf0108_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_66699a4e-78d2-4bee-b123-3b336f839984_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f3312c64-59b0-4c7f-9579-81f36e3d8414_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b7cbc98b-3034-4c36-979b-8176ca5ac2ef_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8d20ac18-7101-4149-b978-7b11879c97d0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_3c1079d0-da44-4b7b-80ad-80d849b27023_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_e1767eac-ad73-4f12-80b0-69720997473d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_67451f05-cfe5-45a1-ae66-282e6b52fe7e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_e2134b1b-61ec-4fb2-9033-9485a3c4b654_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_fb40b9b1-1036-48aa-8d9e-89abe9643272_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_825d5b78-147f-4726-9993-978ee24a9095_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b4b4c31-6268-47ce-b77c-163e1a2b38b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_412b4781-8902-4cf8-8a26-82ea8d8fc889_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2189af75-a7b0-4fb1-9885-b21528d0ee7c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_4b62b234-09ad-4f73-bff2-9da9bb2aafec_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_08b91880-ad21-4f3c-b284-57dd50be5173_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8a1b23e0-d340-4d63-9532-a51a0b5828b9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_6baeeaeb-195a-4cb0-88eb-927b9cd4317f_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_24cccc60-8040-4df6-b190-a60f34e9165b_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OralFormulationProductMember_e63ede18-5006-4eed-b0d1-24241d4857d7_terseLabel_en-US" xlink:label="lab_gild_OralFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation Product</link:label>
    <link:label id="lab_gild_OralFormulationProductMember_label_en-US" xlink:label="lab_gild_OralFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation Product [Member]</link:label>
    <link:label id="lab_gild_OralFormulationProductMember_documentation_en-US" xlink:label="lab_gild_OralFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OralFormulationProductMember" xlink:href="gild-20211231.xsd#gild_OralFormulationProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OralFormulationProductMember" xlink:to="lab_gild_OralFormulationProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_29bce56a-c676-4410-b2c5-7b2167378b33_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of outstanding stock allowed to be purchased</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:to="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalFairValueAxis_e8b600e3-4abb-492a-b84b-acb91da9b314_terseLabel_en-US" xlink:label="lab_gild_TotalFairValueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value [Axis]</link:label>
    <link:label id="lab_gild_TotalFairValueAxis_label_en-US" xlink:label="lab_gild_TotalFairValueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value [Axis]</link:label>
    <link:label id="lab_gild_TotalFairValueAxis_documentation_en-US" xlink:label="lab_gild_TotalFairValueAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalFairValueAxis" xlink:href="gild-20211231.xsd#gild_TotalFairValueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalFairValueAxis" xlink:to="lab_gild_TotalFairValueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_7a0848c8-95f7-4dde-a4fe-cdd8e5bc69b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bcb24601-978a-4572-9e25-ebb3608e142c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_ec4d401c-213b-4148-aa3d-81ddd65f0f51_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a25f1a8d-9ca3-4f79-976c-61e2d5eb4634_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_6c81957b-e690-41e1-be0b-a091764f36b2_terseLabel_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complera/Eviplera</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_label_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_documentation_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember" xlink:href="gild-20211231.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsCompleraEvipleraMember" xlink:to="lab_gild_HIVProductsCompleraEvipleraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3a1011d5-98d2-4ca2-9b21-f9637abc76cc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5fad3ce6-9f82-430f-baac-eabc92305eb8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TangoTherapeuticsIncMember_c02678f3-eee9-4a28-9ec4-a12209846a26_terseLabel_en-US" xlink:label="lab_gild_TangoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tango</link:label>
    <link:label id="lab_gild_TangoTherapeuticsIncMember_label_en-US" xlink:label="lab_gild_TangoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tango Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_TangoTherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_TangoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tango Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember" xlink:href="gild-20211231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TangoTherapeuticsIncMember" xlink:to="lab_gild_TangoTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_014e60aa-66cd-41d6-aa70-d040b2e967c7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves and accruals not currently deductible</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_df90a578-c70a-4f05-94fb-db743e53807e_terseLabel_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Running royalty rate from October 2017</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_label_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate from October 2017</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_documentation_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate from October 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017" xlink:href="gild-20211231.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentRoyaltyRateFromOctober2017" xlink:to="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_eebb515c-de31-46a1-b039-f62d26a0bf18_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_ba406e72-8f5f-4062-975f-1f52c2ab9052_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic tax authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_83941afd-508d-4319-8683-360d58c94027_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9bc66bc4-9fd4-41bd-ac0b-23d54d33a5d5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock (percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4cf765b4-3f5a-429b-81dc-301d440a0ae7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_ab2d3b75-d9f2-458d-b353-b15eba02bc4b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a2ec5319-8b70-4064-a611-f5ae855047a9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherHCVMember_5c7000c1-6c76-4aa2-878c-1c217e77d5f3_terseLabel_en-US" xlink:label="lab_gild_OtherHCVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV</link:label>
    <link:label id="lab_gild_OtherHCVMember_label_en-US" xlink:label="lab_gild_OtherHCVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV [Member]</link:label>
    <link:label id="lab_gild_OtherHCVMember_documentation_en-US" xlink:label="lab_gild_OtherHCVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHCVMember" xlink:href="gild-20211231.xsd#gild_OtherHCVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherHCVMember" xlink:to="lab_gild_OtherHCVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_1774c19b-fd12-4bef-928a-1f5b1e4b96f5_terseLabel_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise&#160;Price (in dollars)</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:href="gild-20211231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:to="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_4959afbc-9c53-4568-92b3-e0a147eaa9e6_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f692c1c7-57f8-42be-972d-5d7c59fc343a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85cc5458-bd28-4d11-8e59-2966d8ccb614_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_a06af659-1dd1-4020-912d-a9fa9d426372_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_f859cc82-70c7-49ed-8284-e611e964a099_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b9e3fff7-c041-4337-876b-2c4f1df0101d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Expenses -Included in Consolidated Statement of Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_f4bc1bbe-d1f3-4e6b-b1fc-a81f5ae0affd_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_417295d2-896e-4b89-ba96-9fe9d3692da9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local income tax expense (benefit), continuing operations</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_86072679-e958-44c8-afa7-41dee974e2ba_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of global and development and commercialization costs</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_label_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Development And Commercialization Costs</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Development And Commercialization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:href="gild-20211231.xsd#gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:to="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_afc86009-5995-497a-b62c-8c57afdd406c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax - intra-entity transfer of intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_deab1144-b0e6-44ae-83f9-01b2adf33c25_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e1b174a3-6152-41f0-8230-17c7e4905831_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_894a6241-0d47-47a4-ad24-2bc78abf6168_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax charge to cost of goods sold</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_fa2d30c4-bdd1-45ca-8a5a-e48be8ab7345_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_65ff553b-f8ab-4de1-b5d3-23b613c8f267_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid, net of amounts capitalized</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3c0828fd-b8c9-4727-ac5c-49a5f64c9eb9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesDonationMember_608184c2-b89a-437b-90d5-06e626ca5e0d_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesDonationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Donation</link:label>
    <link:label id="lab_gild_EquitySecuritiesDonationMember_label_en-US" xlink:label="lab_gild_EquitySecuritiesDonationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Donation [Member]</link:label>
    <link:label id="lab_gild_EquitySecuritiesDonationMember_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesDonationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Donation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesDonationMember" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesDonationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesDonationMember" xlink:to="lab_gild_EquitySecuritiesDonationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2ce50b00-e2fd-4f17-9ef5-d5e8f0b2ac64_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_92221455-001c-4377-a5b1-866a6410c024_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_c881b372-c223-46e0-ad35-9e376dd17e7d_terseLabel_en-US" xlink:label="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future potential clinical, regulatory and commercial milestone payments</link:label>
    <link:label id="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_label_en-US" xlink:label="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Clinical, Regulatory and Commercial Milestone Payments, Maximum</link:label>
    <link:label id="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Clinical, Regulatory and Commercial Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" xlink:href="gild-20211231.xsd#gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" xlink:to="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PreExposureProphylaxisMember_00615620-bcf7-4fbc-b7e7-5cb4e073ff84_terseLabel_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis</link:label>
    <link:label id="lab_gild_PreExposureProphylaxisMember_label_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis [Member]</link:label>
    <link:label id="lab_gild_PreExposureProphylaxisMember_documentation_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember" xlink:href="gild-20211231.xsd#gild_PreExposureProphylaxisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PreExposureProphylaxisMember" xlink:to="lab_gild_PreExposureProphylaxisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4b9e6a76-4b0d-4fee-8ba1-859e01f7305c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_c22fcb1b-6d05-4ec7-9a05-b439c5cbb44e_terseLabel_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_label_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:href="gild-20211231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:to="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalUpfrontPaymentsMade_683cec85-6fd6-424e-aeee-1807ada0c38a_terseLabel_en-US" xlink:label="lab_gild_TotalUpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront payments made</link:label>
    <link:label id="lab_gild_TotalUpfrontPaymentsMade_label_en-US" xlink:label="lab_gild_TotalUpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Upfront Payments Made</link:label>
    <link:label id="lab_gild_TotalUpfrontPaymentsMade_documentation_en-US" xlink:label="lab_gild_TotalUpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Upfront Payments Made</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalUpfrontPaymentsMade" xlink:href="gild-20211231.xsd#gild_TotalUpfrontPaymentsMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalUpfrontPaymentsMade" xlink:to="lab_gild_TotalUpfrontPaymentsMade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_f244082c-e7f2-4caa-8578-5d81b6b81a98_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for sales returns</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_c7627318-cf92-4dc1-bf94-2ab868560ecc_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_44a0d189-d94a-469b-8bd8-abf129d27e00_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_06d8b804-bc06-4d9c-95d6-b944c593ff1f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4cd42be0-1b88-41e0-808a-1907d6caaa1d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_6d3213d4-f20d-45b5-804e-9d8769004345_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6f6525e9-ce9d-426a-88a2-6fdc53349dec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_58a8e16c-fd87-4d0b-a065-dc8c68d39f1c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5691c14c-493f-48d5-8687-3ceba06eb38c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f2ccf518-e231-4f71-8ece-21acd5fdb759_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_7b019bc0-3a59-45d6-9d6f-2e8a4af55e20_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US tax on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_7b0f6b32-8070-4ae3-b461-609bf669af63_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments, year two</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_66110e36-fd10-48e1-9614-317684a8427b_terseLabel_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno</link:label>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_label_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center [Member]</link:label>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_documentation_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:href="gild-20211231.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:to="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalGrantDateFairValueDomain_ae0a7e92-4faf-4ab1-a638-a1472a45e356_terseLabel_en-US" xlink:label="lab_gild_TotalGrantDateFairValueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Grant Date Fair Value [Domain]</link:label>
    <link:label id="lab_gild_TotalGrantDateFairValueDomain_label_en-US" xlink:label="lab_gild_TotalGrantDateFairValueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Grant Date Fair Value [Domain]</link:label>
    <link:label id="lab_gild_TotalGrantDateFairValueDomain_documentation_en-US" xlink:label="lab_gild_TotalGrantDateFairValueDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Total Grant Date Fair Value [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalGrantDateFairValueDomain" xlink:href="gild-20211231.xsd#gild_TotalGrantDateFairValueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalGrantDateFairValueDomain" xlink:to="lab_gild_TotalGrantDateFairValueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_72e6af27-573b-4a52-b02c-c5a017f25ef3_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_d06dfe94-a17c-4626-978c-4b5aa7c1afe3_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_263b17fb-6917-48e4-a6d8-1ebd86566aac_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_37cd197a-8c80-4b6e-8317-6e6c6d793d1e_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_c664df55-1353-4b8a-92a4-409db4920d84_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on discontinuance of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_label_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:to="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c8fda2e5-d914-473f-a515-b67b6aa095fd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_1595ddbe-dc6a-4411-843a-7455452ae4f3_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived assets - IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_3e34e8a5-6ab5-481f-987f-8eb2523e72ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PionyrImmunotherapeuticsIncMember_7f0b2266-10be-4935-b269-b5e60aeaa592_terseLabel_en-US" xlink:label="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr</link:label>
    <link:label id="lab_gild_PionyrImmunotherapeuticsIncMember_label_en-US" xlink:label="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Immunotherapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_PionyrImmunotherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Immunotherapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrImmunotherapeuticsIncMember" xlink:href="gild-20211231.xsd#gild_PionyrImmunotherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PionyrImmunotherapeuticsIncMember" xlink:to="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GileadFoundationMember_c0cd276b-45dc-4c24-a3e7-a1d4dff43308_terseLabel_en-US" xlink:label="lab_gild_GileadFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Foundation</link:label>
    <link:label id="lab_gild_GileadFoundationMember_label_en-US" xlink:label="lab_gild_GileadFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Foundation [Member]</link:label>
    <link:label id="lab_gild_GileadFoundationMember_documentation_en-US" xlink:label="lab_gild_GileadFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadFoundationMember" xlink:href="gild-20211231.xsd#gild_GileadFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GileadFoundationMember" xlink:to="lab_gild_GileadFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_58555c6c-0174-4b47-ae99-929f9828a4c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;long-term&#160;obligations</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_fb2f88d6-ce13-4447-adae-ac12e19dfe86_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_96aa3ac1-d1d3-487f-8dfc-fb76c59226bd_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vemlidy</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:href="gild-20211231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_f8cae436-64df-447f-8bb3-0d8022bddafe_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ff237d04-260d-4db7-83f6-9204f126282d_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_364d5995-5896-4460-8d00-df7768b60b21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Difference Between Provision for Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ad2ccde4-7ca6-4c62-b9a4-a1e22009c42b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_63bd688e-0ad9-46bb-a6de-987c398bc94b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_51de2a1e-cd87-470c-a33d-3697ef09e5a0_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6a77bcb1-98e4-406c-8a90-fb16a38a4cde_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_11b1e17a-fcad-4ece-89c3-c80efd68f31d_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2d1e34e0-6c38-4832-9d7c-3a9cc0d34a31_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ddbe53b8-3d35-4371-8d76-72007f40a21f_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_6ad3d22f-05a2-452b-9291-d196108c503c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_7274736b-4805-4ce9-8ea9-cfec472441d2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_71b3756c-ee8c-4f71-8c38-4db701e32914_terseLabel_en-US" xlink:label="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.52% LIBOR Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.52% LIBOR Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.52% LIBOR Senior Unsecured Notes Due September 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20211231.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_da562b1e-c411-4efd-992d-d49890634148_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_df35ae6a-f9ce-42c0-a8f3-65ade2bf9dc4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4282cf10-dec2-4202-987f-0e1040ab1fa2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99edf411-7d7e-471d-b258-3e62bdc723c9_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_fb93b70a-3102-4faa-9f31-f673dbea014d_terseLabel_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_label_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027 [Member]</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_documentation_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:href="gild-20211231.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:to="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_722a53af-b2df-48ed-88c9-eb5b22f9b6f2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_dac538c4-5cf3-4a3a-81ac-e5f3d2bf020e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_6a0badf4-5bf3-474c-b2be-56a28e0e898e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1472a279-bede-4549-bd6a-633cd2cb8f25_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_5b4e4144-95df-43e0-8932-0604b30469af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_62969551-e42c-4d42-a37e-518dea2b1a86_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_45623d52-1b9b-4d28-80c0-d394c7eeb129_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredCompensationPlanMember_cd478f34-871b-4efa-a1b8-0ff60747d77c_terseLabel_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_label_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_documentation_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember" xlink:href="gild-20211231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredCompensationPlanMember" xlink:to="lab_gild_DeferredCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1edb90d4-249b-460e-84fc-9caebcc158e6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_39a0e650-99a9-4225-a480-0d3cd85f7f26_terseLabel_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaboration arrangements</link:label>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_label_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Arrangements [Member]</link:label>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_documentation_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember" xlink:href="gild-20211231.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherCollaborationArrangementsMember" xlink:to="lab_gild_OtherCollaborationArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_3b72acc0-11cb-4a99-b363-5260bca2f464_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts Offset on the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsStribildMember_d48ab819-99ba-47de-a734-038025d4ceb4_terseLabel_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stribild</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_label_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_documentation_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember" xlink:href="gild-20211231.xsd#gild_HIVProductsStribildMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsStribildMember" xlink:to="lab_gild_HIVProductsStribildMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_547f80ab-9fa2-489a-a82b-14bfd241882f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financing Arrangements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1c9577dc-32f6-4a72-8dce-bb354b6df060_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_3c9617d4-8f49-4fd4-b09d-ad1a126ceb0d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c1b40f92-b082-41ba-92e3-13f2f896330d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_d1a4955d-3c00-4b13-9f5b-898fa457083d_terseLabel_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biktarvy</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_label_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember" xlink:href="gild-20211231.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsBiktarvyMember" xlink:to="lab_gild_HIVProductsBiktarvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_ff975b0f-ae15-45cc-88e9-84e7a903d391_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_52f4b974-9b15-45ae-aa5b-b758b9b5813f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_1c5762b1-d3bd-4a78-8ca3-d6b3f220d33d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GalapagosMember_d195837b-0c68-4144-bd3d-77e527854011_terseLabel_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos</link:label>
    <link:label id="lab_gild_GalapagosMember_label_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos [Member]</link:label>
    <link:label id="lab_gild_GalapagosMember_documentation_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos, a clinical-stage biotechnology company based in Belgium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember" xlink:href="gild-20211231.xsd#gild_GalapagosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GalapagosMember" xlink:to="lab_gild_GalapagosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_3e7b48c1-3fb7-4ad3-a572-e01f5d79454c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts Offset on the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_StandstillRestrictingTerm_508f3dfc-955d-43ee-b4d3-93a9ef7048c3_terseLabel_en-US" xlink:label="lab_gild_StandstillRestrictingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill restricting term</link:label>
    <link:label id="lab_gild_StandstillRestrictingTerm_label_en-US" xlink:label="lab_gild_StandstillRestrictingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill Restricting Term</link:label>
    <link:label id="lab_gild_StandstillRestrictingTerm_documentation_en-US" xlink:label="lab_gild_StandstillRestrictingTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill Restricting Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_StandstillRestrictingTerm" xlink:href="gild-20211231.xsd#gild_StandstillRestrictingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_StandstillRestrictingTerm" xlink:to="lab_gild_StandstillRestrictingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_bd4bcd6e-6582-41f2-83cf-5f93a4ece6c0_terseLabel_en-US" xlink:label="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit) Component [Axis]</link:label>
    <link:label id="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_label_en-US" xlink:label="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit) Component [Axis]</link:label>
    <link:label id="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_documentation_en-US" xlink:label="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit) Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis" xlink:href="gild-20211231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis" xlink:to="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c1910da3-7b91-4e07-9b01-9c214f1ed189_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_4d4d6c74-d0d8-4f26-91e3-e50bc9ac1ca3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other&#160;current&#160;liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_ca3b468d-a6c9-438b-9ae5-3fce7e3963bd_terseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_fc58ea0f-4299-4a54-81f4-36a5071439ed_verboseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_label_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_documentation_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:href="gild-20211231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:to="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_7848a3ba-3dda-450c-9c3a-c4d3adbc8b0d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_b4574fc5-9af0-4ef6-8bc4-cbd88ce3469f_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsOdefseyMember_6acd6a78-a9b2-49ba-81f5-10532f1dc5a2_terseLabel_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Odefsey</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_label_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember" xlink:href="gild-20211231.xsd#gild_HIVProductsOdefseyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsOdefseyMember" xlink:to="lab_gild_HIVProductsOdefseyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_aa7e8136-799c-436e-8e74-7067c219d1ea_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_18676ab1-82ae-4dcc-8aca-7506dc71907d_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6728cd67-dd6b-49b0-8f4e-ce28bb52da2b_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2a84b27c-fb54-4d1d-b2bc-04f425b05fdf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_361ab97c-5e4a-4a07-9bf6-7272dc2466c5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0f935a67-66f1-46d6-9998-e423a93b34d8_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by noncontrolling owners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InventoryReserveForExcessRawMaterials_0f8ca823-2e68-4444-b328-9758a2c54ece_terseLabel_en-US" xlink:label="lab_gild_InventoryReserveForExcessRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-downs for slow-moving and excess raw material and work in process inventory</link:label>
    <link:label id="lab_gild_InventoryReserveForExcessRawMaterials_label_en-US" xlink:label="lab_gild_InventoryReserveForExcessRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve For Excess Raw Materials</link:label>
    <link:label id="lab_gild_InventoryReserveForExcessRawMaterials_documentation_en-US" xlink:label="lab_gild_InventoryReserveForExcessRawMaterials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve For Excess Raw Materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryReserveForExcessRawMaterials" xlink:href="gild-20211231.xsd#gild_InventoryReserveForExcessRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InventoryReserveForExcessRawMaterials" xlink:to="lab_gild_InventoryReserveForExcessRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_5575b121-f4c0-4831-b601-650087166e2f_terseLabel_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV</link:label>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_label_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company [Member]</link:label>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_documentation_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company (&#8220;ViiV&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember" xlink:href="gild-20211231.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ViiVHealthcareCompanyMember" xlink:to="lab_gild_ViiVHealthcareCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_a86b9ea8-c53f-46f0-9fd0-7b5114d912aa_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_6af7bbb3-5221-4d9e-ae3a-e24fc69693ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7d104a52-a155-42c8-8896-005b208129d5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_baf8f526-1264-4f31-8869-c2cea1dcf59e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income (Loss) Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_eec53d3e-1d4c-44a4-bde9-59aa6432b316_terseLabel_en-US" xlink:label="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_label_en-US" xlink:label="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year 5</link:label>
    <link:label id="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_documentation_en-US" xlink:label="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year 5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:href="gild-20211231.xsd#gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:to="lab_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc407a93-6f36-4c1a-b9d5-0dc1fb8d8482_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_494f9cb8-d141-42c6-980b-cd52894c4b37_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_2369d8a4-8439-4250-8b3a-107169c13b17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Potential Effect of Offsetting Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ef6c60a1-5792-4932-b082-fa235669552c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d70d1d93-524e-4da8-9297-f2af2c0711f7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6501fe8a-0ee3-4358-bb88-82d0e62fe2db_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6731fc39-8654-4bd4-9644-c8cba53a64bb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_e8be4db0-36f8-4fd5-9b7f-17a27f6effd5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SummaryOfSignificantAccountingPoliciesTable_14b4a2ad-ea3b-4453-bdf7-c3be1bea89a8_terseLabel_en-US" xlink:label="lab_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gild_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gild_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:href="gild-20211231.xsd#gild_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_69c5d975-935a-4eea-b550-322536f10eaf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_58bf1e56-3058-4db8-903b-bb6f11527cb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_892996fa-3c3a-42ab-881d-4c04ef92c0b1_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_Issuancediscount_6f600283-36db-4919-9112-efbca53fadc9_terseLabel_en-US" xlink:label="lab_gild_Issuancediscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance discount</link:label>
    <link:label id="lab_gild_Issuancediscount_label_en-US" xlink:label="lab_gild_Issuancediscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance discount</link:label>
    <link:label id="lab_gild_Issuancediscount_documentation_en-US" xlink:label="lab_gild_Issuancediscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Issuancediscount" xlink:href="gild-20211231.xsd#gild_Issuancediscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_Issuancediscount" xlink:to="lab_gild_Issuancediscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0954d67c-3324-4dc9-a697-507642528e55_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6016d74d-1dd0-41f5-9f99-f44c33074651_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2401ed96-b35f-4bbc-ac3f-5a2c1cafe761_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_022f8eb6-3dcb-456e-b679-d4cd9ecb4346_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InvestmentOwnedBalanceAdditionalShares_07e18563-c678-47bf-b1cd-28ecf0d2cb68_terseLabel_en-US" xlink:label="lab_gild_InvestmentOwnedBalanceAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares acquired (in shares)</link:label>
    <link:label id="lab_gild_InvestmentOwnedBalanceAdditionalShares_label_en-US" xlink:label="lab_gild_InvestmentOwnedBalanceAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Additional Shares</link:label>
    <link:label id="lab_gild_InvestmentOwnedBalanceAdditionalShares_documentation_en-US" xlink:label="lab_gild_InvestmentOwnedBalanceAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Additional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InvestmentOwnedBalanceAdditionalShares" xlink:href="gild-20211231.xsd#gild_InvestmentOwnedBalanceAdditionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InvestmentOwnedBalanceAdditionalShares" xlink:to="lab_gild_InvestmentOwnedBalanceAdditionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_95b572b4-d2da-4536-8580-703c8156baeb_terseLabel_en-US" xlink:label="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filgotinib agreement</link:label>
    <link:label id="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_label_en-US" xlink:label="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filgotinib License and Collaboration Agreement with Galapagos [Member]</link:label>
    <link:label id="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_documentation_en-US" xlink:label="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filgotinib License and Collaboration Agreement with Galapagos [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" xlink:href="gild-20211231.xsd#gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" xlink:to="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_de879a1d-392c-4957-afb4-fd11e545d2eb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_5c6dea56-6003-45d8-ba36-1e34b3885545_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs charged against allowance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_c5eb92e2-d453-4f46-947b-ee88e2b2f4d2_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viread</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:href="gild-20211231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_6c66176d-7fbe-4f1f-8b27-cbd8ba93bff3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_b4d0a33e-9c6d-4993-8389-65b7b1ef7637_terseLabel_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three year senior unsecured term loan facility</link:label>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_label_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Year Senior Unsecured Term Loan Facility [Member]</link:label>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_documentation_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Year Senior Unsecured Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:href="gild-20211231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:to="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_29d496f2-3bf9-4d34-b5ac-d0362018e82f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_abae50e0-7b53-487e-b5af-d9550222f7d8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_5fff35dc-d8ca-4000-881c-78304e03927e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching contribution expense</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9e401541-769a-4760-a044-5a11ec87a831_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_2c7c530c-4cb9-4bbf-afb6-6c81c83f7697_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_ed30bff6-e52c-493f-bdeb-537555df2787_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire equity method investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_3a2b7f9d-cb29-4773-9788-d63d44cf8160_terseLabel_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments made related to equity investments</link:label>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_label_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments Made Related To Equity Investments</link:label>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_documentation_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments Made Related To Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:href="gild-20211231.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:to="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9a4a7ebf-d900-468e-a1a3-d063bffe8b1a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_0fdbcf6b-e95c-492e-a08e-bea964cd7b25_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_d7e1af16-2334-4fa6-a8e4-196e77d72e7c_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0a4f5f19-5c6b-4047-af2d-a9dada6a5848_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_529910d6-93b4-4e52-910e-addc1f2f600d_terseLabel_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payment for adjustments of budgeted development costs in 2021</link:label>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_label_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments of Budgeted Development Costs, Payments</link:label>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_documentation_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments of Budgeted Development Costs, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" xlink:href="gild-20211231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" xlink:to="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_64fc6c9e-0ee4-4979-8972-33c1a85b3ffa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_dc986203-48f3-40a3-8f67-d638d821878e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_da18a19c-e500-4795-9822-70773711c6b7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments made for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_eafae992-4673-4c5b-af11-ff37a9a8f979_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_5966ec1c-eb30-4bab-9f84-236b624df36b_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_03a934b1-213c-4f0e-b164-976a9021e9c9_totalLabel_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20211231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_64e91537-716b-4903-abbe-a3f3a07350b3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_a6790c8e-391d-430b-96ec-cc405f94ad5e_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements (including leasehold improvements)</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_19845fdf-22d1-4f9c-8000-424ec4f2211d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_f982c3c9-6f50-4ba6-b50f-e3a22278b1d0_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification of Other Equity Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_cf729358-a173-4a3b-b739-a93a160800f3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_70f57d0d-187b-471a-b4f4-38128ea0bcca_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4bb0ad4d-345c-4218-9e7a-02393ab98dda_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_b299e12e-0db8-4525-a9ed-d4eb31d9f84e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts of Recognized Assets/Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_47976d89-158d-442c-9f18-bce94192fb6c_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity on derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_6923fc52-7e90-4d5c-9f2b-7fbcf46c81b8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:to="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0b97a3bb-2e5d-4e81-96ee-5cee786f5d78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) reclassified from AOCI into Product sales</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_b7197d25-1bc5-4d71-b9eb-1cf16dae2a26_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_617ce9c6-4301-4231-9145-88fc8c627469_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_3c8f9ebd-aa0d-418b-aef5-eb0ab8190579_terseLabel_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_label_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales [Member]</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_documentation_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:href="gild-20211231.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:to="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_6701ba6d-b262-4a67-b621-c1e3e8da80ed_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_00ed548b-07f5-42df-abd8-18b584c02591_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_d68ef8a4-7f90-443c-a63a-244af42b7f92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GalapagosCollaborationAgreementMember_adfaf8da-bca9-4d97-be81-dc280687ae41_terseLabel_en-US" xlink:label="lab_gild_GalapagosCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos collaboration agreement</link:label>
    <link:label id="lab_gild_GalapagosCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_GalapagosCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_GalapagosCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_GalapagosCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosCollaborationAgreementMember" xlink:href="gild-20211231.xsd#gild_GalapagosCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GalapagosCollaborationAgreementMember" xlink:to="lab_gild_GalapagosCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9d149467-af50-4273-bcc5-8d904521555f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_f92563af-f5aa-41bd-a849-5a72630fc550_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_eaadcd63-f17c-4cc3-8500-26cb98bc6994_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_caa9f329-c614-452f-8acf-1f02a00849b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_0c3ed24a-7c46-48ea-a4af-77767d1f2e9a_terseLabel_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option fee and potential future milestone payments</link:label>
    <link:label id="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_label_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Option Fee And Potential Future Milestone Payments</link:label>
    <link:label id="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_documentation_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Option Fee And Potential Future Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:href="gild-20211231.xsd#gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:to="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_NumberOfEarlyRepaymentsOfLongTermDebt_3e2fff3a-ca1d-445d-888a-13c61ec1dbce_terseLabel_en-US" xlink:label="lab_gild_NumberOfEarlyRepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of early repayments</link:label>
    <link:label id="lab_gild_NumberOfEarlyRepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_gild_NumberOfEarlyRepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Early Repayments Of Long-Term Debt</link:label>
    <link:label id="lab_gild_NumberOfEarlyRepaymentsOfLongTermDebt_documentation_en-US" xlink:label="lab_gild_NumberOfEarlyRepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Early Repayments Of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfEarlyRepaymentsOfLongTermDebt" xlink:href="gild-20211231.xsd#gild_NumberOfEarlyRepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_NumberOfEarlyRepaymentsOfLongTermDebt" xlink:to="lab_gild_NumberOfEarlyRepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>gild-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4eb1680c-5761-45c7-95ef-3c78b834062a,g:a0cedc55-fc60-4d3f-bea8-ef196ffaa864-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/Cover" xlink:type="simple" xlink:href="gild-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6d798e2a-fe67-4d2a-a3be-27a5f5a85863" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_DocumentType_6d798e2a-fe67-4d2a-a3be-27a5f5a85863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_a0a2b53a-5ce1-4cdd-90e0-a898fb4844bc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_DocumentAnnualReport_a0a2b53a-5ce1-4cdd-90e0-a898fb4844bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_76cbfdf3-3cc7-4af4-99bc-bda3a044fbcf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_DocumentPeriodEndDate_76cbfdf3-3cc7-4af4-99bc-bda3a044fbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_13454790-41a4-450c-be6f-71d18bf2df3a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_CurrentFiscalYearEndDate_13454790-41a4-450c-be6f-71d18bf2df3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9f664c45-8efe-4003-8dad-80834a999595" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_DocumentTransitionReport_9f664c45-8efe-4003-8dad-80834a999595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_dfddbe7d-c507-4676-ae3e-2adda205c1ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityFileNumber_dfddbe7d-c507-4676-ae3e-2adda205c1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_704f11b0-eeab-4101-96ad-9177ac986f25" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityRegistrantName_704f11b0-eeab-4101-96ad-9177ac986f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_85a0b1ea-7126-413b-bdc4-d6b7e5692f3b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_85a0b1ea-7126-413b-bdc4-d6b7e5692f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d4d8c59c-bf58-4ddf-a209-dbf8889aeab6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityTaxIdentificationNumber_d4d8c59c-bf58-4ddf-a209-dbf8889aeab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_008d6d1b-cc52-4668-aff2-ea4a470236de" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityAddressAddressLine1_008d6d1b-cc52-4668-aff2-ea4a470236de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4fb1074a-a7d4-4ef3-baea-2c20f5e3b8f8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityAddressCityOrTown_4fb1074a-a7d4-4ef3-baea-2c20f5e3b8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_02613565-ff28-4ba5-9f75-29449ad4038c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityAddressStateOrProvince_02613565-ff28-4ba5-9f75-29449ad4038c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_da22cb52-c4b9-458d-aee6-749bf6703bc1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityAddressPostalZipCode_da22cb52-c4b9-458d-aee6-749bf6703bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_33440b9f-0e9d-4750-87d1-48cfd1710988" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_CityAreaCode_33440b9f-0e9d-4750-87d1-48cfd1710988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c0157b0e-3344-4efc-b291-ca5cf61f38fc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_LocalPhoneNumber_c0157b0e-3344-4efc-b291-ca5cf61f38fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9ec825bc-983e-4e66-9947-11a60b818cf4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_Security12bTitle_9ec825bc-983e-4e66-9947-11a60b818cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_47bae645-2613-4be6-8435-b4cf6e0a0f05" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_TradingSymbol_47bae645-2613-4be6-8435-b4cf6e0a0f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3a442ae6-9f74-416a-86fb-5f74a0beec4f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_SecurityExchangeName_3a442ae6-9f74-416a-86fb-5f74a0beec4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_ce81ee70-95b4-4087-b645-5a6790948460" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_ce81ee70-95b4-4087-b645-5a6790948460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_dc0246ef-1fe3-4670-becf-8efcbb71081f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityVoluntaryFilers_dc0246ef-1fe3-4670-becf-8efcbb71081f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9b4823f5-6372-4c08-bc2b-549be04a1a4a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityCurrentReportingStatus_9b4823f5-6372-4c08-bc2b-549be04a1a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_310eecac-8da5-4335-89b9-a15a9cd1f05b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityInteractiveDataCurrent_310eecac-8da5-4335-89b9-a15a9cd1f05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_943532c6-67f3-4a02-af5b-88e70cbfe183" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityFilerCategory_943532c6-67f3-4a02-af5b-88e70cbfe183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a4c970fe-3daa-425d-83c8-37c2f5e7835e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntitySmallBusiness_a4c970fe-3daa-425d-83c8-37c2f5e7835e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3c225f6f-b3fd-454e-a851-2e0658de4a1f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityEmergingGrowthCompany_3c225f6f-b3fd-454e-a851-2e0658de4a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_271c760b-2712-4500-b544-3dec7da25664" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_271c760b-2712-4500-b544-3dec7da25664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6f73fa66-75bb-4bba-9840-a9bbd429dd39" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityShellCompany_6f73fa66-75bb-4bba-9840-a9bbd429dd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_54bcddc5-cd7b-4c84-9911-7a99fd486662" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityPublicFloat_54bcddc5-cd7b-4c84-9911-7a99fd486662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2fbecf06-130b-48aa-8a24-9f8474a9508a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2fbecf06-130b-48aa-8a24-9f8474a9508a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_cf6c8ded-40a2-4b7b-8cfa-30a2e6b5cfe5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_cf6c8ded-40a2-4b7b-8cfa-30a2e6b5cfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1d2fe2c6-c892-4461-890d-9b6dc4fc7fa7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_EntityCentralIndexKey_1d2fe2c6-c892-4461-890d-9b6dc4fc7fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_93a2ae4d-6f14-4dd8-b3f7-b4e845bce3c7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_DocumentFiscalYearFocus_93a2ae4d-6f14-4dd8-b3f7-b4e845bce3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ce3a11ae-769a-4ece-8550-86373adec0c2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ce3a11ae-769a-4ece-8550-86373adec0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_11a7512f-62c8-4085-8895-e36c819cd14e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7617fc47-c82d-40c3-a6d9-55c076977ef0" xlink:to="loc_dei_AmendmentFlag_11a7512f-62c8-4085-8895-e36c819cd14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AuditInformation" xlink:type="simple" xlink:href="gild-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_AuditInformationAbstract_ffc776ff-56b7-4fc4-a28a-88e697ca05bf" xlink:href="gild-20211231.xsd#gild_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_c0ff797f-b43e-4443-806e-6bf97c31a203" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_AuditInformationAbstract_ffc776ff-56b7-4fc4-a28a-88e697ca05bf" xlink:to="loc_dei_AuditorName_c0ff797f-b43e-4443-806e-6bf97c31a203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_e96d1327-cbf7-4f54-8b54-fa1c8983a31c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_AuditInformationAbstract_ffc776ff-56b7-4fc4-a28a-88e697ca05bf" xlink:to="loc_dei_AuditorLocation_e96d1327-cbf7-4f54-8b54-fa1c8983a31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_fe903408-d399-4c87-95c9-23d6146ab371" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_AuditInformationAbstract_ffc776ff-56b7-4fc4-a28a-88e697ca05bf" xlink:to="loc_dei_AuditorFirmId_fe903408-d399-4c87-95c9-23d6146ab371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7d8663cd-bef5-4db9-8b00-5d9870e2fdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d9dc6c60-aeee-4c9e-bc91-9aeda5387fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7d8663cd-bef5-4db9-8b00-5d9870e2fdc6" xlink:to="loc_us-gaap_AssetsAbstract_d9dc6c60-aeee-4c9e-bc91-9aeda5387fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_47d7d17a-abe5-4c0c-8295-ed70b223b2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d9dc6c60-aeee-4c9e-bc91-9aeda5387fc3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_47d7d17a-abe5-4c0c-8295-ed70b223b2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61611cca-702d-48e4-a129-056a81b3243b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47d7d17a-abe5-4c0c-8295-ed70b223b2bc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61611cca-702d-48e4-a129-056a81b3243b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_95b6e611-39f2-4e8b-92c2-ad2f83a8792a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47d7d17a-abe5-4c0c-8295-ed70b223b2bc" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_95b6e611-39f2-4e8b-92c2-ad2f83a8792a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_aa6d1a40-a811-4071-913b-18b93f9cbefd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47d7d17a-abe5-4c0c-8295-ed70b223b2bc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_aa6d1a40-a811-4071-913b-18b93f9cbefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_52410851-6de6-469c-b56d-1b2ad2c9abdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47d7d17a-abe5-4c0c-8295-ed70b223b2bc" xlink:to="loc_us-gaap_InventoryNet_52410851-6de6-469c-b56d-1b2ad2c9abdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_216c53ec-0080-42d4-a210-1ddb44212afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47d7d17a-abe5-4c0c-8295-ed70b223b2bc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_216c53ec-0080-42d4-a210-1ddb44212afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_646aee07-2dbd-40cf-a881-72313ea2dcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47d7d17a-abe5-4c0c-8295-ed70b223b2bc" xlink:to="loc_us-gaap_AssetsCurrent_646aee07-2dbd-40cf-a881-72313ea2dcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b52018cb-c8ff-43ae-8c4a-12c5b4380e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d9dc6c60-aeee-4c9e-bc91-9aeda5387fc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b52018cb-c8ff-43ae-8c4a-12c5b4380e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_8e58d086-0d47-43cc-899a-e7c28c7ba9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d9dc6c60-aeee-4c9e-bc91-9aeda5387fc3" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_8e58d086-0d47-43cc-899a-e7c28c7ba9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b352dfb7-a4e9-4082-90cc-f4019eae690d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d9dc6c60-aeee-4c9e-bc91-9aeda5387fc3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b352dfb7-a4e9-4082-90cc-f4019eae690d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_981c99f6-ff5b-4761-b416-d0e521f46fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d9dc6c60-aeee-4c9e-bc91-9aeda5387fc3" xlink:to="loc_us-gaap_Goodwill_981c99f6-ff5b-4761-b416-d0e521f46fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_91a277d2-29a4-4c7c-871e-840e251b0c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d9dc6c60-aeee-4c9e-bc91-9aeda5387fc3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_91a277d2-29a4-4c7c-871e-840e251b0c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_797a51c6-2b82-4a8d-a0bc-694e70db655b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d9dc6c60-aeee-4c9e-bc91-9aeda5387fc3" xlink:to="loc_us-gaap_Assets_797a51c6-2b82-4a8d-a0bc-694e70db655b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bf70e67-d867-4441-ae02-3acc6da5c123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7d8663cd-bef5-4db9-8b00-5d9870e2fdc6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bf70e67-d867-4441-ae02-3acc6da5c123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_98b79d5d-144a-4d5b-b93b-51bcee4a7df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bf70e67-d867-4441-ae02-3acc6da5c123" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_98b79d5d-144a-4d5b-b93b-51bcee4a7df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eefd7660-9b5a-4ca7-99aa-1caa2ab8e795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_98b79d5d-144a-4d5b-b93b-51bcee4a7df9" xlink:to="loc_us-gaap_AccountsPayableCurrent_eefd7660-9b5a-4ca7-99aa-1caa2ab8e795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedGovernmentAndOtherRebates_9942338e-9570-4f8e-bff2-5165e4131664" xlink:href="gild-20211231.xsd#gild_AccruedGovernmentAndOtherRebates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_98b79d5d-144a-4d5b-b93b-51bcee4a7df9" xlink:to="loc_gild_AccruedGovernmentAndOtherRebates_9942338e-9570-4f8e-bff2-5165e4131664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_966ffd89-fa41-44fe-99b2-40c504bb600d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_98b79d5d-144a-4d5b-b93b-51bcee4a7df9" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_966ffd89-fa41-44fe-99b2-40c504bb600d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_9611fd9a-5b2f-49ae-a476-a7373b6e7063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_98b79d5d-144a-4d5b-b93b-51bcee4a7df9" xlink:to="loc_us-gaap_DebtCurrent_9611fd9a-5b2f-49ae-a476-a7373b6e7063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9e2d1134-38f9-4759-82aa-ca0ca75ec804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_98b79d5d-144a-4d5b-b93b-51bcee4a7df9" xlink:to="loc_us-gaap_LiabilitiesCurrent_9e2d1134-38f9-4759-82aa-ca0ca75ec804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_482ff4be-e0e9-47fd-a6f4-e6716485c4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bf70e67-d867-4441-ae02-3acc6da5c123" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_482ff4be-e0e9-47fd-a6f4-e6716485c4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_04144874-80b4-4b8f-baf2-3da84a91ce41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bf70e67-d867-4441-ae02-3acc6da5c123" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_04144874-80b4-4b8f-baf2-3da84a91ce41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1ddba998-67b6-429c-a8e5-4cd262b795a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bf70e67-d867-4441-ae02-3acc6da5c123" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1ddba998-67b6-429c-a8e5-4cd262b795a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_10905807-a30d-49fb-96ca-fc8d7d38467b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bf70e67-d867-4441-ae02-3acc6da5c123" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_10905807-a30d-49fb-96ca-fc8d7d38467b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c10c40f6-12e6-4fdc-825c-53891d31c199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bf70e67-d867-4441-ae02-3acc6da5c123" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c10c40f6-12e6-4fdc-825c-53891d31c199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_20b24c51-26db-47c9-8ea6-5c792dbd3e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bf70e67-d867-4441-ae02-3acc6da5c123" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_20b24c51-26db-47c9-8ea6-5c792dbd3e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_896db191-b083-4439-aa8e-eb45e4233a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_20b24c51-26db-47c9-8ea6-5c792dbd3e94" xlink:to="loc_us-gaap_PreferredStockValue_896db191-b083-4439-aa8e-eb45e4233a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ddf4c1d9-3c62-463b-aae1-7735f5ab2fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_20b24c51-26db-47c9-8ea6-5c792dbd3e94" xlink:to="loc_us-gaap_CommonStockValue_ddf4c1d9-3c62-463b-aae1-7735f5ab2fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f3d1247f-d65f-48e9-a4ff-03c13e205cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_20b24c51-26db-47c9-8ea6-5c792dbd3e94" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f3d1247f-d65f-48e9-a4ff-03c13e205cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc182568-630b-4892-a3ba-3152ae8f4347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_20b24c51-26db-47c9-8ea6-5c792dbd3e94" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc182568-630b-4892-a3ba-3152ae8f4347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2899614c-9b96-4ebd-91ac-1420d6b342e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_20b24c51-26db-47c9-8ea6-5c792dbd3e94" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2899614c-9b96-4ebd-91ac-1420d6b342e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aaa1ba7d-5634-43d4-9d73-7c9598c91503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_20b24c51-26db-47c9-8ea6-5c792dbd3e94" xlink:to="loc_us-gaap_StockholdersEquity_aaa1ba7d-5634-43d4-9d73-7c9598c91503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0cf8164a-6ddc-4a1a-98f9-bf0d60d5f395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_20b24c51-26db-47c9-8ea6-5c792dbd3e94" xlink:to="loc_us-gaap_MinorityInterest_0cf8164a-6ddc-4a1a-98f9-bf0d60d5f395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8d286847-aaec-431c-9f0c-80d90849eb62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_20b24c51-26db-47c9-8ea6-5c792dbd3e94" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8d286847-aaec-431c-9f0c-80d90849eb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_13b74746-4401-4cca-920a-c15b783378e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bf70e67-d867-4441-ae02-3acc6da5c123" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_13b74746-4401-4cca-920a-c15b783378e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9f06ac98-4a6c-4bc7-85a4-fb30ea48d2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_29f8468c-cafa-4811-92c0-f64d89ed8518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9f06ac98-4a6c-4bc7-85a4-fb30ea48d2f9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_29f8468c-cafa-4811-92c0-f64d89ed8518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_46048c68-d8c2-4c44-83e2-cb1fd00cb36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_29f8468c-cafa-4811-92c0-f64d89ed8518" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_46048c68-d8c2-4c44-83e2-cb1fd00cb36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_34901b06-362e-415e-a03e-d2469ae077dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_46048c68-d8c2-4c44-83e2-cb1fd00cb36f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_34901b06-362e-415e-a03e-d2469ae077dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_866f5cf1-7edc-43d2-9808-31528f7fb315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_46048c68-d8c2-4c44-83e2-cb1fd00cb36f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_866f5cf1-7edc-43d2-9808-31528f7fb315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_63192a1d-7e12-4462-abab-ab5206486d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_46048c68-d8c2-4c44-83e2-cb1fd00cb36f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_63192a1d-7e12-4462-abab-ab5206486d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b61593b7-daaf-4663-a490-86a4a977d3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_46048c68-d8c2-4c44-83e2-cb1fd00cb36f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b61593b7-daaf-4663-a490-86a4a977d3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b1e30e8f-8af2-4842-9f1e-aaeca9abb4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_46048c68-d8c2-4c44-83e2-cb1fd00cb36f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b1e30e8f-8af2-4842-9f1e-aaeca9abb4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0fd3daba-0d25-44ec-a299-802c8d7a5f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_46048c68-d8c2-4c44-83e2-cb1fd00cb36f" xlink:to="loc_us-gaap_CommonStockSharesIssued_0fd3daba-0d25-44ec-a299-802c8d7a5f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_50e655b4-ded7-4a18-8caa-e5aad5cbfee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_46048c68-d8c2-4c44-83e2-cb1fd00cb36f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_50e655b4-ded7-4a18-8caa-e5aad5cbfee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_dc15a1dd-c0ad-460e-9078-747c5df2ac4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2d3ce795-a3b8-4688-bd68-2b41e949b2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc15a1dd-c0ad-460e-9078-747c5df2ac4a" xlink:to="loc_us-gaap_StatementTable_2d3ce795-a3b8-4688-bd68-2b41e949b2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5437ff1b-0153-4d41-878a-25ff7c44abd5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2d3ce795-a3b8-4688-bd68-2b41e949b2e0" xlink:to="loc_srt_ProductOrServiceAxis_5437ff1b-0153-4d41-878a-25ff7c44abd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73be9344-c14d-4f21-aee6-61788e2ac6bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5437ff1b-0153-4d41-878a-25ff7c44abd5" xlink:to="loc_srt_ProductsAndServicesDomain_73be9344-c14d-4f21-aee6-61788e2ac6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_aef875d9-e3ec-403f-90b3-bc446b1f3360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_73be9344-c14d-4f21-aee6-61788e2ac6bc" xlink:to="loc_us-gaap_ProductMember_aef875d9-e3ec-403f-90b3-bc446b1f3360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_6ee3be36-cf63-4b17-bca7-9e098390d032" xlink:href="gild-20211231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_73be9344-c14d-4f21-aee6-61788e2ac6bc" xlink:to="loc_gild_RoyaltyContractAndOtherMember_6ee3be36-cf63-4b17-bca7-9e098390d032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2d3ce795-a3b8-4688-bd68-2b41e949b2e0" xlink:to="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a32004a4-591a-4e83-98cc-37acc6db2d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_RevenuesAbstract_a32004a4-591a-4e83-98cc-37acc6db2d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09a8221c-0b18-4c06-b031-331268767059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a32004a4-591a-4e83-98cc-37acc6db2d10" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09a8221c-0b18-4c06-b031-331268767059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_601bb89e-6d8f-4c82-b3e5-510156f0417e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_601bb89e-6d8f-4c82-b3e5-510156f0417e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_299501ac-8333-44b4-97d9-4f4251c98e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_299501ac-8333-44b4-97d9-4f4251c98e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment_e0715240-4df1-4fbe-8093-95e0bdc06ba2" xlink:href="gild-20211231.xsd#gild_ResearchAndDevelopmentInProcessIncludingImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:to="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment_e0715240-4df1-4fbe-8093-95e0bdc06ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_299b7c77-a74f-47e2-b858-6165283cd8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_299b7c77-a74f-47e2-b858-6165283cd8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c89d5f64-a81c-4d00-ac01-12b4f46a1641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4e2913c0-43c2-478b-bde7-378bc9e26932" xlink:to="loc_us-gaap_CostsAndExpenses_c89d5f64-a81c-4d00-ac01-12b4f46a1641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_505e8ff4-f28f-4655-ba58-6ca693605970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_OperatingIncomeLoss_505e8ff4-f28f-4655-ba58-6ca693605970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_cc3d8e7a-e6e1-491f-b89e-88fc5004c0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_InterestExpense_cc3d8e7a-e6e1-491f-b89e-88fc5004c0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_708a5bab-68d4-4a81-99fb-4e33e9c2187d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_708a5bab-68d4-4a81-99fb-4e33e9c2187d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7dadf185-d43f-4959-8727-ccfdebeace32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7dadf185-d43f-4959-8727-ccfdebeace32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5276b889-db62-4c90-8084-6c201c6726c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5276b889-db62-4c90-8084-6c201c6726c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_eb785c7c-5cd1-4d37-a9e2-4c3b62688db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_ProfitLoss_eb785c7c-5cd1-4d37-a9e2-4c3b62688db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d9d5c18f-1c34-4156-b0ba-9e0f233df693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d9d5c18f-1c34-4156-b0ba-9e0f233df693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aac35409-61ec-477f-9623-d41c0ad781c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_NetIncomeLoss_aac35409-61ec-477f-9623-d41c0ad781c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c4e91619-b74f-4a46-b8a8-e8a67c489672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_EarningsPerShareBasic_c4e91619-b74f-4a46-b8a8-e8a67c489672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e1de03d1-45bc-4914-bade-13f0c2812d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e1de03d1-45bc-4914-bade-13f0c2812d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1fc7bf43-4e41-4f7e-a1df-b4a64317eabb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1fc7bf43-4e41-4f7e-a1df-b4a64317eabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6080d545-afd0-4af6-8697-35d990c5166d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1777ffe7-fa51-4f78-8da5-389d66ecfb13" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6080d545-afd0-4af6-8697-35d990c5166d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c81aeec8-8bd5-460c-ad72-16f5c694dd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ca052035-4844-4dc0-bc03-7b0f6da5ef12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c81aeec8-8bd5-460c-ad72-16f5c694dd6c" xlink:to="loc_us-gaap_ProfitLoss_ca052035-4844-4dc0-bc03-7b0f6da5ef12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_af5c037d-06db-4627-9c2d-bf876829bcea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c81aeec8-8bd5-460c-ad72-16f5c694dd6c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_af5c037d-06db-4627-9c2d-bf876829bcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_23fb2cae-5aec-4fab-ac64-fb38f4e5edd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_af5c037d-06db-4627-9c2d-bf876829bcea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_23fb2cae-5aec-4fab-ac64-fb38f4e5edd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_1e6f8a3b-56a6-47bd-a599-6368315ca161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_af5c037d-06db-4627-9c2d-bf876829bcea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_1e6f8a3b-56a6-47bd-a599-6368315ca161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f45a45d8-793c-4fdc-a965-3a31e83a60c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_1e6f8a3b-56a6-47bd-a599-6368315ca161" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f45a45d8-793c-4fdc-a965-3a31e83a60c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_20363bc2-146c-4c6e-a459-e8ec5681f11f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_1e6f8a3b-56a6-47bd-a599-6368315ca161" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_20363bc2-146c-4c6e-a459-e8ec5681f11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_772c654e-945c-4e56-8109-df73e4bb1b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_1e6f8a3b-56a6-47bd-a599-6368315ca161" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_772c654e-945c-4e56-8109-df73e4bb1b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_db29aca1-770d-4e3b-8efc-f89e44317c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_af5c037d-06db-4627-9c2d-bf876829bcea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_db29aca1-770d-4e3b-8efc-f89e44317c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_72cae46e-fdd0-4448-bf4f-777f53ffccf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_db29aca1-770d-4e3b-8efc-f89e44317c7a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_72cae46e-fdd0-4448-bf4f-777f53ffccf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_e87065c5-e81b-4504-b365-4d6af5f07a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_db29aca1-770d-4e3b-8efc-f89e44317c7a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_e87065c5-e81b-4504-b365-4d6af5f07a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_455e8ee7-d231-42d7-893f-0f8b592b9fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_db29aca1-770d-4e3b-8efc-f89e44317c7a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_455e8ee7-d231-42d7-893f-0f8b592b9fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ca89708-310f-4137-b5fc-6b8f587d513e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_af5c037d-06db-4627-9c2d-bf876829bcea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ca89708-310f-4137-b5fc-6b8f587d513e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7760ccfd-77bc-45e5-8bd7-6f2fc8243dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c81aeec8-8bd5-460c-ad72-16f5c694dd6c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7760ccfd-77bc-45e5-8bd7-6f2fc8243dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f506c8d2-ba43-4176-8436-80db75168b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c81aeec8-8bd5-460c-ad72-16f5c694dd6c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f506c8d2-ba43-4176-8436-80db75168b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_32d4a072-87d4-4747-abcc-567075b827ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c81aeec8-8bd5-460c-ad72-16f5c694dd6c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_32d4a072-87d4-4747-abcc-567075b827ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1275be21-0df3-4e4a-83b1-faf98c69e7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c0e0cd65-707b-4287-91e4-67e21ec50d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1275be21-0df3-4e4a-83b1-faf98c69e7d2" xlink:to="loc_us-gaap_StatementTable_c0e0cd65-707b-4287-91e4-67e21ec50d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_32956085-8195-429d-a933-7962318a385c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c0e0cd65-707b-4287-91e4-67e21ec50d68" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_32956085-8195-429d-a933-7962318a385c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32956085-8195-429d-a933-7962318a385c" xlink:to="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6978b0bb-c77c-4e29-a52f-ff98dbb0f6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:to="loc_us-gaap_CommonStockMember_6978b0bb-c77c-4e29-a52f-ff98dbb0f6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_97282e71-c86f-4f21-864b-02e56ec57996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_97282e71-c86f-4f21-864b-02e56ec57996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bbfddce5-5ea0-4ace-ba6c-f64f9db40cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bbfddce5-5ea0-4ace-ba6c-f64f9db40cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d2ca4b2d-5eab-44b2-b3e1-f1d4299af97b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:to="loc_us-gaap_RetainedEarningsMember_d2ca4b2d-5eab-44b2-b3e1-f1d4299af97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e7c40d2f-1d74-455b-93e5-cf55c7fa1ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5f897d48-ed93-40a1-861a-f2bed38a38cd" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e7c40d2f-1d74-455b-93e5-cf55c7fa1ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_623df719-4b7c-4502-9098-1b3502364160" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c0e0cd65-707b-4287-91e4-67e21ec50d68" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_623df719-4b7c-4502-9098-1b3502364160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7484974e-285e-49a7-bc55-1f0a52e13da7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_623df719-4b7c-4502-9098-1b3502364160" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7484974e-285e-49a7-bc55-1f0a52e13da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6b0285c8-4794-4f4e-9c7d-9fc83441f991" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7484974e-285e-49a7-bc55-1f0a52e13da7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6b0285c8-4794-4f4e-9c7d-9fc83441f991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5d3e8066-7799-4fde-87f8-6fa9971abf14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c0e0cd65-707b-4287-91e4-67e21ec50d68" xlink:to="loc_us-gaap_StatementLineItems_5d3e8066-7799-4fde-87f8-6fa9971abf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5d3e8066-7799-4fde-87f8-6fa9971abf14" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_db38f91d-0bb7-4903-907d-5a30e4c24403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_db38f91d-0bb7-4903-907d-5a30e4c24403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_717d859e-5534-461a-b1b8-df2aef45b23b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_717d859e-5534-461a-b1b8-df2aef45b23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_d9521b73-afc6-41fd-9588-bdbf1b642a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_d9521b73-afc6-41fd-9588-bdbf1b642a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9e034b8e-2d28-452b-92bf-db144a3a7dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_ProfitLoss_9e034b8e-2d28-452b-92bf-db144a3a7dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f7d88cef-32f4-416c-8c75-3dfe82a02c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f7d88cef-32f4-416c-8c75-3dfe82a02c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_404cf54c-c804-4535-a2d2-b91b631e6a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_404cf54c-c804-4535-a2d2-b91b631e6a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_276c8936-55f9-4f1e-aa84-318cc2953f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_276c8936-55f9-4f1e-aa84-318cc2953f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_12e34418-09e5-475e-8142-ac58be42e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_12e34418-09e5-475e-8142-ac58be42e84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7fd48bd6-4345-45e4-bd23-0cf91a0e9df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7fd48bd6-4345-45e4-bd23-0cf91a0e9df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f99c7d4-6603-45ee-acc9-5fab73651e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f99c7d4-6603-45ee-acc9-5fab73651e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_129c4c0f-43d4-43a2-a2f9-9545770611de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_129c4c0f-43d4-43a2-a2f9-9545770611de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_6619b381-f590-4979-9591-04feecdfe735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_6619b381-f590-4979-9591-04feecdfe735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_59b273db-b13c-43e4-9af2-d52667d3d9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_Dividends_59b273db-b13c-43e4-9af2-d52667d3d9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f630595a-1b75-43f2-85c2-ca1512641f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f630595a-1b75-43f2-85c2-ca1512641f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2bfdab23-fd5e-42d8-aadc-d1173c2ea987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c16c3def-12e9-4e02-ba75-111f28d1c5c7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2bfdab23-fd5e-42d8-aadc-d1173c2ea987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_19d9f97d-6a0d-408a-af16-429190c4e158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_be1dbb68-b814-49e9-a875-44a1195524ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_19d9f97d-6a0d-408a-af16-429190c4e158" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_be1dbb68-b814-49e9-a875-44a1195524ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="gild-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_00bf9153-7c76-47c5-b867-49ef84d731ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0f4bfe24-788a-4220-8022-ee1856c22741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00bf9153-7c76-47c5-b867-49ef84d731ac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0f4bfe24-788a-4220-8022-ee1856c22741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f66036c7-defa-45fc-b09d-0fd61ef9178a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0f4bfe24-788a-4220-8022-ee1856c22741" xlink:to="loc_us-gaap_ProfitLoss_f66036c7-defa-45fc-b09d-0fd61ef9178a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b17bcc7-6934-40b1-a75d-53c3d8378056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0f4bfe24-788a-4220-8022-ee1856c22741" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b17bcc7-6934-40b1-a75d-53c3d8378056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1e31d0b8-762f-4a36-bf56-b150a6fe5b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b17bcc7-6934-40b1-a75d-53c3d8378056" xlink:to="loc_us-gaap_Depreciation_1e31d0b8-762f-4a36-bf56-b150a6fe5b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_b45ddcf3-3e86-4fc1-9916-d00490a52fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b17bcc7-6934-40b1-a75d-53c3d8378056" xlink:to="loc_us-gaap_AdjustmentForAmortization_b45ddcf3-3e86-4fc1-9916-d00490a52fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_10ddb5e3-bbc3-4b8f-956b-ba4c7f85f62f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b17bcc7-6934-40b1-a75d-53c3d8378056" xlink:to="loc_us-gaap_ShareBasedCompensation_10ddb5e3-bbc3-4b8f-956b-ba4c7f85f62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_de1e4f3f-f48f-4606-a3e2-d033cfa265c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b17bcc7-6934-40b1-a75d-53c3d8378056" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_de1e4f3f-f48f-4606-a3e2-d033cfa265c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_afd58528-aa84-4969-83b6-e69baf0cf0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b17bcc7-6934-40b1-a75d-53c3d8378056" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_afd58528-aa84-4969-83b6-e69baf0cf0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_7ef89e97-ce3e-401f-8df3-102b74c0933a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b17bcc7-6934-40b1-a75d-53c3d8378056" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_7ef89e97-ce3e-401f-8df3-102b74c0933a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_b85c0648-e302-4072-a713-77ce7194591b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b17bcc7-6934-40b1-a75d-53c3d8378056" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_b85c0648-e302-4072-a713-77ce7194591b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryReserveForExcessRawMaterials_f25b4d75-c391-472a-bfaf-ac13d71bc728" xlink:href="gild-20211231.xsd#gild_InventoryReserveForExcessRawMaterials"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b17bcc7-6934-40b1-a75d-53c3d8378056" xlink:to="loc_gild_InventoryReserveForExcessRawMaterials_f25b4d75-c391-472a-bfaf-ac13d71bc728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_eabeb517-a877-42c6-b63c-7aeb0ea84001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b17bcc7-6934-40b1-a75d-53c3d8378056" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_eabeb517-a877-42c6-b63c-7aeb0ea84001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ea25e6f-8cb9-4fe6-92a8-9af753164f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b17bcc7-6934-40b1-a75d-53c3d8378056" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ea25e6f-8cb9-4fe6-92a8-9af753164f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7529a12f-a7aa-4197-9989-6458df1d2bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ea25e6f-8cb9-4fe6-92a8-9af753164f60" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7529a12f-a7aa-4197-9989-6458df1d2bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ee49c80b-2f57-45c0-a48d-9d8bd5ed0f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ea25e6f-8cb9-4fe6-92a8-9af753164f60" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ee49c80b-2f57-45c0-a48d-9d8bd5ed0f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0de37fa1-ba85-484c-bcbf-ba7061bb860f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ea25e6f-8cb9-4fe6-92a8-9af753164f60" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0de37fa1-ba85-484c-bcbf-ba7061bb860f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_05b40236-030e-4073-8a2e-86feae9b8040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ea25e6f-8cb9-4fe6-92a8-9af753164f60" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_05b40236-030e-4073-8a2e-86feae9b8040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_ed45e5dd-fa36-4531-b708-58d087898f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ea25e6f-8cb9-4fe6-92a8-9af753164f60" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_ed45e5dd-fa36-4531-b708-58d087898f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_485941a3-ff85-45b2-b1f0-8c87042d4554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ea25e6f-8cb9-4fe6-92a8-9af753164f60" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_485941a3-ff85-45b2-b1f0-8c87042d4554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e478f237-a353-40e8-a3bb-1ec17217ebfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ea25e6f-8cb9-4fe6-92a8-9af753164f60" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e478f237-a353-40e8-a3bb-1ec17217ebfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71580b5b-495c-49db-8717-f3c995ab0aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00bf9153-7c76-47c5-b867-49ef84d731ac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71580b5b-495c-49db-8717-f3c995ab0aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_59631ff7-1ba8-4076-a79a-e9060ed7dc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71580b5b-495c-49db-8717-f3c995ab0aeb" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_59631ff7-1ba8-4076-a79a-e9060ed7dc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_232d778e-6497-4c70-8294-061a72084671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71580b5b-495c-49db-8717-f3c995ab0aeb" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_232d778e-6497-4c70-8294-061a72084671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_18dd8cee-0eda-48a3-9011-94fb645f31e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71580b5b-495c-49db-8717-f3c995ab0aeb" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_18dd8cee-0eda-48a3-9011-94fb645f31e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6d9f60a1-2a4a-4fe2-bd72-0094bb902e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71580b5b-495c-49db-8717-f3c995ab0aeb" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6d9f60a1-2a4a-4fe2-bd72-0094bb902e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_c24418df-76a0-4ca9-9def-ab209713249a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71580b5b-495c-49db-8717-f3c995ab0aeb" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_c24418df-76a0-4ca9-9def-ab209713249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5b0cf8cf-adee-4e69-8061-37a972fbb2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71580b5b-495c-49db-8717-f3c995ab0aeb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5b0cf8cf-adee-4e69-8061-37a972fbb2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_dcbd1210-b87c-46f1-bdab-f561fdcc939b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71580b5b-495c-49db-8717-f3c995ab0aeb" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_dcbd1210-b87c-46f1-bdab-f561fdcc939b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0316a06-9efc-426a-875a-2bd2810e8d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71580b5b-495c-49db-8717-f3c995ab0aeb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0316a06-9efc-426a-875a-2bd2810e8d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7441afe-f8a5-41de-ac1d-52bd87deac79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00bf9153-7c76-47c5-b867-49ef84d731ac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7441afe-f8a5-41de-ac1d-52bd87deac79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_51a8b9a9-b9ad-4f9a-bb7c-e289f20eb0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7441afe-f8a5-41de-ac1d-52bd87deac79" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_51a8b9a9-b9ad-4f9a-bb7c-e289f20eb0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_99fd1f12-e740-4721-95bd-13b8e226e42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7441afe-f8a5-41de-ac1d-52bd87deac79" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_99fd1f12-e740-4721-95bd-13b8e226e42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_87db998f-dfe1-4a05-806a-a47df6f3c7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7441afe-f8a5-41de-ac1d-52bd87deac79" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_87db998f-dfe1-4a05-806a-a47df6f3c7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_2f96bd05-49ff-47e2-97fe-f830e71876e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7441afe-f8a5-41de-ac1d-52bd87deac79" xlink:to="loc_us-gaap_RepaymentsOfDebt_2f96bd05-49ff-47e2-97fe-f830e71876e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_72c844dd-a2ba-4c5c-a4b4-c9f067b1acbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7441afe-f8a5-41de-ac1d-52bd87deac79" xlink:to="loc_us-gaap_PaymentsOfDividends_72c844dd-a2ba-4c5c-a4b4-c9f067b1acbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_daf8eaf4-77d3-43c2-9c05-b013aae8027e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7441afe-f8a5-41de-ac1d-52bd87deac79" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_daf8eaf4-77d3-43c2-9c05-b013aae8027e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6291842e-3d92-4699-82d7-f92ee76c4db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7441afe-f8a5-41de-ac1d-52bd87deac79" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6291842e-3d92-4699-82d7-f92ee76c4db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a1acf7a2-cc87-48d7-9e4b-77c27bbce29e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00bf9153-7c76-47c5-b867-49ef84d731ac" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a1acf7a2-cc87-48d7-9e4b-77c27bbce29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cc27a271-7db3-441b-ba47-c116e06d97c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00bf9153-7c76-47c5-b867-49ef84d731ac" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cc27a271-7db3-441b-ba47-c116e06d97c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c8b9fde-8ca0-434d-b7c2-6015e7d29084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00bf9153-7c76-47c5-b867-49ef84d731ac" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c8b9fde-8ca0-434d-b7c2-6015e7d29084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0de0ca17-7c97-4545-967f-1d7379b28538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00bf9153-7c76-47c5-b867-49ef84d731ac" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0de0ca17-7c97-4545-967f-1d7379b28538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_17234093-5431-48bf-a789-d09125b39990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_00bf9153-7c76-47c5-b867-49ef84d731ac" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_17234093-5431-48bf-a789-d09125b39990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a6916c4e-47e9-4b4d-82e1-95ef57826b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_17234093-5431-48bf-a789-d09125b39990" xlink:to="loc_us-gaap_InterestPaidNet_a6916c4e-47e9-4b4d-82e1-95ef57826b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_8257de45-b894-45fd-8364-48977184065d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_17234093-5431-48bf-a789-d09125b39990" xlink:to="loc_us-gaap_IncomeTaxesPaid_8257de45-b894-45fd-8364-48977184065d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="gild-20211231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e085882f-d0fe-43a9-8ad4-9d08db79c5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_433eb1cc-71dc-48a6-ab49-23afc72a4e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e085882f-d0fe-43a9-8ad4-9d08db79c5b9" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_433eb1cc-71dc-48a6-ab49-23afc72a4e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gild-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c40e2042-9369-4c20-a9f3-6daa22efcdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c40e2042-9369-4c20-a9f3-6daa22efcdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9af60f67-4dcd-402c-b0dd-b5384a3adce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9af60f67-4dcd-402c-b0dd-b5384a3adce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c4f476f7-8d4e-4596-9570-55fd700bc25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_UseOfEstimates_c4f476f7-8d4e-4596-9570-55fd700bc25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a0b810df-8c90-4ec8-afe3-5a7edb1d5125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a0b810df-8c90-4ec8-afe3-5a7edb1d5125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_034abadc-b779-4f20-ae26-5b0ebd796f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_034abadc-b779-4f20-ae26-5b0ebd796f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_f870ea97-df65-49be-b0b3-2f0c3a60d2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_f870ea97-df65-49be-b0b3-2f0c3a60d2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_604c769a-cbc9-43bf-a363-b422e4a38382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_604c769a-cbc9-43bf-a363-b422e4a38382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1302d098-e078-4a7b-9081-4c0a1b1cdeba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1302d098-e078-4a7b-9081-4c0a1b1cdeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_b287f3d3-4010-43c2-8071-116c164c9e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_b287f3d3-4010-43c2-8071-116c164c9e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_145d1cd5-2a68-4de2-9a88-ff9c14a4ab90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_145d1cd5-2a68-4de2-9a88-ff9c14a4ab90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_00ad1197-af29-46aa-8c89-8b0a63293a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_00ad1197-af29-46aa-8c89-8b0a63293a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_73cdd99b-2fd1-4e13-8532-3af11e7f29b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_73cdd99b-2fd1-4e13-8532-3af11e7f29b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_bec7ece5-56f1-4df0-8fa2-88a76dfadb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_bec7ece5-56f1-4df0-8fa2-88a76dfadb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_ad27c7ca-85ab-4e70-8455-3f6bfebf3ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_ad27c7ca-85ab-4e70-8455-3f6bfebf3ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f52c3161-419d-4f83-bdfa-2dcb812c0ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f52c3161-419d-4f83-bdfa-2dcb812c0ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a39dcbd8-4bdd-4708-beca-49428bc58794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a39dcbd8-4bdd-4708-beca-49428bc58794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_06c3083b-5705-455c-ad80-8f8255ceae76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_06c3083b-5705-455c-ad80-8f8255ceae76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a0b5c752-0f2f-4f2e-b5fb-883ae0748d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a0b5c752-0f2f-4f2e-b5fb-883ae0748d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_92d05bef-2021-4f6a-87ac-4fa64db46b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_92d05bef-2021-4f6a-87ac-4fa64db46b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_90bf775b-df2c-4b68-9b82-9c1e2a2fa138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_90bf775b-df2c-4b68-9b82-9c1e2a2fa138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1f3663d7-57d5-4120-b987-592e4480554f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1f3663d7-57d5-4120-b987-592e4480554f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_909bacda-d603-4d56-b7c3-0790ea22280a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9a12106-5ce9-4898-8273-cfee80d38d91" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_909bacda-d603-4d56-b7c3-0790ea22280a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gild-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c87f378a-6708-4c2b-9e6c-b56c18ba9b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock_af623168-7c5b-457e-93c3-223465bf975d" xlink:href="gild-20211231.xsd#gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c87f378a-6708-4c2b-9e6c-b56c18ba9b1e" xlink:to="loc_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock_af623168-7c5b-457e-93c3-223465bf975d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f8a33cd8-f6d0-4672-9419-4c43d1ad7526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SummaryOfSignificantAccountingPoliciesTable_bc7157a9-5237-4774-9742-fab2f98d5cf7" xlink:href="gild-20211231.xsd#gild_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f8a33cd8-f6d0-4672-9419-4c43d1ad7526" xlink:to="loc_gild_SummaryOfSignificantAccountingPoliciesTable_bc7157a9-5237-4774-9742-fab2f98d5cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3bc28df8-d0b9-453d-ae8f-3f38b5104f3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_bc7157a9-5237-4774-9742-fab2f98d5cf7" xlink:to="loc_srt_RangeAxis_3bc28df8-d0b9-453d-ae8f-3f38b5104f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a24bcb04-ce9e-4750-b183-29740e392133" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3bc28df8-d0b9-453d-ae8f-3f38b5104f3c" xlink:to="loc_srt_RangeMember_a24bcb04-ce9e-4750-b183-29740e392133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_13f04e7f-9a90-4e8a-a4f4-b23e8e3ac4a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a24bcb04-ce9e-4750-b183-29740e392133" xlink:to="loc_srt_MinimumMember_13f04e7f-9a90-4e8a-a4f4-b23e8e3ac4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4052e09-6ec6-4ea7-94c3-612c3605e8b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a24bcb04-ce9e-4750-b183-29740e392133" xlink:to="loc_srt_MaximumMember_a4052e09-6ec6-4ea7-94c3-612c3605e8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d409b165-b6f6-44a9-8123-86322e6d79fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_bc7157a9-5237-4774-9742-fab2f98d5cf7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d409b165-b6f6-44a9-8123-86322e6d79fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b88b623-abd3-42ff-9eb3-6c276bb22009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d409b165-b6f6-44a9-8123-86322e6d79fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b88b623-abd3-42ff-9eb3-6c276bb22009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_36eceb30-326a-4b01-956d-9f6e09abad7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b88b623-abd3-42ff-9eb3-6c276bb22009" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_36eceb30-326a-4b01-956d-9f6e09abad7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_0901708a-386d-4808-93d9-498bbe42d227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b88b623-abd3-42ff-9eb3-6c276bb22009" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_0901708a-386d-4808-93d9-498bbe42d227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2711dd13-849e-443f-9a9b-dfec72a9d287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b88b623-abd3-42ff-9eb3-6c276bb22009" xlink:to="loc_us-gaap_ComputerEquipmentMember_2711dd13-849e-443f-9a9b-dfec72a9d287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:href="gild-20211231.xsd#gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_bc7157a9-5237-4774-9742-fab2f98d5cf7" xlink:to="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_f17abfa2-c2c2-4d23-8875-543398907c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_f17abfa2-c2c2-4d23-8875-543398907c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8f765b7c-9b2e-4cf9-bbe5-802f1359c35c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8f765b7c-9b2e-4cf9-bbe5-802f1359c35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_770afaed-304f-48b5-8ae4-8d0b3e3fc333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:to="loc_us-gaap_AdvertisingExpense_770afaed-304f-48b5-8ae4-8d0b3e3fc333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_a2fcb468-d56c-4897-ab03-2edc8a4010d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_a2fcb468-d56c-4897-ab03-2edc8a4010d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2d56f95d-df28-4cb1-b8c5-9439c41e0667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1070ff05-a647-49a2-95d5-a648052b4f3d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2d56f95d-df28-4cb1-b8c5-9439c41e0667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Revenues" xlink:type="simple" xlink:href="gild-20211231.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0ee35d66-143f-4c07-9689-c0fb0a59fd85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6401abf7-8ae3-4ce7-895f-59fd01b22642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0ee35d66-143f-4c07-9689-c0fb0a59fd85" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6401abf7-8ae3-4ce7-895f-59fd01b22642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesTables" xlink:type="simple" xlink:href="gild-20211231.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_af026b9b-2abe-4ad4-9f88-154f82721a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_03ff9d61-7a30-4139-acf3-4f536810e53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_af026b9b-2abe-4ad4-9f88-154f82721a11" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_03ff9d61-7a30-4139-acf3-4f536810e53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_f67cd018-5a0e-4c0a-9ea6-87318e2c1cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_af026b9b-2abe-4ad4-9f88-154f82721a11" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_f67cd018-5a0e-4c0a-9ea6-87318e2c1cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#RevenuesDisaggregationofRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1e98458c-13e7-4821-83c8-0ccf89284f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_306ef94d-93b8-407e-8c07-91f3c00098ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1e98458c-13e7-4821-83c8-0ccf89284f03" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_306ef94d-93b8-407e-8c07-91f3c00098ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8be6c2f5-7bda-49fc-aae3-ec0245ade4b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_306ef94d-93b8-407e-8c07-91f3c00098ae" xlink:to="loc_srt_ProductOrServiceAxis_8be6c2f5-7bda-49fc-aae3-ec0245ade4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1392908-781c-4c88-88c4-aaccf515445c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8be6c2f5-7bda-49fc-aae3-ec0245ade4b1" xlink:to="loc_srt_ProductsAndServicesDomain_f1392908-781c-4c88-88c4-aaccf515445c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1392908-781c-4c88-88c4-aaccf515445c" xlink:to="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:href="gild-20211231.xsd#gild_HIVProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsAtriplaMember_347842b4-7661-489c-b91f-bdbf6e7cabeb" xlink:href="gild-20211231.xsd#gild_HIVProductsAtriplaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsAtriplaMember_347842b4-7661-489c-b91f-bdbf6e7cabeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_cbb23c70-cc1b-45ed-aaa7-2b8bb0347bbe" xlink:href="gild-20211231.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsBiktarvyMember_cbb23c70-cc1b-45ed-aaa7-2b8bb0347bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_0c81105d-b89f-4d28-98dc-31da43a631c9" xlink:href="gild-20211231.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_0c81105d-b89f-4d28-98dc-31da43a631c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_90cf635f-c971-4993-8511-f831bc64d98d" xlink:href="gild-20211231.xsd#gild_HIVProductsDescovyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsDescovyMember_90cf635f-c971-4993-8511-f831bc64d98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_964e3a59-cd0e-4d02-9c4d-5bb2c5517bcd" xlink:href="gild-20211231.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsGenvoyaMember_964e3a59-cd0e-4d02-9c4d-5bb2c5517bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_3213ddad-870c-4fe1-97c9-b4a1f665279a" xlink:href="gild-20211231.xsd#gild_HIVProductsOdefseyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsOdefseyMember_3213ddad-870c-4fe1-97c9-b4a1f665279a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_aa376418-8e8f-4fd5-a0e3-282e82bfd18f" xlink:href="gild-20211231.xsd#gild_HIVProductsStribildMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsStribildMember_aa376418-8e8f-4fd5-a0e3-282e82bfd18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_72d715ec-ad6e-4d51-a3dd-f91f56d5ef8c" xlink:href="gild-20211231.xsd#gild_HIVProductsTruvadaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_HIVProductsTruvadaMember_72d715ec-ad6e-4d51-a3dd-f91f56d5ef8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_2aa9f730-4701-40ed-919e-8041f909eecb" xlink:href="gild-20211231.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_2aa9f730-4701-40ed-919e-8041f909eecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_292f94a4-aae5-48c3-8328-353a36677c39" xlink:href="gild-20211231.xsd#gild_ProductsOtherHIVMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d660c3ba-949e-484a-822e-4ecaf5d4f659" xlink:to="loc_gild_ProductsOtherHIVMember_292f94a4-aae5-48c3-8328-353a36677c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember_73dcdae7-da54-40f6-9d40-516c69188611" xlink:href="gild-20211231.xsd#gild_VekluryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_VekluryMember_73dcdae7-da54-40f6-9d40-516c69188611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_335a87e5-e6b3-4975-8cec-7d89247a8c1e" xlink:href="gild-20211231.xsd#gild_HCVProductSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_HCVProductSalesMember_335a87e5-e6b3-4975-8cec-7d89247a8c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_9cbb9c7d-0fdf-43cd-8007-5ed2a1590f18" xlink:href="gild-20211231.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_335a87e5-e6b3-4975-8cec-7d89247a8c1e" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_9cbb9c7d-0fdf-43cd-8007-5ed2a1590f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_7ae85b20-300f-4405-a279-694032a386b4" xlink:href="gild-20211231.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_335a87e5-e6b3-4975-8cec-7d89247a8c1e" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_7ae85b20-300f-4405-a279-694032a386b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHCVMember_1cd90462-94a4-43fd-a154-88f701430e76" xlink:href="gild-20211231.xsd#gild_OtherHCVMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_335a87e5-e6b3-4975-8cec-7d89247a8c1e" xlink:to="loc_gild_OtherHCVMember_1cd90462-94a4-43fd-a154-88f701430e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_0f9ef6d3-37b7-4294-a593-985058ef7413" xlink:href="gild-20211231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_0f9ef6d3-37b7-4294-a593-985058ef7413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_8a3445db-9356-48b5-9c5d-b12f391a1339" xlink:href="gild-20211231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_0f9ef6d3-37b7-4294-a593-985058ef7413" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_8a3445db-9356-48b5-9c5d-b12f391a1339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_a0a06e6e-9bdf-49db-a26b-6ce30fe69a42" xlink:href="gild-20211231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_0f9ef6d3-37b7-4294-a593-985058ef7413" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_a0a06e6e-9bdf-49db-a26b-6ce30fe69a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_83a48084-fc9b-449a-942e-1a7bd6a2d8b7" xlink:href="gild-20211231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_0f9ef6d3-37b7-4294-a593-985058ef7413" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_83a48084-fc9b-449a-942e-1a7bd6a2d8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_40193d41-d10c-43af-b725-2e107b19812f" xlink:href="gild-20211231.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_40193d41-d10c-43af-b725-2e107b19812f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_faa409dd-b224-4ffb-826b-069fc85f6748" xlink:href="gild-20211231.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_40193d41-d10c-43af-b725-2e107b19812f" xlink:to="loc_gild_CellTherapyProductsTecartusMember_faa409dd-b224-4ffb-826b-069fc85f6748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsYescartaMember_dc099a71-9bfd-4c31-afb5-5c22d93bd77b" xlink:href="gild-20211231.xsd#gild_OtherProductsYescartaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_40193d41-d10c-43af-b725-2e107b19812f" xlink:to="loc_gild_OtherProductsYescartaMember_dc099a71-9bfd-4c31-afb5-5c22d93bd77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_8865fb5e-80de-4448-98ec-edcc3d52a305" xlink:href="gild-20211231.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_TrodelvyMember_8865fb5e-80de-4448-98ec-edcc3d52a305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:href="gild-20211231.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_8c09b548-c74b-455c-b6d1-a98e4a8f7363" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_7565c889-cd4a-428e-8cd5-b4df0c8c4710" xlink:href="gild-20211231.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:to="loc_gild_OtherProductsAmBisomeMember_7565c889-cd4a-428e-8cd5-b4df0c8c4710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_db90e806-9685-4423-85cb-e0b63e624874" xlink:href="gild-20211231.xsd#gild_OtherProductsLetairisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:to="loc_gild_OtherProductsLetairisMember_db90e806-9685-4423-85cb-e0b63e624874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsRanexaMember_fdbd170e-1f95-44de-b12f-40d1cc41e598" xlink:href="gild-20211231.xsd#gild_OtherProductsRanexaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:to="loc_gild_OtherProductsRanexaMember_fdbd170e-1f95-44de-b12f-40d1cc41e598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsZydeligMember_0359e329-1872-412d-908f-a74a68cf4ae6" xlink:href="gild-20211231.xsd#gild_OtherProductsZydeligMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:to="loc_gild_OtherProductsZydeligMember_0359e329-1872-412d-908f-a74a68cf4ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_e46e13a5-2670-457f-be42-ad73e285002c" xlink:href="gild-20211231.xsd#gild_OtherProductsOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_37297649-7a55-4d90-b915-fb96fd1cfa8b" xlink:to="loc_gild_OtherProductsOtherMember_e46e13a5-2670-457f-be42-ad73e285002c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_84f85015-e54e-4750-8638-190a2f2ee2df" xlink:href="gild-20211231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1392908-781c-4c88-88c4-aaccf515445c" xlink:to="loc_gild_RoyaltyContractAndOtherMember_84f85015-e54e-4750-8638-190a2f2ee2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0137e542-62e8-4f3f-a65d-b6bd3d5a695a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_306ef94d-93b8-407e-8c07-91f3c00098ae" xlink:to="loc_srt_StatementGeographicalAxis_0137e542-62e8-4f3f-a65d-b6bd3d5a695a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c65dce8f-93a7-46e4-881e-03d9d6f283aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0137e542-62e8-4f3f-a65d-b6bd3d5a695a" xlink:to="loc_srt_SegmentGeographicalDomain_c65dce8f-93a7-46e4-881e-03d9d6f283aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9ef47f6d-0555-4358-8781-6992a03fbaee" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c65dce8f-93a7-46e4-881e-03d9d6f283aa" xlink:to="loc_country_US_9ef47f6d-0555-4358-8781-6992a03fbaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_5ea9ac3f-f108-49b1-aebe-decc14f8dbec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c65dce8f-93a7-46e4-881e-03d9d6f283aa" xlink:to="loc_srt_EuropeMember_5ea9ac3f-f108-49b1-aebe-decc14f8dbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_493c3505-caaa-404d-af89-92bab5b53fde" xlink:href="gild-20211231.xsd#gild_OtherInternationalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c65dce8f-93a7-46e4-881e-03d9d6f283aa" xlink:to="loc_gild_OtherInternationalMember_493c3505-caaa-404d-af89-92bab5b53fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6eb8d3f1-e954-4576-aa16-8a3ad1d9bc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_306ef94d-93b8-407e-8c07-91f3c00098ae" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6eb8d3f1-e954-4576-aa16-8a3ad1d9bc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c2dd157-3a68-4b2e-a749-aa65c330ff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6eb8d3f1-e954-4576-aa16-8a3ad1d9bc9a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c2dd157-3a68-4b2e-a749-aa65c330ff2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#RevenuesSummarizedRevenuesfromMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_57cc99fe-f000-4cbc-a134-24dddd7b4256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ffbc0d94-6b6b-43ed-9c4e-184404f58235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_57cc99fe-f000-4cbc-a134-24dddd7b4256" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ffbc0d94-6b6b-43ed-9c4e-184404f58235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1feb23ff-b575-4cd5-97da-091f816e25a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ffbc0d94-6b6b-43ed-9c4e-184404f58235" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1feb23ff-b575-4cd5-97da-091f816e25a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2823a0a1-4cbb-4fbb-9023-23ffb4a0e982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1feb23ff-b575-4cd5-97da-091f816e25a5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2823a0a1-4cbb-4fbb-9023-23ffb4a0e982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_3af93181-1902-4775-a8a9-4410f3cd341e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2823a0a1-4cbb-4fbb-9023-23ffb4a0e982" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_3af93181-1902-4775-a8a9-4410f3cd341e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_08d25965-e559-4fa4-afcc-7b02e8d4ada7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ffbc0d94-6b6b-43ed-9c4e-184404f58235" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_08d25965-e559-4fa4-afcc-7b02e8d4ada7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3c15fcb0-88b3-4085-aab8-86d34816273a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_08d25965-e559-4fa4-afcc-7b02e8d4ada7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3c15fcb0-88b3-4085-aab8-86d34816273a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_11cc303a-ad2b-48ae-957d-8b4e08fd0727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3c15fcb0-88b3-4085-aab8-86d34816273a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_11cc303a-ad2b-48ae-957d-8b4e08fd0727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_872359cf-f507-4e7e-89ec-eca689728e7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ffbc0d94-6b6b-43ed-9c4e-184404f58235" xlink:to="loc_srt_MajorCustomersAxis_872359cf-f507-4e7e-89ec-eca689728e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_37022a98-0274-42a6-b35e-38afa6897378" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_872359cf-f507-4e7e-89ec-eca689728e7d" xlink:to="loc_srt_NameOfMajorCustomerDomain_37022a98-0274-42a6-b35e-38afa6897378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_8e0ff66d-1c0d-4901-8985-565b4c2e87b7" xlink:href="gild-20211231.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_37022a98-0274-42a6-b35e-38afa6897378" xlink:to="loc_gild_AmerisourcebergenCorpMember_8e0ff66d-1c0d-4901-8985-565b4c2e87b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_65e7ef37-d273-42cb-a13e-515ce087e553" xlink:href="gild-20211231.xsd#gild_CardinalHealthIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_37022a98-0274-42a6-b35e-38afa6897378" xlink:to="loc_gild_CardinalHealthIncMember_65e7ef37-d273-42cb-a13e-515ce087e553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_6251fa9d-20fe-4810-8bf0-c059a7fe104d" xlink:href="gild-20211231.xsd#gild_MckessonCorpMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_37022a98-0274-42a6-b35e-38afa6897378" xlink:to="loc_gild_MckessonCorpMember_6251fa9d-20fe-4810-8bf0-c059a7fe104d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_102eb3f7-01ee-426c-a8bb-d6e6f4dc421d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ffbc0d94-6b6b-43ed-9c4e-184404f58235" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_102eb3f7-01ee-426c-a8bb-d6e6f4dc421d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_833c695a-9923-4ae5-b5a5-3a306bab1b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_102eb3f7-01ee-426c-a8bb-d6e6f4dc421d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_833c695a-9923-4ae5-b5a5-3a306bab1b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_802ed7bf-c24f-4e3c-a473-467b39eec6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_6e343281-4e6c-49d9-b375-0f21b4d631e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_802ed7bf-c24f-4e3c-a473-467b39eec6a5" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_6e343281-4e6c-49d9-b375-0f21b4d631e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_4bc3ea51-5cc6-425b-aa93-d2fb3a209213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_802ed7bf-c24f-4e3c-a473-467b39eec6a5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_4bc3ea51-5cc6-425b-aa93-d2fb3a209213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_b33ac6a2-a40b-4c00-9497-91cec36da27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_802ed7bf-c24f-4e3c-a473-467b39eec6a5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_b33ac6a2-a40b-4c00-9497-91cec36da27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="gild-20211231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9c79cf65-7d51-4f84-b220-89d0d838f6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_eb3bc95e-236b-4cf3-8f3d-56d7ae220661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9c79cf65-7d51-4f84-b220-89d0d838f6f8" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_eb3bc95e-236b-4cf3-8f3d-56d7ae220661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="gild-20211231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a7545111-7801-477d-b3b1-4bffbd6edc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6571a402-8ca8-479b-bb96-3ed5e281dd84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a7545111-7801-477d-b3b1-4bffbd6edc7e" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6571a402-8ca8-479b-bb96-3ed5e281dd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_3230be14-23ce-4361-bae7-caa863bbfed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a7545111-7801-477d-b3b1-4bffbd6edc7e" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_3230be14-23ce-4361-bae7-caa863bbfed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ea98713c-6b50-4078-9a32-4e4d6fee1cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ea98713c-6b50-4078-9a32-4e4d6fee1cf1" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_096ede4f-84c0-48c4-820f-3cb4832fa6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_096ede4f-84c0-48c4-820f-3cb4832fa6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_37316d9c-ebf2-4b61-9845-a6134b022041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_096ede4f-84c0-48c4-820f-3cb4832fa6b1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_37316d9c-ebf2-4b61-9845-a6134b022041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8b69a5b5-e0c5-4fd7-8cac-f99ffe0ef173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_37316d9c-ebf2-4b61-9845-a6134b022041" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8b69a5b5-e0c5-4fd7-8cac-f99ffe0ef173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c48099aa-04c0-4855-b52d-96ab9d45bb40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c48099aa-04c0-4855-b52d-96ab9d45bb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d47c09f1-d54a-40fe-b946-902c7c71d725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c48099aa-04c0-4855-b52d-96ab9d45bb40" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d47c09f1-d54a-40fe-b946-902c7c71d725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3d4c6f52-bf9b-46ef-9862-4927200b7eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d47c09f1-d54a-40fe-b946-902c7c71d725" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3d4c6f52-bf9b-46ef-9862-4927200b7eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d83c56b0-5fcd-4c32-b1ca-49571e12d686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d47c09f1-d54a-40fe-b946-902c7c71d725" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d83c56b0-5fcd-4c32-b1ca-49571e12d686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0bf381b8-20fd-4091-9105-35c8d24f26aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d47c09f1-d54a-40fe-b946-902c7c71d725" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0bf381b8-20fd-4091-9105-35c8d24f26aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a48a847d-a4d4-487f-a16e-a358fb2da1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a48a847d-a4d4-487f-a16e-a358fb2da1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1661539c-4ffa-48a5-8d2c-6448b13e65ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a48a847d-a4d4-487f-a16e-a358fb2da1bd" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1661539c-4ffa-48a5-8d2c-6448b13e65ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b05d7a8f-a1b0-45ee-8126-81fa54ae517b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1661539c-4ffa-48a5-8d2c-6448b13e65ed" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b05d7a8f-a1b0-45ee-8126-81fa54ae517b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1a6888f5-05dc-41c2-be59-7d3b0acc2e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b05d7a8f-a1b0-45ee-8126-81fa54ae517b" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1a6888f5-05dc-41c2-be59-7d3b0acc2e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1ff744a0-63ca-49cb-aaac-61dcc9812e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1ff744a0-63ca-49cb-aaac-61dcc9812e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1ff744a0-63ca-49cb-aaac-61dcc9812e8a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_03df277e-8485-4315-98cc-988fa430729f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_03df277e-8485-4315-98cc-988fa430729f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cd7ec023-d1a8-4c10-9302-b5047c618b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_cd7ec023-d1a8-4c10-9302-b5047c618b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_270bd51d-fb55-41d9-ac55-b6d7108b3b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_270bd51d-fb55-41d9-ac55-b6d7108b3b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_969970f6-adcc-4357-aa16-b8cb24657454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_969970f6-adcc-4357-aa16-b8cb24657454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_50cfcf2c-7e06-4c51-b106-b5d5ef5cfb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_50cfcf2c-7e06-4c51-b106-b5d5ef5cfb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_420f1987-060c-4350-a215-2366e7a5e699" xlink:href="gild-20211231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_420f1987-060c-4350-a215-2366e7a5e699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7100b04a-8116-4140-9a78-3a3d4934f75e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7100b04a-8116-4140-9a78-3a3d4934f75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_4b60b299-83bc-4014-8f31-27d96c9a3796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_us-gaap_EquitySecuritiesMember_4b60b299-83bc-4014-8f31-27d96c9a3796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_644281ee-b104-4616-8398-1c5b22a77c95" xlink:href="gild-20211231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_gild_DeferredCompensationPlanMember_644281ee-b104-4616-8398-1c5b22a77c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_2193e25d-e8d3-461b-8eb9-7d0478348580" xlink:href="gild-20211231.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ea8d8c4a-a8ac-4f6e-af13-8022c1d15c5c" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_2193e25d-e8d3-461b-8eb9-7d0478348580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_096d0198-b401-4133-a2cf-e6c62dd69143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_096d0198-b401-4133-a2cf-e6c62dd69143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a58c7826-fab8-44b3-b136-2652a85eeda7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_096d0198-b401-4133-a2cf-e6c62dd69143" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a58c7826-fab8-44b3-b136-2652a85eeda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_21ab4b45-adc2-44e3-9b37-ab7a7ba11b0e" xlink:href="gild-20211231.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a58c7826-fab8-44b3-b136-2652a85eeda7" xlink:to="loc_gild_MYRGmbHMember_21ab4b45-adc2-44e3-9b37-ab7a7ba11b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2de7f2a8-f12e-4496-8a7c-517fa2416636" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2de7f2a8-f12e-4496-8a7c-517fa2416636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_193c23f1-7422-4a45-aa07-2d4af79a058d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2de7f2a8-f12e-4496-8a7c-517fa2416636" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_193c23f1-7422-4a45-aa07-2d4af79a058d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_78cedae9-e669-4b6e-94f8-67b7f776628b" xlink:href="gild-20211231.xsd#gild_GalapagosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_193c23f1-7422-4a45-aa07-2d4af79a058d" xlink:to="loc_gild_GalapagosMember_78cedae9-e669-4b6e-94f8-67b7f776628b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_ae1a68ea-be3d-41d9-b1c8-ccbb24b1d724" xlink:href="gild-20211231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_193c23f1-7422-4a45-aa07-2d4af79a058d" xlink:to="loc_gild_ArcusBiosciencesIncMember_ae1a68ea-be3d-41d9-b1c8-ccbb24b1d724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8de7bf23-49d8-46f1-8924-3465a261c601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c41e6507-c7a2-4ea5-aa5d-af69fa5adb2e" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8de7bf23-49d8-46f1-8924-3465a261c601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6f246a97-2f88-4b24-9f6c-1ea4faa044e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8de7bf23-49d8-46f1-8924-3465a261c601" xlink:to="loc_us-gaap_AssetsAbstract_6f246a97-2f88-4b24-9f6c-1ea4faa044e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a638cece-42fc-4d9f-aa50-669e02176002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6f246a97-2f88-4b24-9f6c-1ea4faa044e8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a638cece-42fc-4d9f-aa50-669e02176002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_cbe8dafb-78b0-408a-aa08-15eb4f077287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6f246a97-2f88-4b24-9f6c-1ea4faa044e8" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_cbe8dafb-78b0-408a-aa08-15eb4f077287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_d75be06e-25aa-4ad1-9b83-bc4033235a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6f246a97-2f88-4b24-9f6c-1ea4faa044e8" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_d75be06e-25aa-4ad1-9b83-bc4033235a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_de976bfa-4c33-4567-b806-ee2808ab4d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6f246a97-2f88-4b24-9f6c-1ea4faa044e8" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_de976bfa-4c33-4567-b806-ee2808ab4d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_98e74709-dfa4-4d2e-a925-40c233652d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8de7bf23-49d8-46f1-8924-3465a261c601" xlink:to="loc_us-gaap_LiabilitiesAbstract_98e74709-dfa4-4d2e-a925-40c233652d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f3c1a49a-5567-4171-bba3-0c6b5818700e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_98e74709-dfa4-4d2e-a925-40c233652d39" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f3c1a49a-5567-4171-bba3-0c6b5818700e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_744da5f0-8ee4-45d9-bec3-051f1e6b2600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_98e74709-dfa4-4d2e-a925-40c233652d39" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_744da5f0-8ee4-45d9-bec3-051f1e6b2600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_cb425d0d-8e2a-402a-ba95-601864b21e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_98e74709-dfa4-4d2e-a925-40c233652d39" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_cb425d0d-8e2a-402a-ba95-601864b21e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0a9e4175-faeb-4464-aa86-7b2f4a868c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_98e74709-dfa4-4d2e-a925-40c233652d39" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0a9e4175-faeb-4464-aa86-7b2f4a868c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_38b4142d-580d-468b-89a5-f45bda261a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b5bf7c2-4b8a-4b8f-b957-794eff7a787a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_38b4142d-580d-468b-89a5-f45bda261a80" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b5bf7c2-4b8a-4b8f-b957-794eff7a787a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3257c88d-feb0-4407-87c4-1c55cfbef7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b5bf7c2-4b8a-4b8f-b957-794eff7a787a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3257c88d-feb0-4407-87c4-1c55cfbef7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8be5ed98-1387-49f6-8f39-e319e90d9cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3257c88d-feb0-4407-87c4-1c55cfbef7a1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8be5ed98-1387-49f6-8f39-e319e90d9cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_5c0d952a-c6b3-4d48-9fba-cbc3b3cb8e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8be5ed98-1387-49f6-8f39-e319e90d9cef" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_5c0d952a-c6b3-4d48-9fba-cbc3b3cb8e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_875f9b6c-f427-4bf5-bc7d-c5c1be1663c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8be5ed98-1387-49f6-8f39-e319e90d9cef" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_875f9b6c-f427-4bf5-bc7d-c5c1be1663c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_eafca7f7-4bd0-4dac-8cbd-f0195e67502c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8be5ed98-1387-49f6-8f39-e319e90d9cef" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_eafca7f7-4bd0-4dac-8cbd-f0195e67502c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_550aa7e4-3e73-4522-9ca4-38a242d0f6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b5bf7c2-4b8a-4b8f-b957-794eff7a787a" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_550aa7e4-3e73-4522-9ca4-38a242d0f6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5a628b64-bfea-4b81-9d40-f11df01bb338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_550aa7e4-3e73-4522-9ca4-38a242d0f6ff" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5a628b64-bfea-4b81-9d40-f11df01bb338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_6e2a113f-cdea-4362-b30b-37a73a79ac95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5a628b64-bfea-4b81-9d40-f11df01bb338" xlink:to="loc_us-gaap_EquitySecuritiesMember_6e2a113f-cdea-4362-b30b-37a73a79ac95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_90d8de9e-82d0-4640-b02a-2067f41aee77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b5bf7c2-4b8a-4b8f-b957-794eff7a787a" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_90d8de9e-82d0-4640-b02a-2067f41aee77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_77f03127-14bc-44d7-8207-4df6b1c87cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_90d8de9e-82d0-4640-b02a-2067f41aee77" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_77f03127-14bc-44d7-8207-4df6b1c87cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b1ef6c96-7f77-4ff8-b160-e0e073afb696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_90d8de9e-82d0-4640-b02a-2067f41aee77" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b1ef6c96-7f77-4ff8-b160-e0e073afb696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5075ec7c-21e0-430e-9745-d79f7e601f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5075ec7c-21e0-430e-9745-d79f7e601f4c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_04c5e829-e5f7-4ff3-bde3-7f06848d771d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_04c5e829-e5f7-4ff3-bde3-7f06848d771d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3d70eb29-ac05-441e-986e-35e9770717b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_04c5e829-e5f7-4ff3-bde3-7f06848d771d" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3d70eb29-ac05-441e-986e-35e9770717b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04319fdd-3947-4fdd-8466-0e232bd83b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3d70eb29-ac05-441e-986e-35e9770717b3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04319fdd-3947-4fdd-8466-0e232bd83b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_12fa33f9-c703-4f03-a698-651a3416f43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04319fdd-3947-4fdd-8466-0e232bd83b38" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_12fa33f9-c703-4f03-a698-651a3416f43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_26e936a6-9936-44e6-bdbe-b5c80d920fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_04319fdd-3947-4fdd-8466-0e232bd83b38" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_26e936a6-9936-44e6-bdbe-b5c80d920fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a29e832-9a5f-41a3-9c77-511dcca8f65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a29e832-9a5f-41a3-9c77-511dcca8f65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2528411-31ad-4d93-a6d1-ee60bda05239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a29e832-9a5f-41a3-9c77-511dcca8f65c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2528411-31ad-4d93-a6d1-ee60bda05239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_58198514-51d3-44ae-8900-a439906c862c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2528411-31ad-4d93-a6d1-ee60bda05239" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_58198514-51d3-44ae-8900-a439906c862c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c4dec1ae-81a2-4953-995b-8bc18fce4f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2528411-31ad-4d93-a6d1-ee60bda05239" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c4dec1ae-81a2-4953-995b-8bc18fce4f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1c5a187f-11a6-4e26-bb0b-457c4d60ec5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1c5a187f-11a6-4e26-bb0b-457c4d60ec5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9758d425-8263-44e0-aa7a-ee384ca5c737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1c5a187f-11a6-4e26-bb0b-457c4d60ec5a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9758d425-8263-44e0-aa7a-ee384ca5c737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesDonationMember_a78210ac-23df-4678-a6d9-79fc85139e63" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesDonationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9758d425-8263-44e0-aa7a-ee384ca5c737" xlink:to="loc_gild_EquitySecuritiesDonationMember_a78210ac-23df-4678-a6d9-79fc85139e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_83464f72-1005-4ce9-adae-5b7b505d0414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_83464f72-1005-4ce9-adae-5b7b505d0414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_de308cdd-3dad-4137-84b5-a2f6fd0571d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_83464f72-1005-4ce9-adae-5b7b505d0414" xlink:to="loc_us-gaap_RelatedPartyDomain_de308cdd-3dad-4137-84b5-a2f6fd0571d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadFoundationMember_50e0b0bd-c67c-42dc-ac1a-ac1606bf7635" xlink:href="gild-20211231.xsd#gild_GileadFoundationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_de308cdd-3dad-4137-84b5-a2f6fd0571d7" xlink:to="loc_gild_GileadFoundationMember_50e0b0bd-c67c-42dc-ac1a-ac1606bf7635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1d5e3035-f290-4868-bf5c-e886d3d041b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1d5e3035-f290-4868-bf5c-e886d3d041b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd615f7e-c6a2-45f3-a824-094fe6bc4f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d5e3035-f290-4868-bf5c-e886d3d041b5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd615f7e-c6a2-45f3-a824-094fe6bc4f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_c9d08c30-bff8-4dfd-9ab9-46c18afe7504" xlink:href="gild-20211231.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd615f7e-c6a2-45f3-a824-094fe6bc4f58" xlink:to="loc_gild_MYRGmbHMember_c9d08c30-bff8-4dfd-9ab9-46c18afe7504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_464d3d77-9495-4b0e-8e10-062431a28565" xlink:href="gild-20211231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd615f7e-c6a2-45f3-a824-094fe6bc4f58" xlink:to="loc_gild_ImmunomedicsIncMember_464d3d77-9495-4b0e-8e10-062431a28565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_KitePharmaIncMember_5da24403-901c-4cff-8466-ce5add3a5a86" xlink:href="gild-20211231.xsd#gild_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd615f7e-c6a2-45f3-a824-094fe6bc4f58" xlink:to="loc_gild_KitePharmaIncMember_5da24403-901c-4cff-8466-ce5add3a5a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80bb84f0-264c-4165-b9c4-40b57c093b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80bb84f0-264c-4165-b9c4-40b57c093b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_248292e5-caeb-4f18-ab64-2833c9c633dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80bb84f0-264c-4165-b9c4-40b57c093b6b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_248292e5-caeb-4f18-ab64-2833c9c633dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_179ac6ba-ea0b-486c-8768-575a4f4a112a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_248292e5-caeb-4f18-ab64-2833c9c633dc" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_179ac6ba-ea0b-486c-8768-575a4f4a112a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_713ecd8d-5a90-4fff-8b1e-f67c04b5f386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_248292e5-caeb-4f18-ab64-2833c9c633dc" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_713ecd8d-5a90-4fff-8b1e-f67c04b5f386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fbfe2d0c-5931-4280-94c1-a7907e2306f8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_7059687c-7df0-4fc1-92fd-5bcc5642f2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_7059687c-7df0-4fc1-92fd-5bcc5642f2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_93009c89-a803-43b2-bde9-e3acc50f47d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_93009c89-a803-43b2-bde9-e3acc50f47d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_837275ac-d92f-4874-b18a-163da1388bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_837275ac-d92f-4874-b18a-163da1388bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_868a4f9b-74bd-4b5e-9407-24958f6f75a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_868a4f9b-74bd-4b5e-9407-24958f6f75a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_8975e19c-c0f4-47d8-a0f0-53eec08fb7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_LongTermDebtFairValue_8975e19c-c0f4-47d8-a0f0-53eec08fb7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a6ec6399-2d23-486f-be69-9f3a6ddc00a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a6ec6399-2d23-486f-be69-9f3a6ddc00a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_72b4f9d7-abbe-48a1-b539-852814c6dc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_72b4f9d7-abbe-48a1-b539-852814c6dc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_e85378c8-181f-443c-a267-fa2facdfd633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_e85378c8-181f-443c-a267-fa2facdfd633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2dacddd8-d2e2-466d-96a6-54ad2595ffd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff8be512-1508-45ad-ada7-29fc84ce0615" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2dacddd8-d2e2-466d-96a6-54ad2595ffd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecurities" xlink:type="simple" xlink:href="gild-20211231.xsd#AvailableforSaleDebtSecurities"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_10475322-8dd0-490b-bb14-01c8dc12ec02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0116cb24-67f5-4a91-ae73-7fd434af1009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_10475322-8dd0-490b-bb14-01c8dc12ec02" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0116cb24-67f5-4a91-ae73-7fd434af1009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="simple" xlink:href="gild-20211231.xsd#AvailableforSaleDebtSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_fad3e747-0f80-453a-ab5c-8a29ea582f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_41d2840d-4fc2-4c63-b0dc-3ef271def62d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_fad3e747-0f80-453a-ab5c-8a29ea582f7b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_41d2840d-4fc2-4c63-b0dc-3ef271def62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_fafaeb42-ab98-478b-b2d6-46d45f792d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_fad3e747-0f80-453a-ab5c-8a29ea582f7b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_fafaeb42-ab98-478b-b2d6-46d45f792d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0c62ff39-82d5-4de6-8774-379f4ffbc4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_fad3e747-0f80-453a-ab5c-8a29ea582f7b" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0c62ff39-82d5-4de6-8774-379f4ffbc4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_90e157ff-d38e-4f3f-9a98-7d437b61bdae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_953e6690-e084-45b0-a567-e640b3c2a5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_90e157ff-d38e-4f3f-9a98-7d437b61bdae" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_953e6690-e084-45b0-a567-e640b3c2a5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_abecfcf7-10dc-4a39-a2d3-10ce2b3fcf27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_953e6690-e084-45b0-a567-e640b3c2a5e2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_abecfcf7-10dc-4a39-a2d3-10ce2b3fcf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_abecfcf7-10dc-4a39-a2d3-10ce2b3fcf27" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f183018c-0e2c-4ba2-a1e7-011f99dee458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f183018c-0e2c-4ba2-a1e7-011f99dee458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5c9b6b22-1b06-4a79-a5e0-807ce6bffe4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5c9b6b22-1b06-4a79-a5e0-807ce6bffe4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_62ba527a-f1a6-412b-b25f-6b413b70883a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_62ba527a-f1a6-412b-b25f-6b413b70883a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0f482c01-5a7d-4054-a702-6b021f9c5eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0f482c01-5a7d-4054-a702-6b021f9c5eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e0f8e335-a021-4733-a947-f28902d3258d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e0f8e335-a021-4733-a947-f28902d3258d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_f8973a51-0c52-4458-bd9e-ff3ce9aab2c2" xlink:href="gild-20211231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127866d2-ceae-4488-8210-1d97a35691ec" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_f8973a51-0c52-4458-bd9e-ff3ce9aab2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5bb462c2-fd26-4ede-90ea-2ab78e2c890b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_953e6690-e084-45b0-a567-e640b3c2a5e2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5bb462c2-fd26-4ede-90ea-2ab78e2c890b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4e96f9d9-3c51-43d6-ad44-00745a63e970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5bb462c2-fd26-4ede-90ea-2ab78e2c890b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4e96f9d9-3c51-43d6-ad44-00745a63e970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f859207a-9d90-498f-aaa6-884814deb76c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5bb462c2-fd26-4ede-90ea-2ab78e2c890b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f859207a-9d90-498f-aaa6-884814deb76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e76334d-9e15-4197-a461-a4f3e38059ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5bb462c2-fd26-4ede-90ea-2ab78e2c890b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e76334d-9e15-4197-a461-a4f3e38059ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_72c4ba86-9b08-4f63-8c2c-32aedfdf094f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5bb462c2-fd26-4ede-90ea-2ab78e2c890b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_72c4ba86-9b08-4f63-8c2c-32aedfdf094f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_51ec0716-fa46-4baa-832f-7ae750542af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_34052fba-6e28-4f5e-bae9-59245b223c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_51ec0716-fa46-4baa-832f-7ae750542af1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_34052fba-6e28-4f5e-bae9-59245b223c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0515563b-0735-41f7-b532-8df54ff02f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_34052fba-6e28-4f5e-bae9-59245b223c75" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0515563b-0735-41f7-b532-8df54ff02f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_613018ca-b60f-4a23-8fce-938948105e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0515563b-0735-41f7-b532-8df54ff02f5b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_613018ca-b60f-4a23-8fce-938948105e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_5c87e2b1-c8ad-45e2-8ce4-8affcbd55560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_613018ca-b60f-4a23-8fce-938948105e29" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_5c87e2b1-c8ad-45e2-8ce4-8affcbd55560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_75c231bf-b267-4cee-b84b-cd81fd5fb076" xlink:href="gild-20211231.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_613018ca-b60f-4a23-8fce-938948105e29" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_75c231bf-b267-4cee-b84b-cd81fd5fb076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_e374abc4-6a31-45a6-85d4-2767bdd35a83" xlink:href="gild-20211231.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_613018ca-b60f-4a23-8fce-938948105e29" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_e374abc4-6a31-45a6-85d4-2767bdd35a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d476a739-a163-4e9d-819f-c932e08058dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_34052fba-6e28-4f5e-bae9-59245b223c75" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d476a739-a163-4e9d-819f-c932e08058dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6e67aa87-c66d-4d78-b7df-02797c212949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d476a739-a163-4e9d-819f-c932e08058dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6e67aa87-c66d-4d78-b7df-02797c212949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f5f8b13d-4a47-472d-a915-b29b5cc44b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_562841ce-bf9b-4a04-9692-fad38838bda4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f5f8b13d-4a47-472d-a915-b29b5cc44b1c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_562841ce-bf9b-4a04-9692-fad38838bda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_27df4fd1-eebd-41ce-9714-a8952bbcae15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_562841ce-bf9b-4a04-9692-fad38838bda4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_27df4fd1-eebd-41ce-9714-a8952bbcae15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32417d08-a3ec-412b-bb8e-e24908602bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_562841ce-bf9b-4a04-9692-fad38838bda4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32417d08-a3ec-412b-bb8e-e24908602bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_6ee09bd5-1be9-416a-ab58-f77bcd2ae923" xlink:href="gild-20211231.xsd#gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_562841ce-bf9b-4a04-9692-fad38838bda4" xlink:to="loc_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5_6ee09bd5-1be9-416a-ab58-f77bcd2ae923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_1076e498-e5d7-468d-a048-b4ab9cca7092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_562841ce-bf9b-4a04-9692-fad38838bda4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_1076e498-e5d7-468d-a048-b4ab9cca7092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8d0ec029-2127-43ce-98be-c3b4461e7a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f5f8b13d-4a47-472d-a915-b29b5cc44b1c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8d0ec029-2127-43ce-98be-c3b4461e7a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_04a49dc3-67a4-43fb-a748-04806f792b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8d0ec029-2127-43ce-98be-c3b4461e7a88" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_04a49dc3-67a4-43fb-a748-04806f792b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_cdab2bf0-bd6a-4638-a497-80ebf86c2376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8d0ec029-2127-43ce-98be-c3b4461e7a88" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_cdab2bf0-bd6a-4638-a497-80ebf86c2376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_bc1fa63a-29ab-4805-b9c8-80bb609885b7" xlink:href="gild-20211231.xsd#gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8d0ec029-2127-43ce-98be-c3b4461e7a88" xlink:to="loc_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_bc1fa63a-29ab-4805-b9c8-80bb609885b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_bba8a74f-f71f-4f6e-a427-03d461d53d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8d0ec029-2127-43ce-98be-c3b4461e7a88" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_bba8a74f-f71f-4f6e-a427-03d461d53d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AvailableforSaleDebtSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9aa07186-8d0a-4851-9faf-3c8174d303ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9676c041-aa5e-4352-b4ee-fde01490b527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9aa07186-8d0a-4851-9faf-3c8174d303ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9676c041-aa5e-4352-b4ee-fde01490b527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_ba63972b-bd02-4291-90aa-de6da637d498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9aa07186-8d0a-4851-9faf-3c8174d303ca" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_ba63972b-bd02-4291-90aa-de6da637d498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="gild-20211231.xsd#DerivativeFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7cf64269-f280-4a5c-8be3-a5b769094408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_41225903-c13c-426a-863f-1d713989211d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7cf64269-f280-4a5c-8be3-a5b769094408" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_41225903-c13c-426a-863f-1d713989211d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="gild-20211231.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9878d4b6-142d-472c-90ca-58b80a480eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_7c151325-32df-4667-a294-55e095c43331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9878d4b6-142d-472c-90ca-58b80a480eb1" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_7c151325-32df-4667-a294-55e095c43331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_11935606-3d70-4fce-b743-a863c46dd4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9878d4b6-142d-472c-90ca-58b80a480eb1" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_11935606-3d70-4fce-b743-a863c46dd4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_aac3ade1-c4c7-40ee-be6f-fdde8c2cb394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9878d4b6-142d-472c-90ca-58b80a480eb1" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_aac3ade1-c4c7-40ee-be6f-fdde8c2cb394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DerivativeFinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c998c8e7-be24-4bd9-b468-a43f4b04153b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_b3892069-42b4-42bc-98fa-76d21c26c420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c998c8e7-be24-4bd9-b468-a43f4b04153b" xlink:to="loc_us-gaap_DerivativeTable_b3892069-42b4-42bc-98fa-76d21c26c420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_21711521-843b-4654-8b88-143a719ec6f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b3892069-42b4-42bc-98fa-76d21c26c420" xlink:to="loc_srt_RangeAxis_21711521-843b-4654-8b88-143a719ec6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52210409-4aa5-4479-8434-304c65e3155b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_21711521-843b-4654-8b88-143a719ec6f9" xlink:to="loc_srt_RangeMember_52210409-4aa5-4479-8434-304c65e3155b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_11dea193-54ac-44ad-a193-0b3079265c7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52210409-4aa5-4479-8434-304c65e3155b" xlink:to="loc_srt_MaximumMember_11dea193-54ac-44ad-a193-0b3079265c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0cc00b0f-ac1d-46ad-a21f-733685c13f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b3892069-42b4-42bc-98fa-76d21c26c420" xlink:to="loc_us-gaap_DerivativeLineItems_0cc00b0f-ac1d-46ad-a21f-733685c13f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_0cfe8ad6-fab4-4fe9-a94f-2a73b711d452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0cc00b0f-ac1d-46ad-a21f-733685c13f37" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_0cfe8ad6-fab4-4fe9-a94f-2a73b711d452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_c6fdfad6-1e31-4948-b3a9-8aae8ebd754b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0cc00b0f-ac1d-46ad-a21f-733685c13f37" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_c6fdfad6-1e31-4948-b3a9-8aae8ebd754b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_be10e06f-d779-4c71-93f1-3be5e8b570e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0cc00b0f-ac1d-46ad-a21f-733685c13f37" xlink:to="loc_us-gaap_DerivativeNotionalAmount_be10e06f-d779-4c71-93f1-3be5e8b570e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_5a722b6b-523d-4a4a-add6-d15ced97c5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0cc00b0f-ac1d-46ad-a21f-733685c13f37" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_5a722b6b-523d-4a4a-add6-d15ced97c5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5f147c17-50a3-4c16-83d2-5567556eb000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7fcd35e3-0810-487e-ac3a-eb5a011f5a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5f147c17-50a3-4c16-83d2-5567556eb000" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7fcd35e3-0810-487e-ac3a-eb5a011f5a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b79cbc2f-85b2-4dae-8505-8ba24d41fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7fcd35e3-0810-487e-ac3a-eb5a011f5a13" xlink:to="loc_us-gaap_HedgingDesignationAxis_b79cbc2f-85b2-4dae-8505-8ba24d41fc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ba72200c-92cd-45f0-83a9-9cd6fce5f8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_b79cbc2f-85b2-4dae-8505-8ba24d41fc0f" xlink:to="loc_us-gaap_HedgingDesignationDomain_ba72200c-92cd-45f0-83a9-9cd6fce5f8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_762c8ba2-b657-481e-b2db-37d1ad5b2624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ba72200c-92cd-45f0-83a9-9cd6fce5f8c5" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_762c8ba2-b657-481e-b2db-37d1ad5b2624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_9f7cdb03-9f0a-4ddd-a4c5-8d5fca2e47bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ba72200c-92cd-45f0-83a9-9cd6fce5f8c5" xlink:to="loc_us-gaap_NondesignatedMember_9f7cdb03-9f0a-4ddd-a4c5-8d5fca2e47bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_95b6c303-e226-4b9b-888a-8fb2ce0f561e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7fcd35e3-0810-487e-ac3a-eb5a011f5a13" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_95b6c303-e226-4b9b-888a-8fb2ce0f561e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3082a8f9-9faa-4d77-9ee7-a82ef8b323d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_95b6c303-e226-4b9b-888a-8fb2ce0f561e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3082a8f9-9faa-4d77-9ee7-a82ef8b323d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0e8a252d-3509-4c33-b4bb-8a48d386f852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3082a8f9-9faa-4d77-9ee7-a82ef8b323d9" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0e8a252d-3509-4c33-b4bb-8a48d386f852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_8ae0af86-63da-4cad-b741-f11145c1c36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3082a8f9-9faa-4d77-9ee7-a82ef8b323d9" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_8ae0af86-63da-4cad-b741-f11145c1c36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_48cacab7-b97b-4f9e-94f5-196800b6600b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3082a8f9-9faa-4d77-9ee7-a82ef8b323d9" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_48cacab7-b97b-4f9e-94f5-196800b6600b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_24a12c0d-0717-4c58-ac58-cd811b8afbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3082a8f9-9faa-4d77-9ee7-a82ef8b323d9" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_24a12c0d-0717-4c58-ac58-cd811b8afbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_338ddcd4-5dc5-4bc8-848b-64c36901bb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7fcd35e3-0810-487e-ac3a-eb5a011f5a13" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_338ddcd4-5dc5-4bc8-848b-64c36901bb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_c9c57827-cd10-49a2-9803-6c5b42f0fd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_338ddcd4-5dc5-4bc8-848b-64c36901bb5e" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_c9c57827-cd10-49a2-9803-6c5b42f0fd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_9503d90d-e119-4ce4-9361-d91ec7b9d5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_338ddcd4-5dc5-4bc8-848b-64c36901bb5e" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_9503d90d-e119-4ce4-9361-d91ec7b9d5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6076af30-0474-413e-b802-0aabaf581145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_44fe20a3-5fa3-4aa5-bf95-f1bc8dde17a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6076af30-0474-413e-b802-0aabaf581145" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_44fe20a3-5fa3-4aa5-bf95-f1bc8dde17a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0b764822-9dfb-445d-b69c-b952187bb534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6076af30-0474-413e-b802-0aabaf581145" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0b764822-9dfb-445d-b69c-b952187bb534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_1ced3a74-bed3-4994-802e-de8d2ac88e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6076af30-0474-413e-b802-0aabaf581145" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_1ced3a74-bed3-4994-802e-de8d2ac88e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_36fa1437-d3e3-4b1e-a5a9-633a2d86c0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract_b3861457-2edc-4432-beae-584a93f563c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_36fa1437-d3e3-4b1e-a5a9-633a2d86c0c1" xlink:to="loc_us-gaap_DerivativeAssetsAbstract_b3861457-2edc-4432-beae-584a93f563c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7a0bd8e9-4dc6-427a-a828-b52c87a08acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_b3861457-2edc-4432-beae-584a93f563c0" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7a0bd8e9-4dc6-427a-a828-b52c87a08acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_c120ad6b-5a5e-455a-b9bc-6bf2585a0a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_b3861457-2edc-4432-beae-584a93f563c0" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_c120ad6b-5a5e-455a-b9bc-6bf2585a0a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_0b05b9dd-bd8e-484e-9a3b-f6de3cee45f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_b3861457-2edc-4432-beae-584a93f563c0" xlink:to="loc_us-gaap_DerivativeAssets_0b05b9dd-bd8e-484e-9a3b-f6de3cee45f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_cea238ae-cff4-498a-813a-103883effc25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_b3861457-2edc-4432-beae-584a93f563c0" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_cea238ae-cff4-498a-813a-103883effc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_5ddcdbeb-f9d7-4b37-a3b6-c4d60ba9475c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_b3861457-2edc-4432-beae-584a93f563c0" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_5ddcdbeb-f9d7-4b37-a3b6-c4d60ba9475c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_ef630e54-c1a5-4f77-af7e-99fe3012b654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_b3861457-2edc-4432-beae-584a93f563c0" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_ef630e54-c1a5-4f77-af7e-99fe3012b654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_352a3290-1a0c-47a2-b872-061d5f244b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_36fa1437-d3e3-4b1e-a5a9-633a2d86c0c1" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_352a3290-1a0c-47a2-b872-061d5f244b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_9ebcaa12-6768-41a2-93fc-77219aa32562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_352a3290-1a0c-47a2-b872-061d5f244b0a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_9ebcaa12-6768-41a2-93fc-77219aa32562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_f8586858-3442-489a-8e75-3a422a8f3f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_352a3290-1a0c-47a2-b872-061d5f244b0a" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_f8586858-3442-489a-8e75-3a422a8f3f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_7ae3375a-9fe5-40c9-ad5f-96a5e690bab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_352a3290-1a0c-47a2-b872-061d5f244b0a" xlink:to="loc_us-gaap_DerivativeLiabilities_7ae3375a-9fe5-40c9-ad5f-96a5e690bab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_0b415413-9d82-437a-8e7b-5a74b2e6cfde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_352a3290-1a0c-47a2-b872-061d5f244b0a" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_0b415413-9d82-437a-8e7b-5a74b2e6cfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_4f0ed557-95cd-4844-9788-42a0f6fe987e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_352a3290-1a0c-47a2-b872-061d5f244b0a" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_4f0ed557-95cd-4844-9788-42a0f6fe987e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_3249d8f2-8729-4d9a-b402-3c03e39a552a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_352a3290-1a0c-47a2-b872-061d5f244b0a" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_3249d8f2-8729-4d9a-b402-3c03e39a552a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Acquisitions" xlink:type="simple" xlink:href="gild-20211231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_95a5b5ce-0905-4c0a-a66a-7e3498b82035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f214f67f-ee00-45f2-9b68-9ffc6b849ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_95a5b5ce-0905-4c0a-a66a-7e3498b82035" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f214f67f-ee00-45f2-9b68-9ffc6b849ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="gild-20211231.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_792ce25a-eeed-4926-8f5a-c9ca8fcea37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_5bb74c89-a32b-4808-8831-c55c762b726b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_792ce25a-eeed-4926-8f5a-c9ca8fcea37e" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_5bb74c89-a32b-4808-8831-c55c762b726b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c007c872-bc5b-430c-9131-737d7a8bb268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c007c872-bc5b-430c-9131-737d7a8bb268" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b60f2e49-f63b-4b5e-b276-de837798b07e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b60f2e49-f63b-4b5e-b276-de837798b07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ea9eca3-4e19-4dde-83a8-3accb9942955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b60f2e49-f63b-4b5e-b276-de837798b07e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ea9eca3-4e19-4dde-83a8-3accb9942955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_b15b4e64-9ea0-4b4e-803d-473fb62c5628" xlink:href="gild-20211231.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ea9eca3-4e19-4dde-83a8-3accb9942955" xlink:to="loc_gild_MYRGmbHMember_b15b4e64-9ea0-4b4e-803d-473fb62c5628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_1ee8a847-0fd0-4980-8ee7-3b30889f1d75" xlink:href="gild-20211231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ea9eca3-4e19-4dde-83a8-3accb9942955" xlink:to="loc_gild_ImmunomedicsIncMember_1ee8a847-0fd0-4980-8ee7-3b30889f1d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_b354a1fd-ab29-4b1d-810b-3e82ac9ac2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_AssetAcquisitionAxis_b354a1fd-ab29-4b1d-810b-3e82ac9ac2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_0ecc8855-a1cc-433f-9674-214c6f514607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_b354a1fd-ab29-4b1d-810b-3e82ac9ac2c6" xlink:to="loc_us-gaap_AssetAcquisitionDomain_0ecc8855-a1cc-433f-9674-214c6f514607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_a20094ca-f94d-47cd-9856-3ebb0c98d855" xlink:href="gild-20211231.xsd#gild_FortySevenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_0ecc8855-a1cc-433f-9674-214c6f514607" xlink:to="loc_gild_FortySevenIncMember_a20094ca-f94d-47cd-9856-3ebb0c98d855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66310901-c5c2-4eae-be02-ab93687c1f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66310901-c5c2-4eae-be02-ab93687c1f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cf7dda9-57b1-48fd-8f3a-9dee8d16441c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_66310901-c5c2-4eae-be02-ab93687c1f37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cf7dda9-57b1-48fd-8f3a-9dee8d16441c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_d33f455b-3f2a-41f1-b54e-5123e07c11a6" xlink:href="gild-20211231.xsd#gild_HepcludexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cf7dda9-57b1-48fd-8f3a-9dee8d16441c" xlink:to="loc_gild_HepcludexMember_d33f455b-3f2a-41f1-b54e-5123e07c11a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_c8877a8b-d4c9-4d85-95cb-904bdaeb4e9a" xlink:href="gild-20211231.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cf7dda9-57b1-48fd-8f3a-9dee8d16441c" xlink:to="loc_gild_TrodelvyMember_c8877a8b-d4c9-4d85-95cb-904bdaeb4e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_89e5d07c-ea84-43d8-b4ad-792fbe1537ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cf7dda9-57b1-48fd-8f3a-9dee8d16441c" xlink:to="loc_us-gaap_LicensingAgreementsMember_89e5d07c-ea84-43d8-b4ad-792fbe1537ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bd60e406-bd0d-44c1-8125-a1b167ead87f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bd60e406-bd0d-44c1-8125-a1b167ead87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_19a68278-fb36-4358-aabb-5e461e2a843a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bd60e406-bd0d-44c1-8125-a1b167ead87f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_19a68278-fb36-4358-aabb-5e461e2a843a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_3d52ae24-0e95-46c1-9e06-2b40c32c211b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_19a68278-fb36-4358-aabb-5e461e2a843a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_3d52ae24-0e95-46c1-9e06-2b40c32c211b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_967c932c-3b48-4fff-a746-22dd44a45921" xlink:href="gild-20211231.xsd#gild_HepcludexMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_19a68278-fb36-4358-aabb-5e461e2a843a" xlink:to="loc_gild_HepcludexMember_967c932c-3b48-4fff-a746-22dd44a45921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d9a36e53-bcd9-4935-81bc-2def9fcffc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_DebtInstrumentAxis_d9a36e53-bcd9-4935-81bc-2def9fcffc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5f98e8f4-29b2-4ca2-a508-9201de1ca24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d9a36e53-bcd9-4935-81bc-2def9fcffc43" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5f98e8f4-29b2-4ca2-a508-9201de1ca24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_abfa1d92-7fad-48c2-b250-c074fcb63ed4" xlink:href="gild-20211231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f98e8f4-29b2-4ca2-a508-9201de1ca24a" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_abfa1d92-7fad-48c2-b250-c074fcb63ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ffddc420-4f55-4a6f-9dd6-280f45d8cbab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ffddc420-4f55-4a6f-9dd6-280f45d8cbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9eafa6b2-c09c-4064-bcdf-f20f23107c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ffddc420-4f55-4a6f-9dd6-280f45d8cbab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9eafa6b2-c09c-4064-bcdf-f20f23107c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_ad641c92-add7-4b01-aca8-3c399aa152ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9eafa6b2-c09c-4064-bcdf-f20f23107c08" xlink:to="loc_us-gaap_MediumTermNotesMember_ad641c92-add7-4b01-aca8-3c399aa152ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6bc068f4-7538-49f9-82b7-56564c86f95e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6bc068f4-7538-49f9-82b7-56564c86f95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_fafd1a75-8373-4839-87bd-685a5b35e03e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6bc068f4-7538-49f9-82b7-56564c86f95e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_fafd1a75-8373-4839-87bd-685a5b35e03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4415fa7f-f828-4934-9a54-00b3e9ac66d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fafd1a75-8373-4839-87bd-685a5b35e03e" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4415fa7f-f828-4934-9a54-00b3e9ac66d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3685b828-eecd-4c8f-844e-deb4d22f4d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fafd1a75-8373-4839-87bd-685a5b35e03e" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3685b828-eecd-4c8f-844e-deb4d22f4d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_99a80c73-f580-447e-83f6-12404240f8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fafd1a75-8373-4839-87bd-685a5b35e03e" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_99a80c73-f580-447e-83f6-12404240f8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f6d5bcdc-6aef-4ea0-8ce4-041915040d93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_srt_RangeAxis_f6d5bcdc-6aef-4ea0-8ce4-041915040d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_074e51f4-7878-4037-86b2-a6183dbd9b20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f6d5bcdc-6aef-4ea0-8ce4-041915040d93" xlink:to="loc_srt_RangeMember_074e51f4-7878-4037-86b2-a6183dbd9b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e161db4b-d492-4d4f-9d16-be9dd60a3a62" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_074e51f4-7878-4037-86b2-a6183dbd9b20" xlink:to="loc_srt_MaximumMember_e161db4b-d492-4d4f-9d16-be9dd60a3a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11136fb9-fc16-49b4-b106-847d9f6ec5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11136fb9-fc16-49b4-b106-847d9f6ec5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c303b906-08ec-40aa-94f0-5028de9ac723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11136fb9-fc16-49b4-b106-847d9f6ec5bc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c303b906-08ec-40aa-94f0-5028de9ac723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d68dc5c6-5427-43ab-8111-d17b75feb23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c303b906-08ec-40aa-94f0-5028de9ac723" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d68dc5c6-5427-43ab-8111-d17b75feb23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_350c695e-3adb-4743-8861-9065f5549b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_350c695e-3adb-4743-8861-9065f5549b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_046131ab-3c6a-4e53-aed9-6fe34a64bd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_350c695e-3adb-4743-8861-9065f5549b71" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_046131ab-3c6a-4e53-aed9-6fe34a64bd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a3e0a2f2-da06-4ac4-947a-dd5324064461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_046131ab-3c6a-4e53-aed9-6fe34a64bd6b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a3e0a2f2-da06-4ac4-947a-dd5324064461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2dce2cc-0ac8-44b4-b1b4-a81a626095ab" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2867f596-6b1c-485d-88cb-8bed2d443a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2867f596-6b1c-485d-88cb-8bed2d443a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_d119403e-beeb-4dd2-84f5-12b4400732d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_d119403e-beeb-4dd2-84f5-12b4400732d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d7e9a043-2b2a-4189-b4a8-92d7108ee7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d7e9a043-2b2a-4189-b4a8-92d7108ee7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3c7b33bf-b47a-48a0-9c48-2e705f93335b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3c7b33bf-b47a-48a0-9c48-2e705f93335b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_6517d3e6-9ae1-45ed-846d-2e8118cc1bd4" xlink:href="gild-20211231.xsd#gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_6517d3e6-9ae1-45ed-846d-2e8118cc1bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_09d69570-b2ff-47cf-a26d-4049a3740300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_09d69570-b2ff-47cf-a26d-4049a3740300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_9c20ad82-3e4b-4874-a1dd-c296ebb0b0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_9c20ad82-3e4b-4874-a1dd-c296ebb0b0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_4fa6c094-7d6f-4b9e-9279-858cc07eec72" xlink:href="gild-20211231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_4fa6c094-7d6f-4b9e-9279-858cc07eec72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_05b9f212-eea2-4a83-8040-8c413bb49ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_GoodwillGross_05b9f212-eea2-4a83-8040-8c413bb49ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_7c559c3b-10f7-404f-9772-a926afa76ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_7c559c3b-10f7-404f-9772-a926afa76ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_2ba047a0-0eb4-4ee9-84ca-728a6cc43772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_2ba047a0-0eb4-4ee9-84ca-728a6cc43772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_9e3f3391-1f9c-4192-ad2a-9dc85f3fa8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_9e3f3391-1f9c-4192-ad2a-9dc85f3fa8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a51b0a62-2a3b-4e3a-884f-2155826b59e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a51b0a62-2a3b-4e3a-884f-2155826b59e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_21fc5d6b-4623-4224-9e82-d9fa2920938b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_21fc5d6b-4623-4224-9e82-d9fa2920938b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_380efe97-26bf-4eb9-bcac-2397aef70354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_380efe97-26bf-4eb9-bcac-2397aef70354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_fd443a2b-12c3-404b-bdc3-10bbd5c6d31b" xlink:href="gild-20211231.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_fd443a2b-12c3-404b-bdc3-10bbd5c6d31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_c366458a-e5a5-4f66-a7df-01fedf76e997" xlink:href="gild-20211231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_c366458a-e5a5-4f66-a7df-01fedf76e997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_4da51c95-56e9-4216-bf32-f4a8376d54b5" xlink:href="gild-20211231.xsd#gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_4da51c95-56e9-4216-bf32-f4a8376d54b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired_fefd4935-0944-4958-8f4d-b926c8169a8c" xlink:href="gild-20211231.xsd#gild_PaymentsToAcquireAssetsNetOfCashAcquired"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired_fefd4935-0944-4958-8f4d-b926c8169a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ad979bdf-8d83-4c32-add0-13d444175be1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a75e1d03-dcce-4bab-bea6-4ca5d9f9c9a3" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ad979bdf-8d83-4c32-add0-13d444175be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_84d01579-61a5-4f88-865e-cb2b595c2996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4b956db-4b6c-4bb9-b5d2-e0a9c113c842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_84d01579-61a5-4f88-865e-cb2b595c2996" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4b956db-4b6c-4bb9-b5d2-e0a9c113c842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f39cf471-4263-475e-aa12-c64656a71f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4b956db-4b6c-4bb9-b5d2-e0a9c113c842" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f39cf471-4263-475e-aa12-c64656a71f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3f38c70-f02d-4980-8e33-ceb9d07674d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f39cf471-4263-475e-aa12-c64656a71f64" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3f38c70-f02d-4980-8e33-ceb9d07674d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_f9288f6f-a73f-4d2c-8e7a-7c1bc7d131a5" xlink:href="gild-20211231.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3f38c70-f02d-4980-8e33-ceb9d07674d7" xlink:to="loc_gild_MYRGmbHMember_f9288f6f-a73f-4d2c-8e7a-7c1bc7d131a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_9ce59465-a545-49c8-ab05-1fa22bcbefe9" xlink:href="gild-20211231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3f38c70-f02d-4980-8e33-ceb9d07674d7" xlink:to="loc_gild_ImmunomedicsIncMember_9ce59465-a545-49c8-ab05-1fa22bcbefe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00a121ac-d725-4fe3-b1a5-a70e764d03d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4b956db-4b6c-4bb9-b5d2-e0a9c113c842" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00a121ac-d725-4fe3-b1a5-a70e764d03d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_37426307-2818-4864-90b3-6e08a1423f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00a121ac-d725-4fe3-b1a5-a70e764d03d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_37426307-2818-4864-90b3-6e08a1423f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_97d2d518-7cb1-4634-b4f4-c25a96b1bf09" xlink:href="gild-20211231.xsd#gild_HepcludexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_37426307-2818-4864-90b3-6e08a1423f33" xlink:to="loc_gild_HepcludexMember_97d2d518-7cb1-4634-b4f4-c25a96b1bf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_60d4a004-2c70-474e-ad9c-09a5035b6d18" xlink:href="gild-20211231.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_37426307-2818-4864-90b3-6e08a1423f33" xlink:to="loc_gild_TrodelvyMember_60d4a004-2c70-474e-ad9c-09a5035b6d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_52720381-4568-432e-bd09-702c164776b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_37426307-2818-4864-90b3-6e08a1423f33" xlink:to="loc_us-gaap_LicensingAgreementsMember_52720381-4568-432e-bd09-702c164776b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f672b722-4e9d-4b3b-a41f-5708d4bb2d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4b956db-4b6c-4bb9-b5d2-e0a9c113c842" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f672b722-4e9d-4b3b-a41f-5708d4bb2d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8630329c-8f66-4f2f-ac5f-4c0934f645fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f672b722-4e9d-4b3b-a41f-5708d4bb2d7d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8630329c-8f66-4f2f-ac5f-4c0934f645fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8419e7da-463a-46b2-8109-31d18555159f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8630329c-8f66-4f2f-ac5f-4c0934f645fd" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8419e7da-463a-46b2-8109-31d18555159f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f4b956db-4b6c-4bb9-b5d2-e0a9c113c842" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c8a1eb0f-7155-4510-b48e-ae510c7a0a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c8a1eb0f-7155-4510-b48e-ae510c7a0a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1b02d385-5e6a-4337-804d-06f84b6984dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1b02d385-5e6a-4337-804d-06f84b6984dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_2666c748-7953-4847-a7e2-6c2842b39a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_2666c748-7953-4847-a7e2-6c2842b39a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_81e3fb5f-fb78-47bc-beee-debb6217645f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_2666c748-7953-4847-a7e2-6c2842b39a3a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_81e3fb5f-fb78-47bc-beee-debb6217645f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a9f2c530-668f-463f-b274-004ce80534f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_2666c748-7953-4847-a7e2-6c2842b39a3a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a9f2c530-668f-463f-b274-004ce80534f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d4542ad3-47c4-48a3-b3bb-0a1241ce8958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d4542ad3-47c4-48a3-b3bb-0a1241ce8958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_7f6ee244-ebb7-4ba8-9586-53d08622a5db" xlink:href="gild-20211231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_7f6ee244-ebb7-4ba8-9586-53d08622a5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_11c8286b-10ee-45ce-ab3d-c59ef7a0450c" xlink:href="gild-20211231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_11c8286b-10ee-45ce-ab3d-c59ef7a0450c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_22af0a33-6626-411e-ab8c-5ebbb238085b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_22af0a33-6626-411e-ab8c-5ebbb238085b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_e3bde7c8-9a9f-443e-9ca5-e7e68241677e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_GoodwillGross_e3bde7c8-9a9f-443e-9ca5-e7e68241677e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b1b3b7ad-dd2e-4031-850a-307b885dd6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8990dc86-91d2-4030-a619-48a130dfab96" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b1b3b7ad-dd2e-4031-850a-307b885dd6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Inventories" xlink:type="simple" xlink:href="gild-20211231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_edb9626c-191a-4a56-8db6-309df81f060d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_612dbc50-a993-498a-93e6-e82c62e20d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_edb9626c-191a-4a56-8db6-309df81f060d" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_612dbc50-a993-498a-93e6-e82c62e20d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesTables" xlink:type="simple" xlink:href="gild-20211231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d8f42fe2-c07f-4006-8586-48ac33372fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e56348e0-66f5-4a17-8928-9fd197b3ba38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d8f42fe2-c07f-4006-8586-48ac33372fa6" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e56348e0-66f5-4a17-8928-9fd197b3ba38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#InventoriesScheduleofinventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f0aa266f-4ef1-4f3c-af09-506b382a9b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable_d4710eaa-1e3a-4b93-b74c-c7ba9934191b" xlink:href="gild-20211231.xsd#gild_ScheduleofInventoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f0aa266f-4ef1-4f3c-af09-506b382a9b07" xlink:to="loc_gild_ScheduleofInventoryTable_d4710eaa-1e3a-4b93-b74c-c7ba9934191b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_37a1f9be-6f41-4f1a-b877-6da5eb987158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryTable_d4710eaa-1e3a-4b93-b74c-c7ba9934191b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_37a1f9be-6f41-4f1a-b877-6da5eb987158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4d675894-3364-473b-8b9d-cb083eab316f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_37a1f9be-6f41-4f1a-b877-6da5eb987158" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4d675894-3364-473b-8b9d-cb083eab316f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsTotalMember_68db28cf-17e6-42b5-b292-8325e2a33966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsTotalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4d675894-3364-473b-8b9d-cb083eab316f" xlink:to="loc_us-gaap_AssetsTotalMember_68db28cf-17e6-42b5-b292-8325e2a33966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:href="gild-20211231.xsd#gild_ScheduleofInventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryTable_d4710eaa-1e3a-4b93-b74c-c7ba9934191b" xlink:to="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_cf292bf0-3e29-4b5a-9aa9-289061d228f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_cf292bf0-3e29-4b5a-9aa9-289061d228f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_183a2af1-75ee-40cc-9c88-6a353b7b22f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_183a2af1-75ee-40cc-9c88-6a353b7b22f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_77e4a581-722e-4bef-9355-7a6790f3cb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_77e4a581-722e-4bef-9355-7a6790f3cb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_96f19233-ab26-4341-9f60-65e39eb6c1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:to="loc_us-gaap_InventoryNet_96f19233-ab26-4341-9f60-65e39eb6c1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_d0b64011-fdca-4cbc-b2ce-6f5cb0a69f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryLineItems_f94ba6a3-cbe9-4f61-ab88-1cc28786ab70" xlink:to="loc_us-gaap_InventoryNoncurrent_d0b64011-fdca-4cbc-b2ce-6f5cb0a69f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4f7d5f05-77ea-493d-80e9-50bb1833ba1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable_5bd41101-4c4e-4b36-96cf-90cdefd4d371" xlink:href="gild-20211231.xsd#gild_ScheduleofInventoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4f7d5f05-77ea-493d-80e9-50bb1833ba1e" xlink:to="loc_gild_ScheduleofInventoryTable_5bd41101-4c4e-4b36-96cf-90cdefd4d371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_8b75dad1-e82d-4ac2-b583-6ef008b2988f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryTable_5bd41101-4c4e-4b36-96cf-90cdefd4d371" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_8b75dad1-e82d-4ac2-b583-6ef008b2988f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_eeb3bdae-0e3e-49bd-90cb-1b2614652dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_8b75dad1-e82d-4ac2-b583-6ef008b2988f" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_eeb3bdae-0e3e-49bd-90cb-1b2614652dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryWritedownsforExcessRawMaterialsMember_293d77e9-ddbe-4b8b-9433-f5c86243860b" xlink:href="gild-20211231.xsd#gild_InventoryWritedownsforExcessRawMaterialsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_eeb3bdae-0e3e-49bd-90cb-1b2614652dc7" xlink:to="loc_gild_InventoryWritedownsforExcessRawMaterialsMember_293d77e9-ddbe-4b8b-9433-f5c86243860b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_517eb80d-b92f-4039-b119-39af6bb9e448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryTable_5bd41101-4c4e-4b36-96cf-90cdefd4d371" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_517eb80d-b92f-4039-b119-39af6bb9e448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_124d6f2e-9ece-4163-b986-b991038728e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_517eb80d-b92f-4039-b119-39af6bb9e448" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_124d6f2e-9ece-4163-b986-b991038728e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_9255aa8e-087f-4e5e-9749-d91091b6345b" xlink:href="gild-20211231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_124d6f2e-9ece-4163-b986-b991038728e0" xlink:to="loc_gild_ImmunomedicsIncMember_9255aa8e-087f-4e5e-9749-d91091b6345b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleOfInventoriesLineItems_2f2aea67-fc57-4adf-8346-5c9a45a2ea02" xlink:href="gild-20211231.xsd#gild_ScheduleOfInventoriesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryTable_5bd41101-4c4e-4b36-96cf-90cdefd4d371" xlink:to="loc_gild_ScheduleOfInventoriesLineItems_2f2aea67-fc57-4adf-8346-5c9a45a2ea02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2b27e2e6-33cc-4311-86bf-86ba8fed7def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleOfInventoriesLineItems_2f2aea67-fc57-4adf-8346-5c9a45a2ea02" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2b27e2e6-33cc-4311-86bf-86ba8fed7def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_35c1d754-1926-495e-ab85-9347bcf39d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleOfInventoriesLineItems_2f2aea67-fc57-4adf-8346-5c9a45a2ea02" xlink:to="loc_us-gaap_InventoryWriteDown_35c1d754-1926-495e-ab85-9347bcf39d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="gild-20211231.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_76a60a10-2abf-4f85-a3a1-23a249f30fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fc7ff1c1-ee31-47f2-a60a-8a90fd25540e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_76a60a10-2abf-4f85-a3a1-23a249f30fe7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fc7ff1c1-ee31-47f2-a60a-8a90fd25540e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="gild-20211231.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b0da5692-846d-4033-b418-5e905d6451c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5b824858-6de6-4cf7-84ec-f99d1ad8ea7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b0da5692-846d-4033-b418-5e905d6451c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5b824858-6de6-4cf7-84ec-f99d1ad8ea7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ba5e43d9-db06-4e32-b726-98746e2d2ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_7c793733-89a8-4e95-beac-6d7752843aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ba5e43d9-db06-4e32-b726-98746e2d2ae2" xlink:to="loc_us-gaap_Land_7c793733-89a8-4e95-beac-6d7752843aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_a212c649-fb9a-4715-bd8c-503227a21fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ba5e43d9-db06-4e32-b726-98746e2d2ae2" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_a212c649-fb9a-4715-bd8c-503227a21fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_ff71934e-99c8-4344-ba86-b245af29c189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ba5e43d9-db06-4e32-b726-98746e2d2ae2" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_ff71934e-99c8-4344-ba86-b245af29c189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_6cf5875c-5ee3-4a2e-b25e-358950fd3bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ba5e43d9-db06-4e32-b726-98746e2d2ae2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_6cf5875c-5ee3-4a2e-b25e-358950fd3bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_e4b8a580-b0f5-4d1e-b917-118092d99b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ba5e43d9-db06-4e32-b726-98746e2d2ae2" xlink:to="loc_us-gaap_ConstructionInProgressGross_e4b8a580-b0f5-4d1e-b917-118092d99b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_91107319-5d02-421f-b14a-17a064bc5775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ba5e43d9-db06-4e32-b726-98746e2d2ae2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_91107319-5d02-421f-b14a-17a064bc5775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d21efe8d-9c21-49d0-8721-cf29ddf14d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ba5e43d9-db06-4e32-b726-98746e2d2ae2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d21efe8d-9c21-49d0-8721-cf29ddf14d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b6da54bf-c2f5-46c9-8319-9246f512605b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ba5e43d9-db06-4e32-b726-98746e2d2ae2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b6da54bf-c2f5-46c9-8319-9246f512605b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e639ca2e-5236-4241-8362-45e2b02a4517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91829d4b-039a-46e7-bde6-02b386f00af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e639ca2e-5236-4241-8362-45e2b02a4517" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91829d4b-039a-46e7-bde6-02b386f00af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e1411997-d7dd-47b2-a423-1f1881f4a0ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91829d4b-039a-46e7-bde6-02b386f00af5" xlink:to="loc_srt_StatementGeographicalAxis_e1411997-d7dd-47b2-a423-1f1881f4a0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0b493100-5710-4fcb-8c71-b866314582b3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e1411997-d7dd-47b2-a423-1f1881f4a0ba" xlink:to="loc_srt_SegmentGeographicalDomain_0b493100-5710-4fcb-8c71-b866314582b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_abdf63d5-0857-40e5-8a1c-b7082797238a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0b493100-5710-4fcb-8c71-b866314582b3" xlink:to="loc_country_US_abdf63d5-0857-40e5-8a1c-b7082797238a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_911c6446-cc56-4d53-902a-4a1f298eef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0b493100-5710-4fcb-8c71-b866314582b3" xlink:to="loc_us-gaap_NonUsMember_911c6446-cc56-4d53-902a-4a1f298eef3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c918a352-56f7-469e-ac74-f70174526dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91829d4b-039a-46e7-bde6-02b386f00af5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c918a352-56f7-469e-ac74-f70174526dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_7edd0761-c7d3-404b-a9f0-ddf0e06c042d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c918a352-56f7-469e-ac74-f70174526dda" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_7edd0761-c7d3-404b-a9f0-ddf0e06c042d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c1bc09c9-eb1e-46b1-8169-3c8f57ef8188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c918a352-56f7-469e-ac74-f70174526dda" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c1bc09c9-eb1e-46b1-8169-3c8f57ef8188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="gild-20211231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_29bda742-0a26-4bd9-9c83-959d55ffdeba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_fa159f79-70da-4d54-ba69-6b1e24a4923b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_29bda742-0a26-4bd9-9c83-959d55ffdeba" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_fa159f79-70da-4d54-ba69-6b1e24a4923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="gild-20211231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8897407-2a3e-46bb-87b1-4644f6250f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_70dd4c7d-aa58-4f3b-a743-186d878a952a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8897407-2a3e-46bb-87b1-4644f6250f2e" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_70dd4c7d-aa58-4f3b-a743-186d878a952a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_cde608ef-2f70-4746-9efd-f4716693c669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8897407-2a3e-46bb-87b1-4644f6250f2e" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_cde608ef-2f70-4746-9efd-f4716693c669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_56f721ab-866d-456e-a1ca-df27fea930ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8897407-2a3e-46bb-87b1-4644f6250f2e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_56f721ab-866d-456e-a1ca-df27fea930ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2c80dcb1-2a9e-4a99-9bcf-e54bc161fed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8897407-2a3e-46bb-87b1-4644f6250f2e" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2c80dcb1-2a9e-4a99-9bcf-e54bc161fed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#GoodwillandIntangibleAssetsGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7ec814d0-cd99-48f7-b30b-f95dfe8037e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_9a8b543b-c11a-46a7-bb8e-9987fffbf710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7ec814d0-cd99-48f7-b30b-f95dfe8037e3" xlink:to="loc_us-gaap_GoodwillRollForward_9a8b543b-c11a-46a7-bb8e-9987fffbf710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f0d2e89a-3da1-44fa-ab08-15c1ad6a11be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9a8b543b-c11a-46a7-bb8e-9987fffbf710" xlink:to="loc_us-gaap_Goodwill_f0d2e89a-3da1-44fa-ab08-15c1ad6a11be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_1964588d-6c0c-494b-b8e2-15d4e255aa37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9a8b543b-c11a-46a7-bb8e-9987fffbf710" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_1964588d-6c0c-494b-b8e2-15d4e255aa37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_26f93afa-8662-4e38-9311-98b7f19b8710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9a8b543b-c11a-46a7-bb8e-9987fffbf710" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_26f93afa-8662-4e38-9311-98b7f19b8710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d9df2fba-f923-4814-ae2c-414266912303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_9a8b543b-c11a-46a7-bb8e-9987fffbf710" xlink:to="loc_us-gaap_Goodwill_d9df2fba-f923-4814-ae2c-414266912303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1c33c40c-0bb9-4260-ae62-812d448140e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6762c520-e1a3-4c5d-a1a1-0e13612d2470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1c33c40c-0bb9-4260-ae62-812d448140e0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6762c520-e1a3-4c5d-a1a1-0e13612d2470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8f8c65f3-81ad-4fe6-9a70-1470ab870204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6762c520-e1a3-4c5d-a1a1-0e13612d2470" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8f8c65f3-81ad-4fe6-9a70-1470ab870204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ab37cd58-d26c-434e-9fa6-2f4becb8ecec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8f8c65f3-81ad-4fe6-9a70-1470ab870204" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ab37cd58-d26c-434e-9fa6-2f4becb8ecec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_744eddc2-fa32-4e9d-a170-58d37afd2530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ab37cd58-d26c-434e-9fa6-2f4becb8ecec" xlink:to="loc_us-gaap_CostOfSalesMember_744eddc2-fa32-4e9d-a170-58d37afd2530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_580fea45-79e8-46d9-9487-d3b23ebaebcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6762c520-e1a3-4c5d-a1a1-0e13612d2470" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_580fea45-79e8-46d9-9487-d3b23ebaebcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f577a4da-2a21-44ec-a6c7-6fe669afc913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_580fea45-79e8-46d9-9487-d3b23ebaebcc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f577a4da-2a21-44ec-a6c7-6fe669afc913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_KitePharmaIncMember_0ad96481-0d9e-4530-acd5-be43d734762d" xlink:href="gild-20211231.xsd#gild_KitePharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f577a4da-2a21-44ec-a6c7-6fe669afc913" xlink:to="loc_gild_KitePharmaIncMember_0ad96481-0d9e-4530-acd5-be43d734762d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d88235fe-7ad7-4e53-978c-33b60ee673be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6762c520-e1a3-4c5d-a1a1-0e13612d2470" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d88235fe-7ad7-4e53-978c-33b60ee673be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ef453feb-963f-4c9d-a378-9e89e8e5f372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d88235fe-7ad7-4e53-978c-33b60ee673be" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ef453feb-963f-4c9d-a378-9e89e8e5f372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c9ff5974-0177-4b6a-989b-c987320659a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d88235fe-7ad7-4e53-978c-33b60ee673be" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c9ff5974-0177-4b6a-989b-c987320659a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_ec5fb33b-947a-40f4-a111-c6995ff424d1" xlink:href="gild-20211231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d88235fe-7ad7-4e53-978c-33b60ee673be" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_ec5fb33b-947a-40f4-a111-c6995ff424d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6be09510-5195-4b5d-85c3-c5425c1dd21b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d88235fe-7ad7-4e53-978c-33b60ee673be" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6be09510-5195-4b5d-85c3-c5425c1dd21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_60a2e573-a621-4b61-a5d0-87bb3fcac17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baedc38f-d0cd-4726-af3e-d2021bf5246f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_60a2e573-a621-4b61-a5d0-87bb3fcac17e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baedc38f-d0cd-4726-af3e-d2021bf5246f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23ddbd7d-6e32-4483-92ce-796f1f11497a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baedc38f-d0cd-4726-af3e-d2021bf5246f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23ddbd7d-6e32-4483-92ce-796f1f11497a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23ddbd7d-6e32-4483-92ce-796f1f11497a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_9504462b-d9cb-4064-8e6b-0b8cca59ddbe" xlink:href="gild-20211231.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_9504462b-d9cb-4064-8e6b-0b8cca59ddbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneCiloleucelDLBCLMember_592d03ee-3a56-4516-ba06-810a6a5cbd41" xlink:href="gild-20211231.xsd#gild_AxicabtageneCiloleucelDLBCLMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:to="loc_gild_AxicabtageneCiloleucelDLBCLMember_592d03ee-3a56-4516-ba06-810a6a5cbd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_ce54df69-1c4a-4335-9e3a-e4cae787885c" xlink:href="gild-20211231.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:to="loc_gild_TrodelvyMember_ce54df69-1c4a-4335-9e3a-e4cae787885c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_c856d69c-3447-4504-a1b5-835bcd73785d" xlink:href="gild-20211231.xsd#gild_HepcludexMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:to="loc_gild_HepcludexMember_c856d69c-3447-4504-a1b5-835bcd73785d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_de8e2688-96b0-4ef4-b15c-0269530deea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_de8e2688-96b0-4ef4-b15c-0269530deea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_9ad4fdf0-445d-4646-b2c3-89a42e215035" xlink:href="gild-20211231.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55bf8ba9-ccd0-429d-bc54-2d87aa858a6d" xlink:to="loc_gild_CellTherapyProductsTecartusMember_9ad4fdf0-445d-4646-b2c3-89a42e215035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bdcf75b-34bb-43c1-a644-93573cfea2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baedc38f-d0cd-4726-af3e-d2021bf5246f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bdcf75b-34bb-43c1-a644-93573cfea2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b1679243-94e2-4162-be76-d84c388c5c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8bdcf75b-34bb-43c1-a644-93573cfea2cb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b1679243-94e2-4162-be76-d84c388c5c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_77c9b5c6-5334-4541-b22c-119c79fb974f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b1679243-94e2-4162-be76-d84c388c5c99" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_77c9b5c6-5334-4541-b22c-119c79fb974f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baedc38f-d0cd-4726-af3e-d2021bf5246f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fde22e23-8401-43bd-b5b7-04597d76d606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fde22e23-8401-43bd-b5b7-04597d76d606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d76a7b7f-76e3-4a4a-9385-c1825396b66e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fde22e23-8401-43bd-b5b7-04597d76d606" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d76a7b7f-76e3-4a4a-9385-c1825396b66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cf9eacdb-e72e-4c92-adc4-f699ef83a3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fde22e23-8401-43bd-b5b7-04597d76d606" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cf9eacdb-e72e-4c92-adc4-f699ef83a3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_939ca16d-55c0-45d9-9f15-38945f2895dc" xlink:href="gild-20211231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fde22e23-8401-43bd-b5b7-04597d76d606" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_939ca16d-55c0-45d9-9f15-38945f2895dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_363b949e-d286-4d97-a08c-50af8769f59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fde22e23-8401-43bd-b5b7-04597d76d606" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_363b949e-d286-4d97-a08c-50af8769f59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d9214f57-978d-40da-ab2a-9d225573d07e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d9214f57-978d-40da-ab2a-9d225573d07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5a6487e0-39ce-4ad8-a1ea-cb3b130d771d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d9214f57-978d-40da-ab2a-9d225573d07e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5a6487e0-39ce-4ad8-a1ea-cb3b130d771d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ca2b48c2-074e-4d4f-a186-106039b3222e" xlink:href="gild-20211231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d9214f57-978d-40da-ab2a-9d225573d07e" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ca2b48c2-074e-4d4f-a186-106039b3222e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_50d26ff2-28f5-4d1e-9158-9d1e8173c764" xlink:href="gild-20211231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d9214f57-978d-40da-ab2a-9d225573d07e" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_50d26ff2-28f5-4d1e-9158-9d1e8173c764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cef93494-ab8a-4417-ac79-06576c8e23b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cef93494-ab8a-4417-ac79-06576c8e23b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_76454827-d608-41db-8e7c-8c23a23a4c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cef93494-ab8a-4417-ac79-06576c8e23b3" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_76454827-d608-41db-8e7c-8c23a23a4c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ec01c8dc-639f-4605-b212-26f0808d76c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cef93494-ab8a-4417-ac79-06576c8e23b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ec01c8dc-639f-4605-b212-26f0808d76c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_9565d2f9-0ea7-4dda-95d5-841470df9464" xlink:href="gild-20211231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cef93494-ab8a-4417-ac79-06576c8e23b3" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_9565d2f9-0ea7-4dda-95d5-841470df9464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f14bc4fa-3a6f-40ea-8c8a-970886e46050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cef93494-ab8a-4417-ac79-06576c8e23b3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f14bc4fa-3a6f-40ea-8c8a-970886e46050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_4efd8ee5-d25b-4569-ad74-1dbd36ca9d83" xlink:href="gild-20211231.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_4efd8ee5-d25b-4569-ad74-1dbd36ca9d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4628d750-68f9-4a06-b922-96a1fccd17ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50d305c3-dd6b-4b6d-8733-429d971c66ed" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4628d750-68f9-4a06-b922-96a1fccd17ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="gild-20211231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a89df41-c78b-4197-9f6a-5fad8af4b82d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2a31826a-757e-49e5-a5e9-eb64c0b55944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a89df41-c78b-4197-9f6a-5fad8af4b82d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2a31826a-757e-49e5-a5e9-eb64c0b55944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bd0d50d5-c033-4a5a-8858-f2e25a866b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a89df41-c78b-4197-9f6a-5fad8af4b82d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bd0d50d5-c033-4a5a-8858-f2e25a866b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0a87796b-c823-4684-9588-f04aea167057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a89df41-c78b-4197-9f6a-5fad8af4b82d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0a87796b-c823-4684-9588-f04aea167057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f47cc946-612b-49bd-8cd5-d79ad4512261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a89df41-c78b-4197-9f6a-5fad8af4b82d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f47cc946-612b-49bd-8cd5-d79ad4512261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0e0a8d16-8f68-45b0-aa35-b83cb20cd6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a89df41-c78b-4197-9f6a-5fad8af4b82d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0e0a8d16-8f68-45b0-aa35-b83cb20cd6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_d3a659c6-c515-49dc-9f9a-aa8a0b1e5b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a89df41-c78b-4197-9f6a-5fad8af4b82d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_d3a659c6-c515-49dc-9f9a-aa8a0b1e5b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fce4cf8c-b408-4636-942a-29fc1892816c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a89df41-c78b-4197-9f6a-5fad8af4b82d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fce4cf8c-b408-4636-942a-29fc1892816c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="gild-20211231.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_a6754403-7ed1-4d34-893c-86f6c0afe7c3" xlink:href="gild-20211231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_e8e5174f-2218-4295-8eb7-9330739fe39b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_a6754403-7ed1-4d34-893c-86f6c0afe7c3" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_e8e5174f-2218-4295-8eb7-9330739fe39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="gild-20211231.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_490bea6b-59b7-4073-9420-d350cf5ec950" xlink:href="gild-20211231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_a98e6dd1-0bb8-4a00-819e-e5b9f3d4ab34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_490bea6b-59b7-4073-9420-d350cf5ec950" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_a98e6dd1-0bb8-4a00-819e-e5b9f3d4ab34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_502a4e22-43e9-44f9-bbaa-af8c2c4b27ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_490bea6b-59b7-4073-9420-d350cf5ec950" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_502a4e22-43e9-44f9-bbaa-af8c2c4b27ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#OtherFinancialInformationAccountsReceivableNetDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_f7324e03-25dd-4278-a4a7-7b3560970b5c" xlink:href="gild-20211231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_4182560b-33e8-4632-ac32-caf029560690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_f7324e03-25dd-4278-a4a7-7b3560970b5c" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_4182560b-33e8-4632-ac32-caf029560690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_12dbb3b9-f2b4-4b5e-8481-b48ba86ea7ef" xlink:href="gild-20211231.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_f7324e03-25dd-4278-a4a7-7b3560970b5c" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_12dbb3b9-f2b4-4b5e-8481-b48ba86ea7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_ce3f8418-557a-4992-96de-d0a72d51d6a3" xlink:href="gild-20211231.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_f7324e03-25dd-4278-a4a7-7b3560970b5c" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_ce3f8418-557a-4992-96de-d0a72d51d6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0207fde8-63cb-46ab-bf85-da3df787980d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_f7324e03-25dd-4278-a4a7-7b3560970b5c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0207fde8-63cb-46ab-bf85-da3df787980d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ab8b2a55-285d-48c9-a43d-77d36f6e82c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_f7324e03-25dd-4278-a4a7-7b3560970b5c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ab8b2a55-285d-48c9-a43d-77d36f6e82c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#OtherFinancialInformationOtherAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_a3ca7749-ff61-4008-bfd8-224e8b3c5fab" xlink:href="gild-20211231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e1af94fa-a924-4be7-bdae-8643508706e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_a3ca7749-ff61-4008-bfd8-224e8b3c5fab" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e1af94fa-a924-4be7-bdae-8643508706e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_094723a3-da83-468e-a3cf-ab284cf73b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_a3ca7749-ff61-4008-bfd8-224e8b3c5fab" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_094723a3-da83-468e-a3cf-ab284cf73b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_2d476930-7cb5-454e-855a-2a8fafbe96cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_a3ca7749-ff61-4008-bfd8-224e8b3c5fab" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_2d476930-7cb5-454e-855a-2a8fafbe96cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_e1df932a-b98f-4e4e-98ac-6caa6f0c747a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_a3ca7749-ff61-4008-bfd8-224e8b3c5fab" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_e1df932a-b98f-4e4e-98ac-6caa6f0c747a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c397094a-ec21-4cc5-bc70-4cbb75f75fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_a3ca7749-ff61-4008-bfd8-224e8b3c5fab" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c397094a-ec21-4cc5-bc70-4cbb75f75fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_63bc1c1f-83cb-4726-918d-b74c48bcdaec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_a3ca7749-ff61-4008-bfd8-224e8b3c5fab" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_63bc1c1f-83cb-4726-918d-b74c48bcdaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="gild-20211231.xsd#CollaborationsandOtherArrangements"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CollaborationsandOtherArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract_6821ae9d-ce9f-44b0-a59a-ca6e890c86d7" xlink:href="gild-20211231.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAndOtherArrangementsTextBlock_d89d0768-703d-4751-a002-3dbc9e3c69b1" xlink:href="gild-20211231.xsd#gild_CollaborativeAndOtherArrangementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract_6821ae9d-ce9f-44b0-a59a-ca6e890c86d7" xlink:to="loc_gild_CollaborativeAndOtherArrangementsTextBlock_d89d0768-703d-4751-a002-3dbc9e3c69b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract_33124c44-c6b3-4222-81ea-c659a6267169" xlink:href="gild-20211231.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract_33124c44-c6b3-4222-81ea-c659a6267169" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1c141efc-ae30-41cc-a393-950008368f6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1c141efc-ae30-41cc-a393-950008368f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1c141efc-ae30-41cc-a393-950008368f6e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_21ef9332-e5c4-47ad-ae57-32e0c77655db" xlink:href="gild-20211231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:to="loc_gild_ArcusBiosciencesIncMember_21ef9332-e5c4-47ad-ae57-32e0c77655db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrImmunotherapeuticsIncMember_d675901d-330f-4c58-86ef-55f9e463c0f1" xlink:href="gild-20211231.xsd#gild_PionyrImmunotherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:to="loc_gild_PionyrImmunotherapeuticsIncMember_d675901d-330f-4c58-86ef-55f9e463c0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaTherapeuticsIncMember_4a471b17-bd47-4354-8d7b-ae30c7b07058" xlink:href="gild-20211231.xsd#gild_TizonaTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:to="loc_gild_TizonaTherapeuticsIncMember_4a471b17-bd47-4354-8d7b-ae30c7b07058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember_5c10e5d1-826f-4aaa-937e-cb171c233898" xlink:href="gild-20211231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:to="loc_gild_TangoTherapeuticsIncMember_5c10e5d1-826f-4aaa-937e-cb171c233898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember_bb437695-621e-4ef5-9d34-0b1686a82de3" xlink:href="gild-20211231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:to="loc_gild_JounceTherapeuticsIncMember_bb437695-621e-4ef5-9d34-0b1686a82de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_bad7d4f6-3638-4b77-84df-e7890f8cbca0" xlink:href="gild-20211231.xsd#gild_GalapagosMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_239dab2a-2285-496a-9e36-8f7bc2acb47d" xlink:to="loc_gild_GalapagosMember_bad7d4f6-3638-4b77-84df-e7890f8cbca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fc0c5e64-652f-4183-b14c-c5486f265b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fc0c5e64-652f-4183-b14c-c5486f265b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc0c5e64-652f-4183-b14c-c5486f265b04" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_40a35c0a-75d4-440c-bb1b-b61c92011541" xlink:href="gild-20211231.xsd#gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_40a35c0a-75d4-440c-bb1b-b61c92011541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_2c5a0738-460f-4281-ba61-2e72f4c1d29d" xlink:href="gild-20211231.xsd#gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_2c5a0738-460f-4281-ba61-2e72f4c1d29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementMember_24d7d749-2486-452b-9ae8-0ff950933770" xlink:href="gild-20211231.xsd#gild_ArcusCollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_ArcusCollaborationAgreementMember_24d7d749-2486-452b-9ae8-0ff950933770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember_c44b6ad1-64bc-48f3-a51e-6d2484e63d98" xlink:href="gild-20211231.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_ArcusStockPurchaseAgreementMember_c44b6ad1-64bc-48f3-a51e-6d2484e63d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrMergerAndOptionAgreementsMember_dffbb22b-540a-4bab-9f8e-5add3b0c8bf7" xlink:href="gild-20211231.xsd#gild_PionyrMergerAndOptionAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_PionyrMergerAndOptionAgreementsMember_dffbb22b-540a-4bab-9f8e-5add3b0c8bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentServiceAgreementMember_8eeb753b-b0b0-488b-852b-14ee9407c108" xlink:href="gild-20211231.xsd#gild_ResearchAndDevelopmentServiceAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_ResearchAndDevelopmentServiceAgreementMember_8eeb753b-b0b0-488b-852b-14ee9407c108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaMergerAndOptionAgreementsMember_371e6eb3-0b10-436e-a37d-add1416990fc" xlink:href="gild-20211231.xsd#gild_TizonaMergerAndOptionAgreementsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_TizonaMergerAndOptionAgreementsMember_371e6eb3-0b10-436e-a37d-add1416990fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JanssenPharmaceuticalsMember_c5c7e994-ed2d-4b38-ac81-559cdd9d3b63" xlink:href="gild-20211231.xsd#gild_JanssenPharmaceuticalsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_JanssenPharmaceuticalsMember_c5c7e994-ed2d-4b38-ac81-559cdd9d3b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_bb1b4112-5541-47e0-abff-0dd33f4c8ae0" xlink:href="gild-20211231.xsd#gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_bb1b4112-5541-47e0-abff-0dd33f4c8ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_36be589b-afbf-45c2-b9da-b3d662b8663d" xlink:href="gild-20211231.xsd#gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_36be589b-afbf-45c2-b9da-b3d662b8663d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosSubscriptionAgreementMember_062048ad-8864-41fb-869d-bd11bb3de5da" xlink:href="gild-20211231.xsd#gild_GalapagosSubscriptionAgreementMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_GalapagosSubscriptionAgreementMember_062048ad-8864-41fb-869d-bd11bb3de5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosCollaborationAgreementMember_b780b5ce-6ffb-4571-85b2-0b920bf8b44c" xlink:href="gild-20211231.xsd#gild_GalapagosCollaborationAgreementMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_GalapagosCollaborationAgreementMember_b780b5ce-6ffb-4571-85b2-0b920bf8b44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DevelopmentAgreementMember_59207bfd-8da5-4450-b672-5e763f1fe43d" xlink:href="gild-20211231.xsd#gild_DevelopmentAgreementMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_DevelopmentAgreementMember_59207bfd-8da5-4450-b672-5e763f1fe43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_599ff833-8dd4-4628-b3c0-5aca49e8e5bc" xlink:href="gild-20211231.xsd#gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_599ff833-8dd4-4628-b3c0-5aca49e8e5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_4133c024-fcdd-4a8d-ae18-c237ebff6d86" xlink:href="gild-20211231.xsd#gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_4133c024-fcdd-4a8d-ae18-c237ebff6d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AgreementWithJapanTobaccoIncMember_99328b55-c82b-470f-b989-51b4a6498363" xlink:href="gild-20211231.xsd#gild_AgreementWithJapanTobaccoIncMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_AgreementWithJapanTobaccoIncMember_99328b55-c82b-470f-b989-51b4a6498363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GadetaBVCollaborationArrangementMember_20743986-ec09-41c0-8652-c4ef77d845aa" xlink:href="gild-20211231.xsd#gild_GadetaBVCollaborationArrangementMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_GadetaBVCollaborationArrangementMember_20743986-ec09-41c0-8652-c4ef77d845aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember_313dcbd3-b386-4fc1-ad87-6f1d9b480f34" xlink:href="gild-20211231.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea1700a-ee3b-4c39-8e9c-e09d5c40b78b" xlink:to="loc_gild_OtherCollaborationArrangementsMember_313dcbd3-b386-4fc1-ad87-6f1d9b480f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_41ef0166-31c3-4c2b-9cbb-3f8776e89164" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_srt_OwnershipAxis_41ef0166-31c3-4c2b-9cbb-3f8776e89164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_073ce8f6-c81b-40de-aace-ac3c2a0251a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_41ef0166-31c3-4c2b-9cbb-3f8776e89164" xlink:to="loc_srt_OwnershipDomain_073ce8f6-c81b-40de-aace-ac3c2a0251a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_d01af766-9f54-47d2-8399-781fb9e6e038" xlink:href="gild-20211231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_073ce8f6-c81b-40de-aace-ac3c2a0251a6" xlink:to="loc_gild_ArcusBiosciencesIncMember_d01af766-9f54-47d2-8399-781fb9e6e038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember_8d6b5112-94a7-4cc5-b9a2-bd6c32caf6ef" xlink:href="gild-20211231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_073ce8f6-c81b-40de-aace-ac3c2a0251a6" xlink:to="loc_gild_TangoTherapeuticsIncMember_8d6b5112-94a7-4cc5-b9a2-bd6c32caf6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember_b344d828-60ea-410b-ac7c-52dd2484154f" xlink:href="gild-20211231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_073ce8f6-c81b-40de-aace-ac3c2a0251a6" xlink:to="loc_gild_JounceTherapeuticsIncMember_b344d828-60ea-410b-ac7c-52dd2484154f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_deb25dbb-74aa-42a1-97fa-a263db72431f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_dei_LegalEntityAxis_deb25dbb-74aa-42a1-97fa-a263db72431f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5cf0104e-8fe4-475c-88d3-3bcc7eb685af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_deb25dbb-74aa-42a1-97fa-a263db72431f" xlink:to="loc_dei_EntityDomain_5cf0104e-8fe4-475c-88d3-3bcc7eb685af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckMember_40e07281-9168-4aa5-9aa1-cd0eb31313d3" xlink:href="gild-20211231.xsd#gild_MerckMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5cf0104e-8fe4-475c-88d3-3bcc7eb685af" xlink:to="loc_gild_MerckMember_40e07281-9168-4aa5-9aa1-cd0eb31313d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c17bde3-ad09-471b-a082-3af42093772d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_srt_ProductOrServiceAxis_8c17bde3-ad09-471b-a082-3af42093772d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_65ded896-8e15-4681-afb5-9460d6929b90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8c17bde3-ad09-471b-a082-3af42093772d" xlink:to="loc_srt_ProductsAndServicesDomain_65ded896-8e15-4681-afb5-9460d6929b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OralFormulationProductMember_f5479836-1b67-4334-8f8f-93f7fef0479e" xlink:href="gild-20211231.xsd#gild_OralFormulationProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_65ded896-8e15-4681-afb5-9460d6929b90" xlink:to="loc_gild_OralFormulationProductMember_f5479836-1b67-4334-8f8f-93f7fef0479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InjectableFormulationProductMember_ae862e13-8e56-46c9-b14f-f1709d6c4461" xlink:href="gild-20211231.xsd#gild_InjectableFormulationProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_65ded896-8e15-4681-afb5-9460d6929b90" xlink:to="loc_gild_InjectableFormulationProductMember_ae862e13-8e56-46c9-b14f-f1709d6c4461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_905dc90a-544e-4a47-b01b-0bdb25ae89de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_srt_RangeAxis_905dc90a-544e-4a47-b01b-0bdb25ae89de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab1657cb-53f6-4613-ac8b-3eac258a4423" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_905dc90a-544e-4a47-b01b-0bdb25ae89de" xlink:to="loc_srt_RangeMember_ab1657cb-53f6-4613-ac8b-3eac258a4423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_45dd2687-6e77-4968-8a07-911bc9e3925a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ab1657cb-53f6-4613-ac8b-3eac258a4423" xlink:to="loc_srt_MaximumMember_45dd2687-6e77-4968-8a07-911bc9e3925a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b48b4f4-028b-418d-b5a8-c8f0f534da51" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_2b47f890-8ff0-46df-a125-72691bece935" xlink:href="gild-20211231.xsd#gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_2b47f890-8ff0-46df-a125-72691bece935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementNetProductSalesThreshold_e402106e-0899-42e3-a7eb-74fc8d6e7472" xlink:href="gild-20211231.xsd#gild_CollaborationArrangementNetProductSalesThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborationArrangementNetProductSalesThreshold_e402106e-0899-42e3-a7eb-74fc8d6e7472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_0b9066d7-bdf2-4ef8-a7d9-17fd47c1abd3" xlink:href="gild-20211231.xsd#gild_CollaborationArrangementPercentOfGlobalProductRevenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_0b9066d7-bdf2-4ef8-a7d9-17fd47c1abd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a44216c1-dc78-4949-b8de-68d2b0326a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a44216c1-dc78-4949-b8de-68d2b0326a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_a89c2788-4e3c-44ba-b0af-6542165e8a83" xlink:href="gild-20211231.xsd#gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_a89c2788-4e3c-44ba-b0af-6542165e8a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_2bff0a70-7dc9-4a8a-a859-c790e9c65c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_2bff0a70-7dc9-4a8a-a859-c790e9c65c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InvestmentOwnedBalanceAdditionalShares_578cb583-7a17-4686-a66a-4cff48d9c8b5" xlink:href="gild-20211231.xsd#gild_InvestmentOwnedBalanceAdditionalShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_InvestmentOwnedBalanceAdditionalShares_578cb583-7a17-4686-a66a-4cff48d9c8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_6cb999a0-457c-4ad0-af3c-e6d7f8be0a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_6cb999a0-457c-4ad0-af3c-e6d7f8be0a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_406662cc-fcd1-47f2-9157-5d4ce8679a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalUpfrontPaymentsMade_dd695499-9c18-489b-a5ba-b01d837338de" xlink:href="gild-20211231.xsd#gild_TotalUpfrontPaymentsMade"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_TotalUpfrontPaymentsMade_dd695499-9c18-489b-a5ba-b01d837338de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a3582717-bac3-49f6-baa4-408afbc0d124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a3582717-bac3-49f6-baa4-408afbc0d124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_8d15ec16-43a5-443b-a760-3312b5613dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_8d15ec16-43a5-443b-a760-3312b5613dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IssuanceDiscountPremium_1484c534-10b6-4f3a-924a-e18dd43454c3" xlink:href="gild-20211231.xsd#gild_IssuanceDiscountPremium"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_IssuanceDiscountPremium_1484c534-10b6-4f3a-924a-e18dd43454c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForDirectTransactionalExpense_7571b644-622d-48ea-bdcb-036d1d347a49" xlink:href="gild-20211231.xsd#gild_PaymentsForDirectTransactionalExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PaymentsForDirectTransactionalExpense_7571b644-622d-48ea-bdcb-036d1d347a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod_0096bdfd-90be-4f1d-bbba-31204b36a0eb" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNIPurchasePeriod_0096bdfd-90be-4f1d-bbba-31204b36a0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_54b7eb08-605d-4d67-b248-7216892bd72f" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_54b7eb08-605d-4d67-b248-7216892bd72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_936b7c23-2675-4502-98a7-46e2f063f643" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_936b7c23-2675-4502-98a7-46e2f063f643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_57002351-337c-45de-972f-8d703cabcc86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_57002351-337c-45de-972f-8d703cabcc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNISharesAcquired_55d3f999-0eae-44f7-877a-f7054dbc32d7" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNISharesAcquired"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNISharesAcquired_55d3f999-0eae-44f7-877a-f7054dbc32d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIShares_c3f44afc-1ae8-4078-b27e-ef2e2fcde14b" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIShares"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNIShares_c3f44afc-1ae8-4078-b27e-ef2e2fcde14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_87ed8320-fd2d-4f5f-a924-edc3b2a11156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_87ed8320-fd2d-4f5f-a924-edc3b2a11156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementOptInTerm_a165f393-2fae-4080-a550-dd24e0f7a947" xlink:href="gild-20211231.xsd#gild_CollaborativeAgreementOptInTerm"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborativeAgreementOptInTerm_a165f393-2fae-4080-a550-dd24e0f7a947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions_14c47299-501a-4727-86fb-2add4e432206" xlink:href="gild-20211231.xsd#gild_NumberOfClinicalStageProgramsWithExercisedOptions"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions_14c47299-501a-4727-86fb-2add4e432206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToOptInTheCollaborativeAgreement_87f789bc-6d80-4b3b-a12c-b7ecb11474cb" xlink:href="gild-20211231.xsd#gild_PaymentsToOptInTheCollaborativeAgreement"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PaymentsToOptInTheCollaborativeAgreement_87f789bc-6d80-4b3b-a12c-b7ecb11474cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_644f595c-7809-4f2b-ad8c-a232b8d9fc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_644f595c-7809-4f2b-ad8c-a232b8d9fc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a9bf5439-3326-4a21-a39d-4a18382345a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_EquityMethodInvestments_a9bf5439-3326-4a21-a39d-4a18382345a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_7ebf8a76-651c-4b8b-9e72-f59a05ff9769" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_7ebf8a76-651c-4b8b-9e72-f59a05ff9769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_c655f655-3803-4c74-a169-1b43b72208aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_c655f655-3803-4c74-a169-1b43b72208aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_2acadff2-831b-420d-b681-3af045692e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_2acadff2-831b-420d-b681-3af045692e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeArrangementTerm_738e8af9-8414-4ced-899b-b88f3ec00b0d" xlink:href="gild-20211231.xsd#gild_CollaborativeArrangementTerm"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborativeArrangementTerm_738e8af9-8414-4ced-899b-b88f3ec00b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4f423443-7915-406b-b65d-5b5430fde839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4f423443-7915-406b-b65d-5b5430fde839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_df4eb310-90fb-4b26-a4bf-544eef7e2f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_SharePrice_df4eb310-90fb-4b26-a4bf-544eef7e2f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_87539394-4fb7-4d4c-8a9f-8b0daa7834df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_87539394-4fb7-4d4c-8a9f-8b0daa7834df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_5cd7413d-5661-407d-8275-797b74a0dc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_5cd7413d-5661-407d-8275-797b74a0dc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionExerciseFee_5b02183b-fe85-46d3-9494-82186fc69a8e" xlink:href="gild-20211231.xsd#gild_EquityMethodInvestmentOptionExerciseFee"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquityMethodInvestmentOptionExerciseFee_5b02183b-fe85-46d3-9494-82186fc69a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum_9fd78b79-4491-43f9-ad93-70f1de345be2" xlink:href="gild-20211231.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PotentialFutureMilestonePaymentsMaximum_9fd78b79-4491-43f9-ad93-70f1de345be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentFutureMaximumPayments_0b317122-6cbd-4fc4-b5da-19627db12f9f" xlink:href="gild-20211231.xsd#gild_ResearchAndDevelopmentFutureMaximumPayments"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_ResearchAndDevelopmentFutureMaximumPayments_0b317122-6cbd-4fc4-b5da-19627db12f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForResearchAndDevelopmentMilestones_4f4dab8e-6fce-4ea6-86f9-3916ef1f0b32" xlink:href="gild-20211231.xsd#gild_PaymentsForResearchAndDevelopmentMilestones"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PaymentsForResearchAndDevelopmentMilestones_4f4dab8e-6fce-4ea6-86f9-3916ef1f0b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_3effca2d-a231-40ce-8068-d8adb68961ef" xlink:href="gild-20211231.xsd#gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_3effca2d-a231-40ce-8068-d8adb68961ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_97177515-691c-4099-8fa8-6820f8ab6e68" xlink:href="gild-20211231.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_97177515-691c-4099-8fa8-6820f8ab6e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfPrograms_93256f0a-d8ec-4d0d-8802-ac8c81de1cb1" xlink:href="gild-20211231.xsd#gild_NumberOfPrograms"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_NumberOfPrograms_93256f0a-d8ec-4d0d-8802-ac8c81de1cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_dbdff62c-bac2-4bff-898c-91da45aed74d" xlink:href="gild-20211231.xsd#gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_dbdff62c-bac2-4bff-898c-91da45aed74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_73fb74a2-d02c-4aec-b74b-7a6829e4285e" xlink:href="gild-20211231.xsd#gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_73fb74a2-d02c-4aec-b74b-7a6829e4285e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_6f3a70a6-57a0-4ff7-a80f-7481d01e3cdb" xlink:href="gild-20211231.xsd#gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_6f3a70a6-57a0-4ff7-a80f-7481d01e3cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_3b6aedcb-08bf-4302-91ae-bbc2995a151f" xlink:href="gild-20211231.xsd#gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_3b6aedcb-08bf-4302-91ae-bbc2995a151f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_1e9a6256-781d-4efa-a994-b29eb165472c" xlink:href="gild-20211231.xsd#gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_1e9a6256-781d-4efa-a994-b29eb165472c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_9f8380a1-75cb-4423-a71a-cf35052f7f31" xlink:href="gild-20211231.xsd#gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_9f8380a1-75cb-4423-a71a-cf35052f7f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_ae1d4f34-ccd4-4c08-b22c-464c029fb03e" xlink:href="gild-20211231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPayments"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_ae1d4f34-ccd4-4c08-b22c-464c029fb03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_8b35a995-d41e-434b-9170-f47f1f76d5d7" xlink:href="gild-20211231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_8b35a995-d41e-434b-9170-f47f1f76d5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_946015a5-c96f-439d-9bfe-b296c4be27de" xlink:href="gild-20211231.xsd#gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_946015a5-c96f-439d-9bfe-b296c4be27de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Issuancediscount_d7c631a2-2303-4d80-bb04-8905041c1d87" xlink:href="gild-20211231.xsd#gild_Issuancediscount"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_Issuancediscount_d7c631a2-2303-4d80-bb04-8905041c1d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_7db5bc69-e552-49dd-b563-7be7ce8cee25" xlink:href="gild-20211231.xsd#gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_7db5bc69-e552-49dd-b563-7be7ce8cee25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_StandstillRestrictingTerm_9cba6034-a257-4aa7-85de-84162368b56f" xlink:href="gild-20211231.xsd#gild_StandstillRestrictingTerm"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_StandstillRestrictingTerm_9cba6034-a257-4aa7-85de-84162368b56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_69f1576d-f288-4737-a327-8051d6bcae90" xlink:href="gild-20211231.xsd#gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_69f1576d-f288-4737-a327-8051d6bcae90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fac5a26f-279e-41f5-bfe9-10cb8ea326a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fac5a26f-279e-41f5-bfe9-10cb8ea326a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4d83e707-f070-4191-a50c-803fbe88d10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="56" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4d83e707-f070-4191-a50c-803fbe88d10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialOptionExerciseFeePerProgram_d1053591-b785-4949-b650-35748dd77bd1" xlink:href="gild-20211231.xsd#gild_PotentialOptionExerciseFeePerProgram"/>
    <link:presentationArc order="57" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PotentialOptionExerciseFeePerProgram_d1053591-b785-4949-b650-35748dd77bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_cb122b5f-8e94-4929-8659-52208ac432e3" xlink:href="gild-20211231.xsd#gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage"/>
    <link:presentationArc order="58" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_cb122b5f-8e94-4929-8659-52208ac432e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_87cf2c23-5a13-4ac3-8675-49029bae544b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="59" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_87cf2c23-5a13-4ac3-8675-49029bae544b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_2460ab27-4965-4b63-9a09-1f82dc0370c2" xlink:href="gild-20211231.xsd#gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination"/>
    <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_2460ab27-4965-4b63-9a09-1f82dc0370c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_f4756f7b-33aa-486b-b653-a621055d8da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="61" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_RoyaltyExpense_f4756f7b-33aa-486b-b653-a621055d8da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_9af5d3e1-9dcd-4a0d-a2e1-2d49e31fef30" xlink:href="gild-20211231.xsd#gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan"/>
    <link:presentationArc order="62" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_9af5d3e1-9dcd-4a0d-a2e1-2d49e31fef30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_5d133c72-75bf-42a9-9335-031f21795167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="63" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_5d133c72-75bf-42a9-9335-031f21795167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_33cac58d-3f71-459a-92d9-413a158be30f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="64" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_33cac58d-3f71-459a-92d9-413a158be30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_13c3dfc2-65da-4f7e-907b-bbcf6851f8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:presentationArc order="65" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_13c3dfc2-65da-4f7e-907b-bbcf6851f8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_183ff308-998d-4883-bb1e-5cf46fa14144" xlink:href="gild-20211231.xsd#gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant"/>
    <link:presentationArc order="66" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_07a0e4d2-c350-429f-8ab4-64a05d7bc61a" xlink:to="loc_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_183ff308-998d-4883-bb1e-5cf46fa14144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilities" xlink:type="simple" xlink:href="gild-20211231.xsd#DebtandCreditFacilities"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d1b5bfb5-e668-4a1e-858c-b5870cd997de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_620fe2c6-4290-44c7-9fe5-725684257554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d1b5bfb5-e668-4a1e-858c-b5870cd997de" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_620fe2c6-4290-44c7-9fe5-725684257554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesTables" xlink:type="simple" xlink:href="gild-20211231.xsd#DebtandCreditFacilitiesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_575f67e1-e1da-4335-8e50-30f7e31575c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_749945d2-a6b3-420a-9c1f-71760fff54d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_575f67e1-e1da-4335-8e50-30f7e31575c9" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_749945d2-a6b3-420a-9c1f-71760fff54d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_34f054c0-b713-43f0-8809-ed1ab12f7eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_575f67e1-e1da-4335-8e50-30f7e31575c9" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_34f054c0-b713-43f0-8809-ed1ab12f7eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fb4179ef-14a2-497b-a186-397dfe4b3343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7d4490fd-88e7-413d-b507-87c25e6403de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fb4179ef-14a2-497b-a186-397dfe4b3343" xlink:to="loc_us-gaap_DebtInstrumentTable_7d4490fd-88e7-413d-b507-87c25e6403de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_79655a26-2d28-4905-85cb-7cf9ee0971dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7d4490fd-88e7-413d-b507-87c25e6403de" xlink:to="loc_us-gaap_VariableRateAxis_79655a26-2d28-4905-85cb-7cf9ee0971dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_41e37914-f251-4c5e-bb99-eeb89a16cb82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_79655a26-2d28-4905-85cb-7cf9ee0971dc" xlink:to="loc_us-gaap_VariableRateDomain_41e37914-f251-4c5e-bb99-eeb89a16cb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_3e556577-d00a-489f-8ce5-731d82e4da1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_41e37914-f251-4c5e-bb99-eeb89a16cb82" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_3e556577-d00a-489f-8ce5-731d82e4da1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3b10a342-b2ac-4bb4-a113-93a6ebdc1144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7d4490fd-88e7-413d-b507-87c25e6403de" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3b10a342-b2ac-4bb4-a113-93a6ebdc1144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bc4e2769-d9fb-4eb2-98d1-6708f7cad5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3b10a342-b2ac-4bb4-a113-93a6ebdc1144" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bc4e2769-d9fb-4eb2-98d1-6708f7cad5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember_52bc580b-2496-4825-b25c-6455a082ab13" xlink:href="gild-20211231.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bc4e2769-d9fb-4eb2-98d1-6708f7cad5ad" xlink:to="loc_gild_SeniorNotesAndMediumTermNotesMember_52bc580b-2496-4825-b25c-6455a082ab13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_15c81179-15f5-441c-8649-0c7a7ff6121c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_52bc580b-2496-4825-b25c-6455a082ab13" xlink:to="loc_us-gaap_SeniorNotesMember_15c81179-15f5-441c-8649-0c7a7ff6121c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_58152691-8b6b-4a46-bd12-42ae22c79c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_52bc580b-2496-4825-b25c-6455a082ab13" xlink:to="loc_us-gaap_MediumTermNotesMember_58152691-8b6b-4a46-bd12-42ae22c79c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_ff86166e-d561-4916-bc3d-9d87676a341f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bc4e2769-d9fb-4eb2-98d1-6708f7cad5ad" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_ff86166e-d561-4916-bc3d-9d87676a341f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fc3b50cb-b74f-42e4-af8d-58ee8d15ab1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7d4490fd-88e7-413d-b507-87c25e6403de" xlink:to="loc_us-gaap_DebtInstrumentAxis_fc3b50cb-b74f-42e4-af8d-58ee8d15ab1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fc3b50cb-b74f-42e4-af8d-58ee8d15ab1e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueApril2021Member_4b2cc6b7-fd54-435c-808d-5ea6c691ac0f" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueApril2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueApril2021Member_4b2cc6b7-fd54-435c-808d-5ea6c691ac0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_240308e2-256f-4499-8e22-190d7b293592" xlink:href="gild-20211231.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_240308e2-256f-4499-8e22-190d7b293592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2021Member_cf53adb9-43af-4866-89dd-f22e85a3771d" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueDecember2021Member_cf53adb9-43af-4866-89dd-f22e85a3771d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_4e8a387e-2735-4f66-9ac2-2ff02d84ac8c" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_4e8a387e-2735-4f66-9ac2-2ff02d84ac8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member_125a8434-fd7f-400b-a355-35687621908d" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2022Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member_125a8434-fd7f-400b-a355-35687621908d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member_2fd38492-d1cd-40b7-ab64-ad5be12bd4f5" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member_2fd38492-d1cd-40b7-ab64-ad5be12bd4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_43a61bdc-a046-4e56-91e7-f5019a17619e" xlink:href="gild-20211231.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_43a61bdc-a046-4e56-91e7-f5019a17619e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_c358ed19-0190-440a-a460-3b8845428136" xlink:href="gild-20211231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_c358ed19-0190-440a-a460-3b8845428136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member_7394a345-89d2-4265-a31b-726a936f117e" xlink:href="gild-20211231.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_VariableTermLoanNoteDueOctober2023Member_7394a345-89d2-4265-a31b-726a936f117e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2024Member_0fa9e812-1f7f-49e5-8f07-0307e5160e4b" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinApril2024Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinApril2024Member_0fa9e812-1f7f-49e5-8f07-0307e5160e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member_25b77e60-4afe-4839-bcd3-f43141db29c9" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2025Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member_25b77e60-4afe-4839-bcd3-f43141db29c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member_95b90938-0e60-4636-94b3-19dc81656fb9" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2026Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member_95b90938-0e60-4636-94b3-19dc81656fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member_805a91f9-cc63-4641-9aeb-f092d11aec4c" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2027Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member_805a91f9-cc63-4641-9aeb-f092d11aec4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_ac58d370-f758-421c-91e3-d93963cc640b" xlink:href="gild-20211231.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_ac58d370-f758-421c-91e3-d93963cc640b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_54b1f51d-9132-4839-a0ff-64305fa8944b" xlink:href="gild-20211231.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_54b1f51d-9132-4839-a0ff-64305fa8944b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member_63218670-650b-4dc7-a64a-12ddf70d682a" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2035Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member_63218670-650b-4dc7-a64a-12ddf70d682a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member_d4fa7489-0b92-42d4-a66e-4369e848a4d4" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2036Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member_d4fa7489-0b92-42d4-a66e-4369e848a4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_5bf0416d-ad45-4beb-8360-8befe072a7ab" xlink:href="gild-20211231.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_5bf0416d-ad45-4beb-8360-8befe072a7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2041Member_ebe6310f-e33d-45a1-a26f-37c52e049ede" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueDecember2041Member_ebe6310f-e33d-45a1-a26f-37c52e049ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2044Member_c73c9ddf-fda2-47dd-8952-6af2e16b19ee" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinApril2044Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinApril2044Member_c73c9ddf-fda2-47dd-8952-6af2e16b19ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member_c91e2e99-1e9d-4929-b053-1ffbb7c75418" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2045Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member_c91e2e99-1e9d-4929-b053-1ffbb7c75418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member_9f6bc481-864c-4385-956c-ffff7dd20e4b" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2046Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member_9f6bc481-864c-4385-956c-ffff7dd20e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member_3d0932e9-dcdc-4f9b-aa5b-21734fb44636" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2047Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member_3d0932e9-dcdc-4f9b-aa5b-21734fb44636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_16bbe74c-8ecc-4552-8e62-4ff66b2e6f54" xlink:href="gild-20211231.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_494ef367-1fcc-462a-8f37-d9c3d56df255" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_16bbe74c-8ecc-4552-8e62-4ff66b2e6f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7d4490fd-88e7-413d-b507-87c25e6403de" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_142e854f-3231-4d77-9a50-e4dd78dbdc97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_142e854f-3231-4d77-9a50-e4dd78dbdc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_beb53e40-1021-4c6b-b5c7-307e85596705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_beb53e40-1021-4c6b-b5c7-307e85596705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_84731526-c462-42c0-ba40-f3760984570d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:to="loc_us-gaap_LongTermDebt_84731526-c462-42c0-ba40-f3760984570d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_67ba9f72-5bdd-4b8e-92a1-2b8c59dd96ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:to="loc_us-gaap_LongTermDebtCurrent_67ba9f72-5bdd-4b8e-92a1-2b8c59dd96ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b7d75f7b-43f5-4e25-9226-751f63587dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b448e3ec-ec90-4b5f-9e7a-5f12efe30271" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b7d75f7b-43f5-4e25-9226-751f63587dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DebtandCreditFacilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_779eac45-c1e7-44a1-9721-cc0bb8ea49d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_779eac45-c1e7-44a1-9721-cc0bb8ea49d2" xlink:to="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a7ce754b-1c29-4792-8b47-91974f4850d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:to="loc_us-gaap_DebtInstrumentAxis_a7ce754b-1c29-4792-8b47-91974f4850d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a7ce754b-1c29-4792-8b47-91974f4850d2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueApril2021Member_534c9c17-4dd5-449e-907c-26e1a19c1f4d" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueApril2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_SeniorUnsecuredNotesDueApril2021Member_534c9c17-4dd5-449e-907c-26e1a19c1f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2021Member_23c54159-9482-4641-9ebd-5731366db3b0" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_SeniorUnsecuredNotesDueDecember2021Member_23c54159-9482-4641-9ebd-5731366db3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_36810930-cfc3-4a81-88e4-efb458bb621a" xlink:href="gild-20211231.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_36810930-cfc3-4a81-88e4-efb458bb621a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_3d8aba5c-8eef-4982-b6d8-02141a2c4a98" xlink:href="gild-20211231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_3d8aba5c-8eef-4982-b6d8-02141a2c4a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_b18dd89d-2e67-44ef-a0ae-d81123b200b4" xlink:href="gild-20211231.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_b18dd89d-2e67-44ef-a0ae-d81123b200b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_fd6fa795-cac6-4139-a4d6-5dcd2dd739c6" xlink:href="gild-20211231.xsd#gild_SeniorUnsecuredNotesDueinMarch2022Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_fd6fa795-cac6-4139-a4d6-5dcd2dd739c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_10ab707c-8c4c-434e-9a3b-15bbc1281e48" xlink:href="gild-20211231.xsd#gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_10ab707c-8c4c-434e-9a3b-15bbc1281e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_fa305822-be04-4278-96e8-c50e6ccd86c9" xlink:href="gild-20211231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_fa305822-be04-4278-96e8-c50e6ccd86c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueMay2021Member_8ae60668-2d33-4d81-b822-9574ab133cac" xlink:href="gild-20211231.xsd#gild_CreditFacilityDueMay2021Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_CreditFacilityDueMay2021Member_8ae60668-2d33-4d81-b822-9574ab133cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_c8ba16b5-59fb-41e0-963a-da6bbef03a1c" xlink:href="gild-20211231.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_CreditFacilityDueJune2025Member_c8ba16b5-59fb-41e0-963a-da6bbef03a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member_086101d2-d14e-464b-b27b-124eeddb4fb6" xlink:href="gild-20211231.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_43ae38f3-41f6-464f-8e33-7d68ca8580f9" xlink:to="loc_gild_VariableTermLoanNoteDueOctober2023Member_086101d2-d14e-464b-b27b-124eeddb4fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_231748b8-a16e-47b3-b385-d74cee6e2790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_231748b8-a16e-47b3-b385-d74cee6e2790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_83798fd6-e8a1-4eb8-8d4e-b0cf1b6d72e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_231748b8-a16e-47b3-b385-d74cee6e2790" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_83798fd6-e8a1-4eb8-8d4e-b0cf1b6d72e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_839e8c07-388d-43c1-8df8-a8572697ec33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_83798fd6-e8a1-4eb8-8d4e-b0cf1b6d72e9" xlink:to="loc_us-gaap_SeniorNotesMember_839e8c07-388d-43c1-8df8-a8572697ec33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_7aba82be-3e1b-4266-80d2-55e7f4131d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_83798fd6-e8a1-4eb8-8d4e-b0cf1b6d72e9" xlink:to="loc_us-gaap_MediumTermNotesMember_7aba82be-3e1b-4266-80d2-55e7f4131d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_9fe2ea3d-5b7f-48a7-bc3c-4ded0e8a2494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_83798fd6-e8a1-4eb8-8d4e-b0cf1b6d72e9" xlink:to="loc_us-gaap_LineOfCreditMember_9fe2ea3d-5b7f-48a7-bc3c-4ded0e8a2494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dba785ca-2741-4dbe-a5a1-e154c3fad961" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:to="loc_srt_RangeAxis_dba785ca-2741-4dbe-a5a1-e154c3fad961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_745411e6-9983-4050-b68a-8b14ba7639e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dba785ca-2741-4dbe-a5a1-e154c3fad961" xlink:to="loc_srt_RangeMember_745411e6-9983-4050-b68a-8b14ba7639e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0182f29b-72b3-4500-a081-cc39ace6a8ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_745411e6-9983-4050-b68a-8b14ba7639e8" xlink:to="loc_srt_MinimumMember_0182f29b-72b3-4500-a081-cc39ace6a8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c630478-afc7-4abd-aee9-21bb4fa254a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_745411e6-9983-4050-b68a-8b14ba7639e8" xlink:to="loc_srt_MaximumMember_0c630478-afc7-4abd-aee9-21bb4fa254a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_3091e1cc-b8c4-4808-b9e2-6144eda2a452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:to="loc_us-gaap_CreditFacilityAxis_3091e1cc-b8c4-4808-b9e2-6144eda2a452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_19580bf8-93a5-440a-8a4b-687a861abbab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_3091e1cc-b8c4-4808-b9e2-6144eda2a452" xlink:to="loc_us-gaap_CreditFacilityDomain_19580bf8-93a5-440a-8a4b-687a861abbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8571738b-4ea3-4a41-9393-13b1b88aaaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_19580bf8-93a5-440a-8a4b-687a861abbab" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8571738b-4ea3-4a41-9393-13b1b88aaaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b88a3c5f-3641-4fb9-a997-6e7c17deafd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b88a3c5f-3641-4fb9-a997-6e7c17deafd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ad90a481-77ae-4194-8043-e8c003bc9857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b88a3c5f-3641-4fb9-a997-6e7c17deafd2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ad90a481-77ae-4194-8043-e8c003bc9857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e041f04f-3397-4d6c-9031-508386afbf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ad90a481-77ae-4194-8043-e8c003bc9857" xlink:to="loc_us-gaap_SubsequentEventMember_e041f04f-3397-4d6c-9031-508386afbf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_81a96651-4bbc-481c-9ee2-5909ca038f5b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ab04b3f8-b99d-4735-812a-fd9d6a701211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ab04b3f8-b99d-4735-812a-fd9d6a701211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_c5f729e9-8a2d-4c19-8dda-b621a617525b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_c5f729e9-8a2d-4c19-8dda-b621a617525b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e941376c-cb05-496b-9203-34a3bcea09f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e941376c-cb05-496b-9203-34a3bcea09f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfEarlyRepaymentsOfLongTermDebt_722250ac-6e36-4107-b461-fbe02b098821" xlink:href="gild-20211231.xsd#gild_NumberOfEarlyRepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_gild_NumberOfEarlyRepaymentsOfLongTermDebt_722250ac-6e36-4107-b461-fbe02b098821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_da3cf407-14ed-46b7-8f62-ff1513f790e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_da3cf407-14ed-46b7-8f62-ff1513f790e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_0da13501-d96a-40d4-8b6c-749d1fb4166a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_0da13501-d96a-40d4-8b6c-749d1fb4166a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_e363e269-4607-47b9-acfc-9ff0678d5725" xlink:href="gild-20211231.xsd#gild_DebtInstrumentCallFeaturePeriodBeforeMaturity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_e363e269-4607-47b9-acfc-9ff0678d5725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9ad8cf39-0407-469e-af97-1aa2ee4f1f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9ad8cf39-0407-469e-af97-1aa2ee4f1f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b63b3f85-8f33-4887-9911-29f6dc339468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_LongTermDebt_b63b3f85-8f33-4887-9911-29f6dc339468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_d0067ffb-d833-4e20-a070-64b3b1178a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_DebtInstrumentTerm_d0067ffb-d833-4e20-a070-64b3b1178a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ba6380fd-ea86-483e-9414-8118ee398195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ba6380fd-ea86-483e-9414-8118ee398195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c9d0cfbc-3e02-4f1e-b785-d9aca14e7e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c9d0cfbc-3e02-4f1e-b785-d9aca14e7e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_54c75c7e-e243-4b0b-a1b2-898f42bee4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_LineOfCredit_54c75c7e-e243-4b0b-a1b2-898f42bee4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt_0e677c3c-406d-4e31-ae78-727578c5a7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_36a37967-2fbc-4f53-92b3-85a6f49fc711" xlink:to="loc_us-gaap_InterestExpenseLongTermDebt_0e677c3c-406d-4e31-ae78-727578c5a7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cc99d6fa-7f1d-4627-8822-642693d60a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ea4c4307-bab8-445c-8a13-51e327a42dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cc99d6fa-7f1d-4627-8822-642693d60a94" xlink:to="loc_us-gaap_DebtInstrumentTable_ea4c4307-bab8-445c-8a13-51e327a42dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_77291d31-5f75-4b1d-823e-0ea8aaae08db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ea4c4307-bab8-445c-8a13-51e327a42dbb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_77291d31-5f75-4b1d-823e-0ea8aaae08db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba8c498f-0910-448d-b299-4e532d3a08c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_77291d31-5f75-4b1d-823e-0ea8aaae08db" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba8c498f-0910-448d-b299-4e532d3a08c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_efcfd4d3-1da0-42b9-8ef0-8c13ee47b378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba8c498f-0910-448d-b299-4e532d3a08c0" xlink:to="loc_us-gaap_SeniorNotesMember_efcfd4d3-1da0-42b9-8ef0-8c13ee47b378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ea4c4307-bab8-445c-8a13-51e327a42dbb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ca18a23d-1bf5-443e-804a-02e57717f4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ca18a23d-1bf5-443e-804a-02e57717f4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_98955ce4-8ebc-476e-99e2-e91ba918ae8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_98955ce4-8ebc-476e-99e2-e91ba918ae8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8911c832-619b-409b-bf59-a60d5413d492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8911c832-619b-409b-bf59-a60d5413d492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6a1b223d-09ff-4937-8247-c73ed5bdb117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6a1b223d-09ff-4937-8247-c73ed5bdb117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a332d9a5-e9e5-4cea-a70b-db5f268ee159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a332d9a5-e9e5-4cea-a70b-db5f268ee159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6db925b8-49b2-4f8e-9fe7-9cb6432bd353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6db925b8-49b2-4f8e-9fe7-9cb6432bd353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5f97d897-3d3c-4d4d-a6e4-749aaf0e61fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a21f6caf-0ec5-49ca-ab26-0f77b4b5fca5" xlink:to="loc_us-gaap_LongTermDebt_5f97d897-3d3c-4d4d-a6e4-749aaf0e61fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Leases" xlink:type="simple" xlink:href="gild-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2f4fd3a7-dd7b-4769-af51-416cebe0e420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_c845b17f-3658-4d24-a159-50806f3c09a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f4fd3a7-dd7b-4769-af51-416cebe0e420" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_c845b17f-3658-4d24-a159-50806f3c09a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesTables" xlink:type="simple" xlink:href="gild-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_261b79ba-5a26-4db7-b7dc-9cdba098e8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_fc80f262-cee3-4089-8b73-98fd3e5f1b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_261b79ba-5a26-4db7-b7dc-9cdba098e8b0" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_fc80f262-cee3-4089-8b73-98fd3e5f1b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7885ec09-4d9a-466d-9439-74f6c1956afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_261b79ba-5a26-4db7-b7dc-9cdba098e8b0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7885ec09-4d9a-466d-9439-74f6c1956afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f119005e-01c9-4d68-bd5f-c826a62d778d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_e1cd59cd-a83a-42e3-9245-4693f8a8bd17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f119005e-01c9-4d68-bd5f-c826a62d778d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_e1cd59cd-a83a-42e3-9245-4693f8a8bd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_51629135-d634-41b3-8082-dc55f1b5d5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f119005e-01c9-4d68-bd5f-c826a62d778d" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_51629135-d634-41b3-8082-dc55f1b5d5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_7a64b250-bf70-43df-ad6b-48480df00ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f119005e-01c9-4d68-bd5f-c826a62d778d" xlink:to="loc_us-gaap_OperatingLeaseExpense_7a64b250-bf70-43df-ad6b-48480df00ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#LeasesBalanceSheetLocationDetailDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dd9b6abe-a956-4bfa-8397-ef59fe26537f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6d82aaa3-f51a-46e5-909e-245d96db7b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd9b6abe-a956-4bfa-8397-ef59fe26537f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6d82aaa3-f51a-46e5-909e-245d96db7b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d24eb502-c122-4cb9-bb84-31c8322f1057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd9b6abe-a956-4bfa-8397-ef59fe26537f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d24eb502-c122-4cb9-bb84-31c8322f1057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_988f762d-625f-4a96-88fe-c1be6caa976c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd9b6abe-a956-4bfa-8397-ef59fe26537f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_988f762d-625f-4a96-88fe-c1be6caa976c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_00e5ac35-e691-4e96-848c-a3d699d81ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd9b6abe-a956-4bfa-8397-ef59fe26537f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_00e5ac35-e691-4e96-848c-a3d699d81ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_16e67157-7333-4d1e-9d23-f522917fa9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd9b6abe-a956-4bfa-8397-ef59fe26537f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_16e67157-7333-4d1e-9d23-f522917fa9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1e4d9f6c-13b0-4e11-8134-a23e594bac11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd9b6abe-a956-4bfa-8397-ef59fe26537f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1e4d9f6c-13b0-4e11-8134-a23e594bac11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_084ec711-a472-4668-a773-63036c83dcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd9b6abe-a956-4bfa-8397-ef59fe26537f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_084ec711-a472-4668-a773-63036c83dcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_5af20a92-3b5f-4201-951b-f94253d20ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd9b6abe-a956-4bfa-8397-ef59fe26537f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_5af20a92-3b5f-4201-951b-f94253d20ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#LeasesSupplementalInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_342dfa34-08a6-4b9c-baaa-2f4d9e71abf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_f08b3dca-fea1-4fff-9703-e7e03fd43638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_342dfa34-08a6-4b9c-baaa-2f4d9e71abf2" xlink:to="loc_us-gaap_OperatingLeasePayments_f08b3dca-fea1-4fff-9703-e7e03fd43638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d7ee741f-5cd6-4501-8f5b-a7b87c33d78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_342dfa34-08a6-4b9c-baaa-2f4d9e71abf2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d7ee741f-5cd6-4501-8f5b-a7b87c33d78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2319ca80-9e52-4d61-86f6-e2942a50aec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bedb5a08-78e0-4d64-b68d-ef8c3944746f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2319ca80-9e52-4d61-86f6-e2942a50aec4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bedb5a08-78e0-4d64-b68d-ef8c3944746f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c16d19b9-a4de-42e3-9049-6ea86dad537d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2319ca80-9e52-4d61-86f6-e2942a50aec4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c16d19b9-a4de-42e3-9049-6ea86dad537d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ef93b937-d6c4-490e-86b5-9e47818d5919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2319ca80-9e52-4d61-86f6-e2942a50aec4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ef93b937-d6c4-490e-86b5-9e47818d5919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_43efb90d-5084-4a13-ac4d-7b523bfa9cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2319ca80-9e52-4d61-86f6-e2942a50aec4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_43efb90d-5084-4a13-ac4d-7b523bfa9cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ce2dbb21-94e3-4775-92c8-7a27289ebf33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2319ca80-9e52-4d61-86f6-e2942a50aec4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ce2dbb21-94e3-4775-92c8-7a27289ebf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1ee042a1-79f0-4648-bdeb-2f0acb9a4033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2319ca80-9e52-4d61-86f6-e2942a50aec4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1ee042a1-79f0-4648-bdeb-2f0acb9a4033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c68838a4-1f03-4751-a6ba-99ca81f9b56d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2319ca80-9e52-4d61-86f6-e2942a50aec4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c68838a4-1f03-4751-a6ba-99ca81f9b56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_50ad1f57-39ab-4c09-8b8d-7bd750a0233e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2319ca80-9e52-4d61-86f6-e2942a50aec4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_50ad1f57-39ab-4c09-8b8d-7bd750a0233e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_987a4b33-d810-49ab-95b8-b2e2f64fd75f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2319ca80-9e52-4d61-86f6-e2942a50aec4" xlink:to="loc_us-gaap_OperatingLeaseLiability_987a4b33-d810-49ab-95b8-b2e2f64fd75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" xlink:type="simple" xlink:href="gild-20211231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gild-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8af0130-ebeb-4845-a649-b0b69d1bb925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a6e76b98-1448-48dd-aa0b-62ab64bdd760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8af0130-ebeb-4845-a649-b0b69d1bb925" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a6e76b98-1448-48dd-aa0b-62ab64bdd760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6e4ba11-c594-4fca-8784-2beaf651b48b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_8e3e8fdd-70eb-4570-9346-28150d6a3ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6e4ba11-c594-4fca-8784-2beaf651b48b" xlink:to="loc_us-gaap_OtherCommitmentsTable_8e3e8fdd-70eb-4570-9346-28150d6a3ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_52b16157-1d05-4ebf-836b-ac6f6f183553" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8e3e8fdd-70eb-4570-9346-28150d6a3ab1" xlink:to="loc_srt_LitigationCaseAxis_52b16157-1d05-4ebf-836b-ac6f6f183553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_52b16157-1d05-4ebf-836b-ac6f6f183553" xlink:to="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember_30cc75fa-0bde-447a-9288-b0dd5f64d2f8" xlink:href="gild-20211231.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_ViiVHealthcareCompanyMember_30cc75fa-0bde-447a-9288-b0dd5f64d2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_d9bd3e5a-2d04-4a02-af0d-0db522659beb" xlink:href="gild-20211231.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_d9bd3e5a-2d04-4a02-af0d-0db522659beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember_86e5b56a-1937-4772-81e2-227427cb45be" xlink:href="gild-20211231.xsd#gild_PreExposureProphylaxisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_PreExposureProphylaxisMember_86e5b56a-1937-4772-81e2-227427cb45be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2024ExpirationMember_8e85c7ca-3428-47fc-a042-e4ba82c4a2e0" xlink:href="gild-20211231.xsd#gild_EuropeanPatentClaims2024ExpirationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_EuropeanPatentClaims2024ExpirationMember_8e85c7ca-3428-47fc-a042-e4ba82c4a2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2026ExpirationMember_8d1c7bd5-1425-469a-8520-4ecc1e57c61a" xlink:href="gild-20211231.xsd#gild_EuropeanPatentClaims2026ExpirationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_EuropeanPatentClaims2026ExpirationMember_8d1c7bd5-1425-469a-8520-4ecc1e57c61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember_161aa991-3d26-44a7-8787-84d1389d5ab5" xlink:href="gild-20211231.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_EuropeanPatentClaims2032ExpirationMember_161aa991-3d26-44a7-8787-84d1389d5ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2027ExpirationMember_1b4b684b-af96-4ec3-8b63-31deba103e31" xlink:href="gild-20211231.xsd#gild_EuropeanPatentClaims2027ExpirationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_EuropeanPatentClaims2027ExpirationMember_1b4b684b-af96-4ec3-8b63-31deba103e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember_4f259cd4-4f01-4e9b-8e61-c4a66a4e1d9f" xlink:href="gild-20211231.xsd#gild_ProductLiabilityMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_ProductLiabilityMember_4f259cd4-4f01-4e9b-8e61-c4a66a4e1d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_QuiTamMember_9d6902fa-1ccf-4eee-9a88-b45022128b83" xlink:href="gild-20211231.xsd#gild_QuiTamMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dff4b46e-efb4-432d-8174-b8bec2607ba6" xlink:to="loc_gild_QuiTamMember_9d6902fa-1ccf-4eee-9a88-b45022128b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2356c026-5ffb-4de7-8356-8d573e8d392b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8e3e8fdd-70eb-4570-9346-28150d6a3ab1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2356c026-5ffb-4de7-8356-8d573e8d392b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_05c5867a-1186-48bb-aeff-1c975f561d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2356c026-5ffb-4de7-8356-8d573e8d392b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_05c5867a-1186-48bb-aeff-1c975f561d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ef8c6f09-00ab-4bbc-bf12-7bdc93234782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_05c5867a-1186-48bb-aeff-1c975f561d49" xlink:to="loc_us-gaap_SubsequentEventMember_ef8c6f09-00ab-4bbc-bf12-7bdc93234782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_abb62fb1-caff-4c98-ad2a-d7b82722b146" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8e3e8fdd-70eb-4570-9346-28150d6a3ab1" xlink:to="loc_srt_StatementScenarioAxis_abb62fb1-caff-4c98-ad2a-d7b82722b146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5774abda-3009-4e30-a4ae-4bb6aedbbd3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_abb62fb1-caff-4c98-ad2a-d7b82722b146" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5774abda-3009-4e30-a4ae-4bb6aedbbd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_bed91208-b531-4ad8-87de-abee7ed6942f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_5774abda-3009-4e30-a4ae-4bb6aedbbd3c" xlink:to="loc_srt_ScenarioForecastMember_bed91208-b531-4ad8-87de-abee7ed6942f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8e3e8fdd-70eb-4570-9346-28150d6a3ab1" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_ddb0b0e2-b413-4c3f-96ee-ded4b46a0b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_ddb0b0e2-b413-4c3f-96ee-ded4b46a0b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_c0cabaae-239b-4405-8dcf-78e61d29a353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_c0cabaae-239b-4405-8dcf-78e61d29a353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_22471570-4584-43ff-9c3b-3bab1e00ab69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_22471570-4584-43ff-9c3b-3bab1e00ab69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017_26c52118-ca74-456b-8aa4-d6cb5f19a5e0" xlink:href="gild-20211231.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_JudgmentRoyaltyRateFromOctober2017_26c52118-ca74-456b-8aa4-d6cb5f19a5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales_052a2194-4b1f-4491-b51d-57a887eaf74f" xlink:href="gild-20211231.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_JudgmentEnhancedDamagesOnPastSales_052a2194-4b1f-4491-b51d-57a887eaf74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales_04b29ee5-f29f-466e-ba88-cb0127c3eddb" xlink:href="gild-20211231.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_JudgmentRoyaltyRateOnFutureSales_04b29ee5-f29f-466e-ba88-cb0127c3eddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_e27ec9ca-3bd6-4953-93a6-07948a7a0426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_e27ec9ca-3bd6-4953-93a6-07948a7a0426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyRoyaltyPercentageOnFutureSales_1a4ac0a6-fd6b-4e3c-a56c-062e638c092a" xlink:href="gild-20211231.xsd#gild_LossContingencyRoyaltyPercentageOnFutureSales"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyRoyaltyPercentageOnFutureSales_1a4ac0a6-fd6b-4e3c-a56c-062e638c092a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber_1375a5cf-c4a9-484f-b568-084b1a657015" xlink:href="gild-20211231.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyMaterialTransferAgreementsNumber_1375a5cf-c4a9-484f-b568-084b1a657015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_f10f691c-0702-426d-8ac1-c676b6ee5e13" xlink:href="gild-20211231.xsd#gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_f10f691c-0702-426d-8ac1-c676b6ee5e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_396d7899-9eb1-4a02-93eb-965d4ece0181" xlink:href="gild-20211231.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_396d7899-9eb1-4a02-93eb-965d4ece0181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_bef34116-9080-49c2-a541-f2f1bc246a58" xlink:href="gild-20211231.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_bef34116-9080-49c2-a541-f2f1bc246a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber_4d5f3ac0-a4af-414c-82dd-8267e8f8b3cf" xlink:href="gild-20211231.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyPartiesAppealedNumber_4d5f3ac0-a4af-414c-82dd-8267e8f8b3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesFilingOppositionNumber_f4020d78-f1ce-4598-a89a-e801a2c6b6e1" xlink:href="gild-20211231.xsd#gild_LossContingencyPartiesFilingOppositionNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_gild_LossContingencyPartiesFilingOppositionNumber_f4020d78-f1ce-4598-a89a-e801a2c6b6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_d3dcba1f-1404-484c-b33f-8a9a12b309e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_d3dcba1f-1404-484c-b33f-8a9a12b309e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_3a8ebdc5-f840-4231-bbe5-a475aaa0b9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_3a8ebdc5-f840-4231-bbe5-a475aaa0b9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_1504878f-9f6b-4852-8eb5-a970aef6ccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_1504878f-9f6b-4852-8eb5-a970aef6ccb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_cb8f9e61-6ab1-45f2-a0a0-2721cb2fde07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_cb8f9e61-6ab1-45f2-a0a0-2721cb2fde07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_85681c75-9b89-4f69-8b40-873212e041e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_85681c75-9b89-4f69-8b40-873212e041e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_0b86d188-cc89-4f85-a20e-1ea9d2857762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_0b86d188-cc89-4f85-a20e-1ea9d2857762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_82693326-ba3e-4584-b7ad-27c8fc1ed835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1409e793-9e29-4073-a496-62e223e4cb8b" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_82693326-ba3e-4584-b7ad-27c8fc1ed835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquity" xlink:type="simple" xlink:href="gild-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_84ce2554-9b04-4e3c-9928-d113bc381271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d3af4fad-e03b-4fcd-8db7-8b16152c9db4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_84ce2554-9b04-4e3c-9928-d113bc381271" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d3af4fad-e03b-4fcd-8db7-8b16152c9db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="gild-20211231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_ffd54ea4-6d62-4eea-9005-71db3d7fc6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_4e8a7d91-66ac-4e2d-a21c-a6d9f964d2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ffd54ea4-6d62-4eea-9005-71db3d7fc6a2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_4e8a7d91-66ac-4e2d-a21c-a6d9f964d2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock_9d67423a-2f24-4c91-82f8-512c5606d6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ffd54ea4-6d62-4eea-9005-71db3d7fc6a2" xlink:to="loc_us-gaap_DividendsDeclaredTableTextBlock_9d67423a-2f24-4c91-82f8-512c5606d6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ab70aaba-ef83-4a3f-97b0-36f4f717cd36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ffd54ea4-6d62-4eea-9005-71db3d7fc6a2" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ab70aaba-ef83-4a3f-97b0-36f4f717cd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#StockholdersEquityRepurchasesofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5bdd6f94-a310-404c-91c3-4efdfb3b133d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a21cec8d-c0d5-4240-b765-3ccbe239f934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5bdd6f94-a310-404c-91c3-4efdfb3b133d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a21cec8d-c0d5-4240-b765-3ccbe239f934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_8238799b-302b-4fba-921c-2963d0a8621a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a21cec8d-c0d5-4240-b765-3ccbe239f934" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_8238799b-302b-4fba-921c-2963d0a8621a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f2b8d3fd-53ab-4b08-b7cb-9b244765fe6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_8238799b-302b-4fba-921c-2963d0a8621a" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f2b8d3fd-53ab-4b08-b7cb-9b244765fe6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember_581c015c-ea60-4de8-a74c-76eb200f6495" xlink:href="gild-20211231.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f2b8d3fd-53ab-4b08-b7cb-9b244765fe6c" xlink:to="loc_gild_A2016StockRepurchaseProgramMember_581c015c-ea60-4de8-a74c-76eb200f6495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember_d6355de1-d710-488b-b909-ccdeb62ee161" xlink:href="gild-20211231.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f2b8d3fd-53ab-4b08-b7cb-9b244765fe6c" xlink:to="loc_gild_A2020StockRepurchaseProgramMember_d6355de1-d710-488b-b909-ccdeb62ee161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PubliclyAnnouncedProgramMember_2f9b141c-b20a-412f-a37c-fc5fce786ce1" xlink:href="gild-20211231.xsd#gild_PubliclyAnnouncedProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f2b8d3fd-53ab-4b08-b7cb-9b244765fe6c" xlink:to="loc_gild_PubliclyAnnouncedProgramMember_2f9b141c-b20a-412f-a37c-fc5fce786ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a21cec8d-c0d5-4240-b765-3ccbe239f934" xlink:to="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fdce29a2-1bc0-4f1d-9266-5bad860d9163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fdce29a2-1bc0-4f1d-9266-5bad860d9163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b51c6070-3daa-49ed-99de-8e78382e04fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b51c6070-3daa-49ed-99de-8e78382e04fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5fc9686f-9a28-4b57-9f74-daeb88c30477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5fc9686f-9a28-4b57-9f74-daeb88c30477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_98cc439c-e5ad-472b-abf3-43016d3fe7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_98cc439c-e5ad-472b-abf3-43016d3fe7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_bb45d573-52ba-4ab2-8bc0-0443748b4e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e63e080a-3225-4374-82d5-00cf4a2ee779" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_bb45d573-52ba-4ab2-8bc0-0443748b4e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#StockholdersEquityDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4e154214-6b7e-4495-9d82-2205f56c5b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f1cc34e0-b352-40e7-828a-34e75dc815dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4e154214-6b7e-4495-9d82-2205f56c5b91" xlink:to="loc_us-gaap_SubsequentEventTable_f1cc34e0-b352-40e7-828a-34e75dc815dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_55d6b76e-c6a4-4edb-be0a-3023120cb8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f1cc34e0-b352-40e7-828a-34e75dc815dd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_55d6b76e-c6a4-4edb-be0a-3023120cb8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_efff6c99-3693-4e6d-9fd7-415c6c23a36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_55d6b76e-c6a4-4edb-be0a-3023120cb8c5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_efff6c99-3693-4e6d-9fd7-415c6c23a36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e1690ae1-d95e-4dc3-9f5e-4a4bf242f90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_efff6c99-3693-4e6d-9fd7-415c6c23a36f" xlink:to="loc_us-gaap_SubsequentEventMember_e1690ae1-d95e-4dc3-9f5e-4a4bf242f90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_919188aa-b33d-4aa7-a25a-328499b03974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f1cc34e0-b352-40e7-828a-34e75dc815dd" xlink:to="loc_us-gaap_SubsequentEventLineItems_919188aa-b33d-4aa7-a25a-328499b03974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_9019b0fd-f4b3-472e-b6cb-313acd80f3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_919188aa-b33d-4aa7-a25a-328499b03974" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_9019b0fd-f4b3-472e-b6cb-313acd80f3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_7da12d0f-11da-498e-9e49-09c71b6106b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_919188aa-b33d-4aa7-a25a-328499b03974" xlink:to="loc_us-gaap_DividendsCommonStockCash_7da12d0f-11da-498e-9e49-09c71b6106b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0f756e66-1682-45f2-b40e-6db7abe0de29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6b4eda84-9dcc-4fa9-a775-a9d3ab049b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0f756e66-1682-45f2-b40e-6db7abe0de29" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6b4eda84-9dcc-4fa9-a775-a9d3ab049b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5be415a9-6a9a-4158-a15c-12e1bf769885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0f756e66-1682-45f2-b40e-6db7abe0de29" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5be415a9-6a9a-4158-a15c-12e1bf769885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_89167c1d-ddda-4a3b-8f2a-d89f4efc0c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0548bedb-4578-43cc-a394-9f41bcd698a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_89167c1d-ddda-4a3b-8f2a-d89f4efc0c64" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0548bedb-4578-43cc-a394-9f41bcd698a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_84374d64-dd2a-4788-a65a-ebe9ac8616ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0548bedb-4578-43cc-a394-9f41bcd698a4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_84374d64-dd2a-4788-a65a-ebe9ac8616ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_34cf9bf5-0a47-4d4b-8607-a7865ed98f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_84374d64-dd2a-4788-a65a-ebe9ac8616ed" xlink:to="loc_us-gaap_EquityComponentDomain_34cf9bf5-0a47-4d4b-8607-a7865ed98f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_01c45385-12d8-4c8e-9933-568b03da433d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_34cf9bf5-0a47-4d4b-8607-a7865ed98f5a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_01c45385-12d8-4c8e-9933-568b03da433d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_0c3d3e88-79a1-4c03-806a-b117f513fd81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_01c45385-12d8-4c8e-9933-568b03da433d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_0c3d3e88-79a1-4c03-806a-b117f513fd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cc58afd5-2b84-4e1c-b74f-f82b6d6d5279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_01c45385-12d8-4c8e-9933-568b03da433d" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cc58afd5-2b84-4e1c-b74f-f82b6d6d5279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_aee5f457-e8a6-4a9f-a3e6-6970d4a67664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_01c45385-12d8-4c8e-9933-568b03da433d" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_aee5f457-e8a6-4a9f-a3e6-6970d4a67664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_eb60bcff-f3b6-44b0-b15f-bd7ad549363e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0548bedb-4578-43cc-a394-9f41bcd698a4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_eb60bcff-f3b6-44b0-b15f-bd7ad549363e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_eb60bcff-f3b6-44b0-b15f-bd7ad549363e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8d117f2-e8d1-46e6-ac38-1b6002065d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8d117f2-e8d1-46e6-ac38-1b6002065d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_4e5d3d5e-1787-4aa1-8619-90dda9d32080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_4e5d3d5e-1787-4aa1-8619-90dda9d32080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6cff41a8-034b-4999-9753-c00ed2da6c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6cff41a8-034b-4999-9753-c00ed2da6c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b45dd90b-ff75-47f3-a2a3-d1d8530de015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b45dd90b-ff75-47f3-a2a3-d1d8530de015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_275d36ba-4c3d-4335-8d3e-a0ef14a55474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d47fc8f-3fbb-4b73-8600-8756eaf632ec" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_275d36ba-4c3d-4335-8d3e-a0ef14a55474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefits" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefits"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2d622d2-6766-48cc-b387-06c7ecee203d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d9d239d1-eae9-488e-965b-9fac72cea69a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2d622d2-6766-48cc-b387-06c7ecee203d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d9d239d1-eae9-488e-965b-9fac72cea69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsTables" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7718f842-ac58-4793-b2f4-b6900161fa81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_22734ffa-1911-4c42-9a3c-a540d54d488b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7718f842-ac58-4793-b2f4-b6900161fa81" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_22734ffa-1911-4c42-9a3c-a540d54d488b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_8e67ca90-6942-4137-84d6-361226ebb802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7718f842-ac58-4793-b2f4-b6900161fa81" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_8e67ca90-6942-4137-84d6-361226ebb802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0d889985-a672-445e-bd2a-55f134217991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7718f842-ac58-4793-b2f4-b6900161fa81" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0d889985-a672-445e-bd2a-55f134217991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_6fafddd6-a7c5-4718-a0d4-7f2ecef42552" xlink:href="gild-20211231.xsd#gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7718f842-ac58-4793-b2f4-b6900161fa81" xlink:to="loc_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_6fafddd6-a7c5-4718-a0d4-7f2ecef42552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6259d218-a85f-4d0d-98e1-e64bc005c1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6259d218-a85f-4d0d-98e1-e64bc005c1a0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalFairValueAxis_6c806132-6125-4625-83c3-0c59763ed911" xlink:href="gild-20211231.xsd#gild_TotalFairValueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_gild_TotalFairValueAxis_6c806132-6125-4625-83c3-0c59763ed911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalGrantDateFairValueDomain_1678cfba-ecfb-4c4c-90f7-71258291b445" xlink:href="gild-20211231.xsd#gild_TotalGrantDateFairValueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_TotalFairValueAxis_6c806132-6125-4625-83c3-0c59763ed911" xlink:to="loc_gild_TotalGrantDateFairValueDomain_1678cfba-ecfb-4c4c-90f7-71258291b445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueatGrantDateMember_b001dcc1-10ea-42cc-a6ec-b0df8e93969f" xlink:href="gild-20211231.xsd#gild_FairValueatGrantDateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_TotalGrantDateFairValueDomain_1678cfba-ecfb-4c4c-90f7-71258291b445" xlink:to="loc_gild_FairValueatGrantDateMember_b001dcc1-10ea-42cc-a6ec-b0df8e93969f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueatVestingDateMember_625c8695-0757-446b-a59b-365d17c2c85b" xlink:href="gild-20211231.xsd#gild_FairValueatVestingDateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_TotalGrantDateFairValueDomain_1678cfba-ecfb-4c4c-90f7-71258291b445" xlink:to="loc_gild_FairValueatVestingDateMember_625c8695-0757-446b-a59b-365d17c2c85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_36b034b0-d63f-4910-b2ab-6c9961220b54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_36b034b0-d63f-4910-b2ab-6c9961220b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_394b77fc-b7cd-4f76-b982-2d09ee060b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_36b034b0-d63f-4910-b2ab-6c9961220b54" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_394b77fc-b7cd-4f76-b982-2d09ee060b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_851524b6-cc42-449c-ab90-633ee86ff55f" xlink:href="gild-20211231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_394b77fc-b7cd-4f76-b982-2d09ee060b47" xlink:to="loc_gild_DeferredCompensationPlanMember_851524b6-cc42-449c-ab90-633ee86ff55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a46f327b-6000-42c1-beb4-c5064fa8612d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a46f327b-6000-42c1-beb4-c5064fa8612d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c948ec9-1739-46f7-80ec-a032660ad15e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a46f327b-6000-42c1-beb4-c5064fa8612d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c948ec9-1739-46f7-80ec-a032660ad15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9777444c-2e39-422f-a93b-8ff1fa971dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c948ec9-1739-46f7-80ec-a032660ad15e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9777444c-2e39-422f-a93b-8ff1fa971dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3ce8bd2c-e622-431b-9869-90aab15c7862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_AwardTypeAxis_3ce8bd2c-e622-431b-9869-90aab15c7862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3ce8bd2c-e622-431b-9869-90aab15c7862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d02c0f39-bee9-4614-9313-ce411a247079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d02c0f39-bee9-4614-9313-ce411a247079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6c485832-3b7b-4f28-a20a-896ea5963f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6c485832-3b7b-4f28-a20a-896ea5963f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a24a940e-fec8-4552-873b-dccae2f7df61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:to="loc_us-gaap_PerformanceSharesMember_a24a940e-fec8-4552-873b-dccae2f7df61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RestrictedStockandPerformanceShareAwardsMember_34e1c3b5-7d0c-4f45-ae43-ee8822376396" xlink:href="gild-20211231.xsd#gild_RestrictedStockandPerformanceShareAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:to="loc_gild_RestrictedStockandPerformanceShareAwardsMember_34e1c3b5-7d0c-4f45-ae43-ee8822376396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ecc7ef4c-de57-4751-bc3a-5f5edbb2af27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_734d2782-58dc-4166-9832-5161ed2add07" xlink:to="loc_us-gaap_EmployeeStockMember_ecc7ef4c-de57-4751-bc3a-5f5edbb2af27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c465520-715e-4621-8c1c-80bb9fc2eccf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_srt_RangeAxis_7c465520-715e-4621-8c1c-80bb9fc2eccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9acf32a3-febc-4a18-b5e9-e563ea41d646" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7c465520-715e-4621-8c1c-80bb9fc2eccf" xlink:to="loc_srt_RangeMember_9acf32a3-febc-4a18-b5e9-e563ea41d646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f4d7091e-1f90-40e0-acbe-37700ace2123" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9acf32a3-febc-4a18-b5e9-e563ea41d646" xlink:to="loc_srt_MinimumMember_f4d7091e-1f90-40e0-acbe-37700ace2123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019f43c7-73c7-40d4-9623-1c98a962b894" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9acf32a3-febc-4a18-b5e9-e563ea41d646" xlink:to="loc_srt_MaximumMember_019f43c7-73c7-40d4-9623-1c98a962b894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_69f2dba4-3d00-42b2-aabf-1e7b26c47857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_PlanNameAxis_69f2dba4-3d00-42b2-aabf-1e7b26c47857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_17bb28cd-e2d1-4b2d-9470-c04f1d2c0590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_69f2dba4-3d00-42b2-aabf-1e7b26c47857" xlink:to="loc_us-gaap_PlanNameDomain_17bb28cd-e2d1-4b2d-9470-c04f1d2c0590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2004EquityIncentivePlanMember_40dd0aa0-2983-48b5-bc09-3fa1fbb5be77" xlink:href="gild-20211231.xsd#gild_GileadSciencesInc2004EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_17bb28cd-e2d1-4b2d-9470-c04f1d2c0590" xlink:to="loc_gild_GileadSciencesInc2004EquityIncentivePlanMember_40dd0aa0-2983-48b5-bc09-3fa1fbb5be77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2018EquityIncentivePlanMember_772e638f-487b-4b73-b5be-48e3927f5164" xlink:href="gild-20211231.xsd#gild_GileadSciencesInc2018EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_17bb28cd-e2d1-4b2d-9470-c04f1d2c0590" xlink:to="loc_gild_GileadSciencesInc2018EquityIncentivePlanMember_772e638f-487b-4b73-b5be-48e3927f5164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_ea717ea2-9c7a-4d76-b8df-c1baab78ef55" xlink:href="gild-20211231.xsd#gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_17bb28cd-e2d1-4b2d-9470-c04f1d2c0590" xlink:to="loc_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_ea717ea2-9c7a-4d76-b8df-c1baab78ef55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fffb5ed8-6a71-4b24-9dfc-2bb80819f675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fffb5ed8-6a71-4b24-9dfc-2bb80819f675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0546a7c3-d432-405b-9dcf-ec2f046fc4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fffb5ed8-6a71-4b24-9dfc-2bb80819f675" xlink:to="loc_us-gaap_ClassOfStockDomain_0546a7c3-d432-405b-9dcf-ec2f046fc4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_55516d9a-29ca-446f-a300-2b4a39fbe881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0546a7c3-d432-405b-9dcf-ec2f046fc4fd" xlink:to="loc_us-gaap_CommonStockMember_55516d9a-29ca-446f-a300-2b4a39fbe881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_25b51fd8-a476-4b0b-a148-d9edf8be5914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_25b51fd8-a476-4b0b-a148-d9edf8be5914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8592f4d6-042b-4c4a-9ee9-e3d99d8b61a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_25b51fd8-a476-4b0b-a148-d9edf8be5914" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8592f4d6-042b-4c4a-9ee9-e3d99d8b61a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d14ab2dc-0256-4b5b-82a5-c082d66f6cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8592f4d6-042b-4c4a-9ee9-e3d99d8b61a0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d14ab2dc-0256-4b5b-82a5-c082d66f6cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_87c6a384-a16c-41ef-973e-e434f9702703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d14ab2dc-0256-4b5b-82a5-c082d66f6cea" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_87c6a384-a16c-41ef-973e-e434f9702703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd6d686-f33d-404d-beab-250f366e4618" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a4b0e4af-fcfe-4f48-ad94-0000d6821f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a4b0e4af-fcfe-4f48-ad94-0000d6821f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_94c61b75-56b4-4131-aef7-f10eb4a75b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_94c61b75-56b4-4131-aef7-f10eb4a75b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3ed2b3b2-8200-4f83-8266-4dfa66a5fead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3ed2b3b2-8200-4f83-8266-4dfa66a5fead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_794c8e30-bed5-41e1-8e58-90f10f7f7a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_794c8e30-bed5-41e1-8e58-90f10f7f7a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e45e53f9-2124-42de-9dc4-c59e2ad465a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e45e53f9-2124-42de-9dc4-c59e2ad465a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4c769ec2-d581-4e51-ab6e-4308876513fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4c769ec2-d581-4e51-ab6e-4308876513fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e8caab7c-0958-4943-b9d5-95e54400146d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e8caab7c-0958-4943-b9d5-95e54400146d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_884b390e-e29b-48f2-b9a0-f34ae61b4f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_884b390e-e29b-48f2-b9a0-f34ae61b4f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_441b33fa-4ba8-4941-a935-07b21498d62b" xlink:href="gild-20211231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_441b33fa-4ba8-4941-a935-07b21498d62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8161ce28-d471-4726-8e64-50e6879ca28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8161ce28-d471-4726-8e64-50e6879ca28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_232d21dd-b9c6-4eeb-8e39-4def4c797b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_232d21dd-b9c6-4eeb-8e39-4def4c797b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5beb3df1-461b-40f3-952d-61c8bd0eb072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5beb3df1-461b-40f3-952d-61c8bd0eb072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_dd1eccbd-c84a-4201-9036-85fdae084eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_dd1eccbd-c84a-4201-9036-85fdae084eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d8d84e80-e771-443d-a4bc-963f5dd97507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d8d84e80-e771-443d-a4bc-963f5dd97507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c093bbfb-b07c-4de8-8d5f-e892fec5d3df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c093bbfb-b07c-4de8-8d5f-e892fec5d3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_fc19742e-5f6a-431f-86ee-3c781ff58aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_fc19742e-5f6a-431f-86ee-3c781ff58aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_cd9d68d8-07b7-4c41-91e7-35fb64abd279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7141f421-7278-41fa-926f-035e6a6d3049" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_cd9d68d8-07b7-4c41-91e7-35fb64abd279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefitsStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_454211a2-8c74-49a3-97b3-05825e52ea25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0849a864-5686-4307-a2c3-04ee83af05e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_454211a2-8c74-49a3-97b3-05825e52ea25" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0849a864-5686-4307-a2c3-04ee83af05e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a1f37ea7-797f-406e-889a-9a3aec409f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0849a864-5686-4307-a2c3-04ee83af05e6" xlink:to="loc_us-gaap_AwardTypeAxis_a1f37ea7-797f-406e-889a-9a3aec409f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13c96ae3-8359-47b8-9c0e-4e3e9d3df6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a1f37ea7-797f-406e-889a-9a3aec409f04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13c96ae3-8359-47b8-9c0e-4e3e9d3df6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1325f4ca-37b8-44b9-ab9c-db45e58e6e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13c96ae3-8359-47b8-9c0e-4e3e9d3df6a0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1325f4ca-37b8-44b9-ab9c-db45e58e6e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0849a864-5686-4307-a2c3-04ee83af05e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_617a4105-c3b3-4081-bb80-7dd1ccd2ac40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_617a4105-c3b3-4081-bb80-7dd1ccd2ac40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3cc74ee0-7a8e-4b07-bc0b-e2a20d944507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3cc74ee0-7a8e-4b07-bc0b-e2a20d944507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1bf2c4f6-e833-403b-9465-b3b7700a6042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1bf2c4f6-e833-403b-9465-b3b7700a6042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9413e618-0b9c-45d8-8512-8fb62281a166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9413e618-0b9c-45d8-8512-8fb62281a166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_70a84405-ffcb-409e-ab43-faaa73dd500d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_70a84405-ffcb-409e-ab43-faaa73dd500d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_462a0176-7c40-414f-bb96-201053367bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_ddde7190-d4f4-4fe2-b576-012749063ce6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_462a0176-7c40-414f-bb96-201053367bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b5ecfcee-dbe4-4f58-b32c-3eb33c09e43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b5ecfcee-dbe4-4f58-b32c-3eb33c09e43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e41ea7e8-c472-4d0f-9712-2e9af5bead0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e41ea7e8-c472-4d0f-9712-2e9af5bead0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:href="gild-20211231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be958ec7-270b-41c8-890a-ca8b600da8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be958ec7-270b-41c8-890a-ca8b600da8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20848b4d-a03c-4bd2-a4b4-7fbdb80d8e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20848b4d-a03c-4bd2-a4b4-7fbdb80d8e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cf5a4998-fc58-4e5d-aa34-372c60334594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cf5a4998-fc58-4e5d-aa34-372c60334594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_94015f30-cad6-4199-9490-971994e23cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_94015f30-cad6-4199-9490-971994e23cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6a58ae2e-3bb4-496f-a00a-be6c03c40804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6a58ae2e-3bb4-496f-a00a-be6c03c40804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95fe14d7-5ea0-4c53-86a8-a787db4852b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_c7d8362a-0715-444e-a3b1-64de78afec54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95fe14d7-5ea0-4c53-86a8-a787db4852b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5713f264-9c03-4ccd-bb02-00e145f151a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5713f264-9c03-4ccd-bb02-00e145f151a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_51c9000f-2836-4caf-810b-4da157dfcf64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_51c9000f-2836-4caf-810b-4da157dfcf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e24c02d6-50e2-4751-8b0e-e45adddf8ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e24c02d6-50e2-4751-8b0e-e45adddf8ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_91cc94e3-dd17-4863-8423-f7f3a5530bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e24c02d6-50e2-4751-8b0e-e45adddf8ece" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_91cc94e3-dd17-4863-8423-f7f3a5530bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21bff5c9-ed6b-4f3e-a220-5a6c82b9cf79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e24c02d6-50e2-4751-8b0e-e45adddf8ece" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21bff5c9-ed6b-4f3e-a220-5a6c82b9cf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7158f921-b5b2-48d0-9f8f-43f85b1c0108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e24c02d6-50e2-4751-8b0e-e45adddf8ece" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7158f921-b5b2-48d0-9f8f-43f85b1c0108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_0518ede9-6fb1-4420-a23a-b6cb8deafe32" xlink:href="gild-20211231.xsd#gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dbfe9a6-478b-496e-b88f-d5b0c2523845" xlink:to="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_0518ede9-6fb1-4420-a23a-b6cb8deafe32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2a4afa35-9987-41a5-a79c-c63738adf61c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_0518ede9-6fb1-4420-a23a-b6cb8deafe32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2a4afa35-9987-41a5-a79c-c63738adf61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7b052e42-dd63-49fc-9951-a8b104fd368c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_0518ede9-6fb1-4420-a23a-b6cb8deafe32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7b052e42-dd63-49fc-9951-a8b104fd368c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4615cc75-5e6f-4238-a833-4c96eb48d4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_0518ede9-6fb1-4420-a23a-b6cb8deafe32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4615cc75-5e6f-4238-a833-4c96eb48d4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b3dcb1b-e305-4976-82a3-01805ac65cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4140dc13-de0e-4ba8-8683-8348d1cfcbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b3dcb1b-e305-4976-82a3-01805ac65cf2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4140dc13-de0e-4ba8-8683-8348d1cfcbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_24b8a9b0-5498-43bf-acdd-64859da46887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4140dc13-de0e-4ba8-8683-8348d1cfcbe4" xlink:to="loc_us-gaap_AwardTypeAxis_24b8a9b0-5498-43bf-acdd-64859da46887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf2431b4-d632-4323-b156-415cb192b24e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_24b8a9b0-5498-43bf-acdd-64859da46887" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf2431b4-d632-4323-b156-415cb192b24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_53e19828-098c-4188-9454-bbee0e1c24e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf2431b4-d632-4323-b156-415cb192b24e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_53e19828-098c-4188-9454-bbee0e1c24e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f4fb3898-b77e-40f8-a9f9-af55cb752f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf2431b4-d632-4323-b156-415cb192b24e" xlink:to="loc_us-gaap_PerformanceSharesMember_f4fb3898-b77e-40f8-a9f9-af55cb752f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e64cc8a-5853-43dd-873b-5097b09766ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4140dc13-de0e-4ba8-8683-8348d1cfcbe4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e64cc8a-5853-43dd-873b-5097b09766ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e64cc8a-5853-43dd-873b-5097b09766ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40f7bdc0-7303-40da-b41e-8357dcfb2b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40f7bdc0-7303-40da-b41e-8357dcfb2b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0e0cfccd-35d8-49be-b5f0-78bb9c30f152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0e0cfccd-35d8-49be-b5f0-78bb9c30f152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e0f3e983-833c-41c9-9b45-f80a2da54620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e0f3e983-833c-41c9-9b45-f80a2da54620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5d1acbce-fbcd-4566-9f92-6de897d56275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5d1acbce-fbcd-4566-9f92-6de897d56275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5dcf121-509c-4f40-aa29-5dc3779ba634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94579640-f526-4d92-ab90-519b51fdaa94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5dcf121-509c-4f40-aa29-5dc3779ba634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:href="gild-20211231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e64cc8a-5853-43dd-873b-5097b09766ed" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fed18151-ece5-49d7-80f9-d44da9980ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fed18151-ece5-49d7-80f9-d44da9980ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78451bcf-287f-4451-97c1-2c8dcd17bb74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78451bcf-287f-4451-97c1-2c8dcd17bb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_72998906-a2c0-43d6-89c2-76720e0c307f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_72998906-a2c0-43d6-89c2-76720e0c307f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9cdf4698-7664-42ce-b228-08bafc7a7262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9cdf4698-7664-42ce-b228-08bafc7a7262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08ee6f26-f3c9-45e3-a5b5-cf99bfbbbdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_d6e25505-8eff-41f5-a282-02515ef2d575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08ee6f26-f3c9-45e3-a5b5-cf99bfbbbdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefitsSummaryofStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_feddb68d-7016-4e22-a3d7-49e8b34b5766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a0d3eca5-2167-446c-b5ad-d85c668788ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_feddb68d-7016-4e22-a3d7-49e8b34b5766" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a0d3eca5-2167-446c-b5ad-d85c668788ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b1c0c4ef-7653-496a-8525-0e8f2e0f4994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a0d3eca5-2167-446c-b5ad-d85c668788ec" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b1c0c4ef-7653-496a-8525-0e8f2e0f4994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4612e89f-3824-4cf1-aa17-2041a115f46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b1c0c4ef-7653-496a-8525-0e8f2e0f4994" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4612e89f-3824-4cf1-aa17-2041a115f46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_e09c20a2-8835-4c23-b558-6521bfa660db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4612e89f-3824-4cf1-aa17-2041a115f46e" xlink:to="loc_us-gaap_CostOfSalesMember_e09c20a2-8835-4c23-b558-6521bfa660db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8ba5238c-5486-43d0-9614-f64d39e867ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4612e89f-3824-4cf1-aa17-2041a115f46e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8ba5238c-5486-43d0-9614-f64d39e867ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a8f11fd7-6a30-49b5-a099-b025e7d0c726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4612e89f-3824-4cf1-aa17-2041a115f46e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a8f11fd7-6a30-49b5-a099-b025e7d0c726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c483a2a1-e3aa-478f-b1d7-c4abd0da6594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a0d3eca5-2167-446c-b5ad-d85c668788ec" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c483a2a1-e3aa-478f-b1d7-c4abd0da6594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c7aa111f-8546-4ac5-8871-e1cd9d76ca1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c483a2a1-e3aa-478f-b1d7-c4abd0da6594" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c7aa111f-8546-4ac5-8871-e1cd9d76ca1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_1c5b977f-5895-41ef-9d75-49b06137f5ca" xlink:href="gild-20211231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c7aa111f-8546-4ac5-8871-e1cd9d76ca1a" xlink:to="loc_gild_ImmunomedicsIncMember_1c5b977f-5895-41ef-9d75-49b06137f5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_8fc6becf-c229-4923-b763-3b7f72c0a72c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a0d3eca5-2167-446c-b5ad-d85c668788ec" xlink:to="loc_us-gaap_AssetAcquisitionAxis_8fc6becf-c229-4923-b763-3b7f72c0a72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_21d501a5-81f7-43bc-9608-9916b86c6219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_8fc6becf-c229-4923-b763-3b7f72c0a72c" xlink:to="loc_us-gaap_AssetAcquisitionDomain_21d501a5-81f7-43bc-9608-9916b86c6219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_6e214cfd-a38b-4f59-ae33-3b8f1074b297" xlink:href="gild-20211231.xsd#gild_FortySevenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_21d501a5-81f7-43bc-9608-9916b86c6219" xlink:to="loc_gild_FortySevenIncMember_6e214cfd-a38b-4f59-ae33-3b8f1074b297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a0d3eca5-2167-446c-b5ad-d85c668788ec" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_75f6d50c-66bf-47d2-b350-f9226095b8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_75f6d50c-66bf-47d2-b350-f9226095b8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ecfbd12c-d81d-4419-b7e1-73e3275d8f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ecfbd12c-d81d-4419-b7e1-73e3275d8f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a5bc77ac-f385-46fc-8b7c-cbe19197ad20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a5bc77ac-f385-46fc-8b7c-cbe19197ad20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4db7906c-5894-407d-8aa2-b2e0ea3ae35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_ShareBasedCompensation_4db7906c-5894-407d-8aa2-b2e0ea3ae35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c7e61b10-1e5e-4d6b-8511-954e1804c4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c7e61b10-1e5e-4d6b-8511-954e1804c4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_c13ebcf6-e690-414e-a315-bf310a6a7e45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1690ccdb-f6ac-47ea-b406-9f226d9517f8" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_c13ebcf6-e690-414e-a315-bf310a6a7e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32b23a86-a23c-4fbc-9db2-8c45e12a31e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5cbc603-4b6b-4143-9537-e2ddfd103e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32b23a86-a23c-4fbc-9db2-8c45e12a31e6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5cbc603-4b6b-4143-9537-e2ddfd103e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8e5e2ace-5c06-4771-83a8-ab1eb2712d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5cbc603-4b6b-4143-9537-e2ddfd103e73" xlink:to="loc_us-gaap_AwardTypeAxis_8e5e2ace-5c06-4771-83a8-ab1eb2712d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe80bfe5-1fb1-4e1d-8e8c-3c7627000453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8e5e2ace-5c06-4771-83a8-ab1eb2712d0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe80bfe5-1fb1-4e1d-8e8c-3c7627000453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5711cc9-345d-48c3-9f7f-51057487420f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe80bfe5-1fb1-4e1d-8e8c-3c7627000453" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5711cc9-345d-48c3-9f7f-51057487420f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4bd5ac54-d445-46f5-85d2-ee7a032ced4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe80bfe5-1fb1-4e1d-8e8c-3c7627000453" xlink:to="loc_us-gaap_EmployeeStockMember_4bd5ac54-d445-46f5-85d2-ee7a032ced4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d119baaa-06ff-4a21-a6fc-538b955ca59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a5cbc603-4b6b-4143-9537-e2ddfd103e73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d119baaa-06ff-4a21-a6fc-538b955ca59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6ee86b2b-ccf3-4105-9985-9019c3a3b61c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d119baaa-06ff-4a21-a6fc-538b955ca59a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6ee86b2b-ccf3-4105-9985-9019c3a3b61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1ab3f10-d6f5-42de-a382-9eea6e1b6e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d119baaa-06ff-4a21-a6fc-538b955ca59a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1ab3f10-d6f5-42de-a382-9eea6e1b6e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_68114e9e-0249-4717-95ff-a2d28bd4ade2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d119baaa-06ff-4a21-a6fc-538b955ca59a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_68114e9e-0249-4717-95ff-a2d28bd4ade2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ef5c677-2840-40ba-8b38-4c7981eff8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d119baaa-06ff-4a21-a6fc-538b955ca59a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ef5c677-2840-40ba-8b38-4c7981eff8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders" xlink:type="simple" xlink:href="gild-20211231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholders"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7f659477-a9f4-4941-919d-18d017f17a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_136bc638-763d-45d2-8aac-f925a130cc00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7f659477-a9f4-4941-919d-18d017f17a64" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_136bc638-763d-45d2-8aac-f925a130cc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables" xlink:type="simple" xlink:href="gild-20211231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_34d9eee5-0696-4de2-95cf-6f91bb8cc935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d7445905-28ee-4dd2-90fb-abd8913c6875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_34d9eee5-0696-4de2-95cf-6f91bb8cc935" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d7445905-28ee-4dd2-90fb-abd8913c6875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ec35a92a-1024-4f6b-84b5-bbc688de113a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_313eb121-b2bd-4f89-b834-490c40813bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ec35a92a-1024-4f6b-84b5-bbc688de113a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_313eb121-b2bd-4f89-b834-490c40813bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_29a184ad-6038-4926-b2f6-3e7ba7fff019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9cb19bee-14f6-4df3-a665-65ac4ad1477d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_29a184ad-6038-4926-b2f6-3e7ba7fff019" xlink:to="loc_us-gaap_NetIncomeLoss_9cb19bee-14f6-4df3-a665-65ac4ad1477d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_504ca6f9-49a2-42b0-84ab-5ac16e66ee58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_29a184ad-6038-4926-b2f6-3e7ba7fff019" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_504ca6f9-49a2-42b0-84ab-5ac16e66ee58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_66b2032c-9fd6-49c7-a727-4634e606964e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_29a184ad-6038-4926-b2f6-3e7ba7fff019" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_66b2032c-9fd6-49c7-a727-4634e606964e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2bfe98e6-462e-4840-9e94-8cdc07d5f931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_29a184ad-6038-4926-b2f6-3e7ba7fff019" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2bfe98e6-462e-4840-9e94-8cdc07d5f931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_30a82e57-c531-4406-9d80-51fd4058a86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_29a184ad-6038-4926-b2f6-3e7ba7fff019" xlink:to="loc_us-gaap_EarningsPerShareBasic_30a82e57-c531-4406-9d80-51fd4058a86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b9271f6d-e9fb-40de-9d82-8317207dcecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_29a184ad-6038-4926-b2f6-3e7ba7fff019" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b9271f6d-e9fb-40de-9d82-8317207dcecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxes" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0f56a34b-1aa1-4dd0-b873-3439cf62d76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f8960842-d5e4-4d4b-81b9-6773092eb231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0f56a34b-1aa1-4dd0-b873-3439cf62d76d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f8960842-d5e4-4d4b-81b9-6773092eb231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3f22b29e-3a82-4c78-a723-497be854cadc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_5d216f0a-6679-4ce9-addf-7c013af88fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3f22b29e-3a82-4c78-a723-497be854cadc" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_5d216f0a-6679-4ce9-addf-7c013af88fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2586cc30-2010-40e8-824c-9aedf9764664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3f22b29e-3a82-4c78-a723-497be854cadc" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2586cc30-2010-40e8-824c-9aedf9764664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_278b4199-0908-464d-9134-c14a748b9a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3f22b29e-3a82-4c78-a723-497be854cadc" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_278b4199-0908-464d-9134-c14a748b9a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2f2d300d-fada-46bf-8408-596e7bef7f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3f22b29e-3a82-4c78-a723-497be854cadc" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2f2d300d-fada-46bf-8408-596e7bef7f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_74fb9bb2-6889-41f8-a81c-c8f4aeea1b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3f22b29e-3a82-4c78-a723-497be854cadc" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_74fb9bb2-6889-41f8-a81c-c8f4aeea1b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8b42d530-1078-4d0e-ad30-d649fca8265b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4a17054c-4597-40a5-9ffa-795546044dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8b42d530-1078-4d0e-ad30-d649fca8265b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4a17054c-4597-40a5-9ffa-795546044dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_67b59828-57fb-4123-a6b2-779961ed178f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8b42d530-1078-4d0e-ad30-d649fca8265b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_67b59828-57fb-4123-a6b2-779961ed178f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8b8b7935-9c02-4018-9b86-076504d98123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8b42d530-1078-4d0e-ad30-d649fca8265b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8b8b7935-9c02-4018-9b86-076504d98123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e5a7981d-4b9e-4e96-81ff-c75a9d0a9737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_972a8565-61a4-42ce-8248-e5224b510918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5a7981d-4b9e-4e96-81ff-c75a9d0a9737" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_972a8565-61a4-42ce-8248-e5224b510918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_8ad6f5b9-35b0-4db8-980a-2a4481729b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_972a8565-61a4-42ce-8248-e5224b510918" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_8ad6f5b9-35b0-4db8-980a-2a4481729b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4c49eced-9e92-494a-9300-e75a201ee052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_972a8565-61a4-42ce-8248-e5224b510918" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4c49eced-9e92-494a-9300-e75a201ee052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_7db100b6-0a4b-46b6-abd5-54dc158e6d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_972a8565-61a4-42ce-8248-e5224b510918" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_7db100b6-0a4b-46b6-abd5-54dc158e6d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_f0af5c4d-eb45-4ebb-8988-ed3c3ac93b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5a7981d-4b9e-4e96-81ff-c75a9d0a9737" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_f0af5c4d-eb45-4ebb-8988-ed3c3ac93b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_377de1c4-231e-4279-9555-7916d3dac757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_f0af5c4d-eb45-4ebb-8988-ed3c3ac93b48" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_377de1c4-231e-4279-9555-7916d3dac757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e7a9b324-370b-4eae-a0eb-cdb9a1d34c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_f0af5c4d-eb45-4ebb-8988-ed3c3ac93b48" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e7a9b324-370b-4eae-a0eb-cdb9a1d34c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_e13059d6-6d36-406b-ac63-1ab39b8fe1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_f0af5c4d-eb45-4ebb-8988-ed3c3ac93b48" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_e13059d6-6d36-406b-ac63-1ab39b8fe1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_81bba3c6-5265-4f9d-97dc-9a7faa7f31a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5a7981d-4b9e-4e96-81ff-c75a9d0a9737" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_81bba3c6-5265-4f9d-97dc-9a7faa7f31a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cf287e75-1982-4ab4-849e-6dc2c14fa851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_81bba3c6-5265-4f9d-97dc-9a7faa7f31a7" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cf287e75-1982-4ab4-849e-6dc2c14fa851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cc6df783-4ff8-4320-92fc-79d4e6ea20ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_81bba3c6-5265-4f9d-97dc-9a7faa7f31a7" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cc6df783-4ff8-4320-92fc-79d4e6ea20ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_78cf2cd5-c72b-4fe9-9b67-1b20fbd0d203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_81bba3c6-5265-4f9d-97dc-9a7faa7f31a7" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_78cf2cd5-c72b-4fe9-9b67-1b20fbd0d203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_79755a7a-fb09-41e3-a028-3c5a5558e96b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5a7981d-4b9e-4e96-81ff-c75a9d0a9737" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_79755a7a-fb09-41e3-a028-3c5a5558e96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ef3be713-b0b8-4504-bfae-7d3fa6af2572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ef3be713-b0b8-4504-bfae-7d3fa6af2572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d2debff4-5379-48ab-9634-696bb86855d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d2debff4-5379-48ab-9634-696bb86855d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cd3d6e66-fdb8-4886-9706-66ff3d3aeca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cd3d6e66-fdb8-4886-9706-66ff3d3aeca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_d33ee0ed-2be8-46af-9422-7b5793b7ac88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_d33ee0ed-2be8-46af-9422-7b5793b7ac88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_2c828609-1c39-4ea7-be7b-cfdac0b20794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_2c828609-1c39-4ea7-be7b-cfdac0b20794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_b45179d2-2431-41aa-ab67-9bc10223fe29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_b45179d2-2431-41aa-ab67-9bc10223fe29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_d9a6af72-b953-4a96-955e-455342c67af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_d9a6af72-b953-4a96-955e-455342c67af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_2f0ce76e-6516-4a20-ad40-28824f8e482b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_2f0ce76e-6516-4a20-ad40-28824f8e482b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_9a93646e-c9fa-49eb-8ec7-85665fd61f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_9a93646e-c9fa-49eb-8ec7-85665fd61f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_99d4fc33-d362-497a-b6c6-a879ab95d545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_99d4fc33-d362-497a-b6c6-a879ab95d545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_8952a5a4-b16f-4d46-8b9a-4fb93e44ccac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_8952a5a4-b16f-4d46-8b9a-4fb93e44ccac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6cd90bbc-df31-42e3-9a01-1bfc6ebf8447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6cd90bbc-df31-42e3-9a01-1bfc6ebf8447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_26056af4-3cd9-40a9-a614-1e16ee5899ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_11840715-359a-4abc-8cca-c29db009b1bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_26056af4-3cd9-40a9-a614-1e16ee5899ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c90734c7-b179-44db-8aac-b4d1f36cfb64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c90734c7-b179-44db-8aac-b4d1f36cfb64" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e970cee8-0cb9-4da0-990a-605441c90ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e970cee8-0cb9-4da0-990a-605441c90ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8d07b15e-6b7c-4a98-a163-c487bec502e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8d07b15e-6b7c-4a98-a163-c487bec502e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_d97d2d2e-aed8-4cb7-8c57-8bf5e40772b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_d97d2d2e-aed8-4cb7-8c57-8bf5e40772b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b4dc7ccc-eb00-46a4-aa1e-c945753c3c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b4dc7ccc-eb00-46a4-aa1e-c945753c3c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_1dd846eb-cd25-4271-99e4-26f7a05830f2" xlink:href="gild-20211231.xsd#gild_DeferredTaxAssetsUpfrontAndMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:to="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_1dd846eb-cd25-4271-99e4-26f7a05830f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3b4dc003-fcf0-4c40-9ac9-e1eb02bfc0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3b4dc003-fcf0-4c40-9ac9-e1eb02bfc0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_c46ffb66-1a0c-4ac0-ab47-9987a99828df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_c46ffb66-1a0c-4ac0-ab47-9987a99828df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_1c8d9aaa-6b69-4ec7-b714-df0f8d94d9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_1c8d9aaa-6b69-4ec7-b714-df0f8d94d9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_7ae57cd4-3a97-4b57-8686-7522eaec3ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_7ae57cd4-3a97-4b57-8686-7522eaec3ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0618c6b2-8682-4e73-acc0-3caa08e25e71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0618c6b2-8682-4e73-acc0-3caa08e25e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_52cfd9f9-35ff-4998-acaf-9bbf1dc4a15d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_52cfd9f9-35ff-4998-acaf-9bbf1dc4a15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c88be168-b3cb-441c-a82e-adb12702823b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b01b6630-b584-4f88-bccb-8b34fd86a8cb" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c88be168-b3cb-441c-a82e-adb12702823b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fb13aed6-ae62-4164-aab1-9a853ea229f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c90734c7-b179-44db-8aac-b4d1f36cfb64" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fb13aed6-ae62-4164-aab1-9a853ea229f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ace4d998-e8c3-44ac-b338-8fcf6cb5d8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fb13aed6-ae62-4164-aab1-9a853ea229f9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ace4d998-e8c3-44ac-b338-8fcf6cb5d8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1b449d62-a4f7-4487-bffe-0c7a5e625908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fb13aed6-ae62-4164-aab1-9a853ea229f9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1b449d62-a4f7-4487-bffe-0c7a5e625908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_4b270b8c-3e86-4100-8304-e2abd487b1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fb13aed6-ae62-4164-aab1-9a853ea229f9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_4b270b8c-3e86-4100-8304-e2abd487b1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_fa05a887-3551-4c22-b56e-d9c2862314fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fb13aed6-ae62-4164-aab1-9a853ea229f9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_fa05a887-3551-4c22-b56e-d9c2862314fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1700e746-4077-4687-80de-db467131e108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c90734c7-b179-44db-8aac-b4d1f36cfb64" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1700e746-4077-4687-80de-db467131e108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_40e1e2b2-affe-41a9-a21f-3ff9e926f617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_954b49e1-ec86-4be2-9cb6-ca1eb415dc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40e1e2b2-affe-41a9-a21f-3ff9e926f617" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_954b49e1-ec86-4be2-9cb6-ca1eb415dc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e2a94b81-caf7-4178-acb5-f98afc325111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_954b49e1-ec86-4be2-9cb6-ca1eb415dc43" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e2a94b81-caf7-4178-acb5-f98afc325111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_38fd1a11-fb97-4096-a018-55be9c597cd3" xlink:href="gild-20211231.xsd#gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_954b49e1-ec86-4be2-9cb6-ca1eb415dc43" xlink:to="loc_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_38fd1a11-fb97-4096-a018-55be9c597cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f581156f-f701-40a9-8f6e-f4eca67744d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_38fd1a11-fb97-4096-a018-55be9c597cd3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f581156f-f701-40a9-8f6e-f4eca67744d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_f89ab140-fe4a-4c02-9272-759fd9b0665a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_38fd1a11-fb97-4096-a018-55be9c597cd3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_f89ab140-fe4a-4c02-9272-759fd9b0665a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_62c1c646-0338-4742-9307-7fe8ea3ceff5" xlink:href="gild-20211231.xsd#gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_954b49e1-ec86-4be2-9cb6-ca1eb415dc43" xlink:to="loc_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_62c1c646-0338-4742-9307-7fe8ea3ceff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5c43382e-31e9-468c-b8c4-2b08f5e033c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_62c1c646-0338-4742-9307-7fe8ea3ceff5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5c43382e-31e9-468c-b8c4-2b08f5e033c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_4ff8e613-ef16-41d0-8565-0babf7f5c404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_62c1c646-0338-4742-9307-7fe8ea3ceff5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_4ff8e613-ef16-41d0-8565-0babf7f5c404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_84056457-9e07-4fc1-b23e-198bae84f9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_954b49e1-ec86-4be2-9cb6-ca1eb415dc43" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_84056457-9e07-4fc1-b23e-198bae84f9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_fcf114dd-0aea-4bea-80fd-a6002452078b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_954b49e1-ec86-4be2-9cb6-ca1eb415dc43" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_fcf114dd-0aea-4bea-80fd-a6002452078b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3bedfb6f-aef2-4ae1-aa17-32ce9a4e971b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_954b49e1-ec86-4be2-9cb6-ca1eb415dc43" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3bedfb6f-aef2-4ae1-aa17-32ce9a4e971b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="gild-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_68c3994e-37a3-4be3-a672-e53582743049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_44179258-169c-4e71-a750-069516e4a800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_68c3994e-37a3-4be3-a672-e53582743049" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_44179258-169c-4e71-a750-069516e4a800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_e4bef188-970c-42a2-b822-bb84390160a2" xlink:href="gild-20211231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_44179258-169c-4e71-a750-069516e4a800" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_e4bef188-970c-42a2-b822-bb84390160a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_5a413c71-7a5e-40cc-84d1-945a71050d05" xlink:href="gild-20211231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_e4bef188-970c-42a2-b822-bb84390160a2" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_5a413c71-7a5e-40cc-84d1-945a71050d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetTransferMember_4af77d59-e096-408b-ae22-cdceb3cf57d7" xlink:href="gild-20211231.xsd#gild_IntangibleAssetTransferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_5a413c71-7a5e-40cc-84d1-945a71050d05" xlink:to="loc_gild_IntangibleAssetTransferMember_4af77d59-e096-408b-ae22-cdceb3cf57d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_32947952-126b-4e3f-9f69-5fde3c6fe157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_44179258-169c-4e71-a750-069516e4a800" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_32947952-126b-4e3f-9f69-5fde3c6fe157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_259239b8-4929-4dd6-b67b-416f02f3e805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_32947952-126b-4e3f-9f69-5fde3c6fe157" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_259239b8-4929-4dd6-b67b-416f02f3e805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_aaaf6551-ed76-4c5a-bb83-de0ab545cfca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_259239b8-4929-4dd6-b67b-416f02f3e805" xlink:to="loc_us-gaap_DomesticCountryMember_aaaf6551-ed76-4c5a-bb83-de0ab545cfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f8ec6128-2b36-468c-b31a-ce4f7159c581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_259239b8-4929-4dd6-b67b-416f02f3e805" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f8ec6128-2b36-468c-b31a-ce4f7159c581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_44179258-169c-4e71-a750-069516e4a800" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0a297f49-e7db-4ad9-9808-4a4d1f65d1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0a297f49-e7db-4ad9-9808-4a4d1f65d1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4a7ac762-8458-4d0f-bdfc-8ac8b02d7c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4a7ac762-8458-4d0f-bdfc-8ac8b02d7c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_52b5048e-a55c-49c4-bdff-df24ef3e3125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_52b5048e-a55c-49c4-bdff-df24ef3e3125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_aeb28c55-c943-49aa-9afa-9f4c7a825a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_aeb28c55-c943-49aa-9afa-9f4c7a825a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_84d68984-e367-4599-8fe9-9a115cecd243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_84d68984-e367-4599-8fe9-9a115cecd243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_92b2e686-eb15-4750-982e-6aba3f4f7df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_92b2e686-eb15-4750-982e-6aba3f4f7df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_dc9073ec-2cd9-4dda-9bd4-559c2b18ac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_dc9073ec-2cd9-4dda-9bd4-559c2b18ac8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_5eb22eab-bc82-4dbe-b5e6-27620ca09138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_5eb22eab-bc82-4dbe-b5e6-27620ca09138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_92848938-ebe4-4b7a-bcf7-c4e5023061f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_92848938-ebe4-4b7a-bcf7-c4e5023061f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_4077f62b-8f44-4823-bf30-0103b81c6bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_4077f62b-8f44-4823-bf30-0103b81c6bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_d57b3fce-e513-40af-a96d-25272f2093e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f0eeef2e-0db3-4219-a7cf-f71d302f68b3" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_d57b3fce-e513-40af-a96d-25272f2093e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gild-20211231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gild-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO;B!+<G5E
M9V5R   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,W,   DI(
M @    ,W,   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( H8#EP,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M (3FH?\ QBC_ (3S2/\ GS\0?^$YJ'_QB@#I**YO_A/-(_Y\_$'_ (3FH?\
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MYI'_ #Y^(/\ PG-0_P#C% '245S?_">:1_SY^(/_  G-0_\ C%'_  GFD?\
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M(_Y\_$'_ (3FH?\ QB@#I**YO_A/-(_Y\_$'_A.:A_\ &*/^$\TC_GS\0?\
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M\0?^$YJ'_P 8H Z2BN;_ .$\TC_GS\0?^$YJ'_QBC_A/-(_Y\_$'_A.:A_\
M&* .DHKF_P#A/-(_Y\_$'_A.:A_\8H_X3S2/^?/Q!_X3FH?_ !B@#I**YO\
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MB@ HHHH YOQ1_P C%X,_[#4G_IOO*Z2N;\4?\C%X,_[#4G_IOO*Z2@ HHHH
M**** "BBB@ KF_ ?_(NW7_8:U7_TX7%=)7-^ _\ D7;K_L-:K_Z<+B@#I***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;\4?\C%X,
M_P"PU)_Z;[RNDKF_%'_(Q>#/^PU)_P"F^\KI* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#F_ ?_(NW7_8:U7_TX7%=)7-^ _\
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MRNDKF_%'_(Q>#/\ L-2?^F^\KI* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#F_ ?\ R+MU_P!AK5?_ $X7%=)7-^ _^1=NO^PU
MJO\ Z<+BNDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*YOQ1_R,7@S_ +#4G_IOO*Z2N;\4?\C%X,_[#4G_ *;[R@#I**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;\!_\B[=?]AK5?_3A
M<5TE<WX#_P"1=NO^PUJO_IPN* .DHHHH **** "BBB@ HHHH **** "BBB@
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M"Q"I?3JJY*] J@ =@ .U>B5S?@/_ )%VZ_[#6J_^G"XI '_"N/!'_0F^'_\
MP5P?_$T?\*X\$?\ 0F^'_P#P5P?_ !-=)10!S?\ PKCP1_T)OA__ ,%<'_Q-
M'_"N/!'_ $)OA_\ \%<'_P 37244 <W_ ,*X\$?]";X?_P#!7!_\31_PKCP1
M_P!";X?_ /!7!_\ $UTE% '-_P#"N/!'_0F^'_\ P5P?_$T?\*X\$?\ 0F^'
M_P#P5P?_ !-=)10!S?\ PKCP1_T)OA__ ,%<'_Q-'_"N/!'_ $)OA_\ \%<'
M_P 37244 <W_ ,*X\$?]";X?_P#!7!_\31_PKCP1_P!";X?_ /!7!_\ $UTE
M% '-_P#"N/!'_0F^'_\ P5P?_$T?\*X\$?\ 0F^'_P#P5P?_ !-=)10!S?\
MPKCP1_T)OA__ ,%<'_Q-'_"N/!'_ $)OA_\ \%<'_P 37244 <W_ ,*X\$?]
M";X?_P#!7!_\31_PKCP1_P!";X?_ /!7!_\ $UTE% '-_P#"N/!'_0F^'_\
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M0!S?_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q-=)10!YWX+\
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M'_0F^'__  5P?_$T?\*X\$?]";X?_P#!7!_\37244 <W_P *X\$?]";X?_\
M!7!_\31_PKCP1_T)OA__ ,%<'_Q-=)10!S?_  KCP1_T)OA__P %<'_Q-'_"
MN/!'_0F^'_\ P5P?_$UTE% '-_\ "N/!'_0F^'__  5P?_$US_@OP#X/NM!N
M9+KPGH<SKJVI1AI--A8A4OIU5<E>@50 .P ':O1*YOP'_P B[=?]AK5?_3A<
M4 '_  KCP1_T)OA__P %<'_Q-'_"N/!'_0F^'_\ P5P?_$UTE% '-_\ "N/!
M'_0F^'__  5P?_$T?\*X\$?]";X?_P#!7!_\37244 <W_P *X\$?]";X?_\
M!7!_\31_PKCP1_T)OA__ ,%<'_Q-=)10!S?_  KCP1_T)OA__P %<'_Q-'_"
MN/!'_0F^'_\ P5P?_$UTE% '-_\ "N/!'_0F^'__  5P?_$T?\*X\$?]";X?
M_P#!7!_\37244 <W_P *X\$?]";X?_\ !7!_\31_PKCP1_T)OA__ ,%<'_Q-
M=)10!S?_  KCP1_T)OA__P %<'_Q-'_"N/!'_0F^'_\ P5P?_$UTE% '-_\
M"N/!'_0F^'__  5P?_$T?\*X\$?]";X?_P#!7!_\37244 <W_P *X\$?]";X
M?_\ !7!_\31_PKCP1_T)OA__ ,%<'_Q-=)10!S?_  KCP1_T)OA__P %<'_Q
M-'_"N/!'_0F^'_\ P5P?_$UTE% '":GX3\.:#XM\'W6AZ!I>FW#ZM+&TMG91
MPNRFPNR5)4 XR <>PKNZXGQKX@L=-\3^&X[K):UO#=N0<>6&BD@R?48E8_\
M :[;KTI7(C4C*3BGJ@HHHIEA1110 4444 %<WX#_ .1=NO\ L-:K_P"G"XKI
M*YOP'_R+MU_V&M5_].%Q0!TE%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '-^*/^1B\&?]AJ3_ --]Y725S?BC_D8O!G_8:D_]-]Y7
M24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^
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M HHHH **** "N;\!_P#(NW7_ &&M5_\ 3A<5TE<WX#_Y%VZ_[#6J_P#IPN*
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M^_&G_P#R+7244 <W_P (OJ__ $/?B#_OQI__ ,BT?\(OJ_\ T/?B#_OQI_\
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M^_&G_P#R+1_PB^K_ /0]^(/^_&G_ /R+7244 <W_ ,(OJ_\ T/?B#_OQI_\
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MHVW!W G()^48(YS'_P (OJ__ $/?B#_OQI__ ,BUTE% '-_\(OJ__0]^(/\
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M'_?C3_\ Y%KI** .;_X1?5_^A[\0?]^-/_\ D6C_ (1?5_\ H>_$'_?C3_\
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MU5%/V"[.X>5"C9XQR<<GCICNZYOQ1_R,7@S_ +#4G_IOO*Z2@ HHHH ****
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M* "BBB@ KF_%'_(Q>#/^PU)_Z;[RNDKF_%'_ ",7@S_L-2?^F^\H Z2BBB@
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M_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\
M)E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE% '-_
M8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "97244 <W]A\;_]##X?
M_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\
MF4?8?&__ $,/A_\ \$,__P F5TE% '-_8?&__0P^'_\ P0S_ /R91]A\;_\
M0P^'_P#P0S__ "97244 <W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#
M/_\ )E=)10!S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F5TE%
M 'G?B.S\8C7O"8GUW0W=M6D$+)HLRA&^PW7+ W1W#;N& 1R0<\8/0?8?&_\
MT,/A_P#\$,__ ,F4>*/^1B\&?]AJ3_TWWE=)0!S?V'QO_P!##X?_ /!#/_\
M)E'V'QO_ -##X?\ _!#/_P#)E=)10!S?V'QO_P!##X?_ /!#/_\ )E'V'QO_
M -##X?\ _!#/_P#)E=)10!S?V'QO_P!##X?_ /!#/_\ )E'V'QO_ -##X?\
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M5P<C&#P<@B/[#XW_ .AA\/\ _@AG_P#DRNDHH YO[#XW_P"AA\/_ /@AG_\
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MR=8;$?<C'H1_3\R:[Q$6-%2-0JJ,!5& !2T4TK&U.E&FM/OZL****9J%%%%
M!1110 4444 %%%% !1110 4444 <WXH_Y&+P9_V&I/\ TWWE=)7-^*/^1B\&
M?]AJ3_TWWE=)0 4444 %%%% !1110 5S?@/_ )%VZ_[#6J_^G"XKI*YOP'_R
M+MU_V&M5_P#3A<4 =)1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!S?BC_ )&+P9_V&I/_ $WWE=)7-^*/^1B\&?\ 8:D_]-]Y724
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^ _\
MD7;K_L-:K_Z<+BNDKF_ ?_(NW7_8:U7_ -.%Q724 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<WXH_Y&+P9_P!AJ3_TWWE=)7-^*/\
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M_P#(NW7_ &&M5_\ 3A<5(!_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\
MO_I__P E5TE% '-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\
M)5=)10!S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "57244
M<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E5TE% '-_\)1J
M_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5=)10!S?_"4:O\ ]")X
M@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "57244 <W_PE&K_ /0B>(/^_P#I
M_P#\E4?\)1J__0B>(/\ O_I__P E5TE% '-_\)1J_P#T(GB#_O\ Z?\ _)5'
M_"4:O_T(GB#_ +_Z?_\ )5=)10!S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]
M")X@_P"_^G__ "57244 <W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\
MO_I__P E5TE% 'G?B/Q'JDFO>$V?P7KD1CU:1E1YK',I^PW0VKBY(S@EOFP,
M*><X!Z#_ (2C5_\ H1/$'_?_ $__ .2J/%'_ ",7@S_L-2?^F^\KI* .;_X2
MC5_^A$\0?]_]/_\ DJC_ (2C5_\ H1/$'_?_ $__ .2JZ2B@#F_^$HU?_H1/
M$'_?_3__ )*H_P"$HU?_ *$3Q!_W_P!/_P#DJNDHH YO_A*-7_Z$3Q!_W_T_
M_P"2J/\ A*-7_P"A$\0?]_\ 3_\ Y*KI** .;_X2C5_^A$\0?]_]/_\ DJC_
M (2C5_\ H1/$'_?_ $__ .2JZ2B@#F_^$HU?_H1/$'_?_3__ )*H_P"$HU?_
M *$3Q!_W_P!/_P#DJNDHH YO_A*-7_Z$3Q!_W_T__P"2J/\ A*-7_P"A$\0?
M]_\ 3_\ Y*KI** .;_X2C5_^A$\0?]_]/_\ DJC_ (2C5_\ H1/$'_?_ $__
M .2JZ2B@#F_^$HU?_H1/$'_?_3__ )*H_P"$HU?_ *$3Q!_W_P!/_P#DJNDH
MH YO_A*-7_Z$3Q!_W_T__P"2J/\ A*-7_P"A$\0?]_\ 3_\ Y*KI** .;_X2
MC5_^A$\0?]_]/_\ DJC_ (2C5_\ H1/$'_?_ $__ .2JZ2B@#SOP7XCU2'0;
ME8_!>N3@ZMJ3%XYK$ $WTY*_-<@Y4DJ>V0<$C!/0?\)1J_\ T(GB#_O_ *?_
M /)5'@/_ )%VZ_[#6J_^G"XKI* .;_X2C5_^A$\0?]_]/_\ DJC_ (2C5_\
MH1/$'_?_ $__ .2JZ2B@#F_^$HU?_H1/$'_?_3__ )*H_P"$HU?_ *$3Q!_W
M_P!/_P#DJNDHH YO_A*-7_Z$3Q!_W_T__P"2JDB\1ZI)',S^"]<B,:!E1YK'
M,IW ;5Q<D9P2WS8&%/.< ]!10!S?_"4:O_T(GB#_ +_Z?_\ )5'_  E&K_\
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M_P!_]/\ _DJI)?$>J1QPLG@O7)3(A9D2:QS$=Q&ULW(&< -\N1AASG('044
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M,]"^"]?\0L)/%^M.L1.?L=J1@?7^'/X'ZUU.C^&-'T)1_9ME'&_>5AN<_P#
MCS2U9GS5ZGPKE7GO]QYCXO\ &'B6ZLUM[RS_ +*L[Q3MB_Y:2*.N2>0/P&:Q
M?!6MIH/B2.YDLFO?,4Q+%'L\S<?N[2Y50<X&2P&">:](^(GC/4/"/]G?V;#;
M2_:O-W_:$8XV[,8PP_O&N&\*?$C4K"\MM-DCL([.YU&2:>616!3S[AI9#G=@
M &1L9'  SGK7J4<GQ5>BJ\+6U_ \VI!1Q"<JCNK=#TO_ (2C5_\ H1/$'_?_
M $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJK_\ PE7A[_H.Z9_X&1_XT?\ "5>'
MO^@[IG_@9'_C7'["M_*_N9[//#N4/^$HU?\ Z$3Q!_W_ -/_ /DJC_A*-7_Z
M$3Q!_P!_]/\ _DJK_P#PE7A[_H.Z9_X&1_XT?\)5X>_Z#NF?^!D?^-'L*W\K
M^YASP[E#_A*-7_Z$3Q!_W_T__P"2J/\ A*-7_P"A$\0?]_\ 3_\ Y*J__P )
M5X>_Z#NF?^!D?^-'_"5>'O\ H.Z9_P"!D?\ C1["M_*_N8<\.Y0_X2C5_P#H
M1/$'_?\ T_\ ^2J/^$HU?_H1/$'_ '_T_P#^2JO_ /"5>'O^@[IG_@9'_C1_
MPE7A[_H.Z9_X&1_XT>PK?RO[F'/#N4/^$HU?_H1/$'_?_3__ )*H_P"$HU?_
M *$3Q!_W_P!/_P#DJK__  E7A[_H.Z9_X&1_XT?\)5X>_P"@[IG_ (&1_P"-
M'L*W\K^YASP[E#_A*-7_ .A$\0?]_P#3_P#Y*H_X2C5_^A$\0?\ ?_3_ /Y*
MJ_\ \)5X>_Z#NF?^!D?^-'_"5>'O^@[IG_@9'_C1["M_*_N8<\.Y0_X2C5_^
MA$\0?]_]/_\ DJC_ (2C5_\ H1/$'_?_ $__ .2JO_\ "5>'O^@[IG_@9'_C
M1_PE7A[_ *#NF?\ @9'_ (T>PK?RO[F'/#N4/^$HU?\ Z$3Q!_W_ -/_ /DJ
MC_A*-7_Z$3Q!_P!_]/\ _DJK_P#PE7A[_H.Z9_X&1_XT?\)5X>_Z#NF?^!D?
M^-'L*W\K^YASP[E#_A*-7_Z$3Q!_W_T__P"2J/\ A*-7_P"A$\0?]_\ 3_\
MY*J__P )5X>_Z#NF?^!D?^-'_"5>'O\ H.Z9_P"!D?\ C1["M_*_N8<\.Y0_
MX2C5_P#H1/$'_?\ T_\ ^2J/^$HU?_H1/$'_ '_T_P#^2JO_ /"5>'O^@[IG
M_@9'_C1_PE7A[_H.Z9_X&1_XT>PK?RO[F'/#N<SJ>LWVH^+?!\5YX:U32D75
MI6$UY):LC'[!=C:/*F=L\YY&.#STSW=>#7_Q0UK4;W3+J>UL%?3;IKJ$)&X#
M,89(<-E^1ME8\8Y ^A]1\ >)KSQ5H$]]J,4$<L=RT($"D+@*I[D\_,:[\5E.
M)PM/VM1*WJ8T\53JRY8G44445Y1TA1110 4444 %<WX#_P"1=NO^PUJO_IPN
M*Z2N;\!_\B[=?]AK5?\ TX7% '24444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <WXH_P"1B\&?]AJ3_P!-]Y725S?BC_D8O!G_ &&I
M/_3?>5TE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!S?@/_ )%VZ_[#6J_^G"XKI*YOP'_R+MU_V&M5_P#3A<5TE !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7-^*/^1B\&?\ 8:D_]-]Y
M725S?BC_ )&+P9_V&I/_ $WWE '24444 %%%% !1110 4444 %%%% !1156_
MU*RTN#SM1NHK:/LTC@9^GK0)M)79:HZ=:X6[^)'VRX-IX3TNXU2?_GH4*H/?
M'7'UQ4/_  B?BCQ*0_BK5_LELW6RM3V]#CC\3NJ>;L<SQ*EI27-^7WFUK/C_
M $'1BT;7/VN<<>5;?.<^YZ#\\UB_VGXW\4'&F6::'9-_RVG^^1^(S^2CZUTV
MC>$=$T+:UA9)YP_Y;R_._P"9Z?ABMJBS>X>SJU/XDK+LO\_^&.,TSX:Z;#-]
MJUNXGU>Z/+-.Q"Y^F<G\2:Z^WMX;2!8;6&.&)1A4C4*H_ 5)7/>(O&VB^&E*
MWMQYMSCBVAPS_C_=_&MJ-&=67)3C=^1I&%*A&ZT.AKEO$7Q T?0'-NKF_OL[
M1:VQR0WHQZ#Z<GVKG\>,_'>,Y\/:.Y]Q+(OZ$_\ CH/O74^'?!.B^&D5K*V$
MMSCFYFPTA^A[?A7H_5\/AM<1+FE_+']9?Y7(YZE3X%9=W^B/.?$>C^.O&WV:
M]N-(6*!-_D6^](VC!QRVX@Y.!U].@[XOASP#K.J7]K/+IWF:<M\UO=,)T&!%
M,8YAC=G@HXR.N,C/%?0%<WX#_P"1=NO^PUJO_IPN*ZH9[7IT_94H1C'IOI^)
MD\%"4N:3;?\ 7D5/^%6^$_\ H'R?^!$G^-'_  JWPG_T#Y/_  (D_P :Z^BO
M-_M#&?\ /V7WLZ/84OY5]QR'_"K?"?\ T#Y/_ B3_&C_ (5;X3_Z!\G_ ($2
M?XUU]%']H8S_ )^R^]A["E_*ON.0_P"%6^$_^@?)_P"!$G^-'_"K?"?_ $#Y
M/_ B3_&NOHH_M#&?\_9?>P]A2_E7W'(?\*M\)_\ 0/D_\")/\:/^%6^$_P#H
M'R?^!$G^-=?11_:&,_Y^R^]A["E_*ON.0_X5;X3_ .@?)_X$2?XT?\*M\)_]
M ^3_ ,")/\:Z^BC^T,9_S]E][#V%+^5?<<A_PJWPG_T#Y/\ P(D_QH_X5;X3
M_P"@?)_X$2?XUU]%']H8S_G[+[V'L*7\J^XY#_A5OA/_ *!\G_@1)_C1_P *
MM\)_] ^3_P ")/\ &NOHH_M#&?\ /V7WL/84OY5]QR'_  JWPG_T#Y/_  (D
M_P :/^%6^$_^@?)_X$2?XUU]%']H8S_G[+[V'L*7\J^XY#_A5OA/_H'R?^!$
MG^-'_"K?"?\ T#Y/_ B3_&NOHH_M#&?\_9?>P]A2_E7W'(?\*M\)_P#0/D_\
M")/\:/\ A5OA/_H'R?\ @1)_C77T4?VAC/\ G[+[V'L*7\J^X^=;KP%XELKF
MR@N=-V2WTQ@MU\^,[W$;R$<-Q\D;G)P.,=2*]:^&>A:CX?\ #5Q:ZO;_ &>=
M[MI%7>KY4H@SE21U!JYXH_Y&+P9_V&I/_3?>5TE=F,SC$8RE[*HDEY7_ ,S*
MEA(4I<T6PHHHKQCK"BBB@ HHHH *YOP'_P B[=?]AK5?_3A<5TE<WX#_ .1=
MNO\ L-:K_P"G"XH Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_GS\0?\ A.:A_P#&*/\ A/-(_P"?/Q!_X3FH?_&*Z2B@#F_^$\TC_GS\0?\
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M([77 0CN3)H%\@PJECRT(&< X'4G  )(%=!10!S?_">:1_SY^(/_  G-0_\
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M\0?^$YJ'_P 8KI** .;_ .$\TC_GS\0?^$YJ'_QBC_A/-(_Y\_$'_A.:A_\
M&*Z2B@#F_P#A/-(_Y\_$'_A.:A_\8H_X3S2/^?/Q!_X3FH?_ !BNDHH YO\
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M ."N#_XF@#I**YO_ (5QX(_Z$WP__P""N#_XFC_A7'@C_H3?#_\ X*X/_B:
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M@#I**YO_ (5QX(_Z$WP__P""N#_XFC_A7'@C_H3?#_\ X*X/_B: .DHKF_\
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MR77A/0YG75M2C#2:;"Q"I?3JJY*] J@ =@ .U 'HE%<W_P *X\$?]";X?_\
M!7!_\31_PKCP1_T)OA__ ,%<'_Q- '245S?_  KCP1_T)OA__P %<'_Q-'_"
MN/!'_0F^'_\ P5P?_$T =)17-_\ "N/!'_0F^'__  5P?_$T?\*X\$?]";X?
M_P#!7!_\30!TE%<W_P *X\$?]";X?_\ !7!_\31_PKCP1_T)OA__ ,%<'_Q-
M '245S?_  KCP1_T)OA__P %<'_Q-'_"N/!'_0F^'_\ P5P?_$T =)17-_\
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MP"1T%<WXH_Y&+P9_V&I/_3?>5TE !1110 4444 %%%% !1110 4444 %%%%
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M,(;'>X(4!3_HVW VDC !^8Y)XQ'_ ,(OJ_\ T/?B#_OQI_\ \BT =)17-_\
M"+ZO_P!#WX@_[\:?_P#(M20>'-4AD+2>--<G!1U"20V( )4@-\ML#E20P[9
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M+#8A) #DJVVV#8/0X(/H10!T%%<W_P (OJ__ $/?B#_OQI__ ,BT?\(OJ_\
MT/?B#_OQI_\ \BT =)17-_\ "+ZO_P!#WX@_[\:?_P#(M22^'-4DCA5/&FN1
M&-"K.D-CF4[B=S9MB,X(7Y<#"CC.20#H**YO_A%]7_Z'OQ!_WXT__P"1:/\
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M)17-_P#"+ZO_ -#WX@_[\:?_ /(M'_"+ZO\ ]#WX@_[\:?\ _(M '245S?\
MPB^K_P#0]^(/^_&G_P#R+1_PB^K_ /0]^(/^_&G_ /R+0!TE%<W_ ,(OJ_\
MT/?B#_OQI_\ \BT?\(OJ_P#T/?B#_OQI_P#\BT =)17-_P#"+ZO_ -#WX@_[
M\:?_ /(M'_"+ZO\ ]#WX@_[\:?\ _(M '245S?\ PB^K_P#0]^(/^_&G_P#R
M+1_PB^K_ /0]^(/^_&G_ /R+0!TE%<W_ ,(OJ_\ T/?B#_OQI_\ \BUB>([J
MU\)6QG\0_%'5[(8RJ/%IYD?_ '4%J6/X"JC&4G:*NP._K'\5ZE+I?AZ26U;9
M///!9Q28!\MYYDA5\'KM,@/X5X;+\0?&_BJ[-K\*[OQ/J:JV#J&H6U@D Y&>
M!; =/5P?:NFT_P"$?B_Q!=0:E\1O'-[)<PL)(K732JQQ.#D-RH3/T3\:ZGA7
M"-ZLE%]MW]RV^9/-?8]3TW0=-TJR-M:6J;6'[UY!O>8]V=CR['N369IT$6@>
M+CI%EE+&_M)+R&V .RW>-XT<)V56\U#M'&0Q'4U6E\3ZSH<FG:?K6@SZA>7L
MQM8+K3)(1#,XC>3)6616CRD;MCY@,$!B<9U=)L+XZA/JNLF);J9!%#;PMN2V
MB!SC<0-S,>6. .% '&3QE&Q1110 4444 %%%% !7-^ _^1=NO^PUJO\ Z<+B
MNDKF_ ?_ "+MU_V&M5_].%Q0!TE%%% !1110 4444 %%%% !114-S=V]E"9K
MRXBMXAU>5PJC\30&Q-17'ZI\3O#]AN2VDEOY!QB!/ES_ +QQ^8S63_PDWC?Q
M#_R M&&GP-@B:89./4,^ 1]%-&YRRQ5).T=7Y:GHDDB0QM)*ZHBC+,QP /K7
M,ZI\1/#NF;E^V?:Y%_@M1OS_ ,"^[^M8<?PWU+5I%F\5Z_-<'.?*A8L!]&;@
M?0+72Z7X(\/Z3M-OIT<D@_Y:S_O&SZ\\ _0"BPN;$3^&*CZZ_@CF#XY\3:\=
MGA;0&6-L@7$PW#ZY.%!]B30/ WB;7SO\4:^R1M@FWA.X?3 PH/N,UZ-TZ44:
M!]6YOXLG+\%]R.7TOX=^'=,VL;/[9(/X[H[\_P# ?N_I731QI#&L<*+&BC"J
MHP /84ZBG=G1"G"FK05@HHHI%G-^*/\ D8O!G_8:D_\ 3?>5TE<_XC6 Z]X3
M,\DB.NK2&%4C#!V^PW7#$D;1MW'(!Y &.<CH* "BBB@ HHHH *CF@AN$V7$2
M2K_==0P_6I**:;6J P[OP7X;O=WGZ+9Y;J8XQ&3^*XK$N_A+X8N ?(CNK0]O
M*G)Q_P!]9KMZ*ZZ>.Q5/X*C7S9E*C3EO%'GY^&VI69!T7Q=J%L%Z1R$L#^3
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M59?!7AN;[^CVPYS\B[?Y5SA^$UG;,S:-K>I6#MT(<$#\MI_6D_X1/QSIZ_\
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M;\4?\C%X,_[#4G_IOO*Z2N?\1K =>\)F>21'75I#"J1A@[?8;KAB2-HV[CD
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MR5MV%Q!$ W/;]YG]*L_\- V<CA;7P7XFE;'(^R#/Z$UVZZ=XU10J:_X>51T
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M01]LY!%3*O3::5-+[_\ ,+/N=2    , = *\Y\<>+Y_!/BR.[TKP]?:XUU:
M:A%8JQ:%0S>5(V%(YQ(O.,@=?EQ4@M/&/AHZ-I1\3V-XNI7SVD4DFE/NM4%M
M-,,$SDOCR=OS$GYN2<<WM*\,^,=*28KXGT6YN+A]]Q=7&ARF25L8&<78  '
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M9X#^(>[&*ZBTD\4Z@H:P\7>%[E3R##HTK@_E>5SRISA\2:'='745S?V'QO\
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ML_&(CF$^NZ&[L@$+)HLRA&W#E@;H[AMW# (Y(.>,&/[#XW_Z&'P__P""&?\
M^3* .DHKF_L/C?\ Z&'P_P#^"&?_ .3*/L/C?_H8?#__ ((9_P#Y,H Z2BN;
M^P^-_P#H8?#_ /X(9_\ Y,H^P^-_^AA\/_\ @AG_ /DR@#I**YO[#XW_ .AA
M\/\ _@AG_P#DRC[#XW_Z&'P__P""&?\ ^3* .DKG_!=M/:Z#<QW4,D+MJVI2
M!9$*DJ]].RM@]BK @]P0>]1_8?&__0P^'_\ P0S_ /R97/\ @NS\8MH-R;77
M=#C3^UM2!6319G);[=/N.1=#@MD@8X! R<9(!Z)17-_8?&__ $,/A_\ \$,_
M_P F4?8?&_\ T,/A_P#\$,__ ,F4 =)17%ZSJ/B'P]9&[USQGX6L(!_'<:+*
MF?89O.3["O-)?C9XNU751I_P_ALO%,H(\R2/09[>-0<X.XW+$=/X@H]ZWI8>
MK5UBM._3[Q-I'OY.!D]*X'Q7\:/!GA1VMY=1_M&^!P+33QYK9]"?NJ?8G/M7
M&7?PS^)WQ"LW;QQXOCT6"4?+IEC%YB*".5<*R@_BS_6NA\*_"2Z\&A6T2Y\,
MK<J,?:YM GDF/_ FO./H,"MO9X>E\<N9]EM][_1"NV8Q\0_%SXA87PYI$7@[
M2W/_ !^7_,[+GL",].>%'^]WK3T#X!:%;78U+QC?WGBG4S@M)?2-Y>1_LY);
M_@3$>U=E]A\;_P#0P^'_ /P0S_\ R91]A\;_ /0P^'__  0S_P#R92>+FERT
MERKRW^_<.5=3=LK&TTVSCM-.M8;2WC&$A@C"(H] !P*GKF_L/C?_ *&'P_\
M^"&?_P"3*/L/C?\ Z&'P_P#^"&?_ .3*X]RCI**YO[#XW_Z&'P__ ."&?_Y,
MH^P^-_\ H8?#_P#X(9__ ),H Z2BN;^P^-_^AA\/_P#@AG_^3*/L/C?_ *&'
MP_\ ^"&?_P"3* .DHKF_L/C?_H8?#_\ X(9__DRC[#XW_P"AA\/_ /@AG_\
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MR17IU%)XW$O3G?RT_(.5'&V?PC\ V**L/A73V"C \Z,RG\2Y.:W;'PMX?TQ
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M4+J!+-0L<+&WN9(E=PHRY/EAMI)4'MD UV%<WX#_ .1=NO\ L-:K_P"G"XH
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M@ZMJ3%XYK$ $WTY*_-<@Y4DJ>V0<$C!,@>B45S?_  E&K_\ 0B>(/^_^G_\
MR51_PE&K_P#0B>(/^_\ I_\ \E4 =)17-_\ "4:O_P!")X@_[_Z?_P#)5'_"
M4:O_ -")X@_[_P"G_P#R50!TE%<W_P )1J__ $(GB#_O_I__ ,E4?\)1J_\
MT(GB#_O_ *?_ /)5 '245S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/
M^_\ I_\ \E4 =)17-_\ "4:O_P!")X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G
M_P#R50!TE%<W_P )1J__ $(GB#_O_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5
M '245S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/^_\ I_\ \E4 =)17
M-_\ "4:O_P!")X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G_P#R50!TE%<W_P )
M1J__ $(GB#_O_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5 '245S?_  E&K_\
M0B>(/^_^G_\ R51_PE&K_P#0B>(/^_\ I_\ \E4 'BC_ )&+P9_V&I/_ $WW
ME=)7G?B/Q'JDFO>$V?P7KD1CU:1E1YK',I^PW0VKBY(S@EOFP,*><X!Z#_A*
M-7_Z$3Q!_P!_]/\ _DJ@#I**YO\ X2C5_P#H1/$'_?\ T_\ ^2J/^$HU?_H1
M/$'_ '_T_P#^2J .DHKF_P#A*-7_ .A$\0?]_P#3_P#Y*H_X2C5_^A$\0?\
M?_3_ /Y*H Z2BN;_ .$HU?\ Z$3Q!_W_ -/_ /DJC_A*-7_Z$3Q!_P!_]/\
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M -/_ /DJC_A*-7_Z$3Q!_P!_]/\ _DJ@#I**YO\ X2C5_P#H1/$'_?\ T_\
M^2J/^$HU?_H1/$'_ '_T_P#^2J #P'_R+MU_V&M5_P#3A<5TE>=^"_$>J0Z#
M<K'X+UR<'5M28O'-8@ F^G)7YKD'*DE3VR#@D8)Z#_A*-7_Z$3Q!_P!_]/\
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M:0K)X+UR !'8/)-8D$A20ORW).6("CMDC) R0 =!17-_\)1J_P#T(GB#_O\
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M%ZY;)(X5II9K$I&"<%FVW); ZG )] : .@HKF_\ A*-7_P"A$\0?]_\ 3_\
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ME3VR#@D8) /1**YO_A*-7_Z$3Q!_W_T__P"2J/\ A*-7_P"A$\0?]_\ 3_\
MY*H Z2BN;_X2C5_^A$\0?]_]/_\ DJC_ (2C5_\ H1/$'_?_ $__ .2J .DH
MKF_^$HU?_H1/$'_?_3__ )*H_P"$HU?_ *$3Q!_W_P!/_P#DJ@#I**YO_A*-
M7_Z$3Q!_W_T__P"2J/\ A*-7_P"A$\0?]_\ 3_\ Y*H Z2BN;_X2C5_^A$\0
M?]_]/_\ DJC_ (2C5_\ H1/$'_?_ $__ .2J .DHKF_^$HU?_H1/$'_?_3__
M )*H_P"$HU?_ *$3Q!_W_P!/_P#DJ@#I**YO_A*-7_Z$3Q!_W_T__P"2J/\
MA*-7_P"A$\0?]_\ 3_\ Y*H Z2BN;_X2C5_^A$\0?]_]/_\ DJC_ (2C5_\
MH1/$'_?_ $__ .2J .DHKF_^$HU?_H1/$'_?_3__ )*H_P"$HU?_ *$3Q!_W
M_P!/_P#DJ@#I**YO_A*-7_Z$3Q!_W_T__P"2J/\ A*-7_P"A$\0?]_\ 3_\
MY*H /%'_ ",7@S_L-2?^F^\KI*X34]9OM1\6^#XKSPUJFE(NK2L)KR2U9&/V
M"[&T>5,[9YSR,<'GIGNZ "BBB@ JEJVD6.N:<]CJMN)[=R&*[BI5@<AE8$%6
M! ((((/2KM% &)%X.T.+2+C31:.\%U()9GEN99)I)!C#F9F,FX8&&W9&!@C%
M7]+TJST:Q6TTZ(QQ ECN=G9V/)9G8EF8]R22:N447 *YOP'_ ,B[=?\ 8:U7
M_P!.%Q725S?@/_D7;K_L-:K_ .G"XH Z2BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#F_%'_(Q>#/^PU)_P"F^\KI*YOQ1_R,7@S_
M +#4G_IOO*Z2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH YOP'_ ,B[=?\ 8:U7_P!.%Q725S?@/_D7;K_L-:K_ .G"XKI* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;\4?\C%X,_P"P
MU)_Z;[RNDKF_%'_(Q>#/^PU)_P"F^\H Z2BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KF_ ?_(NW7_8:U7_TX7%=)7-^ _\ D7;K
M_L-:K_Z<+B@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** .;\4?\C%X,_P"PU)_Z;[RNDKF_%'_(Q>#/^PU)_P"F^\KI* "BBB@
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MF_ ?_(NW7_8:U7_TX7%=)7/^"[F>ZT&YDNII)G75M2C#2.6(5+Z=57)[!5
M[  =J .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M YOQ1_R,7@S_ +#4G_IOO*Z2N;\4?\C%X,_[#4G_ *;[RNDH **** "BBL7Q
M9KTGA[06NK6V^UWDLJ6UI;YP))I&"J">PR<GV!H VJ*\VM?%FIR6::6U_>QZ
M_=:I%87*7=K GV#=&9&:-4+*044E2SR<D9Z$5T_A34[RXN-8TO49VNY](O!;
MBZ=55IT:))%9@H"AL/@X !QG SBG;^ON_P T']?G_D=%7-^ _P#D7;K_ +#6
MJ_\ IPN*TM7\1Z'X?\G^WM9T_3//W>5]MNDA\S;C.W<1G&1G'J*XWP7X^\'V
MN@W,=UXLT.%VU;4I LFI0J2KWT[*V"W0JP(/<$'O2 ]$HKF_^%C^"/\ H<O#
M_P#X-(/_ (JC_A8_@C_H<O#_ /X-(/\ XJ@#I**YO_A8_@C_ *'+P_\ ^#2#
M_P"*H_X6/X(_Z'+P_P#^#2#_ .*H Z2BN;_X6/X(_P"AR\/_ /@T@_\ BJ/^
M%C^"/^AR\/\ _@T@_P#BJ .DHKF_^%C^"/\ H<O#_P#X-(/_ (JC_A8_@C_H
M<O#_ /X-(/\ XJ@#I**YO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_Z'+P_P#^
M#2#_ .*H Z2BN;_X6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#B
MJ .DHKF_^%C^"/\ H<O#_P#X-(/_ (JC_A8_@C_H<O#_ /X-(/\ XJ@#I**Y
MO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_Z'+P_P#^#2#_ .*H Z2BN;_X6/X(
M_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#BJ .DHKF_^%C^"/\ H<O#
M_P#X-(/_ (JC_A8_@C_H<O#_ /X-(/\ XJ@ \4?\C%X,_P"PU)_Z;[RNDKSO
MQ'X^\'SZ]X3D@\6:'(EOJTDDS)J4)$:_8;I=S$-P-S*,GNP'>N@_X6/X(_Z'
M+P__ .#2#_XJ@#I**YO_ (6/X(_Z'+P__P"#2#_XJC_A8_@C_H<O#_\ X-(/
M_BJ .DHKF_\ A8_@C_H<O#__ (-(/_BJ/^%C^"/^AR\/_P#@T@_^*H Z2BN;
M_P"%C^"/^AR\/_\ @T@_^*H_X6/X(_Z'+P__ .#2#_XJ@#I**YO_ (6/X(_Z
M'+P__P"#2#_XJC_A8_@C_H<O#_\ X-(/_BJ .DHKF_\ A8_@C_H<O#__ (-(
M/_BJ/^%C^"/^AR\/_P#@T@_^*H Z2BN;_P"%C^"/^AR\/_\ @T@_^*H_X6/X
M(_Z'+P__ .#2#_XJ@#I**YO_ (6/X(_Z'+P__P"#2#_XJC_A8_@C_H<O#_\
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M .#2#_XJ@#I**YO_ (6/X(_Z'+P__P"#2#_XJC_A8_@C_H<O#_\ X-(/_BJ
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M (JC_A8_@C_H<O#_ /X-(/\ XJ@#I*YOP'_R+MU_V&M5_P#3A<4?\+'\$?\
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M!EPV!N!5EY]<CM6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTIM>T_1_/UBVFCCN]/N;B2W<,C#?!,BL%WA<A68$?=(."#7.M=6UJ&OK58-
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M"%4X^\",] P[*L[0M#LO#VE)8:<C",,TDDCMN>:1CEY';^)F)))K1H ****
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MPV[3RB6SLG4/)9Q@  .W(WG&XA>%)QDXR>@HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH BGMHKE4$Z;@DBR+SC#*<@UR.NOKG_  F?
M]G^'+01F^@MY+K491F*VCCDDW?+U:1@0H'3&2>!@]G10!'!;06RE;:&.%6.2
M(T"Y/KQ4E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&+XCL8_^$3UQ($(:XM9G.T9)?R\ @'(SP/QJKX9&K:O%/JOB:QAM1<2B2PL)
M$#2VD0'&]N1O;[Q X7ID\FNDHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *BGMXKE%69=P1UD7V92"#^8J6B@#CM:_MC_A,IK/P_;F.
M6_M+8S:A(,PVR1R2[B1_$[!@H7OU)PM=9!;06RE;:&.$,<D1H%R?PJ6B@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#P0S__ "90!TE%<W]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\
M)E '245S?V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F4 =)17-_
M8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "90!TE%<W]A\;_]##X?
M_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E '245S?V'QO_T,/A__ ,$,_P#\
MF4?8?&__ $,/A_\ \$,__P F4 =)17-_8?&__0P^'_\ P0S_ /R91]A\;_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  GFD?\ /GX@_P#"<U#_ .,4?\)YI'_/GX@_\)S4/_C%=)10!S?_  GFD?\
M/GX@_P#"<U#_ .,4?\)YI'_/GX@_\)S4/_C%=)10!S?_  GFD?\ /GX@_P#"
M<U#_ .,4?\)YI'_/GX@_\)S4/_C%=)10!S?_  GFD?\ /GX@_P#"<U#_ .,4
M?\)YI'_/GX@_\)S4/_C%=)10!S?_  GFD?\ /GX@_P#"<U#_ .,4?\)YI'_/
MGX@_\)S4/_C%=)10!S?_  GFD?\ /GX@_P#"<U#_ .,4?\)YI'_/GX@_\)S4
M/_C%=)10!S?_  GFD?\ /GX@_P#"<U#_ .,4?\)YI'_/GX@_\)S4/_C%=)10
M!S?_  GFD?\ /GX@_P#"<U#_ .,4?\)YI'_/GX@_\)S4/_C%=)10!S?_  GF
MD?\ /GX@_P#"<U#_ .,4?\)YI'_/GX@_\)S4/_C%=)10!S?_  GFD?\ /GX@
M_P#"<U#_ .,4?\)YI'_/GX@_\)S4/_C%=)10!S?_  GFD?\ /GX@_P#"<U#_
M .,4?\)YI'_/GX@_\)S4/_C%=)10!S?_  GFD?\ /GX@_P#"<U#_ .,4?\)Y
MI'_/GX@_\)S4/_C%=)10!S?_  GFD?\ /GX@_P#"<U#_ .,4?\)YI'_/GX@_
M\)S4/_C%=)10!S?_  GFD?\ /GX@_P#"<U#_ .,4?\)YI'_/GX@_\)S4/_C%
M=)10!S?_  GFD?\ /GX@_P#"<U#_ .,4?\)YI'_/GX@_\)S4/_C%=)10!Q-]
MKL'B#Q1X5CTVQUC_ $74Y)YY+G1KNVCC3[%<IDO+&J_>=1C.<FNVHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585100830136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 18, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GILEAD SCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3047598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Lakeside Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">574-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value, $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GILD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,253,886,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Specified portions of the registrant&#8217;s proxy statement, which will be filed with the Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2022 Annual Meeting of Stockholders, to be held on May 4, 2022, are incorporated by reference into Part&#160;III of this Report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585101500840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585101304632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,338<span></span>
</td>
<td class="nump">$ 5,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">4,493<span></span>
</td>
<td class="nump">4,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,141<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">14,772<span></span>
</td>
<td class="nump">15,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,121<span></span>
</td>
<td class="nump">4,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="nump">1,309<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">33,455<span></span>
</td>
<td class="nump">33,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,332<span></span>
</td>
<td class="nump">8,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="nump">5,708<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">67,952<span></span>
</td>
<td class="nump">68,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccruedGovernmentAndOtherRebates', window );">Accrued government and other rebates</a></td>
<td class="nump">3,244<span></span>
</td>
<td class="nump">3,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">6,145<span></span>
</td>
<td class="nump">4,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of long-term debt and other obligations, net</a></td>
<td class="nump">1,516<span></span>
</td>
<td class="nump">2,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,610<span></span>
</td>
<td class="nump">11,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">25,179<span></span>
</td>
<td class="nump">28,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable</a></td>
<td class="nump">4,767<span></span>
</td>
<td class="nump">5,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">4,356<span></span>
</td>
<td class="nump">3,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">976<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December&#160;31, 2021 and 2020</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">4,661<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">83<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">16,324<span></span>
</td>
<td class="nump">14,381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gilead stockholders&#8217; equity</a></td>
<td class="nump">21,069<span></span>
</td>
<td class="nump">18,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">21,064<span></span>
</td>
<td class="nump">18,221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 67,952<span></span>
</td>
<td class="nump">$ 68,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccruedGovernmentAndOtherRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Government And Other Rebates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccruedGovernmentAndOtherRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585099564120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">5,600,000,000<span></span>
</td>
<td class="nump">5,600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1,254,000,000<span></span>
</td>
<td class="nump">1,254,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">1,254,000,000<span></span>
</td>
<td class="nump">1,254,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585101009144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 27,305<span></span>
</td>
<td class="nump">$ 24,689<span></span>
</td>
<td class="nump">$ 22,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">6,601<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
<td class="nump">4,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">5,363<span></span>
</td>
<td class="nump">5,039<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ResearchAndDevelopmentInProcessIncludingImpairment', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">5,856<span></span>
</td>
<td class="nump">5,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">5,246<span></span>
</td>
<td class="nump">5,151<span></span>
</td>
<td class="nump">4,381<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">17,387<span></span>
</td>
<td class="nump">20,618<span></span>
</td>
<td class="nump">18,162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">9,918<span></span>
</td>
<td class="nump">4,071<span></span>
</td>
<td class="nump">4,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,001)<span></span>
</td>
<td class="num">(984)<span></span>
</td>
<td class="num">(995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(639)<span></span>
</td>
<td class="num">(1,418)<span></span>
</td>
<td class="nump">1,868<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">8,278<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">5,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(2,077)<span></span>
</td>
<td class="num">(1,580)<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">6,201<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">5,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Gilead</a></td>
<td class="nump">$ 6,225<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 5,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share attributable to Gilead common stockholders - basic (in dollars per share)</a></td>
<td class="nump">$ 4.96<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 4.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in per share calculation - basic (in shares)</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)</a></td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in per share calculation - diluted (in shares)</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 27,008<span></span>
</td>
<td class="nump">$ 24,355<span></span>
</td>
<td class="nump">$ 22,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ResearchAndDevelopmentInProcessIncludingImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development in Process, Including Impairment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ResearchAndDevelopmentInProcessIncludingImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585101272840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 6,201<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 5,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss), net of tax</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss), net of tax</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to net income, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Net unrealized gain (loss), net of tax</a></td>
<td class="nump">129<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to net income, net of tax</a></td>
<td class="nump">58<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="nump">187<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">143<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="nump">6,344<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="nump">5,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interest</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Gilead</a></td>
<td class="nump">$ 6,368<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
<td class="nump">$ 5,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585104215992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect from the adoption of new accounting standard</div></th>
<th class="th"><div>Common Stock&#160;</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative effect from the adoption of new accounting standard</div>
</th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 21,534<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2,282<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 19,024<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">5,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(1,868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(3,239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">22,650<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">19,388<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in noncontrolling interest</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(1,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (3,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 18,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">14,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">6,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (3,618)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,618)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 21,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4,661<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 16,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585100815336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared (in dollars per share)</a></td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585101399432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 6,201,000,000<span></span>
</td>
<td class="nump">$ 89,000,000<span></span>
</td>
<td class="nump">$ 5,364,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">329,000,000<span></span>
</td>
<td class="nump">288,000,000<span></span>
</td>
<td class="nump">255,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
<td class="nump">1,721,000,000<span></span>
</td>
<td class="nump">1,192,000,000<span></span>
</td>
<td class="nump">1,149,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">635,000,000<span></span>
</td>
<td class="nump">643,000,000<span></span>
</td>
<td class="nump">636,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="num">(116,000,000)<span></span>
</td>
<td class="num">(214,000,000)<span></span>
</td>
<td class="num">(2,098,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Net (gain) loss from equity securities</a></td>
<td class="nump">610,000,000<span></span>
</td>
<td class="nump">1,662,000,000<span></span>
</td>
<td class="num">(1,241,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">177,000,000<span></span>
</td>
<td class="nump">5,856,000,000<span></span>
</td>
<td class="nump">4,251,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_InventoryReserveForExcessRawMaterials', window );">Write-downs for slow-moving and excess raw material and work in process inventory</a></td>
<td class="nump">121,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">547,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">1,217,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">279,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">313,000,000<span></span>
</td>
<td class="num">(1,171,000,000)<span></span>
</td>
<td class="num">(218,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="num">(195,000,000)<span></span>
</td>
<td class="num">(95,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(42,000,000)<span></span>
</td>
<td class="num">(214,000,000)<span></span>
</td>
<td class="num">(307,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(118,000,000)<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="num">(61,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(364,000,000)<span></span>
</td>
<td class="num">(778,000,000)<span></span>
</td>
<td class="nump">272,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">689,000,000<span></span>
</td>
<td class="nump">640,000,000<span></span>
</td>
<td class="num">(389,000,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">11,384,000,000<span></span>
</td>
<td class="nump">8,168,000,000<span></span>
</td>
<td class="nump">9,144,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable debt securities</a></td>
<td class="num">(3,517,000,000)<span></span>
</td>
<td class="num">(20,315,000,000)<span></span>
</td>
<td class="num">(30,455,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable debt securities</a></td>
<td class="nump">730,000,000<span></span>
</td>
<td class="nump">23,239,000,000<span></span>
</td>
<td class="nump">7,523,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable debt securities</a></td>
<td class="nump">2,180,000,000<span></span>
</td>
<td class="nump">9,479,000,000<span></span>
</td>
<td class="nump">22,398,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, including in-process research and development, net of cash acquired</a></td>
<td class="num">(1,402,000,000)<span></span>
</td>
<td class="num">(25,742,000,000)<span></span>
</td>
<td class="num">(4,251,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchases of equity securities</a></td>
<td class="num">(380,000,000)<span></span>
</td>
<td class="num">(455,000,000)<span></span>
</td>
<td class="num">(1,773,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(579,000,000)<span></span>
</td>
<td class="num">(650,000,000)<span></span>
</td>
<td class="num">(825,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(163,000,000)<span></span>
</td>
<td class="num">(171,000,000)<span></span>
</td>
<td class="num">(434,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in by investing activities</a></td>
<td class="num">(3,131,000,000)<span></span>
</td>
<td class="num">(14,615,000,000)<span></span>
</td>
<td class="num">(7,817,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt financing, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,184,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock</a></td>
<td class="nump">169,000,000<span></span>
</td>
<td class="nump">256,000,000<span></span>
</td>
<td class="nump">209,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(546,000,000)<span></span>
</td>
<td class="num">(1,583,000,000)<span></span>
</td>
<td class="num">(1,749,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt and other obligations</a></td>
<td class="num">(4,750,000,000)<span></span>
</td>
<td class="num">(2,500,000,000)<span></span>
</td>
<td class="num">(2,750,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="num">(3,605,000,000)<span></span>
</td>
<td class="num">(3,449,000,000)<span></span>
</td>
<td class="num">(3,222,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(145,000,000)<span></span>
</td>
<td class="num">(138,000,000)<span></span>
</td>
<td class="num">(122,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(8,877,000,000)<span></span>
</td>
<td class="nump">770,000,000<span></span>
</td>
<td class="num">(7,634,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(35,000,000)<span></span>
</td>
<td class="nump">43,000,000<span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(659,000,000)<span></span>
</td>
<td class="num">(5,634,000,000)<span></span>
</td>
<td class="num">(6,309,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">5,997,000,000<span></span>
</td>
<td class="nump">11,631,000,000<span></span>
</td>
<td class="nump">17,940,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">5,338,000,000<span></span>
</td>
<td class="nump">5,997,000,000<span></span>
</td>
<td class="nump">11,631,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid, net of amounts capitalized</a></td>
<td class="nump">979,000,000<span></span>
</td>
<td class="nump">951,000,000<span></span>
</td>
<td class="nump">982,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">$ 2,509,000,000<span></span>
</td>
<td class="nump">$ 2,639,000,000<span></span>
</td>
<td class="nump">$ 1,793,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InventoryReserveForExcessRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory Reserve For Excess Raw Materials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InventoryReserveForExcessRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102576312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketed products includes AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cayston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Emtriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(bulevirtide), Hepsera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jyseleca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (filgotinib), Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sovaldi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tybost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The approval status of Hepcludex and Jyseleca vary worldwide, and Hepcludex and Jyseleca are not approved in the United States. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the United States through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a variable interest entity (&#8220;VIE&#8221;) at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We did not have any material VIEs as of December&#160;31, 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods in the Consolidated Financial Statements and accompanying notes to conform with the current presentation. Beginning 2020, acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expenses are reported separately from Research and development expenses on our Consolidated Statements of Income. Our Consolidated Statements of Income for the year ended December 31, 2019 was conformed to separately present acquired IPR&amp;D expenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies, Estimates and Judgments </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and  expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease (&#8220;COVID-19&#8221;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to the customer, or in certain cases, upon the corresponding sales by our customer to a third party. The revenues are recognized net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a financing component. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Deductions </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Rebates and Chargebacks</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other rebates and chargebacks include amounts payable to payers and healthcare providers under various programs, and may vary by product, by payer and individual payer plans. Rebates and chargebacks are based on contractual arrangements or statutory requirements which may vary by product, payer and individual payer plans. For qualified programs that can purchase our products through wholesalers or other distributors at a lower contractual price, the wholesalers or distributors charge back to us the difference between their acquisition cost and the lower contractual price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are estimated primarily based on product sales, and expected payer mix and discount rates, which require significant estimates and judgment. Additionally, in developing our estimates, we consider: historical and estimated payer mix; statutory discount requirements and contractual terms; historical claims experience and processing time lags; estimated patient population; known market events or trends; market research; channel inventory data obtained from our major U.S. wholesalers; and other pertinent internal or external information. We assess and update our estimates each reporting period to reflect actual claims and other current information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Government and other rebates that are payable to third party payers and healthcare providers are recorded in Accrued government and other rebates on our Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Discounts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Distributor Fees</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Allowance for Sales Returns</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the United States, we typically permit returns six months prior to and up to one year after the product expiration date. Outside the United States, returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Shipping and Handling</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling activities are considered to be fulfillment activities and not considered to be a separate performance obligation.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty, Contract and Other Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of clinical studies performed by contract research organizations (&#8220;CROs&#8221;), materials and supplies, payments under collaborative and other arrangements including milestone payments, licenses and fees, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations consisting of various support and infrastructure costs. Milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of R&amp;D expenses.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We charge R&amp;D costs, including clinical study costs, to expense when incurred. Clinical study costs are a significant component of R&amp;D expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for R&amp;D services prior to the services being rendered are recorded as prepaid assets in our Consolidated Balance Sheets and are expensed as the services are provided.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquired In-Process Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses reflect IPR&amp;D impairments as well as the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;D projects. The acquired IPR&amp;D is expensed on acquisition date. Future costs to develop these IPR&amp;D projects are recorded in Research and development expenses on our Consolidated Statements of Income as incurred. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses relate to sales and marketing, finance, human resources, legal and other administrative activities. SG&amp;A expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs. SG&amp;A expenses also include the Branded Prescription Drug (&#8220;BPD&#8221;) fee. In the United States, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the BPD fee, which is estimated based on select government sales during the prior year as a percentage of total industry government sales.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $735 million, $795 million and $784 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable and Non-Marketable Securities</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable debt securities are considered available-for-sale and carried at estimated fair values and reported in cash equivalents, short-term marketable debt securities or long-term marketable debt securities. Unrealized gains and losses on available-for-sale debt securities are excluded from net income and reported in Accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) as a separate component of stockholders&#8217; equity. Other income (expense), net, includes interest, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and expected credit losses, if any. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost bases. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in AOCI.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable and Non-Marketable Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities, other than equity method investments, are recorded at fair market value if fair value is readily determinable, and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. We have elected the fair value option to account for our equity investments in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;) and Galapagos NV (&#8220;Galapagos&#8221;) over which we have significant influence. We believe the fair value option best reflects the underlying economics of these investments. See Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Certain investments in equity securities of non-public companies are accounted for using the equity method based on our ownership percentage and other factors that indicate we have significant influence over the investee. See Note 11. Collaborations and Other Arrangements for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in equity securities are recorded in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets. We regularly review our securities for indicators of impairment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe. Additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material for the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated&#160;Useful&#160;Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;35 years or useful&#160;life</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;useful&#160;life or lease&#160;term</span></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at inception. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period, which may be up to one year from the acquisition date, with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration, such as payments upon achievement of various developmental, regulatory and commercial milestones, generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are expensed as incurred on our Consolidated Statements of Income unless there is an alternative future use.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may be subject to adjustment within the measurement period, which may be up to one year from the acquisition date. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. We do not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When development is successfully completed, which generally occurs when regulatory approval is obtained, the associated assets are deemed finite-lived and amortized over their respective estimated useful lives beginning at that point in time. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Contingent Consideration Resulting from a Business Combination</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value in Research and development expenses on our Consolidated Statements of Income until such time that the related product candidate receives marketing approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may differ from estimates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. entity operations are recorded in the functional currency of each entity. Results of operations for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency rates. Assets and liabilities are translated using currency rates at period end. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Foreign currency transaction gains and losses are recorded in Other income (expense), net, on our Consolidated Statements of Income. Net foreign currency transaction gains and losses were not material for the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value accounting for all financial and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:4pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Unrealized changes in the fair value of derivatives designated as part of a hedge transaction are recorded in AOCI. The unrealized gains or losses in AOCI are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide share-based compensation in the form of various types of equity-based awards, including restricted stock units (&#8220;RSU&#8221;s), performance share awards or units (&#8220;PSU&#8221;s) and stock options. Compensation expense is recognized on the Consolidated Statements of Income based on the estimated fair value of the award on the grant date. The estimated fair value of RSUs is based on the closing price of our common stock. For PSUs, depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. For stock option awards, estimated fair value is based on the Black-Scholes option valuation model. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue the best estimate of loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision is computed under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (&#8220;UTB&#8221;) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax (expense) benefit on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for the tax on Global Intangible Low-Taxed Income, enacted as part of the Tax Cuts and Jobs Act, as a component of tax expense in the period in which the tax is incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Significant Accounting Policies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other significant accounting policies are described in the remaining appropriate Notes to the Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102420408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">REVENUES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenues </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HIV </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,828&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,315&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,651&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,315&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,438&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ledipasvir/</span></div><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="27" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis Delta virus (&#8220;HDV&#8221;)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Cell Therapy </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,449&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#8220;Janssen&#8221;).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues From Major Customers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues Recognized from Performance Obligations Satisfied in Prior Periods</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from performance obligations satisfied in prior years related to our revenue share with Janssen, as described in Note 11. Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $851 million, $841 million and $741 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates related to sales made in prior years resulted in $856 million, $101 million and $257 million increase in revenues for the years ended December&#160;31, 2021, 2020 and 2019, respectively. This was primarily related to changes in estimates for accrued government and other rebates and allowances for sales returns upon product expiration.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $174 million and $198 million as of December&#160;31, 2021 and 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were not material as of December&#160;31, 2021 and 2020, respectively. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102416536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: </span></div><div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities; </span></div><div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and </span></div><div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities, and foreign currency exchange contracts are reported at their respective fair values on our Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Consolidated Balance Sheets. The remaining financial instruments are reported on our Consolidated Balance Sheets at amounts that approximate current fair values. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Arcus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,320&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,279&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,008&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Consolidated Balance Sheets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of equity securities resulted in net unrealized losses of $610 million and $1.7 billion and net unrealized gains of $1.2 billion for the years ended December&#160;31, 2021, 2020 and 2019 respectively, which were included in Other income (expense), net, on our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments and other equity investments without readily determinable fair values were $338 million and $262 million as of December&#160;31, 2021 and 2020, respectively, and were excluded from the above tables. These amounts were included in Other long-term assets on our Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transaction</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, we donated certain equity securities at fair value to the Gilead Foundation, a California nonprofit organization (the &#8220;Foundation&#8221;). The Foundation is a related party as certain officers of the company also serve as directors of the Foundation. The donation expense of $212&#160;million was recorded within Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of Level 2 investments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates (&#8220;LIBOR&#8221;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our aggregate short-term and long-term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December&#160;31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our first quarter 2021 acquisition of MYR, we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis, except for the liability for contingent consideration. The estimated fair value of the liability for contingent consideration was $341 million and $317&#160;million as of the acquisition date and December&#160;31, 2021, respectively. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex. See Note 6. Acquisitions for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;), we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis. The liability assumed related to the sale of future royalties is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December&#160;31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December&#160;31, 2021 and 2020. See Note 6. Acquisitions and Note 12. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, in connection with collaborations and other equity arrangements we entered into with Pionyr Immunotherapeutics Inc. (&#8220;Pionyr&#8221;) and Tizona Therapeutics, Inc. (&#8220;Tizona&#8221;), we also measured fair values of our exclusive options to acquire the remaining outstanding capital stock of Pionyr and Tizona on a nonrecurring basis. See Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we measured IPR&amp;D intangible assets acquired in connection with the acquisition of Kite Pharma, Inc. (&#8220;Kite&#8221;) at fair value on a nonrecurring basis, and recognized a pre-tax impairment charge of $800 million. The fair values of the acquired IPR&amp;D assets are estimated based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements, and inputs include estimated revenues, costs, probability of technical and regulatory success and discount rates. Amounts capitalized as IPR&amp;D are subject to impairment testing until the completion or abandonment of the associated R&amp;D efforts. See Note 9. Goodwill and Intangible Assets for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy is to recognize transfers into or out of Level 3 classification as of the actual date of the event or change in circumstances that caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102568424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Available-for-sale Debt Securities</a></td>
<td class="text">AVAILABLE-FOR-SALE DEBT SECURITIES <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>We held a total of 534 and 75 positions which were in unrealized loss positions as of December&#160;31, 2021 and 2020, respectively. Aggregated gross unrealized losses on available-for-sale debt securities were not material for the years ended December&#160;31, 2021 and 2020. No impairment was recognized for the years ended December&#160;31, 2021, 2020 and 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102495256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">DERIVATIVE FINANCIAL INSTRUMENTS<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates, and as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges, and as a result, changes in their fair value are recorded in Other income (expense), net, on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and each reporting period thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in AOCI are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of December&#160;31, 2021 are expected to be reclassified to Product sales within 12 months.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the years ended December&#160;31, 2021, 2020 and 2019 were included within Net cash provided by operating activities on our Consolidated Statements of Cash Flows.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had notional amounts on foreign currency exchange contracts outstanding of $2.9 billion and $2.4 billion as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. The following table summarizes the classification and fair values of derivative instruments in our Consolidated Balance Sheets: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other&#160;current&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other&#160;current&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.339%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other&#160;current&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other&#160;current&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Consolidated Financial Statements:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from AOCI into Product sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Consolidated Statements of Income. There were no discontinuances of cash flow hedges for the years presented.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, we only held foreign currency exchange contracts.&#160;The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Consolidated Balance Sheets:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Offset on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received/Pledged</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount (Legal Offset)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102477144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">ACQUISITIONS <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYR</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#8220;EMA&#8221;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Consolidated Financial Statements from the date of the acquisition. Acquisition-related expenses were not material for the year ended December&#160;31, 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate consideration for this acquisition of &#8364;1.3 billion (or $1.6 billion) primarily consisted of &#8364;1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to &#8364;300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $341 million as of the acquisition date and was initially recorded in Other long-term obligations on our Consolidated Balance Sheets. In the second quarter of 2021, the balance was reclassified to Accrued and other current liabilities on our Consolidated Balance Sheets. The estimated fair value of this contingent liability was $317&#160;million as of December&#160;31, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be generally recognized at fair value as of the acquisition date. The fair value estimates for the assets acquired and liabilities assumed were based upon valuations using information known and knowable as of the date of this filing. Changes to these assumptions and estimates could cause an impact to the valuation of assets acquired, including intangible assets, goodwill and the related tax impacts of the acquisition, as well as legal and other contingencies. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $845 million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 10 years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D consists of Hepcludex for HDV in all other regions without regulatory approval, including the United States. The estimated aggregate fair value of $1.19 billion as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to this asset and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the more significant assumptions inherent in the development of intangible asset fair values include: estimates of projected future cash flows, including revenues and operating profits; probability of success; the discount rate selected; the life of the potential commercialized products and the risks related to the viability of and potential alternative treatments in any future target markets, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. See Note 3. Fair Value Measurements for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $226 million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is not expected to be deductible for income tax purposes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the year ended December 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunomedics</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we completed the acquisition of Immunomedics, a company focused on the development of antibody-drug conjugate technology, for cash consideration of $20.6 billion. Upon closing, Immunomedics became a wholly-owned subsidiary of Gilead. The acquisition was financed with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $1.0 billion borrowing under a new senior unsecured term loan facility and cash on hand. In 2021, we repaid the borrowing under the senior unsecured term loan facility. See Note 12. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded share-based compensation expense of $289 million related to the cash settlement of the accelerated share-based compensation expense attributable to the post-combination period, which was primarily recorded in Selling, general and administrative expenses and Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. We also recorded other acquisition-related expenses of $39 million, primarily representing closing costs and related fees, in Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December 31, 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Immunomedics was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be generally recognized at fair value as of the acquisition date. There were no material measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the year ended December 31, 2021. The fair value estimates for the assets acquired and liabilities assumed have been completed. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value step-up adjustment of $881 million, included in inventories of $946&#160;million as of the acquisition date, was primarily determined by the estimated selling price of finished inventory less the cost to complete the manufacturing process and selling effort. The step-up adjustment is recorded in Cost of goods sold on our Consolidated Statements of Income as the inventory is sold to customers and in Research and development expenses on our Consolidated Statements of Income for inventory used for clinical purposes.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $4.6 billion represents the estimated fair value of Trodelvy for metastatic triple-negative breast cancer (&#8220;TNBC&#8221;) as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Trodelvy for metastatic TNBC and a discount rate of 7.0%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 12 years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D assets consist of Trodelvy for hormone receptor positive, human epidermal growth factor receptor 2 negative, metastatic breast cancer, Trodelvy for non-small cell lung cancer and Trodelvy for urothelial cancer (&#8220;UC&#8221;). The estimated aggregate fair value of&#160;$15.8 billion&#160;as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to these assets and a discount rate of 7.0%. The discount rate used represents the estimated rate that market participants would use to value these intangible assets. Trodelvy for UC was granted accelerated approval by FDA in April 2021 and $1.0 billion was reclassified to finite-lived intangibles from IPR&amp;D. See Note 9. Goodwill and Intangible Assets for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the more significant assumptions inherent in the development of intangible asset fair values include: the amount and timing of projected future cash flows (including revenue, cost of sales, research and development costs, and sales and marketing expenses); probability of success; the discount rate selected to measure the inherent risk of future cash flows; the assessment of the asset&#8217;s life cycle and the competitive trends impacting the asset, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recorded an intangible asset related to a license and supply agreement with a third party, which was entered into by Immunomedics prior to the acquisition. Under the agreement, the third party was granted an exclusive license to develop and commercialize Trodelvy in certain territories in Asia and make certain sales milestones and royalty payments to us. The acquisition date fair value of $175 million was determined by estimating the probability-weighted net cash flows attributable to the outlicense and a discount rate of 7.0%. The discount rate represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 15 years on a straight-line basis. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of Immunomedics.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust (&#8220;RPI&#8221;), prior to our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The acquisition date fair value of the liability was estimated as $1.1 billion, which was primarily determined based on current estimates of future royalty payments to RPI over the life of the arrangement using the real options method and an effective annual interest rate of 2.5%. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over 16 years. The estimated timing and amount of future expected royalty payments over the estimated term will be re-assessed each reporting period. The impact from changes in estimates will be recognized in the liability and the related interest expense prospectively. The inputs used for valuation of this liability are unobservable and are considered Level 3 under the fair value measurement and disclosure guidance. See Note 3. Fair Value Measurements for additional information. The liability related to future royalties was categorized as debt and primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 12. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The&#160;excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $4.0 billion was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for Immunomedics is not expected to be deductible for income tax purposes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forty Seven, Inc. (&#8220;Forty Seven&#8221;) </span></div>In the second quarter of 2020, we completed the acquisition of Forty Seven, a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for total consideration of $4.7 billion, net of acquired cash. Upon closing, Forty Seven became a wholly-owned subsidiary of Gilead. We accounted for the transaction as an asset acquisition since the lead asset, magrolimab, represented substantially all the fair value of the gross assets acquired. During the year ended December 31, 2020, we recorded a $4.5 billion charge representing an acquired IPR&amp;D asset with no alternative future use in Acquired in-process research and development expenses, and stock-based compensation expense of $144 million primarily in Research and development expenses on our Consolidated Statements of Income.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102570568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">INVENTORIES<div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported as Other long-term assets primarily consisted of raw materials as of December&#160;31, 2021 and 2020. Total inventories as of December&#160;31, 2021 and 2020 include $294&#160;million and $797&#160;million, respectively, of fair value adjustments resulting from the Immunomedics acquisition. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventory write-down charges were $228 million, $86 million and $649 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. During the year ended December&#160;31, 2019, $547 million of the $649 million inventory write-down charges was related to slow-moving and excess raw material and work in process inventory primarily due to lower long-term demand for our HCV products.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102942616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Property, plant and equipment, net: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements (including leasehold improvements)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,014&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had unamortized capitalized software costs, included in Office, computer equipment and other, of $131 million and $124 million as of December&#160;31, 2021 and 2020, respectively. Capitalized interest on construction in progress is included in Property, plant and equipment, net on our Consolidated Balance Sheets. Interest capitalized in 2021 and 2020 was not material.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net book value of our property, plant and equipment in the United States was $4.1 billion and $4.0 billion as of December&#160;31, 2021 and 2020, respectively. The corresponding amount in international locations was $963 million and $940 million as of December&#160;31, 2021 and 2020, respectively. All individual international locations accounted for less than 10% of the total balances.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102623736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of Goodwill:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an annual goodwill impairment assessment in the fourth quarter or earlier if impairment indicators exist. As of December&#160;31, 2021, there were no accumulated goodwill impairment losses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,915&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,535&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,897&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes $910&#160;million reclassified in the first quarter of 2021 from indefinite-lived assets - IPR&amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes Trodelvy for metastatic TNBC and Trodelvy for use in adult patients with locally advanced or metastatic UC. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;D upon the accelerated approval by FDA in April 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million was reclassified to finite-lived assets in the fourth quarter of 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes IPR&amp;D from our 2021 acquisition of MYR and remaining IPR&amp;D from our 2020 acquisition of Immunomedics. Gross carrying amount as of December&#160;31, 2020 includes IPR&amp;D from our 2020 acquisition of Immunomedics and remaining IPR&amp;D from our 2017 acquisition of Kite. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $1.7 billion, $1.2 billion and $1.1 billion for the years ended December&#160;31, 2021, 2020 and 2019, respectively, and is primarily included in Cost of goods sold on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts capitalized as IPR&amp;D are subject to impairment testing until the completion or abandonment of the associated R&amp;D efforts</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we performed a qualitative assessment of our IPR&amp;D intangible asset obtained in connection with our first quarter 2021 acquisition of MYR and did not identify any indicators of impairment.</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, 2020 and 2019, we performed quantitative impairment testing of our IPR&amp;D intangible assets, other than the MYR asset described above, using a probability-weighted income approach that discounts expected future cash flows to present value using discount rates of 6.5%, 8.0% and 9.5%, respectively</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rates are based on the estimated weighted-average cost of capital for companies with profiles similar to our profile and represents the rate that market participants would use to value the intangible assets. The discounted cash flow models used in valuing these intangible assets also require the use of Level 3 fair value measurements and inputs including estimated revenues, costs, and probability of technical and regulatory success. No IPR&amp;D impairment charges were recorded in 2021 and 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we lowered our estimated revenues related to our IPR&amp;D intangible asset - axicabtagene ciloleucel for the treatment of indolent B-cell non-Hodgkin lymphoma due to changes in the estimated market opportunities as new therapies or combinations of existing therapies were approved. The lower estimated revenues reduced the fair value of the IPR&amp;D intangible assets below carrying value resulting in the recognition of an impairment charge of $800 million, which was recorded within Acquired in-process research and development expenses on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2021:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585187816008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Financial Information</a></td>
<td class="text">OTHER FINANCIAL INFORMATION<div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net: </span></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,278&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,560&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued and other current liabilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Accrued and other current liabilities:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for settlement related to bictegravir litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See Note 14. Commitments and Contingencies for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102505528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeandOtherArrangementsAbstract', window );"><strong>Collaborative and Other Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeAndOtherArrangementsTextBlock', window );">Collaborations and Other Arrangements</a></td>
<td class="text">COLLABORATIONS AND OTHER ARRANGEMENTS We enter into licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements and cost-sharing arrangements. We also have equity investments in third parties focused on the development and commercialization of products and product candidates. <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merck &amp; Co, Inc. (&#8220;Merck&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2021, we entered into a license and collaboration agreement with Merck Sharp &amp; Dohme Corp., a subsidiary of Merck to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#8217;s investigational capsid inhibitor, lenacapavir, and Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration will initially focus on long-acting oral and injectable formulations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Gilead and Merck will share global development and commercialization costs at 60% and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, Gilead would lead commercialization in the United States, and Merck would lead commercialization in the European Union (&#8220;EU&#8221;) and rest of the world. For long-acting injectable products, if approved, Merck would lead commercialization in the United States and Gilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, Gilead and Merck would jointly promote the combination products in the United States and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of research and development costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Income. Expenses recognized under the agreement were not material for the year ended December 31, 2021. No revenues have been recognized under the agreement for the year ended December 31, 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also have the option to license certain of Merck&#8217;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#8217;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first five years after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out, in which case the non-exercising company will be paid a royalty.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Merck announced the decision of the parties to stop all dosing of participants in the Phase 2 clinical study evaluating an oral-weekly combination treatment regimen of lenacapavir and islatravir following the decision of FDA to place clinical holds on the investigational new drug applications for certain formulations of islatravir. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arcus</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2020, we entered into a transaction with Arcus, a publicly traded oncology-focused biopharmaceutical company, which included entry into an option, license and collaboration agreement (the &#8220;Collaboration Agreement&#8221;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the &#8220;Stock Purchase Agreements&#8221;). In accordance with the terms of the Collaboration Agreement and Stock Purchase Agreements, which closed on July 13, 2020, we made an upfront payment of $175 million and acquired approximately 6.0&#160;million shares of Arcus common stock for approximately $200 million. Of the total $391 million initial cash payments, including transactional costs, made under the agreements, we recorded $135 million as an equity investment which was calculated based on Arcus&#8217; closing stock price on the closing date of the transaction. The remaining $256 million was attributed to (i) the acquired license and option rights of $175 million representing IPR&amp;D assets with no alternative future use, (ii) $65 million of an issuance premium for the equity purchase and (iii) $16 million of direct transactional costs. These amounts were expensed as Acquired in-process research and development expenses during the year ended December 31, 2020 on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Stock Purchase Agreements, we have the right to purchase additional shares of Arcus from Arcus over the five-year period beginning on the closing of the Stock Purchase Agreements, up to a maximum of 35% of the outstanding voting stock. We are subject to a three-year standstill, restricting our ability to acquire voting stock of Arcus exceeding more than 35% of the then-issued and outstanding voting stock of Arcus, subject to certain exceptions. Additionally, we agreed not to dispose of any equity securities of Arcus prior to the second anniversary of the closing of the Stock Purchase Agreements without the prior consent of Arcus, subject to certain exceptions. On May 29, 2020, in a separate secondary equity offering, we acquired 2.2&#160;million shares of common stock of Arcus for approximately $61 million. In the first quarter of 2021, we also acquired approximately 5.7&#160;million additional shares of Arcus common stock for $220 million. As a result, we currently own a total of 13.8&#160;million shares of Arcus, which represented approximately 19.5% of the issued and outstanding voting stock of Arcus immediately following the closing of the first quarter 2021 transaction. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Collaboration Agreement, Gilead had the right to opt in to all current and future clinical-stage product candidates for up to ten years following the closing of the transaction. In November 2021, we exercised our options to three of Arcus&#8217; clinical stage programs and amended the Collaboration Agreement. The option exercise and amendment transaction closed in December 2021, triggering collaboration opt-in payments of $725 million and waiving the $100 million option continuation payment which would have been due to Arcus in the third quarter of 2022. The net option charge of $625 million was recorded within Research and development expenses on our Consolidated Statements of Income for the year ended December&#160;31, 2021. The collaboration opt-in payments of $725 million were recorded in Accrued and other current liabilities on our Consolidated Balance Sheets as of December&#160;31, 2021 and paid to Arcus in January 2022. Our payments to Arcus will be included within Net cash provided by investing activities on our Consolidated Statements of Cash Flows in the first quarter of 2022. Under the amended Collaboration Agreement, the companies will co-develop and share the global costs related to these clinical programs. If the optioned molecules achieve regulatory approval, the companies will co-commercialize and equally share profits in the U.S. Gilead will hold exclusive commercialization rights outside the U.S., subject to any rights of Arcus&#8217;s existing collaboration partners, and will pay to Arcus tiered royalties as a percentage of net sales ranging from the mid-teens and low twenties. Under the Collaboration Agreement, we may also pay an additional $100 million at our option on each of the fourth, sixth and eighth anniversaries of the agreement, unless terminated early, to maintain the rights to opt-in to future Arcus programs for the duration of the contact term. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected and applied the fair value option to account for our equity investment in Arcus whereby the investment is marked to market each reporting period based on the market price of Arcus shares. We believe the fair value option best reflects the underlying economics of the investment. During the years ended December&#160;31, 2021 and 2020, we recorded pre-tax</span><span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrealized gains of</span><span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$127 million and $80 million, respectively, related to our investment in Arcus in Other income (expense), net on our Consolidated Statements of Income. We initially recorded our equity investments in Arcus in Other long-term assets on our Consolidated Balance Sheets as the investments were subject to contractual lock-up provisions for a period of two years from the closing date of the Stock Purchase Agreements, subject to certain conditions. In the third quarter of 2021, we reclassified our equity investments in Arcus to Prepaid and other current assets on our Consolidated Balance Sheets as the contractual lock-up provisions are expected to expire in July 2022. Our equity investment in Arcus was $559 million and $212 million as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pionyr</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, we entered into a transaction with Pionyr, a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate merger agreements, one contemplating the initial acquisition of a 49.9% equity interest in Pionyr, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (together, the &#8220;Pionyr Merger and Option Agreements&#8221;) and a research and development service agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2020, we closed the transaction and made cash payments of $269 million. We account for our investment in Pionyr using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Pionyr. Our investment in Pionyr, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Pionyr's net assets at transaction closing. We determined that the resulting basis difference primarily relates to Pionyr&#8217;s IPR&amp;D which has no alternative future use and that Pionyr is not a business as defined in ASC 805, &#8220;Business Combinations.&#8221; As a result, we immediately recorded a charge for this basis difference of $215 million in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. The carrying value of our equity method investment in Pionyr was zero as of December&#160;31, 2021 and 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Pionyr is approximately $70 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount is recorded in Other long-term assets on our Consolidated Balance Sheets. We may choose to exercise our exclusive option to purchase the remaining equity interest from Pionyr&#8217;s current shareholders for a $315 million option exercise fee and up to $1.2 billion in potential future milestone payments upon achievement of certain development and regulatory milestones. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Pionyr. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the research and development service agreement, we made an initial cash funding of $80 million and recorded a charge in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. In addition, we committed to provide additional payments of up to $115 million to Pionyr upon achievement of certain development milestones. We accrued $70 million in milestone payments, related to the initiation of two Phase 1 studies, with a charge to Research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020, and the payment was made in the first quarter of 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tizona</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, we entered into a transaction with Tizona, a privately held company developing cancer immunotherapies, which included entry into two separate merger agreements, one contemplating the initial acquisition of a 49.9% equity interest in Tizona, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Tizona (together, the &#8220;Tizona Merger and Option Agreements&#8221;) and a development agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, we closed the transaction with Tizona and made cash payments of $302 million to Tizona&#8217;s shareholders in accordance with the terms of the Tizona Merger and Option Agreements. We account for our investment in Tizona using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Tizona. Our investment in Tizona, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Tizona&#8217;s net assets at transaction closing. We determined that the resulting basis difference primarily relates to Tizona&#8217;s IPR&amp;D with no alternative future use and that Tizona is not a business as defined in ASC 805, &#8220;Business Combinations.&#8221; As a result, during the year ended December 31, 2020, we immediately recorded a charge for this basis difference of $272 million in Acquired in-process research and development expenses on our Consolidated Statements of Income. The carrying value of our equity method investment in Tizona was zero as of December&#160;31, 2021 and 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Tizona is approximately $41 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount is recorded in Other long-term assets on our Consolidated Balance Sheets. We may choose to exercise our exclusive option to purchase the remaining equity interest from Tizona&#8217;s current shareholders for a $100 million option exercise fee and up to $1.2 billion in potential future milestone payments upon achievement of certain development and regulatory milestones. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Tizona. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the development agreement, we committed to provide funding to Tizona of $115 million, which was recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tango Therapeutics, Inc. (&#8220;Tango&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2020, we entered into a transaction with Tango, a privately held company pursuing innovative targeted immune evasion therapies for patients with cancer through its proprietary, CRISPR-enabled functional genomics target discovery platform, which included entry into an amended and restated research collaboration and license agreement and a stock purchase agreement (together, the &#8220;Tango Collaboration and Stock Purchase Agreements&#8221;). </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into this transaction, we made an upfront payment of $125 million and a $20 million equity investment in Tango. During the year ended December 31, 2020, we recorded the $125 million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income. In the third quarter of 2021, we made an additional $13 million equity investment. Tango became a publicly traded company in the third quarter of 2021, and accordingly our equity investment is recorded in Prepaid and other current assets on our Consolidated Balance Sheets at fair market value as of December&#160;31, 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tango Collaboration and Stock Purchase Agreements, Gilead has the right to option up to 15 programs over the seven-year collaboration for up to $410 million per program in opt-in, extension and milestone payments. For the products that Tango opts to co-develop and co-promote, the parties will equally split profits and losses, as well as development costs in the U.S. For products that Tango does not opt to co-develop and co-promote, we will pay Tango up to low double-digit tiered royalties on net sales. We will provide Tango milestone payments and royalties on sales outside of the U.S. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jounce Therapeutics, Inc. (&#8220;Jounce&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, we entered into a transaction with Jounce, a publicly traded company developing novel cancer immunotherapies, which included entry into license, registration rights and stock purchase agreements (together, &#8220;Jounce License and Stock Purchase Agreement&#8221;). In October 2020, we closed this transaction and made a total payment of $120 million. We recorded $64 million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income and $56 million as an equity investment in Other long-term assets on our Consolidated Balance Sheets, representing approximately 14% of the issued and outstanding voting stock of Jounce immediately following the transaction, which was calculated based on Jounce&#8217;s closing stock price on the closing date of the transaction. As of December&#160;31, 2021, Jounce was eligible to receive from us up to $660 million in future potential clinical, regulatory and commercial milestone payments upon achievement of certain milestones, and royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Galapagos</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Filgotinib Collaboration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we closed a license and collaboration agreement with Galapagos, a clinical-stage biotechnology company based in Belgium, for the development and commercialization of filgotinib, a JAK1-selective inhibitor being evaluated for inflammatory disease indications (the &#8220;filgotinib agreement&#8221;). Upon closing, we made an upfront license fee payment and an equity investment in Galapagos by subscribing for 6.8 million new ordinary shares of Galapagos at a price of &#8364;58 per share. We amended the terms of the agreement in 2019, 2020 and 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the filgotinib agreement, as amended in 2019 (the &#8220;2019 Agreement&#8221;), we obtained an exclusive, worldwide, royalty-bearing, sublicensable license for filgotinib and products containing filgotinib. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, following a Type A meeting with FDA to discuss the points raised in the Complete Response Letter related to the New Drug Application for filgotinib in the treatment of rheumatoid arthritis, Gilead and Galapagos agreed to amend the 2019 Agreement to allow Galapagos to assume development, manufacturing, commercialization and certain other rights for filgotinib in Europe which the parties reflected in an amendment to the 2019 Agreement in December 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning on January 1, 2021, Galapagos bore the development costs for certain studies, in lieu of the equal cost split contemplated by the 2019 Agreement. The parties transferred filgotinib&#8217;s marketing authorizations in the EU and Great Britain to Galapagos in December 2021. As of January 1, 2022, all commercial economics on filgotinib in Europe transferred to Galapagos, subject to payment of tiered royalties of 8% to 15% of net sales in Europe to Gilead, starting in 2024. In connection with the amendments to the 2019 Agreement, Gilead agreed to irrevocably pay Galapagos &#8364;160 million (or approximately $190 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is subject to certain adjustments for higher-than-budgeted development costs. Of this total amount, Gilead paid &#8364;35 million (or approximately $43 million) in January 2021 and paid an additional &#8364;75 million (or approximately $88 million) in April 2021 and will pay &#8364;50 million (or approximately $60 million) in 2022. We accrued the full amount of this liability with a charge to Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. In addition, Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Collaboration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In&#160;August 2019, we closed an option, license and collaboration Agreement (the &#8220;Galapagos Collaboration Agreement&#8221;) and a subscription agreement (the &#8220;Galapagos Subscription Agreement&#8221;), each with Galapagos, pursuant to which the parties entered into a global collaboration that covers Galapagos&#8217; current and future product portfolio (other than filgotinib). Upon closing, we paid $5.05 billion for the license and option rights and for 6.8 million new ordinary shares of Galapagos at a subscription price of &#8364;140.59 per share with a fair value of $1.13 billion, which included an issuance discount of $63 million calculated based on Galapagos&#8217; closing stock price on the date of closing of the Galapagos Subscription Agreement. The remaining $3.92 billion of the payment was recorded within Acquired in-process research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2019. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Galapagos Subscription Agreement, we were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by Galapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. In 2019, we exercised a warrant to subscribe for 2.6 million ordinary shares of Galapagos at &#8364;140.59 per share and purchased shares on the open market with an aggregate fair value of $586 million, which brought the number of shares owned by us to 16.7 million or approximately 25.8% of the shares then issued and outstanding. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a 10-year standstill restricting our ability to acquire voting securities of Galapagos exceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We agreed not to, without the prior consent of Galapagos, dispose of any equity securities of Galapagos prior to the second anniversary of the closing of the Galapagos Subscription Agreement or dispose of any equity securities of Galapagos thereafter until the fifth anniversary of the closing of the Galapagos Subscription Agreement, if after such disposal we would own less than 20.1% of the then-issued and outstanding voting securities of Galapagos, subject to certain exceptions and termination events. In April 2021, we amended the Galapagos Subscription Agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024. We have two designees appointed to Galapagos&#8217; board of directors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The initial contractual lock-up provision for certain Galapagos shares was due to expire in August 2021. As such, $351 million was included within Prepaid and other current assets on our Consolidated Balance Sheets and the remainder of $1.3 billion was included within Other long-term assets on our Consolidated Balance Sheets as of December&#160;31, 2020. Subsequent to the extension of the contractual lock-up period, all of our equity investment in Galapagos was classified to Other long-term assets on our Consolidated Balance Sheets, and was $931 million as of December&#160;31, 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos&#8217; shares. We believe the fair value option best reflects the underlying economics of the investment. During the years ended December&#160;31, 2021, 2020 and 2019, we recorded pre-tax</span><span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrealized losses of</span><span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$717 million and $1.8 billion and a pre-tax unrealized gain of $1.2 billion, respectively, related to our investment in Galapagos in Other income (expense), net on our Consolidated Statements of Income due to changes in Galapagos&#8217; stock price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Galapagos Collaboration Agreement, we had an exclusive license for the development and commercialization of GLPG-1690, a late-stage candidate for idiopathic pulmonary fibrosis, in our territories and had an option to participate in the development and commercialization of Galapagos&#8217; other current and future clinical programs that have entered clinical development during the first ten years of the collaboration, subject to extension in certain circumstances. Gilead and Galapagos terminated the Phase 3 clinical studies with GLPG-1690 in February 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to all other programs in Galapagos&#8217; current and future pipeline, if we exercise our option to a program, we will pay a $150 million option exercise fee per program. In addition, Galapagos will receive tiered royalties ranging from 20% to 24% on net sales in our territories of each Galapagos product optioned by us. If we exercise our option for a program, the parties will share equally in development costs and mutually agreed commercialization costs incurred subsequent to our exercise of the option. We may terminate the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Janssen</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Complera/Eviplera and Odefsey</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, we entered into a license and collaboration agreement with Janssen, formerly Tibotec Pharmaceuticals, to develop and commercialize a fixed-dose combination of our Truvada and Janssen&#8217;s non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011 and is sold under the brand name Complera in the U.S. and Eviplera in the EU.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen&#8217;s rilpivirine and our emtricitabine and tenofovir alafenamide (&#8220;Odefsey&#8221;).</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party&#8217;s component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen&#8217;s share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen&#8217;s share of revenues is included in Cost of goods sold on our Consolidated Statements of Income. Cost of goods sold relating to Janssen&#8217;s share was $530 million, $570 million and $574 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products, in which case Janssen has the right to become the selling party for such country if the product has launched but has been on the market for fewer than 10 years.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symtuza</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen&#8217;s darunavir and our cobicistat, emtricitabine and tenofovir alafenamide (&#8220;Gilead Compounds&#8221;). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the Gilead Compounds and are the exclusive supplier of the Gilead Compounds. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Symtuza. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party&#8217;s component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Income primarily because we supply the Gilead Compounds to Janssen for Symtuza.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Japan Tobacco, Inc. (&#8220;Japan Tobacco&#8221;) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2005, Japan Tobacco granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Income. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Income. Royalty expenses recognized were $250 million, $291 million and $358 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are expected to be derived from the applicable products in our HIV portfolio. The amortization expense is classified as selling expense and recorded as Selling, general and administrative expenses on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gadeta B.V. (&#8220;Gadeta&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we entered into a collaboration arrangement with Gadeta and made a purchase of equity in Gadeta from Gadeta&#8217;s shareholders. We determined that Gadeta was a VIE, and we were its primary beneficiary because we had the power to direct the activities of Gadeta that most significantly impact its economic performance. Upon the initial consolidation of Gadeta, we recorded $82 million to Noncontrolling interest, primarily reflecting acquired intangible assets related to IPR&amp;D, on our Consolidated Balance Sheets. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we effectively terminated the agreement with Gadeta. Upon the effective termination, we ceased to have a controlling interest and deconsolidated this VIE by removing the related net assets and noncontrolling interest of $82 million from our Consolidated Balance Sheets. The net loss from the deconsolidation was not material.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Collaboration Arrangements That Are Not Individually Significant </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, 2020 and 2019, we entered into several collaborations, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements of $177 million, $129 million and $331 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively, within Acquired in-process research and development expenses on our Consolidated Statements of Income. Cash payments for our equity investments, other than those noted above, during the years ended December&#160;31, 2021, 2020 and 2019 were $147 million, $72 million and $118 million, respectively, which were primarily recorded within Prepaid and other current assets and Other long-term assets on our Consolidated Balance Sheets. </span></div>Under the financial terms of these arrangements, we may be required to make payments upon achievement of various developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Consolidated Statements of Income when the corresponding events become probable. In connection with the regulatory approvals, milestone payments made will be capitalized as intangible assets and will be amortized to Cost of goods sold through the terms of these collaboration arrangements. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeAndOtherArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Arrangements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeAndOtherArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeandOtherArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeandOtherArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102943448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt and Credit Facilities</a></td>
<td class="text">DEBT AND CREDIT FACILITIES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.551%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.15%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.52%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes and term loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,571&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,295&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,695&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,402&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt and other obligations, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes and Term Loan Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we repaid $4.75 billion of debt, consisting of $3.75 billion senior unsecured notes and $1.0 billion of our senior unsecured term loan facility. We repaid $1.0 billion of senior unsecured notes due April 2021 in the first quarter of 2021 and $1.25 billion of senior unsecured notes due December 2021 in the third quarter of 2021. Additionally, we repaid $500 million of senior unsecured floating rate notes due upon maturity in September 2021. In October 2021, we exercised our option to call $500 million of senior unsecured floating rate notes and $500 million of 0.75% senior unsecured notes, both having a final maturity date of September 2023. These two early repayments totaling $1.0&#160;billion principal amount were made in the fourth quarter of 2021. In December 2021, we exercised our option to call $500 million of senior unsecured notes having a final maturity of March 2022. The notes were repaid in February 2022. No new debt was issued in 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our senior unsecured fixed rate notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed and (ii) the sum, as determined by an independent investment banker, of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium as defined in the indenture. The senior unsecured fixed rate notes also have a call feature, exercisable at our option, to redeem the notes at par in whole, or in part, on dates ranging from one month to two years prior to maturity. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption. The $1.5&#160;billion of 0.75% senior unsecured notes due September 2023 also have a call feature, exercisable at our option, to redeem the notes at par, in whole or in part, after September 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of the occurrence of a change in control and a downgrade in the rating of our senior unsecured notes below investment grade by Moody&#8217;s Investors Service, Inc. and S&amp;P Global Ratings, the holders may require us to purchase all or a portion of their notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest to the date of repurchase. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of December&#160;31, 2021 and 2020, we were not in violation of any covenants.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a commitment letter with a group of institutional lenders to provide for a three-year senior unsecured term loan facility in an aggregate principal amount of $1.0&#160;billion. In October 2020, in connection with our acquisition of Immunomedics, we entered into a term loan credit agreement (the &#8220;Term Loan Facility&#8221;) and borrowed an aggregate principal amount of $1.0&#160;billion. In 2021, we repaid $1.0 billion principal amount outstanding under the Term Loan Facility which was due upon maturity in October 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics, we assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI, prior to our acquisition of Immunomedics. The liability related to future royalties was primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 6. Acquisitions for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revolving Credit Facilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we terminated our $2.5 billion five-year revolving credit facility maturing in May 2021 (the &#8220;2016 Revolving Credit Facility&#8221;) and entered into a new $2.5 billion five-year revolving credit facility maturing in June 2025 (the &#8220;2020 Revolving Credit Facility&#8221;). The 2020 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of December&#160;31, 2021 and 2020, there were no amounts outstanding under the 2020 Revolving Credit facility.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Revolving Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default. As of December&#160;31, 2021, we were in compliance with all covenants. Loans under the 2020 Revolving Credit Facility bear interest at either (i) the Eurodollar Rate plus the Applicable Percentage, or (ii) the Base Rate plus the Applicable Percentage, each as defined in the 2020 Revolving Credit Facility agreement. We may terminate or reduce the commitments, and may prepay any loans under the credit facility in whole or in part at any time without premium or penalty.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Maturities of Financing Obligations</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate future principal maturities of our senior unsecured notes as of December&#160;31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div>Interest expense on our debt and credit facilities related to the contractual coupon rates and amortization of the debt discount and issuance costs was $1.0 billion in 2021, 2020 and 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102941496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases consist primarily of properties and equipment for our administrative, manufacturing and R&amp;D activities. Some of our leases include options to extend the terms for up to 15 years and some include options to terminate the lease within one year after the lease commencement date. As of December&#160;31, 2021 and 2020, we did not have material finance leases. Operating lease expense, including variable costs and short-term leases, was $156 million, $171 million and $162 million in 2021, 2020 and 2019, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balance sheet and other information related to our operating leases:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except weighted average amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_bf1a57bf-a703-4b3f-bc9b-0294a5049060"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_c74f8a0a-3c1e-43dc-9a44-91448c3a81f3">Other long-term assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_3f97a2d5-98a1-46a4-8619-f3becdea71f5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_c90d340b-270c-4dd6-bbe4-3b313ad42434">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_511d014a-a5ee-4a2c-a65f-0d75ca7b60e9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_7e2903b1-a222-4253-bf44-fbb3ee9aa161">Other long-term obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to our operating leases:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total discounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102580280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2021, we reversed a $175 million previously recorded litigation accrual following a favorable court decision for the litigation related to axicabtagene ciloleucel described below. In the fourth quarter of 2021, we recorded an accrual of $1.25 billion in Accrued and other current liabilities on our Consolidated Balance Sheets for the settlement related to bictegravir litigation described below.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concludes the inter partes review that it has initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#8217;s patent invalid. In July 2021, the University appealed this decision. The litigation in the U.S. District Court will remain stayed through the appeal proceedings.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with NuCana plc. (&#8220;NuCana&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuCana has obtained European Patent No. 2,955,190 (the &#8220;EP &#8217;190 patent&#8221;) that allegedly covers sofosbuvir. In opposition proceedings before the European Patent Office (&#8220;EPO&#8221;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#8217;190 patent in amended form. We believe that the amended EP &#8217;190 patent claims are invalid. Subsequently, we initiated proceedings to invalidate the UK counterpart of the EP &#8217;190 patent in the High Court of England &amp; Wales. In March 2021, NuCana filed a counterclaim against us in the High Court of England &amp; Wales alleging patent infringement of the UK counterpart and seeking damages and other relief. In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#252;sseldorf alleging patent infringement of the German counterpart of the EP &#8217;190 patent and seeking damages and injunctive relief. The hearing date for the German NuCana case has been scheduled for May 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hearing date for the UK NuCana case has been scheduled for January 2023.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Axicabtagene Ciloleucel</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#8220;&#8217;190 patent&#8221;). A jury trial was held on the &#8217;190 patent, and in December 2019, the jury found that the asserted claims of the &#8217;190 patent were valid, and that we willfully infringed the asserted claims of the &#8217;190 patent. The jury also awarded Juno damages in amounts of $585 million in an upfront payment and a 27.6% running royalty from October 2017 through the date of the jury&#8217;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#8217;s verdict, enhanced the past damages by 50% and maintained the royalties on future Yescarta sales at 27.6%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge, and in July 2021, the appeals court heard oral arguments. In August 2021, the Court of Appeals for the Federal Circuit (the &#8220;CAFC&#8221;) reversed the jury verdict, finding the asserted claims of Juno&#8217;s patent invalid. In October 2021, Juno filed a petition for rehearing with the CAFC. In January 2022, the CAFC denied Juno&#8217;s petition for rehearing. We believe that the likelihood of a material adverse outcome in this matter is remote.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Bictegravir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV Healthcare Company (&#8220;VHC&#8221;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes VHC&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;) covering VHC&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#8217;385 patent. In its lawsuit, VHC was seeking billions of dollars for alleged damages comprised of VHC&#8217;s lost profits and a royalty on U.S. sales of bictegravir from launch through the trial. In addition, should a court find that we are liable for infringement, we also expected VHC to seek a royalty on U.S. sales after the trial.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, VHC also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound infringes VHC&#8217;s Canadian Patent No. 2,606,282 (the &#8220;&#8217;282 patent&#8221;), which was issued to Shionogi &amp; Co. Ltd. and VHC. The &#8217;282 patent is the compound patent covering VHC&#8217;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#8217;282 patent. In November and December 2019, VHC filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206; in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 and 1363875. These patents all relate to molecules that VHC claims would act as integrase inhibitors. We believe that bictegravir does not infringe any valid claims of VHC&#8217;s patents and have prevailed in court proceedings to date in Canada and Germany. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2022, Gilead reached an agreement (the &#8220;Settlement&#8221;) with VHC, ViiV Healthcare UK (No.3) Limited, ViiV Healthcare UK Limited, Shionogi &amp; Co., Ltd. and GlaxoSmithKline Mercury Limited (collectively, &#8220;ViiV&#8221;) for a global resolution of all pending or potential claims related to Gilead&#8217;s sales of Biktarvy, including the litigation pending in the U.S. District Court of Delaware and other jurisdictions outside the United States as described above. In February 2022, the lawsuit pending in the United States was dismissed as well as the lawsuits in Canada, France, Ireland, the UK, Australia, Japan and Korea.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Settlement, ViiV grants Gilead a broad worldwide license and covenant not to sue relating to any past, present or future development or commercialization of bictegravir. In connection with the Settlement, Gilead (1) made a one-time payment to ViiV of $1.25 billion in the first quarter of 2022, and (2) will provide ViiV an ongoing royalty at a rate of 3% on future sales of Biktarvy and the bictegravir component of bictegravir-containing products in the United States until October 5, 2027. In connection with the Settlement, Gilead recorded a pre-tax charge of $1.25 billion to Cost of goods sold on our Consolidated Statements of Income in the fourth quarter of 2021.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine or tenofovir disoproxil fumarate (&#8220;TDF&#8221;) prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the U.S. Court of Federal Claims, alleging violations of four material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and a clinical trial agreement (&#8220;CTA&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Court of Federal Claims has been set for June 2022, and a trial date for the lawsuit in the District Court of Delaware has been set for May 2023.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in December 2019, we received letters from Lupin Ltd., Apotex Inc., Shilpa Medicare Ltd. (&#8220;Shilpa&#8221;), Sunshine Lake Pharma Co. Ltd. (&#8220;Sunshine Lake&#8221;), Laurus Labs, Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (collectively, &#8220;Generic Manufacturers&#8221;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our TAF-containing products. Between them, these Generic Manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. The Generic Manufacturers have challenged the validity of two to four patents listed on the Orange Book and associated with TAF. We filed lawsuits against the Generic Manufacturers, and we intend to enforce and defend our intellectual property. In November 2021, we reached an agreement with Shilpa to resolve the lawsuit against Shilpa. In addition, in January 2022, we reached an agreement with Sunshine Lake to resolve the lawsuit against Sunshine Lake. The settlement agreements have been filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we received a letter from Lupin Ltd. (&#8220;Lupin&#8221;) indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen, filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Lupin asserting infringement of two additional patents in the same court. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. An appeal hearing originally scheduled for July 2021 has been canceled and a new date has not yet been set by the EPO.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. Two of the original opposing parties have appealed, requesting full revocation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. Three parties have appealed this decision. The appeal hearing was held in March 2021, and the validity of all claims were upheld.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, three parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. Two parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the EU could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We (along with Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and Johnson &amp; Johnson, Inc.) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes&#8212;one of direct purchasers consisting largely of wholesalers, and another of indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the fall of 2021, several plaintiffs filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the putative classes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These cases have been coordinated with the class actions. Trial is set for March 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we, along with generic manufacturers Cipla Ltd. and Cipla USA Inc. (together, &#8220;Cipla&#8221;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and Cipla, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we along with BMS and Teva Pharmaceutical Industries Ltd. were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in one class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Maryland, Missouri and New Jersey, involve more than 27,000 plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead&#8217;s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The relator seeks all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two former employees filed a qui tam lawsuit against Gilead in April 2020 in California state court. Following the California Attorney General&#8217;s Office&#8217;s decision not to intervene, relators served Gilead with their complaint in August 2020. The complaint alleges violations of the California False Claims Act (&#8220;CFCA&#8221;) and employment law claims. Relators seek all available relief under the CFCA. In December 2021, Gilead and relators executed a settlement agreement to resolve the lawsuit, and in February 2022, the court issued an order dismissing the lawsuit with prejudice.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement does not have a material impact to our Consolidated Financial Statements. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice Advocates, LLC (&#8220;Health Choice&#8221;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#8217;s dismissal.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. In September 2021, the Texas Court of Appeals for the Sixth Court Appeals District granted our request to stay the Texas litigation. The case is stayed pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.</span></div>Other Commitments In the normal course of business, we enter into firm purchase commitments related to inventory. As of December&#160;31, 2021, these commitments for the next five years were approximately $1.1 billion in 2022, $450 million in 2023, $243 million in 2024, $60 million in 2025 and $31 million in 2026.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102546456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (&#8220;2016 Program&#8221;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), which will commence upon the completion of the 2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the remaining authorized repurchase amount under both programs was $6.3 billion.</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock repurchases under the 2016 Program:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased and retired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to repurchases from the 2016 Program and 2020 Program, we repurchased shares of common stock withheld by us from employee restricted stock awards to satisfy our applicable tax withholding obligations. These shares are excluded from the table above. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the par value method of accounting for our stock repurchases. Under the par value method, common stock is first charged with the par value of the shares involved. The excess of the cost of shares acquired over the par value is allocated to additional paid-in capital based on an estimated average sales price per issued share with the excess amounts charged to retained earnings. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash dividends declared on our common stock:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted stock and performance share awards or units have dividend equivalent rights entitling holders to dividend equivalents to be paid upon vesting for each share of the underlying unit.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;1, 2022, we announced that our Board of Directors declared a quarterly cash dividend of $0.73 per share of our common stock, with a payment date of March&#160;30, 2022 to all stockholders of record as of the close of business on March&#160;15, 2022. Future dividends are subject to declaration by our Board of Directors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 5 million shares of authorized preferred stock issuable in series. Our Board is authorized to determine the designation, powers, preferences and rights of any such series. There was no preferred stock outstanding as of December&#160;31, 2021 and 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts reclassified to net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Consolidated Statements of Income. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net, on our Consolidated Statements of Income. The income tax impact allocated to each component of other comprehensive income was not material for the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102522040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Employee Benefits</a></td>
<td class="text">EMPLOYEE BENEFITS <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2004, our stockholders approved and we adopted the Gilead Sciences, Inc. 2004 Equity Incentive Plan (as amended, the &#8220;2004 Plan&#8221;). The 2004 Plan authorized the issuance of a total of 309 million&#160;shares of common stock. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the Forty Seven acquisition, we assumed the Forty Seven, Inc. 2018 Equity Incentive Plan, which we subsequently amended and restated as the Gilead Sciences, Inc. 2018 Equity Incentive Plan (as amended and restated, the &#8220;2018 Plan&#8221;). The aggregate amount of shares that may be issued under the 2018 Plan on or after the assumption date will not exceed 12&#160;million shares. As part of the Immunomedics acquisition, we assumed the Immunomedics Amended and Restated 2014 Long-Term Incentive Plan (the &#8220;Immunomedics Plan&#8221; and referred together with the 2004 Plan and 2018 Plan as the &#8220;Plans&#8221;), which we subsequently merged into the 2004 Plan. The aggregate amount of shares that may be issued under the Immunomedics Plan on or after the assumption date will not exceed 26&#160;million shares. See Note 6. Acquisitions for additional information on the settlement of stock awards.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plans are broad based incentive plans that provide for the grant of equity-based awards, including stock options, restricted stock units, restricted stock awards and performance share awards, to employees, directors and consultants. As of December&#160;31, 2021, a total of 82&#160;million shares remain available for future grant under the Plans. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plans provide for option grants designated as either non-qualified or incentive stock options. All stock options granted after January&#160;1, 2006 have been non-qualified stock options. Employee stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIzMDE_e5e44bde-010a-4057-a014-5f91fdc040cb">three</span> or four years. All options are exercisable over a period not to exceed the contractual term of ten years from the date the stock options are issued and are granted at prices not less than the fair market value of our common stock on the grant date. Stock option exercises are settled with common stock from the Plans&#8217; previously authorized and available pool of shares. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity and related information under our stock option plans. All option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price<br/>(in dollars)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average <br/>Remaining <br/>Contractual Term <br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>&#160;Intrinsic <br/>Value <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.40&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest, net of estimated forfeitures as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable. Total intrinsic value of options exercised was $48 million, $179 million and $209 million for 2021, 2020 and 2019, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of the stock options granted was $10.05 per share, $11.69 per share and $12.15 per share for 2021, 2020 and 2019, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $47 million of unrecognized compensation cost related to stock options, which is expected to be recognized over an estimated weighted-average period of 2.3 years.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock and Performance Share Awards</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant time-based RSUs to certain employees as part of our annual employee equity compensation review program as well as to new hire employees and to non-employee members of our Board. RSUs are share-based awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. RSUs generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzM4OTI_528fb9fb-324d-4172-b895-26994db1e7b3">three</span> or four years from the date of grant. The fair value of an RSU is equal to the closing price of our common stock on the grant date. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant PSUs which vest upon the achievement of specified market or performance goals, which could include achieving a total shareholder return compared to a pre-determined peer group or achieving revenue targets. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%, and these awards generally vest only when a committee (or subcommittee) of our Board has determined that the specified market and performance goals have been achieved. The fair value of each PSU is estimated at the date of grant or when performance objectives are defined for the grants. Depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have also granted other PSUs to certain of our employees under the 2004 Plan. The vesting of these awards is subject to the achievement of specified individual performance goals, typically within a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzUwNzA_664e182d-33f3-4d5a-92ea-3c6d4ced19cd">one</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzUwNzY_9109fd84-6601-41a5-b36b-3897b4762db9">two</span> year period. The fair value of such an award is equal to the closing price of our common stock on the grant date.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU and PSU activity and related information:</span></div><div style="margin-top:4.5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.87&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Weighted-average grant-date fair value per share excludes shares related to grants that currently have no grant date as the performance objectives have not yet been defined. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs granted was $65.42 per share, $70.94 per share and $64.31 per share for 2021, 2020 and 2019, respectively. The weighted-average grant date fair value of PSUs granted was $71.31 per share, $83.64 per share and $68.30 per share for 2021, 2020 and 2019, respectively. The total grant date fair value of our vested RSUs and PSUs was $503 million, $479 million and $450 million for 2021, 2020 and 2019, respectively, and total fair value as of the respective vesting dates was $471 million, $459 million and $372 million for 2021, 2020 and 2019, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $917 million of unrecognized compensation cost related to unvested RSUs and PSUs, which is expected to be recognized over a weighted-average period of 2.2 years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the &#8220;ESPP&#8221;), employees can purchase shares of our common stock based on a percentage of their compensation subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of our common stock on the offering date or the purchase date. The ESPP offers a six-month look-back feature as well as an automatic reset feature that provides for an offering period to be reset to a new lower-priced offering if the offering price of the new offering period is less than that of the current offering period. ESPP purchases are settled with common stock from the ESPP&#8217;s previously authorized and available pool of shares. During 2021, 2 million shares were issued under the ESPP for $111 million. A total of 79 million shares of common stock have been authorized for issuance under the ESPP, and there were 5 million shares available for issuance under the ESPP as of December&#160;31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock-based compensation expenses included on our Consolidated Statements of Income:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in total costs and expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Pre-tax stock-based compensation expense for the year ended December&#160;31, 2020 of $1.1 billion included $643 million non-cash stock-based expense and $289 million and $144 million of accelerated post-acquisition stock-based expense related to the acquisitions of Immunomedics and Forty Seven, respectively. See Note 6. Acquisitions for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Income tax effect for the year ended December&#160;31, 2019 included a $114 million income tax expense following the U.S. Court of Appeals decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Altera Corp v. Commissioner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, which requires related parties in an intercompany cost sharing arrangement to share expenses related to stock-based compensation.</span><span style="color:#6d6d6d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is recognized as expense over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of options granted under our Plans and purchases under our ESPP were estimated at grant or purchase dates using a Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including expected stock price volatility and expected award life. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the following assumptions to calculate the estimated fair value of the awards: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted was calculated using the single option approach. We use a blend of historical volatility along with implied volatility for traded options on our common stock to determine our expected volatility. The expected term of stock-based awards represents the weighted-average period the awards are expected to remain outstanding. We estimate the weighted-average expected term based on historical cancellation and historical exercise data related to our stock options as well as the contractual term and vesting terms of the awards. The risk-free interest rate is based upon observed interest rates appropriate for the term of the stock-based awards. The dividend yield is based on our history and expectation of dividend payouts. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Compensation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a retirement saving plan under which eligible U.S. employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (the Gilead Sciences 401k Plan). In certain foreign subsidiaries, we maintain defined benefit plans as required by local regulatory requirements. Our total matching contribution expense under the Gilead Sciences 401k Plan and other defined benefit plans was $166 million, $144 million and $110 million during 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a deferred compensation plan under which our directors and key employees may defer compensation. Amounts deferred by participants are deposited into a rabbi trust. The total assets and liabilities associated with the deferred compensation plan were $261 million and $218 million as of December&#160;31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102603960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share Attributable to Gilead Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share Attributable to Gilead Common Shareholders</a></td>
<td class="text">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock method.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common shareholders because their effect would have been antidilutive were 15 million, 13 million and 14 million during 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,225&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,386&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.96&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102408856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes consists of the following:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,587&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,505&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,112&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Income tax (expense) benefit consists of the following:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,646)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,526)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,286)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(803)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,580)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 income tax benefit included a $1.2 billion deferred tax benefit related to intangible asset transfers from a foreign subsidiary to Ireland and the United States. In the fourth quarter of 2019, we completed an intra-entity asset transfer of certain intangible assets from a foreign subsidiary to Ireland. The transaction resulted in a step-up of the Irish tax-deductible basis in the transferred assets, and accordingly, created a temporary difference where the tax basis exceeded the financial statement basis of such intangible assets. As a result, we recognized a deferred tax asset of $1.2 billion on our Consolidated Financial Statements. We expect to be able to realize the deferred tax asset resulting from this intra-entity asset transfer. The impact of the intangible asset transfer from a foreign subsidiary to the United States was not material.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the federal statutory tax rate applied to income before income taxes and our effective tax rate is summarized as follows:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at different rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US tax on foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax - intra-entity transfer of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of tax examinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D and related charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable unrealized (gain)  loss on investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals not currently deductible</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of tax basis over book basis of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront and milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,629&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,109&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,960&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of book basis over tax basis of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,719)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,126)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,572)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,017)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,612)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance was $520 million and $398 million as of December&#160;31, 2021 and 2020, respectively. The increase of our valuation allowance in 2021 was primarily related to California research and development tax credits.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance was $398 million and $217 million as of December&#160;31, 2020 and 2019, respectively. The increase of our valuation allowance in 2020 was primarily related to acquired attributes related to Forty Seven and Immunomedics acquisitions, and capital losses related to our equity method investments.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had U.S. federal net operating loss and tax credit carryforwards of approximately $250 million and $8 million, respectively, which will start to expire in 2022, if not utilized. In addition, we had state net operating loss and tax credit carryforwards of approximately $2.8 billion and $768 million, respectively. The state net operating loss and state tax credit carryforwards will start to expire in 2022 if not utilized.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of net operating losses and tax credits may be subject to an annual limitation due to ownership change limitations provided in the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file federal, state and foreign income tax returns in the United States and in many foreign jurisdictions. For federal income tax purposes, the statute of limitations is open for 2016 and onwards and 2013 and onwards for California income tax purposes. For certain acquired entities, the statute of limitations is open for all years from inception due to our utilization of their net operating losses and credits carried over from prior years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service and Irish tax authorities for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.</span><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total unrecognized tax benefits, $800 million and $1.2 billion as of December&#160;31, 2021 and 2020, respectively, if recognized, would reduce our effective tax rate in the period of recognition. Interest and penalties related to unrecognized tax benefits included income tax expense of $41 million, income tax benefit of $82 million and income tax expense of $105 million on our Consolidated Statements of Income for the years ended December&#160;31, 2021, 2020 and 2019 respectively. Accrued interest and penalties related to unrecognized tax benefits were $218 million</span><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $177 million as of December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we believe that it is reasonably possible that our unrecognized tax benefits will decrease by approximately $100 million in the next 12 months due to potential settlements with various taxing authorities.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our total gross unrecognized tax benefits:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Tax Cuts and Jobs Act, we recorded a federal income tax payable for transition tax on the mandatory deemed repatriation of foreign earnings that is payable over an eight-year period. As of December&#160;31, 2021 and 2020, we have accrued $4.0 billion and $4.5 billion, respectively, for transition tax. Of the amounts accrued as of December&#160;31, 2021, approximately $473 million is expected to be paid within one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102751928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div>We assess whether we are the primary beneficiary of a variable interest entity (&#8220;VIE&#8221;) at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Segment InformationWe have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Significant Accounting Policies, Estimates and Judgments</a></td>
<td class="text">Significant Accounting Policies, Estimates and Judgments The preparation of these Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and  expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease (&#8220;COVID-19&#8221;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to the customer, or in certain cases, upon the corresponding sales by our customer to a third party. The revenues are recognized net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a financing component. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Deductions </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Rebates and Chargebacks</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other rebates and chargebacks include amounts payable to payers and healthcare providers under various programs, and may vary by product, by payer and individual payer plans. Rebates and chargebacks are based on contractual arrangements or statutory requirements which may vary by product, payer and individual payer plans. For qualified programs that can purchase our products through wholesalers or other distributors at a lower contractual price, the wholesalers or distributors charge back to us the difference between their acquisition cost and the lower contractual price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are estimated primarily based on product sales, and expected payer mix and discount rates, which require significant estimates and judgment. Additionally, in developing our estimates, we consider: historical and estimated payer mix; statutory discount requirements and contractual terms; historical claims experience and processing time lags; estimated patient population; known market events or trends; market research; channel inventory data obtained from our major U.S. wholesalers; and other pertinent internal or external information. We assess and update our estimates each reporting period to reflect actual claims and other current information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Government and other rebates that are payable to third party payers and healthcare providers are recorded in Accrued government and other rebates on our Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Discounts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Distributor Fees</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Allowance for Sales Returns</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the United States, we typically permit returns six months prior to and up to one year after the product expiration date. Outside the United States, returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Shipping and Handling</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling activities are considered to be fulfillment activities and not considered to be a separate performance obligation.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty, Contract and Other Revenues</span></div>Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of clinical studies performed by contract research organizations (&#8220;CROs&#8221;), materials and supplies, payments under collaborative and other arrangements including milestone payments, licenses and fees, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations consisting of various support and infrastructure costs. Milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of R&amp;D expenses.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We charge R&amp;D costs, including clinical study costs, to expense when incurred. Clinical study costs are a significant component of R&amp;D expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for R&amp;D services prior to the services being rendered are recorded as prepaid assets in our Consolidated Balance Sheets and are expensed as the services are provided.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In Process Research and Development Expenses</a></td>
<td class="text">Acquired In-Process Research and Development ExpensesAcquired IPR&amp;D expenses reflect IPR&amp;D impairments as well as the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;D projects. The acquired IPR&amp;D is expensed on acquisition date. Future costs to develop these IPR&amp;D projects are recorded in Research and development expenses on our Consolidated Statements of Income as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses relate to sales and marketing, finance, human resources, legal and other administrative activities. SG&amp;A expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs. SG&amp;A expenses also include the Branded Prescription Drug (&#8220;BPD&#8221;) fee. In the United States, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the BPD fee, which is estimated based on select government sales during the prior year as a percentage of total industry government sales.</span></div>We expense the costs of advertising, including promotional expenses, as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash Equivalents We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Marketable and Non-Marketable Securities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable and Non-Marketable Securities</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable debt securities are considered available-for-sale and carried at estimated fair values and reported in cash equivalents, short-term marketable debt securities or long-term marketable debt securities. Unrealized gains and losses on available-for-sale debt securities are excluded from net income and reported in Accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) as a separate component of stockholders&#8217; equity. Other income (expense), net, includes interest, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and expected credit losses, if any. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost bases. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in AOCI.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable and Non-Marketable Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities, other than equity method investments, are recorded at fair market value if fair value is readily determinable, and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. We have elected the fair value option to account for our equity investments in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;) and Galapagos NV (&#8220;Galapagos&#8221;) over which we have significant influence. We believe the fair value option best reflects the underlying economics of these investments. See Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Certain investments in equity securities of non-public companies are accounted for using the equity method based on our ownership percentage and other factors that indicate we have significant influence over the investee. See Note 11. Collaborations and Other Arrangements for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in equity securities are recorded in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets. We regularly review our securities for indicators of impairment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return.</span></div>We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.</span></div>When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated&#160;Useful&#160;Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;35 years or useful&#160;life</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;useful&#160;life or lease&#160;term</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at inception. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.</span></div>As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period, which may be up to one year from the acquisition date, with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration, such as payments upon achievement of various developmental, regulatory and commercial milestones, generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are expensed as incurred on our Consolidated Statements of Income unless there is an alternative future use.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may be subject to adjustment within the measurement period, which may be up to one year from the acquisition date. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. We do not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When development is successfully completed, which generally occurs when regulatory approval is obtained, the associated assets are deemed finite-lived and amortized over their respective estimated useful lives beginning at that point in time. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Valuation of Contingent Consideration Resulting from a Business Combination and Contingencies</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Contingent Consideration Resulting from a Business Combination</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value in Research and development expenses on our Consolidated Statements of Income until such time that the related product candidate receives marketing approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may differ from estimates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue the best estimate of loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. entity operations are recorded in the functional currency of each entity. Results of operations for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency rates. Assets and liabilities are translated using currency rates at period end. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Foreign currency transaction gains and losses are recorded in Other income (expense), net, on our Consolidated Statements of Income. Net foreign currency transaction gains and losses were not material for the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value accounting for all financial and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:4pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Unrealized changes in the fair value of derivatives designated as part of a hedge transaction are recorded in AOCI. The unrealized gains or losses in AOCI are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based CompensationWe provide share-based compensation in the form of various types of equity-based awards, including restricted stock units (&#8220;RSU&#8221;s), performance share awards or units (&#8220;PSU&#8221;s) and stock options. Compensation expense is recognized on the Consolidated Statements of Income based on the estimated fair value of the award on the grant date. The estimated fair value of RSUs is based on the closing price of our common stock. For PSUs, depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. For stock option awards, estimated fair value is based on the Black-Scholes option valuation model.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision is computed under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (&#8220;UTB&#8221;) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax (expense) benefit on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for the tax on Global Intangible Low-Taxed Income, enacted as part of the Tax Cuts and Jobs Act, as a component of tax expense in the period in which the tax is incurred.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102431912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock', window );">Property, Plant and Equipment, Estimated Useful Life</a></td>
<td class="text">Estimated useful lives in years are generally as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated&#160;Useful&#160;Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;35 years or useful&#160;life</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;useful&#160;life or lease&#160;term</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Useful Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102591864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HIV </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,828&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,315&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,651&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,315&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,438&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ledipasvir/</span></div><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="27" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis Delta virus (&#8220;HDV&#8221;)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Cell Therapy </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,449&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#8220;Janssen&#8221;).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Summarized Revenues from Major Customers</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102926264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Arcus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,320&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,279&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,008&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See Note 11. Collaborations and Other Arrangements for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Classification of Other Equity Securities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Consolidated Balance Sheets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585187766760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Available-for-Sale Debt Securities at Estimated Fair Value</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of the Classification of Available-for-Sale Debt Securities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Available-for-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585108311368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of Classification and Fair Value of Derivative Instruments</a></td>
<td class="text">The following table summarizes the classification and fair values of derivative instruments in our Consolidated Balance Sheets: <div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other&#160;current&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other&#160;current&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.339%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other&#160;current&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other&#160;current&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Effect of Foreign Currency Exchange Contracts</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Consolidated Financial Statements:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from AOCI into Product sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Summary of Potential Effect of Offsetting Derivatives</a></td>
<td class="text">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Consolidated Balance Sheets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Offset on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received/Pledged</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount (Legal Offset)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102588888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summarized Fair Values of Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102431912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102506088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Property, plant and equipment, net: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements (including leasehold improvements)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,014&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585107511544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of Goodwill:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,915&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,535&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,897&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes $910&#160;million reclassified in the first quarter of 2021 from indefinite-lived assets - IPR&amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes Trodelvy for metastatic TNBC and Trodelvy for use in adult patients with locally advanced or metastatic UC. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;D upon the accelerated approval by FDA in April 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million was reclassified to finite-lived assets in the fourth quarter of 2021.</span></div>(4)&#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes IPR&amp;D from our 2021 acquisition of MYR and remaining IPR&amp;D from our 2020 acquisition of Immunomedics. Gross carrying amount as of December&#160;31, 2020 includes IPR&amp;D from our 2020 acquisition of Immunomedics and remaining IPR&amp;D from our 2017 acquisition of Kite.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,915&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,535&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,897&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes $910&#160;million reclassified in the first quarter of 2021 from indefinite-lived assets - IPR&amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes Trodelvy for metastatic TNBC and Trodelvy for use in adult patients with locally advanced or metastatic UC. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;D upon the accelerated approval by FDA in April 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million was reclassified to finite-lived assets in the fourth quarter of 2021.</span></div>(4)&#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes IPR&amp;D from our 2021 acquisition of MYR and remaining IPR&amp;D from our 2020 acquisition of Immunomedics. Gross carrying amount as of December&#160;31, 2020 includes IPR&amp;D from our 2020 acquisition of Immunomedics and remaining IPR&amp;D from our 2017 acquisition of Kite.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated Future Amortization Expense of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2021:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585107479640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Accounts Receivable, net</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net: </span></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,278&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,560&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Accrued and other current liabilities:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for settlement related to bictegravir litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See Note 14. Commitments and Contingencies for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585107481032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Financing Arrangements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.551%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.15%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.52%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes and term loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,571&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,295&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,695&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,402&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt and other obligations, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Contractual Maturities of Financing Obligations</a></td>
<td class="text"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate future principal maturities of our senior unsecured notes as of December&#160;31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585187793320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Supplemental Information Related to Operating Leases</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balance sheet and other information related to our operating leases:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except weighted average amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_bf1a57bf-a703-4b3f-bc9b-0294a5049060"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_c74f8a0a-3c1e-43dc-9a44-91448c3a81f3">Other long-term assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_3f97a2d5-98a1-46a4-8619-f3becdea71f5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_c90d340b-270c-4dd6-bbe4-3b313ad42434">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_511d014a-a5ee-4a2c-a65f-0d75ca7b60e9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_7e2903b1-a222-4253-bf44-fbb3ee9aa161">Other long-term obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to our operating leases:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Aggregate Future Lease Payments</a></td>
<td class="text"><div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total discounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585101404040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Stock Repurchases</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock repurchases under the 2016 Program:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased and retired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsDeclaredTableTextBlock', window );">Schedule of Dividends Declared</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash dividends declared on our common stock:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated OCI by Component</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsDeclaredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsDeclaredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585101213832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Activity Under Stock Option Plans</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity and related information under our stock option plans. All option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price<br/>(in dollars)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average <br/>Remaining <br/>Contractual Term <br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>&#160;Intrinsic <br/>Value <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.40&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest, net of estimated forfeitures as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">RSU and PSU Activity</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU and PSU activity and related information:</span></div><div style="margin-top:4.5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.87&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div>(1) &#160;&#160;&#160;&#160;Weighted-average grant-date fair value per share excludes shares related to grants that currently have no grant date as the performance objectives have not yet been defined.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based Compensation Expenses -Included in Consolidated Statement of Income</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock-based compensation expenses included on our Consolidated Statements of Income:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in total costs and expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Pre-tax stock-based compensation expense for the year ended December&#160;31, 2020 of $1.1 billion included $643 million non-cash stock-based expense and $289 million and $144 million of accelerated post-acquisition stock-based expense related to the acquisitions of Immunomedics and Forty Seven, respectively. See Note 6. Acquisitions for additional information.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Income tax effect for the year ended December&#160;31, 2019 included a $114 million income tax expense following the U.S. Court of Appeals decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Altera Corp v. Commissioner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, which requires related parties in an intercompany cost sharing arrangement to share expenses related to stock-based compensation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions to Calculate the Estimated Fair Value of Awards</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the following assumptions to calculate the estimated fair value of the awards: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and ESPP, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102449288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share Attributable to Gilead Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,225&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,386&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.96&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585100840008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) Before Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes consists of the following:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,587&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,505&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,112&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Income tax (expense) benefit consists of the following:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,646)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,526)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,286)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(803)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,580)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Difference Between Provision for Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the federal statutory tax rate applied to income before income taxes and our effective tax rate is summarized as follows:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at different rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US tax on foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax - intra-entity transfer of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of tax examinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D and related charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable unrealized (gain)  loss on investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">Significant components of our deferred tax assets and liabilities are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals not currently deductible</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of tax basis over book basis of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront and milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,629&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,109&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,960&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of book basis over tax basis of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,719)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,126)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,572)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,017)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,612)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our total gross unrecognized tax benefits:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585104230760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>country</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which entity operates | country</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 735,000,000<span></span>
</td>
<td class="nump">$ 795,000,000<span></span>
</td>
<td class="nump">$ 784,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs charged against allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">35 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Office, computer equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Office, computer equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585089575880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Disaggregation of Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 27,305<span></span>
</td>
<td class="nump">$ 24,689<span></span>
</td>
<td class="nump">$ 22,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">19,267<span></span>
</td>
<td class="nump">18,217<span></span>
</td>
<td class="nump">16,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,874<span></span>
</td>
<td class="nump">4,135<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember', window );">Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,164<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27,008<span></span>
</td>
<td class="nump">24,355<span></span>
</td>
<td class="nump">22,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">19,176<span></span>
</td>
<td class="nump">18,141<span></span>
</td>
<td class="nump">16,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,678<span></span>
</td>
<td class="nump">3,894<span></span>
</td>
<td class="nump">3,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,154<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">16,315<span></span>
</td>
<td class="nump">16,938<span></span>
</td>
<td class="nump">16,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12,828<span></span>
</td>
<td class="nump">13,651<span></span>
</td>
<td class="nump">13,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,366<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
<td class="nump">2,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">Atripla</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">Atripla | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">307<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">Atripla | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">Atripla | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8,624<span></span>
</td>
<td class="nump">7,259<span></span>
</td>
<td class="nump">4,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7,049<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">969<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">3,338<span></span>
</td>
<td class="nump">3,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,267<span></span>
</td>
<td class="nump">2,605<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,568<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">1,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">2,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">2,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">488<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,565<span></span>
</td>
<td class="nump">2,811<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,640<span></span>
</td>
<td class="nump">2,026<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">830<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,881<span></span>
</td>
<td class="nump">2,064<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">562<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">864<span></span>
</td>
<td class="nump">971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHCVMember', window );">Other HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHCVMember', window );">Other HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHCVMember', window );">Other HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHCVMember', window );">Other HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">969<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">397<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HB/HDV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HB/HDV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HB/HDV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HB/HDV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">871<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">542<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember', window );">Yescarta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember', window );">Yescarta | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember', window );">Yescarta | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember', window );">Yescarta | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Zydelig</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Zydelig | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Zydelig | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Zydelig | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=gild_OtherInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsStribildMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_VekluryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_VekluryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherHCVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherHCVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585103067320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Summarized Revenues from Major Customers (Details) - Revenue benchmark - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Cardinal Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_MckessonCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_MckessonCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585107564552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized from performance obligations satisfied in prior years</a></td>
<td class="nump">$ 851<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
<td class="nump">$ 741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Revenues recognized</a></td>
<td class="nump">856<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585095084616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 2,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">8,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">3,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Other publicly traded equity securities | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Other publicly traded equity securities | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">3,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Other publicly traded equity securities | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Other publicly traded equity securities | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Other publicly traded equity securities | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Other publicly traded equity securities | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Other publicly traded equity securities | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Other publicly traded equity securities | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585101240216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Classification on Balance Sheet (Details) - Equity Securities - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 5,743<span></span>
</td>
<td class="nump">$ 6,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">3,661<span></span>
</td>
<td class="nump">4,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">885<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">$ 1,197<span></span>
</td>
<td class="nump">$ 1,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585103200072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss on investment of equity securities</a></td>
<td class="nump">$ 610,000,000<span></span>
</td>
<td class="nump">$ 1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Other equity investments without readily determinable fair values</a></td>
<td class="nump">338,000,000<span></span>
</td>
<td class="nump">262,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=gild_EquitySecuritiesDonationMember', window );">Equity Securities Donation | Gilead Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Donation expense</a></td>
<td class="nump">212,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | MYR | Fair value, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | MYR | Fair value, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">317,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair value | MYR | Fair value, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">317,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Short-term and long-term debt</a></td>
<td class="nump">28,600,000,000<span></span>
</td>
<td class="nump">34,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair value | Level 3 | Immunomedics, Inc. | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Future royalties</a></td>
<td class="nump">1,300,000,000<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Short-term and long-term debt</a></td>
<td class="nump">25,600,000,000<span></span>
</td>
<td class="nump">30,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying value | Level 3 | Immunomedics, Inc. | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Future royalties</a></td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=gild_EquitySecuritiesDonationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=gild_EquitySecuritiesDonationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gild_GileadFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gild_GileadFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585104438312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 2,501<span></span>
</td>
<td class="nump">$ 2,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">2,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">408<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember', window );">Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">$ 424<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585101432344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 2,497<span></span>
</td>
<td class="nump">$ 2,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember', window );">Short-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember', window );">Long-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 1,309<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102791304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized&#160;Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within one year</a></td>
<td class="nump">$ 1,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">After one year through five years</a></td>
<td class="nump">1,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5', window );">After five years</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">2,501<span></span>
</td>
<td class="nump">$ 2,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one year through five years</a></td>
<td class="nump">1,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5', window );">After five years</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 2,497<span></span>
</td>
<td class="nump">$ 2,026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year 5</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year 5</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102666408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Securities in unrealized loss positions, number of positions (securities) | position</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Impairment loss recognized | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585107110472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Outstanding notional amounts on foreign currency exchange contracts</a></td>
<td class="nump">$ 2,900,000,000<span></span>
</td>
<td class="nump">$ 2,400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet', window );">Gain (loss) on discontinuance of cash flow hedges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Maturity on derivative instruments</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1', window );">Time estimate for gains (losses) to be reclassified from AOCI to product sales</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585095067384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Accrued and other&#160;current&#160;liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Other&#160;long-term&#160;obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument | Accrued and other&#160;current&#160;liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585107532088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Gain (loss) recognized in AOCI</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="num">$ (118)<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Gain (loss) reclassified from AOCI into Product sales</a></td>
<td class="num">(67)<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gain (loss) recognized in Other income (expense), net</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="num">$ (51)<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585095074360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Derivative assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Gross Amounts of Recognized Assets/Liabilities</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Gross Amounts Offset on the Consolidated Balance Sheets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Derivative Financial Instruments</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash Collateral Received/Pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net Amount (Legal Offset)</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Gross Amounts of Recognized Assets/Liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Gross Amounts Offset on the Consolidated Balance Sheets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Derivative Financial Instruments</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash Collateral Received/Pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net Amount (Legal Offset)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585088597032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 23, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 07, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate', window );">Discount rate of acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,000,000<span></span>
</td>
<td class="nump">$ 5,856,000,000<span></span>
</td>
<td class="nump">$ 4,251,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000,000)<span></span>
</td>
<td class="num">$ (910,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember', window );">Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember', window );">Forty Seven, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Accelerated stock-based expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentsToAcquireAssetsNetOfCashAcquired', window );">Total consideration, net of acquired cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember', window );">Forty Seven, Inc. | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="nump">&#8364; 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payments made for acquisition</a></td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">226,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Level 3 | Fair value, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">341,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Aggregate fair value of acquired IPR&amp;D</a></td>
<td class="nump">1,190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Hepcludex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Aggregate fair value of acquired IPR&amp;D</a></td>
<td class="nump">$ 1,190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Hepcludex | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate', window );">Discount rate of acquired IPR&amp;D</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Hepcludex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="nump">$ 845,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of finite-lived intangible asset acquired</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Hepcludex | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate', window );">Discount rate of finite-lived intangible asset acquired</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,991,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Accelerated stock-based expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory', window );">Fair value step-up adjustment of inventories acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,000,000<span></span>
</td>
<td class="nump">$ 797,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability', window );">Liability related to future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput', window );">Liability related to future royalties, measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput', window );">Liability related to future royalties, measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Three year senior unsecured term loan facility | Medium-term notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowing under the senior unsecured term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Aggregate fair value of acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,760,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate', window );">Discount rate of acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate', window );">Discount rate of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Outlicense contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate', window );">Discount rate of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquired Finite-lived Intangible Assets, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Future Royalties, Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsGrossReclassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Gross, Reclassified</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsGrossReclassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-lived Intangible Assets Acquired, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsToAcquireAssetsNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Assets, Net Of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsToAcquireAssetsNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585089513016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet', window );">Other assets (and liabilities), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Hepcludex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">$ 294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability', window );">Liability related to future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet', window );">Other assets (and liabilities), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Outlicense contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585101242120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ScheduleofInventoryLineItems', window );"><strong>Schedule of Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,112<span></span>
</td>
<td class="nump">$ 1,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">590<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">1,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsTotalMember', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ScheduleofInventoryLineItems', window );"><strong>Schedule of Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 2,734<span></span>
</td>
<td class="nump">$ 3,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ScheduleofInventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Disclosure of information about inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ScheduleofInventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585104379176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ScheduleOfInventoriesLineItems', window );"><strong>Schedule of Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ScheduleOfInventoriesLineItems', window );"><strong>Schedule of Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">$ 294<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=gild_InventoryWritedownsforExcessRawMaterialsMember', window );">Inventory Write-downs for Excess Raw Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ScheduleOfInventoriesLineItems', window );"><strong>Schedule of Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ScheduleOfInventoriesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Inventory [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ScheduleOfInventoriesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=gild_InventoryWritedownsforExcessRawMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=gild_InventoryWritedownsforExcessRawMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585108818456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land and land improvements</a></td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings and improvements (including leasehold improvements)</a></td>
<td class="nump">3,794<span></span>
</td>
<td class="nump">3,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Laboratory and manufacturing equipment</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Office, computer equipment and other</a></td>
<td class="nump">807<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,057<span></span>
</td>
<td class="nump">856<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">7,014<span></span>
</td>
<td class="nump">6,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">1,668<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">$ 5,121<span></span>
</td>
<td class="nump">$ 4,967<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585104157640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Unamortized capitalized software costs</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,121<span></span>
</td>
<td class="nump">4,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 963<span></span>
</td>
<td class="nump">$ 940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585101045016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 8,108<span></span>
</td>
<td class="nump">$ 4,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill resulting from acquisitions</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">3,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustments</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 8,332<span></span>
</td>
<td class="nump">$ 8,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585104437448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate', window );">Discount rate of acquired IPR&amp;D</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 800,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense related to finite-lived intangible assets</a></td>
<td class="nump">$ 1,700,000,000<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-lived Intangible Assets Acquired, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585099485800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">$ 25,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(8,381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">17,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">41,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(8,381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,660)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">33,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived assets - IPR&amp;D</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">15,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">15,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">$ (910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember', window );">Intangible asset - sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">10,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,952)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">5,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,952)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneCiloleucelDLBCLMember', window );">Intangible asset - axicabtagene ciloleucel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">7,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,501)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">5,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,501)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember', window );">Intangible asset - Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">5,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">5,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember', window );">Intangible asset - Hepcludex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">1,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified intangible assets</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified intangible assets</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsGrossReclassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Gross, Reclassified</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsGrossReclassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneCiloleucelDLBCLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneCiloleucelDLBCLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_CellTherapyProductsTecartusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_CellTherapyProductsTecartusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585101237400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">1,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">1,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">1,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">1,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">8,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 17,535<span></span>
</td>
<td class="nump">$ 16,236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585104147672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accounts Receivable, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 5,278<span></span>
</td>
<td class="nump">$ 5,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccountsReceivableChargebacksCurrent', window );">Less: chargebacks</a></td>
<td class="nump">671<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent', window );">Less: cash discounts and other</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowances for credit losses</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 4,493<span></span>
</td>
<td class="nump">$ 4,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Cash Discounts and Other, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableCashDiscountsAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableChargebacksCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Chargebacks, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableChargebacksCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102762440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Other Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and employee benefits</a></td>
<td class="nump">$ 927<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Allowance for sales returns</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueCurrent', window );">Accrual for settlement related to bictegravir litigation</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,930<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 6,145<span></span>
</td>
<td class="nump">$ 4,336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585016360888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Details)<br> &#8364; / shares in Units, &#8364; in Millions, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 25, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 17, 2020 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Jul. 13, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 29, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>May 27, 2020</div></th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 18, 2021 </div>
<div>program</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Feb. 08, 2021</div></th>
<th class="th">
<div>Dec. 15, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Jul. 17, 2020</div></th>
<th class="th"><div>Jun. 19, 2020</div></th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 19, 2016 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,000,000<span></span>
</td>
<td class="nump">$ 5,856,000,000<span></span>
</td>
<td class="nump">$ 4,251,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610,000,000<span></span>
</td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,141,000,000<span></span>
</td>
<td class="nump">2,013,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,963,000,000<span></span>
</td>
<td class="nump">5,708,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,601,000,000<span></span>
</td>
<td class="nump">4,572,000,000<span></span>
</td>
<td class="nump">4,675,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts', window );">Percent of global and development and commercialization costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenues recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod', window );">Option period to license certain inhibitors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp | Oral Formulation Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementNetProductSalesThreshold', window );">Net product sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalProductRevenues', window );">Percent of global product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp | Injectable Formulation Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementNetProductSalesThreshold', window );">Net product sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp | Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts', window );">Percent of global and development and commercialization costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember', window );">Arcus stock purchase agreement | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember', window );">Janssen pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage', window );">Purchase price of goods less specified amount, maximum percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,000,000<span></span>
</td>
<td class="nump">570,000,000<span></span>
</td>
<td class="nump">574,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination', window );">Period subject to termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember', window );">Jounce license and stock purchase agreement | Jounce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember', window );">Japan tobacco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">291,000,000<span></span>
</td>
<td class="nump">358,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 559,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_GadetaBVCollaborationArrangementMember', window );">Gadeta collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInVariableInterestEntity', window );">Noncontrolling interest in variable interest entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember', window );">Other collaboration arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CashPaymentsMadeRelatedToEquityInvestments', window );">Cash payments made related to equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,000,000<span></span>
</td>
<td class="nump">72,000,000<span></span>
</td>
<td class="nump">118,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant', window );">Upfront collaboration expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,000,000<span></span>
</td>
<td class="nump">129,000,000<span></span>
</td>
<td class="nump">331,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares of common stock acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus collaboration agreement and stock purchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to acquire in process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_InvestmentOwnedBalanceAdditionalShares', window );">Additional shares acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalUpfrontPaymentsMade', window );">Total upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,000,000<span></span>
</td>
<td class="nump">212,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IssuanceDiscountPremium', window );">Issuance discount (premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentsForDirectTransactionalExpense', window );">Direct transactional costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeAgreementOptInTerm', window );">Opt-in term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_NumberOfClinicalStageProgramsWithExercisedOptions', window );">Number of clinical stage programs with exercise options | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentsToOptInTheCollaborativeAgreement', window );">Collaboration opt-in payments</a></td>
<td class="nump">$ 725,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries', window );">Additional option fee on fourth, sixth, and eighth anniversaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIPurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased', window );">Maximum percentage of outstanding stock allowed to be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIRestrictionPeriod', window );">Restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNISharesAcquired', window );">Additional shares acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIShares', window );">Number of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember', window );">Pionyr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember', window );">Pionyr | Pionyr merger and option agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquityMethodInvestmentOptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialFutureMilestonePaymentsMaximum', window );">Maximum potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember', window );">Pionyr | Research and development service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ResearchAndDevelopmentFutureMaximumPayments', window );">Research and development future maximum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentsForResearchAndDevelopmentMilestones', window );">Cash payments made for research and development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember', window );">Tizona</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember', window );">Tizona | Tizona merger and option agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquityMethodInvestmentOptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember', window );">Tizona | Tizona merger and option agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments', window );">Option fee and potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember', window );">Tizona | Development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember', window );">Tango | Tango collaboration and stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to acquire in process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeArrangementTerm', window );">Collaboration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CashPaymentsMadeRelatedToEquityInvestments', window );">Cash payments made related to equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_NumberOfPrograms', window );">Number of programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember', window );">Tango | Tango collaboration and stock purchase agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments', window );">Opt-in, extension and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_JounceTherapeuticsIncMember', window );">Jounce | Jounce license and stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalUpfrontPaymentsMade', window );">Total upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CashPaymentsMadeRelatedToEquityInvestments', window );">Cash payments made related to equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum', window );">Future potential clinical, regulatory and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember', window );">Galapagos | Filgotinib agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares of common stock acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember', window );">Galapagos | Amended 2019 agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage', window );">Payment of tiered royalties, low-end percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage', window );">Payment of tiered royalties, high-end percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts', window );">Potential payment for adjustments of budgeted development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts', window );">Payment for adjustments of budgeted development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000,000<span></span>
</td>
<td class="nump">&#8364; 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments', window );">Additional payment for adjustments of budgeted development costs in 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000,000<span></span>
</td>
<td class="nump">&#8364; 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths', window );">Payment for adjustments of budgeted development costs in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember', window );">Galapagos | Galapagos subscription agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_InvestmentOwnedBalanceAdditionalShares', window );">Additional shares acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,920,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares of common stock acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 717,000,000<span></span>
</td>
<td class="nump">1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 140.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 586,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing', window );">Payment for license and option rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,050,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_Issuancediscount', window );">Issuance discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement', window );">Maximum ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_StandstillRestrictingTerm', window );">Standstill restricting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement', window );">Minimum ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember', window );">Galapagos | Galapagos collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage', window );">Payment of tiered royalties, low-end percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage', window );">Payment of tiered royalties, high-end percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialOptionExerciseFeePerProgram', window );">Potential option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments of Budgeted Development Costs, Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AdjustmentsOfBudgetedDevelopmentCostsPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CashPaymentsMadeRelatedToEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Payments Made Related To Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CashPaymentsMadeRelatedToEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementNetProductSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Net Product Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementNetProductSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Percent Of Global Development And Commercialization Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementPercentOfGlobalProductRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Percent Of Global Product Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementPercentOfGlobalProductRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeAgreementOptInTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Opt-In Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeAgreementOptInTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Product Market Period Subject To Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquityMethodInvestmentOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquityMethodInvestmentOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Option Fee And Potential Future Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNISharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNISharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial consideration for acquisition of rights to market and distribute certain products in Japan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InvestmentOwnedBalanceAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment Owned, Balance, Additional Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InvestmentOwnedBalanceAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IssuanceDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Discount (Premium)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IssuanceDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_Issuancediscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_Issuancediscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_NumberOfClinicalStageProgramsWithExercisedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Clinical Stage Programs With Exercised Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_NumberOfClinicalStageProgramsWithExercisedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_NumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_NumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for Adjustments of Budgeted Development Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>payment for license, option rights and equity investments upon closing of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsForDirectTransactionalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Direct Transactional Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsForDirectTransactionalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsForResearchAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Research and Development Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsForResearchAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsToOptInTheCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Opt-In The Collaborative Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsToOptInTheCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Clinical, Regulatory and Commercial Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialFutureMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialFutureMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialOptionExerciseFeePerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Option Exercise Fee Per Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialOptionExerciseFeePerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Payment for Adjustments of Budgeted Development Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Sales Based Tiered Royalties High-end, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Sales Based Tiered Royalty, Low-end, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Price of Goods Less Specified Amount, Maximum Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ResearchAndDevelopmentFutureMaximumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Future Maximum Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ResearchAndDevelopmentFutureMaximumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_StandstillRestrictingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Standstill Restricting Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_StandstillRestrictingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalUpfrontPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Upfront Payments Made</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalUpfrontPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125513658&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestInVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestInVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OralFormulationProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OralFormulationProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gild_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gild_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gild_JounceTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gild_JounceTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_GadetaBVCollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_GadetaBVCollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_PionyrMergerAndOptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_PionyrMergerAndOptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ResearchAndDevelopmentServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ResearchAndDevelopmentServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_TizonaMergerAndOptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_TizonaMergerAndOptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_DevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_DevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_JounceTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_JounceTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_GalapagosCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_GalapagosCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585016740392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Summary of Debt Carrying Amount (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 26,695<span></span>
</td>
<td class="nump">$ 31,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt and other obligations, net</a></td>
<td class="nump">1,516<span></span>
</td>
<td class="nump">2,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, net</a></td>
<td class="nump">25,179<span></span>
</td>
<td class="nump">28,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember', window );">Senior Notes And Medium-Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">25,571<span></span>
</td>
<td class="nump">30,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 25,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.50% Senior Unsecured Notes Due in April 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 0.15% LIBOR Senior Unsecured Notes Due September 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.40% Senior Unsecured Notes Due In December 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 1.95% Senior Unsecured Notes Due in March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.25% Senior Unsecured Notes Due in September 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 999<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.50% Senior Unsecured Notes Due in September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 0.52% LIBOR Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 0.75% Senior Unsecured Notes Due in September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,496<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.70% Senior Unsecured Notes Due in April 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,747<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.50% Senior Unsecured Notes Due in February 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,747<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.65% Senior Unsecured Notes Due in March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 2,739<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.95% Senior Unsecured Notes Due in March 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,247<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 1.20% Senior Unsecured Notes Due October 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 746<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 1.65% Senior Unsecured Notes Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.60% Senior Unsecured Notes Due in September 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.00% Senior Unsecured Notes Due in September 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.60% Senior Unsecured Notes Due October 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 987<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.65% Senior Unsecured Notes Due in December 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 996<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.80% Senior Unsecured Notes Due in April 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.50% Senior Unsecured Notes Due in February 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,733<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.75% Senior Unsecured Notes Due in March 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 2,220<span></span>
</td>
<td class="nump">2,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.15% Senior Unsecured Notes Due in March 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,727<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.80% Senior Unsecured Notes Due October 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,476<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Medium-term notes | Variable Term Loan Note Due October 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Other notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,124<span></span>
</td>
<td class="nump">$ 1,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR rate | Senior notes | 0.15% LIBOR Senior Unsecured Notes Due September 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR rate | Senior notes | 0.52% LIBOR Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueApril2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueApril2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueInSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueInSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinApril2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinApril2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinFebruary2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinFebruary2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinApril2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinApril2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinFebruary2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinFebruary2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_VariableTermLoanNoteDueOctober2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_VariableTermLoanNoteDueOctober2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585095496568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>repayment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Debt issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,695,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,695,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,695,000,000<span></span>
</td>
<td class="nump">$ 31,402,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption price, percentage of principal amount repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Medium-term notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_NumberOfEarlyRepaymentsOfLongTermDebt', window );">Number of early repayments | repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueApril2021Member', window );">4.50% Senior Unsecured Notes Due in April 2021 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2021Member', window );">4.40% Senior Unsecured Notes Due In December 2021 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,249,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member', window );">0.15% LIBOR Senior Unsecured Notes Due September 2021 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">499,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueInSeptember2023Member', window );">0.75% Senior Unsecured Notes Due in September 2023 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,496,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,496,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,496,000,000<span></span>
</td>
<td class="nump">1,992,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member', window );">0.52% LIBOR Senior Unsecured Notes Due September 2023 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">498,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2022Member', window );">1.95% Senior Unsecured Notes Due in March 2022 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="nump">499,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member', window );">the "2020 Fixed Rate Notes" | Senior notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity', window );">Call feature, period prior to maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member', window );">the "2020 Fixed Rate Notes" | Senior notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity', window );">Call feature, period prior to maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember', window );">Three year senior unsecured term loan facility | Medium-term notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueMay2021Member', window );">2016 revolving credit facility | Line of credit | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member', window );">2020 revolving credit facility | Line of credit | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under the facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_VariableTermLoanNoteDueOctober2023Member', window );">Variable Term Loan Note Due October 2023 | Medium-term notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 998,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Call Feature, Period Before Maturity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DebtInstrumentCallFeaturePeriodBeforeMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_NumberOfEarlyRepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Early Repayments Of Long-Term Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_NumberOfEarlyRepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueApril2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueApril2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueInSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueInSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueMay2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueMay2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_VariableTermLoanNoteDueOctober2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_VariableTermLoanNoteDueOctober2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585088520696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 26,695<span></span>
</td>
<td class="nump">$ 31,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">15,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 25,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102666408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term extension</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Termination period</a></td>
<td class="text">one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585096875688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Location Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">$ 542<span></span>
</td>
<td class="nump">$ 646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities - current</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities - noncurrent</a></td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">$ 608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.32%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating lease, right-of-use asset, statement of financial position, extensible enumeration</a></td>
<td class="text">Other long-term assets<span></span>
</td>
<td class="text">Other long-term assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, noncurrent, statement of financial position, extensible enumeration</a></td>
<td class="text">Other long-term obligations<span></span>
</td>
<td class="text">Other long-term obligations<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, current, statement of financial position, extensible enumeration</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102776888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Information Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585016352664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Operating Lease Liabilities Maturity (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total discounted lease payments</a></td>
<td class="nump">$ 590<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585016497944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2022</div></th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>patent</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>plaintiff </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>patent </div>
<div>opposingParty</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>lawsuit </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>party</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber', window );">Number of additional patents allegedly infringed | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo', window );">Number of patents allegedly infringed, scenario two | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne', window );">Number of patents allegedly infringed, scenario one | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary', window );">Purchase commitments, year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary', window );">Purchase commitments, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary', window );">Purchase commitments, year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary', window );">Purchase commitments, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary', window );">Purchase commitments, year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember', window );">ViiV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Pre-tax charge to cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember', window );">ViiV | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember', window );">ViiV | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyRoyaltyPercentageOnFutureSales', window );">Royalty percentage on future sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember', window );">Juno</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease', window );">Amount reversed against previously recorded litigation accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentRoyaltyRateFromOctober2017', window );">Running royalty rate from October 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentEnhancedDamagesOnPastSales', window );">Enhanced damages on past sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentRoyaltyRateOnFutureSales', window );">Running royalty rate on future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember', window );">Pre-Exposure Prophylaxis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyMaterialTransferAgreementsNumber', window );">Number of material transfer agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2024ExpirationMember', window );">European Patent Claims 2024 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed | opposingParty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2026ExpirationMember', window );">European Patent Claims 2026 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed | opposingParty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember', window );">European Patent Claims 2032 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed | opposingParty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2027ExpirationMember', window );">European Patent Claims 2027 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed | opposingParty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesFilingOppositionNumber', window );">Number of parties filing opposition | party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ProductLiabilityMember', window );">Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of claims filed | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_QuiTamMember', window );">Qui Tam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentEnhancedDamagesOnPastSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Enhanced Damages On Past Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentEnhancedDamagesOnPastSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentRoyaltyRateFromOctober2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Royalty Rate from October 2017</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentRoyaltyRateFromOctober2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentRoyaltyRateOnFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Royalty Rate on Future Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentRoyaltyRateOnFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Additional Patents Allegedly Infringed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyMaterialTransferAgreementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Material Transfer Agreements, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyMaterialTransferAgreementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPartiesAppealedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Parties Appealed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPartiesAppealedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPartiesFilingOppositionNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Parties Filing Opposition, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPartiesFilingOppositionNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Patents Allegedly Infringed, Number, Scenario One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyRoyaltyPercentageOnFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Royalty Percentage On Future Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyRoyaltyPercentageOnFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2024ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2024ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2026ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2026ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2027ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2027ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_ProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_ProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_QuiTamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_QuiTamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585099413992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Repurchases of Common Stock (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized amount</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Amount</a></td>
<td class="nump">$ 546<span></span>
</td>
<td class="nump">$ 1,583<span></span>
</td>
<td class="nump">$ 1,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average price per share (in dollars per share)</a></td>
<td class="nump">$ 66.58<span></span>
</td>
<td class="nump">$ 70.64<span></span>
</td>
<td class="nump">$ 66.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember', window );">2016 stock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember', window );">2020 stock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_PubliclyAnnouncedProgramMember', window );">Publicly announced program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased and retired (in shares)</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_PubliclyAnnouncedProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_PubliclyAnnouncedProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585088484376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Dividends (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 904<span></span>
</td>
<td class="nump">$ 905<span></span>
</td>
<td class="nump">$ 903<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
<td class="nump">$ 865<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
<td class="nump">$ 867<span></span>
</td>
<td class="nump">$ 3,618<span></span>
</td>
<td class="nump">$ 3,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585102593160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Preferred Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585108600360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 18,221<span></span>
</td>
<td class="nump">$ 22,650<span></span>
</td>
<td class="nump">$ 21,534<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">143<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">21,064<span></span>
</td>
<td class="nump">18,221<span></span>
</td>
<td class="nump">22,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain</a></td>
<td class="nump">85<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">58<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">143<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">83<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(113)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain</a></td>
<td class="nump">129<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">58<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">187<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="num">$ (113)<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585103535416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Value of stock issued</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Matching contribution expense</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gild_GileadSciencesInc2004EquityIncentivePlanMember', window );">2004 Plan | Common Stock&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant (in shares)</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gild_GileadSciencesInc2018EquityIncentivePlanMember', window );">2018 Plan | Common Stock&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember', window );">Immunomedics Plan | Common Stock&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 10.05<span></span>
</td>
<td class="nump">$ 11.69<span></span>
</td>
<td class="nump">$ 12.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 65.42<span></span>
</td>
<td class="nump">70.94<span></span>
</td>
<td class="nump">64.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 71.31<span></span>
</td>
<td class="nump">$ 83.64<span></span>
</td>
<td class="nump">$ 68.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage', window );">Payout percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage', window );">Payout percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gild_RestrictedStockandPerformanceShareAwardsMember', window );">Restricted stock and performance share awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant (in shares)</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock (percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Value of stock issued</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Capital shares reserved for future issuance (in shares)</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember', window );">Deferred compensation plan | Fair value, recurring | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">$ 261<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalFairValueAxis=gild_FairValueatGrantDateMember', window );">Fair value at grant date | Restricted stock and performance share awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested stock awards as of vesting date</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalFairValueAxis=gild_FairValueatVestingDateMember', window );">Fair value at vesting date | Restricted stock and performance share awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested stock awards as of vesting date</a></td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gild_GileadSciencesInc2004EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gild_GileadSciencesInc2004EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gild_GileadSciencesInc2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gild_GileadSciencesInc2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gild_RestrictedStockandPerformanceShareAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gild_RestrictedStockandPerformanceShareAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalFairValueAxis=gild_FairValueatGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalFairValueAxis=gild_FairValueatGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalFairValueAxis=gild_FairValueatVestingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalFairValueAxis=gild_FairValueatVestingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585089465496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Stock Options (Details) - Stock option<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Shares (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">16.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">16.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">11.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Expected to vest, net of estimated forfeitures (in shares) | shares</a></td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward', window );"><strong>Weighted- Average Exercise&#160;Price (in dollars)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 69.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">64.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">67.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">82.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">37.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">70.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">72.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Expected to vest, net of estimated forfeitures (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 67.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">5 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">3 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Expected to vest, net of estimated forfeitures</a></td>
<td class="text">8 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding | $</a></td>
<td class="nump">$ 101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable | $</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Expected to vest, net of estimated forfeitures | $</a></td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585103220520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Restricted Stock and Performance Share Awards (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">11.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Weighted- Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 69.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">65.42<span></span>
</td>
<td class="nump">$ 70.94<span></span>
</td>
<td class="nump">$ 64.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">70.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">67.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 67.48<span></span>
</td>
<td class="nump">$ 69.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Weighted- Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 84.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">71.31<span></span>
</td>
<td class="nump">$ 83.64<span></span>
</td>
<td class="nump">$ 68.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">88.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">78.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 79.13<span></span>
</td>
<td class="nump">$ 84.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585104030312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Summary of Stock-Based Compensation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">$ 635<span></span>
</td>
<td class="nump">$ 1,076<span></span>
</td>
<td class="nump">$ 636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Stock-based compensation expense, net of tax</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">854<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">643<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Income tax expense following U.S. Court of Appeals decision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember', window );">Forty Seven, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Accelerated stock-based expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Accelerated stock-based expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">$ 299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123452999&amp;loc=d3e28511-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123452999&amp;loc=d3e28446-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585096925480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility:</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years:</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate:</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility:</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years:</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate:</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585107490184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share Attributable to Gilead Common Shareholders - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585107126504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share Attributable to Gilead Common Shareholders - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Gilead</a></td>
<td class="nump">$ 6,225<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 5,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in per share calculation - basic (in shares)</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options and equivalents (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in per share calculation - diluted (in shares)</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share attributable to Gilead common stockholders - basic (in dollars per share)</a></td>
<td class="nump">$ 4.96<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 4.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)</a></td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585108840856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 8,587<span></span>
</td>
<td class="nump">$ 2,505<span></span>
</td>
<td class="nump">$ 4,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(309)<span></span>
</td>
<td class="num">(836)<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">$ 8,278<span></span>
</td>
<td class="nump">$ 1,669<span></span>
</td>
<td class="nump">$ 5,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585108639832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="num">$ (1,776)<span></span>
</td>
<td class="num">$ (1,450)<span></span>
</td>
<td class="num">$ (1,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal income tax expense (benefit), continuing operations</a></td>
<td class="num">(1,526)<span></span>
</td>
<td class="num">(1,286)<span></span>
</td>
<td class="num">(803)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="num">(228)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(185)<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State and local income tax expense (benefit), continuing operations</a></td>
<td class="num">(413)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Foreign:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">47<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Foreign income tax expense (benefit), continuing operations</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">$ (2,077)<span></span>
</td>
<td class="num">$ (1,580)<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585103208312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings at different rates</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Research and other credits</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(6.90%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings', window );">US tax on foreign earnings</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent', window );">Foreign-derived intangible income deduction</a></td>
<td class="num">(0.016)<span></span>
</td>
<td class="num">(0.080)<span></span>
</td>
<td class="num">(0.032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Deferred tax - intra-entity transfer of intangible assets</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="num">(24.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Settlement of tax examinations</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(10.20%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Acquired IPR&amp;D and related charges</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">56.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary', window );">Non-taxable unrealized (gain) loss on investment</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">25.10%<span></span>
</td>
<td class="nump">94.70%<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585016279976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and accruals not currently deductible</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Excess of tax basis over book basis of intangible assets</a></td>
<td class="nump">1,157<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DeferredTaxAssetsUpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and other credit carryforwards</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments', window );">Equity investments</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies', window );">Liability related to future royalties</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">4,629<span></span>
</td>
<td class="nump">4,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(520)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
<td class="num">$ (217)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">4,109<span></span>
</td>
<td class="nump">3,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="num">(227)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Excess of book basis over tax basis of intangible assets</a></td>
<td class="num">(6,719)<span></span>
</td>
<td class="num">(6,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(7,126)<span></span>
</td>
<td class="num">(6,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets (liabilities)</a></td>
<td class="num">$ (3,017)<span></span>
</td>
<td class="num">$ (2,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DeferredTaxAssetsUpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Upfront and Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DeferredTaxAssetsUpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585104439064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning of period</a></td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">$ 2,031<span></span>
</td>
<td class="nump">$ 1,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract', window );"><strong>Tax positions related to current year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Reductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract', window );"><strong>Tax positions related to prior years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(481)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(454)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, end of period</a></td>
<td class="nump">$ 1,713<span></span>
</td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">$ 2,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Current Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140585088525384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 2,077<span></span>
</td>
<td class="nump">$ 1,580<span></span>
</td>
<td class="num">$ (204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Excess of tax basis over book basis of intangible assets</a></td>
<td class="nump">1,157<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Income tax penalties and interest expense</a></td>
<td class="nump">41<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and income tax penalties</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits that is reasonably possible</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Accrued repatriation of foreign earnings</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent', window );">Accrued repatriation of foreign earnings, expected to be paid</a></td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DeferredIncomeTaxExpenseBenefitComponentAxis=gild_IntangibleAssetTransferMember', window );">Intangible Asset Transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Excess of tax basis over book basis of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DeferredIncomeTaxExpenseBenefitComponentAxis=gild_IntangibleAssetTransferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DeferredIncomeTaxExpenseBenefitComponentAxis=gild_IntangibleAssetTransferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>gild-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:gild="http://www.gilead.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gild-20211231.xsd" xlink:type="simple"/>
    <context id="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8055c5201bb24e4ba49e863f9223067f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i115c1ea1db9c44ee8a4f7b1b25c2690f_I20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="iaeaf99ac576f40e684136704e997f1ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc317247ac9840c9b997af09c66368bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4befd4212fc4248a63e9b436b533760_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c51a506a019465dba53c1f088a945dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i203243bdd8194063a5b0d20127c91ead_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1aad07ceecdc471a9ee9d0a50de54618_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7c80ef090990421ba4cb204bcc7a4aed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2f35d93745f44ac84aacec6dc9540d1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id2942187c687440aae7d8307f89a6296_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id50e1295d74143879d750b13cda63300_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8555f34a84a4c3887459093bd255d74_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7703ce81d19946348842d9982c50c0c4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id46d2d21dd6a43a89e740948d75f9380_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7602de391c434d368154fe3329c135b4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i890acc6b92a24d29907006991e3f99d3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8222e290a2284cb0bf64a4ac2b6995b5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie196e7c846694582b374a274089a496d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib588e93b222b4f21902099d1901de114_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifa3d1ac282964e3380614a0c573278a4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibb1cc1349e424089965fc6662bf35a48_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i01dacb3a581346e187edae0a347d2eeb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i85a0c1ca4ff4429d9883b9d439e8e910_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i33a8d6544a084df5b9c6407ecb2d93a0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia4b5ab47f4054d119ad163b7730160e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifbd5347ef13d4d63a1e7031f22995187_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9da767fe6764cc8955010ca3f076633_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i40b1731fe1b744a2b37e1b7157cc1c89_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib64b3709e27d4ea2961642638f9cbf2c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i326d4d7af8aa42a1b1948ed90603ab96_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib1928c028f694d83885d06a82f22ca4d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iac80893052fd42e9be5a92f71c18cdb2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b1636d6a27341d4903b179394689324_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0fc16e772ac480c9e4ad4516e16c190_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icfc1931160c049e2b69a1fafb5719ec8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i851b03314d344a5e8ad436aa9235bf9c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f7ba76a51544cbd895730452d44bb48_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if0fd40f1bbe64b64bafc77d0138fdc55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9832261d41e74ecb88de8acbbbb81ca7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i803ae583deba4f7683154aaeec947d69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab9a9d73e541440bbe6a602affd5a7b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i124557415b5546be81b290394bba971e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81bd8c38c79a44cd82ea0da460afeda2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iffaa88726d364819baced65640a14653_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i626caba187154b4d9558b2cc5d8c94d0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8023d2e7ae2f498fa0385be7010b4f25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b1ea74ddca943afada26dff9a0ef62b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89cf74ab64a34cba879cbc8c8211ff81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d04ab1d0b074473902d53b2c6fa11cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ebb0b9dc1384269a861d7b5216e73fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia37682e7f2e748009cff968cbeae3311_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93ce718fd81f499ba51f827334051126_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4576883c8c04416a8ac3190f1f6a401_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i22f92d3d761342058252995e5000c7e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i187ee787664447d585348e1a2ab56b30_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e6b53c8ca604244a32c0b5e15fd5c66_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibdad0157d3ca4b4ab89aa860186ff56c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i77ab90c3fe714f4582356530234c3e60_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a627bb411ba4fa0a3e31a768339b2a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b2ff7c2261943cab1a06f2276326cdf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id689626e4dac444288f45776a25c0250_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc14ce605c54400c9ebe1fd7a321d9dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1051065ca69b4dd8bb278a9086b3981a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4c1e93ba27243a0aec3ab8933b85547_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iac7be3325a864dcebdad2dd2a9d61b1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8579426159424e1d88ee2838574cdf79_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16010a377327448d8c04798bd84bd4cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1b8647216f134ccfad7f18b6eeda9b4e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9bf76245cb82416b89541253976dc956_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3e5ed4771df344bf88d282203fb2c81a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id41a7b3cfd3a43729906149c4301f905_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81029626ddfb4f7bb7bcfe5c2fdfd743_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i38b5f06b93954d2c8a448f52813c472b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e49c049a1ee4d1da001f9b14eede3d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia257aaf476dc490ea9ce67b59628191f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i319aecbf35ee424caa4536ae8a070bd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id923790754d142bc8a4cff9f0db14fea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i004f42a19a0d4012ba76b651ac1781ad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic2e2462e823a488aadd395993cbcf54c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id3773b5856594296a0e0d5470b07272b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieb1ecc27305240afb7454391b76e7b3f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i955f95df25784bb981f16b33c53d7016_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4364249c081e4a8299d35a203bc4202f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15018f96b285492e9e58e9a7cf7f0920_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i943c0379de1a40db9377d8fb6d67ef66_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4554155264024aac9262c654e677f172_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9044ed3ca9147dab388bcc7b177eecb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07512868ee774a0cb3f3e62e504ffa2d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83c30c6f5a8742afa25ed987810c2b23_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a307049b7074acabfbc2358d76df30a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia7e743ecbe404abcad5a9fe1514264d3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i61b1914f864b447d97ea0e13f1ce972d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0a64962cf3bf49aa9644fc7d563ca33b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3e847a9210e84d69b80c3e8dc9157357_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief23171a182d4edda65a49c01d6e62a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i823165f9f0194830b142fcc6bf699a90_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia58f199843b04c59b0faec348789a897_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i90cc329330df4a528c8cab6d9cd3edf1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i479225886ad945e0b76b956d468e6f12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87fb52f7d4e44663ad1d8a82f09c8017_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia83c565a30a54c94b2209c76652e2a74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc63491101dd42d9a961519e1c143cee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i67f5cfa462304b0ab9cbaf412e605c14_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i216a83afd3da4697ac13672ce7f19d1d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iabce25c37a564a34b5d87a9ca20dccaf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i04ffde7221c6428c97f3d45227146507_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic50c2c139b864d0f9714887a2e19e6db_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb309902460441469df9d941328c83d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d1dc009e9554fdd9f501b84f9a0359f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i936e4f60767e4e1b831396cbdc15a198_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07a10f58aa8a4d788bb183517127b71a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibba1f6a417454414a52eee67b903f766_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i578e91a5c0ef41cd8792efd4d19387a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id40d8621788548d7bf411858ff7ba95c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5afd54b578514567a98284af66dd6ac4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2eb94cadea964808acc7aa15bff37b06_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf61ee83088444bebb4f09663550f050_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia7d0947b224444048e064e12269cb830_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia577fbe14a0c4e0d927470b3a7fbd587_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i977d9314cc04434e91070353392923ff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d310b1fa75d4a7da984b20d948c2184_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6bbc93fa20d84074b84f54ab99be3ff8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73de952e119a4e8193f9d06daafad3e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib1a3692437a140df85ba1b362d2ab850_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia94003099e5143b788e8be9985a431ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae5dc050b70c4243b5d650b622754554_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2b3a4868171e44de9828b7b8b593f50c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e9af54cfc5343f9a51ab0c702ca66b2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib00d8c27b3274579a8ddb2794664ce8c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i925632f08b5b443abc506c4e0023ae1d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i127c66e034bb456aac9234e1af982283_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i02c935862970477fa978f1f0a2d5a975_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56588b2fbaa54723a442c57323d9358e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie911ed307ffe4eb880442fd8415ae516_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47483424d79343caad903d50f18fbc27_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23d5b07c3dba496b87eed5481cc9e061_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6888f767fb5540a89c1b977dc34701f3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8bcfe9bc16c64a6998c2ecc8a00a59a7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iab5c0a688812413b97b23617889fdc29_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4a3ab7f327aa411ca8cd78c5b9c55878_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4f67d4b107054320b3c16b7722812905_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i20615d735e3f4feb876b0d68cb833b1d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iafcee73041034a3bb538769755411935_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08e8a386144940089c04595189b92780_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida4bff1ec94d45e89d93a2f8a45a8829_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if42c088f381c4f66821c3e14150643fd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a12972820c549f7975a5bf002bb6538_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib1f2aad4ccbe4eb0b88c2df952d0f837_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i897e806822094d188dfde4952fccd379_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba451b80fc88410cb6da9b54c955e4ca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i43aa85da84bc4a6aa2f0f6e6c94ce6ab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic75353bae5a445d5bc123e7e2497e07f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iacec9e096e3e44b99059f74fabeb6b7e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib56fe44333d84038b5fbbdbcc054b3c6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53379b0e65dc4f64ae5b9bebdfe46157_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i893bbd6422a34883a23ca3d826e5330b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i448e732ad9d54ac69e5a1bd7cbe328c8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia91566e38f88433997c0da1de1f66272_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ff0ba8e2df54068b6656075016def3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb20f84492cc40dc9b975458263e0c09_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43f373d73c8b47b1b9b16c76da6f8272_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0472aa0ea92940198b6e45b72223726e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib4c4c20540eb44838445a3c3bf6934db_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i736248e52f04435497e629400596475c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83bcf63461a9483abe4dfe87ed5458a8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2faa4357e47d498d8cbb90bc8b52484f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i396c07fd8f3441388406ead2bb7d7a43_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i444aa902d7d24a6bb6ae1f79b9b2c713_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i54a837cfa59946e4a95ef8a3cda149f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id88fe6e33c8e46bb9324f5323a45bae7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieaecb4bf28d542abb8f6e6fd2b7265d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if60bb22a46354d29b9219ed7fef954d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42f5a348b1384a0383f1142c48fbdfd1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa5c024b83bd4d2aa79c46874679d786_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i504f85f6c7224b00875ce2499cf0be63_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i96f908e96d164ff1b01f8baaa3fd197e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia251084190c34f55a95d6b2d64e37c96_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i229cf3b61ba147a3bbcb87ad7c31cda8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifac706cf047e462d9dfc15fd7dac6e57_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3eb81dce73a4ed49c600ae52236de95_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i618a49f5343d4aecbde299dd826aab16_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6dee7da238ca415a918de272a337f32d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibbaf6564706d428191f126d2bc0e85d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie107375dab0449d29330362386bad92f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaeaab2348e4b4632be02c7e9827151b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e04004aaf38470babb8b33e23b0be74_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5e3ea7d2e5d849d7a255cb4ca655164a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7ace274ff98a410dba00afed59352d83_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i465510434439422dbfe78d94feefa0d9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d552aa7c2b84ac880c86df8863dfdb2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1ec344efbbcb4ac58cc8fa406d405f6c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id54f9b7f9d7c4a1eafcfcbb1db87e3c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i71a47ad4a66a490c87ebcbdb533b3462_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c6ba686d4024e4cb3fe4e32aaa54c4a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i628f3e6013424bf6b278bfbb87d91521_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i099a39b4eb484948a229c49d6d7556b0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide13091f185d41cf95813a1577de725f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee9158b1c9f74ee081ba38f7155459e2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief38edf0775b4b9ca4f0e44ff59522b2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6bf73a2b190f407094b4c112c16ea000_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i70e97db273aa4eb795da9d6d163926de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7d2c54277b224652bb5f481e8899b9e6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i941c012023db4169add7305278b25afb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id8b3da75ff53437da4d0ebb7b7fce5dc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie98d85f6a23645e7b3666fb72be32521_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i110bc03b8b9a4f39af6919c8022f5247_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9461e732efa7439c98e730817b44bd6c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i39e0c50452714cc3bed41c678ceb7699_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4a05a18dbff43cda41f2c88b1526af2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i071292c322124b9bbbf6c05bedcf533c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic6d911747d0e4dd896dcbd36aa8d64b6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3db91593e7ae46df9458a6d27efd34e2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ice67dd103e8747c6a85c1155ca7fb3be_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i72885015d43e44598a373a66ba3cd518_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25d706b9871c4ec09d84165adbfdc1bd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9744c1bb608145caa3c32e7f1f1e62c4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieaf61fdee7ed484a8cf5ef1a28ae513c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib68f13d7d65f4a3f9d6b6fa6fe779f16_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad62ec6434ec4a489357913014ef40c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i632ecea3d6a14bcd8aba4b551ab1b109_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6977f8ca20334e9a848c24badc467c74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad186c8130da4cb0a163b46e15ef8e0e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iad332b2083f6422aa4d34ccad607df30_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic402cdf5c95049fab3f5cb084e3b4a9e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie91e317bcce84be491b677bb32bc6edd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i375f98b35c614e57bf7b3740ade479e6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ee01bce4fff478da0c0d8e0717ceab3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i19612080d7a04eb680dd7e62452339bd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0528cba9d58149eeb50487d8e0d93ffa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id10376e1051b4ab49d4409daa6db3caf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaccc6fe1894b406ea52f03be7d11f6d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i08fdcc10444240b5b0e2612cc6f7a33b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6778d1e87c764b129992c37e1b4c7453_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02a3a1f229ec4abb83405668328a28bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1e5ae4a747de409780ccfa5e25f24d81_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id6f226ca327245028082583aeea18794_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic223455e19124079bccd18d5b6d19b66_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i729e30cec34d4651bcc4fffc012176bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53f528f5ab3e479f8750f39c2d1cda40_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c21b57a311843c7928c23075197493b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i165baeb18574423899e97572f4ad2303_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie276a8d1c5114e51906a50380e6079af_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i808173f115644f8887374d0ccd5b7c2b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5af4bf5983dc4d368f5f7d4d273418b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47170c44772d4eca8e1e5e6506def2c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51636ea5513d4d358e7a7b90f6dbbcd9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaf522a1b7f6646bbabcc782e8dc1b51b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1fd3a2239f5b4e01a783ba6d8ec0df2b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6f8928add9a34ec3ad3f06c8d26024e0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7b4a7b3c0e8c4e2a853a78f842c29fa7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4827aab7f394a64b3d94fcd0bb16303_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia26aa6ff603d43d18f70315e2b916968_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i871089dbd36740338ee626df7623365a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b4e1408e03e47fb82f8f85c9eb666a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51ce404a1df3479280a332700013fcf0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i146057c31eb14e13a7a9e858bb60ead3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ed2d462dfa849f6afe13f2ebcd6d4e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b1a81e689e545ee948a81eef2e1c110_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8b28d7f764ed4df6a8fc6e996578f509_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2151dc48e6c947d99adf672da18b5df0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8bb410dca7a24d078ff1663fdf12406a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i94ea9f66d534416db1d7a1827cf95ef3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1647c6936bc43fcbdf243a9abdc515c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0aae349b58074fb090feca87f57d6a14_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8ced3c15a03640a7835d719b1561a52c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i73345ea2314645cfb8820974c816098d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2bd332574d544b2c82443ba3f73ee034_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91bc7aa72e1a4adf90ce08b4fc392bee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8eb76b459c940c1b2329abee0b99396_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i09754db5820b49ccaccb7b061b0de557_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5e265173cbd142768e582d998dc84774_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i172a3eda78c94e1a9b766caab41395d0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4459dfdc5346422aa45ece2ad20dbcf7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieebec0082c664646b4c00fc161a76516_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie7d099c53b1d444b94f937435b1658f9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id2ff0b32543a42a4abba6624736b33da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie7f1ebdb534d481b8b99013849133a98_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i970f012679314778a69b58c8c857088d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff2b48995cec427d8433b77a188fc0e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i11fe2f0b1fc7469e95477b31fceb41b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79f64c38e9ee4bb4a4adfed263dae20a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4513c4c6a873402fb73e21a4c06e9516_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie3976c38729943bca9dadbf1a4d46799_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib547fcae84e34c80b007576498382eda_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ica6cb120280c44aba952a2c8c31a2750_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0079f3b20eae4a329e4b8ab2e229a710_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3c533a97e93b4daea96b3f68f4b71cb1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i336a3356c30a4e60afd917f34ba87b7f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i80ab1d03e53b40818f7339579267f386_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26d26996cce54be89bc4f5b1de53509c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73430cf69e6a4a81b0cb6ca9f2f1bcce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b4092e37bcc4090a2f341d283035c62_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8edb5cc13dcc444f8d32a508d719f99d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id72cab863f9944e49a8a3f6a212cfdf8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6eb6a7e8649e43ea9cb507ca4dfa26de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24161ce3ce19498d973322014f5a38f9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2ca7841873c343278c0054426a718e6c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id98a790faa824c7aa313d67d0d0d9def_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd711f6c7d6a4b3caf2c838786295c50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia3b37a4b21504974b6a12ee7143b36f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2966258a34f945a6a240f933b9ea68a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaacff29670a64fc3b828391eaad52b5c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51653a7404d243bbb8c6b8587d15c302_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2206384caac54219b456deb7b0f73604_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i062b8b99606f460291f3600b276f88f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i65701b8285f24b0196e2fbb93db58af3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie2df490d82b849ba8e735ab25f5a83b8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0c114e0218d342d9bb4a36cbb9d68b4d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8a119fbc00c649cd9b0a5f71bb9c51c3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib9de5a23fb8f43d08be01ea9f3270bb5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i860b9ef8d88648b2bd14fdb1a1c02780_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb532a2686334aa5bead08d5c4f00b78_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic037528273e74f499033a150e619b4ff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f699c45319641abb957b330b47c6d1f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ff2ab162b88421d9ba989dd81c8eca5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if208e11d45a94784a19929ca1f05b974_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic808e56b4fb14e02a5bc2f7449a1a9b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idba5b8558d6d4ff38879057fdcd4aea5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8de715ffb064281b509585e98cc69f2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i92935c1825d54cbd8511cdb6abcb6c47_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3529227ebc7e4c039ce5ffffb338ca93_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ea72c97e32144938bb26b805ed4c89b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i213cbdd848e94530b0d92ccdf1a75dfa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5056823e9ae347a2933637a7bbe6b448_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3b4696f53ab1428d8c9d1112eeaa551e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie2c27d0f7d2c45fb98bdefdbb85bae75_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ceb977bf93a41088454e4c206235415_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ee0f595be264b08b8f9806028bf9b51_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie09f0fd7313646458071d017d8175cb8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab8836d9a4ce4fc5ba393c942ed97e61_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaae822cf2d924f3ea765b050bbaa39b3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i336854a9631445dfa14f917b4c21eb5e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7a0b5eb4e390464fb3247a2dcdbaebac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5e00b704a1f44803ada987adac8e13c0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i293b3b4563e14edfbe7fc51df8a013bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic7df84051b024c53a6a840e6cdfb14a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i961b952327124924a5e23eb37b9e7069_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i137abd7ca81b458e88261321792ec71b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i781c570cd3034947a327d3ee47e152fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f704090e060470bae3918d46cb8a9c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a218e9a42374b4db9008f33b6126318_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e25b298d34d4c5cb36e6a52a778cd3a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4403855d5dcd4d63b3eb5be25dbcfd64_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic35e32326f834884ac9a61bb0b8b479c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i65db5049fdd3411fb63e909ef2ec8e5a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3938c584a5744b148070f5afb631ce36_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i713866d6cf0e4d8fb0f713df57c870bb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i681e654b253346a9b076a1bf6a0ca271_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4a0f560cfb9a4aa2802a62ac6becbf6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i090096a8205c4fea847fc56558d9886b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9722c0087b814ddfb113130f0e25579a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9900dfcf355e4c32bcfd2373bce186dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie52246df773043eaa8b85b321512c538_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3622a78565bc4859927f6689c3c01aa0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i92c7202f262d495b8e4e4a2f24623eba_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie6c9456ecdfe444ea9be0065da372c97_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e0d01fa66074181a48c9de2389193a3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib586d74aa0da4b4185dfddf3ded39f03_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia794817e23b245eea3847eac57b7d78b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if987c46515874fb6a72a3a47e8e1d347_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28e77e92b5ac4b18b7764f67456f114d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i21fe0e0298e4466c9ea8fc6c07e67b92_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7269f1f07c444f62b04e9950f4fb49eb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1134f6515efc48459a0f5a14aacf594e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02940b7802cf4f7d9c2b6a7f03527332_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5221e66f2614f1ebe73bce91d2dfe18_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaac9cbee0c234416b4f8bf6424c7f023_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i32f4fa85bcfe4c6183ce30b8e5b62370_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4aea019cc63f4da6bd0e2026516da88a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i833b13271d42409cbfe54ea29a5832d9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i43cf8de658eb444fb180c5e973190ced_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8e2e3bf847e34446b91d9e3adb7b393a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i206db45c6dbf4ada8039f50d374ad057_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2747de847a5a4b9abe5da80ee4f4328b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c35b4c8bdc540088472e6d5f39ad3af_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8f8f38eb4cc941558bac08a5c690e998_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2dcff95b8dbf48c6be5de5c404ab2dc8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icec3ad77c73243afafa557c15ec72da5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib3eb32f54a11425b833021836e9f39f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id01f488874b24cf494dc9072dca62c34_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5d9115ac2882474086a95ff0a92a7499_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3ba2a5b00213403bba9525748da240d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d9039b4162443b796b32d897293cede_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia7f0bdd9cdd64dc9b7e998b0c6c0cae5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id619cc15e212429087aad1c7c9680827_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74a1f18b294146738afbce7fb84f04c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0cde46ee36a2466ea21eb5d4fc29b9e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f7a8cfea5e24a51b71987e1407913e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47da50f7e1714e2581271c261dcae57b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14e531dc995d488b890a3208e0543ede_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i66a0c129f84b440988cf1c09361bf9a8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8aec4ea6992b43ce82e0f558dfd36b00_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0d020553073843e5b6b7936014d32d7e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1bdf71c266dd49129cd99f86795f30f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iedff3b1944b64c3f8541ba18488844a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4cae6eb7eace4771bc5b03cb7d5d7c3e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieefadac07e0742a9bcc209927edca502_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i805cfc944d9648f5ab99fe13e0bd400c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9340b12589ed4cf8870255d67072e0b2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if302e604d9c647f2aa117693d6731a70_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05f28249859146e18cebb4ada570cbe3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i269a61a8cdb949e899eeb283218bebe3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4ec1ab3dfa64442192f0b94587b08674_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie9783ccaee044c3192afdd2303af4975_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8bb901328ad48a18b0d7ffb9e41d685_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i080a4966175c497dae95d90a6ab9979c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb880ef93270463586306266d0d1d82d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2dd188229a764f009b5c46cdd0daab4e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iade7fb25dc3444df929d6b582363121b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if3c8b2e16b7a4af0bfd9779c4e42717f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i97a22b0fa2914e7a8689aaa9bb993522_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b2f4b1ba3c24bcc9400a0bac9f2f5d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec069c130bc64661af4695041ea3fcc3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaf64712f0538422da3dddc8951a5c75a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9206ff4ea2634a9b8710d3da4ab817eb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ac613e5c50a4f4685f5d72248c51ab0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8b40444516934410acd5af26d4cc9cfa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4de92c1c900c41d58eaceb16cae8dab2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i84f7c42de6914a59a2ad2c63f6e1730b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d6e05e9b75b4907bf54d729d73cccd2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a662c83a2aa4f978862cdbb062bd8a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a71363ffee44c8e958961f85ef4e870_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id771bf711f3a4abf927510c6700ba371_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4949a1736044f93b646e6613b1043f2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8462cf492cfc495cb1b6159e93665280_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i468ec8b3e2f040d686ff31e4dc41d689_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i07489b4d42474f138fdfd6dfb3286ac4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i02d6184cd0bd4777bb8666956ef185f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb89a05869c84c4f8583d492d2024255_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8ffea525fc61463397a9083c8c20ffd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc50225e8b064effa4994483dcb578e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic2623fb937a24938b56dcd468a751f90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18a31f47fe134b108ed30bbed48a5c3f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8db6ad4693a9411eaacfd1efa9b38245_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i307ad909b7ac4a7bad744035b5fdb3ee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idc40e9061b2e4d7e8c573dcda94bbc8e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i63e77ce4e9354eee9898d81ad4e106f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i466b9478bbef4388a85e27c598939910_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5cbf3bc1bc41429b801a094750174f13_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb99587d2f584abeadc910467e333c6f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c2eab591b3243489738a3ce929a3f56_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad5223de57dd4696a199e9db73eaadcc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5015e8cece1d484b8333c5dc5371eb78_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i63ff77f687774eab827d133749a17db9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id462101bfca04327af64a9543c8a833b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic6af6e3232dc45a196b190b37e6c1439_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d6c7b10944a4914acc093ef93f55e30_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idb1faac3f7f34f6cbdca10553062dea9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b21d294f3d14aaa889eb58f573882e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i19d534eb0c65483390415a8fdd2e4915_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4ae8dc2f110f40cfbd42e80f081e08d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i912278219236443aa0a53f2ed6c5335c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if7a8bfac32dd43bdadd46b2b5c450cf9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d8ec0117d844149bf15fb93a66a98b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife19703a21e24deda943371d11289462_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0fc481856f34a4dbd84bccfc4f900e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c0246e87d7d4539b64d5bc5c091b3df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbc5fc480e4b4729b2803202c43ada08_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2286a95065594d6d9ca4944ff53d5394_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0b2d20da4bd4cfbbc5ac7bff1a5b643_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e69d167f82a4883925ec64ac6b590dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf113888c5464692b6ffbe8e4a732bae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if58ceba457fa41819c0289f982ba7126_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia353233b00564c41a4d9cd25abd93e70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cb417101fed43a7b4ac1d574f6f9524_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i195c8db92c30457c89e804d5f743ea65_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23b07529177a4ad8898665bf99bb8bd4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4694f2b970149499d768396c277556c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7fd02cc204a4fcca4854f1cc54fdc75_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa9c593efcab48c292fef975883cb901_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4f01b9dc465412898be06b78bed526e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26d0f95467284563a2793f3b45d55692_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if92ffa56cee1465981e8289446960059_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25ec023f9542416ab812e9b107619ed7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec65128416ed4c2caa95ff502b873f17_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic00702509b5b435495cf0ec01ce3bab9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifad92d842d244ddd8c185fba7ec11571_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf683e991aa04e84b6b581929bc8a52d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i678f3e8e9c0c4393bd7bbbd1dbc823bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17fc0330f5ae4c9aaf6ebfc057402b0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03cf8ed895c84bf6a0b0a590b3791db3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2c6eb6568ed498290563719477a6d6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf0d3c79ea2c4c72810e8c002a5c14b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide6b42f3b50c40e7a356f40b566dd53a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35bf4c1622964f4ba66d71293935d060_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i946749b11bdc47e88afcab1bddcdef12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e50b420b9d24798a8608dae51733253_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb796c40fa2149c29dbc27aa4bb85775_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63935bd985224f0189d1730574c0313e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id37ad7d3e58949e28ec38d38ed20873a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ca1fc3df69c4ea6a527e5aadbaed99e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i314b3d48689b48a78390fdb9120b06f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3331ea5fd3984313b34746715ba4ae93_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25dc7b22e3f541188c657f4004692097_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a8230e74cb644c5a3e520fc9a03f39e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i152a4600edde4d04b65202787532de71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5b6f43984b043f1838533b38d3e5e38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i598fc7abce8f43bdaca52d6637a92fc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d6d92e9d06d49fa842aa61301fede5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i933d89b1d3e04e03901b0acbce724bc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35a96651d23b4cf0b0d1b40e9bd9a52b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i856d25ed6103414d89dbd76e3f9e2cc5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if793cdfa691a4047923ae5fbfa0651eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia68f6c8a6e4b40be839701a8158a7994_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5d5ef90d851431ea311b8514b301646_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c0099914e9b47e3b8c377d2d5605c48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7be17b88e76541728d2d52bc5c2c9912_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ba9f036d1c6491b8d70e0393484bd55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31176ade8b484178bc6cd4473ef6e2aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67cdde391bee4e1aa62b4fe62d765eb8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i319991ed67fc46fe879ccb7ee406b2bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7ec4799858746d28f2672bb3328c313_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie988bf37059d48c0bcc4ac229bbb92d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7858389cba8440abda830a77b3c5dd7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96a6c459ee244343821c1e3c44035a12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d056305515d420da7c42e745bb193c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b510802aa0349f48dcb8a8e7cbf9a21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44c1b6d7dddb473ea3e00bef51b2e0f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1c1f4de39c94a96aee95ff2f88a2128_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib041556bab2d43ea87cd7b61b04e2646_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b8fddfac82b4eac885606ee08c7a905_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d1be345220f478da51f25e82698124a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic404165c5df74a6f8352e0db325e95c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i089e25d92ca54c8985ea2dec50042b89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ada8ca7ebe9435e8e842501c7ad3ae3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i016b509afd8947f3b511effbe125af0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71323cd5e83d4d6d87b2eed504ce751e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i727438de14724066816f95ee9809e17d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b832f22f4be4e61b0de45142590027e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf631f09cad14340965003dda42b76f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic387fe29a75d489788a450be894254a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2093e60191934786be5e9f3c4d997270_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea1fae5ea08948ba843477c2e34181be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ea29fc78efe4c18b496239d1891b476_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9af306f4c8d042af84347454c60ca09d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85a8909028d04fe1a126acdf567947cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90c285b633ed488fbf315d7bcb4b9c40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9869805732e4312926496da94a42e12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92185773c58344ce928789fdf5535c76_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0065f36a81224792b11e6b48f9770c23_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd8ddd71ad6a4934a591d1a60321c3c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id803bb97e7f740d6ad0af3395e67147d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c806a171cbf4ef99d78d293d9736606_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3167c1fc9a3e4a5788cfa0858e185c3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ideec20edc39c49fa90ed919a34d06198_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i271339ca119345d694d3d33dc37ebda3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83fe215fd3514c48a9b0408fc2c8d430_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1d5b54c27be44f58ad2ee7c5da2c1bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e7706841e6648cab9e75afad945d3ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie627b2b228da4beaa2c490c412620ab6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icac8673365254bbdbf17e38b4c77bfd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia43f9293bebd43209b55a1f81a2eb994_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5efa57e75bba46fa80520cf5680bd744_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fbab0dba432455d952aca9feddd5630_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee18145a966642cc8e1ce5da7d258519_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icbb049a4497b4214bac4f90ea6d795dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83d09ac1c4594e0da8f577558b10d846_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3ae968a144943c69767909be7df131b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72ec7b074d434e8bbc8f74ca1c51fa6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba409e656a3f48ab972be2b06a795ed2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id77217ce37d644ed8b218aa4572cd4b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bd3a01aa1b84a7f86ff1f7e00427920_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i863d391d7654400d8d7b18b4f8ed2d6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id24b38f7656b4bdc843563195dcfddce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4bba9a34d1de4972a00d03116c7adcf1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5795fbc1c3341f29a10bb7056a260ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieeba2733f3294d8fbb36b69036097ed7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i537d6236c6684eb8b511aa68e41c2195_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i752e52cf961f4af794ad9d51504ea5ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9957ec642e74491187d1c03568dc54e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82771ba0871b4c818fe4a95aad641c8f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia13c72dd8cf642e199152f20a3bf4a87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f5c1170d657408696883656ec2bd949_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic2adb19e0ca44d459898b6f842970ad2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gild:EquitySecuritiesDonationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gild:GileadFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67a406b4b0a049ffb974da9082946416_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f6470cf7f5d4d0ebb2b950757008455_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99fc02b86f154dc9aef67ccbad4572b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10ea058e4eea4ab9a26e8149179fc6e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i366d837490844422b12ca69c2324a42b_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i601744dfe4a449f588dff2ea9f459c7a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if747ff5ccb394525bf8dd861a2391455_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7987a3dc65e4b51a622b5dcbc55adcc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45bc386594ad4ae993ce88114eb4e62f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i347295d908ea47bd9ef9a8fa1edea941_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2afdba519b8b455cbb7ae9cfc063ba8a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie04ebb87f24d4c1dab5e3b201c5cb6ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b2cbea5bc7c4a8b854e2ea7a3ef27c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5cd664388de741a283f40d467c2b991a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic431d321c32f4a148e09f407728ba829_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b2dfff9a8cf44d0a774eb9d6d1b49d3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f0e3695ed25418e9b23c7b9dfd2aae5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec1287280e9a4deb8aa835abc6a56556_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d59af8c16674ee3b51662b5f23c4dd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i656a88d21ed14481983deda32ba5c61e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12f871061a224dd98a831397d2bb871d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5683ccd60fc477ca7ea1aa59d4ccc1e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81c0aae6ccc84b7db071d1c937c18fe9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf1c274e36c24d35acaf02b87f54cdbc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87a8e5050483425f801196f211abfa22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib77bd1f1f55144c3b95b11c8a831313a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ba0806a7f7a4733846c919f29140932_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iade4a4ff784541f9894f489c3fb0b38b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37b11b51a2b54cf4a3a9e85b864611a7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5810a2be53eb4780af1fcce52fdb4182_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i018037d6d5a34a678330d1e08439237d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7c8d27c7190478abd912de07485cf67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48f32c2561ae4b3293149592ac05f4a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45bc7259ae6041fbb19709a9cae25597_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i971521b0df674be6820599f3a1fc538a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idaf88e28a5724eb4a56d2dfc0bf0392f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47f76a18801e482ab060956da5e0577e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib44df45962204ad590aa3deb292d480c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ef1ef2f4ad142b98639be3f14e6ee99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e8547beeb32459aa1afd7e5ca598ef5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2303cfde655d46948b6bf62eb15ca0de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ea1ac770ed8451ab24e1400a67a9c3e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id145919643ae4857950cf7eea0d60f0c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id29ad5c6bdc744ae996da36f45e56366_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82b12e0c7d5d4ac7972fa5266a3d7e8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3154b2ea498c47eca679490b457a3b8c_D20210304-20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="i359a44a00217459b8f4262c8fc42c933_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="if51b044176e94e2bb20e9f08a40d5ebe_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="ib7c7aac8a2ee4a4ba775220f0d9f2cb3_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i4935cfb394d8470eafcd34defaed7483_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="icb48d6051df7485eb73cdb8b7df0e985_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i921b8d77d4f84f529ce58e9660da8dcf_D20210304-20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="ia2177833d44d42918c6ce32854820034_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i21ced31d30014719bdf7d7d18248633e_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="ia9a673ba30ed4f0e806f09b015c95ec7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cc76f278d7d430794fea351f77cb6c7_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="i1f5da942c50945a2940da6ebd718841a_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icaf63b79601f41cbbbb79ce216ea77a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3183f05cabb4466ba0779104322ecffc_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i40d4bb748a364d08802e6d345ae95f56_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i48fbb200fd474e8c86b19b2980d80c7a_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="iee6771abbf6845e9b749e3f2f831a535_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i4c0a66904d084d55b9dbeacaaa99fc01_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="i4914efbe4a514e3a9b1e8ce1c3d1f7a8_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="iea54bfd7cd894da1a9dc4dab9d27fd06_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i8e4d4939ae6f4eacb0ac9fcf29a6a86b_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="i2cc576f3ddae4cccba9f06dea7d86258_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i17b0826d35c24c928061c1e5a0cc3d90_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="ic064b955d17a405a8e93d4ced0a24b8b_D20200407-20200407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-07</startDate>
            <endDate>2020-04-07</endDate>
        </period>
    </context>
    <context id="if390b664ad9b4a3fa1db0cce3b5ead91_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic616f3942a304ac4ab23e63afeed5a7d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i799ec7afbe884df09fd62386211ca69c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb077705a6144313995575f715ac8647_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9130594e600c402b8c0b978840773abf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2809f8582076480fa7e0927fefc603b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9515dcb5dcd4ed096a37c411b6c94a8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">gild:InventoryWritedownsforExcessRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0ac72ff3c91e41dda636f4481b43d8d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if86d40bd14d6458096e0c4c590a93b2d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i954f79dbc23344e2bc4a6cc0b85ebc55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d05732d25884b3886f2b6eb46e0c7a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e5cf4e62a72481988dcf8c0806f41bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a7db52d1e4a414281cb490a081d6dfc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c2781ca10ac41f5983b9e118c2abf70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneCiloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1ad0c1f171b4177b15cd5e56d09b6c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneCiloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idaf491080c57475991aa98abcc4fbcc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bdf2ca12670410281b8c08d6e3e7fcc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1f8421f3e1d46c38dbaab52dda2ef27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf23ded0c1324053bcaf589d66627968_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30947e974d8c479392d193aad7a782fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d94d5c1399f498a9997b438dd170d14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52f89193810b43f085be64ba7f474b2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4094fc9d8da341cea659d729c71c046d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1d241566dd94df38a909334019a059a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6252373178cb4cf6833d9fea5111db48_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneCiloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i034b60a8653f4767b2a7133e87e4160c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i808afce6234d4f44b02493f616cfcdad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i157409bb1ea342b2a3f94ed6091834b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e62f0a33b96429bb3fe4df85eb86fd7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaaddd81bb83f462cae89580391426788_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="i55469af46ac6444babd1103f64cce260_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gild:MerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="ie62b8bd54ac5417b86b9d244cf6f31e4_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OralFormulationProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="i1366e28f1db34aa6adddcb7dc9cc3fe0_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:InjectableFormulationProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="i0358f4e9723644c2ad88455c39676410_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-13</endDate>
        </period>
    </context>
    <context id="ieb4c98e8e51d40a1b47f8612c6763bdb_I20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-13</instant>
        </period>
    </context>
    <context id="i123ae893a43346c69c0dbe160845d982_D20200713-20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-13</endDate>
        </period>
    </context>
    <context id="i30f6211f84014d5fb004dbfaa00c87ea_I20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="ia724223fb3ac4ac189bcbeacf8570846_D20200529-20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-29</startDate>
            <endDate>2020-05-29</endDate>
        </period>
    </context>
    <context id="i097284d2fd8842978d347c1888e015ca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2ef41f89acb2446a8d12c64235b715ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c0c8d8e8e5041718f4702400109bd45_I20210208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-08</instant>
        </period>
    </context>
    <context id="i1ed865dca089431bac2babc189c7b73e_D20200527-20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-27</startDate>
            <endDate>2020-05-27</endDate>
        </period>
    </context>
    <context id="i6a21258292b74537b89e8497e7a5f1a1_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="i7fffbc21fc7d4b79950ac95fd954ed10_D20211221-20211221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-21</startDate>
            <endDate>2021-12-21</endDate>
        </period>
    </context>
    <context id="if55eb0ad124b4e9881655f8d21b1defb_I20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-13</instant>
        </period>
    </context>
    <context id="ib55eff2de05b4735962a5178e2d0c136_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i91b41bd2879340d590e60e9612a0f797_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide14895bf0d94cfda60b8f404be8046a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5dbdcfe118594570aa52cb141478f07d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if414b8855b364ef693704d5b8001f3de_I20200619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-19</instant>
        </period>
    </context>
    <context id="i2e1550a829c24cdb927d71b758e41d28_D20200713-20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-13</endDate>
        </period>
    </context>
    <context id="if7c095b57994471c805950b5c5648d45_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iade36ecd4b2f43d18bc13b3efe3cfbb6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i440f8eb082024226b3b774d89e0637e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ffb74e13be94db9b8207cb1d854b5c7_I20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-13</instant>
        </period>
    </context>
    <context id="i6d004159e86645f4b54571d61ef34b7a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb5f6c23a9644726bde59d143b28193d_I20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-13</instant>
        </period>
    </context>
    <context id="id404a80a80e44a99a559bfcef8dd06bd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i697aa6050edb4e629c83ae942ed52f29_I20200717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-17</instant>
        </period>
    </context>
    <context id="i397dc877c7694d19958b40ce06f66597_D20200825-20200825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-25</startDate>
            <endDate>2020-08-25</endDate>
        </period>
    </context>
    <context id="i49d256c267ef40f8ab7c6c8aa7a19bf9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9b799eb641ab49b28bf86c39cc6029ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b9c16a178a84867be9f2a8338568380_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib17c6ee7308a4338b6c4a503ef2f8d57_I20200825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-25</instant>
        </period>
    </context>
    <context id="i6db4377ec93e4d7bbbe59b9ebfaba7ca_I20200825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-25</instant>
        </period>
    </context>
    <context id="i339e56a5445e42a7bd636e9572986490_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TangoTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-17</startDate>
            <endDate>2020-08-17</endDate>
        </period>
    </context>
    <context id="i218f3bf11f8c42b7b70c818ee6cc5f8f_D20200817-20200817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TangoTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-17</startDate>
            <endDate>2020-08-17</endDate>
        </period>
    </context>
    <context id="i6623efe8bef84a7791fcfec2fcc2f16b_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="icb7bf0dc4a3e43daaefa71f64c8916e5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9750074cced84b80b470f7d052116226_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i85f6aa2b44894183be1329a1fd12b947_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4143eccc523441058a76f70c0b3fe14a_I20160119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-19</instant>
        </period>
    </context>
    <context id="i38d8e949cd7d431c99be65bf7f658b30_I20201215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-15</instant>
        </period>
    </context>
    <context id="ibfef5580108a40bb81fbb13f508788a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67c0a0b9d43540d6bb4a7d7d6f17ebcc_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i67e54ce58cd24263aa47b0dc690946cc_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i97319e361fc94cc9a211d39a12605abd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i696425f28417451f92ec8151983911c1_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i6ebdcf15388b47788ebf7553317d34c4_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i7927d3d1315d45eab4bbe1b07f2029c6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib85c08bffd6947139520ddf1b963fae1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2011c1fa80f041a5b06d24015e3d5227_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9a5706c39e84b85ac9e1d0f522c9890_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4db427db2e8f4ebfa1972445ce88c38c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6db86d92098f4af891245ad653df5061_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7372c5e4ed6845fca519e44a4bb17431_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i5dad1dfaca274c1799a38e45db78a46f_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="i45c072246c2f4e6d946c5c5570d2fed8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6ce860376b2440a786d96346e8ce0f89_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i578443185f7749589002f4f312b78678_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0dba157973574ff69d357c2d296e62e9_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i58b324bcac2249b5930ebbcdea8ee4c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3bdde946e55442a1aa5d7882ec1e7427_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00e7665e176c479ea7bb308c8eeca6b6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2d244f0e9b79475cb0ba4b314b832cfe_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie60c8cd3db5843dc97136850ade2673e_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GadetaBVCollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="i0ba0c9e44c9746718a04e414e6de9857_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GadetaBVCollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5beb0d51c4e54f94969f8c6cd1ba0419_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8e25b453d1fa4d85a5dca483e607e4d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icde588c2a460402c9deeff992fa80573_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i88553ac9d9624f42958c6f396678542b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4800b053ef3c4136a3cc63c8103e707a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15ff3826397c4b51af10501cdfc1ffbd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic90520151d5e45a5b3bafe9e36c40ab1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbd11fa3c26e4fd38091c2e840bb69d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if49d256ecf4c4fccb417a3006ed896b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2d9c33739db4dc08bf4edd765bd7407_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if32ef749e53840578fa5654cc25b8c69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43afc0414e494b869b770762bc4d9a52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51ed2cd34ce84554940fc25d819f2777_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibab69215b4e64f54a4722114423cf768_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia79e2cc5633d4132a25a764b4a709783_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6efa694deb2427e8f5f99cf4f174aa3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4db7fc21d050453fb55088da46769875_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if57ff25bef0d4bf4a3e07a11a72aa1c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7fe7b7bd7a749eca2309daea67e59ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff239ca5ea6542a1b65cc0ff2d9218fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24f46a74be3740deb3686fa5d733f011_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1dea7ef2353348b9b97eb413fb4c0d7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85abfdacc7a34da5888f65dc84ca6fca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i20a94020fb22453791fa3f7a17071381_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44be2f180cd740a2817d4a90b827ce9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5f33f1a524c46ef989dcaf10d803a74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie05fed16be294c6fb4bbc7419f3eaef4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e4a183e1199483b92ed085372e796c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb302b98be6d4fe8bcaa37065ebb5a54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib60a477703704a5b8d5fee9be6c07b0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d459efd6b0147f8b01649f355747ec3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5fc6d5d4b12c47c9a6edd38827bfbdce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffa4722d53ca492d86cb72a4394bdad1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ee4ce7cca0b42fc81e5cae1b1b19a25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9c38cd0fcf7429e905732a6030b0115_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99ac4c08ddd043138479c7a929366808_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7107a8f3798a4b4f85c5c3934cc538a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42c4206352ed45c49b1ffe6a976a0723_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i067ec910ab5441abb89d5d73967bc967_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8738af8e5e5d481482a0aff98aacdf90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d50e8b499914bcd8bf4ea2da01301ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i671b7a2302524fd38cee3f6ff2f98b3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78530d2e8d6b45118714c099f29d8e67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00e1ab6155ce4b2ca7387b0e499b13ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8027a7afa87d4545a246f3cfa058ecc1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i775bc80f0b4046eb933f175fa23054be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i600f96952ca74888901fe56db25f0a9f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80a1b0b283de4323a915636bf3154c0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57e9c5b3387647bbbf9a05d29bc125b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48f7619e739144e8ad45877990dc8b4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6efa1b3c097d4e8bbb0044de2e0eb97e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00f996e674334831a4b702a6dab1227c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8731d482f54944dcbc86441135f6aadf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if30937e6ac3d4bb5a4c2184d7905886c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i452b8349934f45998316aa6b615f395c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9268c9e7d32a4d089a0df68305d6cdd8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icde2c819b2eb481a82769fd804c55108_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb910542d9424ab9b95e5810565ad466_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iebf9a43b220342c69783776e723e023f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81f6869ed0c24ce4871816f7d2e7cb43_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iba530d87b0864376a38558b02d16b8c3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4a350670d64d4f1e800774de0810abc7_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id678a65bd8bf4578bec8bbcc0aa50cc6_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="if2318fc40c5a4044a5e207e06b104152_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="ide0591f02f274c108fd4f307409ea95c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2149910737774396859ee858a7be3b62_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i23a0d3b2005a437792898712c9d8fd19_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42858b3c72b14dd29fd0366fad42b66d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b6ed812482443698e8524ebc5028ef4_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3e04a1496e924fd6aaa5cf09f6d3974b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib86f88f4366542d4b2110433d8eb2472_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i6a0dca0a129d4621881c8db9cee9561b_I20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueMay2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="i424653e19ba342da9528563065ececec_D20160531-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueMay2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-31</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="iebfeba12e19f4f08b20c868b3c5aae4f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibc9ab8f16b194dca9d59c47d3bca5701_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie345d4f41b194bbebb717ccc62b975f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i811b6102317d403db8c7febef98c0b3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if472a036278a4d88a49fe0a47d9404ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a0a5d98945240a491ca261188cf0b76_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3f4cd81637934eb4bfcfc5bb4da29021_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i06eb7508edc54e1d963da3d320aa56cd_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0515ea18ac744e009b23a9242a725ab9_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i58312b3302b9493cb83df643b7d08e9a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i265d4a6f0a374d1dab17e075aed111ab_D20220201-20220201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="ib937eacd40624de4b33e1818017eaa04_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:PreExposureProphylaxisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i7a0546071ccb452889c1fb141764dfef_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0639e3db3b664793a6beb77eb685f7b0_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i1f23bfe0992f40f3b1234a110848985b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2024ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0d5cca66648457e8765b48c19c1fe65_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2026ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8a659c08da049ae986c9c29e62e00e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2032ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i225c85c01cb74eef9ba4b88802d3cdf6_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2027ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ifa3f8743db084c41b63d403832f512f3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2027ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i327f548a38ab4392948582ff7fef469a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25a9bfaaa2514554b1836ba98b4643cb_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:QuiTamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i3d943fc6896d42a2a402f7355165d0db_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2016StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="ia0ac11cc10c94ff59a93bc7def17ae5b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i88ed2a00d0174820ad767760e9f24578_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:PubliclyAnnouncedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a679c0b45db4ea5bbb87a138014433a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:PubliclyAnnouncedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic28e0d3d171544a895828b1b399da271_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:PubliclyAnnouncedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8488cd00ad754d66a2f89c28ef0113ca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i23e97ce3ab7e42c8b5eddc72bc3e2957_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iee9756a76bba457e81595f5fdbe576fc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9cc38953c3ec4d0c9b3cbf82dde62ac8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5501384b52f44d51a145ef3f4f3e7ca5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2bea2cadcf9646f58956abc926e1586f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6d11aa8c23bc48e69c02c674ce48e4b1_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6bf6d6d327dd4e03a5847141baa75c2b_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ea289ffec3b458087dccbfc47e573d0_D20220201-20220201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="i9cf763f4ea7f4880a47f0e6a403877f4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iff25d3116ceb4bbab1c6c9c8d145401c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id9f1e0014a754c4cb3066bf85c4a2570_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifa632be9dee643cc918655e93fa6c0f6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0ba6a2a2d50c4a6db88d7c68e239a2b0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i39bec68158bd4af6bb2c347ac792a9ae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7f580454e7604d7785de9823f350085c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i031ae4d8e4484c4e9b1cadccb6c88ff9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7baa42c3821a4c50ae27b170e3c7858f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74a7063cdae7438bb8481aee4e692325_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i193cbc90df134a0d9735d84dde8ed9ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d96d9b09d2a48cfa30e6bf373b5f762_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb145868ff1249dab7c2d803aac491ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie75f65899cfb4ee38ea27dd37daca0ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0afde8034f24eb688bd439bf07e61b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5240156832f4cc8ba8aa92faeec8f85_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9d19504e53c460ebb2acf511d875bc6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a09a18820154418b65c5db65a9e8ef6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieaea04c5cb73429c92a11dfc633c9a7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf9f4f8bc79c4814960889868046cc5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6a1104220914dc19840bbf261ce2cf7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica652e76a6974f3cb7f5a6d0f8d94017_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:GileadSciencesInc2004EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib59a14c778a94c75975c4acb8a10179d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:GileadSciencesInc2018EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba210e1a3e384daca10160c7ffbc3ee5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibcb5969787714c0d8190646f3cb425cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i63aedd4c33d5433b8067d84fd5b6f093_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f84634bb8d4414996acc026171d4734_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0729bf1c13614c1dbd5464ad3b216cd1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i354b6ee389b345259779247e1761d741_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i978af2e4f66d4a0598365cc6a4df3a60_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ac2832a817c4b079e7e753df575c2fd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie7c2ae063b354630b9b4eb98c12579cb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea60cbe1d7984731a8c9400ef7641432_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6305a82bd394408e9eb61ee6d9a6b096_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icec935a6b97544d6a97b10b0c0f9a6b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8fcbd9748d94709b73ce8d6ca1b9f32_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic09fef48c1da4be29e79de02aa01573a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8e0958f8c926485eae5d31e7b78ed257_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35a87915496f4f0f918d93a07f297c71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i17e83904e7c84fe4ba24ed426244affb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12f8795691e94495b697bd3ee9e10a01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f4fbfc0f6ca4a74b926e26a7212b4d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i092e7210064445688e64ea085cde62b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i597fc5ca87d64f79987a4deb4814a2cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb8bcd0d8ecf4205b8fe6029870b6fba_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f4b7466ad0243e69a21d012954cb83e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i27e180b4cd6e425b8489f50bc779226d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74136efa08b74a10bd1a8c546eacd605_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7bc9c86928c74673ab301285440c1661_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatVestingDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if0c35aff509b4c369b6860cf48fb5cac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatVestingDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b1a7a2d096046eea14fab1d821f637f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatVestingDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iff82fe9d37f642f6bd89267088886a42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icad35ac1806e4f21a40d3a0946de361d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife2e5f0230844117bbb72a6267db6609_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic63775c3a22e4db9805ee00e5e0ad2f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i09ace142a66d4ef093c014ea5eb86836_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6851218a40374235b12bad014064a29d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9ee369dd27f4f9fa86ebb38e3b71a65_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i94fdbc3b74014794bf026a159fb15aa2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4d0883810134f519ae9afb0d14ed77a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i490b5d2fa50a4d27ba621c355f27e7c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7bea36ad4f2b4224bf60b33eecac3150_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie16d6139caf042729e09c331c0223fee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i49ab5beb24194822982742d602f870c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i77335a2113da496c800ece78587ef758_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie33787d4b92844f0b3f49ee4b16ba703_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="country">
        <measure>gild:country</measure>
    </unit>
    <unit id="segment">
        <measure>gild:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="position">
        <measure>gild:position</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="program">
        <measure>gild:program</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="repayment">
        <measure>gild:repayment</measure>
    </unit>
    <unit id="agreement">
        <measure>gild:agreement</measure>
    </unit>
    <unit id="patent">
        <measure>gild:patent</measure>
    </unit>
    <unit id="opposingparty">
        <measure>gild:opposingParty</measure>
    </unit>
    <unit id="party">
        <measure>gild:party</measure>
    </unit>
    <unit id="lawsuit">
        <measure>gild:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>gild:plaintiff</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV80L2ZyYWc6OWU3YTA4YjhlNzg3NDY0MWJmMjIxZGY5Mjk5YjhhOGYvdGFibGU6N2QzNDc0ZGVlM2Y5NGU3YzhhYmFhNDlhY2NhMmZiNDkvdGFibGVyYW5nZTo3ZDM0NzRkZWUzZjk0ZTdjOGFiYWE0OWFjY2EyZmI0OV8zLTEtMS0xLTEyMTQw_3ca7f6bc-124f-4104-8841-a89be1f55210">0000882095</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV80L2ZyYWc6OWU3YTA4YjhlNzg3NDY0MWJmMjIxZGY5Mjk5YjhhOGYvdGFibGU6N2QzNDc0ZGVlM2Y5NGU3YzhhYmFhNDlhY2NhMmZiNDkvdGFibGVyYW5nZTo3ZDM0NzRkZWUzZjk0ZTdjOGFiYWE0OWFjY2EyZmI0OV80LTEtMS0xLTEyMTQw_eed59f00-9e0d-453d-8fff-83694f801f58">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV80L2ZyYWc6OWU3YTA4YjhlNzg3NDY0MWJmMjIxZGY5Mjk5YjhhOGYvdGFibGU6N2QzNDc0ZGVlM2Y5NGU3YzhhYmFhNDlhY2NhMmZiNDkvdGFibGVyYW5nZTo3ZDM0NzRkZWUzZjk0ZTdjOGFiYWE0OWFjY2EyZmI0OV81LTEtMS0xLTEyMTQw_90803964-6d8b-480f-a72b-b9b26d59baf8">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV80L2ZyYWc6OWU3YTA4YjhlNzg3NDY0MWJmMjIxZGY5Mjk5YjhhOGYvdGFibGU6N2QzNDc0ZGVlM2Y5NGU3YzhhYmFhNDlhY2NhMmZiNDkvdGFibGVyYW5nZTo3ZDM0NzRkZWUzZjk0ZTdjOGFiYWE0OWFjY2EyZmI0OV82LTEtMS0xLTEyMTQw_b686eefc-1436-4c44-8772-e3451a582777">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_bf1a57bf-a703-4b3f-bc9b-0294a5049060">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_c74f8a0a-3c1e-43dc-9a44-91448c3a81f3">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_3f97a2d5-98a1-46a4-8619-f3becdea71f5">http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_c90d340b-270c-4dd6-bbe4-3b313ad42434">http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_511d014a-a5ee-4a2c-a65f-0d75ca7b60e9">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_7e2903b1-a222-4253-bf44-fbb3ee9aa161">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ibcb5969787714c0d8190646f3cb425cf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIzMDE_e5e44bde-010a-4057-a014-5f91fdc040cb">P3Y0M0D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie7c2ae063b354630b9b4eb98c12579cb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzM4OTI_528fb9fb-324d-4172-b895-26994db1e7b3">P3Y0M0D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic8fcbd9748d94709b73ce8d6ca1b9f32_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzUwNzA_664e182d-33f3-4d5a-92ea-3c6d4ced19cd">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic09fef48c1da4be29e79de02aa01573a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzUwNzY_9109fd84-6601-41a5-b36b-3897b4762db9">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM185MA_21be1d2e-559b-43f3-8130-7d457782136f">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6ZTk3MzNlMDcyM2Y2NGMxNmI3NmNiZmE2OTI1OGM3ZGMvdGFibGVyYW5nZTplOTczM2UwNzIzZjY0YzE2Yjc2Y2JmYTY5MjU4YzdkY18wLTAtMS0xLTEyMTQw_d5f445be-c773-40d3-b230-29cf0ed72cc0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18xMTI_c00c19b3-fd9e-465b-b3dc-cc0e410745f2">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18xMTI_f4edbe35-0c8c-46fa-8797-cefeb71d9e8d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6NzZkNmM1MjM2MDdmNGVhOGJjMTk2ZDdkMmVjMDkyMjQvdGFibGVyYW5nZTo3NmQ2YzUyMzYwN2Y0ZWE4YmMxOTZkN2QyZWMwOTIyNF8wLTAtMS0xLTEyMTQw_45b27e31-95bd-4d44-9cab-f134f4d99233">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yMTg_8ef067a9-6cd6-4d9b-ba3c-082213d25eb1">000-19731</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yMjU_b0d26d83-63bc-46f0-b9c2-7518936d11ee">GILEAD SCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6OTNlYTlkMDM5MzM5NGIwM2IzYmVkMTBjMThlMzU5MzcvdGFibGVyYW5nZTo5M2VhOWQwMzkzMzk0YjAzYjNiZWQxMGMxOGUzNTkzN18wLTAtMS0xLTEyMTQw_6684fae1-b3da-4699-b550-e659b7231c08">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6OTNlYTlkMDM5MzM5NGIwM2IzYmVkMTBjMThlMzU5MzcvdGFibGVyYW5nZTo5M2VhOWQwMzkzMzk0YjAzYjNiZWQxMGMxOGUzNTkzN18wLTEtMS0xLTEyMTQw_283dbf85-42ba-4ba1-8cb9-f608a44faa37">94-3047598</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yOTA_802c4d34-e8cc-45f3-b991-64352256be82">333 Lakeside Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yOTQ_ab83156a-b406-4d66-8148-45702a609919">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yOTg_0655eca0-e67a-42c8-922d-ce96c64a7b20">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zMDE_ae62955f-def1-4f1a-b756-6a7832838ae4">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNTc_a13ea46e-d8f4-4c79-a9d3-174525be8e14">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNjA_5c6f116d-1e62-4768-9f2f-fa35c9b7d5fc">574-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6YTQ0YmE5OWU5Mjc3NGQyY2I1Mjk3NmIyNDdjMWYxOGUvdGFibGVyYW5nZTphNDRiYTk5ZTkyNzc0ZDJjYjUyOTc2YjI0N2MxZjE4ZV8xLTAtMS0xLTEyMTQw_2be205bb-27a9-48ef-814b-c369bb5a0110">Common Stock, par value, $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6YTQ0YmE5OWU5Mjc3NGQyY2I1Mjk3NmIyNDdjMWYxOGUvdGFibGVyYW5nZTphNDRiYTk5ZTkyNzc0ZDJjYjUyOTc2YjI0N2MxZjE4ZV8xLTItMS0xLTEyMTQw_d57322d0-9bc7-4c86-94ee-27aa595ad5fe">GILD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGFibGU6YTQ0YmE5OWU5Mjc3NGQyY2I1Mjk3NmIyNDdjMWYxOGUvdGFibGVyYW5nZTphNDRiYTk5ZTkyNzc0ZDJjYjUyOTc2YjI0N2MxZjE4ZV8xLTQtMS0xLTEyMTQw_ff0bdf85-e34f-4c77-887e-d62bb8371f0c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM182MDM_3cb270a0-1b06-45ce-9968-cd604adf8a7b">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM183NTM_fe49b166-ef4b-44a3-a886-52d1547fe5dc">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18xMTA3_c11d4671-6b43-4a76-aa14-7b135fdffb56">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18xNDQ0_8c415a4a-fd46-49af-97c2-d73258dc1a5a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18xNzc1_be3bc2e7-eb49-41e5-80d6-1d4e10cfe9e8">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNzcz_1be45fca-568d-43ff-a94d-c145ca15ea6e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNzc0_336331f8-9a6e-49a4-80f9-9e9bddf56e5a">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNzc1_189f4819-d56e-4681-b37e-c085928875e2">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNzcw_00558739-192e-4773-9613-4aeee472f6fc">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i8055c5201bb24e4ba49e863f9223067f_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yODM5_3c4ed8f8-7500-4afa-bd28-f242d3d950a7"
      unitRef="usd">62600000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i115c1ea1db9c44ee8a4f7b1b25c2690f_I20220218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18yOTIx_a8e596f1-c23d-43a4-a41d-6e0b0ad30d60"
      unitRef="shares">1253886724</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xL2ZyYWc6OWVjZjA4NTRkNWQwNGRhZGEwMDhkMWUxYjE2YzNjMzMvdGV4dHJlZ2lvbjo5ZWNmMDg1NGQ1ZDA0ZGFkYTAwOGQxZTFiMTZjM2MzM18zNzcx_647719fc-656b-4557-bcfe-bcd7d2651cfb">Specified portions of the registrant&#x2019;s proxy statement, which will be filed with the Commission pursuant to Regulation 14A in connection with the registrant&#x2019;s 2022 Annual Meeting of Stockholders, to be held on May 4, 2022, are incorporated by reference into Part&#160;III of this Report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83MC9mcmFnOjRlMTVlZWIyODczYTQ5NTZiOTQ0YWVkZTQ4NGFiN2M5L3RhYmxlOjY0OTgzODk3NWYxZDRlYWViMzIzMTlmYWY3ZGNmYzVkL3RhYmxlcmFuZ2U6NjQ5ODM4OTc1ZjFkNGVhZWIzMjMxOWZhZjdkY2ZjNWRfMC0wLTEtMS05NzUxMC90ZXh0cmVnaW9uOjhjNjUwNjljODNlMjQyNGZiMzI3YjBhNWQzODZlNmEzXzU0OTc1NTgxMzkwNjg_d25c54c3-8fbf-4f02-ba1c-00db3101e9eb">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83My9mcmFnOjlkYmU3ZjlkMDdmMTQ4MTFhODFhZWNlZjgzMDFhNDRiL3RleHRyZWdpb246OWRiZTdmOWQwN2YxNDgxMWE4MWFlY2VmODMwMWE0NGJfNTQ5NzU1ODE0NTYxNw_fdc33d8e-ad39-4b15-b2df-c4a107598ab9">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83My9mcmFnOjlkYmU3ZjlkMDdmMTQ4MTFhODFhZWNlZjgzMDFhNDRiL3RleHRyZWdpb246OWRiZTdmOWQwN2YxNDgxMWE4MWFlY2VmODMwMWE0NGJfNTQ5NzU1ODE0NTYxOA_9206e1f9-6c1e-4df2-8d8a-ffd9956dd615">San Jose, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNC0yLTEtMS0xMjE0MA_28939bc8-360a-4bbd-94b9-7e3279b23482"
      unitRef="usd">5338000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNC00LTEtMS0xMjE0MA_168d7cb3-474e-4d33-bdd8-2be5677eb66d"
      unitRef="usd">5997000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNS0yLTEtMS0xMjE0MA_342173c0-73ec-4c2e-96e1-5ad13e34753b"
      unitRef="usd">1182000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNS00LTEtMS0xMjE0MA_a088a3a6-4e7e-43cd-b6b5-cc9cdb51054b"
      unitRef="usd">1411000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNi0yLTEtMS0xMjE0MA_516f5860-617f-4083-9134-58d19f7554d3"
      unitRef="usd">4493000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNi00LTEtMS0xMjE0MA_a505d8a2-b36f-4d31-b754-5c90c80ecbd7"
      unitRef="usd">4892000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNy0yLTEtMS0xMjE0MA_a70bb646-3b03-4155-8326-535942408f70"
      unitRef="usd">1618000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfNy00LTEtMS0xMjE0MA_ff3e5391-9609-420a-b1bb-523823278433"
      unitRef="usd">1683000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfOC0yLTEtMS0xMjE0MA_acb74504-69eb-4b85-af67-a299db4b5c51"
      unitRef="usd">2141000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfOC00LTEtMS0xMjE0MA_fa0590a5-3c92-4230-8ab8-d519cb45f1f7"
      unitRef="usd">2013000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfOS0yLTEtMS0xMjE0MA_434eb767-8949-4a58-b46e-6b61e61277b9"
      unitRef="usd">14772000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfOS00LTEtMS0xMjE0MA_999d4a56-36bd-44c2-bf26-c738891f5bf0"
      unitRef="usd">15996000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTAtMi0xLTEtMTIxNDA_dc7a1ad1-bbae-4058-a803-b518de11be37"
      unitRef="usd">5121000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTAtNC0xLTEtMTIxNDA_f58af908-5b82-4965-b744-48eeb95535b3"
      unitRef="usd">4967000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTEtMi0xLTEtMTIxNDA_58d952bd-fc4c-4b16-90cf-86e7d71e9cec"
      unitRef="usd">1309000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTEtNC0xLTEtMTIxNDA_9b9cd04f-53b7-43ff-9009-5cc4d1e9773c"
      unitRef="usd">502000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTItMi0xLTEtMTIxNDA_c5236807-3d83-44f1-a7d0-416e51252b06"
      unitRef="usd">33455000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTItNC0xLTEtMTIxNDA_6e47104e-9712-470b-b09b-2964ca6180ac"
      unitRef="usd">33126000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTMtMi0xLTEtMTIxNDA_ba41d54d-b0fb-4e44-bcdf-0312a5ccb4d4"
      unitRef="usd">8332000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTMtNC0xLTEtMTIxNDA_2e7f9794-2c34-4dde-9f31-3f2d595dd48d"
      unitRef="usd">8108000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTQtMi0xLTEtMTIxNDA_fc618e8b-9921-4bc4-a9a3-19f8daf8c95e"
      unitRef="usd">4963000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTQtNC0xLTEtMTIxNDA_0260c83a-d7d3-43c0-bc71-42b44fc1207c"
      unitRef="usd">5708000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTUtMi0xLTEtMTIxNDA_f061996a-d519-43aa-bb25-b975074c8a87"
      unitRef="usd">67952000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTUtNC0xLTEtMTIxNDA_7a6a65f1-00b0-493c-9bab-432754232222"
      unitRef="usd">68407000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTgtMi0xLTEtMTIxNDA_899e6df7-bf8e-451b-8cd3-95bbb73aed97"
      unitRef="usd">705000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTgtNC0xLTEtMTIxNDA_5a0bcfa2-cb53-4219-8de4-49ca70293cd7"
      unitRef="usd">844000000</us-gaap:AccountsPayableCurrent>
    <gild:AccruedGovernmentAndOtherRebates
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTktMi0xLTEtMTIxNDA_7c4f6037-6cb0-4a91-8a36-c47b7f0f0648"
      unitRef="usd">3244000000</gild:AccruedGovernmentAndOtherRebates>
    <gild:AccruedGovernmentAndOtherRebates
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMTktNC0xLTEtMTIxNDA_27c28934-e308-4d94-a2ad-d03e8cce2505"
      unitRef="usd">3460000000</gild:AccruedGovernmentAndOtherRebates>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjAtMi0xLTEtMTIxNDA_3ccad514-cc4f-411a-aed6-c657364ac10e"
      unitRef="usd">6145000000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjAtNC0xLTEtMTIxNDA_4823903a-88bd-46ec-b24b-70af8281603c"
      unitRef="usd">4336000000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:DebtCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjEtMi0xLTEtMTIxNDA_77ff1eac-035b-4982-9c29-2b91022e1c22"
      unitRef="usd">1516000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjEtNC0xLTEtMTIxNDA_cd455780-4c93-439f-8c3c-d64341918f3e"
      unitRef="usd">2757000000</us-gaap:DebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjItMi0xLTEtMTIxNDA_5ea7f7ce-6922-4369-844a-887491d96570"
      unitRef="usd">11610000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjItNC0xLTEtMTIxNDA_a0f2ed74-68f7-4f15-aeda-a74a349bf32c"
      unitRef="usd">11397000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjMtMi0xLTEtMTIxNDA_18793d24-fd46-4443-a126-f2c18e776d49"
      unitRef="usd">25179000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjMtNC0xLTEtMTIxNDA_5fee0b5b-c00e-4b7a-b523-dda294c64ce0"
      unitRef="usd">28645000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjQtMi0xLTEtMTIxNDA_7321422f-398a-4f26-a600-67ae9e4f04fe"
      unitRef="usd">4767000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjQtNC0xLTEtMTIxNDA_668efb65-5a76-48ba-a7e2-c1e6e99c82e5"
      unitRef="usd">5016000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjUtMi0xLTEtNzA3NTk_9e505394-5b6a-42de-8867-44523b0a8c43"
      unitRef="usd">4356000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjUtNC0xLTEtNzA3NzY_134c288c-92e2-41b1-b269-6dcbec5e21f1"
      unitRef="usd">3914000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjUtMi0xLTEtMTIxNDA_bdaf9822-4cc5-4375-bac8-0c060658085e"
      unitRef="usd">976000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjUtNC0xLTEtMTIxNDA_7505dde3-ae32-407b-bb7a-b3c8145494d3"
      unitRef="usd">1214000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjYtMi0xLTEtMTIxNDA_d4c2fcab-9c0b-4e70-8d48-1e74e7529474"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjYtNC0xLTEtMTIxNDA_977a7606-d9d3-47e4-9220-cc36b7ff705c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo4NTE5YmM0MmM4MmE0Zjg3YTUyODhiZjQyMGFkYWY5Zl8zMQ_599f69ee-34b7-4997-9577-3771ef7605a2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo4NTE5YmM0MmM4MmE0Zjg3YTUyODhiZjQyMGFkYWY5Zl8zMQ_f34feac3-f0c4-407c-a9cc-01bc31a864a5"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo4NTE5YmM0MmM4MmE0Zjg3YTUyODhiZjQyMGFkYWY5Zl80NQ_2efac5d4-1070-4b2b-a67d-0f00ef16cea3"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo4NTE5YmM0MmM4MmE0Zjg3YTUyODhiZjQyMGFkYWY5Zl80NQ_5486d027-4509-4829-b657-a7292c12b205"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo4NTE5YmM0MmM4MmE0Zjg3YTUyODhiZjQyMGFkYWY5Zl82Nw_58d1851f-912c-4cb6-af13-a85300970de8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo4NTE5YmM0MmM4MmE0Zjg3YTUyODhiZjQyMGFkYWY5Zl82Nw_92634f53-aebb-48ff-9248-9480bf09ae8b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtMi0xLTEtMTIxNDA_4033250b-0dd2-4225-a468-a3bd287ae375"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjgtNC0xLTEtMTIxNDA_9967b6ef-38a3-478b-8441-be2d54f13b88"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF8yOA_6839cdbb-3d3f-40d8-900e-d9fb7b3c9f8f"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF8yOA_f8c26046-c8ac-4a31-85e1-08e739f79a92"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF80Mg_1a63efec-8677-4fe4-8a76-df1d8b77a462"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF80Mg_e57b97cb-41c1-4b16-9d75-7147b36a1f00"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF81Nw_04305930-f24c-47e8-8611-3612958c9b90"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF81Nw_0ea420cd-35bf-4098-99e8-6f52aca5e58f"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF81Nw_3e27b6f4-1043-4df0-a96b-7e437aafe0cf"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjo5YjBjNDU1N2FjMGQ0OWJiYTU3ODgxNTg0MzI4ZTk2NF81Nw_e8983144-fb39-464c-816a-17c5180ffaa6"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktMi0xLTEtMTIxNDA_f8cd6dd9-c3ce-479d-8db0-5b8b3c3f58da"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMjktNC0xLTEtMTIxNDA_d0a81118-394e-421d-bd5c-2c8daf38ffbd"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzAtMi0xLTEtMTIxNDA_3b1fcba0-beb5-4ba3-a29d-26a924d3beb9"
      unitRef="usd">4661000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzAtNC0xLTEtMTIxNDA_359bdb98-5610-4ef2-8141-f5be67bdf1f0"
      unitRef="usd">3880000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzEtMi0xLTEtMTIxNDA_b49b1de0-aa77-4019-bd97-6c0d1e5f3c11"
      unitRef="usd">83000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzEtNC0xLTEtMTIxNDA_1bc56eec-9356-4acf-8e9c-89b6e1e0dbe8"
      unitRef="usd">-60000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzItMi0xLTEtMTIxNDA_bb22b1b4-aeb3-4903-a035-d249cbdf7458"
      unitRef="usd">16324000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzItNC0xLTEtMTIxNDA_0c76f127-0b55-47dc-8cb7-173872f7089c"
      unitRef="usd">14381000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzMtMi0xLTEtMTIxNDA_7fc24bb8-d50c-4fdd-98a6-e3107ded0137"
      unitRef="usd">21069000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzMtNC0xLTEtMTIxNDA_4d72a38b-f66d-490e-82a8-05e27da572df"
      unitRef="usd">18202000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzQtMi0xLTEtMTIxNDA_5145de7a-5aa3-4b4c-90cd-9fb5763b8653"
      unitRef="usd">-5000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzQtNC0xLTEtMTIxNDA_af668807-3a14-4265-8d13-1f8c64801cfa"
      unitRef="usd">19000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzUtMi0xLTEtMTIxNDA_f78f3d60-a4ca-493f-ad8f-cb9a4dc6329e"
      unitRef="usd">21064000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzUtNC0xLTEtMTIxNDA_85f2e534-1c6c-49df-8222-a295f4b2c494"
      unitRef="usd">18221000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzYtMi0xLTEtMTIxNDA_4dd09549-2f36-4e35-a5da-ac54e2c143aa"
      unitRef="usd">67952000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV83OS9mcmFnOjRkNzU1NTI4M2MxODQ1M2Y5MWFlYzA1YmIzNmIzMTE3L3RhYmxlOjgxNGJkYTUwZjI2ZTRiMTc5NGIwYWNkZGU3ZmI4NWUxL3RhYmxlcmFuZ2U6ODE0YmRhNTBmMjZlNGIxNzk0YjBhY2RkZTdmYjg1ZTFfMzYtNC0xLTEtMTIxNDA_6ff78528-2ce3-41e6-b3a5-4e3acdfa40d4"
      unitRef="usd">68407000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4befd4212fc4248a63e9b436b533760_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMy0yLTEtMS0xMjE0MA_5ebd70c0-58d6-4bb1-9aa2-fe084b0a1c43"
      unitRef="usd">27008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c51a506a019465dba53c1f088a945dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMy00LTEtMS0xMjE0MA_7e884272-f9f9-4763-8a11-a26b1a3836b3"
      unitRef="usd">24355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i203243bdd8194063a5b0d20127c91ead_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMy02LTEtMS0xMjE0MA_8fe819f9-a1bc-4850-b195-496e4da719f9"
      unitRef="usd">22119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1aad07ceecdc471a9ee9d0a50de54618_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNC0yLTEtMS0xMjE0MA_25123195-845a-4e2c-af7f-051bfb1d19f7"
      unitRef="usd">297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c80ef090990421ba4cb204bcc7a4aed_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNC00LTEtMS0xMjE0MA_ff64c034-6397-400c-b706-875193818985"
      unitRef="usd">334000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2f35d93745f44ac84aacec6dc9540d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNC02LTEtMS0xMjE0MA_91670cf2-dca3-41e3-b45b-f214083590f0"
      unitRef="usd">330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNS0yLTEtMS0xMjE0MA_ff7f44ca-700b-4edb-9259-715134ad3e01"
      unitRef="usd">27305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNS00LTEtMS0xMjE0MA_d1ed0952-11f8-476b-ba76-485f08847081"
      unitRef="usd">24689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNS02LTEtMS0xMjE0MA_b4e490d3-d42a-4a0f-9baf-fd0b55c2fcdb"
      unitRef="usd">22449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNy0yLTEtMS0xMjE0MA_74148df6-d6a8-4fcb-9343-2428a67e9c6f"
      unitRef="usd">6601000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNy00LTEtMS0xMjE0MA_1f3dfc1b-6453-40be-b386-ac12ea03d3fb"
      unitRef="usd">4572000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfNy02LTEtMS0xMjE0MA_5423225a-1079-49df-aabe-22c1baefafa4"
      unitRef="usd">4675000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfOC0yLTEtMS0xMjE0MA_7cc6042c-fc89-4d9d-b456-abcee98fe8b6"
      unitRef="usd">5363000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfOC00LTEtMS0xMjE0MA_0c5916f0-63ba-485f-bdd3-9a2e3da82a75"
      unitRef="usd">5039000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfOC02LTEtMS0xMjE0MA_f0109506-b230-4c31-acd0-7f38d2a6fc9d"
      unitRef="usd">4055000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <gild:ResearchAndDevelopmentInProcessIncludingImpairment
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfOS0yLTEtMS0xMjE0MA_1e975d66-9960-420d-9faf-ea273075f414"
      unitRef="usd">177000000</gild:ResearchAndDevelopmentInProcessIncludingImpairment>
    <gild:ResearchAndDevelopmentInProcessIncludingImpairment
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfOS00LTEtMS0xMjE0MA_3ad3791e-36ea-47a4-9b6d-a0a45c38ce4f"
      unitRef="usd">5856000000</gild:ResearchAndDevelopmentInProcessIncludingImpairment>
    <gild:ResearchAndDevelopmentInProcessIncludingImpairment
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfOS02LTEtMS0xMjE0MA_d1577657-0356-474a-a0f0-9e0153424a27"
      unitRef="usd">5051000000</gild:ResearchAndDevelopmentInProcessIncludingImpairment>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTAtMi0xLTEtMTIxNDA_54328236-6ffd-4d79-862e-645aa457f3fa"
      unitRef="usd">5246000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTAtNC0xLTEtMTIxNDA_fd46c80c-7406-417a-bd4c-02ffcd3cafaa"
      unitRef="usd">5151000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTAtNi0xLTEtMTIxNDA_ce00e218-4b19-4b16-9755-fd53e451196a"
      unitRef="usd">4381000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTEtMi0xLTEtMTIxNDA_8340bbd3-27e7-4010-b879-450d6ca0fc1d"
      unitRef="usd">17387000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTEtNC0xLTEtMTIxNDA_087587ed-c4cb-4d8b-b6b9-be81e3103ac9"
      unitRef="usd">20618000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTEtNi0xLTEtMTIxNDA_83f7c113-83c4-4acb-96cf-5fda44ad4d0f"
      unitRef="usd">18162000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTItMi0xLTEtMTIxNDA_1d42be18-473f-4eb3-97fc-b4698a5f8969"
      unitRef="usd">9918000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTItNC0xLTEtMTIxNDA_60102a28-97cc-437c-97aa-ce35b8c2b9a7"
      unitRef="usd">4071000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTItNi0xLTEtMTIxNDA_bb8c1b8f-63c5-4c09-9e3c-3514b359c67b"
      unitRef="usd">4287000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTMtMi0xLTEtMTIxNDA_e86e369a-94e2-48cf-9bb4-499b98020360"
      unitRef="usd">1001000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTMtNC0xLTEtMTIxNDA_98033442-680c-46ba-9ab6-01b407de4f93"
      unitRef="usd">984000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTMtNi0xLTEtMTIxNDA_46eedad2-22f4-4745-8e7f-64ecaddb7717"
      unitRef="usd">995000000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTQtMi0xLTEtMTIxNDA_dba860ad-be89-4a82-a1d3-047f64367bb2"
      unitRef="usd">-639000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTQtNC0xLTEtMTIxNDA_740168dd-946b-451e-90e4-43bd59ab8726"
      unitRef="usd">-1418000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTQtNi0xLTEtMTIxNDA_c1a55473-3c21-418a-9183-218266730804"
      unitRef="usd">1868000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTUtMi0xLTEtMTIxNDA_6bb17998-2e2a-451a-9cde-e79d9ab5e9ce"
      unitRef="usd">8278000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTUtNC0xLTEtMTIxNDA_f732e7dd-2ed2-43d7-86ca-14fbf55d09f0"
      unitRef="usd">1669000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTUtNi0xLTEtMTIxNDA_a4032ea3-2e3d-40d4-8c55-d7986dc09313"
      unitRef="usd">5160000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTYtMi0xLTEtMTIxNDA_572581bb-6f75-4516-ac5f-52acb341c608"
      unitRef="usd">2077000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTYtNC0xLTEtMTIxNDA_6a896311-8972-43ec-954c-59d77e3fe3c5"
      unitRef="usd">1580000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTYtNi0xLTEtMTIxNDA_2934bee4-a3e5-4b21-bf95-108cb9b2f756"
      unitRef="usd">-204000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTctMi0xLTEtMTIxNDA_48752ffa-62b8-445f-a014-79bfeb57b5e9"
      unitRef="usd">6201000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTctNC0xLTEtMTIxNDA_a29e08bb-fd26-4b6e-9cb1-1f719e882a59"
      unitRef="usd">89000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTctNi0xLTEtMTIxNDA_9cad29a0-e125-4971-988b-a8c96302cfc4"
      unitRef="usd">5364000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTgtMi0xLTEtMTIxNDA_d06262c2-a4ed-4a5e-85fb-d09dbbbf9f91"
      unitRef="usd">-24000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTgtNC0xLTEtMTIxNDA_49e8a1f7-489f-4eaa-995c-30fc47841bbd"
      unitRef="usd">-34000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTgtNi0xLTEtMTIxNDA_ac3df37c-a1e7-4bf5-99f4-b06fe761a1ba"
      unitRef="usd">-22000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTktMi0xLTEtMTIxNDA_4d035083-75f9-4c53-8ca3-067bb21abdbe"
      unitRef="usd">6225000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTktNC0xLTEtMTIxNDA_564c8740-2759-4cde-9706-636e6119d92d"
      unitRef="usd">123000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMTktNi0xLTEtMTIxNDA_75966fcf-33a2-4d0f-aca7-ecf019810de9"
      unitRef="usd">5386000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjAtMi0xLTEtMTIxNDA_f451b2d5-dff5-42b7-aee2-9e0ade70c961"
      unitRef="usdPerShare">4.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjAtNC0xLTEtMTIxNDA_bb894a0a-b337-47ba-a7b6-8739bc4a5872"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjAtNi0xLTEtMTIxNDA_07c678cc-c490-45b0-b781-e11dcb1486df"
      unitRef="usdPerShare">4.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjEtMi0xLTEtMTIxNDA_edf0c737-0c72-42a5-9086-6025aec472b1"
      unitRef="shares">1256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjEtNC0xLTEtMTIxNDA_9a729d9f-478e-40ae-8618-149e41c3b76b"
      unitRef="shares">1257000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjEtNi0xLTEtMTIxNDA_ffbcc2a5-a295-461f-95b7-6366a189ab51"
      unitRef="shares">1270000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjItMi0xLTEtMTIxNDA_901700f4-5b8d-43f5-920e-0b6418eae4d8"
      unitRef="usdPerShare">4.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjItNC0xLTEtMTIxNDA_488c9450-b9dd-4a19-b201-86cc053e239b"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjItNi0xLTEtMTIxNDA_ed4779fd-bb9b-4031-8dc0-c751bb10ed14"
      unitRef="usdPerShare">4.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjMtMi0xLTEtMTIxNDA_28e10d48-0e3e-477c-84b2-9065c362e132"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjMtNC0xLTEtMTIxNDA_f35b19a5-7c12-46aa-beb0-3802adf71e48"
      unitRef="shares">1263000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84Mi9mcmFnOjI4ZDE3ZTg3Mzc1ZjQ1OTM4ZjVkYjA5NTViMTE4MTc5L3RhYmxlOmZhNTY2YzBhMzcyNTQ1NzA4ZTBlMDg2ZDhiZmI0NGY3L3RhYmxlcmFuZ2U6ZmE1NjZjMGEzNzI1NDU3MDhlMGUwODZkOGJmYjQ0ZjdfMjMtNi0xLTEtMTIxNDA_c0468eae-2296-4e41-96b1-08e250eba65c"
      unitRef="shares">1277000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMi0yLTEtMS0xMjE0MA_48752ffa-62b8-445f-a014-79bfeb57b5e9"
      unitRef="usd">6201000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMi00LTEtMS0xMjE0MA_a29e08bb-fd26-4b6e-9cb1-1f719e882a59"
      unitRef="usd">89000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMi02LTEtMS0xMjE0MA_9cad29a0-e125-4971-988b-a8c96302cfc4"
      unitRef="usd">5364000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNC0yLTEtMS0xMjE0MA_224ca06f-04ef-49eb-84c9-67a5a1562658"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNC00LTEtMS0xMjE0MA_23b1248e-8580-403e-98df-97e95fc53fe4"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNC02LTEtMS0xMjE0MA_70a23d05-cf5d-475d-a3a4-6914044890e1"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNi0yLTEtMS0xMjE0MA_2b0f06ae-cd22-43a3-ac87-4637d3385fda"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNi00LTEtMS0xMjE0MA_818baaab-5bae-463b-a645-6654f53ac0e4"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNi02LTEtMS0xMjE0MA_adca0572-d87d-4e13-857f-80ce4811be12"
      unitRef="usd">54000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNy0yLTEtMS0xMjE0MA_479ee4e8-e8ee-48f7-8d89-e1d062a9527f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNy00LTEtMS0xMjE0MA_1e96b240-5f12-48fc-bb6d-76c3e686c957"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfNy02LTEtMS0xMjE0MA_f2fc6b16-a412-4f47-ad0b-69865aabdc18"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfOC0yLTEtMS0xMjE0MA_67ebdf88-c061-4051-9d00-5424ce6ae36f"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfOC00LTEtMS0xMjE0MA_7869f7a5-1db2-4c49-8730-74cbce7de540"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfOC02LTEtMS0xMjE0MA_92c92a0a-d06c-431e-99e2-d7d201bbc478"
      unitRef="usd">53000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTAtMi0xLTEtMTIxNDA_49782dd9-d655-4781-b71a-26ccc7e47f6b"
      unitRef="usd">129000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTAtNC0xLTEtMTIxNDA_d30c15f4-160b-4882-b789-91e595895704"
      unitRef="usd">-103000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTAtNi0xLTEtMTIxNDA_d73bc5e8-710c-450a-8afc-7cc96ea90295"
      unitRef="usd">72000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTEtMi0xLTEtMTIxNDA_c95f91df-554c-4c79-8399-a1e91d1babd3"
      unitRef="usd">-58000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTEtNC0xLTEtMTIxNDA_7dacc1d3-6d6f-437e-9810-76a16ebc4ff5"
      unitRef="usd">41000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTEtNi0xLTEtMTIxNDA_e761576b-d191-4662-9701-bc3810563c7e"
      unitRef="usd">126000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTItMi0xLTEtMTIxNDA_b911d015-e76b-44c9-a3df-09f0ba1b77d6"
      unitRef="usd">187000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTItNC0xLTEtMTIxNDA_093abef2-4776-4319-8fdf-411e0478f275"
      unitRef="usd">-144000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTItNi0xLTEtMTIxNDA_367c4632-a51e-4855-b0d2-6b889e8ba785"
      unitRef="usd">-54000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTMtMi0xLTEtMTIxNDA_87a89463-68f9-4f69-b619-659e3370dd82"
      unitRef="usd">143000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTMtNC0xLTEtMTIxNDA_5488c9a0-5d8f-4284-9234-8d3139099a06"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTMtNi0xLTEtMTIxNDA_8a495226-4337-4526-9f2a-2c243df2a22f"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTQtMi0xLTEtMTIxNDA_47c32316-d28a-409a-9d5a-a73e20ad5bae"
      unitRef="usd">6344000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTQtNC0xLTEtMTIxNDA_4ac4137b-e752-4827-a178-3a09f4c72795"
      unitRef="usd">-56000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTQtNi0xLTEtMTIxNDA_ffbcfe17-bb56-4162-a1ff-5415b0596384"
      unitRef="usd">5369000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTUtMi0xLTEtMTIxNDA_4caea9cf-df53-48f2-bf61-447b424b51cb"
      unitRef="usd">-24000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTUtNC0xLTEtMTIxNDA_5d25d6ef-0d21-449a-a78e-cb73888e69e2"
      unitRef="usd">-34000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTUtNi0xLTEtMTIxNDA_51e76f4c-6f5d-4d23-ab5f-d3252fe2e5ff"
      unitRef="usd">-22000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTYtMi0xLTEtMTIxNDA_5d44ca22-a14c-4cbf-ba0c-a728ebb8b8ac"
      unitRef="usd">6368000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTYtNC0xLTEtMTIxNDA_dd03d907-f867-4d3f-b817-c78ff6c25f05"
      unitRef="usd">-22000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84NS9mcmFnOjRiNDEwYTdjYTUyZjRlM2M4OTg3MWJhNzgyYjYzYzM4L3RhYmxlOmQzZDYzNGI5MjAxZTRmOTJhMDA2ZDZiMmYyOWU4ZjdhL3RhYmxlcmFuZ2U6ZDNkNjM0YjkyMDFlNGY5MmEwMDZkNmIyZjI5ZThmN2FfMTYtNi0xLTEtMTIxNDA_3c40d3c0-8d14-480b-a6a0-493c7235f3bc"
      unitRef="usd">5391000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if8555f34a84a4c3887459093bd255d74_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtMi0xLTEtMTIxNDA_f49787c3-c7de-4bc8-b833-0c8ac7722be5"
      unitRef="shares">1282000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8555f34a84a4c3887459093bd255d74_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtNC0xLTEtMTIxNDA_b9fd6a71-e22a-4097-ae07-bc969870f523"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7703ce81d19946348842d9982c50c0c4_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtNi0xLTEtMTIxNDA_4b7df92c-c70c-41ca-88e7-eb6a6bedb6a1"
      unitRef="usd">2282000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id46d2d21dd6a43a89e740948d75f9380_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtOC0xLTEtMTIxNDA_67fd1c94-02ea-4f9a-91de-73f429fc7081"
      unitRef="usd">80000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7602de391c434d368154fe3329c135b4_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtMTAtMS0xLTEyMTQw_2a2d4961-06f5-49a2-84c2-529d9931e532"
      unitRef="usd">19024000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i890acc6b92a24d29907006991e3f99d3_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtMTItMS0xLTEyMTQw_b6f8adb2-dd17-4d95-95e8-c1ad25d1244f"
      unitRef="usd">147000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8222e290a2284cb0bf64a4ac2b6995b5_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTMtMTQtMS0xLTEyMTQw_98fa632c-a7f8-4f5e-8534-2e9503164a06"
      unitRef="usd">21534000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie196e7c846694582b374a274089a496d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTQtMTAtMS0xLTEyMTQw_33316bc7-c87b-45c2-8c10-11f5b5faaf47"
      unitRef="usd">8000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib588e93b222b4f21902099d1901de114_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTQtMTQtMS0xLTEyMTQw_8c1e2521-5b99-4127-96e9-41316be4730c"
      unitRef="usd">8000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ifa3d1ac282964e3380614a0c573278a4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTUtMTAtMS0xLTEyMTQw_aedf12d3-b79e-4a20-ad87-798421572c4b"
      unitRef="usd">5386000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibb1cc1349e424089965fc6662bf35a48_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTUtMTItMS0xLTEyMTQw_6f83b116-9c28-4087-bd4c-07aa492aee1c"
      unitRef="usd">-22000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTUtMTQtMS0xLTEyMTQw_4f21f5f7-9264-4ac8-a2d2-6ad9a0c5a182"
      unitRef="usd">5364000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i01dacb3a581346e187edae0a347d2eeb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTYtOC0xLTEtMTIxNDA_68983345-2204-4239-b8c9-31f157b012e5"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTYtMTQtMS0xLTEyMTQw_39437252-99fe-46b9-a40f-9f6b4e830e00"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i85a0c1ca4ff4429d9883b9d439e8e910_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTctMi0xLTEtMTIxNDA_6f9d08da-d716-49bc-b21c-a558999528b5"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i33a8d6544a084df5b9c6407ecb2d93a0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTctNi0xLTEtMTIxNDA_5ccfc5b8-b77b-4b28-810e-0c255103f7cf"
      unitRef="usd">90000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTctMTQtMS0xLTEyMTQw_85f3d648-8856-4b3d-892c-6cb24f71a093"
      unitRef="usd">90000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i85a0c1ca4ff4429d9883b9d439e8e910_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTgtMi0xLTEtMTIxNDA_10074d67-90fb-4565-b774-00834d945531"
      unitRef="shares">10000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i33a8d6544a084df5b9c6407ecb2d93a0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTgtNi0xLTEtMTIxNDA_c5e37dc7-aa32-48dc-8055-879bb0fdfcb3"
      unitRef="usd">118000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTgtMTQtMS0xLTEyMTQw_aa0ffc3f-10a9-4f25-866a-0394e04a3d1e"
      unitRef="usd">118000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i33a8d6544a084df5b9c6407ecb2d93a0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTktNi0xLTEtMTIxNDA_5fedeb52-3c65-42a2-a1f0-0037ff4800c7"
      unitRef="usd">638000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMTktMTQtMS0xLTEyMTQw_45d0ffbc-037f-420e-a4df-570bca829dce"
      unitRef="usd">638000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i85a0c1ca4ff4429d9883b9d439e8e910_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjAtMi0xLTEtMTIxNDA_d83cf83d-b30b-4233-b6a3-610620f8f2bf"
      unitRef="shares">28000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i33a8d6544a084df5b9c6407ecb2d93a0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjAtNi0xLTEtMTIxNDA_b6ba4586-5452-4100-bf04-342f36693483"
      unitRef="usd">77000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ifa3d1ac282964e3380614a0c573278a4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjAtMTAtMS0xLTEyMTQw_0b18d29d-4d49-4cf3-a76e-f4b646c616ab"
      unitRef="usd">1791000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjAtMTQtMS0xLTEyMTQw_85f992d2-e22d-46a6-a44f-3097d27323b0"
      unitRef="usd">1868000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjEtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjpiYmJhODdkNzYyOWM0MzEyYTFkNGZmYzg5NDdiZDcwOF8yNA_b498e656-e87c-4e0b-be01-ff13f5cf52c0"
      unitRef="usdPerShare">2.52</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="ifa3d1ac282964e3380614a0c573278a4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjEtMTAtMS0xLTEyMTQw_11a2d645-fec8-4dce-8992-2afc1204881c"
      unitRef="usd">3239000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjEtMTQtMS0xLTEyMTQw_eadfbca8-5c0a-4ad9-be61-63a041af1015"
      unitRef="usd">3239000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia4b5ab47f4054d119ad163b7730160e9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItMi0xLTEtMTIxNDA_45786c0e-28f8-4970-818c-263c28b54678"
      unitRef="shares">1266000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4b5ab47f4054d119ad163b7730160e9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItNC0xLTEtMTIxNDA_1024f864-3740-4c3c-bd20-1895cd180c42"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifbd5347ef13d4d63a1e7031f22995187_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItNi0xLTEtMTIxNDA_e467733a-7d00-4a89-89ac-42595a27a24d"
      unitRef="usd">3051000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9da767fe6764cc8955010ca3f076633_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItOC0xLTEtMTIxNDA_0112212e-13a9-41ca-8408-558785d6d753"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40b1731fe1b744a2b37e1b7157cc1c89_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItMTAtMS0xLTEyMTQw_da9bbeec-d5d8-409c-8b4a-2ddd9bb0e63c"
      unitRef="usd">19388000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib64b3709e27d4ea2961642638f9cbf2c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItMTItMS0xLTEyMTQw_3431d338-1239-42ae-83a5-66f7b3d2f237"
      unitRef="usd">125000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjItMTQtMS0xLTEyMTQw_46ae2613-09e9-47ff-b847-77d99958b94f"
      unitRef="usd">22650000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1928c028f694d83885d06a82f22ca4d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjMtMTAtMS0xLTEyMTQw_840d5c71-ac06-4755-a14d-40ec2289c35f"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac80893052fd42e9be5a92f71c18cdb2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjMtMTQtMS0xLTEyMTQw_f73d91f9-cb61-4670-8d5c-485ba09b412c"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i5b1636d6a27341d4903b179394689324_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjQtMTItMS0xLTEyMTQw_8e729b40-7fc9-48de-af99-6767f28dbc73"
      unitRef="usd">-72000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjQtMTQtMS0xLTEyMTQw_59c8809c-11c7-4fa4-8708-da8567596bea"
      unitRef="usd">-72000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:ProfitLoss
      contextRef="id0fc16e772ac480c9e4ad4516e16c190_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjUtMTAtMS0xLTEyMTQw_38d4344f-192e-464b-a6a6-7f642861f31c"
      unitRef="usd">123000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5b1636d6a27341d4903b179394689324_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjUtMTItMS0xLTEyMTQw_ef94f776-4391-40ec-b5ed-1808a2909687"
      unitRef="usd">-34000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjUtMTQtMS0xLTEyMTQw_e77623b0-6063-42a2-b04c-b7cbfbe36008"
      unitRef="usd">89000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icfc1931160c049e2b69a1fafb5719ec8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtNi0xLTEtMTIxNDA_812403a6-959b-4c60-951f-8a2527f8600e"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i851b03314d344a5e8ad436aa9235bf9c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtOC0xLTEtMTIxNDA_922e1e3a-d617-4b8e-9113-bed80fb13d33"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id0fc16e772ac480c9e4ad4516e16c190_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtMTAtMS0xLTEyMTQw_2c71cb2d-b54e-4bcb-a799-96578a9ed76d"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtMTQtMS0xLTEyMTQw_5f5ca1c5-c954-4d7e-8dbe-442c4a37fffc"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i7f7ba76a51544cbd895730452d44bb48_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjctMi0xLTEtMTIxNDA_daab402d-e998-4a17-83f2-877f54ce9ed6"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icfc1931160c049e2b69a1fafb5719ec8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjctNi0xLTEtMTIxNDA_65aeb050-983d-4ff3-ae44-fd7b22a909ae"
      unitRef="usd">100000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjctMTQtMS0xLTEyMTQw_0f0ffd25-082a-4f37-8b45-a308336f229f"
      unitRef="usd">100000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7f7ba76a51544cbd895730452d44bb48_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtMi0xLTEtMTIxNDA_ae669f2d-551e-4279-a9be-e728da63d994"
      unitRef="shares">11000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icfc1931160c049e2b69a1fafb5719ec8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtNi0xLTEtMTIxNDA_03681be9-5cea-4bb2-a613-7f52ad332633"
      unitRef="usd">156000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtMTQtMS0xLTEyMTQw_426a6fa0-efa5-47c8-a458-2d31859e5a93"
      unitRef="usd">156000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icfc1931160c049e2b69a1fafb5719ec8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjktNi0xLTEtMTIxNDA_471f077a-bc88-4872-aa53-af03d4e29d9c"
      unitRef="usd">642000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjktMTQtMS0xLTEyMTQw_18a7401e-4c87-4dd9-9ba0-fc6c5ee38978"
      unitRef="usd">642000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i7f7ba76a51544cbd895730452d44bb48_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMi0xLTEtMTIxNDA_173145e5-aeee-4337-beff-fe9677af0298"
      unitRef="shares">25000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="icfc1931160c049e2b69a1fafb5719ec8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtNi0xLTEtMTIxNDA_82d228f9-011f-45d1-be77-1b7eb879582f"
      unitRef="usd">70000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id0fc16e772ac480c9e4ad4516e16c190_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMTAtMS0xLTEyMTQw_4cd94d58-d564-4c5e-a016-fa45eb242f55"
      unitRef="usd">1658000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMTQtMS0xLTEyMTQw_b14b1693-325e-417d-b882-bf0a714daa3c"
      unitRef="usd">1728000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzEtMC0xLTEtMTIxNDAvdGV4dHJlZ2lvbjoxM2ExYzUwYTNmNjI0Nzc1OTdjN2NiN2M2YjViNWQxZV8yNA_7c0b6bf4-c3e4-4942-a849-248e2213cebf"
      unitRef="usdPerShare">2.72</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="id0fc16e772ac480c9e4ad4516e16c190_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzEtMTAtMS0xLTEyMTQw_46a80ba0-fc34-426f-9575-4cb80cbec130"
      unitRef="usd">3464000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzEtMTQtMS0xLTEyMTQw_0e909fbf-57d4-474e-9507-8ec59370959c"
      unitRef="usd">3464000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if0fd40f1bbe64b64bafc77d0138fdc55_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItMi0xLTEtMTIxNDA_ba735711-c542-4c98-b46a-913ba7bba195"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0fd40f1bbe64b64bafc77d0138fdc55_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItNC0xLTEtMTIxNDA_ad6305b3-775b-4853-a70c-03edc0a3087c"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9832261d41e74ecb88de8acbbbb81ca7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItNi0xLTEtMTIxNDA_d7c40c02-a389-41c7-be01-716c0140d59e"
      unitRef="usd">3880000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i803ae583deba4f7683154aaeec947d69_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItOC0xLTEtMTIxNDA_5f590a53-9f14-4117-9d3f-bc005659c6a1"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab9a9d73e541440bbe6a602affd5a7b0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItMTAtMS0xLTEyMTQw_8d2a0724-c402-46a2-9a19-5a1bcb6810d0"
      unitRef="usd">14381000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i124557415b5546be81b290394bba971e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItMTItMS0xLTEyMTQw_8ade8c06-c29f-44fa-9265-72b7d1aecc72"
      unitRef="usd">19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzItMTQtMS0xLTEyMTQw_32f1535e-ec24-4793-a65d-18c2a12cc179"
      unitRef="usd">18221000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i81bd8c38c79a44cd82ea0da460afeda2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjMtMTAtMS0xLTMxNDk4_9113bea7-522d-414c-a79b-c5ad5c99b389"
      unitRef="usd">6225000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iffaa88726d364819baced65640a14653_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjMtMTItMS0xLTMxNDk4_2728355d-4b34-46c7-a26b-ed7f9ecb9653"
      unitRef="usd">-24000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjMtMTQtMS0xLTMxNDk4_23b047e1-56af-447c-b8a4-c06305d53519"
      unitRef="usd">6201000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i626caba187154b4d9558b2cc5d8c94d0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjQtNi0xLTEtMzE0OTg_2c6aecf9-eff3-4c04-b8db-e4adb39067bf"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8023d2e7ae2f498fa0385be7010b4f25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjQtOC0xLTEtMzE0OTg_c1b1c335-fa62-410f-b4a7-a51505a4f1a6"
      unitRef="usd">143000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i81bd8c38c79a44cd82ea0da460afeda2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjQtMTAtMS0xLTMxNDk4_187398f9-7075-4de8-9537-ddf4fb147a7d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjQtMTQtMS0xLTMxNDk4_d9dcbc26-398c-4be0-ae6f-8cbf570c0ada"
      unitRef="usd">143000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i4b1ea74ddca943afada26dff9a0ef62b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjUtMi0xLTEtMzE0OTg_2ecea73b-494b-446c-aca8-40a78e5cc107"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i626caba187154b4d9558b2cc5d8c94d0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjUtNi0xLTEtMzE0OTg_75015312-70aa-4703-a341-fa4601374585"
      unitRef="usd">111000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjUtMTQtMS0xLTMxNDk4_ab1a1f2f-a9cc-4d21-b85a-b042bf13192a"
      unitRef="usd">111000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4b1ea74ddca943afada26dff9a0ef62b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtMi0xLTEtMzE0OTg_aba3c028-9c92-4fdf-b9c0-67ffd99a147f"
      unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i626caba187154b4d9558b2cc5d8c94d0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtNi0xLTEtMzE0OTg_07a425b8-121d-4b04-86a3-e5af174d042e"
      unitRef="usd">58000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjYtMTQtMS0xLTMxNDk4_ce7f6ee0-4c4e-415b-8644-64967bf39203"
      unitRef="usd">58000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i626caba187154b4d9558b2cc5d8c94d0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjctNi0xLTEtMzE0OTg_df0cc97a-ccb1-41ab-84a8-76de333dc377"
      unitRef="usd">640000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjctMTQtMS0xLTMxNDk4_6bf6e44c-6dd8-4b5c-b173-eef490a1cd6a"
      unitRef="usd">640000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i4b1ea74ddca943afada26dff9a0ef62b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtMi0xLTEtMzE0OTg_c962df7b-f0a0-4a25-a364-9791cdd40b44"
      unitRef="shares">11000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i626caba187154b4d9558b2cc5d8c94d0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtNi0xLTEtMzE0OTg_a043c3d1-a036-4b06-be5e-3339b3feb513"
      unitRef="usd">28000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i81bd8c38c79a44cd82ea0da460afeda2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtMTAtMS0xLTMxNDk4_f64af6af-f86a-4640-ae05-5513e4844542"
      unitRef="usd">664000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjgtMTQtMS0xLTMxNDk4_34440d8d-3fbf-4368-8c8e-f41b0be44dce"
      unitRef="usd">692000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjktMC0xLTEtMzE0OTgvdGV4dHJlZ2lvbjpkMDA2YWU5NWM2Njg0ZWFjOWZmYThlZDQzYzQwOGQ4Yl8xMDk5NTExNjI3ODE3_47dc81db-314c-4989-bfae-95c5e25dc197"
      unitRef="usdPerShare">2.84</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i81bd8c38c79a44cd82ea0da460afeda2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjktMTAtMS0xLTMxNDk4_c3caedc8-52e8-4eee-bec5-01713dee800d"
      unitRef="usd">3618000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMjktMTQtMS0xLTMxNDk4_a5b876f9-e440-432d-83e6-1271225bdbb5"
      unitRef="usd">3618000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i89cf74ab64a34cba879cbc8c8211ff81_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMi0xLTEtMzE0OTg_4fedf596-55f2-487f-ba95-60f153eb4682"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89cf74ab64a34cba879cbc8c8211ff81_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtNC0xLTEtMzE0OTg_3563f93a-1fe6-4b88-9aa2-f96fb83cb567"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d04ab1d0b074473902d53b2c6fa11cf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtNi0xLTEtMzE0OTg_64800b67-d736-446a-b114-f9f223a02307"
      unitRef="usd">4661000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ebb0b9dc1384269a861d7b5216e73fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtOC0xLTEtMzE0OTg_b145b05a-1b2a-494e-8195-384fade87951"
      unitRef="usd">83000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia37682e7f2e748009cff968cbeae3311_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMTAtMS0xLTMxNDk4_da04c6c8-373f-43f3-a611-ed93da2cc163"
      unitRef="usd">16324000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93ce718fd81f499ba51f827334051126_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMTItMS0xLTMxNDk4_7ba32240-86c6-45d1-bca6-c1adefd225e7"
      unitRef="usd">-5000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV84OC9mcmFnOjI2MTBlM2M3MDdmZTRjYWM4MjU1MTYwMzE4Nzc1ZmFjL3RhYmxlOjVkNjRiOGY4YjFmMDRmMWFhZTdhNDZkZThkMjViNmYzL3RhYmxlcmFuZ2U6NWQ2NGI4ZjhiMWYwNGYxYWFlN2E0NmRlOGQyNWI2ZjNfMzAtMTQtMS0xLTMxNDk4_e7bf2f76-cfc8-4664-82ac-3468d03e5ea5"
      unitRef="usd">21064000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMy0yLTEtMS0xMjE0MA_48752ffa-62b8-445f-a014-79bfeb57b5e9"
      unitRef="usd">6201000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMy00LTEtMS0xMjE0MA_a29e08bb-fd26-4b6e-9cb1-1f719e882a59"
      unitRef="usd">89000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMy02LTEtMS0xMjE0MA_9cad29a0-e125-4971-988b-a8c96302cfc4"
      unitRef="usd">5364000000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNS0yLTEtMS0xMjE0MA_d3865c05-07ce-480f-af57-4748062ffcdd"
      unitRef="usd">329000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNS00LTEtMS0xMjE0MA_a06552c1-9210-4647-9c83-4fc9d2b90aa8"
      unitRef="usd">288000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNS02LTEtMS0xMjE0MA_f22bbbd1-9cae-4f59-8833-c3bd8bbab26e"
      unitRef="usd">255000000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNi0yLTEtMS0xMjE0MA_5129bb59-aea6-4703-a14f-2ddf9080dca3"
      unitRef="usd">1721000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNi00LTEtMS0xMjE0MA_33e33f1f-9259-4d49-890f-d7820bf27e44"
      unitRef="usd">1192000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNi02LTEtMS0xMjE0MA_a1b78afa-0c46-44d1-bb50-1a53ed1650a0"
      unitRef="usd">1149000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNy0yLTEtMS0xMjE0MA_e1b9ab2e-ac10-410a-ad40-d0e06cd70854"
      unitRef="usd">635000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNy00LTEtMS0xMjE0MA_3662b40a-bfb6-4ca3-b42f-d36ea2804b1a"
      unitRef="usd">643000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNy02LTEtMS0xMjE0MA_2ffffd5c-7429-4ac8-9b21-99ce9682abb1"
      unitRef="usd">636000000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfOC0yLTEtMS0xMjE0MA_199eced0-2cef-48c5-8ada-c7d92cc58481"
      unitRef="usd">116000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfOC00LTEtMS0xMjE0MA_736befa4-f697-4040-afc2-1cb80de0e157"
      unitRef="usd">214000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfOC02LTEtMS0xMjE0MA_f778062b-29de-4009-b9ef-509fb0072a1b"
      unitRef="usd">2098000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfOS0yLTEtMS0xMjE0MA_93e41a1e-1f95-4c78-b9e5-1cc9a7d4fe24"
      unitRef="usd">-610000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfOS00LTEtMS0xMjE0MA_a3a380ff-73e8-4f95-8450-f8a4a1a9a669"
      unitRef="usd">-1662000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfOS02LTEtMS0xMjE0MA_0971662c-c98d-4471-b8d3-6eb8747d1280"
      unitRef="usd">1241000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTAtMi0xLTEtMTIxNDA_d33684fd-5df7-4c0a-9fd5-8d5ced757bda"
      unitRef="usd">177000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTAtNC0xLTEtMTIxNDA_ebef8831-fb0f-4421-931c-1030d1d308d6"
      unitRef="usd">5856000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTAtNi0xLTEtMTIxNDA_13b5c99c-96f2-4ed4-8267-c0a82b9a87ee"
      unitRef="usd">4251000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTEtMi0xLTEtMTIxNDA_ba210b9f-2e7b-4e11-ac55-a4687b76125a"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTEtNC0xLTEtMTIxNDA_b3296282-82df-4a92-bb4f-fd5206e37649"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTEtNi0xLTEtMTIxNDA_0b30786c-8d76-4d12-a773-fc7a7e55720e"
      unitRef="usd">800000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <gild:InventoryReserveForExcessRawMaterials
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTItMi0xLTEtMTIxNDA_9192e3db-a2df-4c49-a618-4756ae5e7822"
      unitRef="usd">121000000</gild:InventoryReserveForExcessRawMaterials>
    <gild:InventoryReserveForExcessRawMaterials
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTItNC0xLTEtMTIxNDA_88a43171-0eec-4d72-b51d-dc4784141761"
      unitRef="usd">40000000</gild:InventoryReserveForExcessRawMaterials>
    <gild:InventoryReserveForExcessRawMaterials
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTItNi0xLTEtMTIxNDA_f8f485ee-b1e2-4afe-a237-55123ab887f5"
      unitRef="usd">547000000</gild:InventoryReserveForExcessRawMaterials>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTMtMi0xLTEtMTIxNDA_49465e11-4012-4ebc-a84c-f0bcbd836f11"
      unitRef="usd">-1217000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTMtNC0xLTEtMTIxNDA_c273080b-924f-4397-a562-334c5f31dd2f"
      unitRef="usd">-250000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTMtNi0xLTEtMTIxNDA_96dd99e3-820e-4a7f-8bde-7a027b55e35d"
      unitRef="usd">-279000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTUtMi0xLTEtMTIxNDA_6a68e56b-0da8-48b6-bd67-9cd26b56ee6e"
      unitRef="usd">-313000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTUtNC0xLTEtMTIxNDA_c7484366-38f6-492a-b827-e1ec173b57be"
      unitRef="usd">1171000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTUtNi0xLTEtMTIxNDA_192f9189-665e-41c4-acce-336fcb4697fc"
      unitRef="usd">218000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTYtMi0xLTEtMTIxNDA_5207f8b7-729c-462c-8ddb-8e024daa7829"
      unitRef="usd">-11000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTYtNC0xLTEtMTIxNDA_da73fa6b-f37b-484b-8cfe-1800fb775d06"
      unitRef="usd">195000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTYtNi0xLTEtMTIxNDA_55b600f2-7711-45d0-9c09-c3afa2a20585"
      unitRef="usd">95000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTctMi0xLTEtMTIxNDA_6557ae69-2a7e-4d2c-abb7-584b5d6ad3f7"
      unitRef="usd">42000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTctNC0xLTEtMTIxNDA_9278ea80-7150-4f07-b5ce-bb241b1f92b6"
      unitRef="usd">214000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTctNi0xLTEtMTIxNDA_48d81933-41ac-4549-a4bc-0b1e0966c445"
      unitRef="usd">307000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTgtMi0xLTEtMTIxNDA_7896d301-4988-40d8-ba60-de4c5ad13355"
      unitRef="usd">-118000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTgtNC0xLTEtMTIxNDA_11ff5497-32df-48f9-a363-2e314e9ae6f8"
      unitRef="usd">80000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTgtNi0xLTEtMTIxNDA_b7031061-807f-42f3-bb72-5e763c176800"
      unitRef="usd">-61000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTktMi0xLTEtMTIxNDA_b0573da1-dbcc-4262-b8f8-d3e468c6da2f"
      unitRef="usd">-364000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTktNC0xLTEtMTIxNDA_c82a40b3-14ee-4f7c-8176-e4e2c8df809b"
      unitRef="usd">-778000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMTktNi0xLTEtMTIxNDA_d9f3323b-56c7-4b0f-a26c-a8528449c126"
      unitRef="usd">272000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjAtMi0xLTEtMTIxNDA_79016d57-c692-4367-ab87-4b8c9d3f2954"
      unitRef="usd">689000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjAtNC0xLTEtMTIxNDA_514992a3-7e20-4bc6-93ec-fa3c5f689816"
      unitRef="usd">640000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjAtNi0xLTEtMTIxNDA_cfb97b1f-c9e4-4077-a251-6d4a5f4836fe"
      unitRef="usd">-389000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjEtMi0xLTEtMTIxNDA_54c6a486-41c5-43da-82e8-1b14a98d300c"
      unitRef="usd">11384000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjEtNC0xLTEtMTIxNDA_9e6b0692-8ed3-48f8-aff7-ae7d24003dd5"
      unitRef="usd">8168000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjEtNi0xLTEtMTIxNDA_6846c6dd-b9e4-4e61-8e69-4fc03f0e8aeb"
      unitRef="usd">9144000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjQtMi0xLTEtMTIxNDA_45f25d45-9cc2-4fdd-afb2-7f122bb742c5"
      unitRef="usd">3517000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjQtNC0xLTEtMTIxNDA_02a57391-4e7b-48f4-b8ba-69e4442286ce"
      unitRef="usd">20315000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjQtNi0xLTEtMTIxNDA_c7d8f439-4430-4c4f-8ede-05d3d8c65426"
      unitRef="usd">30455000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjUtMi0xLTEtMTIxNDA_9feed519-cccc-4929-a8e2-aaba428c369c"
      unitRef="usd">730000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjUtNC0xLTEtMTIxNDA_b55115cc-bfea-4fc3-99a1-f2866154ce70"
      unitRef="usd">23239000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjUtNi0xLTEtMTIxNDA_4cc79e23-51ac-45b9-9848-16c7a4b18e8d"
      unitRef="usd">7523000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjYtMi0xLTEtMTIxNDA_8ab4cecb-9f69-4523-9640-7066c10c0925"
      unitRef="usd">2180000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjYtNC0xLTEtMTIxNDA_84b5fce4-3212-47bc-b3a0-f736b081bd2e"
      unitRef="usd">9479000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjYtNi0xLTEtMTIxNDA_53e2ac46-1ac3-4589-ad9e-ca3b8ce4b147"
      unitRef="usd">22398000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjctMi0xLTEtMTIxNDA_6104bd80-952a-4d7d-a5d1-a7175d6820cf"
      unitRef="usd">1402000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjctNC0xLTEtMTIxNDA_0dd1f126-e776-4b9e-a9e6-161043ed65e5"
      unitRef="usd">25742000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjctNi0xLTEtMTIxNDA_80f3cd5d-73df-4160-a769-59d227a12e3a"
      unitRef="usd">4251000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjgtMi0xLTEtMTIxNDA_54ecfbf8-92c2-4077-8f4f-674406a26a15"
      unitRef="usd">380000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjgtNC0xLTEtMTIxNDA_01106c01-8d5e-4a48-8e90-a62eae0c7e34"
      unitRef="usd">455000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjgtNi0xLTEtMTIxNDA_71b11598-0736-4e9c-a693-e1af307d12ed"
      unitRef="usd">1773000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjktMi0xLTEtMTIxNDA_39b4d476-30fc-4a92-b708-1e2b54417316"
      unitRef="usd">579000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjktNC0xLTEtMTIxNDA_16be836c-256a-4236-8ead-1e2b67ac351e"
      unitRef="usd">650000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMjktNi0xLTEtMTIxNDA_d1858555-bcd3-43bf-9854-d67f7decda06"
      unitRef="usd">825000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzAtMi0xLTEtMTIxNDA_8aba5f1c-0f9e-4ff3-9b2b-9d6cb1a05fdd"
      unitRef="usd">163000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzAtNC0xLTEtMTIxNDA_2fa98dfb-d3cc-4cda-a27f-b595a573af3c"
      unitRef="usd">171000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzAtNi0xLTEtMTIxNDA_9750804e-5998-4c0c-861b-cef5305f0b0c"
      unitRef="usd">434000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzEtMi0xLTEtMTIxNDA_b5da0106-49a3-4e47-84f4-fbdde3f8bc88"
      unitRef="usd">-3131000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzEtNC0xLTEtMTIxNDA_87e6134b-6060-4a3b-95e6-4a3b1bd6506e"
      unitRef="usd">-14615000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzEtNi0xLTEtMTIxNDA_ae76d583-013e-4b83-9527-4a744bf7072e"
      unitRef="usd">-7817000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzQtMi0xLTEtMTIxNDA_4f54b1fb-8281-4cc6-b837-9ff220d551d0"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzQtNC0xLTEtMTIxNDA_9026a569-bf58-4c6a-a789-e8f4c7aee1e7"
      unitRef="usd">8184000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzQtNi0xLTEtMTIxNDA_4856ee76-9abe-4911-ba5a-125fc1f0e260"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzUtMi0xLTEtMTIxNDA_32c33e78-5256-44e9-aefe-334bc905ad89"
      unitRef="usd">169000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzUtNC0xLTEtMTIxNDA_9c893aa5-76a3-4b5b-bd41-ca131cbf1f60"
      unitRef="usd">256000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzUtNi0xLTEtMTIxNDA_278b63f1-ef8b-4435-af73-1eccd5a96af5"
      unitRef="usd">209000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzYtMi0xLTEtMTIxNDA_e45d1534-d552-4013-9223-cf333effa759"
      unitRef="usd">546000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzYtNC0xLTEtMTIxNDA_b65fc5e6-8cd8-4514-88c3-dfca74f90857"
      unitRef="usd">1583000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzYtNi0xLTEtMTIxNDA_3aa07a87-2868-489b-8ea2-08d97c612a62"
      unitRef="usd">1749000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfDebt
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzctMi0xLTEtMTIxNDA_134b4c8e-366d-44f5-b058-fe4a93141b6f"
      unitRef="usd">4750000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzctNC0xLTEtMTIxNDA_414b7073-bb46-4188-b2be-4d63a7881e8a"
      unitRef="usd">2500000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzctNi0xLTEtMTIxNDA_f45890c0-9ef8-4811-a55b-47e3503294b7"
      unitRef="usd">2750000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfDividends
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzgtMi0xLTEtMTIxNDA_0bcb49ff-040c-4510-9e4f-9c0574d911b6"
      unitRef="usd">3605000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzgtNC0xLTEtMTIxNDA_d3002e66-542e-41ea-a196-e91bafb55e1c"
      unitRef="usd">3449000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzgtNi0xLTEtMTIxNDA_91a1727a-1d7e-4a0b-a661-077bd119eb9d"
      unitRef="usd">3222000000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzktMi0xLTEtMTIxNDA_a59bc57f-2a40-430f-adec-b7ac1044c29f"
      unitRef="usd">-145000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzktNC0xLTEtMTIxNDA_59643ab5-5a3a-4484-8c40-24d58fd03c2a"
      unitRef="usd">-138000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfMzktNi0xLTEtMTIxNDA_4567a73e-488e-496e-b8b8-c99d0ccd06b3"
      unitRef="usd">-122000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDAtMi0xLTEtMTIxNDA_3b5e52b0-a2c4-48bb-a58e-0af340df854e"
      unitRef="usd">-8877000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDAtNC0xLTEtMTIxNDA_98d55575-78be-4272-8240-2cb223cf9c61"
      unitRef="usd">770000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDAtNi0xLTEtMTIxNDA_e6a20188-bcc3-48be-b017-dfce31022bac"
      unitRef="usd">-7634000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDEtMi0xLTEtMTIxNDA_f683b971-e07f-4830-8cd7-a079777cec16"
      unitRef="usd">-35000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDEtNC0xLTEtMTIxNDA_937693cf-ca58-46fb-ba48-2761a2cdb1b9"
      unitRef="usd">43000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDEtNi0xLTEtMTIxNDA_ee964e35-fec8-45d6-af20-9968d773dca0"
      unitRef="usd">-2000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDItMi0xLTEtMTIxNDA_9690e862-91b9-4a9b-abd2-59bf0d84f46d"
      unitRef="usd">-659000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDItNC0xLTEtMTIxNDA_2cb4c50a-7a0c-471f-9bb2-f271bace3a7a"
      unitRef="usd">-5634000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDItNi0xLTEtMTIxNDA_33805e9d-ae10-4fae-9aed-7c1c9c03c97e"
      unitRef="usd">-6309000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDMtMi0xLTEtMTIxNDA_16ac2b84-13e4-46ea-8387-4cdb532456e4"
      unitRef="usd">5997000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDMtMi0xLTEtMTIxNDA_1e52130f-afcd-48b1-850a-d4df2e81a26c"
      unitRef="usd">5997000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDMtNC0xLTEtMTIxNDA_8ed4cb46-ea40-46f0-9a23-38e9d3833b52"
      unitRef="usd">11631000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8222e290a2284cb0bf64a4ac2b6995b5_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDMtNi0xLTEtMTIxNDA_fde0dfd6-9fc3-4952-ad15-efc48c591db8"
      unitRef="usd">17940000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDQtMi0xLTEtMTIxNDA_cfb7e114-5617-42fa-afdd-ae97e8c4119a"
      unitRef="usd">5338000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDQtNC0xLTEtMTIxNDA_16ac2b84-13e4-46ea-8387-4cdb532456e4"
      unitRef="usd">5997000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDQtNC0xLTEtMTIxNDA_1e52130f-afcd-48b1-850a-d4df2e81a26c"
      unitRef="usd">5997000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDQtNi0xLTEtMTIxNDA_c72e891b-ba7c-43d8-a004-cb99a1222f4a"
      unitRef="usd">11631000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDctMi0xLTEtMTIxNDA_9155552f-8201-44e3-a63b-b115cd18a061"
      unitRef="usd">979000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDctNC0xLTEtMTIxNDA_c824cd14-fd8a-46ff-9353-cbfb3711660d"
      unitRef="usd">951000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDctNi0xLTEtMTIxNDA_7dd778a0-6f53-4698-9562-91dd1cf6a62a"
      unitRef="usd">982000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDgtMi0xLTEtMTIxNDA_9f234fb6-5d11-4a61-9f91-aa39fad98086"
      unitRef="usd">2509000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDgtNC0xLTEtMTIxNDA_e8108a6c-5387-43f9-9069-c223225d91e2"
      unitRef="usd">2639000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85MS9mcmFnOmJjNmZjYmUzZmMxZTQ4ZGU4NDJkNDEyMWI4MDc2MjdkL3RhYmxlOjQxNmM3M2M4OWY4YzQzOGU5MzUzN2RkMjZiMjE2M2M4L3RhYmxlcmFuZ2U6NDE2YzczYzg5ZjhjNDM4ZTkzNTM3ZGQyNmIyMTYzYzhfNDgtNi0xLTEtMTIxNDA_e37a5135-9c69-4b91-8afc-f67afa1f1b34"
      unitRef="usd">1793000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5NDQ_63a2c092-8501-4fa8-862c-13da6b06c8dd">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead Sciences, Inc. (&#x201c;Gilead,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of marketed products includes AmBisome&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Atripla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Biktarvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Cayston&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Complera&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Descovy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Descovy for PrEP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Emtriva&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Epclusa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Eviplera&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Genvoya&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Harvoni&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Hepcludex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(bulevirtide), Hepsera&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Jyseleca&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (filgotinib), Letairis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Odefsey&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Ranexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Sovaldi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Stribild&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Tecartus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Truvada&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Truvada for PrEP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Tybost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Veklury&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Vemlidy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Viread&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Vosevi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Yescarta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Zydelig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The approval status of Hepcludex and Jyseleca vary worldwide, and Hepcludex and Jyseleca are not approved in the United States. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the United States through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether we are the primary beneficiary of a variable interest entity (&#x201c;VIE&#x201d;) at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We did not have any material VIEs as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior periods in the Consolidated Financial Statements and accompanying notes to conform with the current presentation. Beginning 2020, acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) expenses are reported separately from Research and development expenses on our Consolidated Statements of Income. Our Consolidated Statements of Income for the year ended December 31, 2019 was conformed to separately present acquired IPR&amp;amp;D expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#x201c;CODM&#x201d;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#x201c;R&amp;amp;D&#x201d;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies, Estimates and Judgments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and  expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease (&#x201c;COVID-19&#x201d;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to the customer, or in certain cases, upon the corresponding sales by our customer to a third party. The revenues are recognized net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a financing component. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gross-to-Net Deductions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government and other rebates and chargebacks include amounts payable to payers and healthcare providers under various programs, and may vary by product, by payer and individual payer plans. Rebates and chargebacks are based on contractual arrangements or statutory requirements which may vary by product, payer and individual payer plans. For qualified programs that can purchase our products through wholesalers or other distributors at a lower contractual price, the wholesalers or distributors charge back to us the difference between their acquisition cost and the lower contractual price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates and chargebacks are estimated primarily based on product sales, and expected payer mix and discount rates, which require significant estimates and judgment. Additionally, in developing our estimates, we consider: historical and estimated payer mix; statutory discount requirements and contractual terms; historical claims experience and processing time lags; estimated patient population; known market events or trends; market research; channel inventory data obtained from our major U.S. wholesalers; and other pertinent internal or external information. We assess and update our estimates each reporting period to reflect actual claims and other current information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government and other chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Government and other rebates that are payable to third party payers and healthcare providers are recorded in Accrued government and other rebates on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cash Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Distributor Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Allowance for Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the United States, we typically permit returns six months prior to and up to one year after the product expiration date. Outside the United States, returns are only allowed in certain countries on a limited basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling activities are considered to be fulfillment activities and not considered to be a separate performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty, Contract and Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses consist primarily of clinical studies performed by contract research organizations (&#x201c;CROs&#x201d;), materials and supplies, payments under collaborative and other arrangements including milestone payments, licenses and fees, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations consisting of various support and infrastructure costs. Milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of R&amp;amp;D expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We charge R&amp;amp;D costs, including clinical study costs, to expense when incurred. Clinical study costs are a significant component of R&amp;amp;D expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for R&amp;amp;D services prior to the services being rendered are recorded as prepaid assets in our Consolidated Balance Sheets and are expensed as the services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquired In-Process Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D expenses reflect IPR&amp;amp;D impairments as well as the initial costs of externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;amp;D projects. The acquired IPR&amp;amp;D is expensed on acquisition date. Future costs to develop these IPR&amp;amp;D projects are recorded in Research and development expenses on our Consolidated Statements of Income as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative (&#x201c;SG&amp;amp;A&#x201d;) expenses relate to sales and marketing, finance, human resources, legal and other administrative activities. SG&amp;amp;A expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs. SG&amp;amp;A expenses also include the Branded Prescription Drug (&#x201c;BPD&#x201d;) fee. In the United States, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the BPD fee, which is estimated based on select government sales during the prior year as a percentage of total industry government sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $735 million, $795 million and $784 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable and Non-Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable debt securities are considered available-for-sale and carried at estimated fair values and reported in cash equivalents, short-term marketable debt securities or long-term marketable debt securities. Unrealized gains and losses on available-for-sale debt securities are excluded from net income and reported in Accumulated other comprehensive income (loss) (&#x201c;AOCI&#x201d;) as a separate component of stockholders&#x2019; equity. Other income (expense), net, includes interest, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and expected credit losses, if any. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost bases. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in AOCI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable and Non-Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities, other than equity method investments, are recorded at fair market value if fair value is readily determinable, and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. We have elected the fair value option to account for our equity investments in Arcus Biosciences, Inc. (&#x201c;Arcus&#x201d;) and Galapagos NV (&#x201c;Galapagos&#x201d;) over which we have significant influence. We believe the fair value option best reflects the underlying economics of these investments. See Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Certain investments in equity securities of non-public companies are accounted for using the equity method based on our ownership percentage and other factors that indicate we have significant influence over the investee. See Note 11. Collaborations and Other Arrangements for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in equity securities are recorded in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets. We regularly review our securities for indicators of impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe. Additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material for the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;35 years or useful&#160;life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;useful&#160;life or lease&#160;term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement contains a lease at inception. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period, which may be up to one year from the acquisition date, with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration, such as payments upon achievement of various developmental, regulatory and commercial milestones, generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are expensed as incurred on our Consolidated Statements of Income unless there is an alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may be subject to adjustment within the measurement period, which may be up to one year from the acquisition date. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;amp;D efforts. We do not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When development is successfully completed, which generally occurs when regulatory approval is obtained, the associated assets are deemed finite-lived and amortized over their respective estimated useful lives beginning at that point in time. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation of Contingent Consideration Resulting from a Business Combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value in Research and development expenses on our Consolidated Statements of Income until such time that the related product candidate receives marketing approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may differ from estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S. entity operations are recorded in the functional currency of each entity. Results of operations for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency rates. Assets and liabilities are translated using currency rates at period end. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Foreign currency transaction gains and losses are recorded in Other income (expense), net, on our Consolidated Statements of Income. Net foreign currency transaction gains and losses were not material for the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply fair value accounting for all financial and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Unrealized changes in the fair value of derivatives designated as part of a hedge transaction are recorded in AOCI. The unrealized gains or losses in AOCI are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide share-based compensation in the form of various types of equity-based awards, including restricted stock units (&#x201c;RSU&#x201d;s), performance share awards or units (&#x201c;PSU&#x201d;s) and stock options. Compensation expense is recognized on the Consolidated Statements of Income based on the estimated fair value of the award on the grant date. The estimated fair value of RSUs is based on the closing price of our common stock. For PSUs, depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. For stock option awards, estimated fair value is based on the Black-Scholes option valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue the best estimate of loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax provision is computed under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (&#x201c;UTB&#x201d;) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax (expense) benefit on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to account for the tax on Global Intangible Low-Taxed Income, enacted as part of the Tax Cuts and Jobs Act, as a component of tax expense in the period in which the tax is incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our other significant accounting policies are described in the remaining appropriate Notes to the Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMTA5OTUxMTY3OTc5Nw_a1fcc056-39fe-44dd-b0da-620af37da4cb"
      unitRef="country">35</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MDk_1fb13489-a3ee-47a7-8f96-9fe39c6e74e4">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;We assess whether we are the primary beneficiary of a variable interest entity (&#x201c;VIE&#x201d;) at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI4ODk_2ae5253a-3836-4269-a9ce-c732cb64797c">Segment InformationWe have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#x201c;CODM&#x201d;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#x201c;R&amp;amp;D&#x201d;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;amp;D portfolio and external opportunities to best support the long-term growth of our business.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfNTQ5NzU1ODE4ODYyMQ_f5598217-ba18-42ec-bd88-e54b387e9abc"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5Mzk_846c3319-7486-40aa-87d9-aba68bf541f1">Significant Accounting Policies, Estimates and Judgments The preparation of these Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and  expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease (&#x201c;COVID-19&#x201d;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MTA_c0089859-02cc-496b-9f8d-2962b7e04f0b">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to the customer, or in certain cases, upon the corresponding sales by our customer to a third party. The revenues are recognized net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a financing component. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gross-to-Net Deductions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government and other rebates and chargebacks include amounts payable to payers and healthcare providers under various programs, and may vary by product, by payer and individual payer plans. Rebates and chargebacks are based on contractual arrangements or statutory requirements which may vary by product, payer and individual payer plans. For qualified programs that can purchase our products through wholesalers or other distributors at a lower contractual price, the wholesalers or distributors charge back to us the difference between their acquisition cost and the lower contractual price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates and chargebacks are estimated primarily based on product sales, and expected payer mix and discount rates, which require significant estimates and judgment. Additionally, in developing our estimates, we consider: historical and estimated payer mix; statutory discount requirements and contractual terms; historical claims experience and processing time lags; estimated patient population; known market events or trends; market research; channel inventory data obtained from our major U.S. wholesalers; and other pertinent internal or external information. We assess and update our estimates each reporting period to reflect actual claims and other current information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government and other chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Government and other rebates that are payable to third party payers and healthcare providers are recorded in Accrued government and other rebates on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cash Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Distributor Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Allowance for Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the United States, we typically permit returns six months prior to and up to one year after the product expiration date. Outside the United States, returns are only allowed in certain countries on a limited basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling activities are considered to be fulfillment activities and not considered to be a separate performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty, Contract and Other Revenues&lt;/span&gt;&lt;/div&gt;Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzMwMDc_59a2fff3-feb5-4c15-a732-0d52087dca4b">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses consist primarily of clinical studies performed by contract research organizations (&#x201c;CROs&#x201d;), materials and supplies, payments under collaborative and other arrangements including milestone payments, licenses and fees, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations consisting of various support and infrastructure costs. Milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of R&amp;amp;D expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We charge R&amp;amp;D costs, including clinical study costs, to expense when incurred. Clinical study costs are a significant component of R&amp;amp;D expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for R&amp;amp;D services prior to the services being rendered are recorded as prepaid assets in our Consolidated Balance Sheets and are expensed as the services are provided.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfNTQ5NzU1ODE4ODkzMg_610ecf82-7720-4f21-a98b-5753203a3a88">Acquired In-Process Research and Development ExpensesAcquired IPR&amp;amp;D expenses reflect IPR&amp;amp;D impairments as well as the initial costs of externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;amp;D projects. The acquired IPR&amp;amp;D is expensed on acquisition date. Future costs to develop these IPR&amp;amp;D projects are recorded in Research and development expenses on our Consolidated Statements of Income as incurred.</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI4NzY_b59152e0-6b10-4d7e-9238-9f0c84a6cca2">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative (&#x201c;SG&amp;amp;A&#x201d;) expenses relate to sales and marketing, finance, human resources, legal and other administrative activities. SG&amp;amp;A expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs. SG&amp;amp;A expenses also include the Branded Prescription Drug (&#x201c;BPD&#x201d;) fee. In the United States, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the BPD fee, which is estimated based on select government sales during the prior year as a percentage of total industry government sales.&lt;/span&gt;&lt;/div&gt;We expense the costs of advertising, including promotional expenses, as incurred.</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMTI3MzE_92086ee9-f647-40ce-87a9-e8938e9c848c"
      unitRef="usd">735000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMTI3MzU_cc6e5d84-b152-4820-83bb-ee5a1d9fea1b"
      unitRef="usd">795000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMTI3NDI_8bd4a03b-d23d-42c8-a494-33ef9e0babee"
      unitRef="usd">784000000</us-gaap:AdvertisingExpense>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MTk_5bc1f486-c9f9-4eaa-ad76-544f5274349b">Cash and Cash Equivalents We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI4OTI_7f7bf27a-30c2-45a9-be14-eeaaac685608">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable and Non-Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable debt securities are considered available-for-sale and carried at estimated fair values and reported in cash equivalents, short-term marketable debt securities or long-term marketable debt securities. Unrealized gains and losses on available-for-sale debt securities are excluded from net income and reported in Accumulated other comprehensive income (loss) (&#x201c;AOCI&#x201d;) as a separate component of stockholders&#x2019; equity. Other income (expense), net, includes interest, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and expected credit losses, if any. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost bases. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in AOCI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable and Non-Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities, other than equity method investments, are recorded at fair market value if fair value is readily determinable, and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. We have elected the fair value option to account for our equity investments in Arcus Biosciences, Inc. (&#x201c;Arcus&#x201d;) and Galapagos NV (&#x201c;Galapagos&#x201d;) over which we have significant influence. We believe the fair value option best reflects the underlying economics of these investments. See Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Certain investments in equity securities of non-public companies are accounted for using the equity method based on our ownership percentage and other factors that indicate we have significant influence over the investee. See Note 11. Collaborations and Other Arrangements for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in equity securities are recorded in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets. We regularly review our securities for indicators of impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI4Nzc_b0c6a859-364d-4f5b-906a-80f7e8711191">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States and Europe.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfNTQ5NzU1ODE5NTc0OQ_0758e778-3b63-4ae8-a44a-27fb7e1a5dbe"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfNTQ5NzU1ODE5NTc0OQ_482d26fc-689a-45a4-9b62-08d5fface78d"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfNTQ5NzU1ODE5NTc0OQ_6bd2fb77-f007-4ebd-8e83-80d0507eab36"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI4OTM_a62aeca9-df0d-4e99-974f-9149215dafa7">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.&lt;/span&gt;&lt;/div&gt;When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5OTc_d3f89158-a0b2-4295-8e2f-8d2705a4d7b3">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;35 years or useful&#160;life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;useful&#160;life or lease&#160;term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <gild:PropertyPlantandEquipmentUsefulLivesTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MTY_68274b4f-aed6-4636-93c4-59fe7ec68c58">Estimated useful lives in years are generally as follows: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;35 years or useful&#160;life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;useful&#160;life or lease&#160;term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gild:PropertyPlantandEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib4576883c8c04416a8ac3190f1f6a401_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RhYmxlOmM5NTMzN2FlMmYwYzRmNjA5YzFmNTMxMWIwMTk2NWI0L3RhYmxlcmFuZ2U6Yzk1MzM3YWUyZjBjNGY2MDljMWY1MzExYjAxOTY1YjRfMS0xLTEtMS0xMjE0MC90ZXh0cmVnaW9uOjFjYzY4ZjhkN2I3NjQwMTE5NTRkMjFlNTU1YTBlZjdhXzE1_a552997f-9d0d-4661-8903-5d0a4e1c3676">P35Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i22f92d3d761342058252995e5000c7e3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RhYmxlOmM5NTMzN2FlMmYwYzRmNjA5YzFmNTMxMWIwMTk2NWI0L3RhYmxlcmFuZ2U6Yzk1MzM3YWUyZjBjNGY2MDljMWY1MzExYjAxOTY1YjRfMi0xLTEtMS0xMjE0MC90ZXh0cmVnaW9uOmJiOWUyY2QwN2VmMjQ3N2NhOWMxNmNiNjczNzM5MmZmXzQ_51196a33-0522-4488-94d1-fb53776f3bf2">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i187ee787664447d585348e1a2ab56b30_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RhYmxlOmM5NTMzN2FlMmYwYzRmNjA5YzFmNTMxMWIwMTk2NWI0L3RhYmxlcmFuZ2U6Yzk1MzM3YWUyZjBjNGY2MDljMWY1MzExYjAxOTY1YjRfMi0xLTEtMS0xMjE0MC90ZXh0cmVnaW9uOmJiOWUyY2QwN2VmMjQ3N2NhOWMxNmNiNjczNzM5MmZmXzc_6255a2af-30ea-4dd5-a264-d81268d758a3">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3e6b53c8ca604244a32c0b5e15fd5c66_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RhYmxlOmM5NTMzN2FlMmYwYzRmNjA5YzFmNTMxMWIwMTk2NWI0L3RhYmxlcmFuZ2U6Yzk1MzM3YWUyZjBjNGY2MDljMWY1MzExYjAxOTY1YjRfMy0xLTEtMS0xMjE0MC90ZXh0cmVnaW9uOmU1NTM2MzI3MjViYzQxYmFiMGRiNjI0OWY5MTZkMDc4XzQ_1667b675-fccd-490e-9ead-ba0c563061da">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibdad0157d3ca4b4ab89aa860186ff56c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RhYmxlOmM5NTMzN2FlMmYwYzRmNjA5YzFmNTMxMWIwMTk2NWI0L3RhYmxlcmFuZ2U6Yzk1MzM3YWUyZjBjNGY2MDljMWY1MzExYjAxOTY1YjRfMy0xLTEtMS0xMjE0MC90ZXh0cmVnaW9uOmU1NTM2MzI3MjViYzQxYmFiMGRiNjI0OWY5MTZkMDc4Xzc_053c07cc-4cb0-4280-a661-d9a80f311624">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5NTQ_4b082052-39e6-4742-b63d-86d3aa016987">&lt;div style="margin-top:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement contains a lease at inception. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.&lt;/span&gt;&lt;/div&gt;As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5NDg_4bbe4380-7758-4f03-a323-0a56f13de2c6">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period, which may be up to one year from the acquisition date, with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration, such as payments upon achievement of various developmental, regulatory and commercial milestones, generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are expensed as incurred on our Consolidated Statements of Income unless there is an alternative future use.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MzY_1ca37286-c661-43fb-a808-fdab8fa4651c">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may be subject to adjustment within the measurement period, which may be up to one year from the acquisition date. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;amp;D efforts. We do not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When development is successfully completed, which generally occurs when regulatory approval is obtained, the associated assets are deemed finite-lived and amortized over their respective estimated useful lives beginning at that point in time. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MzA_81ce0fe4-28d9-4cce-994b-172bae7b5fe7">Impairment of Long-Lived AssetsLong-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5MzE_2366eea8-b629-4c20-b8b1-1e78ce25fbaf">&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation of Contingent Consideration Resulting from a Business Combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value in Research and development expenses on our Consolidated Statements of Income until such time that the related product candidate receives marketing approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may differ from estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue the best estimate of loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5ODc_0819fe33-e60a-4d9b-8e76-8ab50a3861e0">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S. entity operations are recorded in the functional currency of each entity. Results of operations for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency rates. Assets and liabilities are translated using currency rates at period end. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Foreign currency transaction gains and losses are recorded in Other income (expense), net, on our Consolidated Statements of Income. Net foreign currency transaction gains and losses were not material for the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzMwMzU_71791f93-2f6e-4c72-b620-7d74a8f00db7">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply fair value accounting for all financial and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5Mjg_b3828190-eae2-4d18-abe7-d932cba07928">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Unrealized changes in the fair value of derivatives designated as part of a hedge transaction are recorded in AOCI. The unrealized gains or losses in AOCI are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfNTQ5NzU1ODE4ODkzMw_a5b79eff-8a43-4928-8450-b609fc23f384">Share-Based CompensationWe provide share-based compensation in the form of various types of equity-based awards, including restricted stock units (&#x201c;RSU&#x201d;s), performance share awards or units (&#x201c;PSU&#x201d;s) and stock options. Compensation expense is recognized on the Consolidated Statements of Income based on the estimated fair value of the award on the grant date. The estimated fair value of RSUs is based on the closing price of our common stock. For PSUs, depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. For stock option awards, estimated fair value is based on the Black-Scholes option valuation model.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV85Ny9mcmFnOjFlNzZhMzYxZDUzODQxYjFiOWUxMDBiYWQyNGIzOGE3L3RleHRyZWdpb246MWU3NmEzNjFkNTM4NDFiMWI5ZTEwMGJhZDI0YjM4YTdfMzI5ODk_ebf657f5-58c5-450b-963f-fdf0aebe86a8">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax provision is computed under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (&#x201c;UTB&#x201d;) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax (expense) benefit on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to account for the tax on Global Intangible Low-Taxed Income, enacted as part of the Tax Cuts and Jobs Act, as a component of tax expense in the period in which the tax is incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzIzMzk_85958979-d960-4066-b4be-65d1beb07d1e">REVENUES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenues &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Product Sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Atripla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HIV &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis C virus (&#x201c;HCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ledipasvir/&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis B virus (&#x201c;HBV&#x201d;) / Hepatitis Delta virus (&#x201c;HDV&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cell Therapy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Cell Therapy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ranexa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Zydelig&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#x201c;C&#x201d;), emtricitabine (&#x201c;FTC&#x201d;) and tenofovir alafenamide (&#x201c;TAF&#x201d;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#x201c;Janssen&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues From Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues Recognized from Performance Obligations Satisfied in Prior Periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized from performance obligations satisfied in prior years related to our revenue share with Janssen, as described in Note 11. Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $851 million, $841 million and $741 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates related to sales made in prior years resulted in $856 million, $101 million and $257 million increase in revenues for the years ended December&#160;31, 2021, 2020 and 2019, respectively. This was primarily related to changes in estimates for accrued government and other rebates and allowances for sales returns upon product expiration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $174 million and $198 million as of December&#160;31, 2021 and 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were not material as of December&#160;31, 2021 and 2020, respectively. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzIzNDE_9671d4d2-f8d8-486b-9402-d14d750b7343">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Product Sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Atripla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HIV &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis C virus (&#x201c;HCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ledipasvir/&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis B virus (&#x201c;HBV&#x201d;) / Hepatitis Delta virus (&#x201c;HDV&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cell Therapy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Cell Therapy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ranexa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Zydelig&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#x201c;C&#x201d;), emtricitabine (&#x201c;FTC&#x201d;) and tenofovir alafenamide (&#x201c;TAF&#x201d;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#x201c;Janssen&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77ab90c3fe714f4582356530234c3e60_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMi0xLTEtMTIxNDA_db6098e4-c8f7-4b0e-bd1c-d084c06fab06"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a627bb411ba4fa0a3e31a768339b2a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtNC0xLTEtMTIxNDA_408c4a93-8988-45e9-95ff-e66818c97471"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b2ff7c2261943cab1a06f2276326cdf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtNi0xLTEtMTIxNDA_aeef46d2-d884-43b5-9f18-eae6987a76e0"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id689626e4dac444288f45776a25c0250_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtOC0xLTEtMTIxNDA_7ddcca2a-3ffb-45a3-add9-bcb7d9f500ea"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc14ce605c54400c9ebe1fd7a321d9dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMTAtMS0xLTEyMTQw_5d7aac48-adb4-45ec-83ac-f96c380f01b1"
      unitRef="usd">307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1051065ca69b4dd8bb278a9086b3981a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMTItMS0xLTEyMTQw_422ca86b-682f-4b17-860e-bc80f66dd728"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4c1e93ba27243a0aec3ab8933b85547_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMTQtMS0xLTEyMTQw_043860f4-c86c-4e2b-a413-5b395e4a422f"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac7be3325a864dcebdad2dd2a9d61b1d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMTYtMS0xLTEyMTQw_1b4e9024-0666-410b-b2a8-fd84d3e0ca6f"
      unitRef="usd">349000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8579426159424e1d88ee2838574cdf79_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMTgtMS0xLTEyMTQw_dd3589b7-0397-4b92-8658-6afc618387cd"
      unitRef="usd">501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16010a377327448d8c04798bd84bd4cd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMjAtMS0xLTEyMTQw_86211175-bda7-43b1-b13c-895ebd489dc7"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b8647216f134ccfad7f18b6eeda9b4e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMjItMS0xLTEyMTQw_b861557a-f869-4b4c-8e0b-98347844d903"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bf76245cb82416b89541253976dc956_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQtMjQtMS0xLTEyMTQw_6e744c42-133c-4f08-b2eb-a58b26232be4"
      unitRef="usd">600000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e5ed4771df344bf88d282203fb2c81a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMi0xLTEtMTIxNDA_3a2f97ed-78c3-4fcc-8935-077ce7c77982"
      unitRef="usd">7049000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id41a7b3cfd3a43729906149c4301f905_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtNC0xLTEtMTIxNDA_848db8fd-9bed-4839-9add-13ce34c9e970"
      unitRef="usd">969000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81029626ddfb4f7bb7bcfe5c2fdfd743_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtNi0xLTEtMTIxNDA_1bfb594f-ae3d-49cb-a5c7-265f400a7ca4"
      unitRef="usd">606000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38b5f06b93954d2c8a448f52813c472b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtOC0xLTEtMTIxNDA_6220e768-3865-419c-9784-820eb5df110a"
      unitRef="usd">8624000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e49c049a1ee4d1da001f9b14eede3d9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMTAtMS0xLTEyMTQw_c376f065-859b-41cb-8e64-e116f61dd3b0"
      unitRef="usd">6095000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia257aaf476dc490ea9ce67b59628191f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMTItMS0xLTEyMTQw_2a6705ac-0898-4d4f-89d6-070cb01a71a1"
      unitRef="usd">735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i319aecbf35ee424caa4536ae8a070bd7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMTQtMS0xLTEyMTQw_a66da201-0481-43a9-a7ff-c753ca1eec56"
      unitRef="usd">429000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id923790754d142bc8a4cff9f0db14fea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMTYtMS0xLTEyMTQw_02a0fbd2-1f24-438d-b892-2c24b74b39c4"
      unitRef="usd">7259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i004f42a19a0d4012ba76b651ac1781ad_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMTgtMS0xLTEyMTQw_e868ba9b-8feb-456d-a2f8-bb6823d76c16"
      unitRef="usd">4225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2e2462e823a488aadd395993cbcf54c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMjAtMS0xLTEyMTQw_170cf3e9-3ef7-4a2e-bc31-08750f4adf21"
      unitRef="usd">370000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3773b5856594296a0e0d5470b07272b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMjItMS0xLTEyMTQw_fc324cc5-c3f3-4a72-950d-8671e3599675"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb1ecc27305240afb7454391b76e7b3f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzUtMjQtMS0xLTEyMTQw_019d6c93-8749-42fb-8bf8-8d9ac5851dd5"
      unitRef="usd">4738000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i955f95df25784bb981f16b33c53d7016_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMi0xLTEtMTIxNDA_4038194f-fe5d-4307-a4ce-01f19bd8ce21"
      unitRef="usd">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4364249c081e4a8299d35a203bc4202f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtNC0xLTEtMTIxNDA_47ef5c76-3238-4c5d-8763-1a1087b982f0"
      unitRef="usd">142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15018f96b285492e9e58e9a7cf7f0920_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtNi0xLTEtMTIxNDA_6d3f9568-314c-4dab-9cde-bdd8d6f37880"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i943c0379de1a40db9377d8fb6d67ef66_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtOC0xLTEtMTIxNDA_1563d7d5-ca71-48e1-bf33-7c977032a3ac"
      unitRef="usd">258000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4554155264024aac9262c654e677f172_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMTAtMS0xLTEyMTQw_aaa0213a-55de-44a2-bf20-5071a3bcf0c5"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9044ed3ca9147dab388bcc7b177eecb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMTItMS0xLTEyMTQw_e365434c-c554-4121-b476-04bdfd7748f8"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07512868ee774a0cb3f3e62e504ffa2d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMTQtMS0xLTEyMTQw_3d389d5a-4d55-4831-b493-5a0d6562d13d"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83c30c6f5a8742afa25ed987810c2b23_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMTYtMS0xLTEyMTQw_a45492a1-d622-4604-aa48-f58c68f9f188"
      unitRef="usd">269000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a307049b7074acabfbc2358d76df30a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMTgtMS0xLTEyMTQw_966c0785-404d-48cd-978e-4db251e94129"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7e743ecbe404abcad5a9fe1514264d3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMjAtMS0xLTEyMTQw_c39b1874-2829-4a90-b9ba-c02b08ce84cf"
      unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61b1914f864b447d97ea0e13f1ce972d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMjItMS0xLTEyMTQw_3077d2ef-91b6-4a3d-9ac3-a954e936c76f"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a64962cf3bf49aa9644fc7d563ca33b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzYtMjQtMS0xLTEyMTQw_75e8db3a-c6d9-47f1-9cf7-c106785f119b"
      unitRef="usd">406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e847a9210e84d69b80c3e8dc9157357_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMi0xLTEtMTIxNDA_1fc14aa1-905e-4495-893b-4495a4799a2e"
      unitRef="usd">1397000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief23171a182d4edda65a49c01d6e62a4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctNC0xLTEtMTIxNDA_df03a03d-7bbd-4819-9bf3-e893f0d59881"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i823165f9f0194830b142fcc6bf699a90_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctNi0xLTEtMTIxNDA_17d8637c-8f42-4215-81c3-3d98ee9c9d81"
      unitRef="usd">139000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia58f199843b04c59b0faec348789a897_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctOC0xLTEtMTIxNDA_d4bc74b5-5bc5-48b1-bed8-a348bd307d51"
      unitRef="usd">1700000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90cc329330df4a528c8cab6d9cd3edf1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMTAtMS0xLTEyMTQw_1403dda5-92bc-438b-980a-027516b8150d"
      unitRef="usd">1526000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i479225886ad945e0b76b956d468e6f12_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMTItMS0xLTEyMTQw_8f656868-5cdc-4a5d-8451-bd0167d95f21"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87fb52f7d4e44663ad1d8a82f09c8017_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMTQtMS0xLTEyMTQw_522d8416-c66e-4e77-9bee-1feec9298a67"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia83c565a30a54c94b2209c76652e2a74_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMTYtMS0xLTEyMTQw_1e35965b-2081-4be1-a7ca-ba00d2299e02"
      unitRef="usd">1861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc63491101dd42d9a961519e1c143cee_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMTgtMS0xLTEyMTQw_fecd1a5a-3a89-4757-ae37-979a33bf2753"
      unitRef="usd">1078000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67f5cfa462304b0ab9cbaf412e605c14_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMjAtMS0xLTEyMTQw_40e91295-655c-457c-8775-61e9aad11147"
      unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i216a83afd3da4697ac13672ce7f19d1d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMjItMS0xLTEyMTQw_304fc3ce-40fe-49fa-ab1a-1423b225bf55"
      unitRef="usd">167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabce25c37a564a34b5d87a9ca20dccaf_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzctMjQtMS0xLTEyMTQw_c3ffc184-94ce-4337-b57b-950c78353600"
      unitRef="usd">1500000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04ffde7221c6428c97f3d45227146507_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMi0xLTEtMTIxNDA_b8b552a8-54f5-4d27-b1ac-b4b9fa1b9e19"
      unitRef="usd">2267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic50c2c139b864d0f9714887a2e19e6db_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtNC0xLTEtMTIxNDA_899c2862-9311-4985-b1bd-86a441000c8f"
      unitRef="usd">391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb309902460441469df9d941328c83d3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtNi0xLTEtMTIxNDA_62c74d1a-3de1-4f9b-909c-46b335f49ded"
      unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d1dc009e9554fdd9f501b84f9a0359f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtOC0xLTEtMTIxNDA_14581c57-0eb8-4ed5-ac1e-a8fa2e046a10"
      unitRef="usd">2879000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i936e4f60767e4e1b831396cbdc15a198_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMTAtMS0xLTEyMTQw_cc39c7e3-f7f0-453c-81f8-5ec28c1acb90"
      unitRef="usd">2605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07a10f58aa8a4d788bb183517127b71a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMTItMS0xLTEyMTQw_05e25117-ff4d-4bf5-a1ed-f1e0e2a44f50"
      unitRef="usd">490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibba1f6a417454414a52eee67b903f766_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMTQtMS0xLTEyMTQw_1f4d89a6-d0ac-47d8-9ac1-96300905d370"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i578e91a5c0ef41cd8792efd4d19387a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMTYtMS0xLTEyMTQw_c9506ea8-4e22-4101-960f-d5d29c964beb"
      unitRef="usd">3338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id40d8621788548d7bf411858ff7ba95c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMTgtMS0xLTEyMTQw_426ac430-3b22-4f31-9353-b7b73399911e"
      unitRef="usd">2984000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5afd54b578514567a98284af66dd6ac4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMjAtMS0xLTEyMTQw_2fda4757-a50f-40bf-a91b-30f2d0d9cec6"
      unitRef="usd">664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2eb94cadea964808acc7aa15bff37b06_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMjItMS0xLTEyMTQw_bee4c96c-ca2c-450e-950a-1650400793dd"
      unitRef="usd">283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf61ee83088444bebb4f09663550f050_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzgtMjQtMS0xLTEyMTQw_edb08e91-79cd-46dd-b2db-644212d337e0"
      unitRef="usd">3931000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7d0947b224444048e064e12269cb830_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMi0xLTEtMTIxNDA_96575620-d494-4496-a67b-656e2003e56e"
      unitRef="usd">1076000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia577fbe14a0c4e0d927470b3a7fbd587_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktNC0xLTEtMTIxNDA_150acc97-a871-491e-a1ce-1081d0eb043c"
      unitRef="usd">440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i977d9314cc04434e91070353392923ff_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktNi0xLTEtMTIxNDA_c4208e9e-3fc0-4b1a-9d2d-7c73ca05121d"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d310b1fa75d4a7da984b20d948c2184_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktOC0xLTEtMTIxNDA_2a35cd69-0e79-4c86-b331-87c2b2a77c40"
      unitRef="usd">1568000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bbc93fa20d84074b84f54ab99be3ff8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMTAtMS0xLTEyMTQw_0c098ac3-8961-45d4-b2c5-aad0563995d4"
      unitRef="usd">1172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73de952e119a4e8193f9d06daafad3e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMTItMS0xLTEyMTQw_d5ac1bda-b424-4bcf-a03c-3f0a35efde29"
      unitRef="usd">450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1a3692437a140df85ba1b362d2ab850_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMTQtMS0xLTEyMTQw_347616fa-b26a-4c08-b62a-375252d5feaa"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia94003099e5143b788e8be9985a431ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMTYtMS0xLTEyMTQw_7fb4fec2-f10d-41df-983d-51b9a1f9f227"
      unitRef="usd">1672000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae5dc050b70c4243b5d650b622754554_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMTgtMS0xLTEyMTQw_7624b711-1d5f-4739-b424-d1ff867617f2"
      unitRef="usd">1180000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b3a4868171e44de9828b7b8b593f50c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMjAtMS0xLTEyMTQw_5a0c584c-464d-4924-bef7-f986e8a0fdf3"
      unitRef="usd">438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e9af54cfc5343f9a51ab0c702ca66b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMjItMS0xLTEyMTQw_9e74d043-aa11-4467-9a6d-039039c03e23"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib00d8c27b3274579a8ddb2794664ce8c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzktMjQtMS0xLTEyMTQw_51da656f-ea52-4b46-99d6-540b29a5b44b"
      unitRef="usd">1655000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i925632f08b5b443abc506c4e0023ae1d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTItMS0xLTEyMTQw_97a86f83-e428-43d8-a52b-1781dd38a7e2"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i127c66e034bb456aac9234e1af982283_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTQtMS0xLTEyMTQw_43e529ce-4a8d-476d-88bb-7d8dcac745e1"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02c935862970477fa978f1f0a2d5a975_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTYtMS0xLTEyMTQw_f2dbb477-645b-4963-abe2-ab9570e19237"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56588b2fbaa54723a442c57323d9358e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTgtMS0xLTEyMTQw_86334794-ee63-40e0-80ef-53ebfeef7fe2"
      unitRef="usd">189000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie911ed307ffe4eb880442fd8415ae516_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTEwLTEtMS0xMjE0MA_51dd5bd0-b8c6-418c-b0d8-76ba80dc9c63"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47483424d79343caad903d50f18fbc27_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTEyLTEtMS0xMjE0MA_af9ece42-a8c5-4d8f-8ce1-cdb94c6dc57e"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23d5b07c3dba496b87eed5481cc9e061_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTE0LTEtMS0xMjE0MA_93b76bd9-4a13-4698-ba52-c03696051733"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6888f767fb5540a89c1b977dc34701f3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTE2LTEtMS0xMjE0MA_10b75ed3-da14-4537-ab8c-375d84276039"
      unitRef="usd">196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bcfe9bc16c64a6998c2ecc8a00a59a7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTE4LTEtMS0xMjE0MA_d790d7d2-1e75-4361-ac03-f7c2fade9527"
      unitRef="usd">268000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab5c0a688812413b97b23617889fdc29_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTIwLTEtMS0xMjE0MA_0d5f859d-4112-4178-ab36-b7ecea9b76af"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a3ab7f327aa411ca8cd78c5b9c55878_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTIyLTEtMS0xMjE0MA_c8cc9e16-d826-4809-809e-9cfb9e6f4c45"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f67d4b107054320b3c16b7722812905_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEwLTI0LTEtMS0xMjE0MA_c3e794b2-49f2-41ed-aa9c-c3b652510c44"
      unitRef="usd">369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20615d735e3f4feb876b0d68cb833b1d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTItMS0xLTEyMTQw_e62fca8a-de3f-4bfb-8d9c-0a9311ead411"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafcee73041034a3bb538769755411935_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTQtMS0xLTEyMTQw_25625737-95a3-4003-8fd0-b9d5223cd64c"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08e8a386144940089c04595189b92780_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTYtMS0xLTEyMTQw_6964576f-d44e-4063-807d-8e4ad243bd31"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida4bff1ec94d45e89d93a2f8a45a8829_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTgtMS0xLTEyMTQw_06b9db4e-2be3-48b2-b1b0-327e457b221b"
      unitRef="usd">371000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if42c088f381c4f66821c3e14150643fd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTEwLTEtMS0xMjE0MA_f606d7ef-a013-45a3-9195-9fe3d0825030"
      unitRef="usd">1376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a12972820c549f7975a5bf002bb6538_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTEyLTEtMS0xMjE0MA_a46048c2-307e-4643-9eb2-9b93c4bab092"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1f2aad4ccbe4eb0b88c2df952d0f837_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTE0LTEtMS0xMjE0MA_9635cdc1-4ec9-4763-b090-d3476c63b666"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i897e806822094d188dfde4952fccd379_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTE2LTEtMS0xMjE0MA_1c838587-bab5-4945-b324-977725e89ef3"
      unitRef="usd">1448000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba451b80fc88410cb6da9b54c955e4ca_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTE4LTEtMS0xMjE0MA_64908823-b1f9-4746-a543-b3b3060f9309"
      unitRef="usd">2640000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43aa85da84bc4a6aa2f0f6e6c94ce6ab_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTIwLTEtMS0xMjE0MA_4d88dd19-8e58-4e97-9909-980e180ab925"
      unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic75353bae5a445d5bc123e7e2497e07f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTIyLTEtMS0xMjE0MA_a1cc1078-1336-417c-8559-e7fb3b3329d5"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacec9e096e3e44b99059f74fabeb6b7e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzExLTI0LTEtMS0xMjE0MA_dc0616f5-11ba-49e6-a6d6-2e258697b760"
      unitRef="usd">2813000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib56fe44333d84038b5fbbdbcc054b3c6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTItMS0xLTU3NjQ1_949e6a24-ca89-419d-8fa3-c1b5dc8719b5"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53379b0e65dc4f64ae5b9bebdfe46157_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTQtMS0xLTU3NjQ1_64388488-abf1-48f7-b3a4-2c3442289ceb"
      unitRef="usd">165000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i893bbd6422a34883a23ca3d826e5330b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTYtMS0xLTU3NjQ1_b66d3ab1-f7cb-4d21-b0b5-eba0e99ce984"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i448e732ad9d54ac69e5a1bd7cbe328c8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTgtMS0xLTU3NjQ1_3ce1ced9-ba69-40b3-985a-ec7df9bd6600"
      unitRef="usd">531000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia91566e38f88433997c0da1de1f66272_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTEwLTEtMS01NzY0NQ_2247160f-8ad2-4d89-a4a2-6d7df7c9fef6"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ff0ba8e2df54068b6656075016def3f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTEyLTEtMS01NzY0NQ_1ebe554a-a247-4445-b7ff-19d85e577001"
      unitRef="usd">149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb20f84492cc40dc9b975458263e0c09_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTE0LTEtMS01NzY0NQ_4ae277b5-0997-4cc3-8f07-dfa23d824291"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43f373d73c8b47b1b9b16c76da6f8272_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTE2LTEtMS01NzY0NQ_bf547c88-0b77-44c4-9c6c-713555d92a50"
      unitRef="usd">488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0472aa0ea92940198b6e45b72223726e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTE4LTEtMS01NzY0NQ_9041ccdf-9107-4c53-8f90-610cc45424eb"
      unitRef="usd">249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4c4c20540eb44838445a3c3bf6934db_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTIwLTEtMS01NzY0NQ_47c832d7-ebac-4e1e-9cd3-3a6b3ab3ea67"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i736248e52f04435497e629400596475c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTIyLTEtMS01NzY0NQ_8a0b6c13-a8d8-479f-b43b-5f03037f83eb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83bcf63461a9483abe4dfe87ed5458a8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTI0LTEtMS01NzY0NQ_9920af5e-41e6-4311-b464-ec569aa0fdf1"
      unitRef="usd">379000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2faa4357e47d498d8cbb90bc8b52484f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTItMS0xLTEyMTQw_766fa455-8fec-4474-bda3-1ca3c79c5ab3"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i396c07fd8f3441388406ead2bb7d7a43_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTQtMS0xLTEyMTQw_60bd13fd-4885-4649-a806-8fc3348fe31c"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i444aa902d7d24a6bb6ae1f79b9b2c713_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTYtMS0xLTEyMTQw_7db21286-5255-498a-9f46-84ac9bf2f679"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54a837cfa59946e4a95ef8a3cda149f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTgtMS0xLTEyMTQw_88a0b67d-c1f2-449e-9db9-c79383c892f6"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id88fe6e33c8e46bb9324f5323a45bae7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTEwLTEtMS0xMjE0MA_9a5d5679-1d9b-469b-80fc-a00567c640a5"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaecb4bf28d542abb8f6e6fd2b7265d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTEyLTEtMS0xMjE0MA_9a4b8423-3d4c-46ea-8aa7-e77c2822cdfd"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if60bb22a46354d29b9219ed7fef954d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTE0LTEtMS0xMjE0MA_c1a1683a-ba34-41a9-9d9e-ad8a902ee71b"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42f5a348b1384a0383f1142c48fbdfd1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTE2LTEtMS0xMjE0MA_fa465ea9-3e90-463a-9320-a7472d84118b"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa5c024b83bd4d2aa79c46874679d786_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTE4LTEtMS0xMjE0MA_87c81a98-4b93-40a4-822e-f9c39120662b"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i504f85f6c7224b00875ce2499cf0be63_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTIwLTEtMS0xMjE0MA_492876a2-c332-4f90-afb7-810bc5df0768"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96f908e96d164ff1b01f8baaa3fd197e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTIyLTEtMS0xMjE0MA_0eb2e998-401d-46bc-b3ad-0ee149bc2fdd"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia251084190c34f55a95d6b2d64e37c96_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzEyLTI0LTEtMS0xMjE0MA_cc84887e-23c8-490b-ae10-15e3ed3040e3"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i229cf3b61ba147a3bbcb87ad7c31cda8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTItMS0xLTEyMTQw_269fbe1b-fa2d-4db9-8935-a1ea9044847f"
      unitRef="usd">12828000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifac706cf047e462d9dfc15fd7dac6e57_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTQtMS0xLTEyMTQw_8dc11aee-fd7a-4ec3-9bfd-5528235ece3b"
      unitRef="usd">2366000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3eb81dce73a4ed49c600ae52236de95_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTYtMS0xLTEyMTQw_bb689e0c-07e0-48dd-a816-7fdca87b4b34"
      unitRef="usd">1121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i618a49f5343d4aecbde299dd826aab16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTgtMS0xLTEyMTQw_11c75797-5ad5-448d-98ee-92b94842d086"
      unitRef="usd">16315000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6dee7da238ca415a918de272a337f32d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTEwLTEtMS0xMjE0MA_8a3c9f5b-fd72-4c10-a1a6-7333eb06005a"
      unitRef="usd">13651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbaf6564706d428191f126d2bc0e85d9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTEyLTEtMS0xMjE0MA_c879acfb-923c-4f2c-bc83-0bafa9cb86d3"
      unitRef="usd">2287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie107375dab0449d29330362386bad92f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTE0LTEtMS0xMjE0MA_2c361419-67df-4619-bde7-3321fa2ffe4a"
      unitRef="usd">1000000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaeaab2348e4b4632be02c7e9827151b6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTE2LTEtMS0xMjE0MA_b23877d3-ec6d-4f8a-a7a2-f4504d3aac6a"
      unitRef="usd">16938000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e04004aaf38470babb8b33e23b0be74_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTE4LTEtMS0xMjE0MA_94acd3c4-b82f-4ce3-8e0f-1e401764371a"
      unitRef="usd">13315000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e3ea7d2e5d849d7a255cb4ca655164a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTIwLTEtMS0xMjE0MA_5821ed8a-673e-4095-9596-17781a1f91b0"
      unitRef="usd">2312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ace274ff98a410dba00afed59352d83_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTIyLTEtMS0xMjE0MA_9dcf7ef0-7c50-4a36-8ce6-df4a99ac94c1"
      unitRef="usd">811000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i465510434439422dbfe78d94feefa0d9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE0LTI0LTEtMS0xMjE0MA_8c3e5b7f-1017-4e10-bd4f-7260ff45f532"
      unitRef="usd">16438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d552aa7c2b84ac880c86df8863dfdb2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTItMS0xLTk2NzI5_5a190b58-1456-459e-8fc1-54bc315c9416"
      unitRef="usd">3640000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ec344efbbcb4ac58cc8fa406d405f6c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTQtMS0xLTk2NzI5_9dc6b3f6-38ea-4110-870d-35c24581a3f1"
      unitRef="usd">1095000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id54f9b7f9d7c4a1eafcfcbb1db87e3c7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTYtMS0xLTk2NzI5_51fca6df-8a01-4126-b820-01096c97909c"
      unitRef="usd">830000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71a47ad4a66a490c87ebcbdb533b3462_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTgtMS0xLTk2NzI5_e4ce5539-ffb6-4520-9c49-afe603be5571"
      unitRef="usd">5565000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c6ba686d4024e4cb3fe4e32aaa54c4a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTEwLTEtMS05NjcyOQ_68ae3548-8237-4423-95f6-091cbd29b414"
      unitRef="usd">2026000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i628f3e6013424bf6b278bfbb87d91521_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTEyLTEtMS05NjcyOQ_92294aed-3844-4842-a80f-e6ef096f7af9"
      unitRef="usd">607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i099a39b4eb484948a229c49d6d7556b0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTE0LTEtMS05NjcyOQ_b7991e6c-e226-4f9e-b5f2-2c7604f640c7"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide13091f185d41cf95813a1577de725f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTE2LTEtMS05NjcyOQ_2c892e69-df4e-4b62-84c6-866b1a8e17a5"
      unitRef="usd">2811000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee9158b1c9f74ee081ba38f7155459e2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTE4LTEtMS05NjcyOQ_73caba74-b036-41da-868b-ff32a7b08d61"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief38edf0775b4b9ca4f0e44ff59522b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTIwLTEtMS05NjcyOQ_a58c8512-f172-41a4-b2bb-f408cde87012"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bf73a2b190f407094b4c112c16ea000_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTIyLTEtMS05NjcyOQ_3c932f5b-77f1-46c9-8fc2-085a8d692ff7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70e97db273aa4eb795da9d6d163926de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTI0LTEtMS05NjcyOQ_82443a0a-221b-4e1b-aa50-a981f6710101"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d2c54277b224652bb5f481e8899b9e6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTItMS0xLTEyMTQw_ebf52dec-1302-42ec-9198-2dbbaa5b3288"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i941c012023db4169add7305278b25afb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTQtMS0xLTEyMTQw_72b49684-f016-4403-ad13-0fd36724add4"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8b3da75ff53437da4d0ebb7b7fce5dc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTYtMS0xLTEyMTQw_657d6d2e-de2a-41a5-b3a0-a572db7c0ebf"
      unitRef="usd">97000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie98d85f6a23645e7b3666fb72be32521_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTgtMS0xLTEyMTQw_4bcb6266-4ad8-4fa0-beb0-32634ebc96ab"
      unitRef="usd">212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i110bc03b8b9a4f39af6919c8022f5247_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTEwLTEtMS0xMjE0MA_9b7e3ce4-2920-4a0e-a7b8-8ca13e2045b6"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9461e732efa7439c98e730817b44bd6c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTEyLTEtMS0xMjE0MA_f497ba84-3f18-4f00-9757-a74e54a7a82a"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39e0c50452714cc3bed41c678ceb7699_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTE0LTEtMS0xMjE0MA_e00a7539-930a-4249-af3f-348f1e96532e"
      unitRef="usd">151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4a05a18dbff43cda41f2c88b1526af2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTE2LTEtMS0xMjE0MA_417808ce-d289-4312-8db0-8c97322abcc3"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i071292c322124b9bbbf6c05bedcf533c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTE4LTEtMS0xMjE0MA_f3a59e15-b13f-456d-84ee-82ce1b09f73e"
      unitRef="usd">312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6d911747d0e4dd896dcbd36aa8d64b6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTIwLTEtMS0xMjE0MA_48cf18d4-281d-4509-875f-01722e3e9d2a"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3db91593e7ae46df9458a6d27efd34e2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTIyLTEtMS0xMjE0MA_609244ba-0c20-4562-949e-707c4131175b"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice67dd103e8747c6a85c1155ca7fb3be_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE2LTI0LTEtMS0xMjE0MA_5a790ac6-5a6f-4611-9c8f-fab79d1ba249"
      unitRef="usd">643000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72885015d43e44598a373a66ba3cd518_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTItMS0xLTEyMTQw_1e3e423e-95e6-458e-906a-b2d76bbf8fea"
      unitRef="usd">815000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25d706b9871c4ec09d84165adbfdc1bd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTQtMS0xLTEyMTQw_7bd5f0da-13cb-4825-8be2-e14bfab208c0"
      unitRef="usd">316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9744c1bb608145caa3c32e7f1f1e62c4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTYtMS0xLTEyMTQw_c0cd0083-aba5-45cc-a131-7338168df321"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaf61fdee7ed484a8cf5ef1a28ae513c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTgtMS0xLTEyMTQw_db1e96f9-9097-457d-8950-84e6dddfaf39"
      unitRef="usd">1462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib68f13d7d65f4a3f9d6b6fa6fe779f16_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTEwLTEtMS0xMjE0MA_f8a2311e-fdb1-4131-883b-afbe1544e4c4"
      unitRef="usd">864000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad62ec6434ec4a489357913014ef40c6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTEyLTEtMS0xMjE0MA_492d6b02-2bb8-42ce-96b8-43bee2d24a12"
      unitRef="usd">337000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i632ecea3d6a14bcd8aba4b551ab1b109_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTE0LTEtMS0xMjE0MA_a9771c05-99fa-4334-a9ff-fbd70fe4aac6"
      unitRef="usd">398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6977f8ca20334e9a848c24badc467c74_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTE2LTEtMS0xMjE0MA_1362fc4a-6fb3-4525-982e-672f4f86715f"
      unitRef="usd">1599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad186c8130da4cb0a163b46e15ef8e0e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTE4LTEtMS0xMjE0MA_8f629cb1-9f1d-4602-8ba9-e279ae3528be"
      unitRef="usd">971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad332b2083f6422aa4d34ccad607df30_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTIwLTEtMS0xMjE0MA_c160b829-cb95-41c9-a56c-ac0c52bae887"
      unitRef="usd">553000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic402cdf5c95049fab3f5cb084e3b4a9e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTIyLTEtMS0xMjE0MA_f026896a-2fcb-4ea2-8090-7ba73b831d69"
      unitRef="usd">441000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie91e317bcce84be491b677bb32bc6edd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE3LTI0LTEtMS0xMjE0MA_4e37a625-66ab-4bd8-a8b0-8473d6d6912c"
      unitRef="usd">1965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i375f98b35c614e57bf7b3740ade479e6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTItMS0xLTEyMTQw_53ddfdd4-8ae9-4741-b19a-638faabb35a8"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ee01bce4fff478da0c0d8e0717ceab3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTQtMS0xLTEyMTQw_9b818317-3396-4aa2-8bc7-fd004547e777"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19612080d7a04eb680dd7e62452339bd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTYtMS0xLTEyMTQw_8de42229-1d86-4447-bd5a-8434e401c11f"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0528cba9d58149eeb50487d8e0d93ffa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTgtMS0xLTEyMTQw_37648432-32d3-4ff2-8796-3401bc58d5fe"
      unitRef="usd">207000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id10376e1051b4ab49d4409daa6db3caf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTEwLTEtMS0xMjE0MA_02ba0309-c802-4553-8c96-c8ab52ec59f1"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaccc6fe1894b406ea52f03be7d11f6d9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTEyLTEtMS0xMjE0MA_f31302b8-14c7-4834-b91f-0de046e787a2"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08fdcc10444240b5b0e2612cc6f7a33b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTE0LTEtMS0xMjE0MA_ff3724cc-6a54-4def-904b-8f9bcbb1099e"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6778d1e87c764b129992c37e1b4c7453_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTE2LTEtMS0xMjE0MA_8c83b1aa-64d5-4f6b-a025-2aaf6e934bde"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02a3a1f229ec4abb83405668328a28bc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTE4LTEtMS0xMjE0MA_e5d3f7e5-104f-4499-815b-ff799147f1bd"
      unitRef="usd">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e5ae4a747de409780ccfa5e25f24d81_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTIwLTEtMS0xMjE0MA_bc367c3c-712b-49ea-93c6-026c9a2e5c6b"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6f226ca327245028082583aeea18794_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTIyLTEtMS0xMjE0MA_e14b72f6-d9d7-4d39-8ef7-059ba0d5befa"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic223455e19124079bccd18d5b6d19b66_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE4LTI0LTEtMS0xMjE0MA_b9c7d6ee-33bf-4fc0-ad6b-50e56833b2fa"
      unitRef="usd">328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i729e30cec34d4651bcc4fffc012176bf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTItMS0xLTEyMTQw_9bd1997a-7bf7-41d7-af6b-758217f8af23"
      unitRef="usd">1018000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53f528f5ab3e479f8750f39c2d1cda40_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTQtMS0xLTEyMTQw_f269e34e-eede-4495-ac3a-3ad5e487d07d"
      unitRef="usd">421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c21b57a311843c7928c23075197493b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTYtMS0xLTEyMTQw_b69360d6-b7bc-44e3-a236-834db7030c62"
      unitRef="usd">442000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i165baeb18574423899e97572f4ad2303_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTgtMS0xLTEyMTQw_02f4ea72-6d17-4a03-b6e8-4f59f7bbb501"
      unitRef="usd">1881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie276a8d1c5114e51906a50380e6079af_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTEwLTEtMS0xMjE0MA_97298a48-931e-4578-a531-58aaf57b0afe"
      unitRef="usd">1088000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i808173f115644f8887374d0ccd5b7c2b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTEyLTEtMS0xMjE0MA_4dd7cea1-ddbc-47f2-9955-064de089bd3a"
      unitRef="usd">414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5af4bf5983dc4d368f5f7d4d273418b3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTE0LTEtMS0xMjE0MA_c85aa014-7040-4969-94b2-4972a21d2092"
      unitRef="usd">562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47170c44772d4eca8e1e5e6506def2c6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTE2LTEtMS0xMjE0MA_075deae9-f3f5-47b1-b2b7-89299b2a5153"
      unitRef="usd">2064000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51636ea5513d4d358e7a7b90f6dbbcd9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTE4LTEtMS0xMjE0MA_f03cb18e-639f-48a7-803d-c36cdb4cf53c"
      unitRef="usd">1465000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf522a1b7f6646bbabcc782e8dc1b51b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTIwLTEtMS0xMjE0MA_1363afda-bc40-4ad0-be7a-c3d51cf107c0"
      unitRef="usd">742000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fd3a2239f5b4e01a783ba6d8ec0df2b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTIyLTEtMS0xMjE0MA_13fed870-f638-411b-9a6d-c3028f21268d"
      unitRef="usd">729000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f8928add9a34ec3ad3f06c8d26024e0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzE5LTI0LTEtMS0xMjE0MA_395faa65-b3df-4767-9f5a-28ba70a89c4b"
      unitRef="usd">2936000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b4a7b3c0e8c4e2a853a78f842c29fa7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTItMS0xLTI5NzA4_8c38ad69-c156-4379-82bb-fa7cc780bd00"
      unitRef="usd">384000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4827aab7f394a64b3d94fcd0bb16303_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTQtMS0xLTI5NzA4_4eb61d03-a228-4e3e-b798-9f0e1da7c87c"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia26aa6ff603d43d18f70315e2b916968_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTYtMS0xLTI5NzA4_458c34d6-3465-4ba9-841a-5a60aa04f0a5"
      unitRef="usd">396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i871089dbd36740338ee626df7623365a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTgtMS0xLTI5NzA4_31ebd97b-3942-4d05-ac4a-ece9a5e61386"
      unitRef="usd">814000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b4e1408e03e47fb82f8f85c9eb666a6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTEwLTEtMS0yOTcwOA_dfb66970-6227-4b9e-8b42-7d82ba771a2d"
      unitRef="usd">356000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51ce404a1df3479280a332700013fcf0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTEyLTEtMS0yOTcwOA_b70330fd-bc90-4810-8fab-0a214c28992b"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i146057c31eb14e13a7a9e858bb60ead3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTE0LTEtMS0yOTcwOA_e3b7e277-bf42-4142-b193-840e0b25efb5"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ed2d462dfa849f6afe13f2ebcd6d4e9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTE2LTEtMS0yOTcwOA_6a0d574e-e8d0-43a8-9212-b1ccdb87a2e3"
      unitRef="usd">657000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b1a81e689e545ee948a81eef2e1c110_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTE4LTEtMS0yOTcwOA_8beb39c3-1b71-4b2e-a42c-c463290648d0"
      unitRef="usd">309000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b28d7f764ed4df6a8fc6e996578f509_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTIwLTEtMS0yOTcwOA_f4be6c87-cff5-4405-ad5c-4695a1c46283"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2151dc48e6c947d99adf672da18b5df0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTIyLTEtMS0yOTcwOA_eb1c453d-ffac-4b5d-9413-7a54b8c30cca"
      unitRef="usd">158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bb410dca7a24d078ff1663fdf12406a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIyLTI0LTEtMS0yOTcwOA_8f0198bb-6f69-4d22-811d-7771ce704a20"
      unitRef="usd">488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94ea9f66d534416db1d7a1827cf95ef3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTItMS0xLTI5NzE4_7e7b2d6f-f1be-416a-b517-a1eff50c6a3d"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1647c6936bc43fcbdf243a9abdc515c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTQtMS0xLTI5NzE4_95421fb6-28e5-4ec3-8cbb-34c2fef357a8"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0aae349b58074fb090feca87f57d6a14_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTYtMS0xLTI5NzE4_ff31e210-6d81-4d71-895d-984e689b4f60"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ced3c15a03640a7835d719b1561a52c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTgtMS0xLTI5NzE4_a04dfbb1-067c-4763-a7a7-fc9b490c5a26"
      unitRef="usd">111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73345ea2314645cfb8820974c816098d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTEwLTEtMS0yOTcxOA_0f303b7b-fdd7-43f7-87be-2420b425f2bc"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bd332574d544b2c82443ba3f73ee034_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTEyLTEtMS0yOTcxOA_8a05719a-42ab-4a44-9d97-3a331bdf2702"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91bc7aa72e1a4adf90ce08b4fc392bee_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTE0LTEtMS0yOTcxOA_91663bd3-7049-46aa-b5c6-7e908eab7b20"
      unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8eb76b459c940c1b2329abee0b99396_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTE2LTEtMS0yOTcxOA_af0ce96b-32de-439e-8b89-0d7c022d41da"
      unitRef="usd">185000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09754db5820b49ccaccb7b061b0de557_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTE4LTEtMS0yOTcxOA_bc4e98c6-739f-4bcb-a369-24ee8d7b4f7c"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e265173cbd142768e582d998dc84774_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTIwLTEtMS0yOTcxOA_542f6d5d-196a-48cc-a82f-2d17fc218ea8"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i172a3eda78c94e1a9b766caab41395d0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTIyLTEtMS0yOTcxOA_c96ef750-ce19-4547-a22b-55eebe1278f8"
      unitRef="usd">142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4459dfdc5346422aa45ece2ad20dbcf7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzIzLTI0LTEtMS0yOTcxOA_77bf3a12-fb89-4c16-9474-f2965fe2a2e8"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieebec0082c664646b4c00fc161a76516_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTItMS0xLTI5NzM2_4af73a11-1e71-44c0-9273-0dd7bd13366c"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7d099c53b1d444b94f937435b1658f9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTQtMS0xLTI5NzM4_ac20e21a-8bf3-4467-90c4-670321fed51b"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2ff0b32543a42a4abba6624736b33da_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTYtMS0xLTI5NzQw_4c522b38-5a8a-42c2-ac64-5904028347dc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7f1ebdb534d481b8b99013849133a98_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTgtMS0xLTI5NzQ2_9e9b6b45-06a8-4082-a291-ac9ac6b8d891"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i970f012679314778a69b58c8c857088d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTEwLTEtMS0yOTczNA_291eca75-b4dc-4b9d-8938-2ab7162434ef"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff2b48995cec427d8433b77a188fc0e0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTEyLTEtMS0yOTc1Mg_488b3f71-7d55-47e1-a641-4fe2d4238e0c"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11fe2f0b1fc7469e95477b31fceb41b6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTE0LTEtMS0yOTc1NA_a4452a9d-44ca-453a-8b4d-37f9b84456b8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79f64c38e9ee4bb4a4adfed263dae20a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTE2LTEtMS0yOTc2MA_f64aa068-7ac6-4f42-b70d-5708d11cfae2"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4513c4c6a873402fb73e21a4c06e9516_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTE4LTEtMS0yOTc2Mg_cecaebbe-a9c7-4ca6-8562-ca0adda9d61d"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3976c38729943bca9dadbf1a4d46799_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTIwLTEtMS0yOTc2NA_3661618a-8cbb-4a59-976c-317071a7400e"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib547fcae84e34c80b007576498382eda_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTIyLTEtMS0yOTc2Ng_042b937f-d69b-47a1-93ec-97c848ea4b54"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica6cb120280c44aba952a2c8c31a2750_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTI0LTEtMS0yOTc3MA_431828d6-f12b-4057-acb1-af04aa952c85"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0079f3b20eae4a329e4b8ab2e229a710_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTItMS0xLTI5Nzcy_fc3c2233-fdbd-4471-b919-c3dde0fe31e3"
      unitRef="usd">397000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c533a97e93b4daea96b3f68f4b71cb1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTQtMS0xLTI5Nzc0_058f6d7b-7c8e-45fa-b6c3-47b2e6f40b4c"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i336a3356c30a4e60afd917f34ba87b7f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTYtMS0xLTI5Nzc2_ea42ae9f-efea-4a7c-b043-2d0d0f5ced69"
      unitRef="usd">468000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80ab1d03e53b40818f7339579267f386_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTgtMS0xLTI5Nzc4_0c432c64-bc98-46f7-b448-f15efde15bf4"
      unitRef="usd">969000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26d26996cce54be89bc4f5b1de53509c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTEwLTEtMS0yOTc4MA_4436a839-ca35-4ed9-b54a-0bdf58ecb5a6"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73430cf69e6a4a81b0cb6ca9f2f1bcce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTEyLTEtMS0yOTc4Ng_bd10a263-47cf-40c6-bab2-65c650f83654"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b4092e37bcc4090a2f341d283035c62_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTE0LTEtMS0yOTc5Mg_723d4ec3-ef3f-41a6-959b-9615ba857b4b"
      unitRef="usd">409000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8edb5cc13dcc444f8d32a508d719f99d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTE2LTEtMS0yOTc5OA_a6248f88-f3c4-4de5-b7eb-a194b7c2437b"
      unitRef="usd">860000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id72cab863f9944e49a8a3f6a212cfdf8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTE4LTEtMS0yOTgwNA_e0e8d32a-8318-42e1-94d1-88392d398f91"
      unitRef="usd">343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6eb6a7e8649e43ea9cb507ca4dfa26de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTIwLTEtMS0yOTgxMA_4bebaaf0-1249-4aa1-9837-9564cc71c292"
      unitRef="usd">99000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24161ce3ce19498d973322014f5a38f9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTIyLTEtMS0yOTgxMg_57d36e0e-1efb-45cd-a2e5-89a2bc5d3bd6"
      unitRef="usd">300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ca7841873c343278c0054426a718e6c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI1LTI0LTEtMS0yOTgxNA_9f40b359-7895-4d66-aa22-30544982948b"
      unitRef="usd">742000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id98a790faa824c7aa313d67d0d0d9def_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTItMS0xLTU3NzE3_1784b767-3104-4c89-82ee-722a61dc5c01"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd711f6c7d6a4b3caf2c838786295c50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTQtMS0xLTU3NzE3_290e6191-4c8b-4a6b-bea6-2a6a89ce9b63"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3b37a4b21504974b6a12ee7143b36f2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTYtMS0xLTU3NzE3_7698baeb-0773-46b3-8425-16288e2a8cbd"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2966258a34f945a6a240f933b9ea68a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTgtMS0xLTU3NzE3_76953ac6-5dd9-46b2-b30d-8482a2110cc1"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaacff29670a64fc3b828391eaad52b5c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTEwLTEtMS01NzcxNw_8cee0b69-0e82-45fc-a58a-624d60ea3d92"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51653a7404d243bbb8c6b8587d15c302_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTEyLTEtMS01NzcxNw_e1ed0717-7d6c-4502-8ccc-734e7e04083a"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2206384caac54219b456deb7b0f73604_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTE0LTEtMS01NzcxNw_48dd9ea1-5eb7-49a6-b7a9-0c9b484c163a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i062b8b99606f460291f3600b276f88f9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTE2LTEtMS01NzcxNw_7fff3b5b-f154-4fc8-bab8-2ae550c52374"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65701b8285f24b0196e2fbb93db58af3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTE4LTEtMS01NzcxNw_f77ac109-ac0e-420f-b409-d309b7297d22"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2df490d82b849ba8e735ab25f5a83b8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTIwLTEtMS01NzcxNw_343e5578-8d22-474f-b531-62dc857c4491"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c114e0218d342d9bb4a36cbb9d68b4d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTIyLTEtMS01NzcxNw_0febdf7c-9ff0-4b32-8724-e9389d107621"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a119fbc00c649cd9b0a5f71bb9c51c3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMwLTI0LTEtMS01NzcxNw_7a2126a0-9fc0-46e2-8fa7-8cd286f43d66"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9de5a23fb8f43d08be01ea9f3270bb5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTItMS0xLTEyMTQw_4e594508-6c48-41c0-8f08-3e56ebbea66b"
      unitRef="usd">406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i860b9ef8d88648b2bd14fdb1a1c02780_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTQtMS0xLTEyMTQw_355212e2-62d7-4d12-b166-cf30b76a17e2"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb532a2686334aa5bead08d5c4f00b78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTYtMS0xLTEyMTQw_f720911f-c6e0-4391-bfaa-7dec4182e4cb"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic037528273e74f499033a150e619b4ff_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTgtMS0xLTEyMTQw_1dda6a76-b5d7-4632-b8f7-0f2732f3a257"
      unitRef="usd">695000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f699c45319641abb957b330b47c6d1f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTEwLTEtMS0xMjE0MA_b4eb91c8-4bb4-4805-b75e-d1c43cc6191a"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ff2ab162b88421d9ba989dd81c8eca5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTEyLTEtMS0xMjE0MA_9aa381db-8dff-4634-8911-6ce113c99380"
      unitRef="usd">191000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if208e11d45a94784a19929ca1f05b974_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTE0LTEtMS0xMjE0MA_d6455f80-03e6-405f-a8a5-6cc6710c7574"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic808e56b4fb14e02a5bc2f7449a1a9b4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTE2LTEtMS0xMjE0MA_e4f6517b-ae75-4eed-8e38-e84b50bce7c9"
      unitRef="usd">563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idba5b8558d6d4ff38879057fdcd4aea5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTE4LTEtMS0xMjE0MA_7f5abc17-e01b-458d-80d2-8e8f88601016"
      unitRef="usd">373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8de715ffb064281b509585e98cc69f2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTIwLTEtMS0xMjE0MA_4029416e-34bd-4c89-b9ac-bcc601838a71"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92935c1825d54cbd8511cdb6abcb6c47_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTIyLTEtMS0xMjE0MA_2198b03f-0206-4725-a9be-a8198bb521f0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3529227ebc7e4c039ce5ffffb338ca93_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI0LTI0LTEtMS0xMjE0MA_977e385f-724a-4c73-bb51-e915f6dd0393"
      unitRef="usd">456000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ea72c97e32144938bb26b805ed4c89b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTItMS0xLTEyMTQw_fa93e195-8786-4bb2-87cb-94ded7177937"
      unitRef="usd">542000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i213cbdd848e94530b0d92ccdf1a75dfa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTQtMS0xLTEyMTQw_e37d3ae1-5b10-4339-80b4-95405d3864d3"
      unitRef="usd">293000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5056823e9ae347a2933637a7bbe6b448_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTYtMS0xLTEyMTQw_241ee0d4-68d7-4050-8156-78ff4809f727"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b4696f53ab1428d8c9d1112eeaa551e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTgtMS0xLTEyMTQw_104fda3d-994a-4270-9fde-56799f2cf835"
      unitRef="usd">871000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2c27d0f7d2c45fb98bdefdbb85bae75_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTEwLTEtMS0xMjE0MA_f61b9257-4583-4fb3-8f0a-b83dec250634"
      unitRef="usd">396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ceb977bf93a41088454e4c206235415_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTEyLTEtMS0xMjE0MA_38a7b9f1-82c4-4442-8a23-055f2c188cb3"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ee0f595be264b08b8f9806028bf9b51_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTE0LTEtMS0xMjE0MA_b684ad34-2080-4f7b-82b5-73bc29d28a58"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie09f0fd7313646458071d017d8175cb8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTE2LTEtMS0xMjE0MA_6d129da6-ef3e-45cc-b141-a4f7ad43d26e"
      unitRef="usd">607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab8836d9a4ce4fc5ba393c942ed97e61_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTE4LTEtMS0xMjE0MA_6ca22f52-d7ec-45ab-a240-e5f7b62fa282"
      unitRef="usd">373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaae822cf2d924f3ea765b050bbaa39b3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTIwLTEtMS0xMjE0MA_01c0b877-deee-4024-aa61-3f8c1ae603fe"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i336854a9631445dfa14f917b4c21eb5e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTIyLTEtMS0xMjE0MA_abfbc839-15e5-4448-9629-2b123f5c15f6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a0b5eb4e390464fb3247a2dcdbaebac_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI2LTI0LTEtMS0xMjE0MA_a8f2bc18-bc17-4831-87e8-60b5ca6ded20"
      unitRef="usd">456000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e00b704a1f44803ada987adac8e13c0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTItMS0xLTEyMTQw_51f060a1-9e58-4004-8149-2b44d29741e7"
      unitRef="usd">370000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i293b3b4563e14edfbe7fc51df8a013bf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTQtMS0xLTEyMTQw_34e1b100-2c2b-4449-b09d-fe3e184661c8"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7df84051b024c53a6a840e6cdfb14a4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTYtMS0xLTEyMTQw_484665c7-80d5-4009-933a-4a864c93936b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i961b952327124924a5e23eb37b9e7069_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTgtMS0xLTEyMTQw_ea587ccc-002d-4aa8-a483-e85c53d85e9d"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i137abd7ca81b458e88261321792ec71b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTEwLTEtMS0xMjE0MA_8f4f47a8-8d58-4f27-bc42-09672aa693ba"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i781c570cd3034947a327d3ee47e152fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTEyLTEtMS0xMjE0MA_8d11b4c6-8af4-4af9-bb3e-c1d5f460a923"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f704090e060470bae3918d46cb8a9c8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTE0LTEtMS0xMjE0MA_f92152da-d922-4418-a3e1-17e0a3fffc2d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a218e9a42374b4db9008f33b6126318_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTE2LTEtMS0xMjE0MA_186135ab-b79f-4425-8fda-70600a9a905b"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e25b298d34d4c5cb36e6a52a778cd3a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTE4LTEtMS0xMjE0MA_dc9c0665-ed8c-4385-b280-fb39412b7805"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4403855d5dcd4d63b3eb5be25dbcfd64_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTIwLTEtMS0xMjE0MA_7d95b4ca-95c8-404e-ab17-05fc93c17808"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic35e32326f834884ac9a61bb0b8b479c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTIyLTEtMS0xMjE0MA_7dbf5d39-2564-4d6f-b3c9-1280ff4af20c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65db5049fdd3411fb63e909ef2ec8e5a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzI4LTI0LTEtMS0xMjE0MA_4a4b704a-754a-42c8-b363-9c8c9c3ea1ee"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3938c584a5744b148070f5afb631ce36_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTItMS0xLTEyMTQw_6eb6a568-5e42-4d83-8363-4946df944fbf"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i713866d6cf0e4d8fb0f713df57c870bb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTQtMS0xLTEyMTQw_d8582bde-2844-46e4-a03d-70126c9b9fa2"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i681e654b253346a9b076a1bf6a0ca271_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTYtMS0xLTEyMTQw_65e2a30a-b8b9-410d-ac87-e101240835ec"
      unitRef="usd">227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a0f560cfb9a4aa2802a62ac6becbf6a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTgtMS0xLTEyMTQw_be6ce6d5-a919-4dcd-ba48-d43538464d53"
      unitRef="usd">540000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i090096a8205c4fea847fc56558d9886b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTEwLTEtMS0xMjE0MA_e628afd3-1c78-448c-b1a9-f1b0a75ceca5"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9722c0087b814ddfb113130f0e25579a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTEyLTEtMS0xMjE0MA_643b8b87-ef39-4569-9ef8-f14fe016c957"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9900dfcf355e4c32bcfd2373bce186dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTE0LTEtMS0xMjE0MA_22a31864-3672-4eb8-8223-3bd141f31082"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie52246df773043eaa8b85b321512c538_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTE2LTEtMS0xMjE0MA_84cc44c3-2fba-4e5f-b454-2a943b510194"
      unitRef="usd">436000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3622a78565bc4859927f6689c3c01aa0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTE4LTEtMS0xMjE0MA_3498c658-0c30-4911-8580-ecc5d7b11992"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92c7202f262d495b8e4e4a2f24623eba_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTIwLTEtMS0xMjE0MA_05d55bb9-d302-454a-b3fd-b7df08726526"
      unitRef="usd">234000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6c9456ecdfe444ea9be0065da372c97_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTIyLTEtMS0xMjE0MA_bc0618e4-e69f-4dec-84d3-d7baaa662950"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e0d01fa66074181a48c9de2389193a3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMxLTI0LTEtMS0xMjE0MA_8d055ca2-f071-4214-b8ea-eaa80434bf57"
      unitRef="usd">407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib586d74aa0da4b4185dfddf3ded39f03_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTItMS0xLTEyMTQw_82df890c-21f4-4d2b-8c06-16da33515257"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia794817e23b245eea3847eac57b7d78b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTQtMS0xLTEyMTQw_fcf02c20-454e-4d1f-b2e6-4893a01a0bdc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if987c46515874fb6a72a3a47e8e1d347_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTYtMS0xLTEyMTQw_cfc6c513-3c3e-43f2-acb2-a0cc499fd60c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28e77e92b5ac4b18b7764f67456f114d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTgtMS0xLTEyMTQw_b925eb58-8e10-455a-8693-15433a5180ff"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21fe0e0298e4466c9ea8fc6c07e67b92_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTEwLTEtMS0xMjE0MA_71916091-af33-4c1c-8bb3-f05b8cc1014d"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7269f1f07c444f62b04e9950f4fb49eb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTEyLTEtMS0xMjE0MA_2d38fd4c-8a45-49fb-b00b-27e368b104d7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1134f6515efc48459a0f5a14aacf594e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTE0LTEtMS0xMjE0MA_d06798e8-b2e6-4d1d-bff2-7bbc65506199"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02940b7802cf4f7d9c2b6a7f03527332_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTE2LTEtMS0xMjE0MA_58e2e1f7-ab0a-44dc-b87d-ebc0398fb229"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5221e66f2614f1ebe73bce91d2dfe18_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTE4LTEtMS0xMjE0MA_ef91357a-1712-4681-9c3c-710dbfb5eb9e"
      unitRef="usd">618000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaac9cbee0c234416b4f8bf6424c7f023_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTIwLTEtMS0xMjE0MA_4f4131a9-3c28-48fe-8fe2-05e1cd6d0c2b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32f4fa85bcfe4c6183ce30b8e5b62370_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTIyLTEtMS0xMjE0MA_07846b46-6b70-431d-bd84-a2b13c582841"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4aea019cc63f4da6bd0e2026516da88a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMyLTI0LTEtMS0xMjE0MA_068d0213-e2dd-46bb-9bad-2ca5cbbd5d2d"
      unitRef="usd">618000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i833b13271d42409cbfe54ea29a5832d9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTItMS0xLTEyMTQw_bac1cc8b-8b4c-4eab-979e-ee536637e768"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43cf8de658eb444fb180c5e973190ced_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTQtMS0xLTEyMTQw_2fb0fedb-59ef-4bf5-94f3-41abac710986"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e2e3bf847e34446b91d9e3adb7b393a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTYtMS0xLTEyMTQw_dfe9aa1b-f7b4-4151-aed3-50beaf828df3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i206db45c6dbf4ada8039f50d374ad057_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTgtMS0xLTEyMTQw_bd1779cd-d808-4e52-a419-d222a1d7ff67"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2747de847a5a4b9abe5da80ee4f4328b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTEwLTEtMS0xMjE0MA_0a20e662-5d2c-43df-a9f5-11baf72c8fad"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c35b4c8bdc540088472e6d5f39ad3af_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTEyLTEtMS0xMjE0MA_1e907704-404d-40bb-b8fe-66204f75e4e6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f8f38eb4cc941558bac08a5c690e998_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTE0LTEtMS0xMjE0MA_04206771-da3f-49e2-8c8d-173e8994f1cd"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2dcff95b8dbf48c6be5de5c404ab2dc8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTE2LTEtMS0xMjE0MA_c37f6877-7cf2-49b9-bd2c-9816aee5b45a"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icec3ad77c73243afafa557c15ec72da5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTE4LTEtMS0xMjE0MA_891d8675-c3ac-4f4c-8bdb-d274b685ae19"
      unitRef="usd">216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3eb32f54a11425b833021836e9f39f0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTIwLTEtMS0xMjE0MA_b4ff1390-80dd-4b62-8046-70ceb19e9128"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id01f488874b24cf494dc9072dca62c34_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTIyLTEtMS0xMjE0MA_cc3e2ebd-f4e5-4ab3-bb6f-d59ec7cfca21"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d9115ac2882474086a95ff0a92a7499_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzMzLTI0LTEtMS0xMjE0MA_a983d1dc-de6b-4546-813f-47a05474fed0"
      unitRef="usd">216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ba2a5b00213403bba9525748da240d8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTItMS0xLTEyMTQw_311e80ad-53d5-4401-a069-9f1f5480a6ac"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d9039b4162443b796b32d897293cede_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTQtMS0xLTEyMTQw_800ebdb4-f63f-4644-a520-d547881871fd"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7f0bdd9cdd64dc9b7e998b0c6c0cae5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTYtMS0xLTEyMTQw_2a6c9ec1-ccfd-4e66-8fc8-ef92528980e3"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id619cc15e212429087aad1c7c9680827_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTgtMS0xLTEyMTQw_bc049652-974f-4f62-86be-33a5eb4c9232"
      unitRef="usd">62000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74a1f18b294146738afbce7fb84f04c5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTEwLTEtMS0xMjE0MA_2fb74c75-34f1-4028-9b3f-38718f3d4cc5"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cde46ee36a2466ea21eb5d4fc29b9e0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTEyLTEtMS0xMjE0MA_a7cb4355-0176-4cff-ba6c-d05132b4ad2e"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f7a8cfea5e24a51b71987e1407913e6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTE0LTEtMS0xMjE0MA_a879f36b-5b45-4e90-bac0-514c181a7f13"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47da50f7e1714e2581271c261dcae57b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTE2LTEtMS0xMjE0MA_c0452bd3-73e4-49cc-a975-0eef75c9564c"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14e531dc995d488b890a3208e0543ede_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTE4LTEtMS0xMjE0MA_79142bfc-fe26-4989-b12e-9576150f9101"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66a0c129f84b440988cf1c09361bf9a8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTIwLTEtMS0xMjE0MA_dbf6c590-c1df-40db-8fb3-6ea6910480aa"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8aec4ea6992b43ce82e0f558dfd36b00_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTIyLTEtMS0xMjE0MA_7b6157e9-8146-42ca-87f8-3b191cad8b96"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d020553073843e5b6b7936014d32d7e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM2LTI0LTEtMS0xMjE0MA_fff59d24-0a37-4b82-b3e8-fe185acd2c31"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bdf71c266dd49129cd99f86795f30f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTItMS0xLTEyMTQw_de993d4e-36f1-447b-b151-649470dbd490"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedff3b1944b64c3f8541ba18488844a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTQtMS0xLTEyMTQw_e4eccf55-2d93-4bd8-857e-3bd426d21def"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cae6eb7eace4771bc5b03cb7d5d7c3e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTYtMS0xLTEyMTQw_5b9eb143-9a54-470c-acfa-9aa85230b5fc"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieefadac07e0742a9bcc209927edca502_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTgtMS0xLTEyMTQw_3aa85882-bbc5-465d-b6ca-06a9a2693bea"
      unitRef="usd">209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i805cfc944d9648f5ab99fe13e0bd400c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTEwLTEtMS0xMjE0MA_58218693-a362-4a7d-9dad-22462a4020fb"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9340b12589ed4cf8870255d67072e0b2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTEyLTEtMS0xMjE0MA_d7c16ab4-cc07-4bf7-a15b-b4348ab70d0b"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if302e604d9c647f2aa117693d6731a70_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTE0LTEtMS0xMjE0MA_52b2628f-2eb7-475c-ada8-c33e3d0582fa"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05f28249859146e18cebb4ada570cbe3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTE2LTEtMS0xMjE0MA_a20a6728-9bf4-4264-bc42-6090d06164f9"
      unitRef="usd">195000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i269a61a8cdb949e899eeb283218bebe3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTE4LTEtMS0xMjE0MA_e3eaf039-89ef-4ccd-8b34-2c8dd8b7aa9b"
      unitRef="usd">151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ec1ab3dfa64442192f0b94587b08674_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTIwLTEtMS0xMjE0MA_daa816e6-341c-48ef-8548-e03881656e77"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9783ccaee044c3192afdd2303af4975_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTIyLTEtMS0xMjE0MA_dd41f29e-8aa5-4a8d-8120-fad14dbb1e46"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8bb901328ad48a18b0d7ffb9e41d685_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM3LTI0LTEtMS0xMjE0MA_8333e99a-88dc-45d0-bd56-4fb6d150ab97"
      unitRef="usd">203000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i080a4966175c497dae95d90a6ab9979c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTItMS0xLTEyMTQw_ba167c80-8f7c-40f8-be95-0561a61c8e80"
      unitRef="usd">381000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb880ef93270463586306266d0d1d82d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTQtMS0xLTEyMTQw_aea1e8db-7085-42a5-a810-769a8333aceb"
      unitRef="usd">389000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2dd188229a764f009b5c46cdd0daab4e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTYtMS0xLTEyMTQw_4fa80abd-e977-48e1-a90b-c398240e7d85"
      unitRef="usd">257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iade7fb25dc3444df929d6b582363121b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTgtMS0xLTEyMTQw_75fa4209-7fe0-4205-be93-8753d8f75a68"
      unitRef="usd">1027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3c8b2e16b7a4af0bfd9779c4e42717f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTEwLTEtMS0xMjE0MA_4ed65857-8a19-4759-adab-1885defd846f"
      unitRef="usd">551000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97a22b0fa2914e7a8689aaa9bb993522_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTEyLTEtMS0xMjE0MA_831c9791-5504-4338-acc0-e7fa590e7c74"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b2f4b1ba3c24bcc9400a0bac9f2f5d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTE0LTEtMS0xMjE0MA_0d617541-48f2-4d4b-826f-f490fa3dc367"
      unitRef="usd">161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec069c130bc64661af4695041ea3fcc3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTE2LTEtMS0xMjE0MA_1125560f-210d-47f6-9fdc-7fe3cbfe4a23"
      unitRef="usd">1026000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf64712f0538422da3dddc8951a5c75a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTE4LTEtMS0xMjE0MA_f48a2ae4-afd6-4b78-9496-df20f7a9921f"
      unitRef="usd">1069000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9206ff4ea2634a9b8710d3da4ab817eb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTIwLTEtMS0xMjE0MA_9f94a6d6-bba0-4504-a6d9-f9a8ccadc7cb"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ac613e5c50a4f4685f5d72248c51ab0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTIyLTEtMS0xMjE0MA_574e3fee-e1c4-4ed9-ad4e-55f08c180429"
      unitRef="usd">147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b40444516934410acd5af26d4cc9cfa_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM4LTI0LTEtMS0xMjE0MA_173b13bc-dd1b-470d-9071-ecfd2dd93908"
      unitRef="usd">1547000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4de92c1c900c41d58eaceb16cae8dab2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTItMS0xLTEyMTQw_07a09bce-83ca-416e-b41d-e00be90dca2b"
      unitRef="usd">19176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84f7c42de6914a59a2ad2c63f6e1730b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTQtMS0xLTEyMTQw_41835e3d-4691-4de3-b69f-658147ce1158"
      unitRef="usd">4678000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d6e05e9b75b4907bf54d729d73cccd2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTYtMS0xLTEyMTQw_d1200f5e-6d63-456f-9ff3-3381d4dc40df"
      unitRef="usd">3154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4befd4212fc4248a63e9b436b533760_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTgtMS0xLTEyMTQw_cad0dac5-5c3c-4129-a396-8b4fae5012e0"
      unitRef="usd">27008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a662c83a2aa4f978862cdbb062bd8a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTEwLTEtMS0xMjE0MA_e7f99a3a-2e43-4bf5-9bf3-f30b93cd3bca"
      unitRef="usd">18141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a71363ffee44c8e958961f85ef4e870_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTEyLTEtMS0xMjE0MA_692959f1-bbb6-4301-9582-177801087158"
      unitRef="usd">3894000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id771bf711f3a4abf927510c6700ba371_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTE0LTEtMS0xMjE0MA_3369645d-6797-42b0-b77a-18c43a68559e"
      unitRef="usd">2320000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c51a506a019465dba53c1f088a945dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTE2LTEtMS0xMjE0MA_96f1c4dd-e94b-49c3-bb01-85fbe5085aec"
      unitRef="usd">24355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4949a1736044f93b646e6613b1043f2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTE4LTEtMS0xMjE0MA_9304d9c4-df2c-4133-a519-701af67d3679"
      unitRef="usd">16565000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8462cf492cfc495cb1b6159e93665280_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTIwLTEtMS0xMjE0MA_10aa1aa8-2388-4447-bea1-35751c35b10c"
      unitRef="usd">3567000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i468ec8b3e2f040d686ff31e4dc41d689_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTIyLTEtMS0xMjE0MA_2761ec5c-e16e-413b-ac2e-4883e5ead56c"
      unitRef="usd">1987000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i203243bdd8194063a5b0d20127c91ead_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzM5LTI0LTEtMS0xMjE0MA_9c4d183f-1d69-4df4-90dc-882f34ec31c1"
      unitRef="usd">22119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07489b4d42474f138fdfd6dfb3286ac4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTItMS0xLTEyMTQw_13239edc-7d60-4030-b308-b8c85a451579"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02d6184cd0bd4777bb8666956ef185f3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTQtMS0xLTEyMTQw_e68e61eb-f7ed-41a1-985b-63a770877f2f"
      unitRef="usd">196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb89a05869c84c4f8583d492d2024255_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTYtMS0xLTEyMTQw_516d751b-7c54-4327-b073-338e5c7cccc4"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1aad07ceecdc471a9ee9d0a50de54618_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTgtMS0xLTEyMTQw_ab9e487c-89ca-4c83-b351-7a22dbc3d6a0"
      unitRef="usd">297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ffea525fc61463397a9083c8c20ffd7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTEwLTEtMS0xMjE0MA_0cf5c565-8ce5-4d71-bc75-cb6daebc8d61"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc50225e8b064effa4994483dcb578e7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTEyLTEtMS0xMjE0MA_5f8db6b9-3274-4374-8896-8bb86bb1197f"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2623fb937a24938b56dcd468a751f90_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTE0LTEtMS0xMjE0MA_39eb346b-5b72-417e-ba7f-c0afb2173c9e"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c80ef090990421ba4cb204bcc7a4aed_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTE2LTEtMS0xMjE0MA_c6187629-5027-4298-a616-cb177977a3bd"
      unitRef="usd">334000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18a31f47fe134b108ed30bbed48a5c3f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTE4LTEtMS0xMjE0MA_66ec8beb-1e8f-4a2a-9558-abce5bd7997e"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8db6ad4693a9411eaacfd1efa9b38245_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTIwLTEtMS0xMjE0MA_0c71bff3-c602-4125-b31f-a414f451e813"
      unitRef="usd">244000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i307ad909b7ac4a7bad744035b5fdb3ee_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTIyLTEtMS0xMjE0MA_91d25fef-f154-4b97-adc3-473b55b98bd6"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2f35d93745f44ac84aacec6dc9540d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQwLTI0LTEtMS0xMjE0MA_19501dc7-7940-473f-8624-40734d6da50f"
      unitRef="usd">330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc40e9061b2e4d7e8c573dcda94bbc8e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTItMS0xLTEyMTQw_35c27446-16de-4e98-a8a2-01e92b8fb002"
      unitRef="usd">19267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63e77ce4e9354eee9898d81ad4e106f6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTQtMS0xLTEyMTQw_06112e8f-0055-4ee4-ab30-488ab44912d5"
      unitRef="usd">4874000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i466b9478bbef4388a85e27c598939910_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTYtMS0xLTEyMTQw_5db17c9d-3639-4462-b944-6b1bcb3fca2d"
      unitRef="usd">3164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTgtMS0xLTEyMTQw_29940594-d43d-4302-801b-6b4f74f08757"
      unitRef="usd">27305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cbf3bc1bc41429b801a094750174f13_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTEwLTEtMS0xMjE0MA_4b190bf7-2752-4411-b461-4992bbaebdd5"
      unitRef="usd">18217000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb99587d2f584abeadc910467e333c6f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTEyLTEtMS0xMjE0MA_766f1d3d-cb55-40a3-b0f1-c8ba2e86ef80"
      unitRef="usd">4135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c2eab591b3243489738a3ce929a3f56_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTE0LTEtMS0xMjE0MA_b9fdd58c-e2be-4f4e-9466-8eaaec28319c"
      unitRef="usd">2337000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTE2LTEtMS0xMjE0MA_7bbb4e29-bcfe-46c9-9ce4-15538cb717c8"
      unitRef="usd">24689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad5223de57dd4696a199e9db73eaadcc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTE4LTEtMS0xMjE0MA_7f63b8e3-b613-4bb1-a3b2-aac03983b31d"
      unitRef="usd">16645000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5015e8cece1d484b8333c5dc5371eb78_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTIwLTEtMS0xMjE0MA_54f4c096-cf6d-47ce-b49e-c2f963e9e92e"
      unitRef="usd">3811000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63ff77f687774eab827d133749a17db9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTIyLTEtMS0xMjE0MA_efd49aca-7680-4288-bbaf-758cfe935d1e"
      unitRef="usd">1993000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo2NDE4ZjFiNWI4ZTQ0YWE4YWVlZjExZTI5NGZjNDAzOC90YWJsZXJhbmdlOjY0MThmMWI1YjhlNDRhYThhZWVmMTFlMjk0ZmM0MDM4XzQxLTI0LTEtMS0xMjE0MA_5f45695c-42e9-487a-a6de-62a985b8c362"
      unitRef="usd">22449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzIzMzY_4602502d-643c-4f01-9e6b-121456f1ff4f">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id462101bfca04327af64a9543c8a833b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzItMi0xLTEtMTIxNDA_727442ce-e201-493d-9906-d800ad08def1"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic6af6e3232dc45a196b190b37e6c1439_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzItNC0xLTEtMTIxNDA_4896ae68-af75-467a-8db8-c49307f12ee7"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9d6c7b10944a4914acc093ef93f55e30_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzItNi0xLTEtMTIxNDA_c31c09ab-b97f-410e-8adf-30d3d644efd6"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idb1faac3f7f34f6cbdca10553062dea9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzMtMi0xLTEtMTIxNDA_794db2b2-00c3-4746-bc25-64636f4c9e70"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9b21d294f3d14aaa889eb58f573882e6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzMtNC0xLTEtMTIxNDA_76d2bfb6-7e9d-4e4f-b500-c764cf65833b"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i19d534eb0c65483390415a8fdd2e4915_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzMtNi0xLTEtMTIxNDA_fc79f9b4-d330-4cc1-9d2f-2a6a8ae5165e"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4ae8dc2f110f40cfbd42e80f081e08d8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzQtMi0xLTEtMTIxNDA_d8cb6d1d-f409-445f-8b20-14a6e8a8a6e5"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i912278219236443aa0a53f2ed6c5335c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzQtNC0xLTEtMTIxNDA_bf8d3b2b-ba3a-4398-87fb-630844d05aa2"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if7a8bfac32dd43bdadd46b2b5c450cf9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90YWJsZTo1NGE4NWU3YWM1OWY0NDA1OThhNTJlOTBmNmNkMjg4Mi90YWJsZXJhbmdlOjU0YTg1ZTdhYzU5ZjQ0MDU5OGE1MmU5MGY2Y2QyODgyXzQtNi0xLTEtMTIxNDA_33258f61-dac1-45ab-8935-36b07353b944"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzEwOTk1MTE2MzE3NzE_c3ef10ef-775f-4f87-b5b7-283b60e494ed"
      unitRef="usd">851000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzEwOTk1MTE2MzE3Nzg_364b3161-aea6-42fb-8e4f-bae41eff0e6c"
      unitRef="usd">841000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzkzNDU4NDg4NDM1MzY_9be329ba-8014-4dcd-8217-5aa6ff81b21b"
      unitRef="usd">741000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzkzNDU4NDg4NDM0OTg_c5132e52-e8a9-4c8f-9fa4-d43e28b27205"
      unitRef="usd">856000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzkzNDU4NDg4NDM1MTI_d083e9e1-a3f1-4adb-a8cc-76033dbe5d92"
      unitRef="usd">101000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzkzNDU4NDg4NDM1NzI_b5d7cf5f-a289-400c-8a7b-e5a2698481b4"
      unitRef="usd">257000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzE4OTk_89dc9fc9-5b44-4806-96b6-c0376844debb"
      unitRef="usd">174000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDAvZnJhZzplODZiYzRkMWQwODI0ZjAwYjM1MTgwMTE0MmI0ZGFmYS90ZXh0cmVnaW9uOmU4NmJjNGQxZDA4MjRmMDBiMzUxODAxMTQyYjRkYWZhXzE5MDY_10a50ea4-36bf-43a8-b763-04d262d643dc"
      unitRef="usd">198000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzY4MjU_a0473cfb-2dee-408f-bd1c-b36dfdbf8bed">FAIR VALUE MEASUREMENTS &lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 inputs include quoted prices in active markets for identical assets or liabilities; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities, and foreign currency exchange contracts are reported at their respective fair values on our Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Consolidated Balance Sheets. The remaining financial instruments are reported on our Consolidated Balance Sheets at amounts that approximate current fair values. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Arcus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for MYR GmbH (&#x201c;MYR&#x201d;) contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;See Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of equity securities resulted in net unrealized losses of $610 million and $1.7 billion and net unrealized gains of $1.2 billion for the years ended December&#160;31, 2021, 2020 and 2019 respectively, which were included in Other income (expense), net, on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments and other equity investments without readily determinable fair values were $338 million and $262 million as of December&#160;31, 2021 and 2020, respectively, and were excluded from the above tables. These amounts were included in Other long-term assets on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related Party Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021, we donated certain equity securities at fair value to the Gilead Foundation, a California nonprofit organization (the &#x201c;Foundation&#x201d;). The Foundation is a related party as certain officers of the company also serve as directors of the Foundation. The donation expense of $212&#160;million was recorded within Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair values of Level 2 investments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;amp;P Global Ratings, Moody&#x2019;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates (&#x201c;LIBOR&#x201d;) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated fair values of our aggregate short-term and long-term debt, determined using Level 2 inputs based on their quoted market values, were approximately $28.6 billion and $34.6 billion as of December&#160;31, 2021 and 2020, respectively, and the carrying values were $25.6 billion and $30.3 billion as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our first quarter 2021 acquisition of MYR, we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis, except for the liability for contingent consideration. The estimated fair value of the liability for contingent consideration was $341 million and $317&#160;million as of the acquisition date and December&#160;31, 2021, respectively. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of Hepcludex. See Note 6. Acquisitions for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#x201c;Immunomedics&#x201d;), we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis. The liability assumed related to the sale of future royalties is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to the sale of future royalties were $1.3 billion and $1.1 billion as of December&#160;31, 2021 and 2020, respectively, and the carrying value was $1.1 billion as of December&#160;31, 2021 and 2020. See Note 6. Acquisitions and Note 12. Debt and Credit Facilities for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, in connection with collaborations and other equity arrangements we entered into with Pionyr Immunotherapeutics Inc. (&#x201c;Pionyr&#x201d;) and Tizona Therapeutics, Inc. (&#x201c;Tizona&#x201d;), we also measured fair values of our exclusive options to acquire the remaining outstanding capital stock of Pionyr and Tizona on a nonrecurring basis. See Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we measured IPR&amp;amp;D intangible assets acquired in connection with the acquisition of Kite Pharma, Inc. (&#x201c;Kite&#x201d;) at fair value on a nonrecurring basis, and recognized a pre-tax impairment charge of $800 million. The fair values of the acquired IPR&amp;amp;D assets are estimated based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements, and inputs include estimated revenues, costs, probability of technical and regulatory success and discount rates. Amounts capitalized as IPR&amp;amp;D are subject to impairment testing until the completion or abandonment of the associated R&amp;amp;D efforts. See Note 9. Goodwill and Intangible Assets for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our policy is to recognize transfers into or out of Level 3 classification as of the actual date of the event or change in circumstances that caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzY4Mzg_b46f93ac-c768-4650-bfaa-d958189101ac">&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Arcus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for MYR GmbH (&#x201c;MYR&#x201d;) contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;See Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6d8ec0117d844149bf15fb93a66a98b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtMi0xLTEtMTIxNDA_c462e630-a1a8-4312-b95d-a84e01d5227d"
      unitRef="usd">407000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ife19703a21e24deda943371d11289462_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtNC0xLTEtMTIxNDA_75dea9c1-089b-412f-bbaf-2c7f7b23b99e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia0fc481856f34a4dbd84bccfc4f900e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtNi0xLTEtMTIxNDA_fba17926-2576-4b49-86d4-f017b0f013c0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6c0246e87d7d4539b64d5bc5c091b3df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtOC0xLTEtMTIxNDA_ea0a687d-197d-4fb8-91fa-2e80e41d0a32"
      unitRef="usd">407000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="idbc5fc480e4b4729b2803202c43ada08_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtMTAtMS0xLTEyMTQw_85a20025-694a-430b-a480-318723da65aa"
      unitRef="usd">309000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2286a95065594d6d9ca4944ff53d5394_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtMTItMS0xLTEyMTQw_64056525-829c-4b04-a402-bfbf68805527"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib0b2d20da4bd4cfbbc5ac7bff1a5b643_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtMTQtMS0xLTEyMTQw_f8e9e592-78ff-4c3e-a959-95d1c4148f1f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1e69d167f82a4883925ec64ac6b590dc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzQtMTYtMS0xLTEyMTQw_ad8a9213-ed6b-4e40-be54-c9806f485a40"
      unitRef="usd">309000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iaf113888c5464692b6ffbe8e4a732bae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMi0xLTEtNjE5MTM_c6835d15-633b-4b52-b4d6-bd1a014c5fef"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if58ceba457fa41819c0289f982ba7126_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtNC0xLTEtNjE5MTM_5130652d-b070-4500-82e8-9b064b44289d"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia353233b00564c41a4d9cd25abd93e70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtNi0xLTEtNjE5MTM_34fce3ad-dc98-44f1-9289-c7fd361ac1ea"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6cb417101fed43a7b4ac1d574f6f9524_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtOC0xLTEtNjE5MTM_35978ed1-4aba-408e-a59b-81c01b084b6b"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i195c8db92c30457c89e804d5f743ea65_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTAtMS0xLTYxOTEz_414caf8b-3611-4e78-97e7-c078fc2e9b17"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i23b07529177a4ad8898665bf99bb8bd4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTItMS0xLTYxOTEz_b3ad8f04-c344-4122-a4ee-c98bfe87cdce"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic4694f2b970149499d768396c277556c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTQtMS0xLTYxOTEz_3aedac9d-a55d-4d7e-b051-2359741bd240"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id7fd02cc204a4fcca4854f1cc54fdc75_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTYtMS0xLTYxOTEz_aada49a9-a1bc-4676-aafa-b4244463078e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ifa9c593efcab48c292fef975883cb901_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtMi0xLTEtNjE5MTM_8670737d-a491-41c5-a6d5-ad482f0063cc"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie4f01b9dc465412898be06b78bed526e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtNC0xLTEtNjE5MTM_eb64f42f-1015-4240-8fd7-a4b1ef83f091"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i26d0f95467284563a2793f3b45d55692_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtNi0xLTEtNjE5MTM_96394f54-3e86-4cf0-a41d-344cec88609d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if92ffa56cee1465981e8289446960059_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtOC0xLTEtNjE5MTM_e7e494c8-f6cf-4474-8fab-2a29a2fe1114"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i25ec023f9542416ab812e9b107619ed7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtMTAtMS0xLTYxOTEz_4ae885da-da8b-4c6e-a388-2c3bd70a071a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iec65128416ed4c2caa95ff502b873f17_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtMTItMS0xLTYxOTEz_7947b83c-5d25-4506-9382-9a2c75b7b6c4"
      unitRef="usd">43000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic00702509b5b435495cf0ec01ce3bab9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtMTQtMS0xLTYxOTEz_f41d0933-aac8-445f-81da-9938250c8e76"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ifad92d842d244ddd8c185fba7ec11571_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzYtMTYtMS0xLTYxOTEz_e4083589-6951-4128-bede-f8483ce27e6f"
      unitRef="usd">43000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iaf683e991aa04e84b6b581929bc8a52d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMi0xLTEtMTIxNDA_bd203c20-b429-4f95-a2a0-4fdd612fc70c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i678f3e8e9c0c4393bd7bbbd1dbc823bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtNC0xLTEtMTIxNDA_26b79394-00fa-4235-856b-79df3c19a421"
      unitRef="usd">249000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i17fc0330f5ae4c9aaf6ebfc057402b0e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtNi0xLTEtMTIxNDA_51778c71-bc3e-4a69-9a13-b138e62f4c1b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i03cf8ed895c84bf6a0b0a590b3791db3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtOC0xLTEtMTIxNDA_2a279b53-8bc9-4ed8-9680-fb1e070cd983"
      unitRef="usd">249000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id2c6eb6568ed498290563719477a6d6c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTAtMS0xLTEyMTQw_60899bbb-ea59-425c-b679-8f0aef136d97"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="icf0d3c79ea2c4c72810e8c002a5c14b1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTItMS0xLTEyMTQw_ba5f9d35-94c6-4f4b-bc67-9f0c55c995f7"
      unitRef="usd">216000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ide6b42f3b50c40e7a356f40b566dd53a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTQtMS0xLTEyMTQw_d01c8d77-5588-4db5-a3cc-acfa1756d168"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i35bf4c1622964f4ba66d71293935d060_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzUtMTYtMS0xLTEyMTQw_c27787ab-4668-4411-9735-8a3944e72d57"
      unitRef="usd">216000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i946749b11bdc47e88afcab1bddcdef12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtMi0xLTEtMTIxNDA_db736c3b-e588-48ce-8869-94eb6a22fa71"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3e50b420b9d24798a8608dae51733253_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtNC0xLTEtMTIxNDA_93f161fe-add1-4759-83bd-6f4379ce99bc"
      unitRef="usd">1363000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ieb796c40fa2149c29dbc27aa4bb85775_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtNi0xLTEtMTIxNDA_a90414e7-d56d-4bb8-a06b-a8ddfd4a8c1c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i63935bd985224f0189d1730574c0313e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtOC0xLTEtMTIxNDA_7e8af749-2434-44bb-9b11-ce94f99c75f4"
      unitRef="usd">1363000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id37ad7d3e58949e28ec38d38ed20873a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtMTAtMS0xLTEyMTQw_7e2cead2-bb5b-4145-9cbc-317868fa5673"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1ca1fc3df69c4ea6a527e5aadbaed99e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtMTItMS0xLTEyMTQw_f74617e5-4d2d-40a1-9c7d-064ad071cccd"
      unitRef="usd">1142000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i314b3d48689b48a78390fdb9120b06f2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtMTQtMS0xLTEyMTQw_abb4432c-8f2f-459e-ada2-27fcc6c294dd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3331ea5fd3984313b34746715ba4ae93_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzgtMTYtMS0xLTEyMTQw_50b4bc04-0674-4d81-9d45-57baa08effdf"
      unitRef="usd">1142000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i25dc7b22e3f541188c657f4004692097_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktMi0xLTEtMTIxNDA_21ca8254-e6b1-444f-874f-2ec16349326d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2a8230e74cb644c5a3e520fc9a03f39e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktNC0xLTEtMTIxNDA_eef40c1a-fadc-43c7-b648-2c3c4dc57e36"
      unitRef="usd">424000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i152a4600edde4d04b65202787532de71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktNi0xLTEtMTIxNDA_319a987a-0586-4e56-89ae-08a3bafa973f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia5b6f43984b043f1838533b38d3e5e38_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktOC0xLTEtMTIxNDA_a1f48968-75f4-4f9f-aa15-844fcb3474bd"
      unitRef="usd">424000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i598fc7abce8f43bdaca52d6637a92fc4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktMTAtMS0xLTEyMTQw_a3cc7f93-cd2b-4f51-b56d-8dd6fb5bd66f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8d6d92e9d06d49fa842aa61301fede5d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktMTItMS0xLTEyMTQw_775c4fa9-9ab7-4a1e-8cca-1c178233058b"
      unitRef="usd">316000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i933d89b1d3e04e03901b0acbce724bc4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktMTQtMS0xLTEyMTQw_76843ad6-130d-4b15-aa1c-34e494eb7bb4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i35a96651d23b4cf0b0d1b40e9bd9a52b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzktMTYtMS0xLTEyMTQw_221b6b8e-c0a6-48d2-8007-1f15b2a44b39"
      unitRef="usd">316000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i856d25ed6103414d89dbd76e3f9e2cc5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTItMS0xLTYxOTMx_0bef4768-539e-4b72-accf-df2fa08b91c4"
      unitRef="usd">3661000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if793cdfa691a4047923ae5fbfa0651eb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTQtMS0xLTYxOTMx_55bca449-da03-4f8b-8224-b46bedf260f6"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia68f6c8a6e4b40be839701a8158a7994_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTYtMS0xLTYxOTMx_df5636ff-b3ef-462b-bdfe-77e2a28c9949"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id5d5ef90d851431ea311b8514b301646_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTgtMS0xLTYxOTMx_9dec8803-3412-4d96-92c5-a283c1888f2d"
      unitRef="usd">3661000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3c0099914e9b47e3b8c377d2d5605c48_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTEwLTEtMS02MTkzMQ_c9646773-8645-44cd-80d7-144929f3347d"
      unitRef="usd">4361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7be17b88e76541728d2d52bc5c2c9912_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTEyLTEtMS02MTkzMQ_214e1c22-7d4d-4b8c-8b08-b917bc183f7f"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9ba9f036d1c6491b8d70e0393484bd55_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTE0LTEtMS02MTkzMQ_5093a627-180c-4065-a107-4ec226e36aa7"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i31176ade8b484178bc6cd4473ef6e2aa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTE2LTEtMS02MTkzMQ_bde5a8aa-6e2e-4478-93b8-9d951b5f7792"
      unitRef="usd">4361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i67cdde391bee4e1aa62b4fe62d765eb8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTItMS0xLTEyMTQw_7217b031-4d22-4b3d-ba34-1356a4cc7fe6"
      unitRef="usd">931000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i319991ed67fc46fe879ccb7ee406b2bf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTQtMS0xLTEyMTQw_f1f618c1-566a-4d59-b6b3-100712460d72"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic7ec4799858746d28f2672bb3328c313_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTYtMS0xLTEyMTQw_061567c6-aad9-4fcf-9697-7038e9ff5c9d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie988bf37059d48c0bcc4ac229bbb92d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTgtMS0xLTEyMTQw_c9c1d850-ea09-40b2-98f3-7251944ff9c2"
      unitRef="usd">931000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic7858389cba8440abda830a77b3c5dd7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTEwLTEtMS0xMjE0MA_351621e4-cbc9-4156-9a6b-84481529d2cc"
      unitRef="usd">1648000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i96a6c459ee244343821c1e3c44035a12_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTEyLTEtMS0xMjE0MA_4a5e0941-4e9b-423d-838a-1f41d50a5f58"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5d056305515d420da7c42e745bb193c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTE0LTEtMS0xMjE0MA_4853bc36-8faa-4164-be70-fdd40f92d3fb"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9b510802aa0349f48dcb8a8e7cbf9a21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzExLTE2LTEtMS0xMjE0MA_fefd8991-b4a6-4fb2-aee3-fc4ef09ec619"
      unitRef="usd">1648000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i44c1b6d7dddb473ea3e00bef51b2e0f0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTItMS0xLTg5NzAx_ff0ffeb1-97db-42b6-a7ab-b6bf450aaf50"
      unitRef="usd">559000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia1c1f4de39c94a96aee95ff2f88a2128_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTQtMS0xLTg5NzE3_3182642e-415b-4772-96c0-8105c4a2fe6e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib041556bab2d43ea87cd7b61b04e2646_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTYtMS0xLTg5NzE3_96635799-103d-415b-a56b-b686c69d155e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2b8fddfac82b4eac885606ee08c7a905_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTgtMS0xLTg5NzE3_633e91a1-90a5-404d-8dc7-4ed63a1b527d"
      unitRef="usd">559000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7d1be345220f478da51f25e82698124a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTEwLTEtMS04OTcxNw_ad3774ed-fed7-43a1-a5d0-afd0fdbb6968"
      unitRef="usd">212000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic404165c5df74a6f8352e0db325e95c4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTEyLTEtMS04OTcxNw_0802b1aa-34a6-4ae6-8b69-0129df42db9b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i089e25d92ca54c8985ea2dec50042b89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTE0LTEtMS04OTcxNw_fb3ad5cc-9aab-48d4-ac2b-2bb712ad89a4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2ada8ca7ebe9435e8e842501c7ad3ae3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTE2LTEtMS04OTcxNw_fc80f699-9722-45c4-a431-f8a5043b121a"
      unitRef="usd">212000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i016b509afd8947f3b511effbe125af0e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTItMS0xLTEyMTQw_6ab85e54-de70-4b70-8b7d-8174439b6003"
      unitRef="usd">331000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i71323cd5e83d4d6d87b2eed504ce751e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTQtMS0xLTEyMTQw_122d4b20-2a36-40b3-9d36-92385c6f3f6b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i727438de14724066816f95ee9809e17d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTYtMS0xLTEyMTQw_be71393d-e43d-496f-9967-a831ef3f0222"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2b832f22f4be4e61b0de45142590027e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTgtMS0xLTEyMTQw_a7567971-6382-403b-8c7f-1449b8e373c3"
      unitRef="usd">331000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idf631f09cad14340965003dda42b76f2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTEwLTEtMS0xMjE0MA_6149bd62-dc90-476b-a576-25f253b93226"
      unitRef="usd">531000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic387fe29a75d489788a450be894254a2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTEyLTEtMS0xMjE0MA_76cfe03c-bff2-40e9-b7e5-0d8153a9f410"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2093e60191934786be5e9f3c4d997270_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTE0LTEtMS0xMjE0MA_a2784485-4558-432a-b2f5-959bba01a70e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iea1fae5ea08948ba843477c2e34181be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzEzLTE2LTEtMS0xMjE0MA_a1cd4721-8c92-4239-b46d-0a64628133b0"
      unitRef="usd">531000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8ea29fc78efe4c18b496239d1891b476_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTItMS0xLTEyMTQw_32d3fd56-f085-46b9-9bef-b0cb8a3b359d"
      unitRef="usd">261000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9af306f4c8d042af84347454c60ca09d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTQtMS0xLTEyMTQw_8aadbdcb-c459-4baf-89e2-98793e8c524e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i85a8909028d04fe1a126acdf567947cf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTYtMS0xLTEyMTQw_f6c9bf65-47a8-4664-8a01-1bdda32b2928"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i90c285b633ed488fbf315d7bcb4b9c40_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTgtMS0xLTEyMTQw_b6cc51ce-7bd1-4695-8cda-8311b25e36b9"
      unitRef="usd">261000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if9869805732e4312926496da94a42e12_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTEwLTEtMS0xMjE0MA_162c6782-2ead-4f90-b7e8-bc7809691012"
      unitRef="usd">218000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i92185773c58344ce928789fdf5535c76_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTEyLTEtMS0xMjE0MA_c2803d39-4706-454e-81c7-d04cc8374efc"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0065f36a81224792b11e6b48f9770c23_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTE0LTEtMS0xMjE0MA_737561bb-67c1-4cf2-94af-933d6754883a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifd8ddd71ad6a4934a591d1a60321c3c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE0LTE2LTEtMS0xMjE0MA_b334d9dc-a6ba-4bf3-9e50-e13c1dee0b6a"
      unitRef="usd">218000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="id803bb97e7f740d6ad0af3395e67147d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTItMS0xLTEyMTQw_dfe8510d-ad80-4f78-8128-033f1f15dd09"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i1c806a171cbf4ef99d78d293d9736606_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTQtMS0xLTEyMTQw_399b4cb5-234d-403f-998d-3f79e3f2e0d4"
      unitRef="usd">80000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i3167c1fc9a3e4a5788cfa0858e185c3c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTYtMS0xLTEyMTQw_8dcb320d-916b-4d40-8ce6-dfc4f6900d37"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ideec20edc39c49fa90ed919a34d06198_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTgtMS0xLTEyMTQw_01e47f08-2b9a-4cf5-b581-ae1e0e715fa1"
      unitRef="usd">80000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i271339ca119345d694d3d33dc37ebda3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTEwLTEtMS0xMjE0MA_af6b8d3c-47b6-4e6a-a3cb-12cccff852cc"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i83fe215fd3514c48a9b0408fc2c8d430_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTEyLTEtMS0xMjE0MA_40edbd24-975e-4f47-8f99-35279e014411"
      unitRef="usd">12000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ib1d5b54c27be44f58ad2ee7c5da2c1bc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTE0LTEtMS0xMjE0MA_53a14a56-feb1-421c-a56c-f3a409bfe86c"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i0e7706841e6648cab9e75afad945d3ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE1LTE2LTEtMS0xMjE0MA_4f2ea614-60c3-4aa6-b3cf-447135c8e345"
      unitRef="usd">12000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie627b2b228da4beaa2c490c412620ab6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTItMS0xLTEyMTQw_23573df9-6c4a-4246-91ba-47d0e198bb07"
      unitRef="usd">6150000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icac8673365254bbdbf17e38b4c77bfd4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTQtMS0xLTEyMTQw_e45af08b-bc1d-464a-b5e0-d2107a0021dc"
      unitRef="usd">2170000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia43f9293bebd43209b55a1f81a2eb994_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTYtMS0xLTEyMTQw_26a7c68d-fee9-4807-b6e6-9ba72ba14f76"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5efa57e75bba46fa80520cf5680bd744_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTgtMS0xLTEyMTQw_9ba29771-469d-4d2b-9e42-ea416cf98dc6"
      unitRef="usd">8320000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6fbab0dba432455d952aca9feddd5630_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTEwLTEtMS0xMjE0MA_cb80892e-a6c1-4f43-9bb3-1e945717df81"
      unitRef="usd">7279000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee18145a966642cc8e1ce5da7d258519_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTEyLTEtMS0xMjE0MA_7eb3a212-2dc7-4ea8-8655-00916c87ef31"
      unitRef="usd">1729000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icbb049a4497b4214bac4f90ea6d795dd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTE0LTEtMS0xMjE0MA_6e404676-3ac7-4e1a-b1fa-1b5fa7ca6726"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i83d09ac1c4594e0da8f577558b10d846_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE2LTE2LTEtMS0xMjE0MA_fd70fed7-cedb-45ff-bed4-25a85acd3370"
      unitRef="usd">9008000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if3ae968a144943c69767909be7df131b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTItMS0xLTYwMzA1_75ac3e1a-96f2-4df4-9677-d80a9d7a11b8"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i72ec7b074d434e8bbc8f74ca1c51fa6e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTQtMS0xLTYwMzA1_679a24a0-3784-4efa-a46c-ab1433411930"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iba409e656a3f48ab972be2b06a795ed2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTYtMS0xLTYwMzA1_49b91e4a-7436-4157-a384-710ab033a350"
      unitRef="usd">317000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id77217ce37d644ed8b218aa4572cd4b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTgtMS0xLTYwMzA1_2c2d56c5-7085-4d33-8281-20e1545303e5"
      unitRef="usd">317000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7bd3a01aa1b84a7f86ff1f7e00427920_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTEwLTEtMS02MDI4MQ_4d69a41b-9a08-4b00-b651-443043a79943"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i863d391d7654400d8d7b18b4f8ed2d6b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTEyLTEtMS02MDI4MQ_896c56a5-ed57-4ab6-b0c4-998af9927d50"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id24b38f7656b4bdc843563195dcfddce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTE0LTEtMS02MDI4MQ_84b9ad17-3717-475a-b2c7-670343be68c7"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4bba9a34d1de4972a00d03116c7adcf1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTE2LTEtMS02MDI4MQ_bce4183d-1977-489d-ad46-a1bac17ca473"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i8ea29fc78efe4c18b496239d1891b476_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTItMS0xLTEyMTQw_a684c7a6-9438-4670-86f8-4ba36f466e6a"
      unitRef="usd">261000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i9af306f4c8d042af84347454c60ca09d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTQtMS0xLTEyMTQw_90e742e0-1e69-434a-b659-97647155c341"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i85a8909028d04fe1a126acdf567947cf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTYtMS0xLTEyMTQw_45a44351-1213-45ba-a04a-0a9635407abe"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i90c285b633ed488fbf315d7bcb4b9c40_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTgtMS0xLTEyMTQw_22566ca1-d251-4629-b6ff-7a367ed7c6eb"
      unitRef="usd">261000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="if9869805732e4312926496da94a42e12_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTEwLTEtMS0xMjE0MA_4b4fcaf0-4fb4-4bbb-94b3-512172b64d43"
      unitRef="usd">218000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i92185773c58344ce928789fdf5535c76_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTEyLTEtMS0xMjE0MA_08b436de-4496-43ba-817c-04dd312b0897"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i0065f36a81224792b11e6b48f9770c23_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTE0LTEtMS0xMjE0MA_e711c6cd-2c07-4400-814b-2ef8721c7000"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ifd8ddd71ad6a4934a591d1a60321c3c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE4LTE2LTEtMS0xMjE0MA_b908dd88-4b54-4a05-921b-c73b59668c9c"
      unitRef="usd">218000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="id803bb97e7f740d6ad0af3395e67147d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTItMS0xLTEyMTQw_dc83d7a4-8e92-4b9a-83b2-8673eb9caf83"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i1c806a171cbf4ef99d78d293d9736606_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTQtMS0xLTEyMTQw_7d9f5207-9ac9-47af-9bb9-c1372c0b9890"
      unitRef="usd">5000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i3167c1fc9a3e4a5788cfa0858e185c3c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTYtMS0xLTEyMTQw_29b08279-d7d9-46fa-84cb-700a0298a55d"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ideec20edc39c49fa90ed919a34d06198_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTgtMS0xLTEyMTQw_9e205242-2eff-4f99-b3e6-4a221009d826"
      unitRef="usd">5000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i271339ca119345d694d3d33dc37ebda3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTEwLTEtMS0xMjE0MA_471dceb4-ebaf-445b-bdee-fbe5bc0594e3"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i83fe215fd3514c48a9b0408fc2c8d430_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTEyLTEtMS0xMjE0MA_58f79be4-2c4e-47ee-9745-d700ae8ffb43"
      unitRef="usd">121000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ib1d5b54c27be44f58ad2ee7c5da2c1bc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTE0LTEtMS0xMjE0MA_b056517a-ff44-430f-90b3-5eb9cb8e1021"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i0e7706841e6648cab9e75afad945d3ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzE5LTE2LTEtMS0xMjE0MA_09e8b016-0cd2-4a13-9ee5-f7443985c240"
      unitRef="usd">121000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie627b2b228da4beaa2c490c412620ab6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTItMS0xLTEyMTQw_a29f9e18-019b-435e-8d59-5336f898b1f1"
      unitRef="usd">261000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icac8673365254bbdbf17e38b4c77bfd4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTQtMS0xLTEyMTQw_34d027d3-3daa-4dc8-832d-8711cd00bb05"
      unitRef="usd">5000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia43f9293bebd43209b55a1f81a2eb994_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTYtMS0xLTEyMTQw_f8a0aede-84d1-4224-acc7-e8de52de1d26"
      unitRef="usd">317000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5efa57e75bba46fa80520cf5680bd744_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTgtMS0xLTEyMTQw_9ec9e35e-0713-450f-a73d-f863aad425f0"
      unitRef="usd">583000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6fbab0dba432455d952aca9feddd5630_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTEwLTEtMS0xMjE0MA_37858aa6-eae8-4f40-a73f-ad92c72f6b7d"
      unitRef="usd">218000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iee18145a966642cc8e1ce5da7d258519_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTEyLTEtMS0xMjE0MA_73c7003c-3132-479c-ac71-4a204b4c05c1"
      unitRef="usd">121000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icbb049a4497b4214bac4f90ea6d795dd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTE0LTEtMS0xMjE0MA_d40cc040-5d60-4df4-bcff-3204d545ad79"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i83d09ac1c4594e0da8f577558b10d846_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTpiNjNjYWYyMmE2NDk0NmZlYmZmODllNWJiNWVkYTk5MC90YWJsZXJhbmdlOmI2M2NhZjIyYTY0OTQ2ZmViZmY4OWU1YmI1ZWRhOTkwXzIwLTE2LTEtMS0xMjE0MA_d271c2e2-369b-44f9-84d6-6cc12a718579"
      unitRef="usd">339000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzY4NDE_78017401-9c2d-4563-9887-9260dce6ae63">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia5795fbc1c3341f29a10bb7056a260ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzEtMi0xLTEtMTIxNDA_0479b617-0cb8-48fb-a488-56c9f9753651"
      unitRef="usd">3661000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ieeba2733f3294d8fbb36b69036097ed7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzEtNC0xLTEtMTIxNDA_f36b926d-8e6a-469d-b9bb-0ae21061bf58"
      unitRef="usd">4361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i537d6236c6684eb8b511aa68e41c2195_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzItMi0xLTEtMTIxNDA_3378ab17-99c0-45b9-aa43-79295ce0e96e"
      unitRef="usd">885000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i752e52cf961f4af794ad9d51504ea5ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzItNC0xLTEtMTIxNDA_87906d03-3a93-4534-b81d-89d68edc23d4"
      unitRef="usd">853000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9957ec642e74491187d1c03568dc54e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzMtMi0xLTEtMTIxNDA_1bcd9422-a898-44b8-8ddf-f38f3395719b"
      unitRef="usd">1197000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i82771ba0871b4c818fe4a95aad641c8f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzMtNC0xLTEtMTIxNDA_cdec8d46-58d5-4b6d-a765-3eafce60b9e4"
      unitRef="usd">1756000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia13c72dd8cf642e199152f20a3bf4a87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzQtMi0xLTEtMTIxNDA_58c6c785-d350-47e5-be92-4b70d76af8c8"
      unitRef="usd">5743000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2f5c1170d657408696883656ec2bd949_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90YWJsZTo4ODY5OGJlOWFiNTA0NjM1YWQyZDZiNWVlNWJjMjNmMi90YWJsZXJhbmdlOjg4Njk4YmU5YWI1MDQ2MzVhZDJkNmI1ZWU1YmMyM2YyXzQtNC0xLTEtMTIxNDA_1ce55392-9a20-46c9-90d4-9509f60de0c5"
      unitRef="usd">6970000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzM4NDgyOTA3MDc2MTI_0e4bf323-8c78-4a96-8aa3-81b164894f20"
      unitRef="usd">610000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzM4NDgyOTA3MDc2NDU_7d5378fa-771d-4478-9ce7-af8cb484385c"
      unitRef="usd">1700000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzkzNDU4NDg4Njk0NTU_12564fb2-0300-40e6-ab3c-0d428dd028ce"
      unitRef="usd">1200000000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzE4MTQxOTQxODkxMjY2_888ec231-1ea9-40aa-abc9-02ed3b2e8bbf"
      unitRef="usd">338000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzE4MTQxOTQxODkxMjc0_faa1341c-0684-4674-9f2b-c8f244a22a2f"
      unitRef="usd">262000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="ic2adb19e0ca44d459898b6f842970ad2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzQzOTgwNDY1MjU2OTQ_2100fd69-794d-4be8-8d1b-6b5ac625d5ce"
      unitRef="usd">212000000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:LongTermDebtFairValue
      contextRef="i67a406b4b0a049ffb974da9082946416_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzUwNDI_25abd9db-6b53-4b9b-8438-a02a7a8a004c"
      unitRef="usd">28600000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i3f6470cf7f5d4d0ebb2b950757008455_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzUwNDk_2e0f6a64-5bef-48f7-ace1-83cf847f66a3"
      unitRef="usd">34600000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i99fc02b86f154dc9aef67ccbad4572b3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzUxMDk_0c669660-2697-44ce-8690-3b30a783339c"
      unitRef="usd">25600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i10ea058e4eea4ab9a26e8149179fc6e7_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzUxMTY_9494556f-2529-463b-abbb-6aff59640d42"
      unitRef="usd">30300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i366d837490844422b12ca69c2324a42b_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzY1OTcwNjk3ODgzODQ_bc47f63f-9905-488d-b6bd-74a4a6cab9fd"
      unitRef="usd">341000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iba409e656a3f48ab972be2b06a795ed2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzkzNDU4NDg4Njg1NzU_2c717d75-404a-4093-b6f4-e74b000cab84"
      unitRef="usd">317000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i601744dfe4a449f588dff2ea9f459c7a_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzkzNDU4NDg4NjQ5ODE_3ddf76be-8a40-4175-9868-95dbb95fef57"
      unitRef="usd">1300000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="if747ff5ccb394525bf8dd861a2391455_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzEwOTk1MTE2NjIwODE_9af40ae1-4060-40f3-bd1b-27abba196969"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="if7987a3dc65e4b51a622b5dcbc55adcc_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzE3MDQyNDMwMjY0MzA0_89be9f55-8ddb-44b3-aa5a-4b8bad734a32"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i45bc386594ad4ae993ce88114eb4e62f_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzE3MDQyNDMwMjY0MzA0_b102c19f-de0f-48cd-bba1-e84467db84f6"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i347295d908ea47bd9ef9a8fa1edea941_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDMvZnJhZzoxN2ZmZTJjZTI2NDQ0NTEzYTk2NGNiMDI0YjMxYjAyYy90ZXh0cmVnaW9uOjE3ZmZlMmNlMjY0NDQ1MTNhOTY0Y2IwMjRiMzFiMDJjXzU5ODY_1bebdf39-dd3f-486b-bfc9-f9ee1dafcf4e"
      unitRef="usd">800000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzExNjg_26f7661c-53f9-4dc1-9d28-71dae5a06d91">AVAILABLE-FOR-SALE DEBT SECURITIES &lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We held a total of 534 and 75 positions which were in unrealized loss positions as of December&#160;31, 2021 and 2020, respectively. Aggregated gross unrealized losses on available-for-sale debt securities were not material for the years ended December&#160;31, 2021 and 2020. No impairment was recognized for the years ended December&#160;31, 2021, 2020 and 2019.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzExODk_5eb8f4bf-27fd-41da-93e3-786df7de0813">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i2afdba519b8b455cbb7ae9cfc063ba8a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItMi0xLTEtMTIxNDA_8bb7112c-38e5-4e2c-a5a8-f4e15aac27cb"
      unitRef="usd">408000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2afdba519b8b455cbb7ae9cfc063ba8a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItNC0xLTEtMTIxNDA_2c95fb88-78f6-4234-80ba-4ca0b0e5f71f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2afdba519b8b455cbb7ae9cfc063ba8a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItNi0xLTEtMTIxNDA_a00ff8ec-a93a-4bbd-bfee-c68dea9af07d"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2afdba519b8b455cbb7ae9cfc063ba8a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItOC0xLTEtMTIxNDA_dc8d67b4-1400-4962-8592-432f1c9e3dcf"
      unitRef="usd">407000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ie04ebb87f24d4c1dab5e3b201c5cb6ba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItMTAtMS0xLTEyMTQw_c1aea899-d027-401c-acdc-dabf2dee35ea"
      unitRef="usd">308000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie04ebb87f24d4c1dab5e3b201c5cb6ba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItMTItMS0xLTEyMTQw_947dcfda-d00d-41d8-b98d-f8592e40bdf1"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie04ebb87f24d4c1dab5e3b201c5cb6ba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItMTQtMS0xLTEyMTQw_42d84e10-6d72-40a5-974b-2e5148ec5eb6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie04ebb87f24d4c1dab5e3b201c5cb6ba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzItMTYtMS0xLTEyMTQw_58e7c502-430c-4bab-8607-cadfe6ae8f27"
      unitRef="usd">309000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i8b2cbea5bc7c4a8b854e2ea7a3ef27c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMi0xLTEtNjE4NTU_f3b8cd19-ad64-4977-ab5d-7cf72413f113"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8b2cbea5bc7c4a8b854e2ea7a3ef27c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtNC0xLTEtNjE4NTU_c1c228ae-2a6f-4ddd-85f5-4d3328d0fed3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8b2cbea5bc7c4a8b854e2ea7a3ef27c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtNi0xLTEtNjE4NTU_3cdd1e76-e03e-4ee8-923a-29a3a4fa42a8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8b2cbea5bc7c4a8b854e2ea7a3ef27c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtOC0xLTEtNjE4NTU_97dc9927-1f90-42ce-a580-b54480b7db73"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i5cd664388de741a283f40d467c2b991a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTAtMS0xLTYxODU1_1a302771-a9a3-4043-ae9c-33f5f48ed6bd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5cd664388de741a283f40d467c2b991a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTItMS0xLTYxODU1_05225649-d936-4c2c-9f6a-5b7492a551bb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5cd664388de741a283f40d467c2b991a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTQtMS0xLTYxODU1_8b64310d-c8d2-4005-b820-b1fba61356b8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i5cd664388de741a283f40d467c2b991a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTYtMS0xLTYxODU1_9e25c2d9-6c8c-4299-b321-faf9b3e3935f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ic431d321c32f4a148e09f407728ba829_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtMi0xLTEtNjE4NTU_eabb76a8-a40e-40a6-9680-567bd1e16f02"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic431d321c32f4a148e09f407728ba829_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtNC0xLTEtNjE4NTU_d89ce2b8-c02e-4a60-a709-0a9109a58961"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic431d321c32f4a148e09f407728ba829_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtNi0xLTEtNjE4NTU_3f239abd-cb36-43f6-bd4d-6b4bb42a2ad9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic431d321c32f4a148e09f407728ba829_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtOC0xLTEtNjE4NTU_0966c6ab-a5a4-425f-9b17-e2adc786551a"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i1b2dfff9a8cf44d0a774eb9d6d1b49d3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtMTAtMS0xLTYxODU1_efa6b81a-505d-4d9f-b8cf-63f1f9ae27b8"
      unitRef="usd">43000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1b2dfff9a8cf44d0a774eb9d6d1b49d3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtMTItMS0xLTYxODU1_491ade1e-c75d-4188-9832-8e8c051db288"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1b2dfff9a8cf44d0a774eb9d6d1b49d3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtMTQtMS0xLTYxODU1_8ec80737-2515-40a1-af02-47ca0a306db4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1b2dfff9a8cf44d0a774eb9d6d1b49d3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzQtMTYtMS0xLTYxODU1_a837f6b4-9192-4919-bb91-ea54b0b7a884"
      unitRef="usd">43000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i9f0e3695ed25418e9b23c7b9dfd2aae5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMi0xLTEtMTIxNDA_7244e5fb-55db-4125-bee2-600a21cb2d9e"
      unitRef="usd">249000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9f0e3695ed25418e9b23c7b9dfd2aae5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtNC0xLTEtMTIxNDA_0aa52f7c-d9a9-452f-8725-18b1f28d9f2a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9f0e3695ed25418e9b23c7b9dfd2aae5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtNi0xLTEtMTIxNDA_3c2b6cdc-0400-4be9-bee3-925c9f5d6f33"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9f0e3695ed25418e9b23c7b9dfd2aae5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtOC0xLTEtMTIxNDA_d1726309-911a-4f59-bc72-95c49454b865"
      unitRef="usd">249000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="iec1287280e9a4deb8aa835abc6a56556_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTAtMS0xLTEyMTQw_745772a6-6524-4632-8d18-0ce7dd148ab5"
      unitRef="usd">216000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iec1287280e9a4deb8aa835abc6a56556_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTItMS0xLTEyMTQw_92d8317a-d01e-412a-8806-35da2d75018b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iec1287280e9a4deb8aa835abc6a56556_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTQtMS0xLTEyMTQw_aab3bc54-ca82-4868-99b8-b185bc6786ab"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iec1287280e9a4deb8aa835abc6a56556_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzMtMTYtMS0xLTEyMTQw_b097ad15-fef9-4447-a8b3-f137495dabcc"
      unitRef="usd">216000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i0d59af8c16674ee3b51662b5f23c4dd3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtMi0xLTEtMTIxNDA_b006eb41-d9e9-4f07-b564-049019a54f43"
      unitRef="usd">1365000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0d59af8c16674ee3b51662b5f23c4dd3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtNC0xLTEtMTIxNDA_2008fb77-4d74-4497-9989-6dc664329445"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0d59af8c16674ee3b51662b5f23c4dd3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtNi0xLTEtMTIxNDA_600f134d-0e6b-488c-8122-f91347dbef6a"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0d59af8c16674ee3b51662b5f23c4dd3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtOC0xLTEtMTIxNDA_60ce2ab0-6355-45e2-b96a-987f4fd24102"
      unitRef="usd">1363000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i656a88d21ed14481983deda32ba5c61e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtMTAtMS0xLTEyMTQw_3b6e0247-c0d6-4cd1-9218-518bf47c692d"
      unitRef="usd">1140000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i656a88d21ed14481983deda32ba5c61e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtMTItMS0xLTEyMTQw_a094bf45-91c7-4ebf-b361-bfb30351e966"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i656a88d21ed14481983deda32ba5c61e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtMTQtMS0xLTEyMTQw_415a9e93-22d8-47d4-97c5-a0336813758b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i656a88d21ed14481983deda32ba5c61e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzYtMTYtMS0xLTEyMTQw_37aa5a9a-0394-4ab5-9e91-7f5435f1f045"
      unitRef="usd">1142000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i12f871061a224dd98a831397d2bb871d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctMi0xLTEtMTIxNDA_a4f70542-85c3-45b3-9311-db23a9ee7cba"
      unitRef="usd">425000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i12f871061a224dd98a831397d2bb871d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctNC0xLTEtMTIxNDA_629b1c3e-f71a-4f39-9282-e6a0c7242a5c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i12f871061a224dd98a831397d2bb871d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctNi0xLTEtMTIxNDA_1b73172f-b03a-4156-a82a-fa857d15b522"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i12f871061a224dd98a831397d2bb871d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctOC0xLTEtMTIxNDA_962ddf02-488c-47d2-bcf7-f4f5567f3656"
      unitRef="usd">424000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="id5683ccd60fc477ca7ea1aa59d4ccc1e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctMTAtMS0xLTEyMTQw_38f7d33d-af50-40eb-a7ae-145e274892a9"
      unitRef="usd">316000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id5683ccd60fc477ca7ea1aa59d4ccc1e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctMTItMS0xLTEyMTQw_02e29d9b-4a12-41ab-9eb7-a02dcf99ea65"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id5683ccd60fc477ca7ea1aa59d4ccc1e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctMTQtMS0xLTEyMTQw_e848dbe6-224f-4c23-bcdf-368512f426ba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id5683ccd60fc477ca7ea1aa59d4ccc1e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzctMTYtMS0xLTEyMTQw_cf52c05f-e287-487f-ba00-2b84b51a18cf"
      unitRef="usd">316000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtMi0xLTEtMTIxNDA_2b52ca30-f7ef-4360-8265-85907877b151"
      unitRef="usd">2501000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtNC0xLTEtMTIxNDA_36897e5c-323f-4d3a-90b2-cb3b88ee2768"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtNi0xLTEtMTIxNDA_e76109d6-6ad1-4109-9082-897d8195ff3a"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtOC0xLTEtMTIxNDA_a4fecbe9-b0a5-4f71-b700-7f4ded010237"
      unitRef="usd">2497000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtMTAtMS0xLTEyMTQw_5d7a557d-81b0-41ff-a07f-de3307e54e40"
      unitRef="usd">2023000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtMTItMS0xLTEyMTQw_5427752c-31da-41fb-845d-50acf4306089"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtMTQtMS0xLTEyMTQw_97455fda-708a-4317-94b8-d7fbe558e584"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo1ZmQzYTE4ZGVmNTk0MmVmYTA5YTcyMDU3MTRhNmVmZS90YWJsZXJhbmdlOjVmZDNhMThkZWY1OTQyZWZhMDlhNzIwNTcxNGE2ZWZlXzgtMTYtMS0xLTEyMTQw_9b306eee-7511-4ab5-905e-8a31875634a5"
      unitRef="usd">2026000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzExNzk_9066c3d3-0321-49af-9e75-bc3dbb5db39f">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i81c0aae6ccc84b7db071d1c937c18fe9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzEtMi0xLTEtMTIxNDA_10a8abd6-ec64-4ab9-a345-95cf612f16c8"
      unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="icf1c274e36c24d35acaf02b87f54cdbc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzEtNC0xLTEtMTIxNDA_0c12a767-4f6b-42e3-9ea6-1f1471675bc3"
      unitRef="usd">113000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i87a8e5050483425f801196f211abfa22_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzItMi0xLTEtMTIxNDA_d5d3aa2e-5b43-484f-aa57-b886cbb0cea6"
      unitRef="usd">1182000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib77bd1f1f55144c3b95b11c8a831313a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzItNC0xLTEtMTIxNDA_f67bba2e-0f0c-4607-b39b-b14d947fd8dd"
      unitRef="usd">1411000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6ba0806a7f7a4733846c919f29140932_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzMtMi0xLTEtMTIxNDA_299d67b2-df39-433f-9ff9-d41b0ad99a91"
      unitRef="usd">1309000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iade4a4ff784541f9894f489c3fb0b38b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzMtNC0xLTEtMTIxNDA_b979ff2d-b1cb-48a0-8775-e0a7eddc4051"
      unitRef="usd">502000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzQtMi0xLTEtMTIxNDA_6eb98faf-97e2-44aa-88cc-9eee73804485"
      unitRef="usd">2497000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo0N2NkM2VjYjAyYTM0YjhjYjFlMWEzZWI1N2ZiMThjNS90YWJsZXJhbmdlOjQ3Y2QzZWNiMDJhMzRiOGNiMWUxYTNlYjU3ZmIxOGM1XzQtNC0xLTEtMTIxNDA_b8375400-2f9f-4686-bf27-c47a9b2df56b"
      unitRef="usd">2026000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzExNDg_2ab21e8c-5f05-4bcf-a428-c4e954e867a2">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzItMi0xLTEtMTIxNDA_c35fcc77-7749-4c02-8123-9cdb2a8483d9"
      unitRef="usd">1189000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzItNC0xLTEtMTIxNDA_6262a415-523d-47c2-84f4-8d66f28c857c"
      unitRef="usd">1188000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzMtMi0xLTEtMTIxNDA_e38fea78-a135-4b4f-9d60-5197ba47993f"
      unitRef="usd">1288000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzMtNC0xLTEtMTIxNDA_fea8af06-45f9-4932-abf6-f6e3d0946650"
      unitRef="usd">1286000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <gild:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzQtMi0xLTEtMTIxNDA_4118827e-b08d-4c20-bd1e-80d27ba09984"
      unitRef="usd">24000000</gild:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5>
    <gild:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzQtNC0xLTEtMTIxNDA_a63358c7-9dff-4e53-805f-6cce45bc874e"
      unitRef="usd">23000000</gild:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzUtMi0xLTEtMTIxNDA_052127c6-934d-4e0f-8d78-09777b4ade1f"
      unitRef="usd">2501000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90YWJsZTo5ZmI2NzlkZmNhMDY0NzVjOGRjMDI3NzVkNmZkZjI3NS90YWJsZXJhbmdlOjlmYjY3OWRmY2EwNjQ3NWM4ZGMwMjc3NWQ2ZmRmMjc1XzUtNC0xLTEtMTIxNDA_68db7ca7-5367-4bea-8fbf-6f0371ea3c45"
      unitRef="usd">2497000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2Xzc0Mg_561bc761-0e6a-41b8-a75a-622844d16bc0"
      unitRef="position">534</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2Xzc0OQ_fa4fe044-de1d-4f41-b8da-67a84a7164fd"
      unitRef="position">75</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzU0OTc1NTgxNDE5MTI_9b9e31bb-e24d-443d-b8a6-48076570c1f7"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzU0OTc1NTgxNDE5MTI_9df3b0b0-e629-4e9f-868e-37938d68d7bc"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDYvZnJhZzpiMmY4Mjg4YjQzZjE0OTBlYmQ0MDRiMjVkMTdmNjAzNi90ZXh0cmVnaW9uOmIyZjgyODhiNDNmMTQ5MGViZDQwNGIyNWQxN2Y2MDM2XzU0OTc1NTgxNDE5MTI_f0d6ed9a-bbed-493d-8c02-53778f45f1d8"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzI3ODg_cfc73ab8-c2a1-40f7-97b5-9bd2e1826710">DERIVATIVE FINANCIAL INSTRUMENTS&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates, and as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges, and as a result, changes in their fair value are recorded in Other income (expense), net, on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and each reporting period thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in AOCI are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of December&#160;31, 2021 are expected to be reclassified to Product sales within 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash flow effects of our derivative contracts for the years ended December&#160;31, 2021, 2020 and 2019 were included within Net cash provided by operating activities on our Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had notional amounts on foreign currency exchange contracts outstanding of $2.9 billion and $2.4 billion as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. The following table summarizes the classification and fair values of derivative instruments in our Consolidated Balance Sheets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other&#160;current&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other&#160;current&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other&#160;current&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other&#160;current&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our foreign currency exchange contracts on our Consolidated Financial Statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) reclassified from AOCI into Product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Consolidated Statements of Income. There were no discontinuances of cash flow hedges for the years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, we only held foreign currency exchange contracts.&#160;The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts Not Offset on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts of Recognized Assets/Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts Offset on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral Received/Pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount (Legal Offset)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i37b11b51a2b54cf4a3a9e85b864611a7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzEzMjk_0289feac-fa79-4719-a8b8-75284fc5fb56">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1
      contextRef="i37b11b51a2b54cf4a3a9e85b864611a7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzE3NDg_83df4234-3acc-4cb8-87cf-d384fb8ea976">P12M</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzE5OTM_95b4913b-a98a-40cc-aa3c-c6428c663420"
      unitRef="usd">2900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzIwMDA_0f4b4be3-7862-481f-ad19-1d89fc6cdcd6"
      unitRef="usd">2400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzI3NzI_450bfbd5-f9a6-4c1f-92f4-6834f0555de4">The following table summarizes the classification and fair values of derivative instruments in our Consolidated Balance Sheets: &lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other&#160;current&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other&#160;current&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other&#160;current&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other&#160;current&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i5810a2be53eb4780af1fcce52fdb4182_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzQtNC0xLTEtMTIxNDA_147df8c2-22ad-4153-8a6f-a72039c8efba"
      unitRef="usd">75000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i018037d6d5a34a678330d1e08439237d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzQtOC0xLTEtMTIxNDA_b3073e7f-71ac-4486-af85-bc16887b0eee"
      unitRef="usd">4000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ia7c8d27c7190478abd912de07485cf67_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzUtNC0xLTEtMTIxNDA_38c2c872-aeb3-4c46-b936-1c9525592337"
      unitRef="usd">5000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i48f32c2561ae4b3293149592ac05f4a5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzUtOC0xLTEtMTIxNDA_8e11448f-d28e-4ad5-89d9-2428b2f0e7ef"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i45bc7259ae6041fbb19709a9cae25597_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzYtNC0xLTEtMTIxNDA_b82d18a9-9d67-468d-9994-5735f7c4ea2a"
      unitRef="usd">80000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i45bc7259ae6041fbb19709a9cae25597_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzYtOC0xLTEtMTIxNDA_8cc7b71d-c76a-4ca8-b68d-04b270f38357"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i971521b0df674be6820599f3a1fc538a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzgtNC0xLTEtMTIxNDA_83a90254-80f3-4ce1-b5fe-5665977a80db"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="idaf88e28a5724eb4a56d2dfc0bf0392f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzgtOC0xLTEtMTIxNDA_b1fd5764-86a1-44ef-9c6a-8c91e2435e1c"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i47f76a18801e482ab060956da5e0577e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzktNC0xLTEtMTIxNDA_4d8294c9-7eea-4bcf-8eb7-3d274c8e9bf9"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i47f76a18801e482ab060956da5e0577e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzktOC0xLTEtMTIxNDA_c248854a-5316-4d9d-8204-ac233b658958"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzEwLTQtMS0xLTEyMTQw_2319ad68-a91c-460b-bb3c-f0cfd8cb1c53"
      unitRef="usd">80000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyNTI2OTAxMDgyMjA0ZDhjYmU3ZjRlZjlmNTA1NDQ1MC90YWJsZXJhbmdlOjI1MjY5MDEwODIyMDRkOGNiZTdmNGVmOWY1MDU0NDUwXzEwLTgtMS0xLTEyMTQw_6fbcd22e-8bbf-4bbc-9dc2-ed031b2fca61"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ib44df45962204ad590aa3deb292d480c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzQtNC0xLTEtMTIxNDA_3f55287a-713c-41d8-989d-e19db02d2e14"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i7ef1ef2f4ad142b98639be3f14e6ee99_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzQtOC0xLTEtMTIxNDA_ca9d66a7-5621-43a9-abcf-f87c68f66135"
      unitRef="usd">113000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i9e8547beeb32459aa1afd7e5ca598ef5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzUtNC0xLTEtMTIxNDA_f3e7fa47-0c39-40b6-ad3a-eb18d737c341"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i2303cfde655d46948b6bf62eb15ca0de_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzUtOC0xLTEtMTIxNDA_0028863f-948f-45dd-bacb-941bb04f191c"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i2ea1ac770ed8451ab24e1400a67a9c3e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzYtNC0xLTEtMTIxNDA_d6558305-3bf3-4cdc-aa65-6dbed5eda86f"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i2ea1ac770ed8451ab24e1400a67a9c3e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzYtOC0xLTEtMTIxNDA_218c3402-b526-4ec0-ad7a-806f28633cb2"
      unitRef="usd">120000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="id145919643ae4857950cf7eea0d60f0c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzgtNC0xLTEtMTIxNDA_e49fb78a-78c4-43b7-ae22-c4a533885aef"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="id29ad5c6bdc744ae996da36f45e56366_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzgtOC0xLTEtMTIxNDA_6c074d8b-befa-4345-846d-614d5487a4a0"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i82b12e0c7d5d4ac7972fa5266a3d7e8d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzktNC0xLTEtMTIxNDA_d90ae51a-edbd-44ce-8c18-4518c4557545"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i82b12e0c7d5d4ac7972fa5266a3d7e8d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzktOC0xLTEtMTIxNDA_f5d5c380-35e6-43b5-a081-68228e062f0d"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzEwLTQtMS0xLTEyMTQw_5b117319-18ae-4f0b-a8a0-8f84cb99fb93"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToyMmRkNmQ1ZTdhMzQ0MWVkODRkZGVhNWZkODkwOWUwYS90YWJsZXJhbmdlOjIyZGQ2ZDVlN2EzNDQxZWQ4NGRkZWE1ZmQ4OTA5ZTBhXzEwLTgtMS0xLTEyMTQw_cc423ff8-e5ee-4bdc-9a16-9cb5d41739e2"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzI3OTg_83d15b53-3cb6-40ab-bf00-aeb7a188ac2e">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our foreign currency exchange contracts on our Consolidated Financial Statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) reclassified from AOCI into Product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzMtMi0xLTEtMTIxNDA_c08e18e6-6a41-4500-8405-6abe39c899d4"
      unitRef="usd">147000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzMtNC0xLTEtMTIxNDA_4faf7304-636e-466d-8fcc-0dbc28da3a9f"
      unitRef="usd">-118000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzMtNi0xLTEtMTIxNDA_2742e6d5-32de-4a08-a9c5-0fe0da896085"
      unitRef="usd">76000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzQtMi0xLTEtMTIxNDA_310254d1-706f-4844-9243-eb9419dba0e8"
      unitRef="usd">-67000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzQtNC0xLTEtMTIxNDA_f416c261-4cd7-4fd6-8a3b-555c3fdbbfc3"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzQtNi0xLTEtMTIxNDA_829e004c-1539-4253-bc6a-c4b812f8a6e6"
      unitRef="usd">127000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzYtMi0xLTEtMTIxNDA_f1fccd47-973a-4aeb-bc06-e1e3785a60da"
      unitRef="usd">21000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzYtNC0xLTEtMTIxNDA_73be54d9-4271-4388-932c-038352fa8b55"
      unitRef="usd">-51000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZToxY2M0NzhlM2I1NTg0ZWMzYmU0YTA4N2IwNWRkYmYyNy90YWJsZXJhbmdlOjFjYzQ3OGUzYjU1ODRlYzNiZTRhMDg3YjA1ZGRiZjI3XzYtNi0xLTEtMTIxNDA_87cadc29-3f10-4604-829b-41a598aface0"
      unitRef="usd">22000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzI1MTk_018ca302-d202-4b8a-9e69-50ae92281840"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzI1MTk_857dc972-5b2f-4be8-a432-01aa22b1a911"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90ZXh0cmVnaW9uOjMwYTRmZTBhNmRlYjQ3Yzk4YmNmZDEzOGFiYTM4YzQ0XzI3Njg_f00eb1f4-e053-4081-afc9-22eb2417cf9b">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Consolidated Balance Sheets:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts Not Offset on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts of Recognized Assets/Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts Offset on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral Received/Pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount (Legal Offset)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzMtMi0xLTEtMTIxNDA_dd277a4b-3ecf-49ce-a8f7-b7b21ed00543"
      unitRef="usd">80000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzMtNC0xLTEtMTIxNDA_b877a4b8-9960-476c-92be-a40a2cfc8102"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzMtNi0xLTEtMTIxNDA_c7b97523-6396-40c2-9192-fb5d31c8d05c"
      unitRef="usd">80000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzMtOC0xLTEtMTIxNDA_c62167a5-07f1-4261-8e05-c0bb5319bdc6"
      unitRef="usd">4000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzMtMTAtMS0xLTEyMTQw_8b42ad3e-77b6-4331-97cd-55e62e1a8f5e"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzMtMTItMS0xLTEyMTQw_0c19ba12-e7aa-4219-be42-43a40de8362a"
      unitRef="usd">76000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzQtMi0xLTEtMTIxNDA_ab757d03-6a4e-4c5b-a2df-1a48b72d82f1"
      unitRef="usd">5000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzQtNC0xLTEtMTIxNDA_c4799940-f121-4c2e-a24b-5f138f740fe5"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzQtNi0xLTEtMTIxNDA_8a63b983-4e93-4308-9a68-03ee901058d6"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzQtOC0xLTEtMTIxNDA_e156ca75-4448-447c-b433-51de01f32e0c"
      unitRef="usd">4000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzQtMTAtMS0xLTEyMTQw_a9ca3fbe-3106-43c6-b613-16bcaca4422b"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzQtMTItMS0xLTEyMTQw_ff6ad16b-ec22-41e4-b5e4-04c9eaecd479"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzYtMi0xLTEtMTIxNDA_9eca1b84-e6eb-4da0-ac58-777e5c9247da"
      unitRef="usd">12000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzYtNC0xLTEtMTIxNDA_0db3a4d4-1f59-4b85-b17a-afbf428f372f"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzYtNi0xLTEtMTIxNDA_6a4d174a-d4a3-4ddf-a7fb-6038f432a8ef"
      unitRef="usd">12000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzYtOC0xLTEtMTIxNDA_7677fb88-e851-4dff-aed8-6be17b9c4184"
      unitRef="usd">12000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzYtMTAtMS0xLTEyMTQw_1d5fea94-5aeb-434b-8ca3-6109d3f22e24"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzYtMTItMS0xLTEyMTQw_b88d0cb5-d1e8-44c0-a9f1-cb1fda1b26ee"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzctMi0xLTEtMTIxNDA_856d6527-e968-487a-9c85-9a7f391ec180"
      unitRef="usd">121000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzctNC0xLTEtMTIxNDA_7c32f407-d7b7-4ed9-81aa-040407bd216b"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzctNi0xLTEtMTIxNDA_6147b836-e484-41b5-bd63-b1ccb17d9bcc"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzctOC0xLTEtMTIxNDA_3e1699a1-c246-498d-a942-34d47c5b501d"
      unitRef="usd">12000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzctMTAtMS0xLTEyMTQw_cd57e27a-b0dd-4aef-ba66-2cde355b9aeb"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMDkvZnJhZzozMGE0ZmUwYTZkZWI0N2M5OGJjZmQxMzhhYmEzOGM0NC90YWJsZTo4YjgzNzU5NzM5NjE0NTUwYjc1MzZlMDBiZDE5ODAxNC90YWJsZXJhbmdlOjhiODM3NTk3Mzk2MTQ1NTBiNzUzNmUwMGJkMTk4MDE0XzctMTItMS0xLTEyMTQw_bef0c0ee-f295-4b17-8d09-7a6ebd8b21c1"
      unitRef="usd">109000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzEyNjk0_3161c759-0fee-45b3-bd1a-1a4e6ef7f238">ACQUISITIONS &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MYR&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#x201c;EMA&#x201d;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Consolidated Financial Statements from the date of the acquisition. Acquisition-related expenses were not material for the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate consideration for this acquisition of &#x20ac;1.3 billion (or $1.6 billion) primarily consisted of &#x20ac;1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to &#x20ac;300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $341 million as of the acquisition date and was initially recorded in Other long-term obligations on our Consolidated Balance Sheets. In the second quarter of 2021, the balance was reclassified to Accrued and other current liabilities on our Consolidated Balance Sheets. The estimated fair value of this contingent liability was $317&#160;million as of December&#160;31, 2021. The change in estimated fair value from the acquisition date was primarily due to the effect of foreign exchange remeasurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be generally recognized at fair value as of the acquisition date. The fair value estimates for the assets acquired and liabilities assumed were based upon valuations using information known and knowable as of the date of this filing. Changes to these assumptions and estimates could cause an impact to the valuation of assets acquired, including intangible assets, goodwill and the related tax impacts of the acquisition, as well as legal and other contingencies. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The finite-lived intangible asset of $845 million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D consists of Hepcludex for HDV in all other regions without regulatory approval, including the United States. The estimated aggregate fair value of $1.19 billion as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to this asset and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the more significant assumptions inherent in the development of intangible asset fair values include: estimates of projected future cash flows, including revenues and operating profits; probability of success; the discount rate selected; the life of the potential commercialized products and the risks related to the viability of and potential alternative treatments in any future target markets, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. See Note 3. Fair Value Measurements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $226 million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is not expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no material measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Immunomedics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we completed the acquisition of Immunomedics, a company focused on the development of antibody-drug conjugate technology, for cash consideration of $20.6 billion. Upon closing, Immunomedics became a wholly-owned subsidiary of Gilead. The acquisition was financed with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $1.0 billion borrowing under a new senior unsecured term loan facility and cash on hand. In 2021, we repaid the borrowing under the senior unsecured term loan facility. See Note 12. Debt and Credit Facilities for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded share-based compensation expense of $289 million related to the cash settlement of the accelerated share-based compensation expense attributable to the post-combination period, which was primarily recorded in Selling, general and administrative expenses and Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. We also recorded other acquisition-related expenses of $39 million, primarily representing closing costs and related fees, in Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Immunomedics was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be generally recognized at fair value as of the acquisition date. There were no material measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the year ended December 31, 2021. The fair value estimates for the assets acquired and liabilities assumed have been completed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outlicense contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value step-up adjustment of $881 million, included in inventories of $946&#160;million as of the acquisition date, was primarily determined by the estimated selling price of finished inventory less the cost to complete the manufacturing process and selling effort. The step-up adjustment is recorded in Cost of goods sold on our Consolidated Statements of Income as the inventory is sold to customers and in Research and development expenses on our Consolidated Statements of Income for inventory used for clinical purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The finite-lived intangible asset of $4.6 billion represents the estimated fair value of Trodelvy for metastatic triple-negative breast cancer (&#x201c;TNBC&#x201d;) as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Trodelvy for metastatic TNBC and a discount rate of 7.0%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 12 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D assets consist of Trodelvy for hormone receptor positive, human epidermal growth factor receptor 2 negative, metastatic breast cancer, Trodelvy for non-small cell lung cancer and Trodelvy for urothelial cancer (&#x201c;UC&#x201d;). The estimated aggregate fair value of&#160;$15.8 billion&#160;as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to these assets and a discount rate of 7.0%. The discount rate used represents the estimated rate that market participants would use to value these intangible assets. Trodelvy for UC was granted accelerated approval by FDA in April 2021 and $1.0 billion was reclassified to finite-lived intangibles from IPR&amp;amp;D. See Note 9. Goodwill and Intangible Assets for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the more significant assumptions inherent in the development of intangible asset fair values include: the amount and timing of projected future cash flows (including revenue, cost of sales, research and development costs, and sales and marketing expenses); probability of success; the discount rate selected to measure the inherent risk of future cash flows; the assessment of the asset&#x2019;s life cycle and the competitive trends impacting the asset, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also recorded an intangible asset related to a license and supply agreement with a third party, which was entered into by Immunomedics prior to the acquisition. Under the agreement, the third party was granted an exclusive license to develop and commercialize Trodelvy in certain territories in Asia and make certain sales milestones and royalty payments to us. The acquisition date fair value of $175 million was determined by estimating the probability-weighted net cash flows attributable to the outlicense and a discount rate of 7.0%. The discount rate represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 15 years on a straight-line basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of Immunomedics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liability Related to Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust (&#x201c;RPI&#x201d;), prior to our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The acquisition date fair value of the liability was estimated as $1.1 billion, which was primarily determined based on current estimates of future royalty payments to RPI over the life of the arrangement using the real options method and an effective annual interest rate of 2.5%. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over 16 years. The estimated timing and amount of future expected royalty payments over the estimated term will be re-assessed each reporting period. The impact from changes in estimates will be recognized in the liability and the related interest expense prospectively. The inputs used for valuation of this liability are unobservable and are considered Level 3 under the fair value measurement and disclosure guidance. See Note 3. Fair Value Measurements for additional information. The liability related to future royalties was categorized as debt and primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 12. Debt and Credit Facilities for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&#160;excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $4.0 billion was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for Immunomedics is not expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Forty Seven, Inc. (&#x201c;Forty Seven&#x201d;) &lt;/span&gt;&lt;/div&gt;In the second quarter of 2020, we completed the acquisition of Forty Seven, a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for total consideration of $4.7 billion, net of acquired cash. Upon closing, Forty Seven became a wholly-owned subsidiary of Gilead. We accounted for the transaction as an asset acquisition since the lead asset, magrolimab, represented substantially all the fair value of the gross assets acquired. During the year ended December 31, 2020, we recorded a $4.5 billion charge representing an acquired IPR&amp;amp;D asset with no alternative future use in Acquired in-process research and development expenses, and stock-based compensation expense of $144 million primarily in Research and development expenses on our Consolidated Statements of Income.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i3154b2ea498c47eca679490b457a3b8c_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM1NTg_4c982664-6058-4609-a663-ff3ff876e05b"
      unitRef="eur">1300000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i3154b2ea498c47eca679490b457a3b8c_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM1NzU_dbc96857-cb9b-424e-96d7-f0ae59dfac83"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i3154b2ea498c47eca679490b457a3b8c_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM1OTE_734af2db-6433-40dd-9bbd-0656a40ede33"
      unitRef="eur">1000000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i3154b2ea498c47eca679490b457a3b8c_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM2MDc_5ffe6698-d914-44cf-9528-7488a0ed8dcc"
      unitRef="usd">1200000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i359a44a00217459b8f4262c8fc42c933_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM2MjM_d8dac550-8b8f-4f30-bb2d-cec5390374c5"
      unitRef="eur">300000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i366d837490844422b12ca69c2324a42b_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM2NDA_bc47f63f-9905-488d-b6bd-74a4a6cab9fd"
      unitRef="usd">341000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iba409e656a3f48ab972be2b06a795ed2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTM5NzA_2c717d75-404a-4093-b6f4-e74b000cab84"
      unitRef="usd">317000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzU0OTc1NTgyMDM2NjA_194bd33b-825b-45cc-969b-ce6301ff06af">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outlicense contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="if51b044176e94e2bb20e9f08a40d5ebe_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzItMi0xLTEtNjI0OTY_68f40c03-5a67-4617-be7a-34ca9ba6b783"
      unitRef="usd">845000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="ib7c7aac8a2ee4a4ba775220f0d9f2cb3_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzMtMi0xLTEtNjI0OTY_5c40c5bc-77b9-4ef3-90b4-0fdbf3173bd2"
      unitRef="usd">1190000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i4935cfb394d8470eafcd34defaed7483_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzQtMi0xLTEtNjI0OTY_d57f4064-da84-4be3-bea0-958142e2fe74"
      unitRef="usd">513000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet
      contextRef="i4935cfb394d8470eafcd34defaed7483_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzUtMi0xLTEtNjI0OTY_fb6e0727-8985-4c57-86f2-15db7569ccd5"
      unitRef="usd">-187000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i4935cfb394d8470eafcd34defaed7483_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzYtMi0xLTEtNjI0OTY_d90b9573-e1b9-408b-871e-b0814af38dd9"
      unitRef="usd">1335000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillGross
      contextRef="i4935cfb394d8470eafcd34defaed7483_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzctMi0xLTEtNjI0OTY_ddd4af19-7c7c-4651-a039-6b8a73c9e498"
      unitRef="usd">226000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i4935cfb394d8470eafcd34defaed7483_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZTphNjgzYzY2NTljNTU0MzlmOWQ3NjhhNDI4OWUwYjkzOC90YWJsZXJhbmdlOmE2ODNjNjY1OWM1NTQzOWY5ZDc2OGE0Mjg5ZTBiOTM4XzgtMi0xLTEtNjI0OTY_8aa38789-d843-4733-b329-9ec1ad7b6ca0"
      unitRef="usd">1561000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="if51b044176e94e2bb20e9f08a40d5ebe_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzc2OTY1ODE0NjEzMDI_918a5fc8-f085-4285-abbe-ee622b20540f"
      unitRef="usd">845000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate
      contextRef="icb48d6051df7485eb73cdb8b7df0e985_I20210304"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTYwOTA_75b3d72d-3d19-4907-8a85-63af774a810a"
      unitRef="number">0.12</gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i921b8d77d4f84f529ce58e9660da8dcf_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTYwODc_4500dcbc-f692-4f23-a5b3-d2c42b542cf9">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="ia2177833d44d42918c6ce32854820034_I20210304"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTYxMDA_ec7113da-32f2-4cb3-81c1-505b7635418a"
      unitRef="usd">1190000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate
      contextRef="i21ced31d30014719bdf7d7d18248633e_I20210304"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTYxMDc_7cf00d5a-3a8e-4fd6-9b3c-30ee47364fce"
      unitRef="number">0.12</gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate>
    <us-gaap:GoodwillGross
      contextRef="i4935cfb394d8470eafcd34defaed7483_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTY4ODI_76a3ed7e-bf6d-4028-84f0-942f44f278b1"
      unitRef="usd">226000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="ia9a673ba30ed4f0e806f09b015c95ec7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzU0OTc1NTgyMDM2ODE_3367018e-de8c-4b01-a550-8303ab5d8915"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i2cc76f278d7d430794fea351f77cb6c7_D20201023-20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTc0OTI_9f72b4dc-8f65-4e63-a34d-1d7fc52de6b6"
      unitRef="usd">20600000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i1f5da942c50945a2940da6ebd718841a_D20200901-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTc0OTk_08d2c7a3-d513-4a78-9121-b06730423686"
      unitRef="usd">1000000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="icaf63b79601f41cbbbb79ce216ea77a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzkzNDU4NDg4OTU2Njk_2ca52252-dd25-4fb5-84f1-baf8399f84ec"
      unitRef="usd">289000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="icaf63b79601f41cbbbb79ce216ea77a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzEwOTk1MTE2OTI4MzM_762ce030-3ac4-41b8-ad2d-8239da3d44e7"
      unitRef="usd">39000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzEtMi0xLTEtNjI2ODg_0d0351d2-8071-4704-ba57-d8de4a41966f"
      unitRef="usd">726000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzItMi0xLTEtNjI2ODg_351cf13e-7754-4dbf-914b-47d4a80e24bc"
      unitRef="usd">946000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i40d4bb748a364d08802e6d345ae95f56_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzQtMi0xLTEtNjI2ODg_c58f38dd-566d-4354-a2fe-b17e0566aa52"
      unitRef="usd">4600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i48fbb200fd474e8c86b19b2980d80c7a_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzUtMi0xLTEtNjI2ODg_104da7ef-8591-4700-a7d0-c13294b1c9a9"
      unitRef="usd">15760000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="iee6771abbf6845e9b749e3f2f831a535_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzYtMi0xLTEtNjI2ODg_eacfacfa-2f7f-46bd-9004-4d1bb13f2a66"
      unitRef="usd">175000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzctMi0xLTEtNjI2ODg_1253f3e4-4f8a-41d9-8fa7-ca26c71326bb"
      unitRef="usd">4565000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability
      contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzgtMi0xLTEtNjI2ODg_869f01eb-1307-426f-b4e3-ec5889c609b0"
      unitRef="usd">1100000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet
      contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzktMi0xLTEtNjI2ODg_be54b5bc-c583-4d2c-9d30-681fbab86d94"
      unitRef="usd">64000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzEwLTItMS0xLTYyNjg4_26a6786c-efb1-4bd4-ac40-1253bbbcff38"
      unitRef="usd">16606000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillGross
      contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzExLTItMS0xLTYyNjg4_010d7e44-611d-4beb-b89a-167ab1ede5e7"
      unitRef="usd">3991000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90YWJsZToxMjhhNjFhNzllODk0NjE1YWMyYzhlN2FhM2FjMzdjOS90YWJsZXJhbmdlOjEyOGE2MWE3OWU4OTQ2MTVhYzJjOGU3YWEzYWMzN2M5XzEyLTItMS0xLTYyNjg4_2e1d53ea-a09a-4ca4-a384-2df3b6f06bbd"
      unitRef="usd">20597000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory
      contextRef="i2cc76f278d7d430794fea351f77cb6c7_D20201023-20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk3NDk_296d182a-b0fa-4621-8f9f-b79aba0b723c"
      unitRef="usd">881000000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk3NTQ_e0e23b01-192f-4a42-b2b6-231dff31e198"
      unitRef="usd">946000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i40d4bb748a364d08802e6d345ae95f56_I20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzc2OTY1ODE0NjA2Njc_18290be2-2f8e-40a8-af21-032a4d134db9"
      unitRef="usd">4600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate
      contextRef="i40d4bb748a364d08802e6d345ae95f56_I20201023"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4MDc_d700496c-6194-4877-b837-03e424144557"
      unitRef="number">0.070</gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4c0a66904d084d55b9dbeacaaa99fc01_D20201023-20201023"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4MTE_ca150fce-1250-4c13-8290-4d63091f9db2">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i48fbb200fd474e8c86b19b2980d80c7a_I20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzkzNDU4NDg4ODYyMjY_0b26d06e-bf75-4bd6-b0d1-c4f1a3d8143a"
      unitRef="usd">15800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate
      contextRef="i48fbb200fd474e8c86b19b2980d80c7a_I20201023"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4NTE_0b6ecafc-467d-4779-8665-0622be63bf0b"
      unitRef="number">0.070</gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="i4914efbe4a514e3a9b1e8ce1c3d1f7a8_I20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4MjY_4198f800-0704-4983-a6b7-49b304e53af5"
      unitRef="usd">-1000000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="iea54bfd7cd894da1a9dc4dab9d27fd06_I20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4MjY_7f46a8a6-e3bc-4a3d-8aab-2e53bfc496ae"
      unitRef="usd">1000000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="iee6771abbf6845e9b749e3f2f831a535_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4Mzg_eacfacfa-2f7f-46bd-9004-4d1bb13f2a66"
      unitRef="usd">175000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate
      contextRef="iee6771abbf6845e9b749e3f2f831a535_I20201023"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4NDc_c3dfd0f8-84f6-4ddd-b087-82eb29925813"
      unitRef="number">0.070</gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8e4d4939ae6f4eacb0ac9fcf29a6a86b_D20201023-20201023"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4NTU_bcc54671-9005-446b-b13d-8f3a0fb1a92a">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability
      contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzc2OTY1ODE0NjA2NzU_9e242cac-3cce-4421-ad1f-62d9b1f04c1a"
      unitRef="usd">1100000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability>
    <gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput
      contextRef="i2cc576f3ddae4cccba9f06dea7d86258_I20201023"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4ODU_88083ac6-1ccc-4b86-8e9f-027febd3e53b"
      unitRef="number">0.025</gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput>
    <gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput
      contextRef="i17b0826d35c24c928061c1e5a0cc3d90_I20201023"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzIxOTkwMjMzMTk4ODk_65487143-e0db-46c7-9f8c-5cdcc48e500f"
      unitRef="number">16</gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput>
    <us-gaap:GoodwillGross
      contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzE2NDkyNjc1MDY0Nzk_9a484348-7ed0-43c8-b31b-a0f89146afd7"
      unitRef="usd">4000000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i3183f05cabb4466ba0779104322ecffc_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzU0OTc1NTgyMDM2OTM_634ba329-eb89-4ace-9670-9c4a5554931f"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <gild:PaymentsToAcquireAssetsNetOfCashAcquired
      contextRef="ic064b955d17a405a8e93d4ced0a24b8b_D20200407-20200407"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTgzNjk_c3564615-2336-49a2-9852-1969ecd355a6"
      unitRef="usd">4700000000</gild:PaymentsToAcquireAssetsNetOfCashAcquired>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if390b664ad9b4a3fa1db0cce3b5ead91_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTg0MDM_a5c05dc1-f90c-4cfd-8827-8b2a7b3164c2"
      unitRef="usd">4500000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="ic616f3942a304ac4ab23e63afeed5a7d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTIvZnJhZzplZDI3MzFhMmUwMDI0ZTQxOTkwZmI5ZTgwNjdjZTJkZC90ZXh0cmVnaW9uOmVkMjczMWEyZTAwMjRlNDE5OTBmYjllODA2N2NlMmRkXzM4NDgyOTA3MTg0MDY_4e352571-745e-4fa9-b3e7-3b7a8471cd8d"
      unitRef="usd">144000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzg1Mw_0ec24f48-4fea-45c3-8593-933b606e5071">INVENTORIES&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reported as Other long-term assets primarily consisted of raw materials as of December&#160;31, 2021 and 2020. Total inventories as of December&#160;31, 2021 and 2020 include $294&#160;million and $797&#160;million, respectively, of fair value adjustments resulting from the Immunomedics acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Inventory write-down charges were $228 million, $86 million and $649 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. During the year ended December&#160;31, 2019, $547 million of the $649 million inventory write-down charges was related to slow-moving and excess raw material and work in process inventory primarily due to lower long-term demand for our HCV products.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzg1Ng_49668cf7-775b-4846-8b79-6321bf463089">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzItMi0xLTEtMTIxNDA_eae505e3-7b13-4d6b-a296-929c3c6c7316"
      unitRef="usd">1112000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzItNC0xLTEtMTIxNDA_80fd503a-d0b1-42d6-96ed-e4a64535a5c2"
      unitRef="usd">1080000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzMtMi0xLTEtMTIxNDA_608b1f80-76f8-4bdd-a59e-77357991182b"
      unitRef="usd">590000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzMtNC0xLTEtMTIxNDA_683c8ef6-c492-4f79-b6b7-4f96534d989c"
      unitRef="usd">976000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzQtMi0xLTEtMTIxNDA_d67b817f-8008-44cb-866c-10f00024c7e2"
      unitRef="usd">1032000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzQtNC0xLTEtMTIxNDA_e6639eab-eda5-49be-888f-4cb109853c8f"
      unitRef="usd">958000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i799ec7afbe884df09fd62386211ca69c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzUtMi0xLTEtMTIxNDA_1f01344e-34a8-4d6e-b1b7-7c2e10be06b9"
      unitRef="usd">2734000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ibb077705a6144313995575f715ac8647_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzUtNC0xLTEtMTIxNDA_136449b7-348a-4441-b970-f0f3fc645603"
      unitRef="usd">3014000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzgtMi0xLTEtMTIxNDA_6d05d9c7-1393-4522-82cc-e7da946d5812"
      unitRef="usd">1618000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzgtNC0xLTEtMTIxNDA_42d697a7-bd6c-4848-bc51-33e8518d8a75"
      unitRef="usd">1683000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzktMi0xLTEtMTIxNDA_b85926f5-7db7-49c0-97d4-e7fd77a26920"
      unitRef="usd">1116000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzktNC0xLTEtMTIxNDA_a6117921-6a53-49ad-9086-31dd67caf384"
      unitRef="usd">1331000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i799ec7afbe884df09fd62386211ca69c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzEwLTItMS0xLTEyMTQw_3e2b04ed-8489-4beb-a8f9-4bd418b93590"
      unitRef="usd">2734000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ibb077705a6144313995575f715ac8647_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90YWJsZTo4ZjhjNzQyYTczMDc0ZTNjYTU0OWFhOGQ2YTMyN2FkNy90YWJsZXJhbmdlOjhmOGM3NDJhNzMwNzRlM2NhNTQ5YWE4ZDZhMzI3YWQ3XzEwLTQtMS0xLTEyMTQw_5c3cc36f-03cb-4997-ab2a-0503bf2dab60"
      unitRef="usd">3014000000</us-gaap:InventoryNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i9130594e600c402b8c0b978840773abf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzEzNzQzODk1MzUyMzM4_b7cb2558-318d-474a-a692-f462ae69b2dd"
      unitRef="usd">294000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i2809f8582076480fa7e0927fefc603b7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzEzNzQzODk1MzUyMzg2_5c9a4fae-d84b-4351-a739-ab4b753c8fdc"
      unitRef="usd">797000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:InventoryWriteDown
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzkzNDU4NDg4NDA2MzI_b52c3fb3-e40e-4c4f-aecd-f3e9697d1938"
      unitRef="usd">228000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzkzNDU4NDg4NDA5MDY_c9f07d81-e88d-4248-8cdc-246467ecaded"
      unitRef="usd">86000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzkzNDU4NDg4NDA5MTQ_375ea94d-88cf-45cd-8cd8-8076f2e803e1"
      unitRef="usd">649000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ie9515dcb5dcd4ed096a37c411b6c94a8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzM4NDgyOTA2OTkyMDc_5ae3e29d-ce92-4e1a-a516-d3e6abffec39"
      unitRef="usd">547000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTUvZnJhZzphMDI3M2E1NGJhYWQ0NjdiODJjNDYzZmMzODA3ZDU2YS90ZXh0cmVnaW9uOmEwMjczYTU0YmFhZDQ2N2I4MmM0NjNmYzM4MDdkNTZhXzkzNDU4NDg4NDA5OTc_375ea94d-88cf-45cd-8cd8-8076f2e803e1"
      unitRef="usd">649000000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0Xzc2MA_71d4da9e-40b2-4eca-b03b-de979c3e46e4">PROPERTY, PLANT AND EQUIPMENT&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Property, plant and equipment, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements (including leasehold improvements)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had unamortized capitalized software costs, included in Office, computer equipment and other, of $131 million and $124 million as of December&#160;31, 2021 and 2020, respectively. Capitalized interest on construction in progress is included in Property, plant and equipment, net on our Consolidated Balance Sheets. Interest capitalized in 2021 and 2020 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net book value of our property, plant and equipment in the United States was $4.1 billion and $4.0 billion as of December&#160;31, 2021 and 2020, respectively. The corresponding amount in international locations was $963 million and $940 million as of December&#160;31, 2021 and 2020, respectively. All individual international locations accounted for less than 10% of the total balances.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0Xzc0OQ_955145b0-34cd-44cc-af55-e22416769bc4">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Property, plant and equipment, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements (including leasehold improvements)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzItMi0xLTEtMTIxNDA_4db5a2d2-f07b-4ba5-b27f-5fb79909b658"
      unitRef="usd">404000000</us-gaap:Land>
    <us-gaap:Land
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzItNC0xLTEtMTIxNDA_38f498f5-16c7-496c-9c64-cae5b7faf0e6"
      unitRef="usd">404000000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzMtMi0xLTEtMTIxNDA_598a4045-37fa-4d13-a2a8-fe1ae91d0111"
      unitRef="usd">3794000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzMtNC0xLTEtMTIxNDA_c261c68f-b46b-419d-b98f-44c2325722fe"
      unitRef="usd">3678000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzQtMi0xLTEtMTIxNDA_9a09da01-bfbd-4162-afa2-4987a49aed3f"
      unitRef="usd">952000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzQtNC0xLTEtMTIxNDA_35d4c9e5-d02d-4ad9-8af8-4bbedb2e8424"
      unitRef="usd">904000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzUtMi0xLTEtMTIxNDA_b846ea0c-db89-4bee-b687-360a06b038ee"
      unitRef="usd">807000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzUtNC0xLTEtMTIxNDA_d85e725c-d511-4737-bf8c-408ed313f3f9"
      unitRef="usd">793000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:ConstructionInProgressGross
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzYtMi0xLTEtMTIxNDA_74a45f3a-25a4-4112-8417-3135b825b175"
      unitRef="usd">1057000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzYtNC0xLTEtMTIxNDA_f55922a4-06c6-41ab-b91f-e00c7d5da59f"
      unitRef="usd">856000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzctMi0xLTEtMTIxNDA_29e5f838-9a4a-4a1f-a1cd-a8eb7b789ff2"
      unitRef="usd">7014000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzctNC0xLTEtMTIxNDA_091eb6b5-e26e-4fb7-84af-de11d953a1de"
      unitRef="usd">6635000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzgtMi0xLTEtMTIxNDA_ce731bb3-3085-49bc-a8d4-4baa9ef3328c"
      unitRef="usd">1893000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzgtNC0xLTEtMTIxNDA_e5ff2332-b8ec-41a2-9b3b-66f357974d7c"
      unitRef="usd">1668000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzktMi0xLTEtMTIxNDA_e87d50ae-b271-43c1-aee3-117fae3920b2"
      unitRef="usd">5121000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90YWJsZTo0YWI5NjI0MzZiY2E0YjA1OGExMmU5ZjZjMGNiMmRmMC90YWJsZXJhbmdlOjRhYjk2MjQzNmJjYTRiMDU4YTEyZTlmNmMwY2IyZGYwXzktNC0xLTEtMTIxNDA_8ba84aa3-b582-4ec0-8378-c3e94318f8c2"
      unitRef="usd">4967000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0XzE4Nw_d8de61f5-837a-4640-bf97-da79d4ec7723"
      unitRef="usd">131000000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0XzE5NA_17c12b3b-5cd4-4ff9-95ec-657c0cdd7df9"
      unitRef="usd">124000000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0ac72ff3c91e41dda636f4481b43d8d8_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0XzUyMg_0099281d-d803-4d22-8c8c-f33a70bdd7eb"
      unitRef="usd">4100000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if86d40bd14d6458096e0c4c590a93b2d_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0XzQ5NDc4MDIzMjYwNzc_148203cd-9e5d-4212-942f-9ce1370b4382"
      unitRef="usd">4000000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i954f79dbc23344e2bc4a6cc0b85ebc55_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0XzYyMA_744436b4-8dc3-4b04-a5bf-f2f84acddfa2"
      unitRef="usd">963000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0d05732d25884b3886f2b6eb46e0c7a2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMTgvZnJhZzphMDQxMzVhNmIwNTI0ZTIyYjE5MmY3MWQwMmYzODY1NC90ZXh0cmVnaW9uOmEwNDEzNWE2YjA1MjRlMjJiMTkyZjcxZDAyZjM4NjU0XzQ5NDc4MDIzMjYwODQ_1c6f32b2-fa84-4531-8f09-9f1523b34ca3"
      unitRef="usd">940000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzI5Mzk_55edd9fa-3c24-4ab3-af99-8e32f04bb02b">GOODWILL AND INTANGIBLE ASSETS &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of Goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform an annual goodwill impairment assessment in the fourth quarter or earlier if impairment indicators exist. As of December&#160;31, 2021, there were no accumulated goodwill impairment losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Hepcludex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes $910&#160;million reclassified in the first quarter of 2021 from indefinite-lived assets - IPR&amp;amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes Trodelvy for metastatic TNBC and Trodelvy for use in adult patients with locally advanced or metastatic UC. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;amp;D upon the accelerated approval by FDA in April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million was reclassified to finite-lived assets in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes IPR&amp;amp;D from our 2021 acquisition of MYR and remaining IPR&amp;amp;D from our 2020 acquisition of Immunomedics. Gross carrying amount as of December&#160;31, 2020 includes IPR&amp;amp;D from our 2020 acquisition of Immunomedics and remaining IPR&amp;amp;D from our 2017 acquisition of Kite. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense related to finite-lived intangible assets was $1.7 billion, $1.2 billion and $1.1 billion for the years ended December&#160;31, 2021, 2020 and 2019, respectively, and is primarily included in Cost of goods sold on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts capitalized as IPR&amp;amp;D are subject to impairment testing until the completion or abandonment of the associated R&amp;amp;D efforts&lt;/span&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, we performed a qualitative assessment of our IPR&amp;amp;D intangible asset obtained in connection with our first quarter 2021 acquisition of MYR and did not identify any indicators of impairment.&lt;/span&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, 2020 and 2019, we performed quantitative impairment testing of our IPR&amp;amp;D intangible assets, other than the MYR asset described above, using a probability-weighted income approach that discounts expected future cash flows to present value using discount rates of 6.5%, 8.0% and 9.5%, respectively&lt;/span&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount rates are based on the estimated weighted-average cost of capital for companies with profiles similar to our profile and represents the rate that market participants would use to value the intangible assets. The discounted cash flow models used in valuing these intangible assets also require the use of Level 3 fair value measurements and inputs including estimated revenues, costs, and probability of technical and regulatory success. No IPR&amp;amp;D impairment charges were recorded in 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, we lowered our estimated revenues related to our IPR&amp;amp;D intangible asset - axicabtagene ciloleucel for the treatment of indolent B-cell non-Hodgkin lymphoma due to changes in the estimated market opportunities as new therapies or combinations of existing therapies were approved. The lower estimated revenues reduced the fair value of the IPR&amp;amp;D intangible assets below carrying value resulting in the recognition of an impairment charge of $800 million, which was recorded within Acquired in-process research and development expenses on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzI5MTk_4ec9d75c-3281-4af9-b65e-5f884d6bc616">&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of Goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzEtMi0xLTEtMTIxNDA_69c4f0a2-9f71-4c83-b761-d0b5c3015071"
      unitRef="usd">8108000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzItNC0xLTEtOTkyNzM_b92fb2c6-7425-4adb-8890-fc172e61735a"
      unitRef="usd">4117000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzItMi0xLTEtMTIxNDA_bac71c63-4ca0-416f-9c9c-bd575f7e6147"
      unitRef="usd">226000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzMtNC0xLTEtOTkyODc_d4eb9404-0295-4db3-8cbe-f3aab6d82ded"
      unitRef="usd">3991000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzMtMi0xLTEtNjM4MTc_e24675b0-9247-40af-837e-b48bec04e8f0"
      unitRef="usd">-2000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzQtNC0xLTEtOTkzMDM_9ed0f71e-3ad4-4d3e-8880-b972d1708820"
      unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzMtMi0xLTEtMTIxNDA_4502a415-8ebb-40ce-b4c0-971e5a8a1108"
      unitRef="usd">8332000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpiYzc5OTc0MTc0MDk0ZWVlYTFmOGYwMGRlMjBkMGJkOC90YWJsZXJhbmdlOmJjNzk5NzQxNzQwOTRlZWVhMWY4ZjAwZGUyMGQwYmQ4XzUtNC0xLTEtOTkyOTA_25ecdd01-ff47-4706-a2f4-fe1a33a97af2"
      unitRef="usd">8108000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzI0NA_a25514ee-913f-4bff-beed-ac7ed80d0a25"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzI5MTQ_27e7171d-bffe-469b-8335-0b82c62ac071">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Hepcludex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes $910&#160;million reclassified in the first quarter of 2021 from indefinite-lived assets - IPR&amp;amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes Trodelvy for metastatic TNBC and Trodelvy for use in adult patients with locally advanced or metastatic UC. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;amp;D upon the accelerated approval by FDA in April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million was reclassified to finite-lived assets in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;(4)&#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes IPR&amp;amp;D from our 2021 acquisition of MYR and remaining IPR&amp;amp;D from our 2020 acquisition of Immunomedics. Gross carrying amount as of December&#160;31, 2020 includes IPR&amp;amp;D from our 2020 acquisition of Immunomedics and remaining IPR&amp;amp;D from our 2017 acquisition of Kite.</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzI5NDk_f7d548e4-42c5-44cf-9b4b-61e430d245a6">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Hepcludex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes $910&#160;million reclassified in the first quarter of 2021 from indefinite-lived assets - IPR&amp;amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes Trodelvy for metastatic TNBC and Trodelvy for use in adult patients with locally advanced or metastatic UC. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&amp;amp;D upon the accelerated approval by FDA in April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million was reclassified to finite-lived assets in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;(4)&#160;&#160;&#160;&#160;Gross carrying amount as of December&#160;31, 2021 includes IPR&amp;amp;D from our 2021 acquisition of MYR and remaining IPR&amp;amp;D from our 2020 acquisition of Immunomedics. Gross carrying amount as of December&#160;31, 2020 includes IPR&amp;amp;D from our 2020 acquisition of Immunomedics and remaining IPR&amp;amp;D from our 2017 acquisition of Kite.</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3e5cf4e62a72481988dcf8c0806f41bf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtMi0xLTEtMTIxNDA_e9d02b91-f158-488f-8149-6363b148d078"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3e5cf4e62a72481988dcf8c0806f41bf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtNC0xLTEtMTIxNDA_08b4407b-b312-4fc1-9ad7-137c192b76d4"
      unitRef="usd">5651000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i3e5cf4e62a72481988dcf8c0806f41bf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtNi0xLTEtMTIxNDA_840a3a32-dea3-47b0-a430-1e8eaea5fdb4"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3e5cf4e62a72481988dcf8c0806f41bf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtOC0xLTEtMTIxNDA_208df603-cf78-4cf3-9114-badf05a9bdb7"
      unitRef="usd">5069000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4a7db52d1e4a414281cb490a081d6dfc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtMTAtMS0xLTEyMTQw_686576e8-6d9e-4be1-80e1-b558d677a795"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4a7db52d1e4a414281cb490a081d6dfc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtMTItMS0xLTEyMTQw_5ea2527a-d776-4208-8e68-f32e6a3e740d"
      unitRef="usd">4952000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i4a7db52d1e4a414281cb490a081d6dfc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtMTQtMS0xLTEyMTQw_759b9284-7962-48a8-ba99-7c5945a88316"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4a7db52d1e4a414281cb490a081d6dfc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzMtMTYtMS0xLTEyMTQw_e7593475-e35e-4be4-aef9-303e705f2087"
      unitRef="usd">5768000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3c2781ca10ac41f5983b9e118c2abf70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtMi0xLTEtMTIxNDA_af1db4b6-947f-4c01-9f58-8be00419f88a"
      unitRef="usd">7110000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3c2781ca10ac41f5983b9e118c2abf70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtNC0xLTEtMTIxNDA_99719588-00e8-4815-86c5-82303a5d904f"
      unitRef="usd">1501000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i3c2781ca10ac41f5983b9e118c2abf70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtNi0xLTEtMTIxNDA_0e9d9e34-c200-426a-85ff-1a4d42f93cc4"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3c2781ca10ac41f5983b9e118c2abf70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtOC0xLTEtMTIxNDA_6207b285-4bb7-4ff7-9fad-659f1a327968"
      unitRef="usd">5609000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib1ad0c1f171b4177b15cd5e56d09b6c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtMTAtMS0xLTEyMTQw_dda84990-51d6-4b5a-98c7-1c64ffb8bafc"
      unitRef="usd">6200000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib1ad0c1f171b4177b15cd5e56d09b6c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtMTItMS0xLTEyMTQw_d4ccc2a7-65ee-4afd-9d3c-abdd7f770ce1"
      unitRef="usd">1105000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ib1ad0c1f171b4177b15cd5e56d09b6c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtMTQtMS0xLTEyMTQw_b5fca952-16c6-460c-9875-c5891e0dfb08"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib1ad0c1f171b4177b15cd5e56d09b6c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzQtMTYtMS0xLTEyMTQw_a4aade33-0f25-4b5f-af95-444f95a95d94"
      unitRef="usd">5095000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idaf491080c57475991aa98abcc4fbcc0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtMi0xLTEtMTIxNDA_18ba820e-5d67-4a84-84d9-da445e33d050"
      unitRef="usd">5630000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idaf491080c57475991aa98abcc4fbcc0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtNC0xLTEtMTIxNDA_49b8e3cd-62e0-465d-9aee-47636675e0be"
      unitRef="usd">507000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="idaf491080c57475991aa98abcc4fbcc0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtNi0xLTEtMTIxNDA_e5c8c71b-4c37-4667-aae1-477f6638092d"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idaf491080c57475991aa98abcc4fbcc0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtOC0xLTEtMTIxNDA_1ab92e1e-06b9-4719-b54a-9b289bb49f01"
      unitRef="usd">5123000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7bdf2ca12670410281b8c08d6e3e7fcc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtMTAtMS0xLTEyMTQw_30f06f6f-66d3-4a7e-a52e-553f56591438"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7bdf2ca12670410281b8c08d6e3e7fcc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtMTItMS0xLTEyMTQw_13eee71e-a8fd-4e3f-8b6b-fba473661494"
      unitRef="usd">63000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i7bdf2ca12670410281b8c08d6e3e7fcc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtMTQtMS0xLTEyMTQw_14997a01-c9ec-4a7b-9f07-d7bfb0370b32"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7bdf2ca12670410281b8c08d6e3e7fcc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzUtMTYtMS0xLTEyMTQw_5cdd9b1b-e4bc-4a0d-8ca4-e295e6bbfc08"
      unitRef="usd">4537000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia1f8421f3e1d46c38dbaab52dda2ef27_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMi0xLTEtNjM5NzA_d5b6255c-ab0c-402f-91d8-4629959f5923"
      unitRef="usd">845000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia1f8421f3e1d46c38dbaab52dda2ef27_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtNC0xLTEtNjM5NzA_732abc2d-a011-4b54-8f33-470b2ece0d63"
      unitRef="usd">72000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ia1f8421f3e1d46c38dbaab52dda2ef27_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtNi0xLTEtNjM5NzA_00f548f1-6c6e-4947-a537-b3d4e80ef3cf"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia1f8421f3e1d46c38dbaab52dda2ef27_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtOC0xLTEtNjM5NzA_52971745-cd07-4476-a482-c12a069dd566"
      unitRef="usd">773000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaf23ded0c1324053bcaf589d66627968_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTAtMS0xLTYzOTcw_80a995cb-18ea-46b0-8f14-a34b53cea8b0"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaf23ded0c1324053bcaf589d66627968_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTItMS0xLTYzOTcw_559fe069-c6b0-4a97-b1c5-71df0cbcd4cf"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="iaf23ded0c1324053bcaf589d66627968_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTQtMS0xLTYzOTcw_fefce2d0-8e4d-4894-bf41-1aa1dc6f9b22"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaf23ded0c1324053bcaf589d66627968_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTYtMS0xLTYzOTcw_74274c0b-822c-4871-8692-623bdce33bc2"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i30947e974d8c479392d193aad7a782fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMi0xLTEtMTIxNDA_165793ff-6cd9-4b6f-bb05-6f30d7da469a"
      unitRef="usd">1610000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i30947e974d8c479392d193aad7a782fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtNC0xLTEtMTIxNDA_6d787041-0a7d-466c-b24a-37a66a386f93"
      unitRef="usd">650000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i30947e974d8c479392d193aad7a782fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtNi0xLTEtMTIxNDA_36277e03-ba7a-42e7-aac0-82a96fd28263"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i30947e974d8c479392d193aad7a782fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtOC0xLTEtMTIxNDA_799f4c51-98ff-4a23-b6ce-9bb41c44aed7"
      unitRef="usd">961000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1d94d5c1399f498a9997b438dd170d14_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTAtMS0xLTEyMTQw_d09cea8e-7151-4eff-b5be-948b75da1092"
      unitRef="usd">1377000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1d94d5c1399f498a9997b438dd170d14_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTItMS0xLTEyMTQw_1a84ff8b-3aef-48d9-a390-d157b5625c04"
      unitRef="usd">540000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i1d94d5c1399f498a9997b438dd170d14_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTQtMS0xLTEyMTQw_8162bf83-e188-49bc-91eb-a1fa4bf029c9"
      unitRef="usd">-1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1d94d5c1399f498a9997b438dd170d14_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzYtMTYtMS0xLTEyMTQw_d9371bd1-a575-4d6b-a892-99691ae3052b"
      unitRef="usd">836000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctMi0xLTEtMTIxNDA_e86b9e95-892a-447f-a981-7841c6d7167e"
      unitRef="usd">25915000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctNC0xLTEtMTIxNDA_80e4c4e5-025d-415b-a173-e17c240cf174"
      unitRef="usd">8381000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctNi0xLTEtMTIxNDA_7f7466a0-9754-4cb6-823c-a82c0bbdc2c3"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctOC0xLTEtMTIxNDA_502edf7f-5d4f-4b7a-bea8-20c91ef8d67d"
      unitRef="usd">17535000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctMTAtMS0xLTEyMTQw_5ffff38c-7805-4ef4-9475-5f3fa761c4f6"
      unitRef="usd">22897000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctMTItMS0xLTEyMTQw_73950f6c-8063-4d41-a976-06ebd8c64ee6"
      unitRef="usd">6660000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctMTQtMS0xLTEyMTQw_70258890-705a-4bbe-9469-de1e0a612020"
      unitRef="usd">-1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzctMTYtMS0xLTEyMTQw_ac18ca2c-345b-4a98-a185-80da464c8f85"
      unitRef="usd">16236000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i52f89193810b43f085be64ba7f474b2d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzgtMi0xLTEtMTIxNDA_c8320b84-e6a1-49a3-9b19-5cec54c5bef5"
      unitRef="usd">15920000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i52f89193810b43f085be64ba7f474b2d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzgtNi0xLTEtMTIxNDA_230bc1e5-180d-4404-8c60-eafaec8e04f2"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i52f89193810b43f085be64ba7f474b2d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzgtOC0xLTEtMTIxNDA_6c0a1a7e-630c-4dfc-8e6c-6cb40502a1b1"
      unitRef="usd">15920000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4094fc9d8da341cea659d729c71c046d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzgtMTAtMS0xLTEyMTQw_ca9520b2-df5c-4b9f-8df0-0a4e35ae49e4"
      unitRef="usd">16890000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i4094fc9d8da341cea659d729c71c046d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzgtMTQtMS0xLTEyMTQw_4a7231b0-a849-44c4-8092-d5c0f25fa659"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4094fc9d8da341cea659d729c71c046d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzgtMTYtMS0xLTEyMTQw_f5550a84-f6c1-483c-983d-3f91165e8316"
      unitRef="usd">16890000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktMi0xLTEtMTIxNDA_5dfa1538-be9c-4777-afa4-d38c1ea4d3c2"
      unitRef="usd">41835000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktNC0xLTEtMTIxNDA_56cb9011-5e74-49a7-97eb-7fe437e6ec01"
      unitRef="usd">8381000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktNi0xLTEtMTIxNDA_2d896566-0811-4dbd-a870-9c82a5f25fa9"
      unitRef="usd">1000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktOC0xLTEtMTIxNDA_30cc9d6b-ca0b-43c5-a61f-19df7aac74eb"
      unitRef="usd">33455000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktMTAtMS0xLTEyMTQw_9aa31362-dec3-4e4b-90fb-e60a47204d12"
      unitRef="usd">39787000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktMTItMS0xLTEyMTQw_f726dad8-fa72-4a27-ad2a-651cabfb0113"
      unitRef="usd">6660000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktMTQtMS0xLTEyMTQw_6f3c0962-6792-4a17-9ab9-0603ca105c78"
      unitRef="usd">-1000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTpmOGJkNTc4NTU4MWM0NDc5OTE2ZmY4YTk4YTlhYzBjZi90YWJsZXJhbmdlOmY4YmQ1Nzg1NTgxYzQ0Nzk5MTZmZjhhOThhOWFjMGNmXzktMTYtMS0xLTEyMTQw_1a7a2de9-5ed2-421a-b31d-11dc51ca560b"
      unitRef="usd">33126000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="ic1d241566dd94df38a909334019a059a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MDY4ODA_852e8cde-d13f-4acb-8f3c-18a88d8f6f12"
      unitRef="usd">-910000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="i6252373178cb4cf6833d9fea5111db48_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MDY4ODA_d1a66762-e464-4b3b-b853-3536fff9564d"
      unitRef="usd">910000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="i4914efbe4a514e3a9b1e8ce1c3d1f7a8_I20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MDY4OTU_3441c6c0-c3fd-4288-adf1-1b91b5746476"
      unitRef="usd">-1000000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="iea54bfd7cd894da1a9dc4dab9d27fd06_I20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MDY4OTU_352387f8-ec7d-4875-b249-57e2b0602092"
      unitRef="usd">1000000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="i034b60a8653f4767b2a7133e87e4160c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MDc5ODk_c4c31fa6-1655-48ed-a206-cf2e64e0750f"
      unitRef="usd">200000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="i30947e974d8c479392d193aad7a782fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MDc5ODk_f6bc5978-e79b-4e3a-bafa-9db1f3e430d4"
      unitRef="usd">-200000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i808afce6234d4f44b02493f616cfcdad_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzYzNQ_35aefad1-7edb-4667-aa9e-5e1d8b158339"
      unitRef="usd">1700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i157409bb1ea342b2a3f94ed6091834b3_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzYzOQ_1b0fbfa1-c55b-4e59-a6b1-9a4961ddb4c1"
      unitRef="usd">1200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4e62f0a33b96429bb3fe4df85eb86fd7_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzY0Ng_ccd03ac0-52f8-46bb-92cf-e641bffc8e4b"
      unitRef="usd">1100000000</us-gaap:AmortizationOfIntangibleAssets>
    <gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MTg4MDU_5ab37d07-ec15-476a-8c5c-b9d3ae58b046"
      unitRef="number">0.065</gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate>
    <gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzkzNDU4NDg4NTU0MzA_69924854-c073-4a82-abe9-552f72703c35"
      unitRef="number">0.080</gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate>
    <gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate
      contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzkzNDU4NDg4NTU0Mzg_20c26542-8b92-433e-8482-6f984ef9d0c1"
      unitRef="number">0.095</gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzU0OTc1NTgxNjIzMDc_48279e86-3fe5-4890-ba44-dcaf12435b18"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzU0OTc1NTgxNjIzMDc_4df6a240-fe27-400c-a1c0-948d8c3e6bdd"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i347295d908ea47bd9ef9a8fa1edea941_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzM4NDgyOTA3MTQ3NDk_1bebdf39-dd3f-486b-bfc9-f9ee1dafcf4e"
      unitRef="usd">800000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90ZXh0cmVnaW9uOjEwYjNjOGJkMWVmNDRjMWViYmYzYWEzNmJmZDQwYzU2XzI5MjI_c5ba2f3d-b61e-41fa-9809-84d98e7ef6e7">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzEtMi0xLTEtMTIxNDA_b750f926-196a-403f-84b5-67b39f510f5c"
      unitRef="usd">1778000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzItMi0xLTEtMTIxNDA_ebe28946-49ca-4390-998f-40a00d60ee73"
      unitRef="usd">1778000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzMtMi0xLTEtMTIxNDA_bd5673a6-273d-4093-8842-1d52c360e1b5"
      unitRef="usd">1778000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzQtMi0xLTEtMTIxNDA_e6b9e6fe-6478-442e-9e8e-11233dabb361"
      unitRef="usd">1773000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzUtMi0xLTEtMTIxNDA_f0f4f44f-1724-4399-b975-e49ebcf9ffb7"
      unitRef="usd">1765000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzYtMi0xLTEtMTIxNDA_3c03b2d2-53ee-4fcb-819a-881a45e310f0"
      unitRef="usd">8663000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjEvZnJhZzoxMGIzYzhiZDFlZjQ0YzFlYmJmM2FhMzZiZmQ0MGM1Ni90YWJsZTowZWNjMWJiMGI0YWI0NDg4OGEyMDQ2ZDZjMGFhZWRhYS90YWJsZXJhbmdlOjBlY2MxYmIwYjRhYjQ0ODg4YTIwNDZkNmMwYWFlZGFhXzctMi0xLTEtMTIxNDA_3f65f729-28f1-4d4b-8ffb-4688b6b93feb"
      unitRef="usd">17535000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90ZXh0cmVnaW9uOjc0ODdmYjEzZTYwNjQzNjJiNmZmM2UwMWYwMDM4YzVmXzIwNQ_f9031ce0-9fd3-48b9-b1a7-96be85e0cd68">OTHER FINANCIAL INFORMATION&lt;div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Accrued and other current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual for settlement related to bictegravir litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;See Note 14. Commitments and Contingencies for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90ZXh0cmVnaW9uOjc0ODdmYjEzZTYwNjQzNjJiNmZmM2UwMWYwMDM4YzVmXzIwOQ_fbc2d76a-eba2-40ed-9f17-b3c408220275">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzItMi0xLTEtMTIxNDA_52cb5d84-4652-41fd-b2f7-c0c209702bcd"
      unitRef="usd">5278000000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzItNC0xLTEtMTIxNDA_e595cda6-7e27-4fc5-b12e-8fe3173212d0"
      unitRef="usd">5560000000</us-gaap:AccountsReceivableGrossCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzMtMi0xLTEtMTIxNDA_e5256ea7-d8e1-4a06-b325-038fa25a4e13"
      unitRef="usd">671000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzMtNC0xLTEtMTIxNDA_1080a7a7-fae2-4b7e-9b00-bdf40c4b3c15"
      unitRef="usd">552000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzQtMi0xLTEtMTIxNDA_54af22ae-04e6-4c6b-a2dc-de92b20a002a"
      unitRef="usd">67000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzQtNC0xLTEtMTIxNDA_9cb2a3ad-10c5-460e-bc0f-466c68975de5"
      unitRef="usd">72000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzUtMi0xLTEtMTIxNDA_8845d98d-f54f-4ba4-9cfd-2d5f9801b753"
      unitRef="usd">47000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzUtNC0xLTEtMTIxNDA_dcfe2902-e004-455e-8cfd-1dd35f5c77c4"
      unitRef="usd">44000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzYtMi0xLTEtMTIxNDA_c35eca51-f2f4-4678-97e9-9877224e0402"
      unitRef="usd">4493000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZToxYmY5YTZkYjU3Nzg0ODNhOTkzMTgzOGVjOTFiMmZjYi90YWJsZXJhbmdlOjFiZjlhNmRiNTc3ODQ4M2E5OTMxODM4ZWM5MWIyZmNiXzYtNC0xLTEtMTIxNDA_8db9fea2-84fc-4084-8f59-93a2bade2021"
      unitRef="usd">4892000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90ZXh0cmVnaW9uOjc0ODdmYjEzZTYwNjQzNjJiNmZmM2UwMWYwMDM4YzVmXzIxNA_f62999e6-74e1-48e0-89a4-3afb44b0c796">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Accrued and other current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual for settlement related to bictegravir litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;See Note 14. Commitments and Contingencies for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzItMi0xLTEtMTIxNDA_c2e778e7-08d6-483a-865d-85f3a613612c"
      unitRef="usd">927000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzItNC0xLTEtMTIxNDA_ac7a3a2d-8abf-43c1-bf19-d46575cafcb1"
      unitRef="usd">864000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzMtMi0xLTEtMTIxNDA_9fc5fdaf-4d3c-460d-bd83-6f218eebba64"
      unitRef="usd">539000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzMtNC0xLTEtMTIxNDA_f4d4fc72-1a6b-4233-87e1-d94811629afe"
      unitRef="usd">598000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzQtMi0xLTEtMTIxNDA_d3e63481-b470-4eaa-8c7e-2bc43f3f2c4d"
      unitRef="usd">499000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzQtNC0xLTEtMTIxNDA_9c00b022-2c17-483a-b4c4-e8dfb32151a6"
      unitRef="usd">587000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzUtMi0xLTEtOTU4NDc_63d9e471-3bde-4157-bcd1-dd0c96efc52b"
      unitRef="usd">1250000000</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzUtNC0xLTEtOTU4NDc_5a6e8335-2147-485f-bad4-eb411b068321"
      unitRef="usd">0</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzUtMi0xLTEtMTIxNDA_20ee1843-a9a0-417c-b10e-34bb2eb45764"
      unitRef="usd">2930000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzUtNC0xLTEtMTIxNDA_f089e147-8569-4521-86b2-b49bc1ab2c24"
      unitRef="usd">2287000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzYtMi0xLTEtMTIxNDA_09e596d9-8713-4e4c-b2ad-e73972aba7d9"
      unitRef="usd">6145000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjQvZnJhZzo3NDg3ZmIxM2U2MDY0MzYyYjZmZjNlMDFmMDAzOGM1Zi90YWJsZTo4N2Y4Njc2YTE2YjA0M2QwYTg2YjVjYzczYThmNjhlMS90YWJsZXJhbmdlOjg3Zjg2NzZhMTZiMDQzZDBhODZiNWNjNzNhOGY2OGUxXzYtNC0xLTEtMTIxNDA_fd7959d2-7330-45de-9c68-72f9f5f8712d"
      unitRef="usd">4336000000</us-gaap:AccruedLiabilitiesCurrent>
    <gild:CollaborativeAndOtherArrangementsTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM1Mjg5_cd926421-d05f-4580-8b51-7792382c0bd6">COLLABORATIONS AND OTHER ARRANGEMENTS We enter into licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements and cost-sharing arrangements. We also have equity investments in third parties focused on the development and commercialization of products and product candidates. &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Merck &amp;amp; Co, Inc. (&#x201c;Merck&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 13, 2021, we entered into a license and collaboration agreement with Merck Sharp &amp;amp; Dohme Corp., a subsidiary of Merck to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#x2019;s investigational capsid inhibitor, lenacapavir, and Merck&#x2019;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration will initially focus on long-acting oral and injectable formulations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Gilead and Merck will share global development and commercialization costs at 60% and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, Gilead would lead commercialization in the United States, and Merck would lead commercialization in the European Union (&#x201c;EU&#x201d;) and rest of the world. For long-acting injectable products, if approved, Merck would lead commercialization in the United States and Gilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, Gilead and Merck would jointly promote the combination products in the United States and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of research and development costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Income. Expenses recognized under the agreement were not material for the year ended December 31, 2021. No revenues have been recognized under the agreement for the year ended December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will also have the option to license certain of Merck&#x2019;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#x2019;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first five years after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out, in which case the non-exercising company will be paid a royalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, Merck announced the decision of the parties to stop all dosing of participants in the Phase 2 clinical study evaluating an oral-weekly combination treatment regimen of lenacapavir and islatravir following the decision of FDA to place clinical holds on the investigational new drug applications for certain formulations of islatravir. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Arcus&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 27, 2020, we entered into a transaction with Arcus, a publicly traded oncology-focused biopharmaceutical company, which included entry into an option, license and collaboration agreement (the &#x201c;Collaboration Agreement&#x201d;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the &#x201c;Stock Purchase Agreements&#x201d;). In accordance with the terms of the Collaboration Agreement and Stock Purchase Agreements, which closed on July 13, 2020, we made an upfront payment of $175 million and acquired approximately 6.0&#160;million shares of Arcus common stock for approximately $200 million. Of the total $391 million initial cash payments, including transactional costs, made under the agreements, we recorded $135 million as an equity investment which was calculated based on Arcus&#x2019; closing stock price on the closing date of the transaction. The remaining $256 million was attributed to (i) the acquired license and option rights of $175 million representing IPR&amp;amp;D assets with no alternative future use, (ii) $65 million of an issuance premium for the equity purchase and (iii) $16 million of direct transactional costs. These amounts were expensed as Acquired in-process research and development expenses during the year ended December 31, 2020 on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Stock Purchase Agreements, we have the right to purchase additional shares of Arcus from Arcus over the five-year period beginning on the closing of the Stock Purchase Agreements, up to a maximum of 35% of the outstanding voting stock. We are subject to a three-year standstill, restricting our ability to acquire voting stock of Arcus exceeding more than 35% of the then-issued and outstanding voting stock of Arcus, subject to certain exceptions. Additionally, we agreed not to dispose of any equity securities of Arcus prior to the second anniversary of the closing of the Stock Purchase Agreements without the prior consent of Arcus, subject to certain exceptions. On May 29, 2020, in a separate secondary equity offering, we acquired 2.2&#160;million shares of common stock of Arcus for approximately $61 million. In the first quarter of 2021, we also acquired approximately 5.7&#160;million additional shares of Arcus common stock for $220 million. As a result, we currently own a total of 13.8&#160;million shares of Arcus, which represented approximately 19.5% of the issued and outstanding voting stock of Arcus immediately following the closing of the first quarter 2021 transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Collaboration Agreement, Gilead had the right to opt in to all current and future clinical-stage product candidates for up to ten years following the closing of the transaction. In November 2021, we exercised our options to three of Arcus&#x2019; clinical stage programs and amended the Collaboration Agreement. The option exercise and amendment transaction closed in December 2021, triggering collaboration opt-in payments of $725 million and waiving the $100 million option continuation payment which would have been due to Arcus in the third quarter of 2022. The net option charge of $625 million was recorded within Research and development expenses on our Consolidated Statements of Income for the year ended December&#160;31, 2021. The collaboration opt-in payments of $725 million were recorded in Accrued and other current liabilities on our Consolidated Balance Sheets as of December&#160;31, 2021 and paid to Arcus in January 2022. Our payments to Arcus will be included within Net cash provided by investing activities on our Consolidated Statements of Cash Flows in the first quarter of 2022. Under the amended Collaboration Agreement, the companies will co-develop and share the global costs related to these clinical programs. If the optioned molecules achieve regulatory approval, the companies will co-commercialize and equally share profits in the U.S. Gilead will hold exclusive commercialization rights outside the U.S., subject to any rights of Arcus&#x2019;s existing collaboration partners, and will pay to Arcus tiered royalties as a percentage of net sales ranging from the mid-teens and low twenties. Under the Collaboration Agreement, we may also pay an additional $100 million at our option on each of the fourth, sixth and eighth anniversaries of the agreement, unless terminated early, to maintain the rights to opt-in to future Arcus programs for the duration of the contact term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected and applied the fair value option to account for our equity investment in Arcus whereby the investment is marked to market each reporting period based on the market price of Arcus shares. We believe the fair value option best reflects the underlying economics of the investment. During the years ended December&#160;31, 2021 and 2020, we recorded pre-tax&lt;/span&gt;&lt;span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;unrealized gains of&lt;/span&gt;&lt;span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$127 million and $80 million, respectively, related to our investment in Arcus in Other income (expense), net on our Consolidated Statements of Income. We initially recorded our equity investments in Arcus in Other long-term assets on our Consolidated Balance Sheets as the investments were subject to contractual lock-up provisions for a period of two years from the closing date of the Stock Purchase Agreements, subject to certain conditions. In the third quarter of 2021, we reclassified our equity investments in Arcus to Prepaid and other current assets on our Consolidated Balance Sheets as the contractual lock-up provisions are expected to expire in July 2022. Our equity investment in Arcus was $559 million and $212 million as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Pionyr&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2020, we entered into a transaction with Pionyr, a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate merger agreements, one contemplating the initial acquisition of a 49.9% equity interest in Pionyr, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (together, the &#x201c;Pionyr Merger and Option Agreements&#x201d;) and a research and development service agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 13, 2020, we closed the transaction and made cash payments of $269 million. We account for our investment in Pionyr using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Pionyr. Our investment in Pionyr, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Pionyr's net assets at transaction closing. We determined that the resulting basis difference primarily relates to Pionyr&#x2019;s IPR&amp;amp;D which has no alternative future use and that Pionyr is not a business as defined in ASC 805, &#x201c;Business Combinations.&#x201d; As a result, we immediately recorded a charge for this basis difference of $215 million in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. The carrying value of our equity method investment in Pionyr was zero as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Pionyr is approximately $70 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount is recorded in Other long-term assets on our Consolidated Balance Sheets. We may choose to exercise our exclusive option to purchase the remaining equity interest from Pionyr&#x2019;s current shareholders for a $315 million option exercise fee and up to $1.2 billion in potential future milestone payments upon achievement of certain development and regulatory milestones. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Pionyr. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the research and development service agreement, we made an initial cash funding of $80 million and recorded a charge in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. In addition, we committed to provide additional payments of up to $115 million to Pionyr upon achievement of certain development milestones. We accrued $70 million in milestone payments, related to the initiation of two Phase 1 studies, with a charge to Research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020, and the payment was made in the first quarter of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tizona&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 17, 2020, we entered into a transaction with Tizona, a privately held company developing cancer immunotherapies, which included entry into two separate merger agreements, one contemplating the initial acquisition of a 49.9% equity interest in Tizona, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Tizona (together, the &#x201c;Tizona Merger and Option Agreements&#x201d;) and a development agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 25, 2020, we closed the transaction with Tizona and made cash payments of $302 million to Tizona&#x2019;s shareholders in accordance with the terms of the Tizona Merger and Option Agreements. We account for our investment in Tizona using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Tizona. Our investment in Tizona, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Tizona&#x2019;s net assets at transaction closing. We determined that the resulting basis difference primarily relates to Tizona&#x2019;s IPR&amp;amp;D with no alternative future use and that Tizona is not a business as defined in ASC 805, &#x201c;Business Combinations.&#x201d; As a result, during the year ended December 31, 2020, we immediately recorded a charge for this basis difference of $272 million in Acquired in-process research and development expenses on our Consolidated Statements of Income. The carrying value of our equity method investment in Tizona was zero as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Tizona is approximately $41 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount is recorded in Other long-term assets on our Consolidated Balance Sheets. We may choose to exercise our exclusive option to purchase the remaining equity interest from Tizona&#x2019;s current shareholders for a $100 million option exercise fee and up to $1.2 billion in potential future milestone payments upon achievement of certain development and regulatory milestones. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Tizona. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the development agreement, we committed to provide funding to Tizona of $115 million, which was recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tango Therapeutics, Inc. (&#x201c;Tango&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 17, 2020, we entered into a transaction with Tango, a privately held company pursuing innovative targeted immune evasion therapies for patients with cancer through its proprietary, CRISPR-enabled functional genomics target discovery platform, which included entry into an amended and restated research collaboration and license agreement and a stock purchase agreement (together, the &#x201c;Tango Collaboration and Stock Purchase Agreements&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon entering into this transaction, we made an upfront payment of $125 million and a $20 million equity investment in Tango. During the year ended December 31, 2020, we recorded the $125 million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income. In the third quarter of 2021, we made an additional $13 million equity investment. Tango became a publicly traded company in the third quarter of 2021, and accordingly our equity investment is recorded in Prepaid and other current assets on our Consolidated Balance Sheets at fair market value as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Tango Collaboration and Stock Purchase Agreements, Gilead has the right to option up to 15 programs over the seven-year collaboration for up to $410 million per program in opt-in, extension and milestone payments. For the products that Tango opts to co-develop and co-promote, the parties will equally split profits and losses, as well as development costs in the U.S. For products that Tango does not opt to co-develop and co-promote, we will pay Tango up to low double-digit tiered royalties on net sales. We will provide Tango milestone payments and royalties on sales outside of the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Jounce Therapeutics, Inc. (&#x201c;Jounce&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 1, 2020, we entered into a transaction with Jounce, a publicly traded company developing novel cancer immunotherapies, which included entry into license, registration rights and stock purchase agreements (together, &#x201c;Jounce License and Stock Purchase Agreement&#x201d;). In October 2020, we closed this transaction and made a total payment of $120 million. We recorded $64 million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income and $56 million as an equity investment in Other long-term assets on our Consolidated Balance Sheets, representing approximately 14% of the issued and outstanding voting stock of Jounce immediately following the transaction, which was calculated based on Jounce&#x2019;s closing stock price on the closing date of the transaction. As of December&#160;31, 2021, Jounce was eligible to receive from us up to $660 million in future potential clinical, regulatory and commercial milestone payments upon achievement of certain milestones, and royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Galapagos&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Filgotinib Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, we closed a license and collaboration agreement with Galapagos, a clinical-stage biotechnology company based in Belgium, for the development and commercialization of filgotinib, a JAK1-selective inhibitor being evaluated for inflammatory disease indications (the &#x201c;filgotinib agreement&#x201d;). Upon closing, we made an upfront license fee payment and an equity investment in Galapagos by subscribing for 6.8 million new ordinary shares of Galapagos at a price of &#x20ac;58 per share. We amended the terms of the agreement in 2019, 2020 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the filgotinib agreement, as amended in 2019 (the &#x201c;2019 Agreement&#x201d;), we obtained an exclusive, worldwide, royalty-bearing, sublicensable license for filgotinib and products containing filgotinib. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, following a Type A meeting with FDA to discuss the points raised in the Complete Response Letter related to the New Drug Application for filgotinib in the treatment of rheumatoid arthritis, Gilead and Galapagos agreed to amend the 2019 Agreement to allow Galapagos to assume development, manufacturing, commercialization and certain other rights for filgotinib in Europe which the parties reflected in an amendment to the 2019 Agreement in December 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning on January 1, 2021, Galapagos bore the development costs for certain studies, in lieu of the equal cost split contemplated by the 2019 Agreement. The parties transferred filgotinib&#x2019;s marketing authorizations in the EU and Great Britain to Galapagos in December 2021. As of January 1, 2022, all commercial economics on filgotinib in Europe transferred to Galapagos, subject to payment of tiered royalties of 8% to 15% of net sales in Europe to Gilead, starting in 2024. In connection with the amendments to the 2019 Agreement, Gilead agreed to irrevocably pay Galapagos &#x20ac;160 million (or approximately $190 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is subject to certain adjustments for higher-than-budgeted development costs. Of this total amount, Gilead paid &#x20ac;35 million (or approximately $43 million) in January 2021 and paid an additional &#x20ac;75 million (or approximately $88 million) in April 2021 and will pay &#x20ac;50 million (or approximately $60 million) in 2022. We accrued the full amount of this liability with a charge to Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. In addition, Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Global Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In&#160;August 2019, we closed an option, license and collaboration Agreement (the &#x201c;Galapagos Collaboration Agreement&#x201d;) and a subscription agreement (the &#x201c;Galapagos Subscription Agreement&#x201d;), each with Galapagos, pursuant to which the parties entered into a global collaboration that covers Galapagos&#x2019; current and future product portfolio (other than filgotinib). Upon closing, we paid $5.05 billion for the license and option rights and for 6.8 million new ordinary shares of Galapagos at a subscription price of &#x20ac;140.59 per share with a fair value of $1.13 billion, which included an issuance discount of $63 million calculated based on Galapagos&#x2019; closing stock price on the date of closing of the Galapagos Subscription Agreement. The remaining $3.92 billion of the payment was recorded within Acquired in-process research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Galapagos Subscription Agreement, we were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by Galapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. In 2019, we exercised a warrant to subscribe for 2.6 million ordinary shares of Galapagos at &#x20ac;140.59 per share and purchased shares on the open market with an aggregate fair value of $586 million, which brought the number of shares owned by us to 16.7 million or approximately 25.8% of the shares then issued and outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to a 10-year standstill restricting our ability to acquire voting securities of Galapagos exceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We agreed not to, without the prior consent of Galapagos, dispose of any equity securities of Galapagos prior to the second anniversary of the closing of the Galapagos Subscription Agreement or dispose of any equity securities of Galapagos thereafter until the fifth anniversary of the closing of the Galapagos Subscription Agreement, if after such disposal we would own less than 20.1% of the then-issued and outstanding voting securities of Galapagos, subject to certain exceptions and termination events. In April 2021, we amended the Galapagos Subscription Agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024. We have two designees appointed to Galapagos&#x2019; board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The initial contractual lock-up provision for certain Galapagos shares was due to expire in August 2021. As such, $351 million was included within Prepaid and other current assets on our Consolidated Balance Sheets and the remainder of $1.3 billion was included within Other long-term assets on our Consolidated Balance Sheets as of December&#160;31, 2020. Subsequent to the extension of the contractual lock-up period, all of our equity investment in Galapagos was classified to Other long-term assets on our Consolidated Balance Sheets, and was $931 million as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos&#x2019; shares. We believe the fair value option best reflects the underlying economics of the investment. During the years ended December&#160;31, 2021, 2020 and 2019, we recorded pre-tax&lt;/span&gt;&lt;span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;unrealized losses of&lt;/span&gt;&lt;span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$717 million and $1.8 billion and a pre-tax unrealized gain of $1.2 billion, respectively, related to our investment in Galapagos in Other income (expense), net on our Consolidated Statements of Income due to changes in Galapagos&#x2019; stock price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Galapagos Collaboration Agreement, we had an exclusive license for the development and commercialization of GLPG-1690, a late-stage candidate for idiopathic pulmonary fibrosis, in our territories and had an option to participate in the development and commercialization of Galapagos&#x2019; other current and future clinical programs that have entered clinical development during the first ten years of the collaboration, subject to extension in certain circumstances. Gilead and Galapagos terminated the Phase 3 clinical studies with GLPG-1690 in February 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to all other programs in Galapagos&#x2019; current and future pipeline, if we exercise our option to a program, we will pay a $150 million option exercise fee per program. In addition, Galapagos will receive tiered royalties ranging from 20% to 24% on net sales in our territories of each Galapagos product optioned by us. If we exercise our option for a program, the parties will share equally in development costs and mutually agreed commercialization costs incurred subsequent to our exercise of the option. We may terminate the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Complera/Eviplera and Odefsey&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2009, we entered into a license and collaboration agreement with Janssen, formerly Tibotec Pharmaceuticals, to develop and commercialize a fixed-dose combination of our Truvada and Janssen&#x2019;s non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011 and is sold under the brand name Complera in the U.S. and Eviplera in the EU.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen&#x2019;s rilpivirine and our emtricitabine and tenofovir alafenamide (&#x201c;Odefsey&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party&#x2019;s component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen&#x2019;s share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen&#x2019;s share of revenues is included in Cost of goods sold on our Consolidated Statements of Income. Cost of goods sold relating to Janssen&#x2019;s share was $530 million, $570 million and $574 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products, in which case Janssen has the right to become the selling party for such country if the product has launched but has been on the market for fewer than 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Symtuza&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen&#x2019;s darunavir and our cobicistat, emtricitabine and tenofovir alafenamide (&#x201c;Gilead Compounds&#x201d;). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the Gilead Compounds and are the exclusive supplier of the Gilead Compounds. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Symtuza. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party&#x2019;s component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Income primarily because we supply the Gilead Compounds to Janssen for Symtuza.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Japan Tobacco, Inc. (&#x201c;Japan Tobacco&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2005, Japan Tobacco granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Income. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Income. Royalty expenses recognized were $250 million, $291 million and $358 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are expected to be derived from the applicable products in our HIV portfolio. The amortization expense is classified as selling expense and recorded as Selling, general and administrative expenses on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gadeta B.V. (&#x201c;Gadeta&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, we entered into a collaboration arrangement with Gadeta and made a purchase of equity in Gadeta from Gadeta&#x2019;s shareholders. We determined that Gadeta was a VIE, and we were its primary beneficiary because we had the power to direct the activities of Gadeta that most significantly impact its economic performance. Upon the initial consolidation of Gadeta, we recorded $82 million to Noncontrolling interest, primarily reflecting acquired intangible assets related to IPR&amp;amp;D, on our Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, we effectively terminated the agreement with Gadeta. Upon the effective termination, we ceased to have a controlling interest and deconsolidated this VIE by removing the related net assets and noncontrolling interest of $82 million from our Consolidated Balance Sheets. The net loss from the deconsolidation was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Collaboration Arrangements That Are Not Individually Significant &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, 2020 and 2019, we entered into several collaborations, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements of $177 million, $129 million and $331 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively, within Acquired in-process research and development expenses on our Consolidated Statements of Income. Cash payments for our equity investments, other than those noted above, during the years ended December&#160;31, 2021, 2020 and 2019 were $147 million, $72 million and $118 million, respectively, which were primarily recorded within Prepaid and other current assets and Other long-term assets on our Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;Under the financial terms of these arrangements, we may be required to make payments upon achievement of various developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Consolidated Statements of Income when the corresponding events become probable. In connection with the regulatory approvals, milestone payments made will be capitalized as intangible assets and will be amortized to Cost of goods sold through the terms of these collaboration arrangements. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty.</gild:CollaborativeAndOtherArrangementsTextBlock>
    <gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
      contextRef="iaaddd81bb83f462cae89580391426788_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDM5MTA_764fc7dc-d3f2-4fdc-a997-eda99bb939d0"
      unitRef="number">0.60</gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts>
    <gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
      contextRef="i55469af46ac6444babd1103f64cce260_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDM5MTg_f2ce3e41-3bb8-457a-8bee-77ede232d3a8"
      unitRef="number">0.40</gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts>
    <gild:CollaborationArrangementNetProductSalesThreshold
      contextRef="ie62b8bd54ac5417b86b9d244cf6f31e4_D20210313-20210313"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDQ2MDQ_51964d29-fd11-4b97-91b3-2090f45ffd65"
      unitRef="usd">2000000000</gild:CollaborationArrangementNetProductSalesThreshold>
    <gild:CollaborationArrangementPercentOfGlobalProductRevenues
      contextRef="ie62b8bd54ac5417b86b9d244cf6f31e4_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDQ3MTg_1ce33064-5009-4d73-86fc-8b7ba561b1cd"
      unitRef="number">0.65</gild:CollaborationArrangementPercentOfGlobalProductRevenues>
    <gild:CollaborationArrangementNetProductSalesThreshold
      contextRef="i1366e28f1db34aa6adddcb7dc9cc3fe0_D20210313-20210313"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDQ3OTY_ec02d0df-2785-4d0d-a749-45c9407e7d30"
      unitRef="usd">3500000000</gild:CollaborationArrangementNetProductSalesThreshold>
    <gild:CollaborationArrangementPercentOfGlobalProductRevenues
      contextRef="ie62b8bd54ac5417b86b9d244cf6f31e4_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDQ5MTY_1ce33064-5009-4d73-86fc-8b7ba561b1cd"
      unitRef="number">0.65</gild:CollaborationArrangementPercentOfGlobalProductRevenues>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i0358f4e9723644c2ad88455c39676410_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3NDUxNTQ_ecb3b355-4d0f-4290-b71f-f430d5278182"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <gild:CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod
      contextRef="iaaddd81bb83f462cae89580391426788_D20210313-20210313"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzU0OTc1NTgzMzE5MzA_1962851a-6bdb-43cd-a94e-3295b294c814">P5Y</gild:CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM1NTE_9bf213b3-68d6-4502-b8cd-42c4dd51d15a"
      unitRef="usd">175000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <gild:InvestmentOwnedBalanceAdditionalShares
      contextRef="ieb4c98e8e51d40a1b47f8612c6763bdb_I20200713"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM1ODI_9dfd1e42-87b4-41ce-97ba-b9f80bc46e78"
      unitRef="shares">6000000</gild:InvestmentOwnedBalanceAdditionalShares>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM2MzM_57814447-af97-45e3-b511-c05590780b7f"
      unitRef="usd">200000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <gild:TotalUpfrontPaymentsMade
      contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM2NDU_07429dba-5c0d-49f3-ac63-749fc88d5e13"
      unitRef="usd">391000000</gild:TotalUpfrontPaymentsMade>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ieb4c98e8e51d40a1b47f8612c6763bdb_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM3NDg_4628d0fe-2d28-4bf9-8cfe-a9b6b67ddf2b"
      unitRef="usd">135000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM4OTQ_bcc2cfad-b2cd-4dc5-a53f-112acf22bec0"
      unitRef="usd">256000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjM5NTg_ebf6b921-493f-4edb-87a5-3d400404bf78"
      unitRef="usd">175000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <gild:IssuanceDiscountPremium
      contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjQwMjE_ffbe2da9-400b-4719-9275-bee2d6fc78de"
      unitRef="usd">-65000000</gild:IssuanceDiscountPremium>
    <gild:PaymentsForDirectTransactionalExpense
      contextRef="ic2c7fbf2cd7b4cc8b2144a6c9bd748cf_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjQwNzY_23ad27aa-3b08-474d-86a4-5ec49260572f"
      unitRef="usd">16000000</gild:PaymentsForDirectTransactionalExpense>
    <gild:EquitySecuritiesFVNIPurchasePeriod
      contextRef="i123ae893a43346c69c0dbe160845d982_D20200713-20200713"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzU0OTc1NTgzMzE5MzI_03e7239c-2475-4357-abfa-d99f9a0c5ad7">P5Y</gild:EquitySecuritiesFVNIPurchasePeriod>
    <gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
      contextRef="i123ae893a43346c69c0dbe160845d982_D20200713-20200713"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3ODczOTc_2afe01ea-f9c6-4219-a0df-8646d50e08b2"
      unitRef="number">0.35</gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased>
    <gild:EquitySecuritiesFVNIRestrictionPeriod
      contextRef="i123ae893a43346c69c0dbe160845d982_D20200713-20200713"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzU0OTc1NTgzMzE5MzE_9e273ed6-76f0-4c8c-a537-aedf136190e8">P3Y</gild:EquitySecuritiesFVNIRestrictionPeriod>
    <gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
      contextRef="i123ae893a43346c69c0dbe160845d982_D20200713-20200713"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3ODc0MDc_2afe01ea-f9c6-4219-a0df-8646d50e08b2"
      unitRef="number">0.35</gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i30f6211f84014d5fb004dbfaa00c87ea_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDA3Mjk_ebbaf299-0e5d-4581-bf8e-14ff946f824c"
      unitRef="shares">2200000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="ia724223fb3ac4ac189bcbeacf8570846_D20200529-20200529"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDA3NDc_16cc0bbd-f606-4ca4-b81f-a26e00ead497"
      unitRef="usd">61000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <gild:EquitySecuritiesFVNISharesAcquired
      contextRef="i097284d2fd8842978d347c1888e015ca_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3ODc0MjY_6fb19b5b-4ed0-4446-8adb-90a73fd16774"
      unitRef="shares">5700000</gild:EquitySecuritiesFVNISharesAcquired>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i097284d2fd8842978d347c1888e015ca_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3ODc0MzY_2c735839-1f87-42d3-b869-d820a85080af"
      unitRef="usd">220000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <gild:EquitySecuritiesFVNIShares
      contextRef="i2ef41f89acb2446a8d12c64235b715ba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3ODc0NDI_e5d94c6e-d6a5-40c3-8d6c-36ba2be33b12"
      unitRef="shares">13800000</gild:EquitySecuritiesFVNIShares>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i7c0c8d8e8e5041718f4702400109bd45_I20210208"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA3ODc0NTM_ca863a09-9c75-4146-900f-b9a5fe527c71"
      unitRef="number">0.195</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <gild:CollaborativeAgreementOptInTerm
      contextRef="i1ed865dca089431bac2babc189c7b73e_D20200527-20200527"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzU0OTc1NTgzMzE5MzM_07afab4f-408e-43ed-8c0d-4719e4dd4e5a">P10Y</gild:CollaborativeAgreementOptInTerm>
    <gild:NumberOfClinicalStageProgramsWithExercisedOptions
      contextRef="i6a21258292b74537b89e8497e7a5f1a1_I20211118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzU0OTc1NTgzMzE5NjA_9d2de1a2-db29-4516-ba45-e85bf9dd2fec"
      unitRef="program">3</gild:NumberOfClinicalStageProgramsWithExercisedOptions>
    <gild:PaymentsToOptInTheCollaborativeAgreement
      contextRef="i7fffbc21fc7d4b79950ac95fd954ed10_D20211221-20211221"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEwMDU_f52edeec-1a25-48cd-982c-163ac6006bcd"
      unitRef="usd">725000000</gild:PaymentsToOptInTheCollaborativeAgreement>
    <gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries
      contextRef="if55eb0ad124b4e9881655f8d21b1defb_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEwMjM_fd5ddfbb-1401-44e8-b8d1-730d54f067d0"
      unitRef="usd">100000000</gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib55eff2de05b4735962a5178e2d0c136_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwMDg4OTU_fc700c57-c907-47d2-8beb-3b604f9de495"
      unitRef="usd">625000000</us-gaap:ResearchAndDevelopmentExpense>
    <gild:PaymentsToOptInTheCollaborativeAgreement
      contextRef="i7fffbc21fc7d4b79950ac95fd954ed10_D20211221-20211221"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3MDQyNDMwNDUyNzM4_f52edeec-1a25-48cd-982c-163ac6006bcd"
      unitRef="usd">725000000</gild:PaymentsToOptInTheCollaborativeAgreement>
    <gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries
      contextRef="if55eb0ad124b4e9881655f8d21b1defb_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjM0NDg1OTc_fd5ddfbb-1401-44e8-b8d1-730d54f067d0"
      unitRef="usd">100000000</gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="ib55eff2de05b4735962a5178e2d0c136_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNTgxMDM_27c5239d-ce41-4a20-8889-2bd561a78c96"
      unitRef="usd">127000000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="i91b41bd2879340d590e60e9612a0f797_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNTgxMDc_0c147255-58f8-486a-8594-cd3f907129ad"
      unitRef="usd">80000000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ide14895bf0d94cfda60b8f404be8046a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MzE5MTY_21624019-9ac0-4fbf-b69b-73afa4768fbc"
      unitRef="usd">559000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5dbdcfe118594570aa52cb141478f07d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MzM5NDE_44d76466-58fd-42c1-9e97-8d35acc5b992"
      unitRef="usd">212000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="if414b8855b364ef693704d5b8001f3de_I20200619"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjM0MzU4OTY_b9b1efda-c401-46cd-8831-72a69b04ed20"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i2e1550a829c24cdb927d71b758e41d28_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEwNTk_16b67255-bb10-40bc-a666-e616019bd573"
      unitRef="usd">269000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if7c095b57994471c805950b5c5648d45_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEwNDE_a294c246-5904-49c8-8619-ebce04639e20"
      unitRef="usd">215000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:EquityMethodInvestments
      contextRef="iade36ecd4b2f43d18bc13b3efe3cfbb6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNDE0MTI_92071be1-4ab2-4054-9451-afe7feb6f968"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i440f8eb082024226b3b774d89e0637e0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNDE0MTI_f530b755-7fe9-4ffb-b5c3-99309a9739bf"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="i4ffb74e13be94db9b8207cb1d854b5c7_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEwOTI_01323ac7-ab01-4423-94be-22fda457d545"
      unitRef="usd">70000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <gild:EquityMethodInvestmentOptionExerciseFee
      contextRef="i4ffb74e13be94db9b8207cb1d854b5c7_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDExMDc_3d814ca0-674a-4687-9a47-7c08bcc68669"
      unitRef="usd">315000000</gild:EquityMethodInvestmentOptionExerciseFee>
    <gild:PotentialFutureMilestonePaymentsMaximum
      contextRef="i4ffb74e13be94db9b8207cb1d854b5c7_I20200713"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDExMjI_2d5bcd5c-caf9-48b3-83f6-a250a06a2252"
      unitRef="usd">1200000000</gild:PotentialFutureMilestonePaymentsMaximum>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6d004159e86645f4b54571d61ef34b7a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDExNDc_76cdac37-5f05-46d7-ab72-4265f648903b"
      unitRef="usd">80000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:ResearchAndDevelopmentFutureMaximumPayments
      contextRef="ifb5f6c23a9644726bde59d143b28193d_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDExNjI_f91137f9-ba8e-431e-986a-d7cfad486fb1"
      unitRef="usd">115000000</gild:ResearchAndDevelopmentFutureMaximumPayments>
    <gild:PaymentsForResearchAndDevelopmentMilestones
      contextRef="id404a80a80e44a99a559bfcef8dd06bd_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDExNzY_d04bdd38-8c8d-4a73-82d1-d01f3f4667a2"
      unitRef="usd">70000000</gild:PaymentsForResearchAndDevelopmentMilestones>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i697aa6050edb4e629c83ae942ed52f29_I20200717"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjM0MzU5MDQ_85798bd0-6ff7-48b9-af68-268fe6746117"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i397dc877c7694d19958b40ce06f66597_D20200825-20200825"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEzMTY_98d58f86-f953-4206-873c-6c9b16546211"
      unitRef="usd">302000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i49d256c267ef40f8ab7c6c8aa7a19bf9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEzMzQ_5335e87c-61a6-4873-a919-4a5d65f44627"
      unitRef="usd">272000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:EquityMethodInvestments
      contextRef="i9b799eb641ab49b28bf86c39cc6029ff_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNDE0Mjk_5edb840a-cbd8-4920-9a7f-ec3e98c43f0a"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2b9c16a178a84867be9f2a8338568380_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNDE0Mjk_75a39f81-ec2e-476d-86f3-6536de0f64f4"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="ib17c6ee7308a4338b6c4a503ef2f8d57_I20200825"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEzNTE_819ca1ee-36b1-486c-a578-4ed8ca303769"
      unitRef="usd">41000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <gild:EquityMethodInvestmentOptionExerciseFee
      contextRef="ib17c6ee7308a4338b6c4a503ef2f8d57_I20200825"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MzQyMzk_c10d7efc-1daf-4d2b-9f4f-ef00a3961bc7"
      unitRef="usd">100000000</gild:EquityMethodInvestmentOptionExerciseFee>
    <gild:EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments
      contextRef="i6db4377ec93e4d7bbbe59b9ebfaba7ca_I20200825"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEzNjk_98c72c81-17ec-442b-af71-a63e18cb79e5"
      unitRef="usd">1200000000</gild:EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i339e56a5445e42a7bd636e9572986490_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDEzODc_26b99207-de8b-4800-a951-532f89947703"
      unitRef="usd">115000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE0Njk_7661042b-668b-49a6-a321-21116dae7efe"
      unitRef="usd">125000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE0ODQ_bfe89be2-c719-4571-aac7-642352f2cf59"
      unitRef="usd">20000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE1MTE_16a71bb6-14e2-41f5-9caf-9c258d8a974e"
      unitRef="usd">125000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE1Mjk_f0096ac0-613d-409d-aada-277e32f6d7d5"
      unitRef="usd">13000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <gild:NumberOfPrograms
      contextRef="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjM0MzU5MDk_70d999c6-e894-4070-998c-c3172d7ab376"
      unitRef="program">15</gild:NumberOfPrograms>
    <gild:CollaborativeArrangementTerm
      contextRef="i6c1da9825ddb40dc98a51d504a28827e_D20200817-20200817"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzU0OTc1NTgzMzE5ODA_293b516a-ebd2-4580-ba87-e2bd6fbf2a88">P7Y</gild:CollaborativeArrangementTerm>
    <gild:EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments
      contextRef="i218f3bf11f8c42b7b70c818ee6cc5f8f_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE1NTM_0b906424-bde5-456a-8c0f-3b5fbd118946"
      unitRef="usd">410000000</gild:EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments>
    <gild:TotalUpfrontPaymentsMade
      contextRef="i6623efe8bef84a7791fcfec2fcc2f16b_D20201001-20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE1NzA_40ee5e69-f421-4cf8-b606-1902f65646fb"
      unitRef="usd">120000000</gild:TotalUpfrontPaymentsMade>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="icb7bf0dc4a3e43daaefa71f64c8916e5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NDkyNjc2MjY3MTE_6e202f2d-ce9a-4578-a4ab-68e2ac8d8351"
      unitRef="usd">64000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="i6623efe8bef84a7791fcfec2fcc2f16b_D20201001-20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE1ODg_604536e0-3518-4901-9514-401dfc4f5b05"
      unitRef="usd">56000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i9750074cced84b80b470f7d052116226_I20201031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE1OTQ_bf43df15-6de1-4829-87cd-9f703b7abce3"
      unitRef="number">0.14</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <gild:PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum
      contextRef="i85f6aa2b44894183be1329a1fd12b947_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzEwOTk1MTE4MDE2NjE_abdb173a-75ec-4626-a5f4-68ee790a340b"
      unitRef="usd">660000000</gild:PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i4143eccc523441058a76f70c0b3fe14a_I20160119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE0MDU4_49d55973-dd63-48d9-a5ac-bdcd5f2807a1"
      unitRef="shares">6800000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="i4143eccc523441058a76f70c0b3fe14a_I20160119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE0MTA4_976305e6-e1f6-427c-89ef-ae365ba5bfbb"
      unitRef="eurPerShare">58</us-gaap:SharePrice>
    <gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage
      contextRef="i38d8e949cd7d431c99be65bf7f658b30_I20201215"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2Mzcw_77a45880-ac7a-4f72-9d3b-1256c1ae71c3"
      unitRef="number">0.08</gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage>
    <gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage
      contextRef="i38d8e949cd7d431c99be65bf7f658b30_I20201215"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2Mzc2_1950e8d4-04c9-42fc-95c7-327892563e25"
      unitRef="number">0.15</gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage>
    <gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts
      contextRef="i38d8e949cd7d431c99be65bf7f658b30_I20201215"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NTMx_1790dc9f-ddaa-4f35-8f78-81513ed06102"
      unitRef="eur">160000000</gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts>
    <gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts
      contextRef="ibfef5580108a40bb81fbb13f508788a2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NTUy_36c5154e-2a3e-47f1-8fdc-aef0d650c4ee"
      unitRef="usd">190000000</gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts>
    <gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts
      contextRef="i67c0a0b9d43540d6bb4a7d7d6f17ebcc_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2Njc1_030a0665-a96b-485e-95fb-dd8c4d5dec11"
      unitRef="eur">35000000</gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts>
    <gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts
      contextRef="i67c0a0b9d43540d6bb4a7d7d6f17ebcc_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2Njk2_84e5b34e-1ab4-4976-8ccc-fbfab21824ea"
      unitRef="usd">43000000</gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts>
    <gild:AdjustmentsOfBudgetedDevelopmentCostsPayments
      contextRef="i67e54ce58cd24263aa47b0dc690946cc_I20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NzQz_b2718b13-77f5-4dd6-b94d-0cc5ed6bfaa6"
      unitRef="eur">75000000</gild:AdjustmentsOfBudgetedDevelopmentCostsPayments>
    <gild:AdjustmentsOfBudgetedDevelopmentCostsPayments
      contextRef="i67e54ce58cd24263aa47b0dc690946cc_I20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2NzY0_536a1927-b2c8-408c-8302-bd10899305da"
      unitRef="usd">88000000</gild:AdjustmentsOfBudgetedDevelopmentCostsPayments>
    <gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths
      contextRef="i97319e361fc94cc9a211d39a12605abd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2Nzg5_58b1a5c3-4fca-4825-b69f-99e2b29847e9"
      unitRef="eur">50000000</gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths>
    <gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths
      contextRef="i97319e361fc94cc9a211d39a12605abd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE2ODEw_d8646399-f3a2-4741-b523-c5068a73279c"
      unitRef="usd">60000000</gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths>
    <gild:PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing
      contextRef="i696425f28417451f92ec8151983911c1_D20190801-20190831"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3NTUz_3ed08ae0-753a-4515-b9c2-2e8005b6c886"
      unitRef="usd">5050000000.00</gild:PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3NTk4_6f844abc-16b7-494c-9a55-e3c85f2c4c2c"
      unitRef="shares">6800000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3NjYx_90a3d0c7-2630-470c-bc23-1f4862e1bc75"
      unitRef="eurPerShare">140.59</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3Njk1_5b647fd4-5e23-41ed-b2e6-8d4180dc804e"
      unitRef="usd">1130000000</us-gaap:EquityMethodInvestments>
    <gild:Issuancediscount
      contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3NzM4_93fed1d6-6450-44f7-a085-32a6f1f594e7"
      unitRef="usd">63000000</gild:Issuancediscount>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i7927d3d1315d45eab4bbe1b07f2029c6_D20190101-20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE3ODcw_5596c32f-0e0e-4620-ad0d-6dcc59b20cc5"
      unitRef="usd">3920000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement
      contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4MjIz_e964d399-7247-48ef-af16-f8f607a62455"
      unitRef="number">0.299</gild:MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement>
    <gild:InvestmentOwnedBalanceAdditionalShares
      contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4MzQy_abdc39b3-71ab-489a-b6c1-8417d5c2c01d"
      unitRef="shares">2600000</gild:InvestmentOwnedBalanceAdditionalShares>
    <us-gaap:SharePrice
      contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4Mzc3_90a3d0c7-2630-470c-bc23-1f4862e1bc75"
      unitRef="eurPerShare">140.59</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4NDYy_1befe1d3-7171-411f-9961-f6c1026cd8c8"
      unitRef="usd">586000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="ib85c08bffd6947139520ddf1b963fae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4NTE2_48b35c81-02d0-4c8e-9752-4aae2e31ea59"
      unitRef="shares">16700000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4NTM2_12d51d33-4055-4755-be88-21cf4fdf7fe3"
      unitRef="number">0.258</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <gild:StandstillRestrictingTerm
      contextRef="i696425f28417451f92ec8151983911c1_D20190801-20190831"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM1Mjkz_4dc0e383-a66b-4187-9fb2-b121b20e00b6">P10Y</gild:StandstillRestrictingTerm>
    <gild:MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement
      contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE4ODY1_2eb37151-a10e-465d-827f-0b05063fe119"
      unitRef="number">0.299</gild:MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement>
    <gild:MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement
      contextRef="i6ebdcf15388b47788ebf7553317d34c4_I20190831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzE5MzE2_93ef6044-6975-4a62-9d51-fb18b4da5e1e"
      unitRef="number">0.201</gild:MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2011c1fa80f041a5b06d24015e3d5227_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwMDY1Njg_315f0a22-75d5-48fd-96f3-6f33c2e536a6"
      unitRef="usd">351000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2011c1fa80f041a5b06d24015e3d5227_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwMDY1ODI_c86c99f5-0fbb-49d4-b497-d76d003025bb"
      unitRef="usd">1300000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="ia9a5706c39e84b85ac9e1d0f522c9890_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzk4OTU2MDQ4MjY0NzU_54a22ef4-57b3-4cf0-a22f-1464beef1c39"
      unitRef="usd">931000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i4db427db2e8f4ebfa1972445ce88c38c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIwMjE4_46a663aa-ff64-41fe-adae-418e610f1b16"
      unitRef="usd">717000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i6db86d92098f4af891245ad653df5061_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwMTQ2MzA_ba0538ad-bcf9-49d9-b7f7-bc27914f7b7e"
      unitRef="usd">1800000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="i6db86d92098f4af891245ad653df5061_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzkzNDU4NDkwNTc2NjY_1ea14187-d52f-4921-bf5d-73127fb26e17"
      unitRef="usd">1200000000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <gild:PotentialOptionExerciseFeePerProgram
      contextRef="i7372c5e4ed6845fca519e44a4bb17431_I20190831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxMzEw_1969d997-2150-4524-b616-9d4b623421f6"
      unitRef="usd">150000000</gild:PotentialOptionExerciseFeePerProgram>
    <gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage
      contextRef="i7372c5e4ed6845fca519e44a4bb17431_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxNDEy_f24a4620-78d6-40a4-ac6d-1013c852606d"
      unitRef="number">0.20</gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage>
    <gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage
      contextRef="i7372c5e4ed6845fca519e44a4bb17431_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxNDE4_907868f0-c303-4bbc-a316-de49f9680529"
      unitRef="number">0.24</gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage>
    <gild:PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage
      contextRef="i5dad1dfaca274c1799a38e45db78a46f_I20141231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI0MjM5_03ea9333-b71e-406b-9132-3b43163f741c"
      unitRef="number">0.30</gild:PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i45c072246c2f4e6d946c5c5570d2fed8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA4MzE4ODI_7b49692a-43e8-42d7-909d-595d1039f341"
      unitRef="usd">530000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6ce860376b2440a786d96346e8ce0f89_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI0NDQ2_093c6a3c-d729-43b5-94ee-d6e8f2e00d48"
      unitRef="usd">570000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i578443185f7749589002f4f312b78678_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI0NDUw_87d142b4-7b83-4558-b71b-3b5097e1e7b0"
      unitRef="usd">574000000</us-gaap:CostOfGoodsAndServicesSold>
    <gild:CollaborativeAgreementProductMarketPeriodSubjectToTermination
      contextRef="i0dba157973574ff69d357c2d296e62e9_D20140101-20141231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjM0MzU5OTU_5a90cfe6-3a22-49ee-aeef-d433f7b35c85">P10Y</gild:CollaborativeAgreementProductMarketPeriodSubjectToTermination>
    <gild:CollaborativeAgreementProductMarketPeriodSubjectToTermination
      contextRef="i0dba157973574ff69d357c2d296e62e9_D20140101-20141231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjM0MzYwMDA_5a90cfe6-3a22-49ee-aeef-d433f7b35c85">P10Y</gild:CollaborativeAgreementProductMarketPeriodSubjectToTermination>
    <us-gaap:RoyaltyExpense
      contextRef="i58b324bcac2249b5930ebbcdea8ee4c1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM4NDgyOTA4MzE5MDM_976ea28a-5d3d-495c-b534-3e618527ee5b"
      unitRef="usd">250000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i3bdde946e55442a1aa5d7882ec1e7427_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI4NDY1_d8d66a66-4753-4742-a7ee-f214e8861af9"
      unitRef="usd">291000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i00e7665e176c479ea7bb308c8eeca6b6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI4NDY5_095c85bf-1903-4f66-a9e6-67d159f228da"
      unitRef="usd">358000000</us-gaap:RoyaltyExpense>
    <gild:InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan
      contextRef="i2d244f0e9b79475cb0ba4b314b832cfe_D20181201-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI4OTg1_14b80878-6801-4500-9497-67f41b9a23b0"
      unitRef="usd">559000000</gild:InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i2d244f0e9b79475cb0ba4b314b832cfe_D20181201-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI5MTIx_d52e69a8-40fd-4228-a159-b27499e49183"
      unitRef="usd">550000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2d244f0e9b79475cb0ba4b314b832cfe_D20181201-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzI5MzQz_eb4a4921-9813-44a4-80e4-c2133c9c7b1d">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="ie60c8cd3db5843dc97136850ade2673e_I20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzMwMjQ4_8668003f-c14d-4465-aebc-f7469767b933"
      unitRef="usd">82000000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="i0ba0c9e44c9746718a04e414e6de9857_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzMwNTkx_9d309eed-d8a4-4e4b-9779-7edf158e3b25"
      unitRef="usd">82000000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant
      contextRef="i5beb0d51c4e54f94969f8c6cd1ba0419_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM0MTA4_1e35fc37-e05e-449d-92a2-e48fed4d330f"
      unitRef="usd">177000000</gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant>
    <gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant
      contextRef="i8e25b453d1fa4d85a5dca483e607e4d9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjMyOTQ1MDc_e7b7e7f2-e735-4c88-bdf0-acc382b1b13d"
      unitRef="usd">129000000</gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant>
    <gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant
      contextRef="icde588c2a460402c9deeff992fa80573_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzIxOTkwMjMyOTQ1MTE_65e5f47c-5077-4c41-8b6b-71b0512bafa6"
      unitRef="usd">331000000</gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="i5beb0d51c4e54f94969f8c6cd1ba0419_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM0MzM1_a3c31b86-c9fa-4bf5-b981-72e96f032b49"
      unitRef="usd">147000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="i8e25b453d1fa4d85a5dca483e607e4d9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM0MzM5_d8dd2353-3ca3-4df9-9247-7bdf3db4c409"
      unitRef="usd">72000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="icde588c2a460402c9deeff992fa80573_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMjcvZnJhZzo4MTM1NWE4ZGNmYzg0YzE5YTEwODllODY3NTlmNzc4Yi90ZXh0cmVnaW9uOjgxMzU1YThkY2ZjODRjMTlhMTA4OWU4Njc1OWY3NzhiXzM0MzQ2_e959091a-5991-4970-ba78-f9279bcda94c"
      unitRef="usd">118000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2ODc_b609255d-0d88-42f1-9ddd-05d9ac99eac5">DEBT AND CREDIT FACILITIES&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Due Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.52%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;variable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes and term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes and Term Loan Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we repaid $4.75 billion of debt, consisting of $3.75 billion senior unsecured notes and $1.0 billion of our senior unsecured term loan facility. We repaid $1.0 billion of senior unsecured notes due April 2021 in the first quarter of 2021 and $1.25 billion of senior unsecured notes due December 2021 in the third quarter of 2021. Additionally, we repaid $500 million of senior unsecured floating rate notes due upon maturity in September 2021. In October 2021, we exercised our option to call $500 million of senior unsecured floating rate notes and $500 million of 0.75% senior unsecured notes, both having a final maturity date of September 2023. These two early repayments totaling $1.0&#160;billion principal amount were made in the fourth quarter of 2021. In December 2021, we exercised our option to call $500 million of senior unsecured notes having a final maturity of March 2022. The notes were repaid in February 2022. No new debt was issued in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our senior unsecured fixed rate notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed and (ii) the sum, as determined by an independent investment banker, of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium as defined in the indenture. The senior unsecured fixed rate notes also have a call feature, exercisable at our option, to redeem the notes at par in whole, or in part, on dates ranging from one month to two years prior to maturity. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption. The $1.5&#160;billion of 0.75% senior unsecured notes due September 2023 also have a call feature, exercisable at our option, to redeem the notes at par, in whole or in part, after September 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event of the occurrence of a change in control and a downgrade in the rating of our senior unsecured notes below investment grade by Moody&#x2019;s Investors Service, Inc. and S&amp;amp;P Global Ratings, the holders may require us to purchase all or a portion of their notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest to the date of repurchase. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of December&#160;31, 2021 and 2020, we were not in violation of any covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into a commitment letter with a group of institutional lenders to provide for a three-year senior unsecured term loan facility in an aggregate principal amount of $1.0&#160;billion. In October 2020, in connection with our acquisition of Immunomedics, we entered into a term loan credit agreement (the &#x201c;Term Loan Facility&#x201d;) and borrowed an aggregate principal amount of $1.0&#160;billion. In 2021, we repaid $1.0 billion principal amount outstanding under the Term Loan Facility which was due upon maturity in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liability Related to Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Immunomedics, we assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI, prior to our acquisition of Immunomedics. The liability related to future royalties was primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revolving Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, we terminated our $2.5 billion five-year revolving credit facility maturing in May 2021 (the &#x201c;2016 Revolving Credit Facility&#x201d;) and entered into a new $2.5 billion five-year revolving credit facility maturing in June 2025 (the &#x201c;2020 Revolving Credit Facility&#x201d;). The 2020 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of December&#160;31, 2021 and 2020, there were no amounts outstanding under the 2020 Revolving Credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Revolving Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default. As of December&#160;31, 2021, we were in compliance with all covenants. Loans under the 2020 Revolving Credit Facility bear interest at either (i) the Eurodollar Rate plus the Applicable Percentage, or (ii) the Base Rate plus the Applicable Percentage, each as defined in the 2020 Revolving Credit Facility agreement. We may terminate or reduce the commitments, and may prepay any loans under the credit facility in whole or in part at any time without premium or penalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual Maturities of Financing Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate future principal maturities of our senior unsecured notes as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;Interest expense on our debt and credit facilities related to the contractual coupon rates and amortization of the debt discount and issuance costs was $1.0 billion in 2021, 2020 and 2019.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2NjQ_842fe4ce-ce42-45fd-9fbe-94df663ca222">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Due Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.52%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;variable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes and term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i88553ac9d9624f42958c6f396678542b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzQtNi0xLTEtMTIxNDA_4b3cd12c-8016-4f16-baba-8133bd9ee120"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i88553ac9d9624f42958c6f396678542b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzQtOC0xLTEtMTIxNDA_fc1eeeb5-7634-4851-9a72-f1695be3d811"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4800b053ef3c4136a3cc63c8103e707a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzQtMTAtMS0xLTEyMTQw_38d3e032-f5c7-4b58-82cf-2f71ce41af2d"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i15ff3826397c4b51af10501cdfc1ffbd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzUtNi0xLTEtMTIxNDAvdGV4dHJlZ2lvbjpkZDAwMzZhZjQwNTE0MWQ1YTJhNjM2MDU0ZDQ4MmIxZV8yMA_b27a6d93-0264-4bd1-bfcb-b72cfd0bd4ac"
      unitRef="number">0.0015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="ic90520151d5e45a5b3bafe9e36c40ab1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzUtOC0xLTEtMTIxNDA_54b67149-7787-4fb8-8013-77c5addec42a"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="idbd11fa3c26e4fd38091c2e840bb69d9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzUtMTAtMS0xLTEyMTQw_02de088f-b6a6-4282-a1f9-956b9ddc1ae9"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if49d256ecf4c4fccb417a3006ed896b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzYtNi0xLTEtMTIxNDA_4ef552c0-625a-4a4f-90c6-6cfeb532aee7"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if49d256ecf4c4fccb417a3006ed896b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzYtOC0xLTEtMTIxNDA_6336878b-e390-4e66-80ed-f19780024217"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia2d9c33739db4dc08bf4edd765bd7407_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzYtMTAtMS0xLTEyMTQw_6da07ff8-7a23-4f15-945e-b356c211e620"
      unitRef="usd">1249000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if32ef749e53840578fa5654cc25b8c69_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzctNi0xLTEtMTIxNDA_ae475008-abbf-4f64-a476-5737f15a28b2"
      unitRef="number">0.0195</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if32ef749e53840578fa5654cc25b8c69_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzctOC0xLTEtMTIxNDA_187dd779-e7c7-4304-b249-c6f64b658975"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i43afc0414e494b869b770762bc4d9a52_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzctMTAtMS0xLTEyMTQw_1ceb2caf-833c-495a-9311-f28d2b1a6f03"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i51ed2cd34ce84554940fc25d819f2777_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzgtNi0xLTEtMTIxNDA_90699933-44cc-41c3-b61d-44ad2e3b8dd1"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i51ed2cd34ce84554940fc25d819f2777_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzgtOC0xLTEtMTIxNDA_cddf2c38-a653-48d3-8547-e7d3b244155d"
      unitRef="usd">999000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibab69215b4e64f54a4722114423cf768_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzgtMTAtMS0xLTEyMTQw_5595a618-d0ad-4900-a65f-577d73880b86"
      unitRef="usd">998000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia79e2cc5633d4132a25a764b4a709783_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzktNi0xLTEtMTIxNDA_cb3f14c6-ac75-42b8-9e46-ba46b82872c2"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia79e2cc5633d4132a25a764b4a709783_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzktOC0xLTEtMTIxNDA_e5c180f9-0b81-4699-ad13-baea263a4e39"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if6efa694deb2427e8f5f99cf4f174aa3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzktMTAtMS0xLTEyMTQw_08955d50-8157-43b1-aff8-65124a5b2e52"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4db7fc21d050453fb55088da46769875_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEwLTYtMS0xLTEyMTQwL3RleHRyZWdpb246NGU5OWRlNTFhMWYxNDcyOTg1NTM5NTBiZDAzZTIyYWVfMjA_829ec86b-1268-4ed5-9c83-1eaca27a63af"
      unitRef="number">0.0052</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="if57ff25bef0d4bf4a3e07a11a72aa1c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEwLTgtMS0xLTEyMTQw_434a5cc5-eb03-4cdf-b8ac-645893ec8204"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib7fe7b7bd7a749eca2309daea67e59ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEwLTEwLTEtMS0xMjE0MA_9f2544c9-c6ba-4002-bca0-f1d7e2cafaf8"
      unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iff239ca5ea6542a1b65cc0ff2d9218fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzExLTYtMS0xLTEyMTQw_ff076239-5ae5-4978-996b-693bcb4b33d9"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="iff239ca5ea6542a1b65cc0ff2d9218fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzExLTgtMS0xLTEyMTQw_ff1b2a94-3522-4301-aa8f-e54e27397065"
      unitRef="usd">1496000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i24f46a74be3740deb3686fa5d733f011_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzExLTEwLTEtMS0xMjE0MA_ba7aae20-36f4-4e64-bca3-fe1dc649d9a4"
      unitRef="usd">1992000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1dea7ef2353348b9b97eb413fb4c0d7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEyLTgtMS0xLTEyMTQw_b9791fba-1861-4263-a272-b50f7bad2c3d"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i85abfdacc7a34da5888f65dc84ca6fca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEyLTEwLTEtMS0xMjE0MA_fa67e811-081e-470c-8c8f-e855525bd80e"
      unitRef="usd">998000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i20a94020fb22453791fa3f7a17071381_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEzLTYtMS0xLTEyMTQw_23de4d7b-ca7e-4011-892d-c1a3de21dc24"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i20a94020fb22453791fa3f7a17071381_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEzLTgtMS0xLTEyMTQw_5ad840bb-3d2a-4b3f-ad5f-3b4f8cd9874d"
      unitRef="usd">1747000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i44be2f180cd740a2817d4a90b827ce9c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzEzLTEwLTEtMS0xMjE0MA_a30f5f8b-dce3-4933-9f6a-2bfbcb99b763"
      unitRef="usd">1746000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib5f33f1a524c46ef989dcaf10d803a74_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE0LTYtMS0xLTEyMTQw_79616797-2071-4f24-9bf8-cac8225e0e0a"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib5f33f1a524c46ef989dcaf10d803a74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE0LTgtMS0xLTEyMTQw_63f26b62-0d6a-4bbe-be6a-9cd90d60b724"
      unitRef="usd">1747000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie05fed16be294c6fb4bbc7419f3eaef4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE0LTEwLTEtMS0xMjE0MA_cd26ef0e-5d42-48d0-bed0-d2391bd3e440"
      unitRef="usd">1746000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6e4a183e1199483b92ed085372e796c5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE1LTYtMS0xLTEyMTQw_67b1ec99-3b86-4a5c-828c-87c260816f5f"
      unitRef="number">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i6e4a183e1199483b92ed085372e796c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE1LTgtMS0xLTEyMTQw_6e0a326b-aa93-4ca5-8cea-9222654abd31"
      unitRef="usd">2739000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="idb302b98be6d4fe8bcaa37065ebb5a54_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE1LTEwLTEtMS0xMjE0MA_ba722c59-0703-4507-bd65-3527ebcc098c"
      unitRef="usd">2737000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib60a477703704a5b8d5fee9be6c07b0f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE2LTYtMS0xLTEyMTQw_b96eef04-52f0-47e3-bb43-5fb34c4c35ff"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib60a477703704a5b8d5fee9be6c07b0f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE2LTgtMS0xLTEyMTQw_55ef91f7-e86f-4eaa-8bd0-2e256d3f6e9a"
      unitRef="usd">1247000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0d459efd6b0147f8b01649f355747ec3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE2LTEwLTEtMS0xMjE0MA_d926c0c1-697e-4f8a-bb39-52407b95e2ed"
      unitRef="usd">1246000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5fc6d5d4b12c47c9a6edd38827bfbdce_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE3LTYtMS0xLTEyMTQw_9a77c4dd-328d-42c7-827d-ea1ec0e09efe"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5fc6d5d4b12c47c9a6edd38827bfbdce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE3LTgtMS0xLTEyMTQw_98ccafa3-d133-4c24-b312-694efbc8b7a2"
      unitRef="usd">746000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iffa4722d53ca492d86cb72a4394bdad1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE3LTEwLTEtMS0xMjE0MA_b4106f51-7954-4907-88d7-c859a97cb0a9"
      unitRef="usd">745000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6ee4ce7cca0b42fc81e5cae1b1b19a25_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE4LTYtMS0xLTEyMTQw_6ae212ea-b00e-4c68-95c1-5217efd98e26"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i6ee4ce7cca0b42fc81e5cae1b1b19a25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE4LTgtMS0xLTEyMTQw_61a99cd2-77fa-4036-bc84-9586473fa7c1"
      unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id9c38cd0fcf7429e905732a6030b0115_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE4LTEwLTEtMS0xMjE0MA_cc97f245-b24c-4b8d-9cb7-ef8b9f895bb0"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i99ac4c08ddd043138479c7a929366808_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE5LTYtMS0xLTEyMTQw_c7f0160c-1a5d-4d3e-b444-3cf3046fcda6"
      unitRef="number">0.0460</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i99ac4c08ddd043138479c7a929366808_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE5LTgtMS0xLTEyMTQw_21ccc378-04f1-42ec-a9b6-70a04e785c60"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i7107a8f3798a4b4f85c5c3934cc538a6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzE5LTEwLTEtMS0xMjE0MA_e81655d9-3757-476f-a8e8-8eb0c1b47f52"
      unitRef="usd">991000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i42c4206352ed45c49b1ffe6a976a0723_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIwLTYtMS0xLTEyMTQw_a15a25f5-6797-4042-8d9f-423e5d8c0414"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i42c4206352ed45c49b1ffe6a976a0723_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIwLTgtMS0xLTEyMTQw_f14947d9-be96-4620-9325-fff55c7dc2be"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i067ec910ab5441abb89d5d73967bc967_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIwLTEwLTEtMS0xMjE0MA_2c8068cb-656b-4980-8a1c-6455e6b32848"
      unitRef="usd">741000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8738af8e5e5d481482a0aff98aacdf90_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIxLTYtMS0xLTEyMTQw_b9976d89-c157-4309-a23d-5823f88f09b6"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i8738af8e5e5d481482a0aff98aacdf90_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIxLTgtMS0xLTEyMTQw_1b0c4092-a347-4409-9b36-c3078bbec19e"
      unitRef="usd">987000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4d50e8b499914bcd8bf4ea2da01301ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIxLTEwLTEtMS0xMjE0MA_369b0ef2-a5b7-40d0-aeb5-6ab4ccf1747a"
      unitRef="usd">986000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i671b7a2302524fd38cee3f6ff2f98b3c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIyLTYtMS0xLTEyMTQw_1ca9506b-2ba4-48e3-8399-85281db38305"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i671b7a2302524fd38cee3f6ff2f98b3c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIyLTgtMS0xLTEyMTQw_c37e92c8-58d4-4b4c-a461-b44ff9a667c5"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i78530d2e8d6b45118714c099f29d8e67_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIyLTEwLTEtMS0xMjE0MA_c9881492-e30d-421c-afc1-0dc3c43985c3"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i00e1ab6155ce4b2ca7387b0e499b13ca_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIzLTYtMS0xLTEyMTQw_e9e75488-e9d4-4638-bcc3-61241f3dbf9d"
      unitRef="number">0.0480</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i00e1ab6155ce4b2ca7387b0e499b13ca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIzLTgtMS0xLTEyMTQw_4fbba01e-c2a4-4966-a1c7-f98448750317"
      unitRef="usd">1736000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8027a7afa87d4545a246f3cfa058ecc1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzIzLTEwLTEtMS0xMjE0MA_3a3d6775-511f-4f53-b39f-773c523a07a7"
      unitRef="usd">1735000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i775bc80f0b4046eb933f175fa23054be_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI0LTYtMS0xLTEyMTQw_9bbcea90-d5d0-49eb-84ae-b077b76511dc"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i775bc80f0b4046eb933f175fa23054be_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI0LTgtMS0xLTEyMTQw_91eb6b91-2e51-4b48-961d-edf9f0fce1fd"
      unitRef="usd">1733000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i600f96952ca74888901fe56db25f0a9f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI0LTEwLTEtMS0xMjE0MA_29a7724f-0580-43f8-8bbd-d2c69f8b1691"
      unitRef="usd">1732000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i80a1b0b283de4323a915636bf3154c0b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI1LTYtMS0xLTEyMTQw_7a6f599f-ea60-4923-85b8-61292d04b83c"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i80a1b0b283de4323a915636bf3154c0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI1LTgtMS0xLTEyMTQw_23f2f9d4-d432-46b4-b730-a0953e519ba7"
      unitRef="usd">2220000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i57e9c5b3387647bbbf9a05d29bc125b0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI1LTEwLTEtMS0xMjE0MA_edf8c2e6-8eea-4d04-9788-10a0c7231b0a"
      unitRef="usd">2219000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i48f7619e739144e8ad45877990dc8b4d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI2LTYtMS0xLTEyMTQw_5cd6206b-a024-46d3-9f22-d990e85c05f8"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i48f7619e739144e8ad45877990dc8b4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI2LTgtMS0xLTEyMTQw_7f091916-f0b4-49bf-9cd5-467dbc518665"
      unitRef="usd">1727000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6efa1b3c097d4e8bbb0044de2e0eb97e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI2LTEwLTEtMS0xMjE0MA_f70cbc7f-f305-457e-ae19-904886f00d15"
      unitRef="usd">1726000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i00f996e674334831a4b702a6dab1227c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI3LTYtMS0xLTEyMTQw_4f86037a-553b-4c54-bcf2-e9822dd06125"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i00f996e674334831a4b702a6dab1227c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI3LTgtMS0xLTEyMTQw_6f881b8d-63ab-4e45-8eb8-d34da28f0979"
      unitRef="usd">1476000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8731d482f54944dcbc86441135f6aadf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI3LTEwLTEtMS0xMjE0MA_999dc90a-6f0d-44e3-aba6-138825e6c6f7"
      unitRef="usd">1476000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if30937e6ac3d4bb5a4c2184d7905886c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI4LTgtMS0xLTEyMTQw_a9e1e180-0ba0-45fd-a796-ace3c0483147"
      unitRef="usd">25571000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i452b8349934f45998316aa6b615f395c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI4LTEwLTEtMS0xMjE0MA_38fa3162-b5d1-41cc-b3be-d7128159e797"
      unitRef="usd">30295000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i9268c9e7d32a4d089a0df68305d6cdd8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI5LTgtMS0xLTEyMTQw_bccd36ff-99e9-485e-a668-8caf989a963d"
      unitRef="usd">1124000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icde2c819b2eb481a82769fd804c55108_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzI5LTEwLTEtMS0xMjE0MA_e967c4f5-34cf-424c-bd30-ccbb1c20d704"
      unitRef="usd">1107000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzMwLTgtMS0xLTEyMTQw_bbce3eb5-675f-4f35-b802-403513bef0e4"
      unitRef="usd">26695000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzMwLTEwLTEtMS0xMjE0MA_03aa9a1d-5382-452b-81c5-35a56745656e"
      unitRef="usd">31402000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzMxLTgtMS0xLTEyMTQw_e184d12b-8dfb-4073-b84c-2c616173b153"
      unitRef="usd">1516000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzMxLTEwLTEtMS0xMjE0MA_837a5937-0e6d-4eaa-ade7-9966e119a1a1"
      unitRef="usd">2757000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzMyLTgtMS0xLTEyMTQw_3815efb0-7565-40d5-9802-a0369003ae9c"
      unitRef="usd">25179000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo1MjU0YzcxOTcyYzc0MWI2OGU5NzlmNzE5YjhhOWZiZi90YWJsZXJhbmdlOjUyNTRjNzE5NzJjNzQxYjY4ZTk3OWY3MTliOGE5ZmJmXzMyLTEwLTEtMS0xMjE0MA_02efbb88-1878-4e34-b9c2-47432ce849fd"
      unitRef="usd">28645000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzgyNDYzMzcyNTA0MTc_9f07faf4-f3a1-4d8b-8975-6225a80b342d"
      unitRef="usd">4750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="idb910542d9424ab9b95e5810565ad466_D20210101-20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTQ3MjA_90dace5e-4974-4f13-b631-13641ac303bd"
      unitRef="usd">3750000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iebf9a43b220342c69783776e723e023f_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzgyNDYzMzcyNTAzOTk_661616c3-c4ab-44d5-a7be-0f6ea39d98df"
      unitRef="usd">1000000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="i81f6869ed0c24ce4871816f7d2e7cb43_D20210101-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTM4NDU_c1ce5748-7361-4cb0-9ff7-78b8e1327645"
      unitRef="usd">1000000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="iba530d87b0864376a38558b02d16b8c3_D20210701-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTM4NTI_95e2f4da-80eb-4b7b-8404-32c32a2f453c"
      unitRef="usd">1250000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="i4a350670d64d4f1e800774de0810abc7_D20210901-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTM4NjE_62e58ef7-6f9b-45f7-bc3c-c84c1b2e21f7"
      unitRef="usd">500000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id678a65bd8bf4578bec8bbcc0aa50cc6_D20211001-20211031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTM4NzM_12d7d6ec-33a6-4315-bc37-5d6e9ab36026"
      unitRef="usd">500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if2318fc40c5a4044a5e207e06b104152_D20211001-20211031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTM4Nzg_a38a6ca1-6dc8-491c-8b6d-c554a2e42c67"
      unitRef="usd">500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iff239ca5ea6542a1b65cc0ff2d9218fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2Xzc2OTY1ODE0Mzc2MzY_ef83971e-093a-43d2-97d5-f8a04ad66a6e"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <gild:NumberOfEarlyRepaymentsOfLongTermDebt
      contextRef="ide0591f02f274c108fd4f307409ea95c_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU0OTc1NTgxODE1NDg_9af9bf13-4312-4c22-9332-d407df6fa57d"
      unitRef="repayment">2</gild:NumberOfEarlyRepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ide0591f02f274c108fd4f307409ea95c_D20211001-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzgyNDYzMzcyNTA0NTM_7551c76d-87d7-4187-ba76-f6911b8d4e91"
      unitRef="usd">1000000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="i2149910737774396859ee858a7be3b62_D20211201-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTQyNjg_a55b278f-e100-4bc7-8b13-5d24de68c999"
      unitRef="usd">500000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIzNjM5NTAwMDQwMDcw_30f593b7-700e-4238-a5a7-aa404d0afd33"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="idb910542d9424ab9b95e5810565ad466_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzEyMTc_9e019f79-4c2e-484b-8b52-d7b73be72276"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <gild:DebtInstrumentCallFeaturePeriodBeforeMaturity
      contextRef="i23a0d3b2005a437792898712c9d8fd19_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzE4MDY_c3e93f22-6ecd-4cd9-b073-6e1a9cd67108">P1M</gild:DebtInstrumentCallFeaturePeriodBeforeMaturity>
    <gild:DebtInstrumentCallFeaturePeriodBeforeMaturity
      contextRef="i42858b3c72b14dd29fd0366fad42b66d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzE4MTI_4a84a2f2-9785-4d6a-8494-ec68949c8762">P2Y</gild:DebtInstrumentCallFeaturePeriodBeforeMaturity>
    <us-gaap:LongTermDebt
      contextRef="iff239ca5ea6542a1b65cc0ff2d9218fd_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzE2NDkyNjc0ODQ3Mzc_5577b192-554b-4272-bf5f-7611b04a76a7"
      unitRef="usd">1500000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iff239ca5ea6542a1b65cc0ff2d9218fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2Xzc2OTY1ODE0Mzc2MzA_ef83971e-093a-43d2-97d5-f8a04ad66a6e"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="idb910542d9424ab9b95e5810565ad466_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzI0MDA_d58ab0d2-9a17-4624-a89f-e16c79bd416d"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="i9b6ed812482443698e8524ebc5028ef4_D20200901-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2NzU_e13ca8f2-0849-4e96-9cab-8ba88da6b18b">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3e04a1496e924fd6aaa5cf09f6d3974b_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzI4Nzg_b5ec3789-faa9-47ba-b924-5e895d74eb00"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib86f88f4366542d4b2110433d8eb2472_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzMxMDQ_134cc8f5-8627-4147-9941-dc930062c521"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iebf9a43b220342c69783776e723e023f_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzIxOTkwMjMyOTQ3ODk_661616c3-c4ab-44d5-a7be-0f6ea39d98df"
      unitRef="usd">1000000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i6a0dca0a129d4621881c8db9cee9561b_I20160531"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzEwOTk1MTE2NjQ2NDE_0af1ce89-5650-417c-a73a-2efe33b5f5e0"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i424653e19ba342da9528563065ececec_D20160531-20160531"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU0OTc1NTgxODE1NTc_174dcad7-9146-4240-b841-9ea833036811">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iebfeba12e19f4f08b20c868b3c5aae4f_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzEwOTk1MTE2NjQ2NzA_a7581910-204c-4b40-abe4-ba5d05d5c713"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="ibc9ab8f16b194dca9d59c47d3bca5701_D20200601-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU0OTc1NTgxODE1NTY_2ced2916-a42a-4797-8c3a-465bc3aa8dd8">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCredit
      contextRef="ie345d4f41b194bbebb717ccc62b975f2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzEwOTk1MTE2NjQ2NTU_39aa6f2e-ba40-4d1a-8e28-e3a47daa1f14"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i811b6102317d403db8c7febef98c0b3d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzEwOTk1MTE2NjQ2NTU_ea0ce473-1613-473d-928b-ee816dc8c2e6"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2ODA_34765bed-c924-4805-b5d3-5cb8cd1818aa">&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate future principal maturities of our senior unsecured notes as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzEtMi0xLTEtMTIxNDA_873afb90-cc4a-4b73-963f-fb7e5b1436f6"
      unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzItMi0xLTEtMTIxNDA_42fa73e7-4719-408a-b659-be8e37837e65"
      unitRef="usd">2250000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzMtMi0xLTEtMTIxNDA_a5d50c6f-10ca-4a9e-91c0-2d491db5c42e"
      unitRef="usd">1750000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzQtMi0xLTEtMTIxNDA_d35c9614-fc83-4eda-91f5-7c1b522d4e9d"
      unitRef="usd">1750000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzUtMi0xLTEtMTIxNDA_25abca2f-81c5-42d6-ab5a-4ee6249655ca"
      unitRef="usd">2750000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzYtMi0xLTEtMTIxNDA_66e3a622-39d0-4b52-8b1a-169497f00526"
      unitRef="usd">15750000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt
      contextRef="if472a036278a4d88a49fe0a47d9404ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90YWJsZTo5ODI5YmI1YzNhYWQ0YTI4OWNkMzhmNDZmNjNlMGM1MS90YWJsZXJhbmdlOjk4MjliYjVjM2FhZDRhMjg5Y2QzOGY0NmY2M2UwYzUxXzctMi0xLTEtMTIxNDA_44c842ba-657f-45e3-8f27-3684cd3bcaa5"
      unitRef="usd">25750000000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2MTY_3862f767-4bd5-4001-a6fc-16d14bc03dbc"
      unitRef="usd">1000000000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2MTY_76c863bc-f858-47a2-ae01-7aff6ee45f09"
      unitRef="usd">1000000000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzAvZnJhZzo3YWU1ODliNTJmYWY0Y2VjYThkY2VmZTBiNGFiMjdlNi90ZXh0cmVnaW9uOjdhZTU4OWI1MmZhZjRjZWNhOGRjZWZlMGI0YWIyN2U2XzU2MTY_88aac6a2-30c6-4579-9eda-dd62d97f7fa7"
      unitRef="usd">1000000000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzg4Ng_e8ccf249-8647-44f5-a08a-a58220465161">LEASES&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases consist primarily of properties and equipment for our administrative, manufacturing and R&amp;amp;D activities. Some of our leases include options to extend the terms for up to 15 years and some include options to terminate the lease within one year after the lease commencement date. As of December&#160;31, 2021 and 2020, we did not have material finance leases. Operating lease expense, including variable costs and short-term leases, was $156 million, $171 million and $162 million in 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes balance sheet and other information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except weighted average amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_bf1a57bf-a703-4b3f-bc9b-0294a5049060"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_c74f8a0a-3c1e-43dc-9a44-91448c3a81f3"&gt;Other long-term assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_3f97a2d5-98a1-46a4-8619-f3becdea71f5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_c90d340b-270c-4dd6-bbe4-3b313ad42434"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_511d014a-a5ee-4a2c-a65f-0d75ca7b60e9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_7e2903b1-a222-4253-bf44-fbb3ee9aa161"&gt;Other long-term obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes other supplemental information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total discounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzIwMg_6fbcda29-cc43-4625-a6c9-1f19f2fa1b02">P15Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzIxOTkwMjMyNTY2Mjk_4c849f7f-a382-439f-8b97-6f250c34829a">one year</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:OperatingLeaseExpense
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzQzMw_d962d120-4c09-4960-9a40-5c11105026ea"
      unitRef="usd">156000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzQ0MA_88d4be26-d392-4eb9-b00c-b090b0ae4ad7"
      unitRef="usd">171000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzI3NDg3NzkwNzAzOTA_7563ce5c-da3b-4730-a176-6ef751b26262"
      unitRef="usd">162000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzg4NA_4da862b7-8451-4386-9b4f-eb91b85378a8">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes balance sheet and other information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except weighted average amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_bf1a57bf-a703-4b3f-bc9b-0294a5049060"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItMi0xLTEtMTIxNDA_c74f8a0a-3c1e-43dc-9a44-91448c3a81f3"&gt;Other long-term assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_3f97a2d5-98a1-46a4-8619-f3becdea71f5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtMi0xLTEtMTIxNDA_c90d340b-270c-4dd6-bbe4-3b313ad42434"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_511d014a-a5ee-4a2c-a65f-0d75ca7b60e9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtMi0xLTEtMTIxNDA_7e2903b1-a222-4253-bf44-fbb3ee9aa161"&gt;Other long-term obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes other supplemental information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItNC0xLTEtMTIxNDA_7d043954-64b6-4a85-b9c9-5eb001df7214"
      unitRef="usd">542000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzItNi0xLTEtMTIxNDA_44c40ad7-f528-4133-9bd4-1b628ffe8f0d"
      unitRef="usd">646000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtNC0xLTEtMTIxNDA_727d0cab-71da-4e1c-aee4-a1629a8f2823"
      unitRef="usd">101000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzMtNi0xLTEtMTIxNDA_1ff9f279-1277-44f9-bece-e256026d7d98"
      unitRef="usd">107000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtNC0xLTEtMTIxNDA_8098ca2e-406c-4012-b83c-4d7a02925557"
      unitRef="usd">489000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzQtNi0xLTEtMTIxNDA_2c7f0e3f-e392-4a76-806b-c946f68a93d0"
      unitRef="usd">608000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzUtNC0xLTEtMTIxNDA_4981a080-cf21-464c-bcd5-55aa3fda447f">P8Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzUtNi0xLTEtMTIxNDA_28565fd4-4785-4711-9e10-433c307342e0">P8Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzYtNC0xLTEtMTIxNDA_96c5f623-d6d5-474c-9a3d-7e3f96e5d27f"
      unitRef="number">0.0300</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTpjYjcwOTQ0NjE4MTc0YjhkOTRjNjlhZWJkOTJkMTI2MS90YWJsZXJhbmdlOmNiNzA5NDQ2MTgxNzRiOGQ5NGM2OWFlYmQ5MmQxMjYxXzYtNi0xLTEtMTIxNDA_cbc66691-0b84-4410-b670-77b83cea25a2"
      unitRef="number">0.0332</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTo1NjUxYzlhOTRjMzg0ZmNlYjIwZjE5NTdlODhmYmY2Mi90YWJsZXJhbmdlOjU2NTFjOWE5NGMzODRmY2ViMjBmMTk1N2U4OGZiZjYyXzItMi0xLTEtMTIxNDA_a523ad3d-0a5c-43db-b9df-0336c5d35831"
      unitRef="usd">123000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTo1NjUxYzlhOTRjMzg0ZmNlYjIwZjE5NTdlODhmYmY2Mi90YWJsZXJhbmdlOjU2NTFjOWE5NGMzODRmY2ViMjBmMTk1N2U4OGZiZjYyXzItNC0xLTEtMTIxNDA_4d5b8032-3e5a-4fe5-82c1-52d84aefb273"
      unitRef="usd">66000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTo1NjUxYzlhOTRjMzg0ZmNlYjIwZjE5NTdlODhmYmY2Mi90YWJsZXJhbmdlOjU2NTFjOWE5NGMzODRmY2ViMjBmMTk1N2U4OGZiZjYyXzMtMi0xLTEtMTIxNDA_fe21b4b2-8afb-4cc1-87bd-171b9c599af9"
      unitRef="usd">88000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTo1NjUxYzlhOTRjMzg0ZmNlYjIwZjE5NTdlODhmYmY2Mi90YWJsZXJhbmdlOjU2NTFjOWE5NGMzODRmY2ViMjBmMTk1N2U4OGZiZjYyXzMtNC0xLTEtMTIxNDA_6615068c-8d7a-4eff-af5c-428734fa712e"
      unitRef="usd">88000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90ZXh0cmVnaW9uOjA5MzkzYTljZWMzZjQ0YTFhMjkzMzNiZTNkNTM5ZDBmXzg4NQ_27f549e2-06f0-40ae-afa8-674cb346b45f">&lt;div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total discounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzEtMi0xLTEtMTIxNDA_44dec94e-5241-46ce-98a6-d2a6c574465b"
      unitRef="usd">117000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzItMi0xLTEtMTIxNDA_b5e69769-28ac-4019-94ea-df5b725c7061"
      unitRef="usd">108000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzMtMi0xLTEtMTIxNDA_ec7177a8-0be7-4501-9d2d-651f9a876ac6"
      unitRef="usd">92000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzQtMi0xLTEtMTIxNDA_940624c8-d1eb-445e-a6c6-73929214e50e"
      unitRef="usd">61000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzUtMi0xLTEtMTIxNDA_2c46b73b-a8a6-4dbe-87bc-c0a7cf81aa50"
      unitRef="usd">50000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzYtMi0xLTEtMTIxNDA_0105a35f-74b3-4192-8cea-a556582a6de7"
      unitRef="usd">249000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzctMi0xLTEtMTIxNDA_2caa48f4-8f7c-451f-a0be-d0394de78951"
      unitRef="usd">677000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzgtMi0xLTEtMTIxNDA_c685bbd8-9d76-47c6-98b3-c8bc20cc02f3"
      unitRef="usd">87000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzMvZnJhZzowOTM5M2E5Y2VjM2Y0NGExYTI5MzMzYmUzZDUzOWQwZi90YWJsZTozNGZjZmE3ZjlhYmE0ZDBkOGE2MjU1YTFmMTY5YTQxNi90YWJsZXJhbmdlOjM0ZmNmYTdmOWFiYTRkMGQ4YTYyNTVhMWYxNjlhNDE2XzktMi0xLTEtMTIxNDA_d4c19113-4d6d-4ff8-9697-57824bb86314"
      unitRef="usd">590000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI1NTU4_98b3a623-14d4-4ed8-9baf-3c82e8c2534a">COMMITMENTS AND CONTINGENCIES &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the third quarter of 2021, we reversed a $175 million previously recorded litigation accrual following a favorable court decision for the litigation related to axicabtagene ciloleucel described below. In the fourth quarter of 2021, we recorded an accrual of $1.25 billion in Accrued and other current liabilities on our Consolidated Balance Sheets for the settlement related to bictegravir litigation described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Sofosbuvir&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with the University of Minnesota&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The University of Minnesota (the &#x201c;University&#x201d;) has obtained U.S. Patent No. 8,815,830 (the &#x201c;&#x2019;830 patent&#x201d;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#x2019;830 patent. We believe the &#x2019;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concludes the inter partes review that it has initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#x2019;s patent invalid. In July 2021, the University appealed this decision. The litigation in the U.S. District Court will remain stayed through the appeal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with NuCana plc. (&#x201c;NuCana&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NuCana has obtained European Patent No. 2,955,190 (the &#x201c;EP &#x2019;190 patent&#x201d;) that allegedly covers sofosbuvir. In opposition proceedings before the European Patent Office (&#x201c;EPO&#x201d;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#x2019;190 patent in amended form. We believe that the amended EP &#x2019;190 patent claims are invalid. Subsequently, we initiated proceedings to invalidate the UK counterpart of the EP &#x2019;190 patent in the High Court of England &amp;amp; Wales. In March 2021, NuCana filed a counterclaim against us in the High Court of England &amp;amp; Wales alleging patent infringement of the UK counterpart and seeking damages and other relief. In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#xfc;sseldorf alleging patent infringement of the German counterpart of the EP &#x2019;190 patent and seeking damages and injunctive relief. The hearing date for the German NuCana case has been scheduled for May 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The hearing date for the UK NuCana case has been scheduled for January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Axicabtagene Ciloleucel&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#x201c;Juno&#x201d;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#x201c;&#x2019;190 patent&#x201d;). A jury trial was held on the &#x2019;190 patent, and in December 2019, the jury found that the asserted claims of the &#x2019;190 patent were valid, and that we willfully infringed the asserted claims of the &#x2019;190 patent. The jury also awarded Juno damages in amounts of $585 million in an upfront payment and a 27.6% running royalty from October 2017 through the date of the jury&#x2019;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#x2019;s verdict, enhanced the past damages by 50% and maintained the royalties on future Yescarta sales at 27.6%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge, and in July 2021, the appeals court heard oral arguments. In August 2021, the Court of Appeals for the Federal Circuit (the &#x201c;CAFC&#x201d;) reversed the jury verdict, finding the asserted claims of Juno&#x2019;s patent invalid. In October 2021, Juno filed a petition for rehearing with the CAFC. In January 2022, the CAFC denied Juno&#x2019;s petition for rehearing. We believe that the likelihood of a material adverse outcome in this matter is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Bictegravir&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, ViiV Healthcare Company (&#x201c;VHC&#x201d;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes VHC&#x2019;s U.S. Patent No. 8,129,385 (the &#x201c;&#x2019;385 patent&#x201d;) covering VHC&#x2019;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#x2019;385 patent. In its lawsuit, VHC was seeking billions of dollars for alleged damages comprised of VHC&#x2019;s lost profits and a royalty on U.S. sales of bictegravir from launch through the trial. In addition, should a court find that we are liable for infringement, we also expected VHC to seek a royalty on U.S. sales after the trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, VHC also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound infringes VHC&#x2019;s Canadian Patent No. 2,606,282 (the &#x201c;&#x2019;282 patent&#x201d;), which was issued to Shionogi &amp;amp; Co. Ltd. and VHC. The &#x2019;282 patent is the compound patent covering VHC&#x2019;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#x2019;282 patent. In November and December 2019, VHC filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206; in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 and 1363875. These patents all relate to molecules that VHC claims would act as integrase inhibitors. We believe that bictegravir does not infringe any valid claims of VHC&#x2019;s patents and have prevailed in court proceedings to date in Canada and Germany. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2022, Gilead reached an agreement (the &#x201c;Settlement&#x201d;) with VHC, ViiV Healthcare UK (No.3) Limited, ViiV Healthcare UK Limited, Shionogi &amp;amp; Co., Ltd. and GlaxoSmithKline Mercury Limited (collectively, &#x201c;ViiV&#x201d;) for a global resolution of all pending or potential claims related to Gilead&#x2019;s sales of Biktarvy, including the litigation pending in the U.S. District Court of Delaware and other jurisdictions outside the United States as described above. In February 2022, the lawsuit pending in the United States was dismissed as well as the lawsuits in Canada, France, Ireland, the UK, Australia, Japan and Korea.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Settlement, ViiV grants Gilead a broad worldwide license and covenant not to sue relating to any past, present or future development or commercialization of bictegravir. In connection with the Settlement, Gilead (1) made a one-time payment to ViiV of $1.25 billion in the first quarter of 2022, and (2) will provide ViiV an ongoing royalty at a rate of 3% on future sales of Biktarvy and the bictegravir component of bictegravir-containing products in the United States until October 5, 2027. In connection with the Settlement, Gilead recorded a pre-tax charge of $1.25 billion to Cost of goods sold on our Consolidated Statements of Income in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Relating to Pre-Exposure Prophylaxis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#x201c;HHS Patents&#x201d;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine or tenofovir disoproxil fumarate (&#x201c;TDF&#x201d;) prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#x201c;PrEP&#x201d;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the U.S. Court of Federal Claims, alleging violations of four material transfer agreements (&#x201c;MTAs&#x201d;) related to the research underlying the HHS Patents and a clinical trial agreement (&#x201c;CTA&#x201d;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#x2019;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Court of Federal Claims has been set for June 2022, and a trial date for the lawsuit in the District Court of Delaware has been set for May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Generic Manufacturers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#x201c;NCE&#x201d;) exclusivity period during which other manufacturers&#x2019; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#x201c;ANDA&#x201d;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#x2019;s approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in December 2019, we received letters from Lupin Ltd., Apotex Inc., Shilpa Medicare Ltd. (&#x201c;Shilpa&#x201d;), Sunshine Lake Pharma Co. Ltd. (&#x201c;Sunshine Lake&#x201d;), Laurus Labs, Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (collectively, &#x201c;Generic Manufacturers&#x201d;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our TAF-containing products. Between them, these Generic Manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. The Generic Manufacturers have challenged the validity of two to four patents listed on the Orange Book and associated with TAF. We filed lawsuits against the Generic Manufacturers, and we intend to enforce and defend our intellectual property. In November 2021, we reached an agreement with Shilpa to resolve the lawsuit against Shilpa. In addition, in January 2022, we reached an agreement with Sunshine Lake to resolve the lawsuit against Sunshine Lake. The settlement agreements have been filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, we received a letter from Lupin Ltd. (&#x201c;Lupin&#x201d;) indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen, filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Lupin asserting infringement of two additional patents in the same court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Patent Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. An appeal hearing originally scheduled for July 2021 has been canceled and a new date has not yet been set by the EPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. Two of the original opposing parties have appealed, requesting full revocation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. Three parties have appealed this decision. The appeal hearing was held in March 2021, and the validity of all claims were upheld.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, three parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. Two parties have appealed this decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the EU could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust and Consumer Protection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We (along with Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;) and Johnson &amp;amp; Johnson, Inc.) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes&#x2014;one of direct purchasers consisting largely of wholesalers, and another of indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the fall of 2021, several plaintiffs filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the putative classes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These cases have been coordinated with the class actions. Trial is set for March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we, along with generic manufacturers Cipla Ltd. and Cipla USA Inc. (together, &#x201c;Cipla&#x201d;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#x201c;Jacksonville Trust&#x201d;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and Cipla, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, we along with BMS and Teva Pharmaceutical Industries Ltd. were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named as a defendant in one class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Maryland, Missouri and New Jersey, involve more than 27,000 plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we received a subpoena from the U.S. Attorney&#x2019;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#x2019;s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead&#x2019;s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The relator seeks all available relief under these statutes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Two former employees filed a qui tam lawsuit against Gilead in April 2020 in California state court. Following the California Attorney General&#x2019;s Office&#x2019;s decision not to intervene, relators served Gilead with their complaint in August 2020. The complaint alleges violations of the California False Claims Act (&#x201c;CFCA&#x201d;) and employment law claims. Relators seek all available relief under the CFCA. In December 2021, Gilead and relators executed a settlement agreement to resolve the lawsuit, and in February 2022, the court issued an order dismissing the lawsuit with prejudice.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The settlement does not have a material impact to our Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Choice Advocates, LLC (&#x201c;Health Choice&#x201d;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#x2019;s Office&#x2019;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#x2019;s dismissal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#x2019;s Office&#x2019;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#x201c;TMFPA&#x201d;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. In September 2021, the Texas Court of Appeals for the Sixth Court Appeals District granted our request to stay the Texas litigation. The case is stayed pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#x2019; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:25.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.&lt;/span&gt;&lt;/div&gt;Other Commitments In the normal course of business, we enter into firm purchase commitments related to inventory. As of December&#160;31, 2021, these commitments for the next five years were approximately $1.1 billion in 2022, $450 million in 2023, $243 million in 2024, $60 million in 2025 and $31 million in 2026.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease
      contextRef="i3a0a5d98945240a491ca261188cf0b76_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzEwOTk1MTE3ODQ4MjI_fe409b27-9260-473a-bd47-0e35b3f89f65"
      unitRef="usd">-175000000</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i3f4cd81637934eb4bfcfc5bb4da29021_D20211001-20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI3NDg3NzkyMjUwNzQ_fac5c1b1-1c3c-45f8-bbd4-938e9441ffad"
      unitRef="usd">-1250000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i06eb7508edc54e1d963da3d320aa56cd_D20191201-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzEwOTk1MTE3ODQxMzU_06f31cd4-2f5b-4e2f-9abe-cc18357028b1"
      unitRef="usd">585000000</us-gaap:LossContingencyDamagesAwardedValue>
    <gild:JudgmentRoyaltyRateFromOctober2017
      contextRef="i06eb7508edc54e1d963da3d320aa56cd_D20191201-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzM0NjM0NjE2NDQ2ODE0_690ee76e-4415-4608-85cd-9c7ed648edbe"
      unitRef="number">0.276</gild:JudgmentRoyaltyRateFromOctober2017>
    <gild:JudgmentEnhancedDamagesOnPastSales
      contextRef="i0515ea18ac744e009b23a9242a725ab9_I20200430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzEwOTk1MTE3ODQxNjM_30b1d62c-4ed4-45d9-8cb0-7c07097a1753"
      unitRef="number">0.50</gild:JudgmentEnhancedDamagesOnPastSales>
    <gild:JudgmentRoyaltyRateOnFutureSales
      contextRef="i0515ea18ac744e009b23a9242a725ab9_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzM0NjM0NjE2NDQ2ODIz_18798061-80ad-48c7-a019-aad774ff0529"
      unitRef="number">0.276</gild:JudgmentRoyaltyRateOnFutureSales>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i58312b3302b9493cb83df643b7d08e9a_D20220101-20220331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI3NDg3NzkyMjk1OTI_332c3c74-7c39-4a6f-a603-b1d1363d511e"
      unitRef="usd">1250000000</us-gaap:PaymentsForLegalSettlements>
    <gild:LossContingencyRoyaltyPercentageOnFutureSales
      contextRef="i265d4a6f0a374d1dab17e075aed111ab_D20220201-20220201"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzEwOTk1MTE3ODQxMTk_40603967-ad3a-4c24-9416-6cb02d770af2"
      unitRef="number">0.03</gild:LossContingencyRoyaltyPercentageOnFutureSales>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i3f4cd81637934eb4bfcfc5bb4da29021_D20211001-20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzEwOTk1MTE3ODMyOTg_fac5c1b1-1c3c-45f8-bbd4-938e9441ffad"
      unitRef="usd">-1250000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <gild:LossContingencyMaterialTransferAgreementsNumber
      contextRef="ib937eacd40624de4b33e1818017eaa04_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3Mjc_31ac2e78-aa0d-444c-ae5c-1b8690cf59f9"
      unitRef="agreement">4</gild:LossContingencyMaterialTransferAgreementsNumber>
    <gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo
      contextRef="i7a0546071ccb452889c1fb141764dfef_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3NDA_42502e0f-fc9b-4d7d-bbfd-1bd34604451f"
      unitRef="patent">2</gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo>
    <gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne
      contextRef="i7a0546071ccb452889c1fb141764dfef_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3MzQ_a16007d1-964d-4f6b-b5d5-1c85361612a6"
      unitRef="patent">4</gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne>
    <gild:LossContingencyAdditionalPatentsAllegedlyInfringedNumber
      contextRef="i0639e3db3b664793a6beb77eb685f7b0_D20211001-20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzE2NDkyNjc2MTMyNzg_14c320c1-2f48-4796-b370-af9410d44072"
      unitRef="patent">2</gild:LossContingencyAdditionalPatentsAllegedlyInfringedNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="i1f23bfe0992f40f3b1234a110848985b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3NDY_909d551f-6efa-43a8-9244-900efb32cd8d"
      unitRef="opposingparty">2</gild:LossContingencyPartiesAppealedNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="ie0d5cca66648457e8765b48c19c1fe65_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3NTQ_921b6489-c117-464e-971e-364d6c033fdc"
      unitRef="opposingparty">3</gild:LossContingencyPartiesAppealedNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="if8a659c08da049ae986c9c29e62e00e4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3NjI_2c3a4de7-9e17-4298-9a08-1745b5c9e9b8"
      unitRef="opposingparty">3</gild:LossContingencyPartiesAppealedNumber>
    <gild:LossContingencyPartiesFilingOppositionNumber
      contextRef="i225c85c01cb74eef9ba4b88802d3cdf6_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3NzA_dd6e43b9-e9c1-4bf4-b582-f8755a9d399f"
      unitRef="party">3</gild:LossContingencyPartiesFilingOppositionNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="ifa3f8743db084c41b63d403832f512f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3NzY_26413441-4a6d-4ce3-b17a-fb7bb884194b"
      unitRef="opposingparty">2</gild:LossContingencyPartiesAppealedNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i327f548a38ab4392948582ff7fef469a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3ODI_0b29e98e-811f-4ed8-830f-900a7b76ddde"
      unitRef="lawsuit">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i327f548a38ab4392948582ff7fef469a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzkzNDU4NDkwMDc3MDM_aeccc9d1-8108-4d00-92ad-808f08f55639"
      unitRef="plaintiff">27000</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i25a9bfaaa2514554b1836ba98b4643cb_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzMyOTg1MzUwMzk3OTc_e5691bee-dbf9-4e38-9e36-563516ee87a9"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI1NDI1_7a5de6b3-8ed4-42bd-a1b6-dd3b04d8c6ce"
      unitRef="usd">1100000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI1NDM1_a78c306b-55ce-4104-bd73-f0cd266c3982"
      unitRef="usd">450000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI1NDQ1_01b9f1b5-48a2-4c70-928f-5f5207bc23c0"
      unitRef="usd">243000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI1NDU1_31fb49cf-2446-4381-9f20-59c8baffadff"
      unitRef="usd">60000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xMzkvZnJhZzo0MWY2ZTU5Njg0ZWI0MWRmOTI0ZGRlOTQ2NTZhMWM4My90ZXh0cmVnaW9uOjQxZjZlNTk2ODRlYjQxZGY5MjRkZGU5NDY1NmExYzgzXzI1NDY4_3bf24535-e061-48eb-9825-850d20220ed2"
      unitRef="usd">31000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzI3NDc_6c6790fc-f4c7-4c9f-a829-681bda8c262b">STOCKHOLDERS&#x2019; EQUITY &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Repurchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (&#x201c;2016 Program&#x201d;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion&#160;stock repurchase program (&#x201c;2020 Program&#x201d;), which will commence upon the completion of the 2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the remaining authorized repurchase amount under both programs was $6.3 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock repurchases under the 2016 Program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares repurchased and retired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to repurchases from the 2016 Program and 2020 Program, we repurchased shares of common stock withheld by us from employee restricted stock awards to satisfy our applicable tax withholding obligations. These shares are excluded from the table above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the par value method of accounting for our stock repurchases. Under the par value method, common stock is first charged with the par value of the shares involved. The excess of the cost of shares acquired over the par value is allocated to additional paid-in capital based on an estimated average sales price per issued share with the excess amounts charged to retained earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes cash dividends declared on our common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our restricted stock and performance share awards or units have dividend equivalent rights entitling holders to dividend equivalents to be paid upon vesting for each share of the underlying unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;1, 2022, we announced that our Board of Directors declared a quarterly cash dividend of $0.73 per share of our common stock, with a payment date of March&#160;30, 2022 to all stockholders of record as of the close of business on March&#160;15, 2022. Future dividends are subject to declaration by our Board of Directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have 5 million shares of authorized preferred stock issuable in series. Our Board is authorized to determine the designation, powers, preferences and rights of any such series. There was no preferred stock outstanding as of December&#160;31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in AOCI by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts reclassified to net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Consolidated Statements of Income. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net, on our Consolidated Statements of Income. The income tax impact allocated to each component of other comprehensive income was not material for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i3d943fc6896d42a2a402f7355165d0db_I20160331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzEwNA_299ea398-6002-4f52-a461-7a878a0b19f4"
      unitRef="usd">12000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ia0ac11cc10c94ff59a93bc7def17ae5b_I20200331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzM2Nw_6e1a19a2-d32d-4594-b016-81a32e56c3d7"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzYzNQ_3c30f596-d5c3-46a4-9d4f-d736bff84b32"
      unitRef="usd">6300000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzI3NzU_360f1ede-8e14-4c20-abf1-4406129677cf">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock repurchases under the 2016 Program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares repurchased and retired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i88ed2a00d0174820ad767760e9f24578_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzItMi0xLTEtMTIxNDA_5cfbc1f2-0db3-45cd-9b2f-f349e12baf43"
      unitRef="shares">8000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i8a679c0b45db4ea5bbb87a138014433a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzItNC0xLTEtMTIxNDA_ec481fdc-1104-419a-b989-392c7f6fa909"
      unitRef="shares">22000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ic28e0d3d171544a895828b1b399da271_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzItNi0xLTEtMTIxNDA_1712a4fc-7e7a-4623-bca6-0bda37afa19f"
      unitRef="shares">26000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzMtMi0xLTEtMTIxNDA_bf739ddf-ba94-4f60-aede-4dac6e20fea9"
      unitRef="usd">546000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzMtNC0xLTEtMTIxNDA_466f9ca4-7da7-4b24-922b-120f52ac7dc8"
      unitRef="usd">1583000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzMtNi0xLTEtMTIxNDA_e23aacac-5864-41b2-9eeb-7a94104a3e49"
      unitRef="usd">1749000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzQtMi0xLTEtMTIxNDA_c4963ba4-16fc-4e83-9d11-d62c641cff7d"
      unitRef="usdPerShare">66.58</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzQtNC0xLTEtMTIxNDA_68810e53-22af-49fc-a927-9e1e262e2f22"
      unitRef="usdPerShare">70.64</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToyODNhYjU5ODNkYmY0N2EwYmFhNzM5MzZiN2QwNjYwOS90YWJsZXJhbmdlOjI4M2FiNTk4M2RiZjQ3YTBiYWE3MzkzNmI3ZDA2NjA5XzQtNi0xLTEtMTIxNDA_9a9c97ed-1d40-44e4-9e7a-b8e925466c9c"
      unitRef="usdPerShare">66.36</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:DividendsDeclaredTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzI3NTI_0fe5578f-c75c-4359-980c-20bae51c6ca6">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes cash dividends declared on our common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DividendsDeclaredTableTextBlock>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i8488cd00ad754d66a2f89c28ef0113ca_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzItMi0xLTEtMTIxNDA_2b33d1f6-8f00-4a85-a67c-8d580e761750"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i8488cd00ad754d66a2f89c28ef0113ca_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzItNC0xLTEtMTIxNDA_c45f33f4-ce06-4c53-b653-20ae2ceb5a2b"
      unitRef="usd">906000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i23e97ce3ab7e42c8b5eddc72bc3e2957_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzItNi0xLTEtMTIxNDA_91378248-193c-4b1a-b5de-3f0a95078020"
      unitRef="usdPerShare">0.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i23e97ce3ab7e42c8b5eddc72bc3e2957_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzItOC0xLTEtMTIxNDA_1cbf16a3-0122-492c-9f41-24c6605f47cc"
      unitRef="usd">867000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="iee9756a76bba457e81595f5fdbe576fc_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzMtMi0xLTEtMTIxNDA_09434562-f2d3-47c4-a273-70f258e18004"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="iee9756a76bba457e81595f5fdbe576fc_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzMtNC0xLTEtMTIxNDA_6bdfe8a5-e4f5-4f55-aac3-c828b583e8fd"
      unitRef="usd">903000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i9cc38953c3ec4d0c9b3cbf82dde62ac8_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzMtNi0xLTEtMTIxNDA_dd9e8a9b-9493-484f-b5e8-0fe634e88081"
      unitRef="usdPerShare">0.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i9cc38953c3ec4d0c9b3cbf82dde62ac8_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzMtOC0xLTEtMTIxNDA_bc8d4fff-a3e1-4388-b4ec-519def1e13ed"
      unitRef="usd">866000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i5501384b52f44d51a145ef3f4f3e7ca5_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzQtMi0xLTEtMTIxNDA_f5598d8f-2a70-4994-8f83-5b2070bb311e"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i5501384b52f44d51a145ef3f4f3e7ca5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzQtNC0xLTEtMTIxNDA_6d389007-b20d-4775-af99-cb451ccfc266"
      unitRef="usd">905000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2bea2cadcf9646f58956abc926e1586f_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzQtNi0xLTEtMTIxNDA_32f78750-6954-46a0-9e4a-243c087949cd"
      unitRef="usdPerShare">0.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i2bea2cadcf9646f58956abc926e1586f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzQtOC0xLTEtMTIxNDA_be600a4e-1e2d-49fe-817c-cc4f89b405d3"
      unitRef="usd">866000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6d11aa8c23bc48e69c02c674ce48e4b1_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzUtMi0xLTEtMTIxNDA_432accea-df8d-4a2d-9db8-b9dbcdce49b0"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6d11aa8c23bc48e69c02c674ce48e4b1_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzUtNC0xLTEtMTIxNDA_d26b9b1a-e60f-4cdc-9e7f-43a2b27b0356"
      unitRef="usd">904000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6bf6d6d327dd4e03a5847141baa75c2b_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzUtNi0xLTEtMTIxNDA_25dd5a9c-82d2-47f7-a15c-5f4d39239b88"
      unitRef="usdPerShare">0.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6bf6d6d327dd4e03a5847141baa75c2b_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzUtOC0xLTEtMTIxNDA_27937fe8-74d3-4c66-aa98-aca5625fef72"
      unitRef="usd">865000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzYtMi0xLTEtMTIxNDA_8355f299-0dc8-4c8e-aea1-4cda979bc5b7"
      unitRef="usdPerShare">2.84</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzYtNC0xLTEtMTIxNDA_52efeec6-8e58-467c-b541-ff303436e379"
      unitRef="usd">3618000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzYtNi0xLTEtMTIxNDA_3127e184-cf71-4b61-9fae-d6abe81ba7db"
      unitRef="usdPerShare">2.72</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZToxZmJiYzIzNjE4MDM0NWY0OWY5YjU4ODFjNmEwY2MwOS90YWJsZXJhbmdlOjFmYmJjMjM2MTgwMzQ1ZjQ5ZjliNTg4MWM2YTBjYzA5XzYtOC0xLTEtMTIxNDA_92c32d0b-a6b1-40d4-82bf-7ea156232e42"
      unitRef="usd">3464000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i3ea289ffec3b458087dccbfc47e573d0_D20220201-20220201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzE3MjU_f966a5a2-04a0-492a-bd72-c3ffa424000f"
      unitRef="usdPerShare">0.73</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzE5NDY_35d6aa46-8417-4803-a174-8b69e63313f1"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzIxMjE_3fcd5840-aa10-4593-a882-ef097733b894"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzIxMjE_a3fa4fe6-461b-4b70-a6f7-db09498939ef"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90ZXh0cmVnaW9uOmI4NjgwMGQ4YjU5ODQ0NmFhNjJjODYwNmQyN2YzZmZmXzI3NDY_49c8947a-3af2-4b5f-9add-a6f8985b4992">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in AOCI by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cf763f4ea7f4880a47f0e6a403877f4_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEtMi0xLTEtMTIxNDA_bac32f95-f3ad-40a1-9424-e78ac59307eb"
      unitRef="usd">47000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff25d3116ceb4bbab1c6c9c8d145401c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEtNC0xLTEtMTIxNDA_57bf4915-bc3f-45b5-a7d4-9822ff9e6e23"
      unitRef="usd">-52000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9f1e0014a754c4cb3066bf85c4a2570_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEtNi0xLTEtMTIxNDA_cc976abb-9a1c-43c0-8f36-2e63dbaa5ed6"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id46d2d21dd6a43a89e740948d75f9380_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEtOC0xLTEtMTIxNDA_2a02fd32-9408-46e2-a32b-319fe059fbd4"
      unitRef="usd">80000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ifa632be9dee643cc918655e93fa6c0f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzItMi0xLTEtMTIxNDA_a999a4fb-a63a-4317-ab3e-4a0c20044026"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i0ba6a2a2d50c4a6db88d7c68e239a2b0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzItNC0xLTEtMTIxNDA_a54ef9f0-9f90-4f51-9b6a-69ebfc501d45"
      unitRef="usd">54000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i39bec68158bd4af6bb2c347ac792a9ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzItNi0xLTEtMTIxNDA_df01809f-77fc-4446-8e6d-96bf776e52bf"
      unitRef="usd">72000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i01dacb3a581346e187edae0a347d2eeb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzItOC0xLTEtMTIxNDA_f12bdca1-98c7-4e35-ad46-313f95b93d26"
      unitRef="usd">132000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ifa632be9dee643cc918655e93fa6c0f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzMtMi0xLTEtMTIxNDA_4c888690-057a-4cbf-9c1c-1bc8cca8b20d"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i0ba6a2a2d50c4a6db88d7c68e239a2b0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzMtNC0xLTEtMTIxNDA_ff0e8a1b-f4ff-4337-a2d4-03bab0e266ae"
      unitRef="usd">1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i39bec68158bd4af6bb2c347ac792a9ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzMtNi0xLTEtMTIxNDA_8c900147-b457-4c4f-b8eb-90ab95971a30"
      unitRef="usd">126000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i01dacb3a581346e187edae0a347d2eeb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzMtOC0xLTEtMTIxNDA_66557424-7ff4-4ddb-8b4d-9039c2466d6d"
      unitRef="usd">127000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifa632be9dee643cc918655e93fa6c0f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzQtMi0xLTEtMTIxNDA_d73ad2e1-92dd-4612-bd2e-1e8112fd2f31"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0ba6a2a2d50c4a6db88d7c68e239a2b0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzQtNC0xLTEtMTIxNDA_a3575cd5-1532-4667-a816-849f424a8f63"
      unitRef="usd">53000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i39bec68158bd4af6bb2c347ac792a9ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzQtNi0xLTEtMTIxNDA_a2fcf9d6-0f11-4690-9047-2111fc26c40d"
      unitRef="usd">-54000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i01dacb3a581346e187edae0a347d2eeb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzQtOC0xLTEtMTIxNDA_2efbab8d-79b1-4b66-829b-3fd90c812029"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f580454e7604d7785de9823f350085c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzUtMi0xLTEtMTIxNDA_b6519452-e3d1-4c45-88d4-5dc2039e036a"
      unitRef="usd">53000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i031ae4d8e4484c4e9b1cadccb6c88ff9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzUtNC0xLTEtMTIxNDA_aaf728c7-fe90-41f4-a256-9498d472c464"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7baa42c3821a4c50ae27b170e3c7858f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzUtNi0xLTEtMTIxNDA_5b676132-1dec-4b13-988d-32e014b31d3b"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9da767fe6764cc8955010ca3f076633_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzUtOC0xLTEtMTIxNDA_d344a1d9-6ab9-4717-879e-e317cd3e50ed"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i74a7063cdae7438bb8481aee4e692325_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzYtMi0xLTEtMTIxNDA_cf47ce1e-4234-41f4-85a9-b1cdbedacebf"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i193cbc90df134a0d9735d84dde8ed9ec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzYtNC0xLTEtMTIxNDA_b460e081-91b6-4bbc-bad7-da10359dad6f"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3d96d9b09d2a48cfa30e6bf373b5f762_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzYtNi0xLTEtMTIxNDA_a96a750f-2d65-4dda-9e8e-c469369686c8"
      unitRef="usd">-103000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i851b03314d344a5e8ad436aa9235bf9c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzYtOC0xLTEtMTIxNDA_5838a042-b707-497f-bd28-3d1b33a80fd9"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i74a7063cdae7438bb8481aee4e692325_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzctMi0xLTEtMTIxNDA_b12998b9-ae17-4dea-95d3-77590327f09d"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i193cbc90df134a0d9735d84dde8ed9ec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzctNC0xLTEtMTIxNDA_6db2ac8b-5e94-4f14-9c40-92e9b578d392"
      unitRef="usd">42000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3d96d9b09d2a48cfa30e6bf373b5f762_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzctNi0xLTEtMTIxNDA_0a75edd4-0cf3-481a-9df5-669f2818b8cf"
      unitRef="usd">41000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i851b03314d344a5e8ad436aa9235bf9c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzctOC0xLTEtMTIxNDA_ce09dfc3-a649-442b-9854-058cea099dd5"
      unitRef="usd">83000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i74a7063cdae7438bb8481aee4e692325_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzgtMi0xLTEtMTIxNDA_52102296-2876-45b5-8b95-afcec7a5feeb"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i193cbc90df134a0d9735d84dde8ed9ec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzgtNC0xLTEtMTIxNDA_16db38d0-11f6-4b5b-91b0-1851a70132ac"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3d96d9b09d2a48cfa30e6bf373b5f762_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzgtNi0xLTEtMTIxNDA_20dadff1-e660-4434-9b4c-70b3c88a59f9"
      unitRef="usd">-144000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i851b03314d344a5e8ad436aa9235bf9c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzgtOC0xLTEtMTIxNDA_cd565ac9-b081-4aee-a874-3e7ca69c32a8"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibb145868ff1249dab7c2d803aac491ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzktMi0xLTEtMTIxNDA_c99e45b8-4fcd-423e-a0e1-79137d473c00"
      unitRef="usd">51000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie75f65899cfb4ee38ea27dd37daca0ee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzktNC0xLTEtMTIxNDA_11ca03f1-f497-453f-b1d1-1b036ec8fbf4"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0afde8034f24eb688bd439bf07e61b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzktNi0xLTEtMTIxNDA_f8cf1266-f22d-4c87-ab3e-841dfff33a73"
      unitRef="usd">-113000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i803ae583deba4f7683154aaeec947d69_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzktOC0xLTEtMTIxNDA_c3622635-2e67-4e15-bd8c-c626909b32cb"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic5240156832f4cc8ba8aa92faeec8f85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEwLTItMS0xLTEyMTQw_f7d47890-1da4-4536-8dcd-21b1580e40b6"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if9d19504e53c460ebb2acf511d875bc6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEwLTQtMS0xLTEyMTQw_0cd9a320-6165-43e3-ab3f-a9e105987ce6"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6a09a18820154418b65c5db65a9e8ef6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEwLTYtMS0xLTEyMTQw_81598644-bc44-45bf-98e7-79c225a6abd8"
      unitRef="usd">129000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8023d2e7ae2f498fa0385be7010b4f25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEwLTgtMS0xLTEyMTQw_3c3917bb-4c89-485e-b1e0-19a9d08e8f73"
      unitRef="usd">85000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic5240156832f4cc8ba8aa92faeec8f85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzExLTItMS0xLTEyMTQw_dcb5cb2b-91da-461c-b23d-23e7b1657a7d"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if9d19504e53c460ebb2acf511d875bc6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzExLTQtMS0xLTEyMTQw_ae5abcdc-c102-46a2-a59c-d28add030852"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6a09a18820154418b65c5db65a9e8ef6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzExLTYtMS0xLTEyMTQw_6498dc4c-7ef7-4438-932c-c3e50223161b"
      unitRef="usd">-58000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8023d2e7ae2f498fa0385be7010b4f25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzExLTgtMS0xLTEyMTQw_d03e4590-8e6e-4331-bb17-ea62b8135ff4"
      unitRef="usd">-58000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic5240156832f4cc8ba8aa92faeec8f85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEyLTItMS0xLTEyMTQw_7aa10595-980b-442b-954d-5c18fa570c37"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if9d19504e53c460ebb2acf511d875bc6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEyLTQtMS0xLTEyMTQw_82a53782-e4d2-47f8-af9f-9557f2af7fcb"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6a09a18820154418b65c5db65a9e8ef6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEyLTYtMS0xLTEyMTQw_ec4000dc-e270-4ae7-9607-ce314323ab49"
      unitRef="usd">187000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8023d2e7ae2f498fa0385be7010b4f25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEyLTgtMS0xLTEyMTQw_b2c0129f-d6b3-4c0a-ba8e-16cddbce80b5"
      unitRef="usd">143000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieaea04c5cb73429c92a11dfc633c9a7e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEzLTItMS0xLTEyMTQw_9f5f8c98-4284-4403-832d-68ef7537fd1b"
      unitRef="usd">13000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf9f4f8bc79c4814960889868046cc5f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEzLTQtMS0xLTEyMTQw_a83fd778-fa12-4eee-8c93-22a13eadcfb2"
      unitRef="usd">-4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id6a1104220914dc19840bbf261ce2cf7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEzLTYtMS0xLTEyMTQw_e4f8e9fd-b785-4517-ab88-aac95ed39da2"
      unitRef="usd">74000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ebb0b9dc1384269a861d7b5216e73fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDIvZnJhZzpiODY4MDBkOGI1OTg0NDZhYTYyYzg2MDZkMjdmM2ZmZi90YWJsZTo0Zjk5NzY1MTc0MDQ0NWJiOTdjNDBlMDJkNDIwOTA2My90YWJsZXJhbmdlOjRmOTk3NjUxNzQwNDQ1YmI5N2M0MGUwMmQ0MjA5MDYzXzEzLTgtMS0xLTEyMTQw_29df2011-d743-4df3-83d7-afe055ab0e5e"
      unitRef="usd">83000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzEwMzk2_b9e9e67f-a560-42ed-aeb8-911f785603a3">EMPLOYEE BENEFITS &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Incentive Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2004, our stockholders approved and we adopted the Gilead Sciences, Inc. 2004 Equity Incentive Plan (as amended, the &#x201c;2004 Plan&#x201d;). The 2004 Plan authorized the issuance of a total of 309 million&#160;shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As part of the Forty Seven acquisition, we assumed the Forty Seven, Inc. 2018 Equity Incentive Plan, which we subsequently amended and restated as the Gilead Sciences, Inc. 2018 Equity Incentive Plan (as amended and restated, the &#x201c;2018 Plan&#x201d;). The aggregate amount of shares that may be issued under the 2018 Plan on or after the assumption date will not exceed 12&#160;million shares. As part of the Immunomedics acquisition, we assumed the Immunomedics Amended and Restated 2014 Long-Term Incentive Plan (the &#x201c;Immunomedics Plan&#x201d; and referred together with the 2004 Plan and 2018 Plan as the &#x201c;Plans&#x201d;), which we subsequently merged into the 2004 Plan. The aggregate amount of shares that may be issued under the Immunomedics Plan on or after the assumption date will not exceed 26&#160;million shares. See Note 6. Acquisitions for additional information on the settlement of stock awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Plans are broad based incentive plans that provide for the grant of equity-based awards, including stock options, restricted stock units, restricted stock awards and performance share awards, to employees, directors and consultants. As of December&#160;31, 2021, a total of 82&#160;million shares remain available for future grant under the Plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Plans provide for option grants designated as either non-qualified or incentive stock options. All stock options granted after January&#160;1, 2006 have been non-qualified stock options. Employee stock options generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIzMDE_e5e44bde-010a-4057-a014-5f91fdc040cb"&gt;three&lt;/span&gt; or four years. All options are exercisable over a period not to exceed the contractual term of ten years from the date the stock options are issued and are granted at prices not less than the fair market value of our common stock on the grant date. Stock option exercises are settled with common stock from the Plans&#x2019; previously authorized and available pool of shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity and related information under our stock option plans. All option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;(in dollars)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual Term &lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;&#160;Intrinsic &lt;br/&gt;Value &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest, net of estimated forfeitures as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable. Total intrinsic value of options exercised was $48 million, $179 million and $209 million for 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of the stock options granted was $10.05 per share, $11.69 per share and $12.15 per share for 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there was $47 million of unrecognized compensation cost related to stock options, which is expected to be recognized over an estimated weighted-average period of 2.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock and Performance Share Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant time-based RSUs to certain employees as part of our annual employee equity compensation review program as well as to new hire employees and to non-employee members of our Board. RSUs are share-based awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. RSUs generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzM4OTI_528fb9fb-324d-4172-b895-26994db1e7b3"&gt;three&lt;/span&gt; or four years from the date of grant. The fair value of an RSU is equal to the closing price of our common stock on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant PSUs which vest upon the achievement of specified market or performance goals, which could include achieving a total shareholder return compared to a pre-determined peer group or achieving revenue targets. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%, and these awards generally vest only when a committee (or subcommittee) of our Board has determined that the specified market and performance goals have been achieved. The fair value of each PSU is estimated at the date of grant or when performance objectives are defined for the grants. Depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we have also granted other PSUs to certain of our employees under the 2004 Plan. The vesting of these awards is subject to the achievement of specified individual performance goals, typically within a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzUwNzA_664e182d-33f3-4d5a-92ea-3c6d4ced19cd"&gt;one&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzUwNzY_9109fd84-6601-41a5-b36b-3897b4762db9"&gt;two&lt;/span&gt; year period. The fair value of such an award is equal to the closing price of our common stock on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU and PSU activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:right"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Weighted-average grant-date fair value per share excludes shares related to grants that currently have no grant date as the performance objectives have not yet been defined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of RSUs granted was $65.42 per share, $70.94 per share and $64.31 per share for 2021, 2020 and 2019, respectively. The weighted-average grant date fair value of PSUs granted was $71.31 per share, $83.64 per share and $68.30 per share for 2021, 2020 and 2019, respectively. The total grant date fair value of our vested RSUs and PSUs was $503 million, $479 million and $450 million for 2021, 2020 and 2019, respectively, and total fair value as of the respective vesting dates was $471 million, $459 million and $372 million for 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there was $917 million of unrecognized compensation cost related to unvested RSUs and PSUs, which is expected to be recognized over a weighted-average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the &#x201c;ESPP&#x201d;), employees can purchase shares of our common stock based on a percentage of their compensation subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of our common stock on the offering date or the purchase date. The ESPP offers a six-month look-back feature as well as an automatic reset feature that provides for an offering period to be reset to a new lower-priced offering if the offering price of the new offering period is less than that of the current offering period. ESPP purchases are settled with common stock from the ESPP&#x2019;s previously authorized and available pool of shares. During 2021, 2 million shares were issued under the ESPP for $111 million. A total of 79 million shares of common stock have been authorized for issuance under the ESPP, and there were 5 million shares available for issuance under the ESPP as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock-based compensation expenses included on our Consolidated Statements of Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense included in total costs and expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Pre-tax stock-based compensation expense for the year ended December&#160;31, 2020 of $1.1 billion included $643 million non-cash stock-based expense and $289 million and $144 million of accelerated post-acquisition stock-based expense related to the acquisitions of Immunomedics and Forty Seven, respectively. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Income tax effect for the year ended December&#160;31, 2019 included a $114 million income tax expense following the U.S. Court of Appeals decision in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Altera Corp v. Commissioner&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, which requires related parties in an intercompany cost sharing arrangement to share expenses related to stock-based compensation.&lt;/span&gt;&lt;span style="color:#6d6d6d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation is recognized as expense over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of options granted under our Plans and purchases under our ESPP were estimated at grant or purchase dates using a Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including expected stock price volatility and expected award life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used the following assumptions to calculate the estimated fair value of the awards: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted was calculated using the single option approach. We use a blend of historical volatility along with implied volatility for traded options on our common stock to determine our expected volatility. The expected term of stock-based awards represents the weighted-average period the awards are expected to remain outstanding. We estimate the weighted-average expected term based on historical cancellation and historical exercise data related to our stock options as well as the contractual term and vesting terms of the awards. The risk-free interest rate is based upon observed interest rates appropriate for the term of the stock-based awards. The dividend yield is based on our history and expectation of dividend payouts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a retirement saving plan under which eligible U.S. employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (the Gilead Sciences 401k Plan). In certain foreign subsidiaries, we maintain defined benefit plans as required by local regulatory requirements. Our total matching contribution expense under the Gilead Sciences 401k Plan and other defined benefit plans was $166 million, $144 million and $110 million during 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a deferred compensation plan under which our directors and key employees may defer compensation. Amounts deferred by participants are deposited into a rabbi trust. The total assets and liabilities associated with the deferred compensation plan were $261 million and $218 million as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ica652e76a6974f3cb7f5a6d0f8d94017_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzg0Ng_ead2db80-ebcd-4865-997a-361e1f0fbb84"
      unitRef="shares">309000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ib59a14c778a94c75975c4acb8a10179d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzEyMzY_85ed96ee-376f-46ea-90d4-639e6da10b3c"
      unitRef="shares">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ib59a14c778a94c75975c4acb8a10179d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzU0OTc1NTgxNTAzNTc_dede91fa-e35a-4131-a838-c8d7e5d527d2"
      unitRef="shares">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iba210e1a3e384daca10160c7ffbc3ee5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzE2Mzk_5313766d-df17-4ab8-bad6-40475c8033db"
      unitRef="shares">26000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ica652e76a6974f3cb7f5a6d0f8d94017_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzE5OTU_3f8ef2f7-a8ce-40d8-9d2a-c8740b8b8751"
      unitRef="shares">82000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i63aedd4c33d5433b8067d84fd5b6f093_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIzMDc_8cf4d167-f296-492c-a567-2f59d50a2066">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIzOTE_ad015a0d-8b6a-42c3-b033-ac3dca0b3460">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzEwMzc2_29cfc6f2-b0a3-4e5d-9965-3192b51159c2">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity and related information under our stock option plans. All option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;(in dollars)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual Term &lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;&#160;Intrinsic &lt;br/&gt;Value &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest, net of estimated forfeitures as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0729bf1c13614c1dbd5464ad3b216cd1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzEtMi0xLTEtMTIxNDA_732bbe87-96d1-4f58-a5c1-d4c77012c01b"
      unitRef="shares">16600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0729bf1c13614c1dbd5464ad3b216cd1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzEtNC0xLTEtMTIxNDA_15e17086-28bb-49db-b482-5f5386963f27"
      unitRef="usdPerShare">69.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzItMi0xLTEtMTIxNDA_7695cde6-4030-46a4-912a-9d0d9fb20fb4"
      unitRef="shares">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzItNC0xLTEtMTIxNDA_0b24dcc7-8de9-4138-8e34-44657835267d"
      unitRef="usdPerShare">64.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzMtMi0xLTEtMTIxNDA_12a0c3b4-6012-4479-82d1-e3b5a56a3745"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzMtNC0xLTEtMTIxNDA_e82d36ce-49d5-4b0b-a272-4a8e32461d60"
      unitRef="usdPerShare">67.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzQtMi0xLTEtMTIxNDA_d479a9c0-934f-48d9-952f-c70cbeef400f"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzQtNC0xLTEtMTIxNDA_8475d247-cbbf-4ac6-9283-0eed66b84315"
      unitRef="usdPerShare">82.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzUtMi0xLTEtMTIxNDA_a2e53f00-cd3f-406d-8c6e-964d5078e8ba"
      unitRef="shares">1600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzUtNC0xLTEtMTIxNDA_75cf724c-daf9-4656-b6f5-c400354f7920"
      unitRef="usdPerShare">37.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i354b6ee389b345259779247e1761d741_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzYtMi0xLTEtMTIxNDA_a6bce2e5-2287-44cf-9a31-eea9d4dd2e3a"
      unitRef="shares">16800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i354b6ee389b345259779247e1761d741_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzYtNC0xLTEtMTIxNDA_777ce429-41ce-4bb7-b4b8-339dd251e613"
      unitRef="usdPerShare">70.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzYtNi0xLTEtMTIxNDA_002c31ce-553d-4e54-99cc-8025e9338036">P5Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i354b6ee389b345259779247e1761d741_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzYtOC0xLTEtMTIxNDA_5fea69ac-6080-4af8-808e-4efcaed7f6d8"
      unitRef="usd">101000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i354b6ee389b345259779247e1761d741_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzctMi0xLTEtMTIxNDA_e1834fe2-0a69-4487-8fb2-c87c31f3d3eb"
      unitRef="shares">11200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i354b6ee389b345259779247e1761d741_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzctNC0xLTEtMTIxNDA_211d6707-f05b-4bc0-b884-eb4a9f6af813"
      unitRef="usdPerShare">72.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzctNi0xLTEtMTIxNDA_19dd13c5-d01d-4456-bbc7-5f19f56abbc9">P3Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i354b6ee389b345259779247e1761d741_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzctOC0xLTEtMTIxNDA_8d85792a-184a-4694-a039-8213ff072185"
      unitRef="usd">68000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i354b6ee389b345259779247e1761d741_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzgtMi0xLTEtMTIxNDA_ba4f7b0c-063b-4b84-9c2c-53d67e8d9875"
      unitRef="shares">5300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i354b6ee389b345259779247e1761d741_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzgtNC0xLTEtMTIxNDA_a1798403-71f6-4812-9752-3861b1af857e"
      unitRef="usdPerShare">67.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzgtNi0xLTEtMTIxNDA_0469ffe9-66a4-4451-b8e1-671eb4ff655f">P8Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i354b6ee389b345259779247e1761d741_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTo2MWEyZDViZTZjODE0ODliOTNhYmVlZDEzZjI2YmQ4ZC90YWJsZXJhbmdlOjYxYTJkNWJlNmM4MTQ4OWI5M2FiZWVkMTNmMjZiZDhkXzgtOC0xLTEtMTIxNDA_2ddb48c8-02d1-41de-80ca-cdcd689341e1"
      unitRef="usd">32000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYwMjE_26ce7823-1600-42d3-9094-88427db70bf0"
      unitRef="usd">48000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i978af2e4f66d4a0598365cc6a4df3a60_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc1OTA_0ad8d285-20b8-4c67-8bf0-c34d35d25afc"
      unitRef="usd">179000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i8ac2832a817c4b079e7e753df575c2fd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc1OTg_23a4d3b6-9ad7-4521-ab3b-a853bf5e2474"
      unitRef="usd">209000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYwMzk_ddde78ba-0980-4faf-8782-0251cae0bb7a"
      unitRef="usdPerShare">10.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i978af2e4f66d4a0598365cc6a4df3a60_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc2NDg_ec62a6f6-d88c-47c6-aeea-07f763dec534"
      unitRef="usdPerShare">11.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8ac2832a817c4b079e7e753df575c2fd_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc2NjY_8552d799-e6f7-4b61-8bc4-ee445606d3d5"
      unitRef="usdPerShare">12.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i354b6ee389b345259779247e1761d741_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYwNDg_12589f07-0a10-40d4-a4f6-79746e08273e"
      unitRef="usd">47000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYwNTY_754b9c0a-8822-4703-b3e3-9dbbe0a0a06f">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iea60cbe1d7984731a8c9400ef7641432_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzM4OTg_f4210a8e-ec5a-4d81-b9de-925b976e753a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage
      contextRef="i6305a82bd394408e9eb61ee6d9a6b096_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzQzNzI_0bbe79d8-adf9-411e-94bd-782101080adf"
      unitRef="number">0</gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage>
    <gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage
      contextRef="icec935a6b97544d6a97b10b0c0f9a6b1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzQzNzg_3dddbf38-3162-435e-9e6e-90623403058f"
      unitRef="number">2</gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzEwMzk4_246b8703-11ac-4b35-90dc-e6cd555385df">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU and PSU activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:right"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;(1) &#160;&#160;&#160;&#160;Weighted-average grant-date fair value per share excludes shares related to grants that currently have no grant date as the performance objectives have not yet been defined.</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8e0958f8c926485eae5d31e7b78ed257_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzItMi0xLTEtMTIxNDA_ac0cb69c-4012-47d9-bcaa-af9391b3ccda"
      unitRef="shares">19500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i8e0958f8c926485eae5d31e7b78ed257_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzItNC0xLTEtMTIxNDA_0ef6ae3b-b365-44ff-8dfa-67308e4d56d0"
      unitRef="usdPerShare">69.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i35a87915496f4f0f918d93a07f297c71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzItNi0xLTEtMTIxNDA_10493a7f-3f07-4f3d-a4df-5429ae4a96ef"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i35a87915496f4f0f918d93a07f297c71_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzItOC0xLTEtMTIxNDA_d9d9a555-943a-4b2d-861c-bc2236841c64"
      unitRef="usdPerShare">84.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzMtMi0xLTEtMTIxNDA_79369d6e-b812-4133-9a70-f53c4e6d1f26"
      unitRef="shares">11900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzMtNC0xLTEtMTIxNDA_424db7d5-6a3b-4976-ac4d-bb3cdd3ccd2d"
      unitRef="usdPerShare">65.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzMtNi0xLTEtMTIxNDA_f4a015ea-f848-40f0-8160-bda02fafb1a9"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzMtOC0xLTEtMTIxNDA_4e8b8763-7ba8-426e-9d11-072033cf98ec"
      unitRef="usdPerShare">71.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzQtMi0xLTEtMTIxNDA_b600b0d8-55db-4c5c-b72e-80ede7efd430"
      unitRef="shares">7000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzQtNC0xLTEtMTIxNDA_299d969e-edec-4e7e-9959-91b0884c55c6"
      unitRef="usdPerShare">70.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzQtNi0xLTEtMTIxNDA_29a62437-cf4b-4262-953b-a3365dd2e1e3"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzQtOC0xLTEtMTIxNDA_44267b64-8a06-4bc3-b8e0-74ee311bc61c"
      unitRef="usdPerShare">88.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzUtMi0xLTEtMTIxNDA_733704ce-df08-4bd6-91a8-c3423f5fd37b"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzUtNC0xLTEtMTIxNDA_5ae65522-f945-46de-8670-eeaf2490c1c9"
      unitRef="usdPerShare">67.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzUtNi0xLTEtMTIxNDA_8e985dde-c446-4a14-b6e4-622ffecf2003"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzUtOC0xLTEtMTIxNDA_09471bb0-42cd-4dfe-99e0-689e31b74499"
      unitRef="usdPerShare">78.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i17e83904e7c84fe4ba24ed426244affb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzYtMi0xLTEtMTIxNDA_1d206b08-1750-4989-9dd2-242de894fc64"
      unitRef="shares">20900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i17e83904e7c84fe4ba24ed426244affb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzYtNC0xLTEtMTIxNDA_8b7719fa-616c-4030-934e-4663ccb766e1"
      unitRef="usdPerShare">67.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i12f8795691e94495b697bd3ee9e10a01_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzYtNi0xLTEtMTIxNDA_2cd35290-7426-499f-9b23-9a3979cc2d89"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i12f8795691e94495b697bd3ee9e10a01_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTplMmE0NzcwYmYyNDc0NDdjOTcyZTFmNGZiYzQxYjE0Yi90YWJsZXJhbmdlOmUyYTQ3NzBiZjI0NzQ0N2M5NzJlMWY0ZmJjNDFiMTRiXzYtOC0xLTEtMTIxNDA_34a3b535-4018-49a3-ae98-3a0ea9102c40"
      unitRef="usdPerShare">79.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYwOTc_b1d94718-8976-4ae3-a271-4500bf2120d7"
      unitRef="usdPerShare">65.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1f4fbfc0f6ca4a74b926e26a7212b4d4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc3NDk_7712e100-fb32-405d-a8c5-52c24b449504"
      unitRef="usdPerShare">70.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i092e7210064445688e64ea085cde62b9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc3Njc_29f27f32-6190-4ed7-84e2-cdb2155aa3d5"
      unitRef="usdPerShare">64.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i437a711ae74d45e89f355244fe18b7e5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxMTI_4e8b8763-7ba8-426e-9d11-072033cf98ec"
      unitRef="usdPerShare">71.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i597fc5ca87d64f79987a4deb4814a2cc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc4NTQ_5da4869b-3231-4a5b-a5c5-887d0e14d7db"
      unitRef="usdPerShare">83.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibb8bcd0d8ecf4205b8fe6029870b6fba_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc4NzE_f61064c2-4b09-4f5c-a27c-a06b6b3283ea"
      unitRef="usdPerShare">68.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i5f4b7466ad0243e69a21d012954cb83e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxMjc_c42d7d84-b26d-402c-aa5e-c23828f0f247"
      unitRef="usd">503000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i27e180b4cd6e425b8489f50bc779226d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc4MTU_0bb5d6fa-4c91-48c3-bbc6-826b6778994b"
      unitRef="usd">479000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i74136efa08b74a10bd1a8c546eacd605_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc4MjI_07283c78-3cbe-4e36-918d-30ee6c04961c"
      unitRef="usd">450000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i7bc9c86928c74673ab301285440c1661_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxNDM_5beb7726-0c3b-4e27-8cf0-df59eeb89914"
      unitRef="usd">471000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="if0c35aff509b4c369b6860cf48fb5cac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc5NTE_dd718b8b-5841-489d-86c8-0567056603a0"
      unitRef="usd">459000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i1b1a7a2d096046eea14fab1d821f637f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc5NTg_4edb61e5-076d-4906-90c8-195d4be54b4f"
      unitRef="usd">372000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="iff82fe9d37f642f6bd89267088886a42_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxNTE_242c0e08-9589-442e-b7d1-740ff94a55e6"
      unitRef="usd">917000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="icad35ac1806e4f21a40d3a0946de361d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxNjA_d61f5868-0c02-4a46-b2a6-572ed692eb67">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzY0NDA_24c132d8-098e-427f-95e3-2e40a5752021"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxODE_1b62caf9-429f-4594-9b01-13a73d2cf0b5"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxODk_420eb0d4-2229-419e-b892-40699086b6c8"
      unitRef="usd">111000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ife2e5f0230844117bbb72a6267db6609_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYxOTc_19343e8b-70a0-4a58-9a17-fe088094504e"
      unitRef="shares">79000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ife2e5f0230844117bbb72a6267db6609_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYyMDU_fdfbd7a8-8f70-4559-9aae-3a49951a6093"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzEwMzc4_4567c3b1-1411-490b-b809-d749b40512be">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock-based compensation expenses included on our Consolidated Statements of Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense included in total costs and expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Pre-tax stock-based compensation expense for the year ended December&#160;31, 2020 of $1.1 billion included $643 million non-cash stock-based expense and $289 million and $144 million of accelerated post-acquisition stock-based expense related to the acquisitions of Immunomedics and Forty Seven, respectively. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Income tax effect for the year ended December&#160;31, 2019 included a $114 million income tax expense following the U.S. Court of Appeals decision in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Altera Corp v. Commissioner&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, which requires related parties in an intercompany cost sharing arrangement to share expenses related to stock-based compensation.&lt;/span&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i808afce6234d4f44b02493f616cfcdad_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzItMi0xLTEtMTIxNDA_b6952758-2c1a-4048-b6e2-6ec4c510170c"
      unitRef="usd">40000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i157409bb1ea342b2a3f94ed6091834b3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzItNC0xLTEtMTIxNDA_ef051375-2b3d-4cc5-9647-2e114f5e61f6"
      unitRef="usd">109000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e62f0a33b96429bb3fe4df85eb86fd7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzItNi0xLTEtMTIxNDA_f28230f7-2c40-4f79-a8e7-c09cc8feaa0d"
      unitRef="usd">48000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic63775c3a22e4db9805ee00e5e0ad2f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzMtMi0xLTEtMTIxNDA_de47f3ab-7ace-450b-a405-1a2801e60767"
      unitRef="usd">287000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i09ace142a66d4ef093c014ea5eb86836_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzMtNC0xLTEtMTIxNDA_179b0e19-d5ad-4009-94a4-16eaecaf7e55"
      unitRef="usd">462000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6851218a40374235b12bad014064a29d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzMtNi0xLTEtMTIxNDA_6f864295-0575-4e5f-921d-3a3965961f2e"
      unitRef="usd">289000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id9ee369dd27f4f9fa86ebb38e3b71a65_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzQtMi0xLTEtMTIxNDA_d0a49b15-52c6-4eb8-8a80-665780dc8ebf"
      unitRef="usd">308000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94fdbc3b74014794bf026a159fb15aa2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzQtNC0xLTEtMTIxNDA_c2560d7e-a3bb-4f9a-a0c9-5d6edfff87eb"
      unitRef="usd">505000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4d0883810134f519ae9afb0d14ed77a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzQtNi0xLTEtMTIxNDA_23daf278-4ee9-45ed-bc44-0e31274e8b48"
      unitRef="usd">299000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzUtMi0xLTEtMTIxNDA_916c6736-0677-45d1-a1e9-5ec431ed897f"
      unitRef="usd">635000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzUtNC0xLTEtMTIxNDA_14300e5c-710e-4698-8aec-0eb15f936f14"
      unitRef="usd">1076000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzUtNi0xLTEtMTIxNDA_aee6d8f7-f3e6-4750-84f0-afdc84cf39f4"
      unitRef="usd">636000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzYtMi0xLTEtMTIxNDA_7036a8cc-67d9-433a-ab3b-e021945b4607"
      unitRef="usd">100000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzYtNC0xLTEtMTIxNDA_5c3b72c7-58aa-493c-9a09-de4a610af8d8"
      unitRef="usd">222000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzYtNi0xLTEtMTIxNDA_ad69581b-83f7-4e37-9da9-34fa85807690"
      unitRef="usd">-2000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzctMi0xLTEtMTIxNDA_87fc1ec2-e486-4bdc-95c7-70ef0a020fc1"
      unitRef="usd">535000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzctNC0xLTEtMTIxNDA_9a76a677-e306-4437-a14c-5c3cd98568b5"
      unitRef="usd">854000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTowNTJkZTYwMjlmMTM0NDVmYjhhM2FlMjkyNjljYjRmNy90YWJsZXJhbmdlOjA1MmRlNjAyOWYxMzQ0NWZiOGEzYWUyOTI2OWNiNGY3XzctNi0xLTEtMTIxNDA_1aebb835-34d5-43e7-a0c7-5a0b8e90f002"
      unitRef="usd">638000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzE2NDkyNjc0NTMxNDQ_e43c177b-8853-4003-b3a4-1733437700b2"
      unitRef="usd">1100000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzI3NDg3NzkwODAxNjk_7b2acaca-4654-4c49-82f3-d9a7cd5b0aa7"
      unitRef="usd">643000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="icaf63b79601f41cbbbb79ce216ea77a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzczOTQ_2ca52252-dd25-4fb5-84f1-baf8399f84ec"
      unitRef="usd">289000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="ic616f3942a304ac4ab23e63afeed5a7d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzc0MDE_4e352571-745e-4fa9-b3e7-3b7a8471cd8d"
      unitRef="usd">144000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzc2MzE_802ed541-5024-4b57-af4a-2650855ce9e7"
      unitRef="usd">114000000</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <gild:ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzEwMzkx_96936c7d-a86f-44c8-aba0-a5ff1c0e7303">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used the following assumptions to calculate the estimated fair value of the awards: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gild:ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzMtMi0xLTEtMTIxNDA_6700676b-3b04-4099-94a6-6d3cb5271e01"
      unitRef="number">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i978af2e4f66d4a0598365cc6a4df3a60_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzMtNC0xLTEtMTIxNDA_16a8f6ae-1f80-4e2d-b660-d1ee1d71bd4a"
      unitRef="number">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8ac2832a817c4b079e7e753df575c2fd_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzMtNi0xLTEtMTIxNDA_cf4f5bf0-866e-4e6e-9f0e-c0a2f94b9569"
      unitRef="number">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzQtMi0xLTEtMTIxNDA_9fa86b15-eac7-493b-ad25-8a17ea469676"
      unitRef="number">0.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i490b5d2fa50a4d27ba621c355f27e7c5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzQtNC0xLTEtMTIxNDA_5b10a3b2-2b21-4931-a8c3-c56ed15aa7e4"
      unitRef="number">0.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7bea36ad4f2b4224bf60b33eecac3150_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzQtNi0xLTEtMTIxNDA_4aca5d58-f450-41f3-9e10-34c1c0c01ad6"
      unitRef="number">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzYtMi0xLTEtMTIxNDA_705caa0d-4ab7-44b6-bd86-6a8b9cfebb10">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i978af2e4f66d4a0598365cc6a4df3a60_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzYtNC0xLTEtMTIxNDA_7ffa9b6f-0bbf-435e-a42b-5d8413340757">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8ac2832a817c4b079e7e753df575c2fd_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzYtNi0xLTEtMTIxNDA_accea282-f650-4700-b4ae-a13b14bd2ba9">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzctMi0xLTEtMTIxNDA_32ba45ae-1aa0-4de3-a807-b2bac617b8c2">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i490b5d2fa50a4d27ba621c355f27e7c5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzctNC0xLTEtMTIxNDA_81581f76-335b-4bfe-b069-d7658fea6687">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7bea36ad4f2b4224bf60b33eecac3150_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzctNi0xLTEtMTIxNDA_27bce300-e550-408a-a104-90b3945476cf">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3f84634bb8d4414996acc026171d4734_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzktMi0xLTEtMTIxNDA_61fc4229-2cf8-472e-842f-a5a871511455"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i978af2e4f66d4a0598365cc6a4df3a60_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzktNC0xLTEtMTIxNDA_4982b092-54ed-4f49-8359-3f96d2d25a21"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8ac2832a817c4b079e7e753df575c2fd_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzktNi0xLTEtMTIxNDA_4001de47-83fc-4cfa-939d-80aae3112075"
      unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5a386d265aae447bb17b31b7c8a39c3c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzEwLTItMS0xLTEyMTQw_fa54b83e-0add-4f39-9a17-eb9ad93647ae"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i490b5d2fa50a4d27ba621c355f27e7c5_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzEwLTQtMS0xLTEyMTQw_fd69ce93-fcba-4b3b-a779-514224167f32"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7bea36ad4f2b4224bf60b33eecac3150_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzEwLTYtMS0xLTEyMTQw_49c426df-c977-4131-b150-cc3434d20ae1"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzExLTItMS0xLTEyMTQw_2b208d10-d6cd-4000-a51a-31ace5ba7893"
      unitRef="number">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzExLTQtMS0xLTEyMTQw_09588f93-05f9-4505-9671-8a0b21c65555"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90YWJsZTpmMGM5YWIxMDRmZWM0YjQ5YTI0ZTgwZmQyZjEwNGE4MC90YWJsZXJhbmdlOmYwYzlhYjEwNGZlYzRiNDlhMjRlODBmZDJmMTA0YTgwXzExLTYtMS0xLTEyMTQw_ed8b5d9d-1897-424e-9e8b-12a48c824cd1"
      unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjYyMzg_3f6fb4ac-8bb0-4665-ab9c-8a837a59ba38"
      unitRef="usd">166000000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDc5OTc_0240eef8-97ab-4d88-83e0-a69f4b9559d2"
      unitRef="usd">144000000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzkzNDU4NDg4NDgwMDQ_240ffb51-427b-4eda-9786-7d94d4e9d2e3"
      unitRef="usd">110000000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i90c285b633ed488fbf315d7bcb4b9c40_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjc1OTc_b6cc51ce-7bd1-4695-8cda-8311b25e36b9"
      unitRef="usd">261000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifd8ddd71ad6a4934a591d1a60321c3c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDUvZnJhZzphNWFmZjFiNmZiZTk0ODcxOWE3NWNkYzU5ZWYwZGUyYy90ZXh0cmVnaW9uOmE1YWZmMWI2ZmJlOTQ4NzE5YTc1Y2RjNTllZjBkZTJjXzIxOTkwMjMyNjc2MDI_b334d9dc-a6ba-4bf3-9e50-e13c1dee0b6a"
      unitRef="usd">218000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90ZXh0cmVnaW9uOmY5YTI4NTYxYmJkYzRiZDE5YjBjNTFmMzNhMzkxYTQ2Xzk2Mg_0063a44a-e11b-47fd-ab10-246fac811c2d">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common shareholders because their effect would have been antidilutive were 15 million, 13 million and 14 million during 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - diluted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90ZXh0cmVnaW9uOmY5YTI4NTYxYmJkYzRiZDE5YjBjNTFmMzNhMzkxYTQ2Xzc4Mw_18588003-0847-4535-ae3e-b7e9187c9f23"
      unitRef="shares">15000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90ZXh0cmVnaW9uOmY5YTI4NTYxYmJkYzRiZDE5YjBjNTFmMzNhMzkxYTQ2XzIxOTkwMjMyNTY1NTM_7dc73112-f025-4d56-bfdb-44b4f7cfc3a6"
      unitRef="shares">13000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90ZXh0cmVnaW9uOmY5YTI4NTYxYmJkYzRiZDE5YjBjNTFmMzNhMzkxYTQ2XzIxOTkwMjMyNTY1NTk_045a69df-d6dc-4b92-9942-de41c18e8ba7"
      unitRef="shares">14000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90ZXh0cmVnaW9uOmY5YTI4NTYxYmJkYzRiZDE5YjBjNTFmMzNhMzkxYTQ2Xzk3MQ_e4495827-72d1-4422-b85c-e4bae542919b">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - diluted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzItMi0xLTEtMTIxNDA_c15b37d5-937e-4653-ac08-5bc65a955290"
      unitRef="usd">6225000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzItNC0xLTEtMTIxNDA_8e033343-f34e-4c9a-84c7-7c0d0e29ba65"
      unitRef="usd">123000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzItNi0xLTEtMTIxNDA_6e26a8f1-6e99-4e9e-a024-e2d490df86b5"
      unitRef="usd">5386000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzMtMi0xLTEtMTIxNDA_ef43602e-1dab-41bc-b513-bdce0cc162e8"
      unitRef="shares">1256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzMtNC0xLTEtMTIxNDA_d02244cc-a4ea-48e8-a41d-fc457d780973"
      unitRef="shares">1257000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzMtNi0xLTEtMTIxNDA_e6a3fe3b-d9e4-4822-a080-2c7e31bc82d4"
      unitRef="shares">1270000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzQtMi0xLTEtMTIxNDA_c71ee2c0-bf00-4846-990b-89a8391f2a53"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzQtNC0xLTEtMTIxNDA_ae73062b-f054-4036-a1d2-031d4267a8d1"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzQtNi0xLTEtMTIxNDA_79e520d3-2730-4874-bd10-6b3295b012dc"
      unitRef="shares">7000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzUtMi0xLTEtMTIxNDA_caa9d450-8268-419a-a5dc-9931a84888ab"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzUtNC0xLTEtMTIxNDA_223573d3-e9a6-45cf-8aba-18229b7194ad"
      unitRef="shares">1263000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzUtNi0xLTEtMTIxNDA_251e6e6c-76f5-4f2a-af8b-fc59a5ff9109"
      unitRef="shares">1277000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzYtMi0xLTEtMTIxNDA_f451b2d5-dff5-42b7-aee2-9e0ade70c961"
      unitRef="usdPerShare">4.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzYtNC0xLTEtMTIxNDA_bb894a0a-b337-47ba-a7b6-8739bc4a5872"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzYtNi0xLTEtMTIxNDA_07c678cc-c490-45b0-b781-e11dcb1486df"
      unitRef="usdPerShare">4.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzctMi0xLTEtMTIxNDA_901700f4-5b8d-43f5-920e-0b6418eae4d8"
      unitRef="usdPerShare">4.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzctNC0xLTEtMTIxNDA_488c9450-b9dd-4a19-b201-86cc053e239b"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNDgvZnJhZzpmOWEyODU2MWJiZGM0YmQxOWIwYzUxZjMzYTM5MWE0Ni90YWJsZTo2NjNhMjM2YTk2MDk0ZGMyODY2YTk0ZjA0YTM4Mzc3NC90YWJsZXJhbmdlOjY2M2EyMzZhOTYwOTRkYzI4NjZhOTRmMDRhMzgzNzc0XzctNi0xLTEtMTIxNDA_ed4779fd-bb9b-4031-8dc0-c751bb10ed14"
      unitRef="usdPerShare">4.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzQ4OTE_b240e650-e85c-44b6-9ac7-1eb525a22a03">INCOME TAXES &lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Income tax (expense) benefit consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2019 income tax benefit included a $1.2 billion deferred tax benefit related to intangible asset transfers from a foreign subsidiary to Ireland and the United States. In the fourth quarter of 2019, we completed an intra-entity asset transfer of certain intangible assets from a foreign subsidiary to Ireland. The transaction resulted in a step-up of the Irish tax-deductible basis in the transferred assets, and accordingly, created a temporary difference where the tax basis exceeded the financial statement basis of such intangible assets. As a result, we recognized a deferred tax asset of $1.2 billion on our Consolidated Financial Statements. We expect to be able to realize the deferred tax asset resulting from this intra-entity asset transfer. The impact of the intangible asset transfer from a foreign subsidiary to the United States was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the federal statutory tax rate applied to income before income taxes and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings at different rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US tax on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax - intra-entity transfer of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement of tax examinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D and related charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-taxable unrealized (gain)  loss on investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves and accruals not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess of tax basis over book basis of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront and milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess of book basis over tax basis of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance was $520 million and $398 million as of December&#160;31, 2021 and 2020, respectively. The increase of our valuation allowance in 2021 was primarily related to California research and development tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance was $398 million and $217 million as of December&#160;31, 2020 and 2019, respectively. The increase of our valuation allowance in 2020 was primarily related to acquired attributes related to Forty Seven and Immunomedics acquisitions, and capital losses related to our equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, we had U.S. federal net operating loss and tax credit carryforwards of approximately $250 million and $8 million, respectively, which will start to expire in 2022, if not utilized. In addition, we had state net operating loss and tax credit carryforwards of approximately $2.8 billion and $768 million, respectively. The state net operating loss and state tax credit carryforwards will start to expire in 2022 if not utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of net operating losses and tax credits may be subject to an annual limitation due to ownership change limitations provided in the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file federal, state and foreign income tax returns in the United States and in many foreign jurisdictions. For federal income tax purposes, the statute of limitations is open for 2016 and onwards and 2013 and onwards for California income tax purposes. For certain acquired entities, the statute of limitations is open for all years from inception due to our utilization of their net operating losses and credits carried over from prior years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service and Irish tax authorities for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.&lt;/span&gt;&lt;span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the total unrecognized tax benefits, $800 million and $1.2 billion as of December&#160;31, 2021 and 2020, respectively, if recognized, would reduce our effective tax rate in the period of recognition. Interest and penalties related to unrecognized tax benefits included income tax expense of $41 million, income tax benefit of $82 million and income tax expense of $105 million on our Consolidated Statements of Income for the years ended December&#160;31, 2021, 2020 and 2019 respectively. Accrued interest and penalties related to unrecognized tax benefits were $218 million&lt;/span&gt;&lt;span style="color:#dbdbdb;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $177 million as of December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we believe that it is reasonably possible that our unrecognized tax benefits will decrease by approximately $100 million in the next 12 months due to potential settlements with various taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a rollforward of our total gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to current year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to prior years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Tax Cuts and Jobs Act, we recorded a federal income tax payable for transition tax on the mandatory deemed repatriation of foreign earnings that is payable over an eight-year period. As of December&#160;31, 2021 and 2020, we have accrued $4.0 billion and $4.5 billion, respectively, for transition tax. Of the amounts accrued as of December&#160;31, 2021, approximately $473 million is expected to be paid within one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzQ4ODQ_f6fbd486-0da8-4066-93ca-b540fa5ba82b">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzItMi0xLTEtMTIxNDA_c02abafe-4978-45d0-8b8d-b082957b906b"
      unitRef="usd">8587000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzItNC0xLTEtMTIxNDA_d78a6b06-b097-4c3b-bc27-9463a69e6ead"
      unitRef="usd">2505000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzItNi0xLTEtMTIxNDA_27896a6c-a4a5-42e5-89f9-be9ae19f22c9"
      unitRef="usd">4112000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzMtMi0xLTEtMTIxNDA_d44cc193-bb93-409f-ad70-c1a05717eff7"
      unitRef="usd">-309000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzMtNC0xLTEtMTIxNDA_3743b2a1-dcb9-4228-9bfa-5120cd092bf8"
      unitRef="usd">-836000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzMtNi0xLTEtMTIxNDA_50481489-f1e4-47a1-91ca-c594ceacc3be"
      unitRef="usd">1048000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzQtMi0xLTEtMTIxNDA_d2c2e1c9-ccd6-4d83-abf4-a3db68b09562"
      unitRef="usd">8278000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzQtNC0xLTEtMTIxNDA_184cf0fc-8539-4b08-884b-4d39c0d2a7d3"
      unitRef="usd">1669000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTowNWJhMjY4MTRlMzc0ODhhOWI0Mzc4MWVjNjVmNGUyNi90YWJsZXJhbmdlOjA1YmEyNjgxNGUzNzQ4OGE5YjQzNzgxZWM2NWY0ZTI2XzQtNi0xLTEtMTIxNDA_95e05016-e774-4f73-8597-fa1a7b6ed7b8"
      unitRef="usd">5160000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzQ4OTI_3bb581f8-067f-40f7-877b-e8a057e752dd">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Income tax (expense) benefit consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzMtMi0xLTEtMTIxNDA_f3d2982b-4c8c-4917-8efc-ac9c37f62270"
      unitRef="usd">1776000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzMtNC0xLTEtMTIxNDA_b7acbbe5-da0e-4230-ac98-c950633b9e3e"
      unitRef="usd">1450000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzMtNi0xLTEtMTIxNDA_8a7386a4-ad96-4c49-a79e-c304b7f3627c"
      unitRef="usd">1646000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzQtMi0xLTEtMTIxNDA_fa811547-5288-447c-8087-30ea7d37c651"
      unitRef="usd">-250000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzQtNC0xLTEtMTIxNDA_f26c6d11-52bd-4a45-a3d4-ee6f0895b9af"
      unitRef="usd">-164000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzQtNi0xLTEtMTIxNDA_16a748b0-d9b0-46f1-b20f-4265e78e0fc7"
      unitRef="usd">-843000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzUtMi0xLTEtMTIxNDA_978b6478-8097-4aae-84ee-8e632b97888e"
      unitRef="usd">1526000000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzUtNC0xLTEtMTIxNDA_ce37c470-7503-4a24-b05b-05e25c735e72"
      unitRef="usd">1286000000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzUtNi0xLTEtMTIxNDA_64a6325d-735e-4225-9077-bb0a60c81229"
      unitRef="usd">803000000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzctMi0xLTEtMTIxNDA_88f97844-6355-498b-aad1-6cfe632792ff"
      unitRef="usd">228000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzctNC0xLTEtMTIxNDA_30c8efcb-8c9e-4048-92d0-a6faa233f7cf"
      unitRef="usd">198000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzctNi0xLTEtMTIxNDA_63123bea-9f36-489b-ac8a-82d3a8b7effa"
      unitRef="usd">135000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzgtMi0xLTEtMTIxNDA_fff4e8e4-9540-4ad7-ac1a-68a03f898c11"
      unitRef="usd">185000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzgtNC0xLTEtMTIxNDA_29a5fd59-1902-4b16-a7ac-677c249a4773"
      unitRef="usd">-97000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzgtNi0xLTEtMTIxNDA_27e9dd2f-6988-4df3-9228-8f19943fa72a"
      unitRef="usd">-42000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzktMi0xLTEtMTIxNDA_3923c5bc-87b2-40b2-b5a3-27559431cc19"
      unitRef="usd">413000000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzktNC0xLTEtMTIxNDA_0ac2ea67-af0b-4634-a5b0-16644178d5be"
      unitRef="usd">101000000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzktNi0xLTEtMTIxNDA_b6f4d91c-fd74-489a-b0bf-5933453826bc"
      unitRef="usd">93000000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzExLTItMS0xLTEyMTQw_996395e6-d869-4b11-9a4e-01e2bb43ce43"
      unitRef="usd">185000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzExLTQtMS0xLTEyMTQw_86660afe-e094-4bc5-8989-0522f395ecb0"
      unitRef="usd">155000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzExLTYtMS0xLTEyMTQw_13ae7bd6-d442-458d-8c98-229b2891eae6"
      unitRef="usd">124000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzEyLTItMS0xLTEyMTQw_69a8cc62-4a6f-446e-8f15-cd597906ca10"
      unitRef="usd">-47000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzEyLTQtMS0xLTEyMTQw_8a65cdde-ddda-42bf-a64d-453a7efd802d"
      unitRef="usd">38000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzEyLTYtMS0xLTEyMTQw_9a41804f-3ed9-4f85-a0a7-633cba26fca6"
      unitRef="usd">-1224000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzEzLTItMS0xLTEyMTQw_6ce186da-9a21-42d7-98c4-99629960da3e"
      unitRef="usd">138000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzEzLTQtMS0xLTEyMTQw_9db51a47-5c50-45d7-ad78-c7d3cccd5188"
      unitRef="usd">193000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzEzLTYtMS0xLTEyMTQw_27e9319e-6c39-4c65-ae85-f3e9ef2c8ad1"
      unitRef="usd">-1100000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzE0LTItMS0xLTEyMTQw_9a9ce1c7-1646-4fd0-8b4f-b4f8ee4b150d"
      unitRef="usd">2077000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzE0LTQtMS0xLTEyMTQw_762838af-9c60-4c9e-9c4f-dc21a6098b94"
      unitRef="usd">1580000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiNWQ1NWUxODJhMDg0OWIzYTJjOTIwNWY0ZTgwYzBjZC90YWJsZXJhbmdlOmI1ZDU1ZTE4MmEwODQ5YjNhMmM5MjA1ZjRlODBjMGNkXzE0LTYtMS0xLTEyMTQw_d0faeb43-a966-4ad7-830d-f0ddb55cebce"
      unitRef="usd">-204000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie16d6139caf042729e09c331c0223fee_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjUyNDk_d8332c90-b5d2-4c3b-8e5f-0876ebf42389"
      unitRef="usd">-1200000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i49ab5beb24194822982742d602f870c9_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjUyODM_e7a3a3c7-5299-460a-8641-968aedbde451"
      unitRef="usd">1200000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzQ4NzI_2f148eae-2ff2-4996-849d-0f5efe83f390">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the federal statutory tax rate applied to income before income taxes and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings at different rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US tax on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax - intra-entity transfer of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement of tax examinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D and related charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-taxable unrealized (gain)  loss on investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzItMi0xLTEtMTIxNDA_949899c6-6961-4506-a96f-5ccf94d083b8"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzItNC0xLTEtMTIxNDA_68edca6d-b1c5-45f3-82c6-3c776862572f"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzItNi0xLTEtMTIxNDA_9be67080-fe20-40a6-be89-19e8b707a468"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzMtMi0xLTEtMTIxNDA_4a3a492e-6994-493c-9d74-b46ea154f491"
      unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzMtNC0xLTEtMTIxNDA_307dd91b-454f-44fc-ba7e-f89f9c194ffc"
      unitRef="number">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzMtNi0xLTEtMTIxNDA_9932fc41-82f1-4b5a-8c6e-75524c32f625"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzQtMi0xLTEtMTIxNDA_44d3003f-779f-4f7f-86a5-7e1bf43f0404"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzQtNC0xLTEtMTIxNDA_98d509f0-c0b3-4507-ac48-362a0334f5c4"
      unitRef="number">-0.100</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzQtNi0xLTEtMTIxNDA_7b0b43c9-cec6-440d-b38e-25792b35d817"
      unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzUtMi0xLTEtMTIxNDA_b371d939-1bfb-4666-9a53-8a94524de130"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzUtNC0xLTEtMTIxNDA_3ae362cd-c1ad-49e6-a8b3-c90b259befcf"
      unitRef="number">0.069</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzUtNi0xLTEtMTIxNDA_5241342b-853a-439b-b2ba-dd5d86d56cea"
      unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzYtMi0xLTEtMTIxNDA_7f4170d8-d57c-4fd2-8891-a56dd8850543"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzYtNC0xLTEtMTIxNDA_f2edff33-7fb6-48c0-9b8f-d7c43d14e9a3"
      unitRef="number">0.072</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzYtNi0xLTEtMTIxNDA_18e94590-d512-46cc-9922-11b0dfa71294"
      unitRef="number">0.043</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzctMi0xLTEtOTY2OTc_f102d5fb-500b-47c1-ac17-b94b572583c0"
      unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzctNC0xLTEtOTY2OTc_e2cb3508-0683-440c-80fd-1d24a76435ab"
      unitRef="number">-0.080</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzctNi0xLTEtOTY2OTc_69306f60-5770-4138-b5b7-c7ec1372d9b7"
      unitRef="number">-0.032</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzctMi0xLTEtMTIxNDA_27d07d4c-03a0-4766-9608-47b5586c4ae0"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzctNC0xLTEtMTIxNDA_d76debdd-f115-4e34-8a1a-efaa3723f4fd"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzctNi0xLTEtMTIxNDA_0cb14536-cd71-4f1d-9407-cbcf051f343a"
      unitRef="number">-0.240</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzgtMi0xLTEtMTIxNDA_cee35c6e-5f7a-4fec-b5e4-552c44e5f088"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzgtNC0xLTEtMTIxNDA_f9646520-aa1d-487f-b014-45e003f62d18"
      unitRef="number">-0.102</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzgtNi0xLTEtMTIxNDA_24dc3b72-e5da-4892-a3ea-18c18edf8075"
      unitRef="number">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzktMi0xLTEtMTIxNDA_8c4db68b-e369-44f2-983a-b1c3b3cd547e"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzktNC0xLTEtMTIxNDA_5abc821a-5921-45dc-a78d-847ad65c5f0f"
      unitRef="number">0.562</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzktNi0xLTEtMTIxNDA_fa0fd5e8-3319-4199-a342-afa672c7a990"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEwLTItMS0xLTEyMTQw_0df697d6-75f0-4baf-b07f-bdd896e5e7f1"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEwLTQtMS0xLTEyMTQw_81c017d0-73f4-4003-a365-91ae260cc213"
      unitRef="number">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEwLTYtMS0xLTEyMTQw_601dbf94-e878-4313-b0df-cc526612653c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzExLTItMS0xLTEyMTQw_8cac1e0e-be37-42ee-99cf-e5eb620adeb6"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzExLTQtMS0xLTEyMTQw_08f8e7b0-704b-4033-9549-bf4eed61339e"
      unitRef="number">-0.230</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzExLTYtMS0xLTEyMTQw_e68a25e0-7e2b-4a03-8bcc-ca1a65dc3c10"
      unitRef="number">0.050</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEyLTItMS0xLTEyMTQw_5a651de8-f45e-4e53-9afd-9a75586a0ce9"
      unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEyLTQtMS0xLTEyMTQw_633b6f7a-0fb3-415a-8e25-ac6daa0c3dff"
      unitRef="number">0.109</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEyLTYtMS0xLTEyMTQw_a72ea971-c712-47b9-9e79-3d560b36fa6f"
      unitRef="number">0.043</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEzLTItMS0xLTEyMTQw_66b7dd48-cd67-4bff-8a8e-dbf14094a79c"
      unitRef="number">0.251</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEzLTQtMS0xLTEyMTQw_dee11782-794c-4c7a-812d-8f832ccc396f"
      unitRef="number">0.947</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTo1OTQ0MzdjY2IyZDg0ZWFkODZlZjU1MjdiYjIwNzBiNS90YWJsZXJhbmdlOjU5NDQzN2NjYjJkODRlYWQ4NmVmNTUyN2JiMjA3MGI1XzEzLTYtMS0xLTEyMTQw_8a626d00-a946-4bb9-a9bf-0927ae2aba3a"
      unitRef="number">-0.040</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzQ4NjY_0e435777-8090-4a07-bdaf-f12faccf4cfe">Significant components of our deferred tax assets and liabilities are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves and accruals not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess of tax basis over book basis of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront and milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess of book basis over tax basis of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzMtMi0xLTEtMTIxNDA_af947029-07dc-4a65-9225-c339efd5ae6a"
      unitRef="usd">413000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzMtNC0xLTEtMTIxNDA_7cd234bd-6ad8-467f-bc5d-e0d1b6be02a1"
      unitRef="usd">587000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzQtMi0xLTEtMTIxNDA_d42f5dc0-3229-41f9-8e8c-f0262f8b2b06"
      unitRef="usd">117000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzQtNC0xLTEtMTIxNDA_33c85f1d-7d6b-47e3-95b9-442ff87f7ed5"
      unitRef="usd">113000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzUtMi0xLTEtMTIxNDA_cd1a185f-1d10-4f69-b598-945cf2772f3c"
      unitRef="usd">700000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzUtNC0xLTEtMTIxNDA_961f9cf1-91c2-43f3-bc50-c42d47dba594"
      unitRef="usd">444000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzYtMi0xLTEtMTIxNDA_dbf496a9-a3a7-4c2b-a390-6451a2d638d7"
      unitRef="usd">1157000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzYtNC0xLTEtMTIxNDA_c7159469-78ec-4477-9294-9808aec40edf"
      unitRef="usd">1177000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <gild:DeferredTaxAssetsUpfrontAndMilestonePayments
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzctMi0xLTEtMTIxNDA_36fdd640-eb35-41d7-a924-3e09448c284c"
      unitRef="usd">1310000000</gild:DeferredTaxAssetsUpfrontAndMilestonePayments>
    <gild:DeferredTaxAssetsUpfrontAndMilestonePayments
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzctNC0xLTEtMTIxNDA_5d1ee3f3-371b-403c-93d6-56abf4d869e0"
      unitRef="usd">1144000000</gild:DeferredTaxAssetsUpfrontAndMilestonePayments>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzgtMi0xLTEtMTIxNDA_a9f686e9-577e-4755-945b-2465399bf47e"
      unitRef="usd">249000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzgtNC0xLTEtMTIxNDA_5234347a-bc9c-4220-83e4-5f911e5a71eb"
      unitRef="usd">219000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzktMi0xLTEtMTIxNDA_990e0c44-b01f-458f-bb60-879480783c0c"
      unitRef="usd">117000000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzktNC0xLTEtMTIxNDA_669d381b-995b-413c-8908-64eb9ab180a7"
      unitRef="usd">116000000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzEwLTItMS0xLTEyMTQw_f87e17c6-7d18-4417-b7f0-f7e7a4c1f7b7"
      unitRef="usd">274000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzEwLTQtMS0xLTEyMTQw_c628a2c9-ee0b-4bbd-8d89-14967d9e1ac0"
      unitRef="usd">247000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzExLTItMS0xLTEyMTQw_9ac4c7dc-6df7-4b8e-a44b-1a12511b3bac"
      unitRef="usd">292000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzExLTQtMS0xLTEyMTQw_71f79ca3-a9a6-4b8d-aecb-3d8b9764a3fb"
      unitRef="usd">311000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzEyLTItMS0xLTEyMTQw_693c0309-039c-42b1-b290-5434ad5922fa"
      unitRef="usd">4629000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzEyLTQtMS0xLTEyMTQw_f7c3eb91-228f-450c-99ba-6aef00321ef3"
      unitRef="usd">4358000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzEzLTItMS0xLTEyMTQw_f377ac7d-9cd5-4684-8ce6-393f56106f3e"
      unitRef="usd">520000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzEzLTQtMS0xLTEyMTQw_40d0759a-12ef-4fad-99bd-0a37cd196a68"
      unitRef="usd">398000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE0LTItMS0xLTEyMTQw_688a7d92-35a0-4532-9bbc-4f3c32765f9b"
      unitRef="usd">4109000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE0LTQtMS0xLTEyMTQw_5adc65c2-56ca-4581-8dba-8b517e969003"
      unitRef="usd">3960000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE2LTItMS0xLTEyMTQw_1a3904b8-1c7a-41cb-bbb8-8cbfde2c6575"
      unitRef="usd">227000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE2LTQtMS0xLTEyMTQw_d097173a-9faf-4f27-af82-b3a8cfc15222"
      unitRef="usd">202000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE3LTItMS0xLTEyMTQw_5773e126-2d27-4de3-8047-1657aad5fd80"
      unitRef="usd">6719000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE3LTQtMS0xLTEyMTQw_a4505619-058d-4466-9bca-054bcf462675"
      unitRef="usd">6168000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE4LTItMS0xLTEyMTQw_be9e7a35-0b19-4ef7-a85a-a5ff6c6ad244"
      unitRef="usd">180000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE4LTQtMS0xLTEyMTQw_be0097d6-4045-41af-80a0-a91817db7fd2"
      unitRef="usd">202000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE5LTItMS0xLTEyMTQw_e37947d7-7abb-4a27-972a-1db1e41b17e0"
      unitRef="usd">7126000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzE5LTQtMS0xLTEyMTQw_980774c5-8145-462e-bfef-d7f430b62ff5"
      unitRef="usd">6572000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzIwLTItMS0xLTEyMTQw_08c7ff38-a359-4b31-b99e-4ded9e30b404"
      unitRef="usd">3017000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpjNmFlNThiZDBlY2Y0MTcxOTQwZGIyNTMxMjdiY2FhOC90YWJsZXJhbmdlOmM2YWU1OGJkMGVjZjQxNzE5NDBkYjI1MzEyN2JjYWE4XzIwLTQtMS0xLTEyMTQw_ef3adb8c-7aa4-4051-b785-c17e160dc7fb"
      unitRef="usd">2612000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzI3NDg3NzkwNzgxOTA_d1e320fb-58d2-4452-b849-dba78a47dc72"
      unitRef="usd">520000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzI3NDg3NzkwNzc2Njg_99f0f270-5ffb-44ea-afeb-2f5e588c1926"
      unitRef="usd">398000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzI3NDg3NzkwNzY1MjE_99f0f270-5ffb-44ea-afeb-2f5e588c1926"
      unitRef="usd">398000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzI3NDg3NzkwNzY4NTI_b1d2aba1-a1fa-4bc8-bcd6-950ee228e6af"
      unitRef="usd">217000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i77335a2113da496c800ece78587ef758_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA1Njk_0ab88546-4494-4b7a-aa20-3a92f3987440"
      unitRef="usd">250000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i77335a2113da496c800ece78587ef758_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA1Nzg_4b1245b1-55a2-4f7c-b62b-e5ddd31b9067"
      unitRef="usd">8000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ie33787d4b92844f0b3f49ee4b16ba703_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA1ODc_da40eda2-459b-41ba-a1cd-0a231b933845"
      unitRef="usd">2800000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ie33787d4b92844f0b3f49ee4b16ba703_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA1OTk_b95c537a-aa6c-4fa2-974a-d6decede9b6f"
      unitRef="usd">768000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA2MTE_180c1b18-ca08-4a6d-a1bc-78fe215f1173"
      unitRef="usd">800000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA2MDc_bb4a0106-7dbe-47ce-bac5-555cb36f8f7b"
      unitRef="usd">1200000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzkzNDU4NDg4NDc3MDM_48cfe713-0c30-4093-a29a-b4942bcc2cf0"
      unitRef="usd">41000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA2MTk_1c64bd4e-ecf6-4d3f-bdd5-6548586738a5"
      unitRef="usd">-82000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzkzNDU4NDg4NDk3MzI_ef85dcf6-802f-4cab-bb87-b5df9f58a0b7"
      unitRef="usd">105000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA2NDI_441ef70e-37bf-46bf-9696-1f39a4164a08"
      unitRef="usd">218000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzIxOTkwMjMyNjA2Mzg_8ff2489a-0d1d-4cc4-a707-9741b89dcfdb"
      unitRef="usd">177000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzEwOTk1MTE2MzkzMzg_d19c0cae-5953-40ed-a133-a86a68338b80"
      unitRef="usd">100000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzQ4OTY_11befe19-0a8a-4a67-993c-311a3ec1cad8">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a rollforward of our total gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to current year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to prior years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzItMi0xLTEtMTIxNDA_e04ce945-b37d-4a1a-acbe-d73d5ff0df21"
      unitRef="usd">1614000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzItNC0xLTEtMTIxNDA_1ecd07ea-b35b-4902-870d-f233e1f6f2e5"
      unitRef="usd">2031000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8222e290a2284cb0bf64a4ac2b6995b5_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzItNi0xLTEtMTIxNDA_a28c02d0-feba-4c34-873a-2143069a1f4a"
      unitRef="usd">1595000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzQtMi0xLTEtMTIxNDA_abfa89a4-10c1-4762-8621-0b0766dc8cc4"
      unitRef="usd">147000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzQtNC0xLTEtMTIxNDA_25c6b91b-0b91-4183-af3f-d1002c5f9c95"
      unitRef="usd">121000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzQtNi0xLTEtMTIxNDA_cbfbd56c-0f9a-40a4-bf6e-db9e7fe0daf3"
      unitRef="usd">138000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzUtMi0xLTEtMTIxNDA_91465122-2084-44de-8810-108fa6657c75"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzUtNC0xLTEtMTIxNDA_ac76726d-2f8b-456c-aa2d-e7c2b11b8ce6"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzUtNi0xLTEtMTIxNDA_a593c3c0-bab0-446c-9522-c86feaff23db"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzctMi0xLTEtMTIxNDA_19df6009-e380-49f2-9e92-082a5079645b"
      unitRef="usd">161000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzctNC0xLTEtMTIxNDA_aeb3ce6c-924b-4bb6-a6e4-286fe8da7aa9"
      unitRef="usd">398000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzctNi0xLTEtMTIxNDA_76f75e73-1292-4cea-bfae-42b23b342104"
      unitRef="usd">405000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzgtMi0xLTEtMTIxNDA_ea4364ea-ccff-4b1f-89fe-583a67565295"
      unitRef="usd">179000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzgtNC0xLTEtMTIxNDA_06b9cf98-4661-4281-bdf1-4d14fa91d00d"
      unitRef="usd">481000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzgtNi0xLTEtMTIxNDA_cbfd4d45-9d6a-44b5-9f7f-d02065777765"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzktMi0xLTEtMTIxNDA_7b5eba7d-195a-47ed-b0b3-e043d4dd0df5"
      unitRef="usd">28000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzktNC0xLTEtMTIxNDA_1e30881d-6c88-41fd-8232-bc01aa23648d"
      unitRef="usd">454000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzktNi0xLTEtMTIxNDA_c56250f0-8097-4398-8ffb-45fb4cc14455"
      unitRef="usd">104000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzEwLTItMS0xLTEyMTQw_f3ddf463-5961-4bf8-b45e-0d49e340a149"
      unitRef="usd">2000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="id2942187c687440aae7d8307f89a6296_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzEwLTQtMS0xLTEyMTQw_3c9e15ed-bb95-492a-b98f-4b292303fdf5"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="id50e1295d74143879d750b13cda63300_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzEwLTYtMS0xLTEyMTQw_4771a3db-a2cd-4b8c-8f58-cb8273dac5d3"
      unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzExLTItMS0xLTEyMTQw_05a26092-66fd-4a98-a910-5658d544ec70"
      unitRef="usd">1713000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzExLTQtMS0xLTEyMTQw_d4188d45-4ac7-4ae0-9eb8-2f06afcc63bf"
      unitRef="usd">1614000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i326d4d7af8aa42a1b1948ed90603ab96_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90YWJsZTpiZWE1N2E0NTBlMjM0NDE3YWNiZDQ1MGZjNjMzZWE1Yi90YWJsZXJhbmdlOmJlYTU3YTQ1MGUyMzQ0MTdhY2JkNDUwZmM2MzNlYTViXzExLTYtMS0xLTEyMTQw_7664c8fd-ecd3-4c3e-b50e-8101805ffa12"
      unitRef="usd">2031000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzkzNDU4NDg4NDg5MDY_f1f90031-9d12-47af-8f71-a3cf124b8089"
      unitRef="usd">4000000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="ibc317247ac9840c9b997af09c66368bd_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzkzNDU4NDg4NDg5MjU_8c8d372e-4c86-45a9-af3d-f096bd3da603"
      unitRef="usd">4500000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent
      contextRef="iaeaf99ac576f40e684136704e997f1ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyZmFhNGEwYTQ5NzRkY2NhNmRiMmJmNDkxYjYzZDdhL3NlYzo3MmZhYTRhMGE0OTc0ZGNjYTZkYjJiZjQ5MWI2M2Q3YV8xNTEvZnJhZzpiNWM1ZWUyOGU4Nzc0NDVhODgxYjQxOGVmZmVhM2VhNi90ZXh0cmVnaW9uOmI1YzVlZTI4ZTg3NzQ0NWE4ODFiNDE4ZWZmZWEzZWE2XzkzNDU4NDg4NDg5NDM_22daf962-7a8a-4a56-b829-211d4597b5d2"
      unitRef="usd">473000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M*7G[YAUY0X*87 =A")VB+KH:FC /=MT<[GH/1T_ V93<BEC[BLQBCWLO ;K
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M\O:T3HAW#<!)L>P>E<>-B66?&11,$5C*[2OEQ=7B4\8X*^!WR\?WWT%NF?%
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M,4P)T9[_M@^*'YH3T4>N%"^;VSV4229J /R_Y5R]/=0?Z$_A5S\!4$L#!!0
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MK@8:B0VUW55HNZM0$]GOB7Q!'[)2S@FL:)6Q%+P5^V*S84X X6!*D_< PW<
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MSWLONJ\2==Y$^1:P3^Z4F(BMKI0D"O@N4?E&+$?+8NQ2WTD?QB?NQ=RM&%]
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M;BKZ">.\*Q].#1Q?;[^2N\5LNU\(K)5<#C0O\1&Y9=.->_RWXI9V5-$GHLS
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M2L"@AL(,A4.G9V4-._.&,*W;5P,RAZ'&< >QA5_ B HO:&X@@50(\337\(4
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M:4(M<Z5CO5$AMOQJ+O(>I(%IMP_6HB2U='-7H1HSV1NSE6\3(N#S11"C.7)
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M#4<LU:P8:%O)X=L%/+=WN>FH+T6Q)N?)V6)4<;/6H&FIMJKL1%7MF"@*@AG
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MFC=KA0!..E[7+  8[!)#-[SSRB6$F&0V<0UD( #[A";^0<?CV0R42-)E!?S
M'JK4-0HL''^\>'E].8<MAQS[O7N1Y3@\CP.NC'S[V:\/6. _#-@(3:6P$:L4
M5:4]$JZ9NS[5\ZQW&KDGU<;A(\JM,W,C=BYF"[ETO0O@3KWH0*6>6GO(O;Z<
M4>(2"0QV7/^UY?OO/@@T!GN"+>Z7AC[WEQWH,6Y)OW675B:Y/5&_USTHUR<=
MI*\[#U8?O5$4&\2VZ?-I]MCGY/GD.WU-+9@.I[3E M?Z3_;CZ/@/'B?]=_X[
M\?Y?2SX(LU*PL9)+3/5G:7S 3/\O$/U#JS?NJ_]"M]B,N-NU1$4Q)(#W2XT^
M-CS0 N,_ [W^-U!+ P04    " #IAE=4/V[RCO0.  !9+0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6S%6GEO&S<6_RJ$URA20)8UDGPG 1SGJ+%Q
M8]A)@V*Q6% SE,1Z9JAP9NRHGWY_[Y%S:F2[W1:;/QR*0SZ^^R)?/AA[ERV5
MRL7W)$ZS5SO+/%^=[N]GX5(E,AN:E4KQ96YL(G/\M(O];&65C'A3$N^/1Z/#
M_43J=.?U2YZ[MJ]?FB*/=:JNK<B*))%V_4;%YN'53K!33MSHQ3*GB?W7+U=R
MH6Y5_F5U;?%KOX(2Z42EF3:IL&K^:N<\.'TSI?6\X!>M'K+&6! E,V/NZ,=E
M]&IG1 BI6(4Y09#X[UY=J#@F0$#CFX>Y4QU)&YOC$OI[IAVTS&2F+DS\54?Y
M\M7.\8Z(U%P6<7YC'GY2GIX#@A>:..._XL&MG4QW1%ADN4G\9F"0Z-3]+[][
M/C0V'(^V;!C[#6/&VQW$6+Z5N7S]TIH'86DUH-& 2>7=0$ZG))3;W.*KQK[\
M]7NIK?A%QH425TIFA57@>)Z]W,\!G);LAQ[0&P=HO 50,!97)LV7F7B71BIJ
M ]@'5A5JXQ*U-^-'(;Y5X5!,@H$8C\;!(_ F%:D3AC=YFM2W.@MC0]1FXE_G
MLRRWT(Y_/W+&M#ICRF=,_W=V/@'H_/)&_'+^\<L[<?7N_/;+S;NK=S]_OA5?
M%70N5Q:JH$2^5&).)][SB68NYCJ5::AE+&0:B=2D>XV9+%-YQA]B+6<ZUKD&
M_46FTT47U%(K*VVX7 _$PU*'2Z&R7,YB#47+L-8J)6)UK^*,#M7IJLAI6N90
MS;68*0!5D<B-2!P3&J 'P$/,30QOD)V*'_YQ/!X?GHF/!$P$)2B=AG$1*?&M
M,#D K:P.%<UZ(\8I]HYH@5,2.@*'=5@3B+D&?6>=,\;=,\PL4_8>Q*GRBP$S
M+)&3=O :P'>!%R"@C1BAD>E$Q])N0V)S0XWW4[N)\))B9K($1U.3>VZ<T7*'
M<U,2M*A!&]:$( BR"8VU9F:L)(1FZ^8B=XJ(X$D<405L0P)-&<=KIR-%' O2
M/Q(\33#&38379ZQB;:Y/NEPOTDV^5VAGQ6IEK$</('.'?VI*!)EP',4GU=OT
M(M5SL#3-2?<VK8-F"G@G&Z])YS=1'XI/A:U0WF(P)0GYTF0*YD%_&^<D#;MG
MM"I[C;RMD1+0_XF)8$$#$<$;F2(E>D.9+<4<M@$P@!^9V"SHS(:*T"F2(UJN
MPF6JOQ7*X=@D/Y$I0BKA('XKH@4/  -6K!/>["BMG8-.X00+AW1H$'.SG/ $
MOS4D#]XQ9G0,#]2W0@,16C[P0F%)1FJ6BTR%A65>P=A#)BU#  ^59G$/2+40
M+5/$-VM5&JZ%^A["VA:DFRG[8NRD(R#A7F KN>;CF.PE5&6/59(E9=*%^T6X
M#,7%G\,[5#9'2M.+!8 ]@P*6O55>D:&BT#XH"4+.2CDO5BL-!)P* X%<@/4F
MUA';YAL90SI*W%)TSX;B71<7Y I0DB(7E(Z1G$I58YJ:X!TNL/RHTD(RAH:N
M"AEC;RH9,Y*W@0;$*H.^)RM HC4#H><@'T%!1K\A-U',B*8#8?\F'"O8;]&)
MEGR'E6DF.1-[Q/WI]!XJZK30VVLF$SB(+"N4'8(3C\AZ"\-E@@G].QD72'H>
MIS\O"1+EM,2I?BMIG?8T4$((J+#Z.H^U6EGSG<Q1>37*FR)C)'#$@V)G[Q@X
M5S:#"\\?E*IBTZ *;,22VMTR]U;*:A/!8*!VBCR,H\W%7]8"%IM+R<&DC'?E
MZY5B 6SQ@%YMF,E-#XOX3%H&8@@TDF6=L0=GG$A7/59]B<:I0+ZGDAFB6)GS
M;<R,Q L*A3J.28U^K*)SR8"2^,\FA[ >_WK.I)V*\WL)U0,3]J"5>YG<= :G
MXLOP=@@!,-4M^]L5T]$1_E*P"\9GK9'[,AF=;/E.7QCPPMS#\)P-+N!,"'#C
MC'+'M&>T[?^?D?AU8?> /!CU#:>3YO "CI"C2NY4(H+*9SJOEHRG)_WCX+ U
MOC!VQ3E'E[W5JF P.9QL_15,QYU?-RIS3@32)!M?@'NLJJRU>S,9WD%%^S@Y
MGO:.)PV4:;SA;T^IQ%'K,@N9(Y?(Q&1P>!AL2,#-3D'$YC<WZZ'7+H]L]@-\
M!HIADXD7P8_B9+*YF>:"P>'T>..+F^T%>VY12C+(@X.3C8TTA\'&/,U]XKQR
M52#W#YT;IPBR$17%I =5FCOHF:>YMPJ^S+)33E:H\5U&LX+'%.,>EM'<.-BD
MF>;>=V,Q(@Z"/ >R.AJ7.XY'?<,&]1@Z#[$K#@<![&)7C ?!T:AEO,>#R9AF
MC@;C(S+P8' T;AOZR6 T.A8?:Z]Y6OU8<P"\^O5&?$AF/XD7G"J/SC#!H^#L
M1\8;/I3$Q]D82'(<VN)+@J/J;]_WS='_C?\'/:-@'+3&)?_IU%VL*TD[.)[0
M+,[<Y74M%DQ.Q'\>_\<&<(O2]6?48B((D!PB#DHNA3@O(>?A%/[<6DIA7*0G
M:<DHTK2(DP#7"^,LVIO;;6T)SXBO80P7Y9PJ<1U>E9*'3:/Z(W'VZ0SDM!,]
MGQ-OMV;/Q'%V<;O>G5TC%Y(ZXL6N&"V3&I]$'!\?B..#B6=PG;KYS_#I)T=D
M1P>'E?P/!D?3"=OA">SOHLXJ-TN[3>8AXREBX@+6I_#618H 'G,B&!N<R=%L
M]S 8E2QAU'>#X9&8-28Z6Q?("=W.8#BN%I*&$$YK)9&@*6J ;;+7LY2 CD?!
M2:,2B*LV"V=[OL!DS#_YNAYFJL0+]9UL5?TX(+0&O3*_S?%?E4%?\L:A![.I
MK'[&%9NM]+N6H^I&E#]0=S ]NY/)<9O)X\-Q/<&(;BJCX]-X-.@PBN89+$HN
MQZ:Y-8GK1<R0[CB3<_DS*O,RY]["V0T]?$YY<*-BGK^6%HSY7)<VXFUAR]H*
MJFB ZK<"BW 0:'1*\( ,"'Z$J_UM16;'X'TSXX..P6_X6^0=[#G #%AHK*%^
MJ9;4[D-),==4ZB]DJG]W[N4%[?4QIMY;AAI7$-3SJ+78NS@*5TPA1%2B:N9P
M6U2%^/*,P@<J0E2/F1%4!E)'2$0:[BDW];(:OCN/.4"G>8UFBZ)\H]2*!YG5
M!:LO'6X5OJ6+@4!<1#QT/4X90>\T=7 YX'AX_7+LLXV6[6XSW6%51%RZ5M57
M5?92NEU8!EVW&FN;02&4RSO2#IU"H.VP7C5UL'U&C*[56MMHSXFA[!L1FZF-
MZ%C9G15%KLE7X9@(-3H5+#D8)6W4:!V5K2=G$!Q%8.S>S^S1-8?SY"[3+2>H
M8I7ADIH@Q#7GLF0<MUI/OIG7;C\.A-)L;TXSJ*5$7JW\-2 5W\+0TI [#<2J
M].:4U%6K0'AFS9VR^Q'\-4[CKBOK0M5*:'0;FDT=UV$0(:(M[,=?< U0:Z?A
MDIC06KRB6+<FL>[["R!,F=^4;V\X;N'0)?326&YR<$NU]JD;S<\AI5&LL8VN
M5//,!R+YGJZYB&!N7S:;H*46R,KDFKT=4O^A^+I4*5(1LF!-LXV>-+<Y6EV9
MAC."1^!N<UDI,S)%5K6+J[/[R/-KO/3FO>SOZ/P]4B539"W=9_Z!R?=D,UE'
M)[QN02JNS?%T>W[S*@%KEA*_9]1:X0RV1*>_/SX4MZWF.)F!3^0VFH.]"3&?
M!GUO]O((K50$QWL)7:4)V(,22VC0[SYPTB%D6+16N)ZQ)?YHY9M*#%321:%.
MBJ149W(RD _0.]_C-G"5QY%7NOU!)JNS:_$A-C,(_H870^.NC(G6G& ?G65P
M?.3*R*7?.D<S( <Z)'#O=0X_4.WCZ2<<9,[BJYGQJ'.D_5L=I&RI2>WAO#MT
M;/$ND;*:MH][TD?^Q8YNBS/;WDZFC@EX^A&I!%"Z)('/9'HG/LU1OX& &^[+
ME"7DQ\LWG^HBDKOC#W+E@+2/IH23,B+X=%3V#O/.C9&DVC.!)H((;U":S@>'
M?.C).4\OY1QUA4RV(!<+JQ:D!8_VZ0>;MR2=Z[K*J;JNKD?(&Z0[<^"2O$9C
M%9COCH^'AZV,?G<R;<[\B?23$Q]I+=\BM3+=\<'&8:/AY$\>-JQ:EC[KN$S)
M,E+_H(&= /L;;;.\2C0=P! FGNFRO+SZ]8:==EU0^L8N+;,^UC<[O/A>)/V%
M)[+,3NTY('55J[Q*I>)6HV-;+\/I4)_VE"'L>7 X5X10@W:-02V#=HW!)4*#
M,105>6U/J=:6 R'J#9+2]3Z4ZR*D>P*A5U^E174^KV##8<[7]M[^:[-7C?#M
MSW^,_!JE\HH1OMSQ;N^!7Z90*S14*856%Q&Y/_P>/MZQP!8+<=[(I:EP*(N&
MM^>U3R'CNI<<ZWY2*W9?WX=U5^5P*,YK!CS>.]FFSOB#84.?1UU]ODR2(H47
MCW18!IP2V>:G$NN_4?>=;&I%+3>7!907-=\KD*"+G)Y#6+.6<9E;T24[(C($
M2VE$=5M5W](Y/:'L@?TO9%T6[-3=YR7U956M":@+E;_NV0B^#8R?BZES<$'3
MF[E^2? 7^U)GSW\$[B/Z1TM<NV\\! 2Z)<3,A<N+WLNP%/H3>NJPUYL*&VYV
M$%M=$]EL)$(+%4LP<FD.0[C&QK7U*DU;Y4HA7PFSMEZ[9:W8_IGR0LGWA.6>
MCC&X%2TSX$*]LH6>B,UME8QO@5>.*&#JC:6C:P9!B?(F&H=RI2D;0(X8WA$L
M3U<#T:TF]!?W9%E>P4G;ZB^O;SC/?4NL!QS-*4['%?0(N.O20=D_-5"]7DH<
MV.$W?:E%]+S82012IP.))9D]53EJ+Y??&_?N%'OLPC5)CD=5PW*K<5?TU$27
ME-IFQ*URJF:XJ*[V>Y^EH#0,B]C+IIFH3;:]@7$4=A+>&@<4M2KEY(VOYP=-
M7)@>?N02^FX/<DDZW5#&7H0A/4^@Z1+5,M,]]TT_KY2.L5F3'?S*:$8E.ZEW
M@]4YH0:JL%_'58LK5D[X4#JDWTC%W8N:Z@F4"3534\*'RX8?;ZKVR5!\0+!]
MT+&CY++60G<5_:A*TV.=E4&FOJ:( 8PKC6D\#&"?PEV$O&Y"3;JW#<U<*"]<
M:Z+*N$@8_%*HSG9";<,B(3L/RRHSE.Y]W[(^_>]ZKM#W)G._\=PU43 ,>M2;
MN7K8O7RM9JMWP^?NN6R]W#TZOH)=44,_5G-L'0V/#G:$=0]YW8_<K/CQ[,SD
MN4EXN%02N1<MP/>Y@7#]#SJ@>DW]^K]02P,$%     @ Z8975#,4)SD!!
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MI:]!N4SI+X;:"1!_H91]V3@#]>]N^#]02P,$%     @ Z8975 G+V*#$"
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ML ?+T0@J.EMZHHYV&\\=K,X=17.E3D45J2C8=5'B,UE =Y\@6RU$:6KBX\$
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MM?*]@H71M/9]M)6O+*PDJ3,_W+$8#WKG.1ZGT0_G>"8E6LO%L\@;)E\UC(U
MW# >^%+ IL9DNY)AV4<_D3V*5]M#ZS9YMOM/)VQX<I-5W&S\?6W!0[>7VF'U
M\"28M3?A4;Q]3]PSLQ%(3/("5:/NL-\!T][1[<3IVM^+:^WPEO7#$I\UW)
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M-W%%$#$1-!,;;UVCL4/S1K>:?5U;)3N((<+4HQ:V$.[&25Y'\]+ 8R5U7\@
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MOYD=\Q"(T3!MO0L./!JT$&#4M9(^@!F1X QJZ5TG;8L%"ZJ,1(Q4/'#AN.>
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M1FO"V891M KC)RR0G<*2UG(@RT[\9W/3 'KF\&GOHJ(5@+B\ @L8! F(7TT
ME)%A"8Y1R!0Y/GI'[8"_H9%RIHQU B@WPAWVUL;/NMC+O4R.)H30!H:I7G@#
MYG"])NWJ8%V,J3!U9@]GT(L_6,2@;"?4M678\=S#*4L8GQ2U)F=HT)U!,Y3M
M\CF,K*4<D9&UTEA5/&V)]7'!*\?DE9T$=&!-##Z^".A#R/+GI7H.3*KT#P9N
M8RMA"T<W/'F5II734LX%&(G/%;LO-4+W4Y$3(GJ'M0$UXA28K$<D'T1A&!RR
M_R<!VP86F#G^N@W."MUC-H9VX93A\BO9&+!<Z6N%?UA:.-L]5KV5V\]PG!]
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MA>RN/1IOB-C(%B4<87<%H2H$"75T[4D@*-QAA2@$=XC&BO?#])P _/)OX:_
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M_)#OPH<'T -U7'3AZ3;HP^R[EDY4[OJ@0MK-37W8ZN('=@V._;Y,VXB)Q[J
M'Y0&F2;/1^W4?H>&\"2IV_'Y[,3?867E:_SF 9K[D_!BQ/XN>)R?G<S.'WH
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M%YNPN!=MWBW]2R"AVFA^Y6?B6F O9KBM23K7'C?(4I)"L&PP*28:D&^)^.L
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M5;9#&2]9E]C4J]#7<PECN5@#O^!,Y($HV>P80J=*$!6JJ66(M7*[Q(*E^P$
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MRHR43#(AX9/ZSM811]:J%A.S<2]I^"H6MS5XR!>/*CI':0U1B1!R)BI+%E?
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M+W=O<FMS:&5E=',O<VAE970R-"YX;6RM6&M3XS@6_2NWLM0N5*63V'E" U5
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MI1_WW*/)I#>>X3H=]":C\#R<L*>*-%7>!YS>0;TPNOC:TUFC;1^ B\D=E6U
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M@W<^()MX>_G-Y4Z:WZ-!;QKA<CB8^(<)1]UL,J5;F6BL;R;Z:8>#89@RFTP
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M>RI8PA]7XK>T'QW@/Y[XW^F!EYMX"GU^5US"O3V3'7O64O81<> >&P^AX.@
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M7?C;3.+\;7@"WB\T/*1^X W:KZZG_P-02P,$%     @ Z8975"KO1W23$
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ML(_<\MD<%P ZCV1+-(>D1!F "H6#CGX7"OI2!:TDYJ<62AR=I/ITLBUM!@_
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;*U8"V_;NA7^*P=9.B2
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M>0J:I)<FL ]KR83[4B7H5]0N:W9.?T1!X%,H67W$"XL88$-T,:8HY@&1^!1
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M-U]PXB4AEQ$N*@#/^3VP=GDWQ=)T$IT2F))C0 28YR,1]N_,&J4/KV+/WJ#
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MPZ5-__&G?VGKC?O@,J];^,0UUSC4F88%,+ZLZW;_P@N,7^#._P!02P,$%
M  @ Z8975,;4P]<J!0  WPT  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&ULQ1=K;R(W\*]8%%47B< ^6%YY2(3<H]*EC4+NJJJJ*K,[@!7O>L\VY.BO
M[XQWV4!8N/13^<".QYZGY^7+9Z6?S!+ LN^IS,Q58VEM/NIT3+R$E)NVRB'#
MG;G2*;>XU(N.R37PQ!&ELA-X7J^3<I$UKB\=[EY?7ZJ5E2*#>\W,*DVYWMR
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ME_@" TT'<'^N, /*!0FHWG37_P)02P,$%     @ Z8975.4I_Y,C!   C@L
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MU^ATG :@F]>GF5BU\S?^6EEZ/_QP2P\V:F= ^Z52]C!Q ;J_ (OO4$L#!!0
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M!MLS_E:@7BJI-1EG6957@AKL  4,Y:D@YY52K,A6Y$;10F/-%L9QZVGR!K?
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M;B33OD7;C=,+__Z;:D>O2;\LZ?F.A@GH?*;I];/>L(+M#X+QOU!+ P04
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MI/JCV/T%E:"!Q0M%JMQOM"O'#@,/A872(JN"#8.,\?(O?:PFXB @&!P)(%4
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MVW)E<7O,%WT#<X+[0%5Z"W." 4$U>A/S2EBG;D(P1U2Q Q8D55U'/I4! 8Q
M 8RBSERXGSDA@: J'/N!\$%0C=[3O!(V-6>?!T15Q_;4%E361M] 9%-SA3PZ
M3&4E'X0!08"@*KVO.6&!H!J]LWDE,.;AH]\;267(*2-'#P3&'&+;FA/*"!3*
MZ.2!WD^ @#]@"F=[,/20A['9_GB%\U4F(:DCJD**I!=5;22V  &.0 &.J!49
M9V"0<F@*!WL@9! HQ]ODF,'#.#LJ21*QA?"2R)C8NX(01Z 01]2*"WL& 8+
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M$^P'E.-R<CQ)LN-'3X3Y<C[3)*FB3T((3P0*3W1X4/A.>R!5T_-J2P=NPOF
M<F!.C@L\)5M^.*Z0RMG36DD4^_A$\"%0\"'J04:O(% /U*7S-6%^0#DX)\<*
M 1%G3D@[HS,G4A<ZOP,"$H$"$@5&Z/V"T#W@2@=M0OV &QVTG1".F1>"B+TI
M!$VL6Q"4"!24*+#BPIY!8!]PI7,W08! .4@GQY<4!7ZT1=7T:4UP _08[YQR
M>S/,YY-_;!V9/B6?0Q'2!USIS$V0'U".T<FQ@2?EEFUW):DX&R6I;!T!0(#
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M.R',<0M.<%7""5)L%;2'.*%W#,+:H"V=P0F$@\JI.CE>I":GCTZHFCZM"6Z
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M&@BS0:^GG*OMQ!S0-'V3/U!+ P04    " #IAE=4N?[ "JD"   ]!P  &0
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M.M0[V1&I(OF2_" +1<&4&P2&!C2&SNF&3O+7O,PW^7U%V3$4:!G2.;+6):&
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M)G+4)MF=$CG>K,#%Q*ZM*^P^8SD_$0B8.#9X4X%CZ3D:O"G5O=VY@Q0YWJQ
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MN4#DM^;Y@^)3>RT\Y$KQU XG^BV6"B.@?Q]QKE8/QD'YOXO^/U!+ P04
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MFD='%7==,4&Y<M?%3**Y?-PP,=\'H.P!LQ]+B;N)O8&J+X[17U!+ P04
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M^:51)=N.V4ZTJ%T/60AM.I(;EN8G@](&F/VE$'H[L0GZWU;Z#U!+ P04
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MCU%'[3ZL]L$D%[#JQ-0V0U?:'[]V$N) $D!+>!GBY-[CXWNNCSP>;83\J98
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M:C20:R-X#%-%]#J*F/IU"4)NAPYUGF_<\<72V!ON:+!B"YB!N5]-%:[<W$K
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MQ(\04%8 GX<23YK9PAYS\\^:T1]02P,$%     @ Z8975'<F5,>&"   UC
M !D   !X;"]W;W)K<VAE971S+W-H965T-C N>&ULM9MM;]LX$H#_"N&[6[1
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MIW*L-4!AGHDT+H7E#&*6;/X-GDM'5 0(;A @I0#I*F"7 G97 :<4<+H*N*6
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ME7XR;'.E7W40QD#/+SA7NXYY-]K_">,_4$L#!!0    ( .F&5U3;Y[/?V0(
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M^BM4#O4-7R2XLO]D7<H.!PZ)5DJ+K *C!1G+RR]]J@*Q _ / 8(*$+P$] \
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MDREPW5XR%CJS$)AR(8D.[$B_[DD46Z[,5WEYOWN("UN#*%D,W1%;1"B!">W
M'+B7H4I$X/I*S3UK=JRVTR<_!\[3+YU-J*/K"R:X?QG2F7DAA@:I$L;0WGV_
M #M-9!MVK";'BB76H1WKQGX1JF3&+@G[DC16/@D,JB2^(1X9,U""%MI!.ZB<
M5(QJRTEC9BDG25OH#R4,?8PC>L_IFF7,B>(D3]@N8HDM,Q+ ,!@3-Q*4T [*
MH;A1.UL? &4SJ%8$NH;]@"1RD;W]'5(=2-?,8K=?'5HSX&*#5$EQ9*?X"V"#
M5%3W\VLU.58L28[L)#?"!JD\QL3MPT9GY8:F/'8F)O8.>CALD,0K&F_(@33S
M"UTYZ<S,Y229B^PM\^#V:]$$[/95QK8*23XC.Y\UT/M:Y$N6/#S9ED1"%=E;
MV(%S-TE/-.HL JEC!DR0L@LU(PMBI)PD,AIO&H$T@P;L^GVANG$$,DP()8V]
M7S:,\%3J]I-K-3E6+*'LV:%L1)RG\A0#B/J25"L/(].D58+7L\^:AR/.D_CT
M[#WOH#FNVL%J:DEG9:RESKC9CN+A/R^;@%V^'?VZ/!8B0>O90:L!W&>VC9+=
MDCW:5D02U",C$LZ3Y/3L[>A PC71NLL8>/UIF\;(E&!)8L].XD$5J0)VZL.^
M2-7()%(BV+,C^"5H4UFKH,UF<GP?1,(8VV%L1!M6.>K[?;)IC$R*)&PQ&!EK
M6"(3CS=UP)IQ@E)$&B-3 B1[L9V]?_$-LXV:L*0C]D9D!N[</;/#;B SL.:>
M&5%^^^FLD&^X2F+)33S>9 !K?O(3K C5S0\\T[)+$&,[B%]R3U+EK7)34C4Q
MW:/!DLG8SF0S/%2VAD21I!H%IKN26"(8AR/C@TA8DO'F"$0S(%!KJ;'R3ZHE
M(AE*[ WKX+;HDJ@]ZM0X>2$2N.29X0"+:,%WUO1+,)*Q?],3B4HR<B-Y2=1&
M4DW8K/-T3_7PU@TMUG%6.@E;"2_WG2^@5QR>ASH<\'Q;/_!SGW.>I_7+#:-+
M5E0&XO-5GO.?!]4S1.U3:>?_ U!+ P04    " #IAE=4-E,_+8P"  !0!P
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MK&*HC5R(\7##> @RWAP ,I+/7U:X6 +LA@,>O#CH\]"P.QSJAW8$L1MMV(U
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M(Y>3S#] C^/0L\\_;E_&!/,$6,=QUO7/OVK-OZ2M#% #& #8X]Z0!'#FW)H
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M!BWVPG)0I(%Y>J0:U!V;@YPWCPMUQ^8@9SU5&QI J0?I05%6S9V9 MC6D 9
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MK!R^L_($DQ.(VBT(@[!=DS[^>'JPG>X;#RHCPLJ(T.%%S4;\.I\J+<WF^MV
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MVJA= .T72MG=Q!W0_PW,_@%02P,$%     @ Z8975-G]E[*: @  ?@<  !D
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MI>1I^7%-B5*O J"^7W(N7Q^*!IKKK>G_4$L#!!0    ( .F&5U0+1PMPA <
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M1-G'-26R]BL!^?LR2<3NBWI!>1UT]B]02P,$%     @ Z8975)^A?W^'!
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M]1K%K(U 'B(X&O><NFZ-08L18ZS&H&G$VO$')?[@0TD[(RDV'RPB9-A&+6@
M&C5RT[29C/P:L:9-X$W:J8U+:N,/46NC,VZ!4:?38N-[-3IM<3HJ;5+2F;R[
MTHH%M9:XS@\BW9"'X6J(JWJOLEQ=[7; 8XW]+Q2V0;=IUZ2!D%*_'>&T1#CM
M18B-V+RB.CT#2A#"'?:("G6K!N5^2MFC1RV4]O*^"D/\CE'<X$CZJ.BZZ^RZ
MB'@R_7[']%-6 6'])9(D^Q2+)!*A_G$&JKY#/V?CH57GH?VMYV<RX#>E=#+M
MR$#5#6A_.[#\+/.-E)$F6L9]GS&T$FD:?,X,5%I+/R:V/]W\:5-*_7KK;+&A
M[K0FR6V!.CH,K329]HOR/6C@*MQF-")4OECN<%=D.BB=CE+I*IU^RO2S2J29
M^VO27XQ[NDS'M?RW&/E!_=.I-5+'@F>5]K-^[5_ACA4;\!G9X/Y)(2U+B$>X
M4Q/:H"#AIO8]M< JC6?L<]9"U2Z8]XMJP6M\OWONI%X+3:.1.ZK70M.(3>NU
MX!SMJA-0F^QT0B/6?6KR/6CYMCP!N<KV_;7W"WJQS,\QJC#YL<HM5QN1:A+#
M&D.ZPS%V%Y6?5.0/1NZRO?NC-$8FV>T6> 3*&N#_:RG-VX,=H#POFO\/4$L#
M!!0    ( .F&5U2O(URF<P,  !,.   9    >&PO=V]R:W-H965T<R]S:&5E
M=#@Y+GAM;,V7VV[C-A"&7V4@H$ +--;)IP2V@=C:11?H D:,W5X4O6"DL46$
M$E62CN.W+TDILI/HX!I[L3>V2/'[.0>.2,X.7#S)%%'!2\9R.7=2I8H[UY5Q
MBAF1 UY@KM]LN<B(TDVQ<V4AD"06RI@;>-[8S0C-G<7,]JW%8L;WBM$<UP+D
M/LN(."Z1\</<\9W7C@>Z2Y7I<!>S@NQP@^I;L1:ZY=8J"<TPEY3G(' [=^[]
MN\@?&L".^$[Q(,^>P;CRR/F3:7Q)YHYG+$*&L3(21/\]XPH9,TK:CG\K4:>>
MTX#GSZ_JGZWSVIE'(G'%V5\T4>G<F3J0X);LF7K@AS^P<FAD]&+.I/V%0S76
M<R#>2\6S"M869#0O_\E+%8@SP!^W $$%!.^!80L05D#X'IBT ,,*L*%V2U=L
M'"*BR&(F^ &$&:W5S(,-IJ6U^S0W>=\HH=]2S:G%IZQ@_(@(2\QQ2Y6$&]CH
MQ97L&0+?PKW4*Z(P*9+P36("BL.*L'C/B$)0*<)G0@5\)VQ?CC\0D4CX-4)%
M*)._S5REK31SN7%ET;*T*&BQR _@*\]5*N%3GF#R5L#5[M4^!J\^+H-.Q0CC
M 83^[Q!X@=]@T.IRW&O HXMQ_[;#F[#.6&CUPA:]34H$WIBUGL"*9_H#((DM
MH7LA2+Y#790*'H]P/FY-CK;;9@?^_E-+PA>%F?RGPZ!A;=#0&C1L6T(OA2YB
M/4M"GVF">0)'BBQIRGRWT' P]'YIRD\?YC5B43<6#L;OL3?NCVKW1YTZ&\7C
M)^!EC73HC6N]\<^1WTEMT.2R_#YS7?24476\:TINMTIPVY*FU95<U,--/G)O
MW)_6[D\O<U^AR(#F<$0B9&,$NH5&)=D4@FO!Z"(0QI#9+VI'-&[K:-QV2CY0
M^72S%7K#H+D."$H%0N\$C>'H5O(&T^;U<!T6=6/!(.Q<#;YWVC"][O6P6:^[
MA,YV7O_G*'0_.)D4_)!2[Y$)1FVUW@=.VXJ]#^RK=O^TO?KACZKW'J7FLJL"
M<34:786^#<9I:_>[-\G_4^X]4M[ ;UD3?=R'?;J*0S?G?_Q0E$%PST[+&8J=
MO75(B/D^5^6ALNZM;S;W]CS_KG]I;CSV%'Z2*:]+7XG847UB9KC5DMY@HH\0
MHKR!E W%"WLF?^1*G_#M8ZIO;2C, /U^R[EZ;9@)ZGO@XC]02P,$%     @
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M!<QZ]6AVI*D'Q2<LMQ1Z 2,;H P&"70B60]?]4*+G1U'UD+#<&,?"W"42 .
M]QLA]&%A/M!.P//_ 5!+ P04    " #IAE=49@<0?JH"  !"!P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Y,BYX;6R-55U/VS 4_2M6Q -(@WRG!:61*-DT
M)) 0'=O#M <WN6TL'+NS7<K^_6PGS=HT[7AI_''.O>?XUM?IAHM760$H]%Y3
M)B=.I=3JQG5E44&-Y15? =,["RYJK/14+%VY$H!+2ZJI&WA>XM:8,"=+[=J3
MR%*^5I0P>!)(KNL:BS]3H'PS<7QGN_!,EI4R"VZ6KO 29J!>5D]"S]PN2DEJ
M8))PA@0L)LZM?Y,G!F\!WPELY,X8&2=SSE_-Y+Z<.)X1!!0*92)@_7F#.Z#4
M!-(R?K<QG2ZE(>Z.M]&_6._:RQQ+N./T!RE5-7'&#BIA@==4/?/-5VC]Q"9>
MP:FTOVC38CT'%6NI>-V2M8*:L.:+W]MSV"'XR1%"T!*"/B$Z0@A;0OA10M02
M(GLRC15[#CE6.$L%WR!AT#J:&=C#M&QMGS!3]ID2>I=HGLKN6<%K0-_P.TAT
MB6;Z;U6N*2"^0.W6^0.7\@)-0?_' .WASW-0F%"]>XE>9CDZ/[M 9X@P]$@H
MU565J:NT1I/)+5H]TT9/<$2/'Z!'SE0ET6=60KD?P-7F.H?!UN$T.!DQA^(*
MA?XG%'B!/R#H[N-T;X">?YCN7Y]P$W;U"FV\\+_U0CF1!>5RK:OR\W8NE=!W
MZ->)%%&7(K(IHF.2=0*I2#%4O(8YLDS34=ZR<3P>I>[;[H$>@H+8B_=!^2$H
M\OV@ ^TICSOE\4GENA/H>\Z&A#?$9"?=9>A=]X0/@,9ATA-^"/*]:#PL/.F$
M)R>%MU6=-W>,-#-E[MB0E^2P",%HW/-R"/*3I&<X/P3%?N+UO+@[W:4&L;1=
M6J*"KYEJKF&WVCT$M[;_]=:G^H%H^OF_,,WK\HC%DC")*"QT2.]JI ]9-!V[
MF2B^LCULSI7NB'98Z4<.A 'H_07G:CLQ";IG,_L+4$L#!!0    ( .F&5U0V
MEZM1F0,  (<-   9    >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;*U776^C
M.!3]*Q::AU::%FP@D"J)- DSVCY4JB8[N\]NN$G0@)TQ3M/]]VL,@<08IJKF
M)<%PSO4YOM=?LQ,7/\L]@$1O1<[*N;.7\O#@NN5F#P4M[_D!F/JRY:*@4C7%
MSBT/ FBJ247N$L^;N 7-F+.8Z7?/8C'C1YEG#)X%*H]%0<5_2\CY:>Y@Y_SB
M>[;;R^J%NY@=Z [6('\<GH5JN6V4-"N E1EG2,!V[GS!#PD.*X)&_)/!J;QX
M1I65%\Y_5HW'=.YXE2+(82.K$%3]O<(*\KR*I'3\:H(Z;9\5\?+Y'/V;-J_,
MO- 25CS_-TOE?N[$#DIA2X^Y_,Y/?T%C2 O<\+S4O^C48#T';8ZEY$5#5@J*
MC-7_]*T9B L"G@P02$,@)B$8(/@-P7\O(6@(@1Z9VHH>AX1*NI@)?D*B0JMH
MU8,>3,U6]C-6Y7TMA?J:*9Y</+(-+P#]3=^@1'=HK>HJ/>: ^!9UG]#7-U5G
M):";)3#89O(6W20@:9:7MXKT8YV@FT^WZ!/*&'K*\EPEM)RY4LFK.G$WC91E
M+84,2,$$/7$F]R7ZRE)(KP.XRE=KCIS-+<EHQ 0V]\C'GQ'Q"+8(6KV?[EGH
MR;OI>#KBQF]3Y>MX_D"\;Y""H/G#2*B@#17H4,% J-51"&#2EJ.:&&EBM6B\
M+NYP%$UF[NOEP-E00>A=HQ(;:A)TL:ZTAZWV<%1[ EM0ZE.;^)HYN>B0F*)6
M?8S29 CO8^+ M\N>M+(GH[*;[*DIHF>55+,*SK/JI9E5G]%&38",'3.V0VII
M%U0.3:5)3^$=#HF9)AN*Q 8JL:!B;\!NU-J-1HMU+:F$L5*-VT#Q1TLU[NLF
M)#:&P +"4P.4V$!^:!^!:2M\^N$ZG5KZBT-#>1\TC0S=?4A [*JQUVT(WJAN
MG3E$68IROOES!=OT>N4YP+[AV8;"'C9LVU#3@8+%%SLA'E]?N5"G!#96M)AT
MP<A'R[9A_B;[5E08FB-A0Y%@8"BZG0;['Z[=AGI5=)$IOH^Y\\U)9P%A,JB]
MV]KP^-[6I/&/U6U@6QO,5<:*FOJFXSX*8\\;<-QMB'A\1WSLG-XT5F]18]5J
M*>SOR\2+>DFTP' 8FYN\!48\,XONQ0FU +'3)_U29>'(9'V>:]^VMXDO^@QM
MO%]6MPQ]\NW"U%>4)RIV&2M1#EL5TKN/E"Y1G_KKAN0'?0Y^X5*=JO7C7MV4
M0%0 ]7W+N3PWJ@[:N]?B?U!+ P04    " #IAE=4/[1Q4;8$  #'$@  &0
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MWKKR!R(P@V-(K0ZB+$' BAN?&F'2I#?TBQ&&#7J)7XLP+.X-@E*,:BE&85_
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M.Q<[ -^OI#3'&SM!?78U_1=02P,$%     @ Z8975,D_0<I^!   =Q   !D
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MGJBP*N/4$+_+51RV(+N,PIYLQ0W%Q(.8_[/[?H-R9IS <'?.&6D#ZQH%&/<
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MG(M",\KA3B)59!F1/U; Q''A8>]Y84/W!VT7_.4\)WNX!_V0WTDS\^LH*<V
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ Z8975,!@R5S !@  OS\
M  \   !X;"]W;W)K8F]O:RYX;6S%FUMOVS88AO\*X9MEP#+'LHY%4R"-VRU
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MK=N?RS*_,:+_TY]I$H11_V[*LBO+<[?ONKYL9/'T_OG3N_,?_@502P,$%
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MG7H/X^>A#K>>KS6?_YU4CY=[Z^WQU^77R0D[5YS;^XKAZ2]02P,$%     @
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M2P$"% ,4    " #IAE=4!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .F&5U2GQ7K9[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M .F&5U297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ Z8975(]PSI"!!@  [!D  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M .F&5U285 '<'P(  &\%   8              " @<0.  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " #IAE=405L_16\&   O&@  &
M            @($9$0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ Z8975&9&IT*I @  W0@  !@              ("!OA<  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .F&5U3ZH$ OK 4  )$7
M   8              " @9T:  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " #IAE=4SMLY!C4$   2$   &               @(%_(
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ Z8975#)HF$9=
M!P  3R8  !@              ("!ZB0  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( .F&5U2%V(>P^P(  -X*   8              "
M@7TL  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #IAE=4
M,Z4$6JD(  "-*0  &               @(&N+P  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ Z8975$_/6BFZ*@  ?(8  !D
M     ("!C3@  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .F&5U36/I/""!   +\X   9              "
M@:V+  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ Z897
M5,@8WW:/ P  !@@  !D              ("![)L  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " #IAE=4TEV/QO<#   T"0  &0
M        @(&RGP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( .F&5U1/KL&\8PD  &88   9              " @>"C  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ Z8975-.CN>YN P  S@<
M !D              ("!>JT  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " #IAE=4TP%'4#0C  !QA@  &0              @($?L0
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .F&5U2KX0(R
M$@L  #D@   9              " @8K4  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ Z8975*#K@'"D!   N H  !D
M ("!T]\  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #I
MAE=4T5.C23$@   <9P  &0              @(&NY   >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .F&5U38]J33< @  ($5   9
M          " @18% 0!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#
M%     @ Z8975"KO1W23$   *3   !D              ("!O0T! 'AL+W=O
M<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #IAE=499%:4B0$  "_
M"@  &0              @(&''@$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM
M;%!+ 0(4 Q0    ( .F&5U0@7> 5D P  !<B   9              " @>(B
M 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ Z8975.FX
MTD0X)@  ,8   !D              ("!J2\! 'AL+W=O<FMS:&5E=',O<VAE
M970R."YX;6Q02P$"% ,4    " #IAE=46_=I(:@"  ##!0  &0
M    @($85@$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M .F&5U3WTE71_@@  (T3   9              " @?=8 0!X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ Z8975,;4P]<J!0  WPT  !D
M             ("!+&(! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " #IAE=4Y2G_DR,$  "."P  &0              @(&-9P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .F&5U0F2%:\W 0
M *P0   9              " @>=K 0!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ Z8975%CADLAQ P  #@@  !D              ("!
M^G ! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #IAE=4
M%JS<2)T"  !]!0  &0              @(&B= $ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( .F&5U21NE)J]@(  $4&   9
M      " @79W 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ Z8975!1M @<>!@  @Q<  !D              ("!HWH! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #IAE=4(VP31H$#   <"
M&0              @('X@ $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( .F&5U22CY9'& 4  -(-   9              " @;"$ 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ Z8975&J(\MK?
M P  B0D  !D              ("!_XD! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " #IAE=4&SGKXKT$   <#   &0
M@($5C@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .F&
M5U0LLO.]M@8  . 0   9              " @0F3 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ Z8975/A/3CH- P  )P<  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( .F&5U2Y_L *J0(  #T'   9
M  " @5G$ 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
MZ8975)+IA*.!#   7F8  !D              ("!.<<! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " #IAE=4'A&+&]@"  #G"   &0
M            @('QTP$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( .F&5U2P2(:B'P4  ,<8   9              " @0#7 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ Z8975+PRQZ3K!
M]QH  !D              ("!5MP! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " #IAE=445\TNL0"   ("0  &0              @(%X
MX0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .F&5U2T
M>\K.OP(  'T(   9              " @7/D 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ Z8975!778$*9 @  P@8  !D
M     ("!:><! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .F&5U1W)E3'A@@  -8P   9              "
M@3CX 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ Z897
M5# "=5JI!   .1,  !D              ("!]0 " 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    " #IAE=40>";][8"   S"   &0
M        @('5!0( >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( .F&5U3;Y[/?V0(  -T(   9              " @<(( @!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ Z8975'R)B*\H P  7@D
M !D              ("!T@L" 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    " #IAE=4 VUVIY<"   9"   &0              @($Q#P(
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( .F&5U0)NLI7
MIP(   8'   9              " @?\1 @!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ Z8975)L\CUM& P  ?PH  !D
M ("!W10" 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #I
MAE=4Z<?"^7\&  "A)@  &0              @(%:& ( >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( .F&5U0V4S\MC (  % '   9
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M970W,RYX;6Q02P$"% ,4    " #IAE=4EOG:G>,'  !),   &0
M    @(&40@( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M .F&5U3&_^U)L (  $,(   9              " @:Y* @!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ Z8975#R;I'%W @  L 8  !D
M             ("!E4T" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"
M% ,4    " #IAE=4$%70*S0#   D"P  &0              @(%#4 ( >&PO
M=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( .F&5U1QF#<FB (
M !(&   9              " @:Y3 @!X;"]W;W)K<VAE971S+W-H965T-S@N
M>&UL4$L! A0#%     @ Z8975-G]E[*: @  ?@<  !D              ("!
M;58" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    " #IAE=4
M:YQ'0&0&  !E'@  &0              @($^60( >&PO=V]R:W-H965T<R]S
M:&5E=#@P+GAM;%!+ 0(4 Q0    ( .F&5U3"TF[+A@,  '@,   9
M      " @=E? @!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%
M  @ Z8975$Y& LH_ P  1@T  !D              ("!EF," 'AL+W=O<FMS
M:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    " #IAE=4H.C6W1X"   V!0
M&0              @($,9P( >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+
M 0(4 Q0    ( .F&5U2#.W\;> 4  .H:   9              " @6%I @!X
M;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ Z8975 M'"W"$
M!P  &BH  !D              ("!$&\" 'AL+W=O<FMS:&5E=',O<VAE970X
M-2YX;6Q02P$"% ,4    " #IAE=4GZ%_?X<$  #2$@  &0
M@('+=@( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( .F&
M5U0QE[(E300  .L2   9              " @8E[ @!X;"]W;W)K<VAE971S
M+W-H965T.#<N>&UL4$L! A0#%     @ Z8975,#T?K-0!   .Q(  !D
M         ("!#8 " 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6Q02P$"% ,4
M    " #IAE=4KR-<IG,#   3#@  &0              @(&4A ( >&PO=V]R
M:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    ( .F&5U3IQ*MXB (  !(&
M   9              " @3Z( @!X;"]W;W)K<VAE971S+W-H965T.3 N>&UL
M4$L! A0#%     @ Z8975$-]+?UU P  #0L  !D              ("!_8H"
M 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4    " #IAE=49@<0
M?JH"  !"!P  &0              @(&IC@( >&PO=V]R:W-H965T<R]S:&5E
M=#DR+GAM;%!+ 0(4 Q0    ( .F&5U0VEZM1F0,  (<-   9
M  " @8J1 @!X;"]W;W)K<VAE971S+W-H965T.3,N>&UL4$L! A0#%     @
MZ8975#^T<5&V!   QQ(  !D              ("!6I4" 'AL+W=O<FMS:&5E
M=',O<VAE970Y-"YX;6Q02P$"% ,4    " #IAE=4R3]!RGX$  !W$   &0
M            @(%'F@( >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4
M Q0    ( .F&5U24PLR'L@,  #8,   9              " @?R> @!X;"]W
M;W)K<VAE971S+W-H965T.38N>&UL4$L! A0#%     @ Z8975-E ,6A_!
M%1$  !D              ("!Y:(" 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX
M;6Q02P$"% ,4    " #IAE=4T+LO1UP#  #P%0  #0              @ &;
MIP( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .F&5U27BKL<P    !,"   +
M              "  2*K @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .F&5U3
M8,E<P 8  +\_   /              "  0NL @!X;"]W;W)K8F]O:RYX;6Q0
M2P$"% ,4    " #IAE=4M"E^S,("   *.0  &@              @ 'XL@(
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #IAE=4C,4F
MGTX"   G-P  $P              @ 'RM0( 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     :0!I -8<  !QN (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>921</ContextCount>
  <ElementCount>671</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>202</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>17</UnitCount>
  <MyReports>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1007009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105102 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Available-for-Sale Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecurities</Role>
      <ShortName>Available-for-Sale Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127106 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131107 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135108 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2139109 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2145110 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2149111 - Disclosure - Collaborations and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CollaborationsandOtherArrangements</Role>
      <ShortName>Collaborations and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2151112 - Disclosure - Debt and Credit Facilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilities</Role>
      <ShortName>Debt and Credit Facilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2156113 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2162114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2164115 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2170116 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2177117 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders</Role>
      <ShortName>Net Income Per Share Attributable to Gilead Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2181118 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2306302 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/Revenues</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Available-for-Sale Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables</Role>
      <ShortName>Available-for-Sale Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/AvailableforSaleDebtSecurities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Derivative Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>Derivative Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/Acquisitions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/Inventories</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2336308 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2340309 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2346310 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OtherFinancialInformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2352311 - Disclosure - Debt and Credit Facilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilitiesTables</Role>
      <ShortName>Debt and Credit Facilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DebtandCreditFacilities</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2357312 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/Leases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2365313 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/StockholdersEquity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2371314 - Disclosure - Employee Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsTables</Role>
      <ShortName>Employee Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/EmployeeBenefits</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2378315 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables</Role>
      <ShortName>Net Income Per Share Attributable to Gilead Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2382316 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/IncomeTaxes</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Revenues - Disaggregation of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails</Role>
      <ShortName>Revenues - Disaggregation of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Revenues - Summarized Revenues from Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails</Role>
      <ShortName>Revenues - Summarized Revenues from Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Fair Value Measurements - Summary of Classification on Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Classification on Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails</Role>
      <ShortName>Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Available-for-Sale Debt Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Available-for-Sale Debt Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Derivative Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Derivative Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails</Role>
      <ShortName>Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails</Role>
      <ShortName>Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Inventories - Schedule of inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails</Role>
      <ShortName>Inventories - Schedule of inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Inventories - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Property, Plant and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails</Role>
      <ShortName>Property, Plant and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Other Financial Information - Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails</Role>
      <ShortName>Other Financial Information - Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Other Financial Information - Other Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails</Role>
      <ShortName>Other Financial Information - Other Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - Collaborations and Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/CollaborationsandOtherArrangements</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2453429 - Disclosure - Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails</Role>
      <ShortName>Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Debt and Credit Facilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails</Role>
      <ShortName>Debt and Credit Facilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails</Role>
      <ShortName>Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2458432 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2459433 - Disclosure - Leases - Balance Sheet Location Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails</Role>
      <ShortName>Leases - Balance Sheet Location Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - Leases - Supplemental Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Supplemental Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2461435 - Disclosure - Leases - Summary of Operating Lease Liabilities Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails</Role>
      <ShortName>Leases - Summary of Operating Lease Liabilities Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/CommitmentsandContingencies</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2466437 - Disclosure - Stockholders' Equity - Repurchases of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails</Role>
      <ShortName>Stockholders' Equity - Repurchases of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2467438 - Disclosure - Stockholders' Equity - Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityDividendsDetails</Role>
      <ShortName>Stockholders' Equity - Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2468439 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2469440 - Disclosure - Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2472441 - Disclosure - Employee Benefits - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails</Role>
      <ShortName>Employee Benefits - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2473442 - Disclosure - Employee Benefits - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails</Role>
      <ShortName>Employee Benefits - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2474443 - Disclosure - Employee Benefits - Restricted Stock and Performance Share Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails</Role>
      <ShortName>Employee Benefits - Restricted Stock and Performance Share Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2475444 - Disclosure - Employee Benefits - Summary of Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails</Role>
      <ShortName>Employee Benefits - Summary of Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2476445 - Disclosure - Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails</Role>
      <ShortName>Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2479446 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails</Role>
      <ShortName>Net Income Per Share Attributable to Gilead Common Shareholders - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2480447 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails</Role>
      <ShortName>Net Income Per Share Attributable to Gilead Common Shareholders - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2483448 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2484449 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2485450 - Disclosure - Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2486451 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2487452 - Disclosure - Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="gild-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2488453 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="gild-20211231.htm">gild-20211231.htm</File>
    <File>gild-20211231.xsd</File>
    <File>gild-20211231_cal.xml</File>
    <File>gild-20211231_def.xml</File>
    <File>gild-20211231_lab.xml</File>
    <File>gild-20211231_pre.xml</File>
    <File>gild2021form10-kexhibit211.htm</File>
    <File>gild2021form10-kexhibit231.htm</File>
    <File>gild2021form10-kexhibit311.htm</File>
    <File>gild2021form10-kexhibit312.htm</File>
    <File>gild2021form10-kexhibit32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gild-20211231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1964">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>117
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gild-20211231.htm": {
   "axisCustom": 2,
   "axisStandard": 41,
   "contextCount": 921,
   "dts": {
    "calculationLink": {
     "local": [
      "gild-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gild-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "gild-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gild-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gild-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gild-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 974,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 10,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 14
   },
   "keyCustom": 78,
   "keyStandard": 593,
   "memberCustom": 125,
   "memberStandard": 65,
   "nsprefix": "gild",
   "nsuri": "http://www.gilead.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.gilead.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105102 - Disclosure - Revenues",
     "role": "http://www.gilead.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Fair Value Measurements",
     "role": "http://www.gilead.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Available-for-Sale Debt Securities",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecurities",
     "shortName": "Available-for-Sale Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Derivative Financial Instruments",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstruments",
     "shortName": "Derivative Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127106 - Disclosure - Acquisitions",
     "role": "http://www.gilead.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131107 - Disclosure - Inventories",
     "role": "http://www.gilead.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135108 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.gilead.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139109 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145110 - Disclosure - Other Financial Information",
     "role": "http://www.gilead.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.gilead.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborativeAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149111 - Disclosure - Collaborations and Other Arrangements",
     "role": "http://www.gilead.com/role/CollaborationsandOtherArrangements",
     "shortName": "Collaborations and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborativeAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151112 - Disclosure - Debt and Credit Facilities",
     "role": "http://www.gilead.com/role/DebtandCreditFacilities",
     "shortName": "Debt and Credit Facilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156113 - Disclosure - Leases",
     "role": "http://www.gilead.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162114 - Disclosure - Commitments and Contingencies",
     "role": "http://www.gilead.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164115 - Disclosure - Stockholders' Equity",
     "role": "http://www.gilead.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170116 - Disclosure - Employee Benefits",
     "role": "http://www.gilead.com/role/EmployeeBenefits",
     "shortName": "Employee Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2177117 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders",
     "role": "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders",
     "shortName": "Net Income Per Share Attributable to Gilead Common Shareholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2181118 - Disclosure - Income Taxes",
     "role": "http://www.gilead.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:PropertyPlantandEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:PropertyPlantandEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.gilead.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306302 - Disclosure - Revenues (Tables)",
     "role": "http://www.gilead.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.gilead.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Available-for-Sale Debt Securities (Tables)",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables",
     "shortName": "Available-for-Sale Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Derivative Financial Instruments (Tables)",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsTables",
     "shortName": "Derivative Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Acquisitions (Tables)",
     "role": "http://www.gilead.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - Inventories (Tables)",
     "role": "http://www.gilead.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336308 - Disclosure - Property, Plant and Equipment (Tables)",
     "role": "http://www.gilead.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340309 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2346310 - Disclosure - Other Financial Information (Tables)",
     "role": "http://www.gilead.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352311 - Disclosure - Debt and Credit Facilities (Tables)",
     "role": "http://www.gilead.com/role/DebtandCreditFacilitiesTables",
     "shortName": "Debt and Credit Facilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357312 - Disclosure - Leases (Tables)",
     "role": "http://www.gilead.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2365313 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.gilead.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2371314 - Disclosure - Employee Benefits (Tables)",
     "role": "http://www.gilead.com/role/EmployeeBenefitsTables",
     "shortName": "Employee Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2378315 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders (Tables)",
     "role": "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables",
     "shortName": "Net Income Per Share Attributable to Gilead Common Shareholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2382316 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.gilead.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Revenues - Disaggregation of Revenues (Details)",
     "role": "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails",
     "shortName": "Revenues - Disaggregation of Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "idc40e9061b2e4d7e8c573dcda94bbc8e_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "id462101bfca04327af64a9543c8a833b_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Revenues - Summarized Revenues from Major Customers (Details)",
     "role": "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails",
     "shortName": "Revenues - Summarized Revenues from Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "id462101bfca04327af64a9543c8a833b_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Revenues - Narrative (Details)",
     "role": "http://www.gilead.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)",
     "role": "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
     "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i5efa57e75bba46fa80520cf5680bd744_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Income",
     "role": "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ia13c72dd8cf642e199152f20a3bf4a87_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Fair Value Measurements - Summary of Classification on Balance Sheet (Details)",
     "role": "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails",
     "shortName": "Fair Value Measurements - Summary of Classification on Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ia5795fbc1c3341f29a10bb7056a260ae_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
     "shortName": "Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
     "shortName": "Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i81c0aae6ccc84b7db071d1c937c18fe9_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
     "shortName": "Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Available-for-Sale Debt Securities - Additional Information (Details)",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails",
     "shortName": "Available-for-Sale Debt Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Derivative Financial Instruments - Additional Information (Details)",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Derivative Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
     "shortName": "Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails",
     "shortName": "Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details)",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails",
     "shortName": "Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Acquisitions - Narrative (Details)",
     "role": "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ic064b955d17a405a8e93d4ced0a24b8b_D20200407-20200407",
      "decimals": "-8",
      "lang": "en-US",
      "name": "gild:PaymentsToAcquireAssetsNetOfCashAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i4935cfb394d8470eafcd34defaed7483_I20210304",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i4935cfb394d8470eafcd34defaed7483_I20210304",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Inventories - Schedule of inventories (Details)",
     "role": "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails",
     "shortName": "Inventories - Schedule of inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Inventories - Narrative (Details)",
     "role": "http://www.gilead.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)",
     "role": "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedComputerSoftwareNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Property, Plant and Equipment - Narrative (Details)",
     "role": "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
     "shortName": "Property, Plant and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedComputerSoftwareNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ibc317247ac9840c9b997af09c66368bd_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i326d4d7af8aa42a1b1948ed90603ab96_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "if8555f34a84a4c3887459093bd255d74_I20181231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "if8555f34a84a4c3887459093bd255d74_I20181231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Other Financial Information - Accounts Receivable, Net (Details)",
     "role": "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails",
     "shortName": "Other Financial Information - Accounts Receivable, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Other Financial Information - Other Accrued Liabilities (Details)",
     "role": "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails",
     "shortName": "Other Financial Information - Other Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - Collaborations and Other Arrangements (Details)",
     "role": "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
     "shortName": "Collaborations and Other Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaaddd81bb83f462cae89580391426788_D20210313-20210313",
      "decimals": "2",
      "lang": "en-US",
      "name": "gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453429 - Disclosure - Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)",
     "role": "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails",
     "shortName": "Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Debt and Credit Facilities - Narrative (Details)",
     "role": "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
     "shortName": "Debt and Credit Facilities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)",
     "role": "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
     "shortName": "Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "if472a036278a4d88a49fe0a47d9404ee_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458432 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.gilead.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459433 - Disclosure - Leases - Balance Sheet Location Detail (Details)",
     "role": "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails",
     "shortName": "Leases - Balance Sheet Location Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - Leases - Supplemental Information Related to Leases (Details)",
     "role": "http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Supplemental Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461435 - Disclosure - Leases - Summary of Operating Lease Liabilities Maturity (Details)",
     "role": "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails",
     "shortName": "Leases - Summary of Operating Lease Liabilities Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i6d11aa8c23bc48e69c02c674ce48e4b1_D20211001-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i0639e3db3b664793a6beb77eb685f7b0_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gild:LossContingencyAdditionalPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.gilead.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i0639e3db3b664793a6beb77eb685f7b0_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gild:LossContingencyAdditionalPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466437 - Disclosure - Stockholders' Equity - Repurchases of Common Stock (Details)",
     "role": "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails",
     "shortName": "Stockholders' Equity - Repurchases of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i6d11aa8c23bc48e69c02c674ce48e4b1_D20211001-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467438 - Disclosure - Stockholders' Equity - Dividends (Details)",
     "role": "http://www.gilead.com/role/StockholdersEquityDividendsDetails",
     "shortName": "Stockholders' Equity - Dividends (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i6d11aa8c23bc48e69c02c674ce48e4b1_D20211001-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStockCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468439 - Disclosure - Stockholders' Equity - Preferred Stock (Details)",
     "role": "http://www.gilead.com/role/StockholdersEquityPreferredStockDetails",
     "shortName": "Stockholders' Equity - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ibc317247ac9840c9b997af09c66368bd_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469440 - Disclosure - Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)",
     "role": "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i8023d2e7ae2f498fa0385be7010b4f25_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472441 - Disclosure - Employee Benefits - Narrative (Details)",
     "role": "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
     "shortName": "Employee Benefits - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i0729bf1c13614c1dbd5464ad3b216cd1_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473442 - Disclosure - Employee Benefits - Stock Options (Details)",
     "role": "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails",
     "shortName": "Employee Benefits - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i0729bf1c13614c1dbd5464ad3b216cd1_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i8e0958f8c926485eae5d31e7b78ed257_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474443 - Disclosure - Employee Benefits - Restricted Stock and Performance Share Awards (Details)",
     "role": "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
     "shortName": "Employee Benefits - Restricted Stock and Performance Share Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i05fe41cca53649a391c7e58c4961ccca_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475444 - Disclosure - Employee Benefits - Summary of Stock-Based Compensation (Details)",
     "role": "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
     "shortName": "Employee Benefits - Summary of Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gild:ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476445 - Disclosure - Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)",
     "role": "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
     "shortName": "Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gild:ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2479446 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders - Narrative (Details)",
     "role": "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails",
     "shortName": "Net Income Per Share Attributable to Gilead Common Shareholders - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2480447 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "role": "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails",
     "shortName": "Net Income Per Share Attributable to Gilead Common Shareholders - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2483448 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2484449 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Schedule of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2485450 - Disclosure - Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2486451 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ibc317247ac9840c9b997af09c66368bd_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2487452 - Disclosure - Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)",
     "role": "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails",
     "shortName": "Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "i8222e290a2284cb0bf64a4ac2b6995b5_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "ib73a3a8219834e0bb71b426175877d8d_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2488453 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20211231.htm",
      "contextRef": "iaeaf99ac576f40e684136704e997f1ff_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 202,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r841",
      "r842",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r841",
      "r842",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r841",
      "r842",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r841",
      "r842",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r853"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r841",
      "r842",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.15% LIBOR Senior Unsecured Notes Due September 2021",
        "label": "0.15% LIBOR Senior Unsecured Notes Due September 2021 [Member]",
        "terseLabel": "0.15% LIBOR Senior Unsecured Notes Due September 2021"
       }
      }
     },
     "localname": "A015LIBORSeniorUnsecuredNotesDueSeptember2021Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.52% LIBOR Senior Unsecured Notes Due September 2023",
        "label": "0.52% LIBOR Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "0.52% LIBOR Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A052LIBORSeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A075SeniorUnsecuredNotesDueInSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.75% Senior Unsecured Notes Due in September 2023",
        "label": "0.75% Senior Unsecured Notes Due in September 2023 [Member]",
        "terseLabel": "0.75% Senior Unsecured Notes Due in September 2023"
       }
      }
     },
     "localname": "A075SeniorUnsecuredNotesDueInSeptember2023Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A120SeniorUnsecuredNotesDueOctober2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.20% Senior Unsecured Notes Due October 2027",
        "label": "1.20% Senior Unsecured Notes Due October 2027 [Member]",
        "terseLabel": "1.20% Senior Unsecured Notes Due October 2027"
       }
      }
     },
     "localname": "A120SeniorUnsecuredNotesDueOctober2027Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A165SeniorUnsecuredNotesDueOctober2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.65% Senior Unsecured Notes Due October 2030",
        "label": "1.65% Senior Unsecured Notes Due October 2030 [Member]",
        "terseLabel": "1.65% Senior Unsecured Notes Due October 2030"
       }
      }
     },
     "localname": "A165SeniorUnsecuredNotesDueOctober2030Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A2016StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Stock Repurchase Program [Member]",
        "label": "2016 Stock Repurchase Program [Member]",
        "terseLabel": "2016 stock repurchase program"
       }
      }
     },
     "localname": "A2016StockRepurchaseProgramMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A2020StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Repurchase Program [Member]",
        "label": "2020 Stock Repurchase Program [Member]",
        "terseLabel": "2020 stock repurchase program"
       }
      }
     },
     "localname": "A2020StockRepurchaseProgramMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A260SeniorUnsecuredNotesDueOctober2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.60% Senior Unsecured Notes Due October 2040",
        "label": "2.60% Senior Unsecured Notes Due October 2040 [Member]",
        "terseLabel": "2.60% Senior Unsecured Notes Due October 2040"
       }
      }
     },
     "localname": "A260SeniorUnsecuredNotesDueOctober2040Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A280SeniorUnsecuredNotesDueOctober2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.80% Senior Unsecured Notes Due October 2050",
        "label": "2.80% Senior Unsecured Notes Due October 2050 [Member]",
        "terseLabel": "2.80% Senior Unsecured Notes Due October 2050"
       }
      }
     },
     "localname": "A280SeniorUnsecuredNotesDueOctober2050Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AccountsReceivableCashDiscountsAndOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Cash Discounts and Other, Current",
        "label": "Accounts Receivable, Cash Discounts and Other, Current",
        "terseLabel": "Less: cash discounts and other"
       }
      }
     },
     "localname": "AccountsReceivableCashDiscountsAndOtherCurrent",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccountsReceivableChargebacksCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Chargebacks, Current",
        "label": "Accounts Receivable, Chargebacks, Current",
        "terseLabel": "Less: chargebacks"
       }
      }
     },
     "localname": "AccountsReceivableChargebacksCurrent",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccruedGovernmentAndOtherRebates": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Government And Other Rebates",
        "label": "Accrued Government And Other Rebates",
        "terseLabel": "Accrued government and other rebates"
       }
      }
     },
     "localname": "AccruedGovernmentAndOtherRebates",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Finite-lived Intangible Assets, Discount Rate",
        "label": "Acquired Finite-lived Intangible Assets, Discount Rate",
        "terseLabel": "Discount rate of finite-lived intangible asset acquired"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsDiscountRate",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_AdjustmentsOfBudgetedDevelopmentCostsPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments of Budgeted Development Costs, Payments",
        "label": "Adjustments of Budgeted Development Costs, Payments",
        "terseLabel": "Additional payment for adjustments of budgeted development costs in 2021"
       }
      }
     },
     "localname": "AdjustmentsOfBudgetedDevelopmentCostsPayments",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months",
        "label": "Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months",
        "terseLabel": "Payment for adjustments of budgeted development costs in 2022"
       }
      }
     },
     "localname": "AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AgreementWithJapanTobaccoIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with Japan Tobacco, Inc. [Member]",
        "label": "Agreement with Japan Tobacco, Inc. [Member]",
        "terseLabel": "Japan tobacco"
       }
      }
     },
     "localname": "AgreementWithJapanTobaccoIncMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated Research Collaboration and License Agreement and Stock Purchase Agreement",
        "label": "Amended and Restated Research Collaboration and License Agreement and Stock Purchase Agreement [Member]",
        "terseLabel": "Tango collaboration and stock purchase agreement"
       }
      }
     },
     "localname": "AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Filgotinib License and Collaboration Agreement in December 2020",
        "label": "Amended Filgotinib License and Collaboration Agreement in December 2020 [Member]",
        "terseLabel": "Amended 2019 agreement"
       }
      }
     },
     "localname": "AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AmerisourcebergenCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Corp [Member]",
        "label": "AmerisourceBergen Corp [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourcebergenCorpMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Biosciences, Inc.",
        "label": "Arcus Biosciences, Inc. [Member]",
        "terseLabel": "Arcus"
       }
      }
     },
     "localname": "ArcusBiosciencesIncMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Collaboration Agreement and Stock Purchase Agreements",
        "label": "Arcus Collaboration Agreement and Stock Purchase Agreements [Member]",
        "terseLabel": "Arcus collaboration agreement and stock purchase agreements"
       }
      }
     },
     "localname": "ArcusCollaborationAgreementAndStockPurchaseAgreementsMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Collaboration Agreement",
        "label": "Arcus Collaboration Agreement [Member]",
        "terseLabel": "Arcus collaboration agreement"
       }
      }
     },
     "localname": "ArcusCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Stock Purchase Agreement",
        "label": "Arcus Stock Purchase Agreement [Member]",
        "terseLabel": "Arcus stock purchase agreement"
       }
      }
     },
     "localname": "ArcusStockPurchaseAgreementMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.gilead.com/20211231",
     "xbrltype": "stringItemType"
    },
    "gild_AxicabtageneCiloleucelDLBCLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "axicabtagene ciloleucel (DLBCL) [Member]",
        "label": "Axicabtagene Ciloleucel (DLBCL) [Member]",
        "terseLabel": "Intangible asset - axicabtagene ciloleucel"
       }
      }
     },
     "localname": "AxicabtageneCiloleucelDLBCLMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Future Royalties, Liability, Measurement Input",
        "label": "Business Combination, Future Royalties, Liability, Measurement Input",
        "terseLabel": "Liability related to future royalties, measurement Input"
       }
      }
     },
     "localname": "BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability",
        "negatedTerseLabel": "Liability related to future royalties",
        "terseLabel": "Liability related to future royalties"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net",
        "terseLabel": "Other assets (and liabilities), net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health Inc [Member]",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health, Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CashPaymentsMadeRelatedToEquityInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Payments Made Related To Equity Investments",
        "label": "Cash Payments Made Related To Equity Investments",
        "terseLabel": "Cash payments made related to equity investments"
       }
      }
     },
     "localname": "CashPaymentsMadeRelatedToEquityInvestments",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CellTherapyProductsTecartusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Tecartus",
        "label": "Cell Therapy Products, Tecartus [Member]",
        "terseLabel": "Tecartus"
       }
      }
     },
     "localname": "CellTherapyProductsTecartusMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CellTherapyProductsTotalCellTherapyProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Total Cell Therapy Product Sales",
        "label": "Cell Therapy Products, Total Cell Therapy Product Sales [Member]",
        "terseLabel": "Total Cell Therapy"
       }
      }
     },
     "localname": "CellTherapyProductsTotalCellTherapyProductSalesMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period",
        "label": "Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period",
        "terseLabel": "Option period to license certain inhibitors"
       }
      }
     },
     "localname": "CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_CollaborationArrangementNetProductSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Net Product Sales Threshold",
        "label": "Collaboration Arrangement, Net Product Sales Threshold",
        "terseLabel": "Net product sales threshold"
       }
      }
     },
     "localname": "CollaborationArrangementNetProductSalesThreshold",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Percent Of Global Development And Commercialization Costs",
        "label": "Collaboration Arrangement, Percent Of Global Development And Commercialization Costs",
        "terseLabel": "Percent of global and development and commercialization costs"
       }
      }
     },
     "localname": "CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_CollaborationArrangementPercentOfGlobalProductRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Percent Of Global Product Revenues",
        "label": "Collaboration Arrangement, Percent Of Global Product Revenues",
        "terseLabel": "Percent of global product revenues"
       }
      }
     },
     "localname": "CollaborationArrangementPercentOfGlobalProductRevenues",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_CollaborativeAgreementOptInTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Opt-In Term",
        "label": "Collaborative Agreement, Opt-In Term",
        "terseLabel": "Opt-in term"
       }
      }
     },
     "localname": "CollaborativeAgreementOptInTerm",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Product Market Period Subject To Termination",
        "label": "Collaborative Agreement, Product Market Period Subject To Termination",
        "terseLabel": "Period subject to termination"
       }
      }
     },
     "localname": "CollaborativeAgreementProductMarketPeriodSubjectToTermination",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_CollaborativeAndOtherArrangementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and Other Arrangements [Text Block]",
        "label": "Collaborative And Other Arrangements [Text Block]",
        "terseLabel": "Collaborations and Other Arrangements"
       }
      }
     },
     "localname": "CollaborativeAndOtherArrangementsTextBlock",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Collaboration term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_CollaborativeandOtherArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and Other Arrangements [Abstract]",
        "label": "Collaborative and Other Arrangements [Abstract]",
        "terseLabel": "Collaborative and Other Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeandOtherArrangementsAbstract",
     "nsuri": "http://www.gilead.com/20211231",
     "xbrltype": "stringItemType"
    },
    "gild_CreditFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility Due June 2025",
        "label": "Credit Facility Due June 2025 [Member]",
        "terseLabel": "2020 revolving credit facility"
       }
      }
     },
     "localname": "CreditFacilityDueJune2025Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CreditFacilityDueMay2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility Due May 2021 [Member]",
        "label": "Credit Facility Due May 2021 [Member]",
        "terseLabel": "2016 revolving credit facility"
       }
      }
     },
     "localname": "CreditFacilityDueMay2021Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DebtInstrumentCallFeaturePeriodBeforeMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Call Feature, Period Before Maturity",
        "label": "Debt Instrument, Call Feature, Period Before Maturity",
        "terseLabel": "Call feature, period prior to maturity"
       }
      }
     },
     "localname": "DebtInstrumentCallFeaturePeriodBeforeMaturity",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year 5",
        "label": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year 5",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year 5",
        "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year 5",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_DeferredCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Compensation Plan [Member]",
        "label": "Deferred Compensation Plan [Member]",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "DeferredCompensationPlanMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DeferredIncomeTaxExpenseBenefitComponentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Tax Expense (Benefit) Component [Axis]",
        "label": "Deferred Income Tax Expense (Benefit) Component [Axis]",
        "terseLabel": "Deferred Income Tax Expense (Benefit) Component [Axis]"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitComponentAxis",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_DeferredIncomeTaxExpenseBenefitComponentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Deferred Income Tax Expense (Benefit) Component [Axis]",
        "label": "Deferred Income Tax Expense (Benefit) Component [Domain]",
        "terseLabel": "Deferred Income Tax Expense (Benefit) Component [Domain]"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitComponentDomain",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DeferredTaxAssetsUpfrontAndMilestonePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Upfront and Milestone Payments",
        "label": "Deferred Tax Assets, Upfront and Milestone Payments",
        "terseLabel": "Upfront and milestone payments"
       }
      }
     },
     "localname": "DeferredTaxAssetsUpfrontAndMilestonePayments",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_DevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Agreement",
        "label": "Development Agreement [Member]",
        "terseLabel": "Development agreement"
       }
      }
     },
     "localname": "DevelopmentAgreementMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EquityMethodInvestmentOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Option Exercise Fee",
        "label": "Equity Method Investment, Option Exercise Fee",
        "terseLabel": "Option exercise fee"
       }
      }
     },
     "localname": "EquityMethodInvestmentOptionExerciseFee",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Option Fee And Potential Future Milestone Payments",
        "label": "Equity Method Investment, Option Fee And Potential Future Milestone Payments",
        "terseLabel": "Option fee and potential future milestone payments"
       }
      }
     },
     "localname": "EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesDonationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Donation",
        "label": "Equity Securities Donation [Member]",
        "terseLabel": "Equity Securities Donation"
       }
      }
     },
     "localname": "EquitySecuritiesDonationMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries",
        "label": "Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries",
        "terseLabel": "Additional option fee on fourth, sixth, and eighth anniversaries"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased",
        "label": "Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased",
        "terseLabel": "Maximum percentage of outstanding stock allowed to be purchased"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments",
        "label": "Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments",
        "terseLabel": "Opt-in, extension and milestone payments"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesFVNIPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Purchase Period",
        "label": "Equity Securities, FV-NI, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIPurchasePeriod",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_EquitySecuritiesFVNIRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Restriction Period",
        "label": "Equity Securities, FV-NI, Restriction Period",
        "terseLabel": "Restriction period"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIRestrictionPeriod",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_EquitySecuritiesFVNIShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Shares",
        "label": "Equity Securities, FV-NI, Shares",
        "terseLabel": "Number of shares (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIShares",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gild_EquitySecuritiesFVNISharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Shares Acquired",
        "label": "Equity Securities, FV-NI, Shares Acquired",
        "terseLabel": "Additional shares acquired (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNISharesAcquired",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gild_EuropeanPatentClaims2024ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2024 Expiration",
        "label": "European Patent Claims 2024 Expiration [Member]",
        "terseLabel": "European Patent Claims 2024 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2024ExpirationMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EuropeanPatentClaims2026ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2026 Expiration",
        "label": "European Patent Claims 2026 Expiration [Member]",
        "terseLabel": "European Patent Claims 2026 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2026ExpirationMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EuropeanPatentClaims2027ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2027 Expiration",
        "label": "European Patent Claims 2027 Expiration [Member]",
        "terseLabel": "European Patent Claims 2027 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2027ExpirationMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EuropeanPatentClaims2032ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2032 Expiration",
        "label": "European Patent Claims 2032 Expiration [Member]",
        "terseLabel": "European Patent Claims 2032 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2032ExpirationMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FairValueatGrantDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value at Grant Date",
        "label": "Fair Value at Grant Date [Member]",
        "terseLabel": "Fair value at grant date"
       }
      }
     },
     "localname": "FairValueatGrantDateMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FairValueatVestingDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value at Vesting Date [Member]",
        "label": "Fair Value at Vesting Date [Member]",
        "terseLabel": "Fair value at vesting date"
       }
      }
     },
     "localname": "FairValueatVestingDateMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Filgotinib License and Collaboration Agreement with Galapagos [Member]",
        "label": "Filgotinib License and Collaboration Agreement with Galapagos [Member]",
        "terseLabel": "Filgotinib agreement"
       }
      }
     },
     "localname": "FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "totalLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsGrossReclassified": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Gross, Reclassified",
        "label": "Finite-Lived Intangible Assets, Gross, Reclassified",
        "terseLabel": "Reclassified intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGrossReclassified",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Rate Senior Unsecured Note Issued September 2020",
        "label": "Fixed Rate Senior Unsecured Note Issued September 2020 [Member]",
        "terseLabel": "the \"2020 Fixed Rate Notes\""
       }
      }
     },
     "localname": "FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ForeignCurrencyDerivativeContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Derivative Contracts [Member]",
        "label": "Foreign Currency Derivative Contracts [Member]",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeContractsMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FortySevenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forty Seven, Inc. [Member]",
        "label": "Forty Seven, Inc. [Member]",
        "terseLabel": "Forty Seven, Inc."
       }
      }
     },
     "localname": "FortySevenIncMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GadetaBVCollaborationArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gadeta B.V. Collaboration Arrangement",
        "label": "Gadeta B.V. Collaboration Arrangement [Member]",
        "terseLabel": "Gadeta collaboration arrangement"
       }
      }
     },
     "localname": "GadetaBVCollaborationArrangementMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GalapagosCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galapagos Collaboration Agreement",
        "label": "Galapagos Collaboration Agreement [Member]",
        "terseLabel": "Galapagos collaboration agreement"
       }
      }
     },
     "localname": "GalapagosCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GalapagosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galapagos, a clinical-stage biotechnology company based in Belgium",
        "label": "Galapagos [Member]",
        "terseLabel": "Galapagos"
       }
      }
     },
     "localname": "GalapagosMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GalapagosSubscriptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galapagos Subscription Agreement",
        "label": "Galapagos Subscription Agreement [Member]",
        "terseLabel": "Galapagos subscription agreement"
       }
      }
     },
     "localname": "GalapagosSubscriptionAgreementMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GileadFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Foundation",
        "label": "Gilead Foundation [Member]",
        "terseLabel": "Gilead Foundation"
       }
      }
     },
     "localname": "GileadFoundationMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GileadSciencesInc2004EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Sciences, Inc. 2004 Equity Incentive Plan",
        "label": "Gilead Sciences, Inc. 2004 Equity Incentive Plan [Member]",
        "terseLabel": "2004 Plan"
       }
      }
     },
     "localname": "GileadSciencesInc2004EquityIncentivePlanMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GileadSciencesInc2018EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Sciences, Inc. 2018 Equity Incentive Plan",
        "label": "Gilead Sciences, Inc. 2018 Equity Incentive Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "GileadSciencesInc2018EquityIncentivePlanMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Product Sales",
        "label": "HCV Product Sales [Member]",
        "terseLabel": "Total HCV"
       }
      }
     },
     "localname": "HCVProductSalesMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsLedipasvirSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Ledipasvir/Sofosbuvir",
        "label": "HCV Products, Ledipasvir/Sofosbuvir [Member]",
        "terseLabel": "Ledipasvir/Sofosbuvir"
       }
      }
     },
     "localname": "HCVProductsLedipasvirSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsSofosbuvirVelpatasvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Sofosbuvir/Velpatasvir",
        "label": "HCV Products, Sofosbuvir/Velpatasvir [Member]",
        "terseLabel": "Sofosbuvir/Velpatasvir"
       }
      }
     },
     "localname": "HCVProductsSofosbuvirVelpatasvirMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Product Sales",
        "label": "HIV Product Sales [Member]",
        "terseLabel": "Total HIV"
       }
      }
     },
     "localname": "HIVProductSalesMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsAtriplaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Atripla [Member]",
        "label": "HIV Products, Atripla [Member]",
        "terseLabel": "Atripla"
       }
      }
     },
     "localname": "HIVProductsAtriplaMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsBiktarvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Biktarvy [Member]",
        "label": "HIV Products, Biktarvy [Member]",
        "terseLabel": "Biktarvy"
       }
      }
     },
     "localname": "HIVProductsBiktarvyMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsCompleraEvipleraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Complera/Eviplera [Member]",
        "label": "HIV Products, Complera/Eviplera [Member]",
        "terseLabel": "Complera/Eviplera"
       }
      }
     },
     "localname": "HIVProductsCompleraEvipleraMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsDescovyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Descovy [Member]",
        "label": "HIV Products, Descovy [Member]",
        "terseLabel": "Descovy"
       }
      }
     },
     "localname": "HIVProductsDescovyMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsGenvoyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Genvoya [Member]",
        "label": "HIV Products, Genvoya [Member]",
        "terseLabel": "Genvoya"
       }
      }
     },
     "localname": "HIVProductsGenvoyaMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsOdefseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Odefsey [Member]",
        "label": "HIV Products, Odefsey [Member]",
        "terseLabel": "Odefsey"
       }
      }
     },
     "localname": "HIVProductsOdefseyMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsStribildMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Stribild [Member]",
        "label": "HIV Products, Stribild [Member]",
        "terseLabel": "Stribild"
       }
      }
     },
     "localname": "HIVProductsStribildMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsTruvadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Truvada [Member]",
        "label": "HIV Products, Truvada [Member]",
        "terseLabel": "Truvada"
       }
      }
     },
     "localname": "HIVProductsTruvadaMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product [Member]",
        "terseLabel": "Total HBV/HDV"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Other",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Other [Member]",
        "terseLabel": "Other HB/HDV"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductOtherMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]",
        "terseLabel": "Vemlidy"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]",
        "terseLabel": "Viread"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductVireadMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepcludexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepcludex",
        "label": "Hepcludex [Member]",
        "terseLabel": "Intangible asset - Hepcludex",
        "verboseLabel": "Hepcludex"
       }
      }
     },
     "localname": "HepcludexMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunomedics Amended and Restated 2014 Long-Term Incentive Plan",
        "label": "Immunomedics Amended and Restated 2014 Long-Term Incentive Plan [Member]",
        "terseLabel": "Immunomedics Plan"
       }
      }
     },
     "localname": "ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ImmunomedicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunomedics, Inc. (\u201cImmunomedics\u201d), a leading company in antibody-drug conjugate (\u201cADC\u201d) technology",
        "label": "Immunomedics, Inc. [Member]",
        "terseLabel": "Immunomedics, Inc."
       }
      }
     },
     "localname": "ImmunomedicsIncMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-lived Intangible Assets Acquired, Discount Rate",
        "label": "Indefinite-lived Intangible Assets Acquired, Discount Rate",
        "terseLabel": "Discount rate of acquired IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsAcquiredDiscountRate",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial consideration for acquisition of rights to market and distribute certain products in Japan",
        "label": "Initial Consideration for Acquisition of Rights to Market and Distribute Certain Products in Japan",
        "terseLabel": "Cash paid"
       }
      }
     },
     "localname": "InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_InjectableFormulationProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Injectable Formulation Product",
        "label": "Injectable Formulation Product [Member]",
        "terseLabel": "Injectable Formulation Product"
       }
      }
     },
     "localname": "InjectableFormulationProductMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IntangibleAssetSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sofosbuvir [Member]",
        "label": "Intangible Asset - Sofosbuvir [Member]",
        "terseLabel": "Intangible asset - sofosbuvir"
       }
      }
     },
     "localname": "IntangibleAssetSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IntangibleAssetTransferMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Asset Transfer [Member]",
        "label": "Intangible Asset Transfer [Member]",
        "terseLabel": "Intangible Asset Transfer"
       }
      }
     },
     "localname": "IntangibleAssetTransferMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_InventoryReserveForExcessRawMaterials": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Reserve For Excess Raw Materials",
        "label": "Inventory Reserve For Excess Raw Materials",
        "terseLabel": "Write-downs for slow-moving and excess raw material and work in process inventory"
       }
      }
     },
     "localname": "InventoryReserveForExcessRawMaterials",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_InventoryWritedownsforExcessRawMaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Write-downs for Excess Raw Materials [Member]",
        "label": "Inventory Write-downs for Excess Raw Materials [Member]",
        "terseLabel": "Inventory Write-downs for Excess Raw Materials"
       }
      }
     },
     "localname": "InventoryWritedownsforExcessRawMaterialsMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_InvestmentOwnedBalanceAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Owned, Balance, Additional Shares",
        "label": "Investment Owned, Balance, Additional Shares",
        "terseLabel": "Additional shares acquired (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceAdditionalShares",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gild_IssuanceDiscountPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Discount (Premium)",
        "label": "Issuance Discount (Premium)",
        "terseLabel": "Issuance discount (premium)"
       }
      }
     },
     "localname": "IssuanceDiscountPremium",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_Issuancediscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance discount",
        "label": "Issuance discount",
        "terseLabel": "Issuance discount"
       }
      }
     },
     "localname": "Issuancediscount",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_JanssenPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the collaboration with Janssen Pharmaceuticals",
        "label": "Janssen Pharmaceuticals [Member]",
        "terseLabel": "Janssen pharmaceuticals"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_JounceTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jounce Therapeutics, Inc.",
        "label": "Jounce Therapeutics, Inc. [Member]",
        "terseLabel": "Jounce"
       }
      }
     },
     "localname": "JounceTherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_JudgmentEnhancedDamagesOnPastSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Enhanced Damages On Past Sales",
        "label": "Judgment: Enhanced Damages On Past Sales",
        "terseLabel": "Enhanced damages on past sales"
       }
      }
     },
     "localname": "JudgmentEnhancedDamagesOnPastSales",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JudgmentRoyaltyRateFromOctober2017": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Royalty Rate from October 2017",
        "label": "Judgment: Royalty Rate from October 2017",
        "terseLabel": "Running royalty rate from October 2017"
       }
      }
     },
     "localname": "JudgmentRoyaltyRateFromOctober2017",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JudgmentRoyaltyRateOnFutureSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Royalty Rate on Future Sales",
        "label": "Judgment: Royalty Rate on Future Sales",
        "terseLabel": "Running royalty rate on future sales"
       }
      }
     },
     "localname": "JudgmentRoyaltyRateOnFutureSales",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, \u201cJuno\u201d)",
        "label": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center [Member]",
        "terseLabel": "Juno"
       }
      }
     },
     "localname": "JunoTherapeuticsIncAndSloanKetteringCancerCenterMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_KitePharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kite Pharma, Inc.",
        "label": "Kite Pharma, Inc. [Member]",
        "terseLabel": "Kite Pharma, Inc."
       }
      }
     },
     "localname": "KitePharmaIncMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, Registration Rights and Stock Purchase Agreement",
        "label": "License, Registration Rights and Stock Purchase Agreement [Member]",
        "terseLabel": "Jounce license and stock purchase agreement"
       }
      }
     },
     "localname": "LicenseRegistrationRightsAndStockPurchaseAgreementMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Additional Patents Allegedly Infringed, Number",
        "label": "Loss Contingency, Additional Patents Allegedly Infringed, Number",
        "terseLabel": "Number of additional patents allegedly infringed"
       }
      }
     },
     "localname": "LossContingencyAdditionalPatentsAllegedlyInfringedNumber",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyMaterialTransferAgreementsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Material Transfer Agreements, Number",
        "label": "Loss Contingency, Material Transfer Agreements, Number",
        "terseLabel": "Number of material transfer agreements"
       }
      }
     },
     "localname": "LossContingencyMaterialTransferAgreementsNumber",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPartiesAppealedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Parties Appealed, Number",
        "label": "Loss Contingency, Parties Appealed, Number",
        "terseLabel": "Number of parties appealed"
       }
      }
     },
     "localname": "LossContingencyPartiesAppealedNumber",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPartiesFilingOppositionNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Parties Filing Opposition, Number",
        "label": "Loss Contingency, Parties Filing Opposition, Number",
        "terseLabel": "Number of parties filing opposition"
       }
      }
     },
     "localname": "LossContingencyPartiesFilingOppositionNumber",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario One",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario One",
        "terseLabel": "Number of patents allegedly infringed, scenario one"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumberScenarioOne",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two",
        "terseLabel": "Number of patents allegedly infringed, scenario two"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyRoyaltyPercentageOnFutureSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Royalty Percentage On Future Sales",
        "label": "Loss Contingency, Royalty Percentage On Future Sales",
        "terseLabel": "Royalty percentage on future sales"
       }
      }
     },
     "localname": "LossContingencyRoyaltyPercentageOnFutureSales",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_MYRGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MYR GmbH (\u201cMYR\u201d), a German biotechnology company",
        "label": "MYR GmbH [Member]",
        "terseLabel": "MYR"
       }
      }
     },
     "localname": "MYRGmbHMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Current [Member]",
        "label": "Marketable Securities, Current [Member]",
        "terseLabel": "Short-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Noncurrent [Member]",
        "label": "Marketable Securities, Noncurrent [Member]",
        "terseLabel": "Long-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrentMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement",
        "label": "Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement",
        "terseLabel": "Maximum ownership percentage"
       }
      }
     },
     "localname": "MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_MckessonCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corp [Member]",
        "label": "McKesson Corp [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "MckessonCorpMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MerckMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck",
        "label": "Merck [Member]",
        "terseLabel": "Merck"
       }
      }
     },
     "localname": "MerckMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck Sharp &amp; Dohme Corp License And Collaboration Agreement",
        "label": "Merck Sharp &amp; Dohme Corp License And Collaboration Agreement [Member]",
        "terseLabel": "Merck Sharp &amp; Dohme Corp"
       }
      }
     },
     "localname": "MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement",
        "label": "Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement",
        "terseLabel": "Minimum ownership percentage"
       }
      }
     },
     "localname": "MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_NumberOfClinicalStageProgramsWithExercisedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Clinical Stage Programs With Exercised Options",
        "label": "Number Of Clinical Stage Programs With Exercised Options",
        "terseLabel": "Number of clinical stage programs with exercise options"
       }
      }
     },
     "localname": "NumberOfClinicalStageProgramsWithExercisedOptions",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_NumberOfEarlyRepaymentsOfLongTermDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Early Repayments Of Long-Term Debt",
        "label": "Number Of Early Repayments Of Long-Term Debt",
        "terseLabel": "Number of early repayments"
       }
      }
     },
     "localname": "NumberOfEarlyRepaymentsOfLongTermDebt",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_NumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Programs",
        "label": "Number of Programs",
        "terseLabel": "Number of programs"
       }
      }
     },
     "localname": "NumberOfPrograms",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_OralFormulationProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Formulation Product",
        "label": "Oral Formulation Product [Member]",
        "terseLabel": "Oral Formulation Product"
       }
      }
     },
     "localname": "OralFormulationProductMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_OtherCollaborationArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Collaboration Arrangements [Member]",
        "label": "Other Collaboration Arrangements [Member]",
        "terseLabel": "Other collaboration arrangements"
       }
      }
     },
     "localname": "OtherCollaborationArrangementsMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]",
        "terseLabel": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.gilead.com/20211231",
     "xbrltype": "stringItemType"
    },
    "gild_OtherHCVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other HCV",
        "label": "Other HCV [Member]",
        "terseLabel": "Other HCV"
       }
      }
     },
     "localname": "OtherHCVMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other International [Member]",
        "label": "Other International [Member]",
        "terseLabel": "Other International"
       }
      }
     },
     "localname": "OtherInternationalMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsAmBisomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, AmBisome [Member]",
        "label": "Other Products, AmBisome [Member]",
        "terseLabel": "AmBisome"
       }
      }
     },
     "localname": "OtherProductsAmBisomeMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsLetairisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Letairis [Member]",
        "label": "Other Products, Letairis [Member]",
        "terseLabel": "Letairis"
       }
      }
     },
     "localname": "OtherProductsLetairisMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Other [Member]",
        "label": "Other Products, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductsOtherMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsRanexaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Ranexa [Member]",
        "label": "Other Products, Ranexa [Member]",
        "terseLabel": "Ranexa"
       }
      }
     },
     "localname": "OtherProductsRanexaMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsTotalOtherProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Total Other product sales",
        "label": "Other Products, Total Other product sales [Member]",
        "terseLabel": "Total Other"
       }
      }
     },
     "localname": "OtherProductsTotalOtherProductSalesMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsYescartaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Yescarta [Member]",
        "label": "Other Products, Yescarta [Member]",
        "terseLabel": "Yescarta"
       }
      }
     },
     "localname": "OtherProductsYescartaMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsZydeligMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Zydelig [Member]",
        "label": "Other Products, Zydelig [Member]",
        "terseLabel": "Zydelig"
       }
      }
     },
     "localname": "OtherProductsZydeligMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for Adjustments of Budgeted Development Costs",
        "label": "Payment for Adjustments of Budgeted Development Costs",
        "terseLabel": "Payment for adjustments of budgeted development costs"
       }
      }
     },
     "localname": "PaymentForAdjustmentsOfBudgetedDevelopmentCosts",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "payment for license, option rights and equity investments upon closing of collaboration agreement",
        "label": "Payment for License, Option Rights and Equity Investments Upon Closing",
        "terseLabel": "Payment for license and option rights"
       }
      }
     },
     "localname": "PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsForDirectTransactionalExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Direct Transactional Expense",
        "label": "Payments for Direct Transactional Expense",
        "terseLabel": "Direct transactional costs"
       }
      }
     },
     "localname": "PaymentsForDirectTransactionalExpense",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsForResearchAndDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Research and Development Milestones",
        "label": "Payments for Research and Development Milestones",
        "terseLabel": "Cash payments made for research and development milestones"
       }
      }
     },
     "localname": "PaymentsForResearchAndDevelopmentMilestones",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsToAcquireAssetsNetOfCashAcquired": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Assets, Net Of Cash Acquired",
        "label": "Payments To Acquire Assets, Net Of Cash Acquired",
        "terseLabel": "Total consideration, net of acquired cash"
       }
      }
     },
     "localname": "PaymentsToAcquireAssetsNetOfCashAcquired",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsToOptInTheCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Opt-In The Collaborative Agreement",
        "label": "Payments To Opt-In The Collaborative Agreement",
        "terseLabel": "Collaboration opt-in payments"
       }
      }
     },
     "localname": "PaymentsToOptInTheCollaborativeAgreement",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PionyrImmunotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pionyr Immunotherapeutics, Inc.",
        "label": "Pionyr Immunotherapeutics, Inc. [Member]",
        "terseLabel": "Pionyr"
       }
      }
     },
     "localname": "PionyrImmunotherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PionyrMergerAndOptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pionyr Merger and Option Agreements",
        "label": "Pionyr Merger and Option Agreements [Member]",
        "terseLabel": "Pionyr merger and option agreements"
       }
      }
     },
     "localname": "PionyrMergerAndOptionAgreementsMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Clinical, Regulatory and Commercial Milestone Payments, Maximum",
        "label": "Potential Clinical, Regulatory and Commercial Milestone Payments, Maximum",
        "terseLabel": "Future potential clinical, regulatory and commercial milestone payments"
       }
      }
     },
     "localname": "PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialFutureMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments, Maximum",
        "label": "Potential Future Milestone Payments, Maximum",
        "terseLabel": "Maximum potential future milestone payments"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsMaximum",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialOptionExerciseFeePerProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Option Exercise Fee Per Program",
        "label": "Potential Option Exercise Fee Per Program",
        "terseLabel": "Potential option exercise fee"
       }
      }
     },
     "localname": "PotentialOptionExerciseFeePerProgram",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Payment for Adjustments of Budgeted Development Costs",
        "label": "Potential Payment for Adjustments of Budgeted Development Costs",
        "terseLabel": "Potential payment for adjustments of budgeted development costs"
       }
      }
     },
     "localname": "PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Sales Based Tiered Royalties High-end, Percentage",
        "label": "Potential Sales Based Tiered Royalties High-end, Percentage",
        "terseLabel": "Payment of tiered royalties, high-end percentage"
       }
      }
     },
     "localname": "PotentialSalesBasedTieredRoyaltiesHighEndPercentage",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Sales Based Tiered Royalty, Low-end, Percentage",
        "label": "Potential Sales Based Tiered Royalty, Low-end, Percentage",
        "terseLabel": "Payment of tiered royalties, low-end percentage"
       }
      }
     },
     "localname": "PotentialSalesBasedTieredRoyaltyLowEndPercentage",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_PreExposureProphylaxisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Exposure Prophylaxis",
        "label": "Pre-Exposure Prophylaxis [Member]",
        "terseLabel": "Pre-Exposure Prophylaxis"
       }
      }
     },
     "localname": "PreExposureProphylaxisMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability",
        "label": "Product Liability [Member]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsOtherHIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Other HIV [Member]",
        "label": "Products, Other HIV [Member]",
        "terseLabel": "Other HIV"
       }
      }
     },
     "localname": "ProductsOtherHIVMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsRevenueShareSymtuzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Revenue Share-Symtuza [Member]",
        "label": "Products, Revenue Share-Symtuza [Member]",
        "terseLabel": "Revenue share - Symtuza"
       }
      }
     },
     "localname": "ProductsRevenueShareSymtuzaMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant and Equipment, Useful Lives [Table Text Block]",
        "label": "Property Plant and Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantandEquipmentUsefulLivesTableTextBlock",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_PubliclyAnnouncedProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Publicly Announced Program(s)",
        "label": "Publicly Announced Program [Member]",
        "terseLabel": "Publicly announced program"
       }
      }
     },
     "localname": "PubliclyAnnouncedProgramMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Price of Goods Less Specified Amount, Maximum Percentage",
        "label": "Purchase Price of Goods Less Specified Amount, Maximum Percentage",
        "terseLabel": "Purchase price of goods less specified amount, maximum percentage"
       }
      }
     },
     "localname": "PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_QuiTamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qui Tam",
        "label": "Qui Tam [Member]",
        "terseLabel": "Qui Tam"
       }
      }
     },
     "localname": "QuiTamMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ResearchAndDevelopmentFutureMaximumPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Future Maximum Payments",
        "label": "Research and Development Future Maximum Payments",
        "terseLabel": "Research and development future maximum payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentFutureMaximumPayments",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_ResearchAndDevelopmentInProcessIncludingImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development in Process, Including Impairment",
        "label": "Research and Development in Process, Including Impairment",
        "terseLabel": "Acquired in-process research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcessIncludingImpairment",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_ResearchAndDevelopmentServiceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Service Agreement",
        "label": "Research And Development Service Agreement [Member]",
        "terseLabel": "Research and development service agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServiceAgreementMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ResidentialMortgageAndAssetBackedSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Residential Mortgage And Asset-Backed Securities [Member]",
        "label": "Residential Mortgage And Asset-Backed Securities [Member]",
        "terseLabel": "Residential mortgage and asset-backed securities",
        "verboseLabel": "Residential mortgage and asset-backed securities"
       }
      }
     },
     "localname": "ResidentialMortgageAndAssetBackedSecuritiesMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_RestrictedStockandPerformanceShareAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock and Performance Share Awards [Member]",
        "label": "Restricted Stock and Performance Share Awards [Member]",
        "terseLabel": "Restricted stock and performance share awards"
       }
      }
     },
     "localname": "RestrictedStockandPerformanceShareAwardsMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_RoyaltyContractAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Contract, And Other [Member]",
        "label": "Royalty, Contract, And Other [Member]",
        "terseLabel": "Royalty, contract and other revenues"
       }
      }
     },
     "localname": "RoyaltyContractAndOtherMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ScheduleOfInventoriesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Inventory [Line Items]",
        "label": "Schedule of Inventories [Line Items]",
        "terseLabel": "Schedule of Inventory [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInventoriesLineItems",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_ScheduleofInventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Disclosure of information about inventory.",
        "label": "Schedule of Inventory [Line Items]",
        "terseLabel": "Schedule of Inventory [Line Items]"
       }
      }
     },
     "localname": "ScheduleofInventoryLineItems",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_ScheduleofInventoryTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory.",
        "label": "Schedule of Inventory [Table]",
        "terseLabel": "Schedule of Inventory [Table]"
       }
      }
     },
     "localname": "ScheduleofInventoryTable",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/InventoriesNarrativeDetails",
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and ESPP, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options and Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions to Calculate the Estimated Fair Value of Awards"
       }
      }
     },
     "localname": "ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_SeniorNotesAndMediumTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes And Medium-Term Notes",
        "label": "Senior Notes And Medium-Term Notes [Member]",
        "terseLabel": "Senior Notes And Medium-Term Notes"
       }
      }
     },
     "localname": "SeniorNotesAndMediumTermNotesMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueApril2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due April 2021 [Member]",
        "label": "Senior Unsecured Notes Due April 2021 Member",
        "terseLabel": "4.50% Senior Unsecured Notes Due in April 2021"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueApril2021Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueDecember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due December 2021",
        "label": "Senior Unsecured Notes Due December 2021 [Member]",
        "terseLabel": "4.40% Senior Unsecured Notes Due In December 2021"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueDecember2021Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueDecember2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due December 2041 [Member]",
        "label": "Senior Unsecured Notes Due December 2041 [Member]",
        "terseLabel": "5.65% Senior Unsecured Notes Due in December 2041"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueDecember2041Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinApril2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in April 2024 [Member]",
        "label": "Senior Unsecured Notes Due in April 2024 [Member]",
        "terseLabel": "3.70% Senior Unsecured Notes Due in April 2024"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinApril2024Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinApril2044Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in April 2044 [Member]",
        "label": "Senior Unsecured Notes Due in April 2044 [Member]",
        "terseLabel": "4.80% Senior Unsecured Notes Due in April 2044"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinApril2044Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinFebruary2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in February 2025 [Member]",
        "label": "Senior Unsecured Notes Due in February 2025 [Member]",
        "terseLabel": "3.50% Senior Unsecured Notes Due in February 2025"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinFebruary2025Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinFebruary2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in February 2045 [Member]",
        "label": "Senior Unsecured Notes Due in February 2045 [Member]",
        "terseLabel": "4.50% Senior Unsecured Notes Due in February 2045"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinFebruary2045Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2022 [Member]",
        "label": "Senior Unsecured Notes Due in March 2022 [Member]",
        "terseLabel": "1.95% Senior Unsecured Notes Due in March 2022"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2022Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2026",
        "label": "Senior Unsecured Notes Due in March 2026 [Member]",
        "terseLabel": "3.65% Senior Unsecured Notes Due in March 2026"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2026Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2027 [Member]",
        "label": "Senior Unsecured Notes Due in March 2027 [Member]",
        "terseLabel": "2.95% Senior Unsecured Notes Due in March 2027"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2027Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2046",
        "label": "Senior Unsecured Notes Due in March 2046 [Member]",
        "terseLabel": "4.75% Senior Unsecured Notes Due in March 2046"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2046Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2047 [Member]",
        "label": "Senior Unsecured Notes Due in March 2047 [Member]",
        "terseLabel": "4.15% Senior Unsecured Notes Due in March 2047"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2047Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2022",
        "label": "Senior Unsecured Notes Due in September 2022 [Member]",
        "terseLabel": "3.25% Senior Unsecured Notes Due in September 2022"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2022Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2023 [Member]",
        "label": "Senior Unsecured Notes Due in September 2023 [Member]",
        "terseLabel": "2.50% Senior Unsecured Notes Due in September 2023"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2023Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2035",
        "label": "Senior Unsecured Notes Due in September 2035 [Member]",
        "terseLabel": "4.60% Senior Unsecured Notes Due in September 2035"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2035Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2036",
        "label": "Senior Unsecured Notes Due in September 2036 [Member]",
        "terseLabel": "4.00% Senior Unsecured Notes Due in September 2036"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2036Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Intrinsic Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in millions)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted- Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted- Average Exercise\u00a0Price (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage",
        "terseLabel": "Payout percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_StandstillRestrictingTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standstill Restricting Term",
        "label": "Standstill Restricting Term",
        "terseLabel": "Standstill restricting term"
       }
      }
     },
     "localname": "StandstillRestrictingTerm",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_TangoTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tango Therapeutics, Inc.",
        "label": "Tango Therapeutics, Inc. [Member]",
        "terseLabel": "Tango"
       }
      }
     },
     "localname": "TangoTherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Year Senior Unsecured Term Loan Facility",
        "label": "Three Year Senior Unsecured Term Loan Facility [Member]",
        "terseLabel": "Three year senior unsecured term loan facility"
       }
      }
     },
     "localname": "ThreeYearSeniorUnsecuredTermLoanFacilityMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TizonaMergerAndOptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tizona Merger and Option Agreements",
        "label": "Tizona Merger and Option Agreements [Member]",
        "terseLabel": "Tizona merger and option agreements"
       }
      }
     },
     "localname": "TizonaMergerAndOptionAgreementsMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TizonaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tizona Therapeutics, Inc.",
        "label": "Tizona Therapeutics, Inc. [Member]",
        "terseLabel": "Tizona"
       }
      }
     },
     "localname": "TizonaTherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TotalFairValueAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Fair Value",
        "label": "Total Fair Value [Axis]",
        "terseLabel": "Total Fair Value [Axis]"
       }
      }
     },
     "localname": "TotalFairValueAxis",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_TotalGrantDateFairValueDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Total Grant Date Fair Value [Axis]",
        "label": "Total Grant Date Fair Value [Domain]",
        "terseLabel": "Total Grant Date Fair Value [Domain]"
       }
      }
     },
     "localname": "TotalGrantDateFairValueDomain",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.",
        "label": "Total Indefinite Lived Intangible Assets Excluding Goodwill",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_TotalUpfrontPaymentsMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Upfront Payments Made",
        "label": "Total Upfront Payments Made",
        "terseLabel": "Total upfront payments made"
       }
      }
     },
     "localname": "TotalUpfrontPaymentsMade",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_TrodelvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trodelvy",
        "label": "Trodelvy [Member]",
        "terseLabel": "Trodelvy",
        "verboseLabel": "Intangible asset - Trodelvy"
       }
      }
     },
     "localname": "TrodelvyMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Current Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Current Period Tax Positions [Abstract]",
        "terseLabel": "Tax positions related to current year:"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Prior Period Tax Positions [Abstract]",
        "terseLabel": "Tax positions related to prior years:"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant",
        "label": "Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant",
        "terseLabel": "Upfront collaboration expenses"
       }
      }
     },
     "localname": "UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_VariableTermLoanNoteDueOctober2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Term Loan Note Due October 2023",
        "label": "Variable Term Loan Note Due October 2023 [Member]",
        "terseLabel": "Variable Term Loan Note Due October 2023"
       }
      }
     },
     "localname": "VariableTermLoanNoteDueOctober2023Member",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_VekluryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Veklury",
        "label": "Veklury [Member]",
        "terseLabel": "Veklury"
       }
      }
     },
     "localname": "VekluryMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ViiVHealthcareCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare Company (\u201cViiV\u201d)",
        "label": "ViiV Healthcare Company [Member]",
        "terseLabel": "ViiV"
       }
      }
     },
     "localname": "ViiVHealthcareCompanyMember",
     "nsuri": "http://www.gilead.com/20211231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r0",
      "r165",
      "r170",
      "r176",
      "r270",
      "r498",
      "r499",
      "r500",
      "r547",
      "r548",
      "r625",
      "r626",
      "r627",
      "r628",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect from the adoption of new accounting standard"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r0",
      "r165",
      "r170",
      "r176",
      "r270",
      "r498",
      "r499",
      "r500",
      "r547",
      "r548",
      "r625",
      "r626",
      "r627",
      "r628",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r0",
      "r165",
      "r170",
      "r176",
      "r270",
      "r498",
      "r499",
      "r500",
      "r547",
      "r548",
      "r625",
      "r626",
      "r627",
      "r628",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r237",
      "r433",
      "r440",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r350",
      "r388",
      "r458",
      "r461",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r723",
      "r798",
      "r802",
      "r833",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r350",
      "r388",
      "r458",
      "r461",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r723",
      "r798",
      "r802",
      "r833",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r237",
      "r433",
      "r440",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r234",
      "r433",
      "r438",
      "r726",
      "r797",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r234",
      "r433",
      "r438",
      "r726",
      "r797",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r350",
      "r388",
      "r447",
      "r458",
      "r461",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r723",
      "r798",
      "r802",
      "r833",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r350",
      "r388",
      "r447",
      "r458",
      "r461",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r723",
      "r798",
      "r802",
      "r833",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r171",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r171",
      "r176",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r235",
      "r236",
      "r433",
      "r439",
      "r800",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r235",
      "r236",
      "r433",
      "r439",
      "r800",
      "r817",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r171",
      "r176",
      "r329",
      "r459",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r53",
      "r689"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r30",
      "r238",
      "r239"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r22",
      "r746",
      "r779"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r24",
      "r746",
      "r779"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r751",
      "r787"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Future royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r50",
      "r318"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": {
     "auth_ref": [
      "r86",
      "r93",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r93",
      "r103",
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r33",
      "r91",
      "r92",
      "r93",
      "r781",
      "r807",
      "r808"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r103",
      "r104",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r90",
      "r93",
      "r103",
      "r104",
      "r105",
      "r162",
      "r163",
      "r164",
      "r591",
      "r803",
      "r804",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r85",
      "r93",
      "r103",
      "r104",
      "r105",
      "r591",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated useful life of finite-lived intangible asset acquired"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r31",
      "r501",
      "r689"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r498",
      "r499",
      "r500",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r141",
      "r308"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r462",
      "r464",
      "r504",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r464",
      "r495",
      "r503"
     ],
     "calculation": {
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Stock-based compensation expense, net of tax"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r37",
      "r240",
      "r271"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Less: allowances for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Write-offs charged against allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r141",
      "r298",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense related to finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r153",
      "r217",
      "r227",
      "r232",
      "r269",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r585",
      "r592",
      "r652",
      "r687",
      "r689",
      "r744",
      "r778"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r71",
      "r153",
      "r269",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r585",
      "r592",
      "r652",
      "r687",
      "r689"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r631"
     ],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total assets, when it serves as a benchmark in a concentration of risk calculation, representing the sum of all reported assets as of the balance sheet date.",
        "label": "Assets, Total [Member]",
        "verboseLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r245"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r246",
      "r249",
      "r767"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Amortized\u00a0Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r246",
      "r248",
      "r766"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r466",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails",
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r604",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails",
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r11",
      "r317"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings and improvements (including leasehold improvements)"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r457",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.gilead.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r457",
      "r460",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.gilead.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill expected to be deductible for tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r561"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related expenses"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r570",
      "r571",
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r569",
      "r572",
      "r575"
     ],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Liability for MYR GmbH (\u201cMYR\u201d) contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": {
     "auth_ref": [
      "r567"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory",
        "terseLabel": "Fair value step-up adjustment of inventories acquired"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Aggregate fair value of acquired IPR&amp;D",
        "verboseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "Intangible assets:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r564",
      "r565"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Finite-lived intangible asset",
        "verboseLabel": "Finite-lived intangible asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r564",
      "r565"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r564",
      "r565"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "auth_ref": [
      "r835"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.",
        "label": "Capitalized Computer Software, Net",
        "terseLabel": "Unamortized capitalized software costs"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r46",
      "r143"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r135",
      "r143",
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r135",
      "r653"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r150",
      "r153",
      "r179",
      "r183",
      "r184",
      "r186",
      "r188",
      "r197",
      "r198",
      "r199",
      "r269",
      "r336",
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r386",
      "r387",
      "r391",
      "r395",
      "r652",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r62",
      "r328",
      "r752",
      "r786"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r324",
      "r326",
      "r327",
      "r332",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r333",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Contingent Consideration Resulting from a Business Combination and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Capital shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividend Per Share (in dollars per share)",
        "verboseLabel": "Dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r162",
      "r163",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r29",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending period (in shares)",
        "periodStartLabel": "Beginning period (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r29",
      "r689"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.001 per share; 5,600 authorized; 1,254 shares issued and outstanding as of December\u00a031, 2021 and 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r98",
      "r100",
      "r101",
      "r113",
      "r758",
      "r792"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Gilead"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r98",
      "r100",
      "r112",
      "r583",
      "r584",
      "r596",
      "r757",
      "r791"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r98",
      "r100",
      "r111",
      "r582",
      "r596",
      "r756",
      "r790"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Office, computer equipment and other"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r237",
      "r650",
      "r651",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r237",
      "r650",
      "r651",
      "r810",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r237",
      "r650",
      "r651",
      "r810",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r202",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r206",
      "r207",
      "r237",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r237",
      "r650",
      "r651",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r412",
      "r413",
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Revenues recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenues recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized from performance obligations satisfied in prior years"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
        "label": "Contract with Customer, Refund Liability, Current",
        "terseLabel": "Allowance for sales returns"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r448",
      "r456",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r116",
      "r726"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r154",
      "r543",
      "r551"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "negatedTerseLabel": "Current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r154",
      "r543"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "negatedTerseLabel": "Current"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r154",
      "r543",
      "r551"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "negatedTerseLabel": "Current"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r205",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r364",
      "r371",
      "r372",
      "r374",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt and Credit Facilities"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r22",
      "r23",
      "r152",
      "r160",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r377",
      "r378",
      "r379",
      "r380",
      "r667",
      "r745",
      "r748",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r23",
      "r375",
      "r748",
      "r776"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Short-term and long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r347",
      "r377",
      "r378",
      "r665",
      "r667",
      "r668"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r59",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, stated percentage",
        "verboseLabel": "Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r60",
      "r152",
      "r160",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r377",
      "r378",
      "r379",
      "r380",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Redemption price, percentage of principal amount repurchased"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r60",
      "r152",
      "r160",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r377",
      "r378",
      "r379",
      "r380",
      "r403",
      "r406",
      "r407",
      "r408",
      "r664",
      "r665",
      "r667",
      "r668",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      },
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "netLabel": "Total",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Total",
        "verboseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of the Classification of Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r253",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Securities in unrealized loss positions, number of positions (securities)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in unrecognized tax benefits that is reasonably possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "auth_ref": [
      "r446",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Compensation Expense",
        "terseLabel": "Matching contribution expense"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r154",
      "r544",
      "r551"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r154",
      "r544",
      "r551"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r25",
      "r26",
      "r533",
      "r747",
      "r775"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r516",
      "r517"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r154",
      "r544",
      "r551"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsEquityMethodInvestments": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.",
        "label": "Deferred Tax Assets, Equity Method Investments",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "DeferredTaxAssetsEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Excess of tax basis over book basis of intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r539",
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and other credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Reserves and accruals not currently deductible"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies",
        "terseLabel": "Liability related to future royalties"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r535"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r517",
      "r536"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Excess of book basis over tax basis of intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r141",
      "r316"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r72",
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement",
        "terseLabel": "Derivative Assets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r73",
      "r83",
      "r607"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "terseLabel": "Gross Amounts Offset on the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r77",
      "r79"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net Amount (Legal Offset)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r75",
      "r79"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.",
        "label": "Derivative Asset, Not Offset, Policy Election Deduction",
        "negatedTerseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r74",
      "r78",
      "r81",
      "r647"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "totalLabel": "Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset [Abstract]",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r76",
      "r79",
      "r80",
      "r618"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative, Collateral, Obligation to Return Cash",
        "terseLabel": "Cash Collateral Received/Pledged"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r76",
      "r79",
      "r80",
      "r618"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative, Collateral, Right to Reclaim Cash",
        "terseLabel": "Cash Collateral Received/Pledged"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r72",
      "r81",
      "r82",
      "r607",
      "r705"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Gross Amounts of Recognized Assets/Liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r72",
      "r81",
      "r82",
      "r607",
      "r705"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Gross Amounts of Recognized Assets/Liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r624",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer",
        "terseLabel": "Time estimate for gains (losses) to be reclassified from AOCI to product sales"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r612",
      "r614"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gain (loss) recognized in Other income (expense), net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r74",
      "r78",
      "r81",
      "r647"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "totalLabel": "Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Abstract]",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r73",
      "r80",
      "r83",
      "r607"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Fair Value, Gross Asset",
        "terseLabel": "Gross Amounts Offset on the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r72",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r77",
      "r79"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net Amount (Legal Offset)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r75",
      "r79"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.",
        "label": "Derivative Liability, Not Offset, Policy Election Deduction",
        "negatedTerseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r599",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Outstanding notional amounts on foreign currency exchange contracts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Maturity on derivative instruments"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r598",
      "r600",
      "r601",
      "r602",
      "r603",
      "r609",
      "r613",
      "r616",
      "r619",
      "r622",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r159",
      "r598",
      "r600",
      "r602",
      "r603",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r433",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Employee Benefits"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r409",
      "r770"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsDeclaredTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.",
        "label": "Dividends Declared [Table Text Block]",
        "terseLabel": "Schedule of Dividends Declared"
       }
      }
     },
     "localname": "DividendsDeclaredTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic tax authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r114",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r177",
      "r179",
      "r186",
      "r187",
      "r188",
      "r192",
      "r193",
      "r628",
      "r629",
      "r759",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net income per share attributable to Gilead common stockholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r114",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r179",
      "r186",
      "r187",
      "r188",
      "r192",
      "r193",
      "r628",
      "r629",
      "r759",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share Attributable to Gilead Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r653"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r519"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r156",
      "r519",
      "r553"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r519",
      "r553"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Changes in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary": {
     "auth_ref": [
      "r519",
      "r553"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent",
        "negatedTerseLabel": "Non-taxable unrealized (gain) loss on investment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r519",
      "r553"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign earnings at different rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r519",
      "r553"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Acquired IPR&amp;D and related charges"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r519",
      "r553"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Deferred tax - intra-entity transfer of intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r519",
      "r553"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent",
        "terseLabel": "US tax on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r519",
      "r553"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r519",
      "r553"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Research and other credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent": {
     "auth_ref": [
      "r519"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent",
        "terseLabel": "Foreign-derived intangible income deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r519",
      "r553"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Settlement of tax examinations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedTerseLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock option",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r103",
      "r104",
      "r105",
      "r162",
      "r163",
      "r164",
      "r167",
      "r173",
      "r175",
      "r196",
      "r270",
      "r402",
      "r409",
      "r498",
      "r499",
      "r500",
      "r547",
      "r548",
      "r627",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r803",
      "r804",
      "r805",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r47",
      "r218",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity investments balance"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r644"
     ],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Marketable equity securities",
        "verboseLabel": "Equity investment"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "terseLabel": "Unrealized gain on investment of equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "terseLabel": "Unrealized loss on investment of equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r17",
      "r21",
      "r259",
      "r777",
      "r813",
      "r814",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Other publicly traded equity securities",
        "verboseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Other equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r362",
      "r377",
      "r378",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r631",
      "r632",
      "r633",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r631",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r631",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r362",
      "r377",
      "r378",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r632",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r362",
      "r377",
      "r378",
      "r631",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r631",
      "r632",
      "r635",
      "r636",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r362",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r362",
      "r448",
      "r449",
      "r454",
      "r456",
      "r632",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r362",
      "r377",
      "r378",
      "r448",
      "r449",
      "r454",
      "r456",
      "r632",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r362",
      "r377",
      "r378",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r632",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r362",
      "r377",
      "r378",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r631",
      "r632",
      "r635",
      "r636",
      "r638",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r639",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value, recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r643",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r604",
      "r609",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r154",
      "r518"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "negatedTotalLabel": "Federal income tax expense (benefit), continuing operations"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Federal:"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r251",
      "r252",
      "r261",
      "r262",
      "r263",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r373",
      "r400",
      "r624",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Amortization useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r299",
      "r303",
      "r307",
      "r311",
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r307",
      "r728"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r299",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r307",
      "r727"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Finite-lived assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r448",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non-U.S. government securities"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "negatedTotalLabel": "Foreign income tax expense (benefit), continuing operations"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Foreign:"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet": {
     "auth_ref": [
      "r623"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.",
        "label": "Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net",
        "verboseLabel": "Gain (loss) on discontinuance of cash flow hedges"
       }
      }
     },
     "localname": "GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Pre-tax charge to cost of goods sold"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r289",
      "r290",
      "r689",
      "r743"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill resulting from acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r295",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r291",
      "r294"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r291",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r293",
      "r560"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Measurement period adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r602",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r141",
      "r312"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "In-process research and development impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r315",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r51",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In Process Research and Development Expenses"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r155",
      "r552"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r108",
      "r217",
      "r226",
      "r228",
      "r231",
      "r233",
      "r741",
      "r753",
      "r762",
      "r795"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r155",
      "r552"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r320",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r156",
      "r520",
      "r531",
      "r538",
      "r549",
      "r554",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r157",
      "r174",
      "r175",
      "r216",
      "r518",
      "r550",
      "r555",
      "r796"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit",
        "negatedTotalLabel": "Income tax (expense) benefit",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r514",
      "r515",
      "r531",
      "r532",
      "r537",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r137",
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r133",
      "r260"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedTerseLabel": "Net (gain) loss from equity securities"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r188"
     ],
     "calculation": {
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive effect of stock options and equivalents (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r302",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived assets - IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r302",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r297",
      "r305"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r107",
      "r215",
      "r663",
      "r666",
      "r761"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseLongTermDebt": {
     "auth_ref": [
      "r760",
      "r845",
      "r846"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of interest paid or due on all long-term debt.",
        "label": "Interest Expense, Long-term Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r132",
      "r136",
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid, net of amounts capitalized"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r38",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r68",
      "r689"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r69",
      "r147",
      "r195",
      "r284",
      "r286",
      "r288",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r40",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r39",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-downs"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r811",
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Shares of common stock acquired (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r268",
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Marketable and Non-Marketable Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt Securities by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r259",
      "r742",
      "r768",
      "r816",
      "r852"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Available-for-sale Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r10",
      "r49"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land and land improvements"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Supplemental Information Related to Operating Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Aggregate Future Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Termination period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease term extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r36",
      "r153",
      "r269",
      "r652",
      "r689",
      "r750",
      "r784"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r58",
      "r153",
      "r269",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r586",
      "r592",
      "r593",
      "r652",
      "r687",
      "r688",
      "r689"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r631"
     ],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Outlicense contract"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r23",
      "r748",
      "r776"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amounts outstanding under the facility"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR rate"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r23",
      "r361",
      "r376",
      "r377",
      "r378",
      "r748",
      "r780"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Less: current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Short-term and long-term debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r160",
      "r334",
      "r366"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r160",
      "r334",
      "r366"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r160",
      "r334",
      "r366"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r160",
      "r334",
      "r366"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r160",
      "r334",
      "r366"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r160",
      "r334",
      "r366"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Total long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r60",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValueCurrent": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.",
        "label": "Loss Contingency, Accrual, Current",
        "terseLabel": "Accrual for settlement related to bictegravir litigation"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in loss contingency liability.",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "negatedTerseLabel": "Amount reversed against previously recorded litigation accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r328",
      "r330",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of claims filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r11",
      "r317"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r7",
      "r56"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of Classification of Other Equity Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MediumTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instruments with maturities ranging from five to ten years.",
        "label": "Medium-term Notes [Member]",
        "terseLabel": "Medium-term notes"
       }
      }
     },
     "localname": "MediumTermNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r67",
      "r153",
      "r269",
      "r336",
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r652",
      "r749",
      "r783"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage by noncontrolling owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "terseLabel": "Change in noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r135",
      "r139",
      "r142"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r96",
      "r99",
      "r105",
      "r109",
      "r142",
      "r153",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r185",
      "r217",
      "r226",
      "r228",
      "r231",
      "r233",
      "r269",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r629",
      "r652",
      "r754",
      "r788"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Gilead",
        "totalLabel": "Net income attributable to Gilead"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r96",
      "r99",
      "r105",
      "r174",
      "r175",
      "r588",
      "r595"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestInVariableInterestEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).",
        "label": "Noncontrolling Interest in Variable Interest Entity",
        "terseLabel": "Noncontrolling interest in variable interest entity"
       }
      }
     },
     "localname": "NoncontrollingInterestInVariableInterestEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r409",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Other notes payable"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "terseLabel": "Number of countries in which entity operates"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r217",
      "r226",
      "r228",
      "r231",
      "r233"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r672"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r670"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total discounted lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease, current, statement of financial position, extensible enumeration"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease, noncurrent, statement of financial position, extensible enumeration"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r673",
      "r676"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r669"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease, right-of-use asset, statement of financial position, extensible enumeration"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r679",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r678",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r539"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r161",
      "r211",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r57"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]",
        "terseLabel": "Available-for-sale debt securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r87",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r93",
      "r103",
      "r104",
      "r106",
      "r654",
      "r656",
      "r660"
     ],
     "calculation": {
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Net unrealized gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r86",
      "r91"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r86",
      "r91"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Net unrealized gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r86",
      "r91",
      "r606",
      "r610",
      "r621"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain (loss) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r91",
      "r94"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to net income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r91",
      "r94",
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Gain (loss) reclassified from AOCI into Product sales"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Net foreign currency translation gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r97",
      "r100",
      "r103",
      "r104",
      "r106",
      "r110",
      "r402",
      "r654",
      "r659",
      "r660",
      "r755",
      "r789"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r91",
      "r94",
      "r95",
      "r258"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassifications to net income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r87",
      "r91"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Accrued and other\u00a0current\u00a0liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Other Accrued Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other liabilities.",
        "label": "Other Liabilities, Fair Value Disclosure",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "OtherLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other\u00a0long-term\u00a0obligations"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Impairment loss recognized"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r122",
      "r125"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Payment of dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r123",
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash payments made for acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisitions, including in-process research and development, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire equity method investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r133",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "terseLabel": "Payments to acquire shares"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "terseLabel": "Payments to acquire in process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchases of equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r466",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.gilead.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.gilead.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r28",
      "r689"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt financing, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuances of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Debt issued"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Borrowing under the senior unsecured term loan facility"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r120",
      "r121",
      "r242"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r128",
      "r131"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r120",
      "r121",
      "r242"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "verboseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r96",
      "r99",
      "r105",
      "r134",
      "r153",
      "r166",
      "r174",
      "r175",
      "r217",
      "r226",
      "r228",
      "r231",
      "r233",
      "r269",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r582",
      "r587",
      "r589",
      "r595",
      "r596",
      "r629",
      "r652",
      "r762"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r50",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r322",
      "r821",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r49",
      "r317"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r319",
      "r689",
      "r769",
      "r785"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Other, Gross",
        "terseLabel": "Office, computer equipment and other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r48",
      "r319",
      "r821",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r18",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r93",
      "r103",
      "r104",
      "r106",
      "r654",
      "r658",
      "r660"
     ],
     "calculation": {
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassifications to net income"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r455",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r455",
      "r684",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "Donation expense"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r455",
      "r684",
      "r686",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayments of debt and other obligations"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.",
        "label": "Repayments of Unsecured Debt",
        "terseLabel": "Repayments of unsecured debt"
       }
      }
     },
     "localname": "RepaymentsOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r509",
      "r725",
      "r836"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r509"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r32",
      "r409",
      "r501",
      "r689",
      "r782",
      "r806",
      "r808"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r162",
      "r163",
      "r164",
      "r167",
      "r173",
      "r175",
      "r270",
      "r498",
      "r499",
      "r500",
      "r547",
      "r548",
      "r627",
      "r803",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r213",
      "r214",
      "r225",
      "r229",
      "r230",
      "r234",
      "r235",
      "r237",
      "r432",
      "r433",
      "r726"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r206",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r148",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r436",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r677",
      "r682"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Accounts Receivable, net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r93",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated OCI by Component"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "verboseLabel": "Available-for-Sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt Securities at Estimated Fair Value"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r247",
      "r250",
      "r254",
      "r255",
      "r256",
      "r257",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r60",
      "r160",
      "r377",
      "r379",
      "r403",
      "r406",
      "r407",
      "r408",
      "r664",
      "r665",
      "r668",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Financing Arrangements"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r605",
      "r613",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Effect of Foreign Currency Exchange Contracts"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Classification and Fair Value of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r598",
      "r600",
      "r601",
      "r602",
      "r603",
      "r609",
      "r613",
      "r616",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Summary of Potential Effect of Offsetting Derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Difference Between Provision for Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r464",
      "r494",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r464",
      "r494",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-based Compensation Expenses -Included in Consolidated Statement of Income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r299",
      "r306",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r299",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income (Loss) Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r310",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r15",
      "r41",
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Contractual Maturities of Financing Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r50",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Summarized Fair Values of Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Summarized Revenues from Major Customers"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r466",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r473",
      "r484",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Activity Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r63",
      "r150",
      "r197",
      "r198",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r395",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock Repurchases"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r383",
      "r384",
      "r385",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Stock Repurchases"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r530",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated Future Amortization Expense of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.",
        "label": "Share-based Payment Arrangement, Accelerated Cost",
        "terseLabel": "Accelerated stock-based expense"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of vested stock awards as of vesting date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common stock authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r475",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, beginning balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Expected to vest, net of estimated forfeitures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Expected to vest, net of estimated forfeitures (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Expected to vest, net of estimated forfeitures (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r463",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r466",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.",
        "label": "Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]",
        "terseLabel": "RSU and PSU Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r489",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years:"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares (in millions)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Expected to vest, net of estimated forfeitures"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock (percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r154",
      "r518",
      "r550"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "negatedTotalLabel": "State and local income tax expense (benefit), continuing operations"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "State:"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and local jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r150",
      "r153",
      "r179",
      "r183",
      "r184",
      "r186",
      "r188",
      "r197",
      "r198",
      "r199",
      "r269",
      "r336",
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r386",
      "r387",
      "r391",
      "r395",
      "r402",
      "r652",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r65",
      "r103",
      "r104",
      "r105",
      "r162",
      "r163",
      "r164",
      "r167",
      "r173",
      "r175",
      "r196",
      "r270",
      "r402",
      "r409",
      "r498",
      "r499",
      "r500",
      "r547",
      "r548",
      "r627",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r803",
      "r804",
      "r805",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r196",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r28",
      "r29",
      "r402",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Issuances under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r28",
      "r29",
      "r402",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r29",
      "r402",
      "r409",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r28",
      "r29",
      "r402",
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuances under employee stock purchase plan",
        "verboseLabel": "Value of stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r28",
      "r29",
      "r409",
      "r465",
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances under equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "verboseLabel": "Stock repurchase program, remaining authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r28",
      "r29",
      "r402",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Shares repurchased and retired (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r28",
      "r29",
      "r402",
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r28",
      "r29",
      "r402",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchases of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r28",
      "r29",
      "r402",
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r29",
      "r34",
      "r35",
      "r153",
      "r241",
      "r269",
      "r652",
      "r689"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Gilead stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r104",
      "r153",
      "r162",
      "r163",
      "r164",
      "r167",
      "r173",
      "r269",
      "r270",
      "r409",
      "r498",
      "r499",
      "r500",
      "r547",
      "r548",
      "r580",
      "r581",
      "r594",
      "r627",
      "r652",
      "r654",
      "r655",
      "r660",
      "r804",
      "r805",
      "r856"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r151",
      "r387",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r401",
      "r409",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r661",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r661",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r661",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r661",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "auth_ref": [
      "r511",
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.",
        "label": "Tax Adjustments, Settlements, and Unusual Provisions",
        "verboseLabel": "Income tax expense following U.S. Court of Appeals decision"
       }
      }
     },
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r539"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": {
     "auth_ref": [
      "r558"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability",
        "terseLabel": "Accrued repatriation of foreign earnings"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent": {
     "auth_ref": [
      "r558"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as current.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current",
        "terseLabel": "Accrued repatriation of foreign earnings, expected to be paid"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r251",
      "r252",
      "r261",
      "r262",
      "r263",
      "r373",
      "r400",
      "r624",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Average price per share (in dollars per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r158",
      "r448",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agencies securities",
        "verboseLabel": "U.S. government agencies securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r158",
      "r448",
      "r456",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r513",
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "negatedTerseLabel": "Reductions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and income tax penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Income tax penalties and interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Five",
        "terseLabel": "Purchase commitments, year five"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Purchase commitments, year one"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four",
        "terseLabel": "Purchase commitments, year four"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two",
        "terseLabel": "Purchase commitments, year two"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three",
        "terseLabel": "Purchase commitments, year three"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r200",
      "r201",
      "r203",
      "r204",
      "r208",
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Significant Accounting Policies, Estimates and Judgments"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r178",
      "r188"
     ],
     "calculation": {
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in per share calculation - diluted (in shares)",
        "totalLabel": "Shares used in per share calculation - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r177",
      "r188"
     ],
     "calculation": {
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in per share calculation - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 17
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130611-203046-203046"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28511-109314"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28446-109314"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=SL65897772-128472"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.8)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r837": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r838": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r839": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r840": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r841": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r842": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r843": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r844": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r845": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r846": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r847": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r848": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r849": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r850": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r851": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r852": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r853": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r854": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>118
<FILENAME>0000882095-22-000007-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000882095-22-000007-xbrl.zip
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M/^M/2=7:Q4/KSW$]MLL/E[-/!W:]878U#ATPZ%&JH1UA[^5(U? (%")(QX2
MB[/KM=NN'TWH@6"OE6!__QG!<HP]1)0CR>8KH*1V)"6/H]!K;E*U!.-77P%_
MPJ-EA=2!2F^>2M42!]!X)"FE(TP9CG2XF!JJ8,8BL<0W2"5MFKEP=0\Q8@N=
MHOL#6 8T]]ES&[_BK#_GU)?WY,(^<#KU#\]/'SA#KG,/[U]<R-FWUU3ZX,F/
M;W'+.I]Z_WNYZ-?_^MHN)Q^?QG'BPJ2Z^=%7STCUX-[-;SXYO7O_D^.;[J/?
MO?U=N/51>WSKFX_AYC<WO[OSPU?Y[C=WOK_[Z5=/[CSA</>_[H5V^O69?,,/
M;YU^'.]\<_=T'O?NZ5]/G&1X\P<GY^T6[R0GV.V3D[OW/_CN[NV_WG>U_<.-
MCS[^AV5#U&X.K<ML#+D>B=N;HSPXCMZ"KQ?Z]GM_@SOA1OCHM\!KM26Q4'PE
MS%@@*"N:,K68<N6F!WC_6'AOX*W;G_TC)QK*0X\@83]"EP%'2IR/4F'&KM&J
MPN^"M]%HVKDB=<8:6"LTHUZ:1/\^2 =X_UAXO_K>EX)_E((6*?4C@ $N/[,<
M<;+I+I>.S7KDUAW>^)NBJ"WPL.'^=>R"ZHN&5>X6DKAAR!7D .T?#^V=?W!T
M&#KA42E^H3%*/E(H?B,35\5:4E<7?G]+/X?VG9<3FA<VS-?F9I>_D(>=*>5W
M+Z]SW0[^6]<IYG>OGCQP+"^/3Q^<S,3W]7/W+B8W7DJY_NGQI9/KS^^\?(RG
MW__CESX[A\OSAQ?7CZXW.KS[C'!/H?T]8?OG![+KO.KS1\=]/A['=O'6]0G9
M+^Y:^/"S__=RAO"?/_S>\Z=>/OJ#:T(^?W1Y)1=7'[EF?>^Y- KQ^>=^?.W%
M:?8?WQK3$<0?O^+I*\\?/_^2=UZZ4+]XW2CDW+)[;JH)#560C0H,3@E"J<_$
MN"_!80<NU].=%%?/+E8Y@O#B0,]>>;4K\/#L^.G/?WC-OJ=/GKI/\?#"WGNV
MD>'=K[[\Z/G'G[_T_/'\_"]>S1ASBR;1[ZN&:$:"HVI4UZ*^6H:G5W.>/>W6
MU4S7>WKHW[R:E],<7_[L@CZC\_6+O_F*_@9G<:>NZ#_=H;_MBKYLV5X]\K)3
M5R#\.U?@IW>HK^'7"_V+G]>/'_EI_?2MU^N67)U?_,Z;^6>?GT]^9&?GI\=G
MOW385Z7T2X=XY^6S_Y?,=]TTNI]]&@T3DA0P]W]\_<X M80%5K1G/]N^G5KK
MZ</N7_;XP<EQ.[ZZ8:?J7]&/3V><9>ZUO+RX>O=O%^?]8;NZ=?&E73PZ;O;^
MXV,W$<]%WK-7GW[TS^_\XA%?7*H77[R*E=6751=<H;CB92RYJV1H<?CE%<;<
MGRJ2\!R_-W(#KQ6_\.KXA=>&7PKN[X+V&51"%T"2-?2)4VWL:_PU?I&?X1?Y
M@-__B%_D5\;/W_JZ\(LB/=1FUGK#&H7-N >_([ME+)%6;3^G$_7N%^=/Y.3J
MR=SP>B'MZGF^9XO&M#8*YJ(G, =?$MU-:9H":FM54&S=QG1!,!>QK#T-R)VA
M8AZ(T@A%FK72&V<,/:[:LBX'YC)FMB?V&Y)J*U01@XC53A#J():2N"QP9Z[C
M)LC!8N+<*T8$JMQK#AJA=1?Z$,("-\$J^#8HYSP Q:T&-B!G7?9EP85:RO-B
M3G<XTB[:C!>![>=)ZH__^^'<9G-^^N#\S!]>OBS-_/G3\[,OK\[;=Z_?;OSH
MIT=Z;9&*6L-,X,0>V3T>0"),G9E2RZ&%MAUHWN_]>DN!G/Q-COMG9Q_*@^,K
M.5D)3!U+3SW%WHL@"+%5#(SD!F@P4-@.3*T]/'UX,JLZKY??^;X+NS>/]L@^
M.VOGI[82R&H)J1MP; C8H5#,. P@<8N0=3MWUA=V)<=GUC^6B[/CLV\O5X(/
M<9#6BG*2A*Z(.-00"G,T&,P=-H//W*8S1>WYR8G#\YE?@@N[_ /"!W\,2BFE
MN7])4B+W'X..XAI"6E*'*FM^<R@M=04L<C'WI;$4QDQ)W0>3Y.;?Q3IRZ;O+
MT^EP??C4FKOQ_G@,:U=/D_NWQOO]_,'UWH!KJK[2._O]AY=7\ZO_!74/]NUI
M#BH3F6MLOX$41W*_Q''E/OV3;C'N\/JS$&]V!;@AT*-;.')/'%TP4"@1);1<
M(5427$&H9>?NL.5]8-787/@A&Z9IN[GDT4HI20=D0=H>JF]*=RR/K5M4:0J2
MR0$N%JE:%PL"6'LRT^UANXB;MCS0E-T.QR8X!F+BSD2@W!'8?*V-2P0 _V"@
M_]"(UO*  @CUDM'75\(^LG(K&*HU39U!-@CH&XN#+0^NH&91K -#QAXC2X\%
MM%8(<=9/72O@+6#ZIL+._/HTKO;LJZ.-"!U[ 8E6 \21DGOUOGYN!IHEPLZO
M#Z;&76JIPTHMV!IQSFX+F\ (M12 [<"T<-CY]4&&06/U.\FB5E_69KAH_AES
M=??#$=P,9&\T+//Z\-&"#DE@2[6CB?OXL6 J0(.;CM0V@\\"8>?7AQ*DXNM2
ME4$BF"1J9"3KLW,-B')Y<R@MQM/(B5I(- IC)R#*/12AY&NT.T!]=WEZ"#LO
M>>=(HT ,(:>Y$=Y8+0NG46.+U+JF V]V%+BL[AR57B15P-CQNF= 96 LCF?"
M%6S7W-$5:@<VKH718K%:DS2DT-A0.F9_*I86.6P/VS>;4E@&U>:@,L180@OH
M@E(+2QPR--?(UFA[J"X2O%H&7,I1 T#$#N[&92._8:&(KZ60U7V%#8*[=$YA
M&:#KJ"JU2(X9L6DGSA4"YM0157&#=_$;RRDL ^@(KGS#B*KFOK[_5T:KM8?H
M/OX<(/'FBG_7C./KJDI^"1HF2*FXN(U6T9H2=3>L3?T_%)O4S4"S0-CY-<)$
M <0R03>=S1@*@=M&$;/&6'OA[<"T;-CY-4(FRL*]@F6,B&':/BDAR1@]2]6P
M&<C>9%CF->(3$^9<,6;-&8L:19U= =DEAG"-MAE\WGS8^74:ONCZKP&U.MM=
MMT[))'3!$F18EU_LKK9NN-ZPG[Y((?3U<#"JJ70H2)%5FO62"P:)6#)L#]5%
M(FN+8%M2::(2J;I$4>R<,VEJ+?M]S-C7T/%E5Z7E\N!22-"35;$TD&E( ,IJ
MU>&<6^KS!L%=/ :S"-"HT:1B[TT808;X6EOZ&"S!1DF_V+1VW4"_N1C,,G<N
MMU%1M*  -A6:K8<;-7+PQJ#XYEK0K1G'/Z0W'O7@P,0>-%3$"AQ2S^!K9AD2
M8WN#W0&WLE#^(3"!J0;EWB(0IL)")?:J.<T\(HRV'9@6CL&\/L@$:G&/L0[_
M'U((;@,'%VIJ8@!Q.T;OC<9@7A\^#,UJI-$INIQT-S#'0:D"8,@.2]D,/@O$
M8/XME%YT+GTVCOIG[7"O&T0]>_'Y,7ZM'>Z/[76?_II?/N"S%U_E@"]OS</L
M-SJ!ZYF &(N0-(@<1AQ%,,05J=6_79P[-%=/_G;B:+U_UB>O'LQC?/!DSH)^
MF58?//2KYH3R]SW_\S.WU>>/KBFYR=!12H-3AUY+!$PA4\JS0L*RH]&JK2%T
M-#?+?3'[__^X=^[&\=GQZ</3U[6A\C>1Z(:T>[YV7#SYZ1NW2)U9A6J5:BGH
M,KMGRH!D49)H+@IKBDS]X0#_+A++XU<@\2JI S8;5OOR(B5@0O>A4PN:+>;1
M<RME!=39,:LSE=)#ET&;MCC:I<]1,1V:H+J33RSN-H9(98Q<VDII\TKW^8$V
MOW\#7!7ET&"X<X1CMCB"7#*$!-C<$JUAH?H7K67_\[.OG[UZ^?[5Q?&#$WD=
MZ]$+9^Q3.__V0A[<.VYR\O1;G[DJ[W[UY;:HDJ6DJHIQ=I,>$@0,HLP-0L":
M9"U4^17DYLL?/YPVXG50Y'5R<I6$J9K&J&UN^F/T94FCA#)2J@52:?T7ATVN
MBS#78%X'+J_C+&?R-.1\8,]K8$\OQ"45PR[-G:A$Y,M3K452;B'EM9B;O<=Q
MM(C-E41N&3',\B>U.'IUOR9V7OE8E\TJC$4V[\>08RC9/5]6[)U49\\]#E04
MF**LA"I[J3 6(8Q@B[/-IJ2:$%R26H/I^0(HY8QU_839$X6Q#'M:U=D3/ L5
M[,UF""7UGH1[B1KW<65:)8Z4*\_1M=G_C18[D5DB\*?1O8S**^@CMW\*8Z$9
M9\5I(%!G-U]$ZC.)6YFT$VIWMJR$*ONH,!8BC/K:4%,L(P*V-J37$4F+61<7
MJ;9^PNR'PEB&/:RCEH2Y*26,Q95IQI@R<+V>W596PIZ]QQ$L6\=:8Q^ J(.H
M)THIP-#4GCNF6XE%?7#\G5_41T]6+S$6BEMBE*K01@=!J'.V38G(#2'$P6$-
M=2L[QY57%C6K9 S%D&:HN_>A.*IJU38LMS3ZZ!77LL]LES7&*_)TE?0!TCQ"
M4097%]W7(W'/9N1$$9I+US743QV O,Z7FB\3 5FB&?;8)<P50R.ZLV'0>5/Q
MJ.VHC&5BERE7D8'3D4 .)MRL5,V^CI [$N/ E1U6&8LP!B*+M3GPR.84I":"
M&8H82:A!^R%7LIK%:9DNIIR@<JASF <FG2IC5KB-T'V!&K:6W.P!R!!PS*[J
M+*&CXS3['VK)45JL%&4M(?"=6CFVFBYIR1*69)1 D$BD=W<RF*&YAYJQ';BR
MNRIC&<;TF5O33+G,;"P7"19ZQCH;#J1GSN@*&'-0&<O0QS1::ZG.$0889&C%
MC,!1:[&J,%9"GP.0G//@W(>[J82J3''$H@ M0Z\AKJ6*[=];\U\C5V8QTHE=
MR,>/CJ__?XOQ+X3BCBFW0-%0*#%WR)(":$/_H@W4"RRQ.6,?F!-SB#2X:**,
MG(PMD['4-NH(G-92*[#+JF,?:#2KE )4[A8%0U=V,=MI:.FEVEA-Z?4!T!<K
M2LX8<TX%0T*1QJFD5C):J77$FE82M-I7%;+,8!\.B#;+Z#EB[:) I*U5C;6:
M-5T_9_9 A2P36:TY)BID5BM*:.ZO@I5D.> 8DM923W!0(0N7,T"#T,K(0A63
M.'.R=:9*,;2D"59"HP.@+V2E0*@!66MPN]!$A[8$F7HM?4"0E02U]E2%+!,_
MDVH5P>6&X>S8VZ1GX6$Q1W0UVV']G-F^"EF&.;-TT97KH((Z>\]Q-0D68<1F
M7--:\KL'%;(LC8(49/>6!^A %N&".%KMN;AG!+"61-X!T!]K6 BK<(K!_^B%
ME4+SYWKCF"ODNI+@ULZHD(_LLIUO<R.R#0>_1HF4.EKO4K+,O$SLQ?U9P?53
M90GQL6'"D#.@Y+D;,#(2!'65.EHK.@JS\"'_<F#/K_DZF49D)@0-V#)K&+.1
M"U(E%N*UK$Q[CR.'UB Q0.@#)2>:38RU=&X=K(^XDL#5GBF,14)B6#FE3%2D
M,V8+6HMR+AT+61EQ XFY[2J,98+B=6A.H[H>12P%I,=.0FD$;A3BH7KEP)Y?
M4Q@$+;L3 T$R-D9-#FJKI>1D22JNA#U[C^-H!9"CX]0[INZN18DYLL46$9IM
MH!O/!A7&0F'P.G(;@B5!0 VBW%0&QG3=BC;B^JFR686Q#&'2G.4%,CK,F>]<
MI44H-36K[ISV>,B;'-CS:PI#FZ7<H$J^'GNKN5,5;I)";TVV5;BR81SG5JUN
M-:78"B9J7 =TS"G5B"6';<6B/K6S1^=/UM]+=)EP5\NA)5\D>+:([&&P4X3\
MID_FBK3T;?7=>3-4V7:?+U4(S"%AF9-#76/TP9TQPHR40E]+GZ]=(LSODS2K
M9$]U#=I"8..<<?3.(X>HA(,E0.:U5,>]3O:L$D>&8CA*J*4:FB,(OH24IKW%
M+)%I4[&HS2B,A0H*)(:1280$>R52C00YUIBJUM7,0]DEJFR[QY>J7(\AC[-M
M@DL,R<EL]H7C *,^*V \$&;W%<8B[,F5C*/D%FQ@;)TJ)QL=>V28?LT>LF>5
M.'8,G4J*OF!DI%[5T8R4:8RJPGE;79NVHC"6"7=E&3VC^IV?(^92A2D1RBBE
M]R)M+5F27:+*MOM[)5/&)MUF00 %DM:J2,PZ!E0-VYIHL6&%L5!WN%&B&8&C
MB8AJJC@"EP(YAQ&>SG3=,_:L$D>I/3!63<EAQ(!DH:#%E HW=7A7$HO:F7T8
MM[J-2]ODIF#)M0ZU.!LBH(7.J<YND"#^;,^TEH3:CNW#V#!AN-;.$+&U@ CH
M'FFH 3( )TXPUA+GWN5]&!MF3^X0@\8A-7?T9<H=&M3D9@>II4AK*5W;>QR+
M:F,8<_L,8:@X$UT919G5W BL)4NR9PICD7!7A6Z<D\7(@D;1:<,]E"XRI(.M
M)>B]EPICF2Q)%"B<$*I$#'U05HD*)?4D2D^]T'439D\4QC*U)(PAS(T\EB."
M5B(C-6;*@A!U6TG9+>-HN;>0@U9W3-T8:.[%'Y64:IY]0U<2B]HOA;%0T%OG
M^)-"L49#=+5!B;0J:7:MD<-:$FK[J# 6VD5N+',^SF@9T.6HY"@:6@VI22F:
MUD^8_5 8R[!'@SN]+56%5#%7%NI=4V4L!9O16LS-WN/(*1=((_@ZH8@@VG(H
M,P@>$H@]K2C;3"SJRZN+8_7G5K\18Z$)%JFV4BP JF(NU[WJ 2W*<+&1:%NU
M 6^(*]NN)G$MP9"I)*X!:QW"E48<0=)L%5OS2ABSRQKC%7FZ2OKDDHDT#17)
M6.=\1TPM5TC0)ZUL)?0Y &D<HW4(=0Q#4Z+@2(Y.&+-8CFL)?^_4RK'5@A*L
M2( )>V7W2YM(YP ]AQ%I]J1?2Q>EG>+*MBM*?#G(&FJ#KH)<E*I9STBQ-;90
M-M#3;U]4QB+T*40T:IG-VS(&(6Y1YP:?!EA#'-N:9;)E($G;,-862RLHA9E:
MLM9(0I#,4C<5D]J,REBJ%TYN0>:M'Q-&\!M>$Y19CL2CM\0'KNRNREB&,2@@
M6@>D*H(Q-J'6*[6LW'*F2BMAS$%E+$2?46I'G1N%,T(*"KY.::TIN07BD%="
MGP.0R3V*W"MD@X'#W-LH&GJA650"NIJ,R<[LR;A]\?"1]$VV49'1S"H$C %\
M^5#-X&SA.B?^1H8-A+^7V).Q8<($,A*@$A'G#CYW10-FSI%8.57:0,W:XAIC
MP^SI@CI&M,;8,1MQ9Y T2#"+ \PK8<_>XS@P-;^F R@VEXV%4FQ@$6,.!6%L
M8$;S%A7&,G4EXLY#38Y;R\BCNK:0K".$I%I<;:R?*MM5& O5E8PDTK'-J;VF
M08E:ZH-SZF$0K"6[=E 8RT38N1H%7Y <2^R1J(]NZ.09K76HO!+V[#V.ZI(P
M*H71B-PY;5JZL,ZQ,SD;ML.T]UVDRD)Q2Q"AW(50&TH1=RC"*%;<R6A69"TS
MEO=182Q#F%8S9%"Q+(BY9VW.":N6T!>/4-<R96+O%<9">=EF<],.%P-#5.:0
MW:W!(6I:M*YE>M;>XZBY# <0 &9O#"#-0[5K:R&C0BOKCT4]!_$+>V1G#^W+
M>W)A7SXYO7KXP_H;?2ZTW1O<A=!@)?<9]T)?0I3]ON_.I!+S6MIP[21GMEUG
M0@QN70JF)(!$( F:N.5)Q9Q482UC;G9.<_Q^OJZ21HAD%9)T[AFE%78-&[77
MIG8]_V8E-#H ^F,?E)B+2TD:1*Y%F&L+76*W.$I)=0/=XC>M0A:)C<4Q@@I9
MZB-C**2EY!)J#K%T&S .G%F!"EF$.4U3&(3(J34,O;'R;-/C*@0LM+"6Z/A!
MA2Q<  <#*O0*C12K1O>!8FFU="F#]GS16B6@ 6L2"2:<&$-D7U(,L]:4$E1W
M4=8?T]JR"EDH?H8-6PJN0$S=+0%?5K)  QV% ?M:TBX[R9EMUZE4*,G]V)S&
M[$V>9]:E3+L3,A>LJYFL=% AR]*(0-LH@"4*N_T1->S#J,[*ZDRREG*G Z O
MZE:&B-N#:E@[,G5JJAS4169V>X%KF5GP"H!>FX;__.SKU4N/98)F<])OJ*/3
M ,0(1!B*24^JM5>GT($H.ZHWE@J:HPB'U&M/*$6UB,51V=W6U&I<"UUV5F^\
M(DE7R9V,0E#;D,R,[A0+9QOD?DZ7.+>SKX0[>XYB)QI6#*"1H1L AH0CP^S7
MEE5L+7O*=V?!V&IJQ<2:HHY$[D0D4:6YDW2XM*BIY+Z!3CM;51:+T&64H)J2
M8(&,/<T:V,C6Z[#!_L1A!LHZUJ1EDBAIY+D72-V!00E ,&+$U)"&]M'7TA-N
MSU%T8=A"0B70[A9 I'+#0A5+Y5YI Y.<-Z<L%IH1'W!0'J75Y'1Q_&INL^*
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M6=(S#M8Z7&XVE&@RVFBJL<\IK- VD!];1D5LF#(U"E;I**4(LJ\ZU=S$=,T
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M3['[O#FHDD78 VRAY8"N8B.V!FHS"EXJ-?=J"V^@8F@?5<DR39500I9(7<?
MV6H3XTB-2&-.1<8&YHOL(:BAQL2I04HQH;*JCM)"=C/1W(^!M73]WV-5LM"T
M[M(YQHK5G5SLG;CTIAV*"/6"NI9N-GNO2I9A#W3EF!FLBF'I@^=HB-)3M=$!
MMY#7W4-5LI ALE)[CP&,W!JU(I1;C#DWJ4-=[JZ$2@=07\K@)*(<8NX(AIB9
M!"I(*3I;O.=XZ++U&WGS(UN^MI,'<G5-H2T&V5+N-11EJK&AM<"=,)8L[K/T
M%K6OGSA+R)*]H0]71*>)ED 1?0F9D_.2U1%'M)(:KI\^B^N2O>&2R2AQS,9.
MUI%0R!UJ&U$2B>4(:\D''E!]N0-3H1&AUU[R0('!O6@94H;5RB.NI3'*7BN3
M93KJ])*L%73WMJ$@,>3*$4)$&QC:!HBS+\IDF?HHUR'-!'J1B-HZB0IJSE$T
M:CS,B#]PZ3=PB6L=U"0%<&O$0D@MH4IO6&I[VA=J!5PZH/I/"TRDTLB7E"[8
M-$@LH%@LSM%X%M82"-MG9;+08((.D#0%@E$P)1'L@*VY8 FU#]A ><2>*).%
M O 84NLC-\X!>8B"_ZV!T-S\"&_ [NRC,EFHGH^C0:S:FA&J(4<MM:JZ?6K%
M>E\)EPZHOISMK7DP*>16W-O-54=5J!BD&]9-U.,\G7CSX?JGL"T4=C<+49OA
M& ,K=0DM=->L-5;W>74MH\"7)\BV)\9'+M%E:NA5 IH6_ZM7*PES N M)/>6
M41JO2,Y5<B;D1$V%>Z:(;F?412K5:5PZPQBR$L[L*7IS7T\M%D..[DLH<D<,
MW$5*5VBR@>8MVU$.RP2]6FME6*39TR$4DYQ& +7:8QQE-0-1EB?(MB?"!QJ]
MM1@0,6'0K,&2:XG)G2H NA*:[*MR6"9+4MT3B4:UU8(:$_.LDZCF*U&KF&$E
MG-E3]$(2D#A2XIEN5R7 D$LA2"2)= -U+9M1#LL$I:)E,919P6*N*2N%UH9D
M2WDD[!0/!-DQY; ,37IQ&U*:0*H)<T@4*&4",9-(E3<P0VG+RF&AC%A*@#G;
MI .&RMI:C]2SEAY9RUIJX_84O>J2 4*;4RPZEAP=O1F7GIVA8BTZUA\Q^C$'
M]2I#:G9?0"P3F\HP<J*116&FL0;5' 9P2SW.VOAPX,ENZHAEV((M1<U5($9"
M:)43M02AYL@5&=;26VYGV/+[5,LJJ1-+5C&-E"MB F(VKKFF@=*=0AO(COXV
MZJP21$NU"/G2D./< ^'RKT@.0,&**\0M9#(VIRH6B5O1[.P%(\9<$ <15:C8
M@WL06>?(O0-/=E15+,*6+ -U9";H#3L4EZ.C=NRI D;2#<2H]T%5+$(=K+&&
MAEAKZFA-R*)E*SF4;B.MIAYM9U3%,O=_+#"3WCF"W_60R:I4Y3!*5VV;&*B[
M,56Q4(G'R"E)U#I*P:(JVEJE9#2;8N2H!Y[LIJI8*#4V.DA*P",K6HA2"51*
M)VNACW1@RQI4Q4*C=@9Q(NF=91:Z@W08H33JJ<RYGVNI)=L55;%0!D31502T
M8-30DE &-P&#,+7$0]8RF_G70+0'?A->'5]^\/7QQ</+%P\_LI,KN7[JV8>_
MMM.3X_ZOIN3LONQ8)N@UD%(5<=D!C%)0H3..UH.J"]=-1"YWBTC;SJ%(*B)E
MC!+<VX$>:=0 ,5M2CH7+6KH"KH=.>Y1DH1H#<9\MC"L& #(KJ?112P(H>0-U
M(J^96^M$V?V9B($LS)S]4$K#=4UN;%I*D2T$O7;+@FPU39-C,PPHL0_ F<P/
M I"J(QUAM+&60>3K(=*V\S@12\BU032-;J'<W1(VRC0[D9K[T <Z;4+9+%/'
M8CUU+*D/(>119#C!1C)MO72T#93([9BR603EJE$H6B&VC-F,D>9C<Z!CBW$+
M@;?=LB!;3161)NK5_1ZTCMW-!8U6C+GD2B.'+:04=XM(V\XEI9AC;TA6&F/M
MS.*<JJE+),U]'.S2)I3-4J9*,8;>7"TG[,'MTXBEP.ACUMT4.7!K"R@SFKAL
M+3T#8BQ=8Z]N/5)M@[.-O4HB'%^X-[AZ8;/0#NQ8YGPHAJ(-833M(R$(B_:6
M8U[+/(:=:'/Z6@F[2C8%$0-DS10J#@T<QMQ$64>NURW:U\^FA;J>'JA%S3JT
MF"5 P3 W7^5>(VO,)4I.:S%4!Y!_-5X#@-G$L<."N0V]OO@5&\42F/H^1>4V
MHFH6B?LEG=W;<\6>$34U2HB@ J."68"US'(XJ)J=8!-';56D)HN"T@>'9H$4
M1P-.:K9^-AU4S5*=&LFT%L7,C3&TJ F2^UYNI)09>*^V7FP69%<P&;L[12DH
M<FO2FE8-)6KHEG/=IXC<-E3-,C&_;*GD6*%ICYAJ(7-*=79=W AKW4#7K?U4
M-0O5,]4D8-T]:5]Z7-FP+T2EB2A&X-S7DH,ZJ)K=H]8<3M]';QGPV>RL;,V2
M]!2ZMG%8\+8 LIE:\TN>VJR>11>Q_FBT6*)47Z8V,+_FE4&^MC&K%S4+):!J
M#\QN*C1V1%3&P5 1LL:2:?"!1JO<5[/09(PT1E!(&4$PR6QQ+:4DK% 4H*^E
M7F6]FN95*+Q*9ED=T=2=^-G_E**2L@L8(.0((+Q/57:;Q9AK&"&F4AFB^],D
M96:RF_^3J^.P3]FGC2B:1<)]8R1%8L[-&J;:"0&TSMU9-%JP?:J"VI2B6:8&
M*@Y+KFGB:!4+&V>W3 K^T!2CKB5!<% T.\>LRJ-@ S(V0U6\3FU:3\5ULJ4@
M*V'6 >-?"\3E" U;$:J (0VM8"D*ME#<DL0-S%S8J:5HJXDG Z[%345-S C:
MA+MT'4ZDCJZ6]ZGZ:4N*9ADRJ2N8T<0(#;!1T!!JK@69@)+UM=2G'!3-SC&K
M26D:TQQ'U1!%A7.2Y/X[1$DUKR6C><#XU_;2!->MH"G8G%,'B5V[DFBRE%AJ
M7,M\F7]/1+PQ&FTQR@<MSXAM-09%=W6$B\(H-%!K=/NQ?@;MWBZ:3?((B@!D
MU\5!T$J0T3G6 :CN;6E=RT2T]>J8+9**@FCL 2R[<0HTFSD"<*Z<BE.+]FE3
MQ1;A3:6GPEQ:LXQJQ-IP9$?<\<Z!VTIB;@?ULES4%A!"&X6M" I%#4U+$QYI
MS)F<&ZA%V3OULDQ-@B\OG SJ'.0:.$ARY1)[(@B06TGKY]%^JY=EQK19U]Q:
MA.ZDFH/:.B3)@6:A]F#>IPT46X2WU]1$J8!CB6C(0N*>LZ28VNB#5A)?.ZB7
MY0:AF!:I1@79$$RX:0ZU"?8AKHUM_0S:-_6R4/\\C"4V@V:1D:FS>\G)O\&=
M*8%GF\;7S:.]5B\+D:I))8Q4H;F3E2JU$#)B<HL59Z?&E9#J .__H%Z8I'(8
M(I1P]G, UZFE]N#_<+>UQ&M_!=X/[>3DMEL,>?#DV;LN;UOS:_MP_1,B%QK5
MY)Y+'*7-[F6HT&2D1D"52N+<\EJRC3O)F6U7(@DH5.=,BCD@5W3=&Y-9C>@O
ME)%6PIR=4RB_GZ^KI%'B4E)V-QL'8Q;WM3$,!E V*21K258? 'UA%Z2-X:C6
M(&4VD%)*!!Q-I.>D>2T9H)U<4;9:4)1CF;-&,6!/OGRH4BM*F6J/N4%82ZQ^
M)SFS[>JAE$(!PN96)V.*K)A+M]E\:E0H80-]$/=-A2R3+"SINN"YA#*PA,1Q
M.'N"IEH&/>_1L/LT.@#Z(@Z?:XA3>N214$/D8FFH,LPN=?)T>L"Z0UU;5B$+
M%0&E/I!#)[<%R"ID%;)HRB,+N8X]<&;W5<A">_9;C&CN15$'3)UGL2F4YO:F
M%U+L*V'.084L/-A(8N2A+816D)OS*$@>-3J/6HYMKQ>M50+J][]E23"4!D(/
MI!;B'&LT9P:KYI4$MY;=3W)M=9ZSY8Y=3KK(%B-G5(*R#>I$!4G3;(([ND:)
M+:1*:\G%[,+>D;WA3-,,25*A H B64W<S/3<<+C[6M?2M6OGE,?^$"A S8E2
M!:OH[@\' (DY6)G!M+&!30-[ R6,PMPP0^2"45PUYJH 0>?\NQ['2H)8^Z<V
MEIGY,D82C3/P29BB.QO"Q+U3;.22/*^?+9M6&\LT_DN!+,:.61@KH43FQ$WB
M"%FY'K(M!P+]"[5!3J!<7%CH=<#,!6M+HR*RS/D,:R'0 <JWC[LZ>)0S]=)=
M)P)1Y9#KZ*VCV-/U8P7!JKU3&\M$P@9UJS&/H:%@HJC9,:1L3*T5?KI;<-UL
MV;+:6&@"?&+(+5+*/6/33CG&UK6(SHIP7,N0E8/:6(I D!.G5$U;-6P!N)E;
M(+=! -2$-Y!/V1LHR:2FQM4@15>+0*JI*(5L'1NQKB1,M:S:^*7LV_F5G/S\
M^2_EQ#:Y.SG%.5RP$Y(Q9@@:.J?6^HA2<Q\;F)_RQG3(@4W'.>1""8S% *NX
M7H$"5:JJN8^+A^S+@5J_6[LH%BXC@VATAZE3XQ[CK+ 2R3G:2JAU /G7=QRV
M5'L8M:>&>2B3=AM=E;**U0W$X/=.U2RS?;V9<JTZ& 2CHXL9W>-)H23(&#?
MHSU5-<NPR2R,S%DM%=1 2H,IE)#(":8YKI]-!U6S$+4L\ BC5X@P1^IF"C7V
M$&NG6'-[NL5^!=0Z@/RK%<!*!*6S8#,<S:4,,#3&9)VKE;B2L-M!U2P<\Q,Q
M2JF-U#GA )M3MS7DH"K.*%U+^/:@:G:"30"%,@H7B(@SU!=Q<*SJ,CF:Y@UT
MYCNHFH6H524X@10-.+BJ&0II1@-[Z^[%JVR@K]H!Y.-L<T-]0(D#D0)(%Z;J
M_VYD$=I:JC-^!>3;_I*=/'KR.@S&'K922PP*L_\$6$3K0ZVZ^(U]D(0(NI:=
M]+L@5UZ1B:ND2:O." PY:DC8,D@1?VBE];DG4G#]-%E&AVR9,URB<DZ0:DSH
MSI!D2V *5=EJ*+P2SNPI>A&J:*]M#C/!3.87M41(L7*R5J.N/^BU'>6PS,@;
MBBW7T#H$0';7P6_T#F98+>8TUD*0/5(.B] D#G<_ @<+)6 -[EL"1^I8FI)P
M6TOP?%^5PS)5?I(B&0LFJ*C8E1W. : EI@)Q+9S94_2JI:R)9U>A[KY"4RA6
M)">IE7RU6,LD\7U0#LL$I1 #4,X]SZJK7D#=*YAY^]RUC5YP)039'^6PT-QX
MR ;N/I9!@$0HC<5=2@U*BI77$J#>4^6PT"0KMR&SL__HOOK$.+2 <6 ;[K22
MY?U9>U:)'C!0RWZGYXJH$2G4,+),%.=8J0V,67ZI].G]TP^.+\]/7\L:L8>I
MBQJ!2NFEC6#8:<SNV1'ZR+71;%1W8,L?*EU6R9E"T4I&31D B["&6B3J*!*:
MI+J!P1U+<.;WZ9A5$@C%5Z02VE 6%$D4DI0DK:BU2:/])- JH0P< A?QZSH;
M#YH0SM1WF<U!F*BL)8"]8[9@J^D.KBDUQZXJ1>PS[1TA0G#MD7*N+ >V[+3:
M6(8S;F'Z: -R-FR09G@K005M%JGT#4R5VA^UL4SE24X)2Q^U0IB#N85FD26D
MF&-J&3:0"%E";2P")924I)+K"VU(F3G540IQ@Q:B2%A_9&J;:F.I+E*M.OU&
M*JDC9R5#0_''6.8>J@W$,;>L-A::!%0:8R[6^C!$-&&U$$KN M==B Z<68W:
M6&@@D(4>XI!20L5(47#V[[ $Q)%!UE*ZMEMJ8Z$9+MG]BXJN*[J@.IBY#W=:
MH5L''@%6$J;:H3ZGG]N5'%\<;[*CBU1&BM7O=$V8S00(JTG+56NOM)9,RBYL
MR-@;S@RFVK#DF*GBT"(U"8C3ABQV>-KG=-V<V8$^IULF4"*KU3AIEH8:26LM
M.$IU"3MB?#I^< 4$.D Y^U,.<_&8V-U4+.Z&F-!HI85JI2JO91+Z_JF-9?8'
MI\(CCN#+!_H-GS2@,><P?!E!MK7DW?95;2Q311+!J>)BPT9#PLPS#2_1'9PV
M,J.MGS/[HS:6:0^7&.=HP9":VYG:N:6I6=T5SJD"K&6).D#IGD=.*5HI(Y6(
M(YK:=4:58T]]6%S+Q/.]4QM+]>-JW-0LM 2(<4YQ(AT%$S:_^]-:@II[JC86
MVH>>?(T0RMJ&82N1H!D$)<M:$M2UY&H/:F.Q"C<Q\>.U5F!@EZ(]F*^!+F!+
M%Z*MI6^W#"4!:)P]3+HO&<&7DF$931)+)DA] UU,7H+R"SFSQ_]J&,\;T#>K
MC(,AM#DRKF0RG;$-C11:-J[@-WNSK84TWPA7MEV/0I8,=,QTFZM3+.I>#!M(
MUZK L+5R@C?"F#VJ1DFA=,7<_-\#Q:5% !XY=*C^*.2U).%>*WW6"63%VLW-
M@&1!95'+$TTS' B)UA(3WRD[L-5*%&R0%1MI;QDG@EB3E9X'L'20<>#*#JN,
M11A#@P9,3=H:8\R95%H@\76#@S%OK8Q@PRIC$?JDWL:8F]"GRJ!9ZIJ[Y88!
M1?VUO:3/*H%LUMRUJ+552.@KA?^3<VTQ6ZNI2]Y86&HC*F.A'<2S56\:&25&
M3'[S [C@)2C&8VXA/G!E=U7&,HR9M0-(1!4U81O(V!L'-RQ-2FJPEK9N.\68
M/:H^R9UCS-*2PXD5 Q7A/$803E*1>1_ILTH@025)UN#+!6  5<<QY8K4)6'H
M:YDO_:I WGW2[>3XV]7+C(4"X)T#L&(L"1&T<G'5T8EK8FC6-S Q>@&R;#MG
M,G?M:>_<>B]38FB=,0P-<\-Y$\L'RJQ%:"S#GU[FS@QW>E-,F#A0%>FQU<:%
M J6M)4U>C3^K1++.N6:1-#%&+!5(AC:K0PE'P+:6">*[90FVFC8)K1L6,R@N
M0TLQN9Z@V7&TQ,H6#F399:6Q3*9M5*$V;$ZN0LE1:V2J%C%4CF#E0)G5*(UE
M^%.[Y#"<,36BI4PQU=A2B7WJU+JUK/Z;41K+U)^A97#8F'W%(%+B() "6<@(
MS]S4#06GMJ(T%AI",+M)Q\2#4!$#DZ\AL06&$G6PK*5 :;?(LNW<"8DU-"G,
M21&:4;(P9B?BT:%HV%JV;<-*8Z'67=U7NYPAN!/L"U+6HM7M38C8(?6ZG^O3
M*I&,VL>U2"R]HP/%K;.O)*5R'A#&UB847#]8O<Y8)OQE?0S0R(A:L,&@C%$E
MTDS"(SYM*7N@RDZJC(7JD]SM+*:SM9MAK5%;U@!-:\^]-MA:LNU-$&:/\B9F
M0[K,IDZA8A+6UAQ53M5ZDQS2'K)GE3A2R&TT7S4Z%Z2115U@6 0+VC&$K4TE
MV(C"6&: !6#0F#*Q=6R#J(:4<R\U5'=0=6M=<S:E,);IS0,A60EN6EK!.I)(
MC+4P.&4@2MU:DFV["F.9%&T>B1(R98Y8+%(SU5G7FFMH:K"'[%DECJG,2<U"
MK2LC&S&;:2)(D=2>X;BA:-0V%,9"G7*L15'H0PHBILAI!"=-IJJ!2MU:T<"6
M%,9"4TZX$K0F9@&Q@1-&1N\) LA KENK8=NLPEB&/8-4G1R02#J2^'H4>AU#
MV3#V0OO(GE7B&"@(<BFQYN9W?1?CW#E(F<&,RFUCL:C;YU=R\M-GOI03^U?M
MUG9?<BRT_UN)@@V&5 ,6R%0@E)EO"SUV2EOKTK4(=[:=1TF]1P<SL<R1%2&P
MNA4JK3N#1!37DD?9[?Z@OXNWJZ23]%FSD')OLP=<'YRX%\V4H$!,<2WCEP[
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MR185"JZL^>.@_*7O)RGH4*_S'_M7_G)W?ON*LP_[:L.>'9TT*&3*8DU$+-H
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MS;.@YM8L6:FA*."BXKJ5^2X NX>+VIIX;(+H;5HITA).L$VB19,.2*^5G_.
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M8W/7%-PTDP)UIO&8X@ V6*B19CS>:X7RB;'F U;$MS@XLG*<:MJ*50++EO,
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M_^MR<[Z9*HK?2 ?_\)\_?_M"_GTAW+TEUR:A@4$&1Q'%WD Y:HF=ZSH1[U@
M.2&>=\!=< R!O);*N0.R4$OB24+E0?/<THK6QX#6I:38K+44FWIN5@'<4%)$
M9B@MJ8&T%:VS)Y6/DQ.(90Z1.0H"MXZU]]B;3^M@&J4UG[<RV!G%6UBS98K6
M:@$((UJW)M-DL(Z#$%B51:'UE !R0@SV@%V*"22/$&MP6 $Q1<BEYDC%M)OI
M.H?Q4:!U*6E1$.&K!I=H#B/8XF%?0XZQ3DNLM,<5K2N#G2-NN30J731JSA![
M(HY!I(52.=7 "\AJ?<%GO%5_^MS]XON=\N_BN+WB2SY__F1KTU_3--=?^6Q"
MZSV =!8S9 \7W;@+IY9SSXG L(OD*I5"KH&:6YN_35NQ<5]VHTRIFI2KUHK@
M@M-..>:*#E'3(&FG8#=^VOM+WMC7OTWC4/Q\P.3'B^>^ORY?O[@2Z,DBY8 Y
MDI*\).U48P?NC8"-K,02P+GX CIT5J0\C$TA*LVU0O(&0#%BLZAA1'UH6L"7
MW3;^D;(Y($BO(/F7W58_ )5S,2*86HO" <>?H!BQ.S 59JO#X6"?OQ%9H7%?
M$4S,VI(9:I],1R2*)?44.,OP-[BLLZ-96/0#SDSH16-LP6II$+!21<RU5-<D
M1K"L<M59R.: E:")32)Y4 8P*(2$4CM"HA;8TO_WU02%,/[];.X*]+.?\87;
M3[R_>/7+GK?GK).-.__BU9O/O)&C^79SYFS?["ZW=F4-#V5I_^"#O/'.[X+E
MJ]WV+I_@(T S@+&_^&I\G&N5#M-_KU_G]7.O!6J_7_H6PFZ?^0B$U<80IN1]
MX #4NU #8PJ8"(;;7E;OYYP2D/,_!CK@6+3AU5O0WGHQL. B2:B$5MH0.)2R
M*!>R@NA8D677D 1KCP5,B;W7IBIL4XF1Y!.R1%_R?O]JLWWVL[_<[8<O>O)B
M>+F+1XVC XX;#<ZAH(,[ PMQJHX1*+8!L.H+R(BO.)J#/<JU&N8&@PL!0$H2
MDW(E33E-&TEN.A]"#K L'*VU#?.I;1A\/W\6X !HK2&V$2).*3<8/+X@6N_)
MF?J(&K7Q4KWGAZ#U+[OM_F$!^]V+%Y?;W0NWC9Y_M]43KZE8@CX=K.^M0>N]
M#/Z9"4HJTM$,:^24*2XXI%GU:=6G8["IW@@;9]-:'*1$KH-1%5/14MAT 2?,
M\]2G^<8*Q];TDU<I**(9:YF*-8"=**LCQ@@NX#4M:WGMJE*K2AV?]65HB8J-
MD-\9FAAY)\;.T6V$4A"G\[9(-^=MD>:L6_\:*_]S<^$_/>?]"_YSI'SBN5:D
M.Y]KC4L/=:Z5N)MPB20H@ZZK2!LF4KN&FH5Q"?'P9LM;W?#9=P//^\OII]]6
MM+\^_65_99^65W/@83@IP=83&&@TEN)9!@!T2*K*$L8HSTXZ!^Q!E*3B/.A%
M4V 4+.#)>=!W[ZEI/ G=^7;WJ^^W5\\\&V1C.N9WN5B<)A6U6B$CFC>(G#!W
M" :U:1*B>!J:=%19';":!W*TJU6DJ0-'0 \TI-5:PN&2$IV 7MU,C_]=8(M4
MJBC)>I^HGW8 "]S:\%=DU:( V1+6",U94 >L&>C!<[T:EE,@HI.DK&U(JEMB
M]@5TN/RIH+[T_?0>.GCP^8_]JQ%JGM^^WNSUR#4F'-8M.#&8"S)C+BQ:N=12
MEC"'<'[B.> R$RO$'376.NS;(.!E/$I2^E B,%M"Q<V?BF>W?[G;#^$LT@]-
MH\$&LTO1+0)@),SFQCF-R%9K7,)XA3D*Z' :%%/'%L-T+#@B62,<]BUF:I:F
MZ#8N84OW'PGH*DWTLY]?OPF?_;#;7SSC9_YD:U=%]E^P_MUM<2IEI6+6$32%
MKM":<G..S(4,5'71*C4KB1TP&Q$U#"Y7AW@0I)F$H5A1*3>=6LP6$#7=4X?[
M7%1*>]0T"$2N.HS@X'?*?2KD;;V VA+6^\U20 ?4H,;H)90 F"&5CB%&JGTH
M#4L?GFO)&G1=-\C[O_L%RYG_;MUN^KH7HD/2FECLL9<RF)YFH2(QZC6?B'D!
M:;R9BNAP6E2GUN9I-F]O#"UGA*H4J2>*$"B?IA;]WF^\$$5BFRI@>V\(!6(G
M).B I+E+D(P+F)\X7RE]DBY=;C?7(KK*D(S?Z?7]?W%=9'']Z]T^>_LJMT_>
M?CV]S'L%G]LPF%-A69I6#7?@S.18!"O4X>C: EIES_<7G__,V\'8K\0]??D#
M_[9Y<?GB?D_HC]-Y6C"&(2POV04:!A[>3]5+ZB80<0'V]-_=GFVVS[X:(=>S
M[7M(X^T3/N*OFVM_C]D.5A/T$(-OYF+=0\0P#;6RPAFX-LPY6/2 D"F-)U;,
M''+8R U"OM^P;,Z6E.3AIFBI:8L4AFEA,8K)/#3 HKTN8-S(DF"RT'%%@#TG
M3:5&=I"<*$>@0HDUE$$?%G!V^,'RN;LFSP*HLT'*5 F5"K'7,&(*D4@M$).R
MIU+HD9N3N4B)6BPI2K!AX$&\CIM8B'KF02M+7D+%YY]):2BRO1;4RA\_YO2'
M.Z(GY-+2U";!I5JRKD%Z& QR 2T3,\7(LODBM-XJ1\00'3"QA#K$5HV+A]+:
M @9L'Q(6<Y&*3/WL4*BF%("M4&#.YI(H&6!8P+G20EC\T0W\X9+TS7OT/I77
M6H0DA#63>.X1O+K3 H89+@0SQS#X!ZP;=2S0Q'W$?</",$?NUKPH%T+O"^CN
M7Q),%CJT-N60M9O74@PJ 4J57I-+'#@)MH!2H35!\$!(F6K(M+7@AE BRP@N
M(H3 M3%I7@!2'H.4!B,H%*E"YL'RIYTZT\A*]Z'+-?13X)./-4%PR(5V-"(-
MK6+:X&JHPH@"<QUAB)>:ZP(Z%F:*D67S19RF_WG09H,*#$M/+74NJ=81D#9'
M>URPF(M4<BP@P_<"H4)S'>Z6@() :9P%]:;D(P?X;.ZC&H^TKN[=*I WAQ'^
MZRJ0MR[]L"J0UY5 ?KG_IR*@S?D.4FR??_W7GV]__.XE0".2&T8[C,_7AJL7
M[)!J4NP*22GG^4[L_.C*G[D#[%YF7?82)0#$5IW DT@*3CT@0[#BXO.5\QL]
M')L+_W[SJ]MWVW$;GFWDS*^)TA>O?N#_L]N_L</B2D+_[B_U[-+\MQ40_PP(
M:=J8%3GY5/TIW%I):7!ZHYY49JSXM]+X;GC?_B&@^/T'?]KO=,CQ9S_W:233
M8-]?32.7=B\/FNDY(;0 Y:)]FNLYHO41LW-7RS#N/[LUP 6@Y92DH0(XXN\2
MK4_E62XMJPE*LSZL.I;Y2^-$C/F=W^R-H7A7(]Y^>?72WS9*[UXQ3<*;1N/]
M/$CB0F!)*0I::P8=H9=$Z@6=:@W&:-H7%%N<"#Z7$MZ\78DZ0I&I2MFF]5V)
M(FI5SPD+##&'#/.W;A_,3$X*0?=B6U)4MVD45 @16B09KL^:14R -><%Q"\G
M!(K5[;UEKXAKR\(Y^/!\P3'4'DA"+$K%=0&EKG,P% <[5U1MM:<VB(A!#HV@
M.^<2>VLJ5:][VD(,*7]V^V"98OFPT<6?R@3"9S%\EO)=F, [EWX"$XB]&!,D
M+8&@<"(83+*Z6(N($/E:EH&N^Q/'@QP>@RSO_*;?[[;/+GS_8IH3]#[3:YO+
M%[^,Y_^RNSA<\<+T9N\=L_++\[W[?SKOG_IVL]O_=7L^->.Z39_@^QUOOV&=
M3KA>W3N2 ]VQ<?/JTAP.@&3E7K,TJB%VB"KCGS;"HQ2K<VM,-TB^Z;2=]:G8
MO*S2G9MPP\&:<'/$W$-1%@&HTXB#UB@&R"FY]GY;$[$ZEKL=;+[I*SXE0QD,
MAE(!<JY@XZ:%Y-7R<!M.I;^>F_A(I'+G-_WP1,<O^YWYV:_W8*;O!Q?8I\.N
MT T:."I6&=%C(@R&X7;)VZQQL>QSCF5:$_?:6AP6OE>$XC0,"WGNJ6..7'*9
M/VKF;TU>L]2-3J^S??;DV2"(TZ]Y[R5.A[(M&KA6"I._ 2M%R,19F?EJ,7-\
MI+'F(IW/\:-=H C>Q8'+>)"9) Y_Y5&SQ=X8;U*<,-\@]TB>ZI,3@?!&D/<I
M3H,+2+>FA@3&D<ET_#VL0FK=0IV_ .>DD/<B(G0PH#R-)>@P3+4$UF&J>R*N
M/*CA:K&7ZN"/;[^3:FFU9S/V:3"R,/50S;D9UE1P_ISQPX]K?MZ<__V;(=0!
M!M_[^5V.;1YU7!&;!$S5<M$$2@E#C1J]<-#AYBG,'R-',3L?#LRIL48OKI/+
M"\&&A@I"I5AL#*$P.F4#=0N<0/#&-P4([;/;!W,%R95'>#]"OMGM+UX]'=QN
M^R#I8?@LM#NF^M^\]!/<0,\4I%9@(P'.G:/)T.YI58B/[\4%I?KGGGF:#\P>
M_A1":QQ<@R!Q#L *+"E[S=S=K0S*L2"8/68Q-B+7QB/L1P3K@;K5E =?C%&Y
MDBZ@>.1/^QBOK<4ONPL^6T@1B4AHK0T?7"/ M)UFN.56>HN%%2NT^?<NSD<J
M!YQ $G,H!%Y#4)BV96@0:D-OAK RRP(FD<TGI#E@P14.HX5EW*M6 4/GYH%2
MZ]ZUABQ+T)792.5PNN)48C&5\;_!""&H<FX*,4I5 L8%;67_Z5+&%7^]N&E_
M_VX[V,#%;O_J31G=?N]_[P=9M=T_MN=]M__ZMRL*RO_X83CG_8;/[CGM=)RM
M[8&UI=ZS4G2(9ERGV0N 42 ;&L[7*DXMNT\OQJ\]7?^M[Y[M^>7SC?+9M62O
MZH#WKS[_Z]/9V\".U2"(1; *91C$ZL-%Z31^C[*D&<\Z.+8,#L@."O1&)IIR
MAJG%><1$50=%F!KDM,QX-O6?R."-<1-_7<ITT&"AM)PLE4'/)"/6GJ2ZP*08
MC=-B%>+AA'' F1]>M _:G+BEJXVH4S/>(,]3HP+$)?#F#S^7?.>RI[N^.Y?+
M7S?[A2@0<#,IR>+4G!\A852!X4X"1JO6%S!X:RDR.Z">:6I#3AP')8/8"V$6
M\AA1TXA.6SA%/1L/E>6"G_G6O]R<[<[\4OWLJ^^_^/+[A6B:1+:@L<<V&'-L
M;1I5:=/HLA$TC6 IGJ*F'4MJ!QPZQQTH#A>FI4$K1)&9D$45^OCC)'7M@6IM
M#C976JRG80U3;0%B&"YLRMBA5<_>NIZD"WNHXOA#+7V*'2'%GCT:5,UHPCS1
M#N/D/2V@=?7^!C7,18VXIVP^N:B<()0LRKT@6:TU-:IXBFKT,#(Z(/,+!,VI
M@4U3%2G3(.Z4F:UQP]07L&/OHPK[K@:4OGOY0M0J&H$5G<[V!I- )J(F,"R@
MQ18LPHFIU?%$=C@M*ZDC#;W"&(:D>L B7J?)=1T:W&999ZUE"RV0/UA28YC)
MKF1HG"&J<RUD+9&VJ 'JC-/DBQ;@X310HR6(I5:;K&?/PVP&RAE") Z%^'8*
MSRK P\^J.8@ :RHIMQP;JH#V.HW9HNY<8HPF@/,7X'*2'8>36L@@-3#6DH>K
MJTT2MYBS8W.(-2R@2.S#I?:EGYW],K@*OWPU%,\N]>+\%U?>7UPNA6%B0.[J
M-64PZ  2$E#N-5;M:FPWXQ!O*C1G+;[OMKI[X:^/Q=Y?4/;E[OSBQ_Z4S^YC
M1<&[8PGO6JD9#U9G$4L;_$4D^B O::A@[@1N-5#$H9]Y006W,Q/G40IOI_/0
M'CAGH0IIR#5W'Y1F*A; VJTMJ$!J7N(\3A44LYEA%,'A(FM2=J2"(5.$5!OB
M[>S9F#^[?3!7<4[-33_V)_O]M-Q@^MDW9_'Y7O_^]#GO7WZU>_["O]SM7UYW
M5_J@HU_NSLY8=OMKZ=_V6MZ_+<Z?Q3NU6KYSZ2=(NQ2HQ$/0K!6&9V6Q.&3:
M*ZAZJF&5]A](^T\_EOGF\^_]&9]]?76;WOTPIPBFX0@$Q0JP%HAMF/^I8Q^F
M\*CGZ+""Z6/!--52W9#W'_=/??_K>+\W/M&/>S[[9K=_<7EV];8W5YXBQ&*N
MU1/V$6-G8*Z3LU)IIJ0Z>,<2[-6?R/*[[?]QO> 1U7VP1&>*[D4"+>2"'9Q:
MRL,Q:F)#A%(T4VT58EA0S+DX:3]\2*I)6Y>>U)H,YH.2(DQ%SR334I:;A0LA
MM&NS<O5@B=)^LM?+\_=+=8C[Z<5.__[3Y5Z?\Q#_72>,W,G>/1VWPB[/Q@?[
M^K\NKR;37CS?V=1L<GXQO<D_?]?]+_S"W_WL7VQVY[KQK?K#S$1M=[0[[USZ
M*1QJX(_0T4LT"!P%6L<:DPZSD\7D^F1G!>") O"MPZ:W,/4I)_0I3U%\9L@9
MJE;28.*QAN'1C#"=DG5[/X8>$X2.;\-RZ%/;?4<($:QT"0%,.G,(BLUO)L6&
MDFAN,%N2G-\V%>6S1 <P%5-C2TJY2YXF86A$$ITF<78L;9B+>F,JAN@^6V5X
M>%U]4XI_HJMO7OHI<<Z(<! L]2F^2=30,K0A=T2?]J[P.W'.G ^T5]]PCY'6
M6R?PGS+;SSL,ST"LD@ JHTW<%E(NTF(1GO\)_ JS#W%-!^R"T,$>["HT"A!;
MQ XM))@.BD>8#K>[.E/ %3G_A)P?_['U_?GSS<NC0B&DSP(>(J!QPUI,.2!!
MCL*:A&5B*]JD97_-4MHM2YGM@+\U6CXL?;KKC,(W+_T$=U8YQ50P49(&)3=!
M<@1JWKCTR/'&G<6X7*.T O"NCF[\]Y'6[7*[N0;4R_TT)^'%:["\N)[&>OTK
MW3QY^QJWS]U^/;W(^SUG[UTTQ:[-0!I1F89UEVY4P.WV+".F='N6D99+OE:T
MWIG]#V*6[G[.D@[!_GLI+H$'YP<!)\182^EH*4HT[Z>;W7Y,,+N7'+8,Y/2>
MS$,1:+E035QB0T]7#9WU1,YC5QMV;QF,0YT5TS3=0BQAHPS!"@6OP:G&Q*$W
M:@LJ7UZ1N.C*:_,(2$5Z, +MQC4(=@@@C@'J*>325@ ^<):MF)CV:=92(2@M
M,)>D$B%"PQ[: CI+5TP=BKL=;*CG0(\@EB*Y@O=*N06P(CB\9,_F-ZR_QE,]
M2_QIO-BK_?7\XXNK5CR_O'B0*<BA?A8/<2Z</)82&!--ZW9,*#5K45K!:51N
MPA,I(;D6U ^^?^;[81!^?/F6B9B+)7A0.!V_G*0W'1"0TH@ 6E0,A4J0HJ4"
M3@<_IT&X5^S-D&*S>:ZN!I(Z9(LH&K-D[YZUB]1ETZ$5<@]#@ !"1Y\6UH6I
MO*I*EC:-N"(/-3=?P(S%%47'#\V@=VG@P_XXP:!@,FT*&;&988'A#=NRD^<K
MBAXFD5XM!(B%'&N%T@=R1I@?K4;O&:3Q MC4T65Y$,"_?_S1;4/@ W5;'854
M=2F]:LI,=1#ZX0[-"UF$+ DC99NO(5N1-SM[9A" ,8S_'(")N!22KM[1+ QH
M+:" >475LFN:*S7F&DIPDVD:#BEF'APMN974$[VV9[.K0CP0\G[9_-_=EG]Y
M<#[4#F _,C53;$U;':PZ$A44"#HBLUYK>7V<BZE\=OM@;E*\BW9>BVCN]/J!
M@/0N!<+/4KF+R7CGTD\9FD66RN! M7F?D@,L3:LB<^,XW!<M@(6OJ%L<\::I
M^-.E0F0!&FQ;.E;-I%I#HMZ7G<U<P7;?><PDI+%R;,@(6)LX]<28,Y:*&1>>
MQUSQ<_\;HH:7<V\YX#2+ *4J< G9>QKA6KG-8*X4ZZ3P\PYK^J3<I4!NS96R
M@S41\1'L#X_66;@ISQ<_D_!^GC!S+8GIRQ_XM\V+RQ</$9JOR+QO9.9,7BH7
M@.*0N(G57)U*2X05*)P(GW\CL3.WUH9'0^*K1F,:-LZ&-0RFA%RBE0"<!AC:
M;?,KQIOF5SS=M-- Z.[#)'X0+7@ROC:W84E_'A]KB-%N<Y]OEY9N[?N;67I_
M6F3Z$#F.>-?>V#<O_911#Q%[ECX- E)(TJ0%Q8CN5;5T["M0/]5L'H]1K"IP
M-UM=TU0KAN(=@5NCV+6[IJ[C_UCE6@5BN*4%87ZTX$ J\!^[RZWZ$8SU#?Y^
M]F>;\XMK5/Z\>?;\XOQX0(SA[J0A'&C Z3"_?9 %X!$Y96/VSBU.8]Z18O6R
M@/;)%8@GT3W92@AMVBY@"()!H(7>+)0!NIK2;4'M3 WA^\;H/&I O9UF#@?:
M]U1Z94X"@ 01LWC,B3AVBTD(9KQ,>;51,\T\0X3L.N*.E %B*,BM]A&/A&E;
M482KS&&L(<ZO!>TN8OMF<_9L=['9;N3[/QG>_K\W%\^_Y3-^R<]V<\G[W?7S
M?!*68IV\W<?VPKV>S^.7^Y]\/PW,]]= L<VO0\!O7OJ7RQ=#=2]VK\5].ZIG
M<[Z#%-OG7__UY]MW>M\4GW_Z^>F;7_EV]V*S?=_+WMR8Z5.=_ZO7?>LE_NWM
M3__&9>_/<$ZS]PA(K1GDJ$3BM4AOO1:4'&[/CN/L<N\?$,_>79&^VW[E>O56
MTZ_]F#3I.I49#Y$UE^Z]%!QT#QF"",8N$G,O 1LBIRNK/.N-<2NF#F.=Z6">
MOC8-'(2&D2H0K(H MV&S:H_-1?7=>N"X@NLDP?4)9<'Q0 <US0NH%U1+D&IF
MAB;!M%(@J'JS;#A #BL 3Q" ;T^^A<]R.(!UHY8C>:ZQ*X$J\8B#+8_8.-50
M6&R^H?&*J;G&QG7:VUMZ0H@-2NR47#&62)@I1HTW"WSQ9H%OP&6"Z[58GE[*
MN>XW+^<XH/&!'.*T6ACOO%IX7'H8A^C3;*E8,J) &PS?1_A82LZQ60:%:[J_
MXFN9^'J+S;\%F4\9^C\-&LHV2'HQ*,X"(AXEM#Y,(&E=T'+Q%3MS7GLN6#2@
M]&Z5H,5,)06S'H5J[NQQV:F(QXZO>\DTC!<;[*@SAAX@<I%01Z 78O%L):6V
M[&Z:%3+WT$##Q*6%J>7*I]/OPDH>+?0!%R6DA3?0K)"YCY-+$Q@<2))/^ZBE
M<Z26 (HZHF9\-Y^Y8F>9V#E^94XUP6HTA#Z QAT'V8'"5DNV7D*-)]+"L +M
MV T,+;>DQ<&M(I2N7")-LUM&:!<;Y'@B:8!9+P)96AZ@&%NTSLJI@<9&Q!D=
MBDE#AGK5N1YAJ3;I/WA[?N[;GY[S_@7K5<47G]VO:.!P!&4$SBTEJ)H&01D>
M9#PJ6@;/M=3=\$0(RD/): 9$8%#+&G*KTX;6P&UB!35#=50/@Q><"!$XBD"/
MXG!+0QA^%4MO#:B,.#,,5>TYIF$]:\,32:(>0Z#'258&$XZE4<NE0>^5;#S0
M9(FJU^17&AKA5J"K6_P0@<+=!0J'TU"4G$"4=3A2DD(YN(B:,[K#]1'L"?C0
MM\J0_V,0T.TO.V'5W8FN"LMBYH,/>2D B2-SL39NN6OT!NED5H4=3ZQ'\:<A
M>*NU>&Q5H9%S$\D!=>BJ<I53.90\GEB/XU6'_P3HP:<I:="*2A &R=/NHIRT
M7PU6B!C3M5AQ%>L'BQ4G6=U-K'@PL7H-BFK9I"!D4VHQ5RR!S5.=EL5/J0,,
M;9G2_';\&A?\Q=_>SC;]?NF])A%PFL)ZD"3"4+6@4Q9PB =JB\@!'.*43W#"
MZ\E@R[6D1Q72X0Z\B[@$*U'!"W0"JM11JUH<TH-()\)2?YR&9_^1J$XRXX.>
MBD#)%CN#81DT51DP#]/9'.Q4,CY'%>Q1F.J(( NB)H8:("0E<^^=*$U5*Z7E
M$V&JQQ3L<;CJM$TS\Y GU00=$I5AB'NF6AL62#+_0I+O=]MG%[Y_\97+Q23;
M:W'>/OO4MYO=_B^["__D+N7;EYS>Z+OA_/:7[Z#G^KW^NAV_].7>[>I-O[KT
M)R_WF[/I+BZE4 1#D%"R]ZPP*"YGU9H58\C>0N/YEZ.MD#APN5DLO6=,-5-3
MD!*YQU!"5.L:>_^GW2@K-MYXP[_Q?L-RYC\/"_WVFXV/8KOM=^,^[X6W?_^Q
M=Q\8F:[[_KLO?OSYWL'Y),1R]4Y_@-*G_O+BMB?J'I!Z?+JJ%,JP9-/42X=!
M5B4+=Y_:XA0"2UR=WV+ ="^>T,3BB&2RINK0+6.@J,EQ&C%0!V5:/>$2\7'(
M??17VU=<.RAT58'8.(=0W9"JS'B^U,<2ES>Z9/],2 ^.T;E8#4Y&FG/+9 )V
MU0P$;M9J$6L0%M#.L:+B'FQ%3MX;D)<\_$=IV+G4 JJIR BY:?ZV8CZ^Y ]@
MN-G^, T.'O<Q+<140.:N83J>  +!2M)&A%V3*!AQ2?,W%2LH#FXI2G1+.C6R
M#Z99RD!&Z,-*&$;JJ;4%L(H%@.)-NKD4:R$\HHX4R[0;%'H!AI8&$ !2UMXJ
MKM9B4< X8#=H(T^JI>9L$'/B5+A5F :6!6J85XMQ8&#DA5B,7KWSM([6)4%J
MCKUTHA&N]MB .:\68U' .)S% ),V2$6T4 *4W*64(3QCJ*T2MB6,\5\3^N_)
ML95TUQS;/2#U^ G]7EKO(Z#V'@RD3TLJ0N,8N27F>#T8:D7S(L!T/PRZ=6_2
MQ!I/J1CEE ,9.T\C-DG7H^U%XN. 2;J>\H!!&8 H4Y^%U*(:QG>-IB5D"YB*
M^2_$U<H?2.J[#Z(P#P[5N1B/J3ZJ#KLAGAN$0:ESQ=JG3IR<>XAQ_L9C!<>]
M68YHSLV'^2@Y PH)-9<1BW<!#=867T?W@]OF\L4OX_F'\2ZW)'MZQ^]WO)W>
M=:#Q1[W8+8MR8&'IQJJ-,Q@71.RUF"(HU[Y\RO'(@'$XBY$"$XP7[)+2",&G
ME8Z<^XA66F@QXUI\=(C<S&VA)2S$6L!@%ZE'##J5"G#"V R8@F!JZJ1+MQ:/
M"!2'LQ12^F"8D4L"A>J=D$RG$ES#D <A72W% 4#QC<O^DO>OQJTL"S$6'DIW
MBW68# *M?9IIK0TB]>SL'59CL21<',Y>5 >.F#U&(L LE-P"#HJ1O%'5LMJ+
M U:5U(48"Y,<DA"*5X-ID[@RYQ9J<9'"9346RP'% 9E%#0RMM3"0 %P$;7@4
MGQ8R:F@2^OPMQ<?+J)U6*NMPEB(8%/)N54*$UG'\56%PBE(:--<%% VLH#A\
M46+7:L5 8E)H2ES=+ _1->EBZ@NV%$]B"G\ C-^S2B<&C .6&/6K,D0K61DH
M&5:5EA@R@4RS=A=L+1XC, X9A3BH-U4. JDK1B_*'F7\2YS6*.2#D%C_Z'SN
M-1+SGZTMG(O%F+JC4"UT[0T2.4T#1!+7\1L,JA'+_"W&"HQ[L1A$K* !S2Q
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ME5=+L1A0'#);T6E:]-M@ZEG/D4%:2%R-):;4ULSF!Z6\\4]3WF4I9R'8<C3
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MFW/;Z%PG;/W;YK?/]WZ^N]RKGU]_^=S9KCZ/;7[]'_]]_'&C4(-G,O!@FM3
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M<NH/RJ1WDS"$^SH@)/D!][#NG;W(ZW*:W#9YHU6N6ET+KLMAY6ZGURE;W.$
M>+C#KKWS?H];PMF([KL\ORT9> DKN?"C6W'KJ9? 29Z/C5^HE0^J5I*9M1F*
M)46P7/3$;[MR>?C[YSEPJMH0N=&>/3G\^&U\]/&OL^'I>1WV<SZ<?#L;[IW/
MAF=_SRF7 2B@?\-Z7V?#WS\N#^L_JC^_[S=_3(971[#/P_K?LY_?AY>@G,X.
M#Y8HEZ!8UCN\42OW6J9=;MK-9KEG,;/L8"Y2T^[UZHV&5"Z;6ZU<GA[W#T\&
MI$6NIV :CZ);SCE!'DGAO,X+LOCGP[B:;J<$QRFK,$3DS'#"8+)JQX_S9QP8
MUS_PA ZEASOUGR@23X%!.!C3C3!B;!RXH,8<!I6'-*#V*3J,;X+508=\ED+K
MSDHV")W1KRYWJNT.ZY7;EMT&F=,#FX@UK'*U6Z_7&G:]Q<T:Y0*4:[W.HHI]
MNTA@$7]ZIO&G^GKD^^"D>LQ'E)OLQSCK]J61Z]G77V;5KK?M;J/<;IAD$U?+
M9L^JESNM6K?7:-NU&N<[[S\./N_W]XR3W<'^X>[^2<D8'.Y6_HQTK\DG>30L
M[*X7GMF_8E9L(((8@6-D*&.PR#B9<@LSF&S#]8U!'!F[8Q;"5E\_'Y/[9;.U
M1TXW:E5J[=I=8-WL5H"SW;M[H]FK5)OU!W9O"&!OCCGXX&(%DQ+#:1!2@0QE
M(,JTT-W YHN.#AJ@/@V#"USGF;IFA:OCZ!3>=^J=#_>&+?B\=?AQ<#FL#W[_
MF'P['YY^.!N>CKWA[Z_PG37OZF@-Z]_&1_">X>_SW_#_ZH^S_N\?9X?NS^]_
M7PT_#J^./G[]?7AZ_OMP61RMW>XV'<9KZ(!G(,=ZO;+9:E7+O-WJF9TZYO]W
MT;?KL4L6\OOU=;PX]#YE5P.9NBMJP)ZQM?/8>+N?Q]MZMV&;3K=5;M9-P%N3
MU<I=R^R5G7:URYJ TJS1V7G?:Y8;U6:GU>M>B[GWS:&%Z'IHK6NY!_H5L4TC
M"(VC>,Q#0T_=1C4LQV+IL7#$?/<W_?OU0Q#TDT)C<'QBR-JMT,@3'SHU7M_"
M$[FAKIH'YUI]VPYY%,G_?(8-U)XEQ[J[P7=TVO_5K=:MIMUHEGG7 H.OY33
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M ISM[CTDVW<=U?RDC9"^](]/I?I\_T.H'^9DS;5:(<YE -S_S/A'NK;EIQN
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M@:I >Z\';Q/,;SKYDL&Z>&'E1F7)*$R315Q@,YC"G>:[!]GWFA=6,N;FQQ9
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MT#;PJ)(H0BTU@<^I"19)+WR 15$RF6K-^'%YV\7FQB!R!<UR;-=?,8Y@WX#
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M&\=,P=$3V$J<A*FD3%%=[(CK0RTRS,1LJPOF>I13EOX$_8JV+&/ /C]PEFS
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MJOB.2/? E1)?EE&+W+53LM%6?)WS3&DLG_MA@.4B*E,/S6N5EB(26DM"4PV
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MB729_>-Z.5M(&]"0'S*1CGKP [\<P3L\.3PG0?]=?A#%X<GNYUV]A('E])A
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MKBAJO_>*B&WB+B=QZ)JN9[]$TGA +7#+R:)96 W7X4NWT%X4-#YR_R*8%<[
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MALL9^P"BT0P_M8!R8IX^BR,'TG$)^.;UU@Y,NN/4/I1"EE\0@!)@O&$P,?#
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M]#*'*E*<8_5!$O/%="O\'KD2(8=&FV_RR (,)M7JM9=)9]7;FX L_2!8IKD
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MUHG0:'9NG/K9U]?5FO%R45"E7D/J3AHMRFI3.VB%HE"8=\&?^+^K&GL2[.1
MA.#"?\(F#?A8FCF.2M(\WOQCTN.,4"]OFMI],!.<W54KM&YL-O[2),0[ "7L
MYPL!9:14AP.Y:6#P="8\3UTH[=;J>](ST;WOL64^,Q 4[Z6+3.@*8RA)%]#7
M1W6(I[DIR<GH8.S4N9OTTJQ3SJW1M"//171W;=X+&!0@=5$T$9UQX^>_5Y"\
M4:92&U_ET:+N^4X7(FM6T^*:L+'R*G8J38?5KGD^ST3!*:I.YQ.X3H,@GI;C
MYJ1IYZWQHDFSZ*1([-D:T?.1B4D_6.;61"R #9UM:XPMJUPU"D*G#.,E;0A1
MM-4%4)FNEJN"H& ,!Z:U8^DI&(TX00/58V@ [M ]]B09-V1G<8BL:J @^:VX
MH]ZHV<0EW\Y4K,W)5$/GTDV#]Q#$DMF#+WO'LEU7M2&]-9Z7>_O7,/V_HGWO
M;C8?O8Y=@5 Y[CKO2IVL%4!3PX/%JE*?[/5F:GOT/$"P)5DX;NHT,^G;?O%8
M<X(22I@'L?E@<'N7B^O%8C9DO[^S/ BF*4D#9]_W/HT#9.UT7!\]I21G6E>3
M<(VD&Y<-59VE-I*,CE_V5L3-2@R!E@C!.@?2$;K3H!WI*TGWY31?7U2VW!!J
M&*CRUU$M@NCP;.TM4%]<"$-?Y=Z6B1Z%$=)C$/CY5B*/O:XV<LGO$[G#.CGK
MP_4B']@+D?][+.*Q0^_?LO*[3#\;_Y \7T@I!Q',U=#LHADIRE"HQYD$AVV
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MNF2FG70,>7 &#B[(JR@NB)2#'<_)DJI;5TC4M3D_J/>+G#.W];Z8O">*68X
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MT-L)K^GL*7U^/W=?U>*M]WK$YQEVL6A>R0FXQ]O$>)O]>[S-'?-K?\F9?FG
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M15CZOPK5#OF]U"VBR7M.*KMCM%5A.!*N=Q>>+H4R5BI#H&# =452D)(K^-=
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M;$3B)P0;$'@,194RB OV'[[:]6<\BD5)#AT,:_A#/[]_V:$K$N]&@5,$%/X
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M40>R->_Q@N-YQDOW%Z7^T1?O8HM?6SC#D02PD2T2%Y%@)(T+M P] W:=#,'
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M4K#H,5Q*]LF*-.)0#!HLF("K$H'PBBJR2'E:&B4F"V+*32ZWM)@Y@YZ^"UE
M,>&.")ZF?K\+*Q617]Y>6%D)@O"?@.'*YW&8.,RDF)OPN!0NI2+GNB"?,48<
M3=!1*:Z["057R+Y4+_MT>_WA^G&1K,GSF<CS$UP12H1R)VE"-2LD5"/N4UHD
M_9W7W1,>,RQ_AQL(E3?R"Y^/1&TV*A.X5R]0Q=VG-]=+>30+Q)7X>&^RJ1
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M9P+<A1'W"E>\T&)DR1.5.:EBP:_DFN#J6BF.?"(TKP9<" )!VYV<5G2-)EF
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M6!N<]YS )L8Y:,"5!AP-S#%N?!E)06^5AF)I*%+)PMXDVM&!Y^E";7>$=73
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M_V!=36_'0V\]L],X_BFGFN*.A^(Z9KU?=DB"ICA-<4^X-90>RJ'I3=/;$\;
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M1GO#=9654%AZU0@XJV9<.8XKINQY\P)<V_5Z7A^O>5TRA4=2=H77W?)IG&V
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M MQ!FY"''=\3NI1,Q4283)5U"R4A4Y\PP.^"&L^I#]@4O IM?:Q$F@K24&:
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MZCA54+2L+PYQSP^XG?!X'#APV-$\G6R<1#0;3NV@?.=V-\K/0Z8ACU.@1J!
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M 4\PFL$NR""9HMEJC_%&3@B'5ZAYZW+>-G[,/+1:1SC %*<&BI=,X/Y$EP>
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M9419[F*>\V]18$'%^N&YN3+58DR?4+>\$PHLY#..\KX#NG!2)A,Z3U?Y$-)
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MNB'#T!NU>.RZ5KF/>KPD=@QH8E#8K^55+_1V'4#!, $Y!J!1;*^MVQRVR]C
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M[>"(!)\^.%AQ5*W&S_6H-<,"Q,:EO4*Q#XA8-#ASPP'$X('IAWEY:T'Y+]O
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M]Q[C3]]"\//X_!2='+W/Z]OPJCP.^.?^^2[<W_J*A212&P%(!A6@6EL@J9:
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M<AG"G(?V(8BN<[ZHLI7Y-HVM2MSE-8O]PK)(2>R7)/:3%HWT;H@7]@R03%M
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MW$H!K3$#6G(&.35"";ZVF?%UR5[?7J2$;@G=EKSQ*J';(M%MTB[E*E,9RQ&
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M1(N,D9NZ#<X>^$XAGQ=ONB2I?*143MHFRMLD0D .B$(44)PQ("PB .7"9%1
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M\CRC).-:X[7-[(9>0[,#6"IKK[#0+L )F%]HDV._.(F>=!HXA2@3UGK'/M.
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MAPYV(C= Z\P"GAGB,I$9R;CWAQZ3KDR27F5)?\I\99+T)Y3T26<HQ[G)-,J
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M_E'_</SS^,O[9AWO0C^WYL&'OZ_J?IPGY_4;>TWG5'+!#0&&6P>H-@)H00B
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M)6-%96@U&<SW L:$4$IH1(3EJE;$6Z0YUD@(K;0(,BC!-K;TJOH@%B9X.DS
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M.)=M57YU/5L+$3P=(C":42I)X"2"SNR=UB%JZQW\3Q-OU4,305$95L@2\SV
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M"_ JHSR1%K@(?CP[RBEFX((7]:J=%?965LM"-]0*7,T@F5>.8?:JS(5P39[
M/!.[,))\^J8YELK(9B=K&K<[(]T^$.Q,>!KFNP<+IIZZ>5H]MB$VIZVZ(*:F
MN>EPJH?^>#-ICI;-5U+(-P2!Y$5R<7#,CZLJK]>3F5WX1>>7"!-:'^;*!9M
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M$3S0LU22%XSK]7/T%I=8X=J"%$W I#ZPN,8(7>M_+['VLBNHQ-$*AP=_'_N
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MKD(H^4P0W2Z-^,V#UJ&P^>]/' 7XI748_@#F:-]J],?QQ=/O88E F9SO2%0
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MO<6YR2#?P;GR+&>96/(4+>[ 9,X)I+_[/%5S,\X_HH<];8R*PF@0Y8I8Y0(
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M778*++.47%&4!0N'P5.AW&<:4C-;WA\/Y1N$^5)9%I4A- =+9$Z*^,@R\;:
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M9?2RG9UYO/<7Z,J7I&0 Q:Z85-IX9[F5OFB=$IZ/N1QX%[$\+>SG)?G6FJ-
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M\Y;SJ0R\I!+<U.HO:*'V--.<8^[ST9JLHR6T4>>N],P\'AX)GLJJ?73@WG2
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MJ]<REE@NZ&= Q345X'9F%,WBL?8).O@^6=7D64=:,Y95J+72WU%-V!& 9R8
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M7T>J\J59-FCMOA*I7IXL_5QF=YC;NW^V(1NIDP$;SW.0C_YS>##HA+;@,ZP
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M ;PJ "^&/'CCK5-$POG$$CE5+5@851&-R<Y;]FD,=@#? @#7''+.7F%V"-$
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MQ;POX;O%D$Q70(+S3A@<^$ZA(%51*+(5?4+G=5_.ZXS7&>_\R9(L(R;5RB!
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M;\A&YT**:3,T]?KMXO>6Z]_REB6+^N%@PO_<'Z7#R:3LIR.FX,GX+<[&;\M
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MY?N]RMG*65RYF=ZW1KM[#+=7^6D>7K9_ZX,-C*M\_MI@'2U7+IB8C-7)DAC
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M,\%?WQ[X<3?K7S]-J?1VG-D_WS!]>R51.0TS_^GU9T;EXN@DI\'6PP&[<)H
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MD3D!GZ@3B3+/PR3K:0DR!6;MFMZXBT)_A";C*9AX*TS<74@C<!C+Z#A!P42
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MRX$F?]O32I_L]"MU,8A3)HK#*E>D\,E-^&1[Y\T7Q;A--#@D<UU4GN.+QKF
ML!32<AQ#9!6?+#:.71X$*=QP#]Q FYO^BT@I2FDT"H;PG#">D!%4(\6UML ,
M.E3[\>N+^U\SJ&';H3&>L3PGYGKV\O:S87O99@% &1\W1OV[P(HPEG.+@4D4
M%\;IQ"EXFCIY3KUAK"XXN, _"^'#JS709+B7=-$UE3*N8ZDG#Q(^-4L=-K\
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M[S3Y?\ZVS@O$M ZW8$Z[7Z1.''O,D+!2(0ZN%7)16<3 2C?.2J=RUH;F/]U
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MM_ZE\ ;7]<//5\<L4@>,.R"(2PWB+CID=<H_!4ZT,TP8O*3"@V<PG17/LE5
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M$G7@^9:!.HT[^6BA##M4LNXT6U?HO/7W0*^\KT@\GN H?G\UV=9M[!ZC%$F
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MCX(K&_)$Y*16B$ELL728Z0B1DL:WG<6M,AYOP%:7130J6UVJK4Z3C:!%5%2
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M*D&U=&@ZFH2F"-C$N!(H,E&$@1S9F QB&#@5%@F(5I&A4G)9LE7KV&!TK&%
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MD<=*VO),70+#"<LD$Y(R, BC54164(BJ!4M""D,XT_EDO'QZ74)ES*L;1K^
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MZP0-JT49JD3"TNU_JOK">J*]I1XQ+ESNEJ21)5H 6\A'>;G720NP?[E)GUZ
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M4O[D:4#T"*J@\2+ZJ!/KS2AO=EK7_!>R5;/99"A"?=_^6)*@WR]0[FC'@DY
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MD5!DH+>MYL1(&HAFA<\RKQU7$)X4ZTN)$6XU@^G^[U2/$.P+XM-P\D2L_H/
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MH]N!7IK7V^#@FRN!9GR%LZU7J+V((J_*_/--W8B0[:'N&]JDZ5(6 FMX";F
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MP '?(2>%R OGLU#PP'>XPJ^'*YSY)O?'%1H*IMW[,L\D3BJ5IK!@2[+<!Q;
M+Z_!*7>&13M<X<,:^Y.SPZZDRFKJ/4X*HL@V@J-P2XFSRJ35>9:7B&+BZX?<
M[7"%7P!7N!!B/!"N\%//Y0Y7^+!T"W]<']^\ZUJ:.8B)+*%.!\(=,T0%#GY.
MR#*PE04UMMR,#/P!<(6%,SPO2V]5[KDKC3%>* .^<-!&EU:O$1&YL8B :$#
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M)>"1_/]L-%6;CZ94T/@);I[VO^?WB>+ < ',9,)E/M<%YQ:_!)EH-6.824W
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MUYPN<J6[2N[C8D+V=\8^B<*4'("<LC)Q!.1QP-4C'\N#IE'GO$>P ?GBDU)
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M0LH@D^,9(4@: !2K5+7^7K2"KE#X-RYA;X\;CI4JJZJ\EYC-1;5\>;/F'_)
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M6"-NM4#.>(-$/CR6A*1H/N5 \$7W[=HVJ&O$6B/6[DZL.<^(HEQ9;S3'8/B
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M(A^+X5S/9*-\ 6_+N0 5I656RGZ'U,^X:7Q* 1#)8')7'N'\ "K2Z8TZF<:
MN&OFA[&?P%QG_3?'O6X<VOY9*]AC4* 5YUR1Z'(N"JR2'V:#&UY]$K,#:<)1
M%\Y66LZ=@Q.8037M4S#.)GHKWY6_"QL7!MN/ W@6K Y84 F^+0#D -9U,+S
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MX9OS?:*5T5@2I+$-B&NOD,U-@*T-2O&4L*#F,F%X$=7CXARIK>GNV"LY!L\
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MD0-&BT03C<%^MA;SY3DS;W9>?\MBWJYC^'MU9>76^.6#G=IXGS$X0%[Z;'0
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M3EXB(F=J?&)5;_'["'3UU"UAK_#L;[AP%QY?5U\]O<*APD2_Q6YI!;UMNR-
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M43N;R>MR^&_CF-TDU6T<LYM.7NOJ%PUUO0=46Z2N2OBD*/<HV&00ET(B)Y-
M'@2,"9Z4H7AKAZEMOJZTA@T"MR=SCS6Y93<:MZ].?B,/[::="84F%V<9/A**
M>T.&*[B3,3)M'..""J, .;B*1.6.?)Q<4*&SR7O;L!WB<)GW2N<C<%]$J5:(
M<Y^0L8R@&*T)/ 0:F2UY;^N*M[V>%C5.W<:I>Z^\^%: UB2M/1*46^+!2OG(
M:8Z[S3$*SBGDN-.(,0,0)TB4A&WM*+PM[YRT]C1<N(^)PVQ<A<\KE7M26&2F
MI$BN*$)7U@+-!48:O;^>WB^P&XRI9UGEA6 AU[?CR!COD<941,.8QDQN[8AM
MQB]L,]BPBH957-FH_';FT?H:&"PCSJ0 3RF]TYA)-P22MPL$0J1HI;$>2:PQ
MXC9IP! -5"(F;V-0208-9A+>I!/@-9UX;C0 O9XI$KY.M]']U$Q:Z$'?^(U^
ME-]H1DP:O]$M -$O^8TBT8RG2!$&7$2<:X5T<C1W?0'&E5A@,==+(ML7]7VY
M0Q60R]2H.5!M#E2?@>-H!M :Q]$:86[1<01+&:3""B4L'.+.8^2TYB@Z;DV2
MP .+XXAN<]8<H#:.H_4XCBY6[HL<1ZL[$C6.H^OK_6*>K@F!,"]0P"0 O<F!
M$\XK)!(Q24@+OYA<A6::SG8GQU'#*IX)J[A/Q]%Z$&?><40:0^F&2++H.=)!
M"UA4BXCF%G%I.+*8Y;1_PE+"BA(MMG;DG8_7UT@?GD.\T>MO9['TR1WV2AO'
M%ZUNK!KQ#H:@9OF3-,TAW]20I,:!](,<2+G_(["P;AC+S4$O_ZF)1[H;7!XO
M^96<Y4DY[!&6+!M<8&L93ST2#.RPJ(/12I03NPURM#?'@\WQX"/R'5V-98U+
M:8T(M^A2LD09S3%#BB2)N"84&24H8EH21VP"NAA+J92-.DQL8I$>M4OIQCK?
M>)KN"PX60Y3 )$PI&B1SJ6/.!4%.1X*D(M'QE*00:6M';TO2A"@U'&0S/$WW
M2CXF[<2:$*8[ <VB(XJ&X+CV&N%<<)*3$)'&WB(??)#:,$XBV=IA=SZO7W<$
MT[]*9]F=F>[ELQCX:)L13\2\U9[TRJO:_?9CW3AX4/KZSG>:[_0&.46NZOQ;
MF@>/^_]V[&#8@JVZI- %>SYN&YSWYMR .'[SN<%P_=>OXXZ'MNYX.-^1N'4Z
MZ@S;9YUV#"UW7K[1+0Z.,I!*E6% TYR]7G]\A[Q:VZV#WM!VEEYMYLOCYX76
M5SMH_9^;0-D=RRVL'=.6<IK+RR_"UPQM^@GF$H7>$-6C>O38=OM&Y+O?WAY\
M_KKW:>\<1@7_?7U$I8]*4X8 =3#B-#!DL.%(:TY5< J[A+=V^++#?-Q6\L6-
MI,DH;1.-/$D9N,7":":%]T#&0F)6XB)->"Q-R[W]&FG:(&GZ_!V>R?=?'</_
M>_+V .BU#3I0+6#QG$;<2X4T"!#RC <F A4V^:T=,,DO%*?2#OXF$J6MIYI1
MJXGRW&%EHHI*L)"$$IZFD"6*F%JBB&DDZC%)U/$190 -S$ED;% (N#1!UC&'
MK!;,)1&!5?.M'8HOD2B8ZG)\5#5U+0*6)>$%;/V#S(K;7V+G?+LUH5R%^3Q:
MIG.PBFX<Y\XC0%. _R3;[D_Y0:8:%;L9,X7CJKW6U3QA4VJ@W*7I2OGP%4S+
M&YB5></GL3I<UT8.OG\^"B$ .7 689/S,))-2 -9 )M&$&\C=D[E='6\C<6R
M^IT!?2VGC%<PA ODZ(Y,H9&CS0!Q"O\]BEY2*Y-$06N/N/(2V1A!K%12DL&B
M"<9+^+I< >,3.;J:&EP@2G>D"(TH;8HH?3H\TD+0H(Q!42;@ TX28)B>HQAS
MV""6@04!HD2WR660],PXP<NY>)K*PS0.JGF1.0#,R(W] FMR<;X^/>OTSF-\
M'_M?VCZNUJW]7O=+Y<K,:C0HC'KV\U][@^%^;W@887"^=]R%N0FSE1L;OGV=
M+3]#-:%"FX05PI; EH\#1Q;V8*2,XC)B316+6SM\N:_$A&Z#I(VZ_<DR@-1,
MUPE^&0Q!QSJV#@:;XYXO6E]/VOZDU<[^JFG F,M.NLGM>@"3H*\SD6-+;/>L
MX&H>R#V?$]Z;[%8[PYM>O_Y3ON[)G06N36P/#H\4H)'QV"*M*06&@1ER+#)D
M@G,16_A?F<!,G 8RC5W:Q6$[V+X+T-\?J)<[_M0&@6G[:\#\GR!F\$Y9)PKX
ME6T-1*F(3=?'5A'05B6'3V1K^WMLW (:1%0.Y%M_OO\PR,#A8W]HLR^^5M,2
M6'IF^\.Q?]]VNR/;F7S>BO\=M8?G\XC5CU_:,-2S?@^><YKO\#5V.OF_\(0N
M?'+2ACF=>42W@!:(&)K<][3LNX/Q8W_IP0)L5\/,"U(H23UV6Q8']F0[;,'L
MMH>=6(STDUXG /#!G0$+(]"35NI'X"CE#*(D9%<1G9.CB][I::];X^OH#'[,
M(-3N'M?//8Y= ,L.W"#_O4+5N07, (/:W]!)&XS [D_/"%WV^-N#W2-!=7(F
M.<0H#X@319'31B JC>'!D:@<V]H9GL JU*J43V4NVW B6*W>16!'1L,&0ZSV
M!H0Z@@T$^P^CUPU,N8WE4?[YJY* :G-9O9U\[8'TQ>ZSVU'RFA\?)0[S;W5$
M8)%:Q(,FR)D0D:'"&26ST6BW=E+6K[)M+&TFJ=\[+>I:7&V@B@6;MEO9*3?O
M> -% STL5.>_&8- L?/WQB>.]5GC"EVNSQ^G'KTG8Z5,H/R/#% 5%2S@5. K
MO[3U)^WXI0AZGIMLJ;53/C2%%_V<$PKZF?M-MKOC'M@<8U+I>Z-.:+6[OC,*
MXSN5\J<P]?GPM,!GC;+].!SUNV4?@#\6/+>P)!$LAF'LG\+( SP(+LQG\6?Y
ML=/[P7X1N[#&0YC[.!Q4:U]%=,T<ZHZ7M,+L?/J;N2R@<;O4H<]R 3:)'U5$
MV9V/3XC/\R/FSX?+;,$5,$)[WAL-\Q1XF*',A#,NY&\4N;S0N.O6P?1S:"49
M%E93%YCA'.MH(MC:,<I@K'38R-7VW>[^FS%F';<[X>I(.G=1)%VV2F$7[-86
MW!_EW?Z8O-K$:$/TV8'5N^_[WW>/,#!;98)&-N1JTX0 3G$7D-)E$]$8_KZU
MLUQA[__.XGPS6?#1&R9@W0WP;!ZD-<H1[+#'*4O#!;9^(PL_2!:.CU@(P26F
M$2,2S!\F0!9B[J> )64<@RKK;/[@%=+PHF*L)W$0Q^1SD1MVX:>O)[$+$)-Q
MJST< J?]!Z#>8.0F?_CG'+MMG0!!GD'+PF?+8=,B9N>G+X$V?!T8KHOYF17F
MAU6;:(0/,_Z5;73B#ZB?-+<%9XPNKS#[J)[[5+GZ*AH>8BICS;[!R18+ /XJ
M@K!683?5-I3?:A+:4^;LQ=S NBN>WYZ;CHKKPX6QG66[7+^7-:[UJ^UW>N5&
ME?EQ&H<GO0 [\/%YJQ[7)5%)\[3CB?""71""$(H/!#;S6,D&"$EO<E;9*Y/X
MQX+95\OCU#0;=4,]UZ )O/5'QW8KJ:I-HWI)IXH BP8BGH5DS,\N9" P4^TO
M[9!W^1449'A^EL/NLA[!@K>S)C7&5L&O#U_WO[\\DI)'HFE C"4&Q!O8MZ'1
M(N9EX#X&8GS8VNEU)Z96WL*:"1Q/X.&1(=BDH#F2$N=P4RN08Q*,5PU;-5>2
M!F? 6OW:&T]@B5.L'*6KD'4P F2%Z2V*L!8K91Z,+C&3G6*6 ?,D1C->SIB)
MX]DM*[1208=;F\DSGK"JMU-%+F9BH?-FT!Z>'V1_R@$,Z)<.O,NSHQ2O\]D_
M/Z)<.IT=J818C[AC NA$\"A*'X003 O@EV7IVF#OA)?9D6"8,X(Z 6I+.6?8
M.@>$)!F=F(??S!9LT]Z>P5(-^Z.X]8@WI:(RO4ZG][589)4';G0*+P$W&12%
MR/9]\<#F_]:B5?XP/O]H=RL/#,CF3[?:JTM0-TQ _?@Z1KPJW083T;%G@_C3
M^(>?0WMPUK'G/[6[Y77*EWZN;U]%@O^4[[\0(UX>5WW\\]=V&)[D;(AM7&5$
MU&4+ZB?7'V^7CQ8BUZO/N-DFAE[X,=XFM_Q,L(L?>MDW+QLL@=L:T0RV&:S$
M[%JWO:*4QPW2-*^\U"Q=NB(]+-O'L?]CDJCT FRJE3E4^>SA&IET3_7U_UA\
M_6M*S(.F_EWOU?X!5DT= @ &3TY_.1O.QFZ=]D9@32^U;[R;FLR4*<5Y<YQI
M<+.B5.EFRT;%2:^39GJ]EWYFTS<.HT/_X_K_VJF#Z<K/):*NE4/J6CFFKE6"
MZO*Y>'4>OBD2>:E"SQ#"I578!'%=ZP#$-KW&$'X^ R.T<.?"I]M?XL]YUA'=
MULLL-CO<\@T I\@_Y[GVAFO:(Q.+.ZOA8Y>DV_8!N$1"'E6IMZM;2^(-ZA%P
ME3(^R3)O.F(C=-+>4,FUB#:*P') B](Q4*'*<=YR[N7ZRKR]+G%6N]W!L#\J
M;8S+"=_!](1O$C/YI.J\G77V3E_C_>_^Z^'IX?G^*X_W7X5/\,SSCP=O3O=_
M^]@^_/X.QO<:'[87JA&<PGT.WK'][[_ F';A'N_P/MV#]_N]L_?W(?YX^ONG
M_5=OVGL'?[;_]_ON<M])C[V3QB,.RXJX"@8Y;RVRR3!#'/,^Y$0>L[T<-'_G
M_@'7V.\VN8? 7<%BXP#ZQL6 ;S(#CQ0F+\D=NA56KB]EZ/I0^?3SB'XTBB[6
MDL,Q21N9RT=K G&>$M(A6205PSKR(&3 6SO2;.L[][5\=##:\*^;E-FU6ADB
MN)&))YP,T<$PBU6B1GE%&O[UZ)%CL<$!YK# *B&64ZMX8@'E/&8D.#4V<FMD
MS+%ZV_+9X49#OQKZ=6D1W]M 94._G@*(+I;4"R88*X1 AC.+N*,!:4D\6+*4
M,JDY\9)O[6B^K9>S4S<61M?4_:&"/KI-Q8;#WV]5R&;3RN&>.286*8)&>"N8
MY,8R0[R*0GL 4OBKMU>5[?N!9'.^'$;#-6\$DWM+OCYEF#1!1N1RL7-.&$/&
M*HR28)Y'&4BBLA1;6:ZU\N@+GC<%E9\X'[PCK/U 8OC<BOS\:-A;=,YQRH-3
M02!I<RL;HR2RG@?D'/,AY!,.&K9VI-CFFU1SN:$^ZZ<^G"FK"+%1\<!%U"8Q
M(2CG*1+M "T:ZO-D,&"!^B1N,1'1HJ2Y1APGC#1H-G+!8IIL<L2:[&9KVEDU
MS&<S >UBYG-'5&N8SY-!O46_&(_::2494LX"ZM&<]QT(05A1S)A/1D>_M:/(
M-MND%E>WC9-[K(ZOJA7+0X>^/4+R]X\GZ_BJ1*)A?[?"P7?+S4PEQ@X'C80(
M8 %ZX9%3-/?=B2&JF )G&'!P>SDX8RDKY38@M*$'J$^9^#VM;O6/WN4UCV<-
M\5LWX"VZO*@QP4@3$>";1QPP#ADC##+$8:T! (67 'A@[ZXK'FV#<*]A/8_4
MY]6PGKN!0'L1!*RDL/S()^ZR]4>1$;E!#F-2A$ CB2S[O)9MOX;U;)+"-ZSG
MD;J[&M9SOX"WY.X"C%-.<J0MEH@[SW(+9XP4CY$1XCS0XJT=K;?9NJ)IFSBO
MFZO\FUX_Q783Z=5XO&:Q<B(5#?V[%1I^6([V8DQA[B,*"6M PR#!_+,Z=]RD
M+(D4F');.VQ%8N?UZ5]SVKE)].]9G'8^'J=7#6DCP.6&^ZT;[18]7L)&"68
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MD5 T!@AOHI-J:96NT/%ZTD:>P-[*0W#^]N*FF2.ZNA711Z+7J%"N\<>@ZX]
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M!7>:181!NL'C8P892Q2*SMA@F.3*QNSQ3?)KOM/3/ 5XYN[\<@&>10">CV/
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M=;&WNP77;N#MYC@L[.6]";Z]N_=][^1?7_.>P_XZP,+Q+P )OYUL76P?;5W
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M(2CW\)ZD8FD5KSS[V,!;@93WT'EAV,.D$6VW#6/N-6S_LJ*Y7VUX]EX[=[>
M,'OWP=8918-W'-9X".".=[')GU@?24#S6CEV =X' >_'R?"0!S"6+"&E#/AR
M226DI15(1>(29PESS#/P/J=_U73Z<[X^YA9\F0&^/#\T+/@R1_@R'BL:#8ZZ
M21AY[%BNG5#(>JX1D]1BQG@2/I^IQ[?L A2 *0"SF'%B@96IP\J8VZ(<SF2
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MB+C=:0^KB%TK;GP_C>U>''466FN']?@MMCJG)U7&+76Z)[8/ _W>_Y":WV-
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M 6A7H]WI-_P %*?=;YTWKF@BRAG)-^+JC)8=0'!MN.@%ZAX%=9\G^:T#L03
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M8J19Y$@D0T@45I'H0'G)/"GO>TJNU"Q UW@M2T)E,9V0>B&W8O^H$S:O5K,
MV*, [.N$]V$,CMASCAPF"7&A$W). HHIPS56FGGLIU*16Q(F\ZNU,_,^BM9.
M1VO'W0XI36":.&0,1 J L1YI@S62/#IC'='8YNU:(N=(:]]30F34".R\4346
MS)TA.HTTZ ^ZL='MG-M6;CQ5TB$+Z8D\J#"O;K5Z&-L>%KK W:/@;N-LHN5]
MTBH2Y252@6C$.5'(J8114E%9[DE2#O".JF<G@$N.9'XU^G5+;8M&/T^CQSK
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M8=O]?A$G?0!J/^/O9A%^,CMFMWTRB'!=O9< 9TTTA!VD_&R_/CM=JG[$W[Y
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M&C.YV^YQ728YJN\RPZ*Q>% 'B:C.6A#54@X045]^#N>+_@T=)&F.UFL;Y&U
MF=!)-_0NRJ!38'!<%QYPOP2F(9J\ /G2^RCMKRC<&V+,VX19Z9T\\;]UDUY
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M<JF9!@-PD?UHT$-Y>Q:%..IAG@KJGP$X,7ZEK6L8P.3X2'V-:,$T36E+,*U
M8]9K&#%/K^&/,P^O1M^ PHN]8QQ$D?*57V8YDBB%7U,:]IB-@IX-KL+R-3_>
MD2#*QF=%E6H3D6SLNI4$>",=::^73RX;R>07TGI>4%:#-V04"M"8KS2SSYC#
MRBN#KD%/:#0H<Y=PE1,T3\[F8'*HK-L>Q7;Z! :;Q+VY)AWAM5MJ892:-\")
M6PO[3= 2[Q[I#]!S+"Q (U!#G$2IE ,&]#!-*B^SLZ#U(JYZPP@!!@Z?U&.I
MR, 7AK=J,SW5G1%OEQ//B 6D[ 5E7&&L5+E.K%3>O+G:14OE'?5)P>N41(S;
MT,F&.:Q5*CE^A.#WR1!=_VK6&/'97$EHF(\I)35[67*,// 7]4<\A Q8F2=\
MJB8-$9"<L$"V+6,27,JRPONKYHB,+:*RMQGKE4=90A[T.0 ;&#J"5ZJA<_^!
M"1L:W5$Y;F0X)MC,3KI+>3 160? >\+^'B%<,F'DX(=Q_%BQ%3ZY$H/PE=\-
ML<-)=B*UTCC+I7^3_N"-] 50Y4[Z^/%ZE9Y;&^MV!S[Y:X+2?H91HR2-(S+3
MX\UT;7ZT2RQPUA<XW?4L<.H'N,#Y0,J(::R0,((/;3!=1'*;(E5D.E7DZO+V
MYNICA^5]7-]<G;7./]VT.GN1['%$7DNM"2U_'F5^+\E0L9]5.AO-Q.NQ)GV.
M:;5%8V_&=0-GZ9(0AL=\DJ9L":3(><R(!_L*,'^^1Z,XY]@*(;AC(QJ,"(N1
MC[%A?ESZ92SF!'?.NA$-I=8/ZA<L='<5AI'/]A$$Y;VQJU_>.UX8@,<&T9K6
ME#?!>#K]^G2.#:-C]J3Z1KKO1GZ767$!1B)X&/"F %] U8FLFD?T-7M5-8/R
MKS$9:E'@402XZ;,E M75#8R42:3/EZW8 FS9O?K#93]>LX<G.CL3L$+[=.0F
M\8A;2B?<?QJS,8],QBCFV;LX&5/1]))$?+EZW&P9^>+V=+7+(P=+N\=-2S!U
M^VBFCXDP,7*V#,-=SN,J0(&_9D4?Q(3[1RRBCLWCC3*WE;G'P.8CLQHCKWSQ
MK;S[<,1]Y$F-(_<X^KH3R@*!=:)$++6[RH7F2Y/08!%'?G5P\SQ?;3Y'(UV>
MQ-'()I@Z/L --V!"PE?!N4[NQ\ZFSV0MJWFEH^D<\WI#>L=BHL6 N8@PWK&D
M'S]5WI GRP#R*.CYL'A)]^#$U6+RRW!FM?2;'8#6(^_UFI;O]H4B5Q/H/V^1
M=I1M4\4;ZZNV(T?Y48L37,KAA3Y^< K5.>N5T!Y.0#O\5:J6.J3QE=29#F3#
M+*?E!YX4?JU'WJIX(5[,@% O'VGM]18-$> S3C &!7>E+F#2/86'JT$?\R#5
MO*!-F><1CXC"(GE+8I= E(3%40 P1D&[181'S=>G^=Y@QZ?ML*WNZVN^))Z*
MA2TTNQXAG\L3[M:6.E=:6IAC5EE8*"*HHEE6W304R_,2^BJ%6B8VU+4I)]2T
M8GS<TO.!J4>.H^,<CEH"R/P4D6,>""P]XLEH( )/-LH59?Q>3U4;LW:GOI Q
MSKMI(X@XG(4 Q)MQ7(P4,,[W>TQ%4!7Y-R8O'.1X=B>I<LE*KEA/;F0#>I35
M6AYG03PJM0C,2)8X1SQX9&\XY\A_#9 U"I ?N!FU%J!'Z2GQC"']L+X"\3BV
MYNB'JY_,'2G2RL0!VRU%J^'AO,TN]WWK<,IR+1E,@OE1FF-EV\R^JQIG#W=9
M(@]?)D-SAP$K6B>8OI>-C8XA&"C?T*/*D]GGCQ\W[CE+*:N&B:U7^QE'+;?=
MO1/!U&D!OOVE=2.U+]]?W5PT;]M7EWL11GUXS]R* F'KVGY+Q)F0B.FTK_'^
MT9O6A^;-.6XQ!?%HM3]<2K]^NFEWSMMG*"D=Z?:7YJUT?=/ZHW5Y"S+4N6[Q
M&T*&)I2*NYH(;<M^Q.OF#<QFN_T,U-AOT% 5 1HSH'$#LG]UTP'/\'^MLT^W
M[3]:TM7[]^VSU@U?J#R[NKF^NFG>MJ0/5W^T;G"W^IYL4+]=M)S#0B9@Y#*/
M%HUHRBJYE('Z*@>.9]U5+D+"W8 ,C6/<L94.$A[Z\%C&(L;R,"S'%S^R6GX4
M-EIE[$([UVGR8SAVL<NE)5PLJL6M5M@K,2C2K""\@9O1;@M)-9IE0M1$*33L
M!-NP57KM%Y3F91;[Q$[@^I+;5$]',:'Q.E:7DH!5-BO?0(*7>RGG;"66I<ND
M#Y-46TDLW^,/=_*T\#%1;/KVC)\V;@"H [Y=6-,'Q]5;YQ0XXN\":=SAI"A!
MPL*U;.[P9HVJH3UR>^]3C /&P"P!"P:V@-?]C).(9N5*6<694^S>'_22(<[0
ME,,\*P?U)Y#%<+5[',IF+Y7A<DS#G'[]N'9S["C.N5F+;Y5WT4$M'<T>_VL
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MG)8'3I=?+F\WV*VIDZ/X/==H@-I9>%MI++ZWK%E 7MM=J=5''Y,]_XCNE8_
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M="B;)K@2;-DP?NF"R0G_69W,A.Y8 NKGP_6V:UBB +NW_B_B[W6YCH'C)@K
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M@I(=1R&W5$/Z4? ^/L/C/\=NH)ZDM$6N=G9.>L7*M/P26NQD0E_)3I#KC8N
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MB>V=!^3A&M(J&IM QZ?(IX^PRZ,%!MQ.  L)#)@'CR+_GSCDJL2?CKA.8".
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M4?IENNY= X1O[MU])!Y&[D.6U='O=NU$46F78&J*Q00I4)C)K>UKD^@KS[T
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M&G IAFC).>0'FI$AN>='X-O-M;BGL-HY\>/I;+Z:@/-!L:)YL)$ \%+HV<6
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M,2%MR(QUJEO=KB;O<"?HAL.?':5TC-JK\P1(VVJKRR_M6%]U-_!&%57$G/H
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M3+WD>#E?G^A^53V_#W-<G*NYK)EQ2BA@@1$@%*Y>NVE U1N #+=H9)\KTA\
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MPW T9&M.["R!#6M!SU^O/V)8X)__Y?\#4$L#!!0    ( .F&5U3QX31&DKP
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M,#O[A#]^/QV<?!KB\F<?)UC6HE\.N8+2%<Y_UD_[86M,'PG())U&!/HICJK
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MM]<^XL!9?K U^XZ\KZ'ZOV?D20R.E]L/4GN4P@-W5H#B(H-GKM2[_L&X5%3
M#<Y^5C[CP%E^N#W[/AJX!NOJK@\J@UP&"@^,9;4B $4+J 2$;"4*IQD3W9(4
MUSWAP"E^J"W[WB)Y-SX+P]J)>%'#X]DH7]O;4X4>3X-#K<ZKPSHC'7#/@B@"
M4>1N.V5W/N8I7VGMV8@]WUN_:"?\,XZ/*>[_.$AA.+^KS;BTA$> $>A %4GS
MB:G'129F"O>"\;I3':%.]];7PCBHPA7]&+M'9VP.:E'SY"JD<[5W =5[]8JU
M<'9?O:(GNL:M;-WW5+ 67"(DJ=Y_\#)8H+6HIJ!P!":SSZ8()T./4\%N!7!'
M"8M=\K^)B7OD?5[,>W)V]/O[(X]%V6(R,%V]%JEI;:-E#HSW(C!98L"[ZEM-
M,?WE>/SYA_-/7/!\_LV<YCG!E\_;[9+>D^''6UFMY]8$/YW6"I7G+H3&X$,B
M'19.[HGRD4/ NM1A2IS<BQRQORHS5Y_\E'G<RHI-=K]>CV8X&2V:&0^7QRY>
M)JF9AA1"(&^#_(Y0G <O8H@Z:EERMV3V=4]XRA3V9[I=UE)==%88_!OS\B?5
M1K^$_QE/EO41^ZBKNLEC>JNQ^N"QW:BW:HT)/+*4/6:5N8I<1"F<M3*@UR(?
M/>2!VU5[6G1)_L<@X_F3KCWDS96^<P*C+):F3:1X3I@$%/)'R 9-43DIP7.7
MR7CC.E = 6Y?-'J4L$:R52/O!M,_?J/ BGX0CI$?.2E3]7^ 5D )JE[=BCIH
MD('")GKM>.2FR>#O0K7[,[H66KE=0KHG'AK44GV?/F(^'>+;<LL2S\^NOYS/
MS][AI_'D:DOI19Q=2DPL>P6&'&MRKNH]SJ00N%,TEQ?MA-1-I-0#^%U59MV%
MSG;-Y;[KN*Y]OYZ?/<=1^DC+S1_S.) 7C$*60F^6)>^_'I1ZFP,PSXOC!@6]
M<+N9ZVX@V]>VV<Z5<M^,N UC3=HMW,2W1'?N W?!U[2)U'T(]]-!JE]>[Q5-
M#Z3L0SR"7HW  J^MJNG-*?2'9[3X5^Q1!8;>=6I/^$1$<T_7J/UJ9A,N&FCE
MGNK[RY/*4+SDCM>3)E&[]FER"H('I3@K,F6I;MZ3WTU[A'TEUO7+ZF8-$1Y
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MQBE9('OK(\UL+CM9K\?5S9C,@$M:O16W.F*;$ZA[@!V 4%I0L$(B6V_]7S9
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M(<>HLA!%9=[F[F5WC <KG)YHV<%,<]';@)SMY>&>#XXELD'1CJ(W9>N]Y&*
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MDNTH@U%2  :A"'C1;O30!P]@I;\MMQ:X,61ED8!@'2O).*8A%V*!MLRD -J
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M9?DGS+&F4#K,M<658,G5<1]<1P:A<++%"T=N$]>R347@P[B>P"$:EB7;%]2
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MJQ+"JGL>79FZ..:= U8<-SK'I&1V1Y\-=]<Z#ZVW$.P.Q?M&BA\E5;2&DIB
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M0B652Y+,UN)971RRP.GFCC$5ZPT9:=$WH<]A.,^+2 UUM(-2_1)XUU-C;_D
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M7#%JY6PPS,I:Y(?%L) 5>4!16&_!R]PQ)^R!1<Y#N4-)<4>-6R_M7N>];[!
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M;+31?8B>^H@ZC@/;%5N#R+M!FX?;N*Z/SQ6P9(J3@6Y.#Y* )4&_RAE8M%*
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M)=UXR#73TGD6+'J6#$>;4O:V8Z/,P]8]!VXTE/30#93O/L+3Z?8[?+ME&WM
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MBU7N1OAJ/*DUFE^^S!8KH6]N1,TEI\.-%9&0:1-J:^0 ##VOH_7JK7CDW?+
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M*/1PKVT[(7S_)L(PTATP++<"M,;QQW3Q!=.XC#%OYEEV #7X^_I>.*=_8!]
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MGXH"+;I55J#Q\;W$[;W<C""\VLG(A>J?*,XBUC98 @7S:#P+G+Z9Q14'K9[
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MC/^3;.^'^XX\/]+<_V8</>B[^2:O3@9R\M<_JG]/C+S7406.#&6(3/LB:;?
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MR\JY\2RE'*&80)N=Q=HWP6H9G1 F>\UM:4-9V[,BG7/LZV^B$V&K()4G:;K
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M5:2)J^V)13("#)/1\61B;),Y]J?#]P?*@?S[$*E^/$A]<S6?(V536=LH2T)
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M.#S3L(<RSZ[_N/ZH1&S_]W_]?U!+ P04    " #IAE=4?J:(R'>    8"P$
M%    &=I;&0M,C R,3$R,S%?9S$N:G!G['T'6%1+TO8A.01)"I*#!%$0D)P9
M$,D7$"0'R2(Y1X%!D" Y""@H04 DBY)SD"0B&03).4@.#C#,_(/WWMWO@M_*
M[G_O[C[/1\MY/##OJ:ZNKNZNZNI3@_B,F  (Y*1DI0 4%!3  /D/0$P2K$JZ
MF=\#  4%@!D  $P '44(0$7>G4?^(A=H#J C[U&0]^K/7QS]#Y " ,&G)4H
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M"G%\!;D_MF1-V,<C7U TPH"GS?\F.#CX/6H=,YX,F0 _%8M+L*OED0(QX&M
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M#G[D9UTCBR5X%XE4SQ@?#(#5\>[5C;SX0)^2Q]Y#6;)(S]Z,X6*OBZ"78/)
MX0Z$3-_2M2/-C0XL>#=ZG'!32D05 7P=C_,8J T0)C:;A(WJ<E3WI<_)9PG0
M)E4Z]B[W]?W!M:>17;>&5WM6=(8S<-9J6HDW-(M@?@4/P3J5]9;H6LC3+0B)
M#-6D .HG17?DFOL6I1)ZO0\UE26).F[^L^<S?'=WQQ7?/4ALN7;!F.&:D2P_
M & Q1 . 24)'T8;-8_>T$0N[<>N28D<BN)424128AEZJ3K"4'EM*40K$C?).
MTH0IN,B=6XM'OYA3^SU<UU>&05;E%Q]Z#LY /%E2O<IP*1!=WJ)'7M([([;M
M/6V9$.++T_='22F)30S(-*E3?"0!W7^E*\X.I9QJ?)<77(3V=#9"2_P5YC*8
M"(=;VM"W1\.3%3-WTD>#GD\K"O=X4)"7%!J_U/SNP!-,F.70B DE3'+E>THG
MHGG'3ZZ/KPL@@)8]? ?FL9B)Y167/>=DBE;3F%Q>^E4I$4QX\C.>,;KK][/(
M_=5(L=, ;.WJ3S9:@]#M")N"05BPME28<>KGO%>)2-]])BEWOB]IKD!94GD@
M.O@MLD4/_?_YK46R_;F"5_>U[RP)CG94%^>BTW"ZJJ%4 #@$G$JH5:MS7G0'
M\HG:O3PX(K=?./0J]W]*YNR@Y,C"SM:2!1F]+)POM#((WI&[JBVT[XT+[J+.
M;HFYJQBO/=L9;& 'IX[0*WJVJOR.J#"C/"P3W4Y9KY>U=X8I)?]=W<INM<3[
MA.)"_,PEP<BX3VH"6E$&8>>#D18NOP@>EYXU4>_;TIU>V,/E0P\$\"PQISY?
M808!&"P)>L7QN==:OWGPXI"CU*I[I47@DV-4+^5&#<Z[C9#[?%<&];JFE5:L
M98AC))^UV98JE<WHX>&8/ Q'06,B$WU\LGO%: PW:@_/BQYM'R.7 =@SZ<^>
MMDA#"O\H[B*!7$^N:'RW3\]0?S[*?3SH*\R(9PWK\<XH[FBQ.?KUA.L?"&L:
MG=O1G%QQ*P-0*",=F_'%=VDHD(9LXU$@D: 3 ;0].1DN/TY=^?@SL=]M]S/8
M7PBC=IVH!).6^#E8.X_B<<,'^AYJ<6L]CSMP.@B7[)HHD2&=(."TC^GR"FQ&
M.GHWCN(WZ%Q(O\24^OBN+I[M5U&D0Y,:>!0RO8QT9F*N'N"'(7TEPW6DO8=I
MAAS!'[Z;N_\BC%DF%V9$_U0I?\'FJ\_-MI<?4RGL9A]6" 6,-@+A,@+3H.^N
M]!OH.#R YBB,&P"!_Y)VG A+^DE0%IL5S&A0I3BI,K7)1O=I6KSDLU$-X7.&
M3JE!5#)HHGX9W^.E)]3YA$2./#71 6^.@^L6%:L!;&B%[G@A'%*Z;%TD*UKH
M!$," JT3!C$TIQIW*N)FT\21B7FN$E&\_#C4(9P$7Q1[8YS<<'VE!(#0T)E_
M@J,3L-C J4HE8AI"-_E[[])"ETR-/D5=^W*U=]6U$ '([CV97$]#M]%]9RWT
M@RBY:.,T9)_T^XD),J3ORQGQ1T%^#Y$/=#:#3:-T]+HZZIVOT7;?P\P)&,$^
MS&&(U@#1DPI3^M*?LK?E+<&D>7T*[OD+#E\"SVE.==^3-NV\K#EZ0T7ZIGA+
MZJ+>T<;,X?$6'U\6OF_+G$#)LB:'_F(7Q#.*2W7[\;-MK:="-L*O223N?RDR
MB&EE$I[X)\0+)DX.O>6(=3031F(B1\X3>AO*-WS2=E_*# C;0,(&+?\U _TD
M3 -\FJ%_TC/_:\?Y-?+.YE;_Y/?>U&K*T8K^-P#(A*F5Q7!3^&.C08\GR^<E
M'B;E>@&KEH\^E6]06^'NZP<V0NKF$0#-C$AK^F@HL_IMSZR[>K5YP9E-=]GZ
MG;6<O"[>[G6^GC]0]:[7I(30L>W\5BOFM[K=CON+U,"@D_Q@5>' ]F,VD]F,
MZA[3)$FF?%+=%)C+7*4(O51AUU?U7H6'1J$.2NJ.2TJ.&EF,_3'8K.U).94P
MDLR]YZ<2O*K3Z7#_+5KQ8]B53.LI?D^=B=U!'CVVS?$#[=N%0XO1.F6V;_0F
MXLQGT(V%#9PI-_Q&!_FF(O9(JY#3@V$6>'O<_5CL^D\*+/_Z@L'/XMU.3TY#
MYC=2/V&+N.?70P0_NT[P<,QZ/WK3Y11D3G]>086+^;+9934I628 &]">JU*:
ME@?C3PT3\R4\>2YM2?,G>N+TLNO.NY5(3SQLAK-M@(+P&SWU(XC2QX0UPDO<
MJF$WLT,QE'TP6(EZ"HL%E5\5'>R_>1E\+<'_3SI \=.CW*<_W.#H?15)*J0^
M>9<\!@$H?(OMT?C'2ON/B?V$KU,JX4D6CK/YY-0# SAQFOR:B8R1NZE!4+#6
MT^< Z,Y=\Y?0-<7N*J[KO.:L*X?-&0^XU>LQP37ET::==X$G> (,Y KIIBK%
M@A"*PH4_V2O^*&"F/]TC4E&KOWG-G)PG/-"H),$*A\@XVN-=LLJ#A&I)8FEM
M.>96I-=^[D_I1'$O2^*=1[NEU&:QW%81LZW=)9CUC=?.XY?1#L9JB96"W]7$
M6-E4E5]Q2PL6D#6M=+1_CS^2&SAK].""DL=.2*)317'<V!U:V=MII.GW/Z-R
M(!_-'"&0--)QHQ<K7F^!T7</?1@V\%H^7^HHTUWB@"W$84(;&I9NL'G#W/F@
M%B7)R_@\@59+JE?R 2]+YP7I<UGIS9#N%8(&70E"TG/7L"_S WQ/ZUZW$0]!
M*5GS4Z?TV+IO>;@D9V'F3DDVW,Q#MVE->QMP;\*.ZV$O<0:)7Q%_44@8M[90
MO3-MG%G<G-:5:/%0@6=/V\H,#$M-# Q"U0[9Y=YUYZKW*@:U$#"&SYN9&;?=
M<V%\%N$@>R7_  'HU;9O7(37TFQ=[M^1K^9K.Z#V?VT!O[<R;A0]ZIEK3%&U
M>"??K=F#<CH4Z9EO4&?A^3D40MEUGU/IJ!AM=!@!5_8=-.;*0<RR=[[03D3Y
M>ETX.4_2TJP_L4#:271N?G"D\B$7D5AI&"-Y[2%FTE'P91]I/3'^:O.>X?X=
M.*2W#I/.EBUP4TBN]YB1$M&64G7/=;QV@-LU7%9.S\]88W7^VCP_* 4!/$H[
MBDU<?$_S#0$<!2>RA8]O&>+9PB^$Z<,?*1% Q@^1MD+TZQ\\]6M(XPSW;\#A
M"ZWK!^W(.%'$1B#[=F)I.(8DW)( A:\WNI:G54!%+FD(A!YZL0O2H'P44WP\
MA8^< HZ"BFH_<-[_XA9DRU0AM9#R(QQGD(XCQ50ZH87S19VUKF[4\POCO.>(
MMIZC_7K8_9@&'[U?+U6  &XR!8'7X$CWH$VMYT<XU7A1^G[:BKBK521'X5RU
M>\&6!-& '9FK;D#]$B?*#NKOX=SCO((GKQ[%<V]M@ Z1RS72J64^"N@FVQ(N
M^0X(2/ON-+NXW,%,:/$ B + BT)VK@0W9/<4Q:8Y$, )H?YV^.4XOPS4]/U7
M(G.3< 9I4:C\VG@>H_LSL+<[*&KZI)7(M*$Q_'8:^]ACJB<[[7^A'SA5_4!9
M'^G.4U\<H&CO^YCSV H!N'5DCLQQ/(-OK@HPX6SRDL(J?WCH_7C;(Z!R/)!]
M0F%Q! #91KII<K^>>G_OD5H<?6>BVEY/3_7FO<*QB0#&P'W%$=P4RDAO0Q_W
M]R>GHM^/0QQO@ZSUE(C*@]<OX^L]9M_*3&J;WSLZ#X&1:-UFA9<))(O]=A[B
M&!=IQY0I)_U'J"Q&Y(I%:??6C5WW2:O_LPN6E.]="8O?.9RS0_,L)S7\Y  2
M_R>FUPVW"-5H@6<PDOQ;QF(?(GC"385\_N>,>0[\(UD='3$YE5!/!<SSDM?L
MW0[R'%7<9#%=J2ZW35F"8,\P01\[9O\R4(/?/5\;:6<6:Q>R%J&4190HTYQA
MX;0=,UAZ1Z]*+?MEG"WJ\E**28Q]Y@;2JU8+'K_T]8)9:<RM?KKG=MD].C+Y
M7GR27%TU.(.PFPU*),N*A1>3"X>C'N[ *>&@93W%B,DPFIO*AXFFE+9CZA3/
M$4!=!'?Q/<_^)4^66/>U;]3&4PB U"UNJ<-Z[3H">)N[1K02 M>62<N7G<&O
MNU?H29SWRF]*9M7DK>4XQR_R1 ^$.UI65]C4Q#^=DT?Q=2^0@3Z>%I%H  ^-
M#[WY(K];P <9)@SG_=I\H_&@N<P6VU.F+Y>=M6B(_DWXIWGE://9*$VBK55R
M+3Q7 \#$RL0.^.0QF"7-U*3Q,J=A8'!=>#A2^3T3<_C2*+[\J08Y<@@UJ$VN
M[>,M)D/):*#=R&&E$5B[(/0*,F$"F=;U;BC=K"U/ZA06>G**08+4\?58MP=P
MOPHS^#EI.#?D#Z2_LD!8#IXZ-I9+G&+JK/TC(TC5O$N- %)6GR& AU$(((SZ
M.V.!9WR=\76"KX]+'AV[:5/CH";WR;P[<I+]&88\,W&YH=[U+KP1S&966TE2
M_,+;G:YW<2$;$MI]MD[M62M6Q-M?7E4\8K!!XPB0L1OREAK2W @7VZ=17@<]
M+A!62U'R>MV$[M#BT/40-;(,.[-<&-9<N:&ER(2C--PG-_:*>T-UJ3V.">ES
M:CQQ\C_SU7_JJZO5]N46E0FO2"VQW#_@#C_GG52$510[9!'^PM*_$AJUV^YG
M/BG"-JV:#/<@8O8;I[+?:9)  )C)P<)R$M <C0/&=\YOBT6J\?AABDM)-BU<
M[[/,91V]]=V+<Z$(0+P[1&H0;/G<?E;'<UYT/@6VI5D[[,VW(=[\[%X"50RD
MW1R^1Q/4.9.VK,<;-DEU\>;PP"79>?P]6_9/".#9(M2HY/6[!X'O<NY H]]^
MK>V$DTYS=P946'%YY>B4)6M4"+]3?,_F_:P-)IM?,S9&(7.)0M,X@)%4->SF
M:QB&K.ZWH"KKEU!SN;$1]U+^J6%*+CAX%&9IP6VFKOMDVG7&G%0EE2(/+Z#<
MEM!3K'L;Q+LT!S\0DLPK;,-=:$G9=_#*26X)A;F&SC<."R7;7P_9OX@ POW6
M])0"/2\BR1+GYCTJY9^;L^(.7'C@3;QPJ(\?,$C(9@ZY#M&"Q+;.9]V94-<;
M7X@0V*".F"Z@\$K8G9;13%& 2]9LAZ6!*$NF\!1!^HI^->R!PFBY2_&[[]HS
MW1,<QGFJ>[&Z#"0YP@W#AB;20L/+6CN)MT\H<#;9BH?38>Q5*8[%FN3',?4W
M5>9BK!' 74DEJ%H-DL\4SV0H(=/1*H)=V@#9QD?J "H# B!?7BC@.Y! Z@G8
M]-N[M,\J<+5OE($PYG$LI%$DJ@3#C('=1P#^.I/@?5 ;<F*X  ESWE8^3 U%
M ,EO#SX_P-;_4#,=>0Q!LY[CR80 Q/; ZW1*&_DUP> BCN2M7?T'^(;R>QHC
M#G_\/ U.;/L(.;W0,,'19>$\@]W2NP%<<._V-<.OUR#,!^$2?_@<.;/DK2<?
MHLT@5_O'X.:*_:OPKF9(YY#75Q%_]EE]^]8_?A[QA]8/ZDO2#)-V[AVP5P>^
MR8#EK K@_TPZ:;\+Y\TN46VL5\OEXQ#PI#I4"?YP$S)Q*WE:SXL(<M\8//^U
M9I>Z(7ZSH&SF#Q]+_T&PE@4O(U;.F\$.X\<:_S7!S^L4H+C%?9C[@/."SZ2T
MEY1UL#-TS9ZB51JWI8WB^7,\CK[@G8( CTMIDP@ 5U=[:1<!F+U8'9;46]I3
M">**97 ^EW\LXJWW].,T86C&UVR&^%@$\/%#W 6BC(Y+#<%7"TB7S\ZN_:]G
MUU(JJXO?E'*-ZTK:7MAQU[UZ:!E1 XVU9JPO6N_W;\YS\""ZF;6S&+.'LB9;
M%)JM[@]^_*+:<7\PG)L5WV'D+E:F_IZA[5:)UP'^^^#YED"8X=3#RO?:3WM6
M*/(R"E1$\/"WF!;U\$(F7N!(# \,6%Y?1@"L\WOCHFEO8$"&RR[G;FRV)^';
M5030#OOTX #2+'IU6JQ70Z[()EX#[!:A' 5[N-^?@Q]04F#'!I/ULL\9I:X<
M>01W!S^E[O^B+,UNG\NM4RW]$;9[4'*Y^%U)82F!EDZ+[85MF<BKA\P6+'Q:
M&^?B4[3W]O-&[,Z;WGY>>4B2E7<92U'NAH:9A 6+'F&&YC ""-Z.P&VL5*U0
MBPQ-QSI*("@)ST0M!VU(!PN;TXM/4M"_^DQ-#I\Q2$Z=P4]I^T9<F +C[]DN
M]Y][U9%C@;YJGN]MBKM$A "X8N[&]U\SW&EJUY_5KDT<\C8#%S]!FB\UMK;0
M*WR[!:'"SO[=AH*7H@]MTL%545[B2&%X3A\N+0@+K", J?6#ZW-<#SSQ%/KK
MVCJSP_WV#@;O]&80O]!U&O%Z0=R&UUZ0,QI+?DW4'.EAY?DB]5IXY#^0502G
MO_P!V4#S_8GR^ZW!6O1;Q!24%\HI?+9;]P?Q,]QZ54(FJ1/S[](M:3<M:EX.
M4Y5ZI[CY1/EA'17<MS(G]L4*HXXL?;#+37IW8[;LSQ.Q&++40S3*N@')$S@A
MMH&[2915_3WR(5@##X26']PA#.O^EGKUTY?R5N%0OW#!GN6">!A-'7@" ?SR
MH7CC7B9C@KDUY %UK7.VI*%#O,L;IL]\4B;WPFZ_C5265>ED8C!+)>Z%WKE3
M558VP%TMY5*9+%-U:6JQ7RU3ZC&#ND'*52M1/ !$5O>).09*;1EDP[:Z<\O:
M1:>LX-(^BUZ4)(-\,=$MW1>)\J@X,ZLVTJ2?UW<?.6G:S)25D6@,?CLWMSII
MO#D@R^M/H<%DX:\&F#S'>Y6GHX, ="#UH)[Q :15B>7LY=%[:]/["UXJ^XM*
MV\]%7T*JC,E&9]*LEYOMD^R[!BDF:LG-789Q/\A:YE]PMI:MCQ"KL0^H>1'(
M@D563T8EWDI+('DBP0FS&/@?)Q+[W0$^ _U)H*U:0FBO?.+=]<2,_#)TP:+P
M^FV<60:O@$7OVX88X9IVY?QMS2CT*2>RC_YHA_>G*4M_W=X[@_UUL*-]W3#N
M2NMSLPS%@UB")>D3+2GZ_(WZBHVQCT(G0L-39@@PZ2KPCV>_/.[,?-^!<T^'
M="8'@=>?]X&A331_3+'X^R[=/XV1)0GC+D][UC.HBTJ$]UW7;' V_3"O.S3Z
MMS4KWL#Z_:VI?YZPX[0"V\"2CKNU<[.;;AII$<XB0:2=2T6#6F JNE\?^<+I
M1>U599Z1E^MZ;E!WB/XMP(TS-?%:Q2%)<4+4T%<*G_9BT13X-*,MW:\Y0>^C
M/WWQ( KFZB\)&)OGF>.$BVC-@ EG)@!5AOC77>N?9X4E[OD14)TF&*:3R114
MQ9AH;?Q-^]F+PI=W*7,6O_&C$7IV;(6FM+-1T%I;>6"<\"\!R$]D*VGOB)&.
MRS/277]ALY,>0QF:@&9,Z&F>49P;CXJ4"$4V@1/.Q,P;HQM)BE.B=Z+/@8"H
MLGO')9)[*#^EGDR) $RZ\C+[5[_X:ZKZ=PZ2@7U@%LF[&F%5MQUS[KX*,1DU
M\%N+6O-+[JC%_NZ3-E7>T>ULA^UR)T^Y!ESL4$_:NQ*2>W&QE$!@%U55NZ%J
M8SZHV#W%KW&8M3^ONL_WZMK='EF?MCHC-;F4^6@'D(I8?J+4^B7_-.(H5N]^
M.X&M?&_'9,,N;ZW\^$RYZV,SF^I9&^VQ+OKS<.G(H:&%00W4M29':+)JV=)M
MMP?*JM1#FXX1KT1C/W^&%C0FF);Y*?445R+-_4J: -MFK\Y5@?R28',&:\4P
M00@VTB)*/*$\T?KDYG8M.-7Y9;=:]6[>)_DH-J(QAWI!=58)UR^4TL#7 ]MW
M=W]0L=@R\2!H9?+N6[EZL6S9MB'RKX;'.D42_!Z"K[W"EZE>I,&O4='-;JCB
MQ2<LYET<]F #6;5.A36X+L$J/MH,]P&S$?>W>KAU1&J64V= \^JZQ5WNVACU
M*N$]\:#'7I4F#\[C&]]];L?QLKS081:^-* TVSO_C7+U7=R36-@^I)[+.2)H
MOR;G_/+$"MO7X?=BT3!M6:'SD:*:W9K?0&F4)A,&4?+2;]9G-/2'J:\H$2YK
MK+2350F\?EJ_3^IMVQ)AL1-$&S" 'C#,$,!PY,YG1Q@PRSV;'C%N"XA@@&R:
M+2'M31/LL-$EH=K&58$G&Y_"R-'EJ;S4I% C<)< % 3@?6W\N/X1S[WX'JPX
MGASYF(A^CVG\:S#B3B@[<GB6^#E$:R\_>J&C8F?<Q?[<L"#3\$.#E)V4]&T'
M3'3"NS\X/@Z<&2C_7M D#_C"YV51UG6OZN?DZ3851?D*<S'.%D\/,#Y/SH:I
M)GF@)652DO^??['KTP#/"M_-DJUB^?1'A)NO'-:VE=M25**#*[DM.V&.4SEZ
M[$T)E.RDB0>"$Z/M?A\NA4U-)U4R.OHM%5/6,&[PA90V30I=>ONV_MRFYSG;
MU 7\7J81#5S(Q-J%1B^+!/]$BC IQ_.,JX2A;S'';F*-V&]*S3/U4LGDCB1+
M?'QO9"''FWH)]M6U8QI,  UZ"KN<)FP7$U&BA_)P%1P(#O%BEH<$NI(_:7>>
M.C3RNJG<&4-!2'Y@UKN 8>UV!5>[L]%>R[)D[-; ^Q:R+>)OTC"P4](+,(H>
MKHK&R-@+&G-BYKQ:II<'P1XN49F+!.Z"UL_5V\;;=2_M)V5NY#Q15G5AB'Z+
M?37=5;.K\HV:<O3["12QIM?S213WJ2V?J9!&FB9)86>+M.5S:4+CS8@'=R$!
MULG:M39$-[%":5X?C =2[]P<KR=?"S8+WVK1#KE.NZH@.C+!WA<.FHQ9N_OD
M!A['_/OV:/ >U[9^SEN!4<O*.QJ0P#&M/CA#8F7C*RA;@X+V^L;<"AWCMZ\R
MW_BI=XB3&[\<VBPZXU,MJ>BUXJE_('EOOA+5NU"VG[!2U'&E4>K=I0J]7)>N
MB$GQOOV8OF1'#>8D06X-M@O"M6,>;;!]SX?*#@,YM?$W<5@H] 3[K7-9ITO]
M/:0O^*-FO@S>HG!P-9.JER12^?]^$>_/>?OK+TX?F[Q!(7;TNLATU/>W1:(Q
M,,<-*V8?@OYV2'K[=,?:?GA0$P%@%.&FC"1JSH2!BXMIU671HL=MDNU;T7R'
M:(U]Q-J:E<3_0?HE59+X@0KG'%U]):HJEOX9*VST8;FO25E+VL7A$18V/$*O
M5Z:_ZFZ.U3DS?=:@<IUN1^I$KB=A9G5[./FF:0-3&2@3AK.)7+,#D^]7Z$DT
M#?98Q)LE7RW<'/S2%V$#*E98*^Q8&=E^63#?"\=O+> +=>Z\^,M #4[O&+]C
M<<$J@.+];,([<SA_D08O[W+Y 20HGT:CQK@\-/TK:,'[VW1+L0M!/7$1"VZ5
M+)',C=?!1%=W49,E*Q_9+=98%#R#T]@%9P<3 VIH (H/R_,3NR,(@+ ([>[Z
MTR0!JB_JD3?;:&^'[5+D:Q+\[1T=7"II\:.#IE+V ^400IA8=Y5HA^T<Q9?)
MNN+2F?GN"''884X2_,-&8/C;X;Z6FSWZ<#UCFJHHKQ;]@V6:U<%4>30!Z6%U
MS\C5_7W6H4<Y#'O&.?!27N>UH/V[\1SO>HF+K<5>Y."6?DRMQL&?X;2D$F:?
MBB"7>0>MV%XL <6^*>%G6A) 6W+P\G?>!_ES1^ VELH7JT6&"J\=V6/J<#_4
M$DNE?)7&Q4?AM1]W((QO86V[*LD;^FW6" "]H[L*G 'U'FSMR:/W,3X_83J^
M-*I@KBSIWOL\D^E:Y;M4AMA(94EBM%.^/X@ ?(?/==DHY#I()0\/1[(P//SU
M+324>JM(CCI:DVD&M)0_?9]JH%R>;+B!/[V", ;[EUG"1,IS!EAH(G5@N;KU
M@F"3_AJ:SU _C7#^>V6A[YILL"A*8[%3-F7KT/H2%FQ"IWKNF%,Z?"+8,[_N
M3YQ(B5IWX=R#B4-<^S&R]5M9$R)<$AO:_LD*44G7N/,4IX23$W&KT7_!HPH0
MH.EV1<7YT_(MSQ;5!GSSX UC_[SJMW3;TL$B#F)>G71_2%Z4L'V569O/X".*
M@(!0H9YT@)/."ZX#J6]W[H>G9NMYO9JD=>AN>J2JJDY[">6V@UA;6]VB:IYM
M_!ZD_M #3V=Q%&Z[7;KCZ')R8LK(@3I*;(!B#JO3S/>3HRH_'%AG*\RN-KNL
M'NV3B6#8U^"LX_NM%E$\8ZMB2OVXG&.A'!"CX!^D6O-"S4$C10W JT,9CHRX
M=?2U$,=3/*;!B5M\P0L*1R\H8$\@@*G[OWY]Q!GNK\8!QX=,U=I[;Y1U3_)O
MCZ;]&CPHS>US9"D_)%C1RM0:5ECGHF[R,3^G7L*W6#B>MQ.Y3+$DGDCM>H;Z
MMZ#P3UH1+TZ3A?,_T(O1[ !4%',N'!]KP3ZC ?/7?,\C%)9 5=B'3%"%W["/
M(/:_3-QK_J$PF;WPMXI _Z)KIE$)6IG)BH_>%0K<N\?2QL00(T:%*VUOCYN.
MR].7=5Z&LY,>0XUZ9C#6(F<=IH>#?QYZ\6;_6N+#V<7;>Y9KD<]L&R,\$L6A
MTN?CI1" 5G%AK^<GA;AGUI1HU*&W4?9,#OJV7 1,@^8\B^*Y8*);ELK01]_B
M63.A@@T*<LN9SU61--9V^&FT39-]V'8L4R'3UN)KIDLEA;R$(F\Y]MA$7Y7.
MK8/];:P-2ZO6Y^*=B="?QLU]$G")\9&YCM4V7"ZR+L*,?V( OQP<(0;Q>7R"
MZX$G8!W+\D*6.*:E;WWY+XMOIEOZ,%O\\WE_LP5+NJDPB$\FRJ7W%%SGS+JW
M[AI8A\;P@@T/O#$,+%I^<EZCAEI\TU[_N#L<!\UUYDN:K'I\[CVO*X??AZVM
M5C\TIN?;Y[*7I2=%PYNOPEA2]$?F42D4F$'S724CWN6[!?0%&1\V38-#,X)4
M@GM&V:N_W0U,?MQTP!LKQ#5>(,H$O3NN9/F:/:Q[1,TPF!>OA3KT'$A$B3A(
M*4S8]47MAI(Y_G(RK^0A%@)H$?^6#<'VY$JSJ*&JK.KG_O)@R+NO"P&D2S'H
M/228-I_.H;;7BSB14YGWBILGAM:=5(HVY[B2;1W/H0P>P0V5Q.YM"9C01!A)
MHQSYA_&.\A8^+L].J(M^0P7YOY)Y^*ZD=C^+?%):Y99@&FF]-G/+]^_8.8Y2
MT7$#U>^Z*NMI094D?*=(+DA>U[9BWG@C<#Z=31S=A%"+R(E(X^?Y6P&G)R=1
M/T]%#)R:^+^0BOB'/)V.\W\9=<QG.['4'65#0C;$.66DS1DY%LST=%1"N1.L
MKM_,V%[*B:Y&?0VX 'A]* O_?L[/4+^AJ$\<.3ME8N*_ZNLTDC<H\7FK)_DD
M2 F6>H1 4:I1NQ09>^*TA>UX)$QD_'4,3B=2_YX^^S!RS9IX<!1IXH@^BN^&
M2WX/[S++?,)L7<(3!WQ94GYR2NZV#!!M!U*QC!^L>I!QOX?B/E8?^^-AUI5/
M=EXX3C2*2L5&N!1-=[F%=I;]TLU#'5CI:(0B[!% D[>:\&BXN1'QGD%Y<OQ2
MAX+M%/4+0[[/VT^_J-4:%QN7SHIO,SCOGX<3/TVZM$$28J(%T_.P^KJ?YU_8
M,M^'G]6VKZ'WTLU6?ATFQ-VN%A;4^&&<J[:_-E.N[V7'JE)AK((E./H+'$M"
MMIM[!>]+:R^K\4/(8Y]VOKX='N]@YO#T)VJ1RN*75>/XT:*5+&9Y:H/@--TA
M4J57]B<HW7F3P:+^%?B=HOW%Y,26[7%/=+QO?;#WK7H1GO]Z*6'LV<OZN:72
M-\/YG&BE'\<EER#84^ BSP=3G[B_<*\?AB" =O.M.<*D(3+8$R^+U?CU4CE?
M2/%R_,5E/BN'3B&"]$.N&&B,WKAJFK2N@L(#:8UO7VLOLEL*(  \,%\F[$)Q
MR_O*%^HN1>MW0^Q??^#G^I N50.EJLDP]ZN#TV_08PF;Y@N**7HWW;=+^XP
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M7^A=:8 N75RJ:'ML\TJ<B'>]9*8DB'+:'LV18S8<F!2C--EX8O4/4V2=^";
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M.J:BS^L@\;-[.D?KPV_]Z<.O@<_5E3C$J"W6\9293F=-E64.;P$<Y5!'&@
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M2#)H9U[YBRD?_Z^WVYG_#U!+ P04    " #IAE=4B!8'$#O= 0 /L!, %0
M &=I;&0M,C R,3$R,S%?;&%B+GAM;.2]:7/D.)8E^GU^!5[V3$^FF2.3"[AE
M=?>88LM2=V2$+*2LFK:T9VY8)7:Z2!5)5X3JUS^ BR^2.QV@@Q2K7YMUI4(B
MB7,/R(,+X.+>?_D_W^Y7X)$799IG__J=^Z/S'> 9S5F:W?[K=[_=?(#Q=__G
MW_['__B7_P?"__OFRT?P+J?K>YY5X&W!<<49^)I6=^"OC)=_ %'D]^"O>?%'
M^H@A_+?ZIK?YPU.1WMY5P',\[_E?BY\1)VX8.Q0&4>A"%- ()@$7T*=13&(?
M.:&'%[<_8X=R1H, "AHZ$#%?0,)Q#+EPDU (C.,0U0]=I=D?/ZO_(;CD0!J7
ME?4___6[NZIZ^/FGG[Y^_?KC-U*L?LR+VY\\Q_%_ZJ[^KKW\VXOKO_KUU6Z2
M)#_5?]U<6J:'+I2/=7_ZO[]^O*9W_![#-"LKG%'50)G^7-:__)A37-6<G\0%
MCEZA_@6[RZ#Z%70]Z+L_?BO9=__V/P!HZ"CR%?_"!5#__>W+Y=$FDY_4%3]E
M_%;U[!4OTIQ=5[BH/F+"5Q)]_;3JZ8'_ZW=E>O^PXMWO[@HN#C]V511[3U4H
M$X72#17*?SK6V$]GP+>$MWJ)U0*XVMQ/MC#V<?K)&MP;J0]\?, [S9P-N7FA
MWF=LJG=WT]39T,=';.NUR"N\FN"UV#:S WFE?O%1_M0VHQ[4(Z9U.ZUT[T#E
MWRJ>,=ZHY=ZC0<K^]3OYT_(V7;&E4G*V7O%<7&:/<OC+BR?9-K^L^'VYQ%$4
M4=\G,.:,012Q!,8D0=#GG/H."6*,XF6U>;F7/(._77<XZL8T6_K.P-;JR#=;
M\#)?%W0[VMVO#@UA<O12XUW\4X;O>?F VQLD7.48-!;\6X<5Y )LT(+?%5Y0
M _Y__^6GK9'G4+R:CKC5?Q?.6.NJU7[&--SM-3D>A[ML 9$7X%U:TE5>KHN:
MUC23O[NO,0!,\G4E?]-:]>-1<G.Z!W>E_+.\>$Y83O4):X1/72Z%S7-=KW',
M_NGT WYZT>T710</%_1$3[17_$1SZ7,^5'#OA58^NJ$=56[XIC0,2AC?@;Q@
MO)#SB@,F;=[D=0EO,7Y87J\?Y+!1OSZKM[B\^[#*OUYNN_*"E%6!:;4D/$)^
MD"0P($$$D>?&D(1R!L$PYXBZGH@3HB.WANW.3GQW8 .V]P%0:040THS=3^%G
M/5TQ[8U^91Z1X[%U>I=>!1DHS& '-/B]@WU<LK5592!16^>JE#;6+ E<DMK,
M]I$_*?'YB:^JLOM-+4?0<=N9XC^9MCV)/ TDI!.KH;>;25=95,M/\B7Z+'[%
M_Y47;]=EE=_SXEU^C]-LZ8E(A![G$(?<@PC[#.(DYI $/'!=G[N(>#I"U=O*
MW&2I0P=^;_!INC/]3/:+C#5^1I84?6JT94/+]#Z1D _8$0CYK^?BT-_")%*@
M963WX>M=/,Q#N:#2O5VOVL65W[*"XU7Z=\Z4*U162F1^D8U\S,OR5WY/>+%T
M8D:2*, P)$1 )/T3&'M"2%<EBJ,@=F(JN(FK8@I@;N*P10P4T!+@C $%EY=
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MMP6^;T]84(?'W*<"HL!5)6X2 ;&("(P=Y+G<2QR/4^U5@9/-S6W6KO V.11
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MAQF%22)"B&). T0\[NH5#C@'Q-Q&&?DU^6:CRB#J]8:)L0D=6?<5?*CP V7
M K0F/*E3AK@ $JP]F3Z'*JNZ.PC(I$)Z#E7/E?&L9PV-D1&\*#B[P=^ZXS6R
MR5_RG'U-5RLYL;C,*OD6IF2E5)=7Y?-_+P5V8X]Q!J,HX,H9=V$<4!]R!T4.
M9H0(C :DR3X;F-:G.WU2;#GA4ED><@%(GO\!I'^6RG\]JG(!^%OW3P'2C34
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M&+K@Y_2BIH,^4=^,/<IUJRP?=KOAA1._ )TQH+4&-.8 98]%%]\"JW8G .<
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MYDDB?;/(@XGG>9!QCD4<LC# 1EZ:6?-S$ZX68 FV:\2&)_'-V->3KO$X'5G
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M N%!CACC+DN2D!N=K]-I=);#00T:_,JQ@MS41FG0&N96T6)=3\5M<SGV4LY
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MIE:]4<*Y- FR*F.GVIQ4IC0)>"Y#NK=9#<-:AC'U?%].(WV.B/3Y@@3&OA?
M,,%)*'@88==;/M25\:XK7%1Z(G.D-9./XWF;H\^0%H#PVS3+U. OOYBF?2N1
M4DN/)!%V$(.NIPH[(^%#0B33)''"(!2N[SJL)?E]QB:FN&MQ H)YQFQ3JR?:
M%L@:6:R/!H:-'MLU9936+.*M#".GSA3>QJ%4OF0;5O74KC'Q( IBP:7>!EA
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MY:DH(Y\GB10$0TZQCJ? #*:(^E#&-/(\RF5(N,V)ZE! )^>#OI!LH4V"<EE
M'2,,=KL'6[=='FR"S91S"M,VL-;NF BRO)XMO6S8FMF66]@:"G[2GVAL!8VQ
MH+;VY^&CUH:>%:?*/AC84=\%0U-^^/88?#S[Z+M/RF=<?,A7:N1J3RL2-(D0
MIC!) @P1Y0)BF7#HHX"3./%E2GS3D+N#>T]-U2MXH,9GM1-XBK=NY;V2C8'%
MTH8(J^BY,R;W#ID[O-]H<7)G#-D-CCOWD;XN("NJZ/^J8)XN]ETW#UFMBHRN
M*[GXOCPN@K+-&BCG7H0BY*F'.&$X5LM6AB&FGH ^04CX810Q%M@Y>]="FIH
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M/ ,-9G<J9$&04Q4R&7=4%;(@XE"%;"Z](E*.E.*]J/_[,3^,H[U[^9S-DS1
M3/L_/$(,(L0H)#CUH0P0(BR,"*>H1Q*7V>A&S]'X25SZ_?W3 \GRG\%B699
MSWP5[Z96!67OU :CZ3!>4+EB=\2(-:+SN%K(/VN/Z2C58 ;N?H>?/SJ.03-F
MRGV<V>6AQX\E,Z;C9+R8^=4](P7$0OWUX1>1BX(LE#+>\*<LS\I5O3O7*&;9
M1,[0%'->E>7 ?J@/!I5\I9C!4%)!),-):+=\LQI]:AY5 WX&'FKXE3- ]@P
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MN%D#U35-ZT2_\?@WDW77K ZL\&UVI<8[ QO$LRW!ZE\;V [;RUN0Y+;'O,G
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MQM_R8H-3.V/;2"&F++'L_#O*M)OIZ>0F\VT7N#.PL76_,.D,:"/57U?@5:S
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M35J^90]YE3:GRW SIL_M]#[!_7*1L2J;9H.\ZE;WSS5_Z%%VZ(!B,Y'I3]S
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M;F-=HG\%+]\<.R+AY@4DP6^>5#=;$^623E79'7/\D(&KBNU4ICJ9*9?ZUP_
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MH5IL,761:+ UYXF:GH6E1@EV84[TH8R?7.K4=3%FL2'GB;F!-N/.,NAI!\Z
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M?M\)]]L[@MOZ+8.,1U%$84HXA2@62MFTER9.XP"++$JCP*A4@46;HQL;*M2
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MJ./@6\_B#]K('_6?JP)F]SM]^X.V5;T /X+M!O367O!':[%'9>ZS0[Q*>B]
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MWXFR>)A7 UM[-I00$;.80$8B!A%G*201S2!+,0I)+)DT.QMZJ:&QB5*#$^P
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M*SS/([5.%#B1:8P33JQ"S=SD&-L:WJFAG56=(K6SHV64/2*QC$]SG"NS%6"
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M236;I!E/<V4E0L2B B+"2T@CCF&<<Q2G7!*16U7;<9!A;,32.^.?GCKCK_4
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MOHI9-5_\JCA7V:>"_S)?">WCJF8?!%VLR>(EB5#6AH90B7F)RQ(R$G.(RHA
M2B(=BB1QINQ*CHO8V -E,?#8:!#]F$7_"1H%P$8#4*L E ZZ[&RG!=!J6'A
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MR"$2+(&82MW$MY0XC3,LJ5$FD\%88_O":]F 9?>G<UB:?>:>$ K\P6\K7]^
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M=4\W?7_U5\",]T<ZL8$7B7[SA+[>NR&H] 4<[;*@M;\!K?XWH$% !X8W&-R
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M#"^D/,(\.@1XO-SL_+^R:ZAN0*,IT%/<U7FNM?4<TC'.5/B/Y? LY_1!'.,
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MJ^_@*#%I*]68%J(IZ6>, _.2+TWQ,M/SSU3ZD8U.X ?6:/7C#>!;Q4"QU6Q
M(YHA\VEI](TY/1,VM6F:=-13TK9A-(DY;[LI>;6=DITRX.[RE SK@',%GO[[
MY P19OIN.E= =K+GSC7/&Q!__]K$:K.B/#X];3/9[]1/RX+1Y1OY32Z+Q\:1
M8*R\!Q,@9W88]8VU.;?(DB!%24J@)'$&,>89I(JFIBJZE"3%$C&K^!;?@LW-
M5&M5,-OM^UJ)F@/$3I/ZW_Q8%_T;K8Q#U+3/N>TGY9><L9%)^D"KPRUW-X]W
M"C2J@3W=P.VJ=L4<S>'K%YQ#A_#V%YK+B6+8)YU3M_#T$8#OC4'W.=YT@>8C
MH'0033[&\X?MBMXJ)?EZVQA9VP.F1K1QIZQXOLP;]XK)QMO^:G5?MX;JJE%1
MQ?6Z'! 8$Q)#3%(*68(XS'B<4B4$#A*G+IK7"C2WQ7B;#V]V0E!OB]8EA5I.
M4]BS;FVO_VQ6:OV'KB@*K3.PW79#5\^CW:YHRMD9>>'=JK*_+ZKKTA^J<]/D
MZNXIU'30&Z$TF"]TO>Z5KA9JTCV3+PB/]T[>GCNX9!>74E2F>']7+?Z@,MA"
M2,K"$&/( IGHS1&5,(L4T1/*$!4JBCAR*@!Y<<2Y$6TG<--6(M^6U#\JZ.A<
MJ^L"[G:\Z17-D8GQ$,A.VN/*B%ZK==EAX[M6UX51IZ[490?"B3I=EC<.8YZF
M',Q"ABQ,,8U@$L8(XE %,$-1 ,.4IQ*3(,ZB<+&V]WXWCW7BD F<V+6C?)#]
MU<)DQP;NRH_\R=_V:^S\21\JZ/6[;1\]Z<=YJ,[Q%WCTUV&?V4\T7WTHJNJ3
M7#8G-A_R=7Y?FQ6?Y7J]K+>'BXQ@FB"L<1$XA3BE&%*!,$2,IQEE*@F3;$ Y
M/*O!AYP[3;+L2VBV5OPK+>\E6!>U&[/V?1:%7L2J8BG</F6[J;#[TOTA.PT1
M&'G!#T;B'T$KLX%T)S78B>V/+IQ0\LHF=B-/2C9.8!QSD=O- _<B^HWY1;]#
M;XH'/=I"422B@.N-1YUE$7,*,QI3*''&I":E-,)N&X^#Q\]NEZ'_!8QXX(]&
M0-?BOX?@6>X>!D,R]E;!'@WW;<%)I?WN 0Z'F-;@/ZG>,^O^]%7#/MSW*_V%
MR&K]D>;B%[E>)+%2<1PQJ/1G"K&0(62QB""*6!)&/%,H<:KQ??3\N7VZG7C@
M4<MW U:RMA)H';U: ;X+:77[HH]1M?NDK\!JY&]Z"]/'&J:WWTU8M_%Z[@7]
M@NZBFRY61/_]UOC']'(C/6XDSL#DE06.QYB4!LXH>,P#YRX;$- JZX:@/\GB
MOJ2/7W-.E^U:%/$@0YD2D&6<Z,T%2B'E,8>8T%@EF!/)K-*D>D>9&RGL2^BX
MI/>CV4\#WC :>S_@!(];M.LE]:\/>#T[PG0QKY>4/ A[O7CQ@ "LMW4OV<^2
M;\J:F]\4JWH[T$9C)T$69I@C_=$3"G&4,D@"$<,@D0E*.(UE8!7(;C'6W#[]
M1EJP$Q=T\CK$SUR MY\%/(,V]H'I6;R&%'>^ )Q#+)$_ "<*#QKPXKD%^=@A
MTANW<^$1TX7BV.ER$%UC><NP3=0G64E]T]?;E=@+SVF#:!>(RSA@00 ETH84
M5F$*B50Q%+',5, 0Y8E3R9W>T>9&J)VPS\)-VP0 QR.5?J3MMEG>\!N96P^@
MVX\(;$7UMZ.R0L3K_JI_Q$EW6U;*'^^][&X:QB:_:+F+U5KKL#0!(^TNKUT#
M"4(HQ+$VQH*0&]M,;\AB%L(L26B"PX 'R(E,^@:;&Y<<RKKU-[@Q2"^Z=@3B
M"[.1^>,,7".T#K<!Q"M]] XX*7O8J'Y,'E;W#-C6?2S6)HB4+E_K*\Q.\9.\
MWRS-W#T=A K_G"_U>,5*MDG]U<_T>_ZP>5CP+ M9E"+($8H@3F0 J8AB;:Y$
M:2*$Z<-CO_&[5IJYL<^[S=ITW7[LU *\U>L&E%O-CK)HP$.G''ALM7/8#ET]
MGQ8[S2EG:>R#I^W,O-[.S*?#F=GI [8*=:4MJAO0ZC3E%#GL::><JHEVO>-/
MF=LFV1?$O=OHJP>9;J/M"X^#K;BWAPY9(DNIC?2BTDQNFIE^?5KJ9U:M]1<$
M21@G*(",JU1OU!F'3"]Y,.8,RR"-E,JL;.N+(\UM:3/Q4IVP8$]:%R+L ]9F
M'?($U]AKS!FDAG@[>R%S61<\03<5Y[N^;(X4;H%&/SWW/6!"ZK70XY!6;6ZX
MMOC>+>=U:,0OFL.K#P5=59JRW^4KNN)Z*_-)<IE_,R6_=N74,",RH::E)PN,
M]U-*F#$:PBPF,@A5&@6Q4R[@%;+,C78[!<!.UCH$96@E//?)L?-W3 3YR-2]
M7W"\T^,&U)K<@%J7VM[<:K,W*Q/5L1N,[DB5ZMSE>:%:=(.!.U]M;O@C!UBE
MMT$:?Y:KO"A_757FB$J*>MPW&_E^]5E#49.XGJ^HM0XX0HJSD,%$!#'$DJ>0
M4/T3PQ'AVEQE&$MK2]5U]+G1:/"W-/X/T&@ MBHT7S;02ICBHULU@-'#P4AS
MGAH+6W=,P$<F47>LAUC&SJ [6,MC@C^1!>WQA7>SK8=BUVMO.S]T.AM\J+X'
M=OG@APQ82.I<Q5\?M1JK]<YK(N0BR2(N>1;#1 EMBB,L(97:% ^S(*6"!CS*
M[,MDG1ME;@M#D[FY:03=.N#!@Q;5@8S.8FK!]#Z0&IG1&Y!:&;>.5?"S)Y <
MF-D'6!,Q\!#0W*CV$AB]E'KVYNFH\Y+\!Q1Y\>)A;@M3M["D?/U[OO[:]>G\
M)-5F)3[DE.7+?/WT>E.6)G-3(8R##'$H4X4@YI3"+$XS&(LL9 G+0DHR%R^%
M_=!S(TU30?O/NKB#TM9%19?:IBCE>E.ZUF)U0-_.#3$.IB/3:R<T^%-+#3JQ
MS2F7$1QL);\!K>S^' ON>'GU(S@,/ZG;P!V68R_!@">XY^2\WCR80['\FVS*
M##4U[._4K2CJ9I)M2@E/$Y1&80:Y(IJX! \A4P1#1%F69'$22&[E7K4?<FZ$
MM9,:-&+?M"U=:T=?*_J -![+">CGKG%@'9NS_"#JE/GC!M+5:4"6PTV6$^2F
M_GZ"D..= T-2Y?HUK;Y^+(MON9#BU=.OE13O5]L\SUV:YP)C&H@P(U 03"%.
M"(,9$QFD3(6(")3*(' I"F0_M!,Q35 X2$L.N!8=/+:RFX:FQ38UEEY.C;UV
M+NSLJG$0'IFC#+A&:O!Q#]P?C.0@7_TX<@:R.V)^HU_MAY\V%M89EF>1L>Y/
M&$9H7^CWUZ44N1ZN+)_T3L=TZ6Z:5BV"1&0L"S!D/$BT244X)+%((",8\YA$
M2H7*92_8,];<;"E3[I37LFKFV@GK1E!]V-HQDB?$QO:<:; :,<&^G%WS,W]T
M8P&'5W[I&V]20K%0_)A!;&ZYLJ=T4]OM=K?;TW3TLZ0F\$;<K3X9%W]IN&HE
M?BE69??/5[3*JZ:W.^8"(R8#&+(L@SC4/V5!1F%(@E0DG%+JUG'2FV1SHR.C
M&*@U,PZ35MR!;:NOGC4[ZGJ1N1B9Z$Y.0QTLLR]Z&R0S1LML7UB.TV+[:NE>
MIB6W+U#/MO#V-H#/I.SWJ[HX;E4M$A&A,!(8*F0"$V,6:Q;&$A*1I0D) NQ8
MH^[">'/CUEO^[TU>UMLE^-B(",HIDK5W,V#'J!YQ'9DGSR9LYRO02CMVSO8S
M6";(VMZ-.8.\[6< V&5N/[]M&.F\D4P_JUJ7]2ET8S@D*HE1+ GDDFBB00F%
M64:1"<7@<11A(J13!/2),>9&+ONQMA^*U3W4@SX (SC825Y=M!BL(;9CDBN!
M&YD]/&'F3"0]J'@ECU/C3$H8/8H>DT3?I0-3*#:LDO_>F"(1W_3_?,A7LFX%
MLH@SFLDPX5!INP-B$3!(@R2&@F<\R41$5.B6'W%FH-E1Q%9.4 L*_C"B-FUT
M'!GA++9VM. #L;&Y81!8[JD(%Y#PFV=P;K!IDP@NJ/PL0^#2]0-;KM%RI3<_
MIC-0W=C^3;[<K*58Q D)>8A-P<U(09P)O4E)-$]$7#)-$Y)%F5LGM=/CS(T<
MS.E.VRSZ49:@,J("NEZ7.=NLZU2<=0%^RI>2BH-&/E^+I<:\ A"(1C'P@[:]
MA>FLIW^[?=2/CGW4SDR.';UX@'QD=NDD-*?\H);Q!K12>NQCU@^#W_9D9\::
MMNM8O\+/FHE=N'P8K_PN\_NO^C&WWV1)[^4O&Q-A?J?J$:J[S;I:Z[UJZW7A
M"X4X5W&808FB$&*5AC"37$(44BYB)5@:6U7['33ZW#BHD1)LFB/E/1[B=,GK
MD O-.A P(WM-,_5?*T=N<9L@.\89#?:1>:B3&[2"@T9RLR%J)V-/^!M0B^^/
MH :AYI6VW"28E,P&@7-,<<,>,EX/VT_RD6J3HNG3J-X5I99OU?'P(F5!2!@/
M8$1C K&) " B41#)C&*JXEBBP'<3VUZ)YD:0OWZN^]=J%E2-H$"VDOIO4]L_
M59:&V)03,+;)9MNH%NQK9)BTU0ET2KU0RUHKH"?O6=LOU>R:UEJ!.*1KK=V#
MAS'SK^:LS]P@?C5E$$5N!J'+C_K3^$HK><>6;7.J5W19-ZY<?3:RB=O52@M=
M5K1\,MRL$A8AF 5I #&5$60X"6$2$*:2A%"51"[<[$&FN;%S)WN]/\[7;;FT
M)TW18/UGX<;0/J;,CJ,GGHB167JG#3A0!VPG9Z?0C7%I,-EVV/DO,T]?>N;)
MF90](NN5EGW(-2DQ>P3RF)I]/GI ]OC_WJR*+U^U;?XH-^N<5WJ!N%V)S\N"
MKOZ/7&O2TNS_VHQ;OI:F:&W7+B0)PT!&"50BU&2<R1"2),1ZHM,DPS3#*&76
MN>7#9)@;^1HM'+*G!P+?3ZD3P3DRA1H%P+X&-\;B_5L=8E&K ;9Z@$81T&@R
MI.[(P'EPR'$??SXFRH ?/B\_\&*Y;"S0Y=,-^.M?,H2"?YCGU3^&_SCO07-+
MH;\.Z]X$^X&/GB[]_CK=#Y+SKWS4T"HF/Y5TM7ZC=R;;>,(VX9+*@*;2)+LJ
MJK3MST)(DRB#-,0IHCB649RXE3(Y-]3<5I6FZD0M+3#B@EU@KF-^JP7,%HN+
M-_!&7D,FQ<VUX(D/_";B_ ZKNC)$+ZBWWW,?<0GV*%TNAW+V"1/71+FDR?/"
M*!?O&-QFYM>NVG"*9$(52F&<1DQS:HP@"Q"'/*9!F"H42^7D3]E[]MQ(5(NF
M_^O<,^97NUK65P(P,A$VNH_3 .987=_]7GZ=M 1SCV(GNKD\NV1HO:*'QU)^
ME:MJZYW]1:[OU!?Z?2&"1"A)L#9S4@YQ@A)(TDS_Q&)*4QY2)2.7M/J>L9R^
MV GRZ ]$[<*"?E@65?7CF9@@UT)%YV&W^]H]@3GRUW^(8WMN],,'@^,-^*7I
M?*XEO@&W1Z!^I+X+$UV$RW,EHO/C35QZZ*+BSVL-7;YE&-N\U_;BZC[7<]PD
M:NG';ONZ_U04XL]\N5R@)&+: & P(6%J?'N:@!*1P5 RD25QDE#J%']H,^C<
M+(:=S(#60@\HTFX%=I1R$9*4PHQG@6;V1,(LTK G,N&)2$DD0NG"\=[!GJAH
M2IVZ7=?NZ$^D'XZT':W[QF]D?M][3V_;]]2@^<-69M )[<'#-@0CKZ1N-?"D
M[.X"Q3'-.]T[C.]_TEM&L]C?K=[DE>D_F*\VAP?\3=$Z_F1*L+Q;%G_^4XI[
M^68COQ3F DZKM11?]&:T,J6+"I,QQXR)<*=^*=9WO,W?U9(O>))@H>(8AE$<
M:2++*"2(8H@#(A@F*! 97GR3)2MLUXWIA'?YH/=5&.^[-KIW]FZQ F('@*G2
MJ8VVNLB4TCJ#KT9IQ_"K"=\+.]J=YUR/3-[-)'_H)OE(\_W K4[YIOR541_4
M^M>5W[6UOH, [&$ .A#,HS0,8(M#O4KX6Q"FGSVOR\J$XD^Z.$T_+<=+W M(
M,&RAO%M_E>6)?9<1OMM[-546]>]+22OY1C;_O65571AVP3,E*)(Q%"34RUX:
M*4CC,(8L29G>,@4D5DX5?JX7:6Z;JEHC$YMVSK7SGVZKF(=)LUN=IIV*D5>=
M9A8L'4/@CTX#CYYC?W!Z708\B#4IO?N#\9BV/3YYJ)]*2)6O\K7\H <7QSNE
M9]ND[?<<QB06@DDH>$(AQF$(,QQ1F.(XQC&B$KL=:@T59&[4N],#+HTBK5<+
M0/#^XZ>_TH?'?[QQ=;D,G"%;-\SXN(_NFCF"_)FOYJ2;9A3&O19.SUZ<@<),
M[-FY#K+GWIXKGS>T.)&2VL(6V\2/O<)L9GL>R0C+C,8PH2R&. L5)%FJ8"89
MBE$D4R2MN@I:CC<W7NS$K;/:EETG!]?B1/T0VS&>1^!&)K8M9GMI:'O">O8M
M6.+BN6Q1_Y@3ES"R N!Y.2.[VP;$:G[4&_&G\OW#PV95K ^C1+O8(A4PA)($
MAH&VQ3")]#88)02R6"8!E93&!%G':UX<;FZDT@CLTA7^(J#]'.(?II$II)$5
M/!>VC2@?$,=_&4.'*$VO6$X4J7D!4T^1F=;(]$9G7G[*=!&:UAH=1&G:WS6
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M33@?(S/8B:E@QW-P SJ%:L=7JQ+XHU8*&*U K9;'LSU/ /N-SKA2IFDC+?P
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MI'N:KZHUH)UFCI6!'"?$CM-&A'ED9NND!#LQFQ87M3IUJ_?7I=0[4F#.,VY
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MN9;=1"M5C<SFQ^5.:C=[?8P9MK/I7VK"IED0][4S866@T\_$?K0:@JV&35W
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M$LQ%RI!3PKG#V'.S:EO1 5V#/0?T7MR/XS;<818L=^+C8#OV9OP2K".4&!V
ME-_-N,/XT^['W8%YMB4?\(AA//9JH\U 0XPKT?WX_N%1TV=3Z[2+1T]E2%68
M0!1%&&)%$T@SB6%($IFF(D4RY2X,9C7JW+BKD[2JJV[E>_*ZD98=Y'9TY1W(
MD8FJ$[*&</N/?9%'8"HGD+QRE-W(D[*3$QC'O.1V\\#VE"M>ZH5+OI'-?]^O
M[AZE*7NVNG]-'W.]Z]JVN XH5K$*"8RYMJYP@$T%,B0@)8(*FM XPTY1NO9#
MSXV;7G\U\2IU1YRB$[EM+EY_:LN<,I.AH0W?_W3L2VD_'7:4-0[((_-6)S3X
MH1/[1X/U5G+0BCY*ZW%WQ/QVF;0??MK>DLZP/.LHZ?Z$ 6<?M^*_-ZT3[4Z]
MVHA[N9;BC?PFE\6C^>WKHEI7G1-N$2-"PD DD$1,FUHR1E#_6^\8A>"A0J8%
MI; ^_G :>FZ<ME<INST'J4MET9U.)G*)M5H!L5,+<*.7^4#-*^W@NW>;*HO#
MD=$F8&2^NST$N9,<[(D.:MEOMG[]T6!V."49#>Z)#DI\PNYV5C((N=[C$K<G
M3G=B,DC3@T.384\86([7U*=_9?HAGHE/?O6TNZ0=LVZ8V!W@;,/_ZAY*7[2=
MV/;3^TU6:^,;;?KM_2[S^Z_ZW[??] )X+W_2SU^_H>N=WV&18,433B0,I-[Y
M8Y(2F)$4P2CB(<UB%BE%G<K]SD6SN:U[C?AU6Q-ABCZ7%=!62=/BQ+49Z5PP
MMJU;/!=Y9[04>VB=NCUAW\(#FGYX:PW0KK%J^^)MNZK>@ XGT (%:J2 @6K/
MT>RQ$//<YM]OH>?9:#=M(>G9J'UF&S@_ 8?9"J^7M-(625UW^TWQ0//50G"2
M)<B4N<Z4_I^ 1C!326J"Z3*1H3!+,Z<LS>=#S&WUK"4TQG,M(_BCD=*Q.L8)
M).T6L.OP&7DE<87&F;[/:^^51T\,,RFAG5?SF%EZKO24 _!J4^4K656R^JDL
M*KU9IF%&0\*AC$WP5$IB2#*$8!JD:92&(4_8=;'_1P/.[O-_'C9;.XV,\%7M
M3KHRT/\8<,NP H\PCAU+<"*P?R?M#:CE'3&@_PPRXP;R'P_ZL@'\9R"X&+A_
M[KYA7/-!/^M.-9T)M@6^Z/?\8?/PJBC+XL_&3:[_LGY:2*JH) 1!G*3:T. Q
M@U2%(50J2BFAF2(I<>$=E\'GQD&MG(!U@@+>2NK&/4X38,=#8\$Z,B<9L8WA
MTK;)Z"2_ 1W46^'!ZTM0.S/4$,R\LI63 ),RUQ!HCEELT#/<&*TJUPO3_K.L
MON:/K3T?DR21/-2&$HNTH<0H@T1E&*(H80G"0NG_VA#6B6?/C8^VXCGNAD[!
MUD\S5X(Q,HLXX&!-$CT:]W& OFWO^]?_.O[V3SUWDD^[1Z'NR^V[9% #W6W]
MJ]N5>+\24IVOB/6N*&5^OWJ]*4NYXD]?2KJJEK6_YB<MANF?]'KSL#&_^2:[
MWRR"B)((LQ"B,.(0JT!"%B88DC2A1.,N"2<V&273B.M$'Q-DH;0Z@$X)L*<%
MV)V%.76 '7O&+8[F9S6/(S/?0:%!K2W8J7NF^J#>Z/7.NU$2_&#4_/$&['3?
M__VL7@BGML$S>C$F:RT\IQ?$M1/Q1/-UH5OQV%),V=%X(D2/NAY/->IUOE<]
M] =Y3Y>?Y7J]; *?%PF6)(RC%*:AB40F000I8Q+22$4T2*,X8-$0M^N)L>:V
MN]CZ"XV?=6F$!=5.VF'>UE,0NSE:KP1N*A^KP:R6$WRVP&RP<[4'C5'\JJ?&
M>Q&7:H_BY[RI?;=<EV-5&5K;2Y=H#A!HDI* 9Q)&)!001P&#))$<<HZ#6!%,
M1>QT1-L[VMS(XWQ.E8E_XLM-G1^T-,'9II/TP16.L5#]LV#'+MZP'9E?#F'=
ME]3[^8T5)*,D59T>\462J7J5/Y=$U7_3T++>;+V+1_E%OR*MWRXD&8Z54! A
M$4*L"(>9J=F-$98<*Z3-6:NT@DL#S8U@C)Q[@6\WP(@Z,"KD++AVY.$#LI%Y
M8R!: \IA]T/AN<SUF<$F+E_=K_+SLM07KA]&$#_3\E]R7;?X,RV<ZHQ 4]:W
MKNJ[4"1#/.($)BJN#T42R.) 01E1A%":L5!8U5ZS&FUN5/%Y\_! RZ?ZG-'$
M[>0JYXTO0_^FB9=M VEWRK@12#_X=BSB#=*1J60GYQY<X(\O]6]&*21MA8Q7
M9ND?<5)ZL5+^F&/L;KJNP<@7^KWQV.@?NM^UE?/_;W/7TMNX#83O_16\M0<3
MU8-Z70KL+IIV@=UFD2Y0%#T8?#I&'2N0G;3IKR]'#UM>1S(I4XHNNXEB:68^
M6A_)&<[,G=S)XEG".N@=Y\43W>P^Y%O(OI1;#N6GN$J"+(Q23'TX5$)#AED2
M9IAF(?5C3R]@E)57Q8%.<R.M3W5B]TN[.J1ZVC\5$A7Y"]W8LY2+D3-=$4TZ
M'J,OGNJF(]#JN?&1P\^'/]0V0?OGRJIR>];8!3U(6I:Y;S[B .91^H]<H]>;
MM"!Q &17%Q(7CQY&V._$LRSVZYU^7M,W*/%4E A/8#]-&":)3S$CBN P]8-4
M4H]Q;I7R=RYB;G3:TG!8KZ974#3CPNNP&9G:VK X[XW4;;E3MGE%S*3DT6WF
MMUS0\\F!D:M"/M)UPR- (.5VI@J>[2N^J<M.$<8\*HC (8%:A8&?XDPF%'M!
MJ!==+$N%L'KES47/C0IJS<LI.B]W?[Q2NJZK8QG9,A\"PT#7*,".'?>J,6VT
M+L&MMM:UXO7":8QZA=: N0V-F8N?-E)F#<M9X,S^"4.WE,7ZN8SHMSH='2\>
MMD)+%F29] .)/<%23*(@TEM&*; @DH6^@'.^EKTIS03/C<+*B )TCWVJ"XK<
M29ZOMNO_X)!/.2X_?CH6!K/=)1H.ANE6T#W$H^_W&NW00;U%*RV^#K4=_^AR
M1V>'EN-MFZ'PB?=F=I"<;\ L[[^6P^XDN//U&N\SW8/O[<5?DB1+8I%FV(]2
M@0D).,Z47H$Q+C/B9X%B,5_JM2'+[9GK7)S-J]06.J;/N%(-Y5LDCF_7>FA_
MQUZP;7GI.@ GXR)P+M6*HD;3,8BG&XZ1R.85@6]$,-VF=Y-*SSW7$DEK"C^4
MXHRS(%0\"G B,P\3$0&3! PGBG%%H$4CLZJ,VBMM;LN>UL2\N7YY\QJ\MMQQ
M)6AOL) 9I9"I$2 CT<=K$M^(/WJ,[R:0OIL&EI:#JA1PJDZ_DE5@^[=\+RV_
MX_T/F=&7O*WH]TT@'W0=Y9MN!HO;ZE+](J<M^61D_ED=)K.[AGW;*Y]$_O!8
MR'NYW>DWZN.6YP^R3!6@N_N;3?[/KU*L#MD">J]\<@KDO51Y(;_2?Y<>RQ(:
M,H8#&>EENDQ].+$K<<2E3-)812*QFES=J3:WF;A*]ME L@\J#DI+@> K@][=
M?OBH%_?[''HPB2>^1SNZL9VH'8ZK&>.]S6B-S(ZU#[9M%:K,.N9P064=, Z5
MUBU.,[R^-7*!6&DF!,#=T:I[[)U2L$/U)J5K][!^2^TC2!A8(R_?[6_5[\ S
M=;B%)7Z6B"#"/N.1WBHE/F:99-CGRH\%E0$-8JL2>=]*F!LI@X+@#%[EN=BA
MG9YO+8OCG4%H1IQ7 3,R_S68E-J-$'SJM-UM8;PS*=/6Q>LR\JPL7N<'A[[4
MI8>0 U%\W.K%Q$I_-^K$GMA/N,QX#)E5/B9!J!=K/HEPFBJ>\CA(2&Q5F*I'
MUOQ>]*.J4-7WL5;6]G7O!M?TQ7<"V>@4<(I6HZ?SC"D#.!RS0K>\B?GAHN'G
M3''YE@$E9\KE2+WIV'V%&BKM*^VI+>2ITJL!@2GU]%[/3QFF4D58,H^RU,^\
MR*RNG9W8N3%)J6MU4,.BJH<YROT\,AYVD^RJ&J47J 4CD/%QRWMYQ7$-NA:U
M3T9!>:(:)L9H.ZH[8HU5;_T0\Z=-5P?$VL*3>A[V=P\\N R'H:%""&PH]0Y1
M[NJC1\LX\7Q&8X%9$ >8T#C!+-9S)/=E*%-!4T]:);UV2IH;7]>NFSVH"-60
M(<7'\AQS)ZAF:SXG4(U,S[6.C:.KU'+1'$1T>+[Y$A1NCSEW2IOVM/,EH\\.
M/5^\86@[T6?]D+QX^9)OUOSEF&[IZ9<_(GH]YR5Z/4<"H3!E(L5ZB1>EA'M!
ME/EVS4-?%S0_;JCTM Z)=R)IQ@@N\!F9$ XJ+E"E)/JK_G^4A-5+B#CNXMDA
M;.*>G?TFGW?HO/#Y@0ZCBEKJ(F*:;>K#R^_E5JKU?BGB5*J4$IPH.#Y#0HYI
M'%(<$$(5"9B^'"RW<@4)EU\M?$?]8HW>A*QZ$\Z$C^@8N3 A#D+8T'/D +")
MO$=U^D)3$Q'R/FMET0^UN@X*'EH"X]:/=$'FM+XD,P#._$F&MPWP*?U"-_21
MKO+=!VC:Q_*BZB*U*F19WJ?>BU.AJ-);#\PXS3 1F=Z2P $"P8/4B].$2F*T
MZC 7.;?UQT%IQ-M:(]JH;>$#,</<P+OD',F1Z>8(XHG"Z*#Q$(^2&9H6WB3G
MJ$[D2;J(KB,/DA4^O=XCLR=-YSFRLNS$:V1WYT"/T3-=;\ GHN<!\$,=JY]
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MA&5<Z_IBT?5^^AFGJ^7V)VOQ N,732;_QU.HV]=B;-=XMER2<"]YS9Z8J=U
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MCYA.%YLFX7=X_HZ2.)KB@HR@33"@;,P0M/=@I'&2ZQ2X&>9";7C>QCU"&MU
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MG+J+JA&4/+/HP!I10 5I(!9-?W#-@BE87V0,DZ:^1L6XMG1\3-S.9N^KH ;
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M/2P([Y T8DJD =P=IJ$&H/8LGY'/TBW74P#7_:4FUK)0 F:03)4ZY(.(#ZC
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M#,8K)D60SD3U5, \LMZ8]Q6#(:8O^8X-F8WO\V+K^_"4/5.F=H@F!TC)DH%
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M6Z,\V* UJ.SKL&BNH41O2N:I!+>'E7ALR7'*GGK&QC ";@HVSTZ>=\OYR79
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M1 4VB*+H$Q==F^;5(YBZ9K'"V#@;40>C10U'' FVJ>V]N)=*;UG,;_O3S>:
M#7EI\^%?.W-^C(E?T@7%E4B@'5DQ95R@L 0)?4J'5.,2O%^G_J-,_%)!AV)K
M-5UP6#\4"%Y;L%[E4BQ:UVBV^0N?^+4+8O::^+6+8CK84V\S\FYQL;@WY4]2
M:!N=2U!RS5\K9L'9J.J]EGJ;.1,K;4[KMU'4":A&T_W]H'4,170*J,L:&A>R
MSJG>C9*.8FQ?3+V+YR%+[K-GR<?<IL_6=IHF+L >1><#@+2' CJ TAM<?7DU
M3_6?>L3V#4^K1W+5<"$2O9HBEFB")"=6.? ET)<ARB!C(!^W#9B>HJH_..VC
M^?N-+\920P>0^F.9O^(L_?QWO<J9ZSCM3>[F(FQ>7]W^NY@Q9G7QP41R#82M
MTY(UA&@31!UYR+7\-[8YX1Q.X[19M$9P:Z2B#L"WX>/]8AX?825CB6A+Y2*1
MQ4\8P<5 &P#C7F=C-1-M>JD^0=2T&;)&\!I+"1W@:7O#6*T9HLT*9+;U\%8(
M\!'I2X>"@A]63&FS.1[6+'K:X8&'>._CJ*(G3(U]$UYCO>-@%(22-]+EX)-B
M4#A/M+Y"D+)-F>W_:<VB=P+<L9I%[Z+]#E;!EF8R)@OD7!:(J7(AC8 @60!)
MQD&B]?B@ \OT78!>7I/HG; RK O0+HKKHACNX((=\H)<RCZ#$]65,22_4,_W
M!#.V*(ZYV5'L,2[;3#L];!Q'X0B*[="2;FJCK2U,<@K9N*I-N50=WRT8N=VI
MF'H%SL;8IMG+WF7H_5Z\V0D/0PK7=U%.!P#;7L$:>"XF>@/UAFV=?>4@<,,@
ML\S(ZI=@&O7L.ZQLN-\BT$.@-HZ:1L-;^Y*!5REM.JK@Z=MY62S/+O(7(Y<(
M//F25B4!PSD[1@F 9E;G:",(G@F4DF7P5FE(UA>;#>-%-1Y"U+($X++4?YYN
MU=T\XFG3+[Q?S)=W'.\+7Z60$TVK-8+VDH,2CH%7D0,YO<QF(9DI1PF[]V>A
MD_WY4.P]$VH?2<4=;-C/#4QE*NKLA(>LRV8_D!!2EK0],..42];R?L<:'RO:
M/A9<=IQ]O(ON>H+B4]-39;(L!U$GGC!-_C"G1>Y,!JFSMY99;D.CD38O?O;Q
M3G#89_;Q+KKI &^[3$AE2G)?4@+I594=?>:4,<!HB8J0G R-\N4_UNSCG1!R
MP.SC7=35 1)WFZ$K"DI9/$3+)/%&']!X!T9SE(J;HF2;T\0?<_;Q3E Y:/;Q
M#GKK )-O<+G\3K[*A_R5I)G3Q4+>SIXPV4N#!CS]4[N*&MI=0H:@HV/)"U9B
MFPN6.Q(Z;=;G6,ALJ;T.P'G+U;G^]!^SO"2BOGQ_E[_ETPN/!X7/3@KPJ LH
M6F?@H[6@>1W5BZZ8UB.1GZ2ODP1D+S',6)KL"9^W,W4/^;OTBJ+0PBE>482I
M=C.J.T/BD+-A(2'3HE%GA)W([,2]'!$GVZ XNM)Z0N3FU'^UD9BXJAIVW#O-
M%4FI#JU0F,%YQ@"5])Z9Z$RC:L<GB.H$;>-#81OH#M1+IQ"35^.55<J15P9X
M[8CI-:U+KP.X$+DCWT*55@VJMA/5R?8["<3VT4L'$/N03RG<2G_@<OW]TQ+G
M*XS7MW1XU,B=+< Y^;$J"W)A PN@M"4N#<OT\R80>X*H3LIG)O7PQM)9O_"[
M7*/>:I>4T."$J>8ZDZ5&B[1&I5,1=;2R39'7DV1-NY&.IOQAH-I#$U/W=[]?
M]?/3XJ)'TE5;<NL$9QA!R$0.K;&N&GX/UI=(OH'TV=P[[]C2Y/WI]W2)DGVT
MN6@CVGZ-S^KU]]L_V:PL)Y51Q0K@K*;98_: B39Y'6S03">FN#JF)7J$QFG[
ML'2],QZJT<ZP>KF*4Y;,Q9K-3-6#Y=*"4T$#BF)*8MKRU'YW['A+/%CK3X!K
M#Q5,O2W^NJE]^V5Q/D^W;;9FF9&/D" :&VFYI0A(\4O]8)@)Q1HY;.KNX\_O
M!QG[J&PQKOPZL"/;YB+RI$DP4D,1GH%RQD$H.D)VSB19UT5H<_6G[_FDD^YF
M8^BJ4\C='<.8DN&ZV$QKJ.9,=)& 3BA@7I5L0E1%MZD%>:%#3'<"P,Y#3'?1
MQM2;VMTYG-$GLNV2D32*JQ<Z$G@,GB*1R!V6;#4;-K_K10TQW4E?VX>8[B*\
MJ=7^]NSL?+XXRVD6;PT<(]>.T&\M65A/SEU@&5SF#)@12G(43IMAKLRCCY^X
M&4D[&!PNS*GA\+]GZ_S'%UR>X0W].J%0BDGPC)-?%DNYJ/6(66-*$C4Z,P@,
MCSQ\XL8A[:!PJ" [\#8>K]G]99G_Y[PV#KZ( ED(3A4&PBABB1L-P4<%B@5M
M(_,RF#8#-P80U\GHXEY*6$;184^P?(RARV4KE!->9 UQTURX< =8^P0()V7T
MT4B9&E<-;">ND^J!L0 QH%#E$.UT"KC5];J]JJ"MK2%,0,A8CXF<B> L11/:
M:E1%(6V%C;OL/D%=)Y ;"Q)#:J,.T4^OF+N]/UQ-B^8RQ^02:*SQ:ZDN1> 9
MBJ&%J@+Y*_=]LY:P>TA@?W4LS9%WH)9Z M\!KLN[ZUX % .'K+D KAE%P^3J
MUH,""Z(>9:J8&7G8;2$Z!AN=3';NPYD\.BXZ6!2/=4#Y)S&'I[/_$#&+U>K$
M,NV-LQ%L*G69DUB]*+3J0XS:*%$$MKF/_#QMG7@ QP?.@#XV!VBQ>US^NBE2
MD8SYZ#R@J[>[9!#U<FUM@HK$$BO*IN,THWM(6R?^0>>XW%F+'>+ROV?K+XO:
MTP_3[/3[3YG>=#:;;P9J7VMA<Q'LQ$DKR"N/D&C=D:MN%03N$+B1";ET+J0V
M9UA[D_SR2VG;H+B-SCL ]Y8ZF8_YE/[B\Z]YGI=X2G)^E8C?6>T!LYY]RU>-
MRG\A%=ZNKJEBNOW$$V<<!:4^@%4A 04(F9PT1CI07KMB"DFJ3537EJ^77U<W
MSC+I"#T=K*5WB_GG3V08?LKAYA+PB?-69^XC1-K9@/8V"LL9^6-:YAR9*\%B
MFS+11\EY^34TXR#W<%UU +A*_-LY+:OSB^:%%[?1+S<B-#D:Z3V(5&=8.U,@
M9./!%XDFI<A8HV%63U'U\D^RQH'?:)KK (7[C)ZV(I!A3Q8PA$PL(H>@I0>G
MA>,JFA1-FV.M5H/"NTZ8C8/9UGKN ,JO8ER>Y_1A\1U/JWRO!O!L9'HY/>4D
M.RVMBPZXX^3A*QD!A;%04!2,J20CVS1'&T+=(+"Z'Q^LHVNR W2^/?M*\JT;
MQN_E+6EU_GE& >B%J-_.4R[D8Z_S*7G8Z>>_X^EYJC[X8I'^FIV>GHA$'"5R
M:)+( I0Q"7QM1:,5)J&]+J51ZNP0J@>AV?_X:#Z:YOML-OWJ&\Y.:[*E+)8?
M\317[^DF-W.7]F&=I9]YX@AMI'>A>:2>T=>O_.7BE3>ON^[>RYFR6@H!+M5V
MYIX%"($K6K;1I<@%13FBS=[U+&T'6\?YM[Q:;PZNW\ZKM&DY_H;+/_.ZOO9^
M0J\.=\S+-<[FGY98E\O%8KIIV?6)E/*:GO_G">/<Q" 4&%LT*/0<L(X9LB4I
MJ;!PQMHT#FK%T;1':".C](&I[ $&+]&,;D[5&QC3R^<V-ZF/T7\\PUHPR6R5
M!58<059+I)!'1W"U519J)XIM4S[<WK!^C%]R.C_-OY?M[[H[X&JCBIN5HW@2
M3M71\Z4.$(I&0F I@LQ%6$[>BQ%MJ@D.I;Q[0[D+ZNX;RJ.JM8/HZ:ZUN,_S
M/=X*%LQ!"1*G)V?=.MJ!1#+D/2>EB_4B->IIN0N5TY8<-(9G,W5U ,5;/LIF
M"."LS')Z_;UFTZK<SO'T-UQ7SK__A.O[O+)H1*F3?QUQ!2IE \Y:!=+ZHDH)
MD5R3UN[HSE1/6U?0&*I'4^=+="L_GI^=X?+[HCS]:[B^:O.=;OHG[S\YJCE-
MS=W9L>5V/%?8L\RU+062=)F< UG (YEE2W&2#8:'A&UZE/?A"E]4)WLMLS&^
MCG1SBNQ)8(#:6,A&L2"C0)W;)%H&D]B]<[L+CO9Q;G=75 >NP_7,PIO3X\U-
M-_K-6&*QP*L+KI V%!1)TI<QBR#I1Z+1[-O'"9H678W4?_\6P0BZZ !2FQ(L
M>G--AGW,RV^S.)M__KT\PMWJ$SUR]?B/+B\A<6&=,4E S$B+5CD'M?\?\.0M
M2FT\SVT"IS&YF/B.P1BP6G2BXP[P_<^/GY:;P[J',](+=Y)Q%^NT#Q)I0(H@
M>:8@@//B?<I9-6HRM)VF:;$W'4X63936!?Q^77S+R_EF'7_.)*N\NNO#7S75
MB#Z8( 3PP RM;TOK6V<&CMF832@EJS8CIX92.&V^J2-H-E#HWD E2L)B+.=R
ML<RSS_,;]AYERXB 6EB$LNDHS45-MND")B@N@V7.R48- H:0-VVFJ1N0CJ_*
M#DQI/:J=E1G]6I7<3_GK8C5;7\WQ*LJ)2*#1:!,HIA6@98)8(3 5'W4.;;;R
M)XB:]II(-U@<2VU=V,@WB^77Q9)8>71!959<EE(#5K H*R5@G2M7A/.,G'6A
M79NCSB?)FO;21S\X'$UUDR)QTY7M0Z[EUO,U">FWQ7+]&3_G>L^J5J^\QOAG
M3@_=9N>M1$W@B5J0Y+2#D'R&4F3,'C&(>"\CN:7YW<ZOGO;2Q^3P.X*^NK",
M0Y)N[Z[+874(RA +4)*H<TE2!L\R@L!@'05VM.C:%,SL1.:T(<]QTICM]-8%
M+)\N)'AU5F?%_B>G-XO5^KIV^O+VP-LY^:YYM7Y5Z-]7IZ>+O\@NU+]\0XS,
MUILF&RI[4WSR(".M5263 4Q* 6-6:30R>\LFJ!0YE*_^\_=[0G*G,I.CHF/_
M &NQQM-Q[C_=X_^>=&(\/SO?W,_^=4G<W6WK\;H>4.=/^#?M7-H+1E$E,5[+
M=UT!1(HOG5..JY2#;72Y;Q3R^S?YXR#_^+KN((.P+]-U,=\P;;(U4JH$/G,-
MBGL+J RG#T5FZ9CVH4T&;!3RI\V0]0_P_76].\#]!<#G^7,EY C^SK9-[,2*
MJ (Z S[4ZVG%2'!11) "<RJIU#[A$_@QV^B=-K76BW\RBC9?=%7A^DM^C:?5
M\?KX)>?U5?UEW+S]N>*Y]@6&HY!WO%K#\:5YO+)#S7-DEALH9)_KL3""DZ*
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M.C.OHY)2MI'AR(R\7*N["XJW7SD[/AHZB,.>8;^V)*R^^Q8QY.4F 32/MP3
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M7EM0%DM2*9:V"5^R9%P$HUO=GCP&?X,@;UXHY+L!1E>NPZTBT)L,@Q8HA6?
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M@S;+>P_N%BF':W QDCA'G$*_)Q@^+1<IGW[[?DD\.1&V)N8AJ5AC6J=K%64
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M6QT>NEEII:04E6"T-VORU] 4\"G1!NU843JY&%KEQAZA9MK;ST?=W@Y61H>
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M(<ZKCJ[_/I?! ;FW*R%(QX@=;X'6?;W'&3R$B!&$]!9SL4QJ=:Q%<#@[PY;
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M;"-M-Q2I@%(R@X^H(=ML'#E>QMK<!*N[]_B?IN?.(4C;7]0O.12\CM6W+9C
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MJQC/S\Y/:S/_GS(1$6<7?1WRU].\T=<\O3I;+->S_VR^OY7YDR0X<> 2^$B
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MXQ=<?OUI\>4LOUDLO[Z;Q4UWN'FZ<UKVZO,R;WB^B@882AU9;>&=%"C%(H3
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M\0ZS5Y*SLIZ/5$QA$&0=EY14E""$,&W.L;U)[H;&DTR''T>-0QNS^\\XMCV
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MXVIF: C>G,W; NU/>%Y';,T7/^[U_7\VX'6JU 2;9)G+VLP.:XFMCLP!&=R
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M >3O5S.\TZ8I^0C"1L/,>CR/0$Y@5\ RU%KAPA4\G*K6%2'W%QIM1[7>,'*
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M0LQLJEPC^*3)$60\"$YB\9E%&0(=[$;)K(#[=)SN46.H)3]<S]WZ .TB]!%
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M*B92\$!?11\ZW2MU4__=I8?) _2F_KVE. +?=.LW71>HAR)S!,U47M_&1LD
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M\T7M:ST!<K-00V$E%:SUKN1]Y: 9I_^17J2@G3^N+? <*R-_?=0S%OO:"KT
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MC#&E1QJ^=^;[-?<"URGV:^ZCZ0[0?I>NU+[MFX[]V]5XVG*>D@>I= ;E$CF
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MNMTXC.!.G> ^>'ICQ&\SU5V4B_PI+&]&F1U1&CK41X_G-M^60FL'BDGJX$4
MSNJ NE*+ZU74$.G4=BXCY[+1DW C!WHU7T]SM3.2Z"^8KI?3]10II4JS:Q+C
M;3OC]7I;*OZ,C$^+ZSGY@5JX7;<01Q$I;"G.0W2RAD4L*>:XC*7-N,U!R._4
MN>Z#M6?U;R=7ZT6YVOOR]!?/IG!W-IW>%>]-VGBN^C@IMG;EP@?N5,A@6+T7
M\L(0S(L!B38&6TIAC08[M7+E=UKZ<;%:37R*W$>*D#AY#@J3BH1@C :C0R*N
M.:6N;6Y.'Y'1J6O=1_=/7>OA8N[@QO[)!J2?KFOEU+8*9O7S]7JU)JLDD6T,
M=**92H%B>9)0$*!$9'0"A0C$&S=H#$7^;281[47FR,,J6F"LG9HZP"!9SW)S
MR1]F#\Z,U<,SY</B^?7_@Y*LB3%1U)(^\"63U?ED(5AA01FIT-1D5#5;.'$D
M[2-/GVB!UA,KM ,(OV*?VW#FF9E.! 7*WB%Q9@2"JD]2'KT"EW)B-NOB)3^E
M(WV-T)&'49S0E0ZBJ@Z&G+P864\D"TZ@MI"TY* VW=K9,="\9,6T"\ZTV:+R
M(CDC#WQH@:KCQ=Y'U\,3-K96,8E>6%Y,!O0E@F(9*R,"G.16D!4D3&V2AU<(
M&GF@PBD0=(CH^[QSN<F./H0_#GO/>_C7![B[>)6:@>X7[G[_??OU'3Y8T29(
M%8&'P.M3!8/HK 2II$_%B&Q-&S-Z@ZAA-L$]^M7W;S/%U:F_2D#6J(AA8MWQ
MZ,%8*YD7&$6C..<MJGI8Y'4\/E[> S> 'KIW(H>7!CS_)<,ZE(9/^&_!1A8A
MHO (DL*-6M'F:K)4%PG:B$ZK%'*;#I>&;N7^-?CF0_Z"9;'$^P^D?ZW6FU?A
M[^GKTX_S)Z_".@MN"@M@C/4D$_00<BY@$^,R%.=*;N-YCB2\7^>T#\I>?]MO
MK\T.K@/NV:VO:HMYO=*X99W8W<[1W,X^>L*JT,ZD)!GAB]="573@A$K@ ^;B
MK5&F46WA$43WL,&P)6C;:K$KP'Y7"J;Z2GS'9RV?KA/AYFDZFV['&S_FU;JH
MN/? /*.LQZ@,GDL%B:M@E8L^,-L8L?M3W</6PY:0;:S'KC#[[9: .ERPKB.I
MPP1_G(98VSBGVZCL 9M%9,E8AA)R(#9C :>(8>T-I>E8;&%MW@H.)'C<.]CV
M2&VGO:Y ^NM\>3=6\WX^_.K]8C:CF.=N@, ]IU:5Z&,48)RCF(<7DJ[C"9(K
M*B &'DV;>H3#:1[W8K<]5)OJL/N\^[Y\Y[[>X4D@C\>,*3WTHX;-X0_G\@29
M/AW0(FL**SDC!*O,D/(@61NME2^)H&UTFW><YA>(5<PW98CS]71^/9U__/ES
M'6A=&_J>BW^;+TY4X):1]8+2WE*8'33X4@)8K[4R3*D<6]Y\'$1TOQG^/NAZ
M^?JQO18[.-,/8'5[JS$Q-FKO!(4KMC[FD.N#8.AXL-9[PS%SZ]I,L#N<YGYS
M^Q/#]1 =GB=:O_N#!$R:G<[#\LNFN?LGRAKI;Q)I]#$?;T<4D 9<M%Z2N29&
M417C#GQT!I@UFJGL'0FG%SCORE2_%P,GQGL3% Q6(7.J(/?915^; /?5CVD;
MW.[&W0D"6]2ASF'(H"(E:0J]J9MC"R2K@\\L>"O;W"$V#&R_1_(58?:*I%^R
MP3MQ>"N"T[5LG <%2B2LU\<.4 NAHN;,\S:%UH?3W&]8NP^VGOK-$^FP@SCA
MF^ME%?26X6>L3ERHT[RB!ZDCH],GDI=W+( (2CENA8^-9HM^A;!Q<7<J?"S:
M*:N?]9*W-\%O"W6BDO*8,-<Z7%$G;03PDC% LF?!."+3;::I[4;?N G32(!L
MH+I^<+F_3"<V1\Y8I" XJ%B?*4R=1Z!!JYRX=FBR:C,V9W]:QTUX1L)K8Y4>
MC=WAEIZ2*NNL]1_I)P^2<F&AZ*0R8*Q3U#%&<-Z1E+-,,B0OHVH3BAY+>;\7
M5\<$I"?59S]AZ2.VGY\KTMJ,/"F@5)LD*JP'K[4&Z[G),@>2;)OT<2?R1I[2
M?5+$O!RH#JB^?L*"VYAG%P%/T 8?I5 @+:/3 P-"8!@A90K%>984&;49,+4/
ME2,/Q!X3J,V4V0]>#Y7O!+EDVF<#9(P&%#,10C(2ZIAO'UU!'AN5I!Y(\<A3
MJ<?$\4F4W$]XNWV4.T3*CL<89#*@!>40JGC*2FVN);JV!/I'\M F9CB<YG[?
MIHZZ8SV-#OL)9N]Z')Z>*ZD(9]%JX+Y6J86HP"F2I\E))*X*I;MMFE:^0MC(
M=ZPGPL<K=ZQ#**N?(.#NHNY-H4Y2,KE8)TEFQ8&2@H$7)5%$GA4:#()AFR+I
MW>@;^8YU'$ V4%T_N-Q?IA/KR 13UG3("(K""U+6&(T%'@4K,;,L6)OJD_UI
M'?F.=1R\-E9I/T'H:Y9HO=44%P4HD=7J;Y24)@H',NF@M784)36NUCW :X[2
M27),^#B$](?&4OOJI&^GA<C$>2)^U_]$G+];+GZ?KNB#R.P>_(TPOWV3JYGA
M-0'YRZ..L/7B84?NW2\ICW[)T#5/HQ#?JI)J?$V<H#Z+<Z>8Y1JD]J$&NPE<
M2@&2\#F2-40>6Q8N-ZG/VJ5%\FK]ILXF6&1$RR5$%BG8TDQ!+ '!9EF""45H
MVZ8680#B^ZW8V@=MS^8HG5BK'5PK[,+RR_>"N)IDD3&6HD#+.EK!A0C>2 6&
MCL?HC-,ZMWG?/8;J?M]V6T-W$#V>"6:?)A#U)VY/V_4TS"8IRUP'VD*I%6[*
M.4/9"3-@3"DRRX I-!K9/0#U_5[FML;PH'H]$RS3%[\ARJ9KLE0I$1E2H!RQ
MSED(!;P2 FS4ULMH0W+C>=Q[.OO-%EOC\T!='9M$G@R+[_%S6"^GVUT?6VN\
MG3\Y$<D)9RAEYDGZ^KAM@8*A"*GDD%@4S/I&RPV/);W?\0.M$3N<1L_(G5YO
M1H7\;1%75VG]<Q&,VW>X3*2J252:6Y\%"%4'[_(0(-1[1!\39T+(@F*\P.!M
MVL<=;3NVVQU(IV>"XI_7O^'R[DOSCYLNRUM^LZ^IIA40O98D;F]J41Q2.JJE
M$LE8RD-'P_!;E.^$8'N)"!Y,GV>"7_KB+[A>S[9+&T1A":U!,)J;N@&<0<B*
M@7!.J.)0.=%HROS>M.Z$47>)&#U"9V>"RI\6]3+\FGXLSG#[*/2>%$R$_U:W
MB.+O.%M\KNQ/?/#2*.(^^4+"]AC!8;+@M#&Z9,.+-:,A=G<^=D*SOT0T-]+U
MF2#]F]_JQIP?YL]&Z/U[F%W?Z'\V6_PSS!-.O,^J)"DA2U-;[VR :)*!X*P/
M="1EW:@ ?6!&=GNU8)<(]E;J/A.T?_=?U]/UEQ_N\MHZS017=2H?_=1J,9OF
M>HORRW5<3?,T++],G-<BZ* @<E/JU'L#=8HIU*%\$I4BW;29#M:"F]UP?Y'/
M=4T5WT\)W,X9QE7^S^O5>KLH+67/(DD\EYH5"Y3@ R&21)X,QN*4:E/%?@BU
MNV'X(M_MCE)<MP[ZQ2(^89BF3%>!)!;K.#\/P7 %'/EF]:3WV&A9U,XT[@;$
M"WE\.UI)9S2TZUEH%!X-DQZ\D&VWCVM6>G8 MR<H%DN>6:DHM8J\EB*H3)E6
M" FBRKQ(DTILM,*B8;'8,U'_=4E1R!W+D?%HC&00M5,49S@',27B.TI5LC/!
MI3977V_3U6^)USX8>:T18@!=='"R/N-FZZ7G'VN<^TU8+K^4F^'BJPEZRQ*B
M Y8B22T'!M[7M3A,*\5)IEC:-(CM0>2XF!L2&U^#W4"*ZA&#U6BW7]O>JGVS
M^%3_?:/(>;Z=?7^_QOGA#WRSJ'-!,[.1:P03;:H/'@X"-Q*2<C9BTDQ@FQE(
M+;@9M^+PE*@^M>K/ _[U4GGY.];7Z:N4EM=AMIID;[/( B%@=J!2M!2J:_HC
M%HT4Q%O1:"["8?2.6W X+H2/55^/(/WK8I'_.9W-B*<?2)'SC_4-Y.9;$PJC
MDDTI 5+.6.O6%(3 Z]N'TE;+)%.C(JY]J!RWPO"4@!Q*52/"L&;$SQG[]3,)
M=KXFOOY.">MJO9CCN_#EYH:+Y^R4V8S%$;I.=>(4 Z$"88H-3#O)GA:P/,^Z
M]_[4<6L &V"JK=Q[]&MWY;>/0NK;5]V)K 9#=$!)A>PE*0JM0_* G Q(Q))8
M.MVI^P:AXQ;RG?BX'4IA/>+QYOGI[[C^;4'>FX*([0U^4J84DB+PP&J0FQB$
MJ"P9F[/!UQ4AN4U/Y*X4CEN(=TH$#J&B'J&W4R![<[__$>=IBN3]D\L^A$"I
MEZG%WO6*S7(%N;!"WU'TS393,08@?MRJO.XRE,,5VR.6-R^@$QM0VY05R%!W
M?<6:;QEGP&HA,&"2F-HT/[U,S[B5<R>]K-Q;_#V":".@"3/<I;ISBV@79 I6
M0DCDVV4*@3D4&NV)KL$W](Q<DG;21'9O^0_V>#P@BEZHE],BE>Q+W9A1"BA?
M;RQ3[?:+L?"<5."Z3='"8"6/%_&D<J1F^BGF>L;93[B>).<B<D,"DB2@^A $
MP=4+R!RYL$PX(4_T2DS4C%R,=4I4[2O[OGS6@XJ.^Q'!D<N V4# 6M[+3;TT
MC)P2:Z<E!B'(8%HCZ06Z^IW+,5"]P;&ZZ"NF>L#-N^7B,R[77][-PN9:L6;4
M-WT3(2'E%N1UT25)DJM"D]*!*ZF8%'5VH7G$O@NAW=0='(V1G> WC,*Z/# ?
M</G&P\FSAQ0>E?*9Q!M4H=Q&.3+V4A!8LD&3V+5GIP3J'J1W4UQP&NBV4FKO
M8+Y)P56D<".Z!!(I\5:<,7"2*4 18J[U$1S;=*6\050WI0&G >#^BN@/6G?!
MS@.^)B4P'1S9B-2:@TI"4/QL$+)/PADA.<7.3;'U$E7=//.W M?1JNAGE/'+
MTIIPRQA:5?>"6/+"AMAR+!,S41G+)4=^TJ.UW]%IPZ<9>\G^7.88OU_,9MMW
MXD79?.BO\R6FQ<?Y]+^?"F"8GHU#/G'8MHVC>3Y!YX9BR%%$BK9JC*5X[0H2
MO( LI6YL-<7PLUO#_J0/KSR1^FTUZW=_I-EUGLX_7GU:7,_7=6P+Z:#VFWY8
M?/='^#2=;W[\/:ZOE_.-,K^_4>;$:Q651PZ8:AP148!/T4 *'*/B.B?5YL6U
M-6?]=H_L@].G;K8K/'1P'_0*_Q,*@[V*CA/=-?/BMMZ[1PW%NU"2%)KS-H]L
MKQ T+AK[0LUB>!4>C,3/N)PNZM[$Y?KX M-7.-GN8GJW^2CZ^KO%:OIX48ET
M)?/ .918'[:9IXB><0=:1_1)>YNR_%JX<!0%X][A= G/TVFT7S=*I]@2PPIK
M.>3UK);S?$_*>Y7[2=&.<VT*%$N><=.7[0JEC45A"L9:2BG:9%K#T#^.DSXA
MT';SO"VUWB_6O\4]N78^1*X8%%0!5&+D4X058+4OV4=FC ZGQ/J>](_C\;O#
M>DNMCW_M^I:XWQ%ORS>$;43BR2@#K#Z_*:N(4\DLV((.@TQ8BCXF)OG*YX][
M2W9V$<F0VNS71[]\,KW"^T23#&6MDI$<?;U[3!!=4B B<T4C22*UN0\:@OK^
M8I%!(79,)#*$OOO%^,LGTFL\US6I:+@$+'4"+L^LC@35P&*(Q=9%[*Q-/]D0
MU/<7@XR \7;Z'C_^.(CU!P.>_V.Z_HU^OAZPU^O?%LN;-R6GF#9*6_!(HE<E
M<8A"8EUE'0,Z57PXZ=W>86R,^[#<98 S/ERZ-YGW-_.BR14\$L*/X?,*?RY7
MGS_/IBG$&=[L!J0O_3C]-%UOQ^:55#A7.0,+&*I. CA6,@3#F%!:,.O:5' W
M8&;<5OES-)^30:=[(YK(B+E$4R!@$: "R3D$;D&*A#XH]):?U!#&[;8_1S#O
MI<(C7X>^FS_<;M:JJN2GL*SSV'['84I&GOVZ8>M!WJ;V!,4>E-U)[Q4E>S;(
MBBE)OL@*0"VU$U9)IMKTD#0L]GA])-^'ZI@G2G'KA7; C4^U<Y$P;S4#9KSF
M!E5PK,U,NJ\0UF^IQ3XH>>IYAM1&+Z./[F2U[=O?NM,Z F\Q)UE?_3%=39#D
M5+AS=6TI,2:"@.AJ!6AT2GK&#0O[C3[:Y5/'Q="@NGYI]M'@@C\71'V[^$1!
MPD0'Q64BL=7&!U L)7 J<_!*!\N99IGM]IJPW^>.>(O:3O.'X.L -8R-L"?=
M-!^68;XB*OZ.GV+M?PC%VJP]8'T&5,Q%B@1)8BDGC#(5;;/="5!O?LP9X.<0
MS2Z:B+F#._4[8=U> 'W9F)<47EFO!7!A(KEO6< 7XT&7C#*9@EPWK@Q^1,^X
MU58MSKH!Y=\EBK9&)K07TM>M[E[4P=C90#0VULZ;PD21Z)Z>8LUP-.;Y-J2V
MOPJ@ T3? 82(:ERMI^F;>E6R_++UIB&$8FI'%69+WC3I4$]X"1E9B%KI5%*;
MFJ$7R>D-/(=H^FD7TM%B[P []0(6K^;Y1_K)V=^NE]-5GFXN;K?L%(?)<.%
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M'.PW][+&J+F[3?+*N+*$XR2+\O=>V-_P0B/SP;M*];VG;G7RYC5;G$S0PT8
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MR5:3Y5>SQ+P3]7LJ)'Y8UKZ:7>6?F%S&G;%PJ7Y$,B9G_P=02P,$%     @
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MAAO63:DK_<FCYABXX4KQ8NA\#<$;W6"5>AKR'^^@]MN\RNKWX?AO4$L#!!0
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MPJ/BDEX$4+!^P>FYAI40.[9E[X72C852+,3[?(P@2'#!>&85+&7"!-/**7U
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MWUE-X0F<7[GM*1^YR*Y_P[6ZO^"_^"]02P,$%     @ Z8975% 0X9ML!0
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M=W4% &=I;&0M,C R,3$R,S$N>'-D4$L! A0#%     @ Z8975,I:X;W .@
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M:&EB:70R,S$N:'1M4$L! A0#%     @ Z8975%<R_HV_!P  82   !X
M         ( !.A * &=I;&0R,#(Q9F]R;3$P+6ME>&AI8FET,S$Q+FAT;5!+
M 0(4 Q0    ( .F&5U0MOC(/N <  #L@   >              "  348"@!G
M:6QD,C R,69O<FTQ,"UK97AH:6)I=#,Q,BYH=&U02P$"% ,4    " #IAE=4
M4!#AFVP%  "T$@  '0              @ $I( H 9VEL9#(P,C%F;W)M,3 M
D:V5X:&EB:70S,BYH=&U02P4&      P # !' P  T"4*

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
